# newdoc_id = 012debf5a240a496518af146ddfc16c958339c2b
1	Background	_	_	_	_	_	_	_	Seg=B-seg
2	:	_	_	_	_	_	_	_	Seg=O
3	EU	_	_	_	_	_	_	_	Seg=B-seg
4	Decision	_	_	_	_	_	_	_	Seg=O
5	1082/2013	_	_	_	_	_	_	_	Seg=O
6	/	_	_	_	_	_	_	_	Seg=O
7	EU	_	_	_	_	_	_	_	Seg=O
8	on	_	_	_	_	_	_	_	Seg=O
9	serious	_	_	_	_	_	_	_	Seg=O
10	cross	_	_	_	_	_	_	_	Seg=O
11	-	_	_	_	_	_	_	_	Seg=O
12	border	_	_	_	_	_	_	_	Seg=O
13	health	_	_	_	_	_	_	_	Seg=O
14	threats	_	_	_	_	_	_	_	Seg=O
15	provides	_	_	_	_	_	_	_	Seg=O
16	a	_	_	_	_	_	_	_	Seg=O
17	legal	_	_	_	_	_	_	_	Seg=O
18	basis	_	_	_	_	_	_	_	Seg=O
19	for	_	_	_	_	_	_	_	Seg=O
20	collaboration	_	_	_	_	_	_	_	Seg=O
21	between	_	_	_	_	_	_	_	Seg=O
22	EU	_	_	_	_	_	_	_	Seg=O
23	Member	_	_	_	_	_	_	_	Seg=O
24	States	_	_	_	_	_	_	_	Seg=O
25	,	_	_	_	_	_	_	_	Seg=O
26	and	_	_	_	_	_	_	_	Seg=O
27	between	_	_	_	_	_	_	_	Seg=O
28	international	_	_	_	_	_	_	_	Seg=O
29	and	_	_	_	_	_	_	_	Seg=O
30	European	_	_	_	_	_	_	_	Seg=O
31	level	_	_	_	_	_	_	_	Seg=O
32	institutions	_	_	_	_	_	_	_	Seg=O
33	on	_	_	_	_	_	_	_	Seg=O
34	preparedness	_	_	_	_	_	_	_	Seg=O
35	,	_	_	_	_	_	_	_	Seg=O
36	prevention	_	_	_	_	_	_	_	Seg=O
37	,	_	_	_	_	_	_	_	Seg=O
38	and	_	_	_	_	_	_	_	Seg=O
39	mitigation	_	_	_	_	_	_	_	Seg=O
40	in	_	_	_	_	_	_	_	Seg=O
41	the	_	_	_	_	_	_	_	Seg=O
42	event	_	_	_	_	_	_	_	Seg=O
43	of	_	_	_	_	_	_	_	Seg=O
44	a	_	_	_	_	_	_	_	Seg=O
45	public	_	_	_	_	_	_	_	Seg=O
46	health	_	_	_	_	_	_	_	Seg=O
47	emergency	_	_	_	_	_	_	_	Seg=O
48	.	_	_	_	_	_	_	_	Seg=O
49	The	_	_	_	_	_	_	_	Seg=B-seg
50	Decision	_	_	_	_	_	_	_	Seg=O
51	provides	_	_	_	_	_	_	_	Seg=O
52	a	_	_	_	_	_	_	_	Seg=O
53	context	_	_	_	_	_	_	_	Seg=O
54	for	_	_	_	_	_	_	_	Seg=O
55	the	_	_	_	_	_	_	_	Seg=O
56	present	_	_	_	_	_	_	_	Seg=O
57	study	_	_	_	_	_	_	_	Seg=O
58	,	_	_	_	_	_	_	_	Seg=O
59	which	_	_	_	_	_	_	_	Seg=B-seg
60	aims	_	_	_	_	_	_	_	Seg=O
61	to	_	_	_	_	_	_	_	Seg=O
62	identify	_	_	_	_	_	_	_	Seg=O
63	good	_	_	_	_	_	_	_	Seg=O
64	practices	_	_	_	_	_	_	_	Seg=O
65	and	_	_	_	_	_	_	_	Seg=O
66	lessons	_	_	_	_	_	_	_	Seg=O
67	learned	_	_	_	_	_	_	_	Seg=B-seg
68	in	_	_	_	_	_	_	_	Seg=O
69	preparedness	_	_	_	_	_	_	_	Seg=O
70	and	_	_	_	_	_	_	_	Seg=O
71	response	_	_	_	_	_	_	_	Seg=O
72	to	_	_	_	_	_	_	_	Seg=O
73	Middle	_	_	_	_	_	_	_	Seg=O
74	East	_	_	_	_	_	_	_	Seg=O
75	Respiratory	_	_	_	_	_	_	_	Seg=O
76	Syndrome	_	_	_	_	_	_	_	Seg=O
77	(	_	_	_	_	_	_	_	Seg=O
78	MERS	_	_	_	_	_	_	_	Seg=O
79	)	_	_	_	_	_	_	_	Seg=O
80	(	_	_	_	_	_	_	_	Seg=O
81	in	_	_	_	_	_	_	_	Seg=O
82	UK	_	_	_	_	_	_	_	Seg=O
83	,	_	_	_	_	_	_	_	Seg=O
84	Greece	_	_	_	_	_	_	_	Seg=O
85	,	_	_	_	_	_	_	_	Seg=O
86	and	_	_	_	_	_	_	_	Seg=O
87	Spain	_	_	_	_	_	_	_	Seg=O
88	)	_	_	_	_	_	_	_	Seg=O
89	and	_	_	_	_	_	_	_	Seg=O
90	poliomyelitis	_	_	_	_	_	_	_	Seg=O
91	(	_	_	_	_	_	_	_	Seg=O
92	in	_	_	_	_	_	_	_	Seg=O
93	Poland	_	_	_	_	_	_	_	Seg=O
94	and	_	_	_	_	_	_	_	Seg=O
95	Cyprus	_	_	_	_	_	_	_	Seg=O
96	)	_	_	_	_	_	_	_	Seg=O
97	.	_	_	_	_	_	_	_	Seg=O
98	Methods	_	_	_	_	_	_	_	Seg=B-seg
99	:	_	_	_	_	_	_	_	Seg=O
100	Based	_	_	_	_	_	_	_	Seg=B-seg
101	on	_	_	_	_	_	_	_	Seg=O
102	a	_	_	_	_	_	_	_	Seg=O
103	documentary	_	_	_	_	_	_	_	Seg=O
104	review	_	_	_	_	_	_	_	Seg=O
105	,	_	_	_	_	_	_	_	Seg=O
106	followed	_	_	_	_	_	_	_	Seg=B-seg
107	by	_	_	_	_	_	_	_	Seg=O
108	five	_	_	_	_	_	_	_	Seg=O
109	week	_	_	_	_	_	_	_	Seg=O
110	-	_	_	_	_	_	_	_	Seg=O
111	long	_	_	_	_	_	_	_	Seg=O
112	country	_	_	_	_	_	_	_	Seg=O
113	visits	_	_	_	_	_	_	_	Seg=O
114	involving	_	_	_	_	_	_	_	Seg=B-seg
115	a	_	_	_	_	_	_	_	Seg=O
116	total	_	_	_	_	_	_	_	Seg=O
117	of	_	_	_	_	_	_	_	Seg=O
118	61	_	_	_	_	_	_	_	Seg=O
119	interviews	_	_	_	_	_	_	_	Seg=O
120	and	_	_	_	_	_	_	_	Seg=O
121	group	_	_	_	_	_	_	_	Seg=O
122	discussions	_	_	_	_	_	_	_	Seg=O
123	with	_	_	_	_	_	_	_	Seg=O
124	experts	_	_	_	_	_	_	_	Seg=O
125	from	_	_	_	_	_	_	_	Seg=O
126	both	_	_	_	_	_	_	_	Seg=O
127	the	_	_	_	_	_	_	_	Seg=O
128	health	_	_	_	_	_	_	_	Seg=O
129	and	_	_	_	_	_	_	_	Seg=O
130	non	_	_	_	_	_	_	_	Seg=O
131	-	_	_	_	_	_	_	_	Seg=O
132	health	_	_	_	_	_	_	_	Seg=O
133	sectors	_	_	_	_	_	_	_	Seg=O
134	,	_	_	_	_	_	_	_	Seg=O
135	this	_	_	_	_	_	_	_	Seg=B-seg
136	qualitative	_	_	_	_	_	_	_	Seg=O
137	case	_	_	_	_	_	_	_	Seg=O
138	study	_	_	_	_	_	_	_	Seg=O
139	has	_	_	_	_	_	_	_	Seg=O
140	investigated	_	_	_	_	_	_	_	Seg=O
141	six	_	_	_	_	_	_	_	Seg=O
142	issues	_	_	_	_	_	_	_	Seg=O
143	related	_	_	_	_	_	_	_	Seg=B-seg
144	to	_	_	_	_	_	_	_	Seg=O
145	preparedness	_	_	_	_	_	_	_	Seg=O
146	and	_	_	_	_	_	_	_	Seg=O
147	response	_	_	_	_	_	_	_	Seg=O
148	to	_	_	_	_	_	_	_	Seg=O
149	MERS	_	_	_	_	_	_	_	Seg=O
150	and	_	_	_	_	_	_	_	Seg=O
151	poliomyelitis	_	_	_	_	_	_	_	Seg=O
152	:	_	_	_	_	_	_	_	Seg=O
153	national	_	_	_	_	_	_	_	Seg=B-seg
154	plans	_	_	_	_	_	_	_	Seg=O
155	and	_	_	_	_	_	_	_	Seg=O
156	overall	_	_	_	_	_	_	_	Seg=O
157	preparedness	_	_	_	_	_	_	_	Seg=O
158	capacity	_	_	_	_	_	_	_	Seg=O
159	;	_	_	_	_	_	_	_	Seg=O
160	training	_	_	_	_	_	_	_	Seg=O
161	and	_	_	_	_	_	_	_	Seg=O
162	exercises	_	_	_	_	_	_	_	Seg=O
163	;	_	_	_	_	_	_	_	Seg=O
164	risk	_	_	_	_	_	_	_	Seg=O
165	communication	_	_	_	_	_	_	_	Seg=O
166	;	_	_	_	_	_	_	_	Seg=O
167	linking	_	_	_	_	_	_	_	Seg=O
168	policy	_	_	_	_	_	_	_	Seg=O
169	and	_	_	_	_	_	_	_	Seg=O
170	implementation	_	_	_	_	_	_	_	Seg=O
171	;	_	_	_	_	_	_	_	Seg=O
172	interoperability	_	_	_	_	_	_	_	Seg=O
173	between	_	_	_	_	_	_	_	Seg=O
174	the	_	_	_	_	_	_	_	Seg=O
175	health	_	_	_	_	_	_	_	Seg=O
176	and	_	_	_	_	_	_	_	Seg=O
177	non	_	_	_	_	_	_	_	Seg=O
178	-	_	_	_	_	_	_	_	Seg=O
179	health	_	_	_	_	_	_	_	Seg=O
180	sectors	_	_	_	_	_	_	_	Seg=O
181	;	_	_	_	_	_	_	_	Seg=O
182	and	_	_	_	_	_	_	_	Seg=O
183	cross	_	_	_	_	_	_	_	Seg=O
184	-	_	_	_	_	_	_	_	Seg=O
185	border	_	_	_	_	_	_	_	Seg=O
186	collaboration	_	_	_	_	_	_	_	Seg=O
187	.	_	_	_	_	_	_	_	Seg=O
188	Results	_	_	_	_	_	_	_	Seg=B-seg
189	:	_	_	_	_	_	_	_	Seg=O
190	Preparedness	_	_	_	_	_	_	_	Seg=B-seg
191	and	_	_	_	_	_	_	_	Seg=O
192	response	_	_	_	_	_	_	_	Seg=O
193	plans	_	_	_	_	_	_	_	Seg=O
194	for	_	_	_	_	_	_	_	Seg=O
195	MERS	_	_	_	_	_	_	_	Seg=O
196	and	_	_	_	_	_	_	_	Seg=O
197	poliomyelitis	_	_	_	_	_	_	_	Seg=O
198	were	_	_	_	_	_	_	_	Seg=O
199	in	_	_	_	_	_	_	_	Seg=O
200	place	_	_	_	_	_	_	_	Seg=O
201	in	_	_	_	_	_	_	_	Seg=O
202	the	_	_	_	_	_	_	_	Seg=O
203	participating	_	_	_	_	_	_	_	Seg=O
204	countries	_	_	_	_	_	_	_	Seg=O
205	,	_	_	_	_	_	_	_	Seg=O
206	with	_	_	_	_	_	_	_	Seg=B-seg
207	a	_	_	_	_	_	_	_	Seg=O
208	high	_	_	_	_	_	_	_	Seg=O
209	level	_	_	_	_	_	_	_	Seg=O
210	of	_	_	_	_	_	_	_	Seg=O
211	technical	_	_	_	_	_	_	_	Seg=O
212	expertise	_	_	_	_	_	_	_	Seg=O
213	available	_	_	_	_	_	_	_	Seg=O
214	to	_	_	_	_	_	_	_	Seg=O
215	implement	_	_	_	_	_	_	_	Seg=O
216	them	_	_	_	_	_	_	_	Seg=O
217	.	_	_	_	_	_	_	_	Seg=O
218	Nevertheless	_	_	_	_	_	_	_	Seg=B-seg
219	,	_	_	_	_	_	_	_	Seg=O
220	formal	_	_	_	_	_	_	_	Seg=O
221	evaluation	_	_	_	_	_	_	_	Seg=O
222	of	_	_	_	_	_	_	_	Seg=O
223	the	_	_	_	_	_	_	_	Seg=O
224	responses	_	_	_	_	_	_	_	Seg=O
225	to	_	_	_	_	_	_	_	Seg=O
226	previous	_	_	_	_	_	_	_	Seg=O
227	public	_	_	_	_	_	_	_	Seg=O
228	health	_	_	_	_	_	_	_	Seg=O
229	emergencies	_	_	_	_	_	_	_	Seg=O
230	have	_	_	_	_	_	_	_	Seg=O
231	sometimes	_	_	_	_	_	_	_	Seg=O
232	been	_	_	_	_	_	_	_	Seg=O
233	limited	_	_	_	_	_	_	_	Seg=O
234	,	_	_	_	_	_	_	_	Seg=O
235	so	_	_	_	_	_	_	_	Seg=B-seg
236	lessons	_	_	_	_	_	_	_	Seg=O
237	learned	_	_	_	_	_	_	_	Seg=O
238	may	_	_	_	_	_	_	_	Seg=O
239	not	_	_	_	_	_	_	_	Seg=O
240	be	_	_	_	_	_	_	_	Seg=O
241	reflected	_	_	_	_	_	_	_	Seg=O
242	in	_	_	_	_	_	_	_	Seg=O
243	updated	_	_	_	_	_	_	_	Seg=O
244	plans	_	_	_	_	_	_	_	Seg=O
245	,	_	_	_	_	_	_	_	Seg=O
246	thereby	_	_	_	_	_	_	_	Seg=B-seg
247	risking	_	_	_	_	_	_	_	Seg=O
248	mistakes	_	_	_	_	_	_	_	Seg=O
249	being	_	_	_	_	_	_	_	Seg=B-seg
250	repeated	_	_	_	_	_	_	_	Seg=O
251	in	_	_	_	_	_	_	_	Seg=O
252	future	_	_	_	_	_	_	_	Seg=O
253	.	_	_	_	_	_	_	_	Seg=O
254	The	_	_	_	_	_	_	_	Seg=B-seg
255	nature	_	_	_	_	_	_	_	Seg=O
256	and	_	_	_	_	_	_	_	Seg=O
257	extent	_	_	_	_	_	_	_	Seg=O
258	of	_	_	_	_	_	_	_	Seg=O
259	intersectoral	_	_	_	_	_	_	_	Seg=O
260	collaboration	_	_	_	_	_	_	_	Seg=O
261	varied	_	_	_	_	_	_	_	Seg=O
262	according	_	_	_	_	_	_	_	Seg=O
263	to	_	_	_	_	_	_	_	Seg=O
264	the	_	_	_	_	_	_	_	Seg=O
265	sectors	_	_	_	_	_	_	_	Seg=O
266	involved	_	_	_	_	_	_	_	Seg=O
267	,	_	_	_	_	_	_	_	Seg=O
268	with	_	_	_	_	_	_	_	Seg=O
269	those	_	_	_	_	_	_	_	Seg=O
270	sectors	_	_	_	_	_	_	_	Seg=O
271	that	_	_	_	_	_	_	_	Seg=B-seg
272	have	_	_	_	_	_	_	_	Seg=O
273	traditionally	_	_	_	_	_	_	_	Seg=O
274	had	_	_	_	_	_	_	_	Seg=O
275	good	_	_	_	_	_	_	_	Seg=O
276	collaboration	_	_	_	_	_	_	_	Seg=O
277	(	_	_	_	_	_	_	_	Seg=B-seg
278	e.g.	_	_	_	_	_	_	_	Seg=O
279	animal	_	_	_	_	_	_	_	Seg=O
280	health	_	_	_	_	_	_	_	Seg=O
281	and	_	_	_	_	_	_	_	Seg=O
282	food	_	_	_	_	_	_	_	Seg=O
283	safety	_	_	_	_	_	_	_	Seg=O
284	)	_	_	_	_	_	_	_	Seg=O
285	,	_	_	_	_	_	_	_	Seg=O
286	as	_	_	_	_	_	_	_	Seg=B-seg
287	well	_	_	_	_	_	_	_	Seg=O
288	as	_	_	_	_	_	_	_	Seg=O
289	those	_	_	_	_	_	_	_	Seg=O
290	that	_	_	_	_	_	_	_	Seg=B-seg
291	have	_	_	_	_	_	_	_	Seg=O
292	a	_	_	_	_	_	_	_	Seg=O
293	financial	_	_	_	_	_	_	_	Seg=O
294	incentive	_	_	_	_	_	_	_	Seg=O
295	for	_	_	_	_	_	_	_	Seg=O
296	controlling	_	_	_	_	_	_	_	Seg=O
297	infectious	_	_	_	_	_	_	_	Seg=O
298	diseases	_	_	_	_	_	_	_	Seg=O
299	(	_	_	_	_	_	_	_	Seg=B-seg
300	e.g.	_	_	_	_	_	_	_	Seg=O
301	agriculture	_	_	_	_	_	_	_	Seg=O
302	,	_	_	_	_	_	_	_	Seg=O
303	tourism	_	_	_	_	_	_	_	Seg=O
304	,	_	_	_	_	_	_	_	Seg=O
305	and	_	_	_	_	_	_	_	Seg=O
306	air	_	_	_	_	_	_	_	Seg=O
307	travel	_	_	_	_	_	_	_	Seg=O
308	)	_	_	_	_	_	_	_	Seg=O
309	seen	_	_	_	_	_	_	_	Seg=B-seg
310	as	_	_	_	_	_	_	_	Seg=O
311	most	_	_	_	_	_	_	_	Seg=O
312	likely	_	_	_	_	_	_	_	Seg=O
313	to	_	_	_	_	_	_	_	Seg=O
314	have	_	_	_	_	_	_	_	Seg=O
315	integrated	_	_	_	_	_	_	_	Seg=O
316	public	_	_	_	_	_	_	_	Seg=O
317	health	_	_	_	_	_	_	_	Seg=O
318	preparedness	_	_	_	_	_	_	_	Seg=O
319	and	_	_	_	_	_	_	_	Seg=O
320	response	_	_	_	_	_	_	_	Seg=O
321	plans	_	_	_	_	_	_	_	Seg=O
322	.	_	_	_	_	_	_	_	Seg=O
323	Although	_	_	_	_	_	_	_	Seg=B-seg
324	the	_	_	_	_	_	_	_	Seg=O
325	formal	_	_	_	_	_	_	_	Seg=O
326	protocols	_	_	_	_	_	_	_	Seg=O
327	for	_	_	_	_	_	_	_	Seg=O
328	inter	_	_	_	_	_	_	_	Seg=O
329	-	_	_	_	_	_	_	_	Seg=O
330	sectoral	_	_	_	_	_	_	_	Seg=O
331	collaboration	_	_	_	_	_	_	_	Seg=O
332	were	_	_	_	_	_	_	_	Seg=O
333	not	_	_	_	_	_	_	_	Seg=O
334	always	_	_	_	_	_	_	_	Seg=O
335	up	_	_	_	_	_	_	_	Seg=O
336	to	_	_	_	_	_	_	_	Seg=O
337	date	_	_	_	_	_	_	_	Seg=O
338	,	_	_	_	_	_	_	_	Seg=O
339	good	_	_	_	_	_	_	_	Seg=B-seg
340	personal	_	_	_	_	_	_	_	Seg=O
341	relations	_	_	_	_	_	_	_	Seg=O
342	were	_	_	_	_	_	_	_	Seg=O
343	reported	_	_	_	_	_	_	_	Seg=O
344	within	_	_	_	_	_	_	_	Seg=O
345	the	_	_	_	_	_	_	_	Seg=O
346	relevant	_	_	_	_	_	_	_	Seg=O
347	professional	_	_	_	_	_	_	_	Seg=O
348	networks	_	_	_	_	_	_	_	Seg=O
349	,	_	_	_	_	_	_	_	Seg=O
350	which	_	_	_	_	_	_	_	Seg=B-seg
351	could	_	_	_	_	_	_	_	Seg=O
352	be	_	_	_	_	_	_	_	Seg=O
353	brought	_	_	_	_	_	_	_	Seg=O
354	into	_	_	_	_	_	_	_	Seg=O
355	play	_	_	_	_	_	_	_	Seg=O
356	in	_	_	_	_	_	_	_	Seg=O
357	the	_	_	_	_	_	_	_	Seg=O
358	event	_	_	_	_	_	_	_	Seg=O
359	of	_	_	_	_	_	_	_	Seg=O
360	a	_	_	_	_	_	_	_	Seg=O
361	public	_	_	_	_	_	_	_	Seg=O
362	health	_	_	_	_	_	_	_	Seg=O
363	emergency	_	_	_	_	_	_	_	Seg=O
364	.	_	_	_	_	_	_	_	Seg=O
365	Cross	_	_	_	_	_	_	_	Seg=B-seg
366	-	_	_	_	_	_	_	_	Seg=O
367	border	_	_	_	_	_	_	_	Seg=O
368	collaboration	_	_	_	_	_	_	_	Seg=O
369	was	_	_	_	_	_	_	_	Seg=O
370	greatly	_	_	_	_	_	_	_	Seg=O
371	facilitated	_	_	_	_	_	_	_	Seg=O
372	if	_	_	_	_	_	_	_	Seg=B-seg
373	the	_	_	_	_	_	_	_	Seg=O
374	neighbouring	_	_	_	_	_	_	_	Seg=O
375	country	_	_	_	_	_	_	_	Seg=O
376	was	_	_	_	_	_	_	_	Seg=O
377	a	_	_	_	_	_	_	_	Seg=O
378	fellow	_	_	_	_	_	_	_	Seg=O
379	EU	_	_	_	_	_	_	_	Seg=O
380	Member	_	_	_	_	_	_	_	Seg=O
381	State	_	_	_	_	_	_	_	Seg=O
382	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 01fe9408aa72a025bad89a695b389c4e509ed67d
1	Low	_	_	_	_	_	_	_	Seg=B-seg
2	-	_	_	_	_	_	_	_	Seg=O
3	and	_	_	_	_	_	_	_	Seg=O
4	middle	_	_	_	_	_	_	_	Seg=O
5	-	_	_	_	_	_	_	_	Seg=O
6	income	_	_	_	_	_	_	_	Seg=O
7	countries	_	_	_	_	_	_	_	Seg=O
8	,	_	_	_	_	_	_	_	Seg=O
9	where	_	_	_	_	_	_	_	Seg=B-seg
10	emerging	_	_	_	_	_	_	_	Seg=O
11	diseases	_	_	_	_	_	_	_	Seg=O
12	often	_	_	_	_	_	_	_	Seg=O
13	make	_	_	_	_	_	_	_	Seg=O
14	their	_	_	_	_	_	_	_	Seg=O
15	debut	_	_	_	_	_	_	_	Seg=O
16	,	_	_	_	_	_	_	_	Seg=O
17	are	_	_	_	_	_	_	_	Seg=B-seg
18	also	_	_	_	_	_	_	_	Seg=O
19	likely	_	_	_	_	_	_	_	Seg=O
20	to	_	_	_	_	_	_	_	Seg=O
21	bear	_	_	_	_	_	_	_	Seg=O
22	the	_	_	_	_	_	_	_	Seg=O
23	harshest	_	_	_	_	_	_	_	Seg=O
24	consequences	_	_	_	_	_	_	_	Seg=O
25	of	_	_	_	_	_	_	_	Seg=O
26	a	_	_	_	_	_	_	_	Seg=O
27	potential	_	_	_	_	_	_	_	Seg=O
28	influenza	_	_	_	_	_	_	_	Seg=O
29	pandemic	_	_	_	_	_	_	_	Seg=O
30	.	_	_	_	_	_	_	_	Seg=O
31	Yet	_	_	_	_	_	_	_	Seg=B-seg
32	public	_	_	_	_	_	_	_	Seg=O
33	health	_	_	_	_	_	_	_	Seg=O
34	systems	_	_	_	_	_	_	_	Seg=O
35	in	_	_	_	_	_	_	_	Seg=O
36	developing	_	_	_	_	_	_	_	Seg=O
37	countries	_	_	_	_	_	_	_	Seg=O
38	are	_	_	_	_	_	_	_	Seg=O
39	underfunded	_	_	_	_	_	_	_	Seg=O
40	,	_	_	_	_	_	_	_	Seg=O
41	understaffed	_	_	_	_	_	_	_	Seg=O
42	,	_	_	_	_	_	_	_	Seg=O
43	and	_	_	_	_	_	_	_	Seg=O
44	in	_	_	_	_	_	_	_	Seg=O
45	many	_	_	_	_	_	_	_	Seg=O
46	cases	_	_	_	_	_	_	_	Seg=O
47	struggling	_	_	_	_	_	_	_	Seg=O
48	to	_	_	_	_	_	_	_	Seg=O
49	deal	_	_	_	_	_	_	_	Seg=O
50	with	_	_	_	_	_	_	_	Seg=O
51	the	_	_	_	_	_	_	_	Seg=O
52	existing	_	_	_	_	_	_	_	Seg=O
53	burden	_	_	_	_	_	_	_	Seg=O
54	of	_	_	_	_	_	_	_	Seg=O
55	disease	_	_	_	_	_	_	_	Seg=O
56	.	_	_	_	_	_	_	_	Seg=O
57	As	_	_	_	_	_	_	_	Seg=B-seg
58	a	_	_	_	_	_	_	_	Seg=O
59	result	_	_	_	_	_	_	_	Seg=O
60	,	_	_	_	_	_	_	_	Seg=O
61	developed	_	_	_	_	_	_	_	Seg=O
62	countries	_	_	_	_	_	_	_	Seg=O
63	are	_	_	_	_	_	_	_	Seg=O
64	beginning	_	_	_	_	_	_	_	Seg=O
65	to	_	_	_	_	_	_	_	Seg=O
66	expand	_	_	_	_	_	_	_	Seg=O
67	assistance	_	_	_	_	_	_	_	Seg=O
68	for	_	_	_	_	_	_	_	Seg=O
69	emergency	_	_	_	_	_	_	_	Seg=O
70	preparedness	_	_	_	_	_	_	_	Seg=O
71	to	_	_	_	_	_	_	_	Seg=O
72	the	_	_	_	_	_	_	_	Seg=O
73	developing	_	_	_	_	_	_	_	Seg=O
74	world	_	_	_	_	_	_	_	Seg=O
75	.	_	_	_	_	_	_	_	Seg=O
76	Given	_	_	_	_	_	_	_	Seg=B-seg
77	developing	_	_	_	_	_	_	_	Seg=O
78-79	countries'	_	_	_	_	_	_	_	_
78	countries	_	_	_	_	_	_	_	Seg=O
79	'	_	_	_	_	_	_	_	Seg=O
80	weak	_	_	_	_	_	_	_	Seg=O
81	infrastructure	_	_	_	_	_	_	_	Seg=O
82	and	_	_	_	_	_	_	_	Seg=O
83	many	_	_	_	_	_	_	_	Seg=O
84	competing	_	_	_	_	_	_	_	Seg=O
85	public	_	_	_	_	_	_	_	Seg=O
86	health	_	_	_	_	_	_	_	Seg=O
87	priorities	_	_	_	_	_	_	_	Seg=O
88	,	_	_	_	_	_	_	_	Seg=O
89	it	_	_	_	_	_	_	_	Seg=B-seg
90	is	_	_	_	_	_	_	_	Seg=O
91	not	_	_	_	_	_	_	_	Seg=O
92	clear	_	_	_	_	_	_	_	Seg=O
93	how	_	_	_	_	_	_	_	Seg=O
94	to	_	_	_	_	_	_	_	Seg=O
95	best	_	_	_	_	_	_	_	Seg=O
96	direct	_	_	_	_	_	_	_	Seg=O
97	these	_	_	_	_	_	_	_	Seg=O
98	resources	_	_	_	_	_	_	_	Seg=O
99	.	_	_	_	_	_	_	_	Seg=O
100	Evidence	_	_	_	_	_	_	_	Seg=B-seg
101	from	_	_	_	_	_	_	_	Seg=O
102	the	_	_	_	_	_	_	_	Seg=O
103	U.S.	_	_	_	_	_	_	_	Seg=O
104	and	_	_	_	_	_	_	_	Seg=O
105	other	_	_	_	_	_	_	_	Seg=O
106	developed	_	_	_	_	_	_	_	Seg=O
107	countries	_	_	_	_	_	_	_	Seg=O
108	suggests	_	_	_	_	_	_	_	Seg=O
109	that	_	_	_	_	_	_	_	Seg=B-seg
110	some	_	_	_	_	_	_	_	Seg=O
111	investments	_	_	_	_	_	_	_	Seg=O
112	in	_	_	_	_	_	_	_	Seg=O
113	bioterror	_	_	_	_	_	_	_	Seg=O
114	and	_	_	_	_	_	_	_	Seg=O
115	pandemic	_	_	_	_	_	_	_	Seg=O
116	emergency	_	_	_	_	_	_	_	Seg=O
117	preparedness	_	_	_	_	_	_	_	Seg=O
118	,	_	_	_	_	_	_	_	Seg=O
119	although	_	_	_	_	_	_	_	Seg=B-seg
120	initially	_	_	_	_	_	_	_	Seg=O
121	implemented	_	_	_	_	_	_	_	Seg=O
122	as	_	_	_	_	_	_	_	Seg=O
123	vertical	_	_	_	_	_	_	_	Seg=O
124	programs	_	_	_	_	_	_	_	Seg=O
125	,	_	_	_	_	_	_	_	Seg=O
126	have	_	_	_	_	_	_	_	Seg=B-seg
127	the	_	_	_	_	_	_	_	Seg=O
128	potential	_	_	_	_	_	_	_	Seg=O
129	to	_	_	_	_	_	_	_	Seg=O
130	strengthen	_	_	_	_	_	_	_	Seg=O
131	the	_	_	_	_	_	_	_	Seg=O
132	general	_	_	_	_	_	_	_	Seg=O
133	public	_	_	_	_	_	_	_	Seg=O
134	health	_	_	_	_	_	_	_	Seg=O
135	infrastructure	_	_	_	_	_	_	_	Seg=O
136	.	_	_	_	_	_	_	_	Seg=O
137	This	_	_	_	_	_	_	_	Seg=B-seg
138	experience	_	_	_	_	_	_	_	Seg=O
139	may	_	_	_	_	_	_	_	Seg=O
140	hold	_	_	_	_	_	_	_	Seg=O
141	some	_	_	_	_	_	_	_	Seg=O
142	lessons	_	_	_	_	_	_	_	Seg=O
143	for	_	_	_	_	_	_	_	Seg=O
144	how	_	_	_	_	_	_	_	Seg=B-seg
145	global	_	_	_	_	_	_	_	Seg=O
146	funds	_	_	_	_	_	_	_	Seg=O
147	for	_	_	_	_	_	_	_	Seg=O
148	emergency	_	_	_	_	_	_	_	Seg=O
149	preparedness	_	_	_	_	_	_	_	Seg=O
150	could	_	_	_	_	_	_	_	Seg=O
151	be	_	_	_	_	_	_	_	Seg=O
152	invested	_	_	_	_	_	_	_	Seg=O
153	in	_	_	_	_	_	_	_	Seg=O
154	developing	_	_	_	_	_	_	_	Seg=O
155	countries	_	_	_	_	_	_	_	Seg=O
156	to	_	_	_	_	_	_	_	Seg=B-seg
157	support	_	_	_	_	_	_	_	Seg=O
158	struggling	_	_	_	_	_	_	_	Seg=O
159	public	_	_	_	_	_	_	_	Seg=O
160	health	_	_	_	_	_	_	_	Seg=O
161	systems	_	_	_	_	_	_	_	Seg=O
162	in	_	_	_	_	_	_	_	Seg=B-seg
163	responding	_	_	_	_	_	_	_	Seg=O
164	to	_	_	_	_	_	_	_	Seg=O
165	current	_	_	_	_	_	_	_	Seg=O
166	health	_	_	_	_	_	_	_	Seg=O
167	priorities	_	_	_	_	_	_	_	Seg=O
168	as	_	_	_	_	_	_	_	Seg=O
169	well	_	_	_	_	_	_	_	Seg=O
170	as	_	_	_	_	_	_	_	Seg=O
171	potential	_	_	_	_	_	_	_	Seg=O
172	future	_	_	_	_	_	_	_	Seg=O
173	public	_	_	_	_	_	_	_	Seg=O
174	health	_	_	_	_	_	_	_	Seg=O
175	threats	_	_	_	_	_	_	_	Seg=O
176	.	_	_	_	_	_	_	_	Seg=O
177	(	_	_	_	_	_	_	_	Seg=B-seg
178	Am	_	_	_	_	_	_	_	Seg=O
179	J	_	_	_	_	_	_	_	Seg=O
180	Prev	_	_	_	_	_	_	_	Seg=O
181	Med	_	_	_	_	_	_	_	Seg=O
182	2008;34(6):529	_	_	_	_	_	_	_	Seg=O
183	-534	_	_	_	_	_	_	_	Seg=O
184	)	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 03531faa11b00259bcee616d1e215af33ba66bb8
1	The	_	_	_	_	_	_	_	Seg=B-seg
2	analysis	_	_	_	_	_	_	_	Seg=O
3	of	_	_	_	_	_	_	_	Seg=O
4	26	_	_	_	_	_	_	_	Seg=O
5	longevity	_	_	_	_	_	_	_	Seg=O
6	curves	_	_	_	_	_	_	_	Seg=O
7	of	_	_	_	_	_	_	_	Seg=O
8	different	_	_	_	_	_	_	_	Seg=O
9	populations	_	_	_	_	_	_	_	Seg=O
10	of	_	_	_	_	_	_	_	Seg=O
11	inbred	_	_	_	_	_	_	_	Seg=O
12	(	_	_	_	_	_	_	_	Seg=O
13	Fischer	_	_	_	_	_	_	_	Seg=O
14	344	_	_	_	_	_	_	_	Seg=O
15	)	_	_	_	_	_	_	_	Seg=O
16	and	_	_	_	_	_	_	_	Seg=O
17	outbred	_	_	_	_	_	_	_	Seg=O
18	(	_	_	_	_	_	_	_	Seg=O
19	Sprague	_	_	_	_	_	_	_	Seg=O
20	-	_	_	_	_	_	_	_	Seg=O
21	Dawley	_	_	_	_	_	_	_	Seg=O
22	)	_	_	_	_	_	_	_	Seg=O
23	rats	_	_	_	_	_	_	_	Seg=O
24	highlighted	_	_	_	_	_	_	_	Seg=O
25	a	_	_	_	_	_	_	_	Seg=O
26	remarkable	_	_	_	_	_	_	_	Seg=O
27	betweenpopulations	_	_	_	_	_	_	_	Seg=O
28	variability	_	_	_	_	_	_	_	Seg=O
29	in	_	_	_	_	_	_	_	Seg=O
30	survival	_	_	_	_	_	_	_	Seg=O
31	parameters	_	_	_	_	_	_	_	Seg=O
32	.	_	_	_	_	_	_	_	Seg=O
33	This	_	_	_	_	_	_	_	Seg=B-seg
34	variability	_	_	_	_	_	_	_	Seg=O
35	is	_	_	_	_	_	_	_	Seg=O
36	independent	_	_	_	_	_	_	_	Seg=O
37	of	_	_	_	_	_	_	_	Seg=O
38	the	_	_	_	_	_	_	_	Seg=O
39	breeding	_	_	_	_	_	_	_	Seg=O
40	characteristics	_	_	_	_	_	_	_	Seg=O
41	of	_	_	_	_	_	_	_	Seg=O
42	the	_	_	_	_	_	_	_	Seg=O
43	strain	_	_	_	_	_	_	_	Seg=O
44	.	_	_	_	_	_	_	_	Seg=O
45	The	_	_	_	_	_	_	_	Seg=B-seg
46	two	_	_	_	_	_	_	_	Seg=O
47	strains	_	_	_	_	_	_	_	Seg=O
48	differed	_	_	_	_	_	_	_	Seg=O
49	in	_	_	_	_	_	_	_	Seg=O
50	the	_	_	_	_	_	_	_	Seg=O
51	slope	_	_	_	_	_	_	_	Seg=O
52	of	_	_	_	_	_	_	_	Seg=O
53	the	_	_	_	_	_	_	_	Seg=O
54	survival	_	_	_	_	_	_	_	Seg=O
55	curves	_	_	_	_	_	_	_	Seg=O
56	,	_	_	_	_	_	_	_	Seg=O
57	with	_	_	_	_	_	_	_	Seg=O
58	Fischer	_	_	_	_	_	_	_	Seg=O
59	344	_	_	_	_	_	_	_	Seg=O
60	rats	_	_	_	_	_	_	_	Seg=O
61	showing	_	_	_	_	_	_	_	Seg=B-seg
62	a	_	_	_	_	_	_	_	Seg=O
63	higher	_	_	_	_	_	_	_	Seg=O
64	survival	_	_	_	_	_	_	_	Seg=O
65	over	_	_	_	_	_	_	_	Seg=O
66	the	_	_	_	_	_	_	_	Seg=O
67	second	_	_	_	_	_	_	_	Seg=O
68	year	_	_	_	_	_	_	_	Seg=O
69	of	_	_	_	_	_	_	_	Seg=O
70	life	_	_	_	_	_	_	_	Seg=O
71	as	_	_	_	_	_	_	_	Seg=O
72	well	_	_	_	_	_	_	_	Seg=O
73	as	_	_	_	_	_	_	_	Seg=O
74	a	_	_	_	_	_	_	_	Seg=O
75	lower	_	_	_	_	_	_	_	Seg=O
76	interindividual	_	_	_	_	_	_	_	Seg=O
77	variability	_	_	_	_	_	_	_	Seg=O
78	.	_	_	_	_	_	_	_	Seg=O
79	A	_	_	_	_	_	_	_	Seg=B-seg
80	model	_	_	_	_	_	_	_	Seg=O
81	-	_	_	_	_	_	_	_	Seg=O
82	free	_	_	_	_	_	_	_	Seg=O
83	approach	_	_	_	_	_	_	_	Seg=O
84	based	_	_	_	_	_	_	_	Seg=B-seg
85	on	_	_	_	_	_	_	_	Seg=O
86	principal	_	_	_	_	_	_	_	Seg=O
87	component	_	_	_	_	_	_	_	Seg=O
88	analysis	_	_	_	_	_	_	_	Seg=O
89	allowed	_	_	_	_	_	_	_	Seg=B-seg
90	us	_	_	_	_	_	_	_	Seg=O
91	to	_	_	_	_	_	_	_	Seg=O
92	quantify	_	_	_	_	_	_	_	Seg=O
93	these	_	_	_	_	_	_	_	Seg=O
94	differences	_	_	_	_	_	_	_	Seg=O
95	and	_	_	_	_	_	_	_	Seg=O
96	to	_	_	_	_	_	_	_	Seg=O
97	highlight	_	_	_	_	_	_	_	Seg=O
98	some	_	_	_	_	_	_	_	Seg=O
99	limitations	_	_	_	_	_	_	_	Seg=O
100	of	_	_	_	_	_	_	_	Seg=O
101	the	_	_	_	_	_	_	_	Seg=O
102	classical	_	_	_	_	_	_	_	Seg=O
103	Gompertzian	_	_	_	_	_	_	_	Seg=O
104	approach	_	_	_	_	_	_	_	Seg=O
105	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 03706c8c363d9a1885deda1355c2874858dba87c
1	BACKGROUND	_	_	_	_	_	_	_	Seg=B-seg
2	:	_	_	_	_	_	_	_	Seg=O
3	In	_	_	_	_	_	_	_	Seg=B-seg
4	many	_	_	_	_	_	_	_	Seg=O
5	jurisdictions	_	_	_	_	_	_	_	Seg=O
6	public	_	_	_	_	_	_	_	Seg=O
7	health	_	_	_	_	_	_	_	Seg=O
8	authorities	_	_	_	_	_	_	_	Seg=O
9	have	_	_	_	_	_	_	_	Seg=O
10	implemented	_	_	_	_	_	_	_	Seg=O
11	travel	_	_	_	_	_	_	_	Seg=O
12	restrictions	_	_	_	_	_	_	_	Seg=O
13	to	_	_	_	_	_	_	_	Seg=B-seg
14	reduce	_	_	_	_	_	_	_	Seg=O
15	coronavirus	_	_	_	_	_	_	_	Seg=O
16	disease	_	_	_	_	_	_	_	Seg=O
17	2019	_	_	_	_	_	_	_	Seg=O
18	(	_	_	_	_	_	_	_	Seg=O
19	COVID-19	_	_	_	_	_	_	_	Seg=O
20	)	_	_	_	_	_	_	_	Seg=O
21	spread	_	_	_	_	_	_	_	Seg=O
22	.	_	_	_	_	_	_	_	Seg=O
23	Previous	_	_	_	_	_	_	_	Seg=B-seg
24	research	_	_	_	_	_	_	_	Seg=O
25	has	_	_	_	_	_	_	_	Seg=O
26	considered	_	_	_	_	_	_	_	Seg=O
27	the	_	_	_	_	_	_	_	Seg=O
28	impact	_	_	_	_	_	_	_	Seg=O
29	of	_	_	_	_	_	_	_	Seg=O
30	international	_	_	_	_	_	_	_	Seg=O
31	travel	_	_	_	_	_	_	_	Seg=O
32	restrictions	_	_	_	_	_	_	_	Seg=O
33	on	_	_	_	_	_	_	_	Seg=O
34	COVID-19	_	_	_	_	_	_	_	Seg=O
35	dynamics	_	_	_	_	_	_	_	Seg=O
36	,	_	_	_	_	_	_	_	Seg=O
37	but	_	_	_	_	_	_	_	Seg=B-seg
38	in	_	_	_	_	_	_	_	Seg=O
39	response	_	_	_	_	_	_	_	Seg=O
40	to	_	_	_	_	_	_	_	Seg=O
41	the	_	_	_	_	_	_	_	Seg=O
42	pandemic	_	_	_	_	_	_	_	Seg=O
43	,	_	_	_	_	_	_	_	Seg=O
44	policies	_	_	_	_	_	_	_	Seg=O
45	that	_	_	_	_	_	_	_	Seg=B-seg
46	restrict	_	_	_	_	_	_	_	Seg=O
47	travel	_	_	_	_	_	_	_	Seg=O
48	within	_	_	_	_	_	_	_	Seg=O
49	countries	_	_	_	_	_	_	_	Seg=O
50	have	_	_	_	_	_	_	_	Seg=B-seg
51	also	_	_	_	_	_	_	_	Seg=O
52	been	_	_	_	_	_	_	_	Seg=O
53	implemented	_	_	_	_	_	_	_	Seg=O
54	,	_	_	_	_	_	_	_	Seg=O
55	and	_	_	_	_	_	_	_	Seg=B-seg
56	the	_	_	_	_	_	_	_	Seg=O
57	impact	_	_	_	_	_	_	_	Seg=O
58	of	_	_	_	_	_	_	_	Seg=O
59	these	_	_	_	_	_	_	_	Seg=O
60	restrictions	_	_	_	_	_	_	_	Seg=O
61	is	_	_	_	_	_	_	_	Seg=O
62	less	_	_	_	_	_	_	_	Seg=O
63	well	_	_	_	_	_	_	_	Seg=O
64	studied	_	_	_	_	_	_	_	Seg=O
65	.	_	_	_	_	_	_	_	Seg=O
66	On	_	_	_	_	_	_	_	Seg=B-seg
67	May	_	_	_	_	_	_	_	Seg=O
68	4	_	_	_	_	_	_	_	Seg=O
69	th	_	_	_	_	_	_	_	Seg=O
70	,	_	_	_	_	_	_	_	Seg=O
71	2020	_	_	_	_	_	_	_	Seg=O
72	,	_	_	_	_	_	_	_	Seg=O
73	Newfoundland	_	_	_	_	_	_	_	Seg=O
74	and	_	_	_	_	_	_	_	Seg=O
75	Labrador	_	_	_	_	_	_	_	Seg=O
76	(	_	_	_	_	_	_	_	Seg=O
77	NL	_	_	_	_	_	_	_	Seg=O
78	)	_	_	_	_	_	_	_	Seg=O
79	implemented	_	_	_	_	_	_	_	Seg=O
80	travel	_	_	_	_	_	_	_	Seg=O
81	restrictions	_	_	_	_	_	_	_	Seg=O
82	such	_	_	_	_	_	_	_	Seg=B-seg
83	that	_	_	_	_	_	_	_	Seg=O
84	non	_	_	_	_	_	_	_	Seg=O
85	-	_	_	_	_	_	_	_	Seg=O
86	residents	_	_	_	_	_	_	_	Seg=O
87	were	_	_	_	_	_	_	_	Seg=O
88	required	_	_	_	_	_	_	_	Seg=O
89	to	_	_	_	_	_	_	_	Seg=O
90	have	_	_	_	_	_	_	_	Seg=O
91	exemptions	_	_	_	_	_	_	_	Seg=O
92	to	_	_	_	_	_	_	_	Seg=B-seg
93	enter	_	_	_	_	_	_	_	Seg=O
94	the	_	_	_	_	_	_	_	Seg=O
95	province	_	_	_	_	_	_	_	Seg=O
96	.	_	_	_	_	_	_	_	Seg=O
97	METHODS	_	_	_	_	_	_	_	Seg=B-seg
98	:	_	_	_	_	_	_	_	Seg=O
99	We	_	_	_	_	_	_	_	Seg=B-seg
100	fit	_	_	_	_	_	_	_	Seg=O
101	a	_	_	_	_	_	_	_	Seg=O
102	stochastic	_	_	_	_	_	_	_	Seg=O
103	epidemic	_	_	_	_	_	_	_	Seg=O
104	model	_	_	_	_	_	_	_	Seg=O
105	to	_	_	_	_	_	_	_	Seg=O
106	data	_	_	_	_	_	_	_	Seg=O
107	describing	_	_	_	_	_	_	_	Seg=B-seg
108	the	_	_	_	_	_	_	_	Seg=O
109	number	_	_	_	_	_	_	_	Seg=O
110	of	_	_	_	_	_	_	_	Seg=O
111	active	_	_	_	_	_	_	_	Seg=O
112	COVID-19	_	_	_	_	_	_	_	Seg=O
113	cases	_	_	_	_	_	_	_	Seg=O
114	in	_	_	_	_	_	_	_	Seg=O
115	NL	_	_	_	_	_	_	_	Seg=O
116	from	_	_	_	_	_	_	_	Seg=O
117	March	_	_	_	_	_	_	_	Seg=O
118	14	_	_	_	_	_	_	_	Seg=O
119	th	_	_	_	_	_	_	_	Seg=O
120	-May	_	_	_	_	_	_	_	Seg=O
121	4	_	_	_	_	_	_	_	Seg=O
122	th	_	_	_	_	_	_	_	Seg=O
123	.	_	_	_	_	_	_	_	Seg=O
124	We	_	_	_	_	_	_	_	Seg=B-seg
125	then	_	_	_	_	_	_	_	Seg=O
126	predicted	_	_	_	_	_	_	_	Seg=O
127	possible	_	_	_	_	_	_	_	Seg=O
128	outbreaks	_	_	_	_	_	_	_	Seg=O
129	over	_	_	_	_	_	_	_	Seg=O
130	the	_	_	_	_	_	_	_	Seg=O
131	9	_	_	_	_	_	_	_	Seg=O
132	weeks	_	_	_	_	_	_	_	Seg=O
133	subsequent	_	_	_	_	_	_	_	Seg=O
134	to	_	_	_	_	_	_	_	Seg=O
135	May	_	_	_	_	_	_	_	Seg=O
136	4	_	_	_	_	_	_	_	Seg=O
137	th	_	_	_	_	_	_	_	Seg=O
138	,	_	_	_	_	_	_	_	Seg=O
139	with	_	_	_	_	_	_	_	Seg=O
140	and	_	_	_	_	_	_	_	Seg=O
141	without	_	_	_	_	_	_	_	Seg=O
142	the	_	_	_	_	_	_	_	Seg=O
143	travel	_	_	_	_	_	_	_	Seg=O
144	restrictions	_	_	_	_	_	_	_	Seg=O
145	,	_	_	_	_	_	_	_	Seg=O
146	and	_	_	_	_	_	_	_	Seg=O
147	for	_	_	_	_	_	_	_	Seg=O
148	physical	_	_	_	_	_	_	_	Seg=O
149	distancing	_	_	_	_	_	_	_	Seg=O
150	scenarios	_	_	_	_	_	_	_	Seg=O
151	ranging	_	_	_	_	_	_	_	Seg=B-seg
152	from	_	_	_	_	_	_	_	Seg=O
153	a	_	_	_	_	_	_	_	Seg=O
154	40	_	_	_	_	_	_	_	Seg=O
155	%	_	_	_	_	_	_	_	Seg=O
156	to	_	_	_	_	_	_	_	Seg=O
157	70	_	_	_	_	_	_	_	Seg=O
158	%	_	_	_	_	_	_	_	Seg=O
159	reduction	_	_	_	_	_	_	_	Seg=O
160	in	_	_	_	_	_	_	_	Seg=O
161	the	_	_	_	_	_	_	_	Seg=O
162	daily	_	_	_	_	_	_	_	Seg=O
163	contact	_	_	_	_	_	_	_	Seg=O
164	rate	_	_	_	_	_	_	_	Seg=O
165	relative	_	_	_	_	_	_	_	Seg=O
166	to	_	_	_	_	_	_	_	Seg=O
167	pre	_	_	_	_	_	_	_	Seg=O
168	-	_	_	_	_	_	_	_	Seg=O
169	pandemic	_	_	_	_	_	_	_	Seg=O
170	levels	_	_	_	_	_	_	_	Seg=O
171	.	_	_	_	_	_	_	_	Seg=O
172	RESULTS	_	_	_	_	_	_	_	Seg=B-seg
173	:	_	_	_	_	_	_	_	Seg=O
174	We	_	_	_	_	_	_	_	Seg=B-seg
175	find	_	_	_	_	_	_	_	Seg=O
176	that	_	_	_	_	_	_	_	Seg=B-seg
177	the	_	_	_	_	_	_	_	Seg=O
178	mean	_	_	_	_	_	_	_	Seg=O
179	number	_	_	_	_	_	_	_	Seg=O
180	of	_	_	_	_	_	_	_	Seg=O
181	clinical	_	_	_	_	_	_	_	Seg=O
182	COVID-19	_	_	_	_	_	_	_	Seg=O
183	cases	_	_	_	_	_	_	_	Seg=O
184	would	_	_	_	_	_	_	_	Seg=O
185	have	_	_	_	_	_	_	_	Seg=O
186	been	_	_	_	_	_	_	_	Seg=O
187	12.4	_	_	_	_	_	_	_	Seg=O
188	times	_	_	_	_	_	_	_	Seg=O
189	higher	_	_	_	_	_	_	_	Seg=O
190	without	_	_	_	_	_	_	_	Seg=O
191	the	_	_	_	_	_	_	_	Seg=O
192	travel	_	_	_	_	_	_	_	Seg=O
193	restrictions	_	_	_	_	_	_	_	Seg=O
194	.	_	_	_	_	_	_	_	Seg=O
195	Furthermore	_	_	_	_	_	_	_	Seg=B-seg
196	,	_	_	_	_	_	_	_	Seg=O
197	without	_	_	_	_	_	_	_	Seg=O
198	the	_	_	_	_	_	_	_	Seg=O
199	travel	_	_	_	_	_	_	_	Seg=O
200	restrictions	_	_	_	_	_	_	_	Seg=O
201	there	_	_	_	_	_	_	_	Seg=O
202	is	_	_	_	_	_	_	_	Seg=O
203	a	_	_	_	_	_	_	_	Seg=O
204	substantial	_	_	_	_	_	_	_	Seg=O
205	risk	_	_	_	_	_	_	_	Seg=O
206	of	_	_	_	_	_	_	_	Seg=O
207	very	_	_	_	_	_	_	_	Seg=O
208	large	_	_	_	_	_	_	_	Seg=O
209	outbreaks	_	_	_	_	_	_	_	Seg=O
210	.	_	_	_	_	_	_	_	Seg=O
211	INTERPRETATION	_	_	_	_	_	_	_	Seg=B-seg
212	:	_	_	_	_	_	_	_	Seg=O
213	Using	_	_	_	_	_	_	_	Seg=B-seg
214	epidemic	_	_	_	_	_	_	_	Seg=O
215	modelling	_	_	_	_	_	_	_	Seg=O
216	,	_	_	_	_	_	_	_	Seg=O
217	we	_	_	_	_	_	_	_	Seg=B-seg
218	show	_	_	_	_	_	_	_	Seg=O
219	how	_	_	_	_	_	_	_	Seg=B-seg
220	the	_	_	_	_	_	_	_	Seg=O
221	NL	_	_	_	_	_	_	_	Seg=O
222	COVID-19	_	_	_	_	_	_	_	Seg=O
223	outbreak	_	_	_	_	_	_	_	Seg=O
224	could	_	_	_	_	_	_	_	Seg=O
225	have	_	_	_	_	_	_	_	Seg=O
226	unfolded	_	_	_	_	_	_	_	Seg=O
227	had	_	_	_	_	_	_	_	Seg=O
228	the	_	_	_	_	_	_	_	Seg=O
229	travel	_	_	_	_	_	_	_	Seg=O
230	restrictions	_	_	_	_	_	_	_	Seg=O
231	not	_	_	_	_	_	_	_	Seg=O
232	been	_	_	_	_	_	_	_	Seg=O
233	implemented	_	_	_	_	_	_	_	Seg=O
234	.	_	_	_	_	_	_	_	Seg=O
235	Both	_	_	_	_	_	_	_	Seg=B-seg
236	physical	_	_	_	_	_	_	_	Seg=O
237	distancing	_	_	_	_	_	_	_	Seg=O
238	and	_	_	_	_	_	_	_	Seg=O
239	travel	_	_	_	_	_	_	_	Seg=O
240	restrictions	_	_	_	_	_	_	_	Seg=O
241	affect	_	_	_	_	_	_	_	Seg=O
242	the	_	_	_	_	_	_	_	Seg=O
243	local	_	_	_	_	_	_	_	Seg=O
244	dynamics	_	_	_	_	_	_	_	Seg=O
245	of	_	_	_	_	_	_	_	Seg=O
246	the	_	_	_	_	_	_	_	Seg=O
247	epidemic	_	_	_	_	_	_	_	Seg=O
248	.	_	_	_	_	_	_	_	Seg=O
249	Our	_	_	_	_	_	_	_	Seg=B-seg
250	modelling	_	_	_	_	_	_	_	Seg=O
251	shows	_	_	_	_	_	_	_	Seg=O
252	that	_	_	_	_	_	_	_	Seg=B-seg
253	the	_	_	_	_	_	_	_	Seg=O
254	travel	_	_	_	_	_	_	_	Seg=O
255	restrictions	_	_	_	_	_	_	_	Seg=O
256	are	_	_	_	_	_	_	_	Seg=O
257	a	_	_	_	_	_	_	_	Seg=O
258	plausible	_	_	_	_	_	_	_	Seg=O
259	reason	_	_	_	_	_	_	_	Seg=O
260	why	_	_	_	_	_	_	_	Seg=B-seg
261	there	_	_	_	_	_	_	_	Seg=O
262	were	_	_	_	_	_	_	_	Seg=O
263	so	_	_	_	_	_	_	_	Seg=O
264	few	_	_	_	_	_	_	_	Seg=O
265	reported	_	_	_	_	_	_	_	Seg=O
266	COVID-19	_	_	_	_	_	_	_	Seg=O
267	cases	_	_	_	_	_	_	_	Seg=O
268	in	_	_	_	_	_	_	_	Seg=O
269	NL	_	_	_	_	_	_	_	Seg=O
270	in	_	_	_	_	_	_	_	Seg=O
271	the	_	_	_	_	_	_	_	Seg=O
272	9	_	_	_	_	_	_	_	Seg=O
273	weeks	_	_	_	_	_	_	_	Seg=O
274	after	_	_	_	_	_	_	_	Seg=O
275	May	_	_	_	_	_	_	_	Seg=O
276	4	_	_	_	_	_	_	_	Seg=O
277	th	_	_	_	_	_	_	_	Seg=O
278	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 04863be13c7778ac3779da61eba8b49a510d9f40
1	Case	_	_	_	_	_	_	_	Seg=B-seg
2	isolation	_	_	_	_	_	_	_	Seg=O
3	and	_	_	_	_	_	_	_	Seg=O
4	contact	_	_	_	_	_	_	_	Seg=O
5	tracing	_	_	_	_	_	_	_	Seg=O
6	can	_	_	_	_	_	_	_	Seg=O
7	contribute	_	_	_	_	_	_	_	Seg=O
8	to	_	_	_	_	_	_	_	Seg=O
9	the	_	_	_	_	_	_	_	Seg=O
10	control	_	_	_	_	_	_	_	Seg=O
11	of	_	_	_	_	_	_	_	Seg=O
12	COVID-19	_	_	_	_	_	_	_	Seg=O
13	outbreaks	_	_	_	_	_	_	_	Seg=O
14	.	_	_	_	_	_	_	_	Seg=O
15	However	_	_	_	_	_	_	_	Seg=B-seg
16	,	_	_	_	_	_	_	_	Seg=O
17	it	_	_	_	_	_	_	_	Seg=O
18	remains	_	_	_	_	_	_	_	Seg=O
19	unclear	_	_	_	_	_	_	_	Seg=O
20	how	_	_	_	_	_	_	_	Seg=O
21	real	_	_	_	_	_	_	_	Seg=O
22	-	_	_	_	_	_	_	_	Seg=O
23	world	_	_	_	_	_	_	_	Seg=O
24	networks	_	_	_	_	_	_	_	Seg=O
25	could	_	_	_	_	_	_	_	Seg=O
26	influence	_	_	_	_	_	_	_	Seg=O
27	the	_	_	_	_	_	_	_	Seg=O
28	effectiveness	_	_	_	_	_	_	_	Seg=O
29	and	_	_	_	_	_	_	_	Seg=O
30	efficiency	_	_	_	_	_	_	_	Seg=O
31	of	_	_	_	_	_	_	_	Seg=O
32	such	_	_	_	_	_	_	_	Seg=O
33	approaches	_	_	_	_	_	_	_	Seg=O
34	.	_	_	_	_	_	_	_	Seg=O
35	To	_	_	_	_	_	_	_	Seg=B-seg
36	address	_	_	_	_	_	_	_	Seg=O
37	this	_	_	_	_	_	_	_	Seg=O
38	issue	_	_	_	_	_	_	_	Seg=O
39	,	_	_	_	_	_	_	_	Seg=O
40	we	_	_	_	_	_	_	_	Seg=B-seg
41	simulated	_	_	_	_	_	_	_	Seg=O
42	control	_	_	_	_	_	_	_	Seg=O
43	strategies	_	_	_	_	_	_	_	Seg=O
44	for	_	_	_	_	_	_	_	Seg=O
45	SARS	_	_	_	_	_	_	_	Seg=O
46	-	_	_	_	_	_	_	_	Seg=O
47	CoV-2	_	_	_	_	_	_	_	Seg=O
48	in	_	_	_	_	_	_	_	Seg=O
49	a	_	_	_	_	_	_	_	Seg=O
50	real	_	_	_	_	_	_	_	Seg=O
51	-	_	_	_	_	_	_	_	Seg=O
52	world	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 05fd3c2c2f6d9d9101d3007cecdf5cfd472de515
1	Recently	_	_	_	_	_	_	_	Seg=B-seg
2	,	_	_	_	_	_	_	_	Seg=O
3	the	_	_	_	_	_	_	_	Seg=O
4	popularity	_	_	_	_	_	_	_	Seg=O
5	of	_	_	_	_	_	_	_	Seg=O
6	smart	_	_	_	_	_	_	_	Seg=O
7	wearable	_	_	_	_	_	_	_	Seg=O
8	technologies	_	_	_	_	_	_	_	Seg=O
9	,	_	_	_	_	_	_	_	Seg=O
10	such	_	_	_	_	_	_	_	Seg=B-seg
11	as	_	_	_	_	_	_	_	Seg=O
12	Fitbit	_	_	_	_	_	_	_	Seg=O
13	,	_	_	_	_	_	_	_	Seg=O
14	has	_	_	_	_	_	_	_	Seg=B-seg
15	significantly	_	_	_	_	_	_	_	Seg=O
16	increased	_	_	_	_	_	_	_	Seg=O
17	.	_	_	_	_	_	_	_	Seg=O
18	There	_	_	_	_	_	_	_	Seg=B-seg
19	are	_	_	_	_	_	_	_	Seg=O
20	numerous	_	_	_	_	_	_	_	Seg=O
21	potential	_	_	_	_	_	_	_	Seg=O
22	benefits	_	_	_	_	_	_	_	Seg=O
23	in	_	_	_	_	_	_	_	Seg=B-seg
24	using	_	_	_	_	_	_	_	Seg=O
25	these	_	_	_	_	_	_	_	Seg=O
26	devices	_	_	_	_	_	_	_	Seg=O
27	,	_	_	_	_	_	_	_	Seg=O
28	especially	_	_	_	_	_	_	_	Seg=B-seg
29	among	_	_	_	_	_	_	_	Seg=O
30	seniors	_	_	_	_	_	_	_	Seg=O
31	.	_	_	_	_	_	_	_	Seg=O
32	Yet	_	_	_	_	_	_	_	Seg=B-seg
33	,	_	_	_	_	_	_	_	Seg=O
34	little	_	_	_	_	_	_	_	Seg=O
35	is	_	_	_	_	_	_	_	Seg=O
36	known	_	_	_	_	_	_	_	Seg=O
37	about	_	_	_	_	_	_	_	Seg=O
38-39	seniors'	_	_	_	_	_	_	_	_
38	seniors	_	_	_	_	_	_	_	Seg=O
39	'	_	_	_	_	_	_	_	Seg=O
40	adoption	_	_	_	_	_	_	_	Seg=O
41	behavior	_	_	_	_	_	_	_	Seg=O
42	.	_	_	_	_	_	_	_	Seg=O
43	Through	_	_	_	_	_	_	_	Seg=B-seg
44	a	_	_	_	_	_	_	_	Seg=O
45	mixed	_	_	_	_	_	_	_	Seg=O
46	-	_	_	_	_	_	_	_	Seg=O
47	methods	_	_	_	_	_	_	_	Seg=O
48	approach	_	_	_	_	_	_	_	Seg=O
49	,	_	_	_	_	_	_	_	Seg=O
50	this	_	_	_	_	_	_	_	Seg=O
51	study	_	_	_	_	_	_	_	Seg=O
52	investigates	_	_	_	_	_	_	_	Seg=O
53	the	_	_	_	_	_	_	_	Seg=O
54	factors	_	_	_	_	_	_	_	Seg=O
55	that	_	_	_	_	_	_	_	Seg=B-seg
56	impact	_	_	_	_	_	_	_	Seg=O
57-58	seniors'	_	_	_	_	_	_	_	_
57	seniors	_	_	_	_	_	_	_	Seg=O
58	'	_	_	_	_	_	_	_	Seg=O
59	intention	_	_	_	_	_	_	_	Seg=O
60	to	_	_	_	_	_	_	_	Seg=B-seg
61	use	_	_	_	_	_	_	_	Seg=O
62	wearable	_	_	_	_	_	_	_	Seg=O
63	devices	_	_	_	_	_	_	_	Seg=O
64	.	_	_	_	_	_	_	_	Seg=O
65	Results	_	_	_	_	_	_	_	Seg=B-seg
66	from	_	_	_	_	_	_	_	Seg=O
67	an	_	_	_	_	_	_	_	Seg=O
68	online	_	_	_	_	_	_	_	Seg=O
69	survey	_	_	_	_	_	_	_	Seg=O
70	and	_	_	_	_	_	_	_	Seg=O
71	interviews	_	_	_	_	_	_	_	Seg=O
72	showed	_	_	_	_	_	_	_	Seg=O
73	that	_	_	_	_	_	_	_	Seg=B-seg
74-75	seniors'	_	_	_	_	_	_	_	_
74	seniors	_	_	_	_	_	_	_	Seg=O
75	'	_	_	_	_	_	_	_	Seg=O
76	perception	_	_	_	_	_	_	_	Seg=O
77	of	_	_	_	_	_	_	_	Seg=O
78	the	_	_	_	_	_	_	_	Seg=O
79	complexity	_	_	_	_	_	_	_	Seg=O
80	of	_	_	_	_	_	_	_	Seg=B-seg
81	working	_	_	_	_	_	_	_	Seg=O
82	with	_	_	_	_	_	_	_	Seg=O
83	these	_	_	_	_	_	_	_	Seg=O
84	devices	_	_	_	_	_	_	_	Seg=O
85	is	_	_	_	_	_	_	_	Seg=B-seg
86	a	_	_	_	_	_	_	_	Seg=O
87	barrier	_	_	_	_	_	_	_	Seg=O
88	to	_	_	_	_	_	_	_	Seg=O
89	their	_	_	_	_	_	_	_	Seg=O
90	adoption	_	_	_	_	_	_	_	Seg=O
91	decisions	_	_	_	_	_	_	_	Seg=O
92	.	_	_	_	_	_	_	_	Seg=O
93	Looking	_	_	_	_	_	_	_	Seg=B-seg
94	more	_	_	_	_	_	_	_	Seg=O
95	deeply	_	_	_	_	_	_	_	Seg=O
96	into	_	_	_	_	_	_	_	Seg=O
97	the	_	_	_	_	_	_	_	Seg=O
98	role	_	_	_	_	_	_	_	Seg=O
99	of	_	_	_	_	_	_	_	Seg=O
100	complexity	_	_	_	_	_	_	_	Seg=O
101	revealed	_	_	_	_	_	_	_	Seg=O
102	that	_	_	_	_	_	_	_	Seg=B-seg
103-104	seniors'	_	_	_	_	_	_	_	_
103	seniors	_	_	_	_	_	_	_	Seg=O
104	'	_	_	_	_	_	_	_	Seg=O
105	concern	_	_	_	_	_	_	_	Seg=O
106	about	_	_	_	_	_	_	_	Seg=O
107	the	_	_	_	_	_	_	_	Seg=O
108	complexity	_	_	_	_	_	_	_	Seg=O
109	of	_	_	_	_	_	_	_	Seg=B-seg
110	reading	_	_	_	_	_	_	_	Seg=O
111	and	_	_	_	_	_	_	_	Seg=O
112	interpreting	_	_	_	_	_	_	_	Seg=O
113	the	_	_	_	_	_	_	_	Seg=O
114	output	_	_	_	_	_	_	_	Seg=O
115	of	_	_	_	_	_	_	_	Seg=O
116	wearable	_	_	_	_	_	_	_	Seg=O
117	devices	_	_	_	_	_	_	_	Seg=O
118	is	_	_	_	_	_	_	_	Seg=B-seg
119	the	_	_	_	_	_	_	_	Seg=O
120	main	_	_	_	_	_	_	_	Seg=O
121	deterring	_	_	_	_	_	_	_	Seg=O
122	element	_	_	_	_	_	_	_	Seg=O
123	.	_	_	_	_	_	_	_	Seg=O
124	Furthermore	_	_	_	_	_	_	_	Seg=B-seg
125	,	_	_	_	_	_	_	_	Seg=O
126	we	_	_	_	_	_	_	_	Seg=O
127	explored	_	_	_	_	_	_	_	Seg=O
128	the	_	_	_	_	_	_	_	Seg=O
129	role	_	_	_	_	_	_	_	Seg=O
130	of	_	_	_	_	_	_	_	Seg=O
131	two	_	_	_	_	_	_	_	Seg=O
132	important	_	_	_	_	_	_	_	Seg=O
133	elements	_	_	_	_	_	_	_	Seg=O
134	:	_	_	_	_	_	_	_	Seg=O
135-136	seniors'	_	_	_	_	_	_	_	_
135	seniors	_	_	_	_	_	_	_	Seg=B-seg
136	'	_	_	_	_	_	_	_	Seg=O
137	cognitive	_	_	_	_	_	_	_	Seg=O
138	age	_	_	_	_	_	_	_	Seg=O
139	,	_	_	_	_	_	_	_	Seg=O
140	and	_	_	_	_	_	_	_	Seg=O
141	the	_	_	_	_	_	_	_	Seg=O
142	influence	_	_	_	_	_	_	_	Seg=O
143	of	_	_	_	_	_	_	_	Seg=O
144	their	_	_	_	_	_	_	_	Seg=O
145	subjective	_	_	_	_	_	_	_	Seg=O
146	well	_	_	_	_	_	_	_	Seg=O
147	-	_	_	_	_	_	_	_	Seg=O
148	being	_	_	_	_	_	_	_	Seg=O
149	on	_	_	_	_	_	_	_	Seg=O
150	their	_	_	_	_	_	_	_	Seg=O
151	adoption	_	_	_	_	_	_	_	Seg=O
152	behavior	_	_	_	_	_	_	_	Seg=O
153	.	_	_	_	_	_	_	_	Seg=O
154	Results	_	_	_	_	_	_	_	Seg=B-seg
155	demonstrated	_	_	_	_	_	_	_	Seg=O
156	that	_	_	_	_	_	_	_	Seg=B-seg
157	cognitive	_	_	_	_	_	_	_	Seg=O
158	age	_	_	_	_	_	_	_	Seg=O
159	does	_	_	_	_	_	_	_	Seg=O
160	not	_	_	_	_	_	_	_	Seg=O
161	significantly	_	_	_	_	_	_	_	Seg=O
162	impact	_	_	_	_	_	_	_	Seg=O
163	use	_	_	_	_	_	_	_	Seg=O
164	intention	_	_	_	_	_	_	_	Seg=O
165	by	_	_	_	_	_	_	_	Seg=O
166	itself	_	_	_	_	_	_	_	Seg=O
167	;	_	_	_	_	_	_	_	Seg=O
168	nonetheless	_	_	_	_	_	_	_	Seg=B-seg
169	,	_	_	_	_	_	_	_	Seg=O
170	subjective	_	_	_	_	_	_	_	Seg=O
171	wellbeing	_	_	_	_	_	_	_	Seg=O
172	moderates	_	_	_	_	_	_	_	Seg=O
173	its	_	_	_	_	_	_	_	Seg=O
174	effect	_	_	_	_	_	_	_	Seg=O
175	.	_	_	_	_	_	_	_	Seg=O
176	This	_	_	_	_	_	_	_	Seg=B-seg
177	result	_	_	_	_	_	_	_	Seg=O
178	revealed	_	_	_	_	_	_	_	Seg=O
179	an	_	_	_	_	_	_	_	Seg=O
180	interesting	_	_	_	_	_	_	_	Seg=O
181	finding	_	_	_	_	_	_	_	Seg=O
182	,	_	_	_	_	_	_	_	Seg=O
183	which	_	_	_	_	_	_	_	Seg=B-seg
184	is	_	_	_	_	_	_	_	Seg=O
185	that	_	_	_	_	_	_	_	Seg=O
186	the	_	_	_	_	_	_	_	Seg=O
187	influence	_	_	_	_	_	_	_	Seg=O
188	of	_	_	_	_	_	_	_	Seg=O
189	cognitive	_	_	_	_	_	_	_	Seg=O
190	age	_	_	_	_	_	_	_	Seg=O
191	on	_	_	_	_	_	_	_	Seg=O
192-193	seniors'	_	_	_	_	_	_	_	_
192	seniors	_	_	_	_	_	_	_	Seg=O
193	'	_	_	_	_	_	_	_	Seg=O
194	use	_	_	_	_	_	_	_	Seg=O
195	intention	_	_	_	_	_	_	_	Seg=O
196	depends	_	_	_	_	_	_	_	Seg=O
197	on	_	_	_	_	_	_	_	Seg=O
198-199	seniors'	_	_	_	_	_	_	_	_
198	seniors	_	_	_	_	_	_	_	Seg=O
199	'	_	_	_	_	_	_	_	Seg=O
200	level	_	_	_	_	_	_	_	Seg=O
201	of	_	_	_	_	_	_	_	Seg=O
202	subjective	_	_	_	_	_	_	_	Seg=O
203	well	_	_	_	_	_	_	_	Seg=O
204	-	_	_	_	_	_	_	_	Seg=O
205	being	_	_	_	_	_	_	_	Seg=O
206	.	_	_	_	_	_	_	_	Seg=O
207	When	_	_	_	_	_	_	_	Seg=B-seg
208-209	seniors'	_	_	_	_	_	_	_	_
208	seniors	_	_	_	_	_	_	_	Seg=O
209	'	_	_	_	_	_	_	_	Seg=O
210	subjective	_	_	_	_	_	_	_	Seg=O
211	well	_	_	_	_	_	_	_	Seg=O
212	-	_	_	_	_	_	_	_	Seg=O
213	being	_	_	_	_	_	_	_	Seg=O
214	is	_	_	_	_	_	_	_	Seg=O
215	low	_	_	_	_	_	_	_	Seg=O
216	,	_	_	_	_	_	_	_	Seg=O
217	surprisingly	_	_	_	_	_	_	_	Seg=B-seg
218	,	_	_	_	_	_	_	_	Seg=O
219	cognitive	_	_	_	_	_	_	_	Seg=O
220	age	_	_	_	_	_	_	_	Seg=O
221	increases	_	_	_	_	_	_	_	Seg=O
222-223	seniors'	_	_	_	_	_	_	_	_
222	seniors	_	_	_	_	_	_	_	Seg=O
223	'	_	_	_	_	_	_	_	Seg=O
224	intention	_	_	_	_	_	_	_	Seg=O
225	to	_	_	_	_	_	_	_	Seg=B-seg
226	use	_	_	_	_	_	_	_	Seg=O
227	the	_	_	_	_	_	_	_	Seg=O
228	device	_	_	_	_	_	_	_	Seg=O
229	.	_	_	_	_	_	_	_	Seg=O
230	These	_	_	_	_	_	_	_	Seg=B-seg
231	findings	_	_	_	_	_	_	_	Seg=O
232	provide	_	_	_	_	_	_	_	Seg=O
233	interesting	_	_	_	_	_	_	_	Seg=O
234	implications	_	_	_	_	_	_	_	Seg=O
235	for	_	_	_	_	_	_	_	Seg=O
236	practice	_	_	_	_	_	_	_	Seg=O
237	and	_	_	_	_	_	_	_	Seg=O
238	future	_	_	_	_	_	_	_	Seg=O
239	research	_	_	_	_	_	_	_	Seg=O
240	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 066178ded1d6d540be366e6468bc01e78e605a81
1	Genotyping	_	_	_	_	_	_	_	Seg=B-seg
2	of	_	_	_	_	_	_	_	Seg=O
3	avian	_	_	_	_	_	_	_	Seg=O
4	infectious	_	_	_	_	_	_	_	Seg=O
5	bronchitis	_	_	_	_	_	_	_	Seg=O
6	virus	_	_	_	_	_	_	_	Seg=O
7	(	_	_	_	_	_	_	_	Seg=O
8	IBV	_	_	_	_	_	_	_	Seg=O
9	)	_	_	_	_	_	_	_	Seg=O
10	was	_	_	_	_	_	_	_	Seg=O
11	performed	_	_	_	_	_	_	_	Seg=O
12	on	_	_	_	_	_	_	_	Seg=O
13	trachea	_	_	_	_	_	_	_	Seg=O
14	and	_	_	_	_	_	_	_	Seg=O
15	kidney	_	_	_	_	_	_	_	Seg=O
16	samples	_	_	_	_	_	_	_	Seg=O
17	of	_	_	_	_	_	_	_	Seg=O
18	six	_	_	_	_	_	_	_	Seg=O
19	chickens	_	_	_	_	_	_	_	Seg=O
20	obtained	_	_	_	_	_	_	_	Seg=B-seg
21	from	_	_	_	_	_	_	_	Seg=O
22	a	_	_	_	_	_	_	_	Seg=O
23	single	_	_	_	_	_	_	_	Seg=O
24	farm	_	_	_	_	_	_	_	Seg=O
25	in	_	_	_	_	_	_	_	Seg=O
26	Japan	_	_	_	_	_	_	_	Seg=O
27	.	_	_	_	_	_	_	_	Seg=O
28	Using	_	_	_	_	_	_	_	Seg=B-seg
29	two	_	_	_	_	_	_	_	Seg=O
30	primer	_	_	_	_	_	_	_	Seg=O
31	sets	_	_	_	_	_	_	_	Seg=O
32	targeting	_	_	_	_	_	_	_	Seg=B-seg
33	the	_	_	_	_	_	_	_	Seg=O
34	spike	_	_	_	_	_	_	_	Seg=O
35	(	_	_	_	_	_	_	_	Seg=O
36	S	_	_	_	_	_	_	_	Seg=O
37	)	_	_	_	_	_	_	_	Seg=O
38	protein	_	_	_	_	_	_	_	Seg=O
39	gene	_	_	_	_	_	_	_	Seg=O
40	,	_	_	_	_	_	_	_	Seg=O
41	the	_	_	_	_	_	_	_	Seg=B-seg
42	S1	_	_	_	_	_	_	_	Seg=O
43	and	_	_	_	_	_	_	_	Seg=O
44	S2	_	_	_	_	_	_	_	Seg=O
45	regions	_	_	_	_	_	_	_	Seg=O
46	of	_	_	_	_	_	_	_	Seg=O
47	DNA	_	_	_	_	_	_	_	Seg=O
48	fragments	_	_	_	_	_	_	_	Seg=O
49	were	_	_	_	_	_	_	_	Seg=O
50	amplified	_	_	_	_	_	_	_	Seg=O
51	.	_	_	_	_	_	_	_	Seg=O
52	Sequences	_	_	_	_	_	_	_	Seg=B-seg
53	of	_	_	_	_	_	_	_	Seg=O
54	amplified	_	_	_	_	_	_	_	Seg=O
55	S1	_	_	_	_	_	_	_	Seg=O
56	fragments	_	_	_	_	_	_	_	Seg=O
57	extracted	_	_	_	_	_	_	_	Seg=B-seg
58	from	_	_	_	_	_	_	_	Seg=O
59	both	_	_	_	_	_	_	_	Seg=O
60	organs	_	_	_	_	_	_	_	Seg=O
61	were	_	_	_	_	_	_	_	Seg=B-seg
62	identical	_	_	_	_	_	_	_	Seg=O
63	among	_	_	_	_	_	_	_	Seg=O
64	the	_	_	_	_	_	_	_	Seg=O
65	six	_	_	_	_	_	_	_	Seg=O
66	chickens	_	_	_	_	_	_	_	Seg=O
67	,	_	_	_	_	_	_	_	Seg=O
68	showing	_	_	_	_	_	_	_	Seg=B-seg
69	a	_	_	_	_	_	_	_	Seg=O
70	JP	_	_	_	_	_	_	_	Seg=O
71	-	_	_	_	_	_	_	_	Seg=O
72	I	_	_	_	_	_	_	_	Seg=O
73	genotype	_	_	_	_	_	_	_	Seg=O
74	.	_	_	_	_	_	_	_	Seg=O
75	Sequences	_	_	_	_	_	_	_	Seg=B-seg
76	of	_	_	_	_	_	_	_	Seg=O
77	amplified	_	_	_	_	_	_	_	Seg=O
78	S2	_	_	_	_	_	_	_	Seg=O
79	fragments	_	_	_	_	_	_	_	Seg=O
80	differed	_	_	_	_	_	_	_	Seg=O
81	between	_	_	_	_	_	_	_	Seg=O
82	trachea	_	_	_	_	_	_	_	Seg=O
83	and	_	_	_	_	_	_	_	Seg=O
84	kidney	_	_	_	_	_	_	_	Seg=O
85	samples	_	_	_	_	_	_	_	Seg=O
86	.	_	_	_	_	_	_	_	Seg=O
87	The	_	_	_	_	_	_	_	Seg=B-seg
88	kidney	_	_	_	_	_	_	_	Seg=O
89	profile	_	_	_	_	_	_	_	Seg=O
90	showed	_	_	_	_	_	_	_	Seg=O
91	a	_	_	_	_	_	_	_	Seg=O
92	group	_	_	_	_	_	_	_	Seg=O
93	IV	_	_	_	_	_	_	_	Seg=O
94	genotype	_	_	_	_	_	_	_	Seg=O
95	,	_	_	_	_	_	_	_	Seg=O
96	whereas	_	_	_	_	_	_	_	Seg=B-seg
97	the	_	_	_	_	_	_	_	Seg=O
98	trachea	_	_	_	_	_	_	_	Seg=O
99	profile	_	_	_	_	_	_	_	Seg=O
100	showed	_	_	_	_	_	_	_	Seg=O
101	an	_	_	_	_	_	_	_	Seg=O
102	unclassified	_	_	_	_	_	_	_	Seg=O
103	group	_	_	_	_	_	_	_	Seg=O
104	.	_	_	_	_	_	_	_	Seg=O
105	This	_	_	_	_	_	_	_	Seg=B-seg
106	result	_	_	_	_	_	_	_	Seg=O
107	showed	_	_	_	_	_	_	_	Seg=O
108	that	_	_	_	_	_	_	_	Seg=B-seg
109	two	_	_	_	_	_	_	_	Seg=O
110	different	_	_	_	_	_	_	_	Seg=O
111	IBVs	_	_	_	_	_	_	_	Seg=O
112	infected	_	_	_	_	_	_	_	Seg=O
113	the	_	_	_	_	_	_	_	Seg=O
114	six	_	_	_	_	_	_	_	Seg=O
115	chickens	_	_	_	_	_	_	_	Seg=O
116	.	_	_	_	_	_	_	_	Seg=O
117	The	_	_	_	_	_	_	_	Seg=B-seg
118	first	_	_	_	_	_	_	_	Seg=O
119	IBV	_	_	_	_	_	_	_	Seg=O
120	infection	_	_	_	_	_	_	_	Seg=O
121	induced	_	_	_	_	_	_	_	Seg=O
122	poor	_	_	_	_	_	_	_	Seg=O
123	protective	_	_	_	_	_	_	_	Seg=O
124	immunity	_	_	_	_	_	_	_	Seg=O
125	in	_	_	_	_	_	_	_	Seg=O
126	this	_	_	_	_	_	_	_	Seg=O
127	farm	_	_	_	_	_	_	_	Seg=O
128	,	_	_	_	_	_	_	_	Seg=O
129	permitting	_	_	_	_	_	_	_	Seg=B-seg
130	a	_	_	_	_	_	_	_	Seg=O
131	second	_	_	_	_	_	_	_	Seg=O
132	IBV	_	_	_	_	_	_	_	Seg=O
133	infection	_	_	_	_	_	_	_	Seg=O
134	to	_	_	_	_	_	_	_	Seg=O
135	occur	_	_	_	_	_	_	_	Seg=O
136	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 08792e906a1020ea71007183b91e581d378a9261
1	In	_	_	_	_	_	_	_	Seg=B-seg
2	the	_	_	_	_	_	_	_	Seg=O
3	time	_	_	_	_	_	_	_	Seg=O
4	of	_	_	_	_	_	_	_	Seg=O
5	COVID-19	_	_	_	_	_	_	_	Seg=O
6	epidemic	_	_	_	_	_	_	_	Seg=O
7	,	_	_	_	_	_	_	_	Seg=O
8	Italy	_	_	_	_	_	_	_	Seg=O
9	was	_	_	_	_	_	_	_	Seg=O
10	found	_	_	_	_	_	_	_	Seg=O
11	unprepared	_	_	_	_	_	_	_	Seg=O
12	to	_	_	_	_	_	_	_	Seg=O
13	manage	_	_	_	_	_	_	_	Seg=O
14	lockdown	_	_	_	_	_	_	_	Seg=O
15	patients	_	_	_	_	_	_	_	Seg=O
16	with	_	_	_	_	_	_	_	Seg=O
17	chronic	_	_	_	_	_	_	_	Seg=O
18	diseases	_	_	_	_	_	_	_	Seg=O
19	,	_	_	_	_	_	_	_	Seg=O
20	due	_	_	_	_	_	_	_	Seg=B-seg
21	to	_	_	_	_	_	_	_	Seg=O
22	limited	_	_	_	_	_	_	_	Seg=O
23	availability	_	_	_	_	_	_	_	Seg=O
24	and	_	_	_	_	_	_	_	Seg=O
25	diffusion	_	_	_	_	_	_	_	Seg=O
26	of	_	_	_	_	_	_	_	Seg=O
27	large	_	_	_	_	_	_	_	Seg=O
28	-	_	_	_	_	_	_	_	Seg=O
29	scale	_	_	_	_	_	_	_	Seg=O
30	telemedicine	_	_	_	_	_	_	_	Seg=O
31	solutions	_	_	_	_	_	_	_	Seg=O
32	.	_	_	_	_	_	_	_	Seg=O
33	The	_	_	_	_	_	_	_	Seg=B-seg
34	scattered	_	_	_	_	_	_	_	Seg=O
35	distribution	_	_	_	_	_	_	_	Seg=O
36	and	_	_	_	_	_	_	_	Seg=O
37	heterogeneity	_	_	_	_	_	_	_	Seg=O
38	of	_	_	_	_	_	_	_	Seg=O
39	available	_	_	_	_	_	_	_	Seg=O
40	tools	_	_	_	_	_	_	_	Seg=O
41	,	_	_	_	_	_	_	_	Seg=O
42	the	_	_	_	_	_	_	_	Seg=O
43	lack	_	_	_	_	_	_	_	Seg=O
44	of	_	_	_	_	_	_	_	Seg=O
45	integration	_	_	_	_	_	_	_	Seg=O
46	with	_	_	_	_	_	_	_	Seg=O
47	the	_	_	_	_	_	_	_	Seg=O
48	electronic	_	_	_	_	_	_	_	Seg=O
49	health	_	_	_	_	_	_	_	Seg=O
50	record	_	_	_	_	_	_	_	Seg=O
51	of	_	_	_	_	_	_	_	Seg=O
52	the	_	_	_	_	_	_	_	Seg=O
53	national	_	_	_	_	_	_	_	Seg=O
54	health	_	_	_	_	_	_	_	Seg=O
55	system	_	_	_	_	_	_	_	Seg=O
56	,	_	_	_	_	_	_	_	Seg=O
57	the	_	_	_	_	_	_	_	Seg=O
58	poor	_	_	_	_	_	_	_	Seg=O
59	interconnection	_	_	_	_	_	_	_	Seg=O
60	between	_	_	_	_	_	_	_	Seg=O
61	telemedicine	_	_	_	_	_	_	_	Seg=O
62	services	_	_	_	_	_	_	_	Seg=O
63	operating	_	_	_	_	_	_	_	Seg=B-seg
64	at	_	_	_	_	_	_	_	Seg=O
65	different	_	_	_	_	_	_	_	Seg=O
66	levels	_	_	_	_	_	_	_	Seg=O
67	,	_	_	_	_	_	_	_	Seg=O
68	the	_	_	_	_	_	_	_	Seg=B-seg
69	lack	_	_	_	_	_	_	_	Seg=O
70	of	_	_	_	_	_	_	_	Seg=O
71	a	_	_	_	_	_	_	_	Seg=O
72	real	_	_	_	_	_	_	_	Seg=O
73	multidisciplinary	_	_	_	_	_	_	_	Seg=O
74	approach	_	_	_	_	_	_	_	Seg=O
75	to	_	_	_	_	_	_	_	Seg=O
76	the	_	_	_	_	_	_	_	Seg=O
77-78	patient's	_	_	_	_	_	_	_	_
77	patient	_	_	_	_	_	_	_	Seg=O
78	's	_	_	_	_	_	_	_	Seg=O
79	management	_	_	_	_	_	_	_	Seg=O
80	,	_	_	_	_	_	_	_	Seg=O
81	the	_	_	_	_	_	_	_	Seg=O
82	heavy	_	_	_	_	_	_	_	Seg=O
83	privacy	_	_	_	_	_	_	_	Seg=O
84	regulations	_	_	_	_	_	_	_	Seg=O
85	,	_	_	_	_	_	_	_	Seg=O
86	and	_	_	_	_	_	_	_	Seg=O
87	lack	_	_	_	_	_	_	_	Seg=O
88	of	_	_	_	_	_	_	_	Seg=O
89	clear	_	_	_	_	_	_	_	Seg=O
90	guidelines	_	_	_	_	_	_	_	Seg=O
91	,	_	_	_	_	_	_	_	Seg=O
92	together	_	_	_	_	_	_	_	Seg=O
93	with	_	_	_	_	_	_	_	Seg=O
94	the	_	_	_	_	_	_	_	Seg=O
95	lack	_	_	_	_	_	_	_	Seg=O
96	of	_	_	_	_	_	_	_	Seg=O
97	reimbursement	_	_	_	_	_	_	_	Seg=O
98	,	_	_	_	_	_	_	_	Seg=O
99	all	_	_	_	_	_	_	_	Seg=O
100	hinder	_	_	_	_	_	_	_	Seg=O
101	the	_	_	_	_	_	_	_	Seg=O
102	implementation	_	_	_	_	_	_	_	Seg=O
103	of	_	_	_	_	_	_	_	Seg=O
104	effective	_	_	_	_	_	_	_	Seg=O
105	telemedicine	_	_	_	_	_	_	_	Seg=O
106	solutions	_	_	_	_	_	_	_	Seg=O
107	for	_	_	_	_	_	_	_	Seg=O
108	long	_	_	_	_	_	_	_	Seg=O
109	-	_	_	_	_	_	_	_	Seg=O
110	term	_	_	_	_	_	_	_	Seg=O
111-112	patients'	_	_	_	_	_	_	_	_
111	patients	_	_	_	_	_	_	_	Seg=O
112	'	_	_	_	_	_	_	_	Seg=O
113	management	_	_	_	_	_	_	_	Seg=O
114	.	_	_	_	_	_	_	_	Seg=O
115	This	_	_	_	_	_	_	_	Seg=B-seg
116	COVID-19	_	_	_	_	_	_	_	Seg=O
117	epidemic	_	_	_	_	_	_	_	Seg=O
118	should	_	_	_	_	_	_	_	Seg=O
119	help	_	_	_	_	_	_	_	Seg=O
120	promote	_	_	_	_	_	_	_	Seg=O
121	better	_	_	_	_	_	_	_	Seg=O
122	use	_	_	_	_	_	_	_	Seg=O
123	and	_	_	_	_	_	_	_	Seg=O
124	a	_	_	_	_	_	_	_	Seg=O
125	larger	_	_	_	_	_	_	_	Seg=O
126	integration	_	_	_	_	_	_	_	Seg=O
127	of	_	_	_	_	_	_	_	Seg=O
128	telemedicine	_	_	_	_	_	_	_	Seg=O
129	services	_	_	_	_	_	_	_	Seg=O
130	in	_	_	_	_	_	_	_	Seg=O
131	the	_	_	_	_	_	_	_	Seg=O
132	armamentarium	_	_	_	_	_	_	_	Seg=O
133	of	_	_	_	_	_	_	_	Seg=O
134	health	_	_	_	_	_	_	_	Seg=O
135	care	_	_	_	_	_	_	_	Seg=O
136	services	_	_	_	_	_	_	_	Seg=O
137	.	_	_	_	_	_	_	_	Seg=O
138	Telemedicine	_	_	_	_	_	_	_	Seg=B-seg
139	must	_	_	_	_	_	_	_	Seg=O
140	no	_	_	_	_	_	_	_	Seg=O
141	longer	_	_	_	_	_	_	_	Seg=O
142	be	_	_	_	_	_	_	_	Seg=O
143	considered	_	_	_	_	_	_	_	Seg=O
144	as	_	_	_	_	_	_	_	Seg=O
145	an	_	_	_	_	_	_	_	Seg=O
146	option	_	_	_	_	_	_	_	Seg=O
147	or	_	_	_	_	_	_	_	Seg=O
148	add	_	_	_	_	_	_	_	Seg=O
149	-	_	_	_	_	_	_	_	Seg=O
150	on	_	_	_	_	_	_	_	Seg=O
151	to	_	_	_	_	_	_	_	Seg=B-seg
152	react	_	_	_	_	_	_	_	Seg=O
153	to	_	_	_	_	_	_	_	Seg=O
154	an	_	_	_	_	_	_	_	Seg=O
155	emergency	_	_	_	_	_	_	_	Seg=O
156	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 08cd7c215584f4c46d198988d3b3feb276067552
1	The	_	_	_	_	_	_	_	Seg=B-seg
2	emergence	_	_	_	_	_	_	_	Seg=O
3	of	_	_	_	_	_	_	_	Seg=O
4	Severe	_	_	_	_	_	_	_	Seg=O
5	Acute	_	_	_	_	_	_	_	Seg=O
6	Respiratory	_	_	_	_	_	_	_	Seg=O
7	Syndrome	_	_	_	_	_	_	_	Seg=O
8	coronavirus	_	_	_	_	_	_	_	Seg=O
9	(	_	_	_	_	_	_	_	Seg=O
10	SARS	_	_	_	_	_	_	_	Seg=O
11	-	_	_	_	_	_	_	_	Seg=O
12	CoV	_	_	_	_	_	_	_	Seg=O
13	)	_	_	_	_	_	_	_	Seg=O
14	and	_	_	_	_	_	_	_	Seg=O
15	Middle	_	_	_	_	_	_	_	Seg=O
16	East	_	_	_	_	_	_	_	Seg=O
17	Respiratory	_	_	_	_	_	_	_	Seg=O
18	Syndrome	_	_	_	_	_	_	_	Seg=O
19	coronavirus	_	_	_	_	_	_	_	Seg=O
20	(	_	_	_	_	_	_	_	Seg=O
21	MERS	_	_	_	_	_	_	_	Seg=O
22	-	_	_	_	_	_	_	_	Seg=O
23	CoV	_	_	_	_	_	_	_	Seg=O
24	)	_	_	_	_	_	_	_	Seg=O
25	,	_	_	_	_	_	_	_	Seg=O
26	two	_	_	_	_	_	_	_	Seg=B-seg
27	strains	_	_	_	_	_	_	_	Seg=O
28	of	_	_	_	_	_	_	_	Seg=O
29	animal	_	_	_	_	_	_	_	Seg=O
30	coronaviruses	_	_	_	_	_	_	_	Seg=O
31	that	_	_	_	_	_	_	_	Seg=B-seg
32	crossed	_	_	_	_	_	_	_	Seg=O
33	the	_	_	_	_	_	_	_	Seg=O
34	species	_	_	_	_	_	_	_	Seg=O
35	barrier	_	_	_	_	_	_	_	Seg=O
36	to	_	_	_	_	_	_	_	Seg=B-seg
37	infect	_	_	_	_	_	_	_	Seg=O
38	and	_	_	_	_	_	_	_	Seg=O
39	cause	_	_	_	_	_	_	_	Seg=O
40	severe	_	_	_	_	_	_	_	Seg=O
41	respiratory	_	_	_	_	_	_	_	Seg=O
42	infections	_	_	_	_	_	_	_	Seg=O
43	in	_	_	_	_	_	_	_	Seg=O
44	humans	_	_	_	_	_	_	_	Seg=O
45	within	_	_	_	_	_	_	_	Seg=O
46	the	_	_	_	_	_	_	_	Seg=O
47	last	_	_	_	_	_	_	_	Seg=O
48	12	_	_	_	_	_	_	_	Seg=O
49	years	_	_	_	_	_	_	_	Seg=O
50	,	_	_	_	_	_	_	_	Seg=O
51	have	_	_	_	_	_	_	_	Seg=B-seg
52	taught	_	_	_	_	_	_	_	Seg=O
53	us	_	_	_	_	_	_	_	Seg=O
54	that	_	_	_	_	_	_	_	Seg=O
55	coronaviruses	_	_	_	_	_	_	_	Seg=O
56	represent	_	_	_	_	_	_	_	Seg=O
57	a	_	_	_	_	_	_	_	Seg=O
58	global	_	_	_	_	_	_	_	Seg=O
59	threat	_	_	_	_	_	_	_	Seg=O
60	that	_	_	_	_	_	_	_	Seg=B-seg
61	does	_	_	_	_	_	_	_	Seg=O
62	not	_	_	_	_	_	_	_	Seg=O
63	recognize	_	_	_	_	_	_	_	Seg=O
64	international	_	_	_	_	_	_	_	Seg=O
65	borders	_	_	_	_	_	_	_	Seg=O
66	.	_	_	_	_	_	_	_	Seg=O
67	We	_	_	_	_	_	_	_	Seg=B-seg
68	can	_	_	_	_	_	_	_	Seg=O
69	expect	_	_	_	_	_	_	_	Seg=O
70	to	_	_	_	_	_	_	_	Seg=O
71	see	_	_	_	_	_	_	_	Seg=O
72	other	_	_	_	_	_	_	_	Seg=O
73	novel	_	_	_	_	_	_	_	Seg=O
74	coronaviruses	_	_	_	_	_	_	_	Seg=O
75	emerge	_	_	_	_	_	_	_	Seg=O
76	in	_	_	_	_	_	_	_	Seg=O
77	the	_	_	_	_	_	_	_	Seg=O
78	future	_	_	_	_	_	_	_	Seg=O
79	.	_	_	_	_	_	_	_	Seg=O
80	An	_	_	_	_	_	_	_	Seg=B-seg
81	ideal	_	_	_	_	_	_	_	Seg=O
82	animal	_	_	_	_	_	_	_	Seg=O
83	model	_	_	_	_	_	_	_	Seg=O
84	should	_	_	_	_	_	_	_	Seg=O
85	reflect	_	_	_	_	_	_	_	Seg=O
86	the	_	_	_	_	_	_	_	Seg=O
87	clinical	_	_	_	_	_	_	_	Seg=O
88	signs	_	_	_	_	_	_	_	Seg=O
89	,	_	_	_	_	_	_	_	Seg=O
90	viral	_	_	_	_	_	_	_	Seg=O
91	replication	_	_	_	_	_	_	_	Seg=O
92	and	_	_	_	_	_	_	_	Seg=O
93	pathology	_	_	_	_	_	_	_	Seg=O
94	seen	_	_	_	_	_	_	_	Seg=B-seg
95	in	_	_	_	_	_	_	_	Seg=O
96	humans	_	_	_	_	_	_	_	Seg=O
97	.	_	_	_	_	_	_	_	Seg=O
98	In	_	_	_	_	_	_	_	Seg=B-seg
99	this	_	_	_	_	_	_	_	Seg=O
100	review	_	_	_	_	_	_	_	Seg=O
101	,	_	_	_	_	_	_	_	Seg=O
102	we	_	_	_	_	_	_	_	Seg=O
103	present	_	_	_	_	_	_	_	Seg=O
104	factors	_	_	_	_	_	_	_	Seg=O
105	to	_	_	_	_	_	_	_	Seg=B-seg
106	consider	_	_	_	_	_	_	_	Seg=O
107	in	_	_	_	_	_	_	_	Seg=B-seg
108	establishing	_	_	_	_	_	_	_	Seg=O
109	an	_	_	_	_	_	_	_	Seg=O
110	animal	_	_	_	_	_	_	_	Seg=O
111	model	_	_	_	_	_	_	_	Seg=O
112	for	_	_	_	_	_	_	_	Seg=O
113	the	_	_	_	_	_	_	_	Seg=O
114	study	_	_	_	_	_	_	_	Seg=O
115	of	_	_	_	_	_	_	_	Seg=O
116	novel	_	_	_	_	_	_	_	Seg=O
117	coronaviruses	_	_	_	_	_	_	_	Seg=O
118	and	_	_	_	_	_	_	_	Seg=B-seg
119	compare	_	_	_	_	_	_	_	Seg=O
120	the	_	_	_	_	_	_	_	Seg=O
121	different	_	_	_	_	_	_	_	Seg=O
122	animal	_	_	_	_	_	_	_	Seg=O
123	models	_	_	_	_	_	_	_	Seg=O
124	that	_	_	_	_	_	_	_	Seg=B-seg
125	have	_	_	_	_	_	_	_	Seg=O
126	been	_	_	_	_	_	_	_	Seg=O
127	employed	_	_	_	_	_	_	_	Seg=O
128	to	_	_	_	_	_	_	_	Seg=B-seg
129	study	_	_	_	_	_	_	_	Seg=O
130	SARS	_	_	_	_	_	_	_	Seg=O
131	-	_	_	_	_	_	_	_	Seg=O
132	CoV	_	_	_	_	_	_	_	Seg=O
133	and	_	_	_	_	_	_	_	Seg=O
134	MERS	_	_	_	_	_	_	_	Seg=O
135	-	_	_	_	_	_	_	_	Seg=O
136	CoV.	_	_	_	_	_	_	_	Seg=O
137	SARS	_	_	_	_	_	_	_	Seg=B-seg
138	-	_	_	_	_	_	_	_	Seg=O
139	CoV	_	_	_	_	_	_	_	Seg=O
140	was	_	_	_	_	_	_	_	Seg=O
141	shown	_	_	_	_	_	_	_	Seg=O
142	to	_	_	_	_	_	_	_	Seg=O
143	infect	_	_	_	_	_	_	_	Seg=O
144	rhesus	_	_	_	_	_	_	_	Seg=O
145	macaques	_	_	_	_	_	_	_	Seg=O
146	[	_	_	_	_	_	_	_	Seg=O
147	22	_	_	_	_	_	_	_	Seg=O
148	,	_	_	_	_	_	_	_	Seg=O
149	23	_	_	_	_	_	_	_	Seg=O
150	]	_	_	_	_	_	_	_	Seg=O
151	cynomolgus	_	_	_	_	_	_	_	Seg=O
152	macaques	_	_	_	_	_	_	_	Seg=O
153	[	_	_	_	_	_	_	_	Seg=O
154	22	_	_	_	_	_	_	_	Seg=O
155	]	_	_	_	_	_	_	_	Seg=O
156	[	_	_	_	_	_	_	_	Seg=O
157	23	_	_	_	_	_	_	_	Seg=O
158	]	_	_	_	_	_	_	_	Seg=O
159	[	_	_	_	_	_	_	_	Seg=O
160	24	_	_	_	_	_	_	_	Seg=O
161	]	_	_	_	_	_	_	_	Seg=O
162	[	_	_	_	_	_	_	_	Seg=O
163	25	_	_	_	_	_	_	_	Seg=O
164	]	_	_	_	_	_	_	_	Seg=O
165	[	_	_	_	_	_	_	_	Seg=O
166	26	_	_	_	_	_	_	_	Seg=O
167	]	_	_	_	_	_	_	_	Seg=O
168	and	_	_	_	_	_	_	_	Seg=O
169	African	_	_	_	_	_	_	_	Seg=O
170	green	_	_	_	_	_	_	_	Seg=O
171	monkeys	_	_	_	_	_	_	_	Seg=O
172	(	_	_	_	_	_	_	_	Seg=O
173	AGMs	_	_	_	_	_	_	_	Seg=O
174	)	_	_	_	_	_	_	_	Seg=O
175	[	_	_	_	_	_	_	_	Seg=O
176	22	_	_	_	_	_	_	_	Seg=O
177	]	_	_	_	_	_	_	_	Seg=O
178	.	_	_	_	_	_	_	_	Seg=O
179	Clinical	_	_	_	_	_	_	_	Seg=B-seg
180	signs	_	_	_	_	_	_	_	Seg=O
181	,	_	_	_	_	_	_	_	Seg=O
182	viral	_	_	_	_	_	_	_	Seg=O
183	replication	_	_	_	_	_	_	_	Seg=O
184	and	_	_	_	_	_	_	_	Seg=O
185	pathology	_	_	_	_	_	_	_	Seg=O
186	depended	_	_	_	_	_	_	_	Seg=O
187	upon	_	_	_	_	_	_	_	Seg=O
188	the	_	_	_	_	_	_	_	Seg=O
189	species	_	_	_	_	_	_	_	Seg=O
190	.	_	_	_	_	_	_	_	Seg=O
191	There	_	_	_	_	_	_	_	Seg=B-seg
192	is	_	_	_	_	_	_	_	Seg=O
193	at	_	_	_	_	_	_	_	Seg=O
194	least	_	_	_	_	_	_	_	Seg=O
195	one	_	_	_	_	_	_	_	Seg=O
196	report	_	_	_	_	_	_	_	Seg=O
197	of	_	_	_	_	_	_	_	Seg=O
198	pneumonitis	_	_	_	_	_	_	_	Seg=O
199	in	_	_	_	_	_	_	_	Seg=O
200	each	_	_	_	_	_	_	_	Seg=O
201	species	_	_	_	_	_	_	_	Seg=O
202	but	_	_	_	_	_	_	_	Seg=B-seg
203	the	_	_	_	_	_	_	_	Seg=O
204	findings	_	_	_	_	_	_	_	Seg=O
205	in	_	_	_	_	_	_	_	Seg=O
206	non	_	_	_	_	_	_	_	Seg=O
207	-	_	_	_	_	_	_	_	Seg=O
208	human	_	_	_	_	_	_	_	Seg=O
209	primates	_	_	_	_	_	_	_	Seg=O
210	(	_	_	_	_	_	_	_	Seg=O
211	NHPs	_	_	_	_	_	_	_	Seg=O
212	)	_	_	_	_	_	_	_	Seg=O
213	were	_	_	_	_	_	_	_	Seg=O
214	variable	_	_	_	_	_	_	_	Seg=O
215	,	_	_	_	_	_	_	_	Seg=O
216	likely	_	_	_	_	_	_	_	Seg=B-seg
217	because	_	_	_	_	_	_	_	Seg=O
218	of	_	_	_	_	_	_	_	Seg=O
219	genetic	_	_	_	_	_	_	_	Seg=O
220	Gretebeck	_	_	_	_	_	_	_	Seg=O
221	and	_	_	_	_	_	_	_	Seg=O
222	Subbarao	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 0982121b27ae7070996973d0c3d892fe432e8b2a
1	Background	_	_	_	_	_	_	_	Seg=B-seg
2	Surgical	_	_	_	_	_	_	_	Seg=B-seg
3	site	_	_	_	_	_	_	_	Seg=O
4	infections	_	_	_	_	_	_	_	Seg=O
5	(	_	_	_	_	_	_	_	Seg=O
6	SSI	_	_	_	_	_	_	_	Seg=O
7	)	_	_	_	_	_	_	_	Seg=O
8	are	_	_	_	_	_	_	_	Seg=O
9	the	_	_	_	_	_	_	_	Seg=O
10	commonest	_	_	_	_	_	_	_	Seg=O
11	healthcare	_	_	_	_	_	_	_	Seg=O
12	associated	_	_	_	_	_	_	_	Seg=O
13	infections	_	_	_	_	_	_	_	Seg=O
14	.	_	_	_	_	_	_	_	Seg=O
15	They	_	_	_	_	_	_	_	Seg=B-seg
16	severely	_	_	_	_	_	_	_	Seg=O
17	compromise	_	_	_	_	_	_	_	Seg=O
18	patient	_	_	_	_	_	_	_	Seg=O
19	safety	_	_	_	_	_	_	_	Seg=O
20	,	_	_	_	_	_	_	_	Seg=O
21	are	_	_	_	_	_	_	_	Seg=B-seg
22	a	_	_	_	_	_	_	_	Seg=O
23	significant	_	_	_	_	_	_	_	Seg=O
24	burden	_	_	_	_	_	_	_	Seg=O
25	on	_	_	_	_	_	_	_	Seg=O
26	healthcare	_	_	_	_	_	_	_	Seg=O
27	resources	_	_	_	_	_	_	_	Seg=O
28	and	_	_	_	_	_	_	_	Seg=B-seg
29	have	_	_	_	_	_	_	_	Seg=O
30	an	_	_	_	_	_	_	_	Seg=O
31	adverse	_	_	_	_	_	_	_	Seg=O
32	impact	_	_	_	_	_	_	_	Seg=O
33	on	_	_	_	_	_	_	_	Seg=O
34	patient	_	_	_	_	_	_	_	Seg=O
35	quality	_	_	_	_	_	_	_	Seg=O
36	of	_	_	_	_	_	_	_	Seg=O
37	life	_	_	_	_	_	_	_	Seg=O
38	.	_	_	_	_	_	_	_	Seg=O
39	The	_	_	_	_	_	_	_	Seg=B-seg
40	incidence	_	_	_	_	_	_	_	Seg=O
41	of	_	_	_	_	_	_	_	Seg=O
42	SSIs	_	_	_	_	_	_	_	Seg=O
43	can	_	_	_	_	_	_	_	Seg=O
44	be	_	_	_	_	_	_	_	Seg=O
45	as	_	_	_	_	_	_	_	Seg=O
46	high	_	_	_	_	_	_	_	Seg=O
47	as	_	_	_	_	_	_	_	Seg=O
48	10	_	_	_	_	_	_	_	Seg=O
49	%	_	_	_	_	_	_	_	Seg=O
50	after	_	_	_	_	_	_	_	Seg=O
51	colorectal	_	_	_	_	_	_	_	Seg=O
52	procedures	_	_	_	_	_	_	_	Seg=O
53	.	_	_	_	_	_	_	_	Seg=O
54	The	_	_	_	_	_	_	_	Seg=B-seg
55	laparoscopic	_	_	_	_	_	_	_	Seg=O
56	approach	_	_	_	_	_	_	_	Seg=O
57	is	_	_	_	_	_	_	_	Seg=O
58	being	_	_	_	_	_	_	_	Seg=O
59	increasingly	_	_	_	_	_	_	_	Seg=O
60	used	_	_	_	_	_	_	_	Seg=O
61	to	_	_	_	_	_	_	_	Seg=B-seg
62	undertake	_	_	_	_	_	_	_	Seg=O
63	colorectal	_	_	_	_	_	_	_	Seg=O
64	procedures	_	_	_	_	_	_	_	Seg=O
65	.	_	_	_	_	_	_	_	Seg=O
66	It	_	_	_	_	_	_	_	Seg=B-seg
67	provides	_	_	_	_	_	_	_	Seg=O
68	advantages	_	_	_	_	_	_	_	Seg=O
69	over	_	_	_	_	_	_	_	Seg=O
70	the	_	_	_	_	_	_	_	Seg=O
71	traditional	_	_	_	_	_	_	_	Seg=O
72	open	_	_	_	_	_	_	_	Seg=O
73	approach	_	_	_	_	_	_	_	Seg=O
74	with	_	_	_	_	_	_	_	Seg=O
75	smaller	_	_	_	_	_	_	_	Seg=O
76	incisions	_	_	_	_	_	_	_	Seg=O
77	,	_	_	_	_	_	_	_	Seg=O
78	shorter	_	_	_	_	_	_	_	Seg=O
79	hospital	_	_	_	_	_	_	_	Seg=O
80	stay	_	_	_	_	_	_	_	Seg=O
81	and	_	_	_	_	_	_	_	Seg=O
82	equal	_	_	_	_	_	_	_	Seg=O
83	oncological	_	_	_	_	_	_	_	Seg=O
84	outcomes	_	_	_	_	_	_	_	Seg=O
85	.	_	_	_	_	_	_	_	Seg=O
86	The	_	_	_	_	_	_	_	Seg=B-seg
87	aim	_	_	_	_	_	_	_	Seg=O
88	of	_	_	_	_	_	_	_	Seg=O
89	this	_	_	_	_	_	_	_	Seg=O
90	meta	_	_	_	_	_	_	_	Seg=O
91	-	_	_	_	_	_	_	_	Seg=O
92	analysis	_	_	_	_	_	_	_	Seg=O
93	was	_	_	_	_	_	_	_	Seg=O
94	to	_	_	_	_	_	_	_	Seg=O
95	evaluate	_	_	_	_	_	_	_	Seg=O
96	whether	_	_	_	_	_	_	_	Seg=O
97	the	_	_	_	_	_	_	_	Seg=O
98	laparoscopic	_	_	_	_	_	_	_	Seg=O
99	approach	_	_	_	_	_	_	_	Seg=O
100	for	_	_	_	_	_	_	_	Seg=O
101	colorectal	_	_	_	_	_	_	_	Seg=O
102	procedures	_	_	_	_	_	_	_	Seg=O
103	reduces	_	_	_	_	_	_	_	Seg=O
104	the	_	_	_	_	_	_	_	Seg=O
105	incidence	_	_	_	_	_	_	_	Seg=O
106	of	_	_	_	_	_	_	_	Seg=O
107	SSI	_	_	_	_	_	_	_	Seg=O
108	compared	_	_	_	_	_	_	_	Seg=B-seg
109	to	_	_	_	_	_	_	_	Seg=O
110	the	_	_	_	_	_	_	_	Seg=O
111	open	_	_	_	_	_	_	_	Seg=O
112	approach	_	_	_	_	_	_	_	Seg=O
113	.	_	_	_	_	_	_	_	Seg=O
114	Methods	_	_	_	_	_	_	_	Seg=B-seg
115	Randomised	_	_	_	_	_	_	_	Seg=B-seg
116	controlled	_	_	_	_	_	_	_	Seg=O
117	trials	_	_	_	_	_	_	_	Seg=O
118	(	_	_	_	_	_	_	_	Seg=O
119	RCTs	_	_	_	_	_	_	_	Seg=O
120	)	_	_	_	_	_	_	_	Seg=O
121	comparing	_	_	_	_	_	_	_	Seg=B-seg
122	the	_	_	_	_	_	_	_	Seg=O
123	two	_	_	_	_	_	_	_	Seg=O
124	approaches	_	_	_	_	_	_	_	Seg=O
125	published	_	_	_	_	_	_	_	Seg=B-seg
126	since	_	_	_	_	_	_	_	Seg=O
127	2000	_	_	_	_	_	_	_	Seg=O
128	were	_	_	_	_	_	_	_	Seg=B-seg
129	included	_	_	_	_	_	_	_	Seg=O
130	in	_	_	_	_	_	_	_	Seg=O
131	the	_	_	_	_	_	_	_	Seg=O
132	review	_	_	_	_	_	_	_	Seg=O
133	.	_	_	_	_	_	_	_	Seg=O
134	Revman	_	_	_	_	_	_	_	Seg=B-seg
135	5.3	_	_	_	_	_	_	_	Seg=O
136	software	_	_	_	_	_	_	_	Seg=O
137	was	_	_	_	_	_	_	_	Seg=O
138	used	_	_	_	_	_	_	_	Seg=O
139	to	_	_	_	_	_	_	_	Seg=B-seg
140	carry	_	_	_	_	_	_	_	Seg=O
141	out	_	_	_	_	_	_	_	Seg=O
142	the	_	_	_	_	_	_	_	Seg=O
143	review	_	_	_	_	_	_	_	Seg=O
144	.	_	_	_	_	_	_	_	Seg=O
145	Data	_	_	_	_	_	_	_	Seg=B-seg
146	were	_	_	_	_	_	_	_	Seg=O
147	pooled	_	_	_	_	_	_	_	Seg=O
148	and	_	_	_	_	_	_	_	Seg=B-seg
149	the	_	_	_	_	_	_	_	Seg=O
150	results	_	_	_	_	_	_	_	Seg=O
151	were	_	_	_	_	_	_	_	Seg=O
152	shown	_	_	_	_	_	_	_	Seg=O
153	as	_	_	_	_	_	_	_	Seg=O
154	risk	_	_	_	_	_	_	_	Seg=O
155	ratios	_	_	_	_	_	_	_	Seg=O
156	with	_	_	_	_	_	_	_	Seg=O
157	95	_	_	_	_	_	_	_	Seg=O
158	%	_	_	_	_	_	_	_	Seg=O
159	confidence	_	_	_	_	_	_	_	Seg=O
160	intervals	_	_	_	_	_	_	_	Seg=O
161	using	_	_	_	_	_	_	_	Seg=B-seg
162	the	_	_	_	_	_	_	_	Seg=O
163	fixed	_	_	_	_	_	_	_	Seg=O
164	effects	_	_	_	_	_	_	_	Seg=O
165	model	_	_	_	_	_	_	_	Seg=O
166	.	_	_	_	_	_	_	_	Seg=O
167	Results	_	_	_	_	_	_	_	Seg=B-seg
168	Sixteen	_	_	_	_	_	_	_	Seg=B-seg
169-170	RCT's	_	_	_	_	_	_	_	_
169	RCT	_	_	_	_	_	_	_	Seg=O
170	's	_	_	_	_	_	_	_	Seg=O
171	were	_	_	_	_	_	_	_	Seg=O
172	included	_	_	_	_	_	_	_	Seg=O
173	in	_	_	_	_	_	_	_	Seg=O
174	the	_	_	_	_	_	_	_	Seg=O
175	analysis	_	_	_	_	_	_	_	Seg=O
176	comprising	_	_	_	_	_	_	_	Seg=B-seg
177	5797	_	_	_	_	_	_	_	Seg=O
178	patients	_	_	_	_	_	_	_	Seg=O
179	.	_	_	_	_	_	_	_	Seg=O
180	These	_	_	_	_	_	_	_	Seg=B-seg
181	covered	_	_	_	_	_	_	_	Seg=O
182	a	_	_	_	_	_	_	_	Seg=O
183	range	_	_	_	_	_	_	_	Seg=O
184	of	_	_	_	_	_	_	_	Seg=O
185	colorectal	_	_	_	_	_	_	_	Seg=O
186	pathologies	_	_	_	_	_	_	_	Seg=O
187	including	_	_	_	_	_	_	_	Seg=B-seg
188	colon	_	_	_	_	_	_	_	Seg=O
189	cancer	_	_	_	_	_	_	_	Seg=O
190	,	_	_	_	_	_	_	_	Seg=O
191	rectal	_	_	_	_	_	_	_	Seg=O
192	cancer	_	_	_	_	_	_	_	Seg=O
193	,	_	_	_	_	_	_	_	Seg=O
194	inflammatory	_	_	_	_	_	_	_	Seg=O
195	bowel	_	_	_	_	_	_	_	Seg=O
196	disease	_	_	_	_	_	_	_	Seg=O
197	and	_	_	_	_	_	_	_	Seg=O
198	familial	_	_	_	_	_	_	_	Seg=O
199	adenomatous	_	_	_	_	_	_	_	Seg=O
200	polyposis	_	_	_	_	_	_	_	Seg=O
201	syndrome	_	_	_	_	_	_	_	Seg=O
202	.	_	_	_	_	_	_	_	Seg=O
203	Analysis	_	_	_	_	_	_	_	Seg=B-seg
204	showed	_	_	_	_	_	_	_	Seg=O
205	significantly	_	_	_	_	_	_	_	Seg=O
206	lower	_	_	_	_	_	_	_	Seg=O
207	wound	_	_	_	_	_	_	_	Seg=O
208	infection	_	_	_	_	_	_	_	Seg=O
209	rates	_	_	_	_	_	_	_	Seg=O
210	(	_	_	_	_	_	_	_	Seg=B-seg
211	RR	_	_	_	_	_	_	_	Seg=O
212	:	_	_	_	_	_	_	_	Seg=O
213	0.72	_	_	_	_	_	_	_	Seg=O
214	,	_	_	_	_	_	_	_	Seg=O
215	95	_	_	_	_	_	_	_	Seg=O
216	%	_	_	_	_	_	_	_	Seg=O
217	confidence	_	_	_	_	_	_	_	Seg=O
218	interval	_	_	_	_	_	_	_	Seg=O
219	:	_	_	_	_	_	_	_	Seg=O
220	0.60	_	_	_	_	_	_	_	Seg=O
221	-	_	_	_	_	_	_	_	Seg=O
222	0.88	_	_	_	_	_	_	_	Seg=O
223	,	_	_	_	_	_	_	_	Seg=O
224	p	_	_	_	_	_	_	_	Seg=O
225	=	_	_	_	_	_	_	_	Seg=O
226	0.001	_	_	_	_	_	_	_	Seg=O
227	)	_	_	_	_	_	_	_	Seg=O
228	and	_	_	_	_	_	_	_	Seg=B-seg
229	lower	_	_	_	_	_	_	_	Seg=O
230	abdominal	_	_	_	_	_	_	_	Seg=O
231	abscess	_	_	_	_	_	_	_	Seg=O
232	rates	_	_	_	_	_	_	_	Seg=O
233	(	_	_	_	_	_	_	_	Seg=B-seg
234	RR	_	_	_	_	_	_	_	Seg=O
235	:	_	_	_	_	_	_	_	Seg=O
236	0.88	_	_	_	_	_	_	_	Seg=O
237	,	_	_	_	_	_	_	_	Seg=O
238	95	_	_	_	_	_	_	_	Seg=O
239	%	_	_	_	_	_	_	_	Seg=O
240	CI	_	_	_	_	_	_	_	Seg=O
241	0.62	_	_	_	_	_	_	_	Seg=O
242	-	_	_	_	_	_	_	_	Seg=O
243	1.27	_	_	_	_	_	_	_	Seg=O
244	,	_	_	_	_	_	_	_	Seg=O
245	p	_	_	_	_	_	_	_	Seg=O
246	=	_	_	_	_	_	_	_	Seg=O
247	0.51	_	_	_	_	_	_	_	Seg=O
248	)	_	_	_	_	_	_	_	Seg=O
249	.	_	_	_	_	_	_	_	Seg=O
250	The	_	_	_	_	_	_	_	Seg=B-seg
251	combined	_	_	_	_	_	_	_	Seg=O
252	SSI	_	_	_	_	_	_	_	Seg=O
253	rate	_	_	_	_	_	_	_	Seg=O
254	was	_	_	_	_	_	_	_	Seg=O
255	significantly	_	_	_	_	_	_	_	Seg=O
256	lower	_	_	_	_	_	_	_	Seg=O
257	in	_	_	_	_	_	_	_	Seg=O
258	laparoscopic	_	_	_	_	_	_	_	Seg=O
259	compared	_	_	_	_	_	_	_	Seg=B-seg
260	to	_	_	_	_	_	_	_	Seg=O
261	open	_	_	_	_	_	_	_	Seg=O
262	surgery	_	_	_	_	_	_	_	Seg=O
263	(	_	_	_	_	_	_	_	Seg=B-seg
264	RR	_	_	_	_	_	_	_	Seg=O
265	:	_	_	_	_	_	_	_	Seg=O
266	0.76	_	_	_	_	_	_	_	Seg=O
267	,	_	_	_	_	_	_	_	Seg=O
268	95	_	_	_	_	_	_	_	Seg=O
269	%	_	_	_	_	_	_	_	Seg=O
270	CI	_	_	_	_	_	_	_	Seg=O
271	0.64	_	_	_	_	_	_	_	Seg=O
272	-	_	_	_	_	_	_	_	Seg=O
273	0.90	_	_	_	_	_	_	_	Seg=O
274	,	_	_	_	_	_	_	_	Seg=O
275	p	_	_	_	_	_	_	_	Seg=O
276	=	_	_	_	_	_	_	_	Seg=O
277	0.001	_	_	_	_	_	_	_	Seg=O
278	)	_	_	_	_	_	_	_	Seg=O
279	.	_	_	_	_	_	_	_	Seg=O
280	Conclusions	_	_	_	_	_	_	_	Seg=B-seg
281	Laparoscopic	_	_	_	_	_	_	_	Seg=B-seg
282	colorectal	_	_	_	_	_	_	_	Seg=O
283	surgery	_	_	_	_	_	_	_	Seg=O
284	significantly	_	_	_	_	_	_	_	Seg=O
285	lowers	_	_	_	_	_	_	_	Seg=O
286	the	_	_	_	_	_	_	_	Seg=O
287	incidence	_	_	_	_	_	_	_	Seg=O
288	of	_	_	_	_	_	_	_	Seg=O
289	SSI	_	_	_	_	_	_	_	Seg=O
290	compared	_	_	_	_	_	_	_	Seg=B-seg
291	to	_	_	_	_	_	_	_	Seg=O
292	open	_	_	_	_	_	_	_	Seg=O
293	surgery	_	_	_	_	_	_	_	Seg=O
294	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 09a248034a8e29a2341c707ef66771cda8bd7b1b
1	In	_	_	_	_	_	_	_	Seg=B-seg
2	this	_	_	_	_	_	_	_	Seg=O
3	paper	_	_	_	_	_	_	_	Seg=O
4	the	_	_	_	_	_	_	_	Seg=O
5	authors	_	_	_	_	_	_	_	Seg=O
6	question	_	_	_	_	_	_	_	Seg=O
7	whether	_	_	_	_	_	_	_	Seg=O
8	the	_	_	_	_	_	_	_	Seg=O
9	development	_	_	_	_	_	_	_	Seg=O
10	of	_	_	_	_	_	_	_	Seg=O
11	a	_	_	_	_	_	_	_	Seg=O
12	vaccine	_	_	_	_	_	_	_	Seg=O
13	against	_	_	_	_	_	_	_	Seg=O
14	cryptosporidiosis	_	_	_	_	_	_	_	Seg=O
15	could	_	_	_	_	_	_	_	Seg=O
16	be	_	_	_	_	_	_	_	Seg=O
17	taken	_	_	_	_	_	_	_	Seg=O
18	into	_	_	_	_	_	_	_	Seg=O
19	consideration	_	_	_	_	_	_	_	Seg=O
20	.	_	_	_	_	_	_	_	Seg=O
21	The	_	_	_	_	_	_	_	Seg=B-seg
22	necessity	_	_	_	_	_	_	_	Seg=O
23	and	_	_	_	_	_	_	_	Seg=O
24	feasibility	_	_	_	_	_	_	_	Seg=O
25	of	_	_	_	_	_	_	_	Seg=O
26	such	_	_	_	_	_	_	_	Seg=O
27	a	_	_	_	_	_	_	_	Seg=O
28	vaccine	_	_	_	_	_	_	_	Seg=O
29	for	_	_	_	_	_	_	_	Seg=O
30	human	_	_	_	_	_	_	_	Seg=O
31	and	_	_	_	_	_	_	_	Seg=O
32	veterinary	_	_	_	_	_	_	_	Seg=O
33	application	_	_	_	_	_	_	_	Seg=O
34	is	_	_	_	_	_	_	_	Seg=O
35	discussed	_	_	_	_	_	_	_	Seg=O
36	.	_	_	_	_	_	_	_	Seg=O
37	Developmental	_	_	_	_	_	_	_	Seg=B-seg
38	stages	_	_	_	_	_	_	_	Seg=O
39	within	_	_	_	_	_	_	_	Seg=O
40	the	_	_	_	_	_	_	_	Seg=O
41	life	_	_	_	_	_	_	_	Seg=O
42	cycle	_	_	_	_	_	_	_	Seg=O
43	of	_	_	_	_	_	_	_	Seg=O
44	the	_	_	_	_	_	_	_	Seg=O
45	parasite	_	_	_	_	_	_	_	Seg=O
46	that	_	_	_	_	_	_	_	Seg=B-seg
47	might	_	_	_	_	_	_	_	Seg=O
48	act	_	_	_	_	_	_	_	Seg=O
49	as	_	_	_	_	_	_	_	Seg=O
50	possible	_	_	_	_	_	_	_	Seg=O
51	targets	_	_	_	_	_	_	_	Seg=O
52	for	_	_	_	_	_	_	_	Seg=O
53	vaccine	_	_	_	_	_	_	_	Seg=O
54	development	_	_	_	_	_	_	_	Seg=O
55	are	_	_	_	_	_	_	_	Seg=B-seg
56	summarised	_	_	_	_	_	_	_	Seg=O
57	,	_	_	_	_	_	_	_	Seg=O
58	as	_	_	_	_	_	_	_	Seg=O
59	well	_	_	_	_	_	_	_	Seg=O
60	as	_	_	_	_	_	_	_	Seg=O
61	the	_	_	_	_	_	_	_	Seg=O
62	target	_	_	_	_	_	_	_	Seg=O
63	antigens	_	_	_	_	_	_	_	Seg=O
64	oered	_	_	_	_	_	_	_	Seg=B-seg
65	by	_	_	_	_	_	_	_	Seg=O
66	molecular	_	_	_	_	_	_	_	Seg=O
67	biology	_	_	_	_	_	_	_	Seg=O
68	and	_	_	_	_	_	_	_	Seg=O
69	immunology	_	_	_	_	_	_	_	Seg=O
70	studies	_	_	_	_	_	_	_	Seg=O
71	.	_	_	_	_	_	_	_	Seg=O
72	Vaccination	_	_	_	_	_	_	_	Seg=B-seg
73	trials	_	_	_	_	_	_	_	Seg=O
74	against	_	_	_	_	_	_	_	Seg=O
75	cryptosporidiosis	_	_	_	_	_	_	_	Seg=O
76	carried	_	_	_	_	_	_	_	Seg=B-seg
77	out	_	_	_	_	_	_	_	Seg=O
78	so	_	_	_	_	_	_	_	Seg=O
79	far	_	_	_	_	_	_	_	Seg=O
80	,	_	_	_	_	_	_	_	Seg=O
81	including	_	_	_	_	_	_	_	Seg=B-seg
82	the	_	_	_	_	_	_	_	Seg=O
83	active	_	_	_	_	_	_	_	Seg=O
84	and	_	_	_	_	_	_	_	Seg=O
85	passive	_	_	_	_	_	_	_	Seg=O
86	immunisation	_	_	_	_	_	_	_	Seg=O
87	approach	_	_	_	_	_	_	_	Seg=O
88	,	_	_	_	_	_	_	_	Seg=O
89	are	_	_	_	_	_	_	_	Seg=B-seg
90	also	_	_	_	_	_	_	_	Seg=O
91	overviewed	_	_	_	_	_	_	_	Seg=O
92	.	_	_	_	_	_	_	_	Seg=O
93	It	_	_	_	_	_	_	_	Seg=B-seg
94	seems	_	_	_	_	_	_	_	Seg=O
95	that	_	_	_	_	_	_	_	Seg=O
96	with	_	_	_	_	_	_	_	Seg=O
97	respect	_	_	_	_	_	_	_	Seg=O
98	to	_	_	_	_	_	_	_	Seg=O
99	a	_	_	_	_	_	_	_	Seg=O
100	Cryptosporidium	_	_	_	_	_	_	_	Seg=O
101	vaccine	_	_	_	_	_	_	_	Seg=O
102	two	_	_	_	_	_	_	_	Seg=O
103	target	_	_	_	_	_	_	_	Seg=O
104	groups	_	_	_	_	_	_	_	Seg=O
105	can	_	_	_	_	_	_	_	Seg=O
106	be	_	_	_	_	_	_	_	Seg=O
107	considered	_	_	_	_	_	_	_	Seg=O
108	:	_	_	_	_	_	_	_	Seg=O
109	children	_	_	_	_	_	_	_	Seg=B-seg
110	of	_	_	_	_	_	_	_	Seg=O
111	the	_	_	_	_	_	_	_	Seg=O
112	developing	_	_	_	_	_	_	_	Seg=O
113	world	_	_	_	_	_	_	_	Seg=O
114	and	_	_	_	_	_	_	_	Seg=O
115	neonatal	_	_	_	_	_	_	_	Seg=O
116	ruminants	_	_	_	_	_	_	_	Seg=O
117	.	_	_	_	_	_	_	_	Seg=O
118	Antigens	_	_	_	_	_	_	_	Seg=B-seg
119	representing	_	_	_	_	_	_	_	Seg=B-seg
120	possible	_	_	_	_	_	_	_	Seg=O
121	candidates	_	_	_	_	_	_	_	Seg=O
122	for	_	_	_	_	_	_	_	Seg=O
123	a	_	_	_	_	_	_	_	Seg=O
124	subunit	_	_	_	_	_	_	_	Seg=O
125	vaccine	_	_	_	_	_	_	_	Seg=O
126	were	_	_	_	_	_	_	_	Seg=B-seg
127	identi	_	_	_	_	_	_	_	Seg=O
128	®	_	_	_	_	_	_	_	Seg=O
129	e	_	_	_	_	_	_	_	Seg=O
130	based	_	_	_	_	_	_	_	Seg=B-seg
131	on	_	_	_	_	_	_	_	Seg=O
132	their	_	_	_	_	_	_	_	Seg=O
133	function	_	_	_	_	_	_	_	Seg=O
134	,	_	_	_	_	_	_	_	Seg=O
135	location	_	_	_	_	_	_	_	Seg=O
136	and/or	_	_	_	_	_	_	_	Seg=O
137	the	_	_	_	_	_	_	_	Seg=O
138	immune	_	_	_	_	_	_	_	Seg=O
139	response	_	_	_	_	_	_	_	Seg=O
140	they	_	_	_	_	_	_	_	Seg=B-seg
141	evoke	_	_	_	_	_	_	_	Seg=O
142	.	_	_	_	_	_	_	_	Seg=O
143	While	_	_	_	_	_	_	_	Seg=B-seg
144	the	_	_	_	_	_	_	_	Seg=O
145	active	_	_	_	_	_	_	_	Seg=O
146	vaccination	_	_	_	_	_	_	_	Seg=O
147	of	_	_	_	_	_	_	_	Seg=O
148	newborn	_	_	_	_	_	_	_	Seg=O
149	calves	_	_	_	_	_	_	_	Seg=O
150	,	_	_	_	_	_	_	_	Seg=O
151	lambs	_	_	_	_	_	_	_	Seg=O
152	and	_	_	_	_	_	_	_	Seg=O
153	goat	_	_	_	_	_	_	_	Seg=O
154	kids	_	_	_	_	_	_	_	Seg=O
155	has	_	_	_	_	_	_	_	Seg=O
156	to	_	_	_	_	_	_	_	Seg=O
157	face	_	_	_	_	_	_	_	Seg=O
158	a	_	_	_	_	_	_	_	Seg=O
159	number	_	_	_	_	_	_	_	Seg=O
160	of	_	_	_	_	_	_	_	Seg=O
161	important	_	_	_	_	_	_	_	Seg=O
162	limitations	_	_	_	_	_	_	_	Seg=O
163	,	_	_	_	_	_	_	_	Seg=O
164	the	_	_	_	_	_	_	_	Seg=B-seg
165	passive	_	_	_	_	_	_	_	Seg=O
166	immunisation	_	_	_	_	_	_	_	Seg=O
167	approach	_	_	_	_	_	_	_	Seg=O
168	,	_	_	_	_	_	_	_	Seg=O
169	where	_	_	_	_	_	_	_	Seg=B-seg
170	dams	_	_	_	_	_	_	_	Seg=O
171	were	_	_	_	_	_	_	_	Seg=O
172	immunised	_	_	_	_	_	_	_	Seg=O
173	to	_	_	_	_	_	_	_	Seg=B-seg
174	protect	_	_	_	_	_	_	_	Seg=O
175	their	_	_	_	_	_	_	_	Seg=O
176	progeny	_	_	_	_	_	_	_	Seg=O
177	by	_	_	_	_	_	_	_	Seg=O
178	colostral	_	_	_	_	_	_	_	Seg=O
179	transfer	_	_	_	_	_	_	_	Seg=O
180	,	_	_	_	_	_	_	_	Seg=O
181	was	_	_	_	_	_	_	_	Seg=B-seg
182	proven	_	_	_	_	_	_	_	Seg=O
183	to	_	_	_	_	_	_	_	Seg=O
184	be	_	_	_	_	_	_	_	Seg=O
185	a	_	_	_	_	_	_	_	Seg=O
186	valuable	_	_	_	_	_	_	_	Seg=O
187	alternative	_	_	_	_	_	_	_	Seg=O
188	.	_	_	_	_	_	_	_	Seg=O
189	Finally	_	_	_	_	_	_	_	Seg=B-seg
190	,	_	_	_	_	_	_	_	Seg=O
191	a	_	_	_	_	_	_	_	Seg=O
192	number	_	_	_	_	_	_	_	Seg=O
193	of	_	_	_	_	_	_	_	Seg=O
194	points	_	_	_	_	_	_	_	Seg=O
195	of	_	_	_	_	_	_	_	Seg=O
196	action	_	_	_	_	_	_	_	Seg=O
197	for	_	_	_	_	_	_	_	Seg=O
198	the	_	_	_	_	_	_	_	Seg=O
199	near	_	_	_	_	_	_	_	Seg=O
200	future	_	_	_	_	_	_	_	Seg=O
201	are	_	_	_	_	_	_	_	Seg=O
202	put	_	_	_	_	_	_	_	Seg=O
203	forward	_	_	_	_	_	_	_	Seg=O
204	.	_	_	_	_	_	_	_	Seg=O
205	#	_	_	_	_	_	_	_	Seg=B-seg

# newdoc_id = 09be942d1b5283b42743406c8fa6dddeb08b38cc
1	In	_	_	_	_	_	_	_	Seg=B-seg
2	December	_	_	_	_	_	_	_	Seg=O
3	2019	_	_	_	_	_	_	_	Seg=O
4	,	_	_	_	_	_	_	_	Seg=O
5	a	_	_	_	_	_	_	_	Seg=O
6	novel	_	_	_	_	_	_	_	Seg=O
7	coronavirus	_	_	_	_	_	_	_	Seg=O
8	called	_	_	_	_	_	_	_	Seg=B-seg
9	SARS	_	_	_	_	_	_	_	Seg=O
10	-	_	_	_	_	_	_	_	Seg=O
11	CoV-2	_	_	_	_	_	_	_	Seg=O
12	was	_	_	_	_	_	_	_	Seg=B-seg
13	reported	_	_	_	_	_	_	_	Seg=O
14	to	_	_	_	_	_	_	_	Seg=O
15	be	_	_	_	_	_	_	_	Seg=O
16	responsible	_	_	_	_	_	_	_	Seg=O
17	for	_	_	_	_	_	_	_	Seg=O
18	a	_	_	_	_	_	_	_	Seg=O
19	cluster	_	_	_	_	_	_	_	Seg=O
20	of	_	_	_	_	_	_	_	Seg=O
21	acute	_	_	_	_	_	_	_	Seg=O
22	atypical	_	_	_	_	_	_	_	Seg=O
23	respiratory	_	_	_	_	_	_	_	Seg=O
24	pneumonia	_	_	_	_	_	_	_	Seg=O
25	cases	_	_	_	_	_	_	_	Seg=O
26	in	_	_	_	_	_	_	_	Seg=O
27	Wuhan	_	_	_	_	_	_	_	Seg=O
28	,	_	_	_	_	_	_	_	Seg=O
29	in	_	_	_	_	_	_	_	Seg=O
30	Hubei	_	_	_	_	_	_	_	Seg=O
31	province	_	_	_	_	_	_	_	Seg=O
32	,	_	_	_	_	_	_	_	Seg=O
33	China	_	_	_	_	_	_	_	Seg=O
34	.	_	_	_	_	_	_	_	Seg=O
35	The	_	_	_	_	_	_	_	Seg=B-seg
36	disease	_	_	_	_	_	_	_	Seg=O
37	caused	_	_	_	_	_	_	_	Seg=B-seg
38	by	_	_	_	_	_	_	_	Seg=O
39	this	_	_	_	_	_	_	_	Seg=O
40	virus	_	_	_	_	_	_	_	Seg=O
41	is	_	_	_	_	_	_	_	Seg=B-seg
42	called	_	_	_	_	_	_	_	Seg=O
43	COVID-19	_	_	_	_	_	_	_	Seg=O
44	(	_	_	_	_	_	_	_	Seg=O
45	coronavirus	_	_	_	_	_	_	_	Seg=O
46	disease	_	_	_	_	_	_	_	Seg=O
47	2019	_	_	_	_	_	_	_	Seg=O
48	)	_	_	_	_	_	_	_	Seg=O
49	.	_	_	_	_	_	_	_	Seg=O
50	The	_	_	_	_	_	_	_	Seg=B-seg
51	virus	_	_	_	_	_	_	_	Seg=O
52	is	_	_	_	_	_	_	_	Seg=O
53	transmitted	_	_	_	_	_	_	_	Seg=O
54	between	_	_	_	_	_	_	_	Seg=O
55	humans	_	_	_	_	_	_	_	Seg=O
56	and	_	_	_	_	_	_	_	Seg=B-seg
57	the	_	_	_	_	_	_	_	Seg=O
58	outbreak	_	_	_	_	_	_	_	Seg=O
59	was	_	_	_	_	_	_	_	Seg=O
60	declared	_	_	_	_	_	_	_	Seg=O
61	a	_	_	_	_	_	_	_	Seg=O
62	pandemic	_	_	_	_	_	_	_	Seg=O
63	by	_	_	_	_	_	_	_	Seg=O
64	the	_	_	_	_	_	_	_	Seg=O
65	World	_	_	_	_	_	_	_	Seg=O
66	Health	_	_	_	_	_	_	_	Seg=O
67	Organization	_	_	_	_	_	_	_	Seg=O
68	(	_	_	_	_	_	_	_	Seg=O
69	WHO	_	_	_	_	_	_	_	Seg=O
70	)	_	_	_	_	_	_	_	Seg=O
71	on	_	_	_	_	_	_	_	Seg=O
72	11	_	_	_	_	_	_	_	Seg=O
73	March	_	_	_	_	_	_	_	Seg=O
74	2020	_	_	_	_	_	_	_	Seg=O
75	.	_	_	_	_	_	_	_	Seg=O
76	Coagulopathy	_	_	_	_	_	_	_	Seg=B-seg
77	is	_	_	_	_	_	_	_	Seg=O
78	a	_	_	_	_	_	_	_	Seg=O
79	common	_	_	_	_	_	_	_	Seg=O
80	abnormality	_	_	_	_	_	_	_	Seg=O
81	in	_	_	_	_	_	_	_	Seg=O
82	patients	_	_	_	_	_	_	_	Seg=O
83	with	_	_	_	_	_	_	_	Seg=O
84	COVID-19	_	_	_	_	_	_	_	Seg=O
85	due	_	_	_	_	_	_	_	Seg=B-seg
86	to	_	_	_	_	_	_	_	Seg=O
87	inflammation	_	_	_	_	_	_	_	Seg=O
88	,	_	_	_	_	_	_	_	Seg=O
89	hypoxia	_	_	_	_	_	_	_	Seg=O
90	,	_	_	_	_	_	_	_	Seg=O
91	immobilisation	_	_	_	_	_	_	_	Seg=O
92	,	_	_	_	_	_	_	_	Seg=O
93	endothelial	_	_	_	_	_	_	_	Seg=O
94	damage	_	_	_	_	_	_	_	Seg=O
95	and	_	_	_	_	_	_	_	Seg=O
96	diffuse	_	_	_	_	_	_	_	Seg=O
97	intravascular	_	_	_	_	_	_	_	Seg=O
98	coagulation	_	_	_	_	_	_	_	Seg=O
99	.	_	_	_	_	_	_	_	Seg=O
100	However	_	_	_	_	_	_	_	Seg=B-seg
101	,	_	_	_	_	_	_	_	Seg=O
102	the	_	_	_	_	_	_	_	Seg=O
103	data	_	_	_	_	_	_	_	Seg=O
104	on	_	_	_	_	_	_	_	Seg=O
105	this	_	_	_	_	_	_	_	Seg=O
106	topic	_	_	_	_	_	_	_	Seg=O
107	are	_	_	_	_	_	_	_	Seg=O
108	still	_	_	_	_	_	_	_	Seg=O
109	limited	_	_	_	_	_	_	_	Seg=O
110	.	_	_	_	_	_	_	_	Seg=O
111	Here	_	_	_	_	_	_	_	Seg=B-seg
112	we	_	_	_	_	_	_	_	Seg=O
113	report	_	_	_	_	_	_	_	Seg=O
114	the	_	_	_	_	_	_	_	Seg=O
115	case	_	_	_	_	_	_	_	Seg=O
116	of	_	_	_	_	_	_	_	Seg=O
117	a	_	_	_	_	_	_	_	Seg=O
118	man	_	_	_	_	_	_	_	Seg=O
119	presenting	_	_	_	_	_	_	_	Seg=B-seg
120	with	_	_	_	_	_	_	_	Seg=O
121	pneumonia	_	_	_	_	_	_	_	Seg=O
122	complicated	_	_	_	_	_	_	_	Seg=B-seg
123	by	_	_	_	_	_	_	_	Seg=O
124	bilateral	_	_	_	_	_	_	_	Seg=O
125	pulmonary	_	_	_	_	_	_	_	Seg=O
126	embolism	_	_	_	_	_	_	_	Seg=O
127	LEARNING	_	_	_	_	_	_	_	Seg=B-seg
128	POINTS	_	_	_	_	_	_	_	Seg=O
129	•SARS	_	_	_	_	_	_	_	Seg=B-seg
130	-	_	_	_	_	_	_	_	Seg=O
131	CoV-2	_	_	_	_	_	_	_	Seg=O
132	is	_	_	_	_	_	_	_	Seg=O
133	a	_	_	_	_	_	_	_	Seg=O
134	novel	_	_	_	_	_	_	_	Seg=O
135	infectious	_	_	_	_	_	_	_	Seg=O
136	agent	_	_	_	_	_	_	_	Seg=O
137	that	_	_	_	_	_	_	_	Seg=B-seg
138	causes	_	_	_	_	_	_	_	Seg=O
139	COVID-19	_	_	_	_	_	_	_	Seg=O
140	,	_	_	_	_	_	_	_	Seg=O
141	which	_	_	_	_	_	_	_	Seg=B-seg
142	can	_	_	_	_	_	_	_	Seg=O
143	manifest	_	_	_	_	_	_	_	Seg=O
144	in	_	_	_	_	_	_	_	Seg=O
145	several	_	_	_	_	_	_	_	Seg=O
146	ways	_	_	_	_	_	_	_	Seg=O
147	,	_	_	_	_	_	_	_	Seg=O
148	affecting	_	_	_	_	_	_	_	Seg=B-seg
149	endothelial	_	_	_	_	_	_	_	Seg=O
150	cells	_	_	_	_	_	_	_	Seg=O
151	and	_	_	_	_	_	_	_	Seg=O
152	most	_	_	_	_	_	_	_	Seg=O
153	organs	_	_	_	_	_	_	_	Seg=O
154	.	_	_	_	_	_	_	_	Seg=O
155	•There	_	_	_	_	_	_	_	Seg=B-seg
156	is	_	_	_	_	_	_	_	Seg=O
157	growing	_	_	_	_	_	_	_	Seg=O
158	evidenc	_	_	_	_	_	_	_	Seg=O
159	that	_	_	_	_	_	_	_	Seg=B-seg
160	SARS	_	_	_	_	_	_	_	Seg=O
161	-	_	_	_	_	_	_	_	Seg=O
162	CoV-2-mediated	_	_	_	_	_	_	_	Seg=O
163	endothelial	_	_	_	_	_	_	_	Seg=O
164	damage	_	_	_	_	_	_	_	Seg=O
165	is	_	_	_	_	_	_	_	Seg=O
166	due	_	_	_	_	_	_	_	Seg=O
167	to	_	_	_	_	_	_	_	Seg=O
168	direct	_	_	_	_	_	_	_	Seg=O
169	viral	_	_	_	_	_	_	_	Seg=O
170	injury	_	_	_	_	_	_	_	Seg=O
171	and	_	_	_	_	_	_	_	Seg=O
172	the	_	_	_	_	_	_	_	Seg=O
173	systemic	_	_	_	_	_	_	_	Seg=O
174	inflammatory	_	_	_	_	_	_	_	Seg=O
175	response	_	_	_	_	_	_	_	Seg=O
176	,	_	_	_	_	_	_	_	Seg=O
177	possibly	_	_	_	_	_	_	_	Seg=O
178	together	_	_	_	_	_	_	_	Seg=O
179	with	_	_	_	_	_	_	_	Seg=O
180	a	_	_	_	_	_	_	_	Seg=O
181	cytokine	_	_	_	_	_	_	_	Seg=O
182	storm	_	_	_	_	_	_	_	Seg=O
183	.	_	_	_	_	_	_	_	Seg=O
184	•As	_	_	_	_	_	_	_	Seg=B-seg
185	endothelial	_	_	_	_	_	_	_	Seg=O
186	damage	_	_	_	_	_	_	_	Seg=O
187	can	_	_	_	_	_	_	_	Seg=O
188	manifest	_	_	_	_	_	_	_	Seg=O
189	as	_	_	_	_	_	_	_	Seg=O
190	thromboembolic	_	_	_	_	_	_	_	Seg=O
191	disease	_	_	_	_	_	_	_	Seg=O
192	,	_	_	_	_	_	_	_	Seg=O
193	such	_	_	_	_	_	_	_	Seg=B-seg
194	as	_	_	_	_	_	_	_	Seg=O
195	pulmonary	_	_	_	_	_	_	_	Seg=O
196	thromboembolism	_	_	_	_	_	_	_	Seg=O
197	,	_	_	_	_	_	_	_	Seg=O
198	appropriate	_	_	_	_	_	_	_	Seg=B-seg
199	anti	_	_	_	_	_	_	_	Seg=O
200	-	_	_	_	_	_	_	_	Seg=O
201	thrombotic	_	_	_	_	_	_	_	Seg=O
202	preventive	_	_	_	_	_	_	_	Seg=O
203	strategies	_	_	_	_	_	_	_	Seg=O
204	should	_	_	_	_	_	_	_	Seg=O
205	be	_	_	_	_	_	_	_	Seg=O
206	followed	_	_	_	_	_	_	_	Seg=O
207	,	_	_	_	_	_	_	_	Seg=O
208	and	_	_	_	_	_	_	_	Seg=B-seg
209	proper	_	_	_	_	_	_	_	Seg=O
210	screening	_	_	_	_	_	_	_	Seg=O
211	and	_	_	_	_	_	_	_	Seg=O
212	treatment	_	_	_	_	_	_	_	Seg=O
213	for	_	_	_	_	_	_	_	Seg=O
214	thromboembolic	_	_	_	_	_	_	_	Seg=O
215	complications	_	_	_	_	_	_	_	Seg=O
216	should	_	_	_	_	_	_	_	Seg=O
217	be	_	_	_	_	_	_	_	Seg=O
218	implemented	_	_	_	_	_	_	_	Seg=O
219	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 0a1f43c04e0e22fb6efbd94611920bc9680d7ae3
1	Background	_	_	_	_	_	_	_	Seg=B-seg
2	:	_	_	_	_	_	_	_	Seg=O
3	Systemic	_	_	_	_	_	_	_	Seg=B-seg
4	lupus	_	_	_	_	_	_	_	Seg=O
5	erythematosus	_	_	_	_	_	_	_	Seg=O
6	(	_	_	_	_	_	_	_	Seg=O
7	SLE	_	_	_	_	_	_	_	Seg=O
8	)	_	_	_	_	_	_	_	Seg=O
9	is	_	_	_	_	_	_	_	Seg=O
10	associated	_	_	_	_	_	_	_	Seg=O
11	with	_	_	_	_	_	_	_	Seg=O
12	immunogenetic	_	_	_	_	_	_	_	Seg=O
13	factors	_	_	_	_	_	_	_	Seg=O
14	.	_	_	_	_	_	_	_	Seg=O
15	This	_	_	_	_	_	_	_	Seg=B-seg
16	study	_	_	_	_	_	_	_	Seg=O
17	was	_	_	_	_	_	_	_	Seg=O
18	planned	_	_	_	_	_	_	_	Seg=O
19	to	_	_	_	_	_	_	_	Seg=B-seg
20	test	_	_	_	_	_	_	_	Seg=O
21	for	_	_	_	_	_	_	_	Seg=O
22	the	_	_	_	_	_	_	_	Seg=O
23	association	_	_	_	_	_	_	_	Seg=O
24	of	_	_	_	_	_	_	_	Seg=O
25	TNF	_	_	_	_	_	_	_	Seg=O
26	-	_	_	_	_	_	_	_	Seg=O
27	α	_	_	_	_	_	_	_	Seg=O
28	−	_	_	_	_	_	_	_	Seg=O
29	308	_	_	_	_	_	_	_	Seg=O
30	and	_	_	_	_	_	_	_	Seg=O
31	IFN	_	_	_	_	_	_	_	Seg=O
32	-	_	_	_	_	_	_	_	Seg=O
33	γ	_	_	_	_	_	_	_	Seg=O
34	+874	_	_	_	_	_	_	_	Seg=O
35	gene	_	_	_	_	_	_	_	Seg=O
36	polymorphisms	_	_	_	_	_	_	_	Seg=O
37	with	_	_	_	_	_	_	_	Seg=O
38	susceptibility	_	_	_	_	_	_	_	Seg=O
39	and	_	_	_	_	_	_	_	Seg=O
40	severity	_	_	_	_	_	_	_	Seg=O
41	of	_	_	_	_	_	_	_	Seg=O
42	SLE	_	_	_	_	_	_	_	Seg=O
43	in	_	_	_	_	_	_	_	Seg=O
44	Egyptian	_	_	_	_	_	_	_	Seg=O
45	cases	_	_	_	_	_	_	_	Seg=O
46	.	_	_	_	_	_	_	_	Seg=O
47	Subjects	_	_	_	_	_	_	_	Seg=B-seg
48	and	_	_	_	_	_	_	_	Seg=O
49	methods	_	_	_	_	_	_	_	Seg=O
50	:	_	_	_	_	_	_	_	Seg=O
51	This	_	_	_	_	_	_	_	Seg=B-seg
52	is	_	_	_	_	_	_	_	Seg=O
53	a	_	_	_	_	_	_	_	Seg=O
54	case	_	_	_	_	_	_	_	Seg=O
55	controlled	_	_	_	_	_	_	_	Seg=O
56	study	_	_	_	_	_	_	_	Seg=O
57	including	_	_	_	_	_	_	_	Seg=B-seg
58	125	_	_	_	_	_	_	_	Seg=O
59	Egyptian	_	_	_	_	_	_	_	Seg=O
60	cases	_	_	_	_	_	_	_	Seg=O
61	with	_	_	_	_	_	_	_	Seg=O
62	SLE	_	_	_	_	_	_	_	Seg=O
63	in	_	_	_	_	_	_	_	Seg=O
64	addition	_	_	_	_	_	_	_	Seg=O
65	to	_	_	_	_	_	_	_	Seg=O
66	112	_	_	_	_	_	_	_	Seg=O
67	healthy	_	_	_	_	_	_	_	Seg=O
68	unrelated	_	_	_	_	_	_	_	Seg=O
69	individuals	_	_	_	_	_	_	_	Seg=O
70	from	_	_	_	_	_	_	_	Seg=O
71	the	_	_	_	_	_	_	_	Seg=O
72	same	_	_	_	_	_	_	_	Seg=O
73	locality	_	_	_	_	_	_	_	Seg=O
74	.	_	_	_	_	_	_	_	Seg=O
75	For	_	_	_	_	_	_	_	Seg=B-seg
76	all	_	_	_	_	_	_	_	Seg=O
77	participants	_	_	_	_	_	_	_	Seg=O
78	,	_	_	_	_	_	_	_	Seg=O
79	TNF	_	_	_	_	_	_	_	Seg=O
80	-	_	_	_	_	_	_	_	Seg=O
81	α	_	_	_	_	_	_	_	Seg=O
82	−	_	_	_	_	_	_	_	Seg=O
83	308	_	_	_	_	_	_	_	Seg=O
84	G	_	_	_	_	_	_	_	Seg=O
85	NA	_	_	_	_	_	_	_	Seg=O
86	and	_	_	_	_	_	_	_	Seg=O
87	IFN	_	_	_	_	_	_	_	Seg=O
88	-	_	_	_	_	_	_	_	Seg=O
89	γ	_	_	_	_	_	_	_	Seg=O
90	+	_	_	_	_	_	_	_	Seg=O
91	874	_	_	_	_	_	_	_	Seg=O
92	ANT	_	_	_	_	_	_	_	Seg=O
93	genetic	_	_	_	_	_	_	_	Seg=O
94	polymorphisms	_	_	_	_	_	_	_	Seg=O
95	were	_	_	_	_	_	_	_	Seg=O
96	characterized	_	_	_	_	_	_	_	Seg=O
97	using	_	_	_	_	_	_	_	Seg=B-seg
98	the	_	_	_	_	_	_	_	Seg=O
99	PCR	_	_	_	_	_	_	_	Seg=O
100	technique	_	_	_	_	_	_	_	Seg=O
101	.	_	_	_	_	_	_	_	Seg=O
102	Results	_	_	_	_	_	_	_	Seg=B-seg
103	:	_	_	_	_	_	_	_	Seg=O
104	Cases	_	_	_	_	_	_	_	Seg=B-seg
105	with	_	_	_	_	_	_	_	Seg=O
106	SLE	_	_	_	_	_	_	_	Seg=O
107	showed	_	_	_	_	_	_	_	Seg=O
108	a	_	_	_	_	_	_	_	Seg=O
109	significantly	_	_	_	_	_	_	_	Seg=O
110	higher	_	_	_	_	_	_	_	Seg=O
111	TNF	_	_	_	_	_	_	_	Seg=O
112	-	_	_	_	_	_	_	_	Seg=O
113	α	_	_	_	_	_	_	_	Seg=O
114	−308	_	_	_	_	_	_	_	Seg=O
115	A	_	_	_	_	_	_	_	Seg=O
116	allele	_	_	_	_	_	_	_	Seg=O
117	carriage	_	_	_	_	_	_	_	Seg=O
118	rate	_	_	_	_	_	_	_	Seg=O
119	(	_	_	_	_	_	_	_	Seg=B-seg
120	AA	_	_	_	_	_	_	_	Seg=O
121	+	_	_	_	_	_	_	_	Seg=O
122	GA	_	_	_	_	_	_	_	Seg=O
123	genotypes	_	_	_	_	_	_	_	Seg=O
124	)	_	_	_	_	_	_	_	Seg=O
125	compared	_	_	_	_	_	_	_	Seg=B-seg
126	to	_	_	_	_	_	_	_	Seg=O
127	controls	_	_	_	_	_	_	_	Seg=O
128	(	_	_	_	_	_	_	_	Seg=B-seg
129	26.4	_	_	_	_	_	_	_	Seg=O
130	%	_	_	_	_	_	_	_	Seg=O
131	vs.	_	_	_	_	_	_	_	Seg=O
132	12.5	_	_	_	_	_	_	_	Seg=O
133	%	_	_	_	_	_	_	_	Seg=O
134	,	_	_	_	_	_	_	_	Seg=O
135	p	_	_	_	_	_	_	_	Seg=O
136	=	_	_	_	_	_	_	_	Seg=O
137	0.009	_	_	_	_	_	_	_	Seg=O
138	,	_	_	_	_	_	_	_	Seg=O
139	OR	_	_	_	_	_	_	_	Seg=O
140	=	_	_	_	_	_	_	_	Seg=O
141	2.51	_	_	_	_	_	_	_	Seg=O
142	,	_	_	_	_	_	_	_	Seg=O
143	95	_	_	_	_	_	_	_	Seg=O
144	%	_	_	_	_	_	_	_	Seg=O
145	CI	_	_	_	_	_	_	_	Seg=O
146	=	_	_	_	_	_	_	_	Seg=O
147	1.26	_	_	_	_	_	_	_	Seg=O
148	-	_	_	_	_	_	_	_	Seg=O
149	4.99	_	_	_	_	_	_	_	Seg=O
150	)	_	_	_	_	_	_	_	Seg=O
151	.	_	_	_	_	_	_	_	Seg=O
152	These	_	_	_	_	_	_	_	Seg=B-seg
153	cases	_	_	_	_	_	_	_	Seg=O
154	showed	_	_	_	_	_	_	_	Seg=O
155	also	_	_	_	_	_	_	_	Seg=O
156	a	_	_	_	_	_	_	_	Seg=O
157	significantly	_	_	_	_	_	_	_	Seg=O
158	higher	_	_	_	_	_	_	_	Seg=O
159	carriage	_	_	_	_	_	_	_	Seg=O
160	rate	_	_	_	_	_	_	_	Seg=O
161	for	_	_	_	_	_	_	_	Seg=O
162	the	_	_	_	_	_	_	_	Seg=O
163	IFN	_	_	_	_	_	_	_	Seg=O
164	-	_	_	_	_	_	_	_	Seg=O
165	γ	_	_	_	_	_	_	_	Seg=O
166	+874	_	_	_	_	_	_	_	Seg=O
167	T	_	_	_	_	_	_	_	Seg=O
168	allele	_	_	_	_	_	_	_	Seg=O
169	(	_	_	_	_	_	_	_	Seg=B-seg
170	AT	_	_	_	_	_	_	_	Seg=O
171	+	_	_	_	_	_	_	_	Seg=O
172	TT	_	_	_	_	_	_	_	Seg=O
173	genotypes	_	_	_	_	_	_	_	Seg=O
174	)	_	_	_	_	_	_	_	Seg=O
175	compared	_	_	_	_	_	_	_	Seg=B-seg
176	to	_	_	_	_	_	_	_	Seg=O
177	controls	_	_	_	_	_	_	_	Seg=O
178	(	_	_	_	_	_	_	_	Seg=B-seg
179	47.2	_	_	_	_	_	_	_	Seg=O
180	%	_	_	_	_	_	_	_	Seg=O
181	vs.	_	_	_	_	_	_	_	Seg=O
182	32.1	_	_	_	_	_	_	_	Seg=O
183	%	_	_	_	_	_	_	_	Seg=O
184	,	_	_	_	_	_	_	_	Seg=O
185	p	_	_	_	_	_	_	_	Seg=O
186	=	_	_	_	_	_	_	_	Seg=O
187	0.02	_	_	_	_	_	_	_	Seg=O
188	,	_	_	_	_	_	_	_	Seg=O
189	OR	_	_	_	_	_	_	_	Seg=O
190	=	_	_	_	_	_	_	_	Seg=O
191	1.89	_	_	_	_	_	_	_	Seg=O
192	,	_	_	_	_	_	_	_	Seg=O
193	95	_	_	_	_	_	_	_	Seg=O
194	%	_	_	_	_	_	_	_	Seg=O
195	CI	_	_	_	_	_	_	_	Seg=O
196	=	_	_	_	_	_	_	_	Seg=O
197	1.11	_	_	_	_	_	_	_	Seg=O
198	-	_	_	_	_	_	_	_	Seg=O
199	3.21	_	_	_	_	_	_	_	Seg=O
200	)	_	_	_	_	_	_	_	Seg=O
201	.	_	_	_	_	_	_	_	Seg=O
202	Comparing	_	_	_	_	_	_	_	Seg=B-seg
203	age	_	_	_	_	_	_	_	Seg=O
204	,	_	_	_	_	_	_	_	Seg=O
205	gender	_	_	_	_	_	_	_	Seg=O
206	,	_	_	_	_	_	_	_	Seg=O
207	and	_	_	_	_	_	_	_	Seg=O
208	disease	_	_	_	_	_	_	_	Seg=O
209	severity	_	_	_	_	_	_	_	Seg=O
210	presented	_	_	_	_	_	_	_	Seg=B-seg
211	by	_	_	_	_	_	_	_	Seg=O
212	nephritis	_	_	_	_	_	_	_	Seg=O
213	class	_	_	_	_	_	_	_	Seg=O
214	,	_	_	_	_	_	_	_	Seg=O
215	activity	_	_	_	_	_	_	_	Seg=B-seg
216	and	_	_	_	_	_	_	_	Seg=O
217	chronicity	_	_	_	_	_	_	_	Seg=O
218	indices	_	_	_	_	_	_	_	Seg=O
219	in	_	_	_	_	_	_	_	Seg=O
220	cases	_	_	_	_	_	_	_	Seg=O
221	carrying	_	_	_	_	_	_	_	Seg=B-seg
222	the	_	_	_	_	_	_	_	Seg=O
223	TNF	_	_	_	_	_	_	_	Seg=O
224	-	_	_	_	_	_	_	_	Seg=O
225	α	_	_	_	_	_	_	_	Seg=O
226	−308	_	_	_	_	_	_	_	Seg=O
227	A	_	_	_	_	_	_	_	Seg=O
228	allele	_	_	_	_	_	_	_	Seg=O
229	and	_	_	_	_	_	_	_	Seg=B-seg
230	in	_	_	_	_	_	_	_	Seg=O
231	cases	_	_	_	_	_	_	_	Seg=O
232	carrying	_	_	_	_	_	_	_	Seg=B-seg
233	IFN	_	_	_	_	_	_	_	Seg=O
234	-	_	_	_	_	_	_	_	Seg=O
235	γ	_	_	_	_	_	_	_	Seg=O
236	+874	_	_	_	_	_	_	_	Seg=O
237	T	_	_	_	_	_	_	_	Seg=O
238	allele	_	_	_	_	_	_	_	Seg=O
239	versus	_	_	_	_	_	_	_	Seg=B-seg
240	others	_	_	_	_	_	_	_	Seg=O
241	showed	_	_	_	_	_	_	_	Seg=O
242	no	_	_	_	_	_	_	_	Seg=O
243	significant	_	_	_	_	_	_	_	Seg=O
244	difference	_	_	_	_	_	_	_	Seg=O
245	(	_	_	_	_	_	_	_	Seg=O
246	p	_	_	_	_	_	_	_	Seg=O
247	N	_	_	_	_	_	_	_	Seg=O
248	0.05	_	_	_	_	_	_	_	Seg=O
249	)	_	_	_	_	_	_	_	Seg=O
250	.	_	_	_	_	_	_	_	Seg=O
251	Conclusions	_	_	_	_	_	_	_	Seg=B-seg
252	:	_	_	_	_	_	_	_	Seg=O
253	TNF	_	_	_	_	_	_	_	Seg=B-seg
254	-	_	_	_	_	_	_	_	Seg=O
255	α	_	_	_	_	_	_	_	Seg=O
256	−308	_	_	_	_	_	_	_	Seg=O
257	A	_	_	_	_	_	_	_	Seg=O
258	and	_	_	_	_	_	_	_	Seg=O
259	IFN	_	_	_	_	_	_	_	Seg=O
260	-	_	_	_	_	_	_	_	Seg=O
261	γ	_	_	_	_	_	_	_	Seg=O
262	+874	_	_	_	_	_	_	_	Seg=O
263	T	_	_	_	_	_	_	_	Seg=O
264	allele	_	_	_	_	_	_	_	Seg=O
265	carriage	_	_	_	_	_	_	_	Seg=O
266	are	_	_	_	_	_	_	_	Seg=O
267	associated	_	_	_	_	_	_	_	Seg=O
268	with	_	_	_	_	_	_	_	Seg=O
269	susceptibility	_	_	_	_	_	_	_	Seg=O
270	but	_	_	_	_	_	_	_	Seg=O
271	not	_	_	_	_	_	_	_	Seg=O
272	severity	_	_	_	_	_	_	_	Seg=O
273	of	_	_	_	_	_	_	_	Seg=O
274	SLE	_	_	_	_	_	_	_	Seg=O
275	in	_	_	_	_	_	_	_	Seg=O
276	Egyptian	_	_	_	_	_	_	_	Seg=O
277	subjects	_	_	_	_	_	_	_	Seg=O
278	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 0a28be687a48559948dfb278cb34b4ae4185e27f
1	The	_	_	_	_	_	_	_	Seg=B-seg
2	purpose	_	_	_	_	_	_	_	Seg=O
3	of	_	_	_	_	_	_	_	Seg=O
4	this	_	_	_	_	_	_	_	Seg=O
5	form	_	_	_	_	_	_	_	Seg=O
6	is	_	_	_	_	_	_	_	Seg=O
7	to	_	_	_	_	_	_	_	Seg=O
8	provide	_	_	_	_	_	_	_	Seg=O
9	readers	_	_	_	_	_	_	_	Seg=O
10	of	_	_	_	_	_	_	_	Seg=O
11	your	_	_	_	_	_	_	_	Seg=O
12	manuscript	_	_	_	_	_	_	_	Seg=O
13	with	_	_	_	_	_	_	_	Seg=O
14	information	_	_	_	_	_	_	_	Seg=O
15	about	_	_	_	_	_	_	_	Seg=O
16	your	_	_	_	_	_	_	_	Seg=O
17	other	_	_	_	_	_	_	_	Seg=O
18	interests	_	_	_	_	_	_	_	Seg=O
19	that	_	_	_	_	_	_	_	Seg=B-seg
20	could	_	_	_	_	_	_	_	Seg=O
21	influence	_	_	_	_	_	_	_	Seg=O
22	how	_	_	_	_	_	_	_	Seg=O
23	they	_	_	_	_	_	_	_	Seg=O
24	receive	_	_	_	_	_	_	_	Seg=O
25	and	_	_	_	_	_	_	_	Seg=O
26	understand	_	_	_	_	_	_	_	Seg=O
27	your	_	_	_	_	_	_	_	Seg=O
28	work	_	_	_	_	_	_	_	Seg=O
29	.	_	_	_	_	_	_	_	Seg=O
30	The	_	_	_	_	_	_	_	Seg=B-seg
31	form	_	_	_	_	_	_	_	Seg=O
32	is	_	_	_	_	_	_	_	Seg=O
33	designed	_	_	_	_	_	_	_	Seg=O
34	to	_	_	_	_	_	_	_	Seg=B-seg
35	be	_	_	_	_	_	_	_	Seg=O
36	completed	_	_	_	_	_	_	_	Seg=O
37	electronically	_	_	_	_	_	_	_	Seg=O
38	and	_	_	_	_	_	_	_	Seg=B-seg
39	stored	_	_	_	_	_	_	_	Seg=O
40	electronically	_	_	_	_	_	_	_	Seg=O
41	.	_	_	_	_	_	_	_	Seg=O
42	It	_	_	_	_	_	_	_	Seg=B-seg
43	contains	_	_	_	_	_	_	_	Seg=O
44	programming	_	_	_	_	_	_	_	Seg=O
45	that	_	_	_	_	_	_	_	Seg=B-seg
46	allows	_	_	_	_	_	_	_	Seg=O
47	appropriate	_	_	_	_	_	_	_	Seg=O
48	data	_	_	_	_	_	_	_	Seg=O
49	display	_	_	_	_	_	_	_	Seg=O
50	.	_	_	_	_	_	_	_	Seg=O
51	Each	_	_	_	_	_	_	_	Seg=B-seg
52	author	_	_	_	_	_	_	_	Seg=O
53	should	_	_	_	_	_	_	_	Seg=O
54	submit	_	_	_	_	_	_	_	Seg=O
55	a	_	_	_	_	_	_	_	Seg=O
56	separate	_	_	_	_	_	_	_	Seg=O
57	form	_	_	_	_	_	_	_	Seg=O
58	and	_	_	_	_	_	_	_	Seg=B-seg
59	is	_	_	_	_	_	_	_	Seg=O
60	responsible	_	_	_	_	_	_	_	Seg=O
61	for	_	_	_	_	_	_	_	Seg=O
62	the	_	_	_	_	_	_	_	Seg=O
63	accuracy	_	_	_	_	_	_	_	Seg=O
64	and	_	_	_	_	_	_	_	Seg=O
65	completeness	_	_	_	_	_	_	_	Seg=O
66	of	_	_	_	_	_	_	_	Seg=O
67	the	_	_	_	_	_	_	_	Seg=O
68	submitted	_	_	_	_	_	_	_	Seg=O
69	information	_	_	_	_	_	_	_	Seg=O
70	.	_	_	_	_	_	_	_	Seg=O
71	The	_	_	_	_	_	_	_	Seg=B-seg
72	form	_	_	_	_	_	_	_	Seg=O
73	is	_	_	_	_	_	_	_	Seg=O
74	in	_	_	_	_	_	_	_	Seg=O
75	six	_	_	_	_	_	_	_	Seg=O
76	parts	_	_	_	_	_	_	_	Seg=O
77	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 0a6e4bc983e7a8eb31e252398f47cdaaf1e605b1
1	Serine	_	_	_	_	_	_	_	Seg=B-seg
2	proteases	_	_	_	_	_	_	_	Seg=O
3	of	_	_	_	_	_	_	_	Seg=O
4	the	_	_	_	_	_	_	_	Seg=O
5	trypsin	_	_	_	_	_	_	_	Seg=O
6	-	_	_	_	_	_	_	_	Seg=O
7	like	_	_	_	_	_	_	_	Seg=O
8	family	_	_	_	_	_	_	_	Seg=O
9	have	_	_	_	_	_	_	_	Seg=O
10	long	_	_	_	_	_	_	_	Seg=O
11	been	_	_	_	_	_	_	_	Seg=O
12	recognized	_	_	_	_	_	_	_	Seg=O
13	to	_	_	_	_	_	_	_	Seg=O
14	be	_	_	_	_	_	_	_	Seg=O
15	critical	_	_	_	_	_	_	_	Seg=O
16	effectors	_	_	_	_	_	_	_	Seg=O
17	of	_	_	_	_	_	_	_	Seg=O
18	biological	_	_	_	_	_	_	_	Seg=O
19	processes	_	_	_	_	_	_	_	Seg=O
20	as	_	_	_	_	_	_	_	Seg=O
21	diverse	_	_	_	_	_	_	_	Seg=O
22	as	_	_	_	_	_	_	_	Seg=O
23	digestion	_	_	_	_	_	_	_	Seg=O
24	,	_	_	_	_	_	_	_	Seg=O
25	blood	_	_	_	_	_	_	_	Seg=O
26	coagulation	_	_	_	_	_	_	_	Seg=O
27	,	_	_	_	_	_	_	_	Seg=O
28	fibrinolysis	_	_	_	_	_	_	_	Seg=O
29	,	_	_	_	_	_	_	_	Seg=O
30	and	_	_	_	_	_	_	_	Seg=O
31	immunity	_	_	_	_	_	_	_	Seg=O
32	.	_	_	_	_	_	_	_	Seg=O
33	In	_	_	_	_	_	_	_	Seg=B-seg
34	recent	_	_	_	_	_	_	_	Seg=O
35	years	_	_	_	_	_	_	_	Seg=O
36	,	_	_	_	_	_	_	_	Seg=O
37	a	_	_	_	_	_	_	_	Seg=O
38	subgroup	_	_	_	_	_	_	_	Seg=O
39	of	_	_	_	_	_	_	_	Seg=O
40	these	_	_	_	_	_	_	_	Seg=O
41	enzymes	_	_	_	_	_	_	_	Seg=O
42	has	_	_	_	_	_	_	_	Seg=O
43	been	_	_	_	_	_	_	_	Seg=O
44	identified	_	_	_	_	_	_	_	Seg=O
45	that	_	_	_	_	_	_	_	Seg=O
46	are	_	_	_	_	_	_	_	Seg=O
47	anchored	_	_	_	_	_	_	_	Seg=O
48	directly	_	_	_	_	_	_	_	Seg=O
49	to	_	_	_	_	_	_	_	Seg=O
50	plasma	_	_	_	_	_	_	_	Seg=O
51	membranes	_	_	_	_	_	_	_	Seg=O
52	,	_	_	_	_	_	_	_	Seg=O
53	either	_	_	_	_	_	_	_	Seg=O
54	by	_	_	_	_	_	_	_	Seg=O
55	a	_	_	_	_	_	_	_	Seg=O
56	carboxy	_	_	_	_	_	_	_	Seg=O
57	-	_	_	_	_	_	_	_	Seg=O
58	terminal	_	_	_	_	_	_	_	Seg=O
59	transmembrane	_	_	_	_	_	_	_	Seg=O
60	domain	_	_	_	_	_	_	_	Seg=O
61	(	_	_	_	_	_	_	_	Seg=O
62	Type	_	_	_	_	_	_	_	Seg=O
63	I	_	_	_	_	_	_	_	Seg=O
64	)	_	_	_	_	_	_	_	Seg=O
65	,	_	_	_	_	_	_	_	Seg=O
66	an	_	_	_	_	_	_	_	Seg=O
67	amino	_	_	_	_	_	_	_	Seg=O
68	-	_	_	_	_	_	_	_	Seg=O
69	terminal	_	_	_	_	_	_	_	Seg=O
70	transmembrane	_	_	_	_	_	_	_	Seg=O
71	domain	_	_	_	_	_	_	_	Seg=O
72	with	_	_	_	_	_	_	_	Seg=O
73	a	_	_	_	_	_	_	_	Seg=O
74	cytoplasmic	_	_	_	_	_	_	_	Seg=O
75	extension	_	_	_	_	_	_	_	Seg=O
76	(	_	_	_	_	_	_	_	Seg=O
77	Type	_	_	_	_	_	_	_	Seg=O
78	II	_	_	_	_	_	_	_	Seg=O
79	or	_	_	_	_	_	_	_	Seg=O
80	TTSP	_	_	_	_	_	_	_	Seg=O
81	)	_	_	_	_	_	_	_	Seg=O
82	,	_	_	_	_	_	_	_	Seg=O
83	or	_	_	_	_	_	_	_	Seg=O
84	through	_	_	_	_	_	_	_	Seg=O
85	a	_	_	_	_	_	_	_	Seg=O
86	glycosylphosphatidylinositol	_	_	_	_	_	_	_	Seg=O
87	(	_	_	_	_	_	_	_	Seg=O
88	GPI	_	_	_	_	_	_	_	Seg=O
89	)	_	_	_	_	_	_	_	Seg=O
90	linkage	_	_	_	_	_	_	_	Seg=O
91	.	_	_	_	_	_	_	_	Seg=O
92	Recent	_	_	_	_	_	_	_	Seg=B-seg
93	biochemical	_	_	_	_	_	_	_	Seg=O
94	,	_	_	_	_	_	_	_	Seg=O
95	cellular	_	_	_	_	_	_	_	Seg=O
96	,	_	_	_	_	_	_	_	Seg=O
97	and	_	_	_	_	_	_	_	Seg=O
98	in	_	_	_	_	_	_	_	Seg=O
99	vivo	_	_	_	_	_	_	_	Seg=O
100	analyses	_	_	_	_	_	_	_	Seg=O
101	have	_	_	_	_	_	_	_	Seg=O
102	now	_	_	_	_	_	_	_	Seg=O
103	established	_	_	_	_	_	_	_	Seg=O
104	that	_	_	_	_	_	_	_	Seg=B-seg
105	membrane	_	_	_	_	_	_	_	Seg=O
106	-	_	_	_	_	_	_	_	Seg=O
107	anchored	_	_	_	_	_	_	_	Seg=O
108	serine	_	_	_	_	_	_	_	Seg=O
109	proteases	_	_	_	_	_	_	_	Seg=O
110	are	_	_	_	_	_	_	_	Seg=O
111	key	_	_	_	_	_	_	_	Seg=O
112	pericellular	_	_	_	_	_	_	_	Seg=O
113	contributors	_	_	_	_	_	_	_	Seg=O
114	to	_	_	_	_	_	_	_	Seg=O
115	processes	_	_	_	_	_	_	_	Seg=O
116	vital	_	_	_	_	_	_	_	Seg=O
117	for	_	_	_	_	_	_	_	Seg=O
118	development	_	_	_	_	_	_	_	Seg=O
119	and	_	_	_	_	_	_	_	Seg=O
120	the	_	_	_	_	_	_	_	Seg=O
121	maintenance	_	_	_	_	_	_	_	Seg=O
122	of	_	_	_	_	_	_	_	Seg=O
123	homeostasis	_	_	_	_	_	_	_	Seg=O
124	.	_	_	_	_	_	_	_	Seg=O
125	This	_	_	_	_	_	_	_	Seg=B-seg
126	chapter	_	_	_	_	_	_	_	Seg=O
127	will	_	_	_	_	_	_	_	Seg=O
128	review	_	_	_	_	_	_	_	Seg=O
129	our	_	_	_	_	_	_	_	Seg=O
130	current	_	_	_	_	_	_	_	Seg=O
131	knowledge	_	_	_	_	_	_	_	Seg=O
132	of	_	_	_	_	_	_	_	Seg=O
133	the	_	_	_	_	_	_	_	Seg=O
134	biological	_	_	_	_	_	_	_	Seg=O
135	and	_	_	_	_	_	_	_	Seg=O
136	physiological	_	_	_	_	_	_	_	Seg=O
137	functions	_	_	_	_	_	_	_	Seg=O
138	of	_	_	_	_	_	_	_	Seg=O
139	these	_	_	_	_	_	_	_	Seg=O
140	proteases	_	_	_	_	_	_	_	Seg=O
141	,	_	_	_	_	_	_	_	Seg=O
142	their	_	_	_	_	_	_	_	Seg=O
143	molecular	_	_	_	_	_	_	_	Seg=O
144	substrates	_	_	_	_	_	_	_	Seg=O
145	,	_	_	_	_	_	_	_	Seg=O
146	and	_	_	_	_	_	_	_	Seg=O
147	their	_	_	_	_	_	_	_	Seg=O
148	contributions	_	_	_	_	_	_	_	Seg=O
149	to	_	_	_	_	_	_	_	Seg=O
150	disease	_	_	_	_	_	_	_	Seg=O
151	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 0a789bc7f1713d549288d3effb72ff34cd3b0ab0
1	Background	_	_	_	_	_	_	_	Seg=B-seg
2	:	_	_	_	_	_	_	_	Seg=O
3	Host	_	_	_	_	_	_	_	Seg=B-seg
4	proteases	_	_	_	_	_	_	_	Seg=O
5	have	_	_	_	_	_	_	_	Seg=O
6	been	_	_	_	_	_	_	_	Seg=O
7	shown	_	_	_	_	_	_	_	Seg=O
8	to	_	_	_	_	_	_	_	Seg=O
9	play	_	_	_	_	_	_	_	Seg=O
10	important	_	_	_	_	_	_	_	Seg=O
11	roles	_	_	_	_	_	_	_	Seg=O
12	in	_	_	_	_	_	_	_	Seg=O
13	many	_	_	_	_	_	_	_	Seg=O
14	viral	_	_	_	_	_	_	_	Seg=O
15	activities	_	_	_	_	_	_	_	Seg=O
16	such	_	_	_	_	_	_	_	Seg=B-seg
17	as	_	_	_	_	_	_	_	Seg=O
18	entry	_	_	_	_	_	_	_	Seg=O
19	,	_	_	_	_	_	_	_	Seg=O
20	uncoating	_	_	_	_	_	_	_	Seg=O
21	,	_	_	_	_	_	_	_	Seg=O
22	viral	_	_	_	_	_	_	_	Seg=O
23	protein	_	_	_	_	_	_	_	Seg=O
24	production	_	_	_	_	_	_	_	Seg=O
25	and	_	_	_	_	_	_	_	Seg=O
26	disease	_	_	_	_	_	_	_	Seg=O
27	induction	_	_	_	_	_	_	_	Seg=O
28	.	_	_	_	_	_	_	_	Seg=O
29	Therefore	_	_	_	_	_	_	_	Seg=B-seg
30	,	_	_	_	_	_	_	_	Seg=O
31	these	_	_	_	_	_	_	_	Seg=O
32	cellular	_	_	_	_	_	_	_	Seg=O
33	proteases	_	_	_	_	_	_	_	Seg=O
34	are	_	_	_	_	_	_	_	Seg=O
35	putative	_	_	_	_	_	_	_	Seg=O
36	targets	_	_	_	_	_	_	_	Seg=O
37	for	_	_	_	_	_	_	_	Seg=O
38	the	_	_	_	_	_	_	_	Seg=O
39	development	_	_	_	_	_	_	_	Seg=O
40	of	_	_	_	_	_	_	_	Seg=O
41	antivirals	_	_	_	_	_	_	_	Seg=O
42	that	_	_	_	_	_	_	_	Seg=B-seg
43	inhibit	_	_	_	_	_	_	_	Seg=O
44	their	_	_	_	_	_	_	_	Seg=O
45	activity	_	_	_	_	_	_	_	Seg=O
46	.	_	_	_	_	_	_	_	Seg=O
47	Host	_	_	_	_	_	_	_	Seg=B-seg
48	proteases	_	_	_	_	_	_	_	Seg=O
49	have	_	_	_	_	_	_	_	Seg=O
50	been	_	_	_	_	_	_	_	Seg=O
51	described	_	_	_	_	_	_	_	Seg=O
52	to	_	_	_	_	_	_	_	Seg=O
53	play	_	_	_	_	_	_	_	Seg=O
54	essential	_	_	_	_	_	_	_	Seg=O
55	roles	_	_	_	_	_	_	_	Seg=O
56	in	_	_	_	_	_	_	_	Seg=O
57	Ebola	_	_	_	_	_	_	_	Seg=O
58	,	_	_	_	_	_	_	_	Seg=O
59	HCV	_	_	_	_	_	_	_	Seg=O
60	,	_	_	_	_	_	_	_	Seg=O
61	HIV	_	_	_	_	_	_	_	Seg=O
62	and	_	_	_	_	_	_	_	Seg=O
63	influenza	_	_	_	_	_	_	_	Seg=O
64	,	_	_	_	_	_	_	_	Seg=O
65	such	_	_	_	_	_	_	_	Seg=B-seg
66	that	_	_	_	_	_	_	_	Seg=O
67	specific	_	_	_	_	_	_	_	Seg=O
68	protease	_	_	_	_	_	_	_	Seg=O
69	inhibitors	_	_	_	_	_	_	_	Seg=O
70	are	_	_	_	_	_	_	_	Seg=O
71	able	_	_	_	_	_	_	_	Seg=O
72	to	_	_	_	_	_	_	_	Seg=O
73	reduce	_	_	_	_	_	_	_	Seg=O
74	infection	_	_	_	_	_	_	_	Seg=O
75	.	_	_	_	_	_	_	_	Seg=O
76	RSV	_	_	_	_	_	_	_	Seg=B-seg
77	utilizes	_	_	_	_	_	_	_	Seg=O
78	a	_	_	_	_	_	_	_	Seg=O
79	host	_	_	_	_	_	_	_	Seg=O
80	protease	_	_	_	_	_	_	_	Seg=O
81	in	_	_	_	_	_	_	_	Seg=O
82	its	_	_	_	_	_	_	_	Seg=O
83	replication	_	_	_	_	_	_	_	Seg=O
84	cycle	_	_	_	_	_	_	_	Seg=O
85	but	_	_	_	_	_	_	_	Seg=B-seg
86	its	_	_	_	_	_	_	_	Seg=O
87	potential	_	_	_	_	_	_	_	Seg=O
88	as	_	_	_	_	_	_	_	Seg=O
89	antiviral	_	_	_	_	_	_	_	Seg=O
90	target	_	_	_	_	_	_	_	Seg=O
91	is	_	_	_	_	_	_	_	Seg=O
92	unknown	_	_	_	_	_	_	_	Seg=O
93	.	_	_	_	_	_	_	_	Seg=O
94	Therefore	_	_	_	_	_	_	_	Seg=B-seg
95	,	_	_	_	_	_	_	_	Seg=O
96	we	_	_	_	_	_	_	_	Seg=O
97	evaluated	_	_	_	_	_	_	_	Seg=O
98	the	_	_	_	_	_	_	_	Seg=O
99	effect	_	_	_	_	_	_	_	Seg=O
100	of	_	_	_	_	_	_	_	Seg=O
101	protease	_	_	_	_	_	_	_	Seg=O
102	inhibitors	_	_	_	_	_	_	_	Seg=O
103	on	_	_	_	_	_	_	_	Seg=O
104	RSV	_	_	_	_	_	_	_	Seg=O
105	infection	_	_	_	_	_	_	_	Seg=O
106	.	_	_	_	_	_	_	_	Seg=O
107	To	_	_	_	_	_	_	_	Seg=B-seg
108	measure	_	_	_	_	_	_	_	Seg=O
109	the	_	_	_	_	_	_	_	Seg=O
110	sensitivity	_	_	_	_	_	_	_	Seg=O
111	of	_	_	_	_	_	_	_	Seg=O
112	RSV	_	_	_	_	_	_	_	Seg=O
113	infection	_	_	_	_	_	_	_	Seg=O
114	to	_	_	_	_	_	_	_	Seg=O
115	protease	_	_	_	_	_	_	_	Seg=O
116	inhibitors	_	_	_	_	_	_	_	Seg=O
117	,	_	_	_	_	_	_	_	Seg=O
118	cells	_	_	_	_	_	_	_	Seg=B-seg
119	were	_	_	_	_	_	_	_	Seg=O
120	infected	_	_	_	_	_	_	_	Seg=O
121	with	_	_	_	_	_	_	_	Seg=O
122	RSV	_	_	_	_	_	_	_	Seg=O
123	and	_	_	_	_	_	_	_	Seg=B-seg
124	incubated	_	_	_	_	_	_	_	Seg=O
125	for	_	_	_	_	_	_	_	Seg=O
126	18	_	_	_	_	_	_	_	Seg=O
127	h	_	_	_	_	_	_	_	Seg=O
128	in	_	_	_	_	_	_	_	Seg=O
129	the	_	_	_	_	_	_	_	Seg=O
130	presence	_	_	_	_	_	_	_	Seg=O
131	or	_	_	_	_	_	_	_	Seg=O
132	absence	_	_	_	_	_	_	_	Seg=O
133	of	_	_	_	_	_	_	_	Seg=O
134	the	_	_	_	_	_	_	_	Seg=O
135	inhibitors	_	_	_	_	_	_	_	Seg=O
136	.	_	_	_	_	_	_	_	Seg=O
137	Cells	_	_	_	_	_	_	_	Seg=B-seg
138	were	_	_	_	_	_	_	_	Seg=O
139	fixed	_	_	_	_	_	_	_	Seg=O
140	,	_	_	_	_	_	_	_	Seg=O
141	stained	_	_	_	_	_	_	_	Seg=O
142	and	_	_	_	_	_	_	_	Seg=O
143	studied	_	_	_	_	_	_	_	Seg=O
144	using	_	_	_	_	_	_	_	Seg=B-seg
145	fluorescence	_	_	_	_	_	_	_	Seg=O
146	microscopy	_	_	_	_	_	_	_	Seg=O
147	.	_	_	_	_	_	_	_	Seg=O
148	Results	_	_	_	_	_	_	_	Seg=B-seg
149	:	_	_	_	_	_	_	_	Seg=O
150	Several	_	_	_	_	_	_	_	Seg=B-seg
151	protease	_	_	_	_	_	_	_	Seg=O
152	inhibitors	_	_	_	_	_	_	_	Seg=O
153	,	_	_	_	_	_	_	_	Seg=O
154	representing	_	_	_	_	_	_	_	Seg=B-seg
155	different	_	_	_	_	_	_	_	Seg=O
156	classes	_	_	_	_	_	_	_	Seg=O
157	of	_	_	_	_	_	_	_	Seg=O
158	proteases	_	_	_	_	_	_	_	Seg=O
159	(	_	_	_	_	_	_	_	Seg=B-seg
160	AEBSF	_	_	_	_	_	_	_	Seg=O
161	,	_	_	_	_	_	_	_	Seg=O
162	Pepstatin	_	_	_	_	_	_	_	Seg=O
163	A	_	_	_	_	_	_	_	Seg=O
164	,	_	_	_	_	_	_	_	Seg=O
165	E-64	_	_	_	_	_	_	_	Seg=O
166	,	_	_	_	_	_	_	_	Seg=O
167	TPCK	_	_	_	_	_	_	_	Seg=O
168	,	_	_	_	_	_	_	_	Seg=O
169	PMSF	_	_	_	_	_	_	_	Seg=O
170	and	_	_	_	_	_	_	_	Seg=O
171	aprotinin	_	_	_	_	_	_	_	Seg=O
172	)	_	_	_	_	_	_	_	Seg=O
173	,	_	_	_	_	_	_	_	Seg=O
174	were	_	_	_	_	_	_	_	Seg=B-seg
175	tested	_	_	_	_	_	_	_	Seg=O
176	for	_	_	_	_	_	_	_	Seg=O
177	inhibitory	_	_	_	_	_	_	_	Seg=O
178	effects	_	_	_	_	_	_	_	Seg=O
179	on	_	_	_	_	_	_	_	Seg=O
180	an	_	_	_	_	_	_	_	Seg=O
181	RSV	_	_	_	_	_	_	_	Seg=O
182	A2	_	_	_	_	_	_	_	Seg=O
183	infection	_	_	_	_	_	_	_	Seg=O
184	of	_	_	_	_	_	_	_	Seg=O
185	HEp-2	_	_	_	_	_	_	_	Seg=O
186	cells	_	_	_	_	_	_	_	Seg=O
187	.	_	_	_	_	_	_	_	Seg=O
188	Different	_	_	_	_	_	_	_	Seg=B-seg
189	treatment	_	_	_	_	_	_	_	Seg=O
190	durations	_	_	_	_	_	_	_	Seg=O
191	,	_	_	_	_	_	_	_	Seg=O
192	ranging	_	_	_	_	_	_	_	Seg=B-seg
193	from	_	_	_	_	_	_	_	Seg=O
194	1	_	_	_	_	_	_	_	Seg=O
195	h	_	_	_	_	_	_	_	Seg=O
196	prior	_	_	_	_	_	_	_	Seg=O
197	to	_	_	_	_	_	_	_	Seg=O
198	inoculation	_	_	_	_	_	_	_	Seg=O
199	and	_	_	_	_	_	_	_	Seg=B-seg
200	continuing	_	_	_	_	_	_	_	Seg=O
201	for	_	_	_	_	_	_	_	Seg=O
202	18	_	_	_	_	_	_	_	Seg=O
203	h	_	_	_	_	_	_	_	Seg=O
204	during	_	_	_	_	_	_	_	Seg=O
205	the	_	_	_	_	_	_	_	Seg=O
206	assay	_	_	_	_	_	_	_	Seg=O
207	,	_	_	_	_	_	_	_	Seg=O
208	were	_	_	_	_	_	_	_	Seg=B-seg
209	evaluated	_	_	_	_	_	_	_	Seg=O
210	.	_	_	_	_	_	_	_	Seg=O
211	Of	_	_	_	_	_	_	_	Seg=B-seg
212	all	_	_	_	_	_	_	_	Seg=O
213	the	_	_	_	_	_	_	_	Seg=O
214	inhibitors	_	_	_	_	_	_	_	Seg=O
215	tested	_	_	_	_	_	_	_	Seg=B-seg
216	,	_	_	_	_	_	_	_	Seg=O
217	AEBSF	_	_	_	_	_	_	_	Seg=B-seg
218	and	_	_	_	_	_	_	_	Seg=O
219	TPCK	_	_	_	_	_	_	_	Seg=O
220	significantly	_	_	_	_	_	_	_	Seg=O
221	decreased	_	_	_	_	_	_	_	Seg=O
222	RSV	_	_	_	_	_	_	_	Seg=O
223	infection	_	_	_	_	_	_	_	Seg=O
224	.	_	_	_	_	_	_	_	Seg=O
225	To	_	_	_	_	_	_	_	Seg=B-seg
226	ascertain	_	_	_	_	_	_	_	Seg=O
227	that	_	_	_	_	_	_	_	Seg=B-seg
228	the	_	_	_	_	_	_	_	Seg=O
229	observed	_	_	_	_	_	_	_	Seg=O
230	effect	_	_	_	_	_	_	_	Seg=O
231	of	_	_	_	_	_	_	_	Seg=O
232	AEBSF	_	_	_	_	_	_	_	Seg=O
233	was	_	_	_	_	_	_	_	Seg=O
234	not	_	_	_	_	_	_	_	Seg=O
235	a	_	_	_	_	_	_	_	Seg=O
236	specific	_	_	_	_	_	_	_	Seg=O
237	feature	_	_	_	_	_	_	_	Seg=O
238	related	_	_	_	_	_	_	_	Seg=B-seg
239	to	_	_	_	_	_	_	_	Seg=O
240	HEp-2	_	_	_	_	_	_	_	Seg=O
241	cells	_	_	_	_	_	_	_	Seg=O
242	,	_	_	_	_	_	_	_	Seg=O
243	A549	_	_	_	_	_	_	_	Seg=B-seg
244	and	_	_	_	_	_	_	_	Seg=O
245	BEAS-2B	_	_	_	_	_	_	_	Seg=O
246	cells	_	_	_	_	_	_	_	Seg=O
247	were	_	_	_	_	_	_	_	Seg=O
248	also	_	_	_	_	_	_	_	Seg=O
249	used	_	_	_	_	_	_	_	Seg=O
250	.	_	_	_	_	_	_	_	Seg=O
251	Similar	_	_	_	_	_	_	_	Seg=B-seg
252	to	_	_	_	_	_	_	_	Seg=O
253	HEp-2	_	_	_	_	_	_	_	Seg=O
254	,	_	_	_	_	_	_	_	Seg=O
255	an	_	_	_	_	_	_	_	Seg=O
256	almost	_	_	_	_	_	_	_	Seg=O
257	complete	_	_	_	_	_	_	_	Seg=O
258	block	_	_	_	_	_	_	_	Seg=O
259	in	_	_	_	_	_	_	_	Seg=O
260	the	_	_	_	_	_	_	_	Seg=O
261	number	_	_	_	_	_	_	_	Seg=O
262	of	_	_	_	_	_	_	_	Seg=O
263	RSV	_	_	_	_	_	_	_	Seg=O
264	infected	_	_	_	_	_	_	_	Seg=O
265	cells	_	_	_	_	_	_	_	Seg=O
266	after	_	_	_	_	_	_	_	Seg=O
267	18	_	_	_	_	_	_	_	Seg=O
268	h	_	_	_	_	_	_	_	Seg=O
269	of	_	_	_	_	_	_	_	Seg=O
270	incubation	_	_	_	_	_	_	_	Seg=O
271	was	_	_	_	_	_	_	_	Seg=O
272	observed	_	_	_	_	_	_	_	Seg=O
273	and	_	_	_	_	_	_	_	Seg=B-seg
274	the	_	_	_	_	_	_	_	Seg=O
275	effect	_	_	_	_	_	_	_	Seg=O
276	was	_	_	_	_	_	_	_	Seg=O
277	dose	_	_	_	_	_	_	_	Seg=O
278	-	_	_	_	_	_	_	_	Seg=O
279	dependent	_	_	_	_	_	_	_	Seg=O
280	.	_	_	_	_	_	_	_	Seg=O
281	To	_	_	_	_	_	_	_	Seg=B-seg
282	gain	_	_	_	_	_	_	_	Seg=O
283	insight	_	_	_	_	_	_	_	Seg=O
284	into	_	_	_	_	_	_	_	Seg=O
285	the	_	_	_	_	_	_	_	Seg=O
286	mechanism	_	_	_	_	_	_	_	Seg=O
287	of	_	_	_	_	_	_	_	Seg=O
288	this	_	_	_	_	_	_	_	Seg=O
289	inhibition	_	_	_	_	_	_	_	Seg=O
290	,	_	_	_	_	_	_	_	Seg=O
291	AEBSF	_	_	_	_	_	_	_	Seg=B-seg
292	treatment	_	_	_	_	_	_	_	Seg=O
293	was	_	_	_	_	_	_	_	Seg=O
294	applied	_	_	_	_	_	_	_	Seg=O
295	during	_	_	_	_	_	_	_	Seg=O
296	different	_	_	_	_	_	_	_	Seg=O
297	phases	_	_	_	_	_	_	_	Seg=O
298	of	_	_	_	_	_	_	_	Seg=O
299	an	_	_	_	_	_	_	_	Seg=O
300	infection	_	_	_	_	_	_	_	Seg=O
301	cycle	_	_	_	_	_	_	_	Seg=O
302	(	_	_	_	_	_	_	_	Seg=B-seg
303	pre-	_	_	_	_	_	_	_	Seg=O
304	,	_	_	_	_	_	_	_	Seg=O
305	peri	_	_	_	_	_	_	_	Seg=O
306	-	_	_	_	_	_	_	_	Seg=O
307	and	_	_	_	_	_	_	_	Seg=O
308	post	_	_	_	_	_	_	_	Seg=O
309	-	_	_	_	_	_	_	_	Seg=O
310	inoculation	_	_	_	_	_	_	_	Seg=O
311	treatment	_	_	_	_	_	_	_	Seg=O
312	)	_	_	_	_	_	_	_	Seg=O
313	.	_	_	_	_	_	_	_	Seg=O
314	The	_	_	_	_	_	_	_	Seg=B-seg
315	results	_	_	_	_	_	_	_	Seg=O
316	from	_	_	_	_	_	_	_	Seg=O
317	these	_	_	_	_	_	_	_	Seg=O
318	experiments	_	_	_	_	_	_	_	Seg=O
319	indicate	_	_	_	_	_	_	_	Seg=O
320	that	_	_	_	_	_	_	_	Seg=B-seg
321	AEBSF	_	_	_	_	_	_	_	Seg=O
322	is	_	_	_	_	_	_	_	Seg=O
323	mainly	_	_	_	_	_	_	_	Seg=O
324	active	_	_	_	_	_	_	_	Seg=O
325	during	_	_	_	_	_	_	_	Seg=O
326	the	_	_	_	_	_	_	_	Seg=O
327	early	_	_	_	_	_	_	_	Seg=O
328	entry	_	_	_	_	_	_	_	Seg=O
329	phase	_	_	_	_	_	_	_	Seg=O
330	of	_	_	_	_	_	_	_	Seg=O
331	RSV	_	_	_	_	_	_	_	Seg=O
332	.	_	_	_	_	_	_	_	Seg=O
333	The	_	_	_	_	_	_	_	Seg=B-seg
334	inhibitory	_	_	_	_	_	_	_	Seg=O
335	effect	_	_	_	_	_	_	_	Seg=O
336	was	_	_	_	_	_	_	_	Seg=O
337	also	_	_	_	_	_	_	_	Seg=O
338	observed	_	_	_	_	_	_	_	Seg=O
339	with	_	_	_	_	_	_	_	Seg=O
340	other	_	_	_	_	_	_	_	Seg=O
341	RSV	_	_	_	_	_	_	_	Seg=O
342	isolates	_	_	_	_	_	_	_	Seg=O
343	A1998/3	_	_	_	_	_	_	_	Seg=O
344	-	_	_	_	_	_	_	_	Seg=O
345	2	_	_	_	_	_	_	_	Seg=O
346	and	_	_	_	_	_	_	_	Seg=O
347	A2000/3	_	_	_	_	_	_	_	Seg=O
348	-	_	_	_	_	_	_	_	Seg=O
349	4	_	_	_	_	_	_	_	Seg=O
350	,	_	_	_	_	_	_	_	Seg=O
351	suggesting	_	_	_	_	_	_	_	Seg=B-seg
352	that	_	_	_	_	_	_	_	Seg=B-seg
353	this	_	_	_	_	_	_	_	Seg=O
354	is	_	_	_	_	_	_	_	Seg=O
355	a	_	_	_	_	_	_	_	Seg=O
356	general	_	_	_	_	_	_	_	Seg=O
357	feature	_	_	_	_	_	_	_	Seg=O
358	of	_	_	_	_	_	_	_	Seg=O
359	RSV	_	_	_	_	_	_	_	Seg=O
360	.	_	_	_	_	_	_	_	Seg=O
361	Conclusion	_	_	_	_	_	_	_	Seg=B-seg
362	:	_	_	_	_	_	_	_	Seg=O
363	RSV	_	_	_	_	_	_	_	Seg=B-seg
364	infection	_	_	_	_	_	_	_	Seg=O
365	can	_	_	_	_	_	_	_	Seg=O
366	be	_	_	_	_	_	_	_	Seg=O
367	inhibited	_	_	_	_	_	_	_	Seg=O
368	by	_	_	_	_	_	_	_	Seg=O
369	broad	_	_	_	_	_	_	_	Seg=O
370	serine	_	_	_	_	_	_	_	Seg=O
371	protease	_	_	_	_	_	_	_	Seg=O
372	inhibitors	_	_	_	_	_	_	_	Seg=O
373	,	_	_	_	_	_	_	_	Seg=O
374	AEBSF	_	_	_	_	_	_	_	Seg=O
375	and	_	_	_	_	_	_	_	Seg=O
376	TPCK	_	_	_	_	_	_	_	Seg=O
377	.	_	_	_	_	_	_	_	Seg=O
378	We	_	_	_	_	_	_	_	Seg=B-seg
379	confirmed	_	_	_	_	_	_	_	Seg=O
380	that	_	_	_	_	_	_	_	Seg=B-seg
381	AEBSF	_	_	_	_	_	_	_	Seg=O
382	inhibition	_	_	_	_	_	_	_	Seg=O
383	is	_	_	_	_	_	_	_	Seg=O
384	independent	_	_	_	_	_	_	_	Seg=O
385	of	_	_	_	_	_	_	_	Seg=O
386	the	_	_	_	_	_	_	_	Seg=O
387	cell	_	_	_	_	_	_	_	Seg=O
388	line	_	_	_	_	_	_	_	Seg=O
389	used	_	_	_	_	_	_	_	Seg=B-seg
390	or	_	_	_	_	_	_	_	Seg=O
391	RSV	_	_	_	_	_	_	_	Seg=O
392	strain	_	_	_	_	_	_	_	Seg=O
393	.	_	_	_	_	_	_	_	Seg=O
394	The	_	_	_	_	_	_	_	Seg=B-seg
395	time	_	_	_	_	_	_	_	Seg=O
396	point	_	_	_	_	_	_	_	Seg=O
397	at	_	_	_	_	_	_	_	Seg=B-seg
398	which	_	_	_	_	_	_	_	Seg=O
399	treatment	_	_	_	_	_	_	_	Seg=O
400	with	_	_	_	_	_	_	_	Seg=O
401	the	_	_	_	_	_	_	_	Seg=O
402	inhibitor	_	_	_	_	_	_	_	Seg=O
403	was	_	_	_	_	_	_	_	Seg=O
404	most	_	_	_	_	_	_	_	Seg=O
405	potent	_	_	_	_	_	_	_	Seg=O
406	,	_	_	_	_	_	_	_	Seg=O
407	was	_	_	_	_	_	_	_	Seg=B-seg
408	found	_	_	_	_	_	_	_	Seg=O
409	to	_	_	_	_	_	_	_	Seg=O
410	coincide	_	_	_	_	_	_	_	Seg=O
411	with	_	_	_	_	_	_	_	Seg=O
412	the	_	_	_	_	_	_	_	Seg=O
413	expected	_	_	_	_	_	_	_	Seg=O
414	moment	_	_	_	_	_	_	_	Seg=O
415	of	_	_	_	_	_	_	_	Seg=O
416	entry	_	_	_	_	_	_	_	Seg=O
417	of	_	_	_	_	_	_	_	Seg=O
418	the	_	_	_	_	_	_	_	Seg=O
419	virion	_	_	_	_	_	_	_	Seg=O
420	with	_	_	_	_	_	_	_	Seg=O
421	the	_	_	_	_	_	_	_	Seg=O
422	host	_	_	_	_	_	_	_	Seg=O
423	cell	_	_	_	_	_	_	_	Seg=O
424	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 0a91a01d3b6084bfd02cacba098af54c2e38f374
1	Basing	_	_	_	_	_	_	_	Seg=B-seg
2	on	_	_	_	_	_	_	_	Seg=O
3	existence	_	_	_	_	_	_	_	Seg=O
4	of	_	_	_	_	_	_	_	Seg=O
5	the	_	_	_	_	_	_	_	Seg=O
6	mathematically	_	_	_	_	_	_	_	Seg=O
7	sequential	_	_	_	_	_	_	_	Seg=O
8	reduction	_	_	_	_	_	_	_	Seg=O
9	of	_	_	_	_	_	_	_	Seg=O
10	the	_	_	_	_	_	_	_	Seg=O
11	three	_	_	_	_	_	_	_	Seg=O
12	-	_	_	_	_	_	_	_	Seg=O
13	compartmental	_	_	_	_	_	_	_	Seg=O
14	(	_	_	_	_	_	_	_	Seg=B-seg
15	Susceptible	_	_	_	_	_	_	_	Seg=O
16	-	_	_	_	_	_	_	_	Seg=O
17	Infected	_	_	_	_	_	_	_	Seg=O
18	-	_	_	_	_	_	_	_	Seg=O
19	Recovered	_	_	_	_	_	_	_	Seg=O
20	/	_	_	_	_	_	_	_	Seg=O
21	Removed	_	_	_	_	_	_	_	Seg=O
22	)	_	_	_	_	_	_	_	Seg=O
23	model	_	_	_	_	_	_	_	Seg=B-seg
24	to	_	_	_	_	_	_	_	Seg=O
25	the	_	_	_	_	_	_	_	Seg=O
26	Verhulst	_	_	_	_	_	_	_	Seg=O
27	(	_	_	_	_	_	_	_	Seg=O
28	logistic	_	_	_	_	_	_	_	Seg=O
29	)	_	_	_	_	_	_	_	Seg=O
30	equation	_	_	_	_	_	_	_	Seg=O
31	with	_	_	_	_	_	_	_	Seg=O
32	the	_	_	_	_	_	_	_	Seg=O
33	parameters	_	_	_	_	_	_	_	Seg=O
34	determined	_	_	_	_	_	_	_	Seg=B-seg
35	by	_	_	_	_	_	_	_	Seg=O
36	the	_	_	_	_	_	_	_	Seg=O
37	basic	_	_	_	_	_	_	_	Seg=O
38	characteristic	_	_	_	_	_	_	_	Seg=O
39	of	_	_	_	_	_	_	_	Seg=O
40	epidemic	_	_	_	_	_	_	_	Seg=O
41	process	_	_	_	_	_	_	_	Seg=O
42	,	_	_	_	_	_	_	_	Seg=O
43	this	_	_	_	_	_	_	_	Seg=B-seg
44	model	_	_	_	_	_	_	_	Seg=O
45	is	_	_	_	_	_	_	_	Seg=O
46	tested	_	_	_	_	_	_	_	Seg=O
47	in	_	_	_	_	_	_	_	Seg=O
48	application	_	_	_	_	_	_	_	Seg=O
49	to	_	_	_	_	_	_	_	Seg=O
50	the	_	_	_	_	_	_	_	Seg=O
51	recent	_	_	_	_	_	_	_	Seg=O
52	data	_	_	_	_	_	_	_	Seg=O
53	on	_	_	_	_	_	_	_	Seg=O
54	COVID-19	_	_	_	_	_	_	_	Seg=O
55	outbreak	_	_	_	_	_	_	_	Seg=O
56	reported	_	_	_	_	_	_	_	Seg=B-seg
57	by	_	_	_	_	_	_	_	Seg=O
58	the	_	_	_	_	_	_	_	Seg=O
59	European	_	_	_	_	_	_	_	Seg=O
60	Centre	_	_	_	_	_	_	_	Seg=O
61	for	_	_	_	_	_	_	_	Seg=O
62	Disease	_	_	_	_	_	_	_	Seg=O
63	Prevention	_	_	_	_	_	_	_	Seg=O
64	and	_	_	_	_	_	_	_	Seg=O
65	Control	_	_	_	_	_	_	_	Seg=O
66	.	_	_	_	_	_	_	_	Seg=O
67	It	_	_	_	_	_	_	_	Seg=B-seg
68	is	_	_	_	_	_	_	_	Seg=O
69	shown	_	_	_	_	_	_	_	Seg=O
70	that	_	_	_	_	_	_	_	Seg=O
71	such	_	_	_	_	_	_	_	Seg=O
72	a	_	_	_	_	_	_	_	Seg=O
73	simple	_	_	_	_	_	_	_	Seg=O
74	model	_	_	_	_	_	_	_	Seg=O
75	adequately	_	_	_	_	_	_	_	Seg=O
76	reproduces	_	_	_	_	_	_	_	Seg=O
77	the	_	_	_	_	_	_	_	Seg=O
78	epidemic	_	_	_	_	_	_	_	Seg=O
79	dynamics	_	_	_	_	_	_	_	Seg=O
80	not	_	_	_	_	_	_	_	Seg=O
81	only	_	_	_	_	_	_	_	Seg=O
82	qualitatively	_	_	_	_	_	_	_	Seg=O
83	but	_	_	_	_	_	_	_	Seg=O
84	for	_	_	_	_	_	_	_	Seg=O
85	a	_	_	_	_	_	_	_	Seg=O
86	number	_	_	_	_	_	_	_	Seg=O
87	of	_	_	_	_	_	_	_	Seg=O
88	countries	_	_	_	_	_	_	_	Seg=O
89	quantitatively	_	_	_	_	_	_	_	Seg=O
90	with	_	_	_	_	_	_	_	Seg=O
91	a	_	_	_	_	_	_	_	Seg=O
92	high	_	_	_	_	_	_	_	Seg=O
93	degree	_	_	_	_	_	_	_	Seg=O
94	of	_	_	_	_	_	_	_	Seg=O
95	correlation	_	_	_	_	_	_	_	Seg=O
96	that	_	_	_	_	_	_	_	Seg=B-seg
97	allows	_	_	_	_	_	_	_	Seg=O
98	to	_	_	_	_	_	_	_	Seg=O
99	use	_	_	_	_	_	_	_	Seg=O
100	it	_	_	_	_	_	_	_	Seg=O
101	for	_	_	_	_	_	_	_	Seg=O
102	predictive	_	_	_	_	_	_	_	Seg=O
103	estimations	_	_	_	_	_	_	_	Seg=O
104	.	_	_	_	_	_	_	_	Seg=O
105	In	_	_	_	_	_	_	_	Seg=B-seg
106	addition	_	_	_	_	_	_	_	Seg=O
107	,	_	_	_	_	_	_	_	Seg=O
108	some	_	_	_	_	_	_	_	Seg=O
109	features	_	_	_	_	_	_	_	Seg=O
110	of	_	_	_	_	_	_	_	Seg=O
111	SIR	_	_	_	_	_	_	_	Seg=O
112	model	_	_	_	_	_	_	_	Seg=O
113	are	_	_	_	_	_	_	_	Seg=O
114	discussed	_	_	_	_	_	_	_	Seg=O
115	in	_	_	_	_	_	_	_	Seg=O
116	the	_	_	_	_	_	_	_	Seg=O
117	context	_	_	_	_	_	_	_	Seg=O
118	,	_	_	_	_	_	_	_	Seg=O
119	how	_	_	_	_	_	_	_	Seg=B-seg
120	its	_	_	_	_	_	_	_	Seg=O
121	parameters	_	_	_	_	_	_	_	Seg=O
122	and	_	_	_	_	_	_	_	Seg=O
123	conditions	_	_	_	_	_	_	_	Seg=O
124	reflect	_	_	_	_	_	_	_	Seg=O
125	measures	_	_	_	_	_	_	_	Seg=O
126	attempted	_	_	_	_	_	_	_	Seg=B-seg
127	for	_	_	_	_	_	_	_	Seg=O
128	the	_	_	_	_	_	_	_	Seg=O
129	disease	_	_	_	_	_	_	_	Seg=O
130	growth	_	_	_	_	_	_	_	Seg=O
131	prevention	_	_	_	_	_	_	_	Seg=O
132	that	_	_	_	_	_	_	_	Seg=B-seg
133	is	_	_	_	_	_	_	_	Seg=O
134	also	_	_	_	_	_	_	_	Seg=O
135	clearly	_	_	_	_	_	_	_	Seg=O
136	indicated	_	_	_	_	_	_	_	Seg=O
137	by	_	_	_	_	_	_	_	Seg=O
138	deviations	_	_	_	_	_	_	_	Seg=O
139	from	_	_	_	_	_	_	_	Seg=O
140	such	_	_	_	_	_	_	_	Seg=O
141	model	_	_	_	_	_	_	_	Seg=O
142	solutions	_	_	_	_	_	_	_	Seg=O
143	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 0b47e798d50ce617982cb6f89dc887fb829b0fe2
1	Background	_	_	_	_	_	_	_	Seg=B-seg
2	:	_	_	_	_	_	_	_	Seg=O
3	Due	_	_	_	_	_	_	_	Seg=B-seg
4	to	_	_	_	_	_	_	_	Seg=O
5	the	_	_	_	_	_	_	_	Seg=O
6	covid-19	_	_	_	_	_	_	_	Seg=O
7	outbreak	_	_	_	_	_	_	_	Seg=O
8	,	_	_	_	_	_	_	_	Seg=O
9	social	_	_	_	_	_	_	_	Seg=O
10	distancing	_	_	_	_	_	_	_	Seg=O
11	measures	_	_	_	_	_	_	_	Seg=O
12	were	_	_	_	_	_	_	_	Seg=O
13	imposed	_	_	_	_	_	_	_	Seg=O
14	to	_	_	_	_	_	_	_	Seg=B-seg
15	control	_	_	_	_	_	_	_	Seg=O
16	the	_	_	_	_	_	_	_	Seg=O
17	spread	_	_	_	_	_	_	_	Seg=O
18	of	_	_	_	_	_	_	_	Seg=O
19	the	_	_	_	_	_	_	_	Seg=O
20	pandemic	_	_	_	_	_	_	_	Seg=O
21	.	_	_	_	_	_	_	_	Seg=O
22	However	_	_	_	_	_	_	_	Seg=B-seg
23	,	_	_	_	_	_	_	_	Seg=O
24	isolation	_	_	_	_	_	_	_	Seg=O
25	may	_	_	_	_	_	_	_	Seg=O
26	affect	_	_	_	_	_	_	_	Seg=O
27	negatively	_	_	_	_	_	_	_	Seg=O
28	the	_	_	_	_	_	_	_	Seg=O
29	psychological	_	_	_	_	_	_	_	Seg=O
30	well	_	_	_	_	_	_	_	Seg=O
31	-	_	_	_	_	_	_	_	Seg=O
32	being	_	_	_	_	_	_	_	Seg=O
33	and	_	_	_	_	_	_	_	Seg=O
34	impair	_	_	_	_	_	_	_	Seg=O
35	sleep	_	_	_	_	_	_	_	Seg=O
36	quality	_	_	_	_	_	_	_	Seg=O
37	.	_	_	_	_	_	_	_	Seg=O
38	Our	_	_	_	_	_	_	_	Seg=B-seg
39	aim	_	_	_	_	_	_	_	Seg=O
40	was	_	_	_	_	_	_	_	Seg=O
41	to	_	_	_	_	_	_	_	Seg=O
42	evaluate	_	_	_	_	_	_	_	Seg=O
43	the	_	_	_	_	_	_	_	Seg=O
44	sleep	_	_	_	_	_	_	_	Seg=O
45	quality	_	_	_	_	_	_	_	Seg=O
46	of	_	_	_	_	_	_	_	Seg=O
47	respiratory	_	_	_	_	_	_	_	Seg=O
48	patients	_	_	_	_	_	_	_	Seg=O
49	during	_	_	_	_	_	_	_	Seg=O
50	the	_	_	_	_	_	_	_	Seg=O
51	covid-19	_	_	_	_	_	_	_	Seg=O
52	pandemic	_	_	_	_	_	_	_	Seg=O
53	lockdown	_	_	_	_	_	_	_	Seg=O
54	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 0b5b490f075aa99ce120a49126ba2ebd1e86dba7
1	Immunological	_	_	_	_	_	_	_	Seg=B-seg
2	impairment	_	_	_	_	_	_	_	Seg=O
3	by	_	_	_	_	_	_	_	Seg=O
4	porcine	_	_	_	_	_	_	_	Seg=O
5	circovirus	_	_	_	_	_	_	_	Seg=O
6	type	_	_	_	_	_	_	_	Seg=O
7	2	_	_	_	_	_	_	_	Seg=O
8	(	_	_	_	_	_	_	_	Seg=O
9	PCV2	_	_	_	_	_	_	_	Seg=O
10	)	_	_	_	_	_	_	_	Seg=O
11	infection	_	_	_	_	_	_	_	Seg=O
12	is	_	_	_	_	_	_	_	Seg=O
13	well	_	_	_	_	_	_	_	Seg=O
14	documented	_	_	_	_	_	_	_	Seg=O
15	in	_	_	_	_	_	_	_	Seg=O
16	pigs	_	_	_	_	_	_	_	Seg=O
17	suffering	_	_	_	_	_	_	_	Seg=B-seg
18	from	_	_	_	_	_	_	_	Seg=O
19	postweaning	_	_	_	_	_	_	_	Seg=O
20	multisystemic	_	_	_	_	_	_	_	Seg=O
21	wasting	_	_	_	_	_	_	_	Seg=O
22	syndrome	_	_	_	_	_	_	_	Seg=O
23	.	_	_	_	_	_	_	_	Seg=O
24	Nonetheless	_	_	_	_	_	_	_	Seg=B-seg
25	,	_	_	_	_	_	_	_	Seg=O
26	little	_	_	_	_	_	_	_	Seg=O
27	is	_	_	_	_	_	_	_	Seg=O
28	known	_	_	_	_	_	_	_	Seg=O
29	about	_	_	_	_	_	_	_	Seg=O
30	immune	_	_	_	_	_	_	_	Seg=O
31	status	_	_	_	_	_	_	_	Seg=O
32	of	_	_	_	_	_	_	_	Seg=O
33	pigs	_	_	_	_	_	_	_	Seg=O
34	that	_	_	_	_	_	_	_	Seg=B-seg
35	remain	_	_	_	_	_	_	_	Seg=O
36	PCV2	_	_	_	_	_	_	_	Seg=O
37	subclinically	_	_	_	_	_	_	_	Seg=O
38	infected	_	_	_	_	_	_	_	Seg=O
39	.	_	_	_	_	_	_	_	Seg=O
40	Thus	_	_	_	_	_	_	_	Seg=B-seg
41	,	_	_	_	_	_	_	_	Seg=O
42	seven	_	_	_	_	_	_	_	Seg=O
43	pigs	_	_	_	_	_	_	_	Seg=O
44	successfully	_	_	_	_	_	_	_	Seg=B-seg
45	infected	_	_	_	_	_	_	_	Seg=O
46	in	_	_	_	_	_	_	_	Seg=O
47	an	_	_	_	_	_	_	_	Seg=O
48	experimental	_	_	_	_	_	_	_	Seg=O
49	inoculation	_	_	_	_	_	_	_	Seg=O
50	and	_	_	_	_	_	_	_	Seg=O
51	without	_	_	_	_	_	_	_	Seg=O
52	developing	_	_	_	_	_	_	_	Seg=O
53	disease	_	_	_	_	_	_	_	Seg=O
54	and	_	_	_	_	_	_	_	Seg=B-seg
55	nine	_	_	_	_	_	_	_	Seg=O
56	control	_	_	_	_	_	_	_	Seg=O
57	non	_	_	_	_	_	_	_	Seg=O
58	-	_	_	_	_	_	_	_	Seg=O
59	inoculated	_	_	_	_	_	_	_	Seg=O
60	pigs	_	_	_	_	_	_	_	Seg=O
61	were	_	_	_	_	_	_	_	Seg=O
62	examined	_	_	_	_	_	_	_	Seg=O
63	.	_	_	_	_	_	_	_	Seg=O
64	Serological	_	_	_	_	_	_	_	Seg=B-seg
65	,	_	_	_	_	_	_	_	Seg=O
66	virological	_	_	_	_	_	_	_	Seg=O
67	and	_	_	_	_	_	_	_	Seg=O
68	immunological	_	_	_	_	_	_	_	Seg=O
69	determinations	_	_	_	_	_	_	_	Seg=O
70	were	_	_	_	_	_	_	_	Seg=O
71	done	_	_	_	_	_	_	_	Seg=O
72	throughout	_	_	_	_	_	_	_	Seg=O
73	ten	_	_	_	_	_	_	_	Seg=O
74	weeks	_	_	_	_	_	_	_	Seg=O
75	post	_	_	_	_	_	_	_	Seg=O
76	-	_	_	_	_	_	_	_	Seg=O
77	infection	_	_	_	_	_	_	_	Seg=O
78	(	_	_	_	_	_	_	_	Seg=O
79	PI	_	_	_	_	_	_	_	Seg=O
80	)	_	_	_	_	_	_	_	Seg=O
81	.	_	_	_	_	_	_	_	Seg=O
82	At	_	_	_	_	_	_	_	Seg=B-seg
83	week	_	_	_	_	_	_	_	Seg=O
84	3	_	_	_	_	_	_	_	Seg=O
85	PI	_	_	_	_	_	_	_	Seg=O
86	,	_	_	_	_	_	_	_	Seg=O
87	inoculated	_	_	_	_	_	_	_	Seg=O
88	animals	_	_	_	_	_	_	_	Seg=O
89	presented	_	_	_	_	_	_	_	Seg=O
90	the	_	_	_	_	_	_	_	Seg=O
91	peak	_	_	_	_	_	_	_	Seg=O
92	of	_	_	_	_	_	_	_	Seg=O
93	viremia	_	_	_	_	_	_	_	Seg=O
94	and	_	_	_	_	_	_	_	Seg=B-seg
95	produced	_	_	_	_	_	_	_	Seg=O
96	higher	_	_	_	_	_	_	_	Seg=O
97	levels	_	_	_	_	_	_	_	Seg=O
98	of	_	_	_	_	_	_	_	Seg=O
99	IL-10	_	_	_	_	_	_	_	Seg=O
100	than	_	_	_	_	_	_	_	Seg=O
101	the	_	_	_	_	_	_	_	Seg=O
102	controls	_	_	_	_	_	_	_	Seg=O
103	;	_	_	_	_	_	_	_	Seg=O
104	correlation	_	_	_	_	_	_	_	Seg=B-seg
105	between	_	_	_	_	_	_	_	Seg=O
106	viral	_	_	_	_	_	_	_	Seg=O
107	load	_	_	_	_	_	_	_	Seg=O
108	and	_	_	_	_	_	_	_	Seg=O
109	IL-10	_	_	_	_	_	_	_	Seg=O
110	amounts	_	_	_	_	_	_	_	Seg=O
111	was	_	_	_	_	_	_	_	Seg=O
112	observed	_	_	_	_	_	_	_	Seg=O
113	(	_	_	_	_	_	_	_	Seg=B-seg
114	p	_	_	_	_	_	_	_	Seg=O
115	<	_	_	_	_	_	_	_	Seg=O
116	0.05	_	_	_	_	_	_	_	Seg=O
117	)	_	_	_	_	_	_	_	Seg=O
118	.	_	_	_	_	_	_	_	Seg=O
119	Also	_	_	_	_	_	_	_	Seg=B-seg
120	,	_	_	_	_	_	_	_	Seg=O
121	the	_	_	_	_	_	_	_	Seg=O
122	ratio	_	_	_	_	_	_	_	Seg=O
123	IgM	_	_	_	_	_	_	_	Seg=O
124	/	_	_	_	_	_	_	_	Seg=O
125	IgG	_	_	_	_	_	_	_	Seg=O
126	suffered	_	_	_	_	_	_	_	Seg=O
127	a	_	_	_	_	_	_	_	Seg=O
128	shift	_	_	_	_	_	_	_	Seg=O
129	skewing	_	_	_	_	_	_	_	Seg=O
130	IgM	_	_	_	_	_	_	_	Seg=O
131	production	_	_	_	_	_	_	_	Seg=O
132	towards	_	_	_	_	_	_	_	Seg=O
133	an	_	_	_	_	_	_	_	Seg=O
134	IgG	_	_	_	_	_	_	_	Seg=O
135	response	_	_	_	_	_	_	_	Seg=O
136	.	_	_	_	_	_	_	_	Seg=O
137	By	_	_	_	_	_	_	_	Seg=B-seg
138	10	_	_	_	_	_	_	_	Seg=O
139	weeks	_	_	_	_	_	_	_	Seg=O
140	PI	_	_	_	_	_	_	_	Seg=O
141	,	_	_	_	_	_	_	_	Seg=O
142	levels	_	_	_	_	_	_	_	Seg=O
143	of	_	_	_	_	_	_	_	Seg=O
144	IL-10	_	_	_	_	_	_	_	Seg=O
145	disappeared	_	_	_	_	_	_	_	Seg=O
146	and	_	_	_	_	_	_	_	Seg=B-seg
147	the	_	_	_	_	_	_	_	Seg=O
148	viremia	_	_	_	_	_	_	_	Seg=O
149	decreased	_	_	_	_	_	_	_	Seg=O
150	.	_	_	_	_	_	_	_	Seg=O
151	In	_	_	_	_	_	_	_	Seg=B-seg
152	summary	_	_	_	_	_	_	_	Seg=O
153	,	_	_	_	_	_	_	_	Seg=O
154	subclinically	_	_	_	_	_	_	_	Seg=O
155	PCV2-infected	_	_	_	_	_	_	_	Seg=O
156	pigs	_	_	_	_	_	_	_	Seg=O
157	developed	_	_	_	_	_	_	_	Seg=O
158	a	_	_	_	_	_	_	_	Seg=O
159	transient	_	_	_	_	_	_	_	Seg=O
160	PCV2-specific	_	_	_	_	_	_	_	Seg=O
161	IL-10	_	_	_	_	_	_	_	Seg=O
162	response	_	_	_	_	_	_	_	Seg=O
163	during	_	_	_	_	_	_	_	Seg=O
164	the	_	_	_	_	_	_	_	Seg=O
165	viremic	_	_	_	_	_	_	_	Seg=O
166	phase	_	_	_	_	_	_	_	Seg=O
167	of	_	_	_	_	_	_	_	Seg=O
168	infection	_	_	_	_	_	_	_	Seg=O
169	which	_	_	_	_	_	_	_	Seg=B-seg
170	coincided	_	_	_	_	_	_	_	Seg=O
171	with	_	_	_	_	_	_	_	Seg=O
172	the	_	_	_	_	_	_	_	Seg=O
173	inversion	_	_	_	_	_	_	_	Seg=O
174	of	_	_	_	_	_	_	_	Seg=O
175	the	_	_	_	_	_	_	_	Seg=O
176	IgM	_	_	_	_	_	_	_	Seg=O
177	/	_	_	_	_	_	_	_	Seg=O
178	IgG	_	_	_	_	_	_	_	Seg=O
179	ratio	_	_	_	_	_	_	_	Seg=O
180	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 0b8d293a1ef9f95ed9536b3aba23c5f01a344b83
1	The	_	_	_	_	_	_	_	Seg=B-seg
2	Aga	_	_	_	_	_	_	_	Seg=O
3	Khan	_	_	_	_	_	_	_	Seg=O
4	University	_	_	_	_	_	_	_	Seg=O
5	is	_	_	_	_	_	_	_	Seg=O
6	the	_	_	_	_	_	_	_	Seg=O
7	largest	_	_	_	_	_	_	_	Seg=O
8	tertiary	_	_	_	_	_	_	_	Seg=O
9	care	_	_	_	_	_	_	_	Seg=O
10	hospital	_	_	_	_	_	_	_	Seg=O
11	in	_	_	_	_	_	_	_	Seg=O
12	the	_	_	_	_	_	_	_	Seg=O
13	biggest	_	_	_	_	_	_	_	Seg=O
14	metropolis	_	_	_	_	_	_	_	Seg=O
15	of	_	_	_	_	_	_	_	Seg=O
16	Pakistan	_	_	_	_	_	_	_	Seg=O
17	,	_	_	_	_	_	_	_	Seg=O
18	in	_	_	_	_	_	_	_	Seg=B-seg
19	this	_	_	_	_	_	_	_	Seg=O
20	paper	_	_	_	_	_	_	_	Seg=O
21	six	_	_	_	_	_	_	_	Seg=O
22	weeks	_	_	_	_	_	_	_	Seg=O
23	of	_	_	_	_	_	_	_	Seg=O
24	experience	_	_	_	_	_	_	_	Seg=O
25	during	_	_	_	_	_	_	_	Seg=O
26	the	_	_	_	_	_	_	_	Seg=O
27	COVID-19	_	_	_	_	_	_	_	Seg=O
28	pandemic	_	_	_	_	_	_	_	Seg=O
29	is	_	_	_	_	_	_	_	Seg=O
30	shared	_	_	_	_	_	_	_	Seg=O
31	,	_	_	_	_	_	_	_	Seg=O
32	we	_	_	_	_	_	_	_	Seg=B-seg
33	will	_	_	_	_	_	_	_	Seg=O
34	discuss	_	_	_	_	_	_	_	Seg=O
35	the	_	_	_	_	_	_	_	Seg=O
36	measures	_	_	_	_	_	_	_	Seg=O
37	that	_	_	_	_	_	_	_	Seg=B-seg
38	were	_	_	_	_	_	_	_	Seg=O
39	taken	_	_	_	_	_	_	_	Seg=O
40	to	_	_	_	_	_	_	_	Seg=O
41	mitigate	_	_	_	_	_	_	_	Seg=O
42	the	_	_	_	_	_	_	_	Seg=O
43	spread	_	_	_	_	_	_	_	Seg=O
44	of	_	_	_	_	_	_	_	Seg=O
45	COVID-19	_	_	_	_	_	_	_	Seg=O
46	amongst	_	_	_	_	_	_	_	Seg=O
47	dental	_	_	_	_	_	_	_	Seg=O
48	health	_	_	_	_	_	_	_	Seg=O
49	care	_	_	_	_	_	_	_	Seg=O
50	providers	_	_	_	_	_	_	_	Seg=O
51	(	_	_	_	_	_	_	_	Seg=O
52	DHCPS	_	_	_	_	_	_	_	Seg=O
53	)	_	_	_	_	_	_	_	Seg=O
54	and	_	_	_	_	_	_	_	Seg=B-seg
55	provide	_	_	_	_	_	_	_	Seg=O
56	a	_	_	_	_	_	_	_	Seg=O
57	neoteric	_	_	_	_	_	_	_	Seg=O
58	workflow	_	_	_	_	_	_	_	Seg=O
59	for	_	_	_	_	_	_	_	Seg=O
60	the	_	_	_	_	_	_	_	Seg=O
61	provision	_	_	_	_	_	_	_	Seg=O
62	of	_	_	_	_	_	_	_	Seg=O
63	safe	_	_	_	_	_	_	_	Seg=O
64	dental	_	_	_	_	_	_	_	Seg=O
65	care	_	_	_	_	_	_	_	Seg=O
66	as	_	_	_	_	_	_	_	Seg=B-seg
67	dental	_	_	_	_	_	_	_	Seg=O
68	services	_	_	_	_	_	_	_	Seg=O
69	move	_	_	_	_	_	_	_	Seg=O
70	towards	_	_	_	_	_	_	_	Seg=O
71	normalcy	_	_	_	_	_	_	_	Seg=O
72	.	_	_	_	_	_	_	_	Seg=O
73	Furthermore	_	_	_	_	_	_	_	Seg=B-seg
74	topic	_	_	_	_	_	_	_	Seg=O
75	such	_	_	_	_	_	_	_	Seg=B-seg
76	as	_	_	_	_	_	_	_	Seg=O
77	fit	_	_	_	_	_	_	_	Seg=O
78	testing	_	_	_	_	_	_	_	Seg=O
79	,	_	_	_	_	_	_	_	Seg=O
80	contact	_	_	_	_	_	_	_	Seg=O
81	tracing	_	_	_	_	_	_	_	Seg=O
82	,	_	_	_	_	_	_	_	Seg=O
83	employee	_	_	_	_	_	_	_	Seg=O
84	health	_	_	_	_	_	_	_	Seg=O
85	and	_	_	_	_	_	_	_	Seg=O
86	training	_	_	_	_	_	_	_	Seg=O
87	are	_	_	_	_	_	_	_	Seg=B-seg
88	discussed	_	_	_	_	_	_	_	Seg=O
89	and	_	_	_	_	_	_	_	Seg=B-seg
90	experience	_	_	_	_	_	_	_	Seg=O
91	of	_	_	_	_	_	_	_	Seg=O
92	such	_	_	_	_	_	_	_	Seg=O
93	measures	_	_	_	_	_	_	_	Seg=O
94	is	_	_	_	_	_	_	_	Seg=O
95	shared	_	_	_	_	_	_	_	Seg=O
96	.	_	_	_	_	_	_	_	Seg=O
97	It	_	_	_	_	_	_	_	Seg=B-seg
98	is	_	_	_	_	_	_	_	Seg=O
99	hoped	_	_	_	_	_	_	_	Seg=O
100	that	_	_	_	_	_	_	_	Seg=O
101	till	_	_	_	_	_	_	_	Seg=B-seg
102	the	_	_	_	_	_	_	_	Seg=O
103	time	_	_	_	_	_	_	_	Seg=O
104	new	_	_	_	_	_	_	_	Seg=O
105	evidence	_	_	_	_	_	_	_	Seg=O
106	based	_	_	_	_	_	_	_	Seg=O
107	data	_	_	_	_	_	_	_	Seg=O
108	is	_	_	_	_	_	_	_	Seg=O
109	generated	_	_	_	_	_	_	_	Seg=O
110	these	_	_	_	_	_	_	_	Seg=B-seg
111	communications	_	_	_	_	_	_	_	Seg=O
112	may	_	_	_	_	_	_	_	Seg=O
113	help	_	_	_	_	_	_	_	Seg=O
114	spread	_	_	_	_	_	_	_	Seg=O
115	awareness	_	_	_	_	_	_	_	Seg=O
116	to	_	_	_	_	_	_	_	Seg=B-seg
117	help	_	_	_	_	_	_	_	Seg=O
118	setup	_	_	_	_	_	_	_	Seg=O
119	clinical	_	_	_	_	_	_	_	Seg=O
120	protocols	_	_	_	_	_	_	_	Seg=O
121	for	_	_	_	_	_	_	_	Seg=O
122	other	_	_	_	_	_	_	_	Seg=O
123	tertiary	_	_	_	_	_	_	_	Seg=O
124	care	_	_	_	_	_	_	_	Seg=O
125	settings	_	_	_	_	_	_	_	Seg=O
126	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 0c1b5e06659621ae2450ba60f16dcaa0cbf6389c
1	A	_	_	_	_	_	_	_	Seg=B-seg
2	new	_	_	_	_	_	_	_	Seg=O
3	personal	_	_	_	_	_	_	_	Seg=O
4	bioaerosol	_	_	_	_	_	_	_	Seg=O
5	sampler	_	_	_	_	_	_	_	Seg=O
6	has	_	_	_	_	_	_	_	Seg=O
7	recently	_	_	_	_	_	_	_	Seg=O
8	been	_	_	_	_	_	_	_	Seg=O
9	developed	_	_	_	_	_	_	_	Seg=O
10	and	_	_	_	_	_	_	_	Seg=B-seg
11	verified	_	_	_	_	_	_	_	Seg=O
12	to	_	_	_	_	_	_	_	Seg=O
13	be	_	_	_	_	_	_	_	Seg=O
14	very	_	_	_	_	_	_	_	Seg=O
15	efficient	_	_	_	_	_	_	_	Seg=O
16	for	_	_	_	_	_	_	_	Seg=O
17	monitoring	_	_	_	_	_	_	_	Seg=O
18	of	_	_	_	_	_	_	_	Seg=O
19	viable	_	_	_	_	_	_	_	Seg=O
20	airborne	_	_	_	_	_	_	_	Seg=O
21	bacteria	_	_	_	_	_	_	_	Seg=O
22	,	_	_	_	_	_	_	_	Seg=O
23	fungi	_	_	_	_	_	_	_	Seg=O
24	and	_	_	_	_	_	_	_	Seg=O
25	viruses	_	_	_	_	_	_	_	Seg=O
26	.	_	_	_	_	_	_	_	Seg=O
27	The	_	_	_	_	_	_	_	Seg=B-seg
28	device	_	_	_	_	_	_	_	Seg=O
29	is	_	_	_	_	_	_	_	Seg=O
30	capable	_	_	_	_	_	_	_	Seg=O
31	of	_	_	_	_	_	_	_	Seg=O
32	providing	_	_	_	_	_	_	_	Seg=O
33	high	_	_	_	_	_	_	_	Seg=O
34	recovery	_	_	_	_	_	_	_	Seg=O
35	rates	_	_	_	_	_	_	_	Seg=O
36	even	_	_	_	_	_	_	_	Seg=O
37	for	_	_	_	_	_	_	_	Seg=O
38	microorganisms	_	_	_	_	_	_	_	Seg=O
39	which	_	_	_	_	_	_	_	Seg=B-seg
40	are	_	_	_	_	_	_	_	Seg=O
41	rather	_	_	_	_	_	_	_	Seg=O
42	sensitive	_	_	_	_	_	_	_	Seg=O
43	to	_	_	_	_	_	_	_	Seg=O
44	physical	_	_	_	_	_	_	_	Seg=O
45	and	_	_	_	_	_	_	_	Seg=O
46	biological	_	_	_	_	_	_	_	Seg=O
47	stresses	_	_	_	_	_	_	_	Seg=O
48	.	_	_	_	_	_	_	_	Seg=O
49	However	_	_	_	_	_	_	_	Seg=B-seg
50	,	_	_	_	_	_	_	_	Seg=O
51	some	_	_	_	_	_	_	_	Seg=O
52	mathematical	_	_	_	_	_	_	_	Seg=O
53	procedure	_	_	_	_	_	_	_	Seg=O
54	is	_	_	_	_	_	_	_	Seg=O
55	required	_	_	_	_	_	_	_	Seg=O
56	for	_	_	_	_	_	_	_	Seg=O
57	realistic	_	_	_	_	_	_	_	Seg=O
58	calculation	_	_	_	_	_	_	_	Seg=O
59	of	_	_	_	_	_	_	_	Seg=O
60	an	_	_	_	_	_	_	_	Seg=O
61	actual	_	_	_	_	_	_	_	Seg=O
62	concentration	_	_	_	_	_	_	_	Seg=O
63	of	_	_	_	_	_	_	_	Seg=O
64	viable	_	_	_	_	_	_	_	Seg=O
65	bioaerosols	_	_	_	_	_	_	_	Seg=O
66	in	_	_	_	_	_	_	_	Seg=O
67	the	_	_	_	_	_	_	_	Seg=O
68	air	_	_	_	_	_	_	_	Seg=O
69	taking	_	_	_	_	_	_	_	Seg=B-seg
70	into	_	_	_	_	_	_	_	Seg=O
71	account	_	_	_	_	_	_	_	Seg=O
72	a	_	_	_	_	_	_	_	Seg=O
73	rate	_	_	_	_	_	_	_	Seg=O
74	of	_	_	_	_	_	_	_	Seg=O
75	inactivation	_	_	_	_	_	_	_	Seg=O
76	of	_	_	_	_	_	_	_	Seg=O
77	targeted	_	_	_	_	_	_	_	Seg=O
78	microorganisms	_	_	_	_	_	_	_	Seg=O
79	,	_	_	_	_	_	_	_	Seg=O
80	sampling	_	_	_	_	_	_	_	Seg=O
81	parameters	_	_	_	_	_	_	_	Seg=O
82	,	_	_	_	_	_	_	_	Seg=O
83	and	_	_	_	_	_	_	_	Seg=O
84	results	_	_	_	_	_	_	_	Seg=O
85	of	_	_	_	_	_	_	_	Seg=O
86	microbial	_	_	_	_	_	_	_	Seg=O
87	analysis	_	_	_	_	_	_	_	Seg=O
88	of	_	_	_	_	_	_	_	Seg=B-seg
89	collecting	_	_	_	_	_	_	_	Seg=O
90	liquid	_	_	_	_	_	_	_	Seg=O
91	from	_	_	_	_	_	_	_	Seg=O
92	the	_	_	_	_	_	_	_	Seg=O
93	sampler	_	_	_	_	_	_	_	Seg=O
94	.	_	_	_	_	_	_	_	Seg=O
95	In	_	_	_	_	_	_	_	Seg=B-seg
96	this	_	_	_	_	_	_	_	Seg=O
97	paper	_	_	_	_	_	_	_	Seg=O
98	,	_	_	_	_	_	_	_	Seg=O
99	we	_	_	_	_	_	_	_	Seg=O
100	develop	_	_	_	_	_	_	_	Seg=O
101	such	_	_	_	_	_	_	_	Seg=O
102	procedure	_	_	_	_	_	_	_	Seg=O
103	along	_	_	_	_	_	_	_	Seg=O
104	with	_	_	_	_	_	_	_	Seg=O
105	the	_	_	_	_	_	_	_	Seg=O
106	model	_	_	_	_	_	_	_	Seg=O
107	of	_	_	_	_	_	_	_	Seg=O
108	aerosol	_	_	_	_	_	_	_	Seg=O
109	propagation	_	_	_	_	_	_	_	Seg=O
110	for	_	_	_	_	_	_	_	Seg=O
111	outdoor	_	_	_	_	_	_	_	Seg=O
112	conditions	_	_	_	_	_	_	_	Seg=O
113	.	_	_	_	_	_	_	_	Seg=O
114	Combining	_	_	_	_	_	_	_	Seg=B-seg
115	these	_	_	_	_	_	_	_	Seg=O
116	procedures	_	_	_	_	_	_	_	Seg=O
117	allows	_	_	_	_	_	_	_	Seg=O
118	one	_	_	_	_	_	_	_	Seg=O
119	to	_	_	_	_	_	_	_	Seg=O
120	determine	_	_	_	_	_	_	_	Seg=O
121	the	_	_	_	_	_	_	_	Seg=O
122	optimal	_	_	_	_	_	_	_	Seg=O
123	sampling	_	_	_	_	_	_	_	Seg=O
124	locations	_	_	_	_	_	_	_	Seg=O
125	for	_	_	_	_	_	_	_	Seg=O
126	the	_	_	_	_	_	_	_	Seg=O
127	best	_	_	_	_	_	_	_	Seg=O
128	possible	_	_	_	_	_	_	_	Seg=O
129	coverage	_	_	_	_	_	_	_	Seg=O
130	of	_	_	_	_	_	_	_	Seg=O
131	the	_	_	_	_	_	_	_	Seg=O
132	area	_	_	_	_	_	_	_	Seg=O
133	to	_	_	_	_	_	_	_	Seg=B-seg
134	be	_	_	_	_	_	_	_	Seg=O
135	monitored	_	_	_	_	_	_	_	Seg=O
136	.	_	_	_	_	_	_	_	Seg=O
137	A	_	_	_	_	_	_	_	Seg=B-seg
138	hypothetical	_	_	_	_	_	_	_	Seg=O
139	episode	_	_	_	_	_	_	_	Seg=O
140	concerned	_	_	_	_	_	_	_	Seg=B-seg
141	with	_	_	_	_	_	_	_	Seg=O
142-143	terrorists'	_	_	_	_	_	_	_	_
142	terrorists	_	_	_	_	_	_	_	Seg=O
143	'	_	_	_	_	_	_	_	Seg=O
144	attack	_	_	_	_	_	_	_	Seg=O
145	during	_	_	_	_	_	_	_	Seg=O
146	music	_	_	_	_	_	_	_	Seg=O
147	concert	_	_	_	_	_	_	_	Seg=O
148	in	_	_	_	_	_	_	_	Seg=O
149	the	_	_	_	_	_	_	_	Seg=O
150	central	_	_	_	_	_	_	_	Seg=O
151	square	_	_	_	_	_	_	_	Seg=O
152	of	_	_	_	_	_	_	_	Seg=O
153	Novosibirsk	_	_	_	_	_	_	_	Seg=O
154	,	_	_	_	_	_	_	_	Seg=O
155	Russia	_	_	_	_	_	_	_	Seg=O
156	was	_	_	_	_	_	_	_	Seg=B-seg
157	considered	_	_	_	_	_	_	_	Seg=O
158	to	_	_	_	_	_	_	_	Seg=B-seg
159	evaluate	_	_	_	_	_	_	_	Seg=O
160	possible	_	_	_	_	_	_	_	Seg=O
161	coverage	_	_	_	_	_	_	_	Seg=O
162	of	_	_	_	_	_	_	_	Seg=O
163	the	_	_	_	_	_	_	_	Seg=O
164	area	_	_	_	_	_	_	_	Seg=O
165	by	_	_	_	_	_	_	_	Seg=B-seg
166	sampling	_	_	_	_	_	_	_	Seg=O
167	equipment	_	_	_	_	_	_	_	Seg=O
168	to	_	_	_	_	_	_	_	Seg=B-seg
169	detect	_	_	_	_	_	_	_	Seg=O
170	bioaerosols	_	_	_	_	_	_	_	Seg=O
171	at	_	_	_	_	_	_	_	Seg=O
172	various	_	_	_	_	_	_	_	Seg=O
173	locations	_	_	_	_	_	_	_	Seg=O
174	within	_	_	_	_	_	_	_	Seg=O
175	the	_	_	_	_	_	_	_	Seg=O
176	square	_	_	_	_	_	_	_	Seg=O
177	.	_	_	_	_	_	_	_	Seg=O
178	It	_	_	_	_	_	_	_	Seg=B-seg
179	was	_	_	_	_	_	_	_	Seg=O
180	found	_	_	_	_	_	_	_	Seg=O
181	that	_	_	_	_	_	_	_	Seg=O
182	,	_	_	_	_	_	_	_	Seg=O
183	for	_	_	_	_	_	_	_	Seg=O
184	chosen	_	_	_	_	_	_	_	Seg=O
185	bioaerosol	_	_	_	_	_	_	_	Seg=O
186	generation	_	_	_	_	_	_	_	Seg=O
187	parameters	_	_	_	_	_	_	_	Seg=O
188	and	_	_	_	_	_	_	_	Seg=O
189	weather	_	_	_	_	_	_	_	Seg=O
190	conditions	_	_	_	_	_	_	_	Seg=O
191	,	_	_	_	_	_	_	_	Seg=O
192	the	_	_	_	_	_	_	_	Seg=O
193	new	_	_	_	_	_	_	_	Seg=O
194	personal	_	_	_	_	_	_	_	Seg=O
195	sampler	_	_	_	_	_	_	_	Seg=O
196	would	_	_	_	_	_	_	_	Seg=O
197	be	_	_	_	_	_	_	_	Seg=O
198	capable	_	_	_	_	_	_	_	Seg=O
199	to	_	_	_	_	_	_	_	Seg=O
200	reliably	_	_	_	_	_	_	_	Seg=O
201	detect	_	_	_	_	_	_	_	Seg=O
202	pathogens	_	_	_	_	_	_	_	Seg=O
203	at	_	_	_	_	_	_	_	Seg=O
204	all	_	_	_	_	_	_	_	Seg=O
205	locations	_	_	_	_	_	_	_	Seg=O
206	occupied	_	_	_	_	_	_	_	Seg=B-seg
207	by	_	_	_	_	_	_	_	Seg=O
208	crowd	_	_	_	_	_	_	_	Seg=O
209	,	_	_	_	_	_	_	_	Seg=O
210	even	_	_	_	_	_	_	_	Seg=B-seg
211	at	_	_	_	_	_	_	_	Seg=O
212	distances	_	_	_	_	_	_	_	Seg=O
213	of	_	_	_	_	_	_	_	Seg=O
214	up	_	_	_	_	_	_	_	Seg=O
215	to	_	_	_	_	_	_	_	Seg=O
216	600	_	_	_	_	_	_	_	Seg=O
217	m	_	_	_	_	_	_	_	Seg=O
218	from	_	_	_	_	_	_	_	Seg=O
219	the	_	_	_	_	_	_	_	Seg=O
220	source	_	_	_	_	_	_	_	Seg=O
221	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 0fda4597d104be27d5c7eedd815790b6dedfeb1e
1	Increasing	_	_	_	_	_	_	_	Seg=B-seg
2	a	_	_	_	_	_	_	_	Seg=O
3	ceiling	_	_	_	_	_	_	_	Seg=O
4-5	fan's	_	_	_	_	_	_	_	_
4	fan	_	_	_	_	_	_	_	Seg=O
5	's	_	_	_	_	_	_	_	Seg=O
6	speed	_	_	_	_	_	_	_	Seg=O
7	from	_	_	_	_	_	_	_	Seg=O
8	its	_	_	_	_	_	_	_	Seg=O
9	lowest	_	_	_	_	_	_	_	Seg=O
10	setting	_	_	_	_	_	_	_	Seg=O
11	of	_	_	_	_	_	_	_	Seg=O
12	61	_	_	_	_	_	_	_	Seg=O
13	rpm	_	_	_	_	_	_	_	Seg=O
14	,	_	_	_	_	_	_	_	Seg=O
15	which	_	_	_	_	_	_	_	Seg=B-seg
16	resulted	_	_	_	_	_	_	_	Seg=O
17	in	_	_	_	_	_	_	_	Seg=O
18	0.77	_	_	_	_	_	_	_	Seg=O
19	m	_	_	_	_	_	_	_	Seg=O
20	3	_	_	_	_	_	_	_	Seg=O
21	/s	_	_	_	_	_	_	_	Seg=O
22	of	_	_	_	_	_	_	_	Seg=O
23	airflow	_	_	_	_	_	_	_	Seg=O
24	,	_	_	_	_	_	_	_	Seg=O
25	to	_	_	_	_	_	_	_	Seg=B-seg
26	its	_	_	_	_	_	_	_	Seg=O
27	highest	_	_	_	_	_	_	_	Seg=O
28	setting	_	_	_	_	_	_	_	Seg=O
29	of	_	_	_	_	_	_	_	Seg=O
30	176	_	_	_	_	_	_	_	Seg=O
31	rpm	_	_	_	_	_	_	_	Seg=O
32	,	_	_	_	_	_	_	_	Seg=O
33	which	_	_	_	_	_	_	_	Seg=B-seg
34	resulted	_	_	_	_	_	_	_	Seg=O
35	in	_	_	_	_	_	_	_	Seg=O
36	2.5	_	_	_	_	_	_	_	Seg=O
37	m	_	_	_	_	_	_	_	Seg=O
38	3	_	_	_	_	_	_	_	Seg=O
39	/s	_	_	_	_	_	_	_	Seg=O
40	of	_	_	_	_	_	_	_	Seg=O
41	airflow	_	_	_	_	_	_	_	Seg=O
42	,	_	_	_	_	_	_	_	Seg=O
43	or	_	_	_	_	_	_	_	Seg=B-seg
44	having	_	_	_	_	_	_	_	Seg=O
45	the	_	_	_	_	_	_	_	Seg=O
46	fan	_	_	_	_	_	_	_	Seg=O
47	blow	_	_	_	_	_	_	_	Seg=O
48	either	_	_	_	_	_	_	_	Seg=O
49	upward	_	_	_	_	_	_	_	Seg=O
50	or	_	_	_	_	_	_	_	Seg=O
51	downward	_	_	_	_	_	_	_	Seg=O
52	had	_	_	_	_	_	_	_	Seg=O
53	no	_	_	_	_	_	_	_	Seg=O
54	statistically	_	_	_	_	_	_	_	Seg=O
55	significant	_	_	_	_	_	_	_	Seg=O
56	effect	_	_	_	_	_	_	_	Seg=O
57	on	_	_	_	_	_	_	_	Seg=O
58	the	_	_	_	_	_	_	_	Seg=O
59	efficacy	_	_	_	_	_	_	_	Seg=O
60	of	_	_	_	_	_	_	_	Seg=O
61	upper	_	_	_	_	_	_	_	Seg=O
62	-	_	_	_	_	_	_	_	Seg=O
63	room	_	_	_	_	_	_	_	Seg=O
64	ultraviolet	_	_	_	_	_	_	_	Seg=O
65	germicidal	_	_	_	_	_	_	_	Seg=O
66	irradiation	_	_	_	_	_	_	_	Seg=O
67	(	_	_	_	_	_	_	_	Seg=O
68	UVGI	_	_	_	_	_	_	_	Seg=O
69	)	_	_	_	_	_	_	_	Seg=O
70	.	_	_	_	_	_	_	_	Seg=O
71	This	_	_	_	_	_	_	_	Seg=B-seg
72	outcome	_	_	_	_	_	_	_	Seg=O
73	suggests	_	_	_	_	_	_	_	Seg=O
74	that	_	_	_	_	_	_	_	Seg=B-seg
75	air	_	_	_	_	_	_	_	Seg=O
76	circulation	_	_	_	_	_	_	_	Seg=O
77	due	_	_	_	_	_	_	_	Seg=B-seg
78	to	_	_	_	_	_	_	_	Seg=O
79	the	_	_	_	_	_	_	_	Seg=O
80	ceiling	_	_	_	_	_	_	_	Seg=O
81	fan	_	_	_	_	_	_	_	Seg=O
82	was	_	_	_	_	_	_	_	Seg=B-seg
83	sufficient	_	_	_	_	_	_	_	Seg=O
84	and	_	_	_	_	_	_	_	Seg=B-seg
85	that	_	_	_	_	_	_	_	Seg=O
86	any	_	_	_	_	_	_	_	Seg=O
87	additional	_	_	_	_	_	_	_	Seg=O
88	increase	_	_	_	_	_	_	_	Seg=O
89	would	_	_	_	_	_	_	_	Seg=O
90	not	_	_	_	_	_	_	_	Seg=O
91	improve	_	_	_	_	_	_	_	Seg=O
92	efficacy	_	_	_	_	_	_	_	Seg=O
93	.	_	_	_	_	_	_	_	Seg=O
94	Numerous	_	_	_	_	_	_	_	Seg=B-seg
95	experimental	_	_	_	_	_	_	_	Seg=O
96	studies	_	_	_	_	_	_	_	Seg=O
97	on	_	_	_	_	_	_	_	Seg=O
98	upper	_	_	_	_	_	_	_	Seg=O
99	-	_	_	_	_	_	_	_	Seg=O
100	room	_	_	_	_	_	_	_	Seg=O
101	UVGI	_	_	_	_	_	_	_	Seg=O
102	in	_	_	_	_	_	_	_	Seg=B-seg
103	which	_	_	_	_	_	_	_	Seg=O
104	fans	_	_	_	_	_	_	_	Seg=O
105	were	_	_	_	_	_	_	_	Seg=O
106	used	_	_	_	_	_	_	_	Seg=O
107	to	_	_	_	_	_	_	_	Seg=B-seg
108	provide	_	_	_	_	_	_	_	Seg=O
109	air	_	_	_	_	_	_	_	Seg=O
110	mixing	_	_	_	_	_	_	_	Seg=O
111	have	_	_	_	_	_	_	_	Seg=B-seg
112	been	_	_	_	_	_	_	_	Seg=O
113	published	_	_	_	_	_	_	_	Seg=O
114	.	_	_	_	_	_	_	_	Seg=O
115	However	_	_	_	_	_	_	_	Seg=B-seg
116	,	_	_	_	_	_	_	_	Seg=O
117	none	_	_	_	_	_	_	_	Seg=O
118	have	_	_	_	_	_	_	_	Seg=O
119	quantified	_	_	_	_	_	_	_	Seg=O
120	the	_	_	_	_	_	_	_	Seg=O
121	air	_	_	_	_	_	_	_	Seg=O
122	movement	_	_	_	_	_	_	_	Seg=O
123	produced	_	_	_	_	_	_	_	Seg=B-seg
124	by	_	_	_	_	_	_	_	Seg=O
125	these	_	_	_	_	_	_	_	Seg=O
126	fans	_	_	_	_	_	_	_	Seg=O
127	or	_	_	_	_	_	_	_	Seg=B-seg
128	described	_	_	_	_	_	_	_	Seg=O
129	their	_	_	_	_	_	_	_	Seg=O
130	tests	_	_	_	_	_	_	_	Seg=O
131	in	_	_	_	_	_	_	_	Seg=O
132	sufficient	_	_	_	_	_	_	_	Seg=O
133	detail	_	_	_	_	_	_	_	Seg=O
134	to	_	_	_	_	_	_	_	Seg=B-seg
135	allow	_	_	_	_	_	_	_	Seg=O
136	results	_	_	_	_	_	_	_	Seg=O
137	to	_	_	_	_	_	_	_	Seg=O
138	be	_	_	_	_	_	_	_	Seg=O
139	compared	_	_	_	_	_	_	_	Seg=O
140	to	_	_	_	_	_	_	_	Seg=O
141	predictions	_	_	_	_	_	_	_	Seg=O
142	using	_	_	_	_	_	_	_	Seg=B-seg
143	computational	_	_	_	_	_	_	_	Seg=O
144	fluid	_	_	_	_	_	_	_	Seg=O
145	dynamics	_	_	_	_	_	_	_	Seg=O
146	(	_	_	_	_	_	_	_	Seg=O
147	CFD	_	_	_	_	_	_	_	Seg=O
148	)	_	_	_	_	_	_	_	Seg=O
149	.	_	_	_	_	_	_	_	Seg=O
150	The	_	_	_	_	_	_	_	Seg=B-seg
151	present	_	_	_	_	_	_	_	Seg=O
152	work	_	_	_	_	_	_	_	Seg=O
153	provides	_	_	_	_	_	_	_	Seg=O
154	the	_	_	_	_	_	_	_	Seg=O
155	required	_	_	_	_	_	_	_	Seg=O
156	information	_	_	_	_	_	_	_	Seg=O
157	.	_	_	_	_	_	_	_	Seg=O
158	In	_	_	_	_	_	_	_	Seg=B-seg
159	addition	_	_	_	_	_	_	_	Seg=O
160	to	_	_	_	_	_	_	_	Seg=O
161	the	_	_	_	_	_	_	_	Seg=O
162	usual	_	_	_	_	_	_	_	Seg=O
163	boundary	_	_	_	_	_	_	_	Seg=O
164	conditions	_	_	_	_	_	_	_	Seg=O
165	needed	_	_	_	_	_	_	_	Seg=B-seg
166	for	_	_	_	_	_	_	_	Seg=O
167	CFD	_	_	_	_	_	_	_	Seg=O
168	,	_	_	_	_	_	_	_	Seg=O
169	we	_	_	_	_	_	_	_	Seg=B-seg
170	made	_	_	_	_	_	_	_	Seg=O
171	experimental	_	_	_	_	_	_	_	Seg=O
172	measurements	_	_	_	_	_	_	_	Seg=O
173	of	_	_	_	_	_	_	_	Seg=O
174	UV	_	_	_	_	_	_	_	Seg=O
175	susceptibility	_	_	_	_	_	_	_	Seg=O
176	of	_	_	_	_	_	_	_	Seg=O
177	the	_	_	_	_	_	_	_	Seg=O
178	microorganisms	_	_	_	_	_	_	_	Seg=O
179	used	_	_	_	_	_	_	_	Seg=B-seg
180	in	_	_	_	_	_	_	_	Seg=O
181	the	_	_	_	_	_	_	_	Seg=O
182	upper	_	_	_	_	_	_	_	Seg=O
183	-	_	_	_	_	_	_	_	Seg=O
184	room	_	_	_	_	_	_	_	Seg=O
185	UVGI	_	_	_	_	_	_	_	Seg=O
186	tests	_	_	_	_	_	_	_	Seg=O
187	.	_	_	_	_	_	_	_	Seg=O
188	We	_	_	_	_	_	_	_	Seg=B-seg
189	measured	_	_	_	_	_	_	_	Seg=O
190	UV	_	_	_	_	_	_	_	Seg=O
191	susceptibilities	_	_	_	_	_	_	_	Seg=O
192	for	_	_	_	_	_	_	_	Seg=O
193	Mycobacterium	_	_	_	_	_	_	_	Seg=O
194	parafortuitum	_	_	_	_	_	_	_	Seg=O
195	and	_	_	_	_	_	_	_	Seg=O
196	Bacillus	_	_	_	_	_	_	_	Seg=O
197	atrophaeus	_	_	_	_	_	_	_	Seg=O
198	spores	_	_	_	_	_	_	_	Seg=O
199	to	_	_	_	_	_	_	_	Seg=O
200	be	_	_	_	_	_	_	_	Seg=O
201	0.074	_	_	_	_	_	_	_	Seg=O
202	and	_	_	_	_	_	_	_	Seg=O
203	0.018	_	_	_	_	_	_	_	Seg=O
204	m	_	_	_	_	_	_	_	Seg=O
205	2	_	_	_	_	_	_	_	Seg=O
206	/J	_	_	_	_	_	_	_	Seg=O
207	,	_	_	_	_	_	_	_	Seg=O
208	respectively	_	_	_	_	_	_	_	Seg=O
209	.	_	_	_	_	_	_	_	Seg=O
210	In	_	_	_	_	_	_	_	Seg=B-seg
211	a	_	_	_	_	_	_	_	Seg=O
212	previous	_	_	_	_	_	_	_	Seg=O
213	publication	_	_	_	_	_	_	_	Seg=O
214	,	_	_	_	_	_	_	_	Seg=O
215	we	_	_	_	_	_	_	_	Seg=O
216	reported	_	_	_	_	_	_	_	Seg=O
217	the	_	_	_	_	_	_	_	Seg=O
218	spatial	_	_	_	_	_	_	_	Seg=O
219	distribution	_	_	_	_	_	_	_	Seg=O
220	of	_	_	_	_	_	_	_	Seg=O
221	fluence	_	_	_	_	_	_	_	Seg=O
222	rate	_	_	_	_	_	_	_	Seg=O
223	,	_	_	_	_	_	_	_	Seg=O
224	which	_	_	_	_	_	_	_	Seg=B-seg
225	is	_	_	_	_	_	_	_	Seg=O
226	also	_	_	_	_	_	_	_	Seg=O
227	needed	_	_	_	_	_	_	_	Seg=O
228	for	_	_	_	_	_	_	_	Seg=B-seg
229	predicting	_	_	_	_	_	_	_	Seg=O
230	efficacy	_	_	_	_	_	_	_	Seg=O
231	from	_	_	_	_	_	_	_	Seg=O
232	CFD	_	_	_	_	_	_	_	Seg=O
233	.	_	_	_	_	_	_	_	Seg=O
234	In	_	_	_	_	_	_	_	Seg=B-seg
235	a	_	_	_	_	_	_	_	Seg=O
236	companion	_	_	_	_	_	_	_	Seg=O
237	paper	_	_	_	_	_	_	_	Seg=O
238	referred	_	_	_	_	_	_	_	Seg=B-seg
239	to	_	_	_	_	_	_	_	Seg=O
240	as	_	_	_	_	_	_	_	Seg=O
241	Part	_	_	_	_	_	_	_	Seg=O
242	II	_	_	_	_	_	_	_	Seg=O
243	,	_	_	_	_	_	_	_	Seg=O
244	upper	_	_	_	_	_	_	_	Seg=B-seg
245	-	_	_	_	_	_	_	_	Seg=O
246	room	_	_	_	_	_	_	_	Seg=O
247	UVGI	_	_	_	_	_	_	_	Seg=O
248	efficacy	_	_	_	_	_	_	_	Seg=O
249	was	_	_	_	_	_	_	_	Seg=O
250	predicted	_	_	_	_	_	_	_	Seg=O
251	by	_	_	_	_	_	_	_	Seg=O
252	both	_	_	_	_	_	_	_	Seg=O
253	Eulerian	_	_	_	_	_	_	_	Seg=O
254	and	_	_	_	_	_	_	_	Seg=O
255	Lagrangian	_	_	_	_	_	_	_	Seg=O
256	CFD	_	_	_	_	_	_	_	Seg=O
257	and	_	_	_	_	_	_	_	Seg=B-seg
258	compared	_	_	_	_	_	_	_	Seg=O
259	to	_	_	_	_	_	_	_	Seg=O
260	the	_	_	_	_	_	_	_	Seg=O
261	experimental	_	_	_	_	_	_	_	Seg=O
262	results	_	_	_	_	_	_	_	Seg=O
263	from	_	_	_	_	_	_	_	Seg=O
264	the	_	_	_	_	_	_	_	Seg=O
265	present	_	_	_	_	_	_	_	Seg=O
266	study	_	_	_	_	_	_	_	Seg=O
267	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 107ed9d88147de29cb5c3e2a61a57fd074a3f0e0
1	Pericytes	_	_	_	_	_	_	_	Seg=B-seg
2	,	_	_	_	_	_	_	_	Seg=O
3	as	_	_	_	_	_	_	_	Seg=O
4	a	_	_	_	_	_	_	_	Seg=O
5	key	_	_	_	_	_	_	_	Seg=O
6	cellular	_	_	_	_	_	_	_	Seg=O
7	part	_	_	_	_	_	_	_	Seg=O
8	of	_	_	_	_	_	_	_	Seg=O
9	the	_	_	_	_	_	_	_	Seg=O
10	blood	_	_	_	_	_	_	_	Seg=O
11	-	_	_	_	_	_	_	_	Seg=O
12	brain	_	_	_	_	_	_	_	Seg=O
13	barrier	_	_	_	_	_	_	_	Seg=O
14	,	_	_	_	_	_	_	_	Seg=O
15	play	_	_	_	_	_	_	_	Seg=O
16	an	_	_	_	_	_	_	_	Seg=O
17	important	_	_	_	_	_	_	_	Seg=O
18	role	_	_	_	_	_	_	_	Seg=O
19	in	_	_	_	_	_	_	_	Seg=O
20	the	_	_	_	_	_	_	_	Seg=O
21	maintenance	_	_	_	_	_	_	_	Seg=O
22	of	_	_	_	_	_	_	_	Seg=O
23	brain	_	_	_	_	_	_	_	Seg=O
24	neurovascular	_	_	_	_	_	_	_	Seg=O
25	unit	_	_	_	_	_	_	_	Seg=O
26	.	_	_	_	_	_	_	_	Seg=O
27	These	_	_	_	_	_	_	_	Seg=B-seg
28	cells	_	_	_	_	_	_	_	Seg=O
29	participate	_	_	_	_	_	_	_	Seg=O
30	in	_	_	_	_	_	_	_	Seg=O
31	brain	_	_	_	_	_	_	_	Seg=O
32	homeostasis	_	_	_	_	_	_	_	Seg=O
33	by	_	_	_	_	_	_	_	Seg=B-seg
34	regulating	_	_	_	_	_	_	_	Seg=O
35	vascular	_	_	_	_	_	_	_	Seg=O
36	development	_	_	_	_	_	_	_	Seg=O
37	and	_	_	_	_	_	_	_	Seg=O
38	integrity	_	_	_	_	_	_	_	Seg=O
39	mainly	_	_	_	_	_	_	_	Seg=O
40	through	_	_	_	_	_	_	_	Seg=O
41	secreting	_	_	_	_	_	_	_	Seg=O
42	various	_	_	_	_	_	_	_	Seg=O
43	factors	_	_	_	_	_	_	_	Seg=O
44	.	_	_	_	_	_	_	_	Seg=O
45	Pericytes	_	_	_	_	_	_	_	Seg=B-seg
46	per	_	_	_	_	_	_	_	Seg=O
47	se	_	_	_	_	_	_	_	Seg=O
48	show	_	_	_	_	_	_	_	Seg=O
49	different	_	_	_	_	_	_	_	Seg=O
50	restorative	_	_	_	_	_	_	_	Seg=O
51	properties	_	_	_	_	_	_	_	Seg=O
52	after	_	_	_	_	_	_	_	Seg=O
53	blood	_	_	_	_	_	_	_	Seg=O
54	-	_	_	_	_	_	_	_	Seg=O
55	brain	_	_	_	_	_	_	_	Seg=O
56	barrier	_	_	_	_	_	_	_	Seg=O
57	injury	_	_	_	_	_	_	_	Seg=O
58	.	_	_	_	_	_	_	_	Seg=O
59	Upon	_	_	_	_	_	_	_	Seg=B-seg
60	the	_	_	_	_	_	_	_	Seg=O
61	occurrence	_	_	_	_	_	_	_	Seg=O
62	of	_	_	_	_	_	_	_	Seg=O
63	brain	_	_	_	_	_	_	_	Seg=O
64	acute	_	_	_	_	_	_	_	Seg=O
65	and	_	_	_	_	_	_	_	Seg=O
66	chronic	_	_	_	_	_	_	_	Seg=O
67	diseases	_	_	_	_	_	_	_	Seg=O
68	,	_	_	_	_	_	_	_	Seg=O
69	pericytes	_	_	_	_	_	_	_	Seg=O
70	provoke	_	_	_	_	_	_	_	Seg=O
71	immune	_	_	_	_	_	_	_	Seg=O
72	cells	_	_	_	_	_	_	_	Seg=O
73	to	_	_	_	_	_	_	_	Seg=O
74	regulate	_	_	_	_	_	_	_	Seg=O
75	neuro	_	_	_	_	_	_	_	Seg=O
76	-	_	_	_	_	_	_	_	Seg=O
77	inflammatory	_	_	_	_	_	_	_	Seg=O
78	conditions	_	_	_	_	_	_	_	Seg=O
79	.	_	_	_	_	_	_	_	Seg=O
80	Loss	_	_	_	_	_	_	_	Seg=B-seg
81	of	_	_	_	_	_	_	_	Seg=O
82	pericytes	_	_	_	_	_	_	_	Seg=O
83	in	_	_	_	_	_	_	_	Seg=O
84	distinct	_	_	_	_	_	_	_	Seg=O
85	neurologic	_	_	_	_	_	_	_	Seg=O
86	disorders	_	_	_	_	_	_	_	Seg=O
87	intensifies	_	_	_	_	_	_	_	Seg=O
88	blood	_	_	_	_	_	_	_	Seg=O
89	-	_	_	_	_	_	_	_	Seg=O
90	brain	_	_	_	_	_	_	_	Seg=O
91	barrier	_	_	_	_	_	_	_	Seg=O
92	permeability	_	_	_	_	_	_	_	Seg=O
93	and	_	_	_	_	_	_	_	Seg=B-seg
94	leads	_	_	_	_	_	_	_	Seg=O
95	to	_	_	_	_	_	_	_	Seg=O
96	vascular	_	_	_	_	_	_	_	Seg=O
97	dementia	_	_	_	_	_	_	_	Seg=O
98	.	_	_	_	_	_	_	_	Seg=O
99	The	_	_	_	_	_	_	_	Seg=B-seg
100	therapeutic	_	_	_	_	_	_	_	Seg=O
101	potential	_	_	_	_	_	_	_	Seg=O
102	of	_	_	_	_	_	_	_	Seg=O
103	pericytes	_	_	_	_	_	_	_	Seg=O
104	is	_	_	_	_	_	_	_	Seg=O
105	originated	_	_	_	_	_	_	_	Seg=O
106	from	_	_	_	_	_	_	_	Seg=O
107	the	_	_	_	_	_	_	_	Seg=O
108	unique	_	_	_	_	_	_	_	Seg=O
109	morphological	_	_	_	_	_	_	_	Seg=O
110	shape	_	_	_	_	_	_	_	Seg=O
111	,	_	_	_	_	_	_	_	Seg=O
112	location	_	_	_	_	_	_	_	Seg=O
113	,	_	_	_	_	_	_	_	Seg=O
114	and	_	_	_	_	_	_	_	Seg=O
115	their	_	_	_	_	_	_	_	Seg=O
116	ability	_	_	_	_	_	_	_	Seg=O
117	in	_	_	_	_	_	_	_	Seg=B-seg
118	providing	_	_	_	_	_	_	_	Seg=O
119	vast	_	_	_	_	_	_	_	Seg=O
120	paracrine	_	_	_	_	_	_	_	Seg=O
121	and	_	_	_	_	_	_	_	Seg=O
122	juxtacrine	_	_	_	_	_	_	_	Seg=O
123	interactions	_	_	_	_	_	_	_	Seg=O
124	.	_	_	_	_	_	_	_	Seg=O
125	A	_	_	_	_	_	_	_	Seg=B-seg
126	subset	_	_	_	_	_	_	_	Seg=O
127	of	_	_	_	_	_	_	_	Seg=O
128	pericytes	_	_	_	_	_	_	_	Seg=O
129	possesses	_	_	_	_	_	_	_	Seg=O
130	multipotentiality	_	_	_	_	_	_	_	Seg=O
131	and	_	_	_	_	_	_	_	Seg=B-seg
132	exhibit	_	_	_	_	_	_	_	Seg=O
133	trans	_	_	_	_	_	_	_	Seg=O
134	-	_	_	_	_	_	_	_	Seg=O
135	differentiation	_	_	_	_	_	_	_	Seg=O
136	capacity	_	_	_	_	_	_	_	Seg=O
137	in	_	_	_	_	_	_	_	Seg=O
138	the	_	_	_	_	_	_	_	Seg=O
139	context	_	_	_	_	_	_	_	Seg=O
140	of	_	_	_	_	_	_	_	Seg=O
141	damaged	_	_	_	_	_	_	_	Seg=O
142	tissue	_	_	_	_	_	_	_	Seg=O
143	.	_	_	_	_	_	_	_	Seg=O
144	This	_	_	_	_	_	_	_	Seg=B-seg
145	review	_	_	_	_	_	_	_	Seg=O
146	article	_	_	_	_	_	_	_	Seg=O
147	aimed	_	_	_	_	_	_	_	Seg=O
148	to	_	_	_	_	_	_	_	Seg=O
149	highlight	_	_	_	_	_	_	_	Seg=O
150	the	_	_	_	_	_	_	_	Seg=O
151	critical	_	_	_	_	_	_	_	Seg=O
152	role	_	_	_	_	_	_	_	Seg=O
153	of	_	_	_	_	_	_	_	Seg=O
154	pericytes	_	_	_	_	_	_	_	Seg=O
155	in	_	_	_	_	_	_	_	Seg=O
156	restoration	_	_	_	_	_	_	_	Seg=O
157	of	_	_	_	_	_	_	_	Seg=O
158	the	_	_	_	_	_	_	_	Seg=O
159	blood	_	_	_	_	_	_	_	Seg=O
160	-	_	_	_	_	_	_	_	Seg=O
161	brain	_	_	_	_	_	_	_	Seg=O
162	barrier	_	_	_	_	_	_	_	Seg=O
163	after	_	_	_	_	_	_	_	Seg=O
164	injury	_	_	_	_	_	_	_	Seg=O
165	by	_	_	_	_	_	_	_	Seg=B-seg
166	focusing	_	_	_	_	_	_	_	Seg=O
167	on	_	_	_	_	_	_	_	Seg=O
168	the	_	_	_	_	_	_	_	Seg=O
169	dynamics	_	_	_	_	_	_	_	Seg=O
170	of	_	_	_	_	_	_	_	Seg=O
171	pericytes	_	_	_	_	_	_	_	Seg=O
172	and	_	_	_	_	_	_	_	Seg=O
173	cross	_	_	_	_	_	_	_	Seg=O
174	-	_	_	_	_	_	_	_	Seg=O
175	talk	_	_	_	_	_	_	_	Seg=O
176	with	_	_	_	_	_	_	_	Seg=O
177	other	_	_	_	_	_	_	_	Seg=O
178	cell	_	_	_	_	_	_	_	Seg=O
179	types	_	_	_	_	_	_	_	Seg=O
180	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 123589feb77f17e27c7b93326aaae484bff34424
1	This	_	_	_	_	_	_	_	Seg=B-seg
2	study	_	_	_	_	_	_	_	Seg=O
3	is	_	_	_	_	_	_	_	Seg=O
4	aimed	_	_	_	_	_	_	_	Seg=O
5	at	_	_	_	_	_	_	_	Seg=O
6	defining	_	_	_	_	_	_	_	Seg=O
7	the	_	_	_	_	_	_	_	Seg=O
8	relationship	_	_	_	_	_	_	_	Seg=O
9	between	_	_	_	_	_	_	_	Seg=O
10	a	_	_	_	_	_	_	_	Seg=O
11	set	_	_	_	_	_	_	_	Seg=O
12	of	_	_	_	_	_	_	_	Seg=O
13	environmental	_	_	_	_	_	_	_	Seg=O
14	factors	_	_	_	_	_	_	_	Seg=O
15	and	_	_	_	_	_	_	_	Seg=O
16	childhood	_	_	_	_	_	_	_	Seg=O
17	HFMD	_	_	_	_	_	_	_	Seg=O
18	and	_	_	_	_	_	_	_	Seg=O
19	then	_	_	_	_	_	_	_	Seg=O
20	at	_	_	_	_	_	_	_	Seg=O
21	estimating	_	_	_	_	_	_	_	Seg=O
22	the	_	_	_	_	_	_	_	Seg=O
23	related	_	_	_	_	_	_	_	Seg=O
24	effect	_	_	_	_	_	_	_	Seg=O
25	.	_	_	_	_	_	_	_	Seg=O
26	The	_	_	_	_	_	_	_	Seg=B-seg
27	16	_	_	_	_	_	_	_	Seg=O
28	environmental	_	_	_	_	_	_	_	Seg=O
29	factors	_	_	_	_	_	_	_	Seg=O
30	included	_	_	_	_	_	_	_	Seg=O
31	meteorological	_	_	_	_	_	_	_	Seg=O
32	,	_	_	_	_	_	_	_	Seg=O
33	air	_	_	_	_	_	_	_	Seg=O
34	pollution	_	_	_	_	_	_	_	Seg=O
35	,	_	_	_	_	_	_	_	Seg=O
36	and	_	_	_	_	_	_	_	Seg=O
37	sunspot	_	_	_	_	_	_	_	Seg=O
38	.	_	_	_	_	_	_	_	Seg=O
39	A	_	_	_	_	_	_	_	Seg=B-seg
40	traditional	_	_	_	_	_	_	_	Seg=O
41	TSR	_	_	_	_	_	_	_	Seg=O
42	modified	_	_	_	_	_	_	_	Seg=B-seg
43	by	_	_	_	_	_	_	_	Seg=B-seg
44	using	_	_	_	_	_	_	_	Seg=O
45	susceptible	_	_	_	_	_	_	_	Seg=O
46	-	_	_	_	_	_	_	_	Seg=O
47	infectious	_	_	_	_	_	_	_	Seg=O
48	-	_	_	_	_	_	_	_	Seg=O
49	recovery	_	_	_	_	_	_	_	Seg=O
50	models	_	_	_	_	_	_	_	Seg=O
51	and	_	_	_	_	_	_	_	Seg=O
52	distribution	_	_	_	_	_	_	_	Seg=O
53	lag	_	_	_	_	_	_	_	Seg=O
54	nonlinear	_	_	_	_	_	_	_	Seg=O
55	model	_	_	_	_	_	_	_	Seg=O
56	was	_	_	_	_	_	_	_	Seg=B-seg
57	applied	_	_	_	_	_	_	_	Seg=O
58	to	_	_	_	_	_	_	_	Seg=B-seg
59	estimate	_	_	_	_	_	_	_	Seg=O
60	the	_	_	_	_	_	_	_	Seg=O
61	short	_	_	_	_	_	_	_	Seg=O
62	-	_	_	_	_	_	_	_	Seg=O
63	term	_	_	_	_	_	_	_	Seg=O
64	effects	_	_	_	_	_	_	_	Seg=O
65	of	_	_	_	_	_	_	_	Seg=O
66	daily	_	_	_	_	_	_	_	Seg=O
67	environmental	_	_	_	_	_	_	_	Seg=O
68	factors	_	_	_	_	_	_	_	Seg=O
69	on	_	_	_	_	_	_	_	Seg=O
70	children	_	_	_	_	_	_	_	Seg=O
71	HFMD	_	_	_	_	_	_	_	Seg=O
72	occurrence	_	_	_	_	_	_	_	Seg=O
73	in	_	_	_	_	_	_	_	Seg=O
74	2014	_	_	_	_	_	_	_	Seg=O
75	-	_	_	_	_	_	_	_	Seg=O
76	2018	_	_	_	_	_	_	_	Seg=O
77	with	_	_	_	_	_	_	_	Seg=O
78	adjustment	_	_	_	_	_	_	_	Seg=O
79	of	_	_	_	_	_	_	_	Seg=O
80	potential	_	_	_	_	_	_	_	Seg=O
81	confounding	_	_	_	_	_	_	_	Seg=O
82	factors	_	_	_	_	_	_	_	Seg=O
83	.	_	_	_	_	_	_	_	Seg=O
84	A	_	_	_	_	_	_	_	Seg=B-seg
85	total	_	_	_	_	_	_	_	Seg=O
86	of	_	_	_	_	_	_	_	Seg=O
87	70,027	_	_	_	_	_	_	_	Seg=O
88	children	_	_	_	_	_	_	_	Seg=O
89	aged	_	_	_	_	_	_	_	Seg=O
90	0	_	_	_	_	_	_	_	Seg=O
91	-	_	_	_	_	_	_	_	Seg=O
92	15	_	_	_	_	_	_	_	Seg=O
93	years	_	_	_	_	_	_	_	Seg=O
94	with	_	_	_	_	_	_	_	Seg=O
95	HFMD	_	_	_	_	_	_	_	Seg=O
96	were	_	_	_	_	_	_	_	Seg=O
97	enrolled	_	_	_	_	_	_	_	Seg=O
98	.	_	_	_	_	_	_	_	Seg=O
99	No	_	_	_	_	_	_	_	Seg=B-seg
100	significant	_	_	_	_	_	_	_	Seg=O
101	effect	_	_	_	_	_	_	_	Seg=O
102	was	_	_	_	_	_	_	_	Seg=O
103	observed	_	_	_	_	_	_	_	Seg=O
104	for	_	_	_	_	_	_	_	Seg=O
105	daily	_	_	_	_	_	_	_	Seg=O
106	sunspot	_	_	_	_	_	_	_	Seg=O
107	numbers	_	_	_	_	_	_	_	Seg=O
108	and	_	_	_	_	_	_	_	Seg=O
109	average	_	_	_	_	_	_	_	Seg=O
110	visibility	_	_	_	_	_	_	_	Seg=O
111	.	_	_	_	_	_	_	_	Seg=O
112	We	_	_	_	_	_	_	_	Seg=B-seg
113	found	_	_	_	_	_	_	_	Seg=O
114	positive	_	_	_	_	_	_	_	Seg=O
115	effects	_	_	_	_	_	_	_	Seg=O
116	of	_	_	_	_	_	_	_	Seg=O
117	the	_	_	_	_	_	_	_	Seg=O
118	ambient	_	_	_	_	_	_	_	Seg=O
119	average	_	_	_	_	_	_	_	Seg=O
120	temperature	_	_	_	_	_	_	_	Seg=O
121	,	_	_	_	_	_	_	_	Seg=O
122	with	_	_	_	_	_	_	_	Seg=O
123	an	_	_	_	_	_	_	_	Seg=O
124	approximately	_	_	_	_	_	_	_	Seg=O
125	m	_	_	_	_	_	_	_	Seg=O
126	-	_	_	_	_	_	_	_	Seg=O
127	shaped	_	_	_	_	_	_	_	Seg=O
128	curve	_	_	_	_	_	_	_	Seg=O
129	of	_	_	_	_	_	_	_	Seg=O
130	the	_	_	_	_	_	_	_	Seg=O
131	overall	_	_	_	_	_	_	_	Seg=O
132	cumulative	_	_	_	_	_	_	_	Seg=O
133	relationship	_	_	_	_	_	_	_	Seg=O
134	,	_	_	_	_	_	_	_	Seg=O
135	peaking	_	_	_	_	_	_	_	Seg=B-seg
136	at	_	_	_	_	_	_	_	Seg=O
137	25.6	_	_	_	_	_	_	_	Seg=O
138	°	_	_	_	_	_	_	_	Seg=O
139	C	_	_	_	_	_	_	_	Seg=O
140	with	_	_	_	_	_	_	_	Seg=O
141	a	_	_	_	_	_	_	_	Seg=O
142	relative	_	_	_	_	_	_	_	Seg=O
143	risk	_	_	_	_	_	_	_	Seg=O
144	(	_	_	_	_	_	_	_	Seg=O
145	RR	_	_	_	_	_	_	_	Seg=O
146	)	_	_	_	_	_	_	_	Seg=O
147	of	_	_	_	_	_	_	_	Seg=O
148	1.45	_	_	_	_	_	_	_	Seg=O
149	(	_	_	_	_	_	_	_	Seg=B-seg
150	95	_	_	_	_	_	_	_	Seg=O
151	%	_	_	_	_	_	_	_	Seg=O
152	confidence	_	_	_	_	_	_	_	Seg=O
153	intervals	_	_	_	_	_	_	_	Seg=O
154	1.21	_	_	_	_	_	_	_	Seg=O
155	-	_	_	_	_	_	_	_	Seg=O
156	1.73	_	_	_	_	_	_	_	Seg=O
157	)	_	_	_	_	_	_	_	Seg=O
158	.	_	_	_	_	_	_	_	Seg=O
159	The	_	_	_	_	_	_	_	Seg=B-seg
160	largest	_	_	_	_	_	_	_	Seg=O
161	RR	_	_	_	_	_	_	_	Seg=O
162	value	_	_	_	_	_	_	_	Seg=O
163	of	_	_	_	_	_	_	_	Seg=O
164	hot	_	_	_	_	_	_	_	Seg=O
165	effect	_	_	_	_	_	_	_	Seg=O
166	was	_	_	_	_	_	_	_	Seg=O
167	achieved	_	_	_	_	_	_	_	Seg=O
168	on	_	_	_	_	_	_	_	Seg=O
169	the	_	_	_	_	_	_	_	Seg=O
170	current	_	_	_	_	_	_	_	Seg=O
171	day	_	_	_	_	_	_	_	Seg=O
172	and	_	_	_	_	_	_	_	Seg=B-seg
173	then	_	_	_	_	_	_	_	Seg=O
174	decreased	_	_	_	_	_	_	_	Seg=O
175	by	_	_	_	_	_	_	_	Seg=O
176	2	_	_	_	_	_	_	_	Seg=O
177	days	_	_	_	_	_	_	_	Seg=O
178	(	_	_	_	_	_	_	_	Seg=B-seg
179	total	_	_	_	_	_	_	_	Seg=O
180	group	_	_	_	_	_	_	_	Seg=O
181	,	_	_	_	_	_	_	_	Seg=O
182	male	_	_	_	_	_	_	_	Seg=O
183	group	_	_	_	_	_	_	_	Seg=O
184	,	_	_	_	_	_	_	_	Seg=O
185	and	_	_	_	_	_	_	_	Seg=O
186	scatter	_	_	_	_	_	_	_	Seg=O
187	group	_	_	_	_	_	_	_	Seg=O
188	)	_	_	_	_	_	_	_	Seg=O
189	or	_	_	_	_	_	_	_	Seg=B-seg
190	1	_	_	_	_	_	_	_	Seg=O
191	day	_	_	_	_	_	_	_	Seg=O
192	(	_	_	_	_	_	_	_	Seg=B-seg
193	female	_	_	_	_	_	_	_	Seg=O
194	group	_	_	_	_	_	_	_	Seg=O
195	and	_	_	_	_	_	_	_	Seg=O
196	nursery	_	_	_	_	_	_	_	Seg=O
197	group	_	_	_	_	_	_	_	Seg=O
198	)	_	_	_	_	_	_	_	Seg=O
199	,	_	_	_	_	_	_	_	Seg=O
200	and	_	_	_	_	_	_	_	Seg=B-seg
201	the	_	_	_	_	_	_	_	Seg=O
202	effect	_	_	_	_	_	_	_	Seg=O
203	lasted	_	_	_	_	_	_	_	Seg=O
204	about	_	_	_	_	_	_	_	Seg=O
205	6	_	_	_	_	_	_	_	Seg=O
206	to	_	_	_	_	_	_	_	Seg=O
207	8	_	_	_	_	_	_	_	Seg=O
208	days	_	_	_	_	_	_	_	Seg=O
209	from	_	_	_	_	_	_	_	Seg=O
210	the	_	_	_	_	_	_	_	Seg=O
211	lag	_	_	_	_	_	_	_	Seg=O
212	4	_	_	_	_	_	_	_	Seg=O
213	or	_	_	_	_	_	_	_	Seg=O
214	lag	_	_	_	_	_	_	_	Seg=O
215	6	_	_	_	_	_	_	_	Seg=O
216	day	_	_	_	_	_	_	_	Seg=O
217	.	_	_	_	_	_	_	_	Seg=O
218	A	_	_	_	_	_	_	_	Seg=B-seg
219	greater	_	_	_	_	_	_	_	Seg=O
220	association	_	_	_	_	_	_	_	Seg=O
221	of	_	_	_	_	_	_	_	Seg=O
222	temperature	_	_	_	_	_	_	_	Seg=O
223	with	_	_	_	_	_	_	_	Seg=O
224	HFMD	_	_	_	_	_	_	_	Seg=O
225	for	_	_	_	_	_	_	_	Seg=O
226	the	_	_	_	_	_	_	_	Seg=O
227	female	_	_	_	_	_	_	_	Seg=O
228	group	_	_	_	_	_	_	_	Seg=O
229	and	_	_	_	_	_	_	_	Seg=O
230	the	_	_	_	_	_	_	_	Seg=O
231	scattered	_	_	_	_	_	_	_	Seg=O
232	group	_	_	_	_	_	_	_	Seg=O
233	was	_	_	_	_	_	_	_	Seg=O
234	observed	_	_	_	_	_	_	_	Seg=O
235	.	_	_	_	_	_	_	_	Seg=O
236	This	_	_	_	_	_	_	_	Seg=B-seg
237	study	_	_	_	_	_	_	_	Seg=O
238	suggests	_	_	_	_	_	_	_	Seg=O
239	that	_	_	_	_	_	_	_	Seg=B-seg
240	ambient	_	_	_	_	_	_	_	Seg=O
241	average	_	_	_	_	_	_	_	Seg=O
242	temperature	_	_	_	_	_	_	_	Seg=O
243	might	_	_	_	_	_	_	_	Seg=O
244	be	_	_	_	_	_	_	_	Seg=O
245	a	_	_	_	_	_	_	_	Seg=O
246	risk	_	_	_	_	_	_	_	Seg=O
247	factor	_	_	_	_	_	_	_	Seg=O
248	for	_	_	_	_	_	_	_	Seg=O
249	children	_	_	_	_	_	_	_	Seg=O
250	HFMD	_	_	_	_	_	_	_	Seg=O
251	in	_	_	_	_	_	_	_	Seg=O
252	Tianjin	_	_	_	_	_	_	_	Seg=O
253	.	_	_	_	_	_	_	_	Seg=O
254	Further	_	_	_	_	_	_	_	Seg=B-seg
255	studies	_	_	_	_	_	_	_	Seg=O
256	are	_	_	_	_	_	_	_	Seg=O
257	warranted	_	_	_	_	_	_	_	Seg=O
258	to	_	_	_	_	_	_	_	Seg=B-seg
259	confirm	_	_	_	_	_	_	_	Seg=O
260	these	_	_	_	_	_	_	_	Seg=O
261	findings	_	_	_	_	_	_	_	Seg=O
262	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 146171e5a6075515b4218b0a11d05ebc829bd08b
1	Coronavirus	_	_	_	_	_	_	_	Seg=B-seg
2	disease	_	_	_	_	_	_	_	Seg=O
3	2019	_	_	_	_	_	_	_	Seg=O
4	has	_	_	_	_	_	_	_	Seg=O
5	become	_	_	_	_	_	_	_	Seg=O
6	a	_	_	_	_	_	_	_	Seg=O
7	pandemic	_	_	_	_	_	_	_	Seg=O
8	disease	_	_	_	_	_	_	_	Seg=O
9	globally	_	_	_	_	_	_	_	Seg=O
10	.	_	_	_	_	_	_	_	Seg=O
11	While	_	_	_	_	_	_	_	Seg=B-seg
12	it	_	_	_	_	_	_	_	Seg=O
13	mostly	_	_	_	_	_	_	_	Seg=O
14	presents	_	_	_	_	_	_	_	Seg=O
15	with	_	_	_	_	_	_	_	Seg=O
16	respiratory	_	_	_	_	_	_	_	Seg=O
17	symptoms	_	_	_	_	_	_	_	Seg=O
18	,	_	_	_	_	_	_	_	Seg=O
19	it	_	_	_	_	_	_	_	Seg=B-seg
20	has	_	_	_	_	_	_	_	Seg=O
21	already	_	_	_	_	_	_	_	Seg=O
22	been	_	_	_	_	_	_	_	Seg=O
23	found	_	_	_	_	_	_	_	Seg=O
24	that	_	_	_	_	_	_	_	Seg=O
25	it	_	_	_	_	_	_	_	Seg=O
26	could	_	_	_	_	_	_	_	Seg=O
27	manifest	_	_	_	_	_	_	_	Seg=O
28	with	_	_	_	_	_	_	_	Seg=O
29	a	_	_	_	_	_	_	_	Seg=O
30	series	_	_	_	_	_	_	_	Seg=O
31	of	_	_	_	_	_	_	_	Seg=O
32	neurological	_	_	_	_	_	_	_	Seg=O
33	symptoms	_	_	_	_	_	_	_	Seg=O
34	as	_	_	_	_	_	_	_	Seg=O
35	well	_	_	_	_	_	_	_	Seg=O
36	,	_	_	_	_	_	_	_	Seg=O
37	either	_	_	_	_	_	_	_	Seg=O
38	at	_	_	_	_	_	_	_	Seg=O
39	presentation	_	_	_	_	_	_	_	Seg=O
40	or	_	_	_	_	_	_	_	Seg=O
41	during	_	_	_	_	_	_	_	Seg=O
42	the	_	_	_	_	_	_	_	Seg=O
43	course	_	_	_	_	_	_	_	Seg=O
44	of	_	_	_	_	_	_	_	Seg=O
45	the	_	_	_	_	_	_	_	Seg=O
46	disease	_	_	_	_	_	_	_	Seg=O
47	.	_	_	_	_	_	_	_	Seg=O
48	Symptoms	_	_	_	_	_	_	_	Seg=B-seg
49	vary	_	_	_	_	_	_	_	Seg=O
50	from	_	_	_	_	_	_	_	Seg=O
51	non	_	_	_	_	_	_	_	Seg=O
52	-	_	_	_	_	_	_	_	Seg=O
53	specific	_	_	_	_	_	_	_	Seg=O
54	such	_	_	_	_	_	_	_	Seg=B-seg
55	as	_	_	_	_	_	_	_	Seg=O
56	headache	_	_	_	_	_	_	_	Seg=O
57	or	_	_	_	_	_	_	_	Seg=O
58	dizziness	_	_	_	_	_	_	_	Seg=O
59	to	_	_	_	_	_	_	_	Seg=B-seg
60	more	_	_	_	_	_	_	_	Seg=O
61	specific	_	_	_	_	_	_	_	Seg=O
62	such	_	_	_	_	_	_	_	Seg=B-seg
63	as	_	_	_	_	_	_	_	Seg=O
64	convulsions	_	_	_	_	_	_	_	Seg=O
65	and	_	_	_	_	_	_	_	Seg=O
66	cerebrovascular	_	_	_	_	_	_	_	Seg=O
67	disease	_	_	_	_	_	_	_	Seg=O
68	(	_	_	_	_	_	_	_	Seg=O
69	CVD	_	_	_	_	_	_	_	Seg=O
70	)	_	_	_	_	_	_	_	Seg=O
71	.	_	_	_	_	_	_	_	Seg=O
72	This	_	_	_	_	_	_	_	Seg=B-seg
73	study	_	_	_	_	_	_	_	Seg=O
74	aims	_	_	_	_	_	_	_	Seg=O
75	to	_	_	_	_	_	_	_	Seg=O
76	give	_	_	_	_	_	_	_	Seg=O
77	an	_	_	_	_	_	_	_	Seg=O
78	overview	_	_	_	_	_	_	_	Seg=O
79	of	_	_	_	_	_	_	_	Seg=O
80	the	_	_	_	_	_	_	_	Seg=O
81	neurological	_	_	_	_	_	_	_	Seg=O
82	manifestations	_	_	_	_	_	_	_	Seg=O
83	of	_	_	_	_	_	_	_	Seg=O
84	COVID-19	_	_	_	_	_	_	_	Seg=O
85	and	_	_	_	_	_	_	_	Seg=B-seg
86	discuss	_	_	_	_	_	_	_	Seg=O
87	the	_	_	_	_	_	_	_	Seg=O
88	potential	_	_	_	_	_	_	_	Seg=O
89	pathogenetic	_	_	_	_	_	_	_	Seg=O
90	mechanisms	_	_	_	_	_	_	_	Seg=O
91	of	_	_	_	_	_	_	_	Seg=O
92	central	_	_	_	_	_	_	_	Seg=O
93	nervous	_	_	_	_	_	_	_	Seg=O
94	system	_	_	_	_	_	_	_	Seg=O
95	(	_	_	_	_	_	_	_	Seg=O
96	CNS	_	_	_	_	_	_	_	Seg=O
97	)	_	_	_	_	_	_	_	Seg=O
98	involvement	_	_	_	_	_	_	_	Seg=O
99	.	_	_	_	_	_	_	_	Seg=O
100	Clinicians	_	_	_	_	_	_	_	Seg=B-seg
101	and	_	_	_	_	_	_	_	Seg=O
102	especially	_	_	_	_	_	_	_	Seg=O
103	internists	_	_	_	_	_	_	_	Seg=O
104	,	_	_	_	_	_	_	_	Seg=O
105	neurologists	_	_	_	_	_	_	_	Seg=O
106	,	_	_	_	_	_	_	_	Seg=O
107	and	_	_	_	_	_	_	_	Seg=O
108	infectious	_	_	_	_	_	_	_	Seg=O
109	disease	_	_	_	_	_	_	_	Seg=O
110	specialists	_	_	_	_	_	_	_	Seg=O
111	should	_	_	_	_	_	_	_	Seg=O
112	be	_	_	_	_	_	_	_	Seg=O
113	aware	_	_	_	_	_	_	_	Seg=O
114	of	_	_	_	_	_	_	_	Seg=O
115	these	_	_	_	_	_	_	_	Seg=O
116	symptoms	_	_	_	_	_	_	_	Seg=O
117	and	_	_	_	_	_	_	_	Seg=B-seg
118	able	_	_	_	_	_	_	_	Seg=O
119	to	_	_	_	_	_	_	_	Seg=O
120	recognize	_	_	_	_	_	_	_	Seg=O
121	them	_	_	_	_	_	_	_	Seg=O
122	early	_	_	_	_	_	_	_	Seg=O
123	.	_	_	_	_	_	_	_	Seg=O
124	Prompt	_	_	_	_	_	_	_	Seg=B-seg
125	diagnosis	_	_	_	_	_	_	_	Seg=O
126	and	_	_	_	_	_	_	_	Seg=O
127	immediate	_	_	_	_	_	_	_	Seg=O
128	management	_	_	_	_	_	_	_	Seg=O
129	of	_	_	_	_	_	_	_	Seg=O
130	the	_	_	_	_	_	_	_	Seg=O
131	neurological	_	_	_	_	_	_	_	Seg=O
132	manifestations	_	_	_	_	_	_	_	Seg=O
133	of	_	_	_	_	_	_	_	Seg=O
134	the	_	_	_	_	_	_	_	Seg=O
135	novel	_	_	_	_	_	_	_	Seg=O
136	coronavirus	_	_	_	_	_	_	_	Seg=O
137	will	_	_	_	_	_	_	_	Seg=O
138	not	_	_	_	_	_	_	_	Seg=O
139	only	_	_	_	_	_	_	_	Seg=O
140	improve	_	_	_	_	_	_	_	Seg=O
141	the	_	_	_	_	_	_	_	Seg=O
142	prognosis	_	_	_	_	_	_	_	Seg=O
143	of	_	_	_	_	_	_	_	Seg=O
144	COVID-19	_	_	_	_	_	_	_	Seg=O
145	patients	_	_	_	_	_	_	_	Seg=O
146	but	_	_	_	_	_	_	_	Seg=B-seg
147	will	_	_	_	_	_	_	_	Seg=O
148	also	_	_	_	_	_	_	_	Seg=O
149	prevent	_	_	_	_	_	_	_	Seg=O
150	the	_	_	_	_	_	_	_	Seg=O
151	dissemination	_	_	_	_	_	_	_	Seg=O
152	of	_	_	_	_	_	_	_	Seg=O
153	the	_	_	_	_	_	_	_	Seg=O
154	disease	_	_	_	_	_	_	_	Seg=O
155	due	_	_	_	_	_	_	_	Seg=B-seg
156	to	_	_	_	_	_	_	_	Seg=O
157	misdiagnosed	_	_	_	_	_	_	_	Seg=O
158	cases	_	_	_	_	_	_	_	Seg=O
159	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 15be47d73265c344c81f51bc1d87f4264ea63c85
1	We	_	_	_	_	_	_	_	Seg=B-seg
2	describe	_	_	_	_	_	_	_	Seg=O
3	the	_	_	_	_	_	_	_	Seg=O
4	clinical	_	_	_	_	_	_	_	Seg=O
5	course	_	_	_	_	_	_	_	Seg=O
6	of	_	_	_	_	_	_	_	Seg=O
7	57	_	_	_	_	_	_	_	Seg=O
8	children	_	_	_	_	_	_	_	Seg=O
9	with	_	_	_	_	_	_	_	Seg=O
10	coronavirus	_	_	_	_	_	_	_	Seg=O
11	disease	_	_	_	_	_	_	_	Seg=O
12	2019	_	_	_	_	_	_	_	Seg=O
13	(	_	_	_	_	_	_	_	Seg=O
14	COVID-19	_	_	_	_	_	_	_	Seg=O
15	)	_	_	_	_	_	_	_	Seg=O
16	cared	_	_	_	_	_	_	_	Seg=B-seg
17	for	_	_	_	_	_	_	_	Seg=O
18	through	_	_	_	_	_	_	_	Seg=O
19	a	_	_	_	_	_	_	_	Seg=O
20	single	_	_	_	_	_	_	_	Seg=O
21	hospital	_	_	_	_	_	_	_	Seg=O
22	system	_	_	_	_	_	_	_	Seg=O
23	.	_	_	_	_	_	_	_	Seg=O
24	Most	_	_	_	_	_	_	_	Seg=B-seg
25	children	_	_	_	_	_	_	_	Seg=O
26	were	_	_	_	_	_	_	_	Seg=O
27	mildly	_	_	_	_	_	_	_	Seg=O
28	symptomatic	_	_	_	_	_	_	_	Seg=O
29	,	_	_	_	_	_	_	_	Seg=O
30	and	_	_	_	_	_	_	_	Seg=B-seg
31	only	_	_	_	_	_	_	_	Seg=O
32	a	_	_	_	_	_	_	_	Seg=O
33	few	_	_	_	_	_	_	_	Seg=O
34	patients	_	_	_	_	_	_	_	Seg=O
35	with	_	_	_	_	_	_	_	Seg=O
36	underlying	_	_	_	_	_	_	_	Seg=O
37	medical	_	_	_	_	_	_	_	Seg=O
38	conditions	_	_	_	_	_	_	_	Seg=O
39	required	_	_	_	_	_	_	_	Seg=O
40	hospitalization	_	_	_	_	_	_	_	Seg=O
41	.	_	_	_	_	_	_	_	Seg=O
42	Systemwide	_	_	_	_	_	_	_	Seg=B-seg
43	patient	_	_	_	_	_	_	_	Seg=O
44	evaluation	_	_	_	_	_	_	_	Seg=O
45	processes	_	_	_	_	_	_	_	Seg=O
46	allowed	_	_	_	_	_	_	_	Seg=O
47	for	_	_	_	_	_	_	_	Seg=O
48	prompt	_	_	_	_	_	_	_	Seg=O
49	identification	_	_	_	_	_	_	_	Seg=O
50	and	_	_	_	_	_	_	_	Seg=O
51	management	_	_	_	_	_	_	_	Seg=O
52	of	_	_	_	_	_	_	_	Seg=O
53	patients	_	_	_	_	_	_	_	Seg=O
54	with	_	_	_	_	_	_	_	Seg=O
55	COVID-19	_	_	_	_	_	_	_	Seg=O
56	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 1682a84266e105445b492f14d6dc1da178027820
1	The	_	_	_	_	_	_	_	Seg=B-seg
2	2020	_	_	_	_	_	_	_	Seg=O
3	COVID-19	_	_	_	_	_	_	_	Seg=O
4	crisis	_	_	_	_	_	_	_	Seg=O
5	can	_	_	_	_	_	_	_	Seg=O
6	spur	_	_	_	_	_	_	_	Seg=O
7	research	_	_	_	_	_	_	_	Seg=O
8	on	_	_	_	_	_	_	_	Seg=O
9-10	firms'	_	_	_	_	_	_	_	_
9	firms	_	_	_	_	_	_	_	Seg=O
10	'	_	_	_	_	_	_	_	Seg=O
11	corporate	_	_	_	_	_	_	_	Seg=O
12	finance	_	_	_	_	_	_	_	Seg=O
13	decisions	_	_	_	_	_	_	_	Seg=O
14	and	_	_	_	_	_	_	_	Seg=O
15	their	_	_	_	_	_	_	_	Seg=O
16	macroeconomic	_	_	_	_	_	_	_	Seg=O
17	implications	_	_	_	_	_	_	_	Seg=O
18	,	_	_	_	_	_	_	_	Seg=O
19	similar	_	_	_	_	_	_	_	Seg=B-seg
20	to	_	_	_	_	_	_	_	Seg=O
21	the	_	_	_	_	_	_	_	Seg=O
22	wave	_	_	_	_	_	_	_	Seg=O
23	of	_	_	_	_	_	_	_	Seg=O
24	important	_	_	_	_	_	_	_	Seg=O
25	research	_	_	_	_	_	_	_	Seg=O
26	on	_	_	_	_	_	_	_	Seg=O
27	banking	_	_	_	_	_	_	_	Seg=O
28	and	_	_	_	_	_	_	_	Seg=O
29	household	_	_	_	_	_	_	_	Seg=O
30	finance	_	_	_	_	_	_	_	Seg=O
31	triggered	_	_	_	_	_	_	_	Seg=B-seg
32	by	_	_	_	_	_	_	_	Seg=O
33	the	_	_	_	_	_	_	_	Seg=O
34	2008	_	_	_	_	_	_	_	Seg=O
35	financial	_	_	_	_	_	_	_	Seg=O
36	crisis	_	_	_	_	_	_	_	Seg=O
37	.	_	_	_	_	_	_	_	Seg=O
38	What	_	_	_	_	_	_	_	Seg=B-seg
39	are	_	_	_	_	_	_	_	Seg=O
40	the	_	_	_	_	_	_	_	Seg=O
41	relevant	_	_	_	_	_	_	_	Seg=O
42	corporate	_	_	_	_	_	_	_	Seg=O
43	finance	_	_	_	_	_	_	_	Seg=O
44	mechanisms	_	_	_	_	_	_	_	Seg=O
45	in	_	_	_	_	_	_	_	Seg=O
46	this	_	_	_	_	_	_	_	Seg=O
47	crisis	_	_	_	_	_	_	_	Seg=O
48	?	_	_	_	_	_	_	_	Seg=O
49	Modeling	_	_	_	_	_	_	_	Seg=B-seg
50	dynamics	_	_	_	_	_	_	_	Seg=O
51	and	_	_	_	_	_	_	_	Seg=O
52	timing	_	_	_	_	_	_	_	Seg=O
53	considerations	_	_	_	_	_	_	_	Seg=O
54	are	_	_	_	_	_	_	_	Seg=O
55	likely	_	_	_	_	_	_	_	Seg=O
56	important	_	_	_	_	_	_	_	Seg=O
57	,	_	_	_	_	_	_	_	Seg=O
58	as	_	_	_	_	_	_	_	Seg=B-seg
59	is	_	_	_	_	_	_	_	Seg=O
60	integrating	_	_	_	_	_	_	_	Seg=O
61	corporate	_	_	_	_	_	_	_	Seg=O
62	financing	_	_	_	_	_	_	_	Seg=O
63	considerations	_	_	_	_	_	_	_	Seg=O
64	into	_	_	_	_	_	_	_	Seg=O
65	modern	_	_	_	_	_	_	_	Seg=O
66	quantifiable	_	_	_	_	_	_	_	Seg=O
67	macroeconomics	_	_	_	_	_	_	_	Seg=O
68	models	_	_	_	_	_	_	_	Seg=O
69	.	_	_	_	_	_	_	_	Seg=O
70	Recent	_	_	_	_	_	_	_	Seg=B-seg
71	empirical	_	_	_	_	_	_	_	Seg=O
72	work	_	_	_	_	_	_	_	Seg=O
73	,	_	_	_	_	_	_	_	Seg=O
74	including	_	_	_	_	_	_	_	Seg=B-seg
75	articles	_	_	_	_	_	_	_	Seg=O
76	in	_	_	_	_	_	_	_	Seg=O
77	this	_	_	_	_	_	_	_	Seg=O
78	special	_	_	_	_	_	_	_	Seg=O
79	issue	_	_	_	_	_	_	_	Seg=O
80	,	_	_	_	_	_	_	_	Seg=O
81	on	_	_	_	_	_	_	_	Seg=B-seg
82	the	_	_	_	_	_	_	_	Seg=O
83	drag	_	_	_	_	_	_	_	Seg=O
84	from	_	_	_	_	_	_	_	Seg=O
85	debt	_	_	_	_	_	_	_	Seg=O
86	in	_	_	_	_	_	_	_	Seg=O
87	the	_	_	_	_	_	_	_	Seg=O
88	COVID-19	_	_	_	_	_	_	_	Seg=O
89	crisis	_	_	_	_	_	_	_	Seg=O
90	provides	_	_	_	_	_	_	_	Seg=O
91	a	_	_	_	_	_	_	_	Seg=O
92	first	_	_	_	_	_	_	_	Seg=O
93	glimpse	_	_	_	_	_	_	_	Seg=O
94	into	_	_	_	_	_	_	_	Seg=O
95	the	_	_	_	_	_	_	_	Seg=O
96	new	_	_	_	_	_	_	_	Seg=O
97	research	_	_	_	_	_	_	_	Seg=O
98	agenda	_	_	_	_	_	_	_	Seg=O
99	.	_	_	_	_	_	_	_	Seg=O
100	(	_	_	_	_	_	_	_	Seg=B-seg
101	JEL	_	_	_	_	_	_	_	Seg=O
102	E22	_	_	_	_	_	_	_	Seg=O
103	,	_	_	_	_	_	_	_	Seg=O
104	E44	_	_	_	_	_	_	_	Seg=O
105	,	_	_	_	_	_	_	_	Seg=O
106	G32	_	_	_	_	_	_	_	Seg=O
107	,	_	_	_	_	_	_	_	Seg=O
108	G33	_	_	_	_	_	_	_	Seg=O
109	)	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 168a175917680c5b44265ca7c2047b9be68bc5f0
1	Porcine	_	_	_	_	_	_	_	Seg=B-seg
2	epidemic	_	_	_	_	_	_	_	Seg=O
3	diarrhea	_	_	_	_	_	_	_	Seg=O
4	virus	_	_	_	_	_	_	_	Seg=O
5	(	_	_	_	_	_	_	_	Seg=O
6	PEDV	_	_	_	_	_	_	_	Seg=O
7	)	_	_	_	_	_	_	_	Seg=O
8	is	_	_	_	_	_	_	_	Seg=O
9	a	_	_	_	_	_	_	_	Seg=O
10	burdensome	_	_	_	_	_	_	_	Seg=O
11	pathogen	_	_	_	_	_	_	_	Seg=O
12	in	_	_	_	_	_	_	_	Seg=O
13	the	_	_	_	_	_	_	_	Seg=O
14	swine	_	_	_	_	_	_	_	Seg=O
15	industry	_	_	_	_	_	_	_	Seg=O
16	.	_	_	_	_	_	_	_	Seg=O
17	Wild	_	_	_	_	_	_	_	Seg=B-seg
18	boar	_	_	_	_	_	_	_	Seg=O
19	population	_	_	_	_	_	_	_	Seg=O
20	poses	_	_	_	_	_	_	_	Seg=O
21	a	_	_	_	_	_	_	_	Seg=O
22	high	_	_	_	_	_	_	_	Seg=O
23	risk	_	_	_	_	_	_	_	Seg=O
24	for	_	_	_	_	_	_	_	Seg=O
25	reservoir	_	_	_	_	_	_	_	Seg=O
26	of	_	_	_	_	_	_	_	Seg=O
27	viral	_	_	_	_	_	_	_	Seg=O
28	pathogen	_	_	_	_	_	_	_	Seg=O
29	.	_	_	_	_	_	_	_	Seg=O
30	Two	_	_	_	_	_	_	_	Seg=B-seg
31	hundred	_	_	_	_	_	_	_	Seg=O
32	eighty	_	_	_	_	_	_	_	Seg=O
33	seven	_	_	_	_	_	_	_	Seg=O
34	samples	_	_	_	_	_	_	_	Seg=O
35	from	_	_	_	_	_	_	_	Seg=O
36	wild	_	_	_	_	_	_	_	Seg=O
37	boar	_	_	_	_	_	_	_	Seg=O
38	(	_	_	_	_	_	_	_	Seg=O
39	Sus	_	_	_	_	_	_	_	Seg=O
40	scrofa	_	_	_	_	_	_	_	Seg=O
41	)	_	_	_	_	_	_	_	Seg=O
42	collected	_	_	_	_	_	_	_	Seg=B-seg
43	in	_	_	_	_	_	_	_	Seg=O
44	South	_	_	_	_	_	_	_	Seg=O
45	Korea	_	_	_	_	_	_	_	Seg=O
46	during	_	_	_	_	_	_	_	Seg=O
47	2010/11	_	_	_	_	_	_	_	Seg=O
48	were	_	_	_	_	_	_	_	Seg=B-seg
49	analyzed	_	_	_	_	_	_	_	Seg=O
50	using	_	_	_	_	_	_	_	Seg=B-seg
51	RT	_	_	_	_	_	_	_	Seg=O
52	-	_	_	_	_	_	_	_	Seg=O
53	PCR	_	_	_	_	_	_	_	Seg=O
54	,	_	_	_	_	_	_	_	Seg=O
55	revealing	_	_	_	_	_	_	_	Seg=B-seg
56	a	_	_	_	_	_	_	_	Seg=O
57	PEDV	_	_	_	_	_	_	_	Seg=O
58	infection	_	_	_	_	_	_	_	Seg=O
59	rate	_	_	_	_	_	_	_	Seg=O
60	of	_	_	_	_	_	_	_	Seg=O
61	9.75	_	_	_	_	_	_	_	Seg=O
62	%	_	_	_	_	_	_	_	Seg=O
63	(	_	_	_	_	_	_	_	Seg=O
64	28/287	_	_	_	_	_	_	_	Seg=O
65	)	_	_	_	_	_	_	_	Seg=O
66	.	_	_	_	_	_	_	_	Seg=O
67	PEDV	_	_	_	_	_	_	_	Seg=B-seg
68	positive	_	_	_	_	_	_	_	Seg=O
69	samples	_	_	_	_	_	_	_	Seg=O
70	were	_	_	_	_	_	_	_	Seg=O
71	distributed	_	_	_	_	_	_	_	Seg=O
72	throughout	_	_	_	_	_	_	_	Seg=O
73	the	_	_	_	_	_	_	_	Seg=O
74	mainland	_	_	_	_	_	_	_	Seg=O
75	of	_	_	_	_	_	_	_	Seg=O
76	South	_	_	_	_	_	_	_	Seg=O
77	Korea	_	_	_	_	_	_	_	Seg=O
78	,	_	_	_	_	_	_	_	Seg=O
79	clustering	_	_	_	_	_	_	_	Seg=B-seg
80	at	_	_	_	_	_	_	_	Seg=O
81	the	_	_	_	_	_	_	_	Seg=O
82	northern	_	_	_	_	_	_	_	Seg=O
83	border	_	_	_	_	_	_	_	Seg=O
84	adjacent	_	_	_	_	_	_	_	Seg=O
85	to	_	_	_	_	_	_	_	Seg=O
86	the	_	_	_	_	_	_	_	Seg=O
87	Demilitarized	_	_	_	_	_	_	_	Seg=O
88	Zone	_	_	_	_	_	_	_	Seg=O
89	(	_	_	_	_	_	_	_	Seg=O
90	DMZ	_	_	_	_	_	_	_	Seg=O
91	)	_	_	_	_	_	_	_	Seg=O
92	and	_	_	_	_	_	_	_	Seg=O
93	in	_	_	_	_	_	_	_	Seg=O
94	mountainous	_	_	_	_	_	_	_	Seg=O
95	regions	_	_	_	_	_	_	_	Seg=O
96	.	_	_	_	_	_	_	_	Seg=O
97	PEDV	_	_	_	_	_	_	_	Seg=B-seg
98	in	_	_	_	_	_	_	_	Seg=O
99	wild	_	_	_	_	_	_	_	Seg=O
100	boar	_	_	_	_	_	_	_	Seg=O
101	was	_	_	_	_	_	_	_	Seg=O
102	genetically	_	_	_	_	_	_	_	Seg=O
103	similar	_	_	_	_	_	_	_	Seg=O
104	to	_	_	_	_	_	_	_	Seg=O
105	Chinese	_	_	_	_	_	_	_	Seg=O
106	PEDV	_	_	_	_	_	_	_	Seg=O
107	strains	_	_	_	_	_	_	_	Seg=O
108	in	_	_	_	_	_	_	_	Seg=O
109	phylogenetic	_	_	_	_	_	_	_	Seg=O
110	investigations	_	_	_	_	_	_	_	Seg=O
111	.	_	_	_	_	_	_	_	Seg=O
112	Our	_	_	_	_	_	_	_	Seg=B-seg
113	results	_	_	_	_	_	_	_	Seg=O
114	indicated	_	_	_	_	_	_	_	Seg=O
115	that	_	_	_	_	_	_	_	Seg=B-seg
116	PEDV	_	_	_	_	_	_	_	Seg=O
117	is	_	_	_	_	_	_	_	Seg=O
118	circulating	_	_	_	_	_	_	_	Seg=O
119	in	_	_	_	_	_	_	_	Seg=O
120	the	_	_	_	_	_	_	_	Seg=O
121	wild	_	_	_	_	_	_	_	Seg=O
122	boar	_	_	_	_	_	_	_	Seg=O
123	and	_	_	_	_	_	_	_	Seg=B-seg
124	provided	_	_	_	_	_	_	_	Seg=O
125	a	_	_	_	_	_	_	_	Seg=O
126	novel	_	_	_	_	_	_	_	Seg=O
127	knowledge	_	_	_	_	_	_	_	Seg=O
128	into	_	_	_	_	_	_	_	Seg=O
129	epidemiology	_	_	_	_	_	_	_	Seg=O
130	of	_	_	_	_	_	_	_	Seg=O
131	PEDV	_	_	_	_	_	_	_	Seg=O
132	infection	_	_	_	_	_	_	_	Seg=O
133	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 1735d918984252bfb2ef6e6615c9f1b5d8cebac6
1	Poly(A	_	_	_	_	_	_	_	Seg=B-seg
2	)	_	_	_	_	_	_	_	Seg=O
3	tails	_	_	_	_	_	_	_	Seg=O
4	are	_	_	_	_	_	_	_	Seg=O
5	functionally	_	_	_	_	_	_	_	Seg=O
6	important	_	_	_	_	_	_	_	Seg=O
7	features	_	_	_	_	_	_	_	Seg=O
8	of	_	_	_	_	_	_	_	Seg=O
9	all	_	_	_	_	_	_	_	Seg=O
10	picornavirus	_	_	_	_	_	_	_	Seg=O
11	RNA	_	_	_	_	_	_	_	Seg=O
12	genomes	_	_	_	_	_	_	_	Seg=O
13	.	_	_	_	_	_	_	_	Seg=O
14	Some	_	_	_	_	_	_	_	Seg=B-seg
15	viruses	_	_	_	_	_	_	_	Seg=O
16	have	_	_	_	_	_	_	_	Seg=O
17	genomes	_	_	_	_	_	_	_	Seg=O
18	with	_	_	_	_	_	_	_	Seg=O
19	relatively	_	_	_	_	_	_	_	Seg=O
20	short	_	_	_	_	_	_	_	Seg=O
21	poly(A	_	_	_	_	_	_	_	Seg=O
22	)	_	_	_	_	_	_	_	Seg=O
23	tails	_	_	_	_	_	_	_	Seg=O
24	(	_	_	_	_	_	_	_	Seg=B-seg
25	encephalomyocarditis	_	_	_	_	_	_	_	Seg=O
26	virus	_	_	_	_	_	_	_	Seg=O
27	)	_	_	_	_	_	_	_	Seg=O
28	whereas	_	_	_	_	_	_	_	Seg=B-seg
29	others	_	_	_	_	_	_	_	Seg=O
30	have	_	_	_	_	_	_	_	Seg=O
31	genomes	_	_	_	_	_	_	_	Seg=O
32	with	_	_	_	_	_	_	_	Seg=O
33	longer	_	_	_	_	_	_	_	Seg=O
34	poly(A	_	_	_	_	_	_	_	Seg=O
35	)	_	_	_	_	_	_	_	Seg=O
36	tails	_	_	_	_	_	_	_	Seg=O
37	(	_	_	_	_	_	_	_	Seg=B-seg
38	polioviruses	_	_	_	_	_	_	_	Seg=O
39	and	_	_	_	_	_	_	_	Seg=O
40	rhinoviruses	_	_	_	_	_	_	_	Seg=O
41	)	_	_	_	_	_	_	_	Seg=O
42	.	_	_	_	_	_	_	_	Seg=O
43	Here	_	_	_	_	_	_	_	Seg=B-seg
44	we	_	_	_	_	_	_	_	Seg=O
45	review	_	_	_	_	_	_	_	Seg=O
46	the	_	_	_	_	_	_	_	Seg=O
47	polyadenylation	_	_	_	_	_	_	_	Seg=O
48	of	_	_	_	_	_	_	_	Seg=O
49	picornavirus	_	_	_	_	_	_	_	Seg=O
50	RNA	_	_	_	_	_	_	_	Seg=O
51	as	_	_	_	_	_	_	_	Seg=B-seg
52	it	_	_	_	_	_	_	_	Seg=O
53	relates	_	_	_	_	_	_	_	Seg=O
54	to	_	_	_	_	_	_	_	Seg=O
55	the	_	_	_	_	_	_	_	Seg=O
56	structure	_	_	_	_	_	_	_	Seg=O
57	and	_	_	_	_	_	_	_	Seg=O
58	function	_	_	_	_	_	_	_	Seg=O
59	of	_	_	_	_	_	_	_	Seg=O
60	3D	_	_	_	_	_	_	_	Seg=O
61	pol	_	_	_	_	_	_	_	Seg=O
62	.	_	_	_	_	_	_	_	Seg=O
63	Poliovirus	_	_	_	_	_	_	_	Seg=B-seg
64	3D	_	_	_	_	_	_	_	Seg=O
65	pol	_	_	_	_	_	_	_	Seg=O
66	uses	_	_	_	_	_	_	_	Seg=O
67	template	_	_	_	_	_	_	_	Seg=O
68	-	_	_	_	_	_	_	_	Seg=O
69	dependent	_	_	_	_	_	_	_	Seg=O
70	reiterative	_	_	_	_	_	_	_	Seg=O
71	transcription	_	_	_	_	_	_	_	Seg=O
72	mechanisms	_	_	_	_	_	_	_	Seg=O
73	as	_	_	_	_	_	_	_	Seg=B-seg
74	it	_	_	_	_	_	_	_	Seg=O
75	replicates	_	_	_	_	_	_	_	Seg=O
76	the	_	_	_	_	_	_	_	Seg=O
77	poly(A	_	_	_	_	_	_	_	Seg=O
78	)	_	_	_	_	_	_	_	Seg=O
79	tails	_	_	_	_	_	_	_	Seg=O
80	of	_	_	_	_	_	_	_	Seg=O
81	viral	_	_	_	_	_	_	_	Seg=O
82	RNA	_	_	_	_	_	_	_	Seg=O
83	(	_	_	_	_	_	_	_	Seg=O
84	Steil	_	_	_	_	_	_	_	Seg=O
85	et	_	_	_	_	_	_	_	Seg=O
86	al	_	_	_	_	_	_	_	Seg=O
87	.	_	_	_	_	_	_	_	Seg=O
88	,	_	_	_	_	_	_	_	Seg=O
89	2010	_	_	_	_	_	_	_	Seg=O
90	)	_	_	_	_	_	_	_	Seg=O
91	.	_	_	_	_	_	_	_	Seg=O
92	These	_	_	_	_	_	_	_	Seg=B-seg
93	mechanisms	_	_	_	_	_	_	_	Seg=O
94	are	_	_	_	_	_	_	_	Seg=O
95	analogous	_	_	_	_	_	_	_	Seg=O
96	to	_	_	_	_	_	_	_	Seg=O
97	those	_	_	_	_	_	_	_	Seg=O
98	involved	_	_	_	_	_	_	_	Seg=B-seg
99	in	_	_	_	_	_	_	_	Seg=O
100	the	_	_	_	_	_	_	_	Seg=O
101	polyadenylation	_	_	_	_	_	_	_	Seg=O
102	of	_	_	_	_	_	_	_	Seg=O
103	vesicular	_	_	_	_	_	_	_	Seg=O
104	stomatitis	_	_	_	_	_	_	_	Seg=O
105	virus	_	_	_	_	_	_	_	Seg=O
106	and	_	_	_	_	_	_	_	Seg=O
107	influenza	_	_	_	_	_	_	_	Seg=O
108	virus	_	_	_	_	_	_	_	Seg=O
109	mRNAs	_	_	_	_	_	_	_	Seg=O
110	.	_	_	_	_	_	_	_	Seg=O
111	3D	_	_	_	_	_	_	_	Seg=B-seg
112	pol	_	_	_	_	_	_	_	Seg=O
113	residues	_	_	_	_	_	_	_	Seg=O
114	intimately	_	_	_	_	_	_	_	Seg=B-seg
115	associated	_	_	_	_	_	_	_	Seg=O
116	with	_	_	_	_	_	_	_	Seg=O
117	viral	_	_	_	_	_	_	_	Seg=O
118	RNA	_	_	_	_	_	_	_	Seg=O
119	templates	_	_	_	_	_	_	_	Seg=O
120	and	_	_	_	_	_	_	_	Seg=O
121	products	_	_	_	_	_	_	_	Seg=O
122	regulate	_	_	_	_	_	_	_	Seg=B-seg
123	the	_	_	_	_	_	_	_	Seg=O
124	size	_	_	_	_	_	_	_	Seg=O
125	of	_	_	_	_	_	_	_	Seg=O
126	poly(A	_	_	_	_	_	_	_	Seg=O
127	)	_	_	_	_	_	_	_	Seg=O
128	tails	_	_	_	_	_	_	_	Seg=O
129	in	_	_	_	_	_	_	_	Seg=O
130	viral	_	_	_	_	_	_	_	Seg=O
131	RNA	_	_	_	_	_	_	_	Seg=O
132	(	_	_	_	_	_	_	_	Seg=O
133	Kempf	_	_	_	_	_	_	_	Seg=O
134	et	_	_	_	_	_	_	_	Seg=O
135	al	_	_	_	_	_	_	_	Seg=O
136	.	_	_	_	_	_	_	_	Seg=O
137	,	_	_	_	_	_	_	_	Seg=O
138	2013	_	_	_	_	_	_	_	Seg=O
139	)	_	_	_	_	_	_	_	Seg=O
140	.	_	_	_	_	_	_	_	Seg=O
141	Consistent	_	_	_	_	_	_	_	Seg=B-seg
142	with	_	_	_	_	_	_	_	Seg=O
143	their	_	_	_	_	_	_	_	Seg=O
144	ancient	_	_	_	_	_	_	_	Seg=O
145	evolutionary	_	_	_	_	_	_	_	Seg=O
146	origins	_	_	_	_	_	_	_	Seg=O
147	,	_	_	_	_	_	_	_	Seg=O
148	picornavirus	_	_	_	_	_	_	_	Seg=B-seg
149	3D	_	_	_	_	_	_	_	Seg=O
150	pol	_	_	_	_	_	_	_	Seg=O
151	and	_	_	_	_	_	_	_	Seg=O
152	telomerase	_	_	_	_	_	_	_	Seg=O
153	reverse	_	_	_	_	_	_	_	Seg=O
154	transcriptase	_	_	_	_	_	_	_	Seg=O
155	(	_	_	_	_	_	_	_	Seg=O
156	TERT	_	_	_	_	_	_	_	Seg=O
157	)	_	_	_	_	_	_	_	Seg=O
158	share	_	_	_	_	_	_	_	Seg=O
159	structural	_	_	_	_	_	_	_	Seg=O
160	and	_	_	_	_	_	_	_	Seg=O
161	functional	_	_	_	_	_	_	_	Seg=O
162	features	_	_	_	_	_	_	_	Seg=O
163	.	_	_	_	_	_	_	_	Seg=O
164	Structurally	_	_	_	_	_	_	_	Seg=B-seg
165	,	_	_	_	_	_	_	_	Seg=O
166	both	_	_	_	_	_	_	_	Seg=O
167	3D	_	_	_	_	_	_	_	Seg=O
168	pol	_	_	_	_	_	_	_	Seg=O
169	and	_	_	_	_	_	_	_	Seg=O
170	TERT	_	_	_	_	_	_	_	Seg=O
171	assume	_	_	_	_	_	_	_	Seg=O
172	a	_	_	_	_	_	_	_	Seg=O
173	"	_	_	_	_	_	_	_	Seg=O
174	right	_	_	_	_	_	_	_	Seg=O
175	-	_	_	_	_	_	_	_	Seg=O
176	hand	_	_	_	_	_	_	_	Seg=O
177	"	_	_	_	_	_	_	_	Seg=O
178	conformation	_	_	_	_	_	_	_	Seg=O
179	with	_	_	_	_	_	_	_	Seg=O
180	thumb	_	_	_	_	_	_	_	Seg=O
181	,	_	_	_	_	_	_	_	Seg=O
182	palm	_	_	_	_	_	_	_	Seg=O
183	and	_	_	_	_	_	_	_	Seg=O
184	fingers	_	_	_	_	_	_	_	Seg=O
185	domains	_	_	_	_	_	_	_	Seg=O
186	encircling	_	_	_	_	_	_	_	Seg=B-seg
187	templates	_	_	_	_	_	_	_	Seg=O
188	and	_	_	_	_	_	_	_	Seg=O
189	products	_	_	_	_	_	_	_	Seg=O
190	.	_	_	_	_	_	_	_	Seg=O
191	Functionally	_	_	_	_	_	_	_	Seg=B-seg
192	,	_	_	_	_	_	_	_	Seg=O
193	both	_	_	_	_	_	_	_	Seg=O
194	3D	_	_	_	_	_	_	_	Seg=O
195	pol	_	_	_	_	_	_	_	Seg=O
196	and	_	_	_	_	_	_	_	Seg=O
197	TERT	_	_	_	_	_	_	_	Seg=O
198	use	_	_	_	_	_	_	_	Seg=O
199	template	_	_	_	_	_	_	_	Seg=O
200	-	_	_	_	_	_	_	_	Seg=O
201	dependent	_	_	_	_	_	_	_	Seg=O
202	reiterative	_	_	_	_	_	_	_	Seg=O
203	transcription	_	_	_	_	_	_	_	Seg=O
204	mechanisms	_	_	_	_	_	_	_	Seg=O
205	to	_	_	_	_	_	_	_	Seg=B-seg
206	synthesize	_	_	_	_	_	_	_	Seg=O
207	repetitive	_	_	_	_	_	_	_	Seg=O
208	sequences	_	_	_	_	_	_	_	Seg=O
209	:	_	_	_	_	_	_	_	Seg=O
210	poly(A	_	_	_	_	_	_	_	Seg=B-seg
211	)	_	_	_	_	_	_	_	Seg=O
212	tails	_	_	_	_	_	_	_	Seg=O
213	in	_	_	_	_	_	_	_	Seg=O
214	the	_	_	_	_	_	_	_	Seg=O
215	case	_	_	_	_	_	_	_	Seg=O
216	of	_	_	_	_	_	_	_	Seg=O
217	picornavirus	_	_	_	_	_	_	_	Seg=O
218	RNA	_	_	_	_	_	_	_	Seg=O
219	genomes	_	_	_	_	_	_	_	Seg=O
220	and	_	_	_	_	_	_	_	Seg=O
221	DNA	_	_	_	_	_	_	_	Seg=O
222	telomeres	_	_	_	_	_	_	_	Seg=O
223	in	_	_	_	_	_	_	_	Seg=O
224	the	_	_	_	_	_	_	_	Seg=O
225	case	_	_	_	_	_	_	_	Seg=O
226	of	_	_	_	_	_	_	_	Seg=O
227	eukaryotic	_	_	_	_	_	_	_	Seg=O
228	chromosomes	_	_	_	_	_	_	_	Seg=O
229	.	_	_	_	_	_	_	_	Seg=O
230	Thus	_	_	_	_	_	_	_	Seg=B-seg
231	,	_	_	_	_	_	_	_	Seg=O
232	picornaviruses	_	_	_	_	_	_	_	Seg=O
233	and	_	_	_	_	_	_	_	Seg=O
234	their	_	_	_	_	_	_	_	Seg=O
235	eukaryotic	_	_	_	_	_	_	_	Seg=O
236	hosts	_	_	_	_	_	_	_	Seg=O
237	(	_	_	_	_	_	_	_	Seg=B-seg
238	humans	_	_	_	_	_	_	_	Seg=O
239	and	_	_	_	_	_	_	_	Seg=O
240	animals	_	_	_	_	_	_	_	Seg=O
241	)	_	_	_	_	_	_	_	Seg=O
242	maintain	_	_	_	_	_	_	_	Seg=B-seg
243	the	_	_	_	_	_	_	_	Seg=O
244	3	_	_	_	_	_	_	_	Seg=O
245	ends	_	_	_	_	_	_	_	Seg=O
246	of	_	_	_	_	_	_	_	Seg=O
247	their	_	_	_	_	_	_	_	Seg=O
248	respective	_	_	_	_	_	_	_	Seg=O
249	genomes	_	_	_	_	_	_	_	Seg=O
250	via	_	_	_	_	_	_	_	Seg=O
251	evolutionarily	_	_	_	_	_	_	_	Seg=O
252	related	_	_	_	_	_	_	_	Seg=O
253	mechanisms	_	_	_	_	_	_	_	Seg=O
254	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 180a37cecacf1df23085e9dc702d07342c9c0ce2
1	We	_	_	_	_	_	_	_	Seg=B-seg
2	present	_	_	_	_	_	_	_	Seg=O
3	an	_	_	_	_	_	_	_	Seg=O
4	epidemic	_	_	_	_	_	_	_	Seg=O
5	model	_	_	_	_	_	_	_	Seg=O
6	capable	_	_	_	_	_	_	_	Seg=O
7	of	_	_	_	_	_	_	_	Seg=O
8	describing	_	_	_	_	_	_	_	Seg=O
9	key	_	_	_	_	_	_	_	Seg=O
10	features	_	_	_	_	_	_	_	Seg=O
11	of	_	_	_	_	_	_	_	Seg=O
12	the	_	_	_	_	_	_	_	Seg=O
13	present	_	_	_	_	_	_	_	Seg=O
14	Covid-19	_	_	_	_	_	_	_	Seg=O
15	pandemic	_	_	_	_	_	_	_	Seg=O
16	.	_	_	_	_	_	_	_	Seg=O
17	While	_	_	_	_	_	_	_	Seg=B-seg
18	capturing	_	_	_	_	_	_	_	Seg=O
19	several	_	_	_	_	_	_	_	Seg=O
20	qualitative	_	_	_	_	_	_	_	Seg=O
21	properties	_	_	_	_	_	_	_	Seg=O
22	of	_	_	_	_	_	_	_	Seg=O
23	the	_	_	_	_	_	_	_	Seg=O
24	virus	_	_	_	_	_	_	_	Seg=O
25	spreading	_	_	_	_	_	_	_	Seg=O
26	,	_	_	_	_	_	_	_	Seg=O
27	it	_	_	_	_	_	_	_	Seg=B-seg
28	allows	_	_	_	_	_	_	_	Seg=O
29	to	_	_	_	_	_	_	_	Seg=O
30	compute	_	_	_	_	_	_	_	Seg=O
31	the	_	_	_	_	_	_	_	Seg=O
32	basic	_	_	_	_	_	_	_	Seg=O
33	reproduction	_	_	_	_	_	_	_	Seg=O
34	number	_	_	_	_	_	_	_	Seg=O
35	,	_	_	_	_	_	_	_	Seg=O
36	the	_	_	_	_	_	_	_	Seg=O
37	number	_	_	_	_	_	_	_	Seg=O
38	of	_	_	_	_	_	_	_	Seg=O
39	deaths	_	_	_	_	_	_	_	Seg=O
40	due	_	_	_	_	_	_	_	Seg=O
41	to	_	_	_	_	_	_	_	Seg=O
42	the	_	_	_	_	_	_	_	Seg=O
43	virus	_	_	_	_	_	_	_	Seg=O
44	and	_	_	_	_	_	_	_	Seg=O
45	various	_	_	_	_	_	_	_	Seg=O
46	other	_	_	_	_	_	_	_	Seg=O
47	statistics	_	_	_	_	_	_	_	Seg=O
48	.	_	_	_	_	_	_	_	Seg=O
49	Numerical	_	_	_	_	_	_	_	Seg=B-seg
50	integrations	_	_	_	_	_	_	_	Seg=O
51	are	_	_	_	_	_	_	_	Seg=O
52	used	_	_	_	_	_	_	_	Seg=O
53	to	_	_	_	_	_	_	_	Seg=B-seg
54	illustrate	_	_	_	_	_	_	_	Seg=O
55	the	_	_	_	_	_	_	_	Seg=O
56	relevance	_	_	_	_	_	_	_	Seg=O
57	of	_	_	_	_	_	_	_	Seg=O
58	quarantine	_	_	_	_	_	_	_	Seg=O
59	and	_	_	_	_	_	_	_	Seg=O
60	the	_	_	_	_	_	_	_	Seg=O
61	role	_	_	_	_	_	_	_	Seg=O
62	of	_	_	_	_	_	_	_	Seg=O
63	care	_	_	_	_	_	_	_	Seg=O
64	houses	_	_	_	_	_	_	_	Seg=O
65	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 1b154ff0f22d4ac97b61cc3fbc65a21020010468
1	Air	_	_	_	_	_	_	_	Seg=B-seg
2	pollution	_	_	_	_	_	_	_	Seg=O
3	is	_	_	_	_	_	_	_	Seg=O
4	the	_	_	_	_	_	_	_	Seg=O
5	most	_	_	_	_	_	_	_	Seg=O
6	significant	_	_	_	_	_	_	_	Seg=O
7	environmental	_	_	_	_	_	_	_	Seg=O
8	risk	_	_	_	_	_	_	_	Seg=O
9	factor	_	_	_	_	_	_	_	Seg=O
10	for	_	_	_	_	_	_	_	Seg=O
11	all	_	_	_	_	_	_	_	Seg=O
12	-	_	_	_	_	_	_	_	Seg=O
13	cause	_	_	_	_	_	_	_	Seg=O
14	mortality	_	_	_	_	_	_	_	Seg=O
15	,	_	_	_	_	_	_	_	Seg=O
16	and	_	_	_	_	_	_	_	Seg=B-seg
17	it	_	_	_	_	_	_	_	Seg=O
18	has	_	_	_	_	_	_	_	Seg=O
19	caused	_	_	_	_	_	_	_	Seg=O
20	substantial	_	_	_	_	_	_	_	Seg=O
21	disability	_	_	_	_	_	_	_	Seg=O
22	-	_	_	_	_	_	_	_	Seg=O
23	adjusted	_	_	_	_	_	_	_	Seg=O
24	life	_	_	_	_	_	_	_	Seg=O
25	-	_	_	_	_	_	_	_	Seg=O
26	years	_	_	_	_	_	_	_	Seg=O
27	and	_	_	_	_	_	_	_	Seg=O
28	economic	_	_	_	_	_	_	_	Seg=O
29	loss	_	_	_	_	_	_	_	Seg=O
30	.	_	_	_	_	_	_	_	Seg=O
31	Air	_	_	_	_	_	_	_	Seg=B-seg
32	pollution	_	_	_	_	_	_	_	Seg=O
33	intensified	_	_	_	_	_	_	_	Seg=O
34	the	_	_	_	_	_	_	_	Seg=O
35	mortality	_	_	_	_	_	_	_	Seg=O
36	during	_	_	_	_	_	_	_	Seg=O
37	past	_	_	_	_	_	_	_	Seg=O
38	pandemics	_	_	_	_	_	_	_	Seg=O
39	,	_	_	_	_	_	_	_	Seg=O
40	Spanish	_	_	_	_	_	_	_	Seg=O
41	flu	_	_	_	_	_	_	_	Seg=O
42	in	_	_	_	_	_	_	_	Seg=O
43	1918	_	_	_	_	_	_	_	Seg=O
44	and	_	_	_	_	_	_	_	Seg=O
45	SARS	_	_	_	_	_	_	_	Seg=O
46	-	_	_	_	_	_	_	_	Seg=O
47	CoV-1	_	_	_	_	_	_	_	Seg=O
48	in	_	_	_	_	_	_	_	Seg=O
49	2003	_	_	_	_	_	_	_	Seg=O
50	.	_	_	_	_	_	_	_	Seg=O
51	It	_	_	_	_	_	_	_	Seg=B-seg
52	increases	_	_	_	_	_	_	_	Seg=O
53	host	_	_	_	_	_	_	_	Seg=O
54	susceptibility	_	_	_	_	_	_	_	Seg=O
55	and	_	_	_	_	_	_	_	Seg=O
56	virulence	_	_	_	_	_	_	_	Seg=O
57	of	_	_	_	_	_	_	_	Seg=O
58	respiratory	_	_	_	_	_	_	_	Seg=O
59	infections	_	_	_	_	_	_	_	Seg=O
60	and	_	_	_	_	_	_	_	Seg=B-seg
61	reduces	_	_	_	_	_	_	_	Seg=O
62	viral	_	_	_	_	_	_	_	Seg=O
63	clearance	_	_	_	_	_	_	_	Seg=O
64	.	_	_	_	_	_	_	_	Seg=O
65	Thus	_	_	_	_	_	_	_	Seg=B-seg
66	,	_	_	_	_	_	_	_	Seg=O
67	a	_	_	_	_	_	_	_	Seg=O
68	question	_	_	_	_	_	_	_	Seg=O
69	arises	_	_	_	_	_	_	_	Seg=O
70	whether	_	_	_	_	_	_	_	Seg=O
71	there	_	_	_	_	_	_	_	Seg=O
72	will	_	_	_	_	_	_	_	Seg=O
73	be	_	_	_	_	_	_	_	Seg=O
74	any	_	_	_	_	_	_	_	Seg=O
75	impact	_	_	_	_	_	_	_	Seg=O
76	of	_	_	_	_	_	_	_	Seg=O
77	air	_	_	_	_	_	_	_	Seg=O
78	pollution	_	_	_	_	_	_	_	Seg=O
79	on	_	_	_	_	_	_	_	Seg=O
80	the	_	_	_	_	_	_	_	Seg=O
81	current	_	_	_	_	_	_	_	Seg=O
82	pandemic	_	_	_	_	_	_	_	Seg=O
83	coronavirus	_	_	_	_	_	_	_	Seg=O
84	disease	_	_	_	_	_	_	_	Seg=O
85	2019	_	_	_	_	_	_	_	Seg=O
86	(	_	_	_	_	_	_	_	Seg=O
87	COVID-19	_	_	_	_	_	_	_	Seg=O
88	)	_	_	_	_	_	_	_	Seg=O
89	?	_	_	_	_	_	_	_	Seg=O
90	Thus	_	_	_	_	_	_	_	Seg=B-seg
91	far	_	_	_	_	_	_	_	Seg=O
92	,	_	_	_	_	_	_	_	Seg=O
93	history	_	_	_	_	_	_	_	Seg=O
94	and	_	_	_	_	_	_	_	Seg=O
95	science	_	_	_	_	_	_	_	Seg=O
96	are	_	_	_	_	_	_	_	Seg=O
97	directing	_	_	_	_	_	_	_	Seg=O
98	towards	_	_	_	_	_	_	_	Seg=O
99	an	_	_	_	_	_	_	_	Seg=O
100	immense	_	_	_	_	_	_	_	Seg=O
101	potential	_	_	_	_	_	_	_	Seg=O
102	impact	_	_	_	_	_	_	_	Seg=O
103	of	_	_	_	_	_	_	_	Seg=O
104	air	_	_	_	_	_	_	_	Seg=O
105	pollution	_	_	_	_	_	_	_	Seg=O
106	on	_	_	_	_	_	_	_	Seg=O
107	the	_	_	_	_	_	_	_	Seg=O
108	COVID-19	_	_	_	_	_	_	_	Seg=O
109	pandemic	_	_	_	_	_	_	_	Seg=O
110	.	_	_	_	_	_	_	_	Seg=O
111	Some	_	_	_	_	_	_	_	Seg=B-seg
112	of	_	_	_	_	_	_	_	Seg=O
113	the	_	_	_	_	_	_	_	Seg=O
114	devastated	_	_	_	_	_	_	_	Seg=O
115	countries	_	_	_	_	_	_	_	Seg=O
116	with	_	_	_	_	_	_	_	Seg=O
117	the	_	_	_	_	_	_	_	Seg=O
118	current	_	_	_	_	_	_	_	Seg=O
119	pandemic	_	_	_	_	_	_	_	Seg=O
120	are	_	_	_	_	_	_	_	Seg=O
121	those	_	_	_	_	_	_	_	Seg=O
122	with	_	_	_	_	_	_	_	Seg=O
123	a	_	_	_	_	_	_	_	Seg=O
124	poor	_	_	_	_	_	_	_	Seg=O
125	air	_	_	_	_	_	_	_	Seg=O
126	quality	_	_	_	_	_	_	_	Seg=O
127	index	_	_	_	_	_	_	_	Seg=O
128	.	_	_	_	_	_	_	_	Seg=O
129	Further	_	_	_	_	_	_	_	Seg=B-seg
130	epidemiological	_	_	_	_	_	_	_	Seg=O
131	and	_	_	_	_	_	_	_	Seg=O
132	ecological	_	_	_	_	_	_	_	Seg=O
133	studies	_	_	_	_	_	_	_	Seg=O
134	are	_	_	_	_	_	_	_	Seg=O
135	necessary	_	_	_	_	_	_	_	Seg=O
136	to	_	_	_	_	_	_	_	Seg=B-seg
137	confirm	_	_	_	_	_	_	_	Seg=O
138	this	_	_	_	_	_	_	_	Seg=O
139	association	_	_	_	_	_	_	_	Seg=O
140	.	_	_	_	_	_	_	_	Seg=O
141	Also	_	_	_	_	_	_	_	Seg=B-seg
142	,	_	_	_	_	_	_	_	Seg=O
143	countries	_	_	_	_	_	_	_	Seg=O
144	must	_	_	_	_	_	_	_	Seg=O
145	mobilize	_	_	_	_	_	_	_	Seg=O
146	funding	_	_	_	_	_	_	_	Seg=O
147	for	_	_	_	_	_	_	_	Seg=O
148	mitigation	_	_	_	_	_	_	_	Seg=O
149	of	_	_	_	_	_	_	_	Seg=O
150	air	_	_	_	_	_	_	_	Seg=O
151	pollution	_	_	_	_	_	_	_	Seg=O
152	to	_	_	_	_	_	_	_	Seg=B-seg
153	benefit	_	_	_	_	_	_	_	Seg=O
154	environmental	_	_	_	_	_	_	_	Seg=O
155	health	_	_	_	_	_	_	_	Seg=O
156	and	_	_	_	_	_	_	_	Seg=B-seg
157	ameliorate	_	_	_	_	_	_	_	Seg=O
158	its	_	_	_	_	_	_	_	Seg=O
159	potential	_	_	_	_	_	_	_	Seg=O
160	effects	_	_	_	_	_	_	_	Seg=O
161	on	_	_	_	_	_	_	_	Seg=O
162	pandemics	_	_	_	_	_	_	_	Seg=O
163	of	_	_	_	_	_	_	_	Seg=O
164	the	_	_	_	_	_	_	_	Seg=O
165	future	_	_	_	_	_	_	_	Seg=O
166	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 1b8a085682d10dad4baf90417a8cbcde144cc8c9
1	The	_	_	_	_	_	_	_	Seg=B-seg
2	evaluation	_	_	_	_	_	_	_	Seg=O
3	of	_	_	_	_	_	_	_	Seg=O
4	infectious	_	_	_	_	_	_	_	Seg=O
5	and	_	_	_	_	_	_	_	Seg=O
6	noninfectious	_	_	_	_	_	_	_	Seg=O
7	disease	_	_	_	_	_	_	_	Seg=O
8	management	_	_	_	_	_	_	_	Seg=O
9	can	_	_	_	_	_	_	_	Seg=O
10	be	_	_	_	_	_	_	_	Seg=O
11	done	_	_	_	_	_	_	_	Seg=O
12	through	_	_	_	_	_	_	_	Seg=O
13	the	_	_	_	_	_	_	_	Seg=O
14	use	_	_	_	_	_	_	_	Seg=O
15	of	_	_	_	_	_	_	_	Seg=O
16	a	_	_	_	_	_	_	_	Seg=O
17	time	_	_	_	_	_	_	_	Seg=O
18	series	_	_	_	_	_	_	_	Seg=O
19	analysis	_	_	_	_	_	_	_	Seg=O
20	.	_	_	_	_	_	_	_	Seg=O
21	In	_	_	_	_	_	_	_	Seg=B-seg
22	this	_	_	_	_	_	_	_	Seg=O
23	study	_	_	_	_	_	_	_	Seg=O
24	,	_	_	_	_	_	_	_	Seg=O
25	we	_	_	_	_	_	_	_	Seg=O
26	expect	_	_	_	_	_	_	_	Seg=O
27	to	_	_	_	_	_	_	_	Seg=O
28	measure	_	_	_	_	_	_	_	Seg=O
29	the	_	_	_	_	_	_	_	Seg=O
30	results	_	_	_	_	_	_	_	Seg=O
31	and	_	_	_	_	_	_	_	Seg=B-seg
32	prevent	_	_	_	_	_	_	_	Seg=O
33	intervention	_	_	_	_	_	_	_	Seg=O
34	effects	_	_	_	_	_	_	_	Seg=O
35	on	_	_	_	_	_	_	_	Seg=O
36	the	_	_	_	_	_	_	_	Seg=O
37	disease	_	_	_	_	_	_	_	Seg=O
38	.	_	_	_	_	_	_	_	Seg=O
39	Clinical	_	_	_	_	_	_	_	Seg=B-seg
40	studies	_	_	_	_	_	_	_	Seg=O
41	have	_	_	_	_	_	_	_	Seg=O
42	benefited	_	_	_	_	_	_	_	Seg=O
43	from	_	_	_	_	_	_	_	Seg=O
44	the	_	_	_	_	_	_	_	Seg=O
45	use	_	_	_	_	_	_	_	Seg=O
46	of	_	_	_	_	_	_	_	Seg=O
47	these	_	_	_	_	_	_	_	Seg=O
48	techniques	_	_	_	_	_	_	_	Seg=O
49	,	_	_	_	_	_	_	_	Seg=O
50	particularly	_	_	_	_	_	_	_	Seg=O
51	for	_	_	_	_	_	_	_	Seg=O
52	the	_	_	_	_	_	_	_	Seg=O
53	wide	_	_	_	_	_	_	_	Seg=O
54	applicability	_	_	_	_	_	_	_	Seg=O
55	of	_	_	_	_	_	_	_	Seg=O
56	the	_	_	_	_	_	_	_	Seg=O
57	ARIMA	_	_	_	_	_	_	_	Seg=O
58	model	_	_	_	_	_	_	_	Seg=O
59	.	_	_	_	_	_	_	_	Seg=O
60	This	_	_	_	_	_	_	_	Seg=B-seg
61	study	_	_	_	_	_	_	_	Seg=O
62	briefly	_	_	_	_	_	_	_	Seg=O
63	presents	_	_	_	_	_	_	_	Seg=O
64	the	_	_	_	_	_	_	_	Seg=O
65	process	_	_	_	_	_	_	_	Seg=O
66	of	_	_	_	_	_	_	_	Seg=B-seg
67	using	_	_	_	_	_	_	_	Seg=O
68	the	_	_	_	_	_	_	_	Seg=O
69	ARIMA	_	_	_	_	_	_	_	Seg=O
70	model	_	_	_	_	_	_	_	Seg=O
71	.	_	_	_	_	_	_	_	Seg=O
72	This	_	_	_	_	_	_	_	Seg=B-seg
73	analytical	_	_	_	_	_	_	_	Seg=O
74	tool	_	_	_	_	_	_	_	Seg=O
75	offers	_	_	_	_	_	_	_	Seg=O
76	a	_	_	_	_	_	_	_	Seg=O
77	great	_	_	_	_	_	_	_	Seg=O
78	contribution	_	_	_	_	_	_	_	Seg=O
79	for	_	_	_	_	_	_	_	Seg=O
80	researchers	_	_	_	_	_	_	_	Seg=O
81	and	_	_	_	_	_	_	_	Seg=O
82	healthcare	_	_	_	_	_	_	_	Seg=O
83	managers	_	_	_	_	_	_	_	Seg=O
84	in	_	_	_	_	_	_	_	Seg=O
85	the	_	_	_	_	_	_	_	Seg=O
86	evaluation	_	_	_	_	_	_	_	Seg=O
87	of	_	_	_	_	_	_	_	Seg=O
88	healthcare	_	_	_	_	_	_	_	Seg=O
89	interventions	_	_	_	_	_	_	_	Seg=O
90	in	_	_	_	_	_	_	_	Seg=O
91	specific	_	_	_	_	_	_	_	Seg=O
92	populations	_	_	_	_	_	_	_	Seg=O
93	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 1be50b82b258db680534fd344a0da386ee461361
1	Forced	_	_	_	_	_	_	_	Seg=B-seg
2	viral	_	_	_	_	_	_	_	Seg=O
3	adaptation	_	_	_	_	_	_	_	Seg=O
4	is	_	_	_	_	_	_	_	Seg=O
5	a	_	_	_	_	_	_	_	Seg=O
6	powerful	_	_	_	_	_	_	_	Seg=O
7	technique	_	_	_	_	_	_	_	Seg=O
8	employed	_	_	_	_	_	_	_	Seg=B-seg
9	to	_	_	_	_	_	_	_	Seg=B-seg
10	study	_	_	_	_	_	_	_	Seg=O
11	the	_	_	_	_	_	_	_	Seg=O
12	ways	_	_	_	_	_	_	_	Seg=O
13	viruses	_	_	_	_	_	_	_	Seg=B-seg
14	may	_	_	_	_	_	_	_	Seg=O
15	overcome	_	_	_	_	_	_	_	Seg=O
16	various	_	_	_	_	_	_	_	Seg=O
17	selective	_	_	_	_	_	_	_	Seg=O
18	pressures	_	_	_	_	_	_	_	Seg=O
19	that	_	_	_	_	_	_	_	Seg=B-seg
20	reduce	_	_	_	_	_	_	_	Seg=O
21	viral	_	_	_	_	_	_	_	Seg=O
22	replication	_	_	_	_	_	_	_	Seg=O
23	.	_	_	_	_	_	_	_	Seg=O
24	Here	_	_	_	_	_	_	_	Seg=B-seg
25	,	_	_	_	_	_	_	_	Seg=O
26	we	_	_	_	_	_	_	_	Seg=O
27	describe	_	_	_	_	_	_	_	Seg=O
28	methods	_	_	_	_	_	_	_	Seg=O
29	for	_	_	_	_	_	_	_	Seg=O
30	in	_	_	_	_	_	_	_	Seg=O
31	vitro	_	_	_	_	_	_	_	Seg=O
32	serial	_	_	_	_	_	_	_	Seg=O
33	passaging	_	_	_	_	_	_	_	Seg=O
34	of	_	_	_	_	_	_	_	Seg=O
35	Middle	_	_	_	_	_	_	_	Seg=O
36	East	_	_	_	_	_	_	_	Seg=O
37	respiratory	_	_	_	_	_	_	_	Seg=O
38	syndrome	_	_	_	_	_	_	_	Seg=O
39	coronavirus	_	_	_	_	_	_	_	Seg=O
40	(	_	_	_	_	_	_	_	Seg=O
41	MERS	_	_	_	_	_	_	_	Seg=O
42	-	_	_	_	_	_	_	_	Seg=O
43	CoV	_	_	_	_	_	_	_	Seg=O
44	)	_	_	_	_	_	_	_	Seg=O
45	to	_	_	_	_	_	_	_	Seg=B-seg
46	select	_	_	_	_	_	_	_	Seg=O
47	for	_	_	_	_	_	_	_	Seg=O
48	mutations	_	_	_	_	_	_	_	Seg=O
49	which	_	_	_	_	_	_	_	Seg=B-seg
50	increase	_	_	_	_	_	_	_	Seg=O
51	replication	_	_	_	_	_	_	_	Seg=O
52	on	_	_	_	_	_	_	_	Seg=O
53	semi	_	_	_	_	_	_	_	Seg=O
54	-	_	_	_	_	_	_	_	Seg=O
55	permissive	_	_	_	_	_	_	_	Seg=O
56	cell	_	_	_	_	_	_	_	Seg=O
57	lines	_	_	_	_	_	_	_	Seg=O
58	as	_	_	_	_	_	_	_	Seg=B-seg
59	described	_	_	_	_	_	_	_	Seg=O
60	in	_	_	_	_	_	_	_	Seg=O
61	Letko	_	_	_	_	_	_	_	Seg=O
62	et	_	_	_	_	_	_	_	Seg=O
63	al	_	_	_	_	_	_	_	Seg=O
64	.	_	_	_	_	_	_	_	Seg=O
65	,	_	_	_	_	_	_	_	Seg=O
66	Cell	_	_	_	_	_	_	_	Seg=O
67	Rep	_	_	_	_	_	_	_	Seg=O
68	24	_	_	_	_	_	_	_	Seg=O
69	,	_	_	_	_	_	_	_	Seg=O
70	1730	_	_	_	_	_	_	_	Seg=O
71	-	_	_	_	_	_	_	_	Seg=O
72	1737	_	_	_	_	_	_	_	Seg=O
73	,	_	_	_	_	_	_	_	Seg=O
74	2018	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 1dc4f757f425b080168840089f1f4d29bac75f51
1	Compared	_	_	_	_	_	_	_	Seg=B-seg
2	with	_	_	_	_	_	_	_	Seg=O
3	temperate	_	_	_	_	_	_	_	Seg=O
4	areas	_	_	_	_	_	_	_	Seg=O
5	,	_	_	_	_	_	_	_	Seg=O
6	the	_	_	_	_	_	_	_	Seg=B-seg
7	understanding	_	_	_	_	_	_	_	Seg=O
8	of	_	_	_	_	_	_	_	Seg=O
9	seasonal	_	_	_	_	_	_	_	Seg=O
10	variations	_	_	_	_	_	_	_	Seg=O
11	of	_	_	_	_	_	_	_	Seg=O
12	influenza	_	_	_	_	_	_	_	Seg=O
13	infections	_	_	_	_	_	_	_	Seg=O
14	is	_	_	_	_	_	_	_	Seg=O
15	lacking	_	_	_	_	_	_	_	Seg=O
16	in	_	_	_	_	_	_	_	Seg=O
17	subtropical	_	_	_	_	_	_	_	Seg=O
18	and	_	_	_	_	_	_	_	Seg=O
19	tropical	_	_	_	_	_	_	_	Seg=O
20	regions	_	_	_	_	_	_	_	Seg=O
21	.	_	_	_	_	_	_	_	Seg=O
22	Insufficient	_	_	_	_	_	_	_	Seg=B-seg
23	information	_	_	_	_	_	_	_	Seg=O
24	about	_	_	_	_	_	_	_	Seg=O
25	viral	_	_	_	_	_	_	_	Seg=O
26	activity	_	_	_	_	_	_	_	Seg=O
27	increases	_	_	_	_	_	_	_	Seg=O
28	the	_	_	_	_	_	_	_	Seg=O
29	difficulty	_	_	_	_	_	_	_	Seg=O
30	of	_	_	_	_	_	_	_	Seg=B-seg
31	forecasting	_	_	_	_	_	_	_	Seg=O
32	the	_	_	_	_	_	_	_	Seg=O
33	disease	_	_	_	_	_	_	_	Seg=O
34	burden	_	_	_	_	_	_	_	Seg=O
35	and	_	_	_	_	_	_	_	Seg=B-seg
36	thus	_	_	_	_	_	_	_	Seg=O
37	hampers	_	_	_	_	_	_	_	Seg=O
38	official	_	_	_	_	_	_	_	Seg=O
39	preparation	_	_	_	_	_	_	_	Seg=O
40	efforts	_	_	_	_	_	_	_	Seg=O
41	.	_	_	_	_	_	_	_	Seg=O
42	Here	_	_	_	_	_	_	_	Seg=B-seg
43	we	_	_	_	_	_	_	_	Seg=O
44	identified	_	_	_	_	_	_	_	Seg=O
45	potential	_	_	_	_	_	_	_	Seg=O
46	meteorological	_	_	_	_	_	_	_	Seg=O
47	factors	_	_	_	_	_	_	_	Seg=O
48	that	_	_	_	_	_	_	_	Seg=B-seg
49	drove	_	_	_	_	_	_	_	Seg=O
50	the	_	_	_	_	_	_	_	Seg=O
51	seasonal	_	_	_	_	_	_	_	Seg=O
52	variations	_	_	_	_	_	_	_	Seg=O
53	in	_	_	_	_	_	_	_	Seg=O
54	influenza	_	_	_	_	_	_	_	Seg=O
55	infections	_	_	_	_	_	_	_	Seg=O
56	in	_	_	_	_	_	_	_	Seg=O
57	a	_	_	_	_	_	_	_	Seg=O
58	subtropical	_	_	_	_	_	_	_	Seg=O
59	city	_	_	_	_	_	_	_	Seg=O
60	,	_	_	_	_	_	_	_	Seg=O
61	Hong	_	_	_	_	_	_	_	Seg=O
62	Kong	_	_	_	_	_	_	_	Seg=O
63	.	_	_	_	_	_	_	_	Seg=O
64	We	_	_	_	_	_	_	_	Seg=B-seg
65	fitted	_	_	_	_	_	_	_	Seg=O
66	the	_	_	_	_	_	_	_	Seg=O
67	meteorological	_	_	_	_	_	_	_	Seg=O
68	data	_	_	_	_	_	_	_	Seg=O
69	and	_	_	_	_	_	_	_	Seg=O
70	influenza	_	_	_	_	_	_	_	Seg=O
71	mortality	_	_	_	_	_	_	_	Seg=O
72	data	_	_	_	_	_	_	_	Seg=O
73	from	_	_	_	_	_	_	_	Seg=O
74	2002	_	_	_	_	_	_	_	Seg=O
75	to	_	_	_	_	_	_	_	Seg=O
76	2009	_	_	_	_	_	_	_	Seg=O
77	in	_	_	_	_	_	_	_	Seg=O
78	a	_	_	_	_	_	_	_	Seg=O
79	Susceptible	_	_	_	_	_	_	_	Seg=O
80	-	_	_	_	_	_	_	_	Seg=O
81	Infected	_	_	_	_	_	_	_	Seg=O
82	-	_	_	_	_	_	_	_	Seg=O
83	Recovered	_	_	_	_	_	_	_	Seg=O
84	model	_	_	_	_	_	_	_	Seg=O
85	.	_	_	_	_	_	_	_	Seg=O
86	From	_	_	_	_	_	_	_	Seg=B-seg
87	the	_	_	_	_	_	_	_	Seg=O
88	results	_	_	_	_	_	_	_	Seg=O
89	,	_	_	_	_	_	_	_	Seg=O
90	air	_	_	_	_	_	_	_	Seg=O
91	temperature	_	_	_	_	_	_	_	Seg=O
92	was	_	_	_	_	_	_	_	Seg=O
93	a	_	_	_	_	_	_	_	Seg=O
94	common	_	_	_	_	_	_	_	Seg=O
95	significant	_	_	_	_	_	_	_	Seg=O
96	driver	_	_	_	_	_	_	_	Seg=O
97	of	_	_	_	_	_	_	_	Seg=O
98	seasonal	_	_	_	_	_	_	_	Seg=O
99	patterns	_	_	_	_	_	_	_	Seg=O
100	and	_	_	_	_	_	_	_	Seg=B-seg
101	cold	_	_	_	_	_	_	_	Seg=O
102	temperature	_	_	_	_	_	_	_	Seg=O
103	was	_	_	_	_	_	_	_	Seg=O
104	associated	_	_	_	_	_	_	_	Seg=O
105	with	_	_	_	_	_	_	_	Seg=O
106	an	_	_	_	_	_	_	_	Seg=O
107	increase	_	_	_	_	_	_	_	Seg=O
108	in	_	_	_	_	_	_	_	Seg=O
109	transmission	_	_	_	_	_	_	_	Seg=O
110	intensity	_	_	_	_	_	_	_	Seg=O
111	for	_	_	_	_	_	_	_	Seg=O
112	most	_	_	_	_	_	_	_	Seg=O
113	of	_	_	_	_	_	_	_	Seg=O
114	the	_	_	_	_	_	_	_	Seg=O
115	influenza	_	_	_	_	_	_	_	Seg=O
116	epidemics	_	_	_	_	_	_	_	Seg=O
117	.	_	_	_	_	_	_	_	Seg=O
118	Except	_	_	_	_	_	_	_	Seg=B-seg
119	2004	_	_	_	_	_	_	_	Seg=O
120	,	_	_	_	_	_	_	_	Seg=O
121	the	_	_	_	_	_	_	_	Seg=O
122	fitted	_	_	_	_	_	_	_	Seg=O
123	models	_	_	_	_	_	_	_	Seg=O
124	with	_	_	_	_	_	_	_	Seg=O
125	significant	_	_	_	_	_	_	_	Seg=O
126	meteorological	_	_	_	_	_	_	_	Seg=O
127	factors	_	_	_	_	_	_	_	Seg=O
128	could	_	_	_	_	_	_	_	Seg=O
129	account	_	_	_	_	_	_	_	Seg=O
130	for	_	_	_	_	_	_	_	Seg=O
131	more	_	_	_	_	_	_	_	Seg=O
132	than	_	_	_	_	_	_	_	Seg=O
133	10	_	_	_	_	_	_	_	Seg=O
134	%	_	_	_	_	_	_	_	Seg=O
135	of	_	_	_	_	_	_	_	Seg=O
136	the	_	_	_	_	_	_	_	Seg=O
137	variance	_	_	_	_	_	_	_	Seg=O
138	in	_	_	_	_	_	_	_	Seg=O
139	additional	_	_	_	_	_	_	_	Seg=O
140	to	_	_	_	_	_	_	_	Seg=O
141	the	_	_	_	_	_	_	_	Seg=O
142	null	_	_	_	_	_	_	_	Seg=O
143	model	_	_	_	_	_	_	_	Seg=O
144	.	_	_	_	_	_	_	_	Seg=O
145	Rainfall	_	_	_	_	_	_	_	Seg=B-seg
146	was	_	_	_	_	_	_	_	Seg=O
147	also	_	_	_	_	_	_	_	Seg=O
148	found	_	_	_	_	_	_	_	Seg=O
149	to	_	_	_	_	_	_	_	Seg=O
150	be	_	_	_	_	_	_	_	Seg=O
151	a	_	_	_	_	_	_	_	Seg=O
152	significant	_	_	_	_	_	_	_	Seg=O
153	driver	_	_	_	_	_	_	_	Seg=O
154	of	_	_	_	_	_	_	_	Seg=O
155	seasonal	_	_	_	_	_	_	_	Seg=O
156	influenza	_	_	_	_	_	_	_	Seg=O
157	,	_	_	_	_	_	_	_	Seg=O
158	although	_	_	_	_	_	_	_	Seg=B-seg
159	results	_	_	_	_	_	_	_	Seg=O
160	were	_	_	_	_	_	_	_	Seg=O
161	less	_	_	_	_	_	_	_	Seg=O
162	robust	_	_	_	_	_	_	_	Seg=O
163	.	_	_	_	_	_	_	_	Seg=O
164	The	_	_	_	_	_	_	_	Seg=B-seg
165	identified	_	_	_	_	_	_	_	Seg=O
166	meteorological	_	_	_	_	_	_	_	Seg=O
167	indicators	_	_	_	_	_	_	_	Seg=O
168	could	_	_	_	_	_	_	_	Seg=O
169	alert	_	_	_	_	_	_	_	Seg=O
170	officials	_	_	_	_	_	_	_	Seg=O
171	to	_	_	_	_	_	_	_	Seg=O
172	take	_	_	_	_	_	_	_	Seg=O
173	appropriate	_	_	_	_	_	_	_	Seg=O
174	control	_	_	_	_	_	_	_	Seg=O
175	measures	_	_	_	_	_	_	_	Seg=O
176	for	_	_	_	_	_	_	_	Seg=O
177	influenza	_	_	_	_	_	_	_	Seg=O
178	epidemics	_	_	_	_	_	_	_	Seg=O
179	,	_	_	_	_	_	_	_	Seg=O
180	such	_	_	_	_	_	_	_	Seg=B-seg
181	as	_	_	_	_	_	_	_	Seg=O
182	enhancing	_	_	_	_	_	_	_	Seg=O
183	vaccination	_	_	_	_	_	_	_	Seg=O
184	activities	_	_	_	_	_	_	_	Seg=O
185	before	_	_	_	_	_	_	_	Seg=O
186	cold	_	_	_	_	_	_	_	Seg=O
187	seasons	_	_	_	_	_	_	_	Seg=O
188	.	_	_	_	_	_	_	_	Seg=O
189	Further	_	_	_	_	_	_	_	Seg=B-seg
190	studies	_	_	_	_	_	_	_	Seg=O
191	are	_	_	_	_	_	_	_	Seg=O
192	required	_	_	_	_	_	_	_	Seg=O
193	to	_	_	_	_	_	_	_	Seg=B-seg
194	fully	_	_	_	_	_	_	_	Seg=O
195	justify	_	_	_	_	_	_	_	Seg=O
196	the	_	_	_	_	_	_	_	Seg=O
197	associations	_	_	_	_	_	_	_	Seg=O
198	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 1ea8699c1a259ed2a4c0d1c70e1c842eac6c2063
1	Avian	_	_	_	_	_	_	_	Seg=B-seg
2	metapneumovirus	_	_	_	_	_	_	_	Seg=O
3	(	_	_	_	_	_	_	_	Seg=O
4	aMPV	_	_	_	_	_	_	_	Seg=O
5	)	_	_	_	_	_	_	_	Seg=O
6	is	_	_	_	_	_	_	_	Seg=O
7	one	_	_	_	_	_	_	_	Seg=O
8	of	_	_	_	_	_	_	_	Seg=O
9	the	_	_	_	_	_	_	_	Seg=O
10	major	_	_	_	_	_	_	_	Seg=O
11	causes	_	_	_	_	_	_	_	Seg=O
12	of	_	_	_	_	_	_	_	Seg=O
13	serious	_	_	_	_	_	_	_	Seg=O
14	respiratory	_	_	_	_	_	_	_	Seg=O
15	infections	_	_	_	_	_	_	_	Seg=O
16	of	_	_	_	_	_	_	_	Seg=O
17	poultry	_	_	_	_	_	_	_	Seg=O
18	and	_	_	_	_	_	_	_	Seg=B-seg
19	leads	_	_	_	_	_	_	_	Seg=O
20	to	_	_	_	_	_	_	_	Seg=O
21	considerable	_	_	_	_	_	_	_	Seg=O
22	economic	_	_	_	_	_	_	_	Seg=O
23	losses	_	_	_	_	_	_	_	Seg=O
24	to	_	_	_	_	_	_	_	Seg=O
25	food	_	_	_	_	_	_	_	Seg=O
26	animal	_	_	_	_	_	_	_	Seg=O
27	production	_	_	_	_	_	_	_	Seg=O
28	worldwide	_	_	_	_	_	_	_	Seg=O
29	.	_	_	_	_	_	_	_	Seg=O
30	Here	_	_	_	_	_	_	_	Seg=B-seg
31	,	_	_	_	_	_	_	_	Seg=O
32	we	_	_	_	_	_	_	_	Seg=O
33	show	_	_	_	_	_	_	_	Seg=O
34	that	_	_	_	_	_	_	_	Seg=B-seg
35	double	_	_	_	_	_	_	_	Seg=O
36	stranded	_	_	_	_	_	_	_	Seg=O
37	short	_	_	_	_	_	_	_	Seg=O
38	interfering	_	_	_	_	_	_	_	Seg=O
39	RNA	_	_	_	_	_	_	_	Seg=O
40	(	_	_	_	_	_	_	_	Seg=O
41	siRNA	_	_	_	_	_	_	_	Seg=O
42	)	_	_	_	_	_	_	_	Seg=O
43	molecules	_	_	_	_	_	_	_	Seg=O
44	corresponding	_	_	_	_	_	_	_	Seg=B-seg
45	to	_	_	_	_	_	_	_	Seg=O
46	aMPV	_	_	_	_	_	_	_	Seg=O
47	phosphoprotein	_	_	_	_	_	_	_	Seg=O
48	(	_	_	_	_	_	_	_	Seg=O
49	P	_	_	_	_	_	_	_	Seg=O
50	)	_	_	_	_	_	_	_	Seg=O
51	gene	_	_	_	_	_	_	_	Seg=O
52	silence	_	_	_	_	_	_	_	Seg=B-seg
53	P	_	_	_	_	_	_	_	Seg=O
54	RNA	_	_	_	_	_	_	_	Seg=O
55	and	_	_	_	_	_	_	_	Seg=O
56	protein	_	_	_	_	_	_	_	Seg=O
57	expression	_	_	_	_	_	_	_	Seg=O
58	.	_	_	_	_	_	_	_	Seg=O
59	These	_	_	_	_	_	_	_	Seg=B-seg
60	siRNAs	_	_	_	_	_	_	_	Seg=O
61	broadly	_	_	_	_	_	_	_	Seg=O
62	reduced	_	_	_	_	_	_	_	Seg=O
63	the	_	_	_	_	_	_	_	Seg=O
64	expression	_	_	_	_	_	_	_	Seg=O
65	of	_	_	_	_	_	_	_	Seg=O
66	other	_	_	_	_	_	_	_	Seg=O
67	viral	_	_	_	_	_	_	_	Seg=O
68	proteins	_	_	_	_	_	_	_	Seg=O
69	in	_	_	_	_	_	_	_	Seg=O
70	addition	_	_	_	_	_	_	_	Seg=O
71	to	_	_	_	_	_	_	_	Seg=O
72	P	_	_	_	_	_	_	_	Seg=O
73	,	_	_	_	_	_	_	_	Seg=O
74	but	_	_	_	_	_	_	_	Seg=B-seg
75	did	_	_	_	_	_	_	_	Seg=O
76	not	_	_	_	_	_	_	_	Seg=O
77	have	_	_	_	_	_	_	_	Seg=O
78	a	_	_	_	_	_	_	_	Seg=O
79	discernable	_	_	_	_	_	_	_	Seg=O
80	effect	_	_	_	_	_	_	_	Seg=O
81	on	_	_	_	_	_	_	_	Seg=O
82	cellular	_	_	_	_	_	_	_	Seg=O
83	protein	_	_	_	_	_	_	_	Seg=O
84	expression	_	_	_	_	_	_	_	Seg=O
85	.	_	_	_	_	_	_	_	Seg=O
86	The	_	_	_	_	_	_	_	Seg=B-seg
87	exposure	_	_	_	_	_	_	_	Seg=O
88	of	_	_	_	_	_	_	_	Seg=O
89	cells	_	_	_	_	_	_	_	Seg=O
90	to	_	_	_	_	_	_	_	Seg=O
91	P	_	_	_	_	_	_	_	Seg=O
92	-	_	_	_	_	_	_	_	Seg=O
93	specific	_	_	_	_	_	_	_	Seg=O
94	siRNAs	_	_	_	_	_	_	_	Seg=O
95	also	_	_	_	_	_	_	_	Seg=O
96	led	_	_	_	_	_	_	_	Seg=O
97	to	_	_	_	_	_	_	_	Seg=O
98	inhibition	_	_	_	_	_	_	_	Seg=O
99	of	_	_	_	_	_	_	_	Seg=O
100	virus	_	_	_	_	_	_	_	Seg=O
101	replication	_	_	_	_	_	_	_	Seg=O
102	as	_	_	_	_	_	_	_	Seg=B-seg
103	evidenced	_	_	_	_	_	_	_	Seg=O
104	by	_	_	_	_	_	_	_	Seg=O
105	marked	_	_	_	_	_	_	_	Seg=O
106	reduction	_	_	_	_	_	_	_	Seg=O
107	in	_	_	_	_	_	_	_	Seg=O
108	the	_	_	_	_	_	_	_	Seg=O
109	progeny	_	_	_	_	_	_	_	Seg=O
110	virion	_	_	_	_	_	_	_	Seg=O
111	titers	_	_	_	_	_	_	_	Seg=O
112	.	_	_	_	_	_	_	_	Seg=O
113	Taken	_	_	_	_	_	_	_	Seg=B-seg
114	together	_	_	_	_	_	_	_	Seg=O
115	,	_	_	_	_	_	_	_	Seg=O
116	the	_	_	_	_	_	_	_	Seg=B-seg
117	findings	_	_	_	_	_	_	_	Seg=O
118	suggest	_	_	_	_	_	_	_	Seg=O
119	that	_	_	_	_	_	_	_	Seg=B-seg
120	exogenous	_	_	_	_	_	_	_	Seg=O
121	P	_	_	_	_	_	_	_	Seg=O
122	silencing	_	_	_	_	_	_	_	Seg=O
123	siRNAs	_	_	_	_	_	_	_	Seg=O
124	can	_	_	_	_	_	_	_	Seg=O
125	inhibit	_	_	_	_	_	_	_	Seg=O
126	aMPV	_	_	_	_	_	_	_	Seg=O
127	replication	_	_	_	_	_	_	_	Seg=O
128	with	_	_	_	_	_	_	_	Seg=O
129	potential	_	_	_	_	_	_	_	Seg=O
130	implications	_	_	_	_	_	_	_	Seg=O
131	in	_	_	_	_	_	_	_	Seg=O
132	the	_	_	_	_	_	_	_	Seg=O
133	design	_	_	_	_	_	_	_	Seg=O
134	of	_	_	_	_	_	_	_	Seg=O
135	novel	_	_	_	_	_	_	_	Seg=O
136	siRNA	_	_	_	_	_	_	_	Seg=O
137	based	_	_	_	_	_	_	_	Seg=O
138	prophylactics	_	_	_	_	_	_	_	Seg=O
139	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 1f2bbc79b56c51c0ae26ced2d7d8ccf10360fa72
1	Ribonuclease	_	_	_	_	_	_	_	Seg=B-seg
2	L	_	_	_	_	_	_	_	Seg=O
3	(	_	_	_	_	_	_	_	Seg=O
4	RNase	_	_	_	_	_	_	_	Seg=O
5	L	_	_	_	_	_	_	_	Seg=O
6	)	_	_	_	_	_	_	_	Seg=O
7	is	_	_	_	_	_	_	_	Seg=O
8	a	_	_	_	_	_	_	_	Seg=O
9	metal	_	_	_	_	_	_	_	Seg=O
10	-	_	_	_	_	_	_	_	Seg=O
11	ion	_	_	_	_	_	_	_	Seg=O
12	-	_	_	_	_	_	_	_	Seg=O
13	independent	_	_	_	_	_	_	_	Seg=O
14	endoribonuclease	_	_	_	_	_	_	_	Seg=O
15	associated	_	_	_	_	_	_	_	Seg=B-seg
16	with	_	_	_	_	_	_	_	Seg=O
17	antiviral	_	_	_	_	_	_	_	Seg=O
18	and	_	_	_	_	_	_	_	Seg=O
19	antibacterial	_	_	_	_	_	_	_	Seg=O
20	defense	_	_	_	_	_	_	_	Seg=O
21	,	_	_	_	_	_	_	_	Seg=O
22	cancer	_	_	_	_	_	_	_	Seg=O
23	and	_	_	_	_	_	_	_	Seg=O
24	lifespan	_	_	_	_	_	_	_	Seg=O
25	.	_	_	_	_	_	_	_	Seg=O
26	Despite	_	_	_	_	_	_	_	Seg=B-seg
27	the	_	_	_	_	_	_	_	Seg=O
28	biological	_	_	_	_	_	_	_	Seg=O
29	significance	_	_	_	_	_	_	_	Seg=O
30	of	_	_	_	_	_	_	_	Seg=O
31	RNase	_	_	_	_	_	_	_	Seg=O
32	L	_	_	_	_	_	_	_	Seg=O
33	,	_	_	_	_	_	_	_	Seg=O
34	the	_	_	_	_	_	_	_	Seg=B-seg
35	RNAs	_	_	_	_	_	_	_	Seg=O
36	cleaved	_	_	_	_	_	_	_	Seg=B-seg
37	by	_	_	_	_	_	_	_	Seg=O
38	this	_	_	_	_	_	_	_	Seg=O
39	enzyme	_	_	_	_	_	_	_	Seg=O
40	are	_	_	_	_	_	_	_	Seg=B-seg
41	poorly	_	_	_	_	_	_	_	Seg=O
42	defined	_	_	_	_	_	_	_	Seg=O
43	.	_	_	_	_	_	_	_	Seg=O
44	In	_	_	_	_	_	_	_	Seg=B-seg
45	this	_	_	_	_	_	_	_	Seg=O
46	study	_	_	_	_	_	_	_	Seg=O
47	,	_	_	_	_	_	_	_	Seg=O
48	we	_	_	_	_	_	_	_	Seg=O
49	used	_	_	_	_	_	_	_	Seg=O
50	deep	_	_	_	_	_	_	_	Seg=O
51	sequencing	_	_	_	_	_	_	_	Seg=O
52	methods	_	_	_	_	_	_	_	Seg=O
53	to	_	_	_	_	_	_	_	Seg=B-seg
54	reveal	_	_	_	_	_	_	_	Seg=O
55	the	_	_	_	_	_	_	_	Seg=O
56	frequency	_	_	_	_	_	_	_	Seg=O
57	and	_	_	_	_	_	_	_	Seg=O
58	location	_	_	_	_	_	_	_	Seg=O
59	of	_	_	_	_	_	_	_	Seg=O
60	RNase	_	_	_	_	_	_	_	Seg=O
61	L	_	_	_	_	_	_	_	Seg=O
62	cleavage	_	_	_	_	_	_	_	Seg=O
63	sites	_	_	_	_	_	_	_	Seg=O
64	within	_	_	_	_	_	_	_	Seg=O
65	host	_	_	_	_	_	_	_	Seg=O
66	and	_	_	_	_	_	_	_	Seg=O
67	viral	_	_	_	_	_	_	_	Seg=O
68	RNAs	_	_	_	_	_	_	_	Seg=O
69	.	_	_	_	_	_	_	_	Seg=O
70	To	_	_	_	_	_	_	_	Seg=B-seg
71	make	_	_	_	_	_	_	_	Seg=O
72	cDNA	_	_	_	_	_	_	_	Seg=O
73	libraries	_	_	_	_	_	_	_	Seg=O
74	,	_	_	_	_	_	_	_	Seg=O
75	we	_	_	_	_	_	_	_	Seg=B-seg
76	exploited	_	_	_	_	_	_	_	Seg=O
77	the	_	_	_	_	_	_	_	Seg=O
78	2	_	_	_	_	_	_	_	Seg=O
79	0	_	_	_	_	_	_	_	Seg=O
80	,	_	_	_	_	_	_	_	Seg=O
81	3	_	_	_	_	_	_	_	Seg=O
82	0	_	_	_	_	_	_	_	Seg=O
83	-cyclic	_	_	_	_	_	_	_	Seg=O
84	phosphate	_	_	_	_	_	_	_	Seg=O
85	at	_	_	_	_	_	_	_	Seg=O
86	the	_	_	_	_	_	_	_	Seg=O
87	end	_	_	_	_	_	_	_	Seg=O
88	of	_	_	_	_	_	_	_	Seg=O
89	RNA	_	_	_	_	_	_	_	Seg=O
90	fragments	_	_	_	_	_	_	_	Seg=O
91	produced	_	_	_	_	_	_	_	Seg=B-seg
92	by	_	_	_	_	_	_	_	Seg=O
93	RNase	_	_	_	_	_	_	_	Seg=O
94	L	_	_	_	_	_	_	_	Seg=O
95	and	_	_	_	_	_	_	_	Seg=O
96	other	_	_	_	_	_	_	_	Seg=O
97	metal	_	_	_	_	_	_	_	Seg=O
98	-	_	_	_	_	_	_	_	Seg=O
99	ion	_	_	_	_	_	_	_	Seg=O
100	-	_	_	_	_	_	_	_	Seg=O
101	independent	_	_	_	_	_	_	_	Seg=O
102	endoribonucleases	_	_	_	_	_	_	_	Seg=O
103	.	_	_	_	_	_	_	_	Seg=O
104	We	_	_	_	_	_	_	_	Seg=B-seg
105	optimized	_	_	_	_	_	_	_	Seg=O
106	and	_	_	_	_	_	_	_	Seg=O
107	validated	_	_	_	_	_	_	_	Seg=O
108	2	_	_	_	_	_	_	_	Seg=O
109	0	_	_	_	_	_	_	_	Seg=O
110	,	_	_	_	_	_	_	_	Seg=O
111	3	_	_	_	_	_	_	_	Seg=O
112	0	_	_	_	_	_	_	_	Seg=O
113	-cyclic	_	_	_	_	_	_	_	Seg=O
114	phosphate	_	_	_	_	_	_	_	Seg=O
115	cDNA	_	_	_	_	_	_	_	Seg=O
116	synthesis	_	_	_	_	_	_	_	Seg=O
117	and	_	_	_	_	_	_	_	Seg=O
118	Illumina	_	_	_	_	_	_	_	Seg=O
119	sequencing	_	_	_	_	_	_	_	Seg=O
120	methods	_	_	_	_	_	_	_	Seg=O
121	using	_	_	_	_	_	_	_	Seg=B-seg
122	viral	_	_	_	_	_	_	_	Seg=O
123	RNAs	_	_	_	_	_	_	_	Seg=O
124	cleaved	_	_	_	_	_	_	_	Seg=B-seg
125	with	_	_	_	_	_	_	_	Seg=O
126	purified	_	_	_	_	_	_	_	Seg=O
127	RNase	_	_	_	_	_	_	_	Seg=O
128	L	_	_	_	_	_	_	_	Seg=O
129	,	_	_	_	_	_	_	_	Seg=O
130	viral	_	_	_	_	_	_	_	Seg=B-seg
131	RNAs	_	_	_	_	_	_	_	Seg=O
132	cleaved	_	_	_	_	_	_	_	Seg=B-seg
133	with	_	_	_	_	_	_	_	Seg=O
134	purified	_	_	_	_	_	_	_	Seg=O
135	RNase	_	_	_	_	_	_	_	Seg=O
136	A	_	_	_	_	_	_	_	Seg=O
137	and	_	_	_	_	_	_	_	Seg=B-seg
138	RNA	_	_	_	_	_	_	_	Seg=O
139	from	_	_	_	_	_	_	_	Seg=O
140	uninfected	_	_	_	_	_	_	_	Seg=O
141	and	_	_	_	_	_	_	_	Seg=O
142	poliovirus	_	_	_	_	_	_	_	Seg=O
143	-	_	_	_	_	_	_	_	Seg=O
144	infected	_	_	_	_	_	_	_	Seg=O
145	HeLa	_	_	_	_	_	_	_	Seg=O
146	cells	_	_	_	_	_	_	_	Seg=O
147	.	_	_	_	_	_	_	_	Seg=O
148	Using	_	_	_	_	_	_	_	Seg=B-seg
149	these	_	_	_	_	_	_	_	Seg=O
150	methods	_	_	_	_	_	_	_	Seg=O
151	,	_	_	_	_	_	_	_	Seg=O
152	we	_	_	_	_	_	_	_	Seg=B-seg
153	identified	_	_	_	_	_	_	_	Seg=O
154	(	_	_	_	_	_	_	_	Seg=O
155	i	_	_	_	_	_	_	_	Seg=O
156	)	_	_	_	_	_	_	_	Seg=O
157	discrete	_	_	_	_	_	_	_	Seg=O
158	regions	_	_	_	_	_	_	_	Seg=O
159	of	_	_	_	_	_	_	_	Seg=O
160	hepatitis	_	_	_	_	_	_	_	Seg=O
161	C	_	_	_	_	_	_	_	Seg=O
162	virus	_	_	_	_	_	_	_	Seg=O
163	and	_	_	_	_	_	_	_	Seg=O
164	poliovirus	_	_	_	_	_	_	_	Seg=O
165	RNA	_	_	_	_	_	_	_	Seg=O
166	genomes	_	_	_	_	_	_	_	Seg=O
167	that	_	_	_	_	_	_	_	Seg=B-seg
168	were	_	_	_	_	_	_	_	Seg=O
169	profoundly	_	_	_	_	_	_	_	Seg=O
170	susceptible	_	_	_	_	_	_	_	Seg=O
171	to	_	_	_	_	_	_	_	Seg=O
172	RNase	_	_	_	_	_	_	_	Seg=O
173	L	_	_	_	_	_	_	_	Seg=O
174	and	_	_	_	_	_	_	_	Seg=O
175	other	_	_	_	_	_	_	_	Seg=O
176	single	_	_	_	_	_	_	_	Seg=O
177	-	_	_	_	_	_	_	_	Seg=O
178	strand	_	_	_	_	_	_	_	Seg=O
179	specific	_	_	_	_	_	_	_	Seg=O
180	endoribonucleases	_	_	_	_	_	_	_	Seg=O
181	,	_	_	_	_	_	_	_	Seg=O
182	(	_	_	_	_	_	_	_	Seg=B-seg
183	ii	_	_	_	_	_	_	_	Seg=O
184	)	_	_	_	_	_	_	_	Seg=O
185	RNase	_	_	_	_	_	_	_	Seg=O
186	L	_	_	_	_	_	_	_	Seg=O
187	-	_	_	_	_	_	_	_	Seg=O
188	dependent	_	_	_	_	_	_	_	Seg=O
189	and	_	_	_	_	_	_	_	Seg=O
190	RNase	_	_	_	_	_	_	_	Seg=O
191	L	_	_	_	_	_	_	_	Seg=O
192	-	_	_	_	_	_	_	_	Seg=O
193	independent	_	_	_	_	_	_	_	Seg=O
194	cleavage	_	_	_	_	_	_	_	Seg=O
195	sites	_	_	_	_	_	_	_	Seg=O
196	within	_	_	_	_	_	_	_	Seg=O
197	ribosomal	_	_	_	_	_	_	_	Seg=O
198	RNAs	_	_	_	_	_	_	_	Seg=O
199	(	_	_	_	_	_	_	_	Seg=O
200	rRNAs	_	_	_	_	_	_	_	Seg=O
201	)	_	_	_	_	_	_	_	Seg=O
202	and	_	_	_	_	_	_	_	Seg=O
203	(	_	_	_	_	_	_	_	Seg=O
204	iii	_	_	_	_	_	_	_	Seg=O
205	)	_	_	_	_	_	_	_	Seg=O
206	2	_	_	_	_	_	_	_	Seg=O
207	0	_	_	_	_	_	_	_	Seg=O
208	,	_	_	_	_	_	_	_	Seg=O
209	3	_	_	_	_	_	_	_	Seg=O
210	0	_	_	_	_	_	_	_	Seg=O
211	-cyclic	_	_	_	_	_	_	_	Seg=O
212	phosphates	_	_	_	_	_	_	_	Seg=O
213	at	_	_	_	_	_	_	_	Seg=O
214	the	_	_	_	_	_	_	_	Seg=O
215	ends	_	_	_	_	_	_	_	Seg=O
216	of	_	_	_	_	_	_	_	Seg=O
217	5S	_	_	_	_	_	_	_	Seg=O
218	rRNA	_	_	_	_	_	_	_	Seg=O
219	and	_	_	_	_	_	_	_	Seg=O
220	U6	_	_	_	_	_	_	_	Seg=O
221	snRNA	_	_	_	_	_	_	_	Seg=O
222	.	_	_	_	_	_	_	_	Seg=O
223	Monitoring	_	_	_	_	_	_	_	Seg=B-seg
224	the	_	_	_	_	_	_	_	Seg=O
225	frequency	_	_	_	_	_	_	_	Seg=O
226	and	_	_	_	_	_	_	_	Seg=O
227	location	_	_	_	_	_	_	_	Seg=O
228	of	_	_	_	_	_	_	_	Seg=O
229	metal	_	_	_	_	_	_	_	Seg=O
230	-	_	_	_	_	_	_	_	Seg=O
231	ion	_	_	_	_	_	_	_	Seg=O
232	-	_	_	_	_	_	_	_	Seg=O
233	independent	_	_	_	_	_	_	_	Seg=O
234	endoribonuclease	_	_	_	_	_	_	_	Seg=O
235	cleavage	_	_	_	_	_	_	_	Seg=O
236	sites	_	_	_	_	_	_	_	Seg=O
237	within	_	_	_	_	_	_	_	Seg=O
238	host	_	_	_	_	_	_	_	Seg=O
239	and	_	_	_	_	_	_	_	Seg=O
240	viral	_	_	_	_	_	_	_	Seg=O
241	RNAs	_	_	_	_	_	_	_	Seg=O
242	reveals	_	_	_	_	_	_	_	Seg=O
243	,	_	_	_	_	_	_	_	Seg=O
244	in	_	_	_	_	_	_	_	Seg=B-seg
245	part	_	_	_	_	_	_	_	Seg=O
246	,	_	_	_	_	_	_	_	Seg=O
247	how	_	_	_	_	_	_	_	Seg=O
248	these	_	_	_	_	_	_	_	Seg=O
249	enzymes	_	_	_	_	_	_	_	Seg=O
250	contribute	_	_	_	_	_	_	_	Seg=O
251	to	_	_	_	_	_	_	_	Seg=O
252	health	_	_	_	_	_	_	_	Seg=O
253	and	_	_	_	_	_	_	_	Seg=O
254	disease	_	_	_	_	_	_	_	Seg=O
255	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 1f7c4b6fc91f3143baa4824a7f8050f16d9bcccd
1	Background	_	_	_	_	_	_	_	Seg=B-seg
2	:	_	_	_	_	_	_	_	Seg=O
3	Porcine	_	_	_	_	_	_	_	Seg=B-seg
4	reproductive	_	_	_	_	_	_	_	Seg=O
5	and	_	_	_	_	_	_	_	Seg=O
6	respiratory	_	_	_	_	_	_	_	Seg=O
7	syndrome	_	_	_	_	_	_	_	Seg=O
8	(	_	_	_	_	_	_	_	Seg=O
9	PRRS	_	_	_	_	_	_	_	Seg=O
10	)	_	_	_	_	_	_	_	Seg=O
11	viruses	_	_	_	_	_	_	_	Seg=O
12	are	_	_	_	_	_	_	_	Seg=O
13	a	_	_	_	_	_	_	_	Seg=O
14	major	_	_	_	_	_	_	_	Seg=O
15	cause	_	_	_	_	_	_	_	Seg=O
16	of	_	_	_	_	_	_	_	Seg=O
17	disease	_	_	_	_	_	_	_	Seg=O
18	and	_	_	_	_	_	_	_	Seg=O
19	economic	_	_	_	_	_	_	_	Seg=O
20	loss	_	_	_	_	_	_	_	Seg=O
21	in	_	_	_	_	_	_	_	Seg=O
22	pigs	_	_	_	_	_	_	_	Seg=O
23	worldwide	_	_	_	_	_	_	_	Seg=O
24	.	_	_	_	_	_	_	_	Seg=O
25	High	_	_	_	_	_	_	_	Seg=B-seg
26	genetic	_	_	_	_	_	_	_	Seg=O
27	diversity	_	_	_	_	_	_	_	Seg=O
28	among	_	_	_	_	_	_	_	Seg=O
29	PRRSV	_	_	_	_	_	_	_	Seg=O
30	strains	_	_	_	_	_	_	_	Seg=O
31	is	_	_	_	_	_	_	_	Seg=O
32	problematic	_	_	_	_	_	_	_	Seg=O
33	for	_	_	_	_	_	_	_	Seg=O
34	successful	_	_	_	_	_	_	_	Seg=O
35	disease	_	_	_	_	_	_	_	Seg=O
36	control	_	_	_	_	_	_	_	Seg=O
37	by	_	_	_	_	_	_	_	Seg=O
38	vaccination	_	_	_	_	_	_	_	Seg=O
39	.	_	_	_	_	_	_	_	Seg=O
40	Mosaic	_	_	_	_	_	_	_	Seg=B-seg
41	DNA	_	_	_	_	_	_	_	Seg=O
42	and	_	_	_	_	_	_	_	Seg=O
43	vaccinia	_	_	_	_	_	_	_	Seg=O
44	(	_	_	_	_	_	_	_	Seg=O
45	VACV	_	_	_	_	_	_	_	Seg=O
46	)	_	_	_	_	_	_	_	Seg=O
47	vaccines	_	_	_	_	_	_	_	Seg=O
48	were	_	_	_	_	_	_	_	Seg=O
49	developed	_	_	_	_	_	_	_	Seg=O
50	in	_	_	_	_	_	_	_	Seg=B-seg
51	order	_	_	_	_	_	_	_	Seg=O
52	to	_	_	_	_	_	_	_	Seg=O
53	improve	_	_	_	_	_	_	_	Seg=O
54	protection	_	_	_	_	_	_	_	Seg=O
55	against	_	_	_	_	_	_	_	Seg=O
56	heterologous	_	_	_	_	_	_	_	Seg=O
57	PRRSV	_	_	_	_	_	_	_	Seg=O
58	strains	_	_	_	_	_	_	_	Seg=O
59	.	_	_	_	_	_	_	_	Seg=O
60	Methods	_	_	_	_	_	_	_	Seg=B-seg
61	:	_	_	_	_	_	_	_	Seg=O
62	Piglets	_	_	_	_	_	_	_	Seg=B-seg
63	were	_	_	_	_	_	_	_	Seg=O
64	primed	_	_	_	_	_	_	_	Seg=O
65	and	_	_	_	_	_	_	_	Seg=O
66	boosted	_	_	_	_	_	_	_	Seg=O
67	with	_	_	_	_	_	_	_	Seg=O
68	GP5-Mosaic	_	_	_	_	_	_	_	Seg=O
69	DNA	_	_	_	_	_	_	_	Seg=O
70	vaccine	_	_	_	_	_	_	_	Seg=O
71	and	_	_	_	_	_	_	_	Seg=O
72	recombinant	_	_	_	_	_	_	_	Seg=O
73	GP5-Mosaic	_	_	_	_	_	_	_	Seg=O
74	VACV	_	_	_	_	_	_	_	Seg=O
75	(	_	_	_	_	_	_	_	Seg=O
76	rGP5-Mosaic	_	_	_	_	_	_	_	Seg=O
77	VACV	_	_	_	_	_	_	_	Seg=O
78	)	_	_	_	_	_	_	_	Seg=O
79	,	_	_	_	_	_	_	_	Seg=O
80	respectively	_	_	_	_	_	_	_	Seg=O
81	.	_	_	_	_	_	_	_	Seg=O
82	Pigs	_	_	_	_	_	_	_	Seg=B-seg
83	vaccinated	_	_	_	_	_	_	_	Seg=B-seg
84	with	_	_	_	_	_	_	_	Seg=O
85	rGP5-WT	_	_	_	_	_	_	_	Seg=O
86	(	_	_	_	_	_	_	_	Seg=O
87	VR2332	_	_	_	_	_	_	_	Seg=O
88	)	_	_	_	_	_	_	_	Seg=O
89	DNA	_	_	_	_	_	_	_	Seg=O
90	and	_	_	_	_	_	_	_	Seg=O
91	rGP5-WT	_	_	_	_	_	_	_	Seg=O
92	VACV	_	_	_	_	_	_	_	Seg=O
93	,	_	_	_	_	_	_	_	Seg=O
94	or	_	_	_	_	_	_	_	Seg=O
95	empty	_	_	_	_	_	_	_	Seg=O
96	vector	_	_	_	_	_	_	_	Seg=O
97	DNA	_	_	_	_	_	_	_	Seg=O
98	and	_	_	_	_	_	_	_	Seg=O
99	empty	_	_	_	_	_	_	_	Seg=O
100	VACV	_	_	_	_	_	_	_	Seg=O
101	respectively	_	_	_	_	_	_	_	Seg=O
102	,	_	_	_	_	_	_	_	Seg=O
103	served	_	_	_	_	_	_	_	Seg=B-seg
104	as	_	_	_	_	_	_	_	Seg=O
105	controls	_	_	_	_	_	_	_	Seg=O
106	.	_	_	_	_	_	_	_	Seg=O
107	Virus	_	_	_	_	_	_	_	Seg=B-seg
108	challenge	_	_	_	_	_	_	_	Seg=O
109	was	_	_	_	_	_	_	_	Seg=O
110	given	_	_	_	_	_	_	_	Seg=O
111	to	_	_	_	_	_	_	_	Seg=O
112	separate	_	_	_	_	_	_	_	Seg=O
113	groups	_	_	_	_	_	_	_	Seg=O
114	of	_	_	_	_	_	_	_	Seg=O
115	vaccinated	_	_	_	_	_	_	_	Seg=O
116	pigs	_	_	_	_	_	_	_	Seg=O
117	with	_	_	_	_	_	_	_	Seg=O
118	VR2332	_	_	_	_	_	_	_	Seg=O
119	or	_	_	_	_	_	_	_	Seg=O
120	MN184C.	_	_	_	_	_	_	_	Seg=O
121	Necropsies	_	_	_	_	_	_	_	Seg=B-seg
122	were	_	_	_	_	_	_	_	Seg=O
123	performed	_	_	_	_	_	_	_	Seg=O
124	14	_	_	_	_	_	_	_	Seg=O
125	days	_	_	_	_	_	_	_	Seg=O
126	after	_	_	_	_	_	_	_	Seg=O
127	challenge	_	_	_	_	_	_	_	Seg=O
128	.	_	_	_	_	_	_	_	Seg=O
129	Results	_	_	_	_	_	_	_	Seg=B-seg
130	:	_	_	_	_	_	_	_	Seg=O
131	Vaccination	_	_	_	_	_	_	_	Seg=B-seg
132	with	_	_	_	_	_	_	_	Seg=O
133	the	_	_	_	_	_	_	_	Seg=O
134	GP5-Mosaic	_	_	_	_	_	_	_	Seg=O
135	-	_	_	_	_	_	_	_	Seg=O
136	based	_	_	_	_	_	_	_	Seg=O
137	vaccines	_	_	_	_	_	_	_	Seg=O
138	resulted	_	_	_	_	_	_	_	Seg=O
139	in	_	_	_	_	_	_	_	Seg=O
140	cellular	_	_	_	_	_	_	_	Seg=O
141	reactivity	_	_	_	_	_	_	_	Seg=O
142	and	_	_	_	_	_	_	_	Seg=O
143	higher	_	_	_	_	_	_	_	Seg=O
144	levels	_	_	_	_	_	_	_	Seg=O
145	of	_	_	_	_	_	_	_	Seg=O
146	neutralizing	_	_	_	_	_	_	_	Seg=O
147	antibodies	_	_	_	_	_	_	_	Seg=O
148	to	_	_	_	_	_	_	_	Seg=O
149	both	_	_	_	_	_	_	_	Seg=O
150	VR2332	_	_	_	_	_	_	_	Seg=O
151	and	_	_	_	_	_	_	_	Seg=O
152	MN184C	_	_	_	_	_	_	_	Seg=O
153	PRRSV	_	_	_	_	_	_	_	Seg=O
154	strains	_	_	_	_	_	_	_	Seg=O
155	.	_	_	_	_	_	_	_	Seg=O
156	In	_	_	_	_	_	_	_	Seg=B-seg
157	contrast	_	_	_	_	_	_	_	Seg=O
158	,	_	_	_	_	_	_	_	Seg=O
159	vaccination	_	_	_	_	_	_	_	Seg=O
160	of	_	_	_	_	_	_	_	Seg=O
161	animals	_	_	_	_	_	_	_	Seg=O
162	with	_	_	_	_	_	_	_	Seg=O
163	the	_	_	_	_	_	_	_	Seg=O
164	GP5-WT	_	_	_	_	_	_	_	Seg=O
165	vaccines	_	_	_	_	_	_	_	Seg=O
166	induced	_	_	_	_	_	_	_	Seg=O
167	responses	_	_	_	_	_	_	_	Seg=O
168	only	_	_	_	_	_	_	_	Seg=O
169	to	_	_	_	_	_	_	_	Seg=O
170	VR2332	_	_	_	_	_	_	_	Seg=O
171	.	_	_	_	_	_	_	_	Seg=O
172	Furthermore	_	_	_	_	_	_	_	Seg=B-seg
173	,	_	_	_	_	_	_	_	Seg=O
174	vaccination	_	_	_	_	_	_	_	Seg=O
175	with	_	_	_	_	_	_	_	Seg=O
176	the	_	_	_	_	_	_	_	Seg=O
177	GP5-Mosaic	_	_	_	_	_	_	_	Seg=O
178	based	_	_	_	_	_	_	_	Seg=O
179	vaccines	_	_	_	_	_	_	_	Seg=O
180	resulted	_	_	_	_	_	_	_	Seg=O
181	in	_	_	_	_	_	_	_	Seg=O
182	protection	_	_	_	_	_	_	_	Seg=O
183	against	_	_	_	_	_	_	_	Seg=O
184	challenge	_	_	_	_	_	_	_	Seg=O
185	with	_	_	_	_	_	_	_	Seg=O
186	two	_	_	_	_	_	_	_	Seg=O
187	heterologous	_	_	_	_	_	_	_	Seg=O
188	virus	_	_	_	_	_	_	_	Seg=O
189	strains	_	_	_	_	_	_	_	Seg=O
190	,	_	_	_	_	_	_	_	Seg=O
191	as	_	_	_	_	_	_	_	Seg=B-seg
192	demonstrated	_	_	_	_	_	_	_	Seg=O
193	by	_	_	_	_	_	_	_	Seg=O
194	the	_	_	_	_	_	_	_	Seg=O
195	significantly	_	_	_	_	_	_	_	Seg=O
196	lower	_	_	_	_	_	_	_	Seg=O
197	viral	_	_	_	_	_	_	_	Seg=O
198	loads	_	_	_	_	_	_	_	Seg=O
199	in	_	_	_	_	_	_	_	Seg=O
200	serum	_	_	_	_	_	_	_	Seg=O
201	,	_	_	_	_	_	_	_	Seg=O
202	tissues	_	_	_	_	_	_	_	Seg=O
203	,	_	_	_	_	_	_	_	Seg=O
204	porcine	_	_	_	_	_	_	_	Seg=O
205	alveolar	_	_	_	_	_	_	_	Seg=O
206	macrophages	_	_	_	_	_	_	_	Seg=O
207	(	_	_	_	_	_	_	_	Seg=O
208	PAMs	_	_	_	_	_	_	_	Seg=O
209	)	_	_	_	_	_	_	_	Seg=O
210	,	_	_	_	_	_	_	_	Seg=O
211	and	_	_	_	_	_	_	_	Seg=O
212	bronchoalveolar	_	_	_	_	_	_	_	Seg=O
213	lavage	_	_	_	_	_	_	_	Seg=O
214	(	_	_	_	_	_	_	_	Seg=O
215	BAL	_	_	_	_	_	_	_	Seg=O
216	)	_	_	_	_	_	_	_	Seg=O
217	fluids	_	_	_	_	_	_	_	Seg=O
218	,	_	_	_	_	_	_	_	Seg=O
219	and	_	_	_	_	_	_	_	Seg=O
220	less	_	_	_	_	_	_	_	Seg=O
221	severe	_	_	_	_	_	_	_	Seg=O
222	lung	_	_	_	_	_	_	_	Seg=O
223	lesions	_	_	_	_	_	_	_	Seg=O
224	after	_	_	_	_	_	_	_	Seg=O
225	challenge	_	_	_	_	_	_	_	Seg=O
226	with	_	_	_	_	_	_	_	Seg=O
227	either	_	_	_	_	_	_	_	Seg=O
228	MN184C	_	_	_	_	_	_	_	Seg=O
229	or	_	_	_	_	_	_	_	Seg=O
230	VR2332	_	_	_	_	_	_	_	Seg=O
231	,	_	_	_	_	_	_	_	Seg=O
232	which	_	_	_	_	_	_	_	Seg=B-seg
233	have	_	_	_	_	_	_	_	Seg=O
234	only	_	_	_	_	_	_	_	Seg=O
235	85	_	_	_	_	_	_	_	Seg=O
236	%	_	_	_	_	_	_	_	Seg=O
237	identity	_	_	_	_	_	_	_	Seg=O
238	.	_	_	_	_	_	_	_	Seg=O
239	In	_	_	_	_	_	_	_	Seg=B-seg
240	contrast	_	_	_	_	_	_	_	Seg=O
241	,	_	_	_	_	_	_	_	Seg=O
242	significant	_	_	_	_	_	_	_	Seg=O
243	protection	_	_	_	_	_	_	_	Seg=O
244	by	_	_	_	_	_	_	_	Seg=O
245	the	_	_	_	_	_	_	_	Seg=O
246	GP5-WT	_	_	_	_	_	_	_	Seg=O
247	based	_	_	_	_	_	_	_	Seg=O
248	vaccines	_	_	_	_	_	_	_	Seg=O
249	was	_	_	_	_	_	_	_	Seg=O
250	only	_	_	_	_	_	_	_	Seg=O
251	achieved	_	_	_	_	_	_	_	Seg=O
252	against	_	_	_	_	_	_	_	Seg=O
253	the	_	_	_	_	_	_	_	Seg=O
254	VR2332	_	_	_	_	_	_	_	Seg=O
255	strain	_	_	_	_	_	_	_	Seg=O
256	.	_	_	_	_	_	_	_	Seg=O
257	Conclusions	_	_	_	_	_	_	_	Seg=B-seg
258	:	_	_	_	_	_	_	_	Seg=O
259	GP5-Mosaic	_	_	_	_	_	_	_	Seg=B-seg
260	vaccines	_	_	_	_	_	_	_	Seg=O
261	,	_	_	_	_	_	_	_	Seg=O
262	using	_	_	_	_	_	_	_	Seg=B-seg
263	a	_	_	_	_	_	_	_	Seg=O
264	DNA	_	_	_	_	_	_	_	Seg=O
265	-	_	_	_	_	_	_	_	Seg=O
266	prime	_	_	_	_	_	_	_	Seg=O
267	/	_	_	_	_	_	_	_	Seg=O
268	VACV	_	_	_	_	_	_	_	Seg=O
269	boost	_	_	_	_	_	_	_	Seg=O
270	regimen	_	_	_	_	_	_	_	Seg=O
271	,	_	_	_	_	_	_	_	Seg=O
272	conferred	_	_	_	_	_	_	_	Seg=B-seg
273	protection	_	_	_	_	_	_	_	Seg=O
274	in	_	_	_	_	_	_	_	Seg=O
275	pigs	_	_	_	_	_	_	_	Seg=O
276	against	_	_	_	_	_	_	_	Seg=O
277	heterologous	_	_	_	_	_	_	_	Seg=O
278	viruses	_	_	_	_	_	_	_	Seg=O
279	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 202409fc9fbc3fdc1a7dd3ef3e690880287c117c
1	Localization	_	_	_	_	_	_	_	Seg=B-seg
2	of	_	_	_	_	_	_	_	Seg=O
3	neutralizing	_	_	_	_	_	_	_	Seg=O
4	,	_	_	_	_	_	_	_	Seg=O
5	serotype	_	_	_	_	_	_	_	Seg=O
6	specific	_	_	_	_	_	_	_	Seg=O
7	epitopes	_	_	_	_	_	_	_	Seg=O
8	of	_	_	_	_	_	_	_	Seg=O
9	infectious	_	_	_	_	_	_	_	Seg=O
10	bronchitis	_	_	_	_	_	_	_	Seg=O
11	virus	_	_	_	_	_	_	_	Seg=O
12	has	_	_	_	_	_	_	_	Seg=O
13	been	_	_	_	_	_	_	_	Seg=O
14	difficult	_	_	_	_	_	_	_	Seg=O
15	because	_	_	_	_	_	_	_	Seg=B-seg
16	these	_	_	_	_	_	_	_	Seg=O
17	epitopes	_	_	_	_	_	_	_	Seg=O
18	are	_	_	_	_	_	_	_	Seg=O
19	conformationally	_	_	_	_	_	_	_	Seg=O
20	dependent	_	_	_	_	_	_	_	Seg=O
21	.	_	_	_	_	_	_	_	Seg=O
22	We	_	_	_	_	_	_	_	Seg=B-seg
23	identified	_	_	_	_	_	_	_	Seg=O
24	amino	_	_	_	_	_	_	_	Seg=O
25	acids	_	_	_	_	_	_	_	Seg=O
26	involved	_	_	_	_	_	_	_	Seg=B-seg
27	in	_	_	_	_	_	_	_	Seg=O
28	a	_	_	_	_	_	_	_	Seg=O
29	serotype	_	_	_	_	_	_	_	Seg=O
30	specific	_	_	_	_	_	_	_	Seg=O
31	,	_	_	_	_	_	_	_	Seg=O
32	conformationally	_	_	_	_	_	_	_	Seg=O
33	dependent	_	_	_	_	_	_	_	Seg=O
34	epitope	_	_	_	_	_	_	_	Seg=O
35	by	_	_	_	_	_	_	_	Seg=B-seg
36	analysis	_	_	_	_	_	_	_	Seg=O
37	of	_	_	_	_	_	_	_	Seg=O
38	the	_	_	_	_	_	_	_	Seg=O
39	S1	_	_	_	_	_	_	_	Seg=O
40	gene	_	_	_	_	_	_	_	Seg=O
41	of	_	_	_	_	_	_	_	Seg=O
42	13	_	_	_	_	_	_	_	Seg=O
43	monoclonal	_	_	_	_	_	_	_	Seg=O
44	antibody	_	_	_	_	_	_	_	Seg=O
45	-	_	_	_	_	_	_	_	Seg=O
46	neutralization	_	_	_	_	_	_	_	Seg=O
47	-	_	_	_	_	_	_	_	Seg=O
48	resistant	_	_	_	_	_	_	_	Seg=O
49	mutants	_	_	_	_	_	_	_	Seg=O
50	.	_	_	_	_	_	_	_	Seg=O
51	Substitutions	_	_	_	_	_	_	_	Seg=B-seg
52	in	_	_	_	_	_	_	_	Seg=O
53	the	_	_	_	_	_	_	_	Seg=O
54	predicted	_	_	_	_	_	_	_	Seg=O
55	amino	_	_	_	_	_	_	_	Seg=O
56	acid	_	_	_	_	_	_	_	Seg=O
57	sequence	_	_	_	_	_	_	_	Seg=O
58	of	_	_	_	_	_	_	_	Seg=O
59	these	_	_	_	_	_	_	_	Seg=O
60	mutants	_	_	_	_	_	_	_	Seg=O
61	were	_	_	_	_	_	_	_	Seg=O
62	located	_	_	_	_	_	_	_	Seg=O
63	at	_	_	_	_	_	_	_	Seg=O
64	residues	_	_	_	_	_	_	_	Seg=O
65	304	_	_	_	_	_	_	_	Seg=O
66	and/or	_	_	_	_	_	_	_	Seg=O
67	386	_	_	_	_	_	_	_	Seg=O
68	.	_	_	_	_	_	_	_	Seg=O
69	Most	_	_	_	_	_	_	_	Seg=B-seg
70	of	_	_	_	_	_	_	_	Seg=O
71	the	_	_	_	_	_	_	_	Seg=O
72	substitutions	_	_	_	_	_	_	_	Seg=O
73	at	_	_	_	_	_	_	_	Seg=O
74	residue	_	_	_	_	_	_	_	Seg=O
75	304	_	_	_	_	_	_	_	Seg=O
76	were	_	_	_	_	_	_	_	Seg=O
77	from	_	_	_	_	_	_	_	Seg=O
78	threonine	_	_	_	_	_	_	_	Seg=O
79	to	_	_	_	_	_	_	_	Seg=O
80	isoleucine	_	_	_	_	_	_	_	Seg=O
81	,	_	_	_	_	_	_	_	Seg=O
82	whereas	_	_	_	_	_	_	_	Seg=B-seg
83	the	_	_	_	_	_	_	_	Seg=O
84	substitutions	_	_	_	_	_	_	_	Seg=O
85	at	_	_	_	_	_	_	_	Seg=O
86	residue	_	_	_	_	_	_	_	Seg=O
87	386	_	_	_	_	_	_	_	Seg=O
88	were	_	_	_	_	_	_	_	Seg=O
89	from	_	_	_	_	_	_	_	Seg=O
90	arginine	_	_	_	_	_	_	_	Seg=O
91	to	_	_	_	_	_	_	_	Seg=O
92	proline	_	_	_	_	_	_	_	Seg=O
93	,	_	_	_	_	_	_	_	Seg=O
94	histidine	_	_	_	_	_	_	_	Seg=O
95	,	_	_	_	_	_	_	_	Seg=O
96	cysteine	_	_	_	_	_	_	_	Seg=O
97	,	_	_	_	_	_	_	_	Seg=O
98	or	_	_	_	_	_	_	_	Seg=O
99	tryptophan	_	_	_	_	_	_	_	Seg=O
100	.	_	_	_	_	_	_	_	Seg=O
101	Based	_	_	_	_	_	_	_	Seg=B-seg
102	on	_	_	_	_	_	_	_	Seg=O
103	this	_	_	_	_	_	_	_	Seg=O
104	data	_	_	_	_	_	_	_	Seg=O
105	,	_	_	_	_	_	_	_	Seg=O
106	it	_	_	_	_	_	_	_	Seg=B-seg
107	appears	_	_	_	_	_	_	_	Seg=O
108	that	_	_	_	_	_	_	_	Seg=O
109	AA	_	_	_	_	_	_	_	Seg=O
110	residues	_	_	_	_	_	_	_	Seg=O
111	at	_	_	_	_	_	_	_	Seg=O
112	304	_	_	_	_	_	_	_	Seg=O
113	and	_	_	_	_	_	_	_	Seg=O
114	386	_	_	_	_	_	_	_	Seg=O
115	on	_	_	_	_	_	_	_	Seg=O
116	the	_	_	_	_	_	_	_	Seg=O
117	S1	_	_	_	_	_	_	_	Seg=O
118	glycoprotein	_	_	_	_	_	_	_	Seg=O
119	are	_	_	_	_	_	_	_	Seg=O
120	involved	_	_	_	_	_	_	_	Seg=O
121	in	_	_	_	_	_	_	_	Seg=O
122	a	_	_	_	_	_	_	_	Seg=O
123	virus	_	_	_	_	_	_	_	Seg=O
124	neutralizing	_	_	_	_	_	_	_	Seg=O
125	serotype	_	_	_	_	_	_	_	Seg=O
126	specific	_	_	_	_	_	_	_	Seg=O
127	epitope	_	_	_	_	_	_	_	Seg=O
128	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 24c534c1f480d949f6ceeab0a60c1d7958ee34af
1	Topic	_	_	_	_	_	_	_	Seg=B-seg
2	modeling	_	_	_	_	_	_	_	Seg=O
3	is	_	_	_	_	_	_	_	Seg=O
4	frequently	_	_	_	_	_	_	_	Seg=O
5	employed	_	_	_	_	_	_	_	Seg=O
6	for	_	_	_	_	_	_	_	Seg=B-seg
7	discovering	_	_	_	_	_	_	_	Seg=O
8	structures	_	_	_	_	_	_	_	Seg=O
9	(	_	_	_	_	_	_	_	Seg=O
10	or	_	_	_	_	_	_	_	Seg=O
11	patterns	_	_	_	_	_	_	_	Seg=O
12	)	_	_	_	_	_	_	_	Seg=O
13	in	_	_	_	_	_	_	_	Seg=O
14	a	_	_	_	_	_	_	_	Seg=O
15	corpus	_	_	_	_	_	_	_	Seg=O
16	of	_	_	_	_	_	_	_	Seg=O
17	documents	_	_	_	_	_	_	_	Seg=O
18	.	_	_	_	_	_	_	_	Seg=O
19	Its	_	_	_	_	_	_	_	Seg=B-seg
20	utility	_	_	_	_	_	_	_	Seg=O
21	in	_	_	_	_	_	_	_	Seg=O
22	text	_	_	_	_	_	_	_	Seg=O
23	-	_	_	_	_	_	_	_	Seg=O
24	mining	_	_	_	_	_	_	_	Seg=O
25	and	_	_	_	_	_	_	_	Seg=O
26	document	_	_	_	_	_	_	_	Seg=O
27	retrieval	_	_	_	_	_	_	_	Seg=O
28	tasks	_	_	_	_	_	_	_	Seg=O
29	in	_	_	_	_	_	_	_	Seg=O
30	various	_	_	_	_	_	_	_	Seg=O
31	fields	_	_	_	_	_	_	_	Seg=O
32	of	_	_	_	_	_	_	_	Seg=O
33	scientific	_	_	_	_	_	_	_	Seg=O
34	research	_	_	_	_	_	_	_	Seg=O
35	is	_	_	_	_	_	_	_	Seg=O
36	rather	_	_	_	_	_	_	_	Seg=O
37	well	_	_	_	_	_	_	_	Seg=O
38	known	_	_	_	_	_	_	_	Seg=O
39	.	_	_	_	_	_	_	_	Seg=O
40	An	_	_	_	_	_	_	_	Seg=B-seg
41	unsupervised	_	_	_	_	_	_	_	Seg=O
42	machine	_	_	_	_	_	_	_	Seg=O
43	learning	_	_	_	_	_	_	_	Seg=O
44	approach	_	_	_	_	_	_	_	Seg=O
45	,	_	_	_	_	_	_	_	Seg=O
46	Latent	_	_	_	_	_	_	_	Seg=O
47	Dirichlet	_	_	_	_	_	_	_	Seg=O
48	Allocation	_	_	_	_	_	_	_	Seg=O
49	(	_	_	_	_	_	_	_	Seg=O
50	LDA	_	_	_	_	_	_	_	Seg=O
51	)	_	_	_	_	_	_	_	Seg=O
52	has	_	_	_	_	_	_	_	Seg=O
53	particularly	_	_	_	_	_	_	_	Seg=O
54	been	_	_	_	_	_	_	_	Seg=O
55	utilized	_	_	_	_	_	_	_	Seg=O
56	for	_	_	_	_	_	_	_	Seg=B-seg
57	identifying	_	_	_	_	_	_	_	Seg=O
58	latent	_	_	_	_	_	_	_	Seg=O
59	(	_	_	_	_	_	_	_	Seg=O
60	or	_	_	_	_	_	_	_	Seg=O
61	hidden	_	_	_	_	_	_	_	Seg=O
62	)	_	_	_	_	_	_	_	Seg=O
63	topics	_	_	_	_	_	_	_	Seg=O
64	in	_	_	_	_	_	_	_	Seg=O
65	document	_	_	_	_	_	_	_	Seg=O
66	collections	_	_	_	_	_	_	_	Seg=O
67	and	_	_	_	_	_	_	_	Seg=B-seg
68	for	_	_	_	_	_	_	_	Seg=O
69	deciphering	_	_	_	_	_	_	_	Seg=O
70	the	_	_	_	_	_	_	_	Seg=O
71	words	_	_	_	_	_	_	_	Seg=O
72	that	_	_	_	_	_	_	_	Seg=B-seg
73	define	_	_	_	_	_	_	_	Seg=O
74	one	_	_	_	_	_	_	_	Seg=O
75	or	_	_	_	_	_	_	_	Seg=O
76	more	_	_	_	_	_	_	_	Seg=O
77	topics	_	_	_	_	_	_	_	Seg=O
78	using	_	_	_	_	_	_	_	Seg=B-seg
79	a	_	_	_	_	_	_	_	Seg=O
80	generative	_	_	_	_	_	_	_	Seg=O
81	statistical	_	_	_	_	_	_	_	Seg=O
82	model	_	_	_	_	_	_	_	Seg=O
83	.	_	_	_	_	_	_	_	Seg=O
84	Here	_	_	_	_	_	_	_	Seg=B-seg
85	we	_	_	_	_	_	_	_	Seg=O
86	describe	_	_	_	_	_	_	_	Seg=O
87	how	_	_	_	_	_	_	_	Seg=B-seg
88	SARS	_	_	_	_	_	_	_	Seg=O
89	-	_	_	_	_	_	_	_	Seg=O
90	CoV-2	_	_	_	_	_	_	_	Seg=O
91	genomic	_	_	_	_	_	_	_	Seg=O
92	mutation	_	_	_	_	_	_	_	Seg=O
93	profiles	_	_	_	_	_	_	_	Seg=O
94	can	_	_	_	_	_	_	_	Seg=O
95	be	_	_	_	_	_	_	_	Seg=O
96	structured	_	_	_	_	_	_	_	Seg=O
97	into	_	_	_	_	_	_	_	Seg=O
98	a	_	_	_	_	_	_	_	Seg=O
99	'	_	_	_	_	_	_	_	Seg=O
100	Bag	_	_	_	_	_	_	_	Seg=O
101	of	_	_	_	_	_	_	_	Seg=O
102	Words	_	_	_	_	_	_	_	Seg=O
103	'	_	_	_	_	_	_	_	Seg=O
104	to	_	_	_	_	_	_	_	Seg=B-seg
105	enable	_	_	_	_	_	_	_	Seg=O
106	identification	_	_	_	_	_	_	_	Seg=O
107	of	_	_	_	_	_	_	_	Seg=O
108	signatures	_	_	_	_	_	_	_	Seg=O
109	(	_	_	_	_	_	_	_	Seg=O
110	topics	_	_	_	_	_	_	_	Seg=O
111	)	_	_	_	_	_	_	_	Seg=O
112	and	_	_	_	_	_	_	_	Seg=O
113	their	_	_	_	_	_	_	_	Seg=O
114	probabilistic	_	_	_	_	_	_	_	Seg=O
115	distribution	_	_	_	_	_	_	_	Seg=O
116	across	_	_	_	_	_	_	_	Seg=O
117	various	_	_	_	_	_	_	_	Seg=O
118	genomes	_	_	_	_	_	_	_	Seg=O
119	using	_	_	_	_	_	_	_	Seg=B-seg
120	LDA	_	_	_	_	_	_	_	Seg=O
121	.	_	_	_	_	_	_	_	Seg=O
122	Topic	_	_	_	_	_	_	_	Seg=B-seg
123	models	_	_	_	_	_	_	_	Seg=O
124	were	_	_	_	_	_	_	_	Seg=O
125	generated	_	_	_	_	_	_	_	Seg=O
126	using	_	_	_	_	_	_	_	Seg=B-seg
127	~47000	_	_	_	_	_	_	_	Seg=O
128	novel	_	_	_	_	_	_	_	Seg=O
129	corona	_	_	_	_	_	_	_	Seg=O
130	virus	_	_	_	_	_	_	_	Seg=O
131	genomes	_	_	_	_	_	_	_	Seg=O
132	(	_	_	_	_	_	_	_	Seg=B-seg
133	considered	_	_	_	_	_	_	_	Seg=O
134	as	_	_	_	_	_	_	_	Seg=O
135	documents	_	_	_	_	_	_	_	Seg=O
136	)	_	_	_	_	_	_	_	Seg=O
137	,	_	_	_	_	_	_	_	Seg=O
138	leading	_	_	_	_	_	_	_	Seg=B-seg
139	to	_	_	_	_	_	_	_	Seg=O
140	identification	_	_	_	_	_	_	_	Seg=O
141	of	_	_	_	_	_	_	_	Seg=O
142	16	_	_	_	_	_	_	_	Seg=O
143	amino	_	_	_	_	_	_	_	Seg=O
144	acid	_	_	_	_	_	_	_	Seg=O
145	mutation	_	_	_	_	_	_	_	Seg=O
146	signatures	_	_	_	_	_	_	_	Seg=O
147	and	_	_	_	_	_	_	_	Seg=O
148	18	_	_	_	_	_	_	_	Seg=O
149	nucleotide	_	_	_	_	_	_	_	Seg=O
150	mutation	_	_	_	_	_	_	_	Seg=O
151	signatures	_	_	_	_	_	_	_	Seg=O
152	(	_	_	_	_	_	_	_	Seg=B-seg
153	equivalent	_	_	_	_	_	_	_	Seg=O
154	to	_	_	_	_	_	_	_	Seg=O
155	topics	_	_	_	_	_	_	_	Seg=O
156	)	_	_	_	_	_	_	_	Seg=O
157	in	_	_	_	_	_	_	_	Seg=B-seg
158	the	_	_	_	_	_	_	_	Seg=O
159	corpus	_	_	_	_	_	_	_	Seg=O
160	of	_	_	_	_	_	_	_	Seg=O
161	chosen	_	_	_	_	_	_	_	Seg=O
162	genomes	_	_	_	_	_	_	_	Seg=O
163	through	_	_	_	_	_	_	_	Seg=O
164	coherence	_	_	_	_	_	_	_	Seg=O
165	optimization	_	_	_	_	_	_	_	Seg=O
166	.	_	_	_	_	_	_	_	Seg=O
167	The	_	_	_	_	_	_	_	Seg=B-seg
168	document	_	_	_	_	_	_	_	Seg=O
169	assumption	_	_	_	_	_	_	_	Seg=O
170	for	_	_	_	_	_	_	_	Seg=O
171	genomes	_	_	_	_	_	_	_	Seg=O
172	also	_	_	_	_	_	_	_	Seg=O
173	helped	_	_	_	_	_	_	_	Seg=O
174	in	_	_	_	_	_	_	_	Seg=O
175	identification	_	_	_	_	_	_	_	Seg=O
176	of	_	_	_	_	_	_	_	Seg=O
177	contextual	_	_	_	_	_	_	_	Seg=O
178	nucleotide	_	_	_	_	_	_	_	Seg=O
179	mutation	_	_	_	_	_	_	_	Seg=O
180	signatures	_	_	_	_	_	_	_	Seg=O
181	in	_	_	_	_	_	_	_	Seg=O
182	the	_	_	_	_	_	_	_	Seg=O
183	form	_	_	_	_	_	_	_	Seg=O
184	of	_	_	_	_	_	_	_	Seg=O
185	conventional	_	_	_	_	_	_	_	Seg=O
186	Ngrams	_	_	_	_	_	_	_	Seg=O
187	(	_	_	_	_	_	_	_	Seg=B-seg
188	e.g.	_	_	_	_	_	_	_	Seg=O
189	bi	_	_	_	_	_	_	_	Seg=O
190	-	_	_	_	_	_	_	_	Seg=O
191	grams	_	_	_	_	_	_	_	Seg=O
192	and	_	_	_	_	_	_	_	Seg=O
193	tri	_	_	_	_	_	_	_	Seg=O
194	-	_	_	_	_	_	_	_	Seg=O
195	grams	_	_	_	_	_	_	_	Seg=O
196	)	_	_	_	_	_	_	_	Seg=O
197	.	_	_	_	_	_	_	_	Seg=O
198	We	_	_	_	_	_	_	_	Seg=B-seg
199	validated	_	_	_	_	_	_	_	Seg=O
200	the	_	_	_	_	_	_	_	Seg=O
201	signatures	_	_	_	_	_	_	_	Seg=O
202	obtained	_	_	_	_	_	_	_	Seg=B-seg
203	using	_	_	_	_	_	_	_	Seg=B-seg
204	LDA	_	_	_	_	_	_	_	Seg=O
205	driven	_	_	_	_	_	_	_	Seg=O
206	method	_	_	_	_	_	_	_	Seg=O
207	against	_	_	_	_	_	_	_	Seg=B-seg
208	the	_	_	_	_	_	_	_	Seg=O
209	previously	_	_	_	_	_	_	_	Seg=O
210	reported	_	_	_	_	_	_	_	Seg=O
211	recurrent	_	_	_	_	_	_	_	Seg=O
212	mutations	_	_	_	_	_	_	_	Seg=O
213	and	_	_	_	_	_	_	_	Seg=O
214	phylogenetic	_	_	_	_	_	_	_	Seg=O
215	clades	_	_	_	_	_	_	_	Seg=O
216	for	_	_	_	_	_	_	_	Seg=O
217	genomes	_	_	_	_	_	_	_	Seg=O
218	.	_	_	_	_	_	_	_	Seg=O
219	Additionally	_	_	_	_	_	_	_	Seg=B-seg
220	,	_	_	_	_	_	_	_	Seg=O
221	we	_	_	_	_	_	_	_	Seg=O
222	report	_	_	_	_	_	_	_	Seg=O
223	the	_	_	_	_	_	_	_	Seg=O
224	geographical	_	_	_	_	_	_	_	Seg=O
225	distribution	_	_	_	_	_	_	_	Seg=O
226	of	_	_	_	_	_	_	_	Seg=O
227	the	_	_	_	_	_	_	_	Seg=O
228	identified	_	_	_	_	_	_	_	Seg=O
229	mutation	_	_	_	_	_	_	_	Seg=O
230	signatures	_	_	_	_	_	_	_	Seg=O
231	in	_	_	_	_	_	_	_	Seg=O
232	SARS	_	_	_	_	_	_	_	Seg=O
233	-	_	_	_	_	_	_	_	Seg=O
234	CoV-2	_	_	_	_	_	_	_	Seg=O
235	genomes	_	_	_	_	_	_	_	Seg=O
236	on	_	_	_	_	_	_	_	Seg=O
237	the	_	_	_	_	_	_	_	Seg=O
238	global	_	_	_	_	_	_	_	Seg=O
239	map	_	_	_	_	_	_	_	Seg=O
240	.	_	_	_	_	_	_	_	Seg=O
241	Use	_	_	_	_	_	_	_	Seg=B-seg
242	of	_	_	_	_	_	_	_	Seg=O
243	the	_	_	_	_	_	_	_	Seg=O
244	non	_	_	_	_	_	_	_	Seg=O
245	-	_	_	_	_	_	_	_	Seg=O
246	phylogenetic	_	_	_	_	_	_	_	Seg=O
247	albeit	_	_	_	_	_	_	_	Seg=O
248	classical	_	_	_	_	_	_	_	Seg=O
249	approaches	_	_	_	_	_	_	_	Seg=O
250	like	_	_	_	_	_	_	_	Seg=O
251	topic	_	_	_	_	_	_	_	Seg=O
252	modeling	_	_	_	_	_	_	_	Seg=O
253	and	_	_	_	_	_	_	_	Seg=O
254	other	_	_	_	_	_	_	_	Seg=O
255	data	_	_	_	_	_	_	_	Seg=O
256	centric	_	_	_	_	_	_	_	Seg=O
257	pattern	_	_	_	_	_	_	_	Seg=O
258	mining	_	_	_	_	_	_	_	Seg=O
259	algorithms	_	_	_	_	_	_	_	Seg=O
260	is	_	_	_	_	_	_	_	Seg=O
261	therefore	_	_	_	_	_	_	_	Seg=O
262	proposed	_	_	_	_	_	_	_	Seg=O
263	for	_	_	_	_	_	_	_	Seg=O
264	supplementing	_	_	_	_	_	_	_	Seg=O
265	the	_	_	_	_	_	_	_	Seg=O
266	efforts	_	_	_	_	_	_	_	Seg=O
267	towards	_	_	_	_	_	_	_	Seg=B-seg
268	understanding	_	_	_	_	_	_	_	Seg=O
269	the	_	_	_	_	_	_	_	Seg=O
270	genomic	_	_	_	_	_	_	_	Seg=O
271	diversity	_	_	_	_	_	_	_	Seg=O
272	of	_	_	_	_	_	_	_	Seg=O
273	the	_	_	_	_	_	_	_	Seg=O
274	evolving	_	_	_	_	_	_	_	Seg=O
275	SARS	_	_	_	_	_	_	_	Seg=O
276	-	_	_	_	_	_	_	_	Seg=O
277	CoV-2	_	_	_	_	_	_	_	Seg=O
278	genomes	_	_	_	_	_	_	_	Seg=O
279	(	_	_	_	_	_	_	_	Seg=O
280	and	_	_	_	_	_	_	_	Seg=O
281	other	_	_	_	_	_	_	_	Seg=O
282	pathogens	_	_	_	_	_	_	_	Seg=O
283	/	_	_	_	_	_	_	_	Seg=O
284	microbes	_	_	_	_	_	_	_	Seg=O
285	)	_	_	_	_	_	_	_	Seg=O
286	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 26634be503e7252551c4829fa563245b729bf213
1	The	_	_	_	_	_	_	_	Seg=B-seg
2	present	_	_	_	_	_	_	_	Seg=O
3	study	_	_	_	_	_	_	_	Seg=O
4	is	_	_	_	_	_	_	_	Seg=O
5	intended	_	_	_	_	_	_	_	Seg=O
6	to	_	_	_	_	_	_	_	Seg=O
7	analyze	_	_	_	_	_	_	_	Seg=O
8	the	_	_	_	_	_	_	_	Seg=O
9	effect	_	_	_	_	_	_	_	Seg=O
10	of	_	_	_	_	_	_	_	Seg=O
11	global	_	_	_	_	_	_	_	Seg=O
12	quality	_	_	_	_	_	_	_	Seg=O
13	,	_	_	_	_	_	_	_	Seg=O
14	perceived	_	_	_	_	_	_	_	Seg=O
15	value	_	_	_	_	_	_	_	Seg=O
16	,	_	_	_	_	_	_	_	Seg=O
17	general	_	_	_	_	_	_	_	Seg=O
18	satisfaction	_	_	_	_	_	_	_	Seg=O
19	,	_	_	_	_	_	_	_	Seg=O
20	and	_	_	_	_	_	_	_	Seg=O
21	emotions	_	_	_	_	_	_	_	Seg=O
22	on	_	_	_	_	_	_	_	Seg=O
23	future	_	_	_	_	_	_	_	Seg=O
24	behavior	_	_	_	_	_	_	_	Seg=O
25	patterns	_	_	_	_	_	_	_	Seg=O
26	among	_	_	_	_	_	_	_	Seg=O
27	participants	_	_	_	_	_	_	_	Seg=O
28	in	_	_	_	_	_	_	_	Seg=O
29	the	_	_	_	_	_	_	_	Seg=O
30	European	_	_	_	_	_	_	_	Seg=O
31	Duathlon	_	_	_	_	_	_	_	Seg=O
32	Championship	_	_	_	_	_	_	_	Seg=O
33	.	_	_	_	_	_	_	_	Seg=O
34	In	_	_	_	_	_	_	_	Seg=B-seg
35	this	_	_	_	_	_	_	_	Seg=O
36	sense	_	_	_	_	_	_	_	Seg=O
37	,	_	_	_	_	_	_	_	Seg=O
38	a	_	_	_	_	_	_	_	Seg=O
39	questionnaire	_	_	_	_	_	_	_	Seg=O
40	was	_	_	_	_	_	_	_	Seg=O
41	administered	_	_	_	_	_	_	_	Seg=O
42	(	_	_	_	_	_	_	_	Seg=B-seg
43	n	_	_	_	_	_	_	_	Seg=O
44	=	_	_	_	_	_	_	_	Seg=O
45	210	_	_	_	_	_	_	_	Seg=O
46	)	_	_	_	_	_	_	_	Seg=O
47	,	_	_	_	_	_	_	_	Seg=O
48	composed	_	_	_	_	_	_	_	Seg=B-seg
49	of	_	_	_	_	_	_	_	Seg=O
50	four	_	_	_	_	_	_	_	Seg=O
51	sections	_	_	_	_	_	_	_	Seg=O
52	:	_	_	_	_	_	_	_	Seg=O
53	essential	_	_	_	_	_	_	_	Seg=B-seg
54	demographic	_	_	_	_	_	_	_	Seg=O
55	and	_	_	_	_	_	_	_	Seg=O
56	profiling	_	_	_	_	_	_	_	Seg=O
57	variables	_	_	_	_	_	_	_	Seg=O
58	,	_	_	_	_	_	_	_	Seg=O
59	perceived	_	_	_	_	_	_	_	Seg=O
60	quality	_	_	_	_	_	_	_	Seg=O
61	,	_	_	_	_	_	_	_	Seg=O
62	overall	_	_	_	_	_	_	_	Seg=O
63	quality	_	_	_	_	_	_	_	Seg=O
64	,	_	_	_	_	_	_	_	Seg=O
65	and	_	_	_	_	_	_	_	Seg=O
66	emotions	_	_	_	_	_	_	_	Seg=O
67	.	_	_	_	_	_	_	_	Seg=O
68	Consequently	_	_	_	_	_	_	_	Seg=B-seg
69	,	_	_	_	_	_	_	_	Seg=O
70	a	_	_	_	_	_	_	_	Seg=O
71	relational	_	_	_	_	_	_	_	Seg=O
72	model	_	_	_	_	_	_	_	Seg=O
73	was	_	_	_	_	_	_	_	Seg=O
74	designed	_	_	_	_	_	_	_	Seg=O
75	to	_	_	_	_	_	_	_	Seg=B-seg
76	be	_	_	_	_	_	_	_	Seg=O
77	examined	_	_	_	_	_	_	_	Seg=O
78	by	_	_	_	_	_	_	_	Seg=O
79	means	_	_	_	_	_	_	_	Seg=O
80	of	_	_	_	_	_	_	_	Seg=O
81	structural	_	_	_	_	_	_	_	Seg=O
82	equation	_	_	_	_	_	_	_	Seg=O
83	modeling	_	_	_	_	_	_	_	Seg=O
84	(	_	_	_	_	_	_	_	Seg=O
85	SEM	_	_	_	_	_	_	_	Seg=O
86	)	_	_	_	_	_	_	_	Seg=O
87	and	_	_	_	_	_	_	_	Seg=O
88	fuzzy	_	_	_	_	_	_	_	Seg=O
89	set	_	_	_	_	_	_	_	Seg=O
90	qualitative	_	_	_	_	_	_	_	Seg=O
91	comparative	_	_	_	_	_	_	_	Seg=O
92	analysis	_	_	_	_	_	_	_	Seg=O
93	(	_	_	_	_	_	_	_	Seg=O
94	fsQCA	_	_	_	_	_	_	_	Seg=O
95	)	_	_	_	_	_	_	_	Seg=O
96	.	_	_	_	_	_	_	_	Seg=O
97	Results	_	_	_	_	_	_	_	Seg=B-seg
98	reveal	_	_	_	_	_	_	_	Seg=O
99	that	_	_	_	_	_	_	_	Seg=B-seg
100	global	_	_	_	_	_	_	_	Seg=O
101	quality	_	_	_	_	_	_	_	Seg=O
102	and	_	_	_	_	_	_	_	Seg=O
103	general	_	_	_	_	_	_	_	Seg=O
104	satisfaction	_	_	_	_	_	_	_	Seg=O
105	are	_	_	_	_	_	_	_	Seg=O
106	key	_	_	_	_	_	_	_	Seg=O
107	dimensions	_	_	_	_	_	_	_	Seg=O
108	for	_	_	_	_	_	_	_	Seg=B-seg
109	determining	_	_	_	_	_	_	_	Seg=O
110	future	_	_	_	_	_	_	_	Seg=O
111	behaviors	_	_	_	_	_	_	_	Seg=O
112	of	_	_	_	_	_	_	_	Seg=O
113	participants	_	_	_	_	_	_	_	Seg=O
114	,	_	_	_	_	_	_	_	Seg=O
115	but	_	_	_	_	_	_	_	Seg=B-seg
116	not	_	_	_	_	_	_	_	Seg=O
117	so	_	_	_	_	_	_	_	Seg=O
118	the	_	_	_	_	_	_	_	Seg=O
119	perceived	_	_	_	_	_	_	_	Seg=O
120	value	_	_	_	_	_	_	_	Seg=O
121	.	_	_	_	_	_	_	_	Seg=O
122	Moreover	_	_	_	_	_	_	_	Seg=B-seg
123	,	_	_	_	_	_	_	_	Seg=O
124	up	_	_	_	_	_	_	_	Seg=O
125	to	_	_	_	_	_	_	_	Seg=O
126	three	_	_	_	_	_	_	_	Seg=O
127	combinations	_	_	_	_	_	_	_	Seg=O
128	of	_	_	_	_	_	_	_	Seg=O
129	these	_	_	_	_	_	_	_	Seg=O
130	dimensions	_	_	_	_	_	_	_	Seg=O
131	together	_	_	_	_	_	_	_	Seg=O
132	with	_	_	_	_	_	_	_	Seg=O
133	emotions	_	_	_	_	_	_	_	Seg=O
134	-	_	_	_	_	_	_	_	Seg=B-seg
135	pleasure	_	_	_	_	_	_	_	Seg=O
136	and	_	_	_	_	_	_	_	Seg=O
137	arousal	_	_	_	_	_	_	_	Seg=O
138	-	_	_	_	_	_	_	_	Seg=O
139	emerged	_	_	_	_	_	_	_	Seg=B-seg
140	as	_	_	_	_	_	_	_	Seg=O
141	enough	_	_	_	_	_	_	_	Seg=O
142	for	_	_	_	_	_	_	_	Seg=O
143	depicting	_	_	_	_	_	_	_	Seg=O
144	future	_	_	_	_	_	_	_	Seg=O
145	intentions	_	_	_	_	_	_	_	Seg=O
146	to	_	_	_	_	_	_	_	Seg=O
147	a	_	_	_	_	_	_	_	Seg=O
148	great	_	_	_	_	_	_	_	Seg=O
149	extent	_	_	_	_	_	_	_	Seg=O
150	.	_	_	_	_	_	_	_	Seg=O
151	In	_	_	_	_	_	_	_	Seg=B-seg
152	this	_	_	_	_	_	_	_	Seg=O
153	line	_	_	_	_	_	_	_	Seg=O
154	,	_	_	_	_	_	_	_	Seg=O
155	a	_	_	_	_	_	_	_	Seg=O
156	remarkably	_	_	_	_	_	_	_	Seg=O
157	sufficient	_	_	_	_	_	_	_	Seg=O
158	combination	_	_	_	_	_	_	_	Seg=O
159	consists	_	_	_	_	_	_	_	Seg=O
160	of	_	_	_	_	_	_	_	Seg=O
161	global	_	_	_	_	_	_	_	Seg=O
162	quality	_	_	_	_	_	_	_	Seg=O
163	,	_	_	_	_	_	_	_	Seg=O
164	general	_	_	_	_	_	_	_	Seg=O
165	satisfaction	_	_	_	_	_	_	_	Seg=O
166	,	_	_	_	_	_	_	_	Seg=O
167	pleasure	_	_	_	_	_	_	_	Seg=O
168	,	_	_	_	_	_	_	_	Seg=O
169	and	_	_	_	_	_	_	_	Seg=O
170	arousal	_	_	_	_	_	_	_	Seg=O
171	.	_	_	_	_	_	_	_	Seg=O
172	These	_	_	_	_	_	_	_	Seg=B-seg
173	findings	_	_	_	_	_	_	_	Seg=O
174	will	_	_	_	_	_	_	_	Seg=O
175	guide	_	_	_	_	_	_	_	Seg=O
176	organizers	_	_	_	_	_	_	_	Seg=O
177	to	_	_	_	_	_	_	_	Seg=O
178	design	_	_	_	_	_	_	_	Seg=O
179	strategies	_	_	_	_	_	_	_	Seg=O
180	that	_	_	_	_	_	_	_	Seg=B-seg
181	provide	_	_	_	_	_	_	_	Seg=O
182	exciting	_	_	_	_	_	_	_	Seg=O
183	experiences	_	_	_	_	_	_	_	Seg=O
184	,	_	_	_	_	_	_	_	Seg=O
185	as	_	_	_	_	_	_	_	Seg=O
186	well	_	_	_	_	_	_	_	Seg=O
187	as	_	_	_	_	_	_	_	Seg=O
188	quality	_	_	_	_	_	_	_	Seg=O
189	and	_	_	_	_	_	_	_	Seg=O
190	satisfaction	_	_	_	_	_	_	_	Seg=O
191	to	_	_	_	_	_	_	_	Seg=O
192	the	_	_	_	_	_	_	_	Seg=O
193	participants	_	_	_	_	_	_	_	Seg=O
194	of	_	_	_	_	_	_	_	Seg=O
195	sports	_	_	_	_	_	_	_	Seg=O
196	events	_	_	_	_	_	_	_	Seg=O
197	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 269a5e6f3c8a46d3ef96ffc2eede944f372bfac6
1	A	_	_	_	_	_	_	_	Seg=B-seg
2	convex	_	_	_	_	_	_	_	Seg=O
3	polyhedron	_	_	_	_	_	_	_	Seg=O
4	is	_	_	_	_	_	_	_	Seg=O
5	the	_	_	_	_	_	_	_	Seg=O
6	convex	_	_	_	_	_	_	_	Seg=O
7	hull	_	_	_	_	_	_	_	Seg=O
8	of	_	_	_	_	_	_	_	Seg=O
9	a	_	_	_	_	_	_	_	Seg=O
10	finite	_	_	_	_	_	_	_	Seg=O
11	set	_	_	_	_	_	_	_	Seg=O
12	of	_	_	_	_	_	_	_	Seg=O
13	points	_	_	_	_	_	_	_	Seg=O
14	in	_	_	_	_	_	_	_	Seg=O
15	R	_	_	_	_	_	_	_	Seg=O
16	3	_	_	_	_	_	_	_	Seg=O
17	.	_	_	_	_	_	_	_	Seg=O
18	A	_	_	_	_	_	_	_	Seg=B-seg
19	triangulation	_	_	_	_	_	_	_	Seg=O
20	of	_	_	_	_	_	_	_	Seg=O
21	a	_	_	_	_	_	_	_	Seg=O
22	convex	_	_	_	_	_	_	_	Seg=O
23	polyhedron	_	_	_	_	_	_	_	Seg=O
24	is	_	_	_	_	_	_	_	Seg=O
25	a	_	_	_	_	_	_	_	Seg=O
26	decomposition	_	_	_	_	_	_	_	Seg=O
27	into	_	_	_	_	_	_	_	Seg=O
28	a	_	_	_	_	_	_	_	Seg=O
29	finite	_	_	_	_	_	_	_	Seg=O
30	number	_	_	_	_	_	_	_	Seg=O
31	of	_	_	_	_	_	_	_	Seg=O
32	3-simplices	_	_	_	_	_	_	_	Seg=O
33	such	_	_	_	_	_	_	_	Seg=B-seg
34	that	_	_	_	_	_	_	_	Seg=O
35	any	_	_	_	_	_	_	_	Seg=O
36	two	_	_	_	_	_	_	_	Seg=O
37	intersect	_	_	_	_	_	_	_	Seg=O
38	in	_	_	_	_	_	_	_	Seg=O
39	a	_	_	_	_	_	_	_	Seg=O
40	common	_	_	_	_	_	_	_	Seg=O
41	face	_	_	_	_	_	_	_	Seg=O
42	or	_	_	_	_	_	_	_	Seg=B-seg
43	are	_	_	_	_	_	_	_	Seg=O
44	disjoint	_	_	_	_	_	_	_	Seg=O
45	.	_	_	_	_	_	_	_	Seg=O
46	A	_	_	_	_	_	_	_	Seg=B-seg
47	simplicial	_	_	_	_	_	_	_	Seg=O
48	dissection	_	_	_	_	_	_	_	Seg=O
49	is	_	_	_	_	_	_	_	Seg=O
50	a	_	_	_	_	_	_	_	Seg=O
51	decomposition	_	_	_	_	_	_	_	Seg=O
52	into	_	_	_	_	_	_	_	Seg=O
53	a	_	_	_	_	_	_	_	Seg=O
54	finite	_	_	_	_	_	_	_	Seg=O
55	number	_	_	_	_	_	_	_	Seg=O
56	of	_	_	_	_	_	_	_	Seg=O
57	3-simplices	_	_	_	_	_	_	_	Seg=O
58	such	_	_	_	_	_	_	_	Seg=B-seg
59	that	_	_	_	_	_	_	_	Seg=O
60	no	_	_	_	_	_	_	_	Seg=O
61	two	_	_	_	_	_	_	_	Seg=O
62	share	_	_	_	_	_	_	_	Seg=O
63	an	_	_	_	_	_	_	_	Seg=O
64	interior	_	_	_	_	_	_	_	Seg=O
65	point	_	_	_	_	_	_	_	Seg=O
66	.	_	_	_	_	_	_	_	Seg=O
67	We	_	_	_	_	_	_	_	Seg=B-seg
68	present	_	_	_	_	_	_	_	Seg=O
69	an	_	_	_	_	_	_	_	Seg=O
70	algorithm	_	_	_	_	_	_	_	Seg=O
71	to	_	_	_	_	_	_	_	Seg=B-seg
72	classify	_	_	_	_	_	_	_	Seg=O
73	the	_	_	_	_	_	_	_	Seg=O
74	simplicial	_	_	_	_	_	_	_	Seg=O
75	dissections	_	_	_	_	_	_	_	Seg=O
76	of	_	_	_	_	_	_	_	Seg=O
77	a	_	_	_	_	_	_	_	Seg=O
78	regular	_	_	_	_	_	_	_	Seg=O
79	polyhedron	_	_	_	_	_	_	_	Seg=O
80	under	_	_	_	_	_	_	_	Seg=O
81	the	_	_	_	_	_	_	_	Seg=O
82	symmetry	_	_	_	_	_	_	_	Seg=O
83	group	_	_	_	_	_	_	_	Seg=O
84	of	_	_	_	_	_	_	_	Seg=O
85	the	_	_	_	_	_	_	_	Seg=O
86	prolyhedron	_	_	_	_	_	_	_	Seg=O
87	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 273377715ca866a5763943b5b86583bf6d6f91f1
1	For	_	_	_	_	_	_	_	Seg=B-seg
2	infectious	_	_	_	_	_	_	_	Seg=O
3	-	_	_	_	_	_	_	_	Seg=O
4	disease	_	_	_	_	_	_	_	Seg=O
5	outbreaks	_	_	_	_	_	_	_	Seg=O
6	,	_	_	_	_	_	_	_	Seg=O
7	clinical	_	_	_	_	_	_	_	Seg=O
8	solutions	_	_	_	_	_	_	_	Seg=O
9	typically	_	_	_	_	_	_	_	Seg=O
10	focus	_	_	_	_	_	_	_	Seg=O
11	on	_	_	_	_	_	_	_	Seg=O
12	efficient	_	_	_	_	_	_	_	Seg=O
13	pathogen	_	_	_	_	_	_	_	Seg=O
14	destruction	_	_	_	_	_	_	_	Seg=O
15	.	_	_	_	_	_	_	_	Seg=O
16	However	_	_	_	_	_	_	_	Seg=B-seg
17	,	_	_	_	_	_	_	_	Seg=O
18	the	_	_	_	_	_	_	_	Seg=O
19	COVID-19	_	_	_	_	_	_	_	Seg=O
20	pandemic	_	_	_	_	_	_	_	Seg=O
21	provides	_	_	_	_	_	_	_	Seg=O
22	a	_	_	_	_	_	_	_	Seg=O
23	reminder	_	_	_	_	_	_	_	Seg=O
24	that	_	_	_	_	_	_	_	Seg=B-seg
25	infectious	_	_	_	_	_	_	_	Seg=O
26	diseases	_	_	_	_	_	_	_	Seg=O
27	are	_	_	_	_	_	_	_	Seg=O
28	complex	_	_	_	_	_	_	_	Seg=O
29	,	_	_	_	_	_	_	_	Seg=O
30	multisystem	_	_	_	_	_	_	_	Seg=O
31	conditions	_	_	_	_	_	_	_	Seg=O
32	,	_	_	_	_	_	_	_	Seg=O
33	and	_	_	_	_	_	_	_	Seg=B-seg
34	a	_	_	_	_	_	_	_	Seg=O
35	holistic	_	_	_	_	_	_	_	Seg=O
36	understanding	_	_	_	_	_	_	_	Seg=O
37	will	_	_	_	_	_	_	_	Seg=O
38	be	_	_	_	_	_	_	_	Seg=O
39	necessary	_	_	_	_	_	_	_	Seg=O
40	to	_	_	_	_	_	_	_	Seg=B-seg
41	maximize	_	_	_	_	_	_	_	Seg=O
42	survival	_	_	_	_	_	_	_	Seg=O
43	.	_	_	_	_	_	_	_	Seg=O
44	For	_	_	_	_	_	_	_	Seg=B-seg
45	COVID-19	_	_	_	_	_	_	_	Seg=O
46	and	_	_	_	_	_	_	_	Seg=O
47	all	_	_	_	_	_	_	_	Seg=O
48	other	_	_	_	_	_	_	_	Seg=O
49	infectious	_	_	_	_	_	_	_	Seg=O
50	diseases	_	_	_	_	_	_	_	Seg=O
51	,	_	_	_	_	_	_	_	Seg=O
52	metabolic	_	_	_	_	_	_	_	Seg=O
53	processes	_	_	_	_	_	_	_	Seg=O
54	are	_	_	_	_	_	_	_	Seg=O
55	intimately	_	_	_	_	_	_	_	Seg=O
56	connected	_	_	_	_	_	_	_	Seg=O
57	to	_	_	_	_	_	_	_	Seg=O
58	the	_	_	_	_	_	_	_	Seg=O
59	mechanisms	_	_	_	_	_	_	_	Seg=O
60	of	_	_	_	_	_	_	_	Seg=O
61	disease	_	_	_	_	_	_	_	Seg=O
62	pathogenesis	_	_	_	_	_	_	_	Seg=O
63	and	_	_	_	_	_	_	_	Seg=O
64	the	_	_	_	_	_	_	_	Seg=O
65	resulting	_	_	_	_	_	_	_	Seg=O
66	pathology	_	_	_	_	_	_	_	Seg=O
67	and	_	_	_	_	_	_	_	Seg=O
68	pathophysiology	_	_	_	_	_	_	_	Seg=O
69	,	_	_	_	_	_	_	_	Seg=O
70	as	_	_	_	_	_	_	_	Seg=O
71	well	_	_	_	_	_	_	_	Seg=O
72	as	_	_	_	_	_	_	_	Seg=O
73	the	_	_	_	_	_	_	_	Seg=O
74	host	_	_	_	_	_	_	_	Seg=O
75	defence	_	_	_	_	_	_	_	Seg=O
76	response	_	_	_	_	_	_	_	Seg=O
77	to	_	_	_	_	_	_	_	Seg=O
78	the	_	_	_	_	_	_	_	Seg=O
79	infection	_	_	_	_	_	_	_	Seg=O
80	.	_	_	_	_	_	_	_	Seg=O
81	Here	_	_	_	_	_	_	_	Seg=B-seg
82	,	_	_	_	_	_	_	_	Seg=O
83	I	_	_	_	_	_	_	_	Seg=O
84	examine	_	_	_	_	_	_	_	Seg=O
85	the	_	_	_	_	_	_	_	Seg=O
86	relationship	_	_	_	_	_	_	_	Seg=O
87	between	_	_	_	_	_	_	_	Seg=O
88	metabolism	_	_	_	_	_	_	_	Seg=O
89	and	_	_	_	_	_	_	_	Seg=O
90	COVID-19	_	_	_	_	_	_	_	Seg=O
91	.	_	_	_	_	_	_	_	Seg=O
92	I	_	_	_	_	_	_	_	Seg=B-seg
93	discuss	_	_	_	_	_	_	_	Seg=O
94	why	_	_	_	_	_	_	_	Seg=O
95	preexisting	_	_	_	_	_	_	_	Seg=O
96	metabolic	_	_	_	_	_	_	_	Seg=O
97	abnormalities	_	_	_	_	_	_	_	Seg=O
98	,	_	_	_	_	_	_	_	Seg=O
99	such	_	_	_	_	_	_	_	Seg=B-seg
100	as	_	_	_	_	_	_	_	Seg=O
101	type	_	_	_	_	_	_	_	Seg=O
102	2	_	_	_	_	_	_	_	Seg=O
103	diabetes	_	_	_	_	_	_	_	Seg=O
104	and	_	_	_	_	_	_	_	Seg=O
105	hypertension	_	_	_	_	_	_	_	Seg=O
106	,	_	_	_	_	_	_	_	Seg=O
107	may	_	_	_	_	_	_	_	Seg=B-seg
108	be	_	_	_	_	_	_	_	Seg=O
109	important	_	_	_	_	_	_	_	Seg=O
110	risk	_	_	_	_	_	_	_	Seg=O
111	factors	_	_	_	_	_	_	_	Seg=O
112	for	_	_	_	_	_	_	_	Seg=O
113	severe	_	_	_	_	_	_	_	Seg=O
114	and	_	_	_	_	_	_	_	Seg=O
115	critical	_	_	_	_	_	_	_	Seg=O
116	cases	_	_	_	_	_	_	_	Seg=O
117	of	_	_	_	_	_	_	_	Seg=O
118	infection	_	_	_	_	_	_	_	Seg=O
119	,	_	_	_	_	_	_	_	Seg=O
120	highlighting	_	_	_	_	_	_	_	Seg=B-seg
121	parallels	_	_	_	_	_	_	_	Seg=O
122	between	_	_	_	_	_	_	_	Seg=O
123	the	_	_	_	_	_	_	_	Seg=O
124	pathophysiology	_	_	_	_	_	_	_	Seg=O
125	of	_	_	_	_	_	_	_	Seg=O
126	these	_	_	_	_	_	_	_	Seg=O
127	metabolic	_	_	_	_	_	_	_	Seg=O
128	abnormalities	_	_	_	_	_	_	_	Seg=O
129	and	_	_	_	_	_	_	_	Seg=O
130	the	_	_	_	_	_	_	_	Seg=O
131	disease	_	_	_	_	_	_	_	Seg=O
132	course	_	_	_	_	_	_	_	Seg=O
133	of	_	_	_	_	_	_	_	Seg=O
134	COVID-19	_	_	_	_	_	_	_	Seg=O
135	.	_	_	_	_	_	_	_	Seg=O
136	I	_	_	_	_	_	_	_	Seg=B-seg
137	also	_	_	_	_	_	_	_	Seg=O
138	discuss	_	_	_	_	_	_	_	Seg=O
139	how	_	_	_	_	_	_	_	Seg=O
140	metabolism	_	_	_	_	_	_	_	Seg=O
141	at	_	_	_	_	_	_	_	Seg=O
142	the	_	_	_	_	_	_	_	Seg=O
143	cellular	_	_	_	_	_	_	_	Seg=O
144	,	_	_	_	_	_	_	_	Seg=O
145	tissue	_	_	_	_	_	_	_	Seg=O
146	and	_	_	_	_	_	_	_	Seg=O
147	organ	_	_	_	_	_	_	_	Seg=O
148	levels	_	_	_	_	_	_	_	Seg=O
149	might	_	_	_	_	_	_	_	Seg=O
150	be	_	_	_	_	_	_	_	Seg=O
151	harnessed	_	_	_	_	_	_	_	Seg=O
152	to	_	_	_	_	_	_	_	Seg=B-seg
153	promote	_	_	_	_	_	_	_	Seg=O
154	defence	_	_	_	_	_	_	_	Seg=O
155	against	_	_	_	_	_	_	_	Seg=O
156	the	_	_	_	_	_	_	_	Seg=O
157	infection	_	_	_	_	_	_	_	Seg=O
158	,	_	_	_	_	_	_	_	Seg=O
159	with	_	_	_	_	_	_	_	Seg=B-seg
160	a	_	_	_	_	_	_	_	Seg=O
161	focus	_	_	_	_	_	_	_	Seg=O
162	on	_	_	_	_	_	_	_	Seg=O
163	disease	_	_	_	_	_	_	_	Seg=O
164	-	_	_	_	_	_	_	_	Seg=O
165	tolerance	_	_	_	_	_	_	_	Seg=O
166	mechanisms	_	_	_	_	_	_	_	Seg=O
167	,	_	_	_	_	_	_	_	Seg=O
168	and	_	_	_	_	_	_	_	Seg=B-seg
169	speculate	_	_	_	_	_	_	_	Seg=O
170	on	_	_	_	_	_	_	_	Seg=O
171	the	_	_	_	_	_	_	_	Seg=O
172	long	_	_	_	_	_	_	_	Seg=O
173	-	_	_	_	_	_	_	_	Seg=O
174	term	_	_	_	_	_	_	_	Seg=O
175	metabolic	_	_	_	_	_	_	_	Seg=O
176	consequences	_	_	_	_	_	_	_	Seg=O
177	for	_	_	_	_	_	_	_	Seg=O
178	survivors	_	_	_	_	_	_	_	Seg=O
179	of	_	_	_	_	_	_	_	Seg=O
180	COVID-19	_	_	_	_	_	_	_	Seg=O
181	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 2857cb1d4c6c446ac30ab4d0cabca0b42d62c465
1	Background	_	_	_	_	_	_	_	Seg=B-seg
2	:	_	_	_	_	_	_	_	Seg=O
3	Existing	_	_	_	_	_	_	_	Seg=B-seg
4	standard	_	_	_	_	_	_	_	Seg=O
5	non	_	_	_	_	_	_	_	Seg=O
6	-	_	_	_	_	_	_	_	Seg=O
7	molecular	_	_	_	_	_	_	_	Seg=O
8	diagnostic	_	_	_	_	_	_	_	Seg=O
9	methods	_	_	_	_	_	_	_	Seg=O
10	such	_	_	_	_	_	_	_	Seg=B-seg
11	as	_	_	_	_	_	_	_	Seg=O
12	viral	_	_	_	_	_	_	_	Seg=O
13	culture	_	_	_	_	_	_	_	Seg=O
14	and	_	_	_	_	_	_	_	Seg=O
15	immunofluorescent	_	_	_	_	_	_	_	Seg=O
16	(	_	_	_	_	_	_	_	Seg=O
17	DFA	_	_	_	_	_	_	_	Seg=O
18	)	_	_	_	_	_	_	_	Seg=O
19	are	_	_	_	_	_	_	_	Seg=B-seg
20	time	_	_	_	_	_	_	_	Seg=O
21	-	_	_	_	_	_	_	_	Seg=O
22	consuming	_	_	_	_	_	_	_	Seg=O
23	,	_	_	_	_	_	_	_	Seg=O
24	labor	_	_	_	_	_	_	_	Seg=O
25	intensive	_	_	_	_	_	_	_	Seg=O
26	or	_	_	_	_	_	_	_	Seg=O
27	limited	_	_	_	_	_	_	_	Seg=O
28	sensitivity	_	_	_	_	_	_	_	Seg=O
29	.	_	_	_	_	_	_	_	Seg=O
30	Several	_	_	_	_	_	_	_	Seg=B-seg
31	multiplex	_	_	_	_	_	_	_	Seg=O
32	molecular	_	_	_	_	_	_	_	Seg=O
33	assays	_	_	_	_	_	_	_	Seg=O
34	are	_	_	_	_	_	_	_	Seg=O
35	costly	_	_	_	_	_	_	_	Seg=O
36	.	_	_	_	_	_	_	_	Seg=O
37	Therefore	_	_	_	_	_	_	_	Seg=B-seg
38	,	_	_	_	_	_	_	_	Seg=O
39	there	_	_	_	_	_	_	_	Seg=O
40	is	_	_	_	_	_	_	_	Seg=O
41	a	_	_	_	_	_	_	_	Seg=O
42	need	_	_	_	_	_	_	_	Seg=O
43	for	_	_	_	_	_	_	_	Seg=O
44	the	_	_	_	_	_	_	_	Seg=O
45	development	_	_	_	_	_	_	_	Seg=O
46	of	_	_	_	_	_	_	_	Seg=O
47	a	_	_	_	_	_	_	_	Seg=O
48	rapid	_	_	_	_	_	_	_	Seg=O
49	and	_	_	_	_	_	_	_	Seg=O
50	sensitive	_	_	_	_	_	_	_	Seg=O
51	diagnosis	_	_	_	_	_	_	_	Seg=O
52	of	_	_	_	_	_	_	_	Seg=O
53	respiratory	_	_	_	_	_	_	_	Seg=O
54	viral	_	_	_	_	_	_	_	Seg=O
55	pathogens	_	_	_	_	_	_	_	Seg=O
56	.	_	_	_	_	_	_	_	Seg=O
57	Methods	_	_	_	_	_	_	_	Seg=B-seg
58	:	_	_	_	_	_	_	_	Seg=O
59	A	_	_	_	_	_	_	_	Seg=B-seg
60	GeXP	_	_	_	_	_	_	_	Seg=O
61	-	_	_	_	_	_	_	_	Seg=O
62	based	_	_	_	_	_	_	_	Seg=O
63	multiplex	_	_	_	_	_	_	_	Seg=O
64	RT	_	_	_	_	_	_	_	Seg=O
65	-	_	_	_	_	_	_	_	Seg=O
66	PCR	_	_	_	_	_	_	_	Seg=O
67	assay	_	_	_	_	_	_	_	Seg=O
68	(	_	_	_	_	_	_	_	Seg=O
69	GeXP	_	_	_	_	_	_	_	Seg=O
70	assay	_	_	_	_	_	_	_	Seg=O
71	)	_	_	_	_	_	_	_	Seg=O
72	was	_	_	_	_	_	_	_	Seg=O
73	developed	_	_	_	_	_	_	_	Seg=O
74	to	_	_	_	_	_	_	_	Seg=B-seg
75	detect	_	_	_	_	_	_	_	Seg=O
76	simultaneously	_	_	_	_	_	_	_	Seg=O
77	sixteen	_	_	_	_	_	_	_	Seg=O
78	different	_	_	_	_	_	_	_	Seg=O
79	respiratory	_	_	_	_	_	_	_	Seg=O
80	virus	_	_	_	_	_	_	_	Seg=O
81	types	_	_	_	_	_	_	_	Seg=O
82	/	_	_	_	_	_	_	_	Seg=O
83	subtypes	_	_	_	_	_	_	_	Seg=O
84	.	_	_	_	_	_	_	_	Seg=O
85	Seventeen	_	_	_	_	_	_	_	Seg=B-seg
86	sets	_	_	_	_	_	_	_	Seg=O
87	of	_	_	_	_	_	_	_	Seg=O
88	chimeric	_	_	_	_	_	_	_	Seg=O
89	primers	_	_	_	_	_	_	_	Seg=O
90	were	_	_	_	_	_	_	_	Seg=O
91	used	_	_	_	_	_	_	_	Seg=O
92	to	_	_	_	_	_	_	_	Seg=B-seg
93	initiate	_	_	_	_	_	_	_	Seg=O
94	the	_	_	_	_	_	_	_	Seg=O
95	RT	_	_	_	_	_	_	_	Seg=O
96	-	_	_	_	_	_	_	_	Seg=O
97	PCR	_	_	_	_	_	_	_	Seg=O
98	,	_	_	_	_	_	_	_	Seg=O
99	and	_	_	_	_	_	_	_	Seg=B-seg
100	one	_	_	_	_	_	_	_	Seg=O
101	pair	_	_	_	_	_	_	_	Seg=O
102	of	_	_	_	_	_	_	_	Seg=O
103	universal	_	_	_	_	_	_	_	Seg=O
104	primers	_	_	_	_	_	_	_	Seg=O
105	was	_	_	_	_	_	_	_	Seg=O
106	used	_	_	_	_	_	_	_	Seg=O
107	for	_	_	_	_	_	_	_	Seg=O
108	the	_	_	_	_	_	_	_	Seg=O
109	subsequent	_	_	_	_	_	_	_	Seg=O
110	cycles	_	_	_	_	_	_	_	Seg=O
111	of	_	_	_	_	_	_	_	Seg=O
112	the	_	_	_	_	_	_	_	Seg=O
113	RT	_	_	_	_	_	_	_	Seg=O
114	-	_	_	_	_	_	_	_	Seg=O
115	PCR	_	_	_	_	_	_	_	Seg=O
116	.	_	_	_	_	_	_	_	Seg=O
117	The	_	_	_	_	_	_	_	Seg=B-seg
118	specificity	_	_	_	_	_	_	_	Seg=O
119	of	_	_	_	_	_	_	_	Seg=O
120	the	_	_	_	_	_	_	_	Seg=O
121	GeXP	_	_	_	_	_	_	_	Seg=O
122	assay	_	_	_	_	_	_	_	Seg=O
123	was	_	_	_	_	_	_	_	Seg=O
124	examined	_	_	_	_	_	_	_	Seg=O
125	with	_	_	_	_	_	_	_	Seg=O
126	positive	_	_	_	_	_	_	_	Seg=O
127	controls	_	_	_	_	_	_	_	Seg=O
128	for	_	_	_	_	_	_	_	Seg=O
129	each	_	_	_	_	_	_	_	Seg=O
130	virus	_	_	_	_	_	_	_	Seg=O
131	type	_	_	_	_	_	_	_	Seg=O
132	/	_	_	_	_	_	_	_	Seg=O
133	subtype	_	_	_	_	_	_	_	Seg=O
134	.	_	_	_	_	_	_	_	Seg=O
135	The	_	_	_	_	_	_	_	Seg=B-seg
136	sensitivity	_	_	_	_	_	_	_	Seg=O
137	was	_	_	_	_	_	_	_	Seg=O
138	evaluated	_	_	_	_	_	_	_	Seg=O
139	by	_	_	_	_	_	_	_	Seg=B-seg
140	performing	_	_	_	_	_	_	_	Seg=O
141	the	_	_	_	_	_	_	_	Seg=O
142	assay	_	_	_	_	_	_	_	Seg=O
143	on	_	_	_	_	_	_	_	Seg=O
144	serial	_	_	_	_	_	_	_	Seg=O
145	ten	_	_	_	_	_	_	_	Seg=O
146	-	_	_	_	_	_	_	_	Seg=O
147	fold	_	_	_	_	_	_	_	Seg=O
148	dilutions	_	_	_	_	_	_	_	Seg=O
149	of	_	_	_	_	_	_	_	Seg=O
150	in	_	_	_	_	_	_	_	Seg=O
151	vitro	_	_	_	_	_	_	_	Seg=O
152	-	_	_	_	_	_	_	_	Seg=O
153	transcribed	_	_	_	_	_	_	_	Seg=O
154	RNA	_	_	_	_	_	_	_	Seg=O
155	of	_	_	_	_	_	_	_	Seg=O
156	all	_	_	_	_	_	_	_	Seg=O
157	RNA	_	_	_	_	_	_	_	Seg=O
158	viruses	_	_	_	_	_	_	_	Seg=O
159	and	_	_	_	_	_	_	_	Seg=O
160	the	_	_	_	_	_	_	_	Seg=O
161	plasmids	_	_	_	_	_	_	_	Seg=O
162	containing	_	_	_	_	_	_	_	Seg=B-seg
163	the	_	_	_	_	_	_	_	Seg=O
164	Adv	_	_	_	_	_	_	_	Seg=O
165	and	_	_	_	_	_	_	_	Seg=O
166	HBoV	_	_	_	_	_	_	_	Seg=O
167	target	_	_	_	_	_	_	_	Seg=O
168	sequence	_	_	_	_	_	_	_	Seg=O
169	.	_	_	_	_	_	_	_	Seg=O
170	GeXP	_	_	_	_	_	_	_	Seg=B-seg
171	assay	_	_	_	_	_	_	_	Seg=O
172	was	_	_	_	_	_	_	_	Seg=O
173	further	_	_	_	_	_	_	_	Seg=O
174	evaluated	_	_	_	_	_	_	_	Seg=O
175	using	_	_	_	_	_	_	_	Seg=B-seg
176	126	_	_	_	_	_	_	_	Seg=O
177	clinical	_	_	_	_	_	_	_	Seg=O
178	specimens	_	_	_	_	_	_	_	Seg=O
179	and	_	_	_	_	_	_	_	Seg=B-seg
180	compared	_	_	_	_	_	_	_	Seg=O
181	with	_	_	_	_	_	_	_	Seg=O
182	Luminex	_	_	_	_	_	_	_	Seg=O
183	xTAG	_	_	_	_	_	_	_	Seg=O
184	RVP	_	_	_	_	_	_	_	Seg=O
185	Fast	_	_	_	_	_	_	_	Seg=O
186	assay	_	_	_	_	_	_	_	Seg=O
187	.	_	_	_	_	_	_	_	Seg=O
188	Results	_	_	_	_	_	_	_	Seg=B-seg
189	:	_	_	_	_	_	_	_	Seg=O
190	The	_	_	_	_	_	_	_	Seg=B-seg
191	GeXP	_	_	_	_	_	_	_	Seg=O
192	assay	_	_	_	_	_	_	_	Seg=O
193	achieved	_	_	_	_	_	_	_	Seg=O
194	a	_	_	_	_	_	_	_	Seg=O
195	sensitivity	_	_	_	_	_	_	_	Seg=O
196	of	_	_	_	_	_	_	_	Seg=O
197	20	_	_	_	_	_	_	_	Seg=O
198	-	_	_	_	_	_	_	_	Seg=O
199	200	_	_	_	_	_	_	_	Seg=O
200	copies	_	_	_	_	_	_	_	Seg=O
201	for	_	_	_	_	_	_	_	Seg=O
202	a	_	_	_	_	_	_	_	Seg=O
203	single	_	_	_	_	_	_	_	Seg=O
204	virus	_	_	_	_	_	_	_	Seg=O
205	and	_	_	_	_	_	_	_	Seg=O
206	1000	_	_	_	_	_	_	_	Seg=O
207	copies	_	_	_	_	_	_	_	Seg=O
208	when	_	_	_	_	_	_	_	Seg=B-seg
209	all	_	_	_	_	_	_	_	Seg=O
210	of	_	_	_	_	_	_	_	Seg=O
211	the	_	_	_	_	_	_	_	Seg=O
212	16	_	_	_	_	_	_	_	Seg=O
213	pre	_	_	_	_	_	_	_	Seg=O
214	-	_	_	_	_	_	_	_	Seg=O
215	mixed	_	_	_	_	_	_	_	Seg=O
216	viral	_	_	_	_	_	_	_	Seg=O
217	targets	_	_	_	_	_	_	_	Seg=O
218	were	_	_	_	_	_	_	_	Seg=O
219	present	_	_	_	_	_	_	_	Seg=O
220	.	_	_	_	_	_	_	_	Seg=O
221	Analyses	_	_	_	_	_	_	_	Seg=B-seg
222	of	_	_	_	_	_	_	_	Seg=O
223	126	_	_	_	_	_	_	_	Seg=O
224	clinical	_	_	_	_	_	_	_	Seg=O
225	specimens	_	_	_	_	_	_	_	Seg=O
226	using	_	_	_	_	_	_	_	Seg=B-seg
227	the	_	_	_	_	_	_	_	Seg=O
228	GeXP	_	_	_	_	_	_	_	Seg=O
229	assay	_	_	_	_	_	_	_	Seg=O
230	demonstrated	_	_	_	_	_	_	_	Seg=B-seg
231	that	_	_	_	_	_	_	_	Seg=B-seg
232	GeXP	_	_	_	_	_	_	_	Seg=O
233	assay	_	_	_	_	_	_	_	Seg=O
234	and	_	_	_	_	_	_	_	Seg=O
235	the	_	_	_	_	_	_	_	Seg=O
236	RVP	_	_	_	_	_	_	_	Seg=O
237	Fast	_	_	_	_	_	_	_	Seg=O
238	assay	_	_	_	_	_	_	_	Seg=O
239	were	_	_	_	_	_	_	_	Seg=O
240	in	_	_	_	_	_	_	_	Seg=O
241	complete	_	_	_	_	_	_	_	Seg=O
242	agreement	_	_	_	_	_	_	_	Seg=O
243	for	_	_	_	_	_	_	_	Seg=O
244	109/126	_	_	_	_	_	_	_	Seg=O
245	(	_	_	_	_	_	_	_	Seg=O
246	88.51	_	_	_	_	_	_	_	Seg=O
247	%	_	_	_	_	_	_	_	Seg=O
248	)	_	_	_	_	_	_	_	Seg=O
249	of	_	_	_	_	_	_	_	Seg=O
250	the	_	_	_	_	_	_	_	Seg=O
251	specimens	_	_	_	_	_	_	_	Seg=O
252	.	_	_	_	_	_	_	_	Seg=O
253	GeXP	_	_	_	_	_	_	_	Seg=B-seg
254	assay	_	_	_	_	_	_	_	Seg=O
255	was	_	_	_	_	_	_	_	Seg=O
256	more	_	_	_	_	_	_	_	Seg=O
257	sensitive	_	_	_	_	_	_	_	Seg=O
258	than	_	_	_	_	_	_	_	Seg=O
259	the	_	_	_	_	_	_	_	Seg=O
260	RVP	_	_	_	_	_	_	_	Seg=O
261	Fast	_	_	_	_	_	_	_	Seg=O
262	assay	_	_	_	_	_	_	_	Seg=O
263	for	_	_	_	_	_	_	_	Seg=O
264	the	_	_	_	_	_	_	_	Seg=O
265	detection	_	_	_	_	_	_	_	Seg=O
266	of	_	_	_	_	_	_	_	Seg=O
267	HRV	_	_	_	_	_	_	_	Seg=O
268	and	_	_	_	_	_	_	_	Seg=O
269	PIV3	_	_	_	_	_	_	_	Seg=O
270	,	_	_	_	_	_	_	_	Seg=O
271	and	_	_	_	_	_	_	_	Seg=O
272	slightly	_	_	_	_	_	_	_	Seg=O
273	less	_	_	_	_	_	_	_	Seg=O
274	sensitive	_	_	_	_	_	_	_	Seg=O
275	for	_	_	_	_	_	_	_	Seg=O
276	the	_	_	_	_	_	_	_	Seg=O
277	detection	_	_	_	_	_	_	_	Seg=O
278	of	_	_	_	_	_	_	_	Seg=O
279	HMPV	_	_	_	_	_	_	_	Seg=O
280	,	_	_	_	_	_	_	_	Seg=O
281	Adv	_	_	_	_	_	_	_	Seg=O
282	,	_	_	_	_	_	_	_	Seg=O
283	RSVB	_	_	_	_	_	_	_	Seg=O
284	and	_	_	_	_	_	_	_	Seg=O
285	HBoV.	_	_	_	_	_	_	_	Seg=O
286	The	_	_	_	_	_	_	_	Seg=B-seg
287	whole	_	_	_	_	_	_	_	Seg=O
288	process	_	_	_	_	_	_	_	Seg=O
289	of	_	_	_	_	_	_	_	Seg=O
290	the	_	_	_	_	_	_	_	Seg=O
291	GeXP	_	_	_	_	_	_	_	Seg=O
292	assay	_	_	_	_	_	_	_	Seg=O
293	for	_	_	_	_	_	_	_	Seg=O
294	the	_	_	_	_	_	_	_	Seg=O
295	detection	_	_	_	_	_	_	_	Seg=O
296	of	_	_	_	_	_	_	_	Seg=O
297	12	_	_	_	_	_	_	_	Seg=O
298	samples	_	_	_	_	_	_	_	Seg=O
299	was	_	_	_	_	_	_	_	Seg=O
300	completed	_	_	_	_	_	_	_	Seg=O
301	within	_	_	_	_	_	_	_	Seg=O
302	2.5	_	_	_	_	_	_	_	Seg=O
303	hours	_	_	_	_	_	_	_	Seg=O
304	.	_	_	_	_	_	_	_	Seg=O
305	Conclusions	_	_	_	_	_	_	_	Seg=B-seg
306	:	_	_	_	_	_	_	_	Seg=O
307	In	_	_	_	_	_	_	_	Seg=B-seg
308	conclusion	_	_	_	_	_	_	_	Seg=O
309	,	_	_	_	_	_	_	_	Seg=O
310	the	_	_	_	_	_	_	_	Seg=O
311	GeXP	_	_	_	_	_	_	_	Seg=O
312	assay	_	_	_	_	_	_	_	Seg=O
313	is	_	_	_	_	_	_	_	Seg=O
314	a	_	_	_	_	_	_	_	Seg=O
315	rapid	_	_	_	_	_	_	_	Seg=O
316	,	_	_	_	_	_	_	_	Seg=O
317	cost	_	_	_	_	_	_	_	Seg=O
318	-	_	_	_	_	_	_	_	Seg=O
319	effective	_	_	_	_	_	_	_	Seg=O
320	,	_	_	_	_	_	_	_	Seg=O
321	sensitive	_	_	_	_	_	_	_	Seg=O
322	,	_	_	_	_	_	_	_	Seg=O
323	specific	_	_	_	_	_	_	_	Seg=O
324	and	_	_	_	_	_	_	_	Seg=O
325	high	_	_	_	_	_	_	_	Seg=O
326	throughput	_	_	_	_	_	_	_	Seg=O
327	method	_	_	_	_	_	_	_	Seg=O
328	for	_	_	_	_	_	_	_	Seg=O
329	the	_	_	_	_	_	_	_	Seg=O
330	detection	_	_	_	_	_	_	_	Seg=O
331	of	_	_	_	_	_	_	_	Seg=O
332	respiratory	_	_	_	_	_	_	_	Seg=O
333	virus	_	_	_	_	_	_	_	Seg=O
334	infections	_	_	_	_	_	_	_	Seg=O
335	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 2a35cb9b73eda5248a85c9d84532b651ab8a3b3a
1	Improved	_	_	_	_	_	_	_	Seg=B-seg
2	diagnostic	_	_	_	_	_	_	_	Seg=O
3	tools	_	_	_	_	_	_	_	Seg=O
4	for	_	_	_	_	_	_	_	Seg=O
5	rapid	_	_	_	_	_	_	_	Seg=O
6	detection	_	_	_	_	_	_	_	Seg=O
7	,	_	_	_	_	_	_	_	Seg=O
8	quantitation	_	_	_	_	_	_	_	Seg=O
9	,	_	_	_	_	_	_	_	Seg=O
10	and	_	_	_	_	_	_	_	Seg=O
11	subgrouping	_	_	_	_	_	_	_	Seg=O
12	of	_	_	_	_	_	_	_	Seg=O
13	human	_	_	_	_	_	_	_	Seg=O
14	respiratory	_	_	_	_	_	_	_	Seg=O
15	syncytial	_	_	_	_	_	_	_	Seg=O
16	virus	_	_	_	_	_	_	_	Seg=O
17	(	_	_	_	_	_	_	_	Seg=O
18	RSV	_	_	_	_	_	_	_	Seg=O
19	)	_	_	_	_	_	_	_	Seg=O
20	are	_	_	_	_	_	_	_	Seg=O
21	needed	_	_	_	_	_	_	_	Seg=O
22	to	_	_	_	_	_	_	_	Seg=B-seg
23	aid	_	_	_	_	_	_	_	Seg=O
24	the	_	_	_	_	_	_	_	Seg=O
25	development	_	_	_	_	_	_	_	Seg=O
26	and	_	_	_	_	_	_	_	Seg=O
27	evaluation	_	_	_	_	_	_	_	Seg=O
28	of	_	_	_	_	_	_	_	Seg=O
29	novel	_	_	_	_	_	_	_	Seg=O
30	intervention	_	_	_	_	_	_	_	Seg=O
31	strategies	_	_	_	_	_	_	_	Seg=O
32	.	_	_	_	_	_	_	_	Seg=O
33	A	_	_	_	_	_	_	_	Seg=B-seg
34	quantitative	_	_	_	_	_	_	_	Seg=O
35	real	_	_	_	_	_	_	_	Seg=O
36	-	_	_	_	_	_	_	_	Seg=O
37	time	_	_	_	_	_	_	_	Seg=O
38	RT	_	_	_	_	_	_	_	Seg=O
39	-	_	_	_	_	_	_	_	Seg=O
40	PCR	_	_	_	_	_	_	_	Seg=O
41	using	_	_	_	_	_	_	_	Seg=B-seg
42	specific	_	_	_	_	_	_	_	Seg=O
43	locked	_	_	_	_	_	_	_	Seg=O
44	nucleic	_	_	_	_	_	_	_	Seg=O
45	acid	_	_	_	_	_	_	_	Seg=O
46	(	_	_	_	_	_	_	_	Seg=O
47	LNA	_	_	_	_	_	_	_	Seg=O
48	)	_	_	_	_	_	_	_	Seg=O
49	probes	_	_	_	_	_	_	_	Seg=O
50	was	_	_	_	_	_	_	_	Seg=B-seg
51	developed	_	_	_	_	_	_	_	Seg=O
52	to	_	_	_	_	_	_	_	Seg=B-seg
53	identify	_	_	_	_	_	_	_	Seg=O
54	RSV	_	_	_	_	_	_	_	Seg=O
55	and	_	_	_	_	_	_	_	Seg=B-seg
56	to	_	_	_	_	_	_	_	Seg=O
57	distinguish	_	_	_	_	_	_	_	Seg=O
58	RSV	_	_	_	_	_	_	_	Seg=O
59	subgroups	_	_	_	_	_	_	_	Seg=O
60	A	_	_	_	_	_	_	_	Seg=O
61	and	_	_	_	_	_	_	_	Seg=O
62	B	_	_	_	_	_	_	_	Seg=O
63	(	_	_	_	_	_	_	_	Seg=O
64	RSV	_	_	_	_	_	_	_	Seg=O
65	LNA	_	_	_	_	_	_	_	Seg=O
66	assay	_	_	_	_	_	_	_	Seg=O
67	)	_	_	_	_	_	_	_	Seg=O
68	.	_	_	_	_	_	_	_	Seg=O
69	RSV	_	_	_	_	_	_	_	Seg=B-seg
70	subgroup	_	_	_	_	_	_	_	Seg=O
71	diversity	_	_	_	_	_	_	_	Seg=O
72	and	_	_	_	_	_	_	_	Seg=O
73	the	_	_	_	_	_	_	_	Seg=O
74	relationship	_	_	_	_	_	_	_	Seg=O
75	between	_	_	_	_	_	_	_	Seg=O
76	viral	_	_	_	_	_	_	_	Seg=O
77	load	_	_	_	_	_	_	_	Seg=O
78	and	_	_	_	_	_	_	_	Seg=O
79	disease	_	_	_	_	_	_	_	Seg=O
80	severity	_	_	_	_	_	_	_	Seg=O
81	in	_	_	_	_	_	_	_	Seg=O
82	confirmed	_	_	_	_	_	_	_	Seg=O
83	RSV	_	_	_	_	_	_	_	Seg=O
84	infections	_	_	_	_	_	_	_	Seg=O
85	were	_	_	_	_	_	_	_	Seg=O
86	also	_	_	_	_	_	_	_	Seg=O
87	explored	_	_	_	_	_	_	_	Seg=O
88	.	_	_	_	_	_	_	_	Seg=O
89	264	_	_	_	_	_	_	_	Seg=B-seg
90	archived	_	_	_	_	_	_	_	Seg=O
91	respiratory	_	_	_	_	_	_	_	Seg=O
92	specimens	_	_	_	_	_	_	_	Seg=O
93	from	_	_	_	_	_	_	_	Seg=O
94	pediatric	_	_	_	_	_	_	_	Seg=O
95	patients	_	_	_	_	_	_	_	Seg=O
96	were	_	_	_	_	_	_	_	Seg=O
97	tested	_	_	_	_	_	_	_	Seg=O
98	in	_	_	_	_	_	_	_	Seg=O
99	parallel	_	_	_	_	_	_	_	Seg=O
100	using	_	_	_	_	_	_	_	Seg=B-seg
101	the	_	_	_	_	_	_	_	Seg=O
102	commercial	_	_	_	_	_	_	_	Seg=O
103	multiplex	_	_	_	_	_	_	_	Seg=O
104	Seeplex	_	_	_	_	_	_	_	Seg=O
105	TM	_	_	_	_	_	_	_	Seg=O
106	RV	_	_	_	_	_	_	_	Seg=O
107	detection	_	_	_	_	_	_	_	Seg=O
108	kit	_	_	_	_	_	_	_	Seg=O
109	(	_	_	_	_	_	_	_	Seg=O
110	Seegene	_	_	_	_	_	_	_	Seg=O
111	)	_	_	_	_	_	_	_	Seg=O
112	and	_	_	_	_	_	_	_	Seg=O
113	the	_	_	_	_	_	_	_	Seg=O
114	novel	_	_	_	_	_	_	_	Seg=O
115	RSV	_	_	_	_	_	_	_	Seg=O
116	LNA	_	_	_	_	_	_	_	Seg=O
117	assay	_	_	_	_	_	_	_	Seg=O
118	.	_	_	_	_	_	_	_	Seg=O
119	The	_	_	_	_	_	_	_	Seg=B-seg
120	LNA	_	_	_	_	_	_	_	Seg=O
121	assay	_	_	_	_	_	_	_	Seg=O
122	demonstrated	_	_	_	_	_	_	_	Seg=O
123	a	_	_	_	_	_	_	_	Seg=O
124	significantly	_	_	_	_	_	_	_	Seg=O
125	higher	_	_	_	_	_	_	_	Seg=O
126	sensitivity	_	_	_	_	_	_	_	Seg=O
127	than	_	_	_	_	_	_	_	Seg=O
128	Seeplex	_	_	_	_	_	_	_	Seg=O
129	,	_	_	_	_	_	_	_	Seg=O
130	improving	_	_	_	_	_	_	_	Seg=B-seg
131	overall	_	_	_	_	_	_	_	Seg=O
132	detection	_	_	_	_	_	_	_	Seg=O
133	rates	_	_	_	_	_	_	_	Seg=O
134	from	_	_	_	_	_	_	_	Seg=O
135	24	_	_	_	_	_	_	_	Seg=O
136	%	_	_	_	_	_	_	_	Seg=O
137	(	_	_	_	_	_	_	_	Seg=B-seg
138	64/264	_	_	_	_	_	_	_	Seg=O
139	)	_	_	_	_	_	_	_	Seg=O
140	to	_	_	_	_	_	_	_	Seg=B-seg
141	32	_	_	_	_	_	_	_	Seg=O
142	%	_	_	_	_	_	_	_	Seg=O
143	(	_	_	_	_	_	_	_	Seg=B-seg
144	84/264	_	_	_	_	_	_	_	Seg=O
145	)	_	_	_	_	_	_	_	Seg=O
146	.	_	_	_	_	_	_	_	Seg=O
147	Detection	_	_	_	_	_	_	_	Seg=B-seg
148	limits	_	_	_	_	_	_	_	Seg=O
149	of	_	_	_	_	_	_	_	Seg=O
150	9.0	_	_	_	_	_	_	_	Seg=O
151	×	_	_	_	_	_	_	_	Seg=O
152	10	_	_	_	_	_	_	_	Seg=O
153	1	_	_	_	_	_	_	_	Seg=O
154	and	_	_	_	_	_	_	_	Seg=O
155	6.0	_	_	_	_	_	_	_	Seg=O
156	×	_	_	_	_	_	_	_	Seg=O
157	10	_	_	_	_	_	_	_	Seg=O
158	2	_	_	_	_	_	_	_	Seg=O
159	copies	_	_	_	_	_	_	_	Seg=O
160	/	_	_	_	_	_	_	_	Seg=O
161	mL	_	_	_	_	_	_	_	Seg=O
162	were	_	_	_	_	_	_	_	Seg=O
163	observed	_	_	_	_	_	_	_	Seg=O
164	for	_	_	_	_	_	_	_	Seg=O
165	RSV	_	_	_	_	_	_	_	Seg=O
166	A	_	_	_	_	_	_	_	Seg=O
167	and	_	_	_	_	_	_	_	Seg=O
168	B	_	_	_	_	_	_	_	Seg=O
169	,	_	_	_	_	_	_	_	Seg=O
170	respectivel	_	_	_	_	_	_	_	Seg=O
171	.	_	_	_	_	_	_	_	Seg=O
172	RSV	_	_	_	_	_	_	_	Seg=B-seg
173	A	_	_	_	_	_	_	_	Seg=O
174	was	_	_	_	_	_	_	_	Seg=O
175	detected	_	_	_	_	_	_	_	Seg=O
176	in	_	_	_	_	_	_	_	Seg=O
177	53/84	_	_	_	_	_	_	_	Seg=O
178	(	_	_	_	_	_	_	_	Seg=B-seg
179	63	_	_	_	_	_	_	_	Seg=O
180	%	_	_	_	_	_	_	_	Seg=O
181	)	_	_	_	_	_	_	_	Seg=O
182	cases	_	_	_	_	_	_	_	Seg=B-seg
183	,	_	_	_	_	_	_	_	Seg=O
184	and	_	_	_	_	_	_	_	Seg=B-seg
185	31/84	_	_	_	_	_	_	_	Seg=O
186	(	_	_	_	_	_	_	_	Seg=B-seg
187	37	_	_	_	_	_	_	_	Seg=O
188	%	_	_	_	_	_	_	_	Seg=O
189	)	_	_	_	_	_	_	_	Seg=O
190	were	_	_	_	_	_	_	_	Seg=B-seg
191	positive	_	_	_	_	_	_	_	Seg=O
192	for	_	_	_	_	_	_	_	Seg=O
193	RSV	_	_	_	_	_	_	_	Seg=O
194	B.	_	_	_	_	_	_	_	Seg=O
195	This	_	_	_	_	_	_	_	Seg=B-seg
196	novel	_	_	_	_	_	_	_	Seg=O
197	method	_	_	_	_	_	_	_	Seg=O
198	offers	_	_	_	_	_	_	_	Seg=O
199	a	_	_	_	_	_	_	_	Seg=O
200	rapid	_	_	_	_	_	_	_	Seg=O
201	,	_	_	_	_	_	_	_	Seg=O
202	quantitative	_	_	_	_	_	_	_	Seg=O
203	,	_	_	_	_	_	_	_	Seg=O
204	highly	_	_	_	_	_	_	_	Seg=O
205	specific	_	_	_	_	_	_	_	Seg=O
206	and	_	_	_	_	_	_	_	Seg=O
207	sensitive	_	_	_	_	_	_	_	Seg=O
208	approach	_	_	_	_	_	_	_	Seg=O
209	to	_	_	_	_	_	_	_	Seg=O
210	laboratory	_	_	_	_	_	_	_	Seg=O
211	diagnosis	_	_	_	_	_	_	_	Seg=O
212	of	_	_	_	_	_	_	_	Seg=O
213	RSV	_	_	_	_	_	_	_	Seg=O
214	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 2a7c951e191425fd9fa5ac108f07a1f02eb75872
1	It	_	_	_	_	_	_	_	Seg=B-seg
2	has	_	_	_	_	_	_	_	Seg=O
3	been	_	_	_	_	_	_	_	Seg=O
4	nearly	_	_	_	_	_	_	_	Seg=O
5	a	_	_	_	_	_	_	_	Seg=O
6	century	_	_	_	_	_	_	_	Seg=O
7	since	_	_	_	_	_	_	_	Seg=O
8	the	_	_	_	_	_	_	_	Seg=O
9	early	_	_	_	_	_	_	_	Seg=O
10	description	_	_	_	_	_	_	_	Seg=O
11	of	_	_	_	_	_	_	_	Seg=O
12	microglia	_	_	_	_	_	_	_	Seg=O
13	by	_	_	_	_	_	_	_	Seg=O
14	Rio	_	_	_	_	_	_	_	Seg=O
15	-	_	_	_	_	_	_	_	Seg=O
16	Hortega	_	_	_	_	_	_	_	Seg=O
17	;	_	_	_	_	_	_	_	Seg=O
18	since	_	_	_	_	_	_	_	Seg=B-seg
19	then	_	_	_	_	_	_	_	Seg=O
20	many	_	_	_	_	_	_	_	Seg=O
21	more	_	_	_	_	_	_	_	Seg=O
22	biological	_	_	_	_	_	_	_	Seg=O
23	and	_	_	_	_	_	_	_	Seg=O
24	pathological	_	_	_	_	_	_	_	Seg=O
25	features	_	_	_	_	_	_	_	Seg=O
26	of	_	_	_	_	_	_	_	Seg=O
27	microglia	_	_	_	_	_	_	_	Seg=O
28	have	_	_	_	_	_	_	_	Seg=O
29	been	_	_	_	_	_	_	_	Seg=O
30	recognized	_	_	_	_	_	_	_	Seg=O
31	.	_	_	_	_	_	_	_	Seg=O
32	Today	_	_	_	_	_	_	_	Seg=B-seg
33	,	_	_	_	_	_	_	_	Seg=O
34	microglia	_	_	_	_	_	_	_	Seg=O
35	are	_	_	_	_	_	_	_	Seg=O
36	generally	_	_	_	_	_	_	_	Seg=O
37	considered	_	_	_	_	_	_	_	Seg=O
38	to	_	_	_	_	_	_	_	Seg=O
39	be	_	_	_	_	_	_	_	Seg=O
40	beneficial	_	_	_	_	_	_	_	Seg=O
41	to	_	_	_	_	_	_	_	Seg=O
42	homeostasis	_	_	_	_	_	_	_	Seg=O
43	at	_	_	_	_	_	_	_	Seg=O
44	the	_	_	_	_	_	_	_	Seg=O
45	resting	_	_	_	_	_	_	_	Seg=O
46	state	_	_	_	_	_	_	_	Seg=O
47	through	_	_	_	_	_	_	_	Seg=O
48	their	_	_	_	_	_	_	_	Seg=O
49	abilities	_	_	_	_	_	_	_	Seg=O
50	to	_	_	_	_	_	_	_	Seg=B-seg
51	survey	_	_	_	_	_	_	_	Seg=O
52	the	_	_	_	_	_	_	_	Seg=O
53	environment	_	_	_	_	_	_	_	Seg=O
54	and	_	_	_	_	_	_	_	Seg=O
55	phagocytose	_	_	_	_	_	_	_	Seg=O
56	debris	_	_	_	_	_	_	_	Seg=O
57	.	_	_	_	_	_	_	_	Seg=O
58	However	_	_	_	_	_	_	_	Seg=B-seg
59	,	_	_	_	_	_	_	_	Seg=O
60	when	_	_	_	_	_	_	_	Seg=B-seg
61	activated	_	_	_	_	_	_	_	Seg=O
62	microglia	_	_	_	_	_	_	_	Seg=O
63	assume	_	_	_	_	_	_	_	Seg=O
64	diverse	_	_	_	_	_	_	_	Seg=O
65	phenotypes	_	_	_	_	_	_	_	Seg=O
66	ranging	_	_	_	_	_	_	_	Seg=B-seg
67	from	_	_	_	_	_	_	_	Seg=O
68	fully	_	_	_	_	_	_	_	Seg=O
69	inflamed	_	_	_	_	_	_	_	Seg=O
70	,	_	_	_	_	_	_	_	Seg=O
71	which	_	_	_	_	_	_	_	Seg=B-seg
72	involves	_	_	_	_	_	_	_	Seg=O
73	the	_	_	_	_	_	_	_	Seg=O
74	release	_	_	_	_	_	_	_	Seg=O
75	of	_	_	_	_	_	_	_	Seg=O
76	many	_	_	_	_	_	_	_	Seg=O
77	pro	_	_	_	_	_	_	_	Seg=O
78	-	_	_	_	_	_	_	_	Seg=O
79	inflammatory	_	_	_	_	_	_	_	Seg=O
80	cytokines	_	_	_	_	_	_	_	Seg=O
81	,	_	_	_	_	_	_	_	Seg=O
82	to	_	_	_	_	_	_	_	Seg=B-seg
83	alternatively	_	_	_	_	_	_	_	Seg=O
84	activated	_	_	_	_	_	_	_	Seg=O
85	,	_	_	_	_	_	_	_	Seg=O
86	releasing	_	_	_	_	_	_	_	Seg=O
87	antiinflammatory	_	_	_	_	_	_	_	Seg=O
88	cytokines	_	_	_	_	_	_	_	Seg=O
89	or	_	_	_	_	_	_	_	Seg=O
90	neurotrophins	_	_	_	_	_	_	_	Seg=O
91	,	_	_	_	_	_	_	_	Seg=O
92	the	_	_	_	_	_	_	_	Seg=B-seg
93	consequences	_	_	_	_	_	_	_	Seg=O
94	to	_	_	_	_	_	_	_	Seg=O
95	neurons	_	_	_	_	_	_	_	Seg=O
96	can	_	_	_	_	_	_	_	Seg=O
97	range	_	_	_	_	_	_	_	Seg=O
98	from	_	_	_	_	_	_	_	Seg=O
99	detrimental	_	_	_	_	_	_	_	Seg=O
100	to	_	_	_	_	_	_	_	Seg=O
101	supportive	_	_	_	_	_	_	_	Seg=O
102	.	_	_	_	_	_	_	_	Seg=O
103	Due	_	_	_	_	_	_	_	Seg=B-seg
104	to	_	_	_	_	_	_	_	Seg=O
105	the	_	_	_	_	_	_	_	Seg=O
106	different	_	_	_	_	_	_	_	Seg=O
107	experimental	_	_	_	_	_	_	_	Seg=O
108	sets	_	_	_	_	_	_	_	Seg=O
109	and	_	_	_	_	_	_	_	Seg=O
110	conditions	_	_	_	_	_	_	_	Seg=O
111	,	_	_	_	_	_	_	_	Seg=O
112	contradictory	_	_	_	_	_	_	_	Seg=B-seg
113	results	_	_	_	_	_	_	_	Seg=O
114	have	_	_	_	_	_	_	_	Seg=O
115	been	_	_	_	_	_	_	_	Seg=O
116	obtained	_	_	_	_	_	_	_	Seg=O
117	regarding	_	_	_	_	_	_	_	Seg=B-seg
118	the	_	_	_	_	_	_	_	Seg=O
119	controversial	_	_	_	_	_	_	_	Seg=O
120	question	_	_	_	_	_	_	_	Seg=O
121	of	_	_	_	_	_	_	_	Seg=B-seg
122	whether	_	_	_	_	_	_	_	Seg=O
123	microglia	_	_	_	_	_	_	_	Seg=O
124	are	_	_	_	_	_	_	_	Seg=O
125	"	_	_	_	_	_	_	_	Seg=O
126	good	_	_	_	_	_	_	_	Seg=O
127	"	_	_	_	_	_	_	_	Seg=O
128	or	_	_	_	_	_	_	_	Seg=O
129	"	_	_	_	_	_	_	_	Seg=O
130	bad	_	_	_	_	_	_	_	Seg=O
131	.	_	_	_	_	_	_	_	Seg=O
132	"	_	_	_	_	_	_	_	Seg=O
133	While	_	_	_	_	_	_	_	Seg=B-seg
134	it	_	_	_	_	_	_	_	Seg=O
135	is	_	_	_	_	_	_	_	Seg=O
136	well	_	_	_	_	_	_	_	Seg=O
137	understood	_	_	_	_	_	_	_	Seg=O
138	that	_	_	_	_	_	_	_	Seg=O
139	the	_	_	_	_	_	_	_	Seg=O
140	dual	_	_	_	_	_	_	_	Seg=O
141	roles	_	_	_	_	_	_	_	Seg=O
142	of	_	_	_	_	_	_	_	Seg=O
143	activated	_	_	_	_	_	_	_	Seg=O
144	microglia	_	_	_	_	_	_	_	Seg=O
145	depend	_	_	_	_	_	_	_	Seg=O
146	on	_	_	_	_	_	_	_	Seg=O
147	specific	_	_	_	_	_	_	_	Seg=O
148	situations	_	_	_	_	_	_	_	Seg=O
149	,	_	_	_	_	_	_	_	Seg=O
150	the	_	_	_	_	_	_	_	Seg=B-seg
151	underlying	_	_	_	_	_	_	_	Seg=O
152	mechanisms	_	_	_	_	_	_	_	Seg=O
153	have	_	_	_	_	_	_	_	Seg=O
154	remained	_	_	_	_	_	_	_	Seg=O
155	largely	_	_	_	_	_	_	_	Seg=O
156	unclear	_	_	_	_	_	_	_	Seg=O
157	,	_	_	_	_	_	_	_	Seg=O
158	and	_	_	_	_	_	_	_	Seg=B-seg
159	the	_	_	_	_	_	_	_	Seg=O
160	interpretation	_	_	_	_	_	_	_	Seg=O
161	of	_	_	_	_	_	_	_	Seg=O
162	certain	_	_	_	_	_	_	_	Seg=O
163	findings	_	_	_	_	_	_	_	Seg=O
164	related	_	_	_	_	_	_	_	Seg=B-seg
165	to	_	_	_	_	_	_	_	Seg=O
166	diverse	_	_	_	_	_	_	_	Seg=O
167	microglial	_	_	_	_	_	_	_	Seg=O
168	phenotypes	_	_	_	_	_	_	_	Seg=O
169	continues	_	_	_	_	_	_	_	Seg=B-seg
170	to	_	_	_	_	_	_	_	Seg=O
171	be	_	_	_	_	_	_	_	Seg=O
172	problematic	_	_	_	_	_	_	_	Seg=O
173	.	_	_	_	_	_	_	_	Seg=O
174	In	_	_	_	_	_	_	_	Seg=B-seg
175	this	_	_	_	_	_	_	_	Seg=O
176	review	_	_	_	_	_	_	_	Seg=O
177	we	_	_	_	_	_	_	_	Seg=O
178	discuss	_	_	_	_	_	_	_	Seg=O
179	the	_	_	_	_	_	_	_	Seg=O
180	functions	_	_	_	_	_	_	_	Seg=O
181	of	_	_	_	_	_	_	_	Seg=O
182	microglia	_	_	_	_	_	_	_	Seg=O
183	in	_	_	_	_	_	_	_	Seg=O
184	neuronal	_	_	_	_	_	_	_	Seg=O
185	survival	_	_	_	_	_	_	_	Seg=O
186	and	_	_	_	_	_	_	_	Seg=O
187	neurogenesis	_	_	_	_	_	_	_	Seg=O
188	,	_	_	_	_	_	_	_	Seg=O
189	the	_	_	_	_	_	_	_	Seg=O
190	crosstalk	_	_	_	_	_	_	_	Seg=O
191	between	_	_	_	_	_	_	_	Seg=O
192	microglia	_	_	_	_	_	_	_	Seg=O
193	and	_	_	_	_	_	_	_	Seg=O
194	surrounding	_	_	_	_	_	_	_	Seg=O
195	cells	_	_	_	_	_	_	_	Seg=O
196	,	_	_	_	_	_	_	_	Seg=O
197	and	_	_	_	_	_	_	_	Seg=O
198	the	_	_	_	_	_	_	_	Seg=O
199	potential	_	_	_	_	_	_	_	Seg=O
200	factors	_	_	_	_	_	_	_	Seg=O
201	that	_	_	_	_	_	_	_	Seg=B-seg
202	could	_	_	_	_	_	_	_	Seg=O
203	influence	_	_	_	_	_	_	_	Seg=O
204	the	_	_	_	_	_	_	_	Seg=O
205	eventual	_	_	_	_	_	_	_	Seg=O
206	manifestation	_	_	_	_	_	_	_	Seg=O
207	of	_	_	_	_	_	_	_	Seg=O
208	microglia	_	_	_	_	_	_	_	Seg=O
209	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 2b7bf7d309d5b7e2c16feb83d0ebdcb0d3363d76
1	How	_	_	_	_	_	_	_	Seg=B-seg
2	different	_	_	_	_	_	_	_	Seg=O
3	cultures	_	_	_	_	_	_	_	Seg=O
4	react	_	_	_	_	_	_	_	Seg=O
5	and	_	_	_	_	_	_	_	Seg=O
6	respond	_	_	_	_	_	_	_	Seg=O
7	given	_	_	_	_	_	_	_	Seg=B-seg
8	a	_	_	_	_	_	_	_	Seg=O
9	crisis	_	_	_	_	_	_	_	Seg=O
10	is	_	_	_	_	_	_	_	Seg=B-seg
11	predominant	_	_	_	_	_	_	_	Seg=O
12	in	_	_	_	_	_	_	_	Seg=O
13	a	_	_	_	_	_	_	_	Seg=O
14-15	society's	_	_	_	_	_	_	_	_
14	society	_	_	_	_	_	_	_	Seg=O
15	's	_	_	_	_	_	_	_	Seg=O
16	norms	_	_	_	_	_	_	_	Seg=O
17	and	_	_	_	_	_	_	_	Seg=O
18	political	_	_	_	_	_	_	_	Seg=O
19	will	_	_	_	_	_	_	_	Seg=O
20	to	_	_	_	_	_	_	_	Seg=B-seg
21	combat	_	_	_	_	_	_	_	Seg=O
22	the	_	_	_	_	_	_	_	Seg=O
23	situation	_	_	_	_	_	_	_	Seg=O
24	.	_	_	_	_	_	_	_	Seg=O
25	Often	_	_	_	_	_	_	_	Seg=B-seg
26	the	_	_	_	_	_	_	_	Seg=O
27	decisions	_	_	_	_	_	_	_	Seg=O
28	made	_	_	_	_	_	_	_	Seg=B-seg
29	are	_	_	_	_	_	_	_	Seg=B-seg
30	necessitated	_	_	_	_	_	_	_	Seg=O
31	by	_	_	_	_	_	_	_	Seg=O
32	events	_	_	_	_	_	_	_	Seg=O
33	,	_	_	_	_	_	_	_	Seg=O
34	social	_	_	_	_	_	_	_	Seg=O
35	pressure	_	_	_	_	_	_	_	Seg=O
36	,	_	_	_	_	_	_	_	Seg=O
37	or	_	_	_	_	_	_	_	Seg=O
38	the	_	_	_	_	_	_	_	Seg=O
39	need	_	_	_	_	_	_	_	Seg=O
40	of	_	_	_	_	_	_	_	Seg=O
41	the	_	_	_	_	_	_	_	Seg=O
42	hour	_	_	_	_	_	_	_	Seg=O
43	,	_	_	_	_	_	_	_	Seg=O
44	which	_	_	_	_	_	_	_	Seg=B-seg
45	may	_	_	_	_	_	_	_	Seg=O
46	not	_	_	_	_	_	_	_	Seg=O
47	represent	_	_	_	_	_	_	_	Seg=O
48	the	_	_	_	_	_	_	_	Seg=O
49	will	_	_	_	_	_	_	_	Seg=O
50	of	_	_	_	_	_	_	_	Seg=O
51	the	_	_	_	_	_	_	_	Seg=O
52	nation	_	_	_	_	_	_	_	Seg=O
53	.	_	_	_	_	_	_	_	Seg=O
54	While	_	_	_	_	_	_	_	Seg=B-seg
55	some	_	_	_	_	_	_	_	Seg=O
56	are	_	_	_	_	_	_	_	Seg=O
57	pleased	_	_	_	_	_	_	_	Seg=O
58	with	_	_	_	_	_	_	_	Seg=O
59	it	_	_	_	_	_	_	_	Seg=O
60	,	_	_	_	_	_	_	_	Seg=O
61	others	_	_	_	_	_	_	_	Seg=B-seg
62	might	_	_	_	_	_	_	_	Seg=O
63	show	_	_	_	_	_	_	_	Seg=O
64	resentment	_	_	_	_	_	_	_	Seg=O
65	.	_	_	_	_	_	_	_	Seg=O
66	Coronavirus	_	_	_	_	_	_	_	Seg=B-seg
67	(	_	_	_	_	_	_	_	Seg=O
68	COVID-19	_	_	_	_	_	_	_	Seg=O
69	)	_	_	_	_	_	_	_	Seg=O
70	brought	_	_	_	_	_	_	_	Seg=O
71	a	_	_	_	_	_	_	_	Seg=O
72	mix	_	_	_	_	_	_	_	Seg=O
73	of	_	_	_	_	_	_	_	Seg=O
74	similar	_	_	_	_	_	_	_	Seg=O
75	emotions	_	_	_	_	_	_	_	Seg=O
76	from	_	_	_	_	_	_	_	Seg=O
77	the	_	_	_	_	_	_	_	Seg=O
78	nations	_	_	_	_	_	_	_	Seg=O
79	towards	_	_	_	_	_	_	_	Seg=O
80	the	_	_	_	_	_	_	_	Seg=O
81	decisions	_	_	_	_	_	_	_	Seg=O
82	taken	_	_	_	_	_	_	_	Seg=B-seg
83	by	_	_	_	_	_	_	_	Seg=O
84	their	_	_	_	_	_	_	_	Seg=O
85	respective	_	_	_	_	_	_	_	Seg=O
86	governments	_	_	_	_	_	_	_	Seg=O
87	.	_	_	_	_	_	_	_	Seg=O
88	Social	_	_	_	_	_	_	_	Seg=B-seg
89	media	_	_	_	_	_	_	_	Seg=O
90	was	_	_	_	_	_	_	_	Seg=O
91	bombarded	_	_	_	_	_	_	_	Seg=O
92	with	_	_	_	_	_	_	_	Seg=O
93	posts	_	_	_	_	_	_	_	Seg=O
94	containing	_	_	_	_	_	_	_	Seg=B-seg
95	both	_	_	_	_	_	_	_	Seg=O
96	positive	_	_	_	_	_	_	_	Seg=O
97	and	_	_	_	_	_	_	_	Seg=O
98	negative	_	_	_	_	_	_	_	Seg=O
99	sentiments	_	_	_	_	_	_	_	Seg=O
100	on	_	_	_	_	_	_	_	Seg=O
101	the	_	_	_	_	_	_	_	Seg=O
102	COVID-19	_	_	_	_	_	_	_	Seg=O
103	,	_	_	_	_	_	_	_	Seg=O
104	pandemic	_	_	_	_	_	_	_	Seg=O
105	,	_	_	_	_	_	_	_	Seg=O
106	lockdown	_	_	_	_	_	_	_	Seg=O
107	,	_	_	_	_	_	_	_	Seg=O
108	hashtags	_	_	_	_	_	_	_	Seg=O
109	past	_	_	_	_	_	_	_	Seg=O
110	couple	_	_	_	_	_	_	_	Seg=O
111	of	_	_	_	_	_	_	_	Seg=O
112	months	_	_	_	_	_	_	_	Seg=O
113	.	_	_	_	_	_	_	_	Seg=O
114	Despite	_	_	_	_	_	_	_	Seg=B-seg
115	geographically	_	_	_	_	_	_	_	Seg=O
116	close	_	_	_	_	_	_	_	Seg=O
117	,	_	_	_	_	_	_	_	Seg=O
118	many	_	_	_	_	_	_	_	Seg=B-seg
119	neighboring	_	_	_	_	_	_	_	Seg=O
120	countries	_	_	_	_	_	_	_	Seg=O
121	reacted	_	_	_	_	_	_	_	Seg=O
122	differently	_	_	_	_	_	_	_	Seg=O
123	to	_	_	_	_	_	_	_	Seg=O
124	one	_	_	_	_	_	_	_	Seg=O
125	another	_	_	_	_	_	_	_	Seg=O
126	.	_	_	_	_	_	_	_	Seg=O
127	For	_	_	_	_	_	_	_	Seg=B-seg
128	instance	_	_	_	_	_	_	_	Seg=O
129	,	_	_	_	_	_	_	_	Seg=O
130	Denmark	_	_	_	_	_	_	_	Seg=O
131	and	_	_	_	_	_	_	_	Seg=O
132	Sweden	_	_	_	_	_	_	_	Seg=O
133	,	_	_	_	_	_	_	_	Seg=O
134	which	_	_	_	_	_	_	_	Seg=B-seg
135	share	_	_	_	_	_	_	_	Seg=O
136	many	_	_	_	_	_	_	_	Seg=O
137	similarities	_	_	_	_	_	_	_	Seg=O
138	,	_	_	_	_	_	_	_	Seg=O
139	stood	_	_	_	_	_	_	_	Seg=B-seg
140	poles	_	_	_	_	_	_	_	Seg=O
141	apart	_	_	_	_	_	_	_	Seg=O
142	on	_	_	_	_	_	_	_	Seg=O
143	the	_	_	_	_	_	_	_	Seg=O
144	decision	_	_	_	_	_	_	_	Seg=O
145	taken	_	_	_	_	_	_	_	Seg=B-seg
146	by	_	_	_	_	_	_	_	Seg=O
147	their	_	_	_	_	_	_	_	Seg=O
148	respective	_	_	_	_	_	_	_	Seg=O
149	governments	_	_	_	_	_	_	_	Seg=O
150	.	_	_	_	_	_	_	_	Seg=O
151	Yet	_	_	_	_	_	_	_	Seg=B-seg
152	,	_	_	_	_	_	_	_	Seg=O
153	their	_	_	_	_	_	_	_	Seg=O
154-155	nation's	_	_	_	_	_	_	_	_
154	nation	_	_	_	_	_	_	_	Seg=O
155	's	_	_	_	_	_	_	_	Seg=O
156	support	_	_	_	_	_	_	_	Seg=O
157	was	_	_	_	_	_	_	_	Seg=O
158	mostly	_	_	_	_	_	_	_	Seg=O
159	unanimous	_	_	_	_	_	_	_	Seg=O
160	,	_	_	_	_	_	_	_	Seg=O
161	unlike	_	_	_	_	_	_	_	Seg=B-seg
162	the	_	_	_	_	_	_	_	Seg=O
163	South	_	_	_	_	_	_	_	Seg=O
164	Asian	_	_	_	_	_	_	_	Seg=O
165	neighboring	_	_	_	_	_	_	_	Seg=O
166	countries	_	_	_	_	_	_	_	Seg=O
167	where	_	_	_	_	_	_	_	Seg=B-seg
168	people	_	_	_	_	_	_	_	Seg=O
169	showed	_	_	_	_	_	_	_	Seg=O
170	a	_	_	_	_	_	_	_	Seg=O
171	lot	_	_	_	_	_	_	_	Seg=O
172	of	_	_	_	_	_	_	_	Seg=O
173	anxiety	_	_	_	_	_	_	_	Seg=O
174	and	_	_	_	_	_	_	_	Seg=O
175	resentment	_	_	_	_	_	_	_	Seg=O
176	.	_	_	_	_	_	_	_	Seg=O
177	This	_	_	_	_	_	_	_	Seg=B-seg
178	study	_	_	_	_	_	_	_	Seg=O
179	tends	_	_	_	_	_	_	_	Seg=O
180	to	_	_	_	_	_	_	_	Seg=O
181	detect	_	_	_	_	_	_	_	Seg=O
182	and	_	_	_	_	_	_	_	Seg=O
183	analyze	_	_	_	_	_	_	_	Seg=O
184	sentiment	_	_	_	_	_	_	_	Seg=O
185	polarity	_	_	_	_	_	_	_	Seg=O
186	and	_	_	_	_	_	_	_	Seg=O
187	emotions	_	_	_	_	_	_	_	Seg=O
188	demonstrated	_	_	_	_	_	_	_	Seg=B-seg
189	during	_	_	_	_	_	_	_	Seg=O
190	the	_	_	_	_	_	_	_	Seg=O
191	initial	_	_	_	_	_	_	_	Seg=O
192	phase	_	_	_	_	_	_	_	Seg=O
193	of	_	_	_	_	_	_	_	Seg=O
194	the	_	_	_	_	_	_	_	Seg=O
195	pandemic	_	_	_	_	_	_	_	Seg=O
196	and	_	_	_	_	_	_	_	Seg=O
197	the	_	_	_	_	_	_	_	Seg=O
198	lockdown	_	_	_	_	_	_	_	Seg=O
199	period	_	_	_	_	_	_	_	Seg=O
200	employing	_	_	_	_	_	_	_	Seg=B-seg
201	natural	_	_	_	_	_	_	_	Seg=O
202	language	_	_	_	_	_	_	_	Seg=O
203	processing	_	_	_	_	_	_	_	Seg=O
204	(	_	_	_	_	_	_	_	Seg=O
205	NLP	_	_	_	_	_	_	_	Seg=O
206	)	_	_	_	_	_	_	_	Seg=O
207	and	_	_	_	_	_	_	_	Seg=O
208	deep	_	_	_	_	_	_	_	Seg=O
209	learning	_	_	_	_	_	_	_	Seg=O
210	techniques	_	_	_	_	_	_	_	Seg=O
211	on	_	_	_	_	_	_	_	Seg=O
212	Twitter	_	_	_	_	_	_	_	Seg=O
213	posts	_	_	_	_	_	_	_	Seg=O
214	.	_	_	_	_	_	_	_	Seg=O
215	Deep	_	_	_	_	_	_	_	Seg=B-seg
216	long	_	_	_	_	_	_	_	Seg=O
217	short	_	_	_	_	_	_	_	Seg=O
218	-	_	_	_	_	_	_	_	Seg=O
219	term	_	_	_	_	_	_	_	Seg=O
220	memory	_	_	_	_	_	_	_	Seg=O
221	(	_	_	_	_	_	_	_	Seg=O
222	LSTM	_	_	_	_	_	_	_	Seg=O
223	)	_	_	_	_	_	_	_	Seg=O
224	models	_	_	_	_	_	_	_	Seg=O
225	used	_	_	_	_	_	_	_	Seg=B-seg
226	for	_	_	_	_	_	_	_	Seg=B-seg
227	estimating	_	_	_	_	_	_	_	Seg=O
228	the	_	_	_	_	_	_	_	Seg=O
229	sentiment	_	_	_	_	_	_	_	Seg=O
230	polarity	_	_	_	_	_	_	_	Seg=O
231	and	_	_	_	_	_	_	_	Seg=O
232	emotions	_	_	_	_	_	_	_	Seg=O
233	from	_	_	_	_	_	_	_	Seg=O
234	extracted	_	_	_	_	_	_	_	Seg=O
235	tweets	_	_	_	_	_	_	_	Seg=O
236	have	_	_	_	_	_	_	_	Seg=B-seg
237	been	_	_	_	_	_	_	_	Seg=O
238	trained	_	_	_	_	_	_	_	Seg=O
239	to	_	_	_	_	_	_	_	Seg=B-seg
240	achieve	_	_	_	_	_	_	_	Seg=O
241	state	_	_	_	_	_	_	_	Seg=O
242	-	_	_	_	_	_	_	_	Seg=O
243	of	_	_	_	_	_	_	_	Seg=O
244	-	_	_	_	_	_	_	_	Seg=O
245	the	_	_	_	_	_	_	_	Seg=O
246	-	_	_	_	_	_	_	_	Seg=O
247	art	_	_	_	_	_	_	_	Seg=O
248	accuracy	_	_	_	_	_	_	_	Seg=O
249	on	_	_	_	_	_	_	_	Seg=O
250	the	_	_	_	_	_	_	_	Seg=O
251	sentiment140	_	_	_	_	_	_	_	Seg=O
252	dataset	_	_	_	_	_	_	_	Seg=O
253	.	_	_	_	_	_	_	_	Seg=O
254	The	_	_	_	_	_	_	_	Seg=B-seg
255	use	_	_	_	_	_	_	_	Seg=O
256	of	_	_	_	_	_	_	_	Seg=O
257	emoticons	_	_	_	_	_	_	_	Seg=O
258	showed	_	_	_	_	_	_	_	Seg=O
259	a	_	_	_	_	_	_	_	Seg=O
260	unique	_	_	_	_	_	_	_	Seg=O
261	and	_	_	_	_	_	_	_	Seg=O
262	novel	_	_	_	_	_	_	_	Seg=O
263	way	_	_	_	_	_	_	_	Seg=O
264	of	_	_	_	_	_	_	_	Seg=B-seg
265	validating	_	_	_	_	_	_	_	Seg=O
266	the	_	_	_	_	_	_	_	Seg=O
267	supervised	_	_	_	_	_	_	_	Seg=O
268	deep	_	_	_	_	_	_	_	Seg=O
269	learning	_	_	_	_	_	_	_	Seg=O
270	models	_	_	_	_	_	_	_	Seg=O
271	on	_	_	_	_	_	_	_	Seg=O
272	tweets	_	_	_	_	_	_	_	Seg=O
273	extracted	_	_	_	_	_	_	_	Seg=B-seg
274	from	_	_	_	_	_	_	_	Seg=O
275	Twitter	_	_	_	_	_	_	_	Seg=O
276	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 2c08714eb56aedc24e6e4243784ca66870a234c1
1	Children	_	_	_	_	_	_	_	Seg=B-seg
2	of	_	_	_	_	_	_	_	Seg=O
3	today	_	_	_	_	_	_	_	Seg=O
4	have	_	_	_	_	_	_	_	Seg=O
5	been	_	_	_	_	_	_	_	Seg=O
6	surrounded	_	_	_	_	_	_	_	Seg=O
7	by	_	_	_	_	_	_	_	Seg=O
8	digital	_	_	_	_	_	_	_	Seg=O
9	technology	_	_	_	_	_	_	_	Seg=O
10	since	_	_	_	_	_	_	_	Seg=O
11	their	_	_	_	_	_	_	_	Seg=O
12	birth	_	_	_	_	_	_	_	Seg=O
13	.	_	_	_	_	_	_	_	Seg=O
14	However	_	_	_	_	_	_	_	Seg=B-seg
15	,	_	_	_	_	_	_	_	Seg=O
16	children	_	_	_	_	_	_	_	Seg=O
17	of	_	_	_	_	_	_	_	Seg=O
18	today	_	_	_	_	_	_	_	Seg=O
19	are	_	_	_	_	_	_	_	Seg=O
20	not	_	_	_	_	_	_	_	Seg=O
21	equally	_	_	_	_	_	_	_	Seg=O
22	equipped	_	_	_	_	_	_	_	Seg=O
23	for	_	_	_	_	_	_	_	Seg=O
24	their	_	_	_	_	_	_	_	Seg=O
25	technology	_	_	_	_	_	_	_	Seg=O
26	rich	_	_	_	_	_	_	_	Seg=O
27	future	_	_	_	_	_	_	_	Seg=O
28	:	_	_	_	_	_	_	_	Seg=O
29	various	_	_	_	_	_	_	_	Seg=B-seg
30	kinds	_	_	_	_	_	_	_	Seg=O
31	of	_	_	_	_	_	_	_	Seg=O
32	digital	_	_	_	_	_	_	_	Seg=O
33	divides	_	_	_	_	_	_	_	Seg=O
34	still	_	_	_	_	_	_	_	Seg=O
35	prevail	_	_	_	_	_	_	_	Seg=O
36	in	_	_	_	_	_	_	_	Seg=O
37	the	_	_	_	_	_	_	_	Seg=O
38	society	_	_	_	_	_	_	_	Seg=O
39	and	_	_	_	_	_	_	_	Seg=B-seg
40	affect	_	_	_	_	_	_	_	Seg=O
41	the	_	_	_	_	_	_	_	Seg=O
42	young	_	_	_	_	_	_	_	Seg=O
43	generation	_	_	_	_	_	_	_	Seg=O
44	and	_	_	_	_	_	_	_	Seg=O
45	their	_	_	_	_	_	_	_	Seg=O
46	digital	_	_	_	_	_	_	_	Seg=O
47	futures	_	_	_	_	_	_	_	Seg=O
48	.	_	_	_	_	_	_	_	Seg=O
49	Schools	_	_	_	_	_	_	_	Seg=B-seg
50	and	_	_	_	_	_	_	_	Seg=O
51	education	_	_	_	_	_	_	_	Seg=O
52	of	_	_	_	_	_	_	_	Seg=O
53	children	_	_	_	_	_	_	_	Seg=O
54	should	_	_	_	_	_	_	_	Seg=O
55	undergo	_	_	_	_	_	_	_	Seg=O
56	an	_	_	_	_	_	_	_	Seg=O
57	extensive	_	_	_	_	_	_	_	Seg=O
58	digital	_	_	_	_	_	_	_	Seg=O
59	transformation	_	_	_	_	_	_	_	Seg=O
60	to	_	_	_	_	_	_	_	Seg=B-seg
61	be	_	_	_	_	_	_	_	Seg=O
62	able	_	_	_	_	_	_	_	Seg=O
63	to	_	_	_	_	_	_	_	Seg=O
64	meet	_	_	_	_	_	_	_	Seg=O
65	the	_	_	_	_	_	_	_	Seg=O
66	needs	_	_	_	_	_	_	_	Seg=O
67	of	_	_	_	_	_	_	_	Seg=O
68	the	_	_	_	_	_	_	_	Seg=O
69	young	_	_	_	_	_	_	_	Seg=O
70	generation	_	_	_	_	_	_	_	Seg=O
71	and	_	_	_	_	_	_	_	Seg=O
72	their	_	_	_	_	_	_	_	Seg=O
73	digitalized	_	_	_	_	_	_	_	Seg=O
74	future	_	_	_	_	_	_	_	Seg=O
75	.	_	_	_	_	_	_	_	Seg=O
76	The	_	_	_	_	_	_	_	Seg=B-seg
77	COVID-19	_	_	_	_	_	_	_	Seg=O
78	pandemic	_	_	_	_	_	_	_	Seg=O
79	has	_	_	_	_	_	_	_	Seg=O
80	suddenly	_	_	_	_	_	_	_	Seg=O
81	and	_	_	_	_	_	_	_	Seg=O
82	abruptly	_	_	_	_	_	_	_	Seg=O
83	forced	_	_	_	_	_	_	_	Seg=O
84	schools	_	_	_	_	_	_	_	Seg=O
85	and	_	_	_	_	_	_	_	Seg=O
86	education	_	_	_	_	_	_	_	Seg=O
87	indeed	_	_	_	_	_	_	_	Seg=O
88	to	_	_	_	_	_	_	_	Seg=O
89	engage	_	_	_	_	_	_	_	Seg=O
90	in	_	_	_	_	_	_	_	Seg=O
91	such	_	_	_	_	_	_	_	Seg=O
92	a	_	_	_	_	_	_	_	Seg=O
93	transformation	_	_	_	_	_	_	_	Seg=O
94	.	_	_	_	_	_	_	_	Seg=O
95	In	_	_	_	_	_	_	_	Seg=B-seg
96	this	_	_	_	_	_	_	_	Seg=O
97	study	_	_	_	_	_	_	_	Seg=O
98	we	_	_	_	_	_	_	_	Seg=O
99	examine	_	_	_	_	_	_	_	Seg=O
100	the	_	_	_	_	_	_	_	Seg=O
101	digital	_	_	_	_	_	_	_	Seg=O
102	transformation	_	_	_	_	_	_	_	Seg=O
103	initiated	_	_	_	_	_	_	_	Seg=B-seg
104	by	_	_	_	_	_	_	_	Seg=O
105	the	_	_	_	_	_	_	_	Seg=O
106	COVID-19	_	_	_	_	_	_	_	Seg=O
107	pandemic	_	_	_	_	_	_	_	Seg=O
108	in	_	_	_	_	_	_	_	Seg=B-seg
109	the	_	_	_	_	_	_	_	Seg=O
110	basic	_	_	_	_	_	_	_	Seg=O
111	education	_	_	_	_	_	_	_	Seg=O
112	of	_	_	_	_	_	_	_	Seg=O
113	the	_	_	_	_	_	_	_	Seg=O
114	young	_	_	_	_	_	_	_	Seg=O
115	generation	_	_	_	_	_	_	_	Seg=O
116	,	_	_	_	_	_	_	_	Seg=O
117	the	_	_	_	_	_	_	_	Seg=O
118	variety	_	_	_	_	_	_	_	Seg=O
119	of	_	_	_	_	_	_	_	Seg=O
120	digital	_	_	_	_	_	_	_	Seg=O
121	divides	_	_	_	_	_	_	_	Seg=O
122	emerging	_	_	_	_	_	_	_	Seg=B-seg
123	and	_	_	_	_	_	_	_	Seg=O
124	reinforced	_	_	_	_	_	_	_	Seg=O
125	,	_	_	_	_	_	_	_	Seg=O
126	and	_	_	_	_	_	_	_	Seg=B-seg
127	the	_	_	_	_	_	_	_	Seg=O
128	possible	_	_	_	_	_	_	_	Seg=O
129	barriers	_	_	_	_	_	_	_	Seg=O
130	reported	_	_	_	_	_	_	_	Seg=B-seg
131	along	_	_	_	_	_	_	_	Seg=O
132	the	_	_	_	_	_	_	_	Seg=O
133	way	_	_	_	_	_	_	_	Seg=O
134	.	_	_	_	_	_	_	_	Seg=O
135	We	_	_	_	_	_	_	_	Seg=B-seg
136	argue	_	_	_	_	_	_	_	Seg=O
137	that	_	_	_	_	_	_	_	Seg=B-seg
138	information	_	_	_	_	_	_	_	Seg=O
139	management	_	_	_	_	_	_	_	Seg=O
140	research	_	_	_	_	_	_	_	Seg=O
141	should	_	_	_	_	_	_	_	Seg=O
142	better	_	_	_	_	_	_	_	Seg=O
143	acknowledge	_	_	_	_	_	_	_	Seg=O
144	children	_	_	_	_	_	_	_	Seg=O
145	,	_	_	_	_	_	_	_	Seg=O
146	their	_	_	_	_	_	_	_	Seg=O
147	digitalized	_	_	_	_	_	_	_	Seg=O
148	everyday	_	_	_	_	_	_	_	Seg=O
149	life	_	_	_	_	_	_	_	Seg=O
150	and	_	_	_	_	_	_	_	Seg=O
151	their	_	_	_	_	_	_	_	Seg=O
152	basic	_	_	_	_	_	_	_	Seg=O
153	education	_	_	_	_	_	_	_	Seg=O
154	as	_	_	_	_	_	_	_	Seg=O
155	significant	_	_	_	_	_	_	_	Seg=O
156	areas	_	_	_	_	_	_	_	Seg=O
157	of	_	_	_	_	_	_	_	Seg=O
158	concern	_	_	_	_	_	_	_	Seg=O
159	.	_	_	_	_	_	_	_	Seg=O
160	We	_	_	_	_	_	_	_	Seg=B-seg
161	should	_	_	_	_	_	_	_	Seg=O
162	understand	_	_	_	_	_	_	_	Seg=O
163	them	_	_	_	_	_	_	_	Seg=O
164	as	_	_	_	_	_	_	_	Seg=O
165	well	_	_	_	_	_	_	_	Seg=O
166	as	_	_	_	_	_	_	_	Seg=O
167	allow	_	_	_	_	_	_	_	Seg=O
168	them	_	_	_	_	_	_	_	Seg=O
169	to	_	_	_	_	_	_	_	Seg=O
170	shape	_	_	_	_	_	_	_	Seg=O
171	the	_	_	_	_	_	_	_	Seg=O
172	education	_	_	_	_	_	_	_	Seg=O
173	we	_	_	_	_	_	_	_	Seg=B-seg
174	offer	_	_	_	_	_	_	_	Seg=O
175	in	_	_	_	_	_	_	_	Seg=O
176	the	_	_	_	_	_	_	_	Seg=O
177	context	_	_	_	_	_	_	_	Seg=O
178	of	_	_	_	_	_	_	_	Seg=O
179	higher	_	_	_	_	_	_	_	Seg=O
180	education	_	_	_	_	_	_	_	Seg=O
181	,	_	_	_	_	_	_	_	Seg=O
182	but	_	_	_	_	_	_	_	Seg=B-seg
183	we	_	_	_	_	_	_	_	Seg=O
184	should	_	_	_	_	_	_	_	Seg=O
185	also	_	_	_	_	_	_	_	Seg=O
186	aim	_	_	_	_	_	_	_	Seg=O
187	at	_	_	_	_	_	_	_	Seg=O
188	influencing	_	_	_	_	_	_	_	Seg=O
189	the	_	_	_	_	_	_	_	Seg=O
190	basic	_	_	_	_	_	_	_	Seg=O
191	education	_	_	_	_	_	_	_	Seg=O
192	of	_	_	_	_	_	_	_	Seg=O
193	the	_	_	_	_	_	_	_	Seg=O
194	young	_	_	_	_	_	_	_	Seg=O
195	generation	_	_	_	_	_	_	_	Seg=O
196	for	_	_	_	_	_	_	_	Seg=B-seg
197	the	_	_	_	_	_	_	_	Seg=O
198	purpose	_	_	_	_	_	_	_	Seg=O
199	of	_	_	_	_	_	_	_	Seg=O
200	equipping	_	_	_	_	_	_	_	Seg=O
201	them	_	_	_	_	_	_	_	Seg=O
202	with	_	_	_	_	_	_	_	Seg=O
203	important	_	_	_	_	_	_	_	Seg=O
204	skills	_	_	_	_	_	_	_	Seg=O
205	and	_	_	_	_	_	_	_	Seg=O
206	competencies	_	_	_	_	_	_	_	Seg=O
207	for	_	_	_	_	_	_	_	Seg=O
208	their	_	_	_	_	_	_	_	Seg=O
209	digital	_	_	_	_	_	_	_	Seg=O
210	futures	_	_	_	_	_	_	_	Seg=O
211	but	_	_	_	_	_	_	_	Seg=B-seg
212	also	_	_	_	_	_	_	_	Seg=O
213	for	_	_	_	_	_	_	_	Seg=O
214	the	_	_	_	_	_	_	_	Seg=O
215	purpose	_	_	_	_	_	_	_	Seg=O
216	of	_	_	_	_	_	_	_	Seg=O
217	arousing	_	_	_	_	_	_	_	Seg=O
218	their	_	_	_	_	_	_	_	Seg=O
219	interest	_	_	_	_	_	_	_	Seg=O
220	in	_	_	_	_	_	_	_	Seg=O
221	this	_	_	_	_	_	_	_	Seg=O
222	important	_	_	_	_	_	_	_	Seg=O
223	field	_	_	_	_	_	_	_	Seg=O
224	,	_	_	_	_	_	_	_	Seg=O
225	maybe	_	_	_	_	_	_	_	Seg=O
226	even	_	_	_	_	_	_	_	Seg=O
227	as	_	_	_	_	_	_	_	Seg=O
228	a	_	_	_	_	_	_	_	Seg=O
229	career	_	_	_	_	_	_	_	Seg=O
230	option	_	_	_	_	_	_	_	Seg=O
231	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 2d0664c3be770994d502f1d1baae42684652aad4
1	Vaccination	_	_	_	_	_	_	_	Seg=B-seg
2	is	_	_	_	_	_	_	_	Seg=O
3	one	_	_	_	_	_	_	_	Seg=O
4	of	_	_	_	_	_	_	_	Seg=O
5	the	_	_	_	_	_	_	_	Seg=O
6	cheapest	_	_	_	_	_	_	_	Seg=O
7	health	_	_	_	_	_	_	_	Seg=O
8	-	_	_	_	_	_	_	_	Seg=O
9	care	_	_	_	_	_	_	_	Seg=O
10	interventions	_	_	_	_	_	_	_	Seg=O
11	that	_	_	_	_	_	_	_	Seg=B-seg
12	have	_	_	_	_	_	_	_	Seg=O
13	saved	_	_	_	_	_	_	_	Seg=O
14	more	_	_	_	_	_	_	_	Seg=O
15	lives	_	_	_	_	_	_	_	Seg=O
16	than	_	_	_	_	_	_	_	Seg=O
17	any	_	_	_	_	_	_	_	Seg=O
18	other	_	_	_	_	_	_	_	Seg=O
19	drugs	_	_	_	_	_	_	_	Seg=O
20	or	_	_	_	_	_	_	_	Seg=O
21	therapies	_	_	_	_	_	_	_	Seg=O
22	.	_	_	_	_	_	_	_	Seg=O
23	Due	_	_	_	_	_	_	_	Seg=B-seg
24	to	_	_	_	_	_	_	_	Seg=O
25	successful	_	_	_	_	_	_	_	Seg=O
26	immunization	_	_	_	_	_	_	_	Seg=O
27	programs	_	_	_	_	_	_	_	Seg=O
28	we	_	_	_	_	_	_	_	Seg=B-seg
29	rarely	_	_	_	_	_	_	_	Seg=O
30	hear	_	_	_	_	_	_	_	Seg=O
31	about	_	_	_	_	_	_	_	Seg=O
32	some	_	_	_	_	_	_	_	Seg=O
33	of	_	_	_	_	_	_	_	Seg=O
34	the	_	_	_	_	_	_	_	Seg=O
35	common	_	_	_	_	_	_	_	Seg=O
36	diseases	_	_	_	_	_	_	_	Seg=O
37	of	_	_	_	_	_	_	_	Seg=O
38	the	_	_	_	_	_	_	_	Seg=O
39	early	_	_	_	_	_	_	_	Seg=O
40	twentieth	_	_	_	_	_	_	_	Seg=O
41	century	_	_	_	_	_	_	_	Seg=O
42	including	_	_	_	_	_	_	_	Seg=B-seg
43	small	_	_	_	_	_	_	_	Seg=O
44	pox	_	_	_	_	_	_	_	Seg=O
45	and	_	_	_	_	_	_	_	Seg=O
46	polio	_	_	_	_	_	_	_	Seg=O
47	.	_	_	_	_	_	_	_	Seg=O
48	Vaccination	_	_	_	_	_	_	_	Seg=B-seg
49	programs	_	_	_	_	_	_	_	Seg=O
50	have	_	_	_	_	_	_	_	Seg=O
51	also	_	_	_	_	_	_	_	Seg=O
52	helped	_	_	_	_	_	_	_	Seg=O
53	to	_	_	_	_	_	_	_	Seg=O
54	increase	_	_	_	_	_	_	_	Seg=O
55	food	_	_	_	_	_	_	_	Seg=O
56	production	_	_	_	_	_	_	_	Seg=O
57	notably	_	_	_	_	_	_	_	Seg=O
58	poultry	_	_	_	_	_	_	_	Seg=O
59	,	_	_	_	_	_	_	_	Seg=O
60	cattle	_	_	_	_	_	_	_	Seg=O
61	,	_	_	_	_	_	_	_	Seg=O
62	and	_	_	_	_	_	_	_	Seg=O
63	milk	_	_	_	_	_	_	_	Seg=O
64	production	_	_	_	_	_	_	_	Seg=O
65	due	_	_	_	_	_	_	_	Seg=B-seg
66	to	_	_	_	_	_	_	_	Seg=O
67	lower	_	_	_	_	_	_	_	Seg=O
68	incidence	_	_	_	_	_	_	_	Seg=O
69	of	_	_	_	_	_	_	_	Seg=O
70	infectious	_	_	_	_	_	_	_	Seg=O
71	diseases	_	_	_	_	_	_	_	Seg=O
72	in	_	_	_	_	_	_	_	Seg=O
73	farm	_	_	_	_	_	_	_	Seg=O
74	animals	_	_	_	_	_	_	_	Seg=O
75	.	_	_	_	_	_	_	_	Seg=O
76	Though	_	_	_	_	_	_	_	Seg=B-seg
77	vaccination	_	_	_	_	_	_	_	Seg=O
78	programs	_	_	_	_	_	_	_	Seg=O
79	have	_	_	_	_	_	_	_	Seg=O
80	eradicated	_	_	_	_	_	_	_	Seg=O
81	several	_	_	_	_	_	_	_	Seg=O
82	diseases	_	_	_	_	_	_	_	Seg=O
83	and	_	_	_	_	_	_	_	Seg=B-seg
84	increased	_	_	_	_	_	_	_	Seg=O
85	the	_	_	_	_	_	_	_	Seg=O
86	quality	_	_	_	_	_	_	_	Seg=O
87	of	_	_	_	_	_	_	_	Seg=O
88	life	_	_	_	_	_	_	_	Seg=O
89	there	_	_	_	_	_	_	_	Seg=B-seg
90	are	_	_	_	_	_	_	_	Seg=O
91	several	_	_	_	_	_	_	_	Seg=O
92	diseases	_	_	_	_	_	_	_	Seg=O
93	that	_	_	_	_	_	_	_	Seg=O
94	have	_	_	_	_	_	_	_	Seg=O
95	no	_	_	_	_	_	_	_	Seg=O
96	effective	_	_	_	_	_	_	_	Seg=O
97	vaccines	_	_	_	_	_	_	_	Seg=O
98	.	_	_	_	_	_	_	_	Seg=O
99	Currently	_	_	_	_	_	_	_	Seg=B-seg
100	there	_	_	_	_	_	_	_	Seg=O
101	are	_	_	_	_	_	_	_	Seg=O
102	no	_	_	_	_	_	_	_	Seg=O
103	vaccines	_	_	_	_	_	_	_	Seg=O
104	for	_	_	_	_	_	_	_	Seg=O
105	cancer	_	_	_	_	_	_	_	Seg=O
106	,	_	_	_	_	_	_	_	Seg=O
107	neurodegenerative	_	_	_	_	_	_	_	Seg=O
108	diseases	_	_	_	_	_	_	_	Seg=O
109	,	_	_	_	_	_	_	_	Seg=O
110	autoimmune	_	_	_	_	_	_	_	Seg=O
111	diseases	_	_	_	_	_	_	_	Seg=O
112	,	_	_	_	_	_	_	_	Seg=O
113	as	_	_	_	_	_	_	_	Seg=O
114	well	_	_	_	_	_	_	_	Seg=O
115	as	_	_	_	_	_	_	_	Seg=O
116	infectious	_	_	_	_	_	_	_	Seg=O
117	diseases	_	_	_	_	_	_	_	Seg=O
118	like	_	_	_	_	_	_	_	Seg=O
119	tuberculosis	_	_	_	_	_	_	_	Seg=O
120	,	_	_	_	_	_	_	_	Seg=O
121	AIDS	_	_	_	_	_	_	_	Seg=O
122	,	_	_	_	_	_	_	_	Seg=O
123	and	_	_	_	_	_	_	_	Seg=O
124	parasitic	_	_	_	_	_	_	_	Seg=O
125	diseases	_	_	_	_	_	_	_	Seg=O
126	including	_	_	_	_	_	_	_	Seg=B-seg
127	malaria	_	_	_	_	_	_	_	Seg=O
128	.	_	_	_	_	_	_	_	Seg=O
129	Abuse	_	_	_	_	_	_	_	Seg=B-seg
130	of	_	_	_	_	_	_	_	Seg=O
131	antibiotics	_	_	_	_	_	_	_	Seg=O
132	has	_	_	_	_	_	_	_	Seg=O
133	resulted	_	_	_	_	_	_	_	Seg=O
134	in	_	_	_	_	_	_	_	Seg=O
135	the	_	_	_	_	_	_	_	Seg=O
136	generation	_	_	_	_	_	_	_	Seg=O
137	of	_	_	_	_	_	_	_	Seg=O
138	several	_	_	_	_	_	_	_	Seg=O
139	antibiotic	_	_	_	_	_	_	_	Seg=O
140	-	_	_	_	_	_	_	_	Seg=O
141	resistant	_	_	_	_	_	_	_	Seg=O
142	bacterial	_	_	_	_	_	_	_	Seg=O
143	strains	_	_	_	_	_	_	_	Seg=O
144	;	_	_	_	_	_	_	_	Seg=O
145	hence	_	_	_	_	_	_	_	Seg=B-seg
146	there	_	_	_	_	_	_	_	Seg=O
147	is	_	_	_	_	_	_	_	Seg=O
148	a	_	_	_	_	_	_	_	Seg=O
149	need	_	_	_	_	_	_	_	Seg=O
150	to	_	_	_	_	_	_	_	Seg=O
151	develop	_	_	_	_	_	_	_	Seg=O
152	novel	_	_	_	_	_	_	_	Seg=O
153	vaccines	_	_	_	_	_	_	_	Seg=O
154	for	_	_	_	_	_	_	_	Seg=O
155	antibiotic	_	_	_	_	_	_	_	Seg=O
156	-	_	_	_	_	_	_	_	Seg=O
157	resistant	_	_	_	_	_	_	_	Seg=O
158	microorganisms	_	_	_	_	_	_	_	Seg=O
159	.	_	_	_	_	_	_	_	Seg=O
160	Changes	_	_	_	_	_	_	_	Seg=B-seg
161	in	_	_	_	_	_	_	_	Seg=O
162	climate	_	_	_	_	_	_	_	Seg=O
163	is	_	_	_	_	_	_	_	Seg=O
164	another	_	_	_	_	_	_	_	Seg=O
165	concern	_	_	_	_	_	_	_	Seg=O
166	for	_	_	_	_	_	_	_	Seg=O
167	vaccinologists	_	_	_	_	_	_	_	Seg=O
168	.	_	_	_	_	_	_	_	Seg=O
169	Climate	_	_	_	_	_	_	_	Seg=B-seg
170	change	_	_	_	_	_	_	_	Seg=O
171	could	_	_	_	_	_	_	_	Seg=O
172	lead	_	_	_	_	_	_	_	Seg=O
173	to	_	_	_	_	_	_	_	Seg=O
174	generation	_	_	_	_	_	_	_	Seg=O
175	of	_	_	_	_	_	_	_	Seg=O
176	new	_	_	_	_	_	_	_	Seg=O
177	strains	_	_	_	_	_	_	_	Seg=O
178	of	_	_	_	_	_	_	_	Seg=O
179	infectious	_	_	_	_	_	_	_	Seg=O
180	microorganisms	_	_	_	_	_	_	_	Seg=O
181	that	_	_	_	_	_	_	_	Seg=B-seg
182	would	_	_	_	_	_	_	_	Seg=O
183	require	_	_	_	_	_	_	_	Seg=O
184	development	_	_	_	_	_	_	_	Seg=O
185	of	_	_	_	_	_	_	_	Seg=O
186	novel	_	_	_	_	_	_	_	Seg=O
187	vaccines	_	_	_	_	_	_	_	Seg=O
188	.	_	_	_	_	_	_	_	Seg=O
189	Use	_	_	_	_	_	_	_	Seg=B-seg
190	of	_	_	_	_	_	_	_	Seg=O
191	conventional	_	_	_	_	_	_	_	Seg=O
192	vaccination	_	_	_	_	_	_	_	Seg=O
193	strategies	_	_	_	_	_	_	_	Seg=O
194	to	_	_	_	_	_	_	_	Seg=B-seg
195	develop	_	_	_	_	_	_	_	Seg=O
196	vaccines	_	_	_	_	_	_	_	Seg=O
197	has	_	_	_	_	_	_	_	Seg=B-seg
198	severe	_	_	_	_	_	_	_	Seg=O
199	limitations	_	_	_	_	_	_	_	Seg=O
200	;	_	_	_	_	_	_	_	Seg=O
201	hence	_	_	_	_	_	_	_	Seg=B-seg
202	innovative	_	_	_	_	_	_	_	Seg=O
203	strategies	_	_	_	_	_	_	_	Seg=O
204	are	_	_	_	_	_	_	_	Seg=O
205	essential	_	_	_	_	_	_	_	Seg=O
206	in	_	_	_	_	_	_	_	Seg=O
207	the	_	_	_	_	_	_	_	Seg=O
208	development	_	_	_	_	_	_	_	Seg=O
209	of	_	_	_	_	_	_	_	Seg=O
210	novel	_	_	_	_	_	_	_	Seg=O
211	and	_	_	_	_	_	_	_	Seg=O
212	effective	_	_	_	_	_	_	_	Seg=O
213	vaccines	_	_	_	_	_	_	_	Seg=O
214	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 2d9482a26d740c255bf3108d1c628e97fae3cc7a
1	The	_	_	_	_	_	_	_	Seg=B-seg
2	canine	_	_	_	_	_	_	_	Seg=O
3	respiratory	_	_	_	_	_	_	_	Seg=O
4	coronavirus	_	_	_	_	_	_	_	Seg=O
5	(	_	_	_	_	_	_	_	Seg=O
6	CRCoV	_	_	_	_	_	_	_	Seg=O
7	)	_	_	_	_	_	_	_	Seg=O
8	K37	_	_	_	_	_	_	_	Seg=O
9	strain	_	_	_	_	_	_	_	Seg=O
10	of	_	_	_	_	_	_	_	Seg=O
11	the	_	_	_	_	_	_	_	Seg=O
12	family	_	_	_	_	_	_	_	Seg=O
13	Coronaviridae	_	_	_	_	_	_	_	Seg=O
14	,	_	_	_	_	_	_	_	Seg=O
15	group	_	_	_	_	_	_	_	Seg=O
16	2	_	_	_	_	_	_	_	Seg=O
17	,	_	_	_	_	_	_	_	Seg=O
18	was	_	_	_	_	_	_	_	Seg=O
19	isolated	_	_	_	_	_	_	_	Seg=O
20	in	_	_	_	_	_	_	_	Seg=O
21	South	_	_	_	_	_	_	_	Seg=O
22	Korea	_	_	_	_	_	_	_	Seg=O
23	.	_	_	_	_	_	_	_	Seg=O
24	Its	_	_	_	_	_	_	_	Seg=B-seg
25	genome	_	_	_	_	_	_	_	Seg=O
26	was	_	_	_	_	_	_	_	Seg=O
27	analyzed	_	_	_	_	_	_	_	Seg=O
28	by	_	_	_	_	_	_	_	Seg=O
29	nucleotide	_	_	_	_	_	_	_	Seg=O
30	sequencing	_	_	_	_	_	_	_	Seg=O
31	and	_	_	_	_	_	_	_	Seg=B-seg
32	was	_	_	_	_	_	_	_	Seg=O
33	determined	_	_	_	_	_	_	_	Seg=O
34	to	_	_	_	_	_	_	_	Seg=O
35	have	_	_	_	_	_	_	_	Seg=O
36	31,029	_	_	_	_	_	_	_	Seg=O
37	bp	_	_	_	_	_	_	_	Seg=O
38	.	_	_	_	_	_	_	_	Seg=O
39	The	_	_	_	_	_	_	_	Seg=B-seg
40	small	_	_	_	_	_	_	_	Seg=O
41	open	_	_	_	_	_	_	_	Seg=O
42	reading	_	_	_	_	_	_	_	Seg=O
43	frames	_	_	_	_	_	_	_	Seg=O
44	situated	_	_	_	_	_	_	_	Seg=B-seg
45	between	_	_	_	_	_	_	_	Seg=O
46	the	_	_	_	_	_	_	_	Seg=O
47	spike	_	_	_	_	_	_	_	Seg=O
48	and	_	_	_	_	_	_	_	Seg=O
49	envelope	_	_	_	_	_	_	_	Seg=O
50	genes	_	_	_	_	_	_	_	Seg=O
51	of	_	_	_	_	_	_	_	Seg=O
52	most	_	_	_	_	_	_	_	Seg=O
53	of	_	_	_	_	_	_	_	Seg=O
54	the	_	_	_	_	_	_	_	Seg=O
55	CRCoV	_	_	_	_	_	_	_	Seg=O
56	strains	_	_	_	_	_	_	_	Seg=O
57	(	_	_	_	_	_	_	_	Seg=B-seg
58	except	_	_	_	_	_	_	_	Seg=O
59	the	_	_	_	_	_	_	_	Seg=O
60	CRCoV	_	_	_	_	_	_	_	Seg=O
61	4180	_	_	_	_	_	_	_	Seg=O
62	strain	_	_	_	_	_	_	_	Seg=O
63	)	_	_	_	_	_	_	_	Seg=O
64	were	_	_	_	_	_	_	_	Seg=B-seg
65	found	_	_	_	_	_	_	_	Seg=O
66	to	_	_	_	_	_	_	_	Seg=O
67	encode	_	_	_	_	_	_	_	Seg=O
68	three	_	_	_	_	_	_	_	Seg=O
69	nonstructural	_	_	_	_	_	_	_	Seg=O
70	proteins	_	_	_	_	_	_	_	Seg=O
71	(	_	_	_	_	_	_	_	Seg=B-seg
72	4.9	_	_	_	_	_	_	_	Seg=O
73	kDa	_	_	_	_	_	_	_	Seg=O
74	,	_	_	_	_	_	_	_	Seg=O
75	2.7	_	_	_	_	_	_	_	Seg=O
76	kDa	_	_	_	_	_	_	_	Seg=O
77	,	_	_	_	_	_	_	_	Seg=O
78	and	_	_	_	_	_	_	_	Seg=O
79	12.8	_	_	_	_	_	_	_	Seg=O
80	kDa	_	_	_	_	_	_	_	Seg=O
81	)	_	_	_	_	_	_	_	Seg=O
82	,	_	_	_	_	_	_	_	Seg=O
83	while	_	_	_	_	_	_	_	Seg=B-seg
84	those	_	_	_	_	_	_	_	Seg=O
85	of	_	_	_	_	_	_	_	Seg=O
86	bovine	_	_	_	_	_	_	_	Seg=O
87	coronavirus	_	_	_	_	_	_	_	Seg=O
88	(	_	_	_	_	_	_	_	Seg=O
89	BCoV	_	_	_	_	_	_	_	Seg=O
90	)	_	_	_	_	_	_	_	Seg=O
91	encode	_	_	_	_	_	_	_	Seg=O
92	another	_	_	_	_	_	_	_	Seg=O
93	three	_	_	_	_	_	_	_	Seg=O
94	nonstructural	_	_	_	_	_	_	_	Seg=O
95	proteins	_	_	_	_	_	_	_	Seg=O
96	(	_	_	_	_	_	_	_	Seg=B-seg
97	4.9	_	_	_	_	_	_	_	Seg=O
98	kDa	_	_	_	_	_	_	_	Seg=O
99	,	_	_	_	_	_	_	_	Seg=O
100	4.8	_	_	_	_	_	_	_	Seg=O
101	kDa	_	_	_	_	_	_	_	Seg=O
102	,	_	_	_	_	_	_	_	Seg=O
103	and	_	_	_	_	_	_	_	Seg=O
104	12.7	_	_	_	_	_	_	_	Seg=O
105	kDa	_	_	_	_	_	_	_	Seg=O
106	)	_	_	_	_	_	_	_	Seg=O
107	and	_	_	_	_	_	_	_	Seg=B-seg
108	those	_	_	_	_	_	_	_	Seg=O
109	of	_	_	_	_	_	_	_	Seg=O
110	a	_	_	_	_	_	_	_	Seg=O
111	recently	_	_	_	_	_	_	_	Seg=O
112	isolated	_	_	_	_	_	_	_	Seg=O
113	bovine	_	_	_	_	_	_	_	Seg=O
114	respiratory	_	_	_	_	_	_	_	Seg=O
115	coronavirus	_	_	_	_	_	_	_	Seg=O
116	(	_	_	_	_	_	_	_	Seg=O
117	BRCoV	_	_	_	_	_	_	_	Seg=O
118	)	_	_	_	_	_	_	_	Seg=O
119	were	_	_	_	_	_	_	_	Seg=O
120	found	_	_	_	_	_	_	_	Seg=O
121	to	_	_	_	_	_	_	_	Seg=O
122	encode	_	_	_	_	_	_	_	Seg=O
123	only	_	_	_	_	_	_	_	Seg=O
124	two	_	_	_	_	_	_	_	Seg=O
125	nonstructural	_	_	_	_	_	_	_	Seg=O
126	proteins	_	_	_	_	_	_	_	Seg=O
127	(	_	_	_	_	_	_	_	Seg=B-seg
128	4.9	_	_	_	_	_	_	_	Seg=O
129	kDa	_	_	_	_	_	_	_	Seg=O
130	and	_	_	_	_	_	_	_	Seg=O
131	12.7	_	_	_	_	_	_	_	Seg=O
132	kDa	_	_	_	_	_	_	_	Seg=O
133	)	_	_	_	_	_	_	_	Seg=O
134	.	_	_	_	_	_	_	_	Seg=O
135	The	_	_	_	_	_	_	_	Seg=B-seg
136	differences	_	_	_	_	_	_	_	Seg=O
137	in	_	_	_	_	_	_	_	Seg=O
138	the	_	_	_	_	_	_	_	Seg=O
139	genes	_	_	_	_	_	_	_	Seg=O
140	encoding	_	_	_	_	_	_	_	Seg=B-seg
141	these	_	_	_	_	_	_	_	Seg=O
142	small	_	_	_	_	_	_	_	Seg=O
143	nonstructural	_	_	_	_	_	_	_	Seg=O
144	proteins	_	_	_	_	_	_	_	Seg=O
145	may	_	_	_	_	_	_	_	Seg=B-seg
146	be	_	_	_	_	_	_	_	Seg=O
147	associated	_	_	_	_	_	_	_	Seg=O
148	with	_	_	_	_	_	_	_	Seg=O
149	the	_	_	_	_	_	_	_	Seg=O
150	emergence	_	_	_	_	_	_	_	Seg=O
151	of	_	_	_	_	_	_	_	Seg=O
152	highly	_	_	_	_	_	_	_	Seg=O
153	similar	_	_	_	_	_	_	_	Seg=O
154	viruses	_	_	_	_	_	_	_	Seg=O
155	in	_	_	_	_	_	_	_	Seg=O
156	different	_	_	_	_	_	_	_	Seg=O
157	hosts	_	_	_	_	_	_	_	Seg=O
158	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 2dd56fdde263e4c8b6a2e54123a89b858a1ecf46
1	Human	_	_	_	_	_	_	_	Seg=B-seg
2	coronavirus	_	_	_	_	_	_	_	Seg=O
3	HKU1	_	_	_	_	_	_	_	Seg=O
4	(	_	_	_	_	_	_	_	Seg=O
5	HCoV	_	_	_	_	_	_	_	Seg=O
6	-	_	_	_	_	_	_	_	Seg=O
7	HKU1	_	_	_	_	_	_	_	Seg=O
8	)	_	_	_	_	_	_	_	Seg=O
9	,	_	_	_	_	_	_	_	Seg=O
10	which	_	_	_	_	_	_	_	Seg=B-seg
11	mainly	_	_	_	_	_	_	_	Seg=O
12	causes	_	_	_	_	_	_	_	Seg=O
13	acute	_	_	_	_	_	_	_	Seg=O
14	selflimited	_	_	_	_	_	_	_	Seg=O
15	respiratory	_	_	_	_	_	_	_	Seg=O
16	-	_	_	_	_	_	_	_	Seg=O
17	tract	_	_	_	_	_	_	_	Seg=O
18	infections	_	_	_	_	_	_	_	Seg=O
19	,	_	_	_	_	_	_	_	Seg=O
20	belongs	_	_	_	_	_	_	_	Seg=B-seg
21	to	_	_	_	_	_	_	_	Seg=O
22	group	_	_	_	_	_	_	_	Seg=O
23	A	_	_	_	_	_	_	_	Seg=O
24	of	_	_	_	_	_	_	_	Seg=O
25	the	_	_	_	_	_	_	_	Seg=O
26	Betacoronavirus	_	_	_	_	_	_	_	Seg=O
27	genus	_	_	_	_	_	_	_	Seg=O
28	.	_	_	_	_	_	_	_	Seg=O
29	Coronavirus	_	_	_	_	_	_	_	Seg=B-seg
30	genomes	_	_	_	_	_	_	_	Seg=O
31	encode	_	_	_	_	_	_	_	Seg=O
32	16	_	_	_	_	_	_	_	Seg=O
33	nonstructural	_	_	_	_	_	_	_	Seg=O
34	proteins	_	_	_	_	_	_	_	Seg=O
35	(	_	_	_	_	_	_	_	Seg=O
36	nsp1	_	_	_	_	_	_	_	Seg=O
37	-	_	_	_	_	_	_	_	Seg=O
38	16	_	_	_	_	_	_	_	Seg=O
39	)	_	_	_	_	_	_	_	Seg=O
40	,	_	_	_	_	_	_	_	Seg=O
41	which	_	_	_	_	_	_	_	Seg=B-seg
42	assemble	_	_	_	_	_	_	_	Seg=O
43	into	_	_	_	_	_	_	_	Seg=O
44	a	_	_	_	_	_	_	_	Seg=O
45	large	_	_	_	_	_	_	_	Seg=O
46	replication	_	_	_	_	_	_	_	Seg=O
47	-	_	_	_	_	_	_	_	Seg=O
48	transcription	_	_	_	_	_	_	_	Seg=O
49	complex	_	_	_	_	_	_	_	Seg=O
50	mediating	_	_	_	_	_	_	_	Seg=O
51	virus	_	_	_	_	_	_	_	Seg=O
52	propagation	_	_	_	_	_	_	_	Seg=O
53	.	_	_	_	_	_	_	_	Seg=O
54	Nonstructural	_	_	_	_	_	_	_	Seg=B-seg
55	protein	_	_	_	_	_	_	_	Seg=O
56	9	_	_	_	_	_	_	_	Seg=O
57	,	_	_	_	_	_	_	_	Seg=O
58	which	_	_	_	_	_	_	_	Seg=B-seg
59	binds	_	_	_	_	_	_	_	Seg=O
60	to	_	_	_	_	_	_	_	Seg=O
61	the	_	_	_	_	_	_	_	Seg=O
62	single	_	_	_	_	_	_	_	Seg=O
63	-	_	_	_	_	_	_	_	Seg=O
64	stranded	_	_	_	_	_	_	_	Seg=O
65	DNA	_	_	_	_	_	_	_	Seg=O
66	/	_	_	_	_	_	_	_	Seg=O
67	RNA	_	_	_	_	_	_	_	Seg=O
68	,	_	_	_	_	_	_	_	Seg=O
69	has	_	_	_	_	_	_	_	Seg=B-seg
70	been	_	_	_	_	_	_	_	Seg=O
71	shown	_	_	_	_	_	_	_	Seg=O
72	to	_	_	_	_	_	_	_	Seg=O
73	be	_	_	_	_	_	_	_	Seg=O
74	indispensible	_	_	_	_	_	_	_	Seg=O
75	for	_	_	_	_	_	_	_	Seg=O
76	viral	_	_	_	_	_	_	_	Seg=O
77	replication	_	_	_	_	_	_	_	Seg=O
78	.	_	_	_	_	_	_	_	Seg=O
79	Interestingly	_	_	_	_	_	_	_	Seg=B-seg
80	,	_	_	_	_	_	_	_	Seg=O
81	a	_	_	_	_	_	_	_	Seg=O
82	functional	_	_	_	_	_	_	_	Seg=O
83	mutant	_	_	_	_	_	_	_	Seg=O
84	(	_	_	_	_	_	_	_	Seg=B-seg
85	N60	_	_	_	_	_	_	_	Seg=O
86	K	_	_	_	_	_	_	_	Seg=O
87	)	_	_	_	_	_	_	_	Seg=O
88	of	_	_	_	_	_	_	_	Seg=B-seg
89	nsp9	_	_	_	_	_	_	_	Seg=O
90	was	_	_	_	_	_	_	_	Seg=O
91	identified	_	_	_	_	_	_	_	Seg=O
92	to	_	_	_	_	_	_	_	Seg=O
93	compensate	_	_	_	_	_	_	_	Seg=O
94	for	_	_	_	_	_	_	_	Seg=O
95	a	_	_	_	_	_	_	_	Seg=O
96	6	_	_	_	_	_	_	_	Seg=O
97	nt	_	_	_	_	_	_	_	Seg=O
98	insertion	_	_	_	_	_	_	_	Seg=O
99	mutation	_	_	_	_	_	_	_	Seg=O
100	of	_	_	_	_	_	_	_	Seg=O
101	the	_	_	_	_	_	_	_	Seg=O
102	3	_	_	_	_	_	_	_	Seg=O
103	0	_	_	_	_	_	_	_	Seg=O
104	-untranslated	_	_	_	_	_	_	_	Seg=O
105	region	_	_	_	_	_	_	_	Seg=O
106	(	_	_	_	_	_	_	_	Seg=O
107	UTR	_	_	_	_	_	_	_	Seg=O
108	)	_	_	_	_	_	_	_	Seg=O
109	,	_	_	_	_	_	_	_	Seg=O
110	which	_	_	_	_	_	_	_	Seg=B-seg
111	is	_	_	_	_	_	_	_	Seg=O
112	critical	_	_	_	_	_	_	_	Seg=O
113	for	_	_	_	_	_	_	_	Seg=O
114	viral	_	_	_	_	_	_	_	Seg=O
115	RNA	_	_	_	_	_	_	_	Seg=O
116	synthesis	_	_	_	_	_	_	_	Seg=O
117	.	_	_	_	_	_	_	_	Seg=O
118	It	_	_	_	_	_	_	_	Seg=B-seg
119	has	_	_	_	_	_	_	_	Seg=O
120	been	_	_	_	_	_	_	_	Seg=O
121	proposed	_	_	_	_	_	_	_	Seg=O
122	that	_	_	_	_	_	_	_	Seg=O
123	the	_	_	_	_	_	_	_	Seg=O
124	N60	_	_	_	_	_	_	_	Seg=O
125	K	_	_	_	_	_	_	_	Seg=O
126	mutation	_	_	_	_	_	_	_	Seg=O
127	may	_	_	_	_	_	_	_	Seg=O
128	cause	_	_	_	_	_	_	_	Seg=O
129	certain	_	_	_	_	_	_	_	Seg=O
130	conformational	_	_	_	_	_	_	_	Seg=O
131	changes	_	_	_	_	_	_	_	Seg=O
132	of	_	_	_	_	_	_	_	Seg=O
133	nsp9	_	_	_	_	_	_	_	Seg=O
134	to	_	_	_	_	_	_	_	Seg=B-seg
135	rescue	_	_	_	_	_	_	_	Seg=O
136	the	_	_	_	_	_	_	_	Seg=O
137	defective	_	_	_	_	_	_	_	Seg=O
138	insertion	_	_	_	_	_	_	_	Seg=O
139	mutant	_	_	_	_	_	_	_	Seg=O
140	.	_	_	_	_	_	_	_	Seg=O
141	To	_	_	_	_	_	_	_	Seg=B-seg
142	further	_	_	_	_	_	_	_	Seg=O
143	investigate	_	_	_	_	_	_	_	Seg=O
144	the	_	_	_	_	_	_	_	Seg=O
145	underlying	_	_	_	_	_	_	_	Seg=O
146	structural	_	_	_	_	_	_	_	Seg=O
147	mechanism	_	_	_	_	_	_	_	Seg=O
148	,	_	_	_	_	_	_	_	Seg=O
149	the	_	_	_	_	_	_	_	Seg=B-seg
150	N60	_	_	_	_	_	_	_	Seg=O
151	K	_	_	_	_	_	_	_	Seg=O
152	mutant	_	_	_	_	_	_	_	Seg=O
153	of	_	_	_	_	_	_	_	Seg=O
154	nsp9	_	_	_	_	_	_	_	Seg=O
155	from	_	_	_	_	_	_	_	Seg=O
156	HCoV	_	_	_	_	_	_	_	Seg=O
157	-	_	_	_	_	_	_	_	Seg=O
158	HKU1	_	_	_	_	_	_	_	Seg=O
159	was	_	_	_	_	_	_	_	Seg=O
160	successfully	_	_	_	_	_	_	_	Seg=O
161	crystallized	_	_	_	_	_	_	_	Seg=O
162	in	_	_	_	_	_	_	_	Seg=O
163	this	_	_	_	_	_	_	_	Seg=O
164	study	_	_	_	_	_	_	_	Seg=O
165	.	_	_	_	_	_	_	_	Seg=O
166	The	_	_	_	_	_	_	_	Seg=B-seg
167	crystals	_	_	_	_	_	_	_	Seg=O
168	diffracted	_	_	_	_	_	_	_	Seg=O
169	to	_	_	_	_	_	_	_	Seg=O
170	2.6	_	_	_	_	_	_	_	Seg=O
171	Å	_	_	_	_	_	_	_	Seg=O
172	resolution	_	_	_	_	_	_	_	Seg=O
173	and	_	_	_	_	_	_	_	Seg=B-seg
174	belonged	_	_	_	_	_	_	_	Seg=O
175	to	_	_	_	_	_	_	_	Seg=O
176	space	_	_	_	_	_	_	_	Seg=O
177	group	_	_	_	_	_	_	_	Seg=O
178	P2	_	_	_	_	_	_	_	Seg=O
179	1	_	_	_	_	_	_	_	Seg=O
180	2	_	_	_	_	_	_	_	Seg=O
181	1	_	_	_	_	_	_	_	Seg=O
182	2	_	_	_	_	_	_	_	Seg=O
183	1	_	_	_	_	_	_	_	Seg=O
184	,	_	_	_	_	_	_	_	Seg=O
185	with	_	_	_	_	_	_	_	Seg=O
186	unit	_	_	_	_	_	_	_	Seg=O
187	-	_	_	_	_	_	_	_	Seg=O
188	cell	_	_	_	_	_	_	_	Seg=O
189	parameters	_	_	_	_	_	_	_	Seg=O
190	a	_	_	_	_	_	_	_	Seg=O
191	=	_	_	_	_	_	_	_	Seg=O
192	31.9	_	_	_	_	_	_	_	Seg=O
193	,	_	_	_	_	_	_	_	Seg=O
194	b	_	_	_	_	_	_	_	Seg=O
195	=	_	_	_	_	_	_	_	Seg=O
196	85.0	_	_	_	_	_	_	_	Seg=O
197	,	_	_	_	_	_	_	_	Seg=O
198	c	_	_	_	_	_	_	_	Seg=O
199	=	_	_	_	_	_	_	_	Seg=O
200	95.0	_	_	_	_	_	_	_	Seg=O
201	Å	_	_	_	_	_	_	_	Seg=O
202	.	_	_	_	_	_	_	_	Seg=O
203	Two	_	_	_	_	_	_	_	Seg=B-seg
204	molecules	_	_	_	_	_	_	_	Seg=O
205	were	_	_	_	_	_	_	_	Seg=O
206	identified	_	_	_	_	_	_	_	Seg=O
207	per	_	_	_	_	_	_	_	Seg=O
208	asymmetric	_	_	_	_	_	_	_	Seg=O
209	unit	_	_	_	_	_	_	_	Seg=O
210	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 2dfa1f27d87881bc93d1521011a48c234f500113
1	Background	_	_	_	_	_	_	_	Seg=B-seg
2	The	_	_	_	_	_	_	_	Seg=B-seg
3	objectives	_	_	_	_	_	_	_	Seg=O
4	of	_	_	_	_	_	_	_	Seg=O
5	this	_	_	_	_	_	_	_	Seg=O
6	study	_	_	_	_	_	_	_	Seg=O
7	were	_	_	_	_	_	_	_	Seg=O
8	to	_	_	_	_	_	_	_	Seg=O
9	analyze	_	_	_	_	_	_	_	Seg=O
10	the	_	_	_	_	_	_	_	Seg=O
11	clinical	_	_	_	_	_	_	_	Seg=O
12	features	_	_	_	_	_	_	_	Seg=O
13	of	_	_	_	_	_	_	_	Seg=O
14	coronavirus	_	_	_	_	_	_	_	Seg=O
15	disease	_	_	_	_	_	_	_	Seg=O
16	2019	_	_	_	_	_	_	_	Seg=O
17	and	_	_	_	_	_	_	_	Seg=B-seg
18	evaluate	_	_	_	_	_	_	_	Seg=O
19	the	_	_	_	_	_	_	_	Seg=O
20	diagnosis	_	_	_	_	_	_	_	Seg=O
21	and	_	_	_	_	_	_	_	Seg=O
22	treatment	_	_	_	_	_	_	_	Seg=O
23	.	_	_	_	_	_	_	_	Seg=O
24	Methods	_	_	_	_	_	_	_	Seg=B-seg
25	A	_	_	_	_	_	_	_	Seg=B-seg
26	retrospective	_	_	_	_	_	_	_	Seg=O
27	analysis	_	_	_	_	_	_	_	Seg=O
28	of	_	_	_	_	_	_	_	Seg=O
29	the	_	_	_	_	_	_	_	Seg=O
30	clinical	_	_	_	_	_	_	_	Seg=O
31	manifestation	_	_	_	_	_	_	_	Seg=O
32	and	_	_	_	_	_	_	_	Seg=O
33	auxiliary	_	_	_	_	_	_	_	Seg=O
34	examination	_	_	_	_	_	_	_	Seg=O
35	of	_	_	_	_	_	_	_	Seg=O
36	19	_	_	_	_	_	_	_	Seg=O
37	patients	_	_	_	_	_	_	_	Seg=O
38	with	_	_	_	_	_	_	_	Seg=O
39	COVID-19	_	_	_	_	_	_	_	Seg=O
40	from	_	_	_	_	_	_	_	Seg=O
41	the	_	_	_	_	_	_	_	Seg=O
42	Liyuan	_	_	_	_	_	_	_	Seg=O
43	Hospital	_	_	_	_	_	_	_	Seg=O
44	intensive	_	_	_	_	_	_	_	Seg=O
45	care	_	_	_	_	_	_	_	Seg=O
46	unit	_	_	_	_	_	_	_	Seg=O
47	(	_	_	_	_	_	_	_	Seg=O
48	ICU	_	_	_	_	_	_	_	Seg=O
49	)	_	_	_	_	_	_	_	Seg=O
50	between	_	_	_	_	_	_	_	Seg=O
51	January	_	_	_	_	_	_	_	Seg=O
52	16	_	_	_	_	_	_	_	Seg=O
53	,	_	_	_	_	_	_	_	Seg=O
54	2020	_	_	_	_	_	_	_	Seg=O
55	and	_	_	_	_	_	_	_	Seg=O
56	February	_	_	_	_	_	_	_	Seg=O
57	20	_	_	_	_	_	_	_	Seg=O
58	,	_	_	_	_	_	_	_	Seg=O
59	2020	_	_	_	_	_	_	_	Seg=O
60	was	_	_	_	_	_	_	_	Seg=O
61	undertaken	_	_	_	_	_	_	_	Seg=O
62	.	_	_	_	_	_	_	_	Seg=O
63	Results	_	_	_	_	_	_	_	Seg=B-seg
64	There	_	_	_	_	_	_	_	Seg=B-seg
65	were	_	_	_	_	_	_	_	Seg=O
66	11	_	_	_	_	_	_	_	Seg=O
67	male	_	_	_	_	_	_	_	Seg=O
68	and	_	_	_	_	_	_	_	Seg=O
69	8	_	_	_	_	_	_	_	Seg=O
70	female	_	_	_	_	_	_	_	Seg=O
71	cases	_	_	_	_	_	_	_	Seg=O
72	among	_	_	_	_	_	_	_	Seg=O
73	the	_	_	_	_	_	_	_	Seg=O
74	patients	_	_	_	_	_	_	_	Seg=O
75	.	_	_	_	_	_	_	_	Seg=O
76	The	_	_	_	_	_	_	_	Seg=B-seg
77	median	_	_	_	_	_	_	_	Seg=O
78	(	_	_	_	_	_	_	_	Seg=O
79	range	_	_	_	_	_	_	_	Seg=O
80	)	_	_	_	_	_	_	_	Seg=O
81	age	_	_	_	_	_	_	_	Seg=O
82	was	_	_	_	_	_	_	_	Seg=O
83	73	_	_	_	_	_	_	_	Seg=O
84	(	_	_	_	_	_	_	_	Seg=B-seg
85	38	_	_	_	_	_	_	_	Seg=O
86	-	_	_	_	_	_	_	_	Seg=O
87	91	_	_	_	_	_	_	_	Seg=O
88	)	_	_	_	_	_	_	_	Seg=O
89	years	_	_	_	_	_	_	_	Seg=B-seg
90	.	_	_	_	_	_	_	_	Seg=O
91	Of	_	_	_	_	_	_	_	Seg=B-seg
92	these	_	_	_	_	_	_	_	Seg=O
93	patients	_	_	_	_	_	_	_	Seg=O
94	,	_	_	_	_	_	_	_	Seg=O
95	8	_	_	_	_	_	_	_	Seg=O
96	(	_	_	_	_	_	_	_	Seg=B-seg
97	42.1	_	_	_	_	_	_	_	Seg=O
98	%	_	_	_	_	_	_	_	Seg=O
99	)	_	_	_	_	_	_	_	Seg=O
100	had	_	_	_	_	_	_	_	Seg=B-seg
101	died	_	_	_	_	_	_	_	Seg=O
102	and	_	_	_	_	_	_	_	Seg=B-seg
103	the	_	_	_	_	_	_	_	Seg=O
104	median	_	_	_	_	_	_	_	Seg=O
105	duration	_	_	_	_	_	_	_	Seg=O
106	from	_	_	_	_	_	_	_	Seg=O
107	ICU	_	_	_	_	_	_	_	Seg=O
108	admission	_	_	_	_	_	_	_	Seg=O
109	to	_	_	_	_	_	_	_	Seg=O
110	death	_	_	_	_	_	_	_	Seg=O
111	was	_	_	_	_	_	_	_	Seg=O
112	2	_	_	_	_	_	_	_	Seg=O
113	(	_	_	_	_	_	_	_	Seg=B-seg
114	interquartile	_	_	_	_	_	_	_	Seg=O
115	range	_	_	_	_	_	_	_	Seg=O
116	(	_	_	_	_	_	_	_	Seg=O
117	IQR	_	_	_	_	_	_	_	Seg=O
118	)	_	_	_	_	_	_	_	Seg=O
119	:	_	_	_	_	_	_	_	Seg=O
120	1	_	_	_	_	_	_	_	Seg=O
121	-	_	_	_	_	_	_	_	Seg=O
122	10.75	_	_	_	_	_	_	_	Seg=O
123	)	_	_	_	_	_	_	_	Seg=O
124	days	_	_	_	_	_	_	_	Seg=B-seg
125	.	_	_	_	_	_	_	_	Seg=O
126	Seven	_	_	_	_	_	_	_	Seg=B-seg
127	of	_	_	_	_	_	_	_	Seg=O
128	these	_	_	_	_	_	_	_	Seg=O
129	8	_	_	_	_	_	_	_	Seg=O
130	patients	_	_	_	_	_	_	_	Seg=O
131	had	_	_	_	_	_	_	_	Seg=O
132	underlying	_	_	_	_	_	_	_	Seg=O
133	diseases	_	_	_	_	_	_	_	Seg=O
134	.	_	_	_	_	_	_	_	Seg=O
135	The	_	_	_	_	_	_	_	Seg=B-seg
136	auxiliary	_	_	_	_	_	_	_	Seg=O
137	examination	_	_	_	_	_	_	_	Seg=O
138	showed	_	_	_	_	_	_	_	Seg=O
139	fever	_	_	_	_	_	_	_	Seg=O
140	(	_	_	_	_	_	_	_	Seg=B-seg
141	68.4	_	_	_	_	_	_	_	Seg=O
142	%	_	_	_	_	_	_	_	Seg=O
143	)	_	_	_	_	_	_	_	Seg=O
144	,	_	_	_	_	_	_	_	Seg=O
145	dry	_	_	_	_	_	_	_	Seg=B-seg
146	cough	_	_	_	_	_	_	_	Seg=O
147	(	_	_	_	_	_	_	_	Seg=B-seg
148	15.8	_	_	_	_	_	_	_	Seg=O
149	%	_	_	_	_	_	_	_	Seg=O
150	)	_	_	_	_	_	_	_	Seg=O
151	,	_	_	_	_	_	_	_	Seg=O
152	dyspnea	_	_	_	_	_	_	_	Seg=B-seg
153	(	_	_	_	_	_	_	_	Seg=B-seg
154	10.5	_	_	_	_	_	_	_	Seg=O
155	%	_	_	_	_	_	_	_	Seg=O
156	)	_	_	_	_	_	_	_	Seg=O
157	,	_	_	_	_	_	_	_	Seg=O
158	and	_	_	_	_	_	_	_	Seg=B-seg
159	diarrhea	_	_	_	_	_	_	_	Seg=O
160	(	_	_	_	_	_	_	_	Seg=O
161	5.3	_	_	_	_	_	_	_	Seg=O
162	%	_	_	_	_	_	_	_	Seg=O
163	)	_	_	_	_	_	_	_	Seg=O
164	.	_	_	_	_	_	_	_	Seg=O
165	All	_	_	_	_	_	_	_	Seg=B-seg
166	19	_	_	_	_	_	_	_	Seg=O
167	cases	_	_	_	_	_	_	_	Seg=O
168	showed	_	_	_	_	_	_	_	Seg=O
169	ground	_	_	_	_	_	_	_	Seg=O
170	-	_	_	_	_	_	_	_	Seg=O
171	glass	_	_	_	_	_	_	_	Seg=O
172	changes	_	_	_	_	_	_	_	Seg=O
173	on	_	_	_	_	_	_	_	Seg=O
174	chest	_	_	_	_	_	_	_	Seg=O
175	computed	_	_	_	_	_	_	_	Seg=O
176	tomography	_	_	_	_	_	_	_	Seg=O
177	.	_	_	_	_	_	_	_	Seg=O
178	Serum	_	_	_	_	_	_	_	Seg=B-seg
179	hypersensitive	_	_	_	_	_	_	_	Seg=O
180	C	_	_	_	_	_	_	_	Seg=O
181	-	_	_	_	_	_	_	_	Seg=O
182	reactive	_	_	_	_	_	_	_	Seg=O
183	protein	_	_	_	_	_	_	_	Seg=O
184	(	_	_	_	_	_	_	_	Seg=O
185	hs	_	_	_	_	_	_	_	Seg=O
186	-	_	_	_	_	_	_	_	Seg=O
187	CRP	_	_	_	_	_	_	_	Seg=O
188	)	_	_	_	_	_	_	_	Seg=O
189	and	_	_	_	_	_	_	_	Seg=O
190	serum	_	_	_	_	_	_	_	Seg=O
191	amylase	_	_	_	_	_	_	_	Seg=O
192	A	_	_	_	_	_	_	_	Seg=O
193	(	_	_	_	_	_	_	_	Seg=O
194	SAA	_	_	_	_	_	_	_	Seg=O
195	)	_	_	_	_	_	_	_	Seg=O
196	were	_	_	_	_	_	_	_	Seg=O
197	clearly	_	_	_	_	_	_	_	Seg=O
198	increased	_	_	_	_	_	_	_	Seg=O
199	in	_	_	_	_	_	_	_	Seg=O
200	all	_	_	_	_	_	_	_	Seg=O
201	of	_	_	_	_	_	_	_	Seg=O
202	the	_	_	_	_	_	_	_	Seg=O
203	cases	_	_	_	_	_	_	_	Seg=O
204	.	_	_	_	_	_	_	_	Seg=O
205	Among	_	_	_	_	_	_	_	Seg=B-seg
206	the	_	_	_	_	_	_	_	Seg=O
207	19	_	_	_	_	_	_	_	Seg=O
208	cases	_	_	_	_	_	_	_	Seg=O
209	,	_	_	_	_	_	_	_	Seg=O
210	there	_	_	_	_	_	_	_	Seg=O
211	were	_	_	_	_	_	_	_	Seg=O
212	16	_	_	_	_	_	_	_	Seg=O
213	(	_	_	_	_	_	_	_	Seg=B-seg
214	84.2	_	_	_	_	_	_	_	Seg=O
215	%	_	_	_	_	_	_	_	Seg=O
216	)	_	_	_	_	_	_	_	Seg=O
217	cases	_	_	_	_	_	_	_	Seg=B-seg
218	in	_	_	_	_	_	_	_	Seg=B-seg
219	which	_	_	_	_	_	_	_	Seg=O
220	the	_	_	_	_	_	_	_	Seg=O
221	total	_	_	_	_	_	_	_	Seg=O
222	number	_	_	_	_	_	_	_	Seg=O
223	of	_	_	_	_	_	_	_	Seg=O
224	lymphocytes	_	_	_	_	_	_	_	Seg=O
225	decreased	_	_	_	_	_	_	_	Seg=O
226	,	_	_	_	_	_	_	_	Seg=O
227	12	_	_	_	_	_	_	_	Seg=B-seg
228	cases	_	_	_	_	_	_	_	Seg=O
229	(	_	_	_	_	_	_	_	Seg=B-seg
230	63	_	_	_	_	_	_	_	Seg=O
231	%	_	_	_	_	_	_	_	Seg=O
232	)	_	_	_	_	_	_	_	Seg=O
233	had	_	_	_	_	_	_	_	Seg=B-seg
234	reduced	_	_	_	_	_	_	_	Seg=O
235	liver	_	_	_	_	_	_	_	Seg=O
236	function	_	_	_	_	_	_	_	Seg=O
237	,	_	_	_	_	_	_	_	Seg=O
238	and	_	_	_	_	_	_	_	Seg=B-seg
239	11	_	_	_	_	_	_	_	Seg=O
240	cases	_	_	_	_	_	_	_	Seg=O
241	(	_	_	_	_	_	_	_	Seg=B-seg
242	58	_	_	_	_	_	_	_	Seg=O
243	%	_	_	_	_	_	_	_	Seg=O
244	)	_	_	_	_	_	_	_	Seg=O
245	had	_	_	_	_	_	_	_	Seg=B-seg
246	deviant	_	_	_	_	_	_	_	Seg=O
247	results	_	_	_	_	_	_	_	Seg=O
248	for	_	_	_	_	_	_	_	Seg=O
249	fibrinogen	_	_	_	_	_	_	_	Seg=O
250	(	_	_	_	_	_	_	_	Seg=O
251	FIB	_	_	_	_	_	_	_	Seg=O
252	)	_	_	_	_	_	_	_	Seg=O
253	and	_	_	_	_	_	_	_	Seg=O
254	D	_	_	_	_	_	_	_	Seg=O
255	-	_	_	_	_	_	_	_	Seg=O
256	dimer	_	_	_	_	_	_	_	Seg=O
257	,	_	_	_	_	_	_	_	Seg=O
258	in	_	_	_	_	_	_	_	Seg=B-seg
259	particular	_	_	_	_	_	_	_	Seg=O
260	,	_	_	_	_	_	_	_	Seg=O
261	the	_	_	_	_	_	_	_	Seg=O
262	D	_	_	_	_	_	_	_	Seg=O
263	-	_	_	_	_	_	_	_	Seg=O
264	dimer	_	_	_	_	_	_	_	Seg=O
265	level	_	_	_	_	_	_	_	Seg=O
266	was	_	_	_	_	_	_	_	Seg=O
267	significantly	_	_	_	_	_	_	_	Seg=O
268	higher	_	_	_	_	_	_	_	Seg=O
269	in	_	_	_	_	_	_	_	Seg=O
270	the	_	_	_	_	_	_	_	Seg=O
271	non	_	_	_	_	_	_	_	Seg=O
272	-	_	_	_	_	_	_	_	Seg=O
273	survivors	_	_	_	_	_	_	_	Seg=O
274	compared	_	_	_	_	_	_	_	Seg=B-seg
275	with	_	_	_	_	_	_	_	Seg=O
276	the	_	_	_	_	_	_	_	Seg=O
277	survivors	_	_	_	_	_	_	_	Seg=O
278	.	_	_	_	_	_	_	_	Seg=O
279	Conclusion	_	_	_	_	_	_	_	Seg=B-seg
280	There	_	_	_	_	_	_	_	Seg=B-seg
281	were	_	_	_	_	_	_	_	Seg=O
282	more	_	_	_	_	_	_	_	Seg=O
283	men	_	_	_	_	_	_	_	Seg=O
284	than	_	_	_	_	_	_	_	Seg=O
285	women	_	_	_	_	_	_	_	Seg=O
286	among	_	_	_	_	_	_	_	Seg=O
287	critically	_	_	_	_	_	_	_	Seg=O
288	ill	_	_	_	_	_	_	_	Seg=O
289	patients	_	_	_	_	_	_	_	Seg=O
290	.	_	_	_	_	_	_	_	Seg=O
291	All	_	_	_	_	_	_	_	Seg=B-seg
292	of	_	_	_	_	_	_	_	Seg=O
293	the	_	_	_	_	_	_	_	Seg=O
294	cases	_	_	_	_	_	_	_	Seg=O
295	showed	_	_	_	_	_	_	_	Seg=O
296	ground	_	_	_	_	_	_	_	Seg=O
297	-	_	_	_	_	_	_	_	Seg=O
298	glass	_	_	_	_	_	_	_	Seg=O
299	changes	_	_	_	_	_	_	_	Seg=O
300	on	_	_	_	_	_	_	_	Seg=O
301	chest	_	_	_	_	_	_	_	Seg=O
302	computed	_	_	_	_	_	_	_	Seg=O
303	tomography	_	_	_	_	_	_	_	Seg=O
304	and	_	_	_	_	_	_	_	Seg=B-seg
305	the	_	_	_	_	_	_	_	Seg=O
306	vast	_	_	_	_	_	_	_	Seg=O
307	majority	_	_	_	_	_	_	_	Seg=O
308	of	_	_	_	_	_	_	_	Seg=O
309	patients	_	_	_	_	_	_	_	Seg=O
310	displayed	_	_	_	_	_	_	_	Seg=O
311	fever	_	_	_	_	_	_	_	Seg=O
312	and	_	_	_	_	_	_	_	Seg=O
313	dry	_	_	_	_	_	_	_	Seg=O
314	cough	_	_	_	_	_	_	_	Seg=O
315	.	_	_	_	_	_	_	_	Seg=O
316	The	_	_	_	_	_	_	_	Seg=B-seg
317	clinical	_	_	_	_	_	_	_	Seg=O
318	laboratory	_	_	_	_	_	_	_	Seg=O
319	indices	_	_	_	_	_	_	_	Seg=O
320	change	_	_	_	_	_	_	_	Seg=O
321	significantly	_	_	_	_	_	_	_	Seg=O
322	,	_	_	_	_	_	_	_	Seg=O
323	especially	_	_	_	_	_	_	_	Seg=O
324	the	_	_	_	_	_	_	_	Seg=O
325	D	_	_	_	_	_	_	_	Seg=O
326	-	_	_	_	_	_	_	_	Seg=O
327	dimer	_	_	_	_	_	_	_	Seg=O
328	level	_	_	_	_	_	_	_	Seg=O
329	among	_	_	_	_	_	_	_	Seg=O
330	non	_	_	_	_	_	_	_	Seg=O
331	-	_	_	_	_	_	_	_	Seg=O
332	survivors	_	_	_	_	_	_	_	Seg=O
333	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 2ee2bfaa3b2b8d6b098b28103960403ecc7a3188
1	This	_	_	_	_	_	_	_	Seg=B-seg
2	review	_	_	_	_	_	_	_	Seg=O
3	highlights	_	_	_	_	_	_	_	Seg=O
4	the	_	_	_	_	_	_	_	Seg=O
5	clinical	_	_	_	_	_	_	_	Seg=O
6	scoring	_	_	_	_	_	_	_	Seg=O
7	tools	_	_	_	_	_	_	_	Seg=O
8	used	_	_	_	_	_	_	_	Seg=B-seg
9	for	_	_	_	_	_	_	_	Seg=O
10	the	_	_	_	_	_	_	_	Seg=O
11	management	_	_	_	_	_	_	_	Seg=O
12	of	_	_	_	_	_	_	_	Seg=O
13	acute	_	_	_	_	_	_	_	Seg=O
14	pharyngotonsillitis	_	_	_	_	_	_	_	Seg=O
15	in	_	_	_	_	_	_	_	Seg=O
16	primary	_	_	_	_	_	_	_	Seg=O
17	care	_	_	_	_	_	_	_	Seg=O
18	clinics	_	_	_	_	_	_	_	Seg=O
19	.	_	_	_	_	_	_	_	Seg=O
20	It	_	_	_	_	_	_	_	Seg=B-seg
21	will	_	_	_	_	_	_	_	Seg=O
22	include	_	_	_	_	_	_	_	Seg=O
23	the	_	_	_	_	_	_	_	Seg=O
24	prevalence	_	_	_	_	_	_	_	Seg=O
25	of	_	_	_	_	_	_	_	Seg=O
26	group	_	_	_	_	_	_	_	Seg=O
27	A	_	_	_	_	_	_	_	Seg=O
28	pharyngotonsillitis	_	_	_	_	_	_	_	Seg=O
29	among	_	_	_	_	_	_	_	Seg=O
30	children	_	_	_	_	_	_	_	Seg=O
31	and	_	_	_	_	_	_	_	Seg=O
32	adults	_	_	_	_	_	_	_	Seg=O
33	worldwide	_	_	_	_	_	_	_	Seg=O
34	and	_	_	_	_	_	_	_	Seg=O
35	the	_	_	_	_	_	_	_	Seg=O
36	selective	_	_	_	_	_	_	_	Seg=O
37	tests	_	_	_	_	_	_	_	Seg=O
38	employed	_	_	_	_	_	_	_	Seg=B-seg
39	for	_	_	_	_	_	_	_	Seg=B-seg
40	diagnosing	_	_	_	_	_	_	_	Seg=O
41	group	_	_	_	_	_	_	_	Seg=O
42	A	_	_	_	_	_	_	_	Seg=O
43	streptococcal	_	_	_	_	_	_	_	Seg=O
44	pharyngotonsillitis	_	_	_	_	_	_	_	Seg=O
45	.	_	_	_	_	_	_	_	Seg=O
46	Pharyngotonsillitis	_	_	_	_	_	_	_	Seg=B-seg
47	is	_	_	_	_	_	_	_	Seg=O
48	one	_	_	_	_	_	_	_	Seg=O
49	of	_	_	_	_	_	_	_	Seg=O
50	the	_	_	_	_	_	_	_	Seg=O
51	common	_	_	_	_	_	_	_	Seg=O
52	reasons	_	_	_	_	_	_	_	Seg=O
53	for	_	_	_	_	_	_	_	Seg=O
54	visits	_	_	_	_	_	_	_	Seg=O
55	to	_	_	_	_	_	_	_	Seg=O
56	primary	_	_	_	_	_	_	_	Seg=O
57	care	_	_	_	_	_	_	_	Seg=O
58	clinics	_	_	_	_	_	_	_	Seg=O
59	worldwide	_	_	_	_	_	_	_	Seg=O
60	,	_	_	_	_	_	_	_	Seg=O
61	and	_	_	_	_	_	_	_	Seg=B-seg
62	physicians	_	_	_	_	_	_	_	Seg=O
63	tend	_	_	_	_	_	_	_	Seg=O
64	to	_	_	_	_	_	_	_	Seg=O
65	prescribe	_	_	_	_	_	_	_	Seg=O
66	antibiotics	_	_	_	_	_	_	_	Seg=O
67	according	_	_	_	_	_	_	_	Seg=O
68	to	_	_	_	_	_	_	_	Seg=O
69	the	_	_	_	_	_	_	_	Seg=O
70	clinical	_	_	_	_	_	_	_	Seg=O
71	symptoms	_	_	_	_	_	_	_	Seg=O
72	,	_	_	_	_	_	_	_	Seg=O
73	which	_	_	_	_	_	_	_	Seg=B-seg
74	leads	_	_	_	_	_	_	_	Seg=O
75	to	_	_	_	_	_	_	_	Seg=O
76	overprescribing	_	_	_	_	_	_	_	Seg=O
77	antibiotics	_	_	_	_	_	_	_	Seg=O
78	.	_	_	_	_	_	_	_	Seg=O
79	This	_	_	_	_	_	_	_	Seg=B-seg
80	in	_	_	_	_	_	_	_	Seg=O
81	turn	_	_	_	_	_	_	_	Seg=O
82	may	_	_	_	_	_	_	_	Seg=O
83	lead	_	_	_	_	_	_	_	Seg=O
84	to	_	_	_	_	_	_	_	Seg=O
85	serious	_	_	_	_	_	_	_	Seg=O
86	health	_	_	_	_	_	_	_	Seg=O
87	impacts	_	_	_	_	_	_	_	Seg=O
88	and	_	_	_	_	_	_	_	Seg=O
89	severe	_	_	_	_	_	_	_	Seg=O
90	reactions	_	_	_	_	_	_	_	Seg=O
91	and	_	_	_	_	_	_	_	Seg=B-seg
92	may	_	_	_	_	_	_	_	Seg=O
93	promote	_	_	_	_	_	_	_	Seg=O
94	antibiotic	_	_	_	_	_	_	_	Seg=O
95	resistance	_	_	_	_	_	_	_	Seg=O
96	.	_	_	_	_	_	_	_	Seg=O
97	These	_	_	_	_	_	_	_	Seg=B-seg
98	significantly	_	_	_	_	_	_	_	Seg=O
99	add	_	_	_	_	_	_	_	Seg=O
100	on	_	_	_	_	_	_	_	Seg=O
101	to	_	_	_	_	_	_	_	Seg=O
102	the	_	_	_	_	_	_	_	Seg=O
103	health	_	_	_	_	_	_	_	Seg=O
104	care	_	_	_	_	_	_	_	Seg=O
105	costs	_	_	_	_	_	_	_	Seg=O
106	.	_	_	_	_	_	_	_	Seg=O
107	The	_	_	_	_	_	_	_	Seg=B-seg
108	available	_	_	_	_	_	_	_	Seg=O
109	information	_	_	_	_	_	_	_	Seg=O
110	from	_	_	_	_	_	_	_	Seg=O
111	health	_	_	_	_	_	_	_	Seg=O
112	organisations	_	_	_	_	_	_	_	Seg=O
113	and	_	_	_	_	_	_	_	Seg=O
114	previous	_	_	_	_	_	_	_	Seg=O
115	studies	_	_	_	_	_	_	_	Seg=O
116	has	_	_	_	_	_	_	_	Seg=O
117	indicated	_	_	_	_	_	_	_	Seg=O
118	the	_	_	_	_	_	_	_	Seg=O
119	need	_	_	_	_	_	_	_	Seg=O
120	to	_	_	_	_	_	_	_	Seg=B-seg
121	manage	_	_	_	_	_	_	_	Seg=O
122	the	_	_	_	_	_	_	_	Seg=O
123	diagnosis	_	_	_	_	_	_	_	Seg=O
124	of	_	_	_	_	_	_	_	Seg=O
125	pharyngotonsillitis	_	_	_	_	_	_	_	Seg=O
126	to	_	_	_	_	_	_	_	Seg=B-seg
127	improve	_	_	_	_	_	_	_	Seg=O
128	prescribing	_	_	_	_	_	_	_	Seg=O
129	habits	_	_	_	_	_	_	_	Seg=O
130	in	_	_	_	_	_	_	_	Seg=O
131	primary	_	_	_	_	_	_	_	Seg=O
132	care	_	_	_	_	_	_	_	Seg=O
133	clinics	_	_	_	_	_	_	_	Seg=O
134	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 2f904674d4fd87023b02950eeff6497be222926b
1	Massive	_	_	_	_	_	_	_	Seg=B-seg
2	molecular	_	_	_	_	_	_	_	Seg=O
3	testing	_	_	_	_	_	_	_	Seg=O
4	for	_	_	_	_	_	_	_	Seg=O
5	COVID-19	_	_	_	_	_	_	_	Seg=O
6	has	_	_	_	_	_	_	_	Seg=O
7	been	_	_	_	_	_	_	_	Seg=O
8	pointed	_	_	_	_	_	_	_	Seg=O
9	as	_	_	_	_	_	_	_	Seg=O
10	fundamental	_	_	_	_	_	_	_	Seg=O
11	to	_	_	_	_	_	_	_	Seg=B-seg
12	moderate	_	_	_	_	_	_	_	Seg=O
13	the	_	_	_	_	_	_	_	Seg=O
14	spread	_	_	_	_	_	_	_	Seg=O
15	of	_	_	_	_	_	_	_	Seg=O
16	the	_	_	_	_	_	_	_	Seg=O
17	disease	_	_	_	_	_	_	_	Seg=O
18	.	_	_	_	_	_	_	_	Seg=O
19	Pooling	_	_	_	_	_	_	_	Seg=B-seg
20	methods	_	_	_	_	_	_	_	Seg=O
21	can	_	_	_	_	_	_	_	Seg=O
22	enhance	_	_	_	_	_	_	_	Seg=O
23	testing	_	_	_	_	_	_	_	Seg=O
24	efficiency	_	_	_	_	_	_	_	Seg=O
25	,	_	_	_	_	_	_	_	Seg=O
26	but	_	_	_	_	_	_	_	Seg=B-seg
27	they	_	_	_	_	_	_	_	Seg=O
28	are	_	_	_	_	_	_	_	Seg=O
29	viable	_	_	_	_	_	_	_	Seg=O
30	only	_	_	_	_	_	_	_	Seg=O
31	at	_	_	_	_	_	_	_	Seg=O
32	very	_	_	_	_	_	_	_	Seg=O
33	low	_	_	_	_	_	_	_	Seg=O
34	prevalences	_	_	_	_	_	_	_	Seg=O
35	of	_	_	_	_	_	_	_	Seg=O
36	the	_	_	_	_	_	_	_	Seg=O
37	disease	_	_	_	_	_	_	_	Seg=O
38	.	_	_	_	_	_	_	_	Seg=O
39	We	_	_	_	_	_	_	_	Seg=B-seg
40	propose	_	_	_	_	_	_	_	Seg=O
41	Smart	_	_	_	_	_	_	_	Seg=O
42	Pooling	_	_	_	_	_	_	_	Seg=O
43	,	_	_	_	_	_	_	_	Seg=O
44	a	_	_	_	_	_	_	_	Seg=O
45	machine	_	_	_	_	_	_	_	Seg=O
46	learning	_	_	_	_	_	_	_	Seg=O
47	method	_	_	_	_	_	_	_	Seg=O
48	that	_	_	_	_	_	_	_	Seg=B-seg
49	uses	_	_	_	_	_	_	_	Seg=O
50	sociodemographic	_	_	_	_	_	_	_	Seg=O
51	data	_	_	_	_	_	_	_	Seg=O
52	from	_	_	_	_	_	_	_	Seg=O
53	patients	_	_	_	_	_	_	_	Seg=O
54	to	_	_	_	_	_	_	_	Seg=B-seg
55	increase	_	_	_	_	_	_	_	Seg=O
56	the	_	_	_	_	_	_	_	Seg=O
57	efficiency	_	_	_	_	_	_	_	Seg=O
58	of	_	_	_	_	_	_	_	Seg=O
59	pooled	_	_	_	_	_	_	_	Seg=O
60	molecular	_	_	_	_	_	_	_	Seg=O
61	testing	_	_	_	_	_	_	_	Seg=O
62	for	_	_	_	_	_	_	_	Seg=O
63	COVID-19	_	_	_	_	_	_	_	Seg=O
64	by	_	_	_	_	_	_	_	Seg=B-seg
65	arranging	_	_	_	_	_	_	_	Seg=O
66	samples	_	_	_	_	_	_	_	Seg=O
67	into	_	_	_	_	_	_	_	Seg=O
68	all	_	_	_	_	_	_	_	Seg=O
69	-	_	_	_	_	_	_	_	Seg=O
70	negative	_	_	_	_	_	_	_	Seg=O
71	pools	_	_	_	_	_	_	_	Seg=O
72	.	_	_	_	_	_	_	_	Seg=O
73	We	_	_	_	_	_	_	_	Seg=B-seg
74	show	_	_	_	_	_	_	_	Seg=O
75	efficiency	_	_	_	_	_	_	_	Seg=O
76	gains	_	_	_	_	_	_	_	Seg=O
77	of	_	_	_	_	_	_	_	Seg=O
78	42	_	_	_	_	_	_	_	Seg=O
79	%	_	_	_	_	_	_	_	Seg=O
80	with	_	_	_	_	_	_	_	Seg=O
81	respect	_	_	_	_	_	_	_	Seg=O
82	to	_	_	_	_	_	_	_	Seg=O
83	individual	_	_	_	_	_	_	_	Seg=O
84	testing	_	_	_	_	_	_	_	Seg=O
85	at	_	_	_	_	_	_	_	Seg=O
86	disease	_	_	_	_	_	_	_	Seg=O
87	prevalence	_	_	_	_	_	_	_	Seg=O
88	of	_	_	_	_	_	_	_	Seg=O
89	up	_	_	_	_	_	_	_	Seg=O
90	to	_	_	_	_	_	_	_	Seg=O
91	25	_	_	_	_	_	_	_	Seg=O
92	%	_	_	_	_	_	_	_	Seg=O
93	,	_	_	_	_	_	_	_	Seg=O
94	a	_	_	_	_	_	_	_	Seg=O
95	regime	_	_	_	_	_	_	_	Seg=O
96	in	_	_	_	_	_	_	_	Seg=B-seg
97	which	_	_	_	_	_	_	_	Seg=O
98	two	_	_	_	_	_	_	_	Seg=O
99	-	_	_	_	_	_	_	_	Seg=O
100	step	_	_	_	_	_	_	_	Seg=O
101	pooling	_	_	_	_	_	_	_	Seg=O
102	offers	_	_	_	_	_	_	_	Seg=O
103	marginal	_	_	_	_	_	_	_	Seg=O
104	efficiency	_	_	_	_	_	_	_	Seg=O
105	gains	_	_	_	_	_	_	_	Seg=O
106	.	_	_	_	_	_	_	_	Seg=O
107	Additionally	_	_	_	_	_	_	_	Seg=B-seg
108	,	_	_	_	_	_	_	_	Seg=O
109	we	_	_	_	_	_	_	_	Seg=O
110	calculate	_	_	_	_	_	_	_	Seg=O
111	the	_	_	_	_	_	_	_	Seg=O
112	possible	_	_	_	_	_	_	_	Seg=O
113	efficiency	_	_	_	_	_	_	_	Seg=O
114	gains	_	_	_	_	_	_	_	Seg=O
115	of	_	_	_	_	_	_	_	Seg=O
116	one	_	_	_	_	_	_	_	Seg=O
117	-	_	_	_	_	_	_	_	Seg=O
118	and	_	_	_	_	_	_	_	Seg=O
119	two	_	_	_	_	_	_	_	Seg=O
120	-	_	_	_	_	_	_	_	Seg=O
121	dimensional	_	_	_	_	_	_	_	Seg=O
122	two	_	_	_	_	_	_	_	Seg=O
123	-	_	_	_	_	_	_	_	Seg=O
124	step	_	_	_	_	_	_	_	Seg=O
125	pooling	_	_	_	_	_	_	_	Seg=O
126	strategies	_	_	_	_	_	_	_	Seg=O
127	and	_	_	_	_	_	_	_	Seg=B-seg
128	present	_	_	_	_	_	_	_	Seg=O
129	the	_	_	_	_	_	_	_	Seg=O
130	optimal	_	_	_	_	_	_	_	Seg=O
131	strategies	_	_	_	_	_	_	_	Seg=O
132	for	_	_	_	_	_	_	_	Seg=O
133	disease	_	_	_	_	_	_	_	Seg=O
134	prevalences	_	_	_	_	_	_	_	Seg=O
135	up	_	_	_	_	_	_	_	Seg=O
136	to	_	_	_	_	_	_	_	Seg=O
137	25	_	_	_	_	_	_	_	Seg=O
138	%	_	_	_	_	_	_	_	Seg=O
139	.	_	_	_	_	_	_	_	Seg=O
140	We	_	_	_	_	_	_	_	Seg=B-seg
141	discuss	_	_	_	_	_	_	_	Seg=O
142	practical	_	_	_	_	_	_	_	Seg=O
143	limitations	_	_	_	_	_	_	_	Seg=O
144	to	_	_	_	_	_	_	_	Seg=B-seg
145	conduct	_	_	_	_	_	_	_	Seg=O
146	pooling	_	_	_	_	_	_	_	Seg=O
147	in	_	_	_	_	_	_	_	Seg=O
148	the	_	_	_	_	_	_	_	Seg=O
149	laboratory	_	_	_	_	_	_	_	Seg=O
150	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 3053729be9dadd6180b0b30ed2048dec12bd0401
1	Gastroenteritis	_	_	_	_	_	_	_	Seg=B-seg
2	is	_	_	_	_	_	_	_	Seg=O
3	a	_	_	_	_	_	_	_	Seg=O
4	common	_	_	_	_	_	_	_	Seg=O
5	illness	_	_	_	_	_	_	_	Seg=O
6	causing	_	_	_	_	_	_	_	Seg=B-seg
7	considerable	_	_	_	_	_	_	_	Seg=O
8	morbidity	_	_	_	_	_	_	_	Seg=O
9	and	_	_	_	_	_	_	_	Seg=O
10	mortality	_	_	_	_	_	_	_	Seg=O
11	worldwide	_	_	_	_	_	_	_	Seg=O
12	.	_	_	_	_	_	_	_	Seg=O
13	Despite	_	_	_	_	_	_	_	Seg=B-seg
14	improvements	_	_	_	_	_	_	_	Seg=O
15	in	_	_	_	_	_	_	_	Seg=O
16	detection	_	_	_	_	_	_	_	Seg=O
17	methods	_	_	_	_	_	_	_	Seg=O
18	,	_	_	_	_	_	_	_	Seg=O
19	a	_	_	_	_	_	_	_	Seg=B-seg
20	significant	_	_	_	_	_	_	_	Seg=O
21	diagnostic	_	_	_	_	_	_	_	Seg=O
22	gap	_	_	_	_	_	_	_	Seg=O
23	still	_	_	_	_	_	_	_	Seg=O
24	remains	_	_	_	_	_	_	_	Seg=O
25	.	_	_	_	_	_	_	_	Seg=O
26	Human	_	_	_	_	_	_	_	Seg=B-seg
27	bocavirus	_	_	_	_	_	_	_	Seg=O
28	(	_	_	_	_	_	_	_	Seg=O
29	HBoV)s	_	_	_	_	_	_	_	Seg=O
30	,	_	_	_	_	_	_	_	Seg=O
31	which	_	_	_	_	_	_	_	Seg=B-seg
32	are	_	_	_	_	_	_	_	Seg=O
33	associated	_	_	_	_	_	_	_	Seg=O
34	with	_	_	_	_	_	_	_	Seg=O
35	respiratory	_	_	_	_	_	_	_	Seg=O
36	infections	_	_	_	_	_	_	_	Seg=O
37	,	_	_	_	_	_	_	_	Seg=O
38	have	_	_	_	_	_	_	_	Seg=B-seg
39	also	_	_	_	_	_	_	_	Seg=O
40	frequently	_	_	_	_	_	_	_	Seg=O
41	been	_	_	_	_	_	_	_	Seg=O
42	detected	_	_	_	_	_	_	_	Seg=O
43	in	_	_	_	_	_	_	_	Seg=O
44	stool	_	_	_	_	_	_	_	Seg=O
45	samples	_	_	_	_	_	_	_	Seg=O
46	in	_	_	_	_	_	_	_	Seg=O
47	cases	_	_	_	_	_	_	_	Seg=O
48	of	_	_	_	_	_	_	_	Seg=O
49	gastroenteritis	_	_	_	_	_	_	_	Seg=O
50	,	_	_	_	_	_	_	_	Seg=O
51	and	_	_	_	_	_	_	_	Seg=B-seg
52	a	_	_	_	_	_	_	_	Seg=O
53	tentative	_	_	_	_	_	_	_	Seg=O
54	association	_	_	_	_	_	_	_	Seg=O
55	between	_	_	_	_	_	_	_	Seg=O
56	HBoVs	_	_	_	_	_	_	_	Seg=O
57	,	_	_	_	_	_	_	_	Seg=O
58	and	_	_	_	_	_	_	_	Seg=O
59	in	_	_	_	_	_	_	_	Seg=O
60	particular	_	_	_	_	_	_	_	Seg=O
61	type-2	_	_	_	_	_	_	_	Seg=O
62	HBoVs	_	_	_	_	_	_	_	Seg=O
63	,	_	_	_	_	_	_	_	Seg=O
64	and	_	_	_	_	_	_	_	Seg=O
65	gastroenteritis	_	_	_	_	_	_	_	Seg=O
66	has	_	_	_	_	_	_	_	Seg=O
67	previously	_	_	_	_	_	_	_	Seg=O
68	been	_	_	_	_	_	_	_	Seg=O
69	made	_	_	_	_	_	_	_	Seg=O
70	.	_	_	_	_	_	_	_	Seg=O
71	The	_	_	_	_	_	_	_	Seg=B-seg
72	aim	_	_	_	_	_	_	_	Seg=O
73	of	_	_	_	_	_	_	_	Seg=O
74	this	_	_	_	_	_	_	_	Seg=O
75	study	_	_	_	_	_	_	_	Seg=O
76	was	_	_	_	_	_	_	_	Seg=O
77	to	_	_	_	_	_	_	_	Seg=O
78	determine	_	_	_	_	_	_	_	Seg=O
79	the	_	_	_	_	_	_	_	Seg=O
80	role	_	_	_	_	_	_	_	Seg=O
81	of	_	_	_	_	_	_	_	Seg=O
82	HBoVs	_	_	_	_	_	_	_	Seg=O
83	in	_	_	_	_	_	_	_	Seg=O
84	gastroenteritis	_	_	_	_	_	_	_	Seg=O
85	,	_	_	_	_	_	_	_	Seg=O
86	using	_	_	_	_	_	_	_	Seg=B-seg
87	archived	_	_	_	_	_	_	_	Seg=O
88	DNA	_	_	_	_	_	_	_	Seg=O
89	samples	_	_	_	_	_	_	_	Seg=O
90	from	_	_	_	_	_	_	_	Seg=O
91	the	_	_	_	_	_	_	_	Seg=O
92	case	_	_	_	_	_	_	_	Seg=O
93	-	_	_	_	_	_	_	_	Seg=O
94	control	_	_	_	_	_	_	_	Seg=O
95	Infectious	_	_	_	_	_	_	_	Seg=O
96	Intestinal	_	_	_	_	_	_	_	Seg=O
97	Disease	_	_	_	_	_	_	_	Seg=O
98	Study	_	_	_	_	_	_	_	Seg=O
99	(	_	_	_	_	_	_	_	Seg=O
100	IID	_	_	_	_	_	_	_	Seg=O
101	)	_	_	_	_	_	_	_	Seg=O
102	.	_	_	_	_	_	_	_	Seg=O
103	DNA	_	_	_	_	_	_	_	Seg=B-seg
104	extracted	_	_	_	_	_	_	_	Seg=B-seg
105	from	_	_	_	_	_	_	_	Seg=O
106	stool	_	_	_	_	_	_	_	Seg=O
107	samples	_	_	_	_	_	_	_	Seg=O
108	from	_	_	_	_	_	_	_	Seg=O
109	2,256	_	_	_	_	_	_	_	Seg=O
110	cases	_	_	_	_	_	_	_	Seg=O
111	and	_	_	_	_	_	_	_	Seg=O
112	2,124	_	_	_	_	_	_	_	Seg=O
113	controls	_	_	_	_	_	_	_	Seg=O
114	were	_	_	_	_	_	_	_	Seg=B-seg
115	tested	_	_	_	_	_	_	_	Seg=O
116	for	_	_	_	_	_	_	_	Seg=O
117	the	_	_	_	_	_	_	_	Seg=O
118	presence	_	_	_	_	_	_	_	Seg=O
119	of	_	_	_	_	_	_	_	Seg=O
120	HBoV	_	_	_	_	_	_	_	Seg=O
121	DNA	_	_	_	_	_	_	_	Seg=O
122	.	_	_	_	_	_	_	_	Seg=O
123	All	_	_	_	_	_	_	_	Seg=B-seg
124	samples	_	_	_	_	_	_	_	Seg=O
125	were	_	_	_	_	_	_	_	Seg=O
126	screened	_	_	_	_	_	_	_	Seg=O
127	in	_	_	_	_	_	_	_	Seg=O
128	a	_	_	_	_	_	_	_	Seg=O
129	real	_	_	_	_	_	_	_	Seg=O
130	time	_	_	_	_	_	_	_	Seg=O
131	PCR	_	_	_	_	_	_	_	Seg=O
132	pan	_	_	_	_	_	_	_	Seg=O
133	-	_	_	_	_	_	_	_	Seg=O
134	HBoV	_	_	_	_	_	_	_	Seg=O
135	assay	_	_	_	_	_	_	_	Seg=O
136	,	_	_	_	_	_	_	_	Seg=O
137	and	_	_	_	_	_	_	_	Seg=B-seg
138	positive	_	_	_	_	_	_	_	Seg=O
139	samples	_	_	_	_	_	_	_	Seg=O
140	were	_	_	_	_	_	_	_	Seg=O
141	then	_	_	_	_	_	_	_	Seg=O
142	tested	_	_	_	_	_	_	_	Seg=O
143	in	_	_	_	_	_	_	_	Seg=O
144	genotype	_	_	_	_	_	_	_	Seg=O
145	1	_	_	_	_	_	_	_	Seg=O
146	to	_	_	_	_	_	_	_	Seg=O
147	3-specific	_	_	_	_	_	_	_	Seg=O
148	assays	_	_	_	_	_	_	_	Seg=O
149	.	_	_	_	_	_	_	_	Seg=O
150	HBoV	_	_	_	_	_	_	_	Seg=B-seg
151	was	_	_	_	_	_	_	_	Seg=O
152	detected	_	_	_	_	_	_	_	Seg=O
153	in	_	_	_	_	_	_	_	Seg=O
154	7.4	_	_	_	_	_	_	_	Seg=O
155	%	_	_	_	_	_	_	_	Seg=O
156	but	_	_	_	_	_	_	_	Seg=B-seg
157	no	_	_	_	_	_	_	_	Seg=O
158	significantly	_	_	_	_	_	_	_	Seg=O
159	different	_	_	_	_	_	_	_	Seg=O
160	prevalence	_	_	_	_	_	_	_	Seg=O
161	was	_	_	_	_	_	_	_	Seg=O
162	observed	_	_	_	_	_	_	_	Seg=O
163	between	_	_	_	_	_	_	_	Seg=O
164	cases	_	_	_	_	_	_	_	Seg=O
165	and	_	_	_	_	_	_	_	Seg=O
166	controls	_	_	_	_	_	_	_	Seg=O
167	.	_	_	_	_	_	_	_	Seg=O
168	In	_	_	_	_	_	_	_	Seg=B-seg
169	the	_	_	_	_	_	_	_	Seg=O
170	genotype	_	_	_	_	_	_	_	Seg=O
171	-	_	_	_	_	_	_	_	Seg=O
172	specific	_	_	_	_	_	_	_	Seg=O
173	assays	_	_	_	_	_	_	_	Seg=O
174	106	_	_	_	_	_	_	_	Seg=O
175	of	_	_	_	_	_	_	_	Seg=O
176	the	_	_	_	_	_	_	_	Seg=O
177	324	_	_	_	_	_	_	_	Seg=O
178	HBoV	_	_	_	_	_	_	_	Seg=O
179	-	_	_	_	_	_	_	_	Seg=O
180	positive	_	_	_	_	_	_	_	Seg=O
181	samples	_	_	_	_	_	_	_	Seg=O
182	were	_	_	_	_	_	_	_	Seg=O
183	genotyped	_	_	_	_	_	_	_	Seg=O
184	,	_	_	_	_	_	_	_	Seg=O
185	with	_	_	_	_	_	_	_	Seg=B-seg
186	HBoV-1	_	_	_	_	_	_	_	Seg=O
187	predominantly	_	_	_	_	_	_	_	Seg=O
188	found	_	_	_	_	_	_	_	Seg=O
189	in	_	_	_	_	_	_	_	Seg=O
190	controls	_	_	_	_	_	_	_	Seg=O
191	whilst	_	_	_	_	_	_	_	Seg=B-seg
192	HBoV-2	_	_	_	_	_	_	_	Seg=O
193	was	_	_	_	_	_	_	_	Seg=O
194	more	_	_	_	_	_	_	_	Seg=O
195	frequently	_	_	_	_	_	_	_	Seg=O
196	associated	_	_	_	_	_	_	_	Seg=O
197	with	_	_	_	_	_	_	_	Seg=O
198	cases	_	_	_	_	_	_	_	Seg=O
199	of	_	_	_	_	_	_	_	Seg=O
200	gastroenteritis	_	_	_	_	_	_	_	Seg=O
201	(	_	_	_	_	_	_	_	Seg=B-seg
202	p,0.01	_	_	_	_	_	_	_	Seg=O
203	)	_	_	_	_	_	_	_	Seg=O
204	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 3083c8b34f2b52c612601c0cedbd397681f79d46
1	Wildlife	_	_	_	_	_	_	_	Seg=B-seg
2	are	_	_	_	_	_	_	_	Seg=O
3	frequently	_	_	_	_	_	_	_	Seg=O
4	a	_	_	_	_	_	_	_	Seg=O
5	neglected	_	_	_	_	_	_	_	Seg=O
6	component	_	_	_	_	_	_	_	Seg=O
7	of	_	_	_	_	_	_	_	Seg=O
8	One	_	_	_	_	_	_	_	Seg=O
9	Health	_	_	_	_	_	_	_	Seg=O
10	;	_	_	_	_	_	_	_	Seg=O
11	however	_	_	_	_	_	_	_	Seg=B-seg
12	,	_	_	_	_	_	_	_	Seg=O
13	the	_	_	_	_	_	_	_	Seg=O
14	linkages	_	_	_	_	_	_	_	Seg=O
15	between	_	_	_	_	_	_	_	Seg=O
16	the	_	_	_	_	_	_	_	Seg=O
17	health	_	_	_	_	_	_	_	Seg=O
18	of	_	_	_	_	_	_	_	Seg=O
19	wildlife	_	_	_	_	_	_	_	Seg=O
20	and	_	_	_	_	_	_	_	Seg=O
21	human	_	_	_	_	_	_	_	Seg=O
22	,	_	_	_	_	_	_	_	Seg=O
23	domestic	_	_	_	_	_	_	_	Seg=O
24	animal	_	_	_	_	_	_	_	Seg=O
25	,	_	_	_	_	_	_	_	Seg=O
26	and	_	_	_	_	_	_	_	Seg=O
27	environmental	_	_	_	_	_	_	_	Seg=O
28	health	_	_	_	_	_	_	_	Seg=O
29	are	_	_	_	_	_	_	_	Seg=O
30	clear	_	_	_	_	_	_	_	Seg=O
31	.	_	_	_	_	_	_	_	Seg=O
32	The	_	_	_	_	_	_	_	Seg=B-seg
33	majority	_	_	_	_	_	_	_	Seg=O
34	of	_	_	_	_	_	_	_	Seg=O
35	emerging	_	_	_	_	_	_	_	Seg=O
36	zoonotic	_	_	_	_	_	_	_	Seg=O
37	diseases	_	_	_	_	_	_	_	Seg=O
38	are	_	_	_	_	_	_	_	Seg=O
39	linked	_	_	_	_	_	_	_	Seg=O
40	to	_	_	_	_	_	_	_	Seg=O
41	wildlife	_	_	_	_	_	_	_	Seg=O
42	,	_	_	_	_	_	_	_	Seg=O
43	primarily	_	_	_	_	_	_	_	Seg=B-seg
44	driven	_	_	_	_	_	_	_	Seg=O
45	by	_	_	_	_	_	_	_	Seg=O
46	anthropogenic	_	_	_	_	_	_	_	Seg=O
47	land	_	_	_	_	_	_	_	Seg=O
48	changes	_	_	_	_	_	_	_	Seg=O
49	.	_	_	_	_	_	_	_	Seg=O
50	Despite	_	_	_	_	_	_	_	Seg=B-seg
51	this	_	_	_	_	_	_	_	Seg=O
52	risk	_	_	_	_	_	_	_	Seg=O
53	,	_	_	_	_	_	_	_	Seg=O
54	wildlife	_	_	_	_	_	_	_	Seg=B-seg
55	have	_	_	_	_	_	_	_	Seg=O
56	important	_	_	_	_	_	_	_	Seg=O
57	links	_	_	_	_	_	_	_	Seg=O
58	to	_	_	_	_	_	_	_	Seg=O
59	people	_	_	_	_	_	_	_	Seg=O
60	as	_	_	_	_	_	_	_	Seg=O
61	environmental	_	_	_	_	_	_	_	Seg=O
62	indicators	_	_	_	_	_	_	_	Seg=O
63	,	_	_	_	_	_	_	_	Seg=O
64	food	_	_	_	_	_	_	_	Seg=O
65	security	_	_	_	_	_	_	_	Seg=O
66	and	_	_	_	_	_	_	_	Seg=O
67	safety	_	_	_	_	_	_	_	Seg=O
68	,	_	_	_	_	_	_	_	Seg=O
69	and	_	_	_	_	_	_	_	Seg=O
70	through	_	_	_	_	_	_	_	Seg=O
71	human	_	_	_	_	_	_	_	Seg=O
72	livelihoods	_	_	_	_	_	_	_	Seg=O
73	.	_	_	_	_	_	_	_	Seg=O
74	This	_	_	_	_	_	_	_	Seg=B-seg
75	chapter	_	_	_	_	_	_	_	Seg=O
76	will	_	_	_	_	_	_	_	Seg=O
77	describe	_	_	_	_	_	_	_	Seg=O
78	these	_	_	_	_	_	_	_	Seg=O
79	linkages	_	_	_	_	_	_	_	Seg=O
80	and	_	_	_	_	_	_	_	Seg=B-seg
81	demonstrate	_	_	_	_	_	_	_	Seg=O
82	the	_	_	_	_	_	_	_	Seg=O
83	need	_	_	_	_	_	_	_	Seg=O
84	to	_	_	_	_	_	_	_	Seg=B-seg
85	understand	_	_	_	_	_	_	_	Seg=O
86	these	_	_	_	_	_	_	_	Seg=O
87	linkages	_	_	_	_	_	_	_	Seg=O
88	through	_	_	_	_	_	_	_	Seg=O
89	targeted	_	_	_	_	_	_	_	Seg=O
90	surveillance	_	_	_	_	_	_	_	Seg=O
91	and	_	_	_	_	_	_	_	Seg=O
92	understanding	_	_	_	_	_	_	_	Seg=O
93	the	_	_	_	_	_	_	_	Seg=O
94	ecology	_	_	_	_	_	_	_	Seg=O
95	of	_	_	_	_	_	_	_	Seg=O
96	wildlife	_	_	_	_	_	_	_	Seg=O
97	diseases	_	_	_	_	_	_	_	Seg=O
98	.	_	_	_	_	_	_	_	Seg=O
99	While	_	_	_	_	_	_	_	Seg=B-seg
100	the	_	_	_	_	_	_	_	Seg=O
101	management	_	_	_	_	_	_	_	Seg=O
102	of	_	_	_	_	_	_	_	Seg=O
103	wildlife	_	_	_	_	_	_	_	Seg=O
104	diseases	_	_	_	_	_	_	_	Seg=O
105	presents	_	_	_	_	_	_	_	Seg=O
106	a	_	_	_	_	_	_	_	Seg=O
107	significant	_	_	_	_	_	_	_	Seg=O
108	challenge	_	_	_	_	_	_	_	Seg=O
109	,	_	_	_	_	_	_	_	Seg=O
110	such	_	_	_	_	_	_	_	Seg=B-seg
111	practices	_	_	_	_	_	_	_	Seg=O
112	will	_	_	_	_	_	_	_	Seg=O
113	greatly	_	_	_	_	_	_	_	Seg=O
114	improve	_	_	_	_	_	_	_	Seg=O
115	the	_	_	_	_	_	_	_	Seg=O
116	health	_	_	_	_	_	_	_	Seg=O
117	of	_	_	_	_	_	_	_	Seg=O
118	people	_	_	_	_	_	_	_	Seg=O
119	,	_	_	_	_	_	_	_	Seg=O
120	domestic	_	_	_	_	_	_	_	Seg=O
121	animals	_	_	_	_	_	_	_	Seg=O
122	,	_	_	_	_	_	_	_	Seg=O
123	wildlife	_	_	_	_	_	_	_	Seg=O
124	and	_	_	_	_	_	_	_	Seg=O
125	the	_	_	_	_	_	_	_	Seg=O
126	environment	_	_	_	_	_	_	_	Seg=O
127	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 308feddda1dfd44c1ebb38dcc2d06bb6b2d5dddf
1	This	_	_	_	_	_	_	_	Seg=B-seg
2	research	_	_	_	_	_	_	_	Seg=O
3	examines	_	_	_	_	_	_	_	Seg=O
4	whether	_	_	_	_	_	_	_	Seg=O
5	cities	_	_	_	_	_	_	_	Seg=O
6	are	_	_	_	_	_	_	_	Seg=O
7	getting	_	_	_	_	_	_	_	Seg=O
8	more	_	_	_	_	_	_	_	Seg=O
9	equally	_	_	_	_	_	_	_	Seg=O
10	accessible	_	_	_	_	_	_	_	Seg=O
11	and	_	_	_	_	_	_	_	Seg=O
12	connected	_	_	_	_	_	_	_	Seg=O
13	via	_	_	_	_	_	_	_	Seg=O
14	high	_	_	_	_	_	_	_	Seg=O
15	-	_	_	_	_	_	_	_	Seg=O
16	speed	_	_	_	_	_	_	_	Seg=O
17	rail	_	_	_	_	_	_	_	Seg=O
18	(	_	_	_	_	_	_	_	Seg=O
19	HSR	_	_	_	_	_	_	_	Seg=O
20	)	_	_	_	_	_	_	_	Seg=O
21	in	_	_	_	_	_	_	_	Seg=O
22	China	_	_	_	_	_	_	_	Seg=O
23	over	_	_	_	_	_	_	_	Seg=O
24	the	_	_	_	_	_	_	_	Seg=O
25	period	_	_	_	_	_	_	_	Seg=O
26	from	_	_	_	_	_	_	_	Seg=O
27	2010	_	_	_	_	_	_	_	Seg=O
28	to	_	_	_	_	_	_	_	Seg=O
29	2015	_	_	_	_	_	_	_	Seg=O
30	.	_	_	_	_	_	_	_	Seg=O
31	Existing	_	_	_	_	_	_	_	Seg=B-seg
32	studies	_	_	_	_	_	_	_	Seg=O
33	mainly	_	_	_	_	_	_	_	Seg=O
34	use	_	_	_	_	_	_	_	Seg=O
35	network	_	_	_	_	_	_	_	Seg=O
36	centralities	_	_	_	_	_	_	_	Seg=O
37	to	_	_	_	_	_	_	_	Seg=B-seg
38	describe	_	_	_	_	_	_	_	Seg=O
39	the	_	_	_	_	_	_	_	Seg=O
40	spatial	_	_	_	_	_	_	_	Seg=O
41	pattern	_	_	_	_	_	_	_	Seg=O
42	of	_	_	_	_	_	_	_	Seg=O
43	HSR	_	_	_	_	_	_	_	Seg=O
44	network	_	_	_	_	_	_	_	Seg=O
45	without	_	_	_	_	_	_	_	Seg=B-seg
46	measuring	_	_	_	_	_	_	_	Seg=O
47	the	_	_	_	_	_	_	_	Seg=O
48	spatial	_	_	_	_	_	_	_	Seg=O
49	disparity	_	_	_	_	_	_	_	Seg=O
50	of	_	_	_	_	_	_	_	Seg=O
51	these	_	_	_	_	_	_	_	Seg=O
52	centralities	_	_	_	_	_	_	_	Seg=O
53	,	_	_	_	_	_	_	_	Seg=O
54	and	_	_	_	_	_	_	_	Seg=B-seg
55	most	_	_	_	_	_	_	_	Seg=O
56	of	_	_	_	_	_	_	_	Seg=O
57	them	_	_	_	_	_	_	_	Seg=O
58	rely	_	_	_	_	_	_	_	Seg=O
59	on	_	_	_	_	_	_	_	Seg=O
60	the	_	_	_	_	_	_	_	Seg=O
61	infrastructure	_	_	_	_	_	_	_	Seg=O
62	network	_	_	_	_	_	_	_	Seg=O
63	and	_	_	_	_	_	_	_	Seg=B-seg
64	thus	_	_	_	_	_	_	_	Seg=O
65	fail	_	_	_	_	_	_	_	Seg=O
66	to	_	_	_	_	_	_	_	Seg=O
67	incorporate	_	_	_	_	_	_	_	Seg=O
68	HSR	_	_	_	_	_	_	_	Seg=O
69	service	_	_	_	_	_	_	_	Seg=O
70	quality	_	_	_	_	_	_	_	Seg=O
71	in	_	_	_	_	_	_	_	Seg=O
72	the	_	_	_	_	_	_	_	Seg=O
73	centrality	_	_	_	_	_	_	_	Seg=O
74	measures	_	_	_	_	_	_	_	Seg=O
75	.	_	_	_	_	_	_	_	Seg=O
76	Using	_	_	_	_	_	_	_	Seg=B-seg
77	HSR	_	_	_	_	_	_	_	Seg=O
78	timetable	_	_	_	_	_	_	_	Seg=O
79	data	_	_	_	_	_	_	_	Seg=O
80	,	_	_	_	_	_	_	_	Seg=O
81	we	_	_	_	_	_	_	_	Seg=B-seg
82	incorporate	_	_	_	_	_	_	_	Seg=O
83	both	_	_	_	_	_	_	_	Seg=O
84	scheduled	_	_	_	_	_	_	_	Seg=O
85	travel	_	_	_	_	_	_	_	Seg=O
86	time	_	_	_	_	_	_	_	Seg=O
87	and	_	_	_	_	_	_	_	Seg=O
88	daily	_	_	_	_	_	_	_	Seg=O
89	frequency	_	_	_	_	_	_	_	Seg=O
90	of	_	_	_	_	_	_	_	Seg=O
91	each	_	_	_	_	_	_	_	Seg=O
92	origin	_	_	_	_	_	_	_	Seg=O
93	-	_	_	_	_	_	_	_	Seg=O
94	destination	_	_	_	_	_	_	_	Seg=O
95	city	_	_	_	_	_	_	_	Seg=O
96	pair	_	_	_	_	_	_	_	Seg=O
97	into	_	_	_	_	_	_	_	Seg=O
98	three	_	_	_	_	_	_	_	Seg=O
99	centrality	_	_	_	_	_	_	_	Seg=O
100	measures	_	_	_	_	_	_	_	Seg=O
101	and	_	_	_	_	_	_	_	Seg=B-seg
102	further	_	_	_	_	_	_	_	Seg=O
103	quantify	_	_	_	_	_	_	_	Seg=O
104	their	_	_	_	_	_	_	_	Seg=O
105	inequalities	_	_	_	_	_	_	_	Seg=O
106	using	_	_	_	_	_	_	_	Seg=B-seg
107-108	Theil's	_	_	_	_	_	_	_	_
107	Theil	_	_	_	_	_	_	_	Seg=O
108	's	_	_	_	_	_	_	_	Seg=O
109	T	_	_	_	_	_	_	_	Seg=O
110	index	_	_	_	_	_	_	_	Seg=O
111	.	_	_	_	_	_	_	_	Seg=O
112	We	_	_	_	_	_	_	_	Seg=B-seg
113	find	_	_	_	_	_	_	_	Seg=O
114	that	_	_	_	_	_	_	_	Seg=B-seg
115	as	_	_	_	_	_	_	_	Seg=B-seg
116	the	_	_	_	_	_	_	_	Seg=O
117	HSR	_	_	_	_	_	_	_	Seg=O
118	network	_	_	_	_	_	_	_	Seg=O
119	expands	_	_	_	_	_	_	_	Seg=O
120	,	_	_	_	_	_	_	_	Seg=O
121	cities	_	_	_	_	_	_	_	Seg=B-seg
122	appear	_	_	_	_	_	_	_	Seg=O
123	to	_	_	_	_	_	_	_	Seg=O
124	be	_	_	_	_	_	_	_	Seg=O
125	more	_	_	_	_	_	_	_	Seg=O
126	equal	_	_	_	_	_	_	_	Seg=O
127	in	_	_	_	_	_	_	_	Seg=O
128	terms	_	_	_	_	_	_	_	Seg=O
129	of	_	_	_	_	_	_	_	Seg=O
130	accessibility	_	_	_	_	_	_	_	Seg=O
131	,	_	_	_	_	_	_	_	Seg=O
132	but	_	_	_	_	_	_	_	Seg=B-seg
133	their	_	_	_	_	_	_	_	Seg=O
134	disparities	_	_	_	_	_	_	_	Seg=O
135	in	_	_	_	_	_	_	_	Seg=O
136	connectivity	_	_	_	_	_	_	_	Seg=O
137	and	_	_	_	_	_	_	_	Seg=O
138	transitivity	_	_	_	_	_	_	_	Seg=O
139	depend	_	_	_	_	_	_	_	Seg=O
140	on	_	_	_	_	_	_	_	Seg=O
141	the	_	_	_	_	_	_	_	Seg=O
142	dimensions	_	_	_	_	_	_	_	Seg=O
143	of	_	_	_	_	_	_	_	Seg=O
144	comparison	_	_	_	_	_	_	_	Seg=O
145	.	_	_	_	_	_	_	_	Seg=O
146	In	_	_	_	_	_	_	_	Seg=B-seg
147	general	_	_	_	_	_	_	_	Seg=O
148	,	_	_	_	_	_	_	_	Seg=O
149	although	_	_	_	_	_	_	_	Seg=B-seg
150	the	_	_	_	_	_	_	_	Seg=O
151	difference	_	_	_	_	_	_	_	Seg=O
152	between	_	_	_	_	_	_	_	Seg=O
153	economic	_	_	_	_	_	_	_	Seg=O
154	regions	_	_	_	_	_	_	_	Seg=O
155	or	_	_	_	_	_	_	_	Seg=O
156	between	_	_	_	_	_	_	_	Seg=O
157	megalopolises	_	_	_	_	_	_	_	Seg=O
158	has	_	_	_	_	_	_	_	Seg=O
159	reduced	_	_	_	_	_	_	_	Seg=O
160	,	_	_	_	_	_	_	_	Seg=O
161	small	_	_	_	_	_	_	_	Seg=B-seg
162	/	_	_	_	_	_	_	_	Seg=O
163	medium	_	_	_	_	_	_	_	Seg=O
164	-	_	_	_	_	_	_	_	Seg=O
165	sized	_	_	_	_	_	_	_	Seg=O
166	cities	_	_	_	_	_	_	_	Seg=O
167	not	_	_	_	_	_	_	_	Seg=B-seg
168	belonging	_	_	_	_	_	_	_	Seg=O
169	to	_	_	_	_	_	_	_	Seg=O
170	any	_	_	_	_	_	_	_	Seg=O
171	major	_	_	_	_	_	_	_	Seg=O
172	city	_	_	_	_	_	_	_	Seg=O
173	cluster	_	_	_	_	_	_	_	Seg=O
174	are	_	_	_	_	_	_	_	Seg=B-seg
175	further	_	_	_	_	_	_	_	Seg=O
176	lagged	_	_	_	_	_	_	_	Seg=O
177	behind	_	_	_	_	_	_	_	Seg=O
178	in	_	_	_	_	_	_	_	Seg=O
179	HSR	_	_	_	_	_	_	_	Seg=O
180	development	_	_	_	_	_	_	_	Seg=O
181	.	_	_	_	_	_	_	_	Seg=O
182	The	_	_	_	_	_	_	_	Seg=B-seg
183	difference	_	_	_	_	_	_	_	Seg=O
184	between	_	_	_	_	_	_	_	Seg=O
185	core	_	_	_	_	_	_	_	Seg=O
186	and	_	_	_	_	_	_	_	Seg=O
187	non	_	_	_	_	_	_	_	Seg=O
188	-	_	_	_	_	_	_	_	Seg=O
189	core	_	_	_	_	_	_	_	Seg=O
190	cities	_	_	_	_	_	_	_	Seg=O
191	in	_	_	_	_	_	_	_	Seg=O
192	the	_	_	_	_	_	_	_	Seg=O
193	same	_	_	_	_	_	_	_	Seg=O
194	megalopolises	_	_	_	_	_	_	_	Seg=O
195	has	_	_	_	_	_	_	_	Seg=O
196	decreased	_	_	_	_	_	_	_	Seg=O
197	despite	_	_	_	_	_	_	_	Seg=B-seg
198	that	_	_	_	_	_	_	_	Seg=O
199	non	_	_	_	_	_	_	_	Seg=O
200	-	_	_	_	_	_	_	_	Seg=O
201	core	_	_	_	_	_	_	_	Seg=O
202	cities	_	_	_	_	_	_	_	Seg=O
203	are	_	_	_	_	_	_	_	Seg=O
204	increasingly	_	_	_	_	_	_	_	Seg=O
205	relying	_	_	_	_	_	_	_	Seg=O
206	on	_	_	_	_	_	_	_	Seg=O
207	core	_	_	_	_	_	_	_	Seg=O
208	cities	_	_	_	_	_	_	_	Seg=O
209	to	_	_	_	_	_	_	_	Seg=B-seg
210	access	_	_	_	_	_	_	_	Seg=O
211	other	_	_	_	_	_	_	_	Seg=O
212	regions	_	_	_	_	_	_	_	Seg=O
213	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 30d2d2d37c2a884db55ab21d1cbd92abcff95fa2
1	Angiotensin	_	_	_	_	_	_	_	Seg=B-seg
2	II	_	_	_	_	_	_	_	Seg=O
3	(	_	_	_	_	_	_	_	Seg=O
4	Ang	_	_	_	_	_	_	_	Seg=O
5	II	_	_	_	_	_	_	_	Seg=O
6	)	_	_	_	_	_	_	_	Seg=O
7	plays	_	_	_	_	_	_	_	Seg=O
8	an	_	_	_	_	_	_	_	Seg=O
9	important	_	_	_	_	_	_	_	Seg=O
10	role	_	_	_	_	_	_	_	Seg=O
11	in	_	_	_	_	_	_	_	Seg=O
12	cardiomyocyte	_	_	_	_	_	_	_	Seg=O
13	hypertrophy	_	_	_	_	_	_	_	Seg=O
14	.	_	_	_	_	_	_	_	Seg=O
15	The	_	_	_	_	_	_	_	Seg=B-seg
16	combined	_	_	_	_	_	_	_	Seg=O
17	effect	_	_	_	_	_	_	_	Seg=O
18	of	_	_	_	_	_	_	_	Seg=O
19	hepatocyte	_	_	_	_	_	_	_	Seg=O
20	growth	_	_	_	_	_	_	_	Seg=O
21	factor	_	_	_	_	_	_	_	Seg=O
22	(	_	_	_	_	_	_	_	Seg=O
23	HGF	_	_	_	_	_	_	_	Seg=O
24	)	_	_	_	_	_	_	_	Seg=O
25	and	_	_	_	_	_	_	_	Seg=O
26	Ang	_	_	_	_	_	_	_	Seg=O
27	II	_	_	_	_	_	_	_	Seg=O
28	on	_	_	_	_	_	_	_	Seg=O
29	cardiomyocytes	_	_	_	_	_	_	_	Seg=O
30	is	_	_	_	_	_	_	_	Seg=O
31	unknown	_	_	_	_	_	_	_	Seg=O
32	.	_	_	_	_	_	_	_	Seg=O
33	The	_	_	_	_	_	_	_	Seg=B-seg
34	present	_	_	_	_	_	_	_	Seg=O
35	study	_	_	_	_	_	_	_	Seg=O
36	was	_	_	_	_	_	_	_	Seg=O
37	designed	_	_	_	_	_	_	_	Seg=O
38	to	_	_	_	_	_	_	_	Seg=B-seg
39	determine	_	_	_	_	_	_	_	Seg=O
40	the	_	_	_	_	_	_	_	Seg=O
41	effect	_	_	_	_	_	_	_	Seg=O
42	of	_	_	_	_	_	_	_	Seg=O
43	HGF	_	_	_	_	_	_	_	Seg=O
44	on	_	_	_	_	_	_	_	Seg=O
45	cardiomyocyte	_	_	_	_	_	_	_	Seg=O
46	hypertrophy	_	_	_	_	_	_	_	Seg=O
47	and	_	_	_	_	_	_	_	Seg=B-seg
48	to	_	_	_	_	_	_	_	Seg=O
49	explore	_	_	_	_	_	_	_	Seg=O
50	the	_	_	_	_	_	_	_	Seg=O
51	combined	_	_	_	_	_	_	_	Seg=O
52	effect	_	_	_	_	_	_	_	Seg=O
53	of	_	_	_	_	_	_	_	Seg=O
54	HGF	_	_	_	_	_	_	_	Seg=O
55	and	_	_	_	_	_	_	_	Seg=O
56	Ang	_	_	_	_	_	_	_	Seg=O
57	II	_	_	_	_	_	_	_	Seg=O
58	on	_	_	_	_	_	_	_	Seg=O
59	cardiomyocyte	_	_	_	_	_	_	_	Seg=O
60	hypertrophy	_	_	_	_	_	_	_	Seg=O
61	.	_	_	_	_	_	_	_	Seg=O
62	Primary	_	_	_	_	_	_	_	Seg=B-seg
63	cardiomyocytes	_	_	_	_	_	_	_	Seg=O
64	were	_	_	_	_	_	_	_	Seg=O
65	isolated	_	_	_	_	_	_	_	Seg=O
66	from	_	_	_	_	_	_	_	Seg=O
67	neonatal	_	_	_	_	_	_	_	Seg=O
68	rat	_	_	_	_	_	_	_	Seg=O
69	hearts	_	_	_	_	_	_	_	Seg=O
70	and	_	_	_	_	_	_	_	Seg=B-seg
71	cultured	_	_	_	_	_	_	_	Seg=O
72	in	_	_	_	_	_	_	_	Seg=O
73	vitro	_	_	_	_	_	_	_	Seg=O
74	.	_	_	_	_	_	_	_	Seg=O
75	Cells	_	_	_	_	_	_	_	Seg=B-seg
76	were	_	_	_	_	_	_	_	Seg=O
77	treated	_	_	_	_	_	_	_	Seg=O
78	with	_	_	_	_	_	_	_	Seg=O
79	Ang	_	_	_	_	_	_	_	Seg=O
80	II	_	_	_	_	_	_	_	Seg=O
81	(	_	_	_	_	_	_	_	Seg=B-seg
82	1	_	_	_	_	_	_	_	Seg=O
83	µM	_	_	_	_	_	_	_	Seg=O
84	)	_	_	_	_	_	_	_	Seg=O
85	alone	_	_	_	_	_	_	_	Seg=B-seg
86	,	_	_	_	_	_	_	_	Seg=O
87	HGF	_	_	_	_	_	_	_	Seg=O
88	(	_	_	_	_	_	_	_	Seg=B-seg
89	10	_	_	_	_	_	_	_	Seg=O
90	ng	_	_	_	_	_	_	_	Seg=O
91	/	_	_	_	_	_	_	_	Seg=O
92	mL	_	_	_	_	_	_	_	Seg=O
93	)	_	_	_	_	_	_	_	Seg=O
94	alone	_	_	_	_	_	_	_	Seg=B-seg
95	,	_	_	_	_	_	_	_	Seg=O
96	and	_	_	_	_	_	_	_	Seg=O
97	Ang	_	_	_	_	_	_	_	Seg=O
98	II	_	_	_	_	_	_	_	Seg=O
99	(	_	_	_	_	_	_	_	Seg=B-seg
100	1	_	_	_	_	_	_	_	Seg=O
101	µM	_	_	_	_	_	_	_	Seg=O
102	)	_	_	_	_	_	_	_	Seg=O
103	plus	_	_	_	_	_	_	_	Seg=B-seg
104	HGF	_	_	_	_	_	_	_	Seg=O
105	(	_	_	_	_	_	_	_	Seg=B-seg
106	10	_	_	_	_	_	_	_	Seg=O
107	ng	_	_	_	_	_	_	_	Seg=O
108	/	_	_	_	_	_	_	_	Seg=O
109	mL	_	_	_	_	_	_	_	Seg=O
110	)	_	_	_	_	_	_	_	Seg=O
111	for	_	_	_	_	_	_	_	Seg=B-seg
112	24	_	_	_	_	_	_	_	Seg=O
113	,	_	_	_	_	_	_	_	Seg=O
114	48	_	_	_	_	_	_	_	Seg=O
115	,	_	_	_	_	_	_	_	Seg=O
116	and	_	_	_	_	_	_	_	Seg=O
117	72	_	_	_	_	_	_	_	Seg=O
118	h.	_	_	_	_	_	_	_	Seg=O
119	The	_	_	_	_	_	_	_	Seg=B-seg
120	amount	_	_	_	_	_	_	_	Seg=O
121	of	_	_	_	_	_	_	_	Seg=O
122	[	_	_	_	_	_	_	_	Seg=O
123	3	_	_	_	_	_	_	_	Seg=O
124	H]-leucine	_	_	_	_	_	_	_	Seg=O
125	incorporation	_	_	_	_	_	_	_	Seg=O
126	was	_	_	_	_	_	_	_	Seg=O
127	then	_	_	_	_	_	_	_	Seg=O
128	measured	_	_	_	_	_	_	_	Seg=O
129	to	_	_	_	_	_	_	_	Seg=B-seg
130	evaluate	_	_	_	_	_	_	_	Seg=O
131	protein	_	_	_	_	_	_	_	Seg=O
132	synthesis	_	_	_	_	_	_	_	Seg=O
133	.	_	_	_	_	_	_	_	Seg=O
134	The	_	_	_	_	_	_	_	Seg=B-seg
135	mRNA	_	_	_	_	_	_	_	Seg=O
136	levels	_	_	_	_	_	_	_	Seg=O
137	of	_	_	_	_	_	_	_	Seg=O
138	β	_	_	_	_	_	_	_	Seg=O
139	-	_	_	_	_	_	_	_	Seg=O
140	myosin	_	_	_	_	_	_	_	Seg=O
141	heavy	_	_	_	_	_	_	_	Seg=O
142	chain	_	_	_	_	_	_	_	Seg=O
143	and	_	_	_	_	_	_	_	Seg=O
144	atrial	_	_	_	_	_	_	_	Seg=O
145	natriuretic	_	_	_	_	_	_	_	Seg=O
146	factor	_	_	_	_	_	_	_	Seg=O
147	were	_	_	_	_	_	_	_	Seg=O
148	determined	_	_	_	_	_	_	_	Seg=O
149	by	_	_	_	_	_	_	_	Seg=O
150	real	_	_	_	_	_	_	_	Seg=O
151	-	_	_	_	_	_	_	_	Seg=O
152	time	_	_	_	_	_	_	_	Seg=O
153	PCR	_	_	_	_	_	_	_	Seg=O
154	to	_	_	_	_	_	_	_	Seg=B-seg
155	evaluate	_	_	_	_	_	_	_	Seg=O
156	the	_	_	_	_	_	_	_	Seg=O
157	presence	_	_	_	_	_	_	_	Seg=O
158	of	_	_	_	_	_	_	_	Seg=O
159	fetal	_	_	_	_	_	_	_	Seg=O
160	phenotypes	_	_	_	_	_	_	_	Seg=O
161	of	_	_	_	_	_	_	_	Seg=O
162	gene	_	_	_	_	_	_	_	Seg=O
163	expression	_	_	_	_	_	_	_	Seg=O
164	.	_	_	_	_	_	_	_	Seg=O
165	The	_	_	_	_	_	_	_	Seg=B-seg
166	cell	_	_	_	_	_	_	_	Seg=O
167	size	_	_	_	_	_	_	_	Seg=O
168	of	_	_	_	_	_	_	_	Seg=O
169	cardiomyocytes	_	_	_	_	_	_	_	Seg=O
170	was	_	_	_	_	_	_	_	Seg=O
171	also	_	_	_	_	_	_	_	Seg=O
172	studied	_	_	_	_	_	_	_	Seg=O
173	.	_	_	_	_	_	_	_	Seg=O
174	Ang	_	_	_	_	_	_	_	Seg=B-seg
175	II	_	_	_	_	_	_	_	Seg=O
176	(	_	_	_	_	_	_	_	Seg=B-seg
177	1	_	_	_	_	_	_	_	Seg=O
178	µM	_	_	_	_	_	_	_	Seg=O
179	)	_	_	_	_	_	_	_	Seg=O
180	increased	_	_	_	_	_	_	_	Seg=B-seg
181	cardiomyocyte	_	_	_	_	_	_	_	Seg=O
182	hypertrophy	_	_	_	_	_	_	_	Seg=O
183	.	_	_	_	_	_	_	_	Seg=O
184	Similar	_	_	_	_	_	_	_	Seg=B-seg
185	to	_	_	_	_	_	_	_	Seg=O
186	Ang	_	_	_	_	_	_	_	Seg=O
187	II	_	_	_	_	_	_	_	Seg=O
188	,	_	_	_	_	_	_	_	Seg=O
189	treatment	_	_	_	_	_	_	_	Seg=O
190	with	_	_	_	_	_	_	_	Seg=O
191	1	_	_	_	_	_	_	_	Seg=O
192	µM	_	_	_	_	_	_	_	Seg=O
193	HGF	_	_	_	_	_	_	_	Seg=O
194	promoted	_	_	_	_	_	_	_	Seg=O
195	cardiomyocyte	_	_	_	_	_	_	_	Seg=O
196	hypertrophy	_	_	_	_	_	_	_	Seg=O
197	.	_	_	_	_	_	_	_	Seg=O
198	Moreover	_	_	_	_	_	_	_	Seg=B-seg
199	,	_	_	_	_	_	_	_	Seg=O
200	the	_	_	_	_	_	_	_	Seg=O
201	combination	_	_	_	_	_	_	_	Seg=O
202	of	_	_	_	_	_	_	_	Seg=O
203	1	_	_	_	_	_	_	_	Seg=O
204	µM	_	_	_	_	_	_	_	Seg=O
205	Ang	_	_	_	_	_	_	_	Seg=O
206	II	_	_	_	_	_	_	_	Seg=O
207	and	_	_	_	_	_	_	_	Seg=O
208	10	_	_	_	_	_	_	_	Seg=O
209	ng	_	_	_	_	_	_	_	Seg=O
210	/	_	_	_	_	_	_	_	Seg=O
211	mL	_	_	_	_	_	_	_	Seg=O
212	HGF	_	_	_	_	_	_	_	Seg=O
213	clearly	_	_	_	_	_	_	_	Seg=O
214	induced	_	_	_	_	_	_	_	Seg=O
215	a	_	_	_	_	_	_	_	Seg=O
216	combined	_	_	_	_	_	_	_	Seg=O
217	pro	_	_	_	_	_	_	_	Seg=O
218	-	_	_	_	_	_	_	_	Seg=O
219	hypertrophy	_	_	_	_	_	_	_	Seg=O
220	effect	_	_	_	_	_	_	_	Seg=O
221	on	_	_	_	_	_	_	_	Seg=O
222	cardiomyocytes	_	_	_	_	_	_	_	Seg=O
223	.	_	_	_	_	_	_	_	Seg=O
224	The	_	_	_	_	_	_	_	Seg=B-seg
225	present	_	_	_	_	_	_	_	Seg=O
226	study	_	_	_	_	_	_	_	Seg=O
227	demonstrates	_	_	_	_	_	_	_	Seg=O
228	for	_	_	_	_	_	_	_	Seg=O
229	the	_	_	_	_	_	_	_	Seg=O
230	first	_	_	_	_	_	_	_	Seg=O
231	time	_	_	_	_	_	_	_	Seg=O
232	a	_	_	_	_	_	_	_	Seg=O
233	novel	_	_	_	_	_	_	_	Seg=O
234	,	_	_	_	_	_	_	_	Seg=O
235	combined	_	_	_	_	_	_	_	Seg=O
236	effect	_	_	_	_	_	_	_	Seg=O
237	of	_	_	_	_	_	_	_	Seg=O
238	HGF	_	_	_	_	_	_	_	Seg=O
239	and	_	_	_	_	_	_	_	Seg=O
240	Ang	_	_	_	_	_	_	_	Seg=O
241	II	_	_	_	_	_	_	_	Seg=O
242	in	_	_	_	_	_	_	_	Seg=B-seg
243	promoting	_	_	_	_	_	_	_	Seg=O
244	cardiomyocyte	_	_	_	_	_	_	_	Seg=O
245	hypertrophy	_	_	_	_	_	_	_	Seg=O
246	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 30e3307d100a7954c970537d7c295bd689551e31
1	In	_	_	_	_	_	_	_	Seg=B-seg
2	the	_	_	_	_	_	_	_	Seg=O
3	paper	_	_	_	_	_	_	_	Seg=O
4	,	_	_	_	_	_	_	_	Seg=O
5	by	_	_	_	_	_	_	_	Seg=O
6	virtue	_	_	_	_	_	_	_	Seg=O
7	of	_	_	_	_	_	_	_	Seg=O
8	the	_	_	_	_	_	_	_	Seg=O
9	binomial	_	_	_	_	_	_	_	Seg=O
10	inversion	_	_	_	_	_	_	_	Seg=O
11	formula	_	_	_	_	_	_	_	Seg=O
12	,	_	_	_	_	_	_	_	Seg=O
13	a	_	_	_	_	_	_	_	Seg=O
14	general	_	_	_	_	_	_	_	Seg=O
15	formula	_	_	_	_	_	_	_	Seg=O
16	of	_	_	_	_	_	_	_	Seg=O
17	higher	_	_	_	_	_	_	_	Seg=O
18	order	_	_	_	_	_	_	_	Seg=O
19	derivatives	_	_	_	_	_	_	_	Seg=O
20	for	_	_	_	_	_	_	_	Seg=O
21	a	_	_	_	_	_	_	_	Seg=O
22	ratio	_	_	_	_	_	_	_	Seg=O
23	of	_	_	_	_	_	_	_	Seg=O
24	two	_	_	_	_	_	_	_	Seg=O
25	differentiable	_	_	_	_	_	_	_	Seg=O
26	function	_	_	_	_	_	_	_	Seg=O
27	,	_	_	_	_	_	_	_	Seg=O
28	and	_	_	_	_	_	_	_	Seg=O
29	other	_	_	_	_	_	_	_	Seg=O
30	techniques	_	_	_	_	_	_	_	Seg=O
31	,	_	_	_	_	_	_	_	Seg=O
32	the	_	_	_	_	_	_	_	Seg=O
33	authors	_	_	_	_	_	_	_	Seg=O
34	compute	_	_	_	_	_	_	_	Seg=O
35	several	_	_	_	_	_	_	_	Seg=O
36	sums	_	_	_	_	_	_	_	Seg=O
37	in	_	_	_	_	_	_	_	Seg=O
38	terms	_	_	_	_	_	_	_	Seg=O
39	of	_	_	_	_	_	_	_	Seg=O
40	the	_	_	_	_	_	_	_	Seg=O
41	beta	_	_	_	_	_	_	_	Seg=O
42	function	_	_	_	_	_	_	_	Seg=O
43	and	_	_	_	_	_	_	_	Seg=O
44	its	_	_	_	_	_	_	_	Seg=O
45	partial	_	_	_	_	_	_	_	Seg=O
46	derivatives	_	_	_	_	_	_	_	Seg=O
47	,	_	_	_	_	_	_	_	Seg=O
48	polygamma	_	_	_	_	_	_	_	Seg=O
49	functions	_	_	_	_	_	_	_	Seg=O
50	,	_	_	_	_	_	_	_	Seg=O
51	the	_	_	_	_	_	_	_	Seg=O
52	Gauss	_	_	_	_	_	_	_	Seg=O
53	hypergeometric	_	_	_	_	_	_	_	Seg=O
54	function	_	_	_	_	_	_	_	Seg=O
55	,	_	_	_	_	_	_	_	Seg=O
56	and	_	_	_	_	_	_	_	Seg=O
57	a	_	_	_	_	_	_	_	Seg=O
58	determinant	_	_	_	_	_	_	_	Seg=O
59	.	_	_	_	_	_	_	_	Seg=O
60	These	_	_	_	_	_	_	_	Seg=B-seg
61	results	_	_	_	_	_	_	_	Seg=O
62	generalize	_	_	_	_	_	_	_	Seg=O
63	known	_	_	_	_	_	_	_	Seg=O
64	ones	_	_	_	_	_	_	_	Seg=O
65	in	_	_	_	_	_	_	_	Seg=O
66	combinatorics	_	_	_	_	_	_	_	Seg=O
67	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 332fcb86ed263f7c46ee3aea82c682c8198074ed
1	Coronavirus	_	_	_	_	_	_	_	Seg=B-seg
2	2019	_	_	_	_	_	_	_	Seg=O
3	is	_	_	_	_	_	_	_	Seg=O
4	challenging	_	_	_	_	_	_	_	Seg=O
5	nurse	_	_	_	_	_	_	_	Seg=O
6	leaders	_	_	_	_	_	_	_	Seg=O
7	to	_	_	_	_	_	_	_	Seg=O
8	adopt	_	_	_	_	_	_	_	Seg=O
9	new	_	_	_	_	_	_	_	Seg=O
10	decisionmaking	_	_	_	_	_	_	_	Seg=O
11	practices	_	_	_	_	_	_	_	Seg=O
12	.	_	_	_	_	_	_	_	Seg=O
13	Nurse	_	_	_	_	_	_	_	Seg=B-seg
14	leaders	_	_	_	_	_	_	_	Seg=O
15	who	_	_	_	_	_	_	_	Seg=B-seg
16	support	_	_	_	_	_	_	_	Seg=O
17	evidence	_	_	_	_	_	_	_	Seg=O
18	-	_	_	_	_	_	_	_	Seg=O
19	based	_	_	_	_	_	_	_	Seg=O
20	nursing	_	_	_	_	_	_	_	Seg=O
21	practice	_	_	_	_	_	_	_	Seg=O
22	create	_	_	_	_	_	_	_	Seg=B-seg
23	a	_	_	_	_	_	_	_	Seg=O
24	culture	_	_	_	_	_	_	_	Seg=O
25	of	_	_	_	_	_	_	_	Seg=O
26	inquiry	_	_	_	_	_	_	_	Seg=O
27	and	_	_	_	_	_	_	_	Seg=B-seg
28	lay	_	_	_	_	_	_	_	Seg=O
29	the	_	_	_	_	_	_	_	Seg=O
30	foundation	_	_	_	_	_	_	_	Seg=O
31	for	_	_	_	_	_	_	_	Seg=O
32	the	_	_	_	_	_	_	_	Seg=O
33	use	_	_	_	_	_	_	_	Seg=O
34	of	_	_	_	_	_	_	_	Seg=O
35	evidence	_	_	_	_	_	_	_	Seg=O
36	to	_	_	_	_	_	_	_	Seg=B-seg
37	inform	_	_	_	_	_	_	_	Seg=O
38	management	_	_	_	_	_	_	_	Seg=O
39	decisions	_	_	_	_	_	_	_	Seg=O
40	.	_	_	_	_	_	_	_	Seg=O
41	This	_	_	_	_	_	_	_	Seg=B-seg
42	article	_	_	_	_	_	_	_	Seg=O
43	uses	_	_	_	_	_	_	_	Seg=O
44	a	_	_	_	_	_	_	_	Seg=O
45	case	_	_	_	_	_	_	_	Seg=O
46	study	_	_	_	_	_	_	_	Seg=O
47	to	_	_	_	_	_	_	_	Seg=B-seg
48	describe	_	_	_	_	_	_	_	Seg=O
49	the	_	_	_	_	_	_	_	Seg=O
50	evidence	_	_	_	_	_	_	_	Seg=O
51	-	_	_	_	_	_	_	_	Seg=O
52	based	_	_	_	_	_	_	_	Seg=O
53	management	_	_	_	_	_	_	_	Seg=O
54	process	_	_	_	_	_	_	_	Seg=O
55	.	_	_	_	_	_	_	_	Seg=O
56	The	_	_	_	_	_	_	_	Seg=B-seg
57	authors	_	_	_	_	_	_	_	Seg=O
58	provide	_	_	_	_	_	_	_	Seg=O
59	strategies	_	_	_	_	_	_	_	Seg=O
60	for	_	_	_	_	_	_	_	Seg=O
61	nurse	_	_	_	_	_	_	_	Seg=O
62	leaders	_	_	_	_	_	_	_	Seg=O
63	to	_	_	_	_	_	_	_	Seg=B-seg
64	develop	_	_	_	_	_	_	_	Seg=O
65	evidence	_	_	_	_	_	_	_	Seg=O
66	-	_	_	_	_	_	_	_	Seg=O
67	based	_	_	_	_	_	_	_	Seg=O
68	management	_	_	_	_	_	_	_	Seg=O
69	competencies	_	_	_	_	_	_	_	Seg=O
70	and	_	_	_	_	_	_	_	Seg=B-seg
71	build	_	_	_	_	_	_	_	Seg=O
72	a	_	_	_	_	_	_	_	Seg=O
73	culture	_	_	_	_	_	_	_	Seg=O
74	to	_	_	_	_	_	_	_	Seg=B-seg
75	support	_	_	_	_	_	_	_	Seg=O
76	the	_	_	_	_	_	_	_	Seg=O
77	use	_	_	_	_	_	_	_	Seg=O
78	of	_	_	_	_	_	_	_	Seg=O
79	evidence	_	_	_	_	_	_	_	Seg=O
80	to	_	_	_	_	_	_	_	Seg=B-seg
81	inform	_	_	_	_	_	_	_	Seg=O
82	decision	_	_	_	_	_	_	_	Seg=O
83	-	_	_	_	_	_	_	_	Seg=O
84	making	_	_	_	_	_	_	_	Seg=O
85	in	_	_	_	_	_	_	_	Seg=O
86	leadership	_	_	_	_	_	_	_	Seg=O
87	and	_	_	_	_	_	_	_	Seg=O
88	management	_	_	_	_	_	_	_	Seg=O
89	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 339795c794c410e24bee37d47d07c7a3c5081063
1	Diagnostic	_	_	_	_	_	_	_	Seg=B-seg
2	testing	_	_	_	_	_	_	_	Seg=O
3	for	_	_	_	_	_	_	_	Seg=O
4	the	_	_	_	_	_	_	_	Seg=O
5	novel	_	_	_	_	_	_	_	Seg=O
6	coronavirus	_	_	_	_	_	_	_	Seg=O
7	is	_	_	_	_	_	_	_	Seg=O
8	an	_	_	_	_	_	_	_	Seg=O
9	important	_	_	_	_	_	_	_	Seg=O
10	tool	_	_	_	_	_	_	_	Seg=O
11	to	_	_	_	_	_	_	_	Seg=B-seg
12	fight	_	_	_	_	_	_	_	Seg=O
13	the	_	_	_	_	_	_	_	Seg=O
14	coronavirus	_	_	_	_	_	_	_	Seg=O
15	disease	_	_	_	_	_	_	_	Seg=O
16	(	_	_	_	_	_	_	_	Seg=O
17	Covid-19	_	_	_	_	_	_	_	Seg=O
18	)	_	_	_	_	_	_	_	Seg=O
19	pandemic	_	_	_	_	_	_	_	Seg=O
20	.	_	_	_	_	_	_	_	Seg=O
21	However	_	_	_	_	_	_	_	Seg=B-seg
22	,	_	_	_	_	_	_	_	Seg=O
23	testing	_	_	_	_	_	_	_	Seg=O
24	capacities	_	_	_	_	_	_	_	Seg=O
25	are	_	_	_	_	_	_	_	Seg=O
26	limited	_	_	_	_	_	_	_	Seg=O
27	.	_	_	_	_	_	_	_	Seg=O
28	A	_	_	_	_	_	_	_	Seg=B-seg
29	modified	_	_	_	_	_	_	_	Seg=O
30	testing	_	_	_	_	_	_	_	Seg=O
31	protocol	_	_	_	_	_	_	_	Seg=O
32	,	_	_	_	_	_	_	_	Seg=O
33	whereby	_	_	_	_	_	_	_	Seg=B-seg
34	a	_	_	_	_	_	_	_	Seg=O
35	number	_	_	_	_	_	_	_	Seg=O
36	of	_	_	_	_	_	_	_	Seg=O
37	probes	_	_	_	_	_	_	_	Seg=O
38	are	_	_	_	_	_	_	_	Seg=O
39	'	_	_	_	_	_	_	_	Seg=O
40	pooled	_	_	_	_	_	_	_	Seg=O
41	'	_	_	_	_	_	_	_	Seg=O
42	(	_	_	_	_	_	_	_	Seg=O
43	i.e.	_	_	_	_	_	_	_	Seg=O
44	grouped	_	_	_	_	_	_	_	Seg=O
45	)	_	_	_	_	_	_	_	Seg=O
46	,	_	_	_	_	_	_	_	Seg=O
47	is	_	_	_	_	_	_	_	Seg=B-seg
48	known	_	_	_	_	_	_	_	Seg=O
49	to	_	_	_	_	_	_	_	Seg=O
50	increase	_	_	_	_	_	_	_	Seg=O
51	the	_	_	_	_	_	_	_	Seg=O
52	capacity	_	_	_	_	_	_	_	Seg=O
53	for	_	_	_	_	_	_	_	Seg=O
54	testing	_	_	_	_	_	_	_	Seg=O
55	.	_	_	_	_	_	_	_	Seg=O
56	Here	_	_	_	_	_	_	_	Seg=B-seg
57	,	_	_	_	_	_	_	_	Seg=O
58	we	_	_	_	_	_	_	_	Seg=O
59	model	_	_	_	_	_	_	_	Seg=O
60	pooled	_	_	_	_	_	_	_	Seg=O
61	testing	_	_	_	_	_	_	_	Seg=O
62	with	_	_	_	_	_	_	_	Seg=O
63	a	_	_	_	_	_	_	_	Seg=O
64	double	_	_	_	_	_	_	_	Seg=O
65	-	_	_	_	_	_	_	_	Seg=O
66	average	_	_	_	_	_	_	_	Seg=O
67	model	_	_	_	_	_	_	_	Seg=O
68	,	_	_	_	_	_	_	_	Seg=O
69	which	_	_	_	_	_	_	_	Seg=B-seg
70	we	_	_	_	_	_	_	_	Seg=O
71	think	_	_	_	_	_	_	_	Seg=O
72	to	_	_	_	_	_	_	_	Seg=O
73	be	_	_	_	_	_	_	_	Seg=O
74	close	_	_	_	_	_	_	_	Seg=O
75	to	_	_	_	_	_	_	_	Seg=O
76	reality	_	_	_	_	_	_	_	Seg=O
77	for	_	_	_	_	_	_	_	Seg=O
78	Covid-19	_	_	_	_	_	_	_	Seg=O
79	testing	_	_	_	_	_	_	_	Seg=O
80	.	_	_	_	_	_	_	_	Seg=O
81	The	_	_	_	_	_	_	_	Seg=B-seg
82	optimal	_	_	_	_	_	_	_	Seg=O
83	pool	_	_	_	_	_	_	_	Seg=O
84	size	_	_	_	_	_	_	_	Seg=O
85	and	_	_	_	_	_	_	_	Seg=O
86	the	_	_	_	_	_	_	_	Seg=O
87	effect	_	_	_	_	_	_	_	Seg=O
88	of	_	_	_	_	_	_	_	Seg=O
89	test	_	_	_	_	_	_	_	Seg=O
90	errors	_	_	_	_	_	_	_	Seg=O
91	are	_	_	_	_	_	_	_	Seg=O
92	considered	_	_	_	_	_	_	_	Seg=O
93	.	_	_	_	_	_	_	_	Seg=O
94	The	_	_	_	_	_	_	_	Seg=B-seg
95	results	_	_	_	_	_	_	_	Seg=O
96	show	_	_	_	_	_	_	_	Seg=O
97	that	_	_	_	_	_	_	_	Seg=B-seg
98	the	_	_	_	_	_	_	_	Seg=O
99	best	_	_	_	_	_	_	_	Seg=O
100	pool	_	_	_	_	_	_	_	Seg=O
101	size	_	_	_	_	_	_	_	Seg=O
102	is	_	_	_	_	_	_	_	Seg=O
103	three	_	_	_	_	_	_	_	Seg=O
104	to	_	_	_	_	_	_	_	Seg=O
105	five	_	_	_	_	_	_	_	Seg=O
106	,	_	_	_	_	_	_	_	Seg=O
107	under	_	_	_	_	_	_	_	Seg=O
108	reasonable	_	_	_	_	_	_	_	Seg=O
109	assumptions	_	_	_	_	_	_	_	Seg=O
110	.	_	_	_	_	_	_	_	Seg=O
111	Pool	_	_	_	_	_	_	_	Seg=B-seg
112	testing	_	_	_	_	_	_	_	Seg=O
113	even	_	_	_	_	_	_	_	Seg=O
114	reduces	_	_	_	_	_	_	_	Seg=O
115	the	_	_	_	_	_	_	_	Seg=O
116	number	_	_	_	_	_	_	_	Seg=O
117	of	_	_	_	_	_	_	_	Seg=O
118	false	_	_	_	_	_	_	_	Seg=O
119	positives	_	_	_	_	_	_	_	Seg=O
120	in	_	_	_	_	_	_	_	Seg=O
121	the	_	_	_	_	_	_	_	Seg=O
122	absence	_	_	_	_	_	_	_	Seg=O
123	of	_	_	_	_	_	_	_	Seg=O
124	dilution	_	_	_	_	_	_	_	Seg=O
125	effects	_	_	_	_	_	_	_	Seg=O
126	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 33db9d032b967485d628f73408ebfb6953db40a7
1	2019-nCoV	_	_	_	_	_	_	_	Seg=B-seg
2	is	_	_	_	_	_	_	_	Seg=O
3	a	_	_	_	_	_	_	_	Seg=O
4	novel	_	_	_	_	_	_	_	Seg=O
5	coronavirus	_	_	_	_	_	_	_	Seg=O
6	was	_	_	_	_	_	_	_	Seg=B-seg
7	isolated	_	_	_	_	_	_	_	Seg=O
8	and	_	_	_	_	_	_	_	Seg=O
9	identified	_	_	_	_	_	_	_	Seg=O
10	in	_	_	_	_	_	_	_	Seg=O
11	2019	_	_	_	_	_	_	_	Seg=O
12	in	_	_	_	_	_	_	_	Seg=O
13	Wuhan	_	_	_	_	_	_	_	Seg=O
14	,	_	_	_	_	_	_	_	Seg=O
15	China	_	_	_	_	_	_	_	Seg=O
16	.	_	_	_	_	_	_	_	Seg=O
17	On	_	_	_	_	_	_	_	Seg=B-seg
18	17th	_	_	_	_	_	_	_	Seg=O
19	February	_	_	_	_	_	_	_	Seg=O
20	and	_	_	_	_	_	_	_	Seg=O
21	according	_	_	_	_	_	_	_	Seg=O
22	to	_	_	_	_	_	_	_	Seg=O
23	world	_	_	_	_	_	_	_	Seg=O
24	health	_	_	_	_	_	_	_	Seg=O
25	organization	_	_	_	_	_	_	_	Seg=O
26	,	_	_	_	_	_	_	_	Seg=O
27	a	_	_	_	_	_	_	_	Seg=O
28	number	_	_	_	_	_	_	_	Seg=O
29	of	_	_	_	_	_	_	_	Seg=O
30	71	_	_	_	_	_	_	_	Seg=O
31	429	_	_	_	_	_	_	_	Seg=O
32	confirmed	_	_	_	_	_	_	_	Seg=O
33	cases	_	_	_	_	_	_	_	Seg=O
34	worldwide	_	_	_	_	_	_	_	Seg=O
35	,	_	_	_	_	_	_	_	Seg=O
36	among	_	_	_	_	_	_	_	Seg=B-seg
37	them	_	_	_	_	_	_	_	Seg=O
38	2162	_	_	_	_	_	_	_	Seg=O
39	new	_	_	_	_	_	_	_	Seg=O
40	cases	_	_	_	_	_	_	_	Seg=O
41	recorded	_	_	_	_	_	_	_	Seg=O
42	in	_	_	_	_	_	_	_	Seg=O
43	the	_	_	_	_	_	_	_	Seg=O
44	last	_	_	_	_	_	_	_	Seg=O
45	24	_	_	_	_	_	_	_	Seg=O
46	hours	_	_	_	_	_	_	_	Seg=O
47	.	_	_	_	_	_	_	_	Seg=O
48	There	_	_	_	_	_	_	_	Seg=B-seg
49	is	_	_	_	_	_	_	_	Seg=O
50	no	_	_	_	_	_	_	_	Seg=O
51	drug	_	_	_	_	_	_	_	Seg=O
52	or	_	_	_	_	_	_	_	Seg=O
53	vaccine	_	_	_	_	_	_	_	Seg=O
54	for	_	_	_	_	_	_	_	Seg=O
55	human	_	_	_	_	_	_	_	Seg=O
56	and	_	_	_	_	_	_	_	Seg=O
57	animal	_	_	_	_	_	_	_	Seg=O
58	coronavirus	_	_	_	_	_	_	_	Seg=O
59	.	_	_	_	_	_	_	_	Seg=O
60	The	_	_	_	_	_	_	_	Seg=B-seg
61	inhibition	_	_	_	_	_	_	_	Seg=O
62	of	_	_	_	_	_	_	_	Seg=O
63	3CL	_	_	_	_	_	_	_	Seg=O
64	hydrolase	_	_	_	_	_	_	_	Seg=O
65	enzyme	_	_	_	_	_	_	_	Seg=O
66	provides	_	_	_	_	_	_	_	Seg=O
67	a	_	_	_	_	_	_	_	Seg=O
68	promising	_	_	_	_	_	_	_	Seg=O
69	therapeutic	_	_	_	_	_	_	_	Seg=O
70	principle	_	_	_	_	_	_	_	Seg=O
71	for	_	_	_	_	_	_	_	Seg=B-seg
72	developing	_	_	_	_	_	_	_	Seg=O
73	treatments	_	_	_	_	_	_	_	Seg=O
74	against	_	_	_	_	_	_	_	Seg=O
75	CoViD-19	_	_	_	_	_	_	_	Seg=O
76	.	_	_	_	_	_	_	_	Seg=O
77	The	_	_	_	_	_	_	_	Seg=B-seg
78	3CLpro	_	_	_	_	_	_	_	Seg=O
79	(	_	_	_	_	_	_	_	Seg=O
80	Mpro	_	_	_	_	_	_	_	Seg=O
81	)	_	_	_	_	_	_	_	Seg=O
82	known	_	_	_	_	_	_	_	Seg=O
83	for	_	_	_	_	_	_	_	Seg=O
84	involving	_	_	_	_	_	_	_	Seg=O
85	in	_	_	_	_	_	_	_	Seg=O
86	counteracting	_	_	_	_	_	_	_	Seg=O
87	the	_	_	_	_	_	_	_	Seg=O
88	host	_	_	_	_	_	_	_	Seg=O
89	innate	_	_	_	_	_	_	_	Seg=O
90	immune	_	_	_	_	_	_	_	Seg=O
91	response	_	_	_	_	_	_	_	Seg=O
92	.	_	_	_	_	_	_	_	Seg=O
93	This	_	_	_	_	_	_	_	Seg=B-seg
94	work	_	_	_	_	_	_	_	Seg=O
95	presents	_	_	_	_	_	_	_	Seg=O
96	the	_	_	_	_	_	_	_	Seg=O
97	inhibitory	_	_	_	_	_	_	_	Seg=O
98	effect	_	_	_	_	_	_	_	Seg=O
99	of	_	_	_	_	_	_	_	Seg=O
100	some	_	_	_	_	_	_	_	Seg=O
101	natural	_	_	_	_	_	_	_	Seg=O
102	compounds	_	_	_	_	_	_	_	Seg=O
103	against	_	_	_	_	_	_	_	Seg=O
104	3CL	_	_	_	_	_	_	_	Seg=O
105	hydrolase	_	_	_	_	_	_	_	Seg=O
106	enzyme	_	_	_	_	_	_	_	Seg=O
107	,	_	_	_	_	_	_	_	Seg=O
108	and	_	_	_	_	_	_	_	Seg=B-seg
109	explain	_	_	_	_	_	_	_	Seg=O
110	the	_	_	_	_	_	_	_	Seg=O
111	main	_	_	_	_	_	_	_	Seg=O
112	interactions	_	_	_	_	_	_	_	Seg=O
113	in	_	_	_	_	_	_	_	Seg=O
114	inhibitor	_	_	_	_	_	_	_	Seg=O
115	-	_	_	_	_	_	_	_	Seg=O
116	enzyme	_	_	_	_	_	_	_	Seg=O
117	complex	_	_	_	_	_	_	_	Seg=O
118	.	_	_	_	_	_	_	_	Seg=O
119	Molecular	_	_	_	_	_	_	_	Seg=B-seg
120	docking	_	_	_	_	_	_	_	Seg=O
121	study	_	_	_	_	_	_	_	Seg=O
122	carried	_	_	_	_	_	_	_	Seg=O
123	out	_	_	_	_	_	_	_	Seg=O
124	using	_	_	_	_	_	_	_	Seg=B-seg
125	Autodock	_	_	_	_	_	_	_	Seg=O
126	Vina	_	_	_	_	_	_	_	Seg=O
127	.	_	_	_	_	_	_	_	Seg=O
128	By	_	_	_	_	_	_	_	Seg=B-seg
129	screening	_	_	_	_	_	_	_	Seg=O
130	several	_	_	_	_	_	_	_	Seg=O
131	molecules	_	_	_	_	_	_	_	Seg=O
132	,	_	_	_	_	_	_	_	Seg=O
133	we	_	_	_	_	_	_	_	Seg=B-seg
134	identified	_	_	_	_	_	_	_	Seg=O
135	three	_	_	_	_	_	_	_	Seg=O
136	candidate	_	_	_	_	_	_	_	Seg=O
137	agents	_	_	_	_	_	_	_	Seg=O
138	that	_	_	_	_	_	_	_	Seg=B-seg
139	inhibit	_	_	_	_	_	_	_	Seg=O
140	the	_	_	_	_	_	_	_	Seg=O
141	main	_	_	_	_	_	_	_	Seg=O
142	protease	_	_	_	_	_	_	_	Seg=O
143	of	_	_	_	_	_	_	_	Seg=O
144	coronavirus	_	_	_	_	_	_	_	Seg=O
145	.	_	_	_	_	_	_	_	Seg=O
146	Hispidin	_	_	_	_	_	_	_	Seg=B-seg
147	,	_	_	_	_	_	_	_	Seg=O
148	lepidine	_	_	_	_	_	_	_	Seg=O
149	E	_	_	_	_	_	_	_	Seg=O
150	,	_	_	_	_	_	_	_	Seg=O
151	and	_	_	_	_	_	_	_	Seg=O
152	folic	_	_	_	_	_	_	_	Seg=O
153	acid	_	_	_	_	_	_	_	Seg=O
154	bound	_	_	_	_	_	_	_	Seg=O
155	tightly	_	_	_	_	_	_	_	Seg=O
156	in	_	_	_	_	_	_	_	Seg=O
157	the	_	_	_	_	_	_	_	Seg=O
158	enzyme	_	_	_	_	_	_	_	Seg=O
159	,	_	_	_	_	_	_	_	Seg=O
160	strong	_	_	_	_	_	_	_	Seg=O
161	hydrogen	_	_	_	_	_	_	_	Seg=O
162	bonds	_	_	_	_	_	_	_	Seg=O
163	have	_	_	_	_	_	_	_	Seg=O
164	been	_	_	_	_	_	_	_	Seg=O
165	formed	_	_	_	_	_	_	_	Seg=O
166	(	_	_	_	_	_	_	_	Seg=B-seg
167	1.69	_	_	_	_	_	_	_	Seg=O
168	-	_	_	_	_	_	_	_	Seg=O
169	1.80Å	_	_	_	_	_	_	_	Seg=O
170	)	_	_	_	_	_	_	_	Seg=O
171	with	_	_	_	_	_	_	_	Seg=B-seg
172	the	_	_	_	_	_	_	_	Seg=O
173	active	_	_	_	_	_	_	_	Seg=O
174	site	_	_	_	_	_	_	_	Seg=O
175	residues	_	_	_	_	_	_	_	Seg=O
176	.	_	_	_	_	_	_	_	Seg=O
177	This	_	_	_	_	_	_	_	Seg=B-seg
178	study	_	_	_	_	_	_	_	Seg=O
179	provides	_	_	_	_	_	_	_	Seg=O
180	a	_	_	_	_	_	_	_	Seg=O
181	possible	_	_	_	_	_	_	_	Seg=O
182	therapeutic	_	_	_	_	_	_	_	Seg=O
183	strategy	_	_	_	_	_	_	_	Seg=O
184	for	_	_	_	_	_	_	_	Seg=O
185	CoViD-19	_	_	_	_	_	_	_	Seg=O
186	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 343fbf921e4d8fab5e51739b0914eb6e05ec4e34
1	Background	_	_	_	_	_	_	_	Seg=B-seg
2	.	_	_	_	_	_	_	_	Seg=O
3	The	_	_	_	_	_	_	_	Seg=B-seg
4	COVID-19	_	_	_	_	_	_	_	Seg=O
5	outbreak	_	_	_	_	_	_	_	Seg=O
6	required	_	_	_	_	_	_	_	Seg=O
7	the	_	_	_	_	_	_	_	Seg=O
8	significantly	_	_	_	_	_	_	_	Seg=O
9	increased	_	_	_	_	_	_	_	Seg=O
10	working	_	_	_	_	_	_	_	Seg=O
11	time	_	_	_	_	_	_	_	Seg=O
12	and	_	_	_	_	_	_	_	Seg=O
13	intensity	_	_	_	_	_	_	_	Seg=O
14	for	_	_	_	_	_	_	_	Seg=O
15	health	_	_	_	_	_	_	_	Seg=O
16	professionals	_	_	_	_	_	_	_	Seg=O
17	in	_	_	_	_	_	_	_	Seg=O
18	China	_	_	_	_	_	_	_	Seg=O
19	,	_	_	_	_	_	_	_	Seg=O
20	which	_	_	_	_	_	_	_	Seg=B-seg
21	may	_	_	_	_	_	_	_	Seg=O
22	cause	_	_	_	_	_	_	_	Seg=O
23	stress	_	_	_	_	_	_	_	Seg=O
24	signs	_	_	_	_	_	_	_	Seg=O
25	.	_	_	_	_	_	_	_	Seg=O
26	Methods	_	_	_	_	_	_	_	Seg=B-seg
27	.	_	_	_	_	_	_	_	Seg=O
28	From	_	_	_	_	_	_	_	Seg=B-seg
29	March	_	_	_	_	_	_	_	Seg=O
30	2	_	_	_	_	_	_	_	Seg=O
31	-	_	_	_	_	_	_	_	Seg=O
32	13	_	_	_	_	_	_	_	Seg=O
33	of	_	_	_	_	_	_	_	Seg=O
34	2020	_	_	_	_	_	_	_	Seg=O
35	,	_	_	_	_	_	_	_	Seg=O
36	4,618	_	_	_	_	_	_	_	Seg=O
37	health	_	_	_	_	_	_	_	Seg=O
38	professionals	_	_	_	_	_	_	_	Seg=O
39	in	_	_	_	_	_	_	_	Seg=O
40	China	_	_	_	_	_	_	_	Seg=O
41	were	_	_	_	_	_	_	_	Seg=O
42	included	_	_	_	_	_	_	_	Seg=O
43	in	_	_	_	_	_	_	_	Seg=O
44	an	_	_	_	_	_	_	_	Seg=O
45	anonymous	_	_	_	_	_	_	_	Seg=O
46	,	_	_	_	_	_	_	_	Seg=O
47	self	_	_	_	_	_	_	_	Seg=O
48	-	_	_	_	_	_	_	_	Seg=O
49	rated	_	_	_	_	_	_	_	Seg=O
50	online	_	_	_	_	_	_	_	Seg=O
51	survey	_	_	_	_	_	_	_	Seg=O
52	regarding	_	_	_	_	_	_	_	Seg=B-seg
53	their	_	_	_	_	_	_	_	Seg=O
54	concerns	_	_	_	_	_	_	_	Seg=O
55	on	_	_	_	_	_	_	_	Seg=O
56	exposure	_	_	_	_	_	_	_	Seg=O
57	to	_	_	_	_	_	_	_	Seg=O
58	the	_	_	_	_	_	_	_	Seg=O
59	COVID-19	_	_	_	_	_	_	_	Seg=O
60	outbreak	_	_	_	_	_	_	_	Seg=O
61	.	_	_	_	_	_	_	_	Seg=O
62	The	_	_	_	_	_	_	_	Seg=B-seg
63	questionnaires	_	_	_	_	_	_	_	Seg=O
64	consisted	_	_	_	_	_	_	_	Seg=O
65	of	_	_	_	_	_	_	_	Seg=O
66	five	_	_	_	_	_	_	_	Seg=O
67	parts	_	_	_	_	_	_	_	Seg=O
68	:	_	_	_	_	_	_	_	Seg=O
69	basic	_	_	_	_	_	_	_	Seg=B-seg
70	demographic	_	_	_	_	_	_	_	Seg=O
71	information	_	_	_	_	_	_	_	Seg=O
72	and	_	_	_	_	_	_	_	Seg=O
73	epidemiological	_	_	_	_	_	_	_	Seg=O
74	exposure	_	_	_	_	_	_	_	Seg=O
75	;	_	_	_	_	_	_	_	Seg=O
76	occupational	_	_	_	_	_	_	_	Seg=O
77	and	_	_	_	_	_	_	_	Seg=O
78	psychological	_	_	_	_	_	_	_	Seg=O
79	impact	_	_	_	_	_	_	_	Seg=O
80	;	_	_	_	_	_	_	_	Seg=O
81	concerns	_	_	_	_	_	_	_	Seg=O
82	during	_	_	_	_	_	_	_	Seg=O
83	the	_	_	_	_	_	_	_	Seg=O
84	episode	_	_	_	_	_	_	_	Seg=O
85	;	_	_	_	_	_	_	_	Seg=O
86	coping	_	_	_	_	_	_	_	Seg=O
87	strategies	_	_	_	_	_	_	_	Seg=O
88	;	_	_	_	_	_	_	_	Seg=O
89	and	_	_	_	_	_	_	_	Seg=O
90	the	_	_	_	_	_	_	_	Seg=O
91	Huaxi	_	_	_	_	_	_	_	Seg=O
92	Emotional	_	_	_	_	_	_	_	Seg=O
93	-	_	_	_	_	_	_	_	Seg=O
94	Distress	_	_	_	_	_	_	_	Seg=O
95	Index	_	_	_	_	_	_	_	Seg=O
96	(	_	_	_	_	_	_	_	Seg=O
97	HEI	_	_	_	_	_	_	_	Seg=O
98	)	_	_	_	_	_	_	_	Seg=O
99	.	_	_	_	_	_	_	_	Seg=O
100	Results	_	_	_	_	_	_	_	Seg=B-seg
101	.	_	_	_	_	_	_	_	Seg=O
102	About	_	_	_	_	_	_	_	Seg=B-seg
103	24.2	_	_	_	_	_	_	_	Seg=O
104	%	_	_	_	_	_	_	_	Seg=O
105	of	_	_	_	_	_	_	_	Seg=O
106	respondents	_	_	_	_	_	_	_	Seg=O
107	experienced	_	_	_	_	_	_	_	Seg=O
108	high	_	_	_	_	_	_	_	Seg=O
109	levels	_	_	_	_	_	_	_	Seg=O
110	of	_	_	_	_	_	_	_	Seg=O
111	anxiety	_	_	_	_	_	_	_	Seg=O
112	or	_	_	_	_	_	_	_	Seg=O
113	/	_	_	_	_	_	_	_	Seg=O
114	and	_	_	_	_	_	_	_	Seg=O
115	depressive	_	_	_	_	_	_	_	Seg=O
116	symptoms	_	_	_	_	_	_	_	Seg=O
117	since	_	_	_	_	_	_	_	Seg=O
118	the	_	_	_	_	_	_	_	Seg=O
119	COVID-19	_	_	_	_	_	_	_	Seg=O
120	outbreak	_	_	_	_	_	_	_	Seg=O
121	.	_	_	_	_	_	_	_	Seg=O
122	Respondents	_	_	_	_	_	_	_	Seg=B-seg
123	who	_	_	_	_	_	_	_	Seg=B-seg
124	worried	_	_	_	_	_	_	_	Seg=O
125	about	_	_	_	_	_	_	_	Seg=O
126	their	_	_	_	_	_	_	_	Seg=O
127	physical	_	_	_	_	_	_	_	Seg=O
128	health	_	_	_	_	_	_	_	Seg=O
129	and	_	_	_	_	_	_	_	Seg=B-seg
130	those	_	_	_	_	_	_	_	Seg=O
131	who	_	_	_	_	_	_	_	Seg=B-seg
132	had	_	_	_	_	_	_	_	Seg=O
133	COVID-19	_	_	_	_	_	_	_	Seg=O
134	infected	_	_	_	_	_	_	_	Seg=O
135	friends	_	_	_	_	_	_	_	Seg=O
136	or	_	_	_	_	_	_	_	Seg=O
137	close	_	_	_	_	_	_	_	Seg=O
138	relatives	_	_	_	_	_	_	_	Seg=O
139	were	_	_	_	_	_	_	_	Seg=B-seg
140	more	_	_	_	_	_	_	_	Seg=O
141	likely	_	_	_	_	_	_	_	Seg=O
142	to	_	_	_	_	_	_	_	Seg=O
143	have	_	_	_	_	_	_	_	Seg=O
144	high	_	_	_	_	_	_	_	Seg=O
145	HEI	_	_	_	_	_	_	_	Seg=O
146	levels	_	_	_	_	_	_	_	Seg=O
147	,	_	_	_	_	_	_	_	Seg=O
148	than	_	_	_	_	_	_	_	Seg=O
149	those	_	_	_	_	_	_	_	Seg=O
150	without	_	_	_	_	_	_	_	Seg=O
151	these	_	_	_	_	_	_	_	Seg=O
152	characteristics	_	_	_	_	_	_	_	Seg=O
153	.	_	_	_	_	_	_	_	Seg=O
154	Further	_	_	_	_	_	_	_	Seg=B-seg
155	,	_	_	_	_	_	_	_	Seg=O
156	family	_	_	_	_	_	_	_	Seg=O
157	relationship	_	_	_	_	_	_	_	Seg=O
158	was	_	_	_	_	_	_	_	Seg=O
159	found	_	_	_	_	_	_	_	Seg=O
160	to	_	_	_	_	_	_	_	Seg=O
161	have	_	_	_	_	_	_	_	Seg=O
162	an	_	_	_	_	_	_	_	Seg=O
163	independent	_	_	_	_	_	_	_	Seg=O
164	protective	_	_	_	_	_	_	_	Seg=O
165	effect	_	_	_	_	_	_	_	Seg=O
166	against	_	_	_	_	_	_	_	Seg=O
167	high	_	_	_	_	_	_	_	Seg=O
168	HEI	_	_	_	_	_	_	_	Seg=O
169	levels	_	_	_	_	_	_	_	Seg=O
170	.	_	_	_	_	_	_	_	Seg=O
171	Their	_	_	_	_	_	_	_	Seg=B-seg
172	main	_	_	_	_	_	_	_	Seg=O
173	concerns	_	_	_	_	_	_	_	Seg=O
174	were	_	_	_	_	_	_	_	Seg=O
175	that	_	_	_	_	_	_	_	Seg=O
176	their	_	_	_	_	_	_	_	Seg=O
177	families	_	_	_	_	_	_	_	Seg=O
178	would	_	_	_	_	_	_	_	Seg=O
179	not	_	_	_	_	_	_	_	Seg=O
180	be	_	_	_	_	_	_	_	Seg=O
181	cared	_	_	_	_	_	_	_	Seg=O
182	for	_	_	_	_	_	_	_	Seg=O
183	and	_	_	_	_	_	_	_	Seg=O
184	that	_	_	_	_	_	_	_	Seg=O
185	they	_	_	_	_	_	_	_	Seg=O
186	would	_	_	_	_	_	_	_	Seg=O
187	not	_	_	_	_	_	_	_	Seg=O
188	be	_	_	_	_	_	_	_	Seg=O
189	able	_	_	_	_	_	_	_	Seg=O
190	to	_	_	_	_	_	_	_	Seg=O
191	work	_	_	_	_	_	_	_	Seg=O
192	properly	_	_	_	_	_	_	_	Seg=O
193	.	_	_	_	_	_	_	_	Seg=O
194	Compared	_	_	_	_	_	_	_	Seg=B-seg
195	to	_	_	_	_	_	_	_	Seg=O
196	respondents	_	_	_	_	_	_	_	Seg=O
197	with	_	_	_	_	_	_	_	Seg=O
198	clear	_	_	_	_	_	_	_	Seg=O
199	emotional	_	_	_	_	_	_	_	Seg=O
200	problems	_	_	_	_	_	_	_	Seg=O
201	,	_	_	_	_	_	_	_	Seg=O
202	those	_	_	_	_	_	_	_	Seg=B-seg
203	with	_	_	_	_	_	_	_	Seg=O
204	somewhat	_	_	_	_	_	_	_	Seg=O
205	hidden	_	_	_	_	_	_	_	Seg=O
206	emotional	_	_	_	_	_	_	_	Seg=O
207	issues	_	_	_	_	_	_	_	Seg=O
208	adopted	_	_	_	_	_	_	_	Seg=O
209	more	_	_	_	_	_	_	_	Seg=O
210	positive	_	_	_	_	_	_	_	Seg=O
211	coping	_	_	_	_	_	_	_	Seg=O
212	measures	_	_	_	_	_	_	_	Seg=O
213	.	_	_	_	_	_	_	_	Seg=O
214	Conclusions	_	_	_	_	_	_	_	Seg=B-seg
215	.	_	_	_	_	_	_	_	Seg=O
216	About	_	_	_	_	_	_	_	Seg=B-seg
217	a	_	_	_	_	_	_	_	Seg=O
218	quarter	_	_	_	_	_	_	_	Seg=O
219	of	_	_	_	_	_	_	_	Seg=O
220	medical	_	_	_	_	_	_	_	Seg=O
221	staff	_	_	_	_	_	_	_	Seg=O
222	experienced	_	_	_	_	_	_	_	Seg=O
223	psychological	_	_	_	_	_	_	_	Seg=O
224	problems	_	_	_	_	_	_	_	Seg=O
225	during	_	_	_	_	_	_	_	Seg=O
226	the	_	_	_	_	_	_	_	Seg=O
227	pandemic	_	_	_	_	_	_	_	Seg=O
228	of	_	_	_	_	_	_	_	Seg=O
229	COVID-19	_	_	_	_	_	_	_	Seg=O
230	.	_	_	_	_	_	_	_	Seg=O
231	The	_	_	_	_	_	_	_	Seg=B-seg
232	psychological	_	_	_	_	_	_	_	Seg=O
233	impact	_	_	_	_	_	_	_	Seg=O
234	of	_	_	_	_	_	_	_	Seg=O
235	stressful	_	_	_	_	_	_	_	Seg=O
236	events	_	_	_	_	_	_	_	Seg=O
237	was	_	_	_	_	_	_	_	Seg=O
238	related	_	_	_	_	_	_	_	Seg=O
239	to	_	_	_	_	_	_	_	Seg=O
240	worrying	_	_	_	_	_	_	_	Seg=O
241	about	_	_	_	_	_	_	_	Seg=O
242	their	_	_	_	_	_	_	_	Seg=O
243	physical	_	_	_	_	_	_	_	Seg=O
244	health	_	_	_	_	_	_	_	Seg=O
245	,	_	_	_	_	_	_	_	Seg=O
246	having	_	_	_	_	_	_	_	Seg=O
247	close	_	_	_	_	_	_	_	Seg=O
248	COVID-19	_	_	_	_	_	_	_	Seg=O
249	infected	_	_	_	_	_	_	_	Seg=O
250	acquaintances	_	_	_	_	_	_	_	Seg=O
251	and	_	_	_	_	_	_	_	Seg=O
252	family	_	_	_	_	_	_	_	Seg=O
253	relationship	_	_	_	_	_	_	_	Seg=O
254	issues	_	_	_	_	_	_	_	Seg=O
255	.	_	_	_	_	_	_	_	Seg=O
256	Therefore	_	_	_	_	_	_	_	Seg=B-seg
257	,	_	_	_	_	_	_	_	Seg=O
258	the	_	_	_	_	_	_	_	Seg=O
259	psychological	_	_	_	_	_	_	_	Seg=O
260	supprot	_	_	_	_	_	_	_	Seg=O
261	for	_	_	_	_	_	_	_	Seg=O
262	medical	_	_	_	_	_	_	_	Seg=O
263	staff	_	_	_	_	_	_	_	Seg=O
264	fighting	_	_	_	_	_	_	_	Seg=O
265	in	_	_	_	_	_	_	_	Seg=O
266	the	_	_	_	_	_	_	_	Seg=O
267	COVID-19	_	_	_	_	_	_	_	Seg=O
268	pandemic	_	_	_	_	_	_	_	Seg=O
269	may	_	_	_	_	_	_	_	Seg=O
270	be	_	_	_	_	_	_	_	Seg=O
271	needed	_	_	_	_	_	_	_	Seg=O
272	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 351d20dcf8e841056a5e9884ab688e120db82620
1	Avian	_	_	_	_	_	_	_	Seg=B-seg
2	infectious	_	_	_	_	_	_	_	Seg=O
3	bronchitis	_	_	_	_	_	_	_	Seg=O
4	(	_	_	_	_	_	_	_	Seg=O
5	IB	_	_	_	_	_	_	_	Seg=O
6	)	_	_	_	_	_	_	_	Seg=O
7	is	_	_	_	_	_	_	_	Seg=O
8	a	_	_	_	_	_	_	_	Seg=O
9	major	_	_	_	_	_	_	_	Seg=O
10	cause	_	_	_	_	_	_	_	Seg=O
11	of	_	_	_	_	_	_	_	Seg=O
12	economic	_	_	_	_	_	_	_	Seg=O
13	losses	_	_	_	_	_	_	_	Seg=O
14	in	_	_	_	_	_	_	_	Seg=O
15	poultry	_	_	_	_	_	_	_	Seg=O
16	industry	_	_	_	_	_	_	_	Seg=O
17	.	_	_	_	_	_	_	_	Seg=O
18	The	_	_	_	_	_	_	_	Seg=B-seg
19	IB	_	_	_	_	_	_	_	Seg=O
20	virus	_	_	_	_	_	_	_	Seg=O
21	primarily	_	_	_	_	_	_	_	Seg=O
22	affects	_	_	_	_	_	_	_	Seg=O
23	respiratory	_	_	_	_	_	_	_	Seg=O
24	tract	_	_	_	_	_	_	_	Seg=O
25	,	_	_	_	_	_	_	_	Seg=O
26	but	_	_	_	_	_	_	_	Seg=B-seg
27	various	_	_	_	_	_	_	_	Seg=O
28	strains	_	_	_	_	_	_	_	Seg=O
29	differ	_	_	_	_	_	_	_	Seg=O
30	in	_	_	_	_	_	_	_	Seg=O
31	their	_	_	_	_	_	_	_	Seg=O
32	tropism	_	_	_	_	_	_	_	Seg=O
33	for	_	_	_	_	_	_	_	Seg=O
34	other	_	_	_	_	_	_	_	Seg=O
35	target	_	_	_	_	_	_	_	Seg=O
36	organs	_	_	_	_	_	_	_	Seg=O
37	such	_	_	_	_	_	_	_	Seg=B-seg
38	as	_	_	_	_	_	_	_	Seg=O
39	kidney	_	_	_	_	_	_	_	Seg=O
40	and	_	_	_	_	_	_	_	Seg=O
41	alimentary	_	_	_	_	_	_	_	Seg=O
42	tract	_	_	_	_	_	_	_	Seg=O
43	.	_	_	_	_	_	_	_	Seg=O
44	The	_	_	_	_	_	_	_	Seg=B-seg
45	objective	_	_	_	_	_	_	_	Seg=O
46	of	_	_	_	_	_	_	_	Seg=O
47	this	_	_	_	_	_	_	_	Seg=O
48	study	_	_	_	_	_	_	_	Seg=O
49	was	_	_	_	_	_	_	_	Seg=O
50	to	_	_	_	_	_	_	_	Seg=O
51	estimate	_	_	_	_	_	_	_	Seg=O
52	the	_	_	_	_	_	_	_	Seg=O
53	pathogenicity	_	_	_	_	_	_	_	Seg=O
54	of	_	_	_	_	_	_	_	Seg=O
55	Iranian	_	_	_	_	_	_	_	Seg=O
56	IBV	_	_	_	_	_	_	_	Seg=O
57	variant	_	_	_	_	_	_	_	Seg=O
58	(	_	_	_	_	_	_	_	Seg=O
59	IR-1	_	_	_	_	_	_	_	Seg=O
60	)	_	_	_	_	_	_	_	Seg=O
61	,	_	_	_	_	_	_	_	Seg=O
62	which	_	_	_	_	_	_	_	Seg=B-seg
63	is	_	_	_	_	_	_	_	Seg=O
64	limited	_	_	_	_	_	_	_	Seg=O
65	exclusively	_	_	_	_	_	_	_	Seg=O
66	to	_	_	_	_	_	_	_	Seg=O
67	Iran	_	_	_	_	_	_	_	Seg=O
68	.	_	_	_	_	_	_	_	Seg=O
69	Specific	_	_	_	_	_	_	_	Seg=B-seg
70	pathogen	_	_	_	_	_	_	_	Seg=O
71	free	_	_	_	_	_	_	_	Seg=O
72	chicks	_	_	_	_	_	_	_	Seg=O
73	were	_	_	_	_	_	_	_	Seg=O
74	inoculated	_	_	_	_	_	_	_	Seg=O
75	intranasally	_	_	_	_	_	_	_	Seg=O
76	.	_	_	_	_	_	_	_	Seg=O
77	Sera	_	_	_	_	_	_	_	Seg=B-seg
78	,	_	_	_	_	_	_	_	Seg=O
79	fecal	_	_	_	_	_	_	_	Seg=O
80	swabs	_	_	_	_	_	_	_	Seg=O
81	and	_	_	_	_	_	_	_	Seg=O
82	different	_	_	_	_	_	_	_	Seg=O
83	tissue	_	_	_	_	_	_	_	Seg=O
84	samples	_	_	_	_	_	_	_	Seg=O
85	were	_	_	_	_	_	_	_	Seg=O
86	collected	_	_	_	_	_	_	_	Seg=O
87	on	_	_	_	_	_	_	_	Seg=O
88	different	_	_	_	_	_	_	_	Seg=O
89	days	_	_	_	_	_	_	_	Seg=O
90	post	_	_	_	_	_	_	_	Seg=O
91	infection	_	_	_	_	_	_	_	Seg=O
92	(	_	_	_	_	_	_	_	Seg=O
93	DPI	_	_	_	_	_	_	_	Seg=O
94	)	_	_	_	_	_	_	_	Seg=O
95	.	_	_	_	_	_	_	_	Seg=O
96	Clinical	_	_	_	_	_	_	_	Seg=B-seg
97	signs	_	_	_	_	_	_	_	Seg=O
98	,	_	_	_	_	_	_	_	Seg=O
99	gross	_	_	_	_	_	_	_	Seg=O
100	pathology	_	_	_	_	_	_	_	Seg=O
101	and	_	_	_	_	_	_	_	Seg=O
102	histological	_	_	_	_	_	_	_	Seg=O
103	changes	_	_	_	_	_	_	_	Seg=O
104	were	_	_	_	_	_	_	_	Seg=O
105	recorded	_	_	_	_	_	_	_	Seg=O
106	.	_	_	_	_	_	_	_	Seg=O
107	The	_	_	_	_	_	_	_	Seg=B-seg
108	viral	_	_	_	_	_	_	_	Seg=O
109	load	_	_	_	_	_	_	_	Seg=O
110	was	_	_	_	_	_	_	_	Seg=O
111	quantified	_	_	_	_	_	_	_	Seg=O
112	in	_	_	_	_	_	_	_	Seg=O
113	the	_	_	_	_	_	_	_	Seg=O
114	RNA	_	_	_	_	_	_	_	Seg=O
115	extractions	_	_	_	_	_	_	_	Seg=O
116	from	_	_	_	_	_	_	_	Seg=O
117	different	_	_	_	_	_	_	_	Seg=O
118	tissue	_	_	_	_	_	_	_	Seg=O
119	samples	_	_	_	_	_	_	_	Seg=O
120	using	_	_	_	_	_	_	_	Seg=B-seg
121	real	_	_	_	_	_	_	_	Seg=O
122	-	_	_	_	_	_	_	_	Seg=O
123	time	_	_	_	_	_	_	_	Seg=O
124	PCR	_	_	_	_	_	_	_	Seg=O
125	.	_	_	_	_	_	_	_	Seg=O
126	Anti	_	_	_	_	_	_	_	Seg=B-seg
127	-	_	_	_	_	_	_	_	Seg=O
128	IBV	_	_	_	_	_	_	_	Seg=O
129	antibodies	_	_	_	_	_	_	_	Seg=O
130	were	_	_	_	_	_	_	_	Seg=O
131	detected	_	_	_	_	_	_	_	Seg=O
132	in	_	_	_	_	_	_	_	Seg=O
133	serum	_	_	_	_	_	_	_	Seg=O
134	samples	_	_	_	_	_	_	_	Seg=O
135	.	_	_	_	_	_	_	_	Seg=O
136	The	_	_	_	_	_	_	_	Seg=B-seg
137	IgG	_	_	_	_	_	_	_	Seg=O
138	antibody	_	_	_	_	_	_	_	Seg=O
139	were	_	_	_	_	_	_	_	Seg=O
140	found	_	_	_	_	_	_	_	Seg=O
141	on	_	_	_	_	_	_	_	Seg=O
142	21	_	_	_	_	_	_	_	Seg=O
143	and	_	_	_	_	_	_	_	Seg=O
144	28	_	_	_	_	_	_	_	Seg=O
145	DPI	_	_	_	_	_	_	_	Seg=O
146	.	_	_	_	_	_	_	_	Seg=O
147	Severe	_	_	_	_	_	_	_	Seg=B-seg
148	histological	_	_	_	_	_	_	_	Seg=O
149	lesions	_	_	_	_	_	_	_	Seg=O
150	were	_	_	_	_	_	_	_	Seg=O
151	observed	_	_	_	_	_	_	_	Seg=O
152	in	_	_	_	_	_	_	_	Seg=O
153	the	_	_	_	_	_	_	_	Seg=O
154	trachea	_	_	_	_	_	_	_	Seg=O
155	and	_	_	_	_	_	_	_	Seg=O
156	lung	_	_	_	_	_	_	_	Seg=O
157	while	_	_	_	_	_	_	_	Seg=B-seg
158	the	_	_	_	_	_	_	_	Seg=O
159	lesions	_	_	_	_	_	_	_	Seg=O
160	in	_	_	_	_	_	_	_	Seg=O
161	kidney	_	_	_	_	_	_	_	Seg=O
162	were	_	_	_	_	_	_	_	Seg=O
163	appeared	_	_	_	_	_	_	_	Seg=O
164	to	_	_	_	_	_	_	_	Seg=O
165	be	_	_	_	_	_	_	_	Seg=O
166	milder	_	_	_	_	_	_	_	Seg=O
167	.	_	_	_	_	_	_	_	Seg=O
168	Viral	_	_	_	_	_	_	_	Seg=B-seg
169	RNA	_	_	_	_	_	_	_	Seg=O
170	was	_	_	_	_	_	_	_	Seg=O
171	detected	_	_	_	_	_	_	_	Seg=O
172	in	_	_	_	_	_	_	_	Seg=O
173	all	_	_	_	_	_	_	_	Seg=O
174	tested	_	_	_	_	_	_	_	Seg=O
175	tissues	_	_	_	_	_	_	_	Seg=O
176	from	_	_	_	_	_	_	_	Seg=O
177	1	_	_	_	_	_	_	_	Seg=O
178	DPI	_	_	_	_	_	_	_	Seg=O
179	to	_	_	_	_	_	_	_	Seg=O
180	the	_	_	_	_	_	_	_	Seg=O
181	last	_	_	_	_	_	_	_	Seg=O
182	day	_	_	_	_	_	_	_	Seg=O
183	of	_	_	_	_	_	_	_	Seg=O
184	the	_	_	_	_	_	_	_	Seg=O
185	experiment	_	_	_	_	_	_	_	Seg=O
186	.	_	_	_	_	_	_	_	Seg=O
187	The	_	_	_	_	_	_	_	Seg=B-seg
188	highest	_	_	_	_	_	_	_	Seg=O
189	viral	_	_	_	_	_	_	_	Seg=O
190	load	_	_	_	_	_	_	_	Seg=O
191	was	_	_	_	_	_	_	_	Seg=O
192	measured	_	_	_	_	_	_	_	Seg=O
193	in	_	_	_	_	_	_	_	Seg=O
194	the	_	_	_	_	_	_	_	Seg=O
195	trachea	_	_	_	_	_	_	_	Seg=O
196	and	_	_	_	_	_	_	_	Seg=O
197	feces	_	_	_	_	_	_	_	Seg=O
198	on	_	_	_	_	_	_	_	Seg=O
199	1	_	_	_	_	_	_	_	Seg=O
200	st	_	_	_	_	_	_	_	Seg=O
201	and	_	_	_	_	_	_	_	Seg=O
202	5	_	_	_	_	_	_	_	Seg=O
203	th	_	_	_	_	_	_	_	Seg=O
204	DPI	_	_	_	_	_	_	_	Seg=O
205	,	_	_	_	_	_	_	_	Seg=O
206	respectively	_	_	_	_	_	_	_	Seg=O
207	.	_	_	_	_	_	_	_	Seg=O
208	It	_	_	_	_	_	_	_	Seg=B-seg
209	can	_	_	_	_	_	_	_	Seg=O
210	be	_	_	_	_	_	_	_	Seg=O
211	concluded	_	_	_	_	_	_	_	Seg=O
212	the	_	_	_	_	_	_	_	Seg=B-seg
213	IR-1	_	_	_	_	_	_	_	Seg=O
214	had	_	_	_	_	_	_	_	Seg=O
215	broad	_	_	_	_	_	_	_	Seg=O
216	tropism	_	_	_	_	_	_	_	Seg=O
217	for	_	_	_	_	_	_	_	Seg=O
218	respiratory	_	_	_	_	_	_	_	Seg=O
219	tract	_	_	_	_	_	_	_	Seg=O
220	,	_	_	_	_	_	_	_	Seg=O
221	digestive	_	_	_	_	_	_	_	Seg=O
222	system	_	_	_	_	_	_	_	Seg=O
223	,	_	_	_	_	_	_	_	Seg=O
224	and	_	_	_	_	_	_	_	Seg=O
225	renal	_	_	_	_	_	_	_	Seg=O
226	tissue	_	_	_	_	_	_	_	Seg=O
227	,	_	_	_	_	_	_	_	Seg=O
228	reflecting	_	_	_	_	_	_	_	Seg=B-seg
229	its	_	_	_	_	_	_	_	Seg=O
230	epitheliotropic	_	_	_	_	_	_	_	Seg=O
231	nature	_	_	_	_	_	_	_	Seg=O
232	,	_	_	_	_	_	_	_	Seg=O
233	but	_	_	_	_	_	_	_	Seg=B-seg
234	it	_	_	_	_	_	_	_	Seg=O
235	caused	_	_	_	_	_	_	_	Seg=O
236	the	_	_	_	_	_	_	_	Seg=O
237	most	_	_	_	_	_	_	_	Seg=O
238	severe	_	_	_	_	_	_	_	Seg=O
239	lesions	_	_	_	_	_	_	_	Seg=O
240	in	_	_	_	_	_	_	_	Seg=O
241	the	_	_	_	_	_	_	_	Seg=O
242	respiratory	_	_	_	_	_	_	_	Seg=O
243	tract	_	_	_	_	_	_	_	Seg=O
244	.	_	_	_	_	_	_	_	Seg=O
245	This	_	_	_	_	_	_	_	Seg=B-seg
246	was	_	_	_	_	_	_	_	Seg=O
247	the	_	_	_	_	_	_	_	Seg=O
248	first	_	_	_	_	_	_	_	Seg=O
249	pathogenicity	_	_	_	_	_	_	_	Seg=O
250	study	_	_	_	_	_	_	_	Seg=O
251	of	_	_	_	_	_	_	_	Seg=O
252	Iranian	_	_	_	_	_	_	_	Seg=O
253	IR-1	_	_	_	_	_	_	_	Seg=O
254	IBV	_	_	_	_	_	_	_	Seg=O
255	.	_	_	_	_	_	_	_	Seg=O
256	Further	_	_	_	_	_	_	_	Seg=B-seg
257	knowledge	_	_	_	_	_	_	_	Seg=O
258	of	_	_	_	_	_	_	_	Seg=O
259	IBV	_	_	_	_	_	_	_	Seg=O
260	pathogenesis	_	_	_	_	_	_	_	Seg=O
261	provides	_	_	_	_	_	_	_	Seg=O
262	the	_	_	_	_	_	_	_	Seg=O
263	groundwork	_	_	_	_	_	_	_	Seg=O
264	to	_	_	_	_	_	_	_	Seg=B-seg
265	inform	_	_	_	_	_	_	_	Seg=O
266	more	_	_	_	_	_	_	_	Seg=O
267	effective	_	_	_	_	_	_	_	Seg=O
268	prevention	_	_	_	_	_	_	_	Seg=O
269	practices	_	_	_	_	_	_	_	Seg=O
270	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 351fca8e4bd7321d75ec0227794deb0db3567540
1	Porcine	_	_	_	_	_	_	_	Seg=B-seg
2	epidemic	_	_	_	_	_	_	_	Seg=O
3	diarrhea	_	_	_	_	_	_	_	Seg=O
4	virus	_	_	_	_	_	_	_	Seg=O
5	(	_	_	_	_	_	_	_	Seg=O
6	PEDV	_	_	_	_	_	_	_	Seg=O
7	)	_	_	_	_	_	_	_	Seg=O
8	,	_	_	_	_	_	_	_	Seg=O
9	which	_	_	_	_	_	_	_	Seg=B-seg
10	emerged	_	_	_	_	_	_	_	Seg=O
11	in	_	_	_	_	_	_	_	Seg=O
12	the	_	_	_	_	_	_	_	Seg=O
13	United	_	_	_	_	_	_	_	Seg=O
14	States	_	_	_	_	_	_	_	Seg=O
15	in	_	_	_	_	_	_	_	Seg=O
16	2013	_	_	_	_	_	_	_	Seg=O
17	,	_	_	_	_	_	_	_	Seg=O
18	has	_	_	_	_	_	_	_	Seg=B-seg
19	spread	_	_	_	_	_	_	_	Seg=O
20	throughout	_	_	_	_	_	_	_	Seg=O
21	North	_	_	_	_	_	_	_	Seg=O
22	America	_	_	_	_	_	_	_	Seg=O
23	.	_	_	_	_	_	_	_	Seg=O
24	Limited	_	_	_	_	_	_	_	Seg=B-seg
25	availability	_	_	_	_	_	_	_	Seg=O
26	of	_	_	_	_	_	_	_	Seg=O
27	PEDV	_	_	_	_	_	_	_	Seg=O
28	complete	_	_	_	_	_	_	_	Seg=O
29	genomes	_	_	_	_	_	_	_	Seg=O
30	worldwide	_	_	_	_	_	_	_	Seg=O
31	has	_	_	_	_	_	_	_	Seg=O
32	impeded	_	_	_	_	_	_	_	Seg=O
33	our	_	_	_	_	_	_	_	Seg=O
34	understanding	_	_	_	_	_	_	_	Seg=O
35	of	_	_	_	_	_	_	_	Seg=O
36	PEDV	_	_	_	_	_	_	_	Seg=O
37	introduction	_	_	_	_	_	_	_	Seg=O
38	into	_	_	_	_	_	_	_	Seg=O
39	the	_	_	_	_	_	_	_	Seg=O
40	United	_	_	_	_	_	_	_	Seg=O
41	States	_	_	_	_	_	_	_	Seg=O
42	.	_	_	_	_	_	_	_	Seg=O
43	To	_	_	_	_	_	_	_	Seg=B-seg
44	determine	_	_	_	_	_	_	_	Seg=O
45	the	_	_	_	_	_	_	_	Seg=O
46	relationship	_	_	_	_	_	_	_	Seg=O
47	between	_	_	_	_	_	_	_	Seg=O
48	the	_	_	_	_	_	_	_	Seg=O
49	North	_	_	_	_	_	_	_	Seg=O
50	American	_	_	_	_	_	_	_	Seg=O
51	strains	_	_	_	_	_	_	_	Seg=O
52	and	_	_	_	_	_	_	_	Seg=O
53	global	_	_	_	_	_	_	_	Seg=O
54	emerging	_	_	_	_	_	_	_	Seg=O
55	and	_	_	_	_	_	_	_	Seg=O
56	historic	_	_	_	_	_	_	_	Seg=O
57	PEDV	_	_	_	_	_	_	_	Seg=O
58	strains	_	_	_	_	_	_	_	Seg=O
59	,	_	_	_	_	_	_	_	Seg=O
60	we	_	_	_	_	_	_	_	Seg=B-seg
61	sequenced	_	_	_	_	_	_	_	Seg=O
62	and	_	_	_	_	_	_	_	Seg=O
63	analyzed	_	_	_	_	_	_	_	Seg=O
64	complete	_	_	_	_	_	_	_	Seg=O
65	genomes	_	_	_	_	_	_	_	Seg=O
66	of	_	_	_	_	_	_	_	Seg=O
67	74	_	_	_	_	_	_	_	Seg=O
68	strains	_	_	_	_	_	_	_	Seg=O
69	from	_	_	_	_	_	_	_	Seg=O
70	North	_	_	_	_	_	_	_	Seg=O
71	America	_	_	_	_	_	_	_	Seg=O
72	;	_	_	_	_	_	_	_	Seg=O
73	the	_	_	_	_	_	_	_	Seg=B-seg
74	strains	_	_	_	_	_	_	_	Seg=O
75	clustered	_	_	_	_	_	_	_	Seg=O
76	into	_	_	_	_	_	_	_	Seg=O
77	2	_	_	_	_	_	_	_	Seg=O
78	distinct	_	_	_	_	_	_	_	Seg=O
79	clades	_	_	_	_	_	_	_	Seg=O
80	.	_	_	_	_	_	_	_	Seg=O
81	Compared	_	_	_	_	_	_	_	Seg=B-seg
82	with	_	_	_	_	_	_	_	Seg=O
83	the	_	_	_	_	_	_	_	Seg=O
84	initially	_	_	_	_	_	_	_	Seg=O
85	reported	_	_	_	_	_	_	_	Seg=O
86	virulent	_	_	_	_	_	_	_	Seg=O
87	US	_	_	_	_	_	_	_	Seg=O
88	PEDV	_	_	_	_	_	_	_	Seg=O
89	strains	_	_	_	_	_	_	_	Seg=O
90	,	_	_	_	_	_	_	_	Seg=O
91	7	_	_	_	_	_	_	_	Seg=B-seg
92	(	_	_	_	_	_	_	_	Seg=B-seg
93	9.7	_	_	_	_	_	_	_	Seg=O
94	%	_	_	_	_	_	_	_	Seg=O
95	)	_	_	_	_	_	_	_	Seg=O
96	strains	_	_	_	_	_	_	_	Seg=B-seg
97	from	_	_	_	_	_	_	_	Seg=O
98	4	_	_	_	_	_	_	_	Seg=O
99	states	_	_	_	_	_	_	_	Seg=O
100	contained	_	_	_	_	_	_	_	Seg=O
101	insertions	_	_	_	_	_	_	_	Seg=O
102	and	_	_	_	_	_	_	_	Seg=O
103	deletions	_	_	_	_	_	_	_	Seg=O
104	in	_	_	_	_	_	_	_	Seg=O
105	the	_	_	_	_	_	_	_	Seg=O
106	spike	_	_	_	_	_	_	_	Seg=O
107	gene	_	_	_	_	_	_	_	Seg=O
108	(	_	_	_	_	_	_	_	Seg=O
109	S	_	_	_	_	_	_	_	Seg=O
110	INDELs	_	_	_	_	_	_	_	Seg=O
111	)	_	_	_	_	_	_	_	Seg=O
112	.	_	_	_	_	_	_	_	Seg=O
113	These	_	_	_	_	_	_	_	Seg=B-seg
114	S	_	_	_	_	_	_	_	Seg=O
115	INDEL	_	_	_	_	_	_	_	Seg=O
116	strains	_	_	_	_	_	_	_	Seg=O
117	share	_	_	_	_	_	_	_	Seg=O
118	99.8%-100	_	_	_	_	_	_	_	Seg=O
119	%	_	_	_	_	_	_	_	Seg=O
120	nt	_	_	_	_	_	_	_	Seg=O
121	identity	_	_	_	_	_	_	_	Seg=O
122	with	_	_	_	_	_	_	_	Seg=O
123	each	_	_	_	_	_	_	_	Seg=O
124	other	_	_	_	_	_	_	_	Seg=O
125	and	_	_	_	_	_	_	_	Seg=O
126	96.2%-96.7	_	_	_	_	_	_	_	Seg=O
127	%	_	_	_	_	_	_	_	Seg=O
128	nt	_	_	_	_	_	_	_	Seg=O
129	identity	_	_	_	_	_	_	_	Seg=O
130	with	_	_	_	_	_	_	_	Seg=O
131	the	_	_	_	_	_	_	_	Seg=O
132	initial	_	_	_	_	_	_	_	Seg=O
133	US	_	_	_	_	_	_	_	Seg=O
134	strains	_	_	_	_	_	_	_	Seg=O
135	.	_	_	_	_	_	_	_	Seg=O
136	Furthermore	_	_	_	_	_	_	_	Seg=B-seg
137	,	_	_	_	_	_	_	_	Seg=O
138	the	_	_	_	_	_	_	_	Seg=O
139	S	_	_	_	_	_	_	_	Seg=O
140	IN	_	_	_	_	_	_	_	Seg=O
141	-	_	_	_	_	_	_	_	Seg=O
142	DEL	_	_	_	_	_	_	_	Seg=O
143	strains	_	_	_	_	_	_	_	Seg=O
144	form	_	_	_	_	_	_	_	Seg=O
145	a	_	_	_	_	_	_	_	Seg=O
146	distinct	_	_	_	_	_	_	_	Seg=O
147	cluster	_	_	_	_	_	_	_	Seg=O
148	within	_	_	_	_	_	_	_	Seg=O
149	North	_	_	_	_	_	_	_	Seg=O
150	American	_	_	_	_	_	_	_	Seg=O
151	clade	_	_	_	_	_	_	_	Seg=O
152	II	_	_	_	_	_	_	_	Seg=O
153	,	_	_	_	_	_	_	_	Seg=O
154	sharing	_	_	_	_	_	_	_	Seg=O
155	98.6%-100	_	_	_	_	_	_	_	Seg=O
156	%	_	_	_	_	_	_	_	Seg=O
157	nt	_	_	_	_	_	_	_	Seg=O
158	identity	_	_	_	_	_	_	_	Seg=O
159	overall	_	_	_	_	_	_	_	Seg=O
160	.	_	_	_	_	_	_	_	Seg=O
161	In	_	_	_	_	_	_	_	Seg=B-seg
162	the	_	_	_	_	_	_	_	Seg=O
163	United	_	_	_	_	_	_	_	Seg=O
164	States	_	_	_	_	_	_	_	Seg=O
165	,	_	_	_	_	_	_	_	Seg=O
166	the	_	_	_	_	_	_	_	Seg=O
167	S	_	_	_	_	_	_	_	Seg=O
168	INDEL	_	_	_	_	_	_	_	Seg=O
169	and	_	_	_	_	_	_	_	Seg=O
170	original	_	_	_	_	_	_	_	Seg=O
171	PEDV	_	_	_	_	_	_	_	Seg=O
172	strains	_	_	_	_	_	_	_	Seg=O
173	are	_	_	_	_	_	_	_	Seg=O
174	cocirculating	_	_	_	_	_	_	_	Seg=O
175	and	_	_	_	_	_	_	_	Seg=B-seg
176	could	_	_	_	_	_	_	_	Seg=O
177	have	_	_	_	_	_	_	_	Seg=O
178	been	_	_	_	_	_	_	_	Seg=O
179	introduced	_	_	_	_	_	_	_	Seg=O
180	simultaneously	_	_	_	_	_	_	_	Seg=O
181	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 36d1ce29e9a96454ecd03db6c5e970052cb82abb
1	In	_	_	_	_	_	_	_	Seg=B-seg
2	this	_	_	_	_	_	_	_	Seg=O
3	study	_	_	_	_	_	_	_	Seg=O
4	,	_	_	_	_	_	_	_	Seg=O
5	the	_	_	_	_	_	_	_	Seg=O
6	susceptibility	_	_	_	_	_	_	_	Seg=O
7	of	_	_	_	_	_	_	_	Seg=O
8	porcine	_	_	_	_	_	_	_	Seg=O
9	peripheral	_	_	_	_	_	_	_	Seg=O
10	blood	_	_	_	_	_	_	_	Seg=O
11	monocytes	_	_	_	_	_	_	_	Seg=O
12	(	_	_	_	_	_	_	_	Seg=O
13	BMo	_	_	_	_	_	_	_	Seg=O
14	)	_	_	_	_	_	_	_	Seg=O
15	,	_	_	_	_	_	_	_	Seg=O
16	peritoneal	_	_	_	_	_	_	_	Seg=O
17	macrophages	_	_	_	_	_	_	_	Seg=O
18	(	_	_	_	_	_	_	_	Seg=O
19	PMf	_	_	_	_	_	_	_	Seg=O
20	)	_	_	_	_	_	_	_	Seg=O
21	and	_	_	_	_	_	_	_	Seg=O
22	alveolar	_	_	_	_	_	_	_	Seg=O
23	macrophages	_	_	_	_	_	_	_	Seg=O
24	(	_	_	_	_	_	_	_	Seg=O
25	AMf	_	_	_	_	_	_	_	Seg=O
26	)	_	_	_	_	_	_	_	Seg=O
27	to	_	_	_	_	_	_	_	Seg=O
28	PRRSV	_	_	_	_	_	_	_	Seg=O
29	was	_	_	_	_	_	_	_	Seg=O
30	examined	_	_	_	_	_	_	_	Seg=O
31	.	_	_	_	_	_	_	_	Seg=O
32	To	_	_	_	_	_	_	_	Seg=B-seg
33	test	_	_	_	_	_	_	_	Seg=O
34	the	_	_	_	_	_	_	_	Seg=O
35	effect	_	_	_	_	_	_	_	Seg=O
36	of	_	_	_	_	_	_	_	Seg=O
37	differentiation	_	_	_	_	_	_	_	Seg=O
38	and	_	_	_	_	_	_	_	Seg=O
39	activation	_	_	_	_	_	_	_	Seg=O
40	on	_	_	_	_	_	_	_	Seg=O
41	their	_	_	_	_	_	_	_	Seg=O
42	susceptibility	_	_	_	_	_	_	_	Seg=O
43	,	_	_	_	_	_	_	_	Seg=O
44	AMf	_	_	_	_	_	_	_	Seg=B-seg
45	and	_	_	_	_	_	_	_	Seg=O
46	BMo	_	_	_	_	_	_	_	Seg=O
47	were	_	_	_	_	_	_	_	Seg=O
48	aged	_	_	_	_	_	_	_	Seg=O
49	,	_	_	_	_	_	_	_	Seg=O
50	cultivated	_	_	_	_	_	_	_	Seg=B-seg
51	in	_	_	_	_	_	_	_	Seg=O
52	either	_	_	_	_	_	_	_	Seg=O
53	adhesion	_	_	_	_	_	_	_	Seg=O
54	or	_	_	_	_	_	_	_	Seg=O
55	suspension	_	_	_	_	_	_	_	Seg=O
56	and	_	_	_	_	_	_	_	Seg=B-seg
57	treated	_	_	_	_	_	_	_	Seg=O
58	with	_	_	_	_	_	_	_	Seg=O
59	bacterial	_	_	_	_	_	_	_	Seg=O
60	lipopolysaccharide	_	_	_	_	_	_	_	Seg=O
61	(	_	_	_	_	_	_	_	Seg=O
62	LPS	_	_	_	_	_	_	_	Seg=O
63	)	_	_	_	_	_	_	_	Seg=O
64	and	_	_	_	_	_	_	_	Seg=O
65	phorbol	_	_	_	_	_	_	_	Seg=O
66	myristate	_	_	_	_	_	_	_	Seg=O
67	acetate	_	_	_	_	_	_	_	Seg=O
68	(	_	_	_	_	_	_	_	Seg=O
69	PMA	_	_	_	_	_	_	_	Seg=O
70	)	_	_	_	_	_	_	_	Seg=O
71	.	_	_	_	_	_	_	_	Seg=O
72	It	_	_	_	_	_	_	_	Seg=B-seg
73	was	_	_	_	_	_	_	_	Seg=O
74	found	_	_	_	_	_	_	_	Seg=O
75	that	_	_	_	_	_	_	_	Seg=O
76	freshly	_	_	_	_	_	_	_	Seg=O
77	isolated	_	_	_	_	_	_	_	Seg=O
78	PMf	_	_	_	_	_	_	_	Seg=O
79	and	_	_	_	_	_	_	_	Seg=O
80	BMo	_	_	_	_	_	_	_	Seg=O
81	were	_	_	_	_	_	_	_	Seg=O
82	non	_	_	_	_	_	_	_	Seg=O
83	-	_	_	_	_	_	_	_	Seg=O
84	permissive	_	_	_	_	_	_	_	Seg=O
85	to	_	_	_	_	_	_	_	Seg=O
86	PRRSV	_	_	_	_	_	_	_	Seg=O
87	.	_	_	_	_	_	_	_	Seg=O
88	PMf	_	_	_	_	_	_	_	Seg=B-seg
89	remained	_	_	_	_	_	_	_	Seg=O
90	refractory	_	_	_	_	_	_	_	Seg=O
91	but	_	_	_	_	_	_	_	Seg=B-seg
92	a	_	_	_	_	_	_	_	Seg=O
93	few	_	_	_	_	_	_	_	Seg=O
94	BMo	_	_	_	_	_	_	_	Seg=O
95	became	_	_	_	_	_	_	_	Seg=O
96	susceptible	_	_	_	_	_	_	_	Seg=O
97	after	_	_	_	_	_	_	_	Seg=O
98	1	_	_	_	_	_	_	_	Seg=O
99	day	_	_	_	_	_	_	_	Seg=O
100	cultivation	_	_	_	_	_	_	_	Seg=O
101	.	_	_	_	_	_	_	_	Seg=O
102	AMf	_	_	_	_	_	_	_	Seg=B-seg
103	were	_	_	_	_	_	_	_	Seg=O
104	permissive	_	_	_	_	_	_	_	Seg=O
105	with	_	_	_	_	_	_	_	Seg=O
106	a	_	_	_	_	_	_	_	Seg=O
107	significant	_	_	_	_	_	_	_	Seg=O
108	increase	_	_	_	_	_	_	_	Seg=O
109	of	_	_	_	_	_	_	_	Seg=O
110	their	_	_	_	_	_	_	_	Seg=O
111	susceptibility	_	_	_	_	_	_	_	Seg=O
112	after	_	_	_	_	_	_	_	Seg=O
113	one	_	_	_	_	_	_	_	Seg=O
114	day	_	_	_	_	_	_	_	Seg=O
115	cultivation	_	_	_	_	_	_	_	Seg=O
116	.	_	_	_	_	_	_	_	Seg=O
117	In	_	_	_	_	_	_	_	Seg=B-seg
118	a	_	_	_	_	_	_	_	Seg=O
119	binding	_	_	_	_	_	_	_	Seg=O
120	assay	_	_	_	_	_	_	_	Seg=O
121	,	_	_	_	_	_	_	_	Seg=O
122	it	_	_	_	_	_	_	_	Seg=O
123	was	_	_	_	_	_	_	_	Seg=O
124	demonstrated	_	_	_	_	_	_	_	Seg=O
125	that	_	_	_	_	_	_	_	Seg=O
126	the	_	_	_	_	_	_	_	Seg=O
127	attachment	_	_	_	_	_	_	_	Seg=O
128	of	_	_	_	_	_	_	_	Seg=O
129	biotinylated	_	_	_	_	_	_	_	Seg=O
130	PRRSV	_	_	_	_	_	_	_	Seg=O
131	to	_	_	_	_	_	_	_	Seg=O
132	AMf	_	_	_	_	_	_	_	Seg=O
133	is	_	_	_	_	_	_	_	Seg=O
134	much	_	_	_	_	_	_	_	Seg=O
135	more	_	_	_	_	_	_	_	Seg=O
136	efficient	_	_	_	_	_	_	_	Seg=O
137	than	_	_	_	_	_	_	_	Seg=O
138	to	_	_	_	_	_	_	_	Seg=O
139	PMf	_	_	_	_	_	_	_	Seg=O
140	and	_	_	_	_	_	_	_	Seg=O
141	BMo	_	_	_	_	_	_	_	Seg=O
142	.	_	_	_	_	_	_	_	Seg=O
143	Two	_	_	_	_	_	_	_	Seg=B-seg
144	monoclonal	_	_	_	_	_	_	_	Seg=O
145	antibodies	_	_	_	_	_	_	_	Seg=O
146	(	_	_	_	_	_	_	_	Seg=O
147	Mabs	_	_	_	_	_	_	_	Seg=O
148	)	_	_	_	_	_	_	_	Seg=O
149	41D3	_	_	_	_	_	_	_	Seg=O
150	and	_	_	_	_	_	_	_	Seg=O
151	41D5	_	_	_	_	_	_	_	Seg=O
152	which	_	_	_	_	_	_	_	Seg=B-seg
153	block	_	_	_	_	_	_	_	Seg=O
154	PRRSV	_	_	_	_	_	_	_	Seg=O
155	infection	_	_	_	_	_	_	_	Seg=O
156	of	_	_	_	_	_	_	_	Seg=O
157	AMf	_	_	_	_	_	_	_	Seg=O
158	and	_	_	_	_	_	_	_	Seg=B-seg
159	are	_	_	_	_	_	_	_	Seg=O
160	directed	_	_	_	_	_	_	_	Seg=O
161	against	_	_	_	_	_	_	_	Seg=O
162	a	_	_	_	_	_	_	_	Seg=O
163	candidate	_	_	_	_	_	_	_	Seg=O
164	receptor	_	_	_	_	_	_	_	Seg=O
165	for	_	_	_	_	_	_	_	Seg=O
166	PRRSV	_	_	_	_	_	_	_	Seg=O
167	only	_	_	_	_	_	_	_	Seg=B-seg
168	reacted	_	_	_	_	_	_	_	Seg=O
169	with	_	_	_	_	_	_	_	Seg=O
170	the	_	_	_	_	_	_	_	Seg=O
171	cell	_	_	_	_	_	_	_	Seg=O
172	membrane	_	_	_	_	_	_	_	Seg=O
173	of	_	_	_	_	_	_	_	Seg=O
174	AMf	_	_	_	_	_	_	_	Seg=O
175	.	_	_	_	_	_	_	_	Seg=O
176	PMA	_	_	_	_	_	_	_	Seg=B-seg
177	treatment	_	_	_	_	_	_	_	Seg=O
178	of	_	_	_	_	_	_	_	Seg=O
179	AMf	_	_	_	_	_	_	_	Seg=O
180	blocked	_	_	_	_	_	_	_	Seg=O
181	PRRSV	_	_	_	_	_	_	_	Seg=O
182	replication	_	_	_	_	_	_	_	Seg=O
183	in	_	_	_	_	_	_	_	Seg=O
184	the	_	_	_	_	_	_	_	Seg=O
185	cells	_	_	_	_	_	_	_	Seg=O
186	in	_	_	_	_	_	_	_	Seg=O
187	a	_	_	_	_	_	_	_	Seg=O
188	dose	_	_	_	_	_	_	_	Seg=O
189	-	_	_	_	_	_	_	_	Seg=O
190	dependent	_	_	_	_	_	_	_	Seg=O
191	manner	_	_	_	_	_	_	_	Seg=O
192	.	_	_	_	_	_	_	_	Seg=O
193	The	_	_	_	_	_	_	_	Seg=B-seg
194	blocking	_	_	_	_	_	_	_	Seg=O
195	effect	_	_	_	_	_	_	_	Seg=O
196	of	_	_	_	_	_	_	_	Seg=O
197	PMA	_	_	_	_	_	_	_	Seg=O
198	decreased	_	_	_	_	_	_	_	Seg=O
199	after	_	_	_	_	_	_	_	Seg=O
200	9	_	_	_	_	_	_	_	Seg=O
201	h	_	_	_	_	_	_	_	Seg=O
202	continuous	_	_	_	_	_	_	_	Seg=O
203	pre	_	_	_	_	_	_	_	Seg=O
204	-	_	_	_	_	_	_	_	Seg=O
205	treatment	_	_	_	_	_	_	_	Seg=O
206	and	_	_	_	_	_	_	_	Seg=B-seg
207	diminished	_	_	_	_	_	_	_	Seg=O
208	after	_	_	_	_	_	_	_	Seg=O
209	24	_	_	_	_	_	_	_	Seg=O
210	h	_	_	_	_	_	_	_	Seg=O
211	continuous	_	_	_	_	_	_	_	Seg=O
212	pre	_	_	_	_	_	_	_	Seg=O
213	-	_	_	_	_	_	_	_	Seg=O
214	treatment	_	_	_	_	_	_	_	Seg=O
215	.	_	_	_	_	_	_	_	Seg=O
216	PMA	_	_	_	_	_	_	_	Seg=B-seg
217	treatment	_	_	_	_	_	_	_	Seg=O
218	did	_	_	_	_	_	_	_	Seg=O
219	not	_	_	_	_	_	_	_	Seg=O
220	affect	_	_	_	_	_	_	_	Seg=O
221	the	_	_	_	_	_	_	_	Seg=O
222	binding	_	_	_	_	_	_	_	Seg=O
223	of	_	_	_	_	_	_	_	Seg=O
224	PRRSV	_	_	_	_	_	_	_	Seg=O
225	and	_	_	_	_	_	_	_	Seg=O
226	MAb	_	_	_	_	_	_	_	Seg=O
227	41D3	_	_	_	_	_	_	_	Seg=O
228	and	_	_	_	_	_	_	_	Seg=O
229	41D5	_	_	_	_	_	_	_	Seg=O
230	to	_	_	_	_	_	_	_	Seg=O
231	AMf	_	_	_	_	_	_	_	Seg=O
232	.	_	_	_	_	_	_	_	Seg=O
233	Direct	_	_	_	_	_	_	_	Seg=B-seg
234	or	_	_	_	_	_	_	_	Seg=O
235	indirect	_	_	_	_	_	_	_	Seg=O
236	treatment	_	_	_	_	_	_	_	Seg=O
237	of	_	_	_	_	_	_	_	Seg=O
238	AMf	_	_	_	_	_	_	_	Seg=O
239	and	_	_	_	_	_	_	_	Seg=O
240	BMo	_	_	_	_	_	_	_	Seg=O
241	with	_	_	_	_	_	_	_	Seg=O
242	LPS	_	_	_	_	_	_	_	Seg=O
243	or	_	_	_	_	_	_	_	Seg=O
244	cultivation	_	_	_	_	_	_	_	Seg=O
245	in	_	_	_	_	_	_	_	Seg=O
246	suspension	_	_	_	_	_	_	_	Seg=O
247	did	_	_	_	_	_	_	_	Seg=O
248	not	_	_	_	_	_	_	_	Seg=O
249	significantly	_	_	_	_	_	_	_	Seg=O
250	affect	_	_	_	_	_	_	_	Seg=O
251	their	_	_	_	_	_	_	_	Seg=O
252	susceptibility	_	_	_	_	_	_	_	Seg=O
253	.	_	_	_	_	_	_	_	Seg=O
254	These	_	_	_	_	_	_	_	Seg=B-seg
255	results	_	_	_	_	_	_	_	Seg=O
256	provide	_	_	_	_	_	_	_	Seg=O
257	clear	_	_	_	_	_	_	_	Seg=O
258	evidence	_	_	_	_	_	_	_	Seg=O
259	that	_	_	_	_	_	_	_	Seg=B-seg
260	PRRSV	_	_	_	_	_	_	_	Seg=O
261	has	_	_	_	_	_	_	_	Seg=O
262	a	_	_	_	_	_	_	_	Seg=O
263	strongly	_	_	_	_	_	_	_	Seg=O
264	restricted	_	_	_	_	_	_	_	Seg=O
265	tropism	_	_	_	_	_	_	_	Seg=O
266	for	_	_	_	_	_	_	_	Seg=O
267	only	_	_	_	_	_	_	_	Seg=O
268	some	_	_	_	_	_	_	_	Seg=O
269	sub	_	_	_	_	_	_	_	Seg=O
270	-	_	_	_	_	_	_	_	Seg=O
271	populations	_	_	_	_	_	_	_	Seg=O
272	of	_	_	_	_	_	_	_	Seg=O
273	porcine	_	_	_	_	_	_	_	Seg=O
274	monocytes	_	_	_	_	_	_	_	Seg=O
275	/	_	_	_	_	_	_	_	Seg=O
276	macrophages	_	_	_	_	_	_	_	Seg=O
277	and	_	_	_	_	_	_	_	Seg=B-seg
278	that	_	_	_	_	_	_	_	Seg=O
279	some	_	_	_	_	_	_	_	Seg=O
280	specific	_	_	_	_	_	_	_	Seg=O
281	states	_	_	_	_	_	_	_	Seg=O
282	of	_	_	_	_	_	_	_	Seg=O
283	differentiation	_	_	_	_	_	_	_	Seg=O
284	and	_	_	_	_	_	_	_	Seg=O
285	activation	_	_	_	_	_	_	_	Seg=O
286	of	_	_	_	_	_	_	_	Seg=O
287	monocytes	_	_	_	_	_	_	_	Seg=O
288	/	_	_	_	_	_	_	_	Seg=O
289	macrophages	_	_	_	_	_	_	_	Seg=O
290	considerably	_	_	_	_	_	_	_	Seg=O
291	affect	_	_	_	_	_	_	_	Seg=O
292	their	_	_	_	_	_	_	_	Seg=O
293	susceptibility	_	_	_	_	_	_	_	Seg=O
294	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 3835ee8683c9c63e71a30ea92a36903117d467b9
1	As	_	_	_	_	_	_	_	Seg=B-seg
2	the	_	_	_	_	_	_	_	Seg=O
3	ongoing	_	_	_	_	_	_	_	Seg=O
4	COVID-19	_	_	_	_	_	_	_	Seg=O
5	pandemic	_	_	_	_	_	_	_	Seg=O
6	posed	_	_	_	_	_	_	_	Seg=O
7	a	_	_	_	_	_	_	_	Seg=O
8	huge	_	_	_	_	_	_	_	Seg=O
9	challenge	_	_	_	_	_	_	_	Seg=O
10	to	_	_	_	_	_	_	_	Seg=O
11	global	_	_	_	_	_	_	_	Seg=O
12	public	_	_	_	_	_	_	_	Seg=O
13	health	_	_	_	_	_	_	_	Seg=O
14	,	_	_	_	_	_	_	_	Seg=O
15	emphasis	_	_	_	_	_	_	_	Seg=B-seg
16	on	_	_	_	_	_	_	_	Seg=O
17	personal	_	_	_	_	_	_	_	Seg=O
18	hygiene	_	_	_	_	_	_	_	Seg=O
19	caused	_	_	_	_	_	_	_	Seg=O
20	extraordinary	_	_	_	_	_	_	_	Seg=O
21	daily	_	_	_	_	_	_	_	Seg=O
22	use	_	_	_	_	_	_	_	Seg=O
23	of	_	_	_	_	_	_	_	Seg=O
24	detergents	_	_	_	_	_	_	_	Seg=O
25	and	_	_	_	_	_	_	_	Seg=O
26	household	_	_	_	_	_	_	_	Seg=O
27	cleaning	_	_	_	_	_	_	_	Seg=O
28	products	_	_	_	_	_	_	_	Seg=O
29	.	_	_	_	_	_	_	_	Seg=O
30	Since	_	_	_	_	_	_	_	Seg=B-seg
31	antibacterial	_	_	_	_	_	_	_	Seg=O
32	cleaning	_	_	_	_	_	_	_	Seg=O
33	products	_	_	_	_	_	_	_	Seg=O
34	have	_	_	_	_	_	_	_	Seg=O
35	the	_	_	_	_	_	_	_	Seg=O
36	capacity	_	_	_	_	_	_	_	Seg=O
37	to	_	_	_	_	_	_	_	Seg=B-seg
38	change	_	_	_	_	_	_	_	Seg=O
39	the	_	_	_	_	_	_	_	Seg=O
40	environmental	_	_	_	_	_	_	_	Seg=O
41	microbiome	_	_	_	_	_	_	_	Seg=O
42	,	_	_	_	_	_	_	_	Seg=O
43	increased	_	_	_	_	_	_	_	Seg=B-seg
44	exposure	_	_	_	_	_	_	_	Seg=O
45	to	_	_	_	_	_	_	_	Seg=O
46	household	_	_	_	_	_	_	_	Seg=O
47	disinfectants	_	_	_	_	_	_	_	Seg=O
48	could	_	_	_	_	_	_	_	Seg=O
49	be	_	_	_	_	_	_	_	Seg=O
50	associated	_	_	_	_	_	_	_	Seg=O
51	with	_	_	_	_	_	_	_	Seg=O
52	alterations	_	_	_	_	_	_	_	Seg=O
53	in	_	_	_	_	_	_	_	Seg=O
54	human	_	_	_	_	_	_	_	Seg=O
55	microbiota	_	_	_	_	_	_	_	Seg=O
56	composition	_	_	_	_	_	_	_	Seg=O
57	and	_	_	_	_	_	_	_	Seg=O
58	function	_	_	_	_	_	_	_	Seg=O
59	.	_	_	_	_	_	_	_	Seg=O
60	Moreover	_	_	_	_	_	_	_	Seg=B-seg
61	,	_	_	_	_	_	_	_	Seg=O
62	the	_	_	_	_	_	_	_	Seg=O
63	emerging	_	_	_	_	_	_	_	Seg=O
64	links	_	_	_	_	_	_	_	Seg=O
65	between	_	_	_	_	_	_	_	Seg=O
66	household	_	_	_	_	_	_	_	Seg=O
67	cleaning	_	_	_	_	_	_	_	Seg=O
68	products	_	_	_	_	_	_	_	Seg=O
69	and	_	_	_	_	_	_	_	Seg=O
70	occurrence	_	_	_	_	_	_	_	Seg=O
71	of	_	_	_	_	_	_	_	Seg=O
72	non	_	_	_	_	_	_	_	Seg=O
73	-	_	_	_	_	_	_	_	Seg=O
74	communicable	_	_	_	_	_	_	_	Seg=O
75	diseases	_	_	_	_	_	_	_	Seg=O
76	and	_	_	_	_	_	_	_	Seg=O
77	antibiotic	_	_	_	_	_	_	_	Seg=O
78	resistance	_	_	_	_	_	_	_	Seg=O
79	may	_	_	_	_	_	_	_	Seg=O
80	involve	_	_	_	_	_	_	_	Seg=O
81	the	_	_	_	_	_	_	_	Seg=O
82	gut	_	_	_	_	_	_	_	Seg=O
83	microbiome	_	_	_	_	_	_	_	Seg=O
84	.	_	_	_	_	_	_	_	Seg=O
85	The	_	_	_	_	_	_	_	Seg=B-seg
86	mediating	_	_	_	_	_	_	_	Seg=O
87	effects	_	_	_	_	_	_	_	Seg=O
88	of	_	_	_	_	_	_	_	Seg=O
89	disturbed	_	_	_	_	_	_	_	Seg=O
90	gut	_	_	_	_	_	_	_	Seg=O
91	microbiota	_	_	_	_	_	_	_	Seg=O
92	on	_	_	_	_	_	_	_	Seg=O
93	associations	_	_	_	_	_	_	_	Seg=O
94	between	_	_	_	_	_	_	_	Seg=O
95	home	_	_	_	_	_	_	_	Seg=O
96	use	_	_	_	_	_	_	_	Seg=O
97	of	_	_	_	_	_	_	_	Seg=O
98	cleaning	_	_	_	_	_	_	_	Seg=O
99	products	_	_	_	_	_	_	_	Seg=O
100	and	_	_	_	_	_	_	_	Seg=O
101	life	_	_	_	_	_	_	_	Seg=O
102	-	_	_	_	_	_	_	_	Seg=O
103	long	_	_	_	_	_	_	_	Seg=O
104	health	_	_	_	_	_	_	_	Seg=O
105	consequences	_	_	_	_	_	_	_	Seg=O
106	have	_	_	_	_	_	_	_	Seg=O
107	been	_	_	_	_	_	_	_	Seg=O
108	documented	_	_	_	_	_	_	_	Seg=O
109	in	_	_	_	_	_	_	_	Seg=O
110	some	_	_	_	_	_	_	_	Seg=O
111	observational	_	_	_	_	_	_	_	Seg=O
112	studies	_	_	_	_	_	_	_	Seg=O
113	.	_	_	_	_	_	_	_	Seg=O
114	Regarding	_	_	_	_	_	_	_	Seg=B-seg
115	the	_	_	_	_	_	_	_	Seg=O
116	evidence	_	_	_	_	_	_	_	Seg=O
117	associated	_	_	_	_	_	_	_	Seg=O
118	reduction	_	_	_	_	_	_	_	Seg=O
119	in	_	_	_	_	_	_	_	Seg=O
120	exposure	_	_	_	_	_	_	_	Seg=O
121	to	_	_	_	_	_	_	_	Seg=O
122	non	_	_	_	_	_	_	_	Seg=O
123	-	_	_	_	_	_	_	_	Seg=O
124	pathogenic	_	_	_	_	_	_	_	Seg=O
125	commensal	_	_	_	_	_	_	_	Seg=O
126	bacteria	_	_	_	_	_	_	_	Seg=O
127	and	_	_	_	_	_	_	_	Seg=O
128	gut	_	_	_	_	_	_	_	Seg=O
129	dysbiosis	_	_	_	_	_	_	_	Seg=O
130	,	_	_	_	_	_	_	_	Seg=O
131	further	_	_	_	_	_	_	_	Seg=B-seg
132	study	_	_	_	_	_	_	_	Seg=O
133	is	_	_	_	_	_	_	_	Seg=O
134	required	_	_	_	_	_	_	_	Seg=O
135	to	_	_	_	_	_	_	_	Seg=B-seg
136	assess	_	_	_	_	_	_	_	Seg=O
137	the	_	_	_	_	_	_	_	Seg=O
138	effect	_	_	_	_	_	_	_	Seg=O
139	of	_	_	_	_	_	_	_	Seg=O
140	massive	_	_	_	_	_	_	_	Seg=O
141	use	_	_	_	_	_	_	_	Seg=O
142	of	_	_	_	_	_	_	_	Seg=O
143	cleaning	_	_	_	_	_	_	_	Seg=O
144	products	_	_	_	_	_	_	_	Seg=O
145	during	_	_	_	_	_	_	_	Seg=O
146	COVID-19	_	_	_	_	_	_	_	Seg=O
147	pandemic	_	_	_	_	_	_	_	Seg=O
148	on	_	_	_	_	_	_	_	Seg=O
149	long	_	_	_	_	_	_	_	Seg=O
150	-	_	_	_	_	_	_	_	Seg=O
151	term	_	_	_	_	_	_	_	Seg=O
152	host	_	_	_	_	_	_	_	Seg=O
153	health	_	_	_	_	_	_	_	Seg=O
154	mediated	_	_	_	_	_	_	_	Seg=B-seg
155	by	_	_	_	_	_	_	_	Seg=O
156	the	_	_	_	_	_	_	_	Seg=O
157	altered	_	_	_	_	_	_	_	Seg=O
158	microbiota	_	_	_	_	_	_	_	Seg=O
159	.	_	_	_	_	_	_	_	Seg=O
160	In	_	_	_	_	_	_	_	Seg=B-seg
161	this	_	_	_	_	_	_	_	Seg=O
162	context	_	_	_	_	_	_	_	Seg=O
163	,	_	_	_	_	_	_	_	Seg=O
164	recommendations	_	_	_	_	_	_	_	Seg=O
165	to	_	_	_	_	_	_	_	Seg=B-seg
166	consume	_	_	_	_	_	_	_	Seg=O
167	probiotics	_	_	_	_	_	_	_	Seg=O
168	and	_	_	_	_	_	_	_	Seg=O
169	fermented	_	_	_	_	_	_	_	Seg=O
170	foods	_	_	_	_	_	_	_	Seg=O
171	might	_	_	_	_	_	_	_	Seg=B-seg
172	reverse	_	_	_	_	_	_	_	Seg=O
173	the	_	_	_	_	_	_	_	Seg=O
174	consequences	_	_	_	_	_	_	_	Seg=O
175	by	_	_	_	_	_	_	_	Seg=B-seg
176	alleviating	_	_	_	_	_	_	_	Seg=O
177	dysbiosis	_	_	_	_	_	_	_	Seg=O
178	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 38824de74c353c895d96ee1a20ce43956363ff9b
1	Viruses	_	_	_	_	_	_	_	Seg=B-seg
2	use	_	_	_	_	_	_	_	Seg=O
3	cell	_	_	_	_	_	_	_	Seg=O
4	machinery	_	_	_	_	_	_	_	Seg=O
5	to	_	_	_	_	_	_	_	Seg=B-seg
6	replicate	_	_	_	_	_	_	_	Seg=O
7	their	_	_	_	_	_	_	_	Seg=O
8	genome	_	_	_	_	_	_	_	Seg=O
9	and	_	_	_	_	_	_	_	Seg=B-seg
10	produce	_	_	_	_	_	_	_	Seg=O
11	viral	_	_	_	_	_	_	_	Seg=O
12	proteins	_	_	_	_	_	_	_	Seg=O
13	.	_	_	_	_	_	_	_	Seg=O
14	For	_	_	_	_	_	_	_	Seg=B-seg
15	this	_	_	_	_	_	_	_	Seg=O
16	reason	_	_	_	_	_	_	_	Seg=O
17	,	_	_	_	_	_	_	_	Seg=O
18	several	_	_	_	_	_	_	_	Seg=O
19	intracellular	_	_	_	_	_	_	_	Seg=O
20	factors	_	_	_	_	_	_	_	Seg=O
21	,	_	_	_	_	_	_	_	Seg=O
22	including	_	_	_	_	_	_	_	Seg=B-seg
23	the	_	_	_	_	_	_	_	Seg=O
24	redox	_	_	_	_	_	_	_	Seg=O
25	state	_	_	_	_	_	_	_	Seg=O
26	,	_	_	_	_	_	_	_	Seg=O
27	might	_	_	_	_	_	_	_	Seg=B-seg
28	directly	_	_	_	_	_	_	_	Seg=O
29	or	_	_	_	_	_	_	_	Seg=O
30	indirectly	_	_	_	_	_	_	_	Seg=O
31	affect	_	_	_	_	_	_	_	Seg=O
32	the	_	_	_	_	_	_	_	Seg=O
33	progression	_	_	_	_	_	_	_	Seg=O
34	and	_	_	_	_	_	_	_	Seg=O
35	outcome	_	_	_	_	_	_	_	Seg=O
36	of	_	_	_	_	_	_	_	Seg=O
37	viral	_	_	_	_	_	_	_	Seg=O
38	infection	_	_	_	_	_	_	_	Seg=O
39	.	_	_	_	_	_	_	_	Seg=O
40	In	_	_	_	_	_	_	_	Seg=B-seg
41	physiological	_	_	_	_	_	_	_	Seg=O
42	conditions	_	_	_	_	_	_	_	Seg=O
43	,	_	_	_	_	_	_	_	Seg=O
44	the	_	_	_	_	_	_	_	Seg=O
45	redox	_	_	_	_	_	_	_	Seg=O
46	balance	_	_	_	_	_	_	_	Seg=O
47	between	_	_	_	_	_	_	_	Seg=O
48	oxidant	_	_	_	_	_	_	_	Seg=O
49	and	_	_	_	_	_	_	_	Seg=O
50	antioxidant	_	_	_	_	_	_	_	Seg=O
51	species	_	_	_	_	_	_	_	Seg=O
52	is	_	_	_	_	_	_	_	Seg=O
53	maintained	_	_	_	_	_	_	_	Seg=O
54	by	_	_	_	_	_	_	_	Seg=O
55	enzymatic	_	_	_	_	_	_	_	Seg=O
56	and	_	_	_	_	_	_	_	Seg=O
57	non	_	_	_	_	_	_	_	Seg=O
58	-	_	_	_	_	_	_	_	Seg=O
59	enzymatic	_	_	_	_	_	_	_	Seg=O
60	systems	_	_	_	_	_	_	_	Seg=O
61	,	_	_	_	_	_	_	_	Seg=O
62	and	_	_	_	_	_	_	_	Seg=B-seg
63	it	_	_	_	_	_	_	_	Seg=O
64	finely	_	_	_	_	_	_	_	Seg=O
65	regulates	_	_	_	_	_	_	_	Seg=O
66	several	_	_	_	_	_	_	_	Seg=O
67	cell	_	_	_	_	_	_	_	Seg=O
68	functions	_	_	_	_	_	_	_	Seg=O
69	.	_	_	_	_	_	_	_	Seg=O
70	Different	_	_	_	_	_	_	_	Seg=B-seg
71	viruses	_	_	_	_	_	_	_	Seg=O
72	break	_	_	_	_	_	_	_	Seg=O
73	this	_	_	_	_	_	_	_	Seg=O
74	equilibrium	_	_	_	_	_	_	_	Seg=O
75	and	_	_	_	_	_	_	_	Seg=B-seg
76	induce	_	_	_	_	_	_	_	Seg=O
77	an	_	_	_	_	_	_	_	Seg=O
78	oxidative	_	_	_	_	_	_	_	Seg=O
79	stress	_	_	_	_	_	_	_	Seg=O
80	that	_	_	_	_	_	_	_	Seg=B-seg
81	in	_	_	_	_	_	_	_	Seg=O
82	turn	_	_	_	_	_	_	_	Seg=O
83	facilitates	_	_	_	_	_	_	_	Seg=O
84	specific	_	_	_	_	_	_	_	Seg=O
85	steps	_	_	_	_	_	_	_	Seg=O
86	of	_	_	_	_	_	_	_	Seg=O
87	the	_	_	_	_	_	_	_	Seg=O
88	virus	_	_	_	_	_	_	_	Seg=O
89	lifecycle	_	_	_	_	_	_	_	Seg=O
90	and	_	_	_	_	_	_	_	Seg=B-seg
91	activates	_	_	_	_	_	_	_	Seg=O
92	an	_	_	_	_	_	_	_	Seg=O
93	inflammatory	_	_	_	_	_	_	_	Seg=O
94	response	_	_	_	_	_	_	_	Seg=O
95	.	_	_	_	_	_	_	_	Seg=O
96	In	_	_	_	_	_	_	_	Seg=B-seg
97	this	_	_	_	_	_	_	_	Seg=O
98	context	_	_	_	_	_	_	_	Seg=O
99	,	_	_	_	_	_	_	_	Seg=O
100	many	_	_	_	_	_	_	_	Seg=O
101	studies	_	_	_	_	_	_	_	Seg=O
102	highlighted	_	_	_	_	_	_	_	Seg=O
103	the	_	_	_	_	_	_	_	Seg=O
104	importance	_	_	_	_	_	_	_	Seg=O
105	of	_	_	_	_	_	_	_	Seg=O
106	redox	_	_	_	_	_	_	_	Seg=O
107	-	_	_	_	_	_	_	_	Seg=O
108	sensitive	_	_	_	_	_	_	_	Seg=O
109	pathways	_	_	_	_	_	_	_	Seg=O
110	as	_	_	_	_	_	_	_	Seg=O
111	novel	_	_	_	_	_	_	_	Seg=O
112	cell	_	_	_	_	_	_	_	Seg=O
113	-	_	_	_	_	_	_	_	Seg=O
114	based	_	_	_	_	_	_	_	Seg=O
115	targets	_	_	_	_	_	_	_	Seg=O
116	for	_	_	_	_	_	_	_	Seg=O
117	therapies	_	_	_	_	_	_	_	Seg=O
118	aimed	_	_	_	_	_	_	_	Seg=B-seg
119	at	_	_	_	_	_	_	_	Seg=O
120	blocking	_	_	_	_	_	_	_	Seg=O
121	both	_	_	_	_	_	_	_	Seg=O
122	viral	_	_	_	_	_	_	_	Seg=O
123	replication	_	_	_	_	_	_	_	Seg=O
124	and	_	_	_	_	_	_	_	Seg=O
125	virus	_	_	_	_	_	_	_	Seg=O
126	-	_	_	_	_	_	_	_	Seg=O
127	induced	_	_	_	_	_	_	_	Seg=O
128	inflammation	_	_	_	_	_	_	_	Seg=O
129	.	_	_	_	_	_	_	_	Seg=O
130	In	_	_	_	_	_	_	_	Seg=B-seg
131	the	_	_	_	_	_	_	_	Seg=O
132	review	_	_	_	_	_	_	_	Seg=O
133	,	_	_	_	_	_	_	_	Seg=O
134	we	_	_	_	_	_	_	_	Seg=O
135	discuss	_	_	_	_	_	_	_	Seg=O
136	the	_	_	_	_	_	_	_	Seg=O
137	most	_	_	_	_	_	_	_	Seg=O
138	recent	_	_	_	_	_	_	_	Seg=O
139	findings	_	_	_	_	_	_	_	Seg=O
140	in	_	_	_	_	_	_	_	Seg=O
141	this	_	_	_	_	_	_	_	Seg=O
142	field	_	_	_	_	_	_	_	Seg=O
143	.	_	_	_	_	_	_	_	Seg=O
144	In	_	_	_	_	_	_	_	Seg=B-seg
145	particular	_	_	_	_	_	_	_	Seg=O
146	,	_	_	_	_	_	_	_	Seg=O
147	we	_	_	_	_	_	_	_	Seg=O
148	describe	_	_	_	_	_	_	_	Seg=O
149	the	_	_	_	_	_	_	_	Seg=O
150	effects	_	_	_	_	_	_	_	Seg=O
151	of	_	_	_	_	_	_	_	Seg=O
152	natural	_	_	_	_	_	_	_	Seg=O
153	or	_	_	_	_	_	_	_	Seg=O
154	synthetic	_	_	_	_	_	_	_	Seg=O
155	redox	_	_	_	_	_	_	_	Seg=O
156	-	_	_	_	_	_	_	_	Seg=O
157	modulating	_	_	_	_	_	_	_	Seg=O
158	molecules	_	_	_	_	_	_	_	Seg=O
159	in	_	_	_	_	_	_	_	Seg=B-seg
160	inhibiting	_	_	_	_	_	_	_	Seg=O
161	DNA	_	_	_	_	_	_	_	Seg=O
162	or	_	_	_	_	_	_	_	Seg=O
163	RNA	_	_	_	_	_	_	_	Seg=O
164	virus	_	_	_	_	_	_	_	Seg=O
165	replication	_	_	_	_	_	_	_	Seg=O
166	as	_	_	_	_	_	_	_	Seg=O
167	well	_	_	_	_	_	_	_	Seg=O
168	as	_	_	_	_	_	_	_	Seg=O
169	inflammatory	_	_	_	_	_	_	_	Seg=O
170	pathways	_	_	_	_	_	_	_	Seg=O
171	.	_	_	_	_	_	_	_	Seg=O
172	The	_	_	_	_	_	_	_	Seg=B-seg
173	importance	_	_	_	_	_	_	_	Seg=O
174	of	_	_	_	_	_	_	_	Seg=O
175	the	_	_	_	_	_	_	_	Seg=O
176	antioxidant	_	_	_	_	_	_	_	Seg=O
177	transcription	_	_	_	_	_	_	_	Seg=O
178	factor	_	_	_	_	_	_	_	Seg=O
179	Nrf2	_	_	_	_	_	_	_	Seg=O
180	is	_	_	_	_	_	_	_	Seg=O
181	also	_	_	_	_	_	_	_	Seg=O
182	discussed	_	_	_	_	_	_	_	Seg=O
183	.	_	_	_	_	_	_	_	Seg=O
184	Most	_	_	_	_	_	_	_	Seg=B-seg
185	of	_	_	_	_	_	_	_	Seg=O
186	the	_	_	_	_	_	_	_	Seg=O
187	data	_	_	_	_	_	_	_	Seg=O
188	reported	_	_	_	_	_	_	_	Seg=B-seg
189	here	_	_	_	_	_	_	_	Seg=O
190	are	_	_	_	_	_	_	_	Seg=B-seg
191	on	_	_	_	_	_	_	_	Seg=O
192	influenza	_	_	_	_	_	_	_	Seg=O
193	virus	_	_	_	_	_	_	_	Seg=O
194	infection	_	_	_	_	_	_	_	Seg=O
195	.	_	_	_	_	_	_	_	Seg=O
196	We	_	_	_	_	_	_	_	Seg=B-seg
197	believe	_	_	_	_	_	_	_	Seg=O
198	that	_	_	_	_	_	_	_	Seg=B-seg
199	this	_	_	_	_	_	_	_	Seg=O
200	approach	_	_	_	_	_	_	_	Seg=O
201	could	_	_	_	_	_	_	_	Seg=O
202	be	_	_	_	_	_	_	_	Seg=O
203	usefully	_	_	_	_	_	_	_	Seg=O
204	applied	_	_	_	_	_	_	_	Seg=O
205	to	_	_	_	_	_	_	_	Seg=B-seg
206	fight	_	_	_	_	_	_	_	Seg=O
207	other	_	_	_	_	_	_	_	Seg=O
208	acute	_	_	_	_	_	_	_	Seg=O
209	respiratory	_	_	_	_	_	_	_	Seg=O
210	viral	_	_	_	_	_	_	_	Seg=O
211	infections	_	_	_	_	_	_	_	Seg=O
212	characterized	_	_	_	_	_	_	_	Seg=B-seg
213	by	_	_	_	_	_	_	_	Seg=O
214	a	_	_	_	_	_	_	_	Seg=O
215	strong	_	_	_	_	_	_	_	Seg=O
216	inflammatory	_	_	_	_	_	_	_	Seg=O
217	response	_	_	_	_	_	_	_	Seg=O
218	,	_	_	_	_	_	_	_	Seg=O
219	like	_	_	_	_	_	_	_	Seg=O
220	COVID-19	_	_	_	_	_	_	_	Seg=O
221	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 388f183cd243466d793691e37972dd09b651348a
1	People	_	_	_	_	_	_	_	Seg=B-seg
2	most	_	_	_	_	_	_	_	Seg=O
3	at	_	_	_	_	_	_	_	Seg=O
4	risk	_	_	_	_	_	_	_	Seg=O
5	of	_	_	_	_	_	_	_	Seg=O
6	influenza	_	_	_	_	_	_	_	Seg=O
7	complications	_	_	_	_	_	_	_	Seg=O
8	are	_	_	_	_	_	_	_	Seg=O
9	the	_	_	_	_	_	_	_	Seg=O
10	elderly	_	_	_	_	_	_	_	Seg=O
11	with	_	_	_	_	_	_	_	Seg=O
12	impaired	_	_	_	_	_	_	_	Seg=O
13	immunity	_	_	_	_	_	_	_	Seg=O
14	.	_	_	_	_	_	_	_	Seg=O
15	Clinical	_	_	_	_	_	_	_	Seg=B-seg
16	picture	_	_	_	_	_	_	_	Seg=O
17	of	_	_	_	_	_	_	_	Seg=O
18	influenza	_	_	_	_	_	_	_	Seg=O
19	virus	_	_	_	_	_	_	_	Seg=O
20	infection	_	_	_	_	_	_	_	Seg=O
21	includes	_	_	_	_	_	_	_	Seg=O
22	symptoms	_	_	_	_	_	_	_	Seg=O
23	such	_	_	_	_	_	_	_	Seg=B-seg
24	as	_	_	_	_	_	_	_	Seg=O
25	chills	_	_	_	_	_	_	_	Seg=O
26	,	_	_	_	_	_	_	_	Seg=O
27	increased	_	_	_	_	_	_	_	Seg=O
28	body	_	_	_	_	_	_	_	Seg=O
29	temperature	_	_	_	_	_	_	_	Seg=O
30	,	_	_	_	_	_	_	_	Seg=O
31	dry	_	_	_	_	_	_	_	Seg=O
32	cough	_	_	_	_	_	_	_	Seg=O
33	,	_	_	_	_	_	_	_	Seg=O
34	chest	_	_	_	_	_	_	_	Seg=O
35	pain	_	_	_	_	_	_	_	Seg=O
36	,	_	_	_	_	_	_	_	Seg=O
37	or	_	_	_	_	_	_	_	Seg=O
38	dizziness	_	_	_	_	_	_	_	Seg=O
39	as	_	_	_	_	_	_	_	Seg=O
40	well	_	_	_	_	_	_	_	Seg=O
41	as	_	_	_	_	_	_	_	Seg=O
42	headaches	_	_	_	_	_	_	_	Seg=O
43	and	_	_	_	_	_	_	_	Seg=O
44	muscle	_	_	_	_	_	_	_	Seg=O
45	aches	_	_	_	_	_	_	_	Seg=O
46	.	_	_	_	_	_	_	_	Seg=O
47	In	_	_	_	_	_	_	_	Seg=B-seg
48	the	_	_	_	_	_	_	_	Seg=O
49	diagnosis	_	_	_	_	_	_	_	Seg=O
50	of	_	_	_	_	_	_	_	Seg=O
51	influenza	_	_	_	_	_	_	_	Seg=O
52	,	_	_	_	_	_	_	_	Seg=O
53	quick	_	_	_	_	_	_	_	Seg=O
54	and	_	_	_	_	_	_	_	Seg=O
55	effective	_	_	_	_	_	_	_	Seg=O
56	tests	_	_	_	_	_	_	_	Seg=O
57	are	_	_	_	_	_	_	_	Seg=O
58	necessary	_	_	_	_	_	_	_	Seg=O
59	.	_	_	_	_	_	_	_	Seg=O
60	Sensitive	_	_	_	_	_	_	_	Seg=B-seg
61	diagnostic	_	_	_	_	_	_	_	Seg=O
62	methods	_	_	_	_	_	_	_	Seg=O
63	of	_	_	_	_	_	_	_	Seg=O
64	molecular	_	_	_	_	_	_	_	Seg=O
65	biology	_	_	_	_	_	_	_	Seg=O
66	require	_	_	_	_	_	_	_	Seg=O
67	more	_	_	_	_	_	_	_	Seg=O
68	time	_	_	_	_	_	_	_	Seg=O
69	,	_	_	_	_	_	_	_	Seg=O
70	but	_	_	_	_	_	_	_	Seg=B-seg
71	the	_	_	_	_	_	_	_	Seg=O
72	result	_	_	_	_	_	_	_	Seg=O
73	firmly	_	_	_	_	_	_	_	Seg=O
74	confirm	_	_	_	_	_	_	_	Seg=O
75	or	_	_	_	_	_	_	_	Seg=O
76	exclude	_	_	_	_	_	_	_	Seg=O
77	the	_	_	_	_	_	_	_	Seg=O
78	presence	_	_	_	_	_	_	_	Seg=O
79	of	_	_	_	_	_	_	_	Seg=O
80	the	_	_	_	_	_	_	_	Seg=O
81	genetic	_	_	_	_	_	_	_	Seg=O
82	material	_	_	_	_	_	_	_	Seg=O
83	of	_	_	_	_	_	_	_	Seg=O
84	influenza	_	_	_	_	_	_	_	Seg=O
85	or	_	_	_	_	_	_	_	Seg=O
86	other	_	_	_	_	_	_	_	Seg=O
87	respiratory	_	_	_	_	_	_	_	Seg=O
88	viruses	_	_	_	_	_	_	_	Seg=O
89	.	_	_	_	_	_	_	_	Seg=O
90	Influenza	_	_	_	_	_	_	_	Seg=B-seg
91	vaccination	_	_	_	_	_	_	_	Seg=O
92	plays	_	_	_	_	_	_	_	Seg=O
93	an	_	_	_	_	_	_	_	Seg=O
94	important	_	_	_	_	_	_	_	Seg=O
95	role	_	_	_	_	_	_	_	Seg=O
96	in	_	_	_	_	_	_	_	Seg=B-seg
97	combating	_	_	_	_	_	_	_	Seg=O
98	influenza	_	_	_	_	_	_	_	Seg=O
99	infection	_	_	_	_	_	_	_	Seg=O
100	.	_	_	_	_	_	_	_	Seg=O
101	Unfortunately	_	_	_	_	_	_	_	Seg=B-seg
102	,	_	_	_	_	_	_	_	Seg=O
103	the	_	_	_	_	_	_	_	Seg=O
104	awareness	_	_	_	_	_	_	_	Seg=O
105	of	_	_	_	_	_	_	_	Seg=O
106	vaccination	_	_	_	_	_	_	_	Seg=O
107	benefits	_	_	_	_	_	_	_	Seg=O
108	is	_	_	_	_	_	_	_	Seg=O
109	insufficient	_	_	_	_	_	_	_	Seg=O
110	in	_	_	_	_	_	_	_	Seg=O
111	Poland	_	_	_	_	_	_	_	Seg=O
112	.	_	_	_	_	_	_	_	Seg=O
113	In	_	_	_	_	_	_	_	Seg=B-seg
114	this	_	_	_	_	_	_	_	Seg=O
115	study	_	_	_	_	_	_	_	Seg=O
116	we	_	_	_	_	_	_	_	Seg=O
117	demonstrate	_	_	_	_	_	_	_	Seg=O
118	the	_	_	_	_	_	_	_	Seg=O
119	results	_	_	_	_	_	_	_	Seg=O
120	of	_	_	_	_	_	_	_	Seg=O
121	examination	_	_	_	_	_	_	_	Seg=O
122	of	_	_	_	_	_	_	_	Seg=O
123	4,507	_	_	_	_	_	_	_	Seg=O
124	people	_	_	_	_	_	_	_	Seg=O
125	aged	_	_	_	_	_	_	_	Seg=B-seg
126	over	_	_	_	_	_	_	_	Seg=O
127	14	_	_	_	_	_	_	_	Seg=O
128	years	_	_	_	_	_	_	_	Seg=O
129	toward	_	_	_	_	_	_	_	Seg=B-seg
130	the	_	_	_	_	_	_	_	Seg=O
131	influenza	_	_	_	_	_	_	_	Seg=O
132	infection	_	_	_	_	_	_	_	Seg=O
133	in	_	_	_	_	_	_	_	Seg=O
134	the	_	_	_	_	_	_	_	Seg=O
135	epidemic	_	_	_	_	_	_	_	Seg=O
136	season	_	_	_	_	_	_	_	Seg=O
137	of	_	_	_	_	_	_	_	Seg=O
138	2017/18	_	_	_	_	_	_	_	Seg=O
139	.	_	_	_	_	_	_	_	Seg=O
140	Most	_	_	_	_	_	_	_	Seg=B-seg
141	of	_	_	_	_	_	_	_	Seg=O
142	the	_	_	_	_	_	_	_	Seg=O
143	confirmed	_	_	_	_	_	_	_	Seg=O
144	infections	_	_	_	_	_	_	_	Seg=O
145	were	_	_	_	_	_	_	_	Seg=O
146	reported	_	_	_	_	_	_	_	Seg=O
147	in	_	_	_	_	_	_	_	Seg=O
148	older	_	_	_	_	_	_	_	Seg=O
149	people	_	_	_	_	_	_	_	Seg=O
150	aged	_	_	_	_	_	_	_	Seg=B-seg
151	over	_	_	_	_	_	_	_	Seg=O
152	65	_	_	_	_	_	_	_	Seg=O
153	,	_	_	_	_	_	_	_	Seg=O
154	a	_	_	_	_	_	_	_	Seg=B-seg
155	high	_	_	_	_	_	_	_	Seg=O
156	-	_	_	_	_	_	_	_	Seg=O
157	risk	_	_	_	_	_	_	_	Seg=O
158	population	_	_	_	_	_	_	_	Seg=O
159	group	_	_	_	_	_	_	_	Seg=O
160	.	_	_	_	_	_	_	_	Seg=O
161	A	_	_	_	_	_	_	_	Seg=B-seg
162	low	_	_	_	_	_	_	_	Seg=O
163	percentage	_	_	_	_	_	_	_	Seg=O
164	of	_	_	_	_	_	_	_	Seg=O
165	the	_	_	_	_	_	_	_	Seg=O
166	vaccinated	_	_	_	_	_	_	_	Seg=O
167	population	_	_	_	_	_	_	_	Seg=O
168	may	_	_	_	_	_	_	_	Seg=O
169	affect	_	_	_	_	_	_	_	Seg=O
170	an	_	_	_	_	_	_	_	Seg=O
171	increased	_	_	_	_	_	_	_	Seg=O
172	number	_	_	_	_	_	_	_	Seg=O
173	of	_	_	_	_	_	_	_	Seg=O
174	confirmed	_	_	_	_	_	_	_	Seg=O
175	influenza	_	_	_	_	_	_	_	Seg=O
176	viruses	_	_	_	_	_	_	_	Seg=O
177	in	_	_	_	_	_	_	_	Seg=O
178	the	_	_	_	_	_	_	_	Seg=O
179	elderly	_	_	_	_	_	_	_	Seg=O
180	.	_	_	_	_	_	_	_	Seg=O
181	The	_	_	_	_	_	_	_	Seg=B-seg
182	findings	_	_	_	_	_	_	_	Seg=O
183	demonstrate	_	_	_	_	_	_	_	Seg=O
184	a	_	_	_	_	_	_	_	Seg=O
185	need	_	_	_	_	_	_	_	Seg=O
186	to	_	_	_	_	_	_	_	Seg=B-seg
187	increase	_	_	_	_	_	_	_	Seg=O
188	awareness	_	_	_	_	_	_	_	Seg=O
189	of	_	_	_	_	_	_	_	Seg=O
190	vaccination	_	_	_	_	_	_	_	Seg=O
191	benefits	_	_	_	_	_	_	_	Seg=O
192	,	_	_	_	_	_	_	_	Seg=O
193	which	_	_	_	_	_	_	_	Seg=B-seg
194	is	_	_	_	_	_	_	_	Seg=O
195	particularly	_	_	_	_	_	_	_	Seg=O
196	essential	_	_	_	_	_	_	_	Seg=O
197	to	_	_	_	_	_	_	_	Seg=B-seg
198	avoid	_	_	_	_	_	_	_	Seg=O
199	influenza	_	_	_	_	_	_	_	Seg=O
200	infection	_	_	_	_	_	_	_	Seg=O
201	in	_	_	_	_	_	_	_	Seg=O
202	the	_	_	_	_	_	_	_	Seg=O
203	elderly	_	_	_	_	_	_	_	Seg=O
204	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 39037d14bf47bea9a4721c8f331da9661f18fef5
1	In	_	_	_	_	_	_	_	Seg=B-seg
2	this	_	_	_	_	_	_	_	Seg=O
3	work	_	_	_	_	_	_	_	Seg=O
4	we	_	_	_	_	_	_	_	Seg=O
5	construct	_	_	_	_	_	_	_	Seg=O
6	a	_	_	_	_	_	_	_	Seg=O
7	mathematical	_	_	_	_	_	_	_	Seg=O
8	model	_	_	_	_	_	_	_	Seg=O
9	for	_	_	_	_	_	_	_	Seg=O
10	the	_	_	_	_	_	_	_	Seg=O
11	transmission	_	_	_	_	_	_	_	Seg=O
12	and	_	_	_	_	_	_	_	Seg=O
13	spread	_	_	_	_	_	_	_	Seg=O
14	of	_	_	_	_	_	_	_	Seg=O
15	coronavirus	_	_	_	_	_	_	_	Seg=O
16	disease	_	_	_	_	_	_	_	Seg=O
17	2019	_	_	_	_	_	_	_	Seg=O
18	or	_	_	_	_	_	_	_	Seg=O
19	COVID-19	_	_	_	_	_	_	_	Seg=O
20	.	_	_	_	_	_	_	_	Seg=O
21	Our	_	_	_	_	_	_	_	Seg=B-seg
22	model	_	_	_	_	_	_	_	Seg=O
23	features	_	_	_	_	_	_	_	Seg=O
24	delay	_	_	_	_	_	_	_	Seg=O
25	terms	_	_	_	_	_	_	_	Seg=O
26	to	_	_	_	_	_	_	_	Seg=B-seg
27	account	_	_	_	_	_	_	_	Seg=O
28	for	_	_	_	_	_	_	_	Seg=O
29	(	_	_	_	_	_	_	_	Seg=O
30	a	_	_	_	_	_	_	_	Seg=O
31	)	_	_	_	_	_	_	_	Seg=O
32	the	_	_	_	_	_	_	_	Seg=O
33	time	_	_	_	_	_	_	_	Seg=O
34	lapse	_	_	_	_	_	_	_	Seg=O
35	or	_	_	_	_	_	_	_	Seg=O
36	latency	_	_	_	_	_	_	_	Seg=O
37	period	_	_	_	_	_	_	_	Seg=O
38	between	_	_	_	_	_	_	_	Seg=O
39	contracting	_	_	_	_	_	_	_	Seg=O
40	the	_	_	_	_	_	_	_	Seg=O
41	disease	_	_	_	_	_	_	_	Seg=O
42	and	_	_	_	_	_	_	_	Seg=O
43	displaying	_	_	_	_	_	_	_	Seg=O
44	symptoms	_	_	_	_	_	_	_	Seg=O
45	,	_	_	_	_	_	_	_	Seg=O
46	and	_	_	_	_	_	_	_	Seg=O
47	(	_	_	_	_	_	_	_	Seg=O
48	b	_	_	_	_	_	_	_	Seg=O
49	)	_	_	_	_	_	_	_	Seg=O
50	the	_	_	_	_	_	_	_	Seg=O
51	time	_	_	_	_	_	_	_	Seg=O
52	lag	_	_	_	_	_	_	_	Seg=O
53	in	_	_	_	_	_	_	_	Seg=B-seg
54	testing	_	_	_	_	_	_	_	Seg=O
55	patients	_	_	_	_	_	_	_	Seg=O
56	for	_	_	_	_	_	_	_	Seg=O
57	the	_	_	_	_	_	_	_	Seg=O
58	virus	_	_	_	_	_	_	_	Seg=O
59	due	_	_	_	_	_	_	_	Seg=B-seg
60	to	_	_	_	_	_	_	_	Seg=O
61	the	_	_	_	_	_	_	_	Seg=O
62	limited	_	_	_	_	_	_	_	Seg=O
63	numbers	_	_	_	_	_	_	_	Seg=O
64	of	_	_	_	_	_	_	_	Seg=O
65	testing	_	_	_	_	_	_	_	Seg=O
66	facilities	_	_	_	_	_	_	_	Seg=O
67	currently	_	_	_	_	_	_	_	Seg=O
68	available	_	_	_	_	_	_	_	Seg=O
69	.	_	_	_	_	_	_	_	Seg=O
70	We	_	_	_	_	_	_	_	Seg=B-seg
71	find	_	_	_	_	_	_	_	Seg=O
72	that	_	_	_	_	_	_	_	Seg=B-seg
73	the	_	_	_	_	_	_	_	Seg=O
74	delay	_	_	_	_	_	_	_	Seg=O
75	introduces	_	_	_	_	_	_	_	Seg=O
76	a	_	_	_	_	_	_	_	Seg=O
77	significant	_	_	_	_	_	_	_	Seg=O
78	disparity	_	_	_	_	_	_	_	Seg=O
79	between	_	_	_	_	_	_	_	Seg=O
80	the	_	_	_	_	_	_	_	Seg=O
81	actual	_	_	_	_	_	_	_	Seg=O
82	and	_	_	_	_	_	_	_	Seg=O
83	reported	_	_	_	_	_	_	_	Seg=O
84	time	_	_	_	_	_	_	_	Seg=O
85	-	_	_	_	_	_	_	_	Seg=O
86	trajectories	_	_	_	_	_	_	_	Seg=O
87	of	_	_	_	_	_	_	_	Seg=O
88	cases	_	_	_	_	_	_	_	Seg=O
89	in	_	_	_	_	_	_	_	Seg=O
90	a	_	_	_	_	_	_	_	Seg=O
91	particular	_	_	_	_	_	_	_	Seg=O
92	region	_	_	_	_	_	_	_	Seg=O
93	.	_	_	_	_	_	_	_	Seg=O
94	Specifically	_	_	_	_	_	_	_	Seg=B-seg
95	,	_	_	_	_	_	_	_	Seg=O
96	the	_	_	_	_	_	_	_	Seg=O
97	reported	_	_	_	_	_	_	_	Seg=O
98	case	_	_	_	_	_	_	_	Seg=O
99	histories	_	_	_	_	_	_	_	Seg=O
100	lag	_	_	_	_	_	_	_	Seg=O
101	the	_	_	_	_	_	_	_	Seg=O
102	actual	_	_	_	_	_	_	_	Seg=O
103	histories	_	_	_	_	_	_	_	Seg=O
104	by	_	_	_	_	_	_	_	Seg=O
105	a	_	_	_	_	_	_	_	Seg=O
106	few	_	_	_	_	_	_	_	Seg=O
107	days	_	_	_	_	_	_	_	Seg=O
108	.	_	_	_	_	_	_	_	Seg=O
109	Hence	_	_	_	_	_	_	_	Seg=B-seg
110	,	_	_	_	_	_	_	_	Seg=O
111	to	_	_	_	_	_	_	_	Seg=B-seg
112	minimize	_	_	_	_	_	_	_	Seg=O
113	the	_	_	_	_	_	_	_	Seg=O
114	spread	_	_	_	_	_	_	_	Seg=O
115	of	_	_	_	_	_	_	_	Seg=O
116	the	_	_	_	_	_	_	_	Seg=O
117	disease	_	_	_	_	_	_	_	Seg=O
118	,	_	_	_	_	_	_	_	Seg=O
119	lockdowns	_	_	_	_	_	_	_	Seg=B-seg
120	and	_	_	_	_	_	_	_	Seg=O
121	similarly	_	_	_	_	_	_	_	Seg=O
122	drastic	_	_	_	_	_	_	_	Seg=O
123	social	_	_	_	_	_	_	_	Seg=O
124	isolation	_	_	_	_	_	_	_	Seg=O
125	measures	_	_	_	_	_	_	_	Seg=O
126	need	_	_	_	_	_	_	_	Seg=O
127	to	_	_	_	_	_	_	_	Seg=O
128	be	_	_	_	_	_	_	_	Seg=O
129	imposed	_	_	_	_	_	_	_	Seg=O
130	some	_	_	_	_	_	_	_	Seg=B-seg
131	time	_	_	_	_	_	_	_	Seg=O
132	before	_	_	_	_	_	_	_	Seg=O
133	the	_	_	_	_	_	_	_	Seg=O
134	reported	_	_	_	_	_	_	_	Seg=O
135	figures	_	_	_	_	_	_	_	Seg=O
136	are	_	_	_	_	_	_	_	Seg=O
137	approaching	_	_	_	_	_	_	_	Seg=O
138	their	_	_	_	_	_	_	_	Seg=O
139	peak	_	_	_	_	_	_	_	Seg=O
140	values	_	_	_	_	_	_	_	Seg=O
141	.	_	_	_	_	_	_	_	Seg=O
142	We	_	_	_	_	_	_	_	Seg=B-seg
143	then	_	_	_	_	_	_	_	Seg=O
144	account	_	_	_	_	_	_	_	Seg=O
145	for	_	_	_	_	_	_	_	Seg=O
146	the	_	_	_	_	_	_	_	Seg=O
147	social	_	_	_	_	_	_	_	Seg=O
148	reality	_	_	_	_	_	_	_	Seg=O
149	that	_	_	_	_	_	_	_	Seg=B-seg
150	lockdowns	_	_	_	_	_	_	_	Seg=O
151	can	_	_	_	_	_	_	_	Seg=O
152	only	_	_	_	_	_	_	_	Seg=O
153	be	_	_	_	_	_	_	_	Seg=O
154	of	_	_	_	_	_	_	_	Seg=O
155	a	_	_	_	_	_	_	_	Seg=O
156	limited	_	_	_	_	_	_	_	Seg=O
157	duration	_	_	_	_	_	_	_	Seg=O
158	in	_	_	_	_	_	_	_	Seg=O
159	view	_	_	_	_	_	_	_	Seg=O
160	of	_	_	_	_	_	_	_	Seg=O
161	practical	_	_	_	_	_	_	_	Seg=O
162	considerations	_	_	_	_	_	_	_	Seg=O
163	.	_	_	_	_	_	_	_	Seg=O
164	We	_	_	_	_	_	_	_	Seg=B-seg
165	find	_	_	_	_	_	_	_	Seg=O
166	that	_	_	_	_	_	_	_	Seg=B-seg
167	the	_	_	_	_	_	_	_	Seg=O
168	most	_	_	_	_	_	_	_	Seg=O
169	effective	_	_	_	_	_	_	_	Seg=O
170	interval	_	_	_	_	_	_	_	Seg=O
171	for	_	_	_	_	_	_	_	Seg=B-seg
172	imposing	_	_	_	_	_	_	_	Seg=O
173	such	_	_	_	_	_	_	_	Seg=O
174	a	_	_	_	_	_	_	_	Seg=O
175	limited	_	_	_	_	_	_	_	Seg=O
176	-	_	_	_	_	_	_	_	Seg=O
177	time	_	_	_	_	_	_	_	Seg=O
178	lockdown	_	_	_	_	_	_	_	Seg=O
179	is	_	_	_	_	_	_	_	Seg=B-seg
180	one	_	_	_	_	_	_	_	Seg=O
181	where	_	_	_	_	_	_	_	Seg=B-seg
182	the	_	_	_	_	_	_	_	Seg=O
183	midpoint	_	_	_	_	_	_	_	Seg=O
184	of	_	_	_	_	_	_	_	Seg=O
185	the	_	_	_	_	_	_	_	Seg=O
186	lockdown	_	_	_	_	_	_	_	Seg=O
187	period	_	_	_	_	_	_	_	Seg=O
188	coincides	_	_	_	_	_	_	_	Seg=O
189	with	_	_	_	_	_	_	_	Seg=O
190	the	_	_	_	_	_	_	_	Seg=O
191	actual	_	_	_	_	_	_	_	Seg=O
192	peak	_	_	_	_	_	_	_	Seg=O
193	of	_	_	_	_	_	_	_	Seg=O
194	the	_	_	_	_	_	_	_	Seg=O
195	spread	_	_	_	_	_	_	_	Seg=O
196	of	_	_	_	_	_	_	_	Seg=O
197	the	_	_	_	_	_	_	_	Seg=O
198	disease	_	_	_	_	_	_	_	Seg=O
199	in	_	_	_	_	_	_	_	Seg=O
200	the	_	_	_	_	_	_	_	Seg=O
201	absence	_	_	_	_	_	_	_	Seg=O
202	of	_	_	_	_	_	_	_	Seg=O
203	the	_	_	_	_	_	_	_	Seg=O
204	lockdown	_	_	_	_	_	_	_	Seg=O
205	.	_	_	_	_	_	_	_	Seg=O
206	We	_	_	_	_	_	_	_	Seg=B-seg
207	further	_	_	_	_	_	_	_	Seg=O
208	show	_	_	_	_	_	_	_	Seg=O
209	that	_	_	_	_	_	_	_	Seg=B-seg
210	the	_	_	_	_	_	_	_	Seg=O
211	true	_	_	_	_	_	_	_	Seg=O
212	effectivity	_	_	_	_	_	_	_	Seg=O
213	of	_	_	_	_	_	_	_	Seg=B-seg
214	imposing	_	_	_	_	_	_	_	Seg=O
215	a	_	_	_	_	_	_	_	Seg=O
216	lockdown	_	_	_	_	_	_	_	Seg=O
217	may	_	_	_	_	_	_	_	Seg=B-seg
218	be	_	_	_	_	_	_	_	Seg=O
219	misrepresented	_	_	_	_	_	_	_	Seg=O
220	and	_	_	_	_	_	_	_	Seg=O
221	grossly	_	_	_	_	_	_	_	Seg=O
222	underestimated	_	_	_	_	_	_	_	Seg=O
223	by	_	_	_	_	_	_	_	Seg=O
224	the	_	_	_	_	_	_	_	Seg=O
225	reported	_	_	_	_	_	_	_	Seg=O
226	case	_	_	_	_	_	_	_	Seg=O
227	trajectories	_	_	_	_	_	_	_	Seg=O
228	in	_	_	_	_	_	_	_	Seg=O
229	the	_	_	_	_	_	_	_	Seg=O
230	days	_	_	_	_	_	_	_	Seg=O
231	following	_	_	_	_	_	_	_	Seg=B-seg
232	the	_	_	_	_	_	_	_	Seg=O
233	action	_	_	_	_	_	_	_	Seg=O
234	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 3a8a064e3c2e791777f54f39a797baf90c97b653
1	The	_	_	_	_	_	_	_	Seg=B-seg
2	COVID-19	_	_	_	_	_	_	_	Seg=O
3	epidemic	_	_	_	_	_	_	_	Seg=O
4	has	_	_	_	_	_	_	_	Seg=O
5	resulted	_	_	_	_	_	_	_	Seg=O
6	in	_	_	_	_	_	_	_	Seg=O
7	many	_	_	_	_	_	_	_	Seg=O
8	hospitals	_	_	_	_	_	_	_	Seg=O
9	and	_	_	_	_	_	_	_	Seg=O
10	practices	_	_	_	_	_	_	_	Seg=O
11	to	_	_	_	_	_	_	_	Seg=O
12	cancel	_	_	_	_	_	_	_	Seg=O
13	in	_	_	_	_	_	_	_	Seg=O
14	-	_	_	_	_	_	_	_	Seg=O
15	person	_	_	_	_	_	_	_	Seg=O
16	outpatient	_	_	_	_	_	_	_	Seg=O
17	clinic	_	_	_	_	_	_	_	Seg=O
18	visits	_	_	_	_	_	_	_	Seg=O
19	,	_	_	_	_	_	_	_	Seg=O
20	where	_	_	_	_	_	_	_	Seg=B-seg
21	head	_	_	_	_	_	_	_	Seg=O
22	and	_	_	_	_	_	_	_	Seg=O
23	neck	_	_	_	_	_	_	_	Seg=O
24	patients	_	_	_	_	_	_	_	Seg=O
25	receive	_	_	_	_	_	_	_	Seg=O
26	their	_	_	_	_	_	_	_	Seg=O
27	critical	_	_	_	_	_	_	_	Seg=O
28	longitudinal	_	_	_	_	_	_	_	Seg=O
29	care	_	_	_	_	_	_	_	Seg=O
30	.	_	_	_	_	_	_	_	Seg=O
31	Out	_	_	_	_	_	_	_	Seg=B-seg
32	of	_	_	_	_	_	_	_	Seg=O
33	necessity	_	_	_	_	_	_	_	Seg=O
34	,	_	_	_	_	_	_	_	Seg=O
35	most	_	_	_	_	_	_	_	Seg=O
36	practices	_	_	_	_	_	_	_	Seg=O
37	have	_	_	_	_	_	_	_	Seg=O
38	been	_	_	_	_	_	_	_	Seg=O
39	encouraged	_	_	_	_	_	_	_	Seg=O
40	to	_	_	_	_	_	_	_	Seg=O
41	use	_	_	_	_	_	_	_	Seg=O
42	telemedicine	_	_	_	_	_	_	_	Seg=O
43	as	_	_	_	_	_	_	_	Seg=O
44	a	_	_	_	_	_	_	_	Seg=O
45	method	_	_	_	_	_	_	_	Seg=O
46	to	_	_	_	_	_	_	_	Seg=B-seg
47	maintain	_	_	_	_	_	_	_	Seg=O
48	a	_	_	_	_	_	_	_	Seg=O
49	continuum	_	_	_	_	_	_	_	Seg=O
50	of	_	_	_	_	_	_	_	Seg=O
51	care	_	_	_	_	_	_	_	Seg=O
52	with	_	_	_	_	_	_	_	Seg=O
53	their	_	_	_	_	_	_	_	Seg=O
54	patients	_	_	_	_	_	_	_	Seg=O
55	.	_	_	_	_	_	_	_	Seg=O
56	As	_	_	_	_	_	_	_	Seg=B-seg
57	a	_	_	_	_	_	_	_	Seg=O
58	result	_	_	_	_	_	_	_	Seg=O
59	,	_	_	_	_	_	_	_	Seg=O
60	the	_	_	_	_	_	_	_	Seg=O
61	prevalence	_	_	_	_	_	_	_	Seg=O
62	of	_	_	_	_	_	_	_	Seg=O
63	telemedicine	_	_	_	_	_	_	_	Seg=O
64	has	_	_	_	_	_	_	_	Seg=O
65	grown	_	_	_	_	_	_	_	Seg=O
66	rapidly	_	_	_	_	_	_	_	Seg=O
67	during	_	_	_	_	_	_	_	Seg=O
68	this	_	_	_	_	_	_	_	Seg=O
69	pandemic	_	_	_	_	_	_	_	Seg=O
70	,	_	_	_	_	_	_	_	Seg=O
71	without	_	_	_	_	_	_	_	Seg=B-seg
72	allowing	_	_	_	_	_	_	_	Seg=O
73	the	_	_	_	_	_	_	_	Seg=O
74	physicians	_	_	_	_	_	_	_	Seg=O
75	and	_	_	_	_	_	_	_	Seg=O
76	patients	_	_	_	_	_	_	_	Seg=O
77	to	_	_	_	_	_	_	_	Seg=O
78	be	_	_	_	_	_	_	_	Seg=O
79	adequately	_	_	_	_	_	_	_	Seg=O
80	educated	_	_	_	_	_	_	_	Seg=O
81	on	_	_	_	_	_	_	_	Seg=O
82	how	_	_	_	_	_	_	_	Seg=O
83	best	_	_	_	_	_	_	_	Seg=O
84	to	_	_	_	_	_	_	_	Seg=O
85	utilize	_	_	_	_	_	_	_	Seg=O
86	the	_	_	_	_	_	_	_	Seg=O
87	services	_	_	_	_	_	_	_	Seg=O
88	.	_	_	_	_	_	_	_	Seg=O
89	There	_	_	_	_	_	_	_	Seg=B-seg
90	is	_	_	_	_	_	_	_	Seg=O
91	a	_	_	_	_	_	_	_	Seg=O
92	steep	_	_	_	_	_	_	_	Seg=O
93	learning	_	_	_	_	_	_	_	Seg=O
94	curve	_	_	_	_	_	_	_	Seg=O
95	as	_	_	_	_	_	_	_	Seg=O
96	we	_	_	_	_	_	_	_	Seg=O
97	have	_	_	_	_	_	_	_	Seg=O
98	learned	_	_	_	_	_	_	_	Seg=O
99	,	_	_	_	_	_	_	_	Seg=O
100	and	_	_	_	_	_	_	_	Seg=B-seg
101	our	_	_	_	_	_	_	_	Seg=O
102	goal	_	_	_	_	_	_	_	Seg=O
103	is	_	_	_	_	_	_	_	Seg=O
104	to	_	_	_	_	_	_	_	Seg=O
105	provide	_	_	_	_	_	_	_	Seg=O
106	guidelines	_	_	_	_	_	_	_	Seg=O
107	for	_	_	_	_	_	_	_	Seg=O
108	both	_	_	_	_	_	_	_	Seg=O
109	patients	_	_	_	_	_	_	_	Seg=O
110	and	_	_	_	_	_	_	_	Seg=O
111	physicians	_	_	_	_	_	_	_	Seg=O
112	,	_	_	_	_	_	_	_	Seg=O
113	as	_	_	_	_	_	_	_	Seg=O
114	well	_	_	_	_	_	_	_	Seg=O
115	as	_	_	_	_	_	_	_	Seg=O
116	a	_	_	_	_	_	_	_	Seg=O
117	valuable	_	_	_	_	_	_	_	Seg=O
118	patient	_	_	_	_	_	_	_	Seg=O
119	handout	_	_	_	_	_	_	_	Seg=O
120	in	_	_	_	_	_	_	_	Seg=O
121	preparation	_	_	_	_	_	_	_	Seg=O
122	for	_	_	_	_	_	_	_	Seg=O
123	their	_	_	_	_	_	_	_	Seg=O
124	visit	_	_	_	_	_	_	_	Seg=O
125	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 3dc5bf516803b9db568e51276d44ce5f1562d098
1	The	_	_	_	_	_	_	_	Seg=B-seg
2	current	_	_	_	_	_	_	_	Seg=O
3	explosive	_	_	_	_	_	_	_	Seg=O
4	outbreak	_	_	_	_	_	_	_	Seg=O
5	of	_	_	_	_	_	_	_	Seg=O
6	coronavirus	_	_	_	_	_	_	_	Seg=O
7	is	_	_	_	_	_	_	_	Seg=O
8	posing	_	_	_	_	_	_	_	Seg=O
9	serious	_	_	_	_	_	_	_	Seg=O
10	threats	_	_	_	_	_	_	_	Seg=O
11	to	_	_	_	_	_	_	_	Seg=O
12	public	_	_	_	_	_	_	_	Seg=O
13	health	_	_	_	_	_	_	_	Seg=O
14	and	_	_	_	_	_	_	_	Seg=O
15	economy	_	_	_	_	_	_	_	Seg=O
16	around	_	_	_	_	_	_	_	Seg=O
17	the	_	_	_	_	_	_	_	Seg=O
18	world	_	_	_	_	_	_	_	Seg=O
19	.	_	_	_	_	_	_	_	Seg=O
20	To	_	_	_	_	_	_	_	Seg=B-seg
21	clarify	_	_	_	_	_	_	_	Seg=O
22	the	_	_	_	_	_	_	_	Seg=O
23	coupling	_	_	_	_	_	_	_	Seg=O
24	mechanism	_	_	_	_	_	_	_	Seg=O
25	between	_	_	_	_	_	_	_	Seg=O
26	this	_	_	_	_	_	_	_	Seg=O
27	disease	_	_	_	_	_	_	_	Seg=O
28	and	_	_	_	_	_	_	_	Seg=O
29	economy	_	_	_	_	_	_	_	Seg=O
30	,	_	_	_	_	_	_	_	Seg=O
31	a	_	_	_	_	_	_	_	Seg=B-seg
32	new	_	_	_	_	_	_	_	Seg=O
33	dynamical	_	_	_	_	_	_	_	Seg=O
34	system	_	_	_	_	_	_	_	Seg=O
35	is	_	_	_	_	_	_	_	Seg=O
36	established	_	_	_	_	_	_	_	Seg=O
37	.	_	_	_	_	_	_	_	Seg=O
38	It	_	_	_	_	_	_	_	Seg=B-seg
39	is	_	_	_	_	_	_	_	Seg=O
40	theoretically	_	_	_	_	_	_	_	Seg=O
41	proved	_	_	_	_	_	_	_	Seg=O
42	that	_	_	_	_	_	_	_	Seg=O
43	the	_	_	_	_	_	_	_	Seg=O
44	basic	_	_	_	_	_	_	_	Seg=O
45	reproduction	_	_	_	_	_	_	_	Seg=O
46	number	_	_	_	_	_	_	_	Seg=O
47	is	_	_	_	_	_	_	_	Seg=O
48	a	_	_	_	_	_	_	_	Seg=O
49	nonlinear	_	_	_	_	_	_	_	Seg=O
50	combination	_	_	_	_	_	_	_	Seg=O
51	of	_	_	_	_	_	_	_	Seg=O
52	parameters	_	_	_	_	_	_	_	Seg=O
53	regarding	_	_	_	_	_	_	_	Seg=B-seg
54	disease	_	_	_	_	_	_	_	Seg=O
55	transmission	_	_	_	_	_	_	_	Seg=O
56	,	_	_	_	_	_	_	_	Seg=O
57	intervention	_	_	_	_	_	_	_	Seg=O
58	and	_	_	_	_	_	_	_	Seg=O
59	economy	_	_	_	_	_	_	_	Seg=O
60	effect	_	_	_	_	_	_	_	Seg=O
61	,	_	_	_	_	_	_	_	Seg=O
62	which	_	_	_	_	_	_	_	Seg=B-seg
63	totally	_	_	_	_	_	_	_	Seg=O
64	determines	_	_	_	_	_	_	_	Seg=O
65	the	_	_	_	_	_	_	_	Seg=O
66	stability	_	_	_	_	_	_	_	Seg=O
67	of	_	_	_	_	_	_	_	Seg=O
68	the	_	_	_	_	_	_	_	Seg=O
69	disease	_	_	_	_	_	_	_	Seg=O
70	-	_	_	_	_	_	_	_	Seg=O
71	free	_	_	_	_	_	_	_	Seg=O
72	and	_	_	_	_	_	_	_	Seg=O
73	endemic	_	_	_	_	_	_	_	Seg=O
74	equilibria	_	_	_	_	_	_	_	Seg=O
75	.	_	_	_	_	_	_	_	Seg=O
76	Further	_	_	_	_	_	_	_	Seg=B-seg
77	results	_	_	_	_	_	_	_	Seg=O
78	indicate	_	_	_	_	_	_	_	Seg=O
79	the	_	_	_	_	_	_	_	Seg=O
80	existence	_	_	_	_	_	_	_	Seg=O
81	of	_	_	_	_	_	_	_	Seg=O
82	interaction	_	_	_	_	_	_	_	Seg=O
83	and	_	_	_	_	_	_	_	Seg=O
84	mutual	_	_	_	_	_	_	_	Seg=O
85	restraint	_	_	_	_	_	_	_	Seg=O
86	among	_	_	_	_	_	_	_	Seg=O
87	the	_	_	_	_	_	_	_	Seg=O
88	transmission	_	_	_	_	_	_	_	Seg=O
89	,	_	_	_	_	_	_	_	Seg=O
90	intervention	_	_	_	_	_	_	_	Seg=O
91	and	_	_	_	_	_	_	_	Seg=O
92	economy	_	_	_	_	_	_	_	Seg=O
93	,	_	_	_	_	_	_	_	Seg=O
94	in	_	_	_	_	_	_	_	Seg=B-seg
95	which	_	_	_	_	_	_	_	Seg=O
96	strong	_	_	_	_	_	_	_	Seg=O
97	coupling	_	_	_	_	_	_	_	Seg=O
98	of	_	_	_	_	_	_	_	Seg=O
99	COVID-19	_	_	_	_	_	_	_	Seg=O
100	and	_	_	_	_	_	_	_	Seg=O
101	economy	_	_	_	_	_	_	_	Seg=O
102	would	_	_	_	_	_	_	_	Seg=O
103	trigger	_	_	_	_	_	_	_	Seg=O
104	disease	_	_	_	_	_	_	_	Seg=O
105	outbreak	_	_	_	_	_	_	_	Seg=O
106	and	_	_	_	_	_	_	_	Seg=B-seg
107	form	_	_	_	_	_	_	_	Seg=O
108	poverty	_	_	_	_	_	_	_	Seg=O
109	trap	_	_	_	_	_	_	_	Seg=O
110	,	_	_	_	_	_	_	_	Seg=O
111	while	_	_	_	_	_	_	_	Seg=B-seg
112	adaptive	_	_	_	_	_	_	_	Seg=O
113	isolation	_	_	_	_	_	_	_	Seg=O
114	of	_	_	_	_	_	_	_	Seg=O
115	at	_	_	_	_	_	_	_	Seg=O
116	-	_	_	_	_	_	_	_	Seg=O
117	risk	_	_	_	_	_	_	_	Seg=O
118	population	_	_	_	_	_	_	_	Seg=O
119	could	_	_	_	_	_	_	_	Seg=O
120	effectively	_	_	_	_	_	_	_	Seg=O
121	reduce	_	_	_	_	_	_	_	Seg=O
122	morbidity	_	_	_	_	_	_	_	Seg=O
123	at	_	_	_	_	_	_	_	Seg=O
124	the	_	_	_	_	_	_	_	Seg=O
125	cost	_	_	_	_	_	_	_	Seg=O
126	of	_	_	_	_	_	_	_	Seg=O
127	least	_	_	_	_	_	_	_	Seg=O
128	economic	_	_	_	_	_	_	_	Seg=O
129	loss	_	_	_	_	_	_	_	Seg=O
130	.	_	_	_	_	_	_	_	Seg=O
131	Our	_	_	_	_	_	_	_	Seg=B-seg
132	findings	_	_	_	_	_	_	_	Seg=O
133	can	_	_	_	_	_	_	_	Seg=O
134	offer	_	_	_	_	_	_	_	Seg=O
135	new	_	_	_	_	_	_	_	Seg=O
136	insights	_	_	_	_	_	_	_	Seg=O
137	to	_	_	_	_	_	_	_	Seg=B-seg
138	improve	_	_	_	_	_	_	_	Seg=O
139	the	_	_	_	_	_	_	_	Seg=O
140	intervention	_	_	_	_	_	_	_	Seg=O
141	strategies	_	_	_	_	_	_	_	Seg=O
142	against	_	_	_	_	_	_	_	Seg=O
143	COVID-19	_	_	_	_	_	_	_	Seg=O
144	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 3efed917d1be127696f7c6c8194b9ce2ed9cec6a
1	This	_	_	_	_	_	_	_	Seg=B-seg
2	article	_	_	_	_	_	_	_	Seg=O
3	examines	_	_	_	_	_	_	_	Seg=O
4	the	_	_	_	_	_	_	_	Seg=O
5	political	_	_	_	_	_	_	_	Seg=O
6	and	_	_	_	_	_	_	_	Seg=O
7	criminological	_	_	_	_	_	_	_	Seg=O
8	history	_	_	_	_	_	_	_	Seg=O
9	of	_	_	_	_	_	_	_	Seg=O
10	anti	_	_	_	_	_	_	_	Seg=O
11	-	_	_	_	_	_	_	_	Seg=O
12	money	_	_	_	_	_	_	_	Seg=O
13	controls	_	_	_	_	_	_	_	Seg=O
14	,	_	_	_	_	_	_	_	Seg=O
15	including	_	_	_	_	_	_	_	Seg=B-seg
16	the	_	_	_	_	_	_	_	Seg=O
17	involvement	_	_	_	_	_	_	_	Seg=O
18	of	_	_	_	_	_	_	_	Seg=O
19	Asian	_	_	_	_	_	_	_	Seg=O
20	countries	_	_	_	_	_	_	_	Seg=O
21	and	_	_	_	_	_	_	_	Seg=O
22	the	_	_	_	_	_	_	_	Seg=O
23	varied	_	_	_	_	_	_	_	Seg=O
24	motivations	_	_	_	_	_	_	_	Seg=O
25	and	_	_	_	_	_	_	_	Seg=O
26	interests	_	_	_	_	_	_	_	Seg=O
27	engaged	_	_	_	_	_	_	_	Seg=O
28	.	_	_	_	_	_	_	_	Seg=O
29	It	_	_	_	_	_	_	_	Seg=B-seg
30	goes	_	_	_	_	_	_	_	Seg=O
31	on	_	_	_	_	_	_	_	Seg=O
32	to	_	_	_	_	_	_	_	Seg=O
33	review	_	_	_	_	_	_	_	Seg=O
34	where	_	_	_	_	_	_	_	Seg=O
35	empirical	_	_	_	_	_	_	_	Seg=O
36	evidence	_	_	_	_	_	_	_	Seg=O
37	has	_	_	_	_	_	_	_	Seg=O
38	been	_	_	_	_	_	_	_	Seg=O
39	used	_	_	_	_	_	_	_	Seg=O
40	and	_	_	_	_	_	_	_	Seg=O
41	can	_	_	_	_	_	_	_	Seg=O
42	be	_	_	_	_	_	_	_	Seg=O
43	used	_	_	_	_	_	_	_	Seg=O
44	in	_	_	_	_	_	_	_	Seg=B-seg
45	fighting	_	_	_	_	_	_	_	Seg=O
46	the	_	_	_	_	_	_	_	Seg=O
47	financial	_	_	_	_	_	_	_	Seg=O
48	components	_	_	_	_	_	_	_	Seg=O
49	of	_	_	_	_	_	_	_	Seg=B-seg
50	underlying	_	_	_	_	_	_	_	Seg=O
51	crimes	_	_	_	_	_	_	_	Seg=O
52	,	_	_	_	_	_	_	_	Seg=O
53	examining	_	_	_	_	_	_	_	Seg=B-seg
54	the	_	_	_	_	_	_	_	Seg=O
55	denotation	_	_	_	_	_	_	_	Seg=O
56	of	_	_	_	_	_	_	_	Seg=O
57	the	_	_	_	_	_	_	_	Seg=O
58	problem(s	_	_	_	_	_	_	_	Seg=O
59	)	_	_	_	_	_	_	_	Seg=O
60	we	_	_	_	_	_	_	_	Seg=B-seg
61	are	_	_	_	_	_	_	_	Seg=O
62	supposed	_	_	_	_	_	_	_	Seg=O
63	to	_	_	_	_	_	_	_	Seg=O
64	be	_	_	_	_	_	_	_	Seg=O
65	fighting	_	_	_	_	_	_	_	Seg=O
66	-	_	_	_	_	_	_	_	Seg=B-seg
67	money	_	_	_	_	_	_	_	Seg=O
68	laundering	_	_	_	_	_	_	_	Seg=O
69	as	_	_	_	_	_	_	_	Seg=O
70	an	_	_	_	_	_	_	_	Seg=O
71	evil	_	_	_	_	_	_	_	Seg=O
72	in	_	_	_	_	_	_	_	Seg=O
73	itself	_	_	_	_	_	_	_	Seg=O
74	and/or	_	_	_	_	_	_	_	Seg=O
75	the	_	_	_	_	_	_	_	Seg=O
76	underlying	_	_	_	_	_	_	_	Seg=O
77	crimes	_	_	_	_	_	_	_	Seg=O
78	which	_	_	_	_	_	_	_	Seg=B-seg
79	give	_	_	_	_	_	_	_	Seg=O
80	rise	_	_	_	_	_	_	_	Seg=O
81	to	_	_	_	_	_	_	_	Seg=O
82	it	_	_	_	_	_	_	_	Seg=O
83	;	_	_	_	_	_	_	_	Seg=O
84	estimates	_	_	_	_	_	_	_	Seg=B-seg
85	of	_	_	_	_	_	_	_	Seg=O
86	the	_	_	_	_	_	_	_	Seg=O
87	size	_	_	_	_	_	_	_	Seg=O
88	and	_	_	_	_	_	_	_	Seg=O
89	harmfulness	_	_	_	_	_	_	_	Seg=O
90	of	_	_	_	_	_	_	_	Seg=O
91	the	_	_	_	_	_	_	_	Seg=O
92	problems	_	_	_	_	_	_	_	Seg=O
93	and	_	_	_	_	_	_	_	Seg=B-seg
94	identifies	_	_	_	_	_	_	_	Seg=O
95	any	_	_	_	_	_	_	_	Seg=O
96	improvements	_	_	_	_	_	_	_	Seg=O
97	/	_	_	_	_	_	_	_	Seg=O
98	emerging	_	_	_	_	_	_	_	Seg=O
99	problems	_	_	_	_	_	_	_	Seg=O
100	in	_	_	_	_	_	_	_	Seg=O
101	the	_	_	_	_	_	_	_	Seg=O
102	assessment	_	_	_	_	_	_	_	Seg=O
103	of	_	_	_	_	_	_	_	Seg=O
104	money	_	_	_	_	_	_	_	Seg=O
105	laundering	_	_	_	_	_	_	_	Seg=O
106	.	_	_	_	_	_	_	_	Seg=O
107	It	_	_	_	_	_	_	_	Seg=B-seg
108	concludes	_	_	_	_	_	_	_	Seg=O
109	with	_	_	_	_	_	_	_	Seg=O
110	some	_	_	_	_	_	_	_	Seg=O
111	reflections	_	_	_	_	_	_	_	Seg=O
112	on	_	_	_	_	_	_	_	Seg=O
113	assessing	_	_	_	_	_	_	_	Seg=O
114	policy	_	_	_	_	_	_	_	Seg=O
115	effectiveness	_	_	_	_	_	_	_	Seg=O
116	and	_	_	_	_	_	_	_	Seg=O
117	the	_	_	_	_	_	_	_	Seg=O
118	need	_	_	_	_	_	_	_	Seg=O
119	for	_	_	_	_	_	_	_	Seg=O
120	greater	_	_	_	_	_	_	_	Seg=O
121	engagement	_	_	_	_	_	_	_	Seg=O
122	by	_	_	_	_	_	_	_	Seg=O
123	criminologists	_	_	_	_	_	_	_	Seg=O
124	and	_	_	_	_	_	_	_	Seg=O
125	other	_	_	_	_	_	_	_	Seg=O
126	social	_	_	_	_	_	_	_	Seg=O
127	scientists	_	_	_	_	_	_	_	Seg=O
128	in	_	_	_	_	_	_	_	Seg=O
129	this	_	_	_	_	_	_	_	Seg=O
130	process	_	_	_	_	_	_	_	Seg=O
131	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 3f8693d47aa1365387a666ecb41f5ced3ee2fc3e
1	Use	_	_	_	_	_	_	_	Seg=B-seg
2	of	_	_	_	_	_	_	_	Seg=O
3	pecan	_	_	_	_	_	_	_	Seg=O
4	shell	_	_	_	_	_	_	_	Seg=O
5	fiber	_	_	_	_	_	_	_	Seg=O
6	in	_	_	_	_	_	_	_	Seg=O
7	human	_	_	_	_	_	_	_	Seg=O
8	food	_	_	_	_	_	_	_	Seg=O
9	is	_	_	_	_	_	_	_	Seg=O
10	presently	_	_	_	_	_	_	_	Seg=O
11	limited	_	_	_	_	_	_	_	Seg=O
12	,	_	_	_	_	_	_	_	Seg=O
13	but	_	_	_	_	_	_	_	Seg=B-seg
14	could	_	_	_	_	_	_	_	Seg=O
15	increase	_	_	_	_	_	_	_	Seg=O
16	pending	_	_	_	_	_	_	_	Seg=O
17	demonstration	_	_	_	_	_	_	_	Seg=O
18	of	_	_	_	_	_	_	_	Seg=O
19	safety	_	_	_	_	_	_	_	Seg=O
20	.	_	_	_	_	_	_	_	Seg=O
21	In	_	_	_	_	_	_	_	Seg=B-seg
22	a	_	_	_	_	_	_	_	Seg=O
23	91-day	_	_	_	_	_	_	_	Seg=O
24	rat	_	_	_	_	_	_	_	Seg=O
25	study	_	_	_	_	_	_	_	Seg=O
26	,	_	_	_	_	_	_	_	Seg=O
27	pecan	_	_	_	_	_	_	_	Seg=O
28	shell	_	_	_	_	_	_	_	Seg=O
29	fiber	_	_	_	_	_	_	_	Seg=O
30	was	_	_	_	_	_	_	_	Seg=O
31	administered	_	_	_	_	_	_	_	Seg=O
32	at	_	_	_	_	_	_	_	Seg=O
33	dietary	_	_	_	_	_	_	_	Seg=O
34	concentrations	_	_	_	_	_	_	_	Seg=O
35	of	_	_	_	_	_	_	_	Seg=O
36	0	_	_	_	_	_	_	_	Seg=O
37	(	_	_	_	_	_	_	_	Seg=O
38	control	_	_	_	_	_	_	_	Seg=O
39	)	_	_	_	_	_	_	_	Seg=O
40	,	_	_	_	_	_	_	_	Seg=O
41	50	_	_	_	_	_	_	_	Seg=O
42	000	_	_	_	_	_	_	_	Seg=O
43	,	_	_	_	_	_	_	_	Seg=O
44	100	_	_	_	_	_	_	_	Seg=O
45	000	_	_	_	_	_	_	_	Seg=O
46	or	_	_	_	_	_	_	_	Seg=O
47	150	_	_	_	_	_	_	_	Seg=O
48	000	_	_	_	_	_	_	_	Seg=O
49	ppm	_	_	_	_	_	_	_	Seg=O
50	.	_	_	_	_	_	_	_	Seg=O
51	There	_	_	_	_	_	_	_	Seg=B-seg
52	was	_	_	_	_	_	_	_	Seg=O
53	no	_	_	_	_	_	_	_	Seg=O
54	effect	_	_	_	_	_	_	_	Seg=O
55	of	_	_	_	_	_	_	_	Seg=O
56	the	_	_	_	_	_	_	_	Seg=O
57	ingredient	_	_	_	_	_	_	_	Seg=O
58	on	_	_	_	_	_	_	_	Seg=O
59	body	_	_	_	_	_	_	_	Seg=O
60	weight	_	_	_	_	_	_	_	Seg=O
61	of	_	_	_	_	_	_	_	Seg=O
62	males	_	_	_	_	_	_	_	Seg=O
63	or	_	_	_	_	_	_	_	Seg=O
64	females	_	_	_	_	_	_	_	Seg=O
65	or	_	_	_	_	_	_	_	Seg=O
66	food	_	_	_	_	_	_	_	Seg=O
67	consumption	_	_	_	_	_	_	_	Seg=O
68	of	_	_	_	_	_	_	_	Seg=O
69	females	_	_	_	_	_	_	_	Seg=O
70	.	_	_	_	_	_	_	_	Seg=O
71	Statistically	_	_	_	_	_	_	_	Seg=B-seg
72	significant	_	_	_	_	_	_	_	Seg=O
73	increases	_	_	_	_	_	_	_	Seg=O
74	in	_	_	_	_	_	_	_	Seg=O
75	food	_	_	_	_	_	_	_	Seg=O
76	consumption	_	_	_	_	_	_	_	Seg=O
77	were	_	_	_	_	_	_	_	Seg=O
78	observed	_	_	_	_	_	_	_	Seg=O
79	throughout	_	_	_	_	_	_	_	Seg=O
80	the	_	_	_	_	_	_	_	Seg=O
81	study	_	_	_	_	_	_	_	Seg=O
82	in	_	_	_	_	_	_	_	Seg=O
83	100	_	_	_	_	_	_	_	Seg=O
84	000	_	_	_	_	_	_	_	Seg=O
85	and	_	_	_	_	_	_	_	Seg=O
86	150	_	_	_	_	_	_	_	Seg=O
87	000	_	_	_	_	_	_	_	Seg=O
88	ppm	_	_	_	_	_	_	_	Seg=O
89	males	_	_	_	_	_	_	_	Seg=O
90	,	_	_	_	_	_	_	_	Seg=O
91	resulting	_	_	_	_	_	_	_	Seg=B-seg
92	in	_	_	_	_	_	_	_	Seg=O
93	intermittent	_	_	_	_	_	_	_	Seg=O
94	decreases	_	_	_	_	_	_	_	Seg=O
95	in	_	_	_	_	_	_	_	Seg=O
96	food	_	_	_	_	_	_	_	Seg=O
97	efficiency	_	_	_	_	_	_	_	Seg=O
98	(	_	_	_	_	_	_	_	Seg=B-seg
99	150	_	_	_	_	_	_	_	Seg=O
100	000	_	_	_	_	_	_	_	Seg=O
101	ppm	_	_	_	_	_	_	_	Seg=O
102	males	_	_	_	_	_	_	_	Seg=O
103	only	_	_	_	_	_	_	_	Seg=O
104	)	_	_	_	_	_	_	_	Seg=O
105	that	_	_	_	_	_	_	_	Seg=B-seg
106	were	_	_	_	_	_	_	_	Seg=O
107	not	_	_	_	_	_	_	_	Seg=O
108	biologically	_	_	_	_	_	_	_	Seg=O
109	relevant	_	_	_	_	_	_	_	Seg=O
110	.	_	_	_	_	_	_	_	Seg=O
111	All	_	_	_	_	_	_	_	Seg=B-seg
112	animals	_	_	_	_	_	_	_	Seg=O
113	survived	_	_	_	_	_	_	_	Seg=O
114	and	_	_	_	_	_	_	_	Seg=B-seg
115	no	_	_	_	_	_	_	_	Seg=O
116	adverse	_	_	_	_	_	_	_	Seg=O
117	clinical	_	_	_	_	_	_	_	Seg=O
118	signs	_	_	_	_	_	_	_	Seg=O
119	or	_	_	_	_	_	_	_	Seg=O
120	functional	_	_	_	_	_	_	_	Seg=O
121	changes	_	_	_	_	_	_	_	Seg=O
122	were	_	_	_	_	_	_	_	Seg=O
123	attributable	_	_	_	_	_	_	_	Seg=O
124	to	_	_	_	_	_	_	_	Seg=O
125	the	_	_	_	_	_	_	_	Seg=O
126	test	_	_	_	_	_	_	_	Seg=O
127	material	_	_	_	_	_	_	_	Seg=O
128	.	_	_	_	_	_	_	_	Seg=O
129	There	_	_	_	_	_	_	_	Seg=B-seg
130	were	_	_	_	_	_	_	_	Seg=O
131	no	_	_	_	_	_	_	_	Seg=O
132	toxicologically	_	_	_	_	_	_	_	Seg=O
133	relevant	_	_	_	_	_	_	_	Seg=O
134	changes	_	_	_	_	_	_	_	Seg=O
135	in	_	_	_	_	_	_	_	Seg=O
136	hematology	_	_	_	_	_	_	_	Seg=O
137	,	_	_	_	_	_	_	_	Seg=O
138	clinical	_	_	_	_	_	_	_	Seg=O
139	chemistry	_	_	_	_	_	_	_	Seg=O
140	or	_	_	_	_	_	_	_	Seg=O
141	urinalysis	_	_	_	_	_	_	_	Seg=O
142	parameters	_	_	_	_	_	_	_	Seg=O
143	or	_	_	_	_	_	_	_	Seg=O
144	organ	_	_	_	_	_	_	_	Seg=O
145	weights	_	_	_	_	_	_	_	Seg=O
146	in	_	_	_	_	_	_	_	Seg=O
147	rats	_	_	_	_	_	_	_	Seg=O
148	ingesting	_	_	_	_	_	_	_	Seg=B-seg
149	pecan	_	_	_	_	_	_	_	Seg=O
150	shell	_	_	_	_	_	_	_	Seg=O
151	fiber	_	_	_	_	_	_	_	Seg=O
152	.	_	_	_	_	_	_	_	Seg=O
153	Any	_	_	_	_	_	_	_	Seg=B-seg
154	macroscopic	_	_	_	_	_	_	_	Seg=O
155	or	_	_	_	_	_	_	_	Seg=O
156	microscopic	_	_	_	_	_	_	_	Seg=O
157	findings	_	_	_	_	_	_	_	Seg=O
158	were	_	_	_	_	_	_	_	Seg=O
159	incidental	_	_	_	_	_	_	_	Seg=O
160	,	_	_	_	_	_	_	_	Seg=O
161	of	_	_	_	_	_	_	_	Seg=O
162	normal	_	_	_	_	_	_	_	Seg=O
163	variation	_	_	_	_	_	_	_	Seg=O
164	and/or	_	_	_	_	_	_	_	Seg=O
165	of	_	_	_	_	_	_	_	Seg=O
166	minimal	_	_	_	_	_	_	_	Seg=O
167	magnitude	_	_	_	_	_	_	_	Seg=O
168	for	_	_	_	_	_	_	_	Seg=O
169	test	_	_	_	_	_	_	_	Seg=O
170	substance	_	_	_	_	_	_	_	Seg=O
171	association	_	_	_	_	_	_	_	Seg=O
172	.	_	_	_	_	_	_	_	Seg=O
173	Pecan	_	_	_	_	_	_	_	Seg=B-seg
174	shell	_	_	_	_	_	_	_	Seg=O
175	fiber	_	_	_	_	_	_	_	Seg=O
176	was	_	_	_	_	_	_	_	Seg=O
177	non	_	_	_	_	_	_	_	Seg=O
178	-	_	_	_	_	_	_	_	Seg=O
179	mutagenic	_	_	_	_	_	_	_	Seg=O
180	in	_	_	_	_	_	_	_	Seg=O
181	a	_	_	_	_	_	_	_	Seg=O
182	bacterial	_	_	_	_	_	_	_	Seg=O
183	reverse	_	_	_	_	_	_	_	Seg=O
184	mutation	_	_	_	_	_	_	_	Seg=O
185	test	_	_	_	_	_	_	_	Seg=O
186	and	_	_	_	_	_	_	_	Seg=O
187	non	_	_	_	_	_	_	_	Seg=O
188	-	_	_	_	_	_	_	_	Seg=O
189	clastogenic	_	_	_	_	_	_	_	Seg=O
190	in	_	_	_	_	_	_	_	Seg=O
191	a	_	_	_	_	_	_	_	Seg=O
192	mouse	_	_	_	_	_	_	_	Seg=O
193	peripheral	_	_	_	_	_	_	_	Seg=O
194	blood	_	_	_	_	_	_	_	Seg=O
195	micronucleus	_	_	_	_	_	_	_	Seg=O
196	test	_	_	_	_	_	_	_	Seg=O
197	.	_	_	_	_	_	_	_	Seg=O
198	Based	_	_	_	_	_	_	_	Seg=B-seg
199	on	_	_	_	_	_	_	_	Seg=O
200	these	_	_	_	_	_	_	_	Seg=O
201	results	_	_	_	_	_	_	_	Seg=O
202	,	_	_	_	_	_	_	_	Seg=O
203	pecan	_	_	_	_	_	_	_	Seg=B-seg
204	shell	_	_	_	_	_	_	_	Seg=O
205	fiber	_	_	_	_	_	_	_	Seg=O
206	has	_	_	_	_	_	_	_	Seg=O
207	an	_	_	_	_	_	_	_	Seg=O
208	oral	_	_	_	_	_	_	_	Seg=O
209	subchronic	_	_	_	_	_	_	_	Seg=O
210	(	_	_	_	_	_	_	_	Seg=B-seg
211	13-week	_	_	_	_	_	_	_	Seg=O
212	)	_	_	_	_	_	_	_	Seg=O
213	no	_	_	_	_	_	_	_	Seg=B-seg
214	observable	_	_	_	_	_	_	_	Seg=O
215	adverse	_	_	_	_	_	_	_	Seg=O
216	effect	_	_	_	_	_	_	_	Seg=O
217	level	_	_	_	_	_	_	_	Seg=O
218	(	_	_	_	_	_	_	_	Seg=O
219	NOAEL	_	_	_	_	_	_	_	Seg=O
220	)	_	_	_	_	_	_	_	Seg=O
221	of	_	_	_	_	_	_	_	Seg=O
222	150	_	_	_	_	_	_	_	Seg=O
223	000	_	_	_	_	_	_	_	Seg=O
224	ppm	_	_	_	_	_	_	_	Seg=O
225	in	_	_	_	_	_	_	_	Seg=O
226	rats	_	_	_	_	_	_	_	Seg=O
227	and	_	_	_	_	_	_	_	Seg=B-seg
228	is	_	_	_	_	_	_	_	Seg=O
229	not	_	_	_	_	_	_	_	Seg=O
230	genotoxic	_	_	_	_	_	_	_	Seg=O
231	at	_	_	_	_	_	_	_	Seg=O
232	the	_	_	_	_	_	_	_	Seg=O
233	doses	_	_	_	_	_	_	_	Seg=O
234	analyzed	_	_	_	_	_	_	_	Seg=O
235	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 3fe0d4ab3e3152159123b351f7adc98186d01449
1	Coronavirus	_	_	_	_	_	_	_	Seg=B-seg
2	disease	_	_	_	_	_	_	_	Seg=O
3	2019	_	_	_	_	_	_	_	Seg=O
4	,	_	_	_	_	_	_	_	Seg=O
5	i.e.	_	_	_	_	_	_	_	Seg=O
6	COVID-19	_	_	_	_	_	_	_	Seg=O
7	has	_	_	_	_	_	_	_	Seg=O
8	imposed	_	_	_	_	_	_	_	Seg=O
9	the	_	_	_	_	_	_	_	Seg=O
10	public	_	_	_	_	_	_	_	Seg=O
11	health	_	_	_	_	_	_	_	Seg=O
12	measure	_	_	_	_	_	_	_	Seg=O
13	of	_	_	_	_	_	_	_	Seg=B-seg
14	keeping	_	_	_	_	_	_	_	Seg=O
15	social	_	_	_	_	_	_	_	Seg=O
16	distancing	_	_	_	_	_	_	_	Seg=O
17	for	_	_	_	_	_	_	_	Seg=B-seg
18	preventing	_	_	_	_	_	_	_	Seg=O
19	mass	_	_	_	_	_	_	_	Seg=O
20	transmission	_	_	_	_	_	_	_	Seg=O
21	of	_	_	_	_	_	_	_	Seg=O
22	COVID-19	_	_	_	_	_	_	_	Seg=O
23	.	_	_	_	_	_	_	_	Seg=O
24	For	_	_	_	_	_	_	_	Seg=B-seg
25	monitoring	_	_	_	_	_	_	_	Seg=O
26	the	_	_	_	_	_	_	_	Seg=O
27	social	_	_	_	_	_	_	_	Seg=O
28	distancing	_	_	_	_	_	_	_	Seg=O
29	and	_	_	_	_	_	_	_	Seg=B-seg
30	keeping	_	_	_	_	_	_	_	Seg=O
31	the	_	_	_	_	_	_	_	Seg=O
32	trace	_	_	_	_	_	_	_	Seg=O
33	of	_	_	_	_	_	_	_	Seg=O
34	transmission	_	_	_	_	_	_	_	Seg=O
35	,	_	_	_	_	_	_	_	Seg=O
36	we	_	_	_	_	_	_	_	Seg=B-seg
37	are	_	_	_	_	_	_	_	Seg=O
38	obligated	_	_	_	_	_	_	_	Seg=O
39	to	_	_	_	_	_	_	_	Seg=O
40	develop	_	_	_	_	_	_	_	Seg=O
41	various	_	_	_	_	_	_	_	Seg=O
42	types	_	_	_	_	_	_	_	Seg=O
43	of	_	_	_	_	_	_	_	Seg=O
44	digital	_	_	_	_	_	_	_	Seg=O
45	surveillance	_	_	_	_	_	_	_	Seg=O
46	systems	_	_	_	_	_	_	_	Seg=O
47	,	_	_	_	_	_	_	_	Seg=O
48	which	_	_	_	_	_	_	_	Seg=B-seg
49	include	_	_	_	_	_	_	_	Seg=O
50	contact	_	_	_	_	_	_	_	Seg=O
51	tracing	_	_	_	_	_	_	_	Seg=O
52	systems	_	_	_	_	_	_	_	Seg=O
53	and	_	_	_	_	_	_	_	Seg=O
54	drone	_	_	_	_	_	_	_	Seg=O
55	-	_	_	_	_	_	_	_	Seg=O
56	based	_	_	_	_	_	_	_	Seg=O
57	monitoring	_	_	_	_	_	_	_	Seg=O
58	systems	_	_	_	_	_	_	_	Seg=O
59	.	_	_	_	_	_	_	_	Seg=O
60	Due	_	_	_	_	_	_	_	Seg=B-seg
61	to	_	_	_	_	_	_	_	Seg=O
62	the	_	_	_	_	_	_	_	Seg=O
63	inconvenience	_	_	_	_	_	_	_	Seg=O
64	of	_	_	_	_	_	_	_	Seg=O
65	manual	_	_	_	_	_	_	_	Seg=O
66	labor	_	_	_	_	_	_	_	Seg=O
67	,	_	_	_	_	_	_	_	Seg=O
68	traditional	_	_	_	_	_	_	_	Seg=B-seg
69	contact	_	_	_	_	_	_	_	Seg=O
70	tracing	_	_	_	_	_	_	_	Seg=O
71	systems	_	_	_	_	_	_	_	Seg=O
72	are	_	_	_	_	_	_	_	Seg=O
73	gradually	_	_	_	_	_	_	_	Seg=O
74	replaced	_	_	_	_	_	_	_	Seg=O
75	by	_	_	_	_	_	_	_	Seg=O
76	the	_	_	_	_	_	_	_	Seg=O
77	efficient	_	_	_	_	_	_	_	Seg=O
78	automated	_	_	_	_	_	_	_	Seg=O
79	contact	_	_	_	_	_	_	_	Seg=O
80	tracing	_	_	_	_	_	_	_	Seg=O
81	applications	_	_	_	_	_	_	_	Seg=O
82	that	_	_	_	_	_	_	_	Seg=B-seg
83	are	_	_	_	_	_	_	_	Seg=O
84	developed	_	_	_	_	_	_	_	Seg=O
85	for	_	_	_	_	_	_	_	Seg=O
86	smartphones	_	_	_	_	_	_	_	Seg=O
87	.	_	_	_	_	_	_	_	Seg=O
88	However	_	_	_	_	_	_	_	Seg=B-seg
89	,	_	_	_	_	_	_	_	Seg=O
90	the	_	_	_	_	_	_	_	Seg=O
91	commencement	_	_	_	_	_	_	_	Seg=O
92	of	_	_	_	_	_	_	_	Seg=O
93	automated	_	_	_	_	_	_	_	Seg=O
94	contact	_	_	_	_	_	_	_	Seg=O
95	tracing	_	_	_	_	_	_	_	Seg=O
96	applications	_	_	_	_	_	_	_	Seg=O
97	introduces	_	_	_	_	_	_	_	Seg=O
98	the	_	_	_	_	_	_	_	Seg=O
99	inevitable	_	_	_	_	_	_	_	Seg=O
100	privacy	_	_	_	_	_	_	_	Seg=O
101	and	_	_	_	_	_	_	_	Seg=O
102	security	_	_	_	_	_	_	_	Seg=O
103	challenges	_	_	_	_	_	_	_	Seg=O
104	.	_	_	_	_	_	_	_	Seg=O
105	Nevertheless	_	_	_	_	_	_	_	Seg=B-seg
106	,	_	_	_	_	_	_	_	Seg=O
107	unawareness	_	_	_	_	_	_	_	Seg=O
108	and/or	_	_	_	_	_	_	_	Seg=O
109	lack	_	_	_	_	_	_	_	Seg=O
110	of	_	_	_	_	_	_	_	Seg=O
111	smartphone	_	_	_	_	_	_	_	Seg=O
112	usage	_	_	_	_	_	_	_	Seg=O
113	among	_	_	_	_	_	_	_	Seg=O
114	mass	_	_	_	_	_	_	_	Seg=O
115	people	_	_	_	_	_	_	_	Seg=O
116	lead	_	_	_	_	_	_	_	Seg=O
117	to	_	_	_	_	_	_	_	Seg=O
118	drone	_	_	_	_	_	_	_	Seg=O
119	-	_	_	_	_	_	_	_	Seg=O
120	based	_	_	_	_	_	_	_	Seg=O
121	monitoring	_	_	_	_	_	_	_	Seg=O
122	systems	_	_	_	_	_	_	_	Seg=O
123	.	_	_	_	_	_	_	_	Seg=O
124	These	_	_	_	_	_	_	_	Seg=B-seg
125	systems	_	_	_	_	_	_	_	Seg=O
126	also	_	_	_	_	_	_	_	Seg=O
127	invite	_	_	_	_	_	_	_	Seg=O
128	unwelcomed	_	_	_	_	_	_	_	Seg=O
129	privacy	_	_	_	_	_	_	_	Seg=O
130	and	_	_	_	_	_	_	_	Seg=O
131	security	_	_	_	_	_	_	_	Seg=O
132	challenges	_	_	_	_	_	_	_	Seg=O
133	.	_	_	_	_	_	_	_	Seg=O
134	This	_	_	_	_	_	_	_	Seg=B-seg
135	paper	_	_	_	_	_	_	_	Seg=O
136	discusses	_	_	_	_	_	_	_	Seg=O
137	the	_	_	_	_	_	_	_	Seg=O
138	recently	_	_	_	_	_	_	_	Seg=O
139	designed	_	_	_	_	_	_	_	Seg=O
140	and	_	_	_	_	_	_	_	Seg=O
141	developed	_	_	_	_	_	_	_	Seg=O
142	digital	_	_	_	_	_	_	_	Seg=O
143	surveillance	_	_	_	_	_	_	_	Seg=O
144	system	_	_	_	_	_	_	_	Seg=O
145	applications	_	_	_	_	_	_	_	Seg=O
146	with	_	_	_	_	_	_	_	Seg=O
147	their	_	_	_	_	_	_	_	Seg=O
148	protocols	_	_	_	_	_	_	_	Seg=O
149	deployed	_	_	_	_	_	_	_	Seg=B-seg
150	in	_	_	_	_	_	_	_	Seg=O
151	several	_	_	_	_	_	_	_	Seg=O
152	countries	_	_	_	_	_	_	_	Seg=O
153	around	_	_	_	_	_	_	_	Seg=O
154	the	_	_	_	_	_	_	_	Seg=O
155	world	_	_	_	_	_	_	_	Seg=O
156	.	_	_	_	_	_	_	_	Seg=O
157	Their	_	_	_	_	_	_	_	Seg=B-seg
158	privacy	_	_	_	_	_	_	_	Seg=O
159	and	_	_	_	_	_	_	_	Seg=O
160	security	_	_	_	_	_	_	_	Seg=O
161	challenges	_	_	_	_	_	_	_	Seg=O
162	are	_	_	_	_	_	_	_	Seg=O
163	discussed	_	_	_	_	_	_	_	Seg=O
164	as	_	_	_	_	_	_	_	Seg=O
165	well	_	_	_	_	_	_	_	Seg=O
166	as	_	_	_	_	_	_	_	Seg=O
167	analyzed	_	_	_	_	_	_	_	Seg=O
168	from	_	_	_	_	_	_	_	Seg=O
169	the	_	_	_	_	_	_	_	Seg=O
170	viewpoint	_	_	_	_	_	_	_	Seg=O
171	of	_	_	_	_	_	_	_	Seg=O
172	privacy	_	_	_	_	_	_	_	Seg=O
173	acts	_	_	_	_	_	_	_	Seg=O
174	.	_	_	_	_	_	_	_	Seg=O
175	Several	_	_	_	_	_	_	_	Seg=B-seg
176	recommendations	_	_	_	_	_	_	_	Seg=O
177	are	_	_	_	_	_	_	_	Seg=O
178	suggested	_	_	_	_	_	_	_	Seg=O
179	separately	_	_	_	_	_	_	_	Seg=O
180	for	_	_	_	_	_	_	_	Seg=O
181	automated	_	_	_	_	_	_	_	Seg=O
182	contact	_	_	_	_	_	_	_	Seg=O
183	tracing	_	_	_	_	_	_	_	Seg=O
184	systems	_	_	_	_	_	_	_	Seg=O
185	and	_	_	_	_	_	_	_	Seg=O
186	drone	_	_	_	_	_	_	_	Seg=O
187	-	_	_	_	_	_	_	_	Seg=O
188	based	_	_	_	_	_	_	_	Seg=O
189	monitoring	_	_	_	_	_	_	_	Seg=O
190	systems	_	_	_	_	_	_	_	Seg=O
191	,	_	_	_	_	_	_	_	Seg=O
192	which	_	_	_	_	_	_	_	Seg=B-seg
193	could	_	_	_	_	_	_	_	Seg=O
194	further	_	_	_	_	_	_	_	Seg=O
195	be	_	_	_	_	_	_	_	Seg=O
196	explored	_	_	_	_	_	_	_	Seg=O
197	and	_	_	_	_	_	_	_	Seg=O
198	implemented	_	_	_	_	_	_	_	Seg=O
199	afterwards	_	_	_	_	_	_	_	Seg=O
200	to	_	_	_	_	_	_	_	Seg=B-seg
201	prevent	_	_	_	_	_	_	_	Seg=O
202	any	_	_	_	_	_	_	_	Seg=O
203	possible	_	_	_	_	_	_	_	Seg=O
204	privacy	_	_	_	_	_	_	_	Seg=O
205	violation	_	_	_	_	_	_	_	Seg=O
206	and	_	_	_	_	_	_	_	Seg=B-seg
207	protect	_	_	_	_	_	_	_	Seg=O
208	an	_	_	_	_	_	_	_	Seg=O
209	unsuspecting	_	_	_	_	_	_	_	Seg=O
210	person	_	_	_	_	_	_	_	Seg=O
211	from	_	_	_	_	_	_	_	Seg=O
212	any	_	_	_	_	_	_	_	Seg=O
213	potential	_	_	_	_	_	_	_	Seg=O
214	cyber	_	_	_	_	_	_	_	Seg=O
215	attack	_	_	_	_	_	_	_	Seg=O
216	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 4033e2eca1d60dd76eb5d894dad074202cb21d96
1	The	_	_	_	_	_	_	_	Seg=B-seg
2	standard	_	_	_	_	_	_	_	Seg=O
3	of	_	_	_	_	_	_	_	Seg=O
4	reference	_	_	_	_	_	_	_	Seg=O
5	for	_	_	_	_	_	_	_	Seg=B-seg
6	confirming	_	_	_	_	_	_	_	Seg=O
7	COVID-19	_	_	_	_	_	_	_	Seg=O
8	relies	_	_	_	_	_	_	_	Seg=B-seg
9	on	_	_	_	_	_	_	_	Seg=O
10	microbiological	_	_	_	_	_	_	_	Seg=O
11	tests	_	_	_	_	_	_	_	Seg=O
12	such	_	_	_	_	_	_	_	Seg=B-seg
13	as	_	_	_	_	_	_	_	Seg=O
14	real	_	_	_	_	_	_	_	Seg=O
15	-	_	_	_	_	_	_	_	Seg=O
16	time	_	_	_	_	_	_	_	Seg=O
17	polymerase	_	_	_	_	_	_	_	Seg=O
18	chain	_	_	_	_	_	_	_	Seg=O
19	reaction	_	_	_	_	_	_	_	Seg=O
20	(	_	_	_	_	_	_	_	Seg=O
21	RT	_	_	_	_	_	_	_	Seg=O
22	-	_	_	_	_	_	_	_	Seg=O
23	PCR	_	_	_	_	_	_	_	Seg=O
24	)	_	_	_	_	_	_	_	Seg=O
25	or	_	_	_	_	_	_	_	Seg=O
26	sequencing	_	_	_	_	_	_	_	Seg=O
27	.	_	_	_	_	_	_	_	Seg=O
28	However	_	_	_	_	_	_	_	Seg=B-seg
29	,	_	_	_	_	_	_	_	Seg=O
30	these	_	_	_	_	_	_	_	Seg=O
31	tests	_	_	_	_	_	_	_	Seg=O
32	might	_	_	_	_	_	_	_	Seg=O
33	not	_	_	_	_	_	_	_	Seg=O
34	be	_	_	_	_	_	_	_	Seg=O
35	available	_	_	_	_	_	_	_	Seg=O
36	in	_	_	_	_	_	_	_	Seg=O
37	an	_	_	_	_	_	_	_	Seg=O
38	emergency	_	_	_	_	_	_	_	Seg=O
39	setting	_	_	_	_	_	_	_	Seg=O
40	.	_	_	_	_	_	_	_	Seg=O
41	Computed	_	_	_	_	_	_	_	Seg=B-seg
42	tomography	_	_	_	_	_	_	_	Seg=O
43	(	_	_	_	_	_	_	_	Seg=O
44	CT	_	_	_	_	_	_	_	Seg=O
45	)	_	_	_	_	_	_	_	Seg=O
46	can	_	_	_	_	_	_	_	Seg=O
47	be	_	_	_	_	_	_	_	Seg=O
48	used	_	_	_	_	_	_	_	Seg=O
49	as	_	_	_	_	_	_	_	Seg=O
50	an	_	_	_	_	_	_	_	Seg=O
51	important	_	_	_	_	_	_	_	Seg=O
52	complement	_	_	_	_	_	_	_	Seg=O
53	for	_	_	_	_	_	_	_	Seg=O
54	the	_	_	_	_	_	_	_	Seg=O
55	diagnosis	_	_	_	_	_	_	_	Seg=O
56	of	_	_	_	_	_	_	_	Seg=O
57	COVID-19	_	_	_	_	_	_	_	Seg=O
58	pneumonia	_	_	_	_	_	_	_	Seg=O
59	in	_	_	_	_	_	_	_	Seg=O
60	the	_	_	_	_	_	_	_	Seg=O
61	current	_	_	_	_	_	_	_	Seg=O
62	epidemic	_	_	_	_	_	_	_	Seg=O
63	context	_	_	_	_	_	_	_	Seg=O
64	.	_	_	_	_	_	_	_	Seg=O
65	In	_	_	_	_	_	_	_	Seg=B-seg
66	this	_	_	_	_	_	_	_	Seg=O
67	review	_	_	_	_	_	_	_	Seg=O
68	,	_	_	_	_	_	_	_	Seg=O
69	we	_	_	_	_	_	_	_	Seg=O
70	present	_	_	_	_	_	_	_	Seg=O
71	the	_	_	_	_	_	_	_	Seg=O
72	typical	_	_	_	_	_	_	_	Seg=O
73	CT	_	_	_	_	_	_	_	Seg=O
74	features	_	_	_	_	_	_	_	Seg=O
75	of	_	_	_	_	_	_	_	Seg=O
76	COVID-19	_	_	_	_	_	_	_	Seg=O
77	pneumonia	_	_	_	_	_	_	_	Seg=O
78	and	_	_	_	_	_	_	_	Seg=B-seg
79	discuss	_	_	_	_	_	_	_	Seg=O
80	the	_	_	_	_	_	_	_	Seg=O
81	main	_	_	_	_	_	_	_	Seg=O
82	differential	_	_	_	_	_	_	_	Seg=O
83	diagnosis	_	_	_	_	_	_	_	Seg=O
84	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 4043a852290c8823faa76b7592c9f9927c7d0928
1	Patients	_	_	_	_	_	_	_	Seg=B-seg
2	with	_	_	_	_	_	_	_	Seg=O
3	severe	_	_	_	_	_	_	_	Seg=O
4	acute	_	_	_	_	_	_	_	Seg=O
5	respiratory	_	_	_	_	_	_	_	Seg=O
6	syndrome	_	_	_	_	_	_	_	Seg=O
7	(	_	_	_	_	_	_	_	Seg=O
8	SARS	_	_	_	_	_	_	_	Seg=O
9	)	_	_	_	_	_	_	_	Seg=O
10	may	_	_	_	_	_	_	_	Seg=O
11	present	_	_	_	_	_	_	_	Seg=O
12	with	_	_	_	_	_	_	_	Seg=O
13	extra	_	_	_	_	_	_	_	Seg=O
14	-	_	_	_	_	_	_	_	Seg=O
15	pulmonary	_	_	_	_	_	_	_	Seg=O
16	symptoms	_	_	_	_	_	_	_	Seg=O
17	.	_	_	_	_	_	_	_	Seg=O
18	We	_	_	_	_	_	_	_	Seg=B-seg
19	report	_	_	_	_	_	_	_	Seg=O
20	a	_	_	_	_	_	_	_	Seg=O
21	16-year	_	_	_	_	_	_	_	Seg=O
22	-	_	_	_	_	_	_	_	Seg=O
23	old	_	_	_	_	_	_	_	Seg=O
24	adolescent	_	_	_	_	_	_	_	Seg=O
25	with	_	_	_	_	_	_	_	Seg=O
26	SARS	_	_	_	_	_	_	_	Seg=O
27	who	_	_	_	_	_	_	_	Seg=B-seg
28	presented	_	_	_	_	_	_	_	Seg=O
29	with	_	_	_	_	_	_	_	Seg=O
30	diarrhoea	_	_	_	_	_	_	_	Seg=O
31	.	_	_	_	_	_	_	_	Seg=O
32	Treatment	_	_	_	_	_	_	_	Seg=B-seg
33	directed	_	_	_	_	_	_	_	Seg=B-seg
34	against	_	_	_	_	_	_	_	Seg=O
35	SARS	_	_	_	_	_	_	_	Seg=O
36	was	_	_	_	_	_	_	_	Seg=B-seg
37	prompted	_	_	_	_	_	_	_	Seg=O
38	by	_	_	_	_	_	_	_	Seg=O
39	an	_	_	_	_	_	_	_	Seg=O
40	epidemiological	_	_	_	_	_	_	_	Seg=O
41	link	_	_	_	_	_	_	_	Seg=O
42	and	_	_	_	_	_	_	_	Seg=O
43	the	_	_	_	_	_	_	_	Seg=O
44	clinical	_	_	_	_	_	_	_	Seg=O
45	picture	_	_	_	_	_	_	_	Seg=O
46	as	_	_	_	_	_	_	_	Seg=B-seg
47	the	_	_	_	_	_	_	_	Seg=O
48	disease	_	_	_	_	_	_	_	Seg=O
49	evolved	_	_	_	_	_	_	_	Seg=O
50	.	_	_	_	_	_	_	_	Seg=O
51	This	_	_	_	_	_	_	_	Seg=B-seg
52	atypical	_	_	_	_	_	_	_	Seg=O
53	presentation	_	_	_	_	_	_	_	Seg=O
54	posed	_	_	_	_	_	_	_	Seg=O
55	a	_	_	_	_	_	_	_	Seg=O
56	diagnostic	_	_	_	_	_	_	_	Seg=O
57	challenge	_	_	_	_	_	_	_	Seg=O
58	for	_	_	_	_	_	_	_	Seg=O
59	physicians	_	_	_	_	_	_	_	Seg=O
60	.	_	_	_	_	_	_	_	Seg=O
61	Conclusion	_	_	_	_	_	_	_	Seg=B-seg
62	:	_	_	_	_	_	_	_	Seg=O
63	Proper	_	_	_	_	_	_	_	Seg=B-seg
64	disposal	_	_	_	_	_	_	_	Seg=O
65	of	_	_	_	_	_	_	_	Seg=O
66	patient	_	_	_	_	_	_	_	Seg=O
67	excreta	_	_	_	_	_	_	_	Seg=O
68	is	_	_	_	_	_	_	_	Seg=O
69	important	_	_	_	_	_	_	_	Seg=O
70	to	_	_	_	_	_	_	_	Seg=B-seg
71	prevent	_	_	_	_	_	_	_	Seg=O
72	the	_	_	_	_	_	_	_	Seg=O
73	spread	_	_	_	_	_	_	_	Seg=O
74	of	_	_	_	_	_	_	_	Seg=O
75	severe	_	_	_	_	_	_	_	Seg=O
76	acute	_	_	_	_	_	_	_	Seg=O
77	respiratory	_	_	_	_	_	_	_	Seg=O
78	syndrome	_	_	_	_	_	_	_	Seg=O
79	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 41a35d16de1630c28ba07b3ab3b7ab78ccef25ac
1	Mesenchymal	_	_	_	_	_	_	_	Seg=B-seg
2	stem	_	_	_	_	_	_	_	Seg=O
3	cells	_	_	_	_	_	_	_	Seg=O
4	(	_	_	_	_	_	_	_	Seg=O
5	MSCs	_	_	_	_	_	_	_	Seg=O
6	)	_	_	_	_	_	_	_	Seg=O
7	have	_	_	_	_	_	_	_	Seg=O
8	been	_	_	_	_	_	_	_	Seg=O
9	extensively	_	_	_	_	_	_	_	Seg=O
10	investigated	_	_	_	_	_	_	_	Seg=O
11	for	_	_	_	_	_	_	_	Seg=O
12	the	_	_	_	_	_	_	_	Seg=O
13	treatment	_	_	_	_	_	_	_	Seg=O
14	of	_	_	_	_	_	_	_	Seg=O
15	various	_	_	_	_	_	_	_	Seg=O
16	diseases	_	_	_	_	_	_	_	Seg=O
17	.	_	_	_	_	_	_	_	Seg=O
18	The	_	_	_	_	_	_	_	Seg=B-seg
19	therapeutic	_	_	_	_	_	_	_	Seg=O
20	potential	_	_	_	_	_	_	_	Seg=O
21	of	_	_	_	_	_	_	_	Seg=O
22	MSCs	_	_	_	_	_	_	_	Seg=O
23	is	_	_	_	_	_	_	_	Seg=O
24	attributed	_	_	_	_	_	_	_	Seg=O
25	to	_	_	_	_	_	_	_	Seg=O
26	complex	_	_	_	_	_	_	_	Seg=O
27	cellular	_	_	_	_	_	_	_	Seg=O
28	and	_	_	_	_	_	_	_	Seg=O
29	molecular	_	_	_	_	_	_	_	Seg=O
30	mechanisms	_	_	_	_	_	_	_	Seg=O
31	of	_	_	_	_	_	_	_	Seg=O
32	action	_	_	_	_	_	_	_	Seg=O
33	including	_	_	_	_	_	_	_	Seg=B-seg
34	differentiation	_	_	_	_	_	_	_	Seg=O
35	into	_	_	_	_	_	_	_	Seg=O
36	multiple	_	_	_	_	_	_	_	Seg=O
37	cell	_	_	_	_	_	_	_	Seg=O
38	lineages	_	_	_	_	_	_	_	Seg=O
39	and	_	_	_	_	_	_	_	Seg=O
40	regulation	_	_	_	_	_	_	_	Seg=O
41	of	_	_	_	_	_	_	_	Seg=O
42	immune	_	_	_	_	_	_	_	Seg=O
43	responses	_	_	_	_	_	_	_	Seg=O
44	via	_	_	_	_	_	_	_	Seg=O
45	immunomodulation	_	_	_	_	_	_	_	Seg=O
46	.	_	_	_	_	_	_	_	Seg=O
47	The	_	_	_	_	_	_	_	Seg=B-seg
48	plasticity	_	_	_	_	_	_	_	Seg=O
49	of	_	_	_	_	_	_	_	Seg=O
50	MSCs	_	_	_	_	_	_	_	Seg=O
51	in	_	_	_	_	_	_	_	Seg=O
52	immunomodulation	_	_	_	_	_	_	_	Seg=O
53	allow	_	_	_	_	_	_	_	Seg=O
54	these	_	_	_	_	_	_	_	Seg=O
55	cells	_	_	_	_	_	_	_	Seg=O
56	to	_	_	_	_	_	_	_	Seg=O
57	exert	_	_	_	_	_	_	_	Seg=O
58	different	_	_	_	_	_	_	_	Seg=O
59	immune	_	_	_	_	_	_	_	Seg=O
60	effects	_	_	_	_	_	_	_	Seg=O
61	depending	_	_	_	_	_	_	_	Seg=B-seg
62	on	_	_	_	_	_	_	_	Seg=O
63	different	_	_	_	_	_	_	_	Seg=O
64	diseases	_	_	_	_	_	_	_	Seg=O
65	.	_	_	_	_	_	_	_	Seg=O
66	Understanding	_	_	_	_	_	_	_	Seg=B-seg
67	the	_	_	_	_	_	_	_	Seg=O
68	biology	_	_	_	_	_	_	_	Seg=O
69	of	_	_	_	_	_	_	_	Seg=O
70	MSCs	_	_	_	_	_	_	_	Seg=O
71	and	_	_	_	_	_	_	_	Seg=O
72	their	_	_	_	_	_	_	_	Seg=O
73	role	_	_	_	_	_	_	_	Seg=O
74	in	_	_	_	_	_	_	_	Seg=O
75	treatment	_	_	_	_	_	_	_	Seg=O
76	is	_	_	_	_	_	_	_	Seg=O
77	critical	_	_	_	_	_	_	_	Seg=O
78	to	_	_	_	_	_	_	_	Seg=B-seg
79	determine	_	_	_	_	_	_	_	Seg=O
80	their	_	_	_	_	_	_	_	Seg=O
81	potential	_	_	_	_	_	_	_	Seg=O
82	for	_	_	_	_	_	_	_	Seg=O
83	various	_	_	_	_	_	_	_	Seg=O
84	therapeutic	_	_	_	_	_	_	_	Seg=O
85	applications	_	_	_	_	_	_	_	Seg=O
86	and	_	_	_	_	_	_	_	Seg=O
87	for	_	_	_	_	_	_	_	Seg=O
88	the	_	_	_	_	_	_	_	Seg=O
89	development	_	_	_	_	_	_	_	Seg=O
90	of	_	_	_	_	_	_	_	Seg=O
91	MSC	_	_	_	_	_	_	_	Seg=O
92	-	_	_	_	_	_	_	_	Seg=O
93	based	_	_	_	_	_	_	_	Seg=O
94	regenerative	_	_	_	_	_	_	_	Seg=O
95	medicine	_	_	_	_	_	_	_	Seg=O
96	.	_	_	_	_	_	_	_	Seg=O
97	This	_	_	_	_	_	_	_	Seg=B-seg
98	review	_	_	_	_	_	_	_	Seg=O
99	summarizes	_	_	_	_	_	_	_	Seg=O
100	the	_	_	_	_	_	_	_	Seg=O
101	recent	_	_	_	_	_	_	_	Seg=O
102	progress	_	_	_	_	_	_	_	Seg=O
103	of	_	_	_	_	_	_	_	Seg=O
104	particular	_	_	_	_	_	_	_	Seg=O
105	mechanisms	_	_	_	_	_	_	_	Seg=O
106	underlying	_	_	_	_	_	_	_	Seg=B-seg
107	the	_	_	_	_	_	_	_	Seg=O
108	tissue	_	_	_	_	_	_	_	Seg=O
109	regenerative	_	_	_	_	_	_	_	Seg=O
110	properties	_	_	_	_	_	_	_	Seg=O
111	and	_	_	_	_	_	_	_	Seg=O
112	immunomodulatory	_	_	_	_	_	_	_	Seg=O
113	effects	_	_	_	_	_	_	_	Seg=O
114	of	_	_	_	_	_	_	_	Seg=O
115	MSCs	_	_	_	_	_	_	_	Seg=O
116	.	_	_	_	_	_	_	_	Seg=O
117	We	_	_	_	_	_	_	_	Seg=B-seg
118	focused	_	_	_	_	_	_	_	Seg=O
119	on	_	_	_	_	_	_	_	Seg=O
120	discussing	_	_	_	_	_	_	_	Seg=O
121	the	_	_	_	_	_	_	_	Seg=O
122	functional	_	_	_	_	_	_	_	Seg=O
123	roles	_	_	_	_	_	_	_	Seg=O
124	of	_	_	_	_	_	_	_	Seg=O
125	paracrine	_	_	_	_	_	_	_	Seg=O
126	activities	_	_	_	_	_	_	_	Seg=O
127	,	_	_	_	_	_	_	_	Seg=O
128	direct	_	_	_	_	_	_	_	Seg=O
129	cell	_	_	_	_	_	_	_	Seg=O
130	-	_	_	_	_	_	_	_	Seg=O
131	cell	_	_	_	_	_	_	_	Seg=O
132	contact	_	_	_	_	_	_	_	Seg=O
133	,	_	_	_	_	_	_	_	Seg=O
134	mitochondrial	_	_	_	_	_	_	_	Seg=O
135	transfer	_	_	_	_	_	_	_	Seg=O
136	,	_	_	_	_	_	_	_	Seg=O
137	and	_	_	_	_	_	_	_	Seg=O
138	extracellular	_	_	_	_	_	_	_	Seg=O
139	vesicles	_	_	_	_	_	_	_	Seg=O
140	related	_	_	_	_	_	_	_	Seg=B-seg
141	to	_	_	_	_	_	_	_	Seg=O
142	MSC	_	_	_	_	_	_	_	Seg=O
143	-	_	_	_	_	_	_	_	Seg=O
144	mediated	_	_	_	_	_	_	_	Seg=O
145	effects	_	_	_	_	_	_	_	Seg=O
146	on	_	_	_	_	_	_	_	Seg=O
147	immune	_	_	_	_	_	_	_	Seg=O
148	cell	_	_	_	_	_	_	_	Seg=O
149	responses	_	_	_	_	_	_	_	Seg=O
150	,	_	_	_	_	_	_	_	Seg=O
151	cell	_	_	_	_	_	_	_	Seg=O
152	survival	_	_	_	_	_	_	_	Seg=O
153	,	_	_	_	_	_	_	_	Seg=O
154	and	_	_	_	_	_	_	_	Seg=O
155	regeneration	_	_	_	_	_	_	_	Seg=O
156	.	_	_	_	_	_	_	_	Seg=O
157	This	_	_	_	_	_	_	_	Seg=B-seg
158	will	_	_	_	_	_	_	_	Seg=O
159	provide	_	_	_	_	_	_	_	Seg=O
160	an	_	_	_	_	_	_	_	Seg=O
161	overview	_	_	_	_	_	_	_	Seg=O
162	of	_	_	_	_	_	_	_	Seg=O
163	the	_	_	_	_	_	_	_	Seg=O
164	current	_	_	_	_	_	_	_	Seg=O
165	research	_	_	_	_	_	_	_	Seg=O
166	on	_	_	_	_	_	_	_	Seg=O
167	the	_	_	_	_	_	_	_	Seg=O
168	rapid	_	_	_	_	_	_	_	Seg=O
169	development	_	_	_	_	_	_	_	Seg=O
170	of	_	_	_	_	_	_	_	Seg=O
171	MSC	_	_	_	_	_	_	_	Seg=O
172	-	_	_	_	_	_	_	_	Seg=O
173	based	_	_	_	_	_	_	_	Seg=O
174	therapies	_	_	_	_	_	_	_	Seg=O
175	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 4395141eef1089f1c75a14912fade412fd694c19
1	The	_	_	_	_	_	_	_	Seg=B-seg
2	glycosylated	_	_	_	_	_	_	_	Seg=O
3	membrane	_	_	_	_	_	_	_	Seg=O
4	protein	_	_	_	_	_	_	_	Seg=O
5	M	_	_	_	_	_	_	_	Seg=O
6	of	_	_	_	_	_	_	_	Seg=O
7	the	_	_	_	_	_	_	_	Seg=O
8	severe	_	_	_	_	_	_	_	Seg=O
9	acute	_	_	_	_	_	_	_	Seg=O
10	respiratory	_	_	_	_	_	_	_	Seg=O
11	syndrome	_	_	_	_	_	_	_	Seg=O
12	associated	_	_	_	_	_	_	_	Seg=O
13	coronavirus	_	_	_	_	_	_	_	Seg=O
14	(	_	_	_	_	_	_	_	Seg=O
15	SARS	_	_	_	_	_	_	_	Seg=O
16	-	_	_	_	_	_	_	_	Seg=O
17	CoV	_	_	_	_	_	_	_	Seg=O
18	)	_	_	_	_	_	_	_	Seg=O
19	is	_	_	_	_	_	_	_	Seg=O
20	the	_	_	_	_	_	_	_	Seg=O
21	main	_	_	_	_	_	_	_	Seg=O
22	structural	_	_	_	_	_	_	_	Seg=O
23	component	_	_	_	_	_	_	_	Seg=O
24	of	_	_	_	_	_	_	_	Seg=O
25	the	_	_	_	_	_	_	_	Seg=O
26	virion	_	_	_	_	_	_	_	Seg=O
27	and	_	_	_	_	_	_	_	Seg=B-seg
28	mediates	_	_	_	_	_	_	_	Seg=O
29	assembly	_	_	_	_	_	_	_	Seg=O
30	and	_	_	_	_	_	_	_	Seg=O
31	budding	_	_	_	_	_	_	_	Seg=O
32	of	_	_	_	_	_	_	_	Seg=O
33	viral	_	_	_	_	_	_	_	Seg=O
34	particles	_	_	_	_	_	_	_	Seg=O
35	.	_	_	_	_	_	_	_	Seg=O
36	The	_	_	_	_	_	_	_	Seg=B-seg
37	membrane	_	_	_	_	_	_	_	Seg=O
38	topology	_	_	_	_	_	_	_	Seg=O
39	of	_	_	_	_	_	_	_	Seg=O
40	SARS	_	_	_	_	_	_	_	Seg=O
41	-	_	_	_	_	_	_	_	Seg=O
42	CoV	_	_	_	_	_	_	_	Seg=O
43	M	_	_	_	_	_	_	_	Seg=O
44	and	_	_	_	_	_	_	_	Seg=O
45	the	_	_	_	_	_	_	_	Seg=O
46	functional	_	_	_	_	_	_	_	Seg=O
47	significance	_	_	_	_	_	_	_	Seg=O
48	of	_	_	_	_	_	_	_	Seg=O
49	its	_	_	_	_	_	_	_	Seg=O
50	N	_	_	_	_	_	_	_	Seg=O
51	-	_	_	_	_	_	_	_	Seg=O
52	glycosylation	_	_	_	_	_	_	_	Seg=O
53	are	_	_	_	_	_	_	_	Seg=O
54	not	_	_	_	_	_	_	_	Seg=O
55	completely	_	_	_	_	_	_	_	Seg=O
56	understood	_	_	_	_	_	_	_	Seg=O
57	as	_	_	_	_	_	_	_	Seg=B-seg
58	is	_	_	_	_	_	_	_	Seg=O
59	its	_	_	_	_	_	_	_	Seg=O
60	interaction	_	_	_	_	_	_	_	Seg=O
61	with	_	_	_	_	_	_	_	Seg=O
62	the	_	_	_	_	_	_	_	Seg=O
63	surface	_	_	_	_	_	_	_	Seg=O
64	glycoprotein	_	_	_	_	_	_	_	Seg=O
65	S.	_	_	_	_	_	_	_	Seg=O
66	Using	_	_	_	_	_	_	_	Seg=B-seg
67	biochemical	_	_	_	_	_	_	_	Seg=O
68	and	_	_	_	_	_	_	_	Seg=O
69	immunofluorescence	_	_	_	_	_	_	_	Seg=O
70	analyses	_	_	_	_	_	_	_	Seg=O
71	we	_	_	_	_	_	_	_	Seg=B-seg
72	found	_	_	_	_	_	_	_	Seg=O
73	that	_	_	_	_	_	_	_	Seg=B-seg
74	M	_	_	_	_	_	_	_	Seg=O
75	consists	_	_	_	_	_	_	_	Seg=O
76	of	_	_	_	_	_	_	_	Seg=O
77	a	_	_	_	_	_	_	_	Seg=O
78	short	_	_	_	_	_	_	_	Seg=O
79	glycosylated	_	_	_	_	_	_	_	Seg=O
80	N	_	_	_	_	_	_	_	Seg=O
81	-	_	_	_	_	_	_	_	Seg=O
82	terminal	_	_	_	_	_	_	_	Seg=O
83	ectodomain	_	_	_	_	_	_	_	Seg=O
84	,	_	_	_	_	_	_	_	Seg=O
85	three	_	_	_	_	_	_	_	Seg=O
86	transmembrane	_	_	_	_	_	_	_	Seg=O
87	segments	_	_	_	_	_	_	_	Seg=O
88	and	_	_	_	_	_	_	_	Seg=O
89	a	_	_	_	_	_	_	_	Seg=O
90	long	_	_	_	_	_	_	_	Seg=O
91	,	_	_	_	_	_	_	_	Seg=O
92	immunogenic	_	_	_	_	_	_	_	Seg=O
93	C	_	_	_	_	_	_	_	Seg=O
94	-	_	_	_	_	_	_	_	Seg=O
95	terminal	_	_	_	_	_	_	_	Seg=O
96	endodomain	_	_	_	_	_	_	_	Seg=O
97	.	_	_	_	_	_	_	_	Seg=O
98	Although	_	_	_	_	_	_	_	Seg=B-seg
99	the	_	_	_	_	_	_	_	Seg=O
100	N	_	_	_	_	_	_	_	Seg=O
101	-	_	_	_	_	_	_	_	Seg=O
102	glycosylation	_	_	_	_	_	_	_	Seg=O
103	site	_	_	_	_	_	_	_	Seg=O
104	of	_	_	_	_	_	_	_	Seg=O
105	M	_	_	_	_	_	_	_	Seg=O
106	seems	_	_	_	_	_	_	_	Seg=O
107	to	_	_	_	_	_	_	_	Seg=O
108	be	_	_	_	_	_	_	_	Seg=O
109	highly	_	_	_	_	_	_	_	Seg=O
110	conserved	_	_	_	_	_	_	_	Seg=O
111	between	_	_	_	_	_	_	_	Seg=O
112	group	_	_	_	_	_	_	_	Seg=O
113	1	_	_	_	_	_	_	_	Seg=O
114	and	_	_	_	_	_	_	_	Seg=O
115	3	_	_	_	_	_	_	_	Seg=O
116	coronaviruses	_	_	_	_	_	_	_	Seg=O
117	,	_	_	_	_	_	_	_	Seg=O
118	studies	_	_	_	_	_	_	_	Seg=B-seg
119	using	_	_	_	_	_	_	_	Seg=B-seg
120	a	_	_	_	_	_	_	_	Seg=O
121	recombinant	_	_	_	_	_	_	_	Seg=O
122	SARS	_	_	_	_	_	_	_	Seg=O
123	-	_	_	_	_	_	_	_	Seg=O
124	CoV	_	_	_	_	_	_	_	Seg=O
125	expressing	_	_	_	_	_	_	_	Seg=B-seg
126	a	_	_	_	_	_	_	_	Seg=O
127	glycosylation	_	_	_	_	_	_	_	Seg=O
128	-	_	_	_	_	_	_	_	Seg=O
129	deficient	_	_	_	_	_	_	_	Seg=O
130	M	_	_	_	_	_	_	_	Seg=O
131	revealed	_	_	_	_	_	_	_	Seg=B-seg
132	that	_	_	_	_	_	_	_	Seg=B-seg
133	N	_	_	_	_	_	_	_	Seg=O
134	-	_	_	_	_	_	_	_	Seg=O
135	glycosylation	_	_	_	_	_	_	_	Seg=O
136	of	_	_	_	_	_	_	_	Seg=O
137	M	_	_	_	_	_	_	_	Seg=O
138	neither	_	_	_	_	_	_	_	Seg=O
139	influence	_	_	_	_	_	_	_	Seg=O
140	the	_	_	_	_	_	_	_	Seg=O
141	shape	_	_	_	_	_	_	_	Seg=O
142	of	_	_	_	_	_	_	_	Seg=O
143	the	_	_	_	_	_	_	_	Seg=O
144	virions	_	_	_	_	_	_	_	Seg=O
145	nor	_	_	_	_	_	_	_	Seg=O
146	their	_	_	_	_	_	_	_	Seg=O
147	infectivity	_	_	_	_	_	_	_	Seg=O
148	in	_	_	_	_	_	_	_	Seg=O
149	cell	_	_	_	_	_	_	_	Seg=O
150	culture	_	_	_	_	_	_	_	Seg=O
151	.	_	_	_	_	_	_	_	Seg=O
152	Further	_	_	_	_	_	_	_	Seg=B-seg
153	functional	_	_	_	_	_	_	_	Seg=O
154	analysis	_	_	_	_	_	_	_	Seg=O
155	of	_	_	_	_	_	_	_	Seg=O
156	truncated	_	_	_	_	_	_	_	Seg=O
157	M	_	_	_	_	_	_	_	Seg=O
158	proteins	_	_	_	_	_	_	_	Seg=O
159	showed	_	_	_	_	_	_	_	Seg=O
160	that	_	_	_	_	_	_	_	Seg=B-seg
161	the	_	_	_	_	_	_	_	Seg=O
162	N	_	_	_	_	_	_	_	Seg=O
163	-	_	_	_	_	_	_	_	Seg=O
164	terminal	_	_	_	_	_	_	_	Seg=O
165	134	_	_	_	_	_	_	_	Seg=O
166	amino	_	_	_	_	_	_	_	Seg=O
167	acids	_	_	_	_	_	_	_	Seg=O
168	comprising	_	_	_	_	_	_	_	Seg=B-seg
169	the	_	_	_	_	_	_	_	Seg=O
170	three	_	_	_	_	_	_	_	Seg=O
171	transmembrane	_	_	_	_	_	_	_	Seg=O
172	domains	_	_	_	_	_	_	_	Seg=O
173	are	_	_	_	_	_	_	_	Seg=B-seg
174	sufficient	_	_	_	_	_	_	_	Seg=O
175	to	_	_	_	_	_	_	_	Seg=B-seg
176	mediate	_	_	_	_	_	_	_	Seg=O
177	accumulation	_	_	_	_	_	_	_	Seg=O
178	of	_	_	_	_	_	_	_	Seg=O
179	M	_	_	_	_	_	_	_	Seg=O
180	in	_	_	_	_	_	_	_	Seg=O
181	the	_	_	_	_	_	_	_	Seg=O
182	Golgi	_	_	_	_	_	_	_	Seg=O
183	complex	_	_	_	_	_	_	_	Seg=O
184	and	_	_	_	_	_	_	_	Seg=B-seg
185	to	_	_	_	_	_	_	_	Seg=O
186	enforce	_	_	_	_	_	_	_	Seg=O
187	recruitment	_	_	_	_	_	_	_	Seg=O
188	of	_	_	_	_	_	_	_	Seg=O
189	the	_	_	_	_	_	_	_	Seg=O
190	viral	_	_	_	_	_	_	_	Seg=O
191	spike	_	_	_	_	_	_	_	Seg=O
192	protein	_	_	_	_	_	_	_	Seg=O
193	S	_	_	_	_	_	_	_	Seg=O
194	to	_	_	_	_	_	_	_	Seg=O
195	the	_	_	_	_	_	_	_	Seg=O
196	sites	_	_	_	_	_	_	_	Seg=O
197	of	_	_	_	_	_	_	_	Seg=O
198	virus	_	_	_	_	_	_	_	Seg=O
199	assembly	_	_	_	_	_	_	_	Seg=O
200	and	_	_	_	_	_	_	_	Seg=O
201	budding	_	_	_	_	_	_	_	Seg=O
202	in	_	_	_	_	_	_	_	Seg=O
203	the	_	_	_	_	_	_	_	Seg=O
204	ERGIC	_	_	_	_	_	_	_	Seg=O
205	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 43b340eb1776b4c487c7893797fd744fc3fdb04e
1	In	_	_	_	_	_	_	_	Seg=B-seg
2	this	_	_	_	_	_	_	_	Seg=O
3	paper	_	_	_	_	_	_	_	Seg=O
4	,	_	_	_	_	_	_	_	Seg=O
5	we	_	_	_	_	_	_	_	Seg=O
6	suggest	_	_	_	_	_	_	_	Seg=O
7	a	_	_	_	_	_	_	_	Seg=O
8	real	_	_	_	_	_	_	_	Seg=O
9	-	_	_	_	_	_	_	_	Seg=O
10	time	_	_	_	_	_	_	_	Seg=O
11	online	_	_	_	_	_	_	_	Seg=O
12	shopper	_	_	_	_	_	_	_	Seg=O
13	behavior	_	_	_	_	_	_	_	Seg=O
14	prediction	_	_	_	_	_	_	_	Seg=O
15	system	_	_	_	_	_	_	_	Seg=O
16	which	_	_	_	_	_	_	_	Seg=B-seg
17	predicts	_	_	_	_	_	_	_	Seg=O
18	the	_	_	_	_	_	_	_	Seg=O
19-20	visitor's	_	_	_	_	_	_	_	_
19	visitor	_	_	_	_	_	_	_	Seg=O
20	's	_	_	_	_	_	_	_	Seg=O
21	shopping	_	_	_	_	_	_	_	Seg=O
22	intent	_	_	_	_	_	_	_	Seg=O
23	as	_	_	_	_	_	_	_	Seg=B-seg
24	soon	_	_	_	_	_	_	_	Seg=O
25	as	_	_	_	_	_	_	_	Seg=O
26	the	_	_	_	_	_	_	_	Seg=O
27	website	_	_	_	_	_	_	_	Seg=O
28	is	_	_	_	_	_	_	_	Seg=O
29	visited	_	_	_	_	_	_	_	Seg=O
30	.	_	_	_	_	_	_	_	Seg=O
31	To	_	_	_	_	_	_	_	Seg=B-seg
32	do	_	_	_	_	_	_	_	Seg=O
33	that	_	_	_	_	_	_	_	Seg=O
34	,	_	_	_	_	_	_	_	Seg=O
35	we	_	_	_	_	_	_	_	Seg=B-seg
36	rely	_	_	_	_	_	_	_	Seg=O
37	on	_	_	_	_	_	_	_	Seg=O
38	session	_	_	_	_	_	_	_	Seg=O
39	and	_	_	_	_	_	_	_	Seg=O
40	visitor	_	_	_	_	_	_	_	Seg=O
41	information	_	_	_	_	_	_	_	Seg=O
42	and	_	_	_	_	_	_	_	Seg=B-seg
43	we	_	_	_	_	_	_	_	Seg=O
44	investigate	_	_	_	_	_	_	_	Seg=O
45	naïve	_	_	_	_	_	_	_	Seg=O
46	Bayes	_	_	_	_	_	_	_	Seg=O
47	classifier	_	_	_	_	_	_	_	Seg=O
48	,	_	_	_	_	_	_	_	Seg=O
49	C4.5	_	_	_	_	_	_	_	Seg=O
50	decision	_	_	_	_	_	_	_	Seg=O
51	tree	_	_	_	_	_	_	_	Seg=O
52	and	_	_	_	_	_	_	_	Seg=O
53	random	_	_	_	_	_	_	_	Seg=O
54	forest	_	_	_	_	_	_	_	Seg=O
55	.	_	_	_	_	_	_	_	Seg=O
56	Furthermore	_	_	_	_	_	_	_	Seg=B-seg
57	,	_	_	_	_	_	_	_	Seg=O
58	we	_	_	_	_	_	_	_	Seg=O
59	use	_	_	_	_	_	_	_	Seg=O
60	oversampling	_	_	_	_	_	_	_	Seg=O
61	to	_	_	_	_	_	_	_	Seg=B-seg
62	improve	_	_	_	_	_	_	_	Seg=O
63	the	_	_	_	_	_	_	_	Seg=O
64	performance	_	_	_	_	_	_	_	Seg=O
65	and	_	_	_	_	_	_	_	Seg=O
66	the	_	_	_	_	_	_	_	Seg=O
67	scalability	_	_	_	_	_	_	_	Seg=O
68	of	_	_	_	_	_	_	_	Seg=O
69	each	_	_	_	_	_	_	_	Seg=O
70	classifier	_	_	_	_	_	_	_	Seg=O
71	.	_	_	_	_	_	_	_	Seg=O
72	The	_	_	_	_	_	_	_	Seg=B-seg
73	results	_	_	_	_	_	_	_	Seg=O
74	show	_	_	_	_	_	_	_	Seg=O
75	that	_	_	_	_	_	_	_	Seg=B-seg
76	random	_	_	_	_	_	_	_	Seg=O
77	forest	_	_	_	_	_	_	_	Seg=O
78	produces	_	_	_	_	_	_	_	Seg=O
79	significantly	_	_	_	_	_	_	_	Seg=O
80	higher	_	_	_	_	_	_	_	Seg=O
81	accuracy	_	_	_	_	_	_	_	Seg=O
82	and	_	_	_	_	_	_	_	Seg=O
83	F1	_	_	_	_	_	_	_	Seg=O
84	Score	_	_	_	_	_	_	_	Seg=O
85	than	_	_	_	_	_	_	_	Seg=O
86	the	_	_	_	_	_	_	_	Seg=O
87	compared	_	_	_	_	_	_	_	Seg=O
88	techniques	_	_	_	_	_	_	_	Seg=O
89	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 43c284998733a1d7cc474d14c378f08e4b509c63
1	The	_	_	_	_	_	_	_	Seg=B-seg
2	mosquito	_	_	_	_	_	_	_	Seg=O
3	-	_	_	_	_	_	_	_	Seg=O
4	borne	_	_	_	_	_	_	_	Seg=O
5	chikungunya	_	_	_	_	_	_	_	Seg=O
6	virus	_	_	_	_	_	_	_	Seg=O
7	(	_	_	_	_	_	_	_	Seg=O
8	CHIKV	_	_	_	_	_	_	_	Seg=O
9	)	_	_	_	_	_	_	_	Seg=O
10	causes	_	_	_	_	_	_	_	Seg=O
11	chikungunya	_	_	_	_	_	_	_	Seg=O
12	fever	_	_	_	_	_	_	_	Seg=O
13	,	_	_	_	_	_	_	_	Seg=O
14	with	_	_	_	_	_	_	_	Seg=O
15	clinical	_	_	_	_	_	_	_	Seg=O
16	presentations	_	_	_	_	_	_	_	Seg=O
17	such	_	_	_	_	_	_	_	Seg=B-seg
18	as	_	_	_	_	_	_	_	Seg=O
19	severe	_	_	_	_	_	_	_	Seg=O
20	back	_	_	_	_	_	_	_	Seg=O
21	and	_	_	_	_	_	_	_	Seg=O
22	small	_	_	_	_	_	_	_	Seg=O
23	joint	_	_	_	_	_	_	_	Seg=O
24	pain	_	_	_	_	_	_	_	Seg=O
25	,	_	_	_	_	_	_	_	Seg=O
26	and	_	_	_	_	_	_	_	Seg=O
27	debilitating	_	_	_	_	_	_	_	Seg=O
28	arthritis	_	_	_	_	_	_	_	Seg=O
29	associated	_	_	_	_	_	_	_	Seg=B-seg
30	with	_	_	_	_	_	_	_	Seg=O
31	crippling	_	_	_	_	_	_	_	Seg=O
32	pains	_	_	_	_	_	_	_	Seg=O
33	that	_	_	_	_	_	_	_	Seg=B-seg
34	persist	_	_	_	_	_	_	_	Seg=O
35	for	_	_	_	_	_	_	_	Seg=O
36	weeks	_	_	_	_	_	_	_	Seg=O
37	and	_	_	_	_	_	_	_	Seg=O
38	even	_	_	_	_	_	_	_	Seg=O
39	years	_	_	_	_	_	_	_	Seg=O
40	.	_	_	_	_	_	_	_	Seg=O
41	Although	_	_	_	_	_	_	_	Seg=B-seg
42	there	_	_	_	_	_	_	_	Seg=O
43	are	_	_	_	_	_	_	_	Seg=O
44	several	_	_	_	_	_	_	_	Seg=O
45	studies	_	_	_	_	_	_	_	Seg=O
46	to	_	_	_	_	_	_	_	Seg=B-seg
47	evaluate	_	_	_	_	_	_	_	Seg=O
48	the	_	_	_	_	_	_	_	Seg=O
49	efficacy	_	_	_	_	_	_	_	Seg=O
50	of	_	_	_	_	_	_	_	Seg=O
51	drugs	_	_	_	_	_	_	_	Seg=O
52	against	_	_	_	_	_	_	_	Seg=O
53	CHIKV	_	_	_	_	_	_	_	Seg=O
54	,	_	_	_	_	_	_	_	Seg=O
55	the	_	_	_	_	_	_	_	Seg=B-seg
56	treatment	_	_	_	_	_	_	_	Seg=O
57	for	_	_	_	_	_	_	_	Seg=O
58	chikungunya	_	_	_	_	_	_	_	Seg=O
59	fever	_	_	_	_	_	_	_	Seg=O
60	is	_	_	_	_	_	_	_	Seg=O
61	mainly	_	_	_	_	_	_	_	Seg=O
62	symptom	_	_	_	_	_	_	_	Seg=O
63	-	_	_	_	_	_	_	_	Seg=O
64	based	_	_	_	_	_	_	_	Seg=O
65	and	_	_	_	_	_	_	_	Seg=B-seg
66	no	_	_	_	_	_	_	_	Seg=O
67	effective	_	_	_	_	_	_	_	Seg=O
68	licensed	_	_	_	_	_	_	_	Seg=O
69	vaccine	_	_	_	_	_	_	_	Seg=O
70	or	_	_	_	_	_	_	_	Seg=O
71	antiviral	_	_	_	_	_	_	_	Seg=O
72	are	_	_	_	_	_	_	_	Seg=O
73	available	_	_	_	_	_	_	_	Seg=O
74	.	_	_	_	_	_	_	_	Seg=O
75	Here	_	_	_	_	_	_	_	Seg=B-seg
76	,	_	_	_	_	_	_	_	Seg=O
77	we	_	_	_	_	_	_	_	Seg=O
78	investigated	_	_	_	_	_	_	_	Seg=O
79	the	_	_	_	_	_	_	_	Seg=O
80	antiviral	_	_	_	_	_	_	_	Seg=O
81	activity	_	_	_	_	_	_	_	Seg=O
82	of	_	_	_	_	_	_	_	Seg=O
83	three	_	_	_	_	_	_	_	Seg=O
84	types	_	_	_	_	_	_	_	Seg=O
85	of	_	_	_	_	_	_	_	Seg=O
86	flavonoids	_	_	_	_	_	_	_	Seg=O
87	against	_	_	_	_	_	_	_	Seg=O
88	CHIKV	_	_	_	_	_	_	_	Seg=O
89	in	_	_	_	_	_	_	_	Seg=O
90	vitro	_	_	_	_	_	_	_	Seg=O
91	replication	_	_	_	_	_	_	_	Seg=O
92	.	_	_	_	_	_	_	_	Seg=O
93	Three	_	_	_	_	_	_	_	Seg=B-seg
94	compounds	_	_	_	_	_	_	_	Seg=O
95	:	_	_	_	_	_	_	_	Seg=O
96	silymarin	_	_	_	_	_	_	_	Seg=B-seg
97	,	_	_	_	_	_	_	_	Seg=O
98	quercetin	_	_	_	_	_	_	_	Seg=O
99	and	_	_	_	_	_	_	_	Seg=O
100	kaempferol	_	_	_	_	_	_	_	Seg=O
101	were	_	_	_	_	_	_	_	Seg=B-seg
102	evaluated	_	_	_	_	_	_	_	Seg=O
103	for	_	_	_	_	_	_	_	Seg=O
104	their	_	_	_	_	_	_	_	Seg=O
105	in	_	_	_	_	_	_	_	Seg=O
106	vitro	_	_	_	_	_	_	_	Seg=O
107	antiviral	_	_	_	_	_	_	_	Seg=O
108	activities	_	_	_	_	_	_	_	Seg=O
109	against	_	_	_	_	_	_	_	Seg=O
110	CHIKV	_	_	_	_	_	_	_	Seg=O
111	using	_	_	_	_	_	_	_	Seg=B-seg
112	a	_	_	_	_	_	_	_	Seg=O
113	CHIKV	_	_	_	_	_	_	_	Seg=O
114	replicon	_	_	_	_	_	_	_	Seg=O
115	cell	_	_	_	_	_	_	_	Seg=O
116	line	_	_	_	_	_	_	_	Seg=O
117	and	_	_	_	_	_	_	_	Seg=O
118	clinical	_	_	_	_	_	_	_	Seg=O
119	isolate	_	_	_	_	_	_	_	Seg=O
120	of	_	_	_	_	_	_	_	Seg=O
121	CHIKV	_	_	_	_	_	_	_	Seg=O
122	of	_	_	_	_	_	_	_	Seg=O
123	Central	_	_	_	_	_	_	_	Seg=O
124	/	_	_	_	_	_	_	_	Seg=O
125	East	_	_	_	_	_	_	_	Seg=O
126	African	_	_	_	_	_	_	_	Seg=O
127	genotype	_	_	_	_	_	_	_	Seg=O
128	.	_	_	_	_	_	_	_	Seg=O
129	A	_	_	_	_	_	_	_	Seg=B-seg
130	cytopathic	_	_	_	_	_	_	_	Seg=O
131	effect	_	_	_	_	_	_	_	Seg=O
132	inhibition	_	_	_	_	_	_	_	Seg=O
133	assay	_	_	_	_	_	_	_	Seg=O
134	was	_	_	_	_	_	_	_	Seg=O
135	used	_	_	_	_	_	_	_	Seg=O
136	to	_	_	_	_	_	_	_	Seg=B-seg
137	determine	_	_	_	_	_	_	_	Seg=O
138	their	_	_	_	_	_	_	_	Seg=O
139	activities	_	_	_	_	_	_	_	Seg=O
140	on	_	_	_	_	_	_	_	Seg=O
141	CHIKV	_	_	_	_	_	_	_	Seg=O
142	viral	_	_	_	_	_	_	_	Seg=O
143	replication	_	_	_	_	_	_	_	Seg=O
144	and	_	_	_	_	_	_	_	Seg=B-seg
145	quantitative	_	_	_	_	_	_	_	Seg=O
146	reverse	_	_	_	_	_	_	_	Seg=O
147	transcription	_	_	_	_	_	_	_	Seg=O
148	PCR	_	_	_	_	_	_	_	Seg=O
149	was	_	_	_	_	_	_	_	Seg=O
150	used	_	_	_	_	_	_	_	Seg=O
151	to	_	_	_	_	_	_	_	Seg=B-seg
152	calculate	_	_	_	_	_	_	_	Seg=O
153	virus	_	_	_	_	_	_	_	Seg=O
154	yield	_	_	_	_	_	_	_	Seg=O
155	.	_	_	_	_	_	_	_	Seg=O
156	Antiviral	_	_	_	_	_	_	_	Seg=B-seg
157	activity	_	_	_	_	_	_	_	Seg=O
158	of	_	_	_	_	_	_	_	Seg=O
159	effective	_	_	_	_	_	_	_	Seg=O
160	compound	_	_	_	_	_	_	_	Seg=O
161	was	_	_	_	_	_	_	_	Seg=O
162	further	_	_	_	_	_	_	_	Seg=O
163	investigated	_	_	_	_	_	_	_	Seg=O
164	by	_	_	_	_	_	_	_	Seg=O
165	evaluation	_	_	_	_	_	_	_	Seg=O
166	of	_	_	_	_	_	_	_	Seg=O
167	CHIKV	_	_	_	_	_	_	_	Seg=O
168	protein	_	_	_	_	_	_	_	Seg=O
169	expression	_	_	_	_	_	_	_	Seg=O
170	using	_	_	_	_	_	_	_	Seg=B-seg
171	western	_	_	_	_	_	_	_	Seg=O
172	blotting	_	_	_	_	_	_	_	Seg=O
173	for	_	_	_	_	_	_	_	Seg=O
174	CHIKV	_	_	_	_	_	_	_	Seg=O
175	nsP1	_	_	_	_	_	_	_	Seg=O
176	,	_	_	_	_	_	_	_	Seg=O
177	nsP3	_	_	_	_	_	_	_	Seg=O
178	,	_	_	_	_	_	_	_	Seg=O
179	and	_	_	_	_	_	_	_	Seg=O
180	E2E1	_	_	_	_	_	_	_	Seg=O
181	proteins	_	_	_	_	_	_	_	Seg=O
182	.	_	_	_	_	_	_	_	Seg=O
183	Briefly	_	_	_	_	_	_	_	Seg=B-seg
184	,	_	_	_	_	_	_	_	Seg=O
185	silymarin	_	_	_	_	_	_	_	Seg=O
186	exhibited	_	_	_	_	_	_	_	Seg=O
187	significant	_	_	_	_	_	_	_	Seg=O
188	antiviral	_	_	_	_	_	_	_	Seg=O
189	activity	_	_	_	_	_	_	_	Seg=O
190	against	_	_	_	_	_	_	_	Seg=O
191	CHIKV	_	_	_	_	_	_	_	Seg=O
192	,	_	_	_	_	_	_	_	Seg=O
193	reducing	_	_	_	_	_	_	_	Seg=B-seg
194	both	_	_	_	_	_	_	_	Seg=O
195	CHIKV	_	_	_	_	_	_	_	Seg=O
196	replication	_	_	_	_	_	_	_	Seg=O
197	efficiency	_	_	_	_	_	_	_	Seg=O
198	and	_	_	_	_	_	_	_	Seg=O
199	down	_	_	_	_	_	_	_	Seg=O
200	-	_	_	_	_	_	_	_	Seg=O
201	regulating	_	_	_	_	_	_	_	Seg=O
202	production	_	_	_	_	_	_	_	Seg=O
203	of	_	_	_	_	_	_	_	Seg=O
204	viral	_	_	_	_	_	_	_	Seg=O
205	proteins	_	_	_	_	_	_	_	Seg=O
206	involved	_	_	_	_	_	_	_	Seg=B-seg
207	in	_	_	_	_	_	_	_	Seg=O
208	replication	_	_	_	_	_	_	_	Seg=O
209	.	_	_	_	_	_	_	_	Seg=O
210	This	_	_	_	_	_	_	_	Seg=B-seg
211	study	_	_	_	_	_	_	_	Seg=O
212	may	_	_	_	_	_	_	_	Seg=O
213	have	_	_	_	_	_	_	_	Seg=O
214	important	_	_	_	_	_	_	_	Seg=O
215	consequence	_	_	_	_	_	_	_	Seg=O
216	for	_	_	_	_	_	_	_	Seg=B-seg
217	broaden	_	_	_	_	_	_	_	Seg=O
218	the	_	_	_	_	_	_	_	Seg=O
219	chance	_	_	_	_	_	_	_	Seg=O
220	of	_	_	_	_	_	_	_	Seg=B-seg
221	getting	_	_	_	_	_	_	_	Seg=O
222	the	_	_	_	_	_	_	_	Seg=O
223	effective	_	_	_	_	_	_	_	Seg=O
224	antiviral	_	_	_	_	_	_	_	Seg=O
225	for	_	_	_	_	_	_	_	Seg=O
226	CHIKV	_	_	_	_	_	_	_	Seg=O
227	infection	_	_	_	_	_	_	_	Seg=O
228	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 43d2016cbba1ca1e17e68352c290dd58c52349ab
1	Background	_	_	_	_	_	_	_	Seg=B-seg
2	The	_	_	_	_	_	_	_	Seg=B-seg
3	aim	_	_	_	_	_	_	_	Seg=O
4	of	_	_	_	_	_	_	_	Seg=O
5	this	_	_	_	_	_	_	_	Seg=O
6	study	_	_	_	_	_	_	_	Seg=O
7	was	_	_	_	_	_	_	_	Seg=O
8	to	_	_	_	_	_	_	_	Seg=O
9	assess	_	_	_	_	_	_	_	Seg=O
10	multiplex	_	_	_	_	_	_	_	Seg=O
11	PCR	_	_	_	_	_	_	_	Seg=O
12	analysis	_	_	_	_	_	_	_	Seg=O
13	in	_	_	_	_	_	_	_	Seg=B-seg
14	detecting	_	_	_	_	_	_	_	Seg=O
15	causative	_	_	_	_	_	_	_	Seg=O
16	viruses	_	_	_	_	_	_	_	Seg=O
17	in	_	_	_	_	_	_	_	Seg=O
18	children	_	_	_	_	_	_	_	Seg=O
19	with	_	_	_	_	_	_	_	Seg=O
20	febrile	_	_	_	_	_	_	_	Seg=O
21	seizures	_	_	_	_	_	_	_	Seg=O
22	.	_	_	_	_	_	_	_	Seg=O
23	Methods	_	_	_	_	_	_	_	Seg=B-seg
24	The	_	_	_	_	_	_	_	Seg=B-seg
25	study	_	_	_	_	_	_	_	Seg=O
26	was	_	_	_	_	_	_	_	Seg=O
27	a	_	_	_	_	_	_	_	Seg=O
28	retrospective	_	_	_	_	_	_	_	Seg=O
29	analysis	_	_	_	_	_	_	_	Seg=O
30	comparing	_	_	_	_	_	_	_	Seg=B-seg
31	data	_	_	_	_	_	_	_	Seg=O
32	from	_	_	_	_	_	_	_	Seg=O
33	a	_	_	_	_	_	_	_	Seg=O
34	pre	_	_	_	_	_	_	_	Seg=O
35	-	_	_	_	_	_	_	_	Seg=O
36	multiplex	_	_	_	_	_	_	_	Seg=O
37	era	_	_	_	_	_	_	_	Seg=O
38	(	_	_	_	_	_	_	_	Seg=O
39	2009	_	_	_	_	_	_	_	Seg=O
40	)	_	_	_	_	_	_	_	Seg=O
41	with	_	_	_	_	_	_	_	Seg=O
42	a	_	_	_	_	_	_	_	Seg=O
43	period	_	_	_	_	_	_	_	Seg=O
44	after	_	_	_	_	_	_	_	Seg=O
45	the	_	_	_	_	_	_	_	Seg=O
46	introduction	_	_	_	_	_	_	_	Seg=O
47	of	_	_	_	_	_	_	_	Seg=O
48	routine	_	_	_	_	_	_	_	Seg=O
49	respiratory	_	_	_	_	_	_	_	Seg=O
50	multiplex	_	_	_	_	_	_	_	Seg=O
51	analysis	_	_	_	_	_	_	_	Seg=O
52	(	_	_	_	_	_	_	_	Seg=O
53	2010	_	_	_	_	_	_	_	Seg=O
54	-	_	_	_	_	_	_	_	Seg=O
55	2013	_	_	_	_	_	_	_	Seg=O
56	)	_	_	_	_	_	_	_	Seg=O
57	in	_	_	_	_	_	_	_	Seg=O
58	children	_	_	_	_	_	_	_	Seg=O
59	with	_	_	_	_	_	_	_	Seg=O
60	febrile	_	_	_	_	_	_	_	Seg=O
61	seizures	_	_	_	_	_	_	_	Seg=O
62	.	_	_	_	_	_	_	_	Seg=O
63	Results	_	_	_	_	_	_	_	Seg=B-seg
64	We	_	_	_	_	_	_	_	Seg=B-seg
65	included	_	_	_	_	_	_	_	Seg=O
66	200	_	_	_	_	_	_	_	Seg=O
67	children	_	_	_	_	_	_	_	Seg=O
68	with	_	_	_	_	_	_	_	Seg=O
69	febrile	_	_	_	_	_	_	_	Seg=O
70	seizures	_	_	_	_	_	_	_	Seg=O
71	(	_	_	_	_	_	_	_	Seg=B-seg
72	mean	_	_	_	_	_	_	_	Seg=O
73	age	_	_	_	_	_	_	_	Seg=O
74	:	_	_	_	_	_	_	_	Seg=O
75	29.5	_	_	_	_	_	_	_	Seg=O
76	±	_	_	_	_	_	_	_	Seg=O
77	1.4.months	_	_	_	_	_	_	_	Seg=O
78	;	_	_	_	_	_	_	_	Seg=O
79	104	_	_	_	_	_	_	_	Seg=O
80	male	_	_	_	_	_	_	_	Seg=O
81	)	_	_	_	_	_	_	_	Seg=O
82	in	_	_	_	_	_	_	_	Seg=B-seg
83	the	_	_	_	_	_	_	_	Seg=O
84	study	_	_	_	_	_	_	_	Seg=O
85	.	_	_	_	_	_	_	_	Seg=O
86	In	_	_	_	_	_	_	_	Seg=B-seg
87	2009	_	_	_	_	_	_	_	Seg=O
88	,	_	_	_	_	_	_	_	Seg=O
89	in	_	_	_	_	_	_	_	Seg=O
90	10	_	_	_	_	_	_	_	Seg=O
91	out	_	_	_	_	_	_	_	Seg=O
92	of	_	_	_	_	_	_	_	Seg=O
93	49	_	_	_	_	_	_	_	Seg=O
94	(	_	_	_	_	_	_	_	Seg=B-seg
95	20	_	_	_	_	_	_	_	Seg=O
96	%	_	_	_	_	_	_	_	Seg=O
97	)	_	_	_	_	_	_	_	Seg=O
98	children	_	_	_	_	_	_	_	Seg=B-seg
99	,	_	_	_	_	_	_	_	Seg=O
100	microbiology	_	_	_	_	_	_	_	Seg=O
101	testing	_	_	_	_	_	_	_	Seg=O
102	(	_	_	_	_	_	_	_	Seg=B-seg
103	bacterial	_	_	_	_	_	_	_	Seg=O
104	/	_	_	_	_	_	_	_	Seg=O
105	fungal	_	_	_	_	_	_	_	Seg=O
106	)	_	_	_	_	_	_	_	Seg=O
107	was	_	_	_	_	_	_	_	Seg=B-seg
108	positive	_	_	_	_	_	_	_	Seg=O
109	compared	_	_	_	_	_	_	_	Seg=B-seg
110	with	_	_	_	_	_	_	_	Seg=O
111	a	_	_	_	_	_	_	_	Seg=O
112	rate	_	_	_	_	_	_	_	Seg=O
113	of	_	_	_	_	_	_	_	Seg=O
114	74	_	_	_	_	_	_	_	Seg=O
115	out	_	_	_	_	_	_	_	Seg=O
116	of	_	_	_	_	_	_	_	Seg=O
117	151	_	_	_	_	_	_	_	Seg=O
118	(	_	_	_	_	_	_	_	Seg=B-seg
119	49	_	_	_	_	_	_	_	Seg=O
120	%	_	_	_	_	_	_	_	Seg=O
121	)	_	_	_	_	_	_	_	Seg=O
122	children	_	_	_	_	_	_	_	Seg=B-seg
123	during	_	_	_	_	_	_	_	Seg=O
124	2010	_	_	_	_	_	_	_	Seg=O
125	-	_	_	_	_	_	_	_	Seg=O
126	2013	_	_	_	_	_	_	_	Seg=O
127	(	_	_	_	_	_	_	_	Seg=B-seg
128	p	_	_	_	_	_	_	_	Seg=O
129	<	_	_	_	_	_	_	_	Seg=O
130	0.01	_	_	_	_	_	_	_	Seg=O
131	)	_	_	_	_	_	_	_	Seg=O
132	.	_	_	_	_	_	_	_	Seg=O
133	The	_	_	_	_	_	_	_	Seg=B-seg
134	rate	_	_	_	_	_	_	_	Seg=O
135	of	_	_	_	_	_	_	_	Seg=O
136	positive	_	_	_	_	_	_	_	Seg=O
137	virological	_	_	_	_	_	_	_	Seg=O
138	studies	_	_	_	_	_	_	_	Seg=O
139	increased	_	_	_	_	_	_	_	Seg=O
140	from	_	_	_	_	_	_	_	Seg=O
141	10	_	_	_	_	_	_	_	Seg=O
142	(	_	_	_	_	_	_	_	Seg=B-seg
143	20	_	_	_	_	_	_	_	Seg=O
144	%	_	_	_	_	_	_	_	Seg=O
145	)	_	_	_	_	_	_	_	Seg=O
146	in	_	_	_	_	_	_	_	Seg=B-seg
147	2009	_	_	_	_	_	_	_	Seg=O
148	to	_	_	_	_	_	_	_	Seg=O
149	73	_	_	_	_	_	_	_	Seg=O
150	(	_	_	_	_	_	_	_	Seg=B-seg
151	48.3	_	_	_	_	_	_	_	Seg=O
152	%	_	_	_	_	_	_	_	Seg=O
153	)	_	_	_	_	_	_	_	Seg=O
154	in	_	_	_	_	_	_	_	Seg=B-seg
155	the	_	_	_	_	_	_	_	Seg=O
156	period	_	_	_	_	_	_	_	Seg=O
157	2010	_	_	_	_	_	_	_	Seg=O
158	-	_	_	_	_	_	_	_	Seg=O
159	2013	_	_	_	_	_	_	_	Seg=O
160	(	_	_	_	_	_	_	_	Seg=B-seg
161	p	_	_	_	_	_	_	_	Seg=O
162	<	_	_	_	_	_	_	_	Seg=O
163	0.01	_	_	_	_	_	_	_	Seg=O
164	)	_	_	_	_	_	_	_	Seg=O
165	.	_	_	_	_	_	_	_	Seg=O
166	Multiplex	_	_	_	_	_	_	_	Seg=B-seg
167	PCR	_	_	_	_	_	_	_	Seg=O
168	analysis	_	_	_	_	_	_	_	Seg=O
169	confirmed	_	_	_	_	_	_	_	Seg=O
170	viral	_	_	_	_	_	_	_	Seg=O
171	infections	_	_	_	_	_	_	_	Seg=O
172	in	_	_	_	_	_	_	_	Seg=O
173	52	_	_	_	_	_	_	_	Seg=O
174	of	_	_	_	_	_	_	_	Seg=O
175	73	_	_	_	_	_	_	_	Seg=O
176	cases	_	_	_	_	_	_	_	Seg=O
177	(	_	_	_	_	_	_	_	Seg=B-seg
178	71.2	_	_	_	_	_	_	_	Seg=O
179	%	_	_	_	_	_	_	_	Seg=O
180	)	_	_	_	_	_	_	_	Seg=O
181	.	_	_	_	_	_	_	_	Seg=O
182	Conclusion	_	_	_	_	_	_	_	Seg=B-seg
183	Routine	_	_	_	_	_	_	_	Seg=B-seg
184	multiplex	_	_	_	_	_	_	_	Seg=O
185	PCR	_	_	_	_	_	_	_	Seg=O
186	analysis	_	_	_	_	_	_	_	Seg=O
187	fosters	_	_	_	_	_	_	_	Seg=O
188	the	_	_	_	_	_	_	_	Seg=O
189	detection	_	_	_	_	_	_	_	Seg=O
190	of	_	_	_	_	_	_	_	Seg=O
191	respiratory	_	_	_	_	_	_	_	Seg=O
192	viruses	_	_	_	_	_	_	_	Seg=O
193	in	_	_	_	_	_	_	_	Seg=O
194	children	_	_	_	_	_	_	_	Seg=O
195	with	_	_	_	_	_	_	_	Seg=O
196	febrile	_	_	_	_	_	_	_	Seg=O
197	seizure	_	_	_	_	_	_	_	Seg=O
198	.	_	_	_	_	_	_	_	Seg=O
199	The	_	_	_	_	_	_	_	Seg=B-seg
200	precise	_	_	_	_	_	_	_	Seg=O
201	role	_	_	_	_	_	_	_	Seg=O
202	of	_	_	_	_	_	_	_	Seg=O
203	multiplex	_	_	_	_	_	_	_	Seg=O
204	analysis	_	_	_	_	_	_	_	Seg=O
205	in	_	_	_	_	_	_	_	Seg=O
206	the	_	_	_	_	_	_	_	Seg=O
207	J.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 44436dae14d853ef48bf49b19ffb683eea51f798
1	The	_	_	_	_	_	_	_	Seg=B-seg
2	uncertainties	_	_	_	_	_	_	_	Seg=O
3	of	_	_	_	_	_	_	_	Seg=O
4	healthcare	_	_	_	_	_	_	_	Seg=O
5	payment	_	_	_	_	_	_	_	Seg=O
6	and	_	_	_	_	_	_	_	Seg=O
7	delivery	_	_	_	_	_	_	_	Seg=O
8	reform	_	_	_	_	_	_	_	Seg=O
9	on	_	_	_	_	_	_	_	Seg=O
10	income	_	_	_	_	_	_	_	Seg=O
11	and	_	_	_	_	_	_	_	Seg=O
12	care	_	_	_	_	_	_	_	Seg=O
13	process	_	_	_	_	_	_	_	Seg=O
14	have	_	_	_	_	_	_	_	Seg=O
15	created	_	_	_	_	_	_	_	Seg=O
16	a	_	_	_	_	_	_	_	Seg=O
17	sense	_	_	_	_	_	_	_	Seg=O
18	of	_	_	_	_	_	_	_	Seg=O
19	foreboding	_	_	_	_	_	_	_	Seg=O
20	,	_	_	_	_	_	_	_	Seg=O
21	concern	_	_	_	_	_	_	_	Seg=O
22	,	_	_	_	_	_	_	_	Seg=O
23	and	_	_	_	_	_	_	_	Seg=O
24	fear	_	_	_	_	_	_	_	Seg=O
25	that	_	_	_	_	_	_	_	Seg=B-seg
26	a	_	_	_	_	_	_	_	Seg=O
27	career	_	_	_	_	_	_	_	Seg=O
28	in	_	_	_	_	_	_	_	Seg=O
29	medicine	_	_	_	_	_	_	_	Seg=O
30	is	_	_	_	_	_	_	_	Seg=O
31	not	_	_	_	_	_	_	_	Seg=O
32	what	_	_	_	_	_	_	_	Seg=O
33	it	_	_	_	_	_	_	_	Seg=O
34	used	_	_	_	_	_	_	_	Seg=O
35	to	_	_	_	_	_	_	_	Seg=O
36	be	_	_	_	_	_	_	_	Seg=O
37	and	_	_	_	_	_	_	_	Seg=B-seg
38	that	_	_	_	_	_	_	_	Seg=O
39	a	_	_	_	_	_	_	_	Seg=O
40	career	_	_	_	_	_	_	_	Seg=O
41	in	_	_	_	_	_	_	_	Seg=O
42	infectious	_	_	_	_	_	_	_	Seg=O
43	diseases	_	_	_	_	_	_	_	Seg=O
44	in	_	_	_	_	_	_	_	Seg=O
45	particular	_	_	_	_	_	_	_	Seg=O
46	may	_	_	_	_	_	_	_	Seg=O
47	no	_	_	_	_	_	_	_	Seg=O
48	longer	_	_	_	_	_	_	_	Seg=O
49	be	_	_	_	_	_	_	_	Seg=O
50	viable	_	_	_	_	_	_	_	Seg=O
51	.	_	_	_	_	_	_	_	Seg=O
52	Fears	_	_	_	_	_	_	_	Seg=B-seg
53	have	_	_	_	_	_	_	_	Seg=O
54	been	_	_	_	_	_	_	_	Seg=O
55	raised	_	_	_	_	_	_	_	Seg=O
56	that	_	_	_	_	_	_	_	Seg=B-seg
57	the	_	_	_	_	_	_	_	Seg=O
58	need	_	_	_	_	_	_	_	Seg=O
59	for	_	_	_	_	_	_	_	Seg=O
60	infectious	_	_	_	_	_	_	_	Seg=O
61	diseases	_	_	_	_	_	_	_	Seg=O
62	consultation	_	_	_	_	_	_	_	Seg=O
63	and	_	_	_	_	_	_	_	Seg=O
64	management	_	_	_	_	_	_	_	Seg=O
65	will	_	_	_	_	_	_	_	Seg=O
66	be	_	_	_	_	_	_	_	Seg=O
67	curtailed	_	_	_	_	_	_	_	Seg=O
68	because	_	_	_	_	_	_	_	Seg=B-seg
69	we	_	_	_	_	_	_	_	Seg=O
70	provide	_	_	_	_	_	_	_	Seg=O
71	cognitive	_	_	_	_	_	_	_	Seg=O
72	services	_	_	_	_	_	_	_	Seg=O
73	that	_	_	_	_	_	_	_	Seg=B-seg
74	are	_	_	_	_	_	_	_	Seg=O
75	not	_	_	_	_	_	_	_	Seg=O
76	perceived	_	_	_	_	_	_	_	Seg=O
77	as	_	_	_	_	_	_	_	Seg=O
78	being	_	_	_	_	_	_	_	Seg=O
79	needed	_	_	_	_	_	_	_	Seg=O
80	in	_	_	_	_	_	_	_	Seg=O
81	a	_	_	_	_	_	_	_	Seg=O
82	health	_	_	_	_	_	_	_	Seg=O
83	system	_	_	_	_	_	_	_	Seg=O
84	filled	_	_	_	_	_	_	_	Seg=B-seg
85	with	_	_	_	_	_	_	_	Seg=O
86	intensivists	_	_	_	_	_	_	_	Seg=O
87	,	_	_	_	_	_	_	_	Seg=O
88	hospitalists	_	_	_	_	_	_	_	Seg=O
89	,	_	_	_	_	_	_	_	Seg=O
90	and	_	_	_	_	_	_	_	Seg=O
91	skilled	_	_	_	_	_	_	_	Seg=O
92	nursing	_	_	_	_	_	_	_	Seg=O
93	facility	_	_	_	_	_	_	_	Seg=O
94	physicians	_	_	_	_	_	_	_	Seg=O
95	.	_	_	_	_	_	_	_	Seg=O
96	Now	_	_	_	_	_	_	_	Seg=B-seg
97	is	_	_	_	_	_	_	_	Seg=O
98	the	_	_	_	_	_	_	_	Seg=O
99	time	_	_	_	_	_	_	_	Seg=O
100	for	_	_	_	_	_	_	_	Seg=O
101	us	_	_	_	_	_	_	_	Seg=O
102	to	_	_	_	_	_	_	_	Seg=O
103	reframe	_	_	_	_	_	_	_	Seg=O
104	our	_	_	_	_	_	_	_	Seg=O
105	role	_	_	_	_	_	_	_	Seg=O
106	in	_	_	_	_	_	_	_	Seg=O
107	the	_	_	_	_	_	_	_	Seg=O
108	health	_	_	_	_	_	_	_	Seg=O
109	system	_	_	_	_	_	_	_	Seg=O
110	that	_	_	_	_	_	_	_	Seg=B-seg
111	is	_	_	_	_	_	_	_	Seg=O
112	evolving	_	_	_	_	_	_	_	Seg=O
113	to	_	_	_	_	_	_	_	Seg=O
114	a	_	_	_	_	_	_	_	Seg=O
115	process	_	_	_	_	_	_	_	Seg=O
116	of	_	_	_	_	_	_	_	Seg=O
117	care	_	_	_	_	_	_	_	Seg=O
118	focused	_	_	_	_	_	_	_	Seg=B-seg
119	on	_	_	_	_	_	_	_	Seg=O
120	population	_	_	_	_	_	_	_	Seg=O
121	health	_	_	_	_	_	_	_	Seg=O
122	and	_	_	_	_	_	_	_	Seg=O
123	patient	_	_	_	_	_	_	_	Seg=O
124	safety	_	_	_	_	_	_	_	Seg=O
125	that	_	_	_	_	_	_	_	Seg=B-seg
126	pays	_	_	_	_	_	_	_	Seg=O
127	providers	_	_	_	_	_	_	_	Seg=O
128	for	_	_	_	_	_	_	_	Seg=O
129	value	_	_	_	_	_	_	_	Seg=O
130	they	_	_	_	_	_	_	_	Seg=B-seg
131	bring	_	_	_	_	_	_	_	Seg=O
132	to	_	_	_	_	_	_	_	Seg=B-seg
133	achieve	_	_	_	_	_	_	_	Seg=O
134	those	_	_	_	_	_	_	_	Seg=O
135	goals	_	_	_	_	_	_	_	Seg=O
136	.	_	_	_	_	_	_	_	Seg=O
137	Specific	_	_	_	_	_	_	_	Seg=B-seg
138	suggestions	_	_	_	_	_	_	_	Seg=O
139	are	_	_	_	_	_	_	_	Seg=O
140	made	_	_	_	_	_	_	_	Seg=O
141	to	_	_	_	_	_	_	_	Seg=B-seg
142	enhance	_	_	_	_	_	_	_	Seg=O
143	the	_	_	_	_	_	_	_	Seg=O
144	infectious	_	_	_	_	_	_	_	Seg=O
145	diseases	_	_	_	_	_	_	_	Seg=O
146-147	physician's	_	_	_	_	_	_	_	_
146	physician	_	_	_	_	_	_	_	Seg=O
147	's	_	_	_	_	_	_	_	Seg=O
148	profile	_	_	_	_	_	_	_	Seg=O
149	with	_	_	_	_	_	_	_	Seg=O
150	the	_	_	_	_	_	_	_	Seg=O
151	intent	_	_	_	_	_	_	_	Seg=O
152	of	_	_	_	_	_	_	_	Seg=B-seg
153	encouraging	_	_	_	_	_	_	_	Seg=O
154	debate	_	_	_	_	_	_	_	Seg=O
155	,	_	_	_	_	_	_	_	Seg=O
156	discussion	_	_	_	_	_	_	_	Seg=O
157	,	_	_	_	_	_	_	_	Seg=O
158	and	_	_	_	_	_	_	_	Seg=O
159	action	_	_	_	_	_	_	_	Seg=O
160	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 444cc65fbe22dd6583120260c488dd621ebadab4
1	Background	_	_	_	_	_	_	_	Seg=B-seg
2	:	_	_	_	_	_	_	_	Seg=O
3	The	_	_	_	_	_	_	_	Seg=B-seg
4	neutral	_	_	_	_	_	_	_	Seg=O
5	theory	_	_	_	_	_	_	_	Seg=O
6	of	_	_	_	_	_	_	_	Seg=O
7	Motoo	_	_	_	_	_	_	_	Seg=O
8	Kimura	_	_	_	_	_	_	_	Seg=O
9	stipulates	_	_	_	_	_	_	_	Seg=O
10	that	_	_	_	_	_	_	_	Seg=B-seg
11	evolution	_	_	_	_	_	_	_	Seg=O
12	is	_	_	_	_	_	_	_	Seg=O
13	mostly	_	_	_	_	_	_	_	Seg=O
14	driven	_	_	_	_	_	_	_	Seg=O
15	by	_	_	_	_	_	_	_	Seg=O
16	neutral	_	_	_	_	_	_	_	Seg=O
17	mutations	_	_	_	_	_	_	_	Seg=O
18	.	_	_	_	_	_	_	_	Seg=O
19	However	_	_	_	_	_	_	_	Seg=B-seg
20	adaptive	_	_	_	_	_	_	_	Seg=O
21	pressure	_	_	_	_	_	_	_	Seg=O
22	eventually	_	_	_	_	_	_	_	Seg=O
23	leads	_	_	_	_	_	_	_	Seg=O
24	to	_	_	_	_	_	_	_	Seg=O
25	changes	_	_	_	_	_	_	_	Seg=O
26	in	_	_	_	_	_	_	_	Seg=O
27	phenotype	_	_	_	_	_	_	_	Seg=O
28	that	_	_	_	_	_	_	_	Seg=B-seg
29	involve	_	_	_	_	_	_	_	Seg=O
30	non	_	_	_	_	_	_	_	Seg=O
31	-	_	_	_	_	_	_	_	Seg=O
32	neutral	_	_	_	_	_	_	_	Seg=O
33	mutations	_	_	_	_	_	_	_	Seg=O
34	.	_	_	_	_	_	_	_	Seg=O
35	The	_	_	_	_	_	_	_	Seg=B-seg
36	relation	_	_	_	_	_	_	_	Seg=O
37	between	_	_	_	_	_	_	_	Seg=O
38	neutrality	_	_	_	_	_	_	_	Seg=O
39	and	_	_	_	_	_	_	_	Seg=O
40	adaptation	_	_	_	_	_	_	_	Seg=O
41	has	_	_	_	_	_	_	_	Seg=O
42	been	_	_	_	_	_	_	_	Seg=O
43	studied	_	_	_	_	_	_	_	Seg=O
44	in	_	_	_	_	_	_	_	Seg=O
45	the	_	_	_	_	_	_	_	Seg=O
46	context	_	_	_	_	_	_	_	Seg=O
47	of	_	_	_	_	_	_	_	Seg=O
48	RNA	_	_	_	_	_	_	_	Seg=O
49	before	_	_	_	_	_	_	_	Seg=O
50	and	_	_	_	_	_	_	_	Seg=B-seg
51	here	_	_	_	_	_	_	_	Seg=O
52	we	_	_	_	_	_	_	_	Seg=O
53	further	_	_	_	_	_	_	_	Seg=O
54	study	_	_	_	_	_	_	_	Seg=O
55	transitional	_	_	_	_	_	_	_	Seg=O
56	mutations	_	_	_	_	_	_	_	Seg=O
57	in	_	_	_	_	_	_	_	Seg=O
58	the	_	_	_	_	_	_	_	Seg=O
59	context	_	_	_	_	_	_	_	Seg=O
60	of	_	_	_	_	_	_	_	Seg=O
61	degenerate	_	_	_	_	_	_	_	Seg=O
62	(	_	_	_	_	_	_	_	Seg=O
63	plastic	_	_	_	_	_	_	_	Seg=O
64	)	_	_	_	_	_	_	_	Seg=O
65	RNA	_	_	_	_	_	_	_	Seg=O
66	sequences	_	_	_	_	_	_	_	Seg=O
67	and	_	_	_	_	_	_	_	Seg=O
68	genetic	_	_	_	_	_	_	_	Seg=O
69	assimilation	_	_	_	_	_	_	_	Seg=O
70	.	_	_	_	_	_	_	_	Seg=O
71	We	_	_	_	_	_	_	_	Seg=B-seg
72	propose	_	_	_	_	_	_	_	Seg=O
73	quasineutral	_	_	_	_	_	_	_	Seg=O
74	mutations	_	_	_	_	_	_	_	Seg=O
75	,	_	_	_	_	_	_	_	Seg=O
76	i.e.	_	_	_	_	_	_	_	Seg=B-seg
77	mutations	_	_	_	_	_	_	_	Seg=O
78	which	_	_	_	_	_	_	_	Seg=B-seg
79	preserve	_	_	_	_	_	_	_	Seg=O
80	an	_	_	_	_	_	_	_	Seg=O
81	element	_	_	_	_	_	_	_	Seg=O
82	of	_	_	_	_	_	_	_	Seg=O
83	the	_	_	_	_	_	_	_	Seg=O
84	phenotype	_	_	_	_	_	_	_	Seg=O
85	set	_	_	_	_	_	_	_	Seg=O
86	,	_	_	_	_	_	_	_	Seg=O
87	as	_	_	_	_	_	_	_	Seg=B-seg
88	minimal	_	_	_	_	_	_	_	Seg=O
89	mutations	_	_	_	_	_	_	_	Seg=O
90	and	_	_	_	_	_	_	_	Seg=B-seg
91	study	_	_	_	_	_	_	_	Seg=O
92	their	_	_	_	_	_	_	_	Seg=O
93	properties	_	_	_	_	_	_	_	Seg=O
94	.	_	_	_	_	_	_	_	Seg=O
95	We	_	_	_	_	_	_	_	Seg=B-seg
96	also	_	_	_	_	_	_	_	Seg=O
97	propose	_	_	_	_	_	_	_	Seg=O
98	a	_	_	_	_	_	_	_	Seg=O
99	general	_	_	_	_	_	_	_	Seg=O
100	probabilistic	_	_	_	_	_	_	_	Seg=O
101	interpretation	_	_	_	_	_	_	_	Seg=O
102	of	_	_	_	_	_	_	_	Seg=O
103	genetic	_	_	_	_	_	_	_	Seg=O
104	assimilation	_	_	_	_	_	_	_	Seg=O
105	and	_	_	_	_	_	_	_	Seg=B-seg
106	specialize	_	_	_	_	_	_	_	Seg=O
107	it	_	_	_	_	_	_	_	Seg=O
108	to	_	_	_	_	_	_	_	Seg=O
109	the	_	_	_	_	_	_	_	Seg=O
110	Boltzmann	_	_	_	_	_	_	_	Seg=O
111	ensemble	_	_	_	_	_	_	_	Seg=O
112	of	_	_	_	_	_	_	_	Seg=O
113	RNA	_	_	_	_	_	_	_	Seg=O
114	sequences	_	_	_	_	_	_	_	Seg=O
115	.	_	_	_	_	_	_	_	Seg=O
116	Results	_	_	_	_	_	_	_	Seg=B-seg
117	:	_	_	_	_	_	_	_	Seg=O
118	We	_	_	_	_	_	_	_	Seg=B-seg
119	show	_	_	_	_	_	_	_	Seg=O
120	that	_	_	_	_	_	_	_	Seg=B-seg
121	degenerate	_	_	_	_	_	_	_	Seg=O
122	sequences	_	_	_	_	_	_	_	Seg=O
123	i.e.	_	_	_	_	_	_	_	Seg=B-seg
124	sequences	_	_	_	_	_	_	_	Seg=O
125	with	_	_	_	_	_	_	_	Seg=O
126	more	_	_	_	_	_	_	_	Seg=O
127	than	_	_	_	_	_	_	_	Seg=O
128	one	_	_	_	_	_	_	_	Seg=O
129	structure	_	_	_	_	_	_	_	Seg=O
130	at	_	_	_	_	_	_	_	Seg=O
131	the	_	_	_	_	_	_	_	Seg=O
132	MFE	_	_	_	_	_	_	_	Seg=O
133	level	_	_	_	_	_	_	_	Seg=O
134	have	_	_	_	_	_	_	_	Seg=B-seg
135	the	_	_	_	_	_	_	_	Seg=O
136	highest	_	_	_	_	_	_	_	Seg=O
137	evolvability	_	_	_	_	_	_	_	Seg=O
138	among	_	_	_	_	_	_	_	Seg=O
139	all	_	_	_	_	_	_	_	Seg=O
140	sequences	_	_	_	_	_	_	_	Seg=O
141	and	_	_	_	_	_	_	_	Seg=B-seg
142	are	_	_	_	_	_	_	_	Seg=O
143	central	_	_	_	_	_	_	_	Seg=O
144	to	_	_	_	_	_	_	_	Seg=O
145	evolutionary	_	_	_	_	_	_	_	Seg=O
146	innovation	_	_	_	_	_	_	_	Seg=O
147	.	_	_	_	_	_	_	_	Seg=O
148	Degenerate	_	_	_	_	_	_	_	Seg=B-seg
149	sequences	_	_	_	_	_	_	_	Seg=O
150	also	_	_	_	_	_	_	_	Seg=O
151	tend	_	_	_	_	_	_	_	Seg=O
152	to	_	_	_	_	_	_	_	Seg=O
153	cluster	_	_	_	_	_	_	_	Seg=O
154	together	_	_	_	_	_	_	_	Seg=O
155	in	_	_	_	_	_	_	_	Seg=O
156	the	_	_	_	_	_	_	_	Seg=O
157	sequence	_	_	_	_	_	_	_	Seg=O
158	space	_	_	_	_	_	_	_	Seg=O
159	.	_	_	_	_	_	_	_	Seg=O
160	The	_	_	_	_	_	_	_	Seg=B-seg
161	selective	_	_	_	_	_	_	_	Seg=O
162	pressure	_	_	_	_	_	_	_	Seg=O
163	in	_	_	_	_	_	_	_	Seg=O
164	an	_	_	_	_	_	_	_	Seg=O
165	evolutionary	_	_	_	_	_	_	_	Seg=O
166	simulation	_	_	_	_	_	_	_	Seg=O
167	causes	_	_	_	_	_	_	_	Seg=O
168	the	_	_	_	_	_	_	_	Seg=O
169	population	_	_	_	_	_	_	_	Seg=O
170	to	_	_	_	_	_	_	_	Seg=O
171	move	_	_	_	_	_	_	_	Seg=O
172	towards	_	_	_	_	_	_	_	Seg=O
173	regions	_	_	_	_	_	_	_	Seg=O
174	with	_	_	_	_	_	_	_	Seg=O
175	more	_	_	_	_	_	_	_	Seg=O
176	degenerate	_	_	_	_	_	_	_	Seg=O
177	sequences	_	_	_	_	_	_	_	Seg=O
178	,	_	_	_	_	_	_	_	Seg=O
179	i.e.	_	_	_	_	_	_	_	Seg=B-seg
180	regions	_	_	_	_	_	_	_	Seg=O
181	at	_	_	_	_	_	_	_	Seg=O
182	the	_	_	_	_	_	_	_	Seg=O
183	intersection	_	_	_	_	_	_	_	Seg=O
184	of	_	_	_	_	_	_	_	Seg=O
185	different	_	_	_	_	_	_	_	Seg=O
186	neutral	_	_	_	_	_	_	_	Seg=O
187	networks	_	_	_	_	_	_	_	Seg=O
188	,	_	_	_	_	_	_	_	Seg=O
189	and	_	_	_	_	_	_	_	Seg=B-seg
190	this	_	_	_	_	_	_	_	Seg=O
191	causes	_	_	_	_	_	_	_	Seg=O
192	the	_	_	_	_	_	_	_	Seg=O
193	number	_	_	_	_	_	_	_	Seg=O
194	of	_	_	_	_	_	_	_	Seg=O
195	such	_	_	_	_	_	_	_	Seg=O
196	sequences	_	_	_	_	_	_	_	Seg=O
197	to	_	_	_	_	_	_	_	Seg=O
198	increase	_	_	_	_	_	_	_	Seg=O
199	well	_	_	_	_	_	_	_	Seg=O
200	beyond	_	_	_	_	_	_	_	Seg=O
201	the	_	_	_	_	_	_	_	Seg=O
202	average	_	_	_	_	_	_	_	Seg=O
203	percentage	_	_	_	_	_	_	_	Seg=O
204	of	_	_	_	_	_	_	_	Seg=O
205	degenerate	_	_	_	_	_	_	_	Seg=O
206	sequences	_	_	_	_	_	_	_	Seg=O
207	in	_	_	_	_	_	_	_	Seg=O
208	the	_	_	_	_	_	_	_	Seg=O
209	sequence	_	_	_	_	_	_	_	Seg=O
210	space	_	_	_	_	_	_	_	Seg=O
211	.	_	_	_	_	_	_	_	Seg=O
212	We	_	_	_	_	_	_	_	Seg=B-seg
213	also	_	_	_	_	_	_	_	Seg=O
214	observe	_	_	_	_	_	_	_	Seg=O
215	that	_	_	_	_	_	_	_	Seg=B-seg
216	evolution	_	_	_	_	_	_	_	Seg=O
217	by	_	_	_	_	_	_	_	Seg=O
218	quasineutral	_	_	_	_	_	_	_	Seg=O
219	mutations	_	_	_	_	_	_	_	Seg=O
220	tends	_	_	_	_	_	_	_	Seg=O
221	to	_	_	_	_	_	_	_	Seg=O
222	conserve	_	_	_	_	_	_	_	Seg=O
223	the	_	_	_	_	_	_	_	Seg=O
224	number	_	_	_	_	_	_	_	Seg=O
225	of	_	_	_	_	_	_	_	Seg=O
226	base	_	_	_	_	_	_	_	Seg=O
227	pairs	_	_	_	_	_	_	_	Seg=O
228	in	_	_	_	_	_	_	_	Seg=O
229	structures	_	_	_	_	_	_	_	Seg=O
230	and	_	_	_	_	_	_	_	Seg=B-seg
231	thereby	_	_	_	_	_	_	_	Seg=O
232	maintains	_	_	_	_	_	_	_	Seg=O
233	structural	_	_	_	_	_	_	_	Seg=O
234	integrity	_	_	_	_	_	_	_	Seg=O
235	even	_	_	_	_	_	_	_	Seg=O
236	in	_	_	_	_	_	_	_	Seg=O
237	the	_	_	_	_	_	_	_	Seg=O
238	presence	_	_	_	_	_	_	_	Seg=O
239	of	_	_	_	_	_	_	_	Seg=O
240	pressure	_	_	_	_	_	_	_	Seg=O
241	to	_	_	_	_	_	_	_	Seg=O
242	the	_	_	_	_	_	_	_	Seg=O
243	contrary	_	_	_	_	_	_	_	Seg=O
244	.	_	_	_	_	_	_	_	Seg=O
245	Conclusions	_	_	_	_	_	_	_	Seg=B-seg
246	:	_	_	_	_	_	_	_	Seg=O
247	We	_	_	_	_	_	_	_	Seg=B-seg
248	conclude	_	_	_	_	_	_	_	Seg=O
249	that	_	_	_	_	_	_	_	Seg=B-seg
250	degenerate	_	_	_	_	_	_	_	Seg=O
251	RNA	_	_	_	_	_	_	_	Seg=O
252	sequences	_	_	_	_	_	_	_	Seg=O
253	play	_	_	_	_	_	_	_	Seg=O
254	a	_	_	_	_	_	_	_	Seg=O
255	major	_	_	_	_	_	_	_	Seg=O
256	role	_	_	_	_	_	_	_	Seg=O
257	in	_	_	_	_	_	_	_	Seg=O
258	evolutionary	_	_	_	_	_	_	_	Seg=O
259	adaptation	_	_	_	_	_	_	_	Seg=O
260	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 44970b3883429431bcec3d70c78b5f9ac5171eae
1	Novel	_	_	_	_	_	_	_	Seg=B-seg
2	pathogens	_	_	_	_	_	_	_	Seg=O
3	have	_	_	_	_	_	_	_	Seg=O
4	the	_	_	_	_	_	_	_	Seg=O
5	potential	_	_	_	_	_	_	_	Seg=O
6	to	_	_	_	_	_	_	_	Seg=B-seg
7	become	_	_	_	_	_	_	_	Seg=O
8	critical	_	_	_	_	_	_	_	Seg=O
9	issues	_	_	_	_	_	_	_	Seg=O
10	of	_	_	_	_	_	_	_	Seg=O
11	national	_	_	_	_	_	_	_	Seg=O
12	security	_	_	_	_	_	_	_	Seg=O
13	,	_	_	_	_	_	_	_	Seg=O
14	public	_	_	_	_	_	_	_	Seg=O
15	health	_	_	_	_	_	_	_	Seg=O
16	and	_	_	_	_	_	_	_	Seg=O
17	economic	_	_	_	_	_	_	_	Seg=O
18	welfare	_	_	_	_	_	_	_	Seg=O
19	.	_	_	_	_	_	_	_	Seg=O
20	As	_	_	_	_	_	_	_	Seg=B-seg
21	demonstrated	_	_	_	_	_	_	_	Seg=O
22	by	_	_	_	_	_	_	_	Seg=O
23	the	_	_	_	_	_	_	_	Seg=O
24	response	_	_	_	_	_	_	_	Seg=O
25	to	_	_	_	_	_	_	_	Seg=O
26	Severe	_	_	_	_	_	_	_	Seg=O
27	Acute	_	_	_	_	_	_	_	Seg=O
28	Respiratory	_	_	_	_	_	_	_	Seg=O
29	Syndrome	_	_	_	_	_	_	_	Seg=O
30	(	_	_	_	_	_	_	_	Seg=O
31	SARS	_	_	_	_	_	_	_	Seg=O
32	)	_	_	_	_	_	_	_	Seg=O
33	and	_	_	_	_	_	_	_	Seg=O
34	influenza	_	_	_	_	_	_	_	Seg=O
35	,	_	_	_	_	_	_	_	Seg=O
36	genomic	_	_	_	_	_	_	_	Seg=B-seg
37	sequencing	_	_	_	_	_	_	_	Seg=O
38	has	_	_	_	_	_	_	_	Seg=O
39	become	_	_	_	_	_	_	_	Seg=O
40	an	_	_	_	_	_	_	_	Seg=O
41	important	_	_	_	_	_	_	_	Seg=O
42	method	_	_	_	_	_	_	_	Seg=O
43	for	_	_	_	_	_	_	_	Seg=B-seg
44	diagnosing	_	_	_	_	_	_	_	Seg=O
45	agents	_	_	_	_	_	_	_	Seg=O
46	of	_	_	_	_	_	_	_	Seg=O
47	infectious	_	_	_	_	_	_	_	Seg=O
48	disease	_	_	_	_	_	_	_	Seg=O
49	.	_	_	_	_	_	_	_	Seg=O
50	Despite	_	_	_	_	_	_	_	Seg=B-seg
51	the	_	_	_	_	_	_	_	Seg=O
52	value	_	_	_	_	_	_	_	Seg=O
53	of	_	_	_	_	_	_	_	Seg=O
54	genomic	_	_	_	_	_	_	_	Seg=O
55	sequences	_	_	_	_	_	_	_	Seg=O
56	in	_	_	_	_	_	_	_	Seg=B-seg
57	characterizing	_	_	_	_	_	_	_	Seg=O
58	novel	_	_	_	_	_	_	_	Seg=O
59	pathogens	_	_	_	_	_	_	_	Seg=O
60	,	_	_	_	_	_	_	_	Seg=O
61	raw	_	_	_	_	_	_	_	Seg=B-seg
62	data	_	_	_	_	_	_	_	Seg=O
63	on	_	_	_	_	_	_	_	Seg=O
64	their	_	_	_	_	_	_	_	Seg=O
65	own	_	_	_	_	_	_	_	Seg=O
66	do	_	_	_	_	_	_	_	Seg=O
67	not	_	_	_	_	_	_	_	Seg=O
68	provide	_	_	_	_	_	_	_	Seg=O
69	the	_	_	_	_	_	_	_	Seg=O
70	information	_	_	_	_	_	_	_	Seg=O
71	needed	_	_	_	_	_	_	_	Seg=B-seg
72	by	_	_	_	_	_	_	_	Seg=O
73	public	_	_	_	_	_	_	_	Seg=O
74	health	_	_	_	_	_	_	_	Seg=O
75	officials	_	_	_	_	_	_	_	Seg=O
76	and	_	_	_	_	_	_	_	Seg=O
77	researchers	_	_	_	_	_	_	_	Seg=O
78	.	_	_	_	_	_	_	_	Seg=O
79	One	_	_	_	_	_	_	_	Seg=B-seg
80	must	_	_	_	_	_	_	_	Seg=O
81	integrate	_	_	_	_	_	_	_	Seg=O
82	knowledge	_	_	_	_	_	_	_	Seg=O
83	of	_	_	_	_	_	_	_	Seg=O
84	the	_	_	_	_	_	_	_	Seg=O
85	genomes	_	_	_	_	_	_	_	Seg=O
86	of	_	_	_	_	_	_	_	Seg=O
87	pathogens	_	_	_	_	_	_	_	Seg=O
88	with	_	_	_	_	_	_	_	Seg=O
89	host	_	_	_	_	_	_	_	Seg=O
90	biology	_	_	_	_	_	_	_	Seg=O
91	and	_	_	_	_	_	_	_	Seg=O
92	geography	_	_	_	_	_	_	_	Seg=O
93	to	_	_	_	_	_	_	_	Seg=B-seg
94	understand	_	_	_	_	_	_	_	Seg=O
95	the	_	_	_	_	_	_	_	Seg=O
96	etiology	_	_	_	_	_	_	_	Seg=O
97	of	_	_	_	_	_	_	_	Seg=O
98	epidemics	_	_	_	_	_	_	_	Seg=O
99	.	_	_	_	_	_	_	_	Seg=O
100	To	_	_	_	_	_	_	_	Seg=B-seg
101	these	_	_	_	_	_	_	_	Seg=O
102	ends	_	_	_	_	_	_	_	Seg=O
103	,	_	_	_	_	_	_	_	Seg=O
104	we	_	_	_	_	_	_	_	Seg=O
105	have	_	_	_	_	_	_	_	Seg=O
106	created	_	_	_	_	_	_	_	Seg=O
107	an	_	_	_	_	_	_	_	Seg=O
108	application	_	_	_	_	_	_	_	Seg=O
109	called	_	_	_	_	_	_	_	Seg=B-seg
110	Supramap	_	_	_	_	_	_	_	Seg=O
111	(	_	_	_	_	_	_	_	Seg=B-seg
112	http://supramap.osu.edu	_	_	_	_	_	_	_	Seg=O
113	)	_	_	_	_	_	_	_	Seg=O
114	to	_	_	_	_	_	_	_	Seg=B-seg
115	put	_	_	_	_	_	_	_	Seg=O
116	information	_	_	_	_	_	_	_	Seg=O
117	on	_	_	_	_	_	_	_	Seg=O
118	the	_	_	_	_	_	_	_	Seg=O
119	spread	_	_	_	_	_	_	_	Seg=O
120	of	_	_	_	_	_	_	_	Seg=O
121	pathogens	_	_	_	_	_	_	_	Seg=O
122	and	_	_	_	_	_	_	_	Seg=O
123	key	_	_	_	_	_	_	_	Seg=O
124	mutations	_	_	_	_	_	_	_	Seg=O
125	across	_	_	_	_	_	_	_	Seg=O
126	time	_	_	_	_	_	_	_	Seg=O
127	,	_	_	_	_	_	_	_	Seg=O
128	space	_	_	_	_	_	_	_	Seg=O
129	and	_	_	_	_	_	_	_	Seg=O
130	various	_	_	_	_	_	_	_	Seg=O
131	hosts	_	_	_	_	_	_	_	Seg=O
132	into	_	_	_	_	_	_	_	Seg=O
133	a	_	_	_	_	_	_	_	Seg=O
134	geographic	_	_	_	_	_	_	_	Seg=O
135	information	_	_	_	_	_	_	_	Seg=O
136	system	_	_	_	_	_	_	_	Seg=O
137	(	_	_	_	_	_	_	_	Seg=O
138	GIS	_	_	_	_	_	_	_	Seg=O
139	)	_	_	_	_	_	_	_	Seg=O
140	.	_	_	_	_	_	_	_	Seg=O
141	To	_	_	_	_	_	_	_	Seg=B-seg
142	build	_	_	_	_	_	_	_	Seg=O
143	this	_	_	_	_	_	_	_	Seg=O
144	application	_	_	_	_	_	_	_	Seg=O
145	,	_	_	_	_	_	_	_	Seg=O
146	we	_	_	_	_	_	_	_	Seg=B-seg
147	created	_	_	_	_	_	_	_	Seg=O
148	a	_	_	_	_	_	_	_	Seg=O
149	web	_	_	_	_	_	_	_	Seg=O
150	service	_	_	_	_	_	_	_	Seg=O
151	for	_	_	_	_	_	_	_	Seg=O
152	integrated	_	_	_	_	_	_	_	Seg=O
153	sequence	_	_	_	_	_	_	_	Seg=O
154	alignment	_	_	_	_	_	_	_	Seg=O
155	and	_	_	_	_	_	_	_	Seg=O
156	phylogenetic	_	_	_	_	_	_	_	Seg=O
157	analysis	_	_	_	_	_	_	_	Seg=O
158	as	_	_	_	_	_	_	_	Seg=O
159	well	_	_	_	_	_	_	_	Seg=O
160	as	_	_	_	_	_	_	_	Seg=O
161	methods	_	_	_	_	_	_	_	Seg=O
162	to	_	_	_	_	_	_	_	Seg=B-seg
163	describe	_	_	_	_	_	_	_	Seg=O
164	the	_	_	_	_	_	_	_	Seg=O
165	tree	_	_	_	_	_	_	_	Seg=O
166	,	_	_	_	_	_	_	_	Seg=O
167	mutations	_	_	_	_	_	_	_	Seg=O
168	,	_	_	_	_	_	_	_	Seg=O
169	and	_	_	_	_	_	_	_	Seg=O
170	host	_	_	_	_	_	_	_	Seg=O
171	shifts	_	_	_	_	_	_	_	Seg=O
172	in	_	_	_	_	_	_	_	Seg=O
173	Keyhole	_	_	_	_	_	_	_	Seg=O
174	Markup	_	_	_	_	_	_	_	Seg=O
175	Language	_	_	_	_	_	_	_	Seg=O
176	(	_	_	_	_	_	_	_	Seg=O
177	KML	_	_	_	_	_	_	_	Seg=O
178	)	_	_	_	_	_	_	_	Seg=O
179	.	_	_	_	_	_	_	_	Seg=O
180	We	_	_	_	_	_	_	_	Seg=B-seg
181	apply	_	_	_	_	_	_	_	Seg=O
182	the	_	_	_	_	_	_	_	Seg=O
183	application	_	_	_	_	_	_	_	Seg=O
184	to	_	_	_	_	_	_	_	Seg=O
185	239	_	_	_	_	_	_	_	Seg=O
186	sequences	_	_	_	_	_	_	_	Seg=O
187	of	_	_	_	_	_	_	_	Seg=O
188	the	_	_	_	_	_	_	_	Seg=O
189	polymerase	_	_	_	_	_	_	_	Seg=O
190	basic	_	_	_	_	_	_	_	Seg=O
191	2	_	_	_	_	_	_	_	Seg=O
192	(	_	_	_	_	_	_	_	Seg=O
193	PB2	_	_	_	_	_	_	_	Seg=O
194	)	_	_	_	_	_	_	_	Seg=O
195	gene	_	_	_	_	_	_	_	Seg=O
196	of	_	_	_	_	_	_	_	Seg=O
197	recent	_	_	_	_	_	_	_	Seg=O
198	isolates	_	_	_	_	_	_	_	Seg=O
199	of	_	_	_	_	_	_	_	Seg=O
200	avian	_	_	_	_	_	_	_	Seg=O
201	influenza	_	_	_	_	_	_	_	Seg=O
202	(	_	_	_	_	_	_	_	Seg=O
203	H5N1	_	_	_	_	_	_	_	Seg=O
204	)	_	_	_	_	_	_	_	Seg=O
205	.	_	_	_	_	_	_	_	Seg=O
206	We	_	_	_	_	_	_	_	Seg=B-seg
207	map	_	_	_	_	_	_	_	Seg=O
208	a	_	_	_	_	_	_	_	Seg=O
209	mutation	_	_	_	_	_	_	_	Seg=O
210	,	_	_	_	_	_	_	_	Seg=O
211	glutamic	_	_	_	_	_	_	_	Seg=O
212	acid	_	_	_	_	_	_	_	Seg=O
213	to	_	_	_	_	_	_	_	Seg=O
214	lysine	_	_	_	_	_	_	_	Seg=O
215	at	_	_	_	_	_	_	_	Seg=O
216	position	_	_	_	_	_	_	_	Seg=O
217	627	_	_	_	_	_	_	_	Seg=O
218	in	_	_	_	_	_	_	_	Seg=O
219	the	_	_	_	_	_	_	_	Seg=O
220	PB2	_	_	_	_	_	_	_	Seg=O
221	protein	_	_	_	_	_	_	_	Seg=O
222	(	_	_	_	_	_	_	_	Seg=O
223	E627	_	_	_	_	_	_	_	Seg=O
224	K	_	_	_	_	_	_	_	Seg=O
225	)	_	_	_	_	_	_	_	Seg=O
226	,	_	_	_	_	_	_	_	Seg=O
227	in	_	_	_	_	_	_	_	Seg=O
228	H5N1	_	_	_	_	_	_	_	Seg=O
229	influenza	_	_	_	_	_	_	_	Seg=O
230	that	_	_	_	_	_	_	_	Seg=B-seg
231	allows	_	_	_	_	_	_	_	Seg=O
232	for	_	_	_	_	_	_	_	Seg=O
233	increased	_	_	_	_	_	_	_	Seg=O
234	replication	_	_	_	_	_	_	_	Seg=O
235	of	_	_	_	_	_	_	_	Seg=O
236	the	_	_	_	_	_	_	_	Seg=O
237	virus	_	_	_	_	_	_	_	Seg=O
238	in	_	_	_	_	_	_	_	Seg=O
239	mammals	_	_	_	_	_	_	_	Seg=O
240	.	_	_	_	_	_	_	_	Seg=O
241	We	_	_	_	_	_	_	_	Seg=B-seg
242	use	_	_	_	_	_	_	_	Seg=O
243	a	_	_	_	_	_	_	_	Seg=O
244	statistical	_	_	_	_	_	_	_	Seg=O
245	test	_	_	_	_	_	_	_	Seg=O
246	to	_	_	_	_	_	_	_	Seg=B-seg
247	support	_	_	_	_	_	_	_	Seg=O
248	the	_	_	_	_	_	_	_	Seg=O
249	hypothesis	_	_	_	_	_	_	_	Seg=O
250	of	_	_	_	_	_	_	_	Seg=O
251	a	_	_	_	_	_	_	_	Seg=O
252	correlation	_	_	_	_	_	_	_	Seg=O
253	of	_	_	_	_	_	_	_	Seg=O
254	E627	_	_	_	_	_	_	_	Seg=O
255	K	_	_	_	_	_	_	_	Seg=O
256	mutations	_	_	_	_	_	_	_	Seg=O
257	with	_	_	_	_	_	_	_	Seg=O
258	avian	_	_	_	_	_	_	_	Seg=O
259	-	_	_	_	_	_	_	_	Seg=O
260	mammalian	_	_	_	_	_	_	_	Seg=O
261	host	_	_	_	_	_	_	_	Seg=O
262	shifts	_	_	_	_	_	_	_	Seg=O
263	but	_	_	_	_	_	_	_	Seg=B-seg
264	reject	_	_	_	_	_	_	_	Seg=O
265	the	_	_	_	_	_	_	_	Seg=O
266	hypothesis	_	_	_	_	_	_	_	Seg=O
267	that	_	_	_	_	_	_	_	Seg=B-seg
268	lineages	_	_	_	_	_	_	_	Seg=O
269	with	_	_	_	_	_	_	_	Seg=O
270	E627	_	_	_	_	_	_	_	Seg=O
271	K	_	_	_	_	_	_	_	Seg=O
272	are	_	_	_	_	_	_	_	Seg=O
273	moving	_	_	_	_	_	_	_	Seg=O
274	westward	_	_	_	_	_	_	_	Seg=O
275	.	_	_	_	_	_	_	_	Seg=O
276	Data	_	_	_	_	_	_	_	Seg=B-seg
277	,	_	_	_	_	_	_	_	Seg=O
278	instructions	_	_	_	_	_	_	_	Seg=O
279	for	_	_	_	_	_	_	_	Seg=O
280	use	_	_	_	_	_	_	_	Seg=O
281	,	_	_	_	_	_	_	_	Seg=O
282	and	_	_	_	_	_	_	_	Seg=O
283	visualizations	_	_	_	_	_	_	_	Seg=O
284	are	_	_	_	_	_	_	_	Seg=O
285	included	_	_	_	_	_	_	_	Seg=O
286	as	_	_	_	_	_	_	_	Seg=O
287	supplemental	_	_	_	_	_	_	_	Seg=O
288	materials	_	_	_	_	_	_	_	Seg=O
289	at	_	_	_	_	_	_	_	Seg=O
290	:	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 45566b6f9efb4bb0f40394a60c10c14bc2a70471
1	In	_	_	_	_	_	_	_	Seg=B-seg
2	a	_	_	_	_	_	_	_	Seg=O
3	preliminary	_	_	_	_	_	_	_	Seg=O
4	clinical	_	_	_	_	_	_	_	Seg=O
5	study	_	_	_	_	_	_	_	Seg=O
6	,	_	_	_	_	_	_	_	Seg=O
7	we	_	_	_	_	_	_	_	Seg=O
8	observed	_	_	_	_	_	_	_	Seg=O
9	that	_	_	_	_	_	_	_	Seg=B-seg
10	the	_	_	_	_	_	_	_	Seg=O
11	combination	_	_	_	_	_	_	_	Seg=O
12	of	_	_	_	_	_	_	_	Seg=O
13	hydroxychloroquine	_	_	_	_	_	_	_	Seg=O
14	and	_	_	_	_	_	_	_	Seg=O
15	azithromycin	_	_	_	_	_	_	_	Seg=O
16	was	_	_	_	_	_	_	_	Seg=O
17	effective	_	_	_	_	_	_	_	Seg=O
18	against	_	_	_	_	_	_	_	Seg=O
19	SARS	_	_	_	_	_	_	_	Seg=O
20	-	_	_	_	_	_	_	_	Seg=O
21	CoV-2	_	_	_	_	_	_	_	Seg=O
22	by	_	_	_	_	_	_	_	Seg=B-seg
23	shortening	_	_	_	_	_	_	_	Seg=O
24	the	_	_	_	_	_	_	_	Seg=O
25	duration	_	_	_	_	_	_	_	Seg=O
26	of	_	_	_	_	_	_	_	Seg=O
27	viral	_	_	_	_	_	_	_	Seg=O
28	load	_	_	_	_	_	_	_	Seg=O
29	in	_	_	_	_	_	_	_	Seg=O
30	Covid-19	_	_	_	_	_	_	_	Seg=O
31	patients	_	_	_	_	_	_	_	Seg=O
32	.	_	_	_	_	_	_	_	Seg=O
33	It	_	_	_	_	_	_	_	Seg=B-seg
34	is	_	_	_	_	_	_	_	Seg=O
35	of	_	_	_	_	_	_	_	Seg=O
36	paramount	_	_	_	_	_	_	_	Seg=O
37	importance	_	_	_	_	_	_	_	Seg=O
38	to	_	_	_	_	_	_	_	Seg=O
39	define	_	_	_	_	_	_	_	Seg=O
40	when	_	_	_	_	_	_	_	Seg=O
41	a	_	_	_	_	_	_	_	Seg=O
42	treated	_	_	_	_	_	_	_	Seg=O
43	patient	_	_	_	_	_	_	_	Seg=O
44	can	_	_	_	_	_	_	_	Seg=O
45	be	_	_	_	_	_	_	_	Seg=O
46	considered	_	_	_	_	_	_	_	Seg=O
47	as	_	_	_	_	_	_	_	Seg=O
48	no	_	_	_	_	_	_	_	Seg=O
49	longer	_	_	_	_	_	_	_	Seg=O
50	contagious	_	_	_	_	_	_	_	Seg=O
51	.	_	_	_	_	_	_	_	Seg=O
52	Correlation	_	_	_	_	_	_	_	Seg=B-seg
53	between	_	_	_	_	_	_	_	Seg=O
54	successful	_	_	_	_	_	_	_	Seg=O
55	isolation	_	_	_	_	_	_	_	Seg=O
56	of	_	_	_	_	_	_	_	Seg=O
57	virus	_	_	_	_	_	_	_	Seg=O
58	in	_	_	_	_	_	_	_	Seg=O
59	cell	_	_	_	_	_	_	_	Seg=O
60	culture	_	_	_	_	_	_	_	Seg=O
61	and	_	_	_	_	_	_	_	Seg=O
62	Ct	_	_	_	_	_	_	_	Seg=O
63	value	_	_	_	_	_	_	_	Seg=O
64	of	_	_	_	_	_	_	_	Seg=O
65	quantitative	_	_	_	_	_	_	_	Seg=O
66	RT	_	_	_	_	_	_	_	Seg=O
67	-	_	_	_	_	_	_	_	Seg=O
68	PCR	_	_	_	_	_	_	_	Seg=O
69	targeting	_	_	_	_	_	_	_	Seg=O
70	E	_	_	_	_	_	_	_	Seg=O
71	gene	_	_	_	_	_	_	_	Seg=O
72	suggests	_	_	_	_	_	_	_	Seg=O
73	that	_	_	_	_	_	_	_	Seg=B-seg
74	patients	_	_	_	_	_	_	_	Seg=O
75	with	_	_	_	_	_	_	_	Seg=O
76	Ct	_	_	_	_	_	_	_	Seg=O
77	above	_	_	_	_	_	_	_	Seg=O
78	33	_	_	_	_	_	_	_	Seg=O
79	-	_	_	_	_	_	_	_	Seg=O
80	34	_	_	_	_	_	_	_	Seg=O
81	using	_	_	_	_	_	_	_	Seg=B-seg
82	our	_	_	_	_	_	_	_	Seg=O
83	RT	_	_	_	_	_	_	_	Seg=O
84	-	_	_	_	_	_	_	_	Seg=O
85	PCR	_	_	_	_	_	_	_	Seg=O
86	system	_	_	_	_	_	_	_	Seg=O
87	are	_	_	_	_	_	_	_	Seg=B-seg
88	not	_	_	_	_	_	_	_	Seg=O
89	contagious	_	_	_	_	_	_	_	Seg=O
90	and	_	_	_	_	_	_	_	Seg=B-seg
91	thus	_	_	_	_	_	_	_	Seg=O
92	can	_	_	_	_	_	_	_	Seg=O
93	be	_	_	_	_	_	_	_	Seg=O
94	discharged	_	_	_	_	_	_	_	Seg=O
95	from	_	_	_	_	_	_	_	Seg=O
96	hospital	_	_	_	_	_	_	_	Seg=O
97	care	_	_	_	_	_	_	_	Seg=O
98	or	_	_	_	_	_	_	_	Seg=O
99	strict	_	_	_	_	_	_	_	Seg=O
100	confinement	_	_	_	_	_	_	_	Seg=O
101	for	_	_	_	_	_	_	_	Seg=O
102	non	_	_	_	_	_	_	_	Seg=O
103	-	_	_	_	_	_	_	_	Seg=O
104	hospitalized	_	_	_	_	_	_	_	Seg=O
105	patients	_	_	_	_	_	_	_	Seg=O
106	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 4589d4013cf69c396e0fdb67131022fc11119654
1	In	_	_	_	_	_	_	_	Seg=B-seg
2	early	_	_	_	_	_	_	_	Seg=O
3	2013	_	_	_	_	_	_	_	Seg=O
4	,	_	_	_	_	_	_	_	Seg=O
5	a	_	_	_	_	_	_	_	Seg=O
6	novel	_	_	_	_	_	_	_	Seg=O
7	avian	_	_	_	_	_	_	_	Seg=O
8	-	_	_	_	_	_	_	_	Seg=O
9	origin	_	_	_	_	_	_	_	Seg=O
10	influenza	_	_	_	_	_	_	_	Seg=O
11	A(H7N9	_	_	_	_	_	_	_	Seg=O
12	)	_	_	_	_	_	_	_	Seg=O
13	virus	_	_	_	_	_	_	_	Seg=O
14	emerged	_	_	_	_	_	_	_	Seg=O
15	in	_	_	_	_	_	_	_	Seg=O
16	China	_	_	_	_	_	_	_	Seg=O
17	,	_	_	_	_	_	_	_	Seg=O
18	and	_	_	_	_	_	_	_	Seg=B-seg
19	has	_	_	_	_	_	_	_	Seg=O
20	caused	_	_	_	_	_	_	_	Seg=O
21	sporadic	_	_	_	_	_	_	_	Seg=O
22	human	_	_	_	_	_	_	_	Seg=O
23	infections	_	_	_	_	_	_	_	Seg=O
24	.	_	_	_	_	_	_	_	Seg=O
25	The	_	_	_	_	_	_	_	Seg=B-seg
26	incubation	_	_	_	_	_	_	_	Seg=O
27	period	_	_	_	_	_	_	_	Seg=O
28	is	_	_	_	_	_	_	_	Seg=O
29	the	_	_	_	_	_	_	_	Seg=O
30	delay	_	_	_	_	_	_	_	Seg=O
31	from	_	_	_	_	_	_	_	Seg=O
32	infection	_	_	_	_	_	_	_	Seg=O
33	until	_	_	_	_	_	_	_	Seg=O
34	onset	_	_	_	_	_	_	_	Seg=O
35	of	_	_	_	_	_	_	_	Seg=O
36	symptoms	_	_	_	_	_	_	_	Seg=O
37	,	_	_	_	_	_	_	_	Seg=O
38	and	_	_	_	_	_	_	_	Seg=B-seg
39	varies	_	_	_	_	_	_	_	Seg=O
40	from	_	_	_	_	_	_	_	Seg=O
41	person	_	_	_	_	_	_	_	Seg=O
42	to	_	_	_	_	_	_	_	Seg=O
43	person	_	_	_	_	_	_	_	Seg=O
44	.	_	_	_	_	_	_	_	Seg=O
45	Few	_	_	_	_	_	_	_	Seg=B-seg
46	previous	_	_	_	_	_	_	_	Seg=O
47	studies	_	_	_	_	_	_	_	Seg=O
48	have	_	_	_	_	_	_	_	Seg=O
49	examined	_	_	_	_	_	_	_	Seg=O
50	whether	_	_	_	_	_	_	_	Seg=O
51	the	_	_	_	_	_	_	_	Seg=O
52	duration	_	_	_	_	_	_	_	Seg=O
53	of	_	_	_	_	_	_	_	Seg=O
54	the	_	_	_	_	_	_	_	Seg=O
55	incubation	_	_	_	_	_	_	_	Seg=O
56	period	_	_	_	_	_	_	_	Seg=O
57	correlates	_	_	_	_	_	_	_	Seg=O
58	with	_	_	_	_	_	_	_	Seg=O
59	subsequent	_	_	_	_	_	_	_	Seg=O
60	disease	_	_	_	_	_	_	_	Seg=O
61	severity	_	_	_	_	_	_	_	Seg=O
62	.	_	_	_	_	_	_	_	Seg=O
63	We	_	_	_	_	_	_	_	Seg=B-seg
64	analyzed	_	_	_	_	_	_	_	Seg=O
65	data	_	_	_	_	_	_	_	Seg=O
66	of	_	_	_	_	_	_	_	Seg=O
67	period	_	_	_	_	_	_	_	Seg=O
68	of	_	_	_	_	_	_	_	Seg=O
69	exposure	_	_	_	_	_	_	_	Seg=O
70	on	_	_	_	_	_	_	_	Seg=O
71	395	_	_	_	_	_	_	_	Seg=O
72	human	_	_	_	_	_	_	_	Seg=O
73	cases	_	_	_	_	_	_	_	Seg=O
74	of	_	_	_	_	_	_	_	Seg=O
75	laboratory	_	_	_	_	_	_	_	Seg=O
76	-	_	_	_	_	_	_	_	Seg=O
77	confirmed	_	_	_	_	_	_	_	Seg=O
78	influenza	_	_	_	_	_	_	_	Seg=O
79	A(H7N9	_	_	_	_	_	_	_	Seg=O
80	)	_	_	_	_	_	_	_	Seg=O
81	virus	_	_	_	_	_	_	_	Seg=O
82	infection	_	_	_	_	_	_	_	Seg=O
83	in	_	_	_	_	_	_	_	Seg=O
84	China	_	_	_	_	_	_	_	Seg=O
85	in	_	_	_	_	_	_	_	Seg=O
86	a	_	_	_	_	_	_	_	Seg=O
87	Bayesian	_	_	_	_	_	_	_	Seg=O
88	framework	_	_	_	_	_	_	_	Seg=O
89	using	_	_	_	_	_	_	_	Seg=B-seg
90	a	_	_	_	_	_	_	_	Seg=O
91	Weibull	_	_	_	_	_	_	_	Seg=O
92	distribution	_	_	_	_	_	_	_	Seg=O
93	.	_	_	_	_	_	_	_	Seg=O
94	We	_	_	_	_	_	_	_	Seg=B-seg
95	found	_	_	_	_	_	_	_	Seg=O
96	a	_	_	_	_	_	_	_	Seg=O
97	longer	_	_	_	_	_	_	_	Seg=O
98	incubation	_	_	_	_	_	_	_	Seg=O
99	period	_	_	_	_	_	_	_	Seg=O
100	for	_	_	_	_	_	_	_	Seg=O
101	the	_	_	_	_	_	_	_	Seg=O
102	173	_	_	_	_	_	_	_	Seg=O
103	fatal	_	_	_	_	_	_	_	Seg=O
104	cases	_	_	_	_	_	_	_	Seg=O
105	with	_	_	_	_	_	_	_	Seg=O
106	a	_	_	_	_	_	_	_	Seg=O
107	mean	_	_	_	_	_	_	_	Seg=O
108	of	_	_	_	_	_	_	_	Seg=O
109	3.7	_	_	_	_	_	_	_	Seg=O
110	days	_	_	_	_	_	_	_	Seg=O
111	(	_	_	_	_	_	_	_	Seg=B-seg
112	95	_	_	_	_	_	_	_	Seg=O
113	%	_	_	_	_	_	_	_	Seg=O
114	credibility	_	_	_	_	_	_	_	Seg=O
115	interval	_	_	_	_	_	_	_	Seg=O
116	,	_	_	_	_	_	_	_	Seg=O
117	CrI	_	_	_	_	_	_	_	Seg=O
118	:	_	_	_	_	_	_	_	Seg=O
119	3.4	_	_	_	_	_	_	_	Seg=O
120	-	_	_	_	_	_	_	_	Seg=O
121	4.1	_	_	_	_	_	_	_	Seg=O
122	)	_	_	_	_	_	_	_	Seg=O
123	,	_	_	_	_	_	_	_	Seg=O
124	compared	_	_	_	_	_	_	_	Seg=B-seg
125	to	_	_	_	_	_	_	_	Seg=O
126	a	_	_	_	_	_	_	_	Seg=O
127	mean	_	_	_	_	_	_	_	Seg=O
128	of	_	_	_	_	_	_	_	Seg=O
129	3.3	_	_	_	_	_	_	_	Seg=O
130	days	_	_	_	_	_	_	_	Seg=O
131	(	_	_	_	_	_	_	_	Seg=B-seg
132	95	_	_	_	_	_	_	_	Seg=O
133	%	_	_	_	_	_	_	_	Seg=O
134	CrI	_	_	_	_	_	_	_	Seg=O
135	:	_	_	_	_	_	_	_	Seg=O
136	2.9	_	_	_	_	_	_	_	Seg=O
137	-	_	_	_	_	_	_	_	Seg=O
138	3.6	_	_	_	_	_	_	_	Seg=O
139	)	_	_	_	_	_	_	_	Seg=O
140	for	_	_	_	_	_	_	_	Seg=B-seg
141	the	_	_	_	_	_	_	_	Seg=O
142	222	_	_	_	_	_	_	_	Seg=O
143	non	_	_	_	_	_	_	_	Seg=O
144	-	_	_	_	_	_	_	_	Seg=O
145	fatal	_	_	_	_	_	_	_	Seg=O
146	cases	_	_	_	_	_	_	_	Seg=O
147	,	_	_	_	_	_	_	_	Seg=O
148	and	_	_	_	_	_	_	_	Seg=B-seg
149	the	_	_	_	_	_	_	_	Seg=O
150	difference	_	_	_	_	_	_	_	Seg=O
151	in	_	_	_	_	_	_	_	Seg=O
152	means	_	_	_	_	_	_	_	Seg=O
153	was	_	_	_	_	_	_	_	Seg=O
154	marginally	_	_	_	_	_	_	_	Seg=O
155	significant	_	_	_	_	_	_	_	Seg=O
156	at	_	_	_	_	_	_	_	Seg=O
157	0.47	_	_	_	_	_	_	_	Seg=O
158	days	_	_	_	_	_	_	_	Seg=O
159	(	_	_	_	_	_	_	_	Seg=B-seg
160	95	_	_	_	_	_	_	_	Seg=O
161	%	_	_	_	_	_	_	_	Seg=O
162	CrI	_	_	_	_	_	_	_	Seg=O
163	:	_	_	_	_	_	_	_	Seg=O
164	-0.04	_	_	_	_	_	_	_	Seg=O
165	,	_	_	_	_	_	_	_	Seg=O
166	0.99	_	_	_	_	_	_	_	Seg=O
167	)	_	_	_	_	_	_	_	Seg=O
168	.	_	_	_	_	_	_	_	Seg=O
169	There	_	_	_	_	_	_	_	Seg=B-seg
170	was	_	_	_	_	_	_	_	Seg=O
171	a	_	_	_	_	_	_	_	Seg=O
172	statistically	_	_	_	_	_	_	_	Seg=O
173	significant	_	_	_	_	_	_	_	Seg=O
174	correlation	_	_	_	_	_	_	_	Seg=O
175	between	_	_	_	_	_	_	_	Seg=O
176	a	_	_	_	_	_	_	_	Seg=O
177	longer	_	_	_	_	_	_	_	Seg=O
178	incubation	_	_	_	_	_	_	_	Seg=O
179	period	_	_	_	_	_	_	_	Seg=O
180	and	_	_	_	_	_	_	_	Seg=O
181	an	_	_	_	_	_	_	_	Seg=O
182	increased	_	_	_	_	_	_	_	Seg=O
183	risk	_	_	_	_	_	_	_	Seg=O
184	of	_	_	_	_	_	_	_	Seg=O
185	death	_	_	_	_	_	_	_	Seg=O
186	after	_	_	_	_	_	_	_	Seg=O
187	adjustment	_	_	_	_	_	_	_	Seg=O
188	for	_	_	_	_	_	_	_	Seg=O
189	age	_	_	_	_	_	_	_	Seg=O
190	,	_	_	_	_	_	_	_	Seg=O
191	sex	_	_	_	_	_	_	_	Seg=O
192	,	_	_	_	_	_	_	_	Seg=O
193	geographical	_	_	_	_	_	_	_	Seg=O
194	location	_	_	_	_	_	_	_	Seg=O
195	and	_	_	_	_	_	_	_	Seg=O
196	underlying	_	_	_	_	_	_	_	Seg=O
197	medical	_	_	_	_	_	_	_	Seg=O
198	conditions	_	_	_	_	_	_	_	Seg=O
199	(	_	_	_	_	_	_	_	Seg=B-seg
200	adjusted	_	_	_	_	_	_	_	Seg=O
201	odds	_	_	_	_	_	_	_	Seg=O
202	ratio	_	_	_	_	_	_	_	Seg=O
203	1.70	_	_	_	_	_	_	_	Seg=O
204	per	_	_	_	_	_	_	_	Seg=O
205	day	_	_	_	_	_	_	_	Seg=O
206	increase	_	_	_	_	_	_	_	Seg=O
207	in	_	_	_	_	_	_	_	Seg=O
208	incubation	_	_	_	_	_	_	_	Seg=O
209	period	_	_	_	_	_	_	_	Seg=O
210	;	_	_	_	_	_	_	_	Seg=O
211	95	_	_	_	_	_	_	_	Seg=B-seg
212	%	_	_	_	_	_	_	_	Seg=O
213	credibility	_	_	_	_	_	_	_	Seg=O
214	interval	_	_	_	_	_	_	_	Seg=O
215	1.47	_	_	_	_	_	_	_	Seg=O
216	-	_	_	_	_	_	_	_	Seg=O
217	1.97	_	_	_	_	_	_	_	Seg=O
218	)	_	_	_	_	_	_	_	Seg=O
219	.	_	_	_	_	_	_	_	Seg=O
220	We	_	_	_	_	_	_	_	Seg=B-seg
221	found	_	_	_	_	_	_	_	Seg=O
222	a	_	_	_	_	_	_	_	Seg=O
223	significant	_	_	_	_	_	_	_	Seg=O
224	association	_	_	_	_	_	_	_	Seg=O
225	between	_	_	_	_	_	_	_	Seg=O
226	a	_	_	_	_	_	_	_	Seg=O
227	longer	_	_	_	_	_	_	_	Seg=O
228	incubation	_	_	_	_	_	_	_	Seg=O
229	period	_	_	_	_	_	_	_	Seg=O
230	and	_	_	_	_	_	_	_	Seg=O
231	a	_	_	_	_	_	_	_	Seg=O
232	greater	_	_	_	_	_	_	_	Seg=O
233	risk	_	_	_	_	_	_	_	Seg=O
234	of	_	_	_	_	_	_	_	Seg=O
235	death	_	_	_	_	_	_	_	Seg=O
236	among	_	_	_	_	_	_	_	Seg=O
237	human	_	_	_	_	_	_	_	Seg=O
238	H7N9	_	_	_	_	_	_	_	Seg=O
239	cases	_	_	_	_	_	_	_	Seg=O
240	.	_	_	_	_	_	_	_	Seg=O
241	The	_	_	_	_	_	_	_	Seg=B-seg
242	underlying	_	_	_	_	_	_	_	Seg=O
243	biological	_	_	_	_	_	_	_	Seg=O
244	mechanisms	_	_	_	_	_	_	_	Seg=O
245	leading	_	_	_	_	_	_	_	Seg=B-seg
246	to	_	_	_	_	_	_	_	Seg=O
247	this	_	_	_	_	_	_	_	Seg=O
248	association	_	_	_	_	_	_	_	Seg=O
249	deserve	_	_	_	_	_	_	_	Seg=B-seg
250	further	_	_	_	_	_	_	_	Seg=O
251	exploration	_	_	_	_	_	_	_	Seg=O
252	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 45ca49b78fd033c5e37ec5482918b446f5841c93
1	The	_	_	_	_	_	_	_	Seg=B-seg
2	antigenic	_	_	_	_	_	_	_	Seg=O
3	structure	_	_	_	_	_	_	_	Seg=O
4	of	_	_	_	_	_	_	_	Seg=O
5	transmissible	_	_	_	_	_	_	_	Seg=O
6	gastroenteritis	_	_	_	_	_	_	_	Seg=O
7	(	_	_	_	_	_	_	_	Seg=O
8	TGE	_	_	_	_	_	_	_	Seg=O
9	)	_	_	_	_	_	_	_	Seg=O
10	virus	_	_	_	_	_	_	_	Seg=O
11	E2	_	_	_	_	_	_	_	Seg=O
12	glycoprotein	_	_	_	_	_	_	_	Seg=O
13	has	_	_	_	_	_	_	_	Seg=O
14	been	_	_	_	_	_	_	_	Seg=O
15	defined	_	_	_	_	_	_	_	Seg=O
16	at	_	_	_	_	_	_	_	Seg=O
17	three	_	_	_	_	_	_	_	Seg=O
18	levels	_	_	_	_	_	_	_	Seg=O
19	:	_	_	_	_	_	_	_	Seg=O
20	antigenic	_	_	_	_	_	_	_	Seg=B-seg
21	sites	_	_	_	_	_	_	_	Seg=O
22	,	_	_	_	_	_	_	_	Seg=O
23	antigenic	_	_	_	_	_	_	_	Seg=O
24	subsites	_	_	_	_	_	_	_	Seg=O
25	and	_	_	_	_	_	_	_	Seg=O
26	epitopes	_	_	_	_	_	_	_	Seg=O
27	.	_	_	_	_	_	_	_	Seg=O
28	Four	_	_	_	_	_	_	_	Seg=B-seg
29	antigenic	_	_	_	_	_	_	_	Seg=O
30	sites	_	_	_	_	_	_	_	Seg=O
31	(	_	_	_	_	_	_	_	Seg=B-seg
32	A	_	_	_	_	_	_	_	Seg=O
33	,	_	_	_	_	_	_	_	Seg=O
34	B	_	_	_	_	_	_	_	Seg=O
35	,	_	_	_	_	_	_	_	Seg=O
36	C	_	_	_	_	_	_	_	Seg=O
37	and	_	_	_	_	_	_	_	Seg=O
38	D	_	_	_	_	_	_	_	Seg=O
39	)	_	_	_	_	_	_	_	Seg=O
40	were	_	_	_	_	_	_	_	Seg=B-seg
41	defined	_	_	_	_	_	_	_	Seg=O
42	by	_	_	_	_	_	_	_	Seg=O
43	competitive	_	_	_	_	_	_	_	Seg=O
44	radioimmunoassay	_	_	_	_	_	_	_	Seg=O
45	(	_	_	_	_	_	_	_	Seg=O
46	RIA	_	_	_	_	_	_	_	Seg=O
47	)	_	_	_	_	_	_	_	Seg=O
48	using	_	_	_	_	_	_	_	Seg=B-seg
49	monoclonal	_	_	_	_	_	_	_	Seg=O
50	antibodies	_	_	_	_	_	_	_	Seg=O
51	(	_	_	_	_	_	_	_	Seg=O
52	MAbs	_	_	_	_	_	_	_	Seg=O
53	)	_	_	_	_	_	_	_	Seg=O
54	selected	_	_	_	_	_	_	_	Seg=B-seg
55	from	_	_	_	_	_	_	_	Seg=O
56	9	_	_	_	_	_	_	_	Seg=O
57	fusions	_	_	_	_	_	_	_	Seg=O
58	.	_	_	_	_	_	_	_	Seg=O
59	About	_	_	_	_	_	_	_	Seg=B-seg
60	20	_	_	_	_	_	_	_	Seg=O
61	%	_	_	_	_	_	_	_	Seg=O
62	(	_	_	_	_	_	_	_	Seg=B-seg
63	197	_	_	_	_	_	_	_	Seg=O
64	)	_	_	_	_	_	_	_	Seg=O
65	of	_	_	_	_	_	_	_	Seg=B-seg
66	the	_	_	_	_	_	_	_	Seg=O
67	hybridomas	_	_	_	_	_	_	_	Seg=O
68	specific	_	_	_	_	_	_	_	Seg=O
69	for	_	_	_	_	_	_	_	Seg=O
70	TGE	_	_	_	_	_	_	_	Seg=O
71	virus	_	_	_	_	_	_	_	Seg=O
72	produced	_	_	_	_	_	_	_	Seg=O
73	neutralizing	_	_	_	_	_	_	_	Seg=O
74	MAbs	_	_	_	_	_	_	_	Seg=O
75	specific	_	_	_	_	_	_	_	Seg=O
76	for	_	_	_	_	_	_	_	Seg=O
77	site	_	_	_	_	_	_	_	Seg=O
78	A	_	_	_	_	_	_	_	Seg=O
79	,	_	_	_	_	_	_	_	Seg=O
80	which	_	_	_	_	_	_	_	Seg=B-seg
81	was	_	_	_	_	_	_	_	Seg=O
82	one	_	_	_	_	_	_	_	Seg=O
83	of	_	_	_	_	_	_	_	Seg=O
84	the	_	_	_	_	_	_	_	Seg=O
85	antigenically	_	_	_	_	_	_	_	Seg=O
86	dominant	_	_	_	_	_	_	_	Seg=O
87	determinants	_	_	_	_	_	_	_	Seg=O
88	.	_	_	_	_	_	_	_	Seg=O
89	Site	_	_	_	_	_	_	_	Seg=B-seg
90	A	_	_	_	_	_	_	_	Seg=O
91	was	_	_	_	_	_	_	_	Seg=O
92	differentiated	_	_	_	_	_	_	_	Seg=O
93	in	_	_	_	_	_	_	_	Seg=O
94	three	_	_	_	_	_	_	_	Seg=O
95	antigenic	_	_	_	_	_	_	_	Seg=O
96	subsites	_	_	_	_	_	_	_	Seg=O
97	:	_	_	_	_	_	_	_	Seg=O
98	a	_	_	_	_	_	_	_	Seg=B-seg
99	,	_	_	_	_	_	_	_	Seg=O
100	b	_	_	_	_	_	_	_	Seg=O
101	and	_	_	_	_	_	_	_	Seg=O
102	c	_	_	_	_	_	_	_	Seg=O
103	,	_	_	_	_	_	_	_	Seg=O
104	by	_	_	_	_	_	_	_	Seg=B-seg
105	characterization	_	_	_	_	_	_	_	Seg=O
106	of	_	_	_	_	_	_	_	Seg=O
107	11	_	_	_	_	_	_	_	Seg=O
108	MAb	_	_	_	_	_	_	_	Seg=O
109	resistant	_	_	_	_	_	_	_	Seg=O
110	(	_	_	_	_	_	_	_	Seg=O
111	mar	_	_	_	_	_	_	_	Seg=O
112	)	_	_	_	_	_	_	_	Seg=O
113	mutants	_	_	_	_	_	_	_	Seg=O
114	,	_	_	_	_	_	_	_	Seg=O
115	that	_	_	_	_	_	_	_	Seg=B-seg
116	were	_	_	_	_	_	_	_	Seg=O
117	defined	_	_	_	_	_	_	_	Seg=O
118	by	_	_	_	_	_	_	_	Seg=O
119	8	_	_	_	_	_	_	_	Seg=O
120	,	_	_	_	_	_	_	_	Seg=O
121	3	_	_	_	_	_	_	_	Seg=O
122	,	_	_	_	_	_	_	_	Seg=O
123	and	_	_	_	_	_	_	_	Seg=O
124	3	_	_	_	_	_	_	_	Seg=O
125	MAbs	_	_	_	_	_	_	_	Seg=O
126	,	_	_	_	_	_	_	_	Seg=O
127	respectively	_	_	_	_	_	_	_	Seg=O
128	.	_	_	_	_	_	_	_	Seg=O
129	These	_	_	_	_	_	_	_	Seg=B-seg
130	subsites	_	_	_	_	_	_	_	Seg=O
131	were	_	_	_	_	_	_	_	Seg=O
132	further	_	_	_	_	_	_	_	Seg=O
133	subdivided	_	_	_	_	_	_	_	Seg=O
134	in	_	_	_	_	_	_	_	Seg=O
135	epitopes	_	_	_	_	_	_	_	Seg=O
136	.	_	_	_	_	_	_	_	Seg=O
137	A	_	_	_	_	_	_	_	Seg=B-seg
138	total	_	_	_	_	_	_	_	Seg=O
139	of	_	_	_	_	_	_	_	Seg=O
140	11	_	_	_	_	_	_	_	Seg=O
141	epitopes	_	_	_	_	_	_	_	Seg=O
142	were	_	_	_	_	_	_	_	Seg=O
143	defined	_	_	_	_	_	_	_	Seg=O
144	in	_	_	_	_	_	_	_	Seg=O
145	E2	_	_	_	_	_	_	_	Seg=O
146	glycoprotein	_	_	_	_	_	_	_	Seg=O
147	,	_	_	_	_	_	_	_	Seg=O
148	eight	_	_	_	_	_	_	_	Seg=B-seg
149	of	_	_	_	_	_	_	_	Seg=O
150	which	_	_	_	_	_	_	_	Seg=O
151	were	_	_	_	_	_	_	_	Seg=O
152	critical	_	_	_	_	_	_	_	Seg=O
153	for	_	_	_	_	_	_	_	Seg=O
154	virus	_	_	_	_	_	_	_	Seg=O
155	neutralization	_	_	_	_	_	_	_	Seg=O
156	.	_	_	_	_	_	_	_	Seg=O
157	Neutralizing	_	_	_	_	_	_	_	Seg=B-seg
158	MAbs	_	_	_	_	_	_	_	Seg=O
159	were	_	_	_	_	_	_	_	Seg=O
160	obtained	_	_	_	_	_	_	_	Seg=O
161	only	_	_	_	_	_	_	_	Seg=B-seg
162	when	_	_	_	_	_	_	_	Seg=O
163	native	_	_	_	_	_	_	_	Seg=O
164	virus	_	_	_	_	_	_	_	Seg=O
165	was	_	_	_	_	_	_	_	Seg=O
166	used	_	_	_	_	_	_	_	Seg=O
167	to	_	_	_	_	_	_	_	Seg=B-seg
168	immunize	_	_	_	_	_	_	_	Seg=O
169	mice	_	_	_	_	_	_	_	Seg=O
170	,	_	_	_	_	_	_	_	Seg=O
171	although	_	_	_	_	_	_	_	Seg=B-seg
172	to	_	_	_	_	_	_	_	Seg=B-seg
173	produce	_	_	_	_	_	_	_	Seg=O
174	hybridomas	_	_	_	_	_	_	_	Seg=O
175	mice	_	_	_	_	_	_	_	Seg=O
176	immunizations	_	_	_	_	_	_	_	Seg=B-seg
177	were	_	_	_	_	_	_	_	Seg=O
178	made	_	_	_	_	_	_	_	Seg=O
179	with	_	_	_	_	_	_	_	Seg=O
180	antigen	_	_	_	_	_	_	_	Seg=O
181	in	_	_	_	_	_	_	_	Seg=O
182	the	_	_	_	_	_	_	_	Seg=O
183	native	_	_	_	_	_	_	_	Seg=O
184	,	_	_	_	_	_	_	_	Seg=O
185	denatured	_	_	_	_	_	_	_	Seg=O
186	,	_	_	_	_	_	_	_	Seg=O
187	or	_	_	_	_	_	_	_	Seg=O
188	mixtures	_	_	_	_	_	_	_	Seg=O
189	of	_	_	_	_	_	_	_	Seg=O
190	native	_	_	_	_	_	_	_	Seg=O
191	and	_	_	_	_	_	_	_	Seg=O
192	denatured	_	_	_	_	_	_	_	Seg=O
193	form	_	_	_	_	_	_	_	Seg=O
194	.	_	_	_	_	_	_	_	Seg=O
195	All	_	_	_	_	_	_	_	Seg=B-seg
196	neutralizing	_	_	_	_	_	_	_	Seg=O
197	MAbs	_	_	_	_	_	_	_	Seg=O
198	reacted	_	_	_	_	_	_	_	Seg=O
199	to	_	_	_	_	_	_	_	Seg=O
200	conformational	_	_	_	_	_	_	_	Seg=O
201	epitopes	_	_	_	_	_	_	_	Seg=O
202	.	_	_	_	_	_	_	_	Seg=O
203	The	_	_	_	_	_	_	_	Seg=B-seg
204	antigenic	_	_	_	_	_	_	_	Seg=O
205	structure	_	_	_	_	_	_	_	Seg=O
206	of	_	_	_	_	_	_	_	Seg=O
207	the	_	_	_	_	_	_	_	Seg=O
208	EZglycoprotein	_	_	_	_	_	_	_	Seg=O
209	has	_	_	_	_	_	_	_	Seg=O
210	been	_	_	_	_	_	_	_	Seg=O
211	defined	_	_	_	_	_	_	_	Seg=O
212	with	_	_	_	_	_	_	_	Seg=O
213	murine	_	_	_	_	_	_	_	Seg=O
214	MAbs	_	_	_	_	_	_	_	Seg=O
215	,	_	_	_	_	_	_	_	Seg=O
216	but	_	_	_	_	_	_	_	Seg=B-seg
217	the	_	_	_	_	_	_	_	Seg=O
218	antigenic	_	_	_	_	_	_	_	Seg=O
219	sites	_	_	_	_	_	_	_	Seg=O
220	were	_	_	_	_	_	_	_	Seg=O
221	relevant	_	_	_	_	_	_	_	Seg=O
222	in	_	_	_	_	_	_	_	Seg=O
223	the	_	_	_	_	_	_	_	Seg=O
224	swine	_	_	_	_	_	_	_	Seg=O
225	,	_	_	_	_	_	_	_	Seg=O
226	the	_	_	_	_	_	_	_	Seg=O
227	natural	_	_	_	_	_	_	_	Seg=O
228	host	_	_	_	_	_	_	_	Seg=O
229	of	_	_	_	_	_	_	_	Seg=O
230	the	_	_	_	_	_	_	_	Seg=O
231	virus	_	_	_	_	_	_	_	Seg=O
232	,	_	_	_	_	_	_	_	Seg=O
233	because	_	_	_	_	_	_	_	Seg=B-seg
234	porcine	_	_	_	_	_	_	_	Seg=O
235	sera	_	_	_	_	_	_	_	Seg=O
236	reacted	_	_	_	_	_	_	_	Seg=O
237	against	_	_	_	_	_	_	_	Seg=O
238	these	_	_	_	_	_	_	_	Seg=O
239	sites	_	_	_	_	_	_	_	Seg=O
240	.	_	_	_	_	_	_	_	Seg=O
241	MAbs	_	_	_	_	_	_	_	Seg=B-seg
242	specific	_	_	_	_	_	_	_	Seg=O
243	for	_	_	_	_	_	_	_	Seg=O
244	TGE	_	_	_	_	_	_	_	Seg=O
245	virus	_	_	_	_	_	_	_	Seg=O
246	site	_	_	_	_	_	_	_	Seg=O
247	C	_	_	_	_	_	_	_	Seg=O
248	reacted	_	_	_	_	_	_	_	Seg=O
249	to	_	_	_	_	_	_	_	Seg=O
250	non	_	_	_	_	_	_	_	Seg=O
251	-	_	_	_	_	_	_	_	Seg=O
252	immune	_	_	_	_	_	_	_	Seg=O
253	porcine	_	_	_	_	_	_	_	Seg=O
254	sera	_	_	_	_	_	_	_	Seg=O
255	.	_	_	_	_	_	_	_	Seg=O
256	This	_	_	_	_	_	_	_	Seg=B-seg
257	reactivity	_	_	_	_	_	_	_	Seg=O
258	was	_	_	_	_	_	_	_	Seg=O
259	not	_	_	_	_	_	_	_	Seg=O
260	directed	_	_	_	_	_	_	_	Seg=O
261	against	_	_	_	_	_	_	_	Seg=O
262	porcine	_	_	_	_	_	_	_	Seg=O
263	immunoglobulins	_	_	_	_	_	_	_	Seg=O
264	.	_	_	_	_	_	_	_	Seg=O
265	These	_	_	_	_	_	_	_	Seg=B-seg
266	results	_	_	_	_	_	_	_	Seg=O
267	indicated	_	_	_	_	_	_	_	Seg=O
268	that	_	_	_	_	_	_	_	Seg=B-seg
269	TGE	_	_	_	_	_	_	_	Seg=O
270	virus	_	_	_	_	_	_	_	Seg=O
271	contains	_	_	_	_	_	_	_	Seg=O
272	epitope(s	_	_	_	_	_	_	_	Seg=O
273	)	_	_	_	_	_	_	_	Seg=O
274	also	_	_	_	_	_	_	_	Seg=O
275	present	_	_	_	_	_	_	_	Seg=O
276	in	_	_	_	_	_	_	_	Seg=O
277	some	_	_	_	_	_	_	_	Seg=O
278	non	_	_	_	_	_	_	_	Seg=O
279	-	_	_	_	_	_	_	_	Seg=O
280	immunoglobulin	_	_	_	_	_	_	_	Seg=O
281	component	_	_	_	_	_	_	_	Seg=O
282	of	_	_	_	_	_	_	_	Seg=O
283	porcine	_	_	_	_	_	_	_	Seg=O
284	serum	_	_	_	_	_	_	_	Seg=O
285	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 45edbd85cb93950fecbc8da86f684a9e45c1d8f1
1	The	_	_	_	_	_	_	_	Seg=B-seg
2	control	_	_	_	_	_	_	_	Seg=O
3	of	_	_	_	_	_	_	_	Seg=O
4	infectious	_	_	_	_	_	_	_	Seg=O
5	diseases	_	_	_	_	_	_	_	Seg=O
6	such	_	_	_	_	_	_	_	Seg=B-seg
7	as	_	_	_	_	_	_	_	Seg=O
8	swine	_	_	_	_	_	_	_	Seg=O
9	influenza	_	_	_	_	_	_	_	Seg=O
10	viruses	_	_	_	_	_	_	_	Seg=O
11	(	_	_	_	_	_	_	_	Seg=O
12	SwIV	_	_	_	_	_	_	_	Seg=O
13	)	_	_	_	_	_	_	_	Seg=O
14	plays	_	_	_	_	_	_	_	Seg=B-seg
15	an	_	_	_	_	_	_	_	Seg=O
16	important	_	_	_	_	_	_	_	Seg=O
17	role	_	_	_	_	_	_	_	Seg=O
18	in	_	_	_	_	_	_	_	Seg=O
19	food	_	_	_	_	_	_	_	Seg=O
20	production	_	_	_	_	_	_	_	Seg=O
21	both	_	_	_	_	_	_	_	Seg=O
22	from	_	_	_	_	_	_	_	Seg=O
23	the	_	_	_	_	_	_	_	Seg=O
24	animal	_	_	_	_	_	_	_	Seg=O
25	health	_	_	_	_	_	_	_	Seg=O
26	and	_	_	_	_	_	_	_	Seg=O
27	from	_	_	_	_	_	_	_	Seg=O
28	the	_	_	_	_	_	_	_	Seg=O
29	public	_	_	_	_	_	_	_	Seg=O
30	health	_	_	_	_	_	_	_	Seg=O
31	point	_	_	_	_	_	_	_	Seg=O
32	of	_	_	_	_	_	_	_	Seg=O
33	view	_	_	_	_	_	_	_	Seg=O
34	.	_	_	_	_	_	_	_	Seg=O
35	Probiotic	_	_	_	_	_	_	_	Seg=B-seg
36	microorganisms	_	_	_	_	_	_	_	Seg=O
37	and	_	_	_	_	_	_	_	Seg=O
38	other	_	_	_	_	_	_	_	Seg=O
39	health	_	_	_	_	_	_	_	Seg=O
40	improving	_	_	_	_	_	_	_	Seg=O
41	food	_	_	_	_	_	_	_	Seg=O
42	supplements	_	_	_	_	_	_	_	Seg=O
43	have	_	_	_	_	_	_	_	Seg=O
44	been	_	_	_	_	_	_	_	Seg=O
45	given	_	_	_	_	_	_	_	Seg=O
46	increasing	_	_	_	_	_	_	_	Seg=O
47	attention	_	_	_	_	_	_	_	Seg=O
48	in	_	_	_	_	_	_	_	Seg=O
49	recent	_	_	_	_	_	_	_	Seg=O
50	years	_	_	_	_	_	_	_	Seg=O
51	,	_	_	_	_	_	_	_	Seg=O
52	but	_	_	_	_	_	_	_	Seg=B-seg
53	,	_	_	_	_	_	_	_	Seg=O
54	no	_	_	_	_	_	_	_	Seg=O
55	information	_	_	_	_	_	_	_	Seg=O
56	on	_	_	_	_	_	_	_	Seg=O
57	the	_	_	_	_	_	_	_	Seg=O
58	effects	_	_	_	_	_	_	_	Seg=O
59	of	_	_	_	_	_	_	_	Seg=O
60	probiotics	_	_	_	_	_	_	_	Seg=O
61	on	_	_	_	_	_	_	_	Seg=O
62	swine	_	_	_	_	_	_	_	Seg=O
63	influenza	_	_	_	_	_	_	_	Seg=O
64	virus	_	_	_	_	_	_	_	Seg=O
65	is	_	_	_	_	_	_	_	Seg=O
66	available	_	_	_	_	_	_	_	Seg=O
67	.	_	_	_	_	_	_	_	Seg=O
68	Here	_	_	_	_	_	_	_	Seg=B-seg
69	we	_	_	_	_	_	_	_	Seg=O
70	address	_	_	_	_	_	_	_	Seg=O
71	this	_	_	_	_	_	_	_	Seg=O
72	question	_	_	_	_	_	_	_	Seg=O
73	by	_	_	_	_	_	_	_	Seg=B-seg
74	assessing	_	_	_	_	_	_	_	Seg=O
75	the	_	_	_	_	_	_	_	Seg=O
76	inhibitory	_	_	_	_	_	_	_	Seg=O
77	potential	_	_	_	_	_	_	_	Seg=O
78	of	_	_	_	_	_	_	_	Seg=O
79	the	_	_	_	_	_	_	_	Seg=O
80	probiotic	_	_	_	_	_	_	_	Seg=O
81	Enterococcus	_	_	_	_	_	_	_	Seg=O
82	faecium	_	_	_	_	_	_	_	Seg=O
83	NCIMB	_	_	_	_	_	_	_	Seg=O
84	10415	_	_	_	_	_	_	_	Seg=O
85	(	_	_	_	_	_	_	_	Seg=O
86	E.	_	_	_	_	_	_	_	Seg=O
87	faecium	_	_	_	_	_	_	_	Seg=O
88	)	_	_	_	_	_	_	_	Seg=O
89	on	_	_	_	_	_	_	_	Seg=O
90	the	_	_	_	_	_	_	_	Seg=O
91	replication	_	_	_	_	_	_	_	Seg=O
92	of	_	_	_	_	_	_	_	Seg=O
93	two	_	_	_	_	_	_	_	Seg=O
94	porcine	_	_	_	_	_	_	_	Seg=O
95	strains	_	_	_	_	_	_	_	Seg=O
96	of	_	_	_	_	_	_	_	Seg=O
97	influenza	_	_	_	_	_	_	_	Seg=O
98	virus	_	_	_	_	_	_	_	Seg=O
99	(	_	_	_	_	_	_	_	Seg=B-seg
100	H1N1	_	_	_	_	_	_	_	Seg=O
101	and	_	_	_	_	_	_	_	Seg=O
102	H3N2	_	_	_	_	_	_	_	Seg=O
103	strain	_	_	_	_	_	_	_	Seg=O
104	)	_	_	_	_	_	_	_	Seg=O
105	in	_	_	_	_	_	_	_	Seg=B-seg
106	a	_	_	_	_	_	_	_	Seg=O
107	continuous	_	_	_	_	_	_	_	Seg=O
108	porcine	_	_	_	_	_	_	_	Seg=O
109	macrophage	_	_	_	_	_	_	_	Seg=O
110	cell	_	_	_	_	_	_	_	Seg=O
111	line	_	_	_	_	_	_	_	Seg=O
112	(	_	_	_	_	_	_	_	Seg=B-seg
113	3D4/21	_	_	_	_	_	_	_	Seg=O
114	)	_	_	_	_	_	_	_	Seg=O
115	and	_	_	_	_	_	_	_	Seg=B-seg
116	in	_	_	_	_	_	_	_	Seg=O
117	MDBK	_	_	_	_	_	_	_	Seg=O
118	cells	_	_	_	_	_	_	_	Seg=O
119	.	_	_	_	_	_	_	_	Seg=O
120	Cell	_	_	_	_	_	_	_	Seg=B-seg
121	cultures	_	_	_	_	_	_	_	Seg=O
122	were	_	_	_	_	_	_	_	Seg=O
123	treated	_	_	_	_	_	_	_	Seg=O
124	with	_	_	_	_	_	_	_	Seg=O
125	E.	_	_	_	_	_	_	_	Seg=O
126	faecium	_	_	_	_	_	_	_	Seg=O
127	at	_	_	_	_	_	_	_	Seg=O
128	the	_	_	_	_	_	_	_	Seg=O
129	nontoxic	_	_	_	_	_	_	_	Seg=O
130	concentration	_	_	_	_	_	_	_	Seg=O
131	of	_	_	_	_	_	_	_	Seg=O
132	1610	_	_	_	_	_	_	_	Seg=O
133	6	_	_	_	_	_	_	_	Seg=O
134	CFU	_	_	_	_	_	_	_	Seg=O
135	/	_	_	_	_	_	_	_	Seg=O
136	ml	_	_	_	_	_	_	_	Seg=O
137	in	_	_	_	_	_	_	_	Seg=O
138	growth	_	_	_	_	_	_	_	Seg=O
139	medium	_	_	_	_	_	_	_	Seg=O
140	for	_	_	_	_	_	_	_	Seg=O
141	60	_	_	_	_	_	_	_	Seg=O
142	to	_	_	_	_	_	_	_	Seg=O
143	90	_	_	_	_	_	_	_	Seg=O
144	min	_	_	_	_	_	_	_	Seg=O
145	before	_	_	_	_	_	_	_	Seg=O
146	,	_	_	_	_	_	_	_	Seg=O
147	during	_	_	_	_	_	_	_	Seg=O
148	and	_	_	_	_	_	_	_	Seg=O
149	after	_	_	_	_	_	_	_	Seg=O
150	SwIV	_	_	_	_	_	_	_	Seg=O
151	infection	_	_	_	_	_	_	_	Seg=O
152	.	_	_	_	_	_	_	_	Seg=O
153	After	_	_	_	_	_	_	_	Seg=B-seg
154	further	_	_	_	_	_	_	_	Seg=O
155	incubation	_	_	_	_	_	_	_	Seg=O
156	of	_	_	_	_	_	_	_	Seg=O
157	cultures	_	_	_	_	_	_	_	Seg=O
158	in	_	_	_	_	_	_	_	Seg=O
159	probiotic	_	_	_	_	_	_	_	Seg=O
160	-	_	_	_	_	_	_	_	Seg=O
161	free	_	_	_	_	_	_	_	Seg=O
162	growth	_	_	_	_	_	_	_	Seg=O
163	medium	_	_	_	_	_	_	_	Seg=O
164	,	_	_	_	_	_	_	_	Seg=O
165	cell	_	_	_	_	_	_	_	Seg=O
166	viability	_	_	_	_	_	_	_	Seg=O
167	and	_	_	_	_	_	_	_	Seg=O
168	virus	_	_	_	_	_	_	_	Seg=O
169	propagation	_	_	_	_	_	_	_	Seg=O
170	were	_	_	_	_	_	_	_	Seg=O
171	determined	_	_	_	_	_	_	_	Seg=O
172	at	_	_	_	_	_	_	_	Seg=O
173	48	_	_	_	_	_	_	_	Seg=O
174	h	_	_	_	_	_	_	_	Seg=O
175	or	_	_	_	_	_	_	_	Seg=O
176	96	_	_	_	_	_	_	_	Seg=O
177	h	_	_	_	_	_	_	_	Seg=O
178	post	_	_	_	_	_	_	_	Seg=O
179	infection	_	_	_	_	_	_	_	Seg=O
180	.	_	_	_	_	_	_	_	Seg=O
181	The	_	_	_	_	_	_	_	Seg=B-seg
182	results	_	_	_	_	_	_	_	Seg=O
183	obtained	_	_	_	_	_	_	_	Seg=B-seg
184	reveal	_	_	_	_	_	_	_	Seg=B-seg
185	an	_	_	_	_	_	_	_	Seg=O
186	almost	_	_	_	_	_	_	_	Seg=O
187	complete	_	_	_	_	_	_	_	Seg=O
188	recovery	_	_	_	_	_	_	_	Seg=O
189	of	_	_	_	_	_	_	_	Seg=O
190	viability	_	_	_	_	_	_	_	Seg=O
191	of	_	_	_	_	_	_	_	Seg=O
192	SwIV	_	_	_	_	_	_	_	Seg=O
193	infected	_	_	_	_	_	_	_	Seg=O
194	cells	_	_	_	_	_	_	_	Seg=O
195	and	_	_	_	_	_	_	_	Seg=O
196	an	_	_	_	_	_	_	_	Seg=O
197	inhibition	_	_	_	_	_	_	_	Seg=O
198	of	_	_	_	_	_	_	_	Seg=O
199	virus	_	_	_	_	_	_	_	Seg=O
200	multiplication	_	_	_	_	_	_	_	Seg=O
201	by	_	_	_	_	_	_	_	Seg=O
202	up	_	_	_	_	_	_	_	Seg=O
203	to	_	_	_	_	_	_	_	Seg=O
204	four	_	_	_	_	_	_	_	Seg=O
205	log	_	_	_	_	_	_	_	Seg=O
206	units	_	_	_	_	_	_	_	Seg=O
207	in	_	_	_	_	_	_	_	Seg=O
208	the	_	_	_	_	_	_	_	Seg=O
209	E.	_	_	_	_	_	_	_	Seg=O
210	faecium	_	_	_	_	_	_	_	Seg=O
211	treated	_	_	_	_	_	_	_	Seg=O
212	cells	_	_	_	_	_	_	_	Seg=O
213	.	_	_	_	_	_	_	_	Seg=O
214	In	_	_	_	_	_	_	_	Seg=B-seg
215	both	_	_	_	_	_	_	_	Seg=O
216	3D4/21-and	_	_	_	_	_	_	_	Seg=O
217	MDBK	_	_	_	_	_	_	_	Seg=O
218	-	_	_	_	_	_	_	_	Seg=O
219	cells	_	_	_	_	_	_	_	Seg=O
220	a	_	_	_	_	_	_	_	Seg=O
221	60	_	_	_	_	_	_	_	Seg=O
222	min	_	_	_	_	_	_	_	Seg=O
223	treatment	_	_	_	_	_	_	_	Seg=O
224	with	_	_	_	_	_	_	_	Seg=O
225	E.	_	_	_	_	_	_	_	Seg=O
226	faecium	_	_	_	_	_	_	_	Seg=O
227	stimulated	_	_	_	_	_	_	_	Seg=O
228	nitric	_	_	_	_	_	_	_	Seg=O
229	oxide	_	_	_	_	_	_	_	Seg=O
230	(	_	_	_	_	_	_	_	Seg=O
231	NO	_	_	_	_	_	_	_	Seg=O
232	)	_	_	_	_	_	_	_	Seg=O
233	release	_	_	_	_	_	_	_	Seg=O
234	which	_	_	_	_	_	_	_	Seg=B-seg
235	is	_	_	_	_	_	_	_	Seg=O
236	in	_	_	_	_	_	_	_	Seg=O
237	line	_	_	_	_	_	_	_	Seg=O
238	with	_	_	_	_	_	_	_	Seg=O
239	published	_	_	_	_	_	_	_	Seg=O
240	evidence	_	_	_	_	_	_	_	Seg=O
241	for	_	_	_	_	_	_	_	Seg=O
242	an	_	_	_	_	_	_	_	Seg=O
243	antiviral	_	_	_	_	_	_	_	Seg=O
244	function	_	_	_	_	_	_	_	Seg=O
245	of	_	_	_	_	_	_	_	Seg=O
246	NO	_	_	_	_	_	_	_	Seg=O
247	.	_	_	_	_	_	_	_	Seg=O
248	Furthermore	_	_	_	_	_	_	_	Seg=B-seg
249	,	_	_	_	_	_	_	_	Seg=O
250	E.	_	_	_	_	_	_	_	Seg=O
251	faecium	_	_	_	_	_	_	_	Seg=O
252	caused	_	_	_	_	_	_	_	Seg=O
253	a	_	_	_	_	_	_	_	Seg=O
254	modified	_	_	_	_	_	_	_	Seg=O
255	cellular	_	_	_	_	_	_	_	Seg=O
256	expression	_	_	_	_	_	_	_	Seg=O
257	of	_	_	_	_	_	_	_	Seg=O
258	selected	_	_	_	_	_	_	_	Seg=O
259	mediators	_	_	_	_	_	_	_	Seg=O
260	of	_	_	_	_	_	_	_	Seg=O
261	defence	_	_	_	_	_	_	_	Seg=O
262	in	_	_	_	_	_	_	_	Seg=O
263	3D4-cells	_	_	_	_	_	_	_	Seg=O
264	:	_	_	_	_	_	_	_	Seg=O
265	while	_	_	_	_	_	_	_	Seg=B-seg
266	the	_	_	_	_	_	_	_	Seg=O
267	expression	_	_	_	_	_	_	_	Seg=O
268	of	_	_	_	_	_	_	_	Seg=O
269	TNF	_	_	_	_	_	_	_	Seg=O
270	-	_	_	_	_	_	_	_	Seg=O
271	a	_	_	_	_	_	_	_	Seg=O
272	,	_	_	_	_	_	_	_	Seg=O
273	TLR-3	_	_	_	_	_	_	_	Seg=O
274	and	_	_	_	_	_	_	_	Seg=O
275	IL-6	_	_	_	_	_	_	_	Seg=O
276	were	_	_	_	_	_	_	_	Seg=O
277	decreased	_	_	_	_	_	_	_	Seg=O
278	in	_	_	_	_	_	_	_	Seg=O
279	the	_	_	_	_	_	_	_	Seg=O
280	SwIV	_	_	_	_	_	_	_	Seg=O
281	-	_	_	_	_	_	_	_	Seg=O
282	infected	_	_	_	_	_	_	_	Seg=O
283	and	_	_	_	_	_	_	_	Seg=O
284	probiotic	_	_	_	_	_	_	_	Seg=O
285	treated	_	_	_	_	_	_	_	Seg=O
286	cells	_	_	_	_	_	_	_	Seg=O
287	,	_	_	_	_	_	_	_	Seg=O
288	IL-10	_	_	_	_	_	_	_	Seg=B-seg
289	was	_	_	_	_	_	_	_	Seg=O
290	found	_	_	_	_	_	_	_	Seg=O
291	to	_	_	_	_	_	_	_	Seg=O
292	be	_	_	_	_	_	_	_	Seg=O
293	increased	_	_	_	_	_	_	_	Seg=O
294	.	_	_	_	_	_	_	_	Seg=O
295	Since	_	_	_	_	_	_	_	Seg=B-seg
296	we	_	_	_	_	_	_	_	Seg=O
297	obtained	_	_	_	_	_	_	_	Seg=O
298	experimental	_	_	_	_	_	_	_	Seg=O
299	evidence	_	_	_	_	_	_	_	Seg=O
300	for	_	_	_	_	_	_	_	Seg=O
301	the	_	_	_	_	_	_	_	Seg=O
302	direct	_	_	_	_	_	_	_	Seg=O
303	adsorptive	_	_	_	_	_	_	_	Seg=O
304	trapping	_	_	_	_	_	_	_	Seg=O
305	of	_	_	_	_	_	_	_	Seg=O
306	SwIV	_	_	_	_	_	_	_	Seg=O
307	through	_	_	_	_	_	_	_	Seg=O
308	E.	_	_	_	_	_	_	_	Seg=O
309	faecium	_	_	_	_	_	_	_	Seg=O
310	,	_	_	_	_	_	_	_	Seg=O
311	this	_	_	_	_	_	_	_	Seg=B-seg
312	probiotic	_	_	_	_	_	_	_	Seg=O
313	microorganism	_	_	_	_	_	_	_	Seg=O
314	inhibits	_	_	_	_	_	_	_	Seg=O
315	influenza	_	_	_	_	_	_	_	Seg=O
316	viruses	_	_	_	_	_	_	_	Seg=O
317	by	_	_	_	_	_	_	_	Seg=O
318	at	_	_	_	_	_	_	_	Seg=O
319	least	_	_	_	_	_	_	_	Seg=O
320	two	_	_	_	_	_	_	_	Seg=O
321	mechanisms	_	_	_	_	_	_	_	Seg=O
322	,	_	_	_	_	_	_	_	Seg=O
323	direct	_	_	_	_	_	_	_	Seg=O
324	physical	_	_	_	_	_	_	_	Seg=O
325	interaction	_	_	_	_	_	_	_	Seg=O
326	and	_	_	_	_	_	_	_	Seg=O
327	strengthening	_	_	_	_	_	_	_	Seg=O
328	of	_	_	_	_	_	_	_	Seg=O
329	innate	_	_	_	_	_	_	_	Seg=O
330	defence	_	_	_	_	_	_	_	Seg=O
331	at	_	_	_	_	_	_	_	Seg=O
332	the	_	_	_	_	_	_	_	Seg=O
333	cellular	_	_	_	_	_	_	_	Seg=O
334	level	_	_	_	_	_	_	_	Seg=O
335	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 480f67bf4f825dbc367fb67ec6de5b1664299eb5
1	A	_	_	_	_	_	_	_	Seg=B-seg
2	highly	_	_	_	_	_	_	_	Seg=O
3	infectious	_	_	_	_	_	_	_	Seg=O
4	disease	_	_	_	_	_	_	_	Seg=O
5	(	_	_	_	_	_	_	_	Seg=O
6	HID	_	_	_	_	_	_	_	Seg=O
7	)	_	_	_	_	_	_	_	Seg=O
8	that	_	_	_	_	_	_	_	Seg=B-seg
9	is	_	_	_	_	_	_	_	Seg=O
10	transmissible	_	_	_	_	_	_	_	Seg=O
11	from	_	_	_	_	_	_	_	Seg=O
12	person	_	_	_	_	_	_	_	Seg=O
13	to	_	_	_	_	_	_	_	Seg=O
14	person	_	_	_	_	_	_	_	Seg=O
15	causes	_	_	_	_	_	_	_	Seg=B-seg
16	life	_	_	_	_	_	_	_	Seg=O
17	-	_	_	_	_	_	_	_	Seg=O
18	threatening	_	_	_	_	_	_	_	Seg=O
19	illness	_	_	_	_	_	_	_	Seg=O
20	and	_	_	_	_	_	_	_	Seg=B-seg
21	presents	_	_	_	_	_	_	_	Seg=O
22	a	_	_	_	_	_	_	_	Seg=O
23	serious	_	_	_	_	_	_	_	Seg=O
24	hazard	_	_	_	_	_	_	_	Seg=O
25	in	_	_	_	_	_	_	_	Seg=O
26	the	_	_	_	_	_	_	_	Seg=O
27	healthcare	_	_	_	_	_	_	_	Seg=O
28	setting	_	_	_	_	_	_	_	Seg=O
29	and	_	_	_	_	_	_	_	Seg=O
30	in	_	_	_	_	_	_	_	Seg=O
31	the	_	_	_	_	_	_	_	Seg=O
32	community	_	_	_	_	_	_	_	Seg=O
33	that	_	_	_	_	_	_	_	Seg=B-seg
34	requires	_	_	_	_	_	_	_	Seg=O
35	specific	_	_	_	_	_	_	_	Seg=O
36	control	_	_	_	_	_	_	_	Seg=O
37	measures	_	_	_	_	_	_	_	Seg=O
38	.	_	_	_	_	_	_	_	Seg=O
39	Due	_	_	_	_	_	_	_	Seg=B-seg
40	to	_	_	_	_	_	_	_	Seg=O
41	environmental	_	_	_	_	_	_	_	Seg=O
42	factors	_	_	_	_	_	_	_	Seg=O
43	,	_	_	_	_	_	_	_	Seg=O
44	changes	_	_	_	_	_	_	_	Seg=O
45	in	_	_	_	_	_	_	_	Seg=O
46	lifestyle	_	_	_	_	_	_	_	Seg=O
47	and	_	_	_	_	_	_	_	Seg=O
48	many	_	_	_	_	_	_	_	Seg=O
49	other	_	_	_	_	_	_	_	Seg=O
50	unknown	_	_	_	_	_	_	_	Seg=O
51	factors	_	_	_	_	_	_	_	Seg=O
52	,	_	_	_	_	_	_	_	Seg=O
53	the	_	_	_	_	_	_	_	Seg=B-seg
54	emergence	_	_	_	_	_	_	_	Seg=O
55	of	_	_	_	_	_	_	_	Seg=O
56	such	_	_	_	_	_	_	_	Seg=O
57	HIDs	_	_	_	_	_	_	_	Seg=O
58	is	_	_	_	_	_	_	_	Seg=O
59	becoming	_	_	_	_	_	_	_	Seg=O
60	more	_	_	_	_	_	_	_	Seg=O
61	and	_	_	_	_	_	_	_	Seg=O
62	more	_	_	_	_	_	_	_	Seg=O
63	likely	_	_	_	_	_	_	_	Seg=O
64	.	_	_	_	_	_	_	_	Seg=O
65	As	_	_	_	_	_	_	_	Seg=B-seg
66	has	_	_	_	_	_	_	_	Seg=O
67	already	_	_	_	_	_	_	_	Seg=O
68	been	_	_	_	_	_	_	_	Seg=O
69	demonstrated	_	_	_	_	_	_	_	Seg=O
70	during	_	_	_	_	_	_	_	Seg=O
71	the	_	_	_	_	_	_	_	Seg=O
72	SARS	_	_	_	_	_	_	_	Seg=O
73	outbreak	_	_	_	_	_	_	_	Seg=O
74	,	_	_	_	_	_	_	_	Seg=O
75	healthcare	_	_	_	_	_	_	_	Seg=B-seg
76	facilities	_	_	_	_	_	_	_	Seg=O
77	are	_	_	_	_	_	_	_	Seg=O
78	likely	_	_	_	_	_	_	_	Seg=O
79	to	_	_	_	_	_	_	_	Seg=O
80	be	_	_	_	_	_	_	_	Seg=O
81	the	_	_	_	_	_	_	_	Seg=O
82	origin	_	_	_	_	_	_	_	Seg=O
83	of	_	_	_	_	_	_	_	Seg=O
84	future	_	_	_	_	_	_	_	Seg=O
85	HID	_	_	_	_	_	_	_	Seg=O
86	outbreaks	_	_	_	_	_	_	_	Seg=O
87	.	_	_	_	_	_	_	_	Seg=O
88	Preparedness	_	_	_	_	_	_	_	Seg=B-seg
89	planning	_	_	_	_	_	_	_	Seg=O
90	will	_	_	_	_	_	_	_	Seg=O
91	be	_	_	_	_	_	_	_	Seg=O
92	essential	_	_	_	_	_	_	_	Seg=O
93	in	_	_	_	_	_	_	_	Seg=B-seg
94	helping	_	_	_	_	_	_	_	Seg=O
95	facilities	_	_	_	_	_	_	_	Seg=O
96	manage	_	_	_	_	_	_	_	Seg=O
97	future	_	_	_	_	_	_	_	Seg=O
98	outbreaks	_	_	_	_	_	_	_	Seg=O
99	of	_	_	_	_	_	_	_	Seg=O
100	emerging	_	_	_	_	_	_	_	Seg=O
101	or	_	_	_	_	_	_	_	Seg=O
102	resurgent	_	_	_	_	_	_	_	Seg=O
103	infectious	_	_	_	_	_	_	_	Seg=O
104	diseases	_	_	_	_	_	_	_	Seg=O
105	.	_	_	_	_	_	_	_	Seg=O
106	Guidelines	_	_	_	_	_	_	_	Seg=B-seg
107	have	_	_	_	_	_	_	_	Seg=O
108	been	_	_	_	_	_	_	_	Seg=O
109	developed	_	_	_	_	_	_	_	Seg=O
110	by	_	_	_	_	_	_	_	Seg=O
111	national	_	_	_	_	_	_	_	Seg=O
112	and	_	_	_	_	_	_	_	Seg=O
113	international	_	_	_	_	_	_	_	Seg=O
114	institutions	_	_	_	_	_	_	_	Seg=O
115	.	_	_	_	_	_	_	_	Seg=O
116	To	_	_	_	_	_	_	_	Seg=B-seg
117	avoid	_	_	_	_	_	_	_	Seg=O
118	contamination	_	_	_	_	_	_	_	Seg=O
119	of	_	_	_	_	_	_	_	Seg=O
120	healthcare	_	_	_	_	_	_	_	Seg=O
121	workers	_	_	_	_	_	_	_	Seg=O
122	,	_	_	_	_	_	_	_	Seg=O
123	the	_	_	_	_	_	_	_	Seg=B-seg
124	care	_	_	_	_	_	_	_	Seg=O
125	of	_	_	_	_	_	_	_	Seg=O
126	HID	_	_	_	_	_	_	_	Seg=O
127	patients	_	_	_	_	_	_	_	Seg=O
128	should	_	_	_	_	_	_	_	Seg=O
129	follow	_	_	_	_	_	_	_	Seg=O
130	the	_	_	_	_	_	_	_	Seg=O
131	same	_	_	_	_	_	_	_	Seg=O
132	infection	_	_	_	_	_	_	_	Seg=O
133	control	_	_	_	_	_	_	_	Seg=O
134	rules	_	_	_	_	_	_	_	Seg=O
135	that	_	_	_	_	_	_	_	Seg=B-seg
136	are	_	_	_	_	_	_	_	Seg=O
137	applied	_	_	_	_	_	_	_	Seg=O
138	to	_	_	_	_	_	_	_	Seg=O
139	laboratory	_	_	_	_	_	_	_	Seg=O
140	workers	_	_	_	_	_	_	_	Seg=O
141	exposed	_	_	_	_	_	_	_	Seg=B-seg
142	to	_	_	_	_	_	_	_	Seg=O
143	similar	_	_	_	_	_	_	_	Seg=O
144	agents	_	_	_	_	_	_	_	Seg=O
145	.	_	_	_	_	_	_	_	Seg=O
146	Here	_	_	_	_	_	_	_	Seg=B-seg
147	,	_	_	_	_	_	_	_	Seg=O
148	the	_	_	_	_	_	_	_	Seg=O
149	current	_	_	_	_	_	_	_	Seg=O
150	knowledge	_	_	_	_	_	_	_	Seg=O
151	concerning	_	_	_	_	_	_	_	Seg=B-seg
152	the	_	_	_	_	_	_	_	Seg=O
153	clinical	_	_	_	_	_	_	_	Seg=O
154	care	_	_	_	_	_	_	_	Seg=O
155	of	_	_	_	_	_	_	_	Seg=O
156	patients	_	_	_	_	_	_	_	Seg=O
157	with	_	_	_	_	_	_	_	Seg=O
158	HIDs	_	_	_	_	_	_	_	Seg=O
159	is	_	_	_	_	_	_	_	Seg=B-seg
160	reviewed	_	_	_	_	_	_	_	Seg=O
161	,	_	_	_	_	_	_	_	Seg=O
162	and	_	_	_	_	_	_	_	Seg=B-seg
163	specific	_	_	_	_	_	_	_	Seg=O
164	aspects	_	_	_	_	_	_	_	Seg=O
165	of	_	_	_	_	_	_	_	Seg=O
166	the	_	_	_	_	_	_	_	Seg=O
167	management	_	_	_	_	_	_	_	Seg=O
168	of	_	_	_	_	_	_	_	Seg=O
169	such	_	_	_	_	_	_	_	Seg=O
170	diseases	_	_	_	_	_	_	_	Seg=O
171	are	_	_	_	_	_	_	_	Seg=O
172	introduced	_	_	_	_	_	_	_	Seg=O
173	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 48522c9977177ec26e13ed9809b541d614b78160
1	The	_	_	_	_	_	_	_	Seg=B-seg
2	outbreak	_	_	_	_	_	_	_	Seg=O
3	of	_	_	_	_	_	_	_	Seg=O
4	COVID-2019	_	_	_	_	_	_	_	Seg=O
5	initiated	_	_	_	_	_	_	_	Seg=B-seg
6	at	_	_	_	_	_	_	_	Seg=O
7	Wuhan	_	_	_	_	_	_	_	Seg=O
8	,	_	_	_	_	_	_	_	Seg=O
9	China	_	_	_	_	_	_	_	Seg=O
10	has	_	_	_	_	_	_	_	Seg=B-seg
11	become	_	_	_	_	_	_	_	Seg=O
12	a	_	_	_	_	_	_	_	Seg=O
13	global	_	_	_	_	_	_	_	Seg=O
14	threat	_	_	_	_	_	_	_	Seg=O
15	by	_	_	_	_	_	_	_	Seg=O
16	rapid	_	_	_	_	_	_	_	Seg=O
17	transmission	_	_	_	_	_	_	_	Seg=O
18	and	_	_	_	_	_	_	_	Seg=O
19	severe	_	_	_	_	_	_	_	Seg=O
20	fatalities	_	_	_	_	_	_	_	Seg=O
21	.	_	_	_	_	_	_	_	Seg=O
22	Recent	_	_	_	_	_	_	_	Seg=B-seg
23	studies	_	_	_	_	_	_	_	Seg=O
24	have	_	_	_	_	_	_	_	Seg=O
25	uncovered	_	_	_	_	_	_	_	Seg=O
26	whole	_	_	_	_	_	_	_	Seg=O
27	genome	_	_	_	_	_	_	_	Seg=O
28	sequence	_	_	_	_	_	_	_	Seg=O
29	of	_	_	_	_	_	_	_	Seg=O
30	SARS	_	_	_	_	_	_	_	Seg=O
31	-	_	_	_	_	_	_	_	Seg=O
32	CoV-2	_	_	_	_	_	_	_	Seg=O
33	(	_	_	_	_	_	_	_	Seg=B-seg
34	causing	_	_	_	_	_	_	_	Seg=O
35	COVID-2019	_	_	_	_	_	_	_	Seg=O
36	)	_	_	_	_	_	_	_	Seg=O
37	.	_	_	_	_	_	_	_	Seg=O
38	In	_	_	_	_	_	_	_	Seg=B-seg
39	addition	_	_	_	_	_	_	_	Seg=O
40	,	_	_	_	_	_	_	_	Seg=O
41	lung	_	_	_	_	_	_	_	Seg=O
42	metagenomic	_	_	_	_	_	_	_	Seg=O
43	studies	_	_	_	_	_	_	_	Seg=O
44	on	_	_	_	_	_	_	_	Seg=O
45	infected	_	_	_	_	_	_	_	Seg=O
46	patients	_	_	_	_	_	_	_	Seg=O
47	revealed	_	_	_	_	_	_	_	Seg=O
48	overrepresented	_	_	_	_	_	_	_	Seg=O
49	Prevotella	_	_	_	_	_	_	_	Seg=O
50	spp	_	_	_	_	_	_	_	Seg=O
51	.	_	_	_	_	_	_	_	Seg=O
52	producing	_	_	_	_	_	_	_	Seg=O
53	certain	_	_	_	_	_	_	_	Seg=O
54	proteins	_	_	_	_	_	_	_	Seg=O
55	in	_	_	_	_	_	_	_	Seg=O
56	abundance	_	_	_	_	_	_	_	Seg=O
57	.	_	_	_	_	_	_	_	Seg=O
58	We	_	_	_	_	_	_	_	Seg=B-seg
59	performed	_	_	_	_	_	_	_	Seg=O
60	host	_	_	_	_	_	_	_	Seg=O
61	-	_	_	_	_	_	_	_	Seg=O
62	pathogen	_	_	_	_	_	_	_	Seg=O
63	protein	_	_	_	_	_	_	_	Seg=O
64	-	_	_	_	_	_	_	_	Seg=O
65	protein	_	_	_	_	_	_	_	Seg=O
66	interaction	_	_	_	_	_	_	_	Seg=O
67	analysis	_	_	_	_	_	_	_	Seg=O
68	between	_	_	_	_	_	_	_	Seg=O
69	SARS	_	_	_	_	_	_	_	Seg=O
70	-	_	_	_	_	_	_	_	Seg=O
71	CoV-2	_	_	_	_	_	_	_	Seg=O
72	and	_	_	_	_	_	_	_	Seg=O
73	overrepresented	_	_	_	_	_	_	_	Seg=O
74	Prevotella	_	_	_	_	_	_	_	Seg=O
75	proteins	_	_	_	_	_	_	_	Seg=O
76	with	_	_	_	_	_	_	_	Seg=O
77	human	_	_	_	_	_	_	_	Seg=O
78	proteome	_	_	_	_	_	_	_	Seg=O
79	.	_	_	_	_	_	_	_	Seg=O
80	We	_	_	_	_	_	_	_	Seg=B-seg
81	also	_	_	_	_	_	_	_	Seg=O
82	performed	_	_	_	_	_	_	_	Seg=O
83	functional	_	_	_	_	_	_	_	Seg=O
84	overrepresentation	_	_	_	_	_	_	_	Seg=O
85	analysis	_	_	_	_	_	_	_	Seg=O
86	of	_	_	_	_	_	_	_	Seg=O
87	interacting	_	_	_	_	_	_	_	Seg=O
88	proteins	_	_	_	_	_	_	_	Seg=O
89	to	_	_	_	_	_	_	_	Seg=B-seg
90	understand	_	_	_	_	_	_	_	Seg=O
91	their	_	_	_	_	_	_	_	Seg=O
92	role	_	_	_	_	_	_	_	Seg=O
93	in	_	_	_	_	_	_	_	Seg=O
94	COVID-2019	_	_	_	_	_	_	_	Seg=O
95	severity	_	_	_	_	_	_	_	Seg=O
96	.	_	_	_	_	_	_	_	Seg=O
97	Results	_	_	_	_	_	_	_	Seg=B-seg
98	:	_	_	_	_	_	_	_	Seg=O
99	It	_	_	_	_	_	_	_	Seg=B-seg
100	was	_	_	_	_	_	_	_	Seg=O
101	found	_	_	_	_	_	_	_	Seg=O
102	that	_	_	_	_	_	_	_	Seg=O
103	over	_	_	_	_	_	_	_	Seg=O
104	-	_	_	_	_	_	_	_	Seg=O
105	expressed	_	_	_	_	_	_	_	Seg=O
106	Prevotella	_	_	_	_	_	_	_	Seg=O
107	proteins	_	_	_	_	_	_	_	Seg=O
108	can	_	_	_	_	_	_	_	Seg=O
109	promote	_	_	_	_	_	_	_	Seg=O
110	viral	_	_	_	_	_	_	_	Seg=O
111	infection	_	_	_	_	_	_	_	Seg=O
112	.	_	_	_	_	_	_	_	Seg=O
113	As	_	_	_	_	_	_	_	Seg=B-seg
114	per	_	_	_	_	_	_	_	Seg=O
115	the	_	_	_	_	_	_	_	Seg=O
116	results	_	_	_	_	_	_	_	Seg=O
117	,	_	_	_	_	_	_	_	Seg=O
118	Prevotella	_	_	_	_	_	_	_	Seg=O
119	proteins	_	_	_	_	_	_	_	Seg=O
120	,	_	_	_	_	_	_	_	Seg=O
121	but	_	_	_	_	_	_	_	Seg=O
122	not	_	_	_	_	_	_	_	Seg=O
123	viral	_	_	_	_	_	_	_	Seg=O
124	proteins	_	_	_	_	_	_	_	Seg=O
125	are	_	_	_	_	_	_	_	Seg=O
126	involved	_	_	_	_	_	_	_	Seg=O
127	in	_	_	_	_	_	_	_	Seg=O
128	multiple	_	_	_	_	_	_	_	Seg=O
129	interactions	_	_	_	_	_	_	_	Seg=O
130	with	_	_	_	_	_	_	_	Seg=O
131	NF	_	_	_	_	_	_	_	Seg=O
132	-	_	_	_	_	_	_	_	Seg=O
133	kB	_	_	_	_	_	_	_	Seg=O
134	,	_	_	_	_	_	_	_	Seg=O
135	which	_	_	_	_	_	_	_	Seg=B-seg
136	is	_	_	_	_	_	_	_	Seg=O
137	involved	_	_	_	_	_	_	_	Seg=O
138	in	_	_	_	_	_	_	_	Seg=O
139	increasing	_	_	_	_	_	_	_	Seg=O
140	clinical	_	_	_	_	_	_	_	Seg=O
141	severity	_	_	_	_	_	_	_	Seg=O
142	of	_	_	_	_	_	_	_	Seg=O
143	COVID-2019	_	_	_	_	_	_	_	Seg=O
144	.	_	_	_	_	_	_	_	Seg=O
145	Prevotella	_	_	_	_	_	_	_	Seg=B-seg
146	may	_	_	_	_	_	_	_	Seg=O
147	have	_	_	_	_	_	_	_	Seg=O
148	role	_	_	_	_	_	_	_	Seg=O
149	in	_	_	_	_	_	_	_	Seg=O
150	COVID-2019	_	_	_	_	_	_	_	Seg=O
151	outbreak	_	_	_	_	_	_	_	Seg=O
152	and	_	_	_	_	_	_	_	Seg=B-seg
153	should	_	_	_	_	_	_	_	Seg=O
154	be	_	_	_	_	_	_	_	Seg=O
155	given	_	_	_	_	_	_	_	Seg=O
156	importance	_	_	_	_	_	_	_	Seg=O
157	for	_	_	_	_	_	_	_	Seg=B-seg
158	understanding	_	_	_	_	_	_	_	Seg=O
159	disease	_	_	_	_	_	_	_	Seg=O
160	mechanisms	_	_	_	_	_	_	_	Seg=O
161	and	_	_	_	_	_	_	_	Seg=B-seg
162	improving	_	_	_	_	_	_	_	Seg=O
163	treatment	_	_	_	_	_	_	_	Seg=O
164	outcomes	_	_	_	_	_	_	_	Seg=O
165	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 4a7a1d6fa1a47905fb52c387ace37f8bca5fae42
1	Background	_	_	_	_	_	_	_	Seg=B-seg
2	:	_	_	_	_	_	_	_	Seg=O
3	Hospitalized	_	_	_	_	_	_	_	Seg=B-seg
4	bronchiolitis	_	_	_	_	_	_	_	Seg=O
5	imposes	_	_	_	_	_	_	_	Seg=O
6	a	_	_	_	_	_	_	_	Seg=O
7	significant	_	_	_	_	_	_	_	Seg=O
8	burden	_	_	_	_	_	_	_	Seg=O
9	among	_	_	_	_	_	_	_	Seg=O
10	infants	_	_	_	_	_	_	_	Seg=O
11	,	_	_	_	_	_	_	_	Seg=O
12	particularly	_	_	_	_	_	_	_	Seg=O
13	among	_	_	_	_	_	_	_	Seg=O
14	Indigenous	_	_	_	_	_	_	_	Seg=O
15	children	_	_	_	_	_	_	_	Seg=O
16	.	_	_	_	_	_	_	_	Seg=O
17	Traditional	_	_	_	_	_	_	_	Seg=B-seg
18	or	_	_	_	_	_	_	_	Seg=O
19	known	_	_	_	_	_	_	_	Seg=O
20	risk	_	_	_	_	_	_	_	Seg=O
21	factors	_	_	_	_	_	_	_	Seg=O
22	for	_	_	_	_	_	_	_	Seg=O
23	severe	_	_	_	_	_	_	_	Seg=O
24	disease	_	_	_	_	_	_	_	Seg=O
25	are	_	_	_	_	_	_	_	Seg=O
26	well	_	_	_	_	_	_	_	Seg=O
27	described	_	_	_	_	_	_	_	Seg=O
28	,	_	_	_	_	_	_	_	Seg=O
29	but	_	_	_	_	_	_	_	Seg=B-seg
30	there	_	_	_	_	_	_	_	Seg=O
31	are	_	_	_	_	_	_	_	Seg=O
32	limited	_	_	_	_	_	_	_	Seg=O
33	data	_	_	_	_	_	_	_	Seg=O
34	on	_	_	_	_	_	_	_	Seg=O
35	risks	_	_	_	_	_	_	_	Seg=O
36	for	_	_	_	_	_	_	_	Seg=O
37	prolonged	_	_	_	_	_	_	_	Seg=O
38	hospitalization	_	_	_	_	_	_	_	Seg=O
39	and	_	_	_	_	_	_	_	Seg=O
40	persistent	_	_	_	_	_	_	_	Seg=O
41	symptoms	_	_	_	_	_	_	_	Seg=O
42	.	_	_	_	_	_	_	_	Seg=O
43	Our	_	_	_	_	_	_	_	Seg=B-seg
44	aims	_	_	_	_	_	_	_	Seg=O
45	were	_	_	_	_	_	_	_	Seg=O
46	to	_	_	_	_	_	_	_	Seg=O
47	determine	_	_	_	_	_	_	_	Seg=O
48	factors	_	_	_	_	_	_	_	Seg=O
49	(	_	_	_	_	_	_	_	Seg=O
50	clinical	_	_	_	_	_	_	_	Seg=O
51	and	_	_	_	_	_	_	_	Seg=O
52	microbiological	_	_	_	_	_	_	_	Seg=O
53	)	_	_	_	_	_	_	_	Seg=O
54	associated	_	_	_	_	_	_	_	Seg=O
55	with	_	_	_	_	_	_	_	Seg=O
56	(	_	_	_	_	_	_	_	Seg=O
57	i	_	_	_	_	_	_	_	Seg=O
58	)	_	_	_	_	_	_	_	Seg=O
59	prolonged	_	_	_	_	_	_	_	Seg=O
60	length	_	_	_	_	_	_	_	Seg=O
61	of	_	_	_	_	_	_	_	Seg=O
62	stay	_	_	_	_	_	_	_	Seg=O
63	(	_	_	_	_	_	_	_	Seg=O
64	LOS	_	_	_	_	_	_	_	Seg=O
65	)	_	_	_	_	_	_	_	Seg=O
66	;	_	_	_	_	_	_	_	Seg=O
67	(	_	_	_	_	_	_	_	Seg=O
68	ii	_	_	_	_	_	_	_	Seg=O
69	)	_	_	_	_	_	_	_	Seg=O
70	persistent	_	_	_	_	_	_	_	Seg=O
71	respiratory	_	_	_	_	_	_	_	Seg=O
72	symptoms	_	_	_	_	_	_	_	Seg=O
73	at	_	_	_	_	_	_	_	Seg=O
74	3	_	_	_	_	_	_	_	Seg=O
75	weeks	_	_	_	_	_	_	_	Seg=O
76	;	_	_	_	_	_	_	_	Seg=O
77	(	_	_	_	_	_	_	_	Seg=O
78	iii	_	_	_	_	_	_	_	Seg=O
79	)	_	_	_	_	_	_	_	Seg=O
80	bronchiectasis	_	_	_	_	_	_	_	Seg=O
81	up	_	_	_	_	_	_	_	Seg=O
82	to	_	_	_	_	_	_	_	Seg=O
83	$	_	_	_	_	_	_	_	Seg=O
84	24	_	_	_	_	_	_	_	Seg=O
85	months	_	_	_	_	_	_	_	Seg=O
86	post	_	_	_	_	_	_	_	Seg=O
87	-	_	_	_	_	_	_	_	Seg=O
88	hospitalisation	_	_	_	_	_	_	_	Seg=O
89	;	_	_	_	_	_	_	_	Seg=O
90	and	_	_	_	_	_	_	_	Seg=O
91	(	_	_	_	_	_	_	_	Seg=O
92	iv	_	_	_	_	_	_	_	Seg=O
93	)	_	_	_	_	_	_	_	Seg=O
94	risk	_	_	_	_	_	_	_	Seg=O
95	of	_	_	_	_	_	_	_	Seg=O
96	respiratory	_	_	_	_	_	_	_	Seg=O
97	readmissions	_	_	_	_	_	_	_	Seg=O
98	within	_	_	_	_	_	_	_	Seg=O
99	6	_	_	_	_	_	_	_	Seg=O
100	months	_	_	_	_	_	_	_	Seg=O
101	.	_	_	_	_	_	_	_	Seg=O
102	Methods	_	_	_	_	_	_	_	Seg=B-seg
103	:	_	_	_	_	_	_	_	Seg=O
104	Indigenous	_	_	_	_	_	_	_	Seg=B-seg
105	infants	_	_	_	_	_	_	_	Seg=O
106	hospitalized	_	_	_	_	_	_	_	Seg=B-seg
107	with	_	_	_	_	_	_	_	Seg=O
108	bronchiolitis	_	_	_	_	_	_	_	Seg=O
109	were	_	_	_	_	_	_	_	Seg=B-seg
110	enrolled	_	_	_	_	_	_	_	Seg=O
111	at	_	_	_	_	_	_	_	Seg=O
112	Royal	_	_	_	_	_	_	_	Seg=O
113	Darwin	_	_	_	_	_	_	_	Seg=O
114	Hospital	_	_	_	_	_	_	_	Seg=O
115	between	_	_	_	_	_	_	_	Seg=O
116	2008	_	_	_	_	_	_	_	Seg=O
117	and	_	_	_	_	_	_	_	Seg=O
118	2013	_	_	_	_	_	_	_	Seg=O
119	.	_	_	_	_	_	_	_	Seg=O
120	Standardized	_	_	_	_	_	_	_	Seg=B-seg
121	forms	_	_	_	_	_	_	_	Seg=O
122	were	_	_	_	_	_	_	_	Seg=O
123	used	_	_	_	_	_	_	_	Seg=O
124	to	_	_	_	_	_	_	_	Seg=B-seg
125	record	_	_	_	_	_	_	_	Seg=O
126	clinical	_	_	_	_	_	_	_	Seg=O
127	data	_	_	_	_	_	_	_	Seg=O
128	.	_	_	_	_	_	_	_	Seg=O
129	A	_	_	_	_	_	_	_	Seg=B-seg
130	nasopharyngeal	_	_	_	_	_	_	_	Seg=O
131	swab	_	_	_	_	_	_	_	Seg=O
132	was	_	_	_	_	_	_	_	Seg=O
133	collected	_	_	_	_	_	_	_	Seg=O
134	at	_	_	_	_	_	_	_	Seg=O
135	enrolment	_	_	_	_	_	_	_	Seg=O
136	to	_	_	_	_	_	_	_	Seg=B-seg
137	identify	_	_	_	_	_	_	_	Seg=O
138	respiratory	_	_	_	_	_	_	_	Seg=O
139	viruses	_	_	_	_	_	_	_	Seg=O
140	and	_	_	_	_	_	_	_	Seg=O
141	bacteria	_	_	_	_	_	_	_	Seg=O
142	.	_	_	_	_	_	_	_	Seg=O
143	Results	_	_	_	_	_	_	_	Seg=B-seg
144	:	_	_	_	_	_	_	_	Seg=O
145	The	_	_	_	_	_	_	_	Seg=B-seg
146	median	_	_	_	_	_	_	_	Seg=O
147	age	_	_	_	_	_	_	_	Seg=O
148	of	_	_	_	_	_	_	_	Seg=O
149	232	_	_	_	_	_	_	_	Seg=O
150	infants	_	_	_	_	_	_	_	Seg=O
151	was	_	_	_	_	_	_	_	Seg=O
152	5	_	_	_	_	_	_	_	Seg=O
153	months	_	_	_	_	_	_	_	Seg=O
154	(	_	_	_	_	_	_	_	Seg=B-seg
155	interquartile	_	_	_	_	_	_	_	Seg=O
156	range	_	_	_	_	_	_	_	Seg=O
157	3	_	_	_	_	_	_	_	Seg=O
158	-	_	_	_	_	_	_	_	Seg=O
159	9	_	_	_	_	_	_	_	Seg=O
160	)	_	_	_	_	_	_	_	Seg=O
161	;	_	_	_	_	_	_	_	Seg=O
162	65	_	_	_	_	_	_	_	Seg=B-seg
163	%	_	_	_	_	_	_	_	Seg=O
164	male	_	_	_	_	_	_	_	Seg=O
165	.	_	_	_	_	_	_	_	Seg=O
166	On	_	_	_	_	_	_	_	Seg=B-seg
167	multivariate	_	_	_	_	_	_	_	Seg=O
168	regression	_	_	_	_	_	_	_	Seg=O
169	,	_	_	_	_	_	_	_	Seg=O
170	our	_	_	_	_	_	_	_	Seg=O
171	12	_	_	_	_	_	_	_	Seg=O
172	point	_	_	_	_	_	_	_	Seg=O
173	severity	_	_	_	_	_	_	_	Seg=O
174	score	_	_	_	_	_	_	_	Seg=O
175	(	_	_	_	_	_	_	_	Seg=B-seg
176	including	_	_	_	_	_	_	_	Seg=O
177	accessory	_	_	_	_	_	_	_	Seg=O
178	muscle	_	_	_	_	_	_	_	Seg=O
179	use	_	_	_	_	_	_	_	Seg=O
180	)	_	_	_	_	_	_	_	Seg=O
181	was	_	_	_	_	_	_	_	Seg=B-seg
182	the	_	_	_	_	_	_	_	Seg=O
183	only	_	_	_	_	_	_	_	Seg=O
184	factor	_	_	_	_	_	_	_	Seg=O
185	associated	_	_	_	_	_	_	_	Seg=B-seg
186	with	_	_	_	_	_	_	_	Seg=O
187	prolonged	_	_	_	_	_	_	_	Seg=O
188	LOS	_	_	_	_	_	_	_	Seg=O
189	but	_	_	_	_	_	_	_	Seg=B-seg
190	the	_	_	_	_	_	_	_	Seg=O
191	effect	_	_	_	_	_	_	_	Seg=O
192	was	_	_	_	_	_	_	_	Seg=O
193	modest	_	_	_	_	_	_	_	Seg=O
194	(	_	_	_	_	_	_	_	Seg=B-seg
195	þ3.0	_	_	_	_	_	_	_	Seg=O
196	hr	_	_	_	_	_	_	_	Seg=O
197	per	_	_	_	_	_	_	_	Seg=O
198	point	_	_	_	_	_	_	_	Seg=O
199	,	_	_	_	_	_	_	_	Seg=O
200	95%CI	_	_	_	_	_	_	_	Seg=O
201	:	_	_	_	_	_	_	_	Seg=O
202	0.7	_	_	_	_	_	_	_	Seg=O
203	,	_	_	_	_	_	_	_	Seg=O
204	5.1	_	_	_	_	_	_	_	Seg=O
205	,	_	_	_	_	_	_	_	Seg=O
206	P	_	_	_	_	_	_	_	Seg=O
207	¼	_	_	_	_	_	_	_	Seg=O
208	0.01	_	_	_	_	_	_	_	Seg=O
209	)	_	_	_	_	_	_	_	Seg=O
210	.	_	_	_	_	_	_	_	Seg=O
211	Presence	_	_	_	_	_	_	_	Seg=B-seg
212	of	_	_	_	_	_	_	_	Seg=O
213	cough	_	_	_	_	_	_	_	Seg=O
214	at	_	_	_	_	_	_	_	Seg=O
215	3	_	_	_	_	_	_	_	Seg=O
216	weeks	_	_	_	_	_	_	_	Seg=O
217	increased	_	_	_	_	_	_	_	Seg=O
218	the	_	_	_	_	_	_	_	Seg=O
219	odds	_	_	_	_	_	_	_	Seg=O
220	of	_	_	_	_	_	_	_	Seg=O
221	bronchiectasis	_	_	_	_	_	_	_	Seg=O
222	(	_	_	_	_	_	_	_	Seg=B-seg
223	OR	_	_	_	_	_	_	_	Seg=O
224	3.0	_	_	_	_	_	_	_	Seg=O
225	,	_	_	_	_	_	_	_	Seg=O
226	95%CI	_	_	_	_	_	_	_	Seg=O
227	:	_	_	_	_	_	_	_	Seg=O
228	1.1	_	_	_	_	_	_	_	Seg=O
229	,	_	_	_	_	_	_	_	Seg=O
230	7.0	_	_	_	_	_	_	_	Seg=O
231	,	_	_	_	_	_	_	_	Seg=O
232	P	_	_	_	_	_	_	_	Seg=O
233	¼	_	_	_	_	_	_	_	Seg=O
234	0.03	_	_	_	_	_	_	_	Seg=O
235	)	_	_	_	_	_	_	_	Seg=O
236	.	_	_	_	_	_	_	_	Seg=O
237	Factors	_	_	_	_	_	_	_	Seg=B-seg
238	associated	_	_	_	_	_	_	_	Seg=B-seg
239	with	_	_	_	_	_	_	_	Seg=O
240	respiratory	_	_	_	_	_	_	_	Seg=O
241	readmissions	_	_	_	_	_	_	_	Seg=O
242	were	_	_	_	_	_	_	_	Seg=B-seg
243	:	_	_	_	_	_	_	_	Seg=O
244	previous	_	_	_	_	_	_	_	Seg=O
245	respiratory	_	_	_	_	_	_	_	Seg=O
246	hospitalization	_	_	_	_	_	_	_	Seg=O
247	(	_	_	_	_	_	_	_	Seg=B-seg
248	OR	_	_	_	_	_	_	_	Seg=O
249	2.3	_	_	_	_	_	_	_	Seg=O
250	,	_	_	_	_	_	_	_	Seg=O
251	95%CI	_	_	_	_	_	_	_	Seg=O
252	:	_	_	_	_	_	_	_	Seg=O
253	1.0	_	_	_	_	_	_	_	Seg=O
254	,	_	_	_	_	_	_	_	Seg=O
255	5.4	_	_	_	_	_	_	_	Seg=O
256	,	_	_	_	_	_	_	_	Seg=O
257	P	_	_	_	_	_	_	_	Seg=O
258	¼	_	_	_	_	_	_	_	Seg=O
259	0.05	_	_	_	_	_	_	_	Seg=O
260	)	_	_	_	_	_	_	_	Seg=O
261	and	_	_	_	_	_	_	_	Seg=B-seg
262	household	_	_	_	_	_	_	_	Seg=O
263	smoke	_	_	_	_	_	_	_	Seg=O
264	(	_	_	_	_	_	_	_	Seg=B-seg
265	OR	_	_	_	_	_	_	_	Seg=O
266	2.6	_	_	_	_	_	_	_	Seg=O
267	,	_	_	_	_	_	_	_	Seg=O
268	95%CI	_	_	_	_	_	_	_	Seg=O
269	:	_	_	_	_	_	_	_	Seg=O
270	1.0	_	_	_	_	_	_	_	Seg=O
271	,	_	_	_	_	_	_	_	Seg=O
272	6.3	_	_	_	_	_	_	_	Seg=O
273	,	_	_	_	_	_	_	_	Seg=O
274	P	_	_	_	_	_	_	_	Seg=O
275	¼	_	_	_	_	_	_	_	Seg=O
276	0.04	_	_	_	_	_	_	_	Seg=O
277	)	_	_	_	_	_	_	_	Seg=O
278	.	_	_	_	_	_	_	_	Seg=O
279	Conclusion	_	_	_	_	_	_	_	Seg=B-seg
280	:	_	_	_	_	_	_	_	Seg=O
281	Increased	_	_	_	_	_	_	_	Seg=B-seg
282	severity	_	_	_	_	_	_	_	Seg=O
283	score	_	_	_	_	_	_	_	Seg=O
284	is	_	_	_	_	_	_	_	Seg=O
285	associated	_	_	_	_	_	_	_	Seg=O
286	with	_	_	_	_	_	_	_	Seg=O
287	prolonged	_	_	_	_	_	_	_	Seg=O
288	LOS	_	_	_	_	_	_	_	Seg=O
289	in	_	_	_	_	_	_	_	Seg=O
290	Indigenous	_	_	_	_	_	_	_	Seg=O
291	children	_	_	_	_	_	_	_	Seg=O
292	hospitalized	_	_	_	_	_	_	_	Seg=B-seg
293	with	_	_	_	_	_	_	_	Seg=O
294	bronchiolitis	_	_	_	_	_	_	_	Seg=O
295	.	_	_	_	_	_	_	_	Seg=O
296	As	_	_	_	_	_	_	_	Seg=B-seg
297	persistent	_	_	_	_	_	_	_	Seg=O
298	symptoms	_	_	_	_	_	_	_	Seg=O
299	at	_	_	_	_	_	_	_	Seg=O
300	3	_	_	_	_	_	_	_	Seg=O
301	weeks	_	_	_	_	_	_	_	Seg=O
302	post	_	_	_	_	_	_	_	Seg=O
303	-	_	_	_	_	_	_	_	Seg=O
304	hospitalization	_	_	_	_	_	_	_	Seg=O
305	are	_	_	_	_	_	_	_	Seg=O
306	associated	_	_	_	_	_	_	_	Seg=O
307	with	_	_	_	_	_	_	_	Seg=O
308	future	_	_	_	_	_	_	_	Seg=O
309	diagnosis	_	_	_	_	_	_	_	Seg=O
310	of	_	_	_	_	_	_	_	Seg=O
311	bronchiectasis	_	_	_	_	_	_	_	Seg=O
312	,	_	_	_	_	_	_	_	Seg=O
313	optimising	_	_	_	_	_	_	_	Seg=B-seg
314	clinical	_	_	_	_	_	_	_	Seg=O
315	care	_	_	_	_	_	_	_	Seg=O
316	beyond	_	_	_	_	_	_	_	Seg=O
317	hospitalization	_	_	_	_	_	_	_	Seg=O
318	is	_	_	_	_	_	_	_	Seg=O
319	needed	_	_	_	_	_	_	_	Seg=O
320	to	_	_	_	_	_	_	_	Seg=B-seg
321	improve	_	_	_	_	_	_	_	Seg=O
322	long	_	_	_	_	_	_	_	Seg=O
323	-	_	_	_	_	_	_	_	Seg=O
324	term	_	_	_	_	_	_	_	Seg=O
325	respiratory	_	_	_	_	_	_	_	Seg=O
326	outcomes	_	_	_	_	_	_	_	Seg=O
327	for	_	_	_	_	_	_	_	Seg=O
328	infants	_	_	_	_	_	_	_	Seg=O
329	at	_	_	_	_	_	_	_	Seg=O
330	risk	_	_	_	_	_	_	_	Seg=O
331	of	_	_	_	_	_	_	_	Seg=O
332	respiratory	_	_	_	_	_	_	_	Seg=O
333	disease	_	_	_	_	_	_	_	Seg=O
334	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 4db77ad7a1c0aaa52615c22c0f58e9b2ddd96a02
1	Coronavirus	_	_	_	_	_	_	_	Seg=B-seg
2	epidemic	_	_	_	_	_	_	_	Seg=O
3	caused	_	_	_	_	_	_	_	Seg=O
4	announcing	_	_	_	_	_	_	_	Seg=O
5	emergency	_	_	_	_	_	_	_	Seg=O
6	case	_	_	_	_	_	_	_	Seg=O
7	in	_	_	_	_	_	_	_	Seg=O
8	South	_	_	_	_	_	_	_	Seg=O
9	Korea	_	_	_	_	_	_	_	Seg=O
10	.	_	_	_	_	_	_	_	Seg=O
11	The	_	_	_	_	_	_	_	Seg=B-seg
12	virus	_	_	_	_	_	_	_	Seg=O
13	started	_	_	_	_	_	_	_	Seg=O
14	with	_	_	_	_	_	_	_	Seg=O
15	one	_	_	_	_	_	_	_	Seg=O
16	infected	_	_	_	_	_	_	_	Seg=O
17	case	_	_	_	_	_	_	_	Seg=O
18	by	_	_	_	_	_	_	_	Seg=O
19	January	_	_	_	_	_	_	_	Seg=O
20	20	_	_	_	_	_	_	_	Seg=O
21	,	_	_	_	_	_	_	_	Seg=O
22	2020	_	_	_	_	_	_	_	Seg=O
23	,	_	_	_	_	_	_	_	Seg=O
24	where	_	_	_	_	_	_	_	Seg=B-seg
25	9583	_	_	_	_	_	_	_	Seg=O
26	announced	_	_	_	_	_	_	_	Seg=O
27	cases	_	_	_	_	_	_	_	Seg=O
28	were	_	_	_	_	_	_	_	Seg=O
29	reported	_	_	_	_	_	_	_	Seg=O
30	by	_	_	_	_	_	_	_	Seg=O
31	March	_	_	_	_	_	_	_	Seg=O
32	29	_	_	_	_	_	_	_	Seg=O
33	,	_	_	_	_	_	_	_	Seg=O
34	2020	_	_	_	_	_	_	_	Seg=O
35	.	_	_	_	_	_	_	_	Seg=O
36	This	_	_	_	_	_	_	_	Seg=B-seg
37	indicates	_	_	_	_	_	_	_	Seg=O
38	that	_	_	_	_	_	_	_	Seg=B-seg
39	the	_	_	_	_	_	_	_	Seg=O
40	number	_	_	_	_	_	_	_	Seg=O
41	of	_	_	_	_	_	_	_	Seg=O
42	confirmed	_	_	_	_	_	_	_	Seg=O
43	cases	_	_	_	_	_	_	_	Seg=O
44	is	_	_	_	_	_	_	_	Seg=O
45	increasing	_	_	_	_	_	_	_	Seg=O
46	rapidly	_	_	_	_	_	_	_	Seg=O
47	,	_	_	_	_	_	_	_	Seg=O
48	which	_	_	_	_	_	_	_	Seg=B-seg
49	can	_	_	_	_	_	_	_	Seg=O
50	cause	_	_	_	_	_	_	_	Seg=O
51	national	_	_	_	_	_	_	_	Seg=O
52	crises	_	_	_	_	_	_	_	Seg=O
53	for	_	_	_	_	_	_	_	Seg=O
54	South	_	_	_	_	_	_	_	Seg=O
55	Korea	_	_	_	_	_	_	_	Seg=O
56	.	_	_	_	_	_	_	_	Seg=O
57	The	_	_	_	_	_	_	_	Seg=B-seg
58	aim	_	_	_	_	_	_	_	Seg=O
59	of	_	_	_	_	_	_	_	Seg=O
60	this	_	_	_	_	_	_	_	Seg=O
61	study	_	_	_	_	_	_	_	Seg=O
62	is	_	_	_	_	_	_	_	Seg=O
63	to	_	_	_	_	_	_	_	Seg=O
64	fill	_	_	_	_	_	_	_	Seg=O
65	a	_	_	_	_	_	_	_	Seg=O
66	gap	_	_	_	_	_	_	_	Seg=O
67	between	_	_	_	_	_	_	_	Seg=O
68	previous	_	_	_	_	_	_	_	Seg=O
69	studies	_	_	_	_	_	_	_	Seg=O
70	and	_	_	_	_	_	_	_	Seg=O
71	the	_	_	_	_	_	_	_	Seg=O
72	current	_	_	_	_	_	_	_	Seg=O
73	development	_	_	_	_	_	_	_	Seg=O
74	of	_	_	_	_	_	_	_	Seg=O
75	CoVID-19	_	_	_	_	_	_	_	Seg=O
76	spreading	_	_	_	_	_	_	_	Seg=O
77	,	_	_	_	_	_	_	_	Seg=O
78	by	_	_	_	_	_	_	_	Seg=B-seg
79	extracting	_	_	_	_	_	_	_	Seg=O
80	a	_	_	_	_	_	_	_	Seg=O
81	relationship	_	_	_	_	_	_	_	Seg=O
82	between	_	_	_	_	_	_	_	Seg=O
83	independent	_	_	_	_	_	_	_	Seg=O
84	variables	_	_	_	_	_	_	_	Seg=O
85	and	_	_	_	_	_	_	_	Seg=O
86	dependent	_	_	_	_	_	_	_	Seg=O
87	variable	_	_	_	_	_	_	_	Seg=O
88	.	_	_	_	_	_	_	_	Seg=O
89	This	_	_	_	_	_	_	_	Seg=B-seg
90	research	_	_	_	_	_	_	_	Seg=O
91	statistically	_	_	_	_	_	_	_	Seg=O
92	analyzed	_	_	_	_	_	_	_	Seg=O
93	the	_	_	_	_	_	_	_	Seg=O
94	effect	_	_	_	_	_	_	_	Seg=O
95	of	_	_	_	_	_	_	_	Seg=O
96	sex	_	_	_	_	_	_	_	Seg=O
97	,	_	_	_	_	_	_	_	Seg=O
98	region	_	_	_	_	_	_	_	Seg=O
99	,	_	_	_	_	_	_	_	Seg=O
100	infection	_	_	_	_	_	_	_	Seg=O
101	reasons	_	_	_	_	_	_	_	Seg=O
102	,	_	_	_	_	_	_	_	Seg=O
103	birth	_	_	_	_	_	_	_	Seg=O
104	year	_	_	_	_	_	_	_	Seg=O
105	,	_	_	_	_	_	_	_	Seg=O
106	and	_	_	_	_	_	_	_	Seg=O
107	released	_	_	_	_	_	_	_	Seg=O
108	or	_	_	_	_	_	_	_	Seg=O
109	diseased	_	_	_	_	_	_	_	Seg=O
110	date	_	_	_	_	_	_	_	Seg=O
111	on	_	_	_	_	_	_	_	Seg=O
112	the	_	_	_	_	_	_	_	Seg=O
113	reported	_	_	_	_	_	_	_	Seg=O
114	numbers	_	_	_	_	_	_	_	Seg=O
115	of	_	_	_	_	_	_	_	Seg=O
116	recovered	_	_	_	_	_	_	_	Seg=O
117	and	_	_	_	_	_	_	_	Seg=O
118	deceased	_	_	_	_	_	_	_	Seg=O
119	cases	_	_	_	_	_	_	_	Seg=O
120	.	_	_	_	_	_	_	_	Seg=O
121	The	_	_	_	_	_	_	_	Seg=B-seg
122	results	_	_	_	_	_	_	_	Seg=O
123	found	_	_	_	_	_	_	_	Seg=O
124	that	_	_	_	_	_	_	_	Seg=B-seg
125	sex	_	_	_	_	_	_	_	Seg=O
126	,	_	_	_	_	_	_	_	Seg=O
127	region	_	_	_	_	_	_	_	Seg=O
128	,	_	_	_	_	_	_	_	Seg=O
129	and	_	_	_	_	_	_	_	Seg=O
130	infection	_	_	_	_	_	_	_	Seg=O
131	reasons	_	_	_	_	_	_	_	Seg=O
132	affected	_	_	_	_	_	_	_	Seg=O
133	on	_	_	_	_	_	_	_	Seg=O
134	both	_	_	_	_	_	_	_	Seg=O
135	recovered	_	_	_	_	_	_	_	Seg=O
136	and	_	_	_	_	_	_	_	Seg=O
137	deceased	_	_	_	_	_	_	_	Seg=O
138	cases	_	_	_	_	_	_	_	Seg=O
139	,	_	_	_	_	_	_	_	Seg=O
140	while	_	_	_	_	_	_	_	Seg=B-seg
141	birth	_	_	_	_	_	_	_	Seg=O
142	year	_	_	_	_	_	_	_	Seg=O
143	only	_	_	_	_	_	_	_	Seg=O
144	affected	_	_	_	_	_	_	_	Seg=O
145	on	_	_	_	_	_	_	_	Seg=O
146	deceased	_	_	_	_	_	_	_	Seg=O
147	cases	_	_	_	_	_	_	_	Seg=O
148	.	_	_	_	_	_	_	_	Seg=O
149	Besides	_	_	_	_	_	_	_	Seg=B-seg
150	,	_	_	_	_	_	_	_	Seg=O
151	no	_	_	_	_	_	_	_	Seg=O
152	deceased	_	_	_	_	_	_	_	Seg=O
153	cases	_	_	_	_	_	_	_	Seg=O
154	are	_	_	_	_	_	_	_	Seg=O
155	reported	_	_	_	_	_	_	_	Seg=O
156	for	_	_	_	_	_	_	_	Seg=O
157	released	_	_	_	_	_	_	_	Seg=O
158	cases	_	_	_	_	_	_	_	Seg=O
159	,	_	_	_	_	_	_	_	Seg=O
160	while	_	_	_	_	_	_	_	Seg=B-seg
161	11.3	_	_	_	_	_	_	_	Seg=O
162	%	_	_	_	_	_	_	_	Seg=O
163	of	_	_	_	_	_	_	_	Seg=O
164	deceased	_	_	_	_	_	_	_	Seg=O
165	cases	_	_	_	_	_	_	_	Seg=O
166	positive	_	_	_	_	_	_	_	Seg=O
167	confirmed	_	_	_	_	_	_	_	Seg=O
168	after	_	_	_	_	_	_	_	Seg=O
169	their	_	_	_	_	_	_	_	Seg=O
170	deceased	_	_	_	_	_	_	_	Seg=O
171	.	_	_	_	_	_	_	_	Seg=O
172	Unknown	_	_	_	_	_	_	_	Seg=B-seg
173	reason	_	_	_	_	_	_	_	Seg=O
174	of	_	_	_	_	_	_	_	Seg=O
175	infection	_	_	_	_	_	_	_	Seg=O
176	is	_	_	_	_	_	_	_	Seg=O
177	the	_	_	_	_	_	_	_	Seg=O
178	main	_	_	_	_	_	_	_	Seg=O
179	variable	_	_	_	_	_	_	_	Seg=O
180	that	_	_	_	_	_	_	_	Seg=B-seg
181	detected	_	_	_	_	_	_	_	Seg=O
182	in	_	_	_	_	_	_	_	Seg=O
183	South	_	_	_	_	_	_	_	Seg=O
184	Korea	_	_	_	_	_	_	_	Seg=O
185	with	_	_	_	_	_	_	_	Seg=O
186	more	_	_	_	_	_	_	_	Seg=O
187	than	_	_	_	_	_	_	_	Seg=O
188	33	_	_	_	_	_	_	_	Seg=O
189	%	_	_	_	_	_	_	_	Seg=O
190	of	_	_	_	_	_	_	_	Seg=O
191	total	_	_	_	_	_	_	_	Seg=O
192	infected	_	_	_	_	_	_	_	Seg=O
193	cases	_	_	_	_	_	_	_	Seg=O
194	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 4e20e6a3d99bde2aea75bc215333524538fe17ef
1	Respiratory	_	_	_	_	_	_	_	Seg=B-seg
2	infections	_	_	_	_	_	_	_	Seg=O
3	are	_	_	_	_	_	_	_	Seg=O
4	the	_	_	_	_	_	_	_	Seg=O
5	most	_	_	_	_	_	_	_	Seg=O
6	frequent	_	_	_	_	_	_	_	Seg=O
7	reason	_	_	_	_	_	_	_	Seg=O
8	for	_	_	_	_	_	_	_	Seg=O
9	primary	_	_	_	_	_	_	_	Seg=O
10	health	_	_	_	_	_	_	_	Seg=O
11	care	_	_	_	_	_	_	_	Seg=O
12	consultation	_	_	_	_	_	_	_	Seg=O
13	.	_	_	_	_	_	_	_	Seg=O
14	The	_	_	_	_	_	_	_	Seg=B-seg
15	main	_	_	_	_	_	_	_	Seg=O
16	causes	_	_	_	_	_	_	_	Seg=O
17	of	_	_	_	_	_	_	_	Seg=O
18	respiratory	_	_	_	_	_	_	_	Seg=O
19	tract	_	_	_	_	_	_	_	Seg=O
20	infections	_	_	_	_	_	_	_	Seg=O
21	in	_	_	_	_	_	_	_	Seg=O
22	children	_	_	_	_	_	_	_	Seg=O
23	are	_	_	_	_	_	_	_	Seg=O
24	viruses	_	_	_	_	_	_	_	Seg=O
25	and	_	_	_	_	_	_	_	Seg=B-seg
26	the	_	_	_	_	_	_	_	Seg=O
27	most	_	_	_	_	_	_	_	Seg=O
28	common	_	_	_	_	_	_	_	Seg=O
29	types	_	_	_	_	_	_	_	Seg=O
30	are	_	_	_	_	_	_	_	Seg=O
31	upper	_	_	_	_	_	_	_	Seg=O
32	respiratory	_	_	_	_	_	_	_	Seg=O
33	tract	_	_	_	_	_	_	_	Seg=O
34	infections	_	_	_	_	_	_	_	Seg=O
35	:	_	_	_	_	_	_	_	Seg=O
36	common	_	_	_	_	_	_	_	Seg=B-seg
37	cold	_	_	_	_	_	_	_	Seg=O
38	,	_	_	_	_	_	_	_	Seg=O
39	pharyngitis	_	_	_	_	_	_	_	Seg=O
40	,	_	_	_	_	_	_	_	Seg=O
41	otitis	_	_	_	_	_	_	_	Seg=O
42	media	_	_	_	_	_	_	_	Seg=O
43	and	_	_	_	_	_	_	_	Seg=O
44	sinusitis	_	_	_	_	_	_	_	Seg=O
45	.	_	_	_	_	_	_	_	Seg=O
46	Pneumonia	_	_	_	_	_	_	_	Seg=B-seg
47	is	_	_	_	_	_	_	_	Seg=O
48	much	_	_	_	_	_	_	_	Seg=O
49	more	_	_	_	_	_	_	_	Seg=O
50	serious	_	_	_	_	_	_	_	Seg=O
51	.	_	_	_	_	_	_	_	Seg=O
52	As	_	_	_	_	_	_	_	Seg=B-seg
53	well	_	_	_	_	_	_	_	Seg=O
54	as	_	_	_	_	_	_	_	Seg=O
55	viruses	_	_	_	_	_	_	_	Seg=O
56	,	_	_	_	_	_	_	_	Seg=O
57	bacteria	_	_	_	_	_	_	_	Seg=O
58	are	_	_	_	_	_	_	_	Seg=O
59	often	_	_	_	_	_	_	_	Seg=O
60	involved	_	_	_	_	_	_	_	Seg=O
61	in	_	_	_	_	_	_	_	Seg=O
62	respiratory	_	_	_	_	_	_	_	Seg=O
63	tract	_	_	_	_	_	_	_	Seg=O
64	infections	_	_	_	_	_	_	_	Seg=O
65	.	_	_	_	_	_	_	_	Seg=O
66	Three	_	_	_	_	_	_	_	Seg=B-seg
67	bacterial	_	_	_	_	_	_	_	Seg=O
68	species	_	_	_	_	_	_	_	Seg=O
69	are	_	_	_	_	_	_	_	Seg=O
70	most	_	_	_	_	_	_	_	Seg=O
71	commonly	_	_	_	_	_	_	_	Seg=O
72	isolated	_	_	_	_	_	_	_	Seg=O
73	:	_	_	_	_	_	_	_	Seg=O
74	Streptococcus	_	_	_	_	_	_	_	Seg=B-seg
75	pneumoniae	_	_	_	_	_	_	_	Seg=O
76	,	_	_	_	_	_	_	_	Seg=O
77	non	_	_	_	_	_	_	_	Seg=O
78	-	_	_	_	_	_	_	_	Seg=O
79	encapsulated	_	_	_	_	_	_	_	Seg=O
80	Haemophilus	_	_	_	_	_	_	_	Seg=O
81	influenzae	_	_	_	_	_	_	_	Seg=O
82	and	_	_	_	_	_	_	_	Seg=O
83	Moraxella	_	_	_	_	_	_	_	Seg=O
84	(	_	_	_	_	_	_	_	Seg=O
85	Branhamella	_	_	_	_	_	_	_	Seg=O
86	)	_	_	_	_	_	_	_	Seg=O
87	catarrhalis	_	_	_	_	_	_	_	Seg=O
88	.	_	_	_	_	_	_	_	Seg=O
89	The	_	_	_	_	_	_	_	Seg=B-seg
90	most	_	_	_	_	_	_	_	Seg=O
91	common	_	_	_	_	_	_	_	Seg=O
92	bacterial	_	_	_	_	_	_	_	Seg=O
93	cause	_	_	_	_	_	_	_	Seg=O
94	of	_	_	_	_	_	_	_	Seg=O
95	pharyngitis	_	_	_	_	_	_	_	Seg=O
96	is	_	_	_	_	_	_	_	Seg=O
97	Streptococcus	_	_	_	_	_	_	_	Seg=O
98	pyogenes	_	_	_	_	_	_	_	Seg=O
99	.	_	_	_	_	_	_	_	Seg=O
100	Bacteria	_	_	_	_	_	_	_	Seg=B-seg
101	isolated	_	_	_	_	_	_	_	Seg=B-seg
102	from	_	_	_	_	_	_	_	Seg=O
103	community	_	_	_	_	_	_	_	Seg=O
104	-	_	_	_	_	_	_	_	Seg=O
105	acquired	_	_	_	_	_	_	_	Seg=O
106	infection	_	_	_	_	_	_	_	Seg=O
107	usually	_	_	_	_	_	_	_	Seg=B-seg
108	are	_	_	_	_	_	_	_	Seg=O
109	sensitive	_	_	_	_	_	_	_	Seg=O
110	to	_	_	_	_	_	_	_	Seg=O
111	the	_	_	_	_	_	_	_	Seg=O
112	majority	_	_	_	_	_	_	_	Seg=O
113	of	_	_	_	_	_	_	_	Seg=O
114	suitable	_	_	_	_	_	_	_	Seg=O
115	drugs	_	_	_	_	_	_	_	Seg=O
116	,	_	_	_	_	_	_	_	Seg=O
117	but	_	_	_	_	_	_	_	Seg=B-seg
118	during	_	_	_	_	_	_	_	Seg=O
119	the	_	_	_	_	_	_	_	Seg=O
120	past	_	_	_	_	_	_	_	Seg=O
121	two	_	_	_	_	_	_	_	Seg=O
122	decades	_	_	_	_	_	_	_	Seg=O
123	,	_	_	_	_	_	_	_	Seg=O
124	significant	_	_	_	_	_	_	_	Seg=O
125	antibiotic	_	_	_	_	_	_	_	Seg=O
126	resistance	_	_	_	_	_	_	_	Seg=O
127	has	_	_	_	_	_	_	_	Seg=O
128	emerged	_	_	_	_	_	_	_	Seg=O
129	.	_	_	_	_	_	_	_	Seg=O
130	Resistance	_	_	_	_	_	_	_	Seg=B-seg
131	to	_	_	_	_	_	_	_	Seg=O
132	penicillins	_	_	_	_	_	_	_	Seg=O
133	has	_	_	_	_	_	_	_	Seg=O
134	spread	_	_	_	_	_	_	_	Seg=O
135	among	_	_	_	_	_	_	_	Seg=O
136	H.	_	_	_	_	_	_	_	Seg=O
137	influenzae	_	_	_	_	_	_	_	Seg=O
138	and	_	_	_	_	_	_	_	Seg=O
139	S.	_	_	_	_	_	_	_	Seg=O
140	pneumoniae	_	_	_	_	_	_	_	Seg=O
141	.	_	_	_	_	_	_	_	Seg=O
142	The	_	_	_	_	_	_	_	Seg=B-seg
143	mechanism	_	_	_	_	_	_	_	Seg=O
144	of	_	_	_	_	_	_	_	Seg=O
145	penicillin	_	_	_	_	_	_	_	Seg=O
146	resistance	_	_	_	_	_	_	_	Seg=O
147	in	_	_	_	_	_	_	_	Seg=O
148	H.	_	_	_	_	_	_	_	Seg=O
149	influenzae	_	_	_	_	_	_	_	Seg=O
150	is	_	_	_	_	_	_	_	Seg=O
151	mainly	_	_	_	_	_	_	_	Seg=O
152	by	_	_	_	_	_	_	_	Seg=O
153	production	_	_	_	_	_	_	_	Seg=O
154	of	_	_	_	_	_	_	_	Seg=O
155	b	_	_	_	_	_	_	_	Seg=O
156	-	_	_	_	_	_	_	_	Seg=O
157	lactamases	_	_	_	_	_	_	_	Seg=O
158	TEM-1	_	_	_	_	_	_	_	Seg=O
159	and	_	_	_	_	_	_	_	Seg=O
160	ROB-1	_	_	_	_	_	_	_	Seg=O
161	,	_	_	_	_	_	_	_	Seg=O
162	whereas	_	_	_	_	_	_	_	Seg=B-seg
163	in	_	_	_	_	_	_	_	Seg=O
164	S.	_	_	_	_	_	_	_	Seg=O
165	pneumoniae	_	_	_	_	_	_	_	Seg=O
166	resistance	_	_	_	_	_	_	_	Seg=O
167	is	_	_	_	_	_	_	_	Seg=O
168	an	_	_	_	_	_	_	_	Seg=O
169	effect	_	_	_	_	_	_	_	Seg=O
170	of	_	_	_	_	_	_	_	Seg=O
171	the	_	_	_	_	_	_	_	Seg=O
172	changes	_	_	_	_	_	_	_	Seg=O
173	in	_	_	_	_	_	_	_	Seg=O
174	penicillin	_	_	_	_	_	_	_	Seg=O
175	binding	_	_	_	_	_	_	_	Seg=O
176	proteins	_	_	_	_	_	_	_	Seg=O
177	.	_	_	_	_	_	_	_	Seg=O
178	Among	_	_	_	_	_	_	_	Seg=B-seg
179	respiratory	_	_	_	_	_	_	_	Seg=O
180	pathogens	_	_	_	_	_	_	_	Seg=O
181	,	_	_	_	_	_	_	_	Seg=O
182	resistance	_	_	_	_	_	_	_	Seg=O
183	to	_	_	_	_	_	_	_	Seg=O
184	tetracyclines	_	_	_	_	_	_	_	Seg=O
185	,	_	_	_	_	_	_	_	Seg=O
186	macrolides	_	_	_	_	_	_	_	Seg=O
187	,	_	_	_	_	_	_	_	Seg=O
188	trimethoprim	_	_	_	_	_	_	_	Seg=O
189	-	_	_	_	_	_	_	_	Seg=O
190	sulphamethoxazole	_	_	_	_	_	_	_	Seg=O
191	and	_	_	_	_	_	_	_	Seg=O
192	fluoroquinolones	_	_	_	_	_	_	_	Seg=O
193	has	_	_	_	_	_	_	_	Seg=O
194	also	_	_	_	_	_	_	_	Seg=O
195	appeared	_	_	_	_	_	_	_	Seg=O
196	.	_	_	_	_	_	_	_	Seg=O
197	Several	_	_	_	_	_	_	_	Seg=B-seg
198	mechanisms	_	_	_	_	_	_	_	Seg=O
199	depending	_	_	_	_	_	_	_	Seg=B-seg
200	on	_	_	_	_	_	_	_	Seg=O
201	changes	_	_	_	_	_	_	_	Seg=O
202	in	_	_	_	_	_	_	_	Seg=O
203	target	_	_	_	_	_	_	_	Seg=O
204	,	_	_	_	_	_	_	_	Seg=O
205	active	_	_	_	_	_	_	_	Seg=O
206	efflux	_	_	_	_	_	_	_	Seg=O
207	and	_	_	_	_	_	_	_	Seg=O
208	modifying	_	_	_	_	_	_	_	Seg=O
209	enzymes	_	_	_	_	_	_	_	Seg=O
210	are	_	_	_	_	_	_	_	Seg=B-seg
211	involved	_	_	_	_	_	_	_	Seg=O
212	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 4fc5ea08bc8213609b854d5e4ffd02bd609298a7
1	Though	_	_	_	_	_	_	_	Seg=B-seg
2	viruses	_	_	_	_	_	_	_	Seg=O
3	have	_	_	_	_	_	_	_	Seg=O
4	generally	_	_	_	_	_	_	_	Seg=O
5	been	_	_	_	_	_	_	_	Seg=O
6	characterized	_	_	_	_	_	_	_	Seg=O
7	by	_	_	_	_	_	_	_	Seg=O
8	their	_	_	_	_	_	_	_	Seg=O
9	pathogenic	_	_	_	_	_	_	_	Seg=O
10	and	_	_	_	_	_	_	_	Seg=O
11	more	_	_	_	_	_	_	_	Seg=O
12	generally	_	_	_	_	_	_	_	Seg=O
13	harmful	_	_	_	_	_	_	_	Seg=O
14	effects	_	_	_	_	_	_	_	Seg=O
15	,	_	_	_	_	_	_	_	Seg=O
16	many	_	_	_	_	_	_	_	Seg=B-seg
17	examples	_	_	_	_	_	_	_	Seg=O
18	of	_	_	_	_	_	_	_	Seg=O
19	mutualistic	_	_	_	_	_	_	_	Seg=O
20	viruses	_	_	_	_	_	_	_	Seg=O
21	exist	_	_	_	_	_	_	_	Seg=O
22	.	_	_	_	_	_	_	_	Seg=O
23	Here	_	_	_	_	_	_	_	Seg=B-seg
24	I	_	_	_	_	_	_	_	Seg=O
25	explain	_	_	_	_	_	_	_	Seg=O
26	how	_	_	_	_	_	_	_	Seg=O
27	the	_	_	_	_	_	_	_	Seg=O
28	idea	_	_	_	_	_	_	_	Seg=O
29	of	_	_	_	_	_	_	_	Seg=O
30	mutualistic	_	_	_	_	_	_	_	Seg=O
31	viruses	_	_	_	_	_	_	_	Seg=O
32	has	_	_	_	_	_	_	_	Seg=O
33	been	_	_	_	_	_	_	_	Seg=O
34	defended	_	_	_	_	_	_	_	Seg=O
35	in	_	_	_	_	_	_	_	Seg=O
36	recent	_	_	_	_	_	_	_	Seg=O
37	virology	_	_	_	_	_	_	_	Seg=O
38	,	_	_	_	_	_	_	_	Seg=O
39	and	_	_	_	_	_	_	_	Seg=B-seg
40	I	_	_	_	_	_	_	_	Seg=O
41	explore	_	_	_	_	_	_	_	Seg=O
42	four	_	_	_	_	_	_	_	Seg=O
43	important	_	_	_	_	_	_	_	Seg=O
44	conceptual	_	_	_	_	_	_	_	Seg=O
45	and	_	_	_	_	_	_	_	Seg=O
46	practical	_	_	_	_	_	_	_	Seg=O
47	consequences	_	_	_	_	_	_	_	Seg=O
48	of	_	_	_	_	_	_	_	Seg=O
49	this	_	_	_	_	_	_	_	Seg=O
50	idea	_	_	_	_	_	_	_	Seg=O
51	.	_	_	_	_	_	_	_	Seg=O
52	I	_	_	_	_	_	_	_	Seg=B-seg
53	ask	_	_	_	_	_	_	_	Seg=O
54	to	_	_	_	_	_	_	_	Seg=B-seg
55	what	_	_	_	_	_	_	_	Seg=O
56	extent	_	_	_	_	_	_	_	Seg=O
57	this	_	_	_	_	_	_	_	Seg=O
58	research	_	_	_	_	_	_	_	Seg=O
59	modifies	_	_	_	_	_	_	_	Seg=O
60	the	_	_	_	_	_	_	_	Seg=O
61	way	_	_	_	_	_	_	_	Seg=O
62	scientists	_	_	_	_	_	_	_	Seg=B-seg
63	might	_	_	_	_	_	_	_	Seg=O
64	search	_	_	_	_	_	_	_	Seg=O
65	for	_	_	_	_	_	_	_	Seg=O
66	new	_	_	_	_	_	_	_	Seg=O
67	viruses	_	_	_	_	_	_	_	Seg=O
68	,	_	_	_	_	_	_	_	Seg=O
69	our	_	_	_	_	_	_	_	Seg=B-seg
70	notion	_	_	_	_	_	_	_	Seg=O
71	of	_	_	_	_	_	_	_	Seg=B-seg
72	how	_	_	_	_	_	_	_	Seg=O
73	the	_	_	_	_	_	_	_	Seg=O
74	host	_	_	_	_	_	_	_	Seg=O
75	immune	_	_	_	_	_	_	_	Seg=O
76	system	_	_	_	_	_	_	_	Seg=O
77	interacts	_	_	_	_	_	_	_	Seg=O
78	with	_	_	_	_	_	_	_	Seg=O
79	microbes	_	_	_	_	_	_	_	Seg=O
80	,	_	_	_	_	_	_	_	Seg=O
81	the	_	_	_	_	_	_	_	Seg=B-seg
82	development	_	_	_	_	_	_	_	Seg=O
83	of	_	_	_	_	_	_	_	Seg=O
84	new	_	_	_	_	_	_	_	Seg=O
85	therapeutic	_	_	_	_	_	_	_	Seg=O
86	approaches	_	_	_	_	_	_	_	Seg=O
87	,	_	_	_	_	_	_	_	Seg=O
88	and	_	_	_	_	_	_	_	Seg=O
89	,	_	_	_	_	_	_	_	Seg=O
90	finally	_	_	_	_	_	_	_	Seg=O
91	,	_	_	_	_	_	_	_	Seg=O
92	the	_	_	_	_	_	_	_	Seg=O
93	role	_	_	_	_	_	_	_	Seg=O
94	played	_	_	_	_	_	_	_	Seg=B-seg
95	by	_	_	_	_	_	_	_	Seg=O
96	the	_	_	_	_	_	_	_	Seg=O
97	criterion	_	_	_	_	_	_	_	Seg=O
98	of	_	_	_	_	_	_	_	Seg=O
99	autonomy	_	_	_	_	_	_	_	Seg=O
100	in	_	_	_	_	_	_	_	Seg=B-seg
101	our	_	_	_	_	_	_	_	Seg=O
102	understanding	_	_	_	_	_	_	_	Seg=O
103	of	_	_	_	_	_	_	_	Seg=O
104	living	_	_	_	_	_	_	_	Seg=O
105	things	_	_	_	_	_	_	_	Seg=O
106	.	_	_	_	_	_	_	_	Seg=O
107	Overall	_	_	_	_	_	_	_	Seg=B-seg
108	,	_	_	_	_	_	_	_	Seg=O
109	I	_	_	_	_	_	_	_	Seg=O
110	suggest	_	_	_	_	_	_	_	Seg=O
111	that	_	_	_	_	_	_	_	Seg=B-seg
112	the	_	_	_	_	_	_	_	Seg=O
113	recognition	_	_	_	_	_	_	_	Seg=O
114	of	_	_	_	_	_	_	_	Seg=O
115	mutualistic	_	_	_	_	_	_	_	Seg=O
116	viruses	_	_	_	_	_	_	_	Seg=O
117	plays	_	_	_	_	_	_	_	Seg=O
118	a	_	_	_	_	_	_	_	Seg=O
119	major	_	_	_	_	_	_	_	Seg=O
120	role	_	_	_	_	_	_	_	Seg=O
121	in	_	_	_	_	_	_	_	Seg=O
122	a	_	_	_	_	_	_	_	Seg=O
123	wider	_	_	_	_	_	_	_	Seg=O
124	ongoing	_	_	_	_	_	_	_	Seg=O
125	revision	_	_	_	_	_	_	_	Seg=O
126	of	_	_	_	_	_	_	_	Seg=O
127	our	_	_	_	_	_	_	_	Seg=O
128	conception	_	_	_	_	_	_	_	Seg=O
129	of	_	_	_	_	_	_	_	Seg=O
130	viruses	_	_	_	_	_	_	_	Seg=O
131	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 5054b46cdd142f945f9583e393706d5e139f760b
1	This	_	_	_	_	_	_	_	Seg=B-seg
2	content	_	_	_	_	_	_	_	Seg=O
3	analysis	_	_	_	_	_	_	_	Seg=O
4	provides	_	_	_	_	_	_	_	Seg=O
5	an	_	_	_	_	_	_	_	Seg=O
6	overview	_	_	_	_	_	_	_	Seg=O
7	of	_	_	_	_	_	_	_	Seg=O
8	articles	_	_	_	_	_	_	_	Seg=O
9	specific	_	_	_	_	_	_	_	Seg=O
10	to	_	_	_	_	_	_	_	Seg=O
11	technology	_	_	_	_	_	_	_	Seg=O
12	integration	_	_	_	_	_	_	_	Seg=O
13	in	_	_	_	_	_	_	_	Seg=O
14	the	_	_	_	_	_	_	_	Seg=O
15	field	_	_	_	_	_	_	_	Seg=O
16	of	_	_	_	_	_	_	_	Seg=O
17	counseling	_	_	_	_	_	_	_	Seg=O
18	published	_	_	_	_	_	_	_	Seg=B-seg
19	in	_	_	_	_	_	_	_	Seg=O
20	American	_	_	_	_	_	_	_	Seg=O
21	Counseling	_	_	_	_	_	_	_	Seg=O
22	Association	_	_	_	_	_	_	_	Seg=O
23	(	_	_	_	_	_	_	_	Seg=O
24	ACA	_	_	_	_	_	_	_	Seg=O
25	)	_	_	_	_	_	_	_	Seg=O
26	journals	_	_	_	_	_	_	_	Seg=O
27	between	_	_	_	_	_	_	_	Seg=O
28	the	_	_	_	_	_	_	_	Seg=O
29	years	_	_	_	_	_	_	_	Seg=O
30	2000	_	_	_	_	_	_	_	Seg=O
31	and	_	_	_	_	_	_	_	Seg=O
32	2018	_	_	_	_	_	_	_	Seg=O
33	.	_	_	_	_	_	_	_	Seg=O
34	In	_	_	_	_	_	_	_	Seg=B-seg
35	addition	_	_	_	_	_	_	_	Seg=O
36	to	_	_	_	_	_	_	_	Seg=O
37	the	_	_	_	_	_	_	_	Seg=O
38	number	_	_	_	_	_	_	_	Seg=O
39	of	_	_	_	_	_	_	_	Seg=O
40	articles	_	_	_	_	_	_	_	Seg=O
41	on	_	_	_	_	_	_	_	Seg=O
42	this	_	_	_	_	_	_	_	Seg=O
43	topic	_	_	_	_	_	_	_	Seg=O
44	published	_	_	_	_	_	_	_	Seg=B-seg
45	during	_	_	_	_	_	_	_	Seg=O
46	this	_	_	_	_	_	_	_	Seg=O
47	time	_	_	_	_	_	_	_	Seg=O
48	period	_	_	_	_	_	_	_	Seg=O
49	,	_	_	_	_	_	_	_	Seg=O
50	the	_	_	_	_	_	_	_	Seg=B-seg
51	study	_	_	_	_	_	_	_	Seg=O
52	identified	_	_	_	_	_	_	_	Seg=O
53	other	_	_	_	_	_	_	_	Seg=O
54	aspects	_	_	_	_	_	_	_	Seg=O
55	such	_	_	_	_	_	_	_	Seg=B-seg
56	as	_	_	_	_	_	_	_	Seg=O
57	authors	_	_	_	_	_	_	_	Seg=O
58	and	_	_	_	_	_	_	_	Seg=O
59	institutional	_	_	_	_	_	_	_	Seg=O
60	affiliations	_	_	_	_	_	_	_	Seg=O
61	;	_	_	_	_	_	_	_	Seg=O
62	methodology	_	_	_	_	_	_	_	Seg=O
63	,	_	_	_	_	_	_	_	Seg=O
64	study	_	_	_	_	_	_	_	Seg=O
65	locations	_	_	_	_	_	_	_	Seg=O
66	,	_	_	_	_	_	_	_	Seg=O
67	and	_	_	_	_	_	_	_	Seg=O
68	application	_	_	_	_	_	_	_	Seg=O
69	settings	_	_	_	_	_	_	_	Seg=O
70	;	_	_	_	_	_	_	_	Seg=O
71	target	_	_	_	_	_	_	_	Seg=O
72	populations	_	_	_	_	_	_	_	Seg=O
73	and	_	_	_	_	_	_	_	Seg=O
74	sample	_	_	_	_	_	_	_	Seg=O
75	characteristics	_	_	_	_	_	_	_	Seg=O
76	;	_	_	_	_	_	_	_	Seg=O
77	and	_	_	_	_	_	_	_	Seg=O
78	areas	_	_	_	_	_	_	_	Seg=O
79	and	_	_	_	_	_	_	_	Seg=O
80	types	_	_	_	_	_	_	_	Seg=O
81	of	_	_	_	_	_	_	_	Seg=O
82	technology	_	_	_	_	_	_	_	Seg=O
83	integration	_	_	_	_	_	_	_	Seg=O
84	.	_	_	_	_	_	_	_	Seg=O
85	Recommendations	_	_	_	_	_	_	_	Seg=B-seg
86	are	_	_	_	_	_	_	_	Seg=O
87	provided	_	_	_	_	_	_	_	Seg=O
88	for	_	_	_	_	_	_	_	Seg=O
89	counseling	_	_	_	_	_	_	_	Seg=O
90	research	_	_	_	_	_	_	_	Seg=O
91	in	_	_	_	_	_	_	_	Seg=O
92	general	_	_	_	_	_	_	_	Seg=O
93	and	_	_	_	_	_	_	_	Seg=O
94	for	_	_	_	_	_	_	_	Seg=O
95	future	_	_	_	_	_	_	_	Seg=O
96	research	_	_	_	_	_	_	_	Seg=O
97	extending	_	_	_	_	_	_	_	Seg=B-seg
98	from	_	_	_	_	_	_	_	Seg=O
99	specific	_	_	_	_	_	_	_	Seg=O
100	circumstances	_	_	_	_	_	_	_	Seg=O
101	such	_	_	_	_	_	_	_	Seg=B-seg
102	as	_	_	_	_	_	_	_	Seg=O
103	the	_	_	_	_	_	_	_	Seg=O
104	COVID-19	_	_	_	_	_	_	_	Seg=O
105	pandemic	_	_	_	_	_	_	_	Seg=O
106	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 54943a77892dcdfac090664c4c09ff219b28c6d7
1	Simultaneous	_	_	_	_	_	_	_	Seg=B-seg
2	extraction	_	_	_	_	_	_	_	Seg=O
3	and	_	_	_	_	_	_	_	Seg=O
4	separation	_	_	_	_	_	_	_	Seg=O
5	of	_	_	_	_	_	_	_	Seg=O
6	liquiritin	_	_	_	_	_	_	_	Seg=O
7	,	_	_	_	_	_	_	_	Seg=O
8	glycyrrhizic	_	_	_	_	_	_	_	Seg=O
9	acid	_	_	_	_	_	_	_	Seg=O
10	,	_	_	_	_	_	_	_	Seg=O
11	and	_	_	_	_	_	_	_	Seg=O
12	glabridin	_	_	_	_	_	_	_	Seg=O
13	from	_	_	_	_	_	_	_	Seg=O
14	licorice	_	_	_	_	_	_	_	Seg=O
15	were	_	_	_	_	_	_	_	Seg=O
16	developed	_	_	_	_	_	_	_	Seg=O
17	by	_	_	_	_	_	_	_	Seg=O
18	liquidliquid	_	_	_	_	_	_	_	Seg=O
19	extraction	_	_	_	_	_	_	_	Seg=O
20	with	_	_	_	_	_	_	_	Seg=O
21	liquid	_	_	_	_	_	_	_	Seg=O
22	chromatography	_	_	_	_	_	_	_	Seg=O
23	separation	_	_	_	_	_	_	_	Seg=O
24	.	_	_	_	_	_	_	_	Seg=O
25	By	_	_	_	_	_	_	_	Seg=B-seg
26	utilizing	_	_	_	_	_	_	_	Seg=O
27	different	_	_	_	_	_	_	_	Seg=O
28	extraction	_	_	_	_	_	_	_	Seg=O
29	solvents	_	_	_	_	_	_	_	Seg=O
30	,	_	_	_	_	_	_	_	Seg=O
31	procedures	_	_	_	_	_	_	_	Seg=O
32	,	_	_	_	_	_	_	_	Seg=O
33	and	_	_	_	_	_	_	_	Seg=O
34	times	_	_	_	_	_	_	_	Seg=O
35	,	_	_	_	_	_	_	_	Seg=O
36	the	_	_	_	_	_	_	_	Seg=B-seg
37	optimum	_	_	_	_	_	_	_	Seg=O
38	extraction	_	_	_	_	_	_	_	Seg=O
39	conditions	_	_	_	_	_	_	_	Seg=O
40	were	_	_	_	_	_	_	_	Seg=O
41	established	_	_	_	_	_	_	_	Seg=O
42	.	_	_	_	_	_	_	_	Seg=O
43	The	_	_	_	_	_	_	_	Seg=B-seg
44	extracts	_	_	_	_	_	_	_	Seg=O
45	of	_	_	_	_	_	_	_	Seg=O
46	licorice	_	_	_	_	_	_	_	Seg=O
47	were	_	_	_	_	_	_	_	Seg=O
48	separated	_	_	_	_	_	_	_	Seg=O
49	and	_	_	_	_	_	_	_	Seg=O
50	determined	_	_	_	_	_	_	_	Seg=O
51	using	_	_	_	_	_	_	_	Seg=B-seg
52	a	_	_	_	_	_	_	_	Seg=O
53	C	_	_	_	_	_	_	_	Seg=O
54	18	_	_	_	_	_	_	_	Seg=O
55	column	_	_	_	_	_	_	_	Seg=O
56	with	_	_	_	_	_	_	_	Seg=O
57	a	_	_	_	_	_	_	_	Seg=O
58	mobile	_	_	_	_	_	_	_	Seg=O
59	phase	_	_	_	_	_	_	_	Seg=O
60	consisting	_	_	_	_	_	_	_	Seg=B-seg
61	of	_	_	_	_	_	_	_	Seg=O
62	acetonitrile	_	_	_	_	_	_	_	Seg=O
63	-	_	_	_	_	_	_	_	Seg=O
64	water	_	_	_	_	_	_	_	Seg=O
65	(	_	_	_	_	_	_	_	Seg=B-seg
66	containing	_	_	_	_	_	_	_	Seg=O
67	1.0	_	_	_	_	_	_	_	Seg=O
68	%	_	_	_	_	_	_	_	Seg=O
69	acetic	_	_	_	_	_	_	_	Seg=O
70	acid	_	_	_	_	_	_	_	Seg=O
71	)	_	_	_	_	_	_	_	Seg=O
72	with	_	_	_	_	_	_	_	Seg=B-seg
73	a	_	_	_	_	_	_	_	Seg=O
74	gradient	_	_	_	_	_	_	_	Seg=O
75	elution	_	_	_	_	_	_	_	Seg=O
76	of	_	_	_	_	_	_	_	Seg=O
77	0~10	_	_	_	_	_	_	_	Seg=O
78	min	_	_	_	_	_	_	_	Seg=O
79	from	_	_	_	_	_	_	_	Seg=O
80	20:80	_	_	_	_	_	_	_	Seg=O
81	to	_	_	_	_	_	_	_	Seg=O
82	60:40	_	_	_	_	_	_	_	Seg=O
83	(	_	_	_	_	_	_	_	Seg=O
84	v	_	_	_	_	_	_	_	Seg=O
85	/	_	_	_	_	_	_	_	Seg=O
86	v	_	_	_	_	_	_	_	Seg=O
87	)	_	_	_	_	_	_	_	Seg=O
88	.	_	_	_	_	_	_	_	Seg=O
89	Preparative	_	_	_	_	_	_	_	Seg=B-seg
90	columns	_	_	_	_	_	_	_	Seg=O
91	with	_	_	_	_	_	_	_	Seg=O
92	different	_	_	_	_	_	_	_	Seg=O
93	packing	_	_	_	_	_	_	_	Seg=O
94	sizes	_	_	_	_	_	_	_	Seg=O
95	were	_	_	_	_	_	_	_	Seg=O
96	investigated	_	_	_	_	_	_	_	Seg=O
97	to	_	_	_	_	_	_	_	Seg=B-seg
98	isolate	_	_	_	_	_	_	_	Seg=O
99	the	_	_	_	_	_	_	_	Seg=O
100	three	_	_	_	_	_	_	_	Seg=O
101	compounds	_	_	_	_	_	_	_	Seg=O
102	from	_	_	_	_	_	_	_	Seg=O
103	the	_	_	_	_	_	_	_	Seg=O
104	extracts	_	_	_	_	_	_	_	Seg=O
105	of	_	_	_	_	_	_	_	Seg=O
106	licorice	_	_	_	_	_	_	_	Seg=O
107	.	_	_	_	_	_	_	_	Seg=O
108	The	_	_	_	_	_	_	_	Seg=B-seg
109	12	_	_	_	_	_	_	_	Seg=O
110	μm	_	_	_	_	_	_	_	Seg=O
111	chromatographic	_	_	_	_	_	_	_	Seg=O
112	column	_	_	_	_	_	_	_	Seg=O
113	showed	_	_	_	_	_	_	_	Seg=O
114	better	_	_	_	_	_	_	_	Seg=O
115	separation	_	_	_	_	_	_	_	Seg=O
116	for	_	_	_	_	_	_	_	Seg=O
117	the	_	_	_	_	_	_	_	Seg=O
118	three	_	_	_	_	_	_	_	Seg=O
119	compounds	_	_	_	_	_	_	_	Seg=O
120	from	_	_	_	_	_	_	_	Seg=O
121	licorice	_	_	_	_	_	_	_	Seg=O
122	.	_	_	_	_	_	_	_	Seg=O
123	0.29	_	_	_	_	_	_	_	Seg=B-seg
124	mg	_	_	_	_	_	_	_	Seg=O
125	/	_	_	_	_	_	_	_	Seg=O
126	g	_	_	_	_	_	_	_	Seg=O
127	for	_	_	_	_	_	_	_	Seg=O
128	liquiritin	_	_	_	_	_	_	_	Seg=O
129	,	_	_	_	_	_	_	_	Seg=O
130	1.43	_	_	_	_	_	_	_	Seg=O
131	mg	_	_	_	_	_	_	_	Seg=O
132	/	_	_	_	_	_	_	_	Seg=O
133	g	_	_	_	_	_	_	_	Seg=O
134	for	_	_	_	_	_	_	_	Seg=O
135	glycyrrhizic	_	_	_	_	_	_	_	Seg=O
136	acid	_	_	_	_	_	_	_	Seg=O
137	,	_	_	_	_	_	_	_	Seg=O
138	and	_	_	_	_	_	_	_	Seg=O
139	0.07	_	_	_	_	_	_	_	Seg=O
140	mg	_	_	_	_	_	_	_	Seg=O
141	/	_	_	_	_	_	_	_	Seg=O
142	g	_	_	_	_	_	_	_	Seg=O
143	for	_	_	_	_	_	_	_	Seg=O
144	glabridin	_	_	_	_	_	_	_	Seg=O
145	were	_	_	_	_	_	_	_	Seg=O
146	obtained	_	_	_	_	_	_	_	Seg=O
147	and	_	_	_	_	_	_	_	Seg=B-seg
148	the	_	_	_	_	_	_	_	Seg=O
149	recoveries	_	_	_	_	_	_	_	Seg=O
150	were	_	_	_	_	_	_	_	Seg=O
151	80.8	_	_	_	_	_	_	_	Seg=O
152	,	_	_	_	_	_	_	_	Seg=O
153	89.7	_	_	_	_	_	_	_	Seg=O
154	,	_	_	_	_	_	_	_	Seg=O
155	and	_	_	_	_	_	_	_	Seg=O
156	72.5	_	_	_	_	_	_	_	Seg=O
157	%	_	_	_	_	_	_	_	Seg=O
158	,	_	_	_	_	_	_	_	Seg=O
159	respectively	_	_	_	_	_	_	_	Seg=O
160	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 54cbb1fc4b77ae332cdb8f44a321f9db35afe2f1
1	This	_	_	_	_	_	_	_	Seg=B-seg
2	paper	_	_	_	_	_	_	_	Seg=O
3	highlights	_	_	_	_	_	_	_	Seg=O
4	the	_	_	_	_	_	_	_	Seg=O
5	enormous	_	_	_	_	_	_	_	Seg=O
6	economic	_	_	_	_	_	_	_	Seg=O
7	and	_	_	_	_	_	_	_	Seg=O
8	social	_	_	_	_	_	_	_	Seg=O
9	impact	_	_	_	_	_	_	_	Seg=O
10	of	_	_	_	_	_	_	_	Seg=O
11	COVID-19	_	_	_	_	_	_	_	Seg=O
12	with	_	_	_	_	_	_	_	Seg=O
13	respect	_	_	_	_	_	_	_	Seg=O
14	to	_	_	_	_	_	_	_	Seg=O
15	articles	_	_	_	_	_	_	_	Seg=O
16	that	_	_	_	_	_	_	_	Seg=B-seg
17	have	_	_	_	_	_	_	_	Seg=O
18	either	_	_	_	_	_	_	_	Seg=O
19	prognosticated	_	_	_	_	_	_	_	Seg=O
20	such	_	_	_	_	_	_	_	Seg=O
21	a	_	_	_	_	_	_	_	Seg=O
22	large	_	_	_	_	_	_	_	Seg=O
23	-	_	_	_	_	_	_	_	Seg=O
24	scale	_	_	_	_	_	_	_	Seg=O
25	event	_	_	_	_	_	_	_	Seg=O
26	,	_	_	_	_	_	_	_	Seg=O
27	and	_	_	_	_	_	_	_	Seg=O
28	its	_	_	_	_	_	_	_	Seg=O
29	economic	_	_	_	_	_	_	_	Seg=O
30	consequences	_	_	_	_	_	_	_	Seg=O
31	,	_	_	_	_	_	_	_	Seg=O
32	or	_	_	_	_	_	_	_	Seg=B-seg
33	have	_	_	_	_	_	_	_	Seg=O
34	assessed	_	_	_	_	_	_	_	Seg=O
35	the	_	_	_	_	_	_	_	Seg=O
36	impacts	_	_	_	_	_	_	_	Seg=O
37	of	_	_	_	_	_	_	_	Seg=O
38	other	_	_	_	_	_	_	_	Seg=O
39	epidemics	_	_	_	_	_	_	_	Seg=O
40	and	_	_	_	_	_	_	_	Seg=O
41	pandemics	_	_	_	_	_	_	_	Seg=O
42	.	_	_	_	_	_	_	_	Seg=O
43	A	_	_	_	_	_	_	_	Seg=B-seg
44	consideration	_	_	_	_	_	_	_	Seg=O
45	of	_	_	_	_	_	_	_	Seg=O
46	possible	_	_	_	_	_	_	_	Seg=O
47	impacts	_	_	_	_	_	_	_	Seg=O
48	of	_	_	_	_	_	_	_	Seg=O
49	COVID-19	_	_	_	_	_	_	_	Seg=O
50	on	_	_	_	_	_	_	_	Seg=O
51	financial	_	_	_	_	_	_	_	Seg=O
52	markets	_	_	_	_	_	_	_	Seg=O
53	and	_	_	_	_	_	_	_	Seg=O
54	institutions	_	_	_	_	_	_	_	Seg=O
55	,	_	_	_	_	_	_	_	Seg=O
56	either	_	_	_	_	_	_	_	Seg=O
57	directly	_	_	_	_	_	_	_	Seg=O
58	or	_	_	_	_	_	_	_	Seg=O
59	indirectly	_	_	_	_	_	_	_	Seg=O
60	,	_	_	_	_	_	_	_	Seg=O
61	is	_	_	_	_	_	_	_	Seg=O
62	briefly	_	_	_	_	_	_	_	Seg=O
63	outlined	_	_	_	_	_	_	_	Seg=O
64	by	_	_	_	_	_	_	_	Seg=B-seg
65	drawing	_	_	_	_	_	_	_	Seg=O
66	on	_	_	_	_	_	_	_	Seg=O
67	a	_	_	_	_	_	_	_	Seg=O
68	variety	_	_	_	_	_	_	_	Seg=O
69	of	_	_	_	_	_	_	_	Seg=O
70	literatures	_	_	_	_	_	_	_	Seg=O
71	.	_	_	_	_	_	_	_	Seg=O
72	A	_	_	_	_	_	_	_	Seg=B-seg
73	consideration	_	_	_	_	_	_	_	Seg=O
74	of	_	_	_	_	_	_	_	Seg=O
75	the	_	_	_	_	_	_	_	Seg=O
76	characteristics	_	_	_	_	_	_	_	Seg=O
77	of	_	_	_	_	_	_	_	Seg=O
78	COVID-19	_	_	_	_	_	_	_	Seg=O
79	,	_	_	_	_	_	_	_	Seg=O
80	along	_	_	_	_	_	_	_	Seg=O
81	with	_	_	_	_	_	_	_	Seg=O
82	what	_	_	_	_	_	_	_	Seg=O
83	research	_	_	_	_	_	_	_	Seg=O
84	suggests	_	_	_	_	_	_	_	Seg=O
85	have	_	_	_	_	_	_	_	Seg=O
86	been	_	_	_	_	_	_	_	Seg=O
87	the	_	_	_	_	_	_	_	Seg=O
88	impacts	_	_	_	_	_	_	_	Seg=O
89	of	_	_	_	_	_	_	_	Seg=O
90	other	_	_	_	_	_	_	_	Seg=O
91	past	_	_	_	_	_	_	_	Seg=O
92	events	_	_	_	_	_	_	_	Seg=O
93	that	_	_	_	_	_	_	_	Seg=B-seg
94	in	_	_	_	_	_	_	_	Seg=O
95	some	_	_	_	_	_	_	_	Seg=O
96	ways	_	_	_	_	_	_	_	Seg=O
97	roughly	_	_	_	_	_	_	_	Seg=O
98	parallel	_	_	_	_	_	_	_	Seg=O
99	COVID-19	_	_	_	_	_	_	_	Seg=O
100	,	_	_	_	_	_	_	_	Seg=O
101	points	_	_	_	_	_	_	_	Seg=B-seg
102	toward	_	_	_	_	_	_	_	Seg=O
103	avenues	_	_	_	_	_	_	_	Seg=O
104	of	_	_	_	_	_	_	_	Seg=O
105	future	_	_	_	_	_	_	_	Seg=O
106	investigation	_	_	_	_	_	_	_	Seg=O
107	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 587118e335a8dd365f56caf0db8c2230cb9aa7cd
1	In	_	_	_	_	_	_	_	Seg=B-seg
2	late	_	_	_	_	_	_	_	Seg=O
3	2019	_	_	_	_	_	_	_	Seg=O
4	,	_	_	_	_	_	_	_	Seg=O
5	the	_	_	_	_	_	_	_	Seg=O
6	world	_	_	_	_	_	_	_	Seg=O
7	encountered	_	_	_	_	_	_	_	Seg=O
8	an	_	_	_	_	_	_	_	Seg=O
9	unexpected	_	_	_	_	_	_	_	Seg=O
10	new	_	_	_	_	_	_	_	Seg=O
11	virus	_	_	_	_	_	_	_	Seg=O
12	,	_	_	_	_	_	_	_	Seg=O
13	resulting	_	_	_	_	_	_	_	Seg=B-seg
14	in	_	_	_	_	_	_	_	Seg=O
15	a	_	_	_	_	_	_	_	Seg=O
16	highly	_	_	_	_	_	_	_	Seg=O
17	challenging	_	_	_	_	_	_	_	Seg=O
18	new	_	_	_	_	_	_	_	Seg=O
19	pandemic	_	_	_	_	_	_	_	Seg=O
20	.	_	_	_	_	_	_	_	Seg=O
21	The	_	_	_	_	_	_	_	Seg=B-seg
22	case	_	_	_	_	_	_	_	Seg=O
23	presented	_	_	_	_	_	_	_	Seg=B-seg
24	here	_	_	_	_	_	_	_	Seg=O
25	involves	_	_	_	_	_	_	_	Seg=B-seg
26	a	_	_	_	_	_	_	_	Seg=O
27	73-year	_	_	_	_	_	_	_	Seg=O
28	-	_	_	_	_	_	_	_	Seg=O
29	old	_	_	_	_	_	_	_	Seg=O
30	man	_	_	_	_	_	_	_	Seg=O
31	experiencing	_	_	_	_	_	_	_	Seg=B-seg
32	fever	_	_	_	_	_	_	_	Seg=O
33	and	_	_	_	_	_	_	_	Seg=O
34	respiratory	_	_	_	_	_	_	_	Seg=O
35	distress	_	_	_	_	_	_	_	Seg=O
36	,	_	_	_	_	_	_	_	Seg=O
37	who	_	_	_	_	_	_	_	Seg=B-seg
38	was	_	_	_	_	_	_	_	Seg=O
39	ultimately	_	_	_	_	_	_	_	Seg=O
40	diagnosed	_	_	_	_	_	_	_	Seg=O
41	with	_	_	_	_	_	_	_	Seg=O
42	COVID-19	_	_	_	_	_	_	_	Seg=O
43	.	_	_	_	_	_	_	_	Seg=O
44	During	_	_	_	_	_	_	_	Seg=B-seg
45	the	_	_	_	_	_	_	_	Seg=O
46	course	_	_	_	_	_	_	_	Seg=O
47	of	_	_	_	_	_	_	_	Seg=O
48	his	_	_	_	_	_	_	_	Seg=O
49	hospitalization	_	_	_	_	_	_	_	Seg=O
50	,	_	_	_	_	_	_	_	Seg=O
51	the	_	_	_	_	_	_	_	Seg=O
52	patient	_	_	_	_	_	_	_	Seg=O
53	developed	_	_	_	_	_	_	_	Seg=O
54	acute	_	_	_	_	_	_	_	Seg=O
55	respiratory	_	_	_	_	_	_	_	Seg=O
56	distress	_	_	_	_	_	_	_	Seg=O
57	syndrome	_	_	_	_	_	_	_	Seg=O
58	(	_	_	_	_	_	_	_	Seg=O
59	ARDS	_	_	_	_	_	_	_	Seg=O
60	)	_	_	_	_	_	_	_	Seg=O
61	,	_	_	_	_	_	_	_	Seg=O
62	followed	_	_	_	_	_	_	_	Seg=B-seg
63	by	_	_	_	_	_	_	_	Seg=O
64	being	_	_	_	_	_	_	_	Seg=O
65	intubated	_	_	_	_	_	_	_	Seg=O
66	due	_	_	_	_	_	_	_	Seg=B-seg
67	to	_	_	_	_	_	_	_	Seg=O
68	his	_	_	_	_	_	_	_	Seg=O
69	breathing	_	_	_	_	_	_	_	Seg=O
70	difficulties	_	_	_	_	_	_	_	Seg=O
71	.	_	_	_	_	_	_	_	Seg=O
72	Because	_	_	_	_	_	_	_	Seg=B-seg
73	of	_	_	_	_	_	_	_	Seg=O
74	variations	_	_	_	_	_	_	_	Seg=O
75	in	_	_	_	_	_	_	_	Seg=O
76	the	_	_	_	_	_	_	_	Seg=O
77-78	patient's	_	_	_	_	_	_	_	_
77	patient	_	_	_	_	_	_	_	Seg=O
78	's	_	_	_	_	_	_	_	Seg=O
79	clinical	_	_	_	_	_	_	_	Seg=O
80	features	_	_	_	_	_	_	_	Seg=O
81	,	_	_	_	_	_	_	_	Seg=O
82	we	_	_	_	_	_	_	_	Seg=B-seg
83	decided	_	_	_	_	_	_	_	Seg=O
84	to	_	_	_	_	_	_	_	Seg=O
85	perform	_	_	_	_	_	_	_	Seg=O
86	hemoperfusion	_	_	_	_	_	_	_	Seg=O
87	to	_	_	_	_	_	_	_	Seg=B-seg
88	remove	_	_	_	_	_	_	_	Seg=O
89	cytokines	_	_	_	_	_	_	_	Seg=O
90	.	_	_	_	_	_	_	_	Seg=O
91	Afterward	_	_	_	_	_	_	_	Seg=B-seg
92	,	_	_	_	_	_	_	_	Seg=O
93	his	_	_	_	_	_	_	_	Seg=O
94	clinical	_	_	_	_	_	_	_	Seg=O
95	status	_	_	_	_	_	_	_	Seg=O
96	improved	_	_	_	_	_	_	_	Seg=O
97	significantly	_	_	_	_	_	_	_	Seg=O
98	,	_	_	_	_	_	_	_	Seg=O
99	and	_	_	_	_	_	_	_	Seg=B-seg
100	he	_	_	_	_	_	_	_	Seg=O
101	was	_	_	_	_	_	_	_	Seg=O
102	discharged	_	_	_	_	_	_	_	Seg=O
103	in	_	_	_	_	_	_	_	Seg=O
104	stable	_	_	_	_	_	_	_	Seg=O
105	condition	_	_	_	_	_	_	_	Seg=O
106	.	_	_	_	_	_	_	_	Seg=O
107	However	_	_	_	_	_	_	_	Seg=B-seg
108	,	_	_	_	_	_	_	_	Seg=O
109	26	_	_	_	_	_	_	_	Seg=O
110	days	_	_	_	_	_	_	_	Seg=O
111	later	_	_	_	_	_	_	_	Seg=O
112	,	_	_	_	_	_	_	_	Seg=O
113	fever	_	_	_	_	_	_	_	Seg=O
114	and	_	_	_	_	_	_	_	Seg=O
115	respiratory	_	_	_	_	_	_	_	Seg=O
116	distress	_	_	_	_	_	_	_	Seg=O
117	manifested	_	_	_	_	_	_	_	Seg=O
118	again	_	_	_	_	_	_	_	Seg=O
119	.	_	_	_	_	_	_	_	Seg=O
120	After	_	_	_	_	_	_	_	Seg=B-seg
121	evaluation	_	_	_	_	_	_	_	Seg=O
122	,	_	_	_	_	_	_	_	Seg=O
123	pulmonary	_	_	_	_	_	_	_	Seg=O
124	thromboembolism	_	_	_	_	_	_	_	Seg=O
125	was	_	_	_	_	_	_	_	Seg=O
126	confirmed	_	_	_	_	_	_	_	Seg=O
127	through	_	_	_	_	_	_	_	Seg=O
128	computed	_	_	_	_	_	_	_	Seg=O
129	tomography	_	_	_	_	_	_	_	Seg=O
130	(	_	_	_	_	_	_	_	Seg=B-seg
131	ie	_	_	_	_	_	_	_	Seg=O
132	,	_	_	_	_	_	_	_	Seg=O
133	CT	_	_	_	_	_	_	_	Seg=O
134	scan	_	_	_	_	_	_	_	Seg=O
135	)	_	_	_	_	_	_	_	Seg=O
136	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 59fe5a3ec925d965c06ea6764db86bca9fb0b8b6
1	The	_	_	_	_	_	_	_	Seg=B-seg
2	novel	_	_	_	_	_	_	_	Seg=O
3	coronavirus	_	_	_	_	_	_	_	Seg=O
4	disease	_	_	_	_	_	_	_	Seg=O
5	2019	_	_	_	_	_	_	_	Seg=O
6	(	_	_	_	_	_	_	_	Seg=O
7	COVID-19	_	_	_	_	_	_	_	Seg=O
8	)	_	_	_	_	_	_	_	Seg=O
9	pandemic	_	_	_	_	_	_	_	Seg=O
10	is	_	_	_	_	_	_	_	Seg=O
11	a	_	_	_	_	_	_	_	Seg=O
12	major	_	_	_	_	_	_	_	Seg=O
13	global	_	_	_	_	_	_	_	Seg=O
14	threat	_	_	_	_	_	_	_	Seg=O
15	affecting	_	_	_	_	_	_	_	Seg=B-seg
16	millions	_	_	_	_	_	_	_	Seg=O
17	of	_	_	_	_	_	_	_	Seg=O
18	lives	_	_	_	_	_	_	_	Seg=O
19	throughout	_	_	_	_	_	_	_	Seg=O
20	the	_	_	_	_	_	_	_	Seg=O
21	world	_	_	_	_	_	_	_	Seg=O
22	physically	_	_	_	_	_	_	_	Seg=O
23	and	_	_	_	_	_	_	_	Seg=O
24	psychologically	_	_	_	_	_	_	_	Seg=O
25	.	_	_	_	_	_	_	_	Seg=O
26	With	_	_	_	_	_	_	_	Seg=B-seg
27	the	_	_	_	_	_	_	_	Seg=O
28	asymptomatic	_	_	_	_	_	_	_	Seg=O
29	presentation	_	_	_	_	_	_	_	Seg=O
30	of	_	_	_	_	_	_	_	Seg=O
31	COVID-19	_	_	_	_	_	_	_	Seg=O
32	in	_	_	_	_	_	_	_	Seg=O
33	many	_	_	_	_	_	_	_	Seg=O
34	patients	_	_	_	_	_	_	_	Seg=O
35	and	_	_	_	_	_	_	_	Seg=O
36	the	_	_	_	_	_	_	_	Seg=O
37	similarity	_	_	_	_	_	_	_	Seg=O
38	of	_	_	_	_	_	_	_	Seg=O
39	its	_	_	_	_	_	_	_	Seg=O
40	symptoms	_	_	_	_	_	_	_	Seg=O
41	with	_	_	_	_	_	_	_	Seg=O
42	the	_	_	_	_	_	_	_	Seg=O
43	common	_	_	_	_	_	_	_	Seg=O
44	cold	_	_	_	_	_	_	_	Seg=O
45	and	_	_	_	_	_	_	_	Seg=O
46	influenza	_	_	_	_	_	_	_	Seg=O
47	,	_	_	_	_	_	_	_	Seg=O
48	the	_	_	_	_	_	_	_	Seg=O
49	need	_	_	_	_	_	_	_	Seg=O
50	for	_	_	_	_	_	_	_	Seg=O
51	accurate	_	_	_	_	_	_	_	Seg=O
52	information	_	_	_	_	_	_	_	Seg=O
53	on	_	_	_	_	_	_	_	Seg=O
54	the	_	_	_	_	_	_	_	Seg=O
55	disease	_	_	_	_	_	_	_	Seg=O
56	is	_	_	_	_	_	_	_	Seg=O
57	very	_	_	_	_	_	_	_	Seg=O
58	important	_	_	_	_	_	_	_	Seg=O
59	for	_	_	_	_	_	_	_	Seg=O
60	its	_	_	_	_	_	_	_	Seg=O
61	identification	_	_	_	_	_	_	_	Seg=O
62	and	_	_	_	_	_	_	_	Seg=O
63	proper	_	_	_	_	_	_	_	Seg=O
64	management	_	_	_	_	_	_	_	Seg=O
65	.	_	_	_	_	_	_	_	Seg=O
66	Accurate	_	_	_	_	_	_	_	Seg=B-seg
67	information	_	_	_	_	_	_	_	Seg=O
68	on	_	_	_	_	_	_	_	Seg=O
69	the	_	_	_	_	_	_	_	Seg=O
70	disease	_	_	_	_	_	_	_	Seg=O
71	,	_	_	_	_	_	_	_	Seg=O
72	its	_	_	_	_	_	_	_	Seg=O
73	prevention	_	_	_	_	_	_	_	Seg=O
74	and	_	_	_	_	_	_	_	Seg=O
75	treatment	_	_	_	_	_	_	_	Seg=O
76	can	_	_	_	_	_	_	_	Seg=O
77	be	_	_	_	_	_	_	_	Seg=O
78	disseminated	_	_	_	_	_	_	_	Seg=O
79	through	_	_	_	_	_	_	_	Seg=O
80	drug	_	_	_	_	_	_	_	Seg=O
81	information	_	_	_	_	_	_	_	Seg=O
82	centers	_	_	_	_	_	_	_	Seg=O
83	(	_	_	_	_	_	_	_	Seg=O
84	DICs	_	_	_	_	_	_	_	Seg=O
85	)	_	_	_	_	_	_	_	Seg=O
86	.	_	_	_	_	_	_	_	Seg=O
87	DICs	_	_	_	_	_	_	_	Seg=B-seg
88	are	_	_	_	_	_	_	_	Seg=O
89	usually	_	_	_	_	_	_	_	Seg=O
90	staffed	_	_	_	_	_	_	_	Seg=O
91	by	_	_	_	_	_	_	_	Seg=O
92	pharmacists	_	_	_	_	_	_	_	Seg=O
93	and/or	_	_	_	_	_	_	_	Seg=O
94	clinical	_	_	_	_	_	_	_	Seg=O
95	pharmacists	_	_	_	_	_	_	_	Seg=O
96	/	_	_	_	_	_	_	_	Seg=O
97	pharmacologists	_	_	_	_	_	_	_	Seg=O
98	.	_	_	_	_	_	_	_	Seg=O
99	DICs	_	_	_	_	_	_	_	Seg=B-seg
100	are	_	_	_	_	_	_	_	Seg=O
101	a	_	_	_	_	_	_	_	Seg=O
102	reliable	_	_	_	_	_	_	_	Seg=O
103	source	_	_	_	_	_	_	_	Seg=O
104	of	_	_	_	_	_	_	_	Seg=O
105	current	_	_	_	_	_	_	_	Seg=O
106	and	_	_	_	_	_	_	_	Seg=O
107	unbiased	_	_	_	_	_	_	_	Seg=O
108	information	_	_	_	_	_	_	_	Seg=O
109	on	_	_	_	_	_	_	_	Seg=O
110	COVID-19	_	_	_	_	_	_	_	Seg=O
111	and	_	_	_	_	_	_	_	Seg=O
112	its	_	_	_	_	_	_	_	Seg=O
113	associated	_	_	_	_	_	_	_	Seg=O
114	complications	_	_	_	_	_	_	_	Seg=O
115	,	_	_	_	_	_	_	_	Seg=O
116	including	_	_	_	_	_	_	_	Seg=B-seg
117	management	_	_	_	_	_	_	_	Seg=O
118	options	_	_	_	_	_	_	_	Seg=O
119	for	_	_	_	_	_	_	_	Seg=O
120	healthcare	_	_	_	_	_	_	_	Seg=O
121	professionals	_	_	_	_	_	_	_	Seg=O
122	and	_	_	_	_	_	_	_	Seg=O
123	the	_	_	_	_	_	_	_	Seg=O
124	public	_	_	_	_	_	_	_	Seg=O
125	.	_	_	_	_	_	_	_	Seg=O
126	In	_	_	_	_	_	_	_	Seg=B-seg
127	addition	_	_	_	_	_	_	_	Seg=O
128	to	_	_	_	_	_	_	_	Seg=O
129	health	_	_	_	_	_	_	_	Seg=O
130	and	_	_	_	_	_	_	_	Seg=O
131	drug	_	_	_	_	_	_	_	Seg=O
132	information	_	_	_	_	_	_	_	Seg=O
133	,	_	_	_	_	_	_	_	Seg=O
134	pharmacists	_	_	_	_	_	_	_	Seg=O
135	working	_	_	_	_	_	_	_	Seg=B-seg
136	in	_	_	_	_	_	_	_	Seg=O
137	the	_	_	_	_	_	_	_	Seg=O
138	DICs	_	_	_	_	_	_	_	Seg=O
139	can	_	_	_	_	_	_	_	Seg=B-seg
140	be	_	_	_	_	_	_	_	Seg=O
141	involved	_	_	_	_	_	_	_	Seg=O
142	in	_	_	_	_	_	_	_	Seg=O
143	the	_	_	_	_	_	_	_	Seg=O
144	management	_	_	_	_	_	_	_	Seg=O
145	of	_	_	_	_	_	_	_	Seg=O
146	the	_	_	_	_	_	_	_	Seg=O
147-148	patients'	_	_	_	_	_	_	_	_
147	patients	_	_	_	_	_	_	_	Seg=O
148	'	_	_	_	_	_	_	_	Seg=O
149	health	_	_	_	_	_	_	_	Seg=O
150	by	_	_	_	_	_	_	_	Seg=B-seg
151	providing	_	_	_	_	_	_	_	Seg=O
152	information	_	_	_	_	_	_	_	Seg=O
153	on	_	_	_	_	_	_	_	Seg=O
154	home	_	_	_	_	_	_	_	Seg=O
155	care	_	_	_	_	_	_	_	Seg=O
156	and	_	_	_	_	_	_	_	Seg=O
157	safety	_	_	_	_	_	_	_	Seg=O
158	,	_	_	_	_	_	_	_	Seg=O
159	medication	_	_	_	_	_	_	_	Seg=B-seg
160	management	_	_	_	_	_	_	_	Seg=O
161	of	_	_	_	_	_	_	_	Seg=O
162	patients	_	_	_	_	_	_	_	Seg=O
163	with	_	_	_	_	_	_	_	Seg=O
164	chronic	_	_	_	_	_	_	_	Seg=O
165	comorbid	_	_	_	_	_	_	_	Seg=O
166	illnesses	_	_	_	_	_	_	_	Seg=O
167	,	_	_	_	_	_	_	_	Seg=O
168	and	_	_	_	_	_	_	_	Seg=O
169	psychological	_	_	_	_	_	_	_	Seg=O
170	advice	_	_	_	_	_	_	_	Seg=O
171	.	_	_	_	_	_	_	_	Seg=O
172	This	_	_	_	_	_	_	_	Seg=B-seg
173	article	_	_	_	_	_	_	_	Seg=O
174	explores	_	_	_	_	_	_	_	Seg=O
175	the	_	_	_	_	_	_	_	Seg=O
176	possible	_	_	_	_	_	_	_	Seg=O
177	additional	_	_	_	_	_	_	_	Seg=O
178	roles	_	_	_	_	_	_	_	Seg=O
179	DICs	_	_	_	_	_	_	_	Seg=B-seg
180	can	_	_	_	_	_	_	_	Seg=O
181	play	_	_	_	_	_	_	_	Seg=O
182	,	_	_	_	_	_	_	_	Seg=O
183	besides	_	_	_	_	_	_	_	Seg=B-seg
184	providing	_	_	_	_	_	_	_	Seg=O
185	drug	_	_	_	_	_	_	_	Seg=O
186	information	_	_	_	_	_	_	_	Seg=O
187	within	_	_	_	_	_	_	_	Seg=O
188	the	_	_	_	_	_	_	_	Seg=O
189	hospital	_	_	_	_	_	_	_	Seg=O
190	or	_	_	_	_	_	_	_	Seg=O
191	in	_	_	_	_	_	_	_	Seg=O
192	the	_	_	_	_	_	_	_	Seg=O
193	community	_	_	_	_	_	_	_	Seg=O
194	.	_	_	_	_	_	_	_	Seg=O
195	All	_	_	_	_	_	_	_	Seg=B-seg
196	authors	_	_	_	_	_	_	_	Seg=O
197	have	_	_	_	_	_	_	_	Seg=O
198	an	_	_	_	_	_	_	_	Seg=O
199	equal	_	_	_	_	_	_	_	Seg=O
200	contribution	_	_	_	_	_	_	_	Seg=O
201	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 5b775e63051b1d160f67b9734aa57f1b56df5e5d
1	Invasive	_	_	_	_	_	_	_	Seg=B-seg
2	,	_	_	_	_	_	_	_	Seg=O
3	non	_	_	_	_	_	_	_	Seg=O
4	-	_	_	_	_	_	_	_	Seg=O
5	native	_	_	_	_	_	_	_	Seg=O
6	species	_	_	_	_	_	_	_	Seg=O
7	are	_	_	_	_	_	_	_	Seg=O
8	a	_	_	_	_	_	_	_	Seg=O
9	major	_	_	_	_	_	_	_	Seg=O
10	threat	_	_	_	_	_	_	_	Seg=O
11	to	_	_	_	_	_	_	_	Seg=O
12	global	_	_	_	_	_	_	_	Seg=O
13	biodiversity	_	_	_	_	_	_	_	Seg=O
14	.	_	_	_	_	_	_	_	Seg=O
15	Stoats	_	_	_	_	_	_	_	Seg=B-seg
16	were	_	_	_	_	_	_	_	Seg=O
17	introduced	_	_	_	_	_	_	_	Seg=O
18	from	_	_	_	_	_	_	_	Seg=O
19	Britain	_	_	_	_	_	_	_	Seg=O
20	to	_	_	_	_	_	_	_	Seg=O
21	New	_	_	_	_	_	_	_	Seg=O
22	Zealand	_	_	_	_	_	_	_	Seg=O
23	in	_	_	_	_	_	_	_	Seg=O
24	the	_	_	_	_	_	_	_	Seg=O
25	1880s	_	_	_	_	_	_	_	Seg=O
26	and	_	_	_	_	_	_	_	Seg=B-seg
27	have	_	_	_	_	_	_	_	Seg=O
28	since	_	_	_	_	_	_	_	Seg=O
29	caused	_	_	_	_	_	_	_	Seg=O
30	grave	_	_	_	_	_	_	_	Seg=O
31	conservation	_	_	_	_	_	_	_	Seg=O
32	problems	_	_	_	_	_	_	_	Seg=O
33	.	_	_	_	_	_	_	_	Seg=O
34	A	_	_	_	_	_	_	_	Seg=B-seg
35	histopathological	_	_	_	_	_	_	_	Seg=O
36	and	_	_	_	_	_	_	_	Seg=O
37	serological	_	_	_	_	_	_	_	Seg=O
38	survey	_	_	_	_	_	_	_	Seg=O
39	of	_	_	_	_	_	_	_	Seg=O
40	disease	_	_	_	_	_	_	_	Seg=O
41	and	_	_	_	_	_	_	_	Seg=O
42	infection	_	_	_	_	_	_	_	Seg=O
43	in	_	_	_	_	_	_	_	Seg=O
44	stoats	_	_	_	_	_	_	_	Seg=O
45	from	_	_	_	_	_	_	_	Seg=O
46	New	_	_	_	_	_	_	_	Seg=O
47	Zealand	_	_	_	_	_	_	_	Seg=O
48	was	_	_	_	_	_	_	_	Seg=O
49	undertaken	_	_	_	_	_	_	_	Seg=O
50	to	_	_	_	_	_	_	_	Seg=B-seg
51	identify	_	_	_	_	_	_	_	Seg=O
52	agents	_	_	_	_	_	_	_	Seg=O
53	that	_	_	_	_	_	_	_	Seg=B-seg
54	might	_	_	_	_	_	_	_	Seg=O
55	be	_	_	_	_	_	_	_	Seg=O
56	used	_	_	_	_	_	_	_	Seg=O
57	or	_	_	_	_	_	_	_	Seg=O
58	modified	_	_	_	_	_	_	_	Seg=O
59	to	_	_	_	_	_	_	_	Seg=B-seg
60	control	_	_	_	_	_	_	_	Seg=O
61	this	_	_	_	_	_	_	_	Seg=O
62	population	_	_	_	_	_	_	_	Seg=O
63	.	_	_	_	_	_	_	_	Seg=O
64	Of	_	_	_	_	_	_	_	Seg=B-seg
65	60	_	_	_	_	_	_	_	Seg=O
66	stoats	_	_	_	_	_	_	_	Seg=O
67	examined	_	_	_	_	_	_	_	Seg=O
68	,	_	_	_	_	_	_	_	Seg=O
69	63	_	_	_	_	_	_	_	Seg=O
70	%	_	_	_	_	_	_	_	Seg=O
71	exhibited	_	_	_	_	_	_	_	Seg=O
72	inflammation	_	_	_	_	_	_	_	Seg=O
73	of	_	_	_	_	_	_	_	Seg=O
74	the	_	_	_	_	_	_	_	Seg=O
75	lung	_	_	_	_	_	_	_	Seg=O
76	,	_	_	_	_	_	_	_	Seg=O
77	mostly	_	_	_	_	_	_	_	Seg=B-seg
78	occurring	_	_	_	_	_	_	_	Seg=O
79	as	_	_	_	_	_	_	_	Seg=O
80	local	_	_	_	_	_	_	_	Seg=O
81	or	_	_	_	_	_	_	_	Seg=O
82	diffuse	_	_	_	_	_	_	_	Seg=O
83	interstitial	_	_	_	_	_	_	_	Seg=O
84	pneumonia	_	_	_	_	_	_	_	Seg=O
85	,	_	_	_	_	_	_	_	Seg=O
86	30	_	_	_	_	_	_	_	Seg=B-seg
87	%	_	_	_	_	_	_	_	Seg=O
88	showed	_	_	_	_	_	_	_	Seg=O
89	signs	_	_	_	_	_	_	_	Seg=O
90	of	_	_	_	_	_	_	_	Seg=O
91	inflammatory	_	_	_	_	_	_	_	Seg=O
92	liver	_	_	_	_	_	_	_	Seg=O
93	disease	_	_	_	_	_	_	_	Seg=O
94	and	_	_	_	_	_	_	_	Seg=B-seg
95	14	_	_	_	_	_	_	_	Seg=O
96	%	_	_	_	_	_	_	_	Seg=O
97	were	_	_	_	_	_	_	_	Seg=O
98	positive	_	_	_	_	_	_	_	Seg=O
99	for	_	_	_	_	_	_	_	Seg=O
100	antibodies	_	_	_	_	_	_	_	Seg=O
101	reactive	_	_	_	_	_	_	_	Seg=O
102	with	_	_	_	_	_	_	_	Seg=O
103	feline	_	_	_	_	_	_	_	Seg=O
104	calicivirus	_	_	_	_	_	_	_	Seg=O
105	.	_	_	_	_	_	_	_	Seg=O
106	In	_	_	_	_	_	_	_	Seg=B-seg
107	Britain	_	_	_	_	_	_	_	Seg=O
108	only	_	_	_	_	_	_	_	Seg=O
109	11	_	_	_	_	_	_	_	Seg=O
110	%	_	_	_	_	_	_	_	Seg=O
111	of	_	_	_	_	_	_	_	Seg=O
112	44	_	_	_	_	_	_	_	Seg=O
113	stoats	_	_	_	_	_	_	_	Seg=O
114	exhibited	_	_	_	_	_	_	_	Seg=O
115	symptoms	_	_	_	_	_	_	_	Seg=O
116	of	_	_	_	_	_	_	_	Seg=O
117	pulmonary	_	_	_	_	_	_	_	Seg=O
118	inflammatory	_	_	_	_	_	_	_	Seg=O
119	disease	_	_	_	_	_	_	_	Seg=O
120	,	_	_	_	_	_	_	_	Seg=O
121	suggesting	_	_	_	_	_	_	_	Seg=B-seg
122	higher	_	_	_	_	_	_	_	Seg=O
123	rates	_	_	_	_	_	_	_	Seg=O
124	of	_	_	_	_	_	_	_	Seg=O
125	infection	_	_	_	_	_	_	_	Seg=O
126	or	_	_	_	_	_	_	_	Seg=O
127	compromise	_	_	_	_	_	_	_	Seg=O
128	of	_	_	_	_	_	_	_	Seg=O
129	the	_	_	_	_	_	_	_	Seg=O
130	pulmonary	_	_	_	_	_	_	_	Seg=O
131	immune	_	_	_	_	_	_	_	Seg=O
132	system	_	_	_	_	_	_	_	Seg=O
133	among	_	_	_	_	_	_	_	Seg=O
134	invasive	_	_	_	_	_	_	_	Seg=O
135	stoats	_	_	_	_	_	_	_	Seg=O
136	,	_	_	_	_	_	_	_	Seg=O
137	possibly	_	_	_	_	_	_	_	Seg=B-seg
138	related	_	_	_	_	_	_	_	Seg=O
139	to	_	_	_	_	_	_	_	Seg=O
140	genetic	_	_	_	_	_	_	_	Seg=O
141	founder	_	_	_	_	_	_	_	Seg=O
142	effects	_	_	_	_	_	_	_	Seg=O
143	or	_	_	_	_	_	_	_	Seg=O
144	environmental	_	_	_	_	_	_	_	Seg=O
145	variation	_	_	_	_	_	_	_	Seg=O
146	.	_	_	_	_	_	_	_	Seg=O
147	These	_	_	_	_	_	_	_	Seg=B-seg
148	findings	_	_	_	_	_	_	_	Seg=O
149	could	_	_	_	_	_	_	_	Seg=O
150	be	_	_	_	_	_	_	_	Seg=O
151	exploited	_	_	_	_	_	_	_	Seg=O
152	in	_	_	_	_	_	_	_	Seg=O
153	biological	_	_	_	_	_	_	_	Seg=O
154	control	_	_	_	_	_	_	_	Seg=O
155	programmes	_	_	_	_	_	_	_	Seg=O
156	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 5cd27ed55a88051c9919a142ae44719c2274eb5a
1	The	_	_	_	_	_	_	_	Seg=B-seg
2	world	_	_	_	_	_	_	_	Seg=O
3	is	_	_	_	_	_	_	_	Seg=O
4	facing	_	_	_	_	_	_	_	Seg=O
5	a	_	_	_	_	_	_	_	Seg=O
6	medical	_	_	_	_	_	_	_	Seg=O
7	crisis	_	_	_	_	_	_	_	Seg=O
8	amid	_	_	_	_	_	_	_	Seg=O
9	the	_	_	_	_	_	_	_	Seg=O
10	CoViD-19	_	_	_	_	_	_	_	Seg=O
11	pandemic	_	_	_	_	_	_	_	Seg=O
12	and	_	_	_	_	_	_	_	Seg=B-seg
13	the	_	_	_	_	_	_	_	Seg=O
14	role	_	_	_	_	_	_	_	Seg=O
15	of	_	_	_	_	_	_	_	Seg=O
16	adequate	_	_	_	_	_	_	_	Seg=O
17	hygiene	_	_	_	_	_	_	_	Seg=O
18	and	_	_	_	_	_	_	_	Seg=O
19	hand	_	_	_	_	_	_	_	Seg=O
20	sanitisers	_	_	_	_	_	_	_	Seg=O
21	is	_	_	_	_	_	_	_	Seg=O
22	inevitable	_	_	_	_	_	_	_	Seg=O
23	in	_	_	_	_	_	_	_	Seg=B-seg
24	controlling	_	_	_	_	_	_	_	Seg=O
25	the	_	_	_	_	_	_	_	Seg=O
26	spread	_	_	_	_	_	_	_	Seg=O
27	of	_	_	_	_	_	_	_	Seg=O
28	infection	_	_	_	_	_	_	_	Seg=O
29	in	_	_	_	_	_	_	_	Seg=O
30	public	_	_	_	_	_	_	_	Seg=O
31	places	_	_	_	_	_	_	_	Seg=O
32	and	_	_	_	_	_	_	_	Seg=O
33	healthcare	_	_	_	_	_	_	_	Seg=O
34	institutions	_	_	_	_	_	_	_	Seg=O
35	.	_	_	_	_	_	_	_	Seg=O
36	There	_	_	_	_	_	_	_	Seg=B-seg
37	has	_	_	_	_	_	_	_	Seg=O
38	been	_	_	_	_	_	_	_	Seg=O
39	a	_	_	_	_	_	_	_	Seg=O
40	great	_	_	_	_	_	_	_	Seg=O
41	surge	_	_	_	_	_	_	_	Seg=O
42	in	_	_	_	_	_	_	_	Seg=O
43	demand	_	_	_	_	_	_	_	Seg=O
44	for	_	_	_	_	_	_	_	Seg=O
45	hand	_	_	_	_	_	_	_	Seg=O
46	sanitisation	_	_	_	_	_	_	_	Seg=O
47	products	_	_	_	_	_	_	_	Seg=O
48	leading	_	_	_	_	_	_	_	Seg=B-seg
49	to	_	_	_	_	_	_	_	Seg=O
50	shortages	_	_	_	_	_	_	_	Seg=O
51	in	_	_	_	_	_	_	_	Seg=O
52	their	_	_	_	_	_	_	_	Seg=O
53	supply	_	_	_	_	_	_	_	Seg=O
54	.	_	_	_	_	_	_	_	Seg=O
55	A	_	_	_	_	_	_	_	Seg=B-seg
56	consequent	_	_	_	_	_	_	_	Seg=O
57	increase	_	_	_	_	_	_	_	Seg=O
58	of	_	_	_	_	_	_	_	Seg=O
59	substandard	_	_	_	_	_	_	_	Seg=O
60	products	_	_	_	_	_	_	_	Seg=O
61	in	_	_	_	_	_	_	_	Seg=O
62	the	_	_	_	_	_	_	_	Seg=O
63	market	_	_	_	_	_	_	_	Seg=O
64	has	_	_	_	_	_	_	_	Seg=O
65	raised	_	_	_	_	_	_	_	Seg=O
66	safety	_	_	_	_	_	_	_	Seg=O
67	concerns	_	_	_	_	_	_	_	Seg=O
68	.	_	_	_	_	_	_	_	Seg=O
69	This	_	_	_	_	_	_	_	Seg=B-seg
70	article	_	_	_	_	_	_	_	Seg=O
71	,	_	_	_	_	_	_	_	Seg=O
72	therefore	_	_	_	_	_	_	_	Seg=O
73	,	_	_	_	_	_	_	_	Seg=O
74	presents	_	_	_	_	_	_	_	Seg=O
75	a	_	_	_	_	_	_	_	Seg=O
76	critical	_	_	_	_	_	_	_	Seg=O
77	review	_	_	_	_	_	_	_	Seg=O
78	of	_	_	_	_	_	_	_	Seg=O
79	hand	_	_	_	_	_	_	_	Seg=O
80	sanitation	_	_	_	_	_	_	_	Seg=O
81	approaches	_	_	_	_	_	_	_	Seg=O
82	and	_	_	_	_	_	_	_	Seg=O
83	products	_	_	_	_	_	_	_	Seg=O
84	available	_	_	_	_	_	_	_	Seg=O
85	on	_	_	_	_	_	_	_	Seg=O
86	the	_	_	_	_	_	_	_	Seg=O
87	market	_	_	_	_	_	_	_	Seg=O
88	in	_	_	_	_	_	_	_	Seg=O
89	light	_	_	_	_	_	_	_	Seg=O
90	of	_	_	_	_	_	_	_	Seg=O
91	the	_	_	_	_	_	_	_	Seg=O
92	scientific	_	_	_	_	_	_	_	Seg=O
93	evidence	_	_	_	_	_	_	_	Seg=O
94	available	_	_	_	_	_	_	_	Seg=O
95	to	_	_	_	_	_	_	_	Seg=O
96	date	_	_	_	_	_	_	_	Seg=O
97	.	_	_	_	_	_	_	_	Seg=O
98	This	_	_	_	_	_	_	_	Seg=B-seg
99	review	_	_	_	_	_	_	_	Seg=O
100	also	_	_	_	_	_	_	_	Seg=O
101	provides	_	_	_	_	_	_	_	Seg=O
102	a	_	_	_	_	_	_	_	Seg=O
103	range	_	_	_	_	_	_	_	Seg=O
104	of	_	_	_	_	_	_	_	Seg=O
105	hand	_	_	_	_	_	_	_	Seg=O
106	sanitisation	_	_	_	_	_	_	_	Seg=O
107	product	_	_	_	_	_	_	_	Seg=O
108	formulations	_	_	_	_	_	_	_	Seg=O
109	,	_	_	_	_	_	_	_	Seg=O
110	and	_	_	_	_	_	_	_	Seg=O
111	manufacturing	_	_	_	_	_	_	_	Seg=O
112	instructions	_	_	_	_	_	_	_	Seg=O
113	to	_	_	_	_	_	_	_	Seg=B-seg
114	allow	_	_	_	_	_	_	_	Seg=O
115	for	_	_	_	_	_	_	_	Seg=O
116	extemporaneous	_	_	_	_	_	_	_	Seg=O
117	preparations	_	_	_	_	_	_	_	Seg=O
118	at	_	_	_	_	_	_	_	Seg=O
119	the	_	_	_	_	_	_	_	Seg=O
120	community	_	_	_	_	_	_	_	Seg=O
121	and	_	_	_	_	_	_	_	Seg=O
122	hospital	_	_	_	_	_	_	_	Seg=O
123	pharmacies	_	_	_	_	_	_	_	Seg=O
124	during	_	_	_	_	_	_	_	Seg=O
125	this	_	_	_	_	_	_	_	Seg=O
126	urgent	_	_	_	_	_	_	_	Seg=O
127	crisis	_	_	_	_	_	_	_	Seg=O
128	.	_	_	_	_	_	_	_	Seg=O
129	In	_	_	_	_	_	_	_	Seg=B-seg
130	addition	_	_	_	_	_	_	_	Seg=O
131	,	_	_	_	_	_	_	_	Seg=O
132	this	_	_	_	_	_	_	_	Seg=O
133	emergent	_	_	_	_	_	_	_	Seg=O
134	situation	_	_	_	_	_	_	_	Seg=O
135	is	_	_	_	_	_	_	_	Seg=O
136	expected	_	_	_	_	_	_	_	Seg=O
137	to	_	_	_	_	_	_	_	Seg=O
138	continue	_	_	_	_	_	_	_	Seg=O
139	,	_	_	_	_	_	_	_	Seg=O
140	hence	_	_	_	_	_	_	_	Seg=B-seg
141	hand	_	_	_	_	_	_	_	Seg=O
142	sanitisers	_	_	_	_	_	_	_	Seg=O
143	will	_	_	_	_	_	_	_	Seg=O
144	be	_	_	_	_	_	_	_	Seg=O
145	in	_	_	_	_	_	_	_	Seg=O
146	demand	_	_	_	_	_	_	_	Seg=O
147	for	_	_	_	_	_	_	_	Seg=O
148	an	_	_	_	_	_	_	_	Seg=O
149	extended	_	_	_	_	_	_	_	Seg=O
150	time	_	_	_	_	_	_	_	Seg=O
151	,	_	_	_	_	_	_	_	Seg=O
152	and	_	_	_	_	_	_	_	Seg=B-seg
153	the	_	_	_	_	_	_	_	Seg=O
154	availability	_	_	_	_	_	_	_	Seg=O
155	and	_	_	_	_	_	_	_	Seg=O
156	purchase	_	_	_	_	_	_	_	Seg=O
157	of	_	_	_	_	_	_	_	Seg=O
158	substandard	_	_	_	_	_	_	_	Seg=O
159	products	_	_	_	_	_	_	_	Seg=O
160	on	_	_	_	_	_	_	_	Seg=O
161	the	_	_	_	_	_	_	_	Seg=O
162	market	_	_	_	_	_	_	_	Seg=O
163	create	_	_	_	_	_	_	_	Seg=O
164	an	_	_	_	_	_	_	_	Seg=O
165	ongoing	_	_	_	_	_	_	_	Seg=O
166	safety	_	_	_	_	_	_	_	Seg=O
167	concern	_	_	_	_	_	_	_	Seg=O
168	.	_	_	_	_	_	_	_	Seg=O
169	Therefore	_	_	_	_	_	_	_	Seg=B-seg
170	,	_	_	_	_	_	_	_	Seg=O
171	this	_	_	_	_	_	_	_	Seg=O
172	article	_	_	_	_	_	_	_	Seg=O
173	shall	_	_	_	_	_	_	_	Seg=O
174	also	_	_	_	_	_	_	_	Seg=O
175	provide	_	_	_	_	_	_	_	Seg=O
176	various	_	_	_	_	_	_	_	Seg=O
177	commercial	_	_	_	_	_	_	_	Seg=O
178	organisations	_	_	_	_	_	_	_	Seg=O
179	,	_	_	_	_	_	_	_	Seg=O
180	interested	_	_	_	_	_	_	_	Seg=B-seg
181	in	_	_	_	_	_	_	_	Seg=O
182	stepping	_	_	_	_	_	_	_	Seg=O
183	forward	_	_	_	_	_	_	_	Seg=O
184	the	_	_	_	_	_	_	_	Seg=O
185	production	_	_	_	_	_	_	_	Seg=O
186	and	_	_	_	_	_	_	_	Seg=O
187	marketing	_	_	_	_	_	_	_	Seg=O
188	of	_	_	_	_	_	_	_	Seg=O
189	hand	_	_	_	_	_	_	_	Seg=O
190	sanitisers	_	_	_	_	_	_	_	Seg=O
191	,	_	_	_	_	_	_	_	Seg=O
192	with	_	_	_	_	_	_	_	Seg=O
193	a	_	_	_	_	_	_	_	Seg=O
194	guide	_	_	_	_	_	_	_	Seg=O
195	on	_	_	_	_	_	_	_	Seg=O
196	the	_	_	_	_	_	_	_	Seg=O
197	development	_	_	_	_	_	_	_	Seg=O
198	of	_	_	_	_	_	_	_	Seg=O
199	products	_	_	_	_	_	_	_	Seg=O
200	of	_	_	_	_	_	_	_	Seg=O
201	standardised	_	_	_	_	_	_	_	Seg=O
202	ingredients	_	_	_	_	_	_	_	Seg=O
203	and	_	_	_	_	_	_	_	Seg=O
204	formulations	_	_	_	_	_	_	_	Seg=O
205	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 5d2ed78357c0c88b4500d644f4a717d0192a0d2d
1	In	_	_	_	_	_	_	_	Seg=B-seg
2	the	_	_	_	_	_	_	_	Seg=O
3	present	_	_	_	_	_	_	_	Seg=O
4	studies	_	_	_	_	_	_	_	Seg=O
5	,	_	_	_	_	_	_	_	Seg=O
6	we	_	_	_	_	_	_	_	Seg=O
7	report	_	_	_	_	_	_	_	Seg=O
8	the	_	_	_	_	_	_	_	Seg=O
9	cloning	_	_	_	_	_	_	_	Seg=O
10	and	_	_	_	_	_	_	_	Seg=O
11	structural	_	_	_	_	_	_	_	Seg=O
12	characterization	_	_	_	_	_	_	_	Seg=O
13	of	_	_	_	_	_	_	_	Seg=O
14	the	_	_	_	_	_	_	_	Seg=O
15	HFGL2	_	_	_	_	_	_	_	Seg=O
16	gene	_	_	_	_	_	_	_	Seg=O
17	and	_	_	_	_	_	_	_	Seg=O
18	its	_	_	_	_	_	_	_	Seg=O
19	functional	_	_	_	_	_	_	_	Seg=O
20	role	_	_	_	_	_	_	_	Seg=O
21	in	_	_	_	_	_	_	_	Seg=O
22	human	_	_	_	_	_	_	_	Seg=O
23	fulminant	_	_	_	_	_	_	_	Seg=O
24	hepatitis	_	_	_	_	_	_	_	Seg=O
25	.	_	_	_	_	_	_	_	Seg=O
26	The	_	_	_	_	_	_	_	Seg=B-seg
27	HFGL2	_	_	_	_	_	_	_	Seg=O
28	gene	_	_	_	_	_	_	_	Seg=O
29	is	_	_	_	_	_	_	_	Seg=O
30	approximately	_	_	_	_	_	_	_	Seg=O
31	7	_	_	_	_	_	_	_	Seg=O
32	kb	_	_	_	_	_	_	_	Seg=O
33	in	_	_	_	_	_	_	_	Seg=O
34	length	_	_	_	_	_	_	_	Seg=O
35	with	_	_	_	_	_	_	_	Seg=O
36	2	_	_	_	_	_	_	_	Seg=O
37	exons	_	_	_	_	_	_	_	Seg=O
38	.	_	_	_	_	_	_	_	Seg=O
39	The	_	_	_	_	_	_	_	Seg=B-seg
40	putative	_	_	_	_	_	_	_	Seg=O
41	promoter	_	_	_	_	_	_	_	Seg=O
42	contains	_	_	_	_	_	_	_	Seg=O
43	cis	_	_	_	_	_	_	_	Seg=O
44	element	_	_	_	_	_	_	_	Seg=O
45	consensus	_	_	_	_	_	_	_	Seg=O
46	sequences	_	_	_	_	_	_	_	Seg=O
47	that	_	_	_	_	_	_	_	Seg=B-seg
48	strongly	_	_	_	_	_	_	_	Seg=O
49	suggest	_	_	_	_	_	_	_	Seg=O
50	the	_	_	_	_	_	_	_	Seg=O
51	inducibility	_	_	_	_	_	_	_	Seg=O
52	of	_	_	_	_	_	_	_	Seg=O
53	its	_	_	_	_	_	_	_	Seg=O
54	expression	_	_	_	_	_	_	_	Seg=O
55	.	_	_	_	_	_	_	_	Seg=O
56	From	_	_	_	_	_	_	_	Seg=B-seg
57	the	_	_	_	_	_	_	_	Seg=O
58	nucleotide	_	_	_	_	_	_	_	Seg=O
59	sequence	_	_	_	_	_	_	_	Seg=O
60	of	_	_	_	_	_	_	_	Seg=O
61	the	_	_	_	_	_	_	_	Seg=O
62	human	_	_	_	_	_	_	_	Seg=O
63	gene	_	_	_	_	_	_	_	Seg=O
64	,	_	_	_	_	_	_	_	Seg=O
65	a	_	_	_	_	_	_	_	Seg=O
66	439-amino	_	_	_	_	_	_	_	Seg=O
67	acid	_	_	_	_	_	_	_	Seg=O
68	long	_	_	_	_	_	_	_	Seg=O
69	protein	_	_	_	_	_	_	_	Seg=O
70	is	_	_	_	_	_	_	_	Seg=O
71	predicted	_	_	_	_	_	_	_	Seg=O
72	.	_	_	_	_	_	_	_	Seg=O
73	The	_	_	_	_	_	_	_	Seg=B-seg
74	overall	_	_	_	_	_	_	_	Seg=O
75	identity	_	_	_	_	_	_	_	Seg=O
76	between	_	_	_	_	_	_	_	Seg=O
77	the	_	_	_	_	_	_	_	Seg=O
78	murine	_	_	_	_	_	_	_	Seg=O
79	fgl2	_	_	_	_	_	_	_	Seg=O
80	and	_	_	_	_	_	_	_	Seg=O
81	hfgl2	_	_	_	_	_	_	_	Seg=O
82	coded	_	_	_	_	_	_	_	Seg=O
83	proteins	_	_	_	_	_	_	_	Seg=O
84	is	_	_	_	_	_	_	_	Seg=O
85	over	_	_	_	_	_	_	_	Seg=O
86	70	_	_	_	_	_	_	_	Seg=O
87	%	_	_	_	_	_	_	_	Seg=O
88	.	_	_	_	_	_	_	_	Seg=O
89	About	_	_	_	_	_	_	_	Seg=B-seg
90	225	_	_	_	_	_	_	_	Seg=O
91	amino	_	_	_	_	_	_	_	Seg=O
92	acids	_	_	_	_	_	_	_	Seg=O
93	at	_	_	_	_	_	_	_	Seg=O
94	the	_	_	_	_	_	_	_	Seg=O
95	carboxyl	_	_	_	_	_	_	_	Seg=O
96	end	_	_	_	_	_	_	_	Seg=O
97	of	_	_	_	_	_	_	_	Seg=O
98	these	_	_	_	_	_	_	_	Seg=O
99	molecules	_	_	_	_	_	_	_	Seg=O
100	are	_	_	_	_	_	_	_	Seg=O
101	almost	_	_	_	_	_	_	_	Seg=O
102	90	_	_	_	_	_	_	_	Seg=O
103	%	_	_	_	_	_	_	_	Seg=O
104	identical	_	_	_	_	_	_	_	Seg=O
105	,	_	_	_	_	_	_	_	Seg=O
106	and	_	_	_	_	_	_	_	Seg=B-seg
107	correspond	_	_	_	_	_	_	_	Seg=O
108	to	_	_	_	_	_	_	_	Seg=O
109	a	_	_	_	_	_	_	_	Seg=O
110	well	_	_	_	_	_	_	_	Seg=O
111	-	_	_	_	_	_	_	_	Seg=O
112	conserved	_	_	_	_	_	_	_	Seg=O
113	fibrinogen	_	_	_	_	_	_	_	Seg=O
114	-	_	_	_	_	_	_	_	Seg=O
115	related	_	_	_	_	_	_	_	Seg=O
116	domain	_	_	_	_	_	_	_	Seg=O
117	.	_	_	_	_	_	_	_	Seg=O
118	Both	_	_	_	_	_	_	_	Seg=B-seg
119	HFGL2	_	_	_	_	_	_	_	Seg=O
120	and	_	_	_	_	_	_	_	Seg=O
121	FGL2	_	_	_	_	_	_	_	Seg=O
122	encode	_	_	_	_	_	_	_	Seg=O
123	a	_	_	_	_	_	_	_	Seg=O
124	type	_	_	_	_	_	_	_	Seg=O
125	II	_	_	_	_	_	_	_	Seg=O
126	transmembrane	_	_	_	_	_	_	_	Seg=O
127	protein	_	_	_	_	_	_	_	Seg=O
128	with	_	_	_	_	_	_	_	Seg=O
129	a	_	_	_	_	_	_	_	Seg=O
130	predicted	_	_	_	_	_	_	_	Seg=O
131	catalytic	_	_	_	_	_	_	_	Seg=O
132	domain	_	_	_	_	_	_	_	Seg=O
133	toward	_	_	_	_	_	_	_	Seg=O
134	the	_	_	_	_	_	_	_	Seg=O
135	amino	_	_	_	_	_	_	_	Seg=O
136	terminus	_	_	_	_	_	_	_	Seg=O
137	of	_	_	_	_	_	_	_	Seg=O
138	the	_	_	_	_	_	_	_	Seg=O
139	protein	_	_	_	_	_	_	_	Seg=O
140	.	_	_	_	_	_	_	_	Seg=O
141	Transient	_	_	_	_	_	_	_	Seg=B-seg
142	transfection	_	_	_	_	_	_	_	Seg=O
143	of	_	_	_	_	_	_	_	Seg=O
144	Chinese	_	_	_	_	_	_	_	Seg=O
145	hamster	_	_	_	_	_	_	_	Seg=O
146	ovary	_	_	_	_	_	_	_	Seg=O
147	(	_	_	_	_	_	_	_	Seg=O
148	CHO	_	_	_	_	_	_	_	Seg=O
149	)	_	_	_	_	_	_	_	Seg=O
150	cells	_	_	_	_	_	_	_	Seg=O
151	with	_	_	_	_	_	_	_	Seg=O
152	a	_	_	_	_	_	_	_	Seg=O
153	fulllength	_	_	_	_	_	_	_	Seg=O
154	cDNA	_	_	_	_	_	_	_	Seg=O
155	of	_	_	_	_	_	_	_	Seg=O
156	HFGL2	_	_	_	_	_	_	_	Seg=O
157	coding	_	_	_	_	_	_	_	Seg=O
158	region	_	_	_	_	_	_	_	Seg=O
159	resulted	_	_	_	_	_	_	_	Seg=O
160	in	_	_	_	_	_	_	_	Seg=O
161	high	_	_	_	_	_	_	_	Seg=O
162	levels	_	_	_	_	_	_	_	Seg=O
163	of	_	_	_	_	_	_	_	Seg=O
164	prothrombinase	_	_	_	_	_	_	_	Seg=O
165	activity	_	_	_	_	_	_	_	Seg=O
166	.	_	_	_	_	_	_	_	Seg=O
167	Livers	_	_	_	_	_	_	_	Seg=B-seg
168	from	_	_	_	_	_	_	_	Seg=O
169	8	_	_	_	_	_	_	_	Seg=O
170	patients	_	_	_	_	_	_	_	Seg=O
171	transplanted	_	_	_	_	_	_	_	Seg=B-seg
172	for	_	_	_	_	_	_	_	Seg=O
173	fulminant	_	_	_	_	_	_	_	Seg=O
174	viral	_	_	_	_	_	_	_	Seg=O
175	hepatitis	_	_	_	_	_	_	_	Seg=O
176	were	_	_	_	_	_	_	_	Seg=B-seg
177	examined	_	_	_	_	_	_	_	Seg=O
178	for	_	_	_	_	_	_	_	Seg=O
179	extent	_	_	_	_	_	_	_	Seg=O
180	of	_	_	_	_	_	_	_	Seg=O
181	necrosis	_	_	_	_	_	_	_	Seg=O
182	,	_	_	_	_	_	_	_	Seg=O
183	inflammation	_	_	_	_	_	_	_	Seg=O
184	,	_	_	_	_	_	_	_	Seg=O
185	fibrin	_	_	_	_	_	_	_	Seg=O
186	deposition	_	_	_	_	_	_	_	Seg=O
187	,	_	_	_	_	_	_	_	Seg=O
188	and	_	_	_	_	_	_	_	Seg=O
189	HFGL2	_	_	_	_	_	_	_	Seg=O
190	induction	_	_	_	_	_	_	_	Seg=O
191	.	_	_	_	_	_	_	_	Seg=O
192	In	_	_	_	_	_	_	_	Seg=B-seg
193	situ	_	_	_	_	_	_	_	Seg=O
194	hybridization	_	_	_	_	_	_	_	Seg=O
195	showed	_	_	_	_	_	_	_	Seg=O
196	positive	_	_	_	_	_	_	_	Seg=O
197	staining	_	_	_	_	_	_	_	Seg=O
198	of	_	_	_	_	_	_	_	Seg=O
199	macrophages	_	_	_	_	_	_	_	Seg=O
200	in	_	_	_	_	_	_	_	Seg=O
201	areas	_	_	_	_	_	_	_	Seg=O
202	of	_	_	_	_	_	_	_	Seg=O
203	active	_	_	_	_	_	_	_	Seg=O
204	hepatocellular	_	_	_	_	_	_	_	Seg=O
205	necrosis	_	_	_	_	_	_	_	Seg=O
206	.	_	_	_	_	_	_	_	Seg=O
207	Fibrin	_	_	_	_	_	_	_	Seg=B-seg
208	stained	_	_	_	_	_	_	_	Seg=O
209	positively	_	_	_	_	_	_	_	Seg=O
210	in	_	_	_	_	_	_	_	Seg=O
211	these	_	_	_	_	_	_	_	Seg=O
212	areas	_	_	_	_	_	_	_	Seg=O
213	and	_	_	_	_	_	_	_	Seg=B-seg
214	was	_	_	_	_	_	_	_	Seg=O
215	confirmed	_	_	_	_	_	_	_	Seg=O
216	by	_	_	_	_	_	_	_	Seg=O
217	electron	_	_	_	_	_	_	_	Seg=O
218	microscopy	_	_	_	_	_	_	_	Seg=O
219	.	_	_	_	_	_	_	_	Seg=O
220	These	_	_	_	_	_	_	_	Seg=B-seg
221	studies	_	_	_	_	_	_	_	Seg=O
222	define	_	_	_	_	_	_	_	Seg=O
223	a	_	_	_	_	_	_	_	Seg=O
224	unique	_	_	_	_	_	_	_	Seg=O
225	prothrombinase	_	_	_	_	_	_	_	Seg=O
226	gene	_	_	_	_	_	_	_	Seg=O
227	(	_	_	_	_	_	_	_	Seg=O
228	HFGL2	_	_	_	_	_	_	_	Seg=O
229	)	_	_	_	_	_	_	_	Seg=O
230	and	_	_	_	_	_	_	_	Seg=B-seg
231	implicate	_	_	_	_	_	_	_	Seg=O
232	its	_	_	_	_	_	_	_	Seg=O
233	importance	_	_	_	_	_	_	_	Seg=O
234	in	_	_	_	_	_	_	_	Seg=O
235	the	_	_	_	_	_	_	_	Seg=O
236	pathogenesis	_	_	_	_	_	_	_	Seg=O
237	of	_	_	_	_	_	_	_	Seg=O
238	fulminant	_	_	_	_	_	_	_	Seg=O
239	viral	_	_	_	_	_	_	_	Seg=O
240	hepatitis	_	_	_	_	_	_	_	Seg=O
241	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 5daee51840f3c189675dbb151da2abb907ab6a96
1	The	_	_	_	_	_	_	_	Seg=B-seg
2	COVID19	_	_	_	_	_	_	_	Seg=O
3	pandemic	_	_	_	_	_	_	_	Seg=O
4	,	_	_	_	_	_	_	_	Seg=O
5	designated	_	_	_	_	_	_	_	Seg=B-seg
6	as	_	_	_	_	_	_	_	Seg=O
7	a	_	_	_	_	_	_	_	Seg=O
8	public	_	_	_	_	_	_	_	Seg=O
9	health	_	_	_	_	_	_	_	Seg=O
10	crisis	_	_	_	_	_	_	_	Seg=O
11	by	_	_	_	_	_	_	_	Seg=O
12	the	_	_	_	_	_	_	_	Seg=O
13	World	_	_	_	_	_	_	_	Seg=O
14	Health	_	_	_	_	_	_	_	Seg=O
15	Organization	_	_	_	_	_	_	_	Seg=O
16	(	_	_	_	_	_	_	_	Seg=O
17	WHO	_	_	_	_	_	_	_	Seg=O
18	)	_	_	_	_	_	_	_	Seg=O
19	,	_	_	_	_	_	_	_	Seg=O
20	is	_	_	_	_	_	_	_	Seg=B-seg
21	rapidly	_	_	_	_	_	_	_	Seg=O
22	spreading	_	_	_	_	_	_	_	Seg=O
23	around	_	_	_	_	_	_	_	Seg=O
24	the	_	_	_	_	_	_	_	Seg=O
25	world	_	_	_	_	_	_	_	Seg=O
26	impacting	_	_	_	_	_	_	_	Seg=B-seg
27	the	_	_	_	_	_	_	_	Seg=O
28	health	_	_	_	_	_	_	_	Seg=O
29	and	_	_	_	_	_	_	_	Seg=O
30	economy	_	_	_	_	_	_	_	Seg=O
31	of	_	_	_	_	_	_	_	Seg=O
32	almost	_	_	_	_	_	_	_	Seg=O
33	all	_	_	_	_	_	_	_	Seg=O
34	the	_	_	_	_	_	_	_	Seg=O
35	countries	_	_	_	_	_	_	_	Seg=O
36	.	_	_	_	_	_	_	_	Seg=O
37	The	_	_	_	_	_	_	_	Seg=B-seg
38	data	_	_	_	_	_	_	_	Seg=O
39	of	_	_	_	_	_	_	_	Seg=O
40	hospitalized	_	_	_	_	_	_	_	Seg=O
41	COVID19	_	_	_	_	_	_	_	Seg=O
42	patients	_	_	_	_	_	_	_	Seg=O
43	,	_	_	_	_	_	_	_	Seg=O
44	especially	_	_	_	_	_	_	_	Seg=O
45	those	_	_	_	_	_	_	_	Seg=O
46	with	_	_	_	_	_	_	_	Seg=O
47	serious	_	_	_	_	_	_	_	Seg=O
48	illness	_	_	_	_	_	_	_	Seg=O
49	,	_	_	_	_	_	_	_	Seg=O
50	indicate	_	_	_	_	_	_	_	Seg=O
51	the	_	_	_	_	_	_	_	Seg=O
52	involvement	_	_	_	_	_	_	_	Seg=O
53	of	_	_	_	_	_	_	_	Seg=O
54	immunopathological	_	_	_	_	_	_	_	Seg=O
55	complications	_	_	_	_	_	_	_	Seg=O
56	.	_	_	_	_	_	_	_	Seg=O
57	As	_	_	_	_	_	_	_	Seg=B-seg
58	no	_	_	_	_	_	_	_	Seg=O
59	effective	_	_	_	_	_	_	_	Seg=O
60	treatment	_	_	_	_	_	_	_	Seg=O
61	is	_	_	_	_	_	_	_	Seg=O
62	currently	_	_	_	_	_	_	_	Seg=O
63	available	_	_	_	_	_	_	_	Seg=O
64	,	_	_	_	_	_	_	_	Seg=O
65	we	_	_	_	_	_	_	_	Seg=B-seg
66	propose	_	_	_	_	_	_	_	Seg=O
67	'	_	_	_	_	_	_	_	Seg=O
68	Primed	_	_	_	_	_	_	_	Seg=O
69	'	_	_	_	_	_	_	_	Seg=O
70	Mesenchymal	_	_	_	_	_	_	_	Seg=O
71	Stem	_	_	_	_	_	_	_	Seg=O
72	Cells	_	_	_	_	_	_	_	Seg=O
73	(	_	_	_	_	_	_	_	Seg=O
74	MSCs	_	_	_	_	_	_	_	Seg=O
75	)	_	_	_	_	_	_	_	Seg=O
76	as	_	_	_	_	_	_	_	Seg=O
77	a	_	_	_	_	_	_	_	Seg=O
78	therapeutic	_	_	_	_	_	_	_	Seg=O
79	alternative	_	_	_	_	_	_	_	Seg=O
80	to	_	_	_	_	_	_	_	Seg=B-seg
81	tackle	_	_	_	_	_	_	_	Seg=O
82	devastating	_	_	_	_	_	_	_	Seg=O
83	epidemic	_	_	_	_	_	_	_	Seg=O
84	.	_	_	_	_	_	_	_	Seg=O
85	The	_	_	_	_	_	_	_	Seg=B-seg
86	individual	_	_	_	_	_	_	_	Seg=O
87	response	_	_	_	_	_	_	_	Seg=O
88	to	_	_	_	_	_	_	_	Seg=O
89	MSCs	_	_	_	_	_	_	_	Seg=O
90	treatment	_	_	_	_	_	_	_	Seg=O
91	is	_	_	_	_	_	_	_	Seg=O
92	heterogeneous	_	_	_	_	_	_	_	Seg=O
93	.	_	_	_	_	_	_	_	Seg=O
94	During	_	_	_	_	_	_	_	Seg=B-seg
95	the	_	_	_	_	_	_	_	Seg=O
96	treatment	_	_	_	_	_	_	_	Seg=O
97	of	_	_	_	_	_	_	_	Seg=O
98	infectious	_	_	_	_	_	_	_	Seg=O
99	pathology	_	_	_	_	_	_	_	Seg=O
100	,	_	_	_	_	_	_	_	Seg=O
101	the	_	_	_	_	_	_	_	Seg=O
102	effectiveness	_	_	_	_	_	_	_	Seg=O
103	of	_	_	_	_	_	_	_	Seg=O
104	the	_	_	_	_	_	_	_	Seg=O
105	treatment	_	_	_	_	_	_	_	Seg=O
106	may	_	_	_	_	_	_	_	Seg=O
107	vary	_	_	_	_	_	_	_	Seg=O
108	based	_	_	_	_	_	_	_	Seg=B-seg
109	on	_	_	_	_	_	_	_	Seg=O
110	the	_	_	_	_	_	_	_	Seg=O
111	disease	_	_	_	_	_	_	_	Seg=O
112	scenario	_	_	_	_	_	_	_	Seg=O
113	.	_	_	_	_	_	_	_	Seg=O
114	Interestingly	_	_	_	_	_	_	_	Seg=B-seg
115	,	_	_	_	_	_	_	_	Seg=O
116	when	_	_	_	_	_	_	_	Seg=B-seg
117	transplanted	_	_	_	_	_	_	_	Seg=O
118	in	_	_	_	_	_	_	_	Seg=O
119	vivo	_	_	_	_	_	_	_	Seg=O
120	,	_	_	_	_	_	_	_	Seg=O
121	MSCs	_	_	_	_	_	_	_	Seg=B-seg
122	are	_	_	_	_	_	_	_	Seg=O
123	governed	_	_	_	_	_	_	_	Seg=O
124	by	_	_	_	_	_	_	_	Seg=O
125	the	_	_	_	_	_	_	_	Seg=O
126	locally	_	_	_	_	_	_	_	Seg=O
127	regulated	_	_	_	_	_	_	_	Seg=O
128	microenvironment	_	_	_	_	_	_	_	Seg=O
129	,	_	_	_	_	_	_	_	Seg=O
130	suggesting	_	_	_	_	_	_	_	Seg=B-seg
131	that	_	_	_	_	_	_	_	Seg=B-seg
132	the	_	_	_	_	_	_	_	Seg=O
133	restorative	_	_	_	_	_	_	_	Seg=O
134	variability	_	_	_	_	_	_	_	Seg=O
135	could	_	_	_	_	_	_	_	Seg=O
136	be	_	_	_	_	_	_	_	Seg=O
137	tailored	_	_	_	_	_	_	_	Seg=O
138	by	_	_	_	_	_	_	_	Seg=B-seg
139	choosing	_	_	_	_	_	_	_	Seg=O
140	a	_	_	_	_	_	_	_	Seg=O
141	priming	_	_	_	_	_	_	_	Seg=O
142	regimen	_	_	_	_	_	_	_	Seg=O
143	to	_	_	_	_	_	_	_	Seg=B-seg
144	specifically	_	_	_	_	_	_	_	Seg=O
145	correct	_	_	_	_	_	_	_	Seg=O
146	a	_	_	_	_	_	_	_	Seg=O
147	given	_	_	_	_	_	_	_	Seg=O
148	pathology	_	_	_	_	_	_	_	Seg=O
149	.	_	_	_	_	_	_	_	Seg=O
150	Therefore	_	_	_	_	_	_	_	Seg=B-seg
151	,	_	_	_	_	_	_	_	Seg=O
152	in	_	_	_	_	_	_	_	Seg=O
153	our	_	_	_	_	_	_	_	Seg=O
154	opinion	_	_	_	_	_	_	_	Seg=O
155	,	_	_	_	_	_	_	_	Seg=O
156	the	_	_	_	_	_	_	_	Seg=O
157	priming	_	_	_	_	_	_	_	Seg=O
158	of	_	_	_	_	_	_	_	Seg=O
159	MSCs	_	_	_	_	_	_	_	Seg=O
160	could	_	_	_	_	_	_	_	Seg=O
161	be	_	_	_	_	_	_	_	Seg=O
162	a	_	_	_	_	_	_	_	Seg=O
163	novel	_	_	_	_	_	_	_	Seg=O
164	approach	_	_	_	_	_	_	_	Seg=O
165	to	_	_	_	_	_	_	_	Seg=B-seg
166	improve	_	_	_	_	_	_	_	Seg=O
167	the	_	_	_	_	_	_	_	Seg=O
168	responses	_	_	_	_	_	_	_	Seg=O
169	of	_	_	_	_	_	_	_	Seg=O
170	COVID19	_	_	_	_	_	_	_	Seg=O
171	patients	_	_	_	_	_	_	_	Seg=O
172	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 5dc2712f3e118ac903e215c2e0d155f2ede7ad39
1	The	_	_	_	_	_	_	_	Seg=B-seg
2	pathology	_	_	_	_	_	_	_	Seg=O
3	of	_	_	_	_	_	_	_	Seg=O
4	2	_	_	_	_	_	_	_	Seg=O
5	zoonotic	_	_	_	_	_	_	_	Seg=O
6	human	_	_	_	_	_	_	_	Seg=O
7	viral	_	_	_	_	_	_	_	Seg=O
8	infections	_	_	_	_	_	_	_	Seg=O
9	that	_	_	_	_	_	_	_	Seg=B-seg
10	recently	_	_	_	_	_	_	_	Seg=O
11	emerged	_	_	_	_	_	_	_	Seg=O
12	,	_	_	_	_	_	_	_	Seg=O
13	severe	_	_	_	_	_	_	_	Seg=B-seg
14	acute	_	_	_	_	_	_	_	Seg=O
15	respiratory	_	_	_	_	_	_	_	Seg=O
16	syndrome	_	_	_	_	_	_	_	Seg=O
17	(	_	_	_	_	_	_	_	Seg=O
18	SARS	_	_	_	_	_	_	_	Seg=O
19	)	_	_	_	_	_	_	_	Seg=O
20	due	_	_	_	_	_	_	_	Seg=B-seg
21	to	_	_	_	_	_	_	_	Seg=O
22	coronavirus	_	_	_	_	_	_	_	Seg=O
23	(	_	_	_	_	_	_	_	Seg=O
24	SARS	_	_	_	_	_	_	_	Seg=O
25	-	_	_	_	_	_	_	_	Seg=O
26	CoV	_	_	_	_	_	_	_	Seg=O
27	)	_	_	_	_	_	_	_	Seg=O
28	and	_	_	_	_	_	_	_	Seg=O
29	avian	_	_	_	_	_	_	_	Seg=O
30	influenza	_	_	_	_	_	_	_	Seg=O
31	A	_	_	_	_	_	_	_	Seg=O
32	subtype	_	_	_	_	_	_	_	Seg=O
33	H5N1	_	_	_	_	_	_	_	Seg=O
34	,	_	_	_	_	_	_	_	Seg=O
35	is	_	_	_	_	_	_	_	Seg=B-seg
36	reviewed	_	_	_	_	_	_	_	Seg=O
37	and	_	_	_	_	_	_	_	Seg=O
38	compared	_	_	_	_	_	_	_	Seg=O
39	based	_	_	_	_	_	_	_	Seg=O
40	on	_	_	_	_	_	_	_	Seg=O
41	the	_	_	_	_	_	_	_	Seg=O
42	literature	_	_	_	_	_	_	_	Seg=O
43	and	_	_	_	_	_	_	_	Seg=O
44	the	_	_	_	_	_	_	_	Seg=O
45	cases	_	_	_	_	_	_	_	Seg=O
46	examined	_	_	_	_	_	_	_	Seg=B-seg
47	by	_	_	_	_	_	_	_	Seg=O
48	the	_	_	_	_	_	_	_	Seg=O
49	authors	_	_	_	_	_	_	_	Seg=O
50	.	_	_	_	_	_	_	_	Seg=O
51	Pneumocytes	_	_	_	_	_	_	_	Seg=B-seg
52	are	_	_	_	_	_	_	_	Seg=O
53	the	_	_	_	_	_	_	_	Seg=O
54	primary	_	_	_	_	_	_	_	Seg=O
55	target	_	_	_	_	_	_	_	Seg=O
56	of	_	_	_	_	_	_	_	Seg=O
57	infection	_	_	_	_	_	_	_	Seg=O
58	resulting	_	_	_	_	_	_	_	Seg=B-seg
59	in	_	_	_	_	_	_	_	Seg=O
60	diffuse	_	_	_	_	_	_	_	Seg=O
61	alveolar	_	_	_	_	_	_	_	Seg=O
62	damage	_	_	_	_	_	_	_	Seg=O
63	.	_	_	_	_	_	_	_	Seg=O
64	Systemic	_	_	_	_	_	_	_	Seg=B-seg
65	cytokine	_	_	_	_	_	_	_	Seg=O
66	activation	_	_	_	_	_	_	_	Seg=O
67	results	_	_	_	_	_	_	_	Seg=O
68	in	_	_	_	_	_	_	_	Seg=O
69	hemophagocytic	_	_	_	_	_	_	_	Seg=O
70	syndrome	_	_	_	_	_	_	_	Seg=O
71	,	_	_	_	_	_	_	_	Seg=O
72	lymphoid	_	_	_	_	_	_	_	Seg=O
73	depletion	_	_	_	_	_	_	_	Seg=O
74	,	_	_	_	_	_	_	_	Seg=O
75	and	_	_	_	_	_	_	_	Seg=O
76	skeletal	_	_	_	_	_	_	_	Seg=O
77	muscle	_	_	_	_	_	_	_	Seg=O
78	fiber	_	_	_	_	_	_	_	Seg=O
79	necrosis	_	_	_	_	_	_	_	Seg=O
80	.	_	_	_	_	_	_	_	Seg=O
81	Severe	_	_	_	_	_	_	_	Seg=B-seg
82	acute	_	_	_	_	_	_	_	Seg=O
83	respiratory	_	_	_	_	_	_	_	Seg=O
84	syndrome	_	_	_	_	_	_	_	Seg=O
85	induces	_	_	_	_	_	_	_	Seg=O
86	a	_	_	_	_	_	_	_	Seg=O
87	more	_	_	_	_	_	_	_	Seg=O
88	fibrocellular	_	_	_	_	_	_	_	Seg=O
89	intra	_	_	_	_	_	_	_	Seg=O
90	-	_	_	_	_	_	_	_	Seg=O
91	alveolar	_	_	_	_	_	_	_	Seg=O
92	organization	_	_	_	_	_	_	_	Seg=O
93	with	_	_	_	_	_	_	_	Seg=O
94	a	_	_	_	_	_	_	_	Seg=O
95	bbronchiolitis	_	_	_	_	_	_	_	Seg=O
96	obliterans	_	_	_	_	_	_	_	Seg=O
97	organizing	_	_	_	_	_	_	_	Seg=B-seg
98	pneumoniaQ	_	_	_	_	_	_	_	Seg=O
99	-	_	_	_	_	_	_	_	Seg=O
100	like	_	_	_	_	_	_	_	Seg=O
101	pattern	_	_	_	_	_	_	_	Seg=O
102	and	_	_	_	_	_	_	_	Seg=O
103	presence	_	_	_	_	_	_	_	Seg=O
104	of	_	_	_	_	_	_	_	Seg=O
105	multinucleated	_	_	_	_	_	_	_	Seg=O
106	histiocytes	_	_	_	_	_	_	_	Seg=O
107	and	_	_	_	_	_	_	_	Seg=O
108	pneumocytes	_	_	_	_	_	_	_	Seg=O
109	.	_	_	_	_	_	_	_	Seg=O
110	H5N1	_	_	_	_	_	_	_	Seg=B-seg
111	causes	_	_	_	_	_	_	_	Seg=O
112	a	_	_	_	_	_	_	_	Seg=O
113	more	_	_	_	_	_	_	_	Seg=O
114	fulminant	_	_	_	_	_	_	_	Seg=O
115	and	_	_	_	_	_	_	_	Seg=O
116	necrotizing	_	_	_	_	_	_	_	Seg=O
117	diffuse	_	_	_	_	_	_	_	Seg=O
118	alveolar	_	_	_	_	_	_	_	Seg=O
119	damage	_	_	_	_	_	_	_	Seg=O
120	with	_	_	_	_	_	_	_	Seg=O
121	patchy	_	_	_	_	_	_	_	Seg=O
122	and	_	_	_	_	_	_	_	Seg=O
123	interstitial	_	_	_	_	_	_	_	Seg=O
124	paucicellular	_	_	_	_	_	_	_	Seg=O
125	fibrosis	_	_	_	_	_	_	_	Seg=O
126	.	_	_	_	_	_	_	_	Seg=O
127	Severe	_	_	_	_	_	_	_	Seg=B-seg
128	acute	_	_	_	_	_	_	_	Seg=O
129	respiratory	_	_	_	_	_	_	_	Seg=O
130	syndrome	_	_	_	_	_	_	_	Seg=O
131	associated	_	_	_	_	_	_	_	Seg=O
132	coronavirus	_	_	_	_	_	_	_	Seg=O
133	persists	_	_	_	_	_	_	_	Seg=O
134	in	_	_	_	_	_	_	_	Seg=O
135	the	_	_	_	_	_	_	_	Seg=O
136	lung	_	_	_	_	_	_	_	Seg=O
137	up	_	_	_	_	_	_	_	Seg=O
138	to	_	_	_	_	_	_	_	Seg=O
139	the	_	_	_	_	_	_	_	Seg=O
140	second	_	_	_	_	_	_	_	Seg=O
141	month	_	_	_	_	_	_	_	Seg=O
142	,	_	_	_	_	_	_	_	Seg=O
143	whereas	_	_	_	_	_	_	_	Seg=B-seg
144	H5N1	_	_	_	_	_	_	_	Seg=O
145	persists	_	_	_	_	_	_	_	Seg=O
146	in	_	_	_	_	_	_	_	Seg=O
147	the	_	_	_	_	_	_	_	Seg=O
148	lung	_	_	_	_	_	_	_	Seg=O
149	up	_	_	_	_	_	_	_	Seg=O
150	to	_	_	_	_	_	_	_	Seg=O
151	the	_	_	_	_	_	_	_	Seg=O
152	third	_	_	_	_	_	_	_	Seg=O
153	week	_	_	_	_	_	_	_	Seg=O
154	.	_	_	_	_	_	_	_	Seg=O
155	Severe	_	_	_	_	_	_	_	Seg=B-seg
156	acute	_	_	_	_	_	_	_	Seg=O
157	respiratory	_	_	_	_	_	_	_	Seg=O
158	syndrome	_	_	_	_	_	_	_	Seg=O
159	associated	_	_	_	_	_	_	_	Seg=O
160	coronavirus	_	_	_	_	_	_	_	Seg=O
161	disseminates	_	_	_	_	_	_	_	Seg=O
162	to	_	_	_	_	_	_	_	Seg=O
163	blood	_	_	_	_	_	_	_	Seg=O
164	,	_	_	_	_	_	_	_	Seg=O
165	urine	_	_	_	_	_	_	_	Seg=O
166	,	_	_	_	_	_	_	_	Seg=O
167	feces	_	_	_	_	_	_	_	Seg=O
168	,	_	_	_	_	_	_	_	Seg=O
169	gastrointestinal	_	_	_	_	_	_	_	Seg=O
170	tract	_	_	_	_	_	_	_	Seg=O
171	,	_	_	_	_	_	_	_	Seg=O
172	and	_	_	_	_	_	_	_	Seg=O
173	liver	_	_	_	_	_	_	_	Seg=O
174	.	_	_	_	_	_	_	_	Seg=O
175	There	_	_	_	_	_	_	_	Seg=B-seg
176	is	_	_	_	_	_	_	_	Seg=O
177	recent	_	_	_	_	_	_	_	Seg=O
178	report	_	_	_	_	_	_	_	Seg=O
179	of	_	_	_	_	_	_	_	Seg=O
180	possible	_	_	_	_	_	_	_	Seg=O
181	cerebral	_	_	_	_	_	_	_	Seg=O
182	involvement	_	_	_	_	_	_	_	Seg=O
183	by	_	_	_	_	_	_	_	Seg=O
184	H5N1	_	_	_	_	_	_	_	Seg=O
185	and	_	_	_	_	_	_	_	Seg=O
186	its	_	_	_	_	_	_	_	Seg=O
187	isolation	_	_	_	_	_	_	_	Seg=O
188	in	_	_	_	_	_	_	_	Seg=O
189	the	_	_	_	_	_	_	_	Seg=O
190	blood	_	_	_	_	_	_	_	Seg=O
191	,	_	_	_	_	_	_	_	Seg=O
192	gastrointestinal	_	_	_	_	_	_	_	Seg=O
193	tract	_	_	_	_	_	_	_	Seg=O
194	,	_	_	_	_	_	_	_	Seg=O
195	and	_	_	_	_	_	_	_	Seg=O
196	cerebrospinal	_	_	_	_	_	_	_	Seg=O
197	fluid	_	_	_	_	_	_	_	Seg=O
198	.	_	_	_	_	_	_	_	Seg=O
199	More	_	_	_	_	_	_	_	Seg=B-seg
200	pathologic	_	_	_	_	_	_	_	Seg=O
201	studies	_	_	_	_	_	_	_	Seg=O
202	are	_	_	_	_	_	_	_	Seg=O
203	urgently	_	_	_	_	_	_	_	Seg=O
204	needed	_	_	_	_	_	_	_	Seg=O
205	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 5ddc3c732b0e2be8ffe373107ca6e56e49c4513e
1	A	_	_	_	_	_	_	_	Seg=B-seg
2	molecular	_	_	_	_	_	_	_	Seg=O
3	docking	_	_	_	_	_	_	_	Seg=O
4	study	_	_	_	_	_	_	_	Seg=O
5	was	_	_	_	_	_	_	_	Seg=O
6	performed	_	_	_	_	_	_	_	Seg=O
7	on	_	_	_	_	_	_	_	Seg=O
8	several	_	_	_	_	_	_	_	Seg=O
9	structurally	_	_	_	_	_	_	_	Seg=O
10	diverse	_	_	_	_	_	_	_	Seg=O
11	A	_	_	_	_	_	_	_	Seg=O
12	2A	_	_	_	_	_	_	_	Seg=O
13	AR	_	_	_	_	_	_	_	Seg=O
14	antagonists	_	_	_	_	_	_	_	Seg=O
15	,	_	_	_	_	_	_	_	Seg=O
16	including	_	_	_	_	_	_	_	Seg=B-seg
17	xanthines	_	_	_	_	_	_	_	Seg=O
18	,	_	_	_	_	_	_	_	Seg=O
19	and	_	_	_	_	_	_	_	Seg=B-seg
20	non	_	_	_	_	_	_	_	Seg=O
21	-	_	_	_	_	_	_	_	Seg=O
22	xanthine	_	_	_	_	_	_	_	Seg=O
23	type	_	_	_	_	_	_	_	Seg=O
24	antagonists	_	_	_	_	_	_	_	Seg=O
25	to	_	_	_	_	_	_	_	Seg=B-seg
26	investigate	_	_	_	_	_	_	_	Seg=O
27	their	_	_	_	_	_	_	_	Seg=O
28	binding	_	_	_	_	_	_	_	Seg=O
29	modes	_	_	_	_	_	_	_	Seg=O
30	with	_	_	_	_	_	_	_	Seg=O
31	A	_	_	_	_	_	_	_	Seg=O
32	2A	_	_	_	_	_	_	_	Seg=O
33	adenosine	_	_	_	_	_	_	_	Seg=O
34	receptor	_	_	_	_	_	_	_	Seg=O
35	(	_	_	_	_	_	_	_	Seg=O
36	AR	_	_	_	_	_	_	_	Seg=O
37	)	_	_	_	_	_	_	_	Seg=O
38	,	_	_	_	_	_	_	_	Seg=O
39	one	_	_	_	_	_	_	_	Seg=B-seg
40	of	_	_	_	_	_	_	_	Seg=O
41	the	_	_	_	_	_	_	_	Seg=O
42	four	_	_	_	_	_	_	_	Seg=O
43	subtypes	_	_	_	_	_	_	_	Seg=O
44	of	_	_	_	_	_	_	_	Seg=O
45	AR	_	_	_	_	_	_	_	Seg=O
46	,	_	_	_	_	_	_	_	Seg=O
47	which	_	_	_	_	_	_	_	Seg=B-seg
48	is	_	_	_	_	_	_	_	Seg=O
49	currently	_	_	_	_	_	_	_	Seg=O
50	of	_	_	_	_	_	_	_	Seg=O
51	great	_	_	_	_	_	_	_	Seg=O
52	interest	_	_	_	_	_	_	_	Seg=O
53	as	_	_	_	_	_	_	_	Seg=O
54	a	_	_	_	_	_	_	_	Seg=O
55	target	_	_	_	_	_	_	_	Seg=O
56	for	_	_	_	_	_	_	_	Seg=O
57	therapeutic	_	_	_	_	_	_	_	Seg=O
58	intervention	_	_	_	_	_	_	_	Seg=O
59	,	_	_	_	_	_	_	_	Seg=O
60	in	_	_	_	_	_	_	_	Seg=O
61	particular	_	_	_	_	_	_	_	Seg=O
62	for	_	_	_	_	_	_	_	Seg=O
63-64	Parkinson's	_	_	_	_	_	_	_	_
63	Parkinson	_	_	_	_	_	_	_	Seg=O
64	's	_	_	_	_	_	_	_	Seg=O
65	disease	_	_	_	_	_	_	_	Seg=O
66	.	_	_	_	_	_	_	_	Seg=O
67	The	_	_	_	_	_	_	_	Seg=B-seg
68	high	_	_	_	_	_	_	_	Seg=O
69	-	_	_	_	_	_	_	_	Seg=O
70	affinity	_	_	_	_	_	_	_	Seg=O
71	binding	_	_	_	_	_	_	_	Seg=O
72	site	_	_	_	_	_	_	_	Seg=O
73	was	_	_	_	_	_	_	_	Seg=O
74	found	_	_	_	_	_	_	_	Seg=O
75	to	_	_	_	_	_	_	_	Seg=O
76	be	_	_	_	_	_	_	_	Seg=O
77	a	_	_	_	_	_	_	_	Seg=O
78	hydrophobic	_	_	_	_	_	_	_	Seg=O
79	pocket	_	_	_	_	_	_	_	Seg=O
80	with	_	_	_	_	_	_	_	Seg=O
81	the	_	_	_	_	_	_	_	Seg=O
82	involvement	_	_	_	_	_	_	_	Seg=O
83	of	_	_	_	_	_	_	_	Seg=O
84	hydrogen	_	_	_	_	_	_	_	Seg=O
85	bonding	_	_	_	_	_	_	_	Seg=O
86	interactions	_	_	_	_	_	_	_	Seg=O
87	as	_	_	_	_	_	_	_	Seg=O
88	well	_	_	_	_	_	_	_	Seg=O
89	as	_	_	_	_	_	_	_	Seg=O
90	p	_	_	_	_	_	_	_	Seg=O
91	-	_	_	_	_	_	_	_	Seg=O
92	p	_	_	_	_	_	_	_	Seg=O
93	stacking	_	_	_	_	_	_	_	Seg=O
94	interactions	_	_	_	_	_	_	_	Seg=O
95	with	_	_	_	_	_	_	_	Seg=O
96	the	_	_	_	_	_	_	_	Seg=O
97	ligands	_	_	_	_	_	_	_	Seg=O
98	.	_	_	_	_	_	_	_	Seg=O
99	The	_	_	_	_	_	_	_	Seg=B-seg
100	detailed	_	_	_	_	_	_	_	Seg=O
101	binding	_	_	_	_	_	_	_	Seg=O
102	modes	_	_	_	_	_	_	_	Seg=O
103	for	_	_	_	_	_	_	_	Seg=O
104	both	_	_	_	_	_	_	_	Seg=O
105	xanthine	_	_	_	_	_	_	_	Seg=O
106	and	_	_	_	_	_	_	_	Seg=O
107	non	_	_	_	_	_	_	_	Seg=O
108	-	_	_	_	_	_	_	_	Seg=O
109	xanthine	_	_	_	_	_	_	_	Seg=O
110	type	_	_	_	_	_	_	_	Seg=O
111	A	_	_	_	_	_	_	_	Seg=O
112	2A	_	_	_	_	_	_	_	Seg=O
113	antagonists	_	_	_	_	_	_	_	Seg=O
114	were	_	_	_	_	_	_	_	Seg=O
115	compared	_	_	_	_	_	_	_	Seg=O
116	and	_	_	_	_	_	_	_	Seg=B-seg
117	the	_	_	_	_	_	_	_	Seg=O
118	essential	_	_	_	_	_	_	_	Seg=O
119	features	_	_	_	_	_	_	_	Seg=O
120	were	_	_	_	_	_	_	_	Seg=O
121	extracted	_	_	_	_	_	_	_	Seg=O
122	and	_	_	_	_	_	_	_	Seg=B-seg
123	converted	_	_	_	_	_	_	_	Seg=O
124	to	_	_	_	_	_	_	_	Seg=O
125	database	_	_	_	_	_	_	_	Seg=O
126	searchable	_	_	_	_	_	_	_	Seg=O
127	queries	_	_	_	_	_	_	_	Seg=O
128	for	_	_	_	_	_	_	_	Seg=O
129	virtual	_	_	_	_	_	_	_	Seg=O
130	screening	_	_	_	_	_	_	_	Seg=O
131	study	_	_	_	_	_	_	_	Seg=O
132	of	_	_	_	_	_	_	_	Seg=O
133	novel	_	_	_	_	_	_	_	Seg=O
134	A	_	_	_	_	_	_	_	Seg=O
135	2A	_	_	_	_	_	_	_	Seg=O
136	AR	_	_	_	_	_	_	_	Seg=O
137	antagonists	_	_	_	_	_	_	_	Seg=O
138	.	_	_	_	_	_	_	_	Seg=O
139	Findings	_	_	_	_	_	_	_	Seg=B-seg
140	from	_	_	_	_	_	_	_	Seg=O
141	this	_	_	_	_	_	_	_	Seg=O
142	study	_	_	_	_	_	_	_	Seg=O
143	are	_	_	_	_	_	_	_	Seg=O
144	helpful	_	_	_	_	_	_	_	Seg=O
145	for	_	_	_	_	_	_	_	Seg=O
146	elucidating	_	_	_	_	_	_	_	Seg=O
147	the	_	_	_	_	_	_	_	Seg=O
148	binding	_	_	_	_	_	_	_	Seg=O
149	pattern	_	_	_	_	_	_	_	Seg=O
150	of	_	_	_	_	_	_	_	Seg=O
151	A	_	_	_	_	_	_	_	Seg=O
152	2A	_	_	_	_	_	_	_	Seg=O
153	AR	_	_	_	_	_	_	_	Seg=O
154	antagonists	_	_	_	_	_	_	_	Seg=O
155	and	_	_	_	_	_	_	_	Seg=O
156	for	_	_	_	_	_	_	_	Seg=O
157	the	_	_	_	_	_	_	_	Seg=O
158	design	_	_	_	_	_	_	_	Seg=O
159	of	_	_	_	_	_	_	_	Seg=O
160	novel	_	_	_	_	_	_	_	Seg=O
161	active	_	_	_	_	_	_	_	Seg=O
162	ligands	_	_	_	_	_	_	_	Seg=O
163	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 6140703a4f59d2feadfcc54c1185770cbaa651dc
1	As	_	_	_	_	_	_	_	Seg=B-seg
2	SARS	_	_	_	_	_	_	_	Seg=O
3	-	_	_	_	_	_	_	_	Seg=O
4	COV-2	_	_	_	_	_	_	_	Seg=O
5	and	_	_	_	_	_	_	_	Seg=O
6	the	_	_	_	_	_	_	_	Seg=O
7	disease	_	_	_	_	_	_	_	Seg=O
8	COVID-19	_	_	_	_	_	_	_	Seg=O
9	is	_	_	_	_	_	_	_	Seg=O
10	sweeping	_	_	_	_	_	_	_	Seg=O
11	through	_	_	_	_	_	_	_	Seg=O
12	countries	_	_	_	_	_	_	_	Seg=O
13	after	_	_	_	_	_	_	_	Seg=O
14	countries	_	_	_	_	_	_	_	Seg=O
15	around	_	_	_	_	_	_	_	Seg=O
16	the	_	_	_	_	_	_	_	Seg=O
17	globe	_	_	_	_	_	_	_	Seg=O
18	,	_	_	_	_	_	_	_	Seg=O
19	it	_	_	_	_	_	_	_	Seg=B-seg
20	is	_	_	_	_	_	_	_	Seg=O
21	critical	_	_	_	_	_	_	_	Seg=O
22	to	_	_	_	_	_	_	_	Seg=O
23	understand	_	_	_	_	_	_	_	Seg=O
24	potential	_	_	_	_	_	_	_	Seg=O
25	burden	_	_	_	_	_	_	_	Seg=O
26	of	_	_	_	_	_	_	_	Seg=O
27	a	_	_	_	_	_	_	_	Seg=O
28	future	_	_	_	_	_	_	_	Seg=O
29	outbreak	_	_	_	_	_	_	_	Seg=O
30	in	_	_	_	_	_	_	_	Seg=O
31	cities	_	_	_	_	_	_	_	Seg=O
32	of	_	_	_	_	_	_	_	Seg=O
33	Colombia	_	_	_	_	_	_	_	Seg=O
34	.	_	_	_	_	_	_	_	Seg=O
35	This	_	_	_	_	_	_	_	Seg=B-seg
36	pandemic	_	_	_	_	_	_	_	Seg=O
37	has	_	_	_	_	_	_	_	Seg=O
38	affected	_	_	_	_	_	_	_	Seg=O
39	most	_	_	_	_	_	_	_	Seg=O
40	of	_	_	_	_	_	_	_	Seg=O
41	the	_	_	_	_	_	_	_	Seg=O
42	countries	_	_	_	_	_	_	_	Seg=O
43	in	_	_	_	_	_	_	_	Seg=O
44	the	_	_	_	_	_	_	_	Seg=O
45	world	_	_	_	_	_	_	_	Seg=O
46	because	_	_	_	_	_	_	_	Seg=B-seg
47	the	_	_	_	_	_	_	_	Seg=O
48	high	_	_	_	_	_	_	_	Seg=O
49	global	_	_	_	_	_	_	_	Seg=O
50	movement	_	_	_	_	_	_	_	Seg=O
51	of	_	_	_	_	_	_	_	Seg=O
52	individuals	_	_	_	_	_	_	_	Seg=O
53	and	_	_	_	_	_	_	_	Seg=O
54	excessive	_	_	_	_	_	_	_	Seg=O
55	cost	_	_	_	_	_	_	_	Seg=O
56	in	_	_	_	_	_	_	_	Seg=O
57	interventions	_	_	_	_	_	_	_	Seg=O
58	.	_	_	_	_	_	_	_	Seg=O
59	Objective	_	_	_	_	_	_	_	Seg=B-seg
60	:	_	_	_	_	_	_	_	Seg=O
61	Using	_	_	_	_	_	_	_	Seg=B-seg
62	demographic	_	_	_	_	_	_	_	Seg=O
63	data	_	_	_	_	_	_	_	Seg=O
64	from	_	_	_	_	_	_	_	Seg=O
65	city	_	_	_	_	_	_	_	Seg=O
66	of	_	_	_	_	_	_	_	Seg=O
67	Cali	_	_	_	_	_	_	_	Seg=O
68	,	_	_	_	_	_	_	_	Seg=O
69	disease	_	_	_	_	_	_	_	Seg=O
70	epidemiological	_	_	_	_	_	_	_	Seg=O
71	information	_	_	_	_	_	_	_	Seg=O
72	from	_	_	_	_	_	_	_	Seg=O
73	affected	_	_	_	_	_	_	_	Seg=O
74	countries	_	_	_	_	_	_	_	Seg=O
75	and	_	_	_	_	_	_	_	Seg=O
76	mathematical	_	_	_	_	_	_	_	Seg=O
77	models	_	_	_	_	_	_	_	Seg=O
78	,	_	_	_	_	_	_	_	Seg=O
79	we	_	_	_	_	_	_	_	Seg=B-seg
80	estimated	_	_	_	_	_	_	_	Seg=O
81	the	_	_	_	_	_	_	_	Seg=O
82	rate	_	_	_	_	_	_	_	Seg=O
83	of	_	_	_	_	_	_	_	Seg=O
84	initial	_	_	_	_	_	_	_	Seg=O
85	exponential	_	_	_	_	_	_	_	Seg=O
86	growth	_	_	_	_	_	_	_	Seg=O
87	of	_	_	_	_	_	_	_	Seg=O
88	new	_	_	_	_	_	_	_	Seg=O
89	cases	_	_	_	_	_	_	_	Seg=O
90	and	_	_	_	_	_	_	_	Seg=O
91	the	_	_	_	_	_	_	_	Seg=O
92	basic	_	_	_	_	_	_	_	Seg=O
93	reproductive	_	_	_	_	_	_	_	Seg=O
94	rate	_	_	_	_	_	_	_	Seg=O
95	for	_	_	_	_	_	_	_	Seg=O
96	a	_	_	_	_	_	_	_	Seg=O
97	potential	_	_	_	_	_	_	_	Seg=O
98	outbreak	_	_	_	_	_	_	_	Seg=O
99	in	_	_	_	_	_	_	_	Seg=O
100	city	_	_	_	_	_	_	_	Seg=O
101	of	_	_	_	_	_	_	_	Seg=O
102	Cali	_	_	_	_	_	_	_	Seg=O
103	in	_	_	_	_	_	_	_	Seg=O
104	Colombia	_	_	_	_	_	_	_	Seg=O
105	.	_	_	_	_	_	_	_	Seg=O
106	Materials	_	_	_	_	_	_	_	Seg=B-seg
107	and	_	_	_	_	_	_	_	Seg=O
108	methods	_	_	_	_	_	_	_	Seg=O
109	:	_	_	_	_	_	_	_	Seg=O
110	We	_	_	_	_	_	_	_	Seg=B-seg
111	used	_	_	_	_	_	_	_	Seg=O
112	dynamical	_	_	_	_	_	_	_	Seg=O
113	models	_	_	_	_	_	_	_	Seg=O
114	with	_	_	_	_	_	_	_	Seg=O
115	different	_	_	_	_	_	_	_	Seg=O
116	modeling	_	_	_	_	_	_	_	Seg=O
117	assumptions	_	_	_	_	_	_	_	Seg=O
118	such	_	_	_	_	_	_	_	Seg=B-seg
119	as	_	_	_	_	_	_	_	Seg=O
120	use	_	_	_	_	_	_	_	Seg=O
121	of	_	_	_	_	_	_	_	Seg=O
122	various	_	_	_	_	_	_	_	Seg=O
123	types	_	_	_	_	_	_	_	Seg=O
124	of	_	_	_	_	_	_	_	Seg=O
125	interventions	_	_	_	_	_	_	_	Seg=O
126	and/or	_	_	_	_	_	_	_	Seg=O
127	epidemiological	_	_	_	_	_	_	_	Seg=O
128	characteristics	_	_	_	_	_	_	_	Seg=O
129	to	_	_	_	_	_	_	_	Seg=B-seg
130	compare	_	_	_	_	_	_	_	Seg=O
131	and	_	_	_	_	_	_	_	Seg=O
132	contrast	_	_	_	_	_	_	_	Seg=O
133	the	_	_	_	_	_	_	_	Seg=O
134	differences	_	_	_	_	_	_	_	Seg=O
135	between	_	_	_	_	_	_	_	Seg=O
136	Colombian	_	_	_	_	_	_	_	Seg=O
137	cities	_	_	_	_	_	_	_	Seg=O
138	and	_	_	_	_	_	_	_	Seg=O
139	between	_	_	_	_	_	_	_	Seg=O
140	Latin	_	_	_	_	_	_	_	Seg=O
141	American	_	_	_	_	_	_	_	Seg=O
142	countries	_	_	_	_	_	_	_	Seg=O
143	.	_	_	_	_	_	_	_	Seg=O
144	Results	_	_	_	_	_	_	_	Seg=B-seg
145	:	_	_	_	_	_	_	_	Seg=O
146	Under	_	_	_	_	_	_	_	Seg=B-seg
147	the	_	_	_	_	_	_	_	Seg=O
148	assumption	_	_	_	_	_	_	_	Seg=O
149	of	_	_	_	_	_	_	_	Seg=O
150	homogeneously	_	_	_	_	_	_	_	Seg=O
151	mixing	_	_	_	_	_	_	_	Seg=O
152	population	_	_	_	_	_	_	_	Seg=O
153	and	_	_	_	_	_	_	_	Seg=O
154	limited	_	_	_	_	_	_	_	Seg=O
155	resources	_	_	_	_	_	_	_	Seg=O
156	,	_	_	_	_	_	_	_	Seg=O
157	we	_	_	_	_	_	_	_	Seg=B-seg
158	predicted	_	_	_	_	_	_	_	Seg=O
159	expected	_	_	_	_	_	_	_	Seg=O
160	number	_	_	_	_	_	_	_	Seg=O
161	of	_	_	_	_	_	_	_	Seg=O
162	infected	_	_	_	_	_	_	_	Seg=O
163	,	_	_	_	_	_	_	_	Seg=O
164	hospitalized	_	_	_	_	_	_	_	Seg=O
165	,	_	_	_	_	_	_	_	Seg=O
166	in	_	_	_	_	_	_	_	Seg=O
167	Intensive	_	_	_	_	_	_	_	Seg=O
168	Care	_	_	_	_	_	_	_	Seg=O
169	Units	_	_	_	_	_	_	_	Seg=O
170	(	_	_	_	_	_	_	_	Seg=O
171	ICU	_	_	_	_	_	_	_	Seg=O
172	)	_	_	_	_	_	_	_	Seg=O
173	and	_	_	_	_	_	_	_	Seg=O
174	deaths	_	_	_	_	_	_	_	Seg=O
175	during	_	_	_	_	_	_	_	Seg=O
176	this	_	_	_	_	_	_	_	Seg=O
177	potential	_	_	_	_	_	_	_	Seg=O
178	COVID-19	_	_	_	_	_	_	_	Seg=O
179	outbreak	_	_	_	_	_	_	_	Seg=O
180	.	_	_	_	_	_	_	_	Seg=O
181	Our	_	_	_	_	_	_	_	Seg=B-seg
182	results	_	_	_	_	_	_	_	Seg=O
183	suggest	_	_	_	_	_	_	_	Seg=O
184	that	_	_	_	_	_	_	_	Seg=B-seg
185	on	_	_	_	_	_	_	_	Seg=O
186	a	_	_	_	_	_	_	_	Seg=O
187	given	_	_	_	_	_	_	_	Seg=O
188	day	_	_	_	_	_	_	_	Seg=O
189	in	_	_	_	_	_	_	_	Seg=O
190	Cali	_	_	_	_	_	_	_	Seg=O
191	there	_	_	_	_	_	_	_	Seg=O
192	may	_	_	_	_	_	_	_	Seg=O
193	be	_	_	_	_	_	_	_	Seg=O
194	up	_	_	_	_	_	_	_	Seg=O
195	to	_	_	_	_	_	_	_	Seg=O
196	around	_	_	_	_	_	_	_	Seg=O
197	73000	_	_	_	_	_	_	_	Seg=O
198	cases	_	_	_	_	_	_	_	Seg=O
199	who	_	_	_	_	_	_	_	Seg=B-seg
200	might	_	_	_	_	_	_	_	Seg=O
201	need	_	_	_	_	_	_	_	Seg=O
202	hospitalization	_	_	_	_	_	_	_	Seg=O
203	under	_	_	_	_	_	_	_	Seg=O
204	no	_	_	_	_	_	_	_	Seg=O
205	intervention	_	_	_	_	_	_	_	Seg=O
206	.	_	_	_	_	_	_	_	Seg=O
207	However	_	_	_	_	_	_	_	Seg=B-seg
208	,	_	_	_	_	_	_	_	Seg=O
209	this	_	_	_	_	_	_	_	Seg=O
210	number	_	_	_	_	_	_	_	Seg=O
211	drastically	_	_	_	_	_	_	_	Seg=O
212	reduces	_	_	_	_	_	_	_	Seg=O
213	if	_	_	_	_	_	_	_	Seg=B-seg
214	we	_	_	_	_	_	_	_	Seg=O
215	carry	_	_	_	_	_	_	_	Seg=O
216	out	_	_	_	_	_	_	_	Seg=O
217	only	_	_	_	_	_	_	_	Seg=O
218	-	_	_	_	_	_	_	_	Seg=O
219	isolation	_	_	_	_	_	_	_	Seg=O
220	intervention	_	_	_	_	_	_	_	Seg=O
221	(	_	_	_	_	_	_	_	Seg=B-seg
222	with	_	_	_	_	_	_	_	Seg=O
223	16	_	_	_	_	_	_	_	Seg=O
224	days	_	_	_	_	_	_	_	Seg=O
225	of	_	_	_	_	_	_	_	Seg=O
226	symptomatic	_	_	_	_	_	_	_	Seg=O
227	infection	_	_	_	_	_	_	_	Seg=O
228	;	_	_	_	_	_	_	_	Seg=O
229	~13,000	_	_	_	_	_	_	_	Seg=O
230	cases	_	_	_	_	_	_	_	Seg=O
231	)	_	_	_	_	_	_	_	Seg=O
232	versus	_	_	_	_	_	_	_	Seg=B-seg
233	both	_	_	_	_	_	_	_	Seg=O
234	quarantining	_	_	_	_	_	_	_	Seg=O
235	for	_	_	_	_	_	_	_	Seg=O
236	6	_	_	_	_	_	_	_	Seg=O
237	days	_	_	_	_	_	_	_	Seg=O
238	and	_	_	_	_	_	_	_	Seg=O
239	isolation	_	_	_	_	_	_	_	Seg=O
240	within	_	_	_	_	_	_	_	Seg=O
241	16	_	_	_	_	_	_	_	Seg=O
242	days	_	_	_	_	_	_	_	Seg=O
243	(	_	_	_	_	_	_	_	Seg=B-seg
244	~3500	_	_	_	_	_	_	_	Seg=O
245	cases	_	_	_	_	_	_	_	Seg=O
246	)	_	_	_	_	_	_	_	Seg=O
247	.	_	_	_	_	_	_	_	Seg=O
248	The	_	_	_	_	_	_	_	Seg=B-seg
249	peak	_	_	_	_	_	_	_	Seg=O
250	in	_	_	_	_	_	_	_	Seg=O
251	Cali	_	_	_	_	_	_	_	Seg=O
252	will	_	_	_	_	_	_	_	Seg=O
253	reach	_	_	_	_	_	_	_	Seg=O
254	in	_	_	_	_	_	_	_	Seg=O
255	2	_	_	_	_	_	_	_	Seg=O
256	-	_	_	_	_	_	_	_	Seg=O
257	3	_	_	_	_	_	_	_	Seg=O
258	months	_	_	_	_	_	_	_	Seg=O
259	.	_	_	_	_	_	_	_	Seg=O
260	Conclusions	_	_	_	_	_	_	_	Seg=B-seg
261	.	_	_	_	_	_	_	_	Seg=O
262	The	_	_	_	_	_	_	_	Seg=B-seg
263	estimates	_	_	_	_	_	_	_	Seg=O
264	from	_	_	_	_	_	_	_	Seg=O
265	these	_	_	_	_	_	_	_	Seg=O
266	studies	_	_	_	_	_	_	_	Seg=O
267	provides	_	_	_	_	_	_	_	Seg=O
268	different	_	_	_	_	_	_	_	Seg=O
269	scenarios	_	_	_	_	_	_	_	Seg=O
270	of	_	_	_	_	_	_	_	Seg=O
271	outbreaks	_	_	_	_	_	_	_	Seg=O
272	and	_	_	_	_	_	_	_	Seg=B-seg
273	can	_	_	_	_	_	_	_	Seg=O
274	help	_	_	_	_	_	_	_	Seg=O
275	Cali	_	_	_	_	_	_	_	Seg=O
276	to	_	_	_	_	_	_	_	Seg=O
277	be	_	_	_	_	_	_	_	Seg=O
278	better	_	_	_	_	_	_	_	Seg=O
279	prepared	_	_	_	_	_	_	_	Seg=O
280	during	_	_	_	_	_	_	_	Seg=O
281	the	_	_	_	_	_	_	_	Seg=O
282	ongoing	_	_	_	_	_	_	_	Seg=O
283	COVID-19	_	_	_	_	_	_	_	Seg=O
284	outbreak	_	_	_	_	_	_	_	Seg=O
285	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 6170c6d5c7e660f19226bfd026159c4ba6915fda
1	We	_	_	_	_	_	_	_	Seg=B-seg
2	compared	_	_	_	_	_	_	_	Seg=O
3	the	_	_	_	_	_	_	_	Seg=O
4	prevalence	_	_	_	_	_	_	_	Seg=O
5	of	_	_	_	_	_	_	_	Seg=O
6	8	_	_	_	_	_	_	_	Seg=O
7	polymorphisms	_	_	_	_	_	_	_	Seg=O
8	in	_	_	_	_	_	_	_	Seg=O
9	the	_	_	_	_	_	_	_	Seg=O
10	tumor	_	_	_	_	_	_	_	Seg=O
11	necrosis	_	_	_	_	_	_	_	Seg=O
12	factor	_	_	_	_	_	_	_	Seg=O
13	and	_	_	_	_	_	_	_	Seg=O
14	mannose	_	_	_	_	_	_	_	Seg=O
15	-	_	_	_	_	_	_	_	Seg=O
16	binding	_	_	_	_	_	_	_	Seg=O
17	lectin	_	_	_	_	_	_	_	Seg=O
18	genes	_	_	_	_	_	_	_	Seg=O
19	among	_	_	_	_	_	_	_	Seg=O
20	105	_	_	_	_	_	_	_	Seg=O
21	children	_	_	_	_	_	_	_	Seg=O
22	and	_	_	_	_	_	_	_	Seg=O
23	young	_	_	_	_	_	_	_	Seg=O
24	adults	_	_	_	_	_	_	_	Seg=O
25	with	_	_	_	_	_	_	_	Seg=O
26	fatal	_	_	_	_	_	_	_	Seg=O
27	infl	_	_	_	_	_	_	_	Seg=O
28	uenza	_	_	_	_	_	_	_	Seg=O
29	with	_	_	_	_	_	_	_	Seg=O
30	US	_	_	_	_	_	_	_	Seg=O
31	population	_	_	_	_	_	_	_	Seg=O
32	estimates	_	_	_	_	_	_	_	Seg=O
33	and	_	_	_	_	_	_	_	Seg=B-seg
34	determined	_	_	_	_	_	_	_	Seg=O
35	in	_	_	_	_	_	_	_	Seg=O
36	subanalyses	_	_	_	_	_	_	_	Seg=O
37	whether	_	_	_	_	_	_	_	Seg=O
38	these	_	_	_	_	_	_	_	Seg=O
39	polymorphisms	_	_	_	_	_	_	_	Seg=O
40	were	_	_	_	_	_	_	_	Seg=O
41	associated	_	_	_	_	_	_	_	Seg=O
42	with	_	_	_	_	_	_	_	Seg=O
43	sudden	_	_	_	_	_	_	_	Seg=O
44	death	_	_	_	_	_	_	_	Seg=O
45	and	_	_	_	_	_	_	_	Seg=O
46	bacterial	_	_	_	_	_	_	_	Seg=O
47	co	_	_	_	_	_	_	_	Seg=O
48	-	_	_	_	_	_	_	_	Seg=O
49	infection	_	_	_	_	_	_	_	Seg=O
50	among	_	_	_	_	_	_	_	Seg=O
51	persons	_	_	_	_	_	_	_	Seg=O
52	with	_	_	_	_	_	_	_	Seg=O
53	fatal	_	_	_	_	_	_	_	Seg=O
54	infl	_	_	_	_	_	_	_	Seg=O
55	uenza	_	_	_	_	_	_	_	Seg=O
56	.	_	_	_	_	_	_	_	Seg=O
57	No	_	_	_	_	_	_	_	Seg=B-seg
58	differences	_	_	_	_	_	_	_	Seg=O
59	were	_	_	_	_	_	_	_	Seg=O
60	observed	_	_	_	_	_	_	_	Seg=O
61	in	_	_	_	_	_	_	_	Seg=O
62	genotype	_	_	_	_	_	_	_	Seg=O
63	prevalence	_	_	_	_	_	_	_	Seg=O
64	or	_	_	_	_	_	_	_	Seg=O
65	minor	_	_	_	_	_	_	_	Seg=O
66	allele	_	_	_	_	_	_	_	Seg=O
67	frequencies	_	_	_	_	_	_	_	Seg=O
68	between	_	_	_	_	_	_	_	Seg=O
69	persons	_	_	_	_	_	_	_	Seg=O
70	with	_	_	_	_	_	_	_	Seg=O
71	fatal	_	_	_	_	_	_	_	Seg=O
72	infl	_	_	_	_	_	_	_	Seg=O
73	uenza	_	_	_	_	_	_	_	Seg=O
74	and	_	_	_	_	_	_	_	Seg=O
75	the	_	_	_	_	_	_	_	Seg=O
76	reference	_	_	_	_	_	_	_	Seg=O
77	sample	_	_	_	_	_	_	_	Seg=O
78	.	_	_	_	_	_	_	_	Seg=O
79	Fatal	_	_	_	_	_	_	_	Seg=B-seg
80	cases	_	_	_	_	_	_	_	Seg=O
81	with	_	_	_	_	_	_	_	Seg=O
82	low	_	_	_	_	_	_	_	Seg=O
83	-	_	_	_	_	_	_	_	Seg=O
84	producing	_	_	_	_	_	_	_	Seg=O
85	MBL2	_	_	_	_	_	_	_	Seg=O
86	genotypes	_	_	_	_	_	_	_	Seg=O
87	had	_	_	_	_	_	_	_	Seg=O
88	a	_	_	_	_	_	_	_	Seg=O
89	7-fold	_	_	_	_	_	_	_	Seg=O
90	increased	_	_	_	_	_	_	_	Seg=O
91	risk	_	_	_	_	_	_	_	Seg=O
92	for	_	_	_	_	_	_	_	Seg=O
93	invasive	_	_	_	_	_	_	_	Seg=O
94	methicillin	_	_	_	_	_	_	_	Seg=O
95	-	_	_	_	_	_	_	_	Seg=O
96	resistant	_	_	_	_	_	_	_	Seg=O
97	Staphylococcus	_	_	_	_	_	_	_	Seg=O
98	aureus	_	_	_	_	_	_	_	Seg=O
99	(	_	_	_	_	_	_	_	Seg=O
100	MRSA	_	_	_	_	_	_	_	Seg=O
101	)	_	_	_	_	_	_	_	Seg=O
102	co	_	_	_	_	_	_	_	Seg=O
103	-	_	_	_	_	_	_	_	Seg=O
104	infection	_	_	_	_	_	_	_	Seg=O
105	compared	_	_	_	_	_	_	_	Seg=B-seg
106	with	_	_	_	_	_	_	_	Seg=O
107	fatal	_	_	_	_	_	_	_	Seg=O
108	cases	_	_	_	_	_	_	_	Seg=O
109	with	_	_	_	_	_	_	_	Seg=O
110	highand	_	_	_	_	_	_	_	Seg=O
111	intermediate	_	_	_	_	_	_	_	Seg=O
112	-	_	_	_	_	_	_	_	Seg=O
113	producing	_	_	_	_	_	_	_	Seg=O
114	MBL2	_	_	_	_	_	_	_	Seg=O
115	genotypes	_	_	_	_	_	_	_	Seg=O
116	(	_	_	_	_	_	_	_	Seg=B-seg
117	odds	_	_	_	_	_	_	_	Seg=O
118	ratio	_	_	_	_	_	_	_	Seg=O
119	7.1	_	_	_	_	_	_	_	Seg=O
120	,	_	_	_	_	_	_	_	Seg=O
121	95	_	_	_	_	_	_	_	Seg=O
122	%	_	_	_	_	_	_	_	Seg=O
123	confi	_	_	_	_	_	_	_	Seg=O
124	dence	_	_	_	_	_	_	_	Seg=O
125	interval	_	_	_	_	_	_	_	Seg=O
126	1.6	_	_	_	_	_	_	_	Seg=O
127	-	_	_	_	_	_	_	_	Seg=O
128	32.1	_	_	_	_	_	_	_	Seg=O
129	)	_	_	_	_	_	_	_	Seg=O
130	.	_	_	_	_	_	_	_	Seg=O
131	Limited	_	_	_	_	_	_	_	Seg=B-seg
132	analysis	_	_	_	_	_	_	_	Seg=O
133	of	_	_	_	_	_	_	_	Seg=O
134	2	_	_	_	_	_	_	_	Seg=O
135	genes	_	_	_	_	_	_	_	Seg=O
136	important	_	_	_	_	_	_	_	Seg=O
137	to	_	_	_	_	_	_	_	Seg=O
138	the	_	_	_	_	_	_	_	Seg=O
139	innate	_	_	_	_	_	_	_	Seg=O
140	immune	_	_	_	_	_	_	_	Seg=O
141	response	_	_	_	_	_	_	_	Seg=O
142	found	_	_	_	_	_	_	_	Seg=O
143	no	_	_	_	_	_	_	_	Seg=O
144	association	_	_	_	_	_	_	_	Seg=O
145	between	_	_	_	_	_	_	_	Seg=O
146	genetic	_	_	_	_	_	_	_	Seg=O
147	variants	_	_	_	_	_	_	_	Seg=O
148	and	_	_	_	_	_	_	_	Seg=O
149	fatal	_	_	_	_	_	_	_	Seg=O
150	infl	_	_	_	_	_	_	_	Seg=O
151	uenza	_	_	_	_	_	_	_	Seg=O
152	infection	_	_	_	_	_	_	_	Seg=O
153	.	_	_	_	_	_	_	_	Seg=O
154	Among	_	_	_	_	_	_	_	Seg=B-seg
155	children	_	_	_	_	_	_	_	Seg=O
156	and	_	_	_	_	_	_	_	Seg=O
157	young	_	_	_	_	_	_	_	Seg=O
158	adults	_	_	_	_	_	_	_	Seg=O
159	who	_	_	_	_	_	_	_	Seg=B-seg
160	died	_	_	_	_	_	_	_	Seg=O
161	of	_	_	_	_	_	_	_	Seg=O
162	infl	_	_	_	_	_	_	_	Seg=O
163	uenza	_	_	_	_	_	_	_	Seg=O
164	,	_	_	_	_	_	_	_	Seg=O
165	low	_	_	_	_	_	_	_	Seg=B-seg
166	-	_	_	_	_	_	_	_	Seg=O
167	producing	_	_	_	_	_	_	_	Seg=O
168	MBL2	_	_	_	_	_	_	_	Seg=O
169	genotypes	_	_	_	_	_	_	_	Seg=O
170	may	_	_	_	_	_	_	_	Seg=O
171	have	_	_	_	_	_	_	_	Seg=O
172	increased	_	_	_	_	_	_	_	Seg=O
173	risk	_	_	_	_	_	_	_	Seg=O
174	for	_	_	_	_	_	_	_	Seg=O
175	MRSA	_	_	_	_	_	_	_	Seg=O
176	co	_	_	_	_	_	_	_	Seg=O
177	-	_	_	_	_	_	_	_	Seg=O
178	infection	_	_	_	_	_	_	_	Seg=O
179	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 61bd28fd5d95c6873aa7644a692e7a191326df44
1	Digital	_	_	_	_	_	_	_	Seg=B-seg
2	contact	_	_	_	_	_	_	_	Seg=O
3	tracing	_	_	_	_	_	_	_	Seg=O
4	applications	_	_	_	_	_	_	_	Seg=O
5	are	_	_	_	_	_	_	_	Seg=O
6	being	_	_	_	_	_	_	_	Seg=O
7	developed	_	_	_	_	_	_	_	Seg=O
8	by	_	_	_	_	_	_	_	Seg=O
9	governments	_	_	_	_	_	_	_	Seg=O
10	across	_	_	_	_	_	_	_	Seg=O
11	the	_	_	_	_	_	_	_	Seg=O
12	world	_	_	_	_	_	_	_	Seg=O
13	,	_	_	_	_	_	_	_	Seg=O
14	to	_	_	_	_	_	_	_	Seg=B-seg
15	track	_	_	_	_	_	_	_	Seg=O
16	and	_	_	_	_	_	_	_	Seg=O
17	trace	_	_	_	_	_	_	_	Seg=O
18	contacts	_	_	_	_	_	_	_	Seg=O
19	.	_	_	_	_	_	_	_	Seg=O
20	With	_	_	_	_	_	_	_	Seg=B-seg
21	little	_	_	_	_	_	_	_	Seg=O
22	evidence	_	_	_	_	_	_	_	Seg=O
23	,	_	_	_	_	_	_	_	Seg=O
24	citizens	_	_	_	_	_	_	_	Seg=O
25	are	_	_	_	_	_	_	_	Seg=O
26	being	_	_	_	_	_	_	_	Seg=O
27	forced	_	_	_	_	_	_	_	Seg=O
28	and	_	_	_	_	_	_	_	Seg=O
29	made	_	_	_	_	_	_	_	Seg=O
30	to	_	_	_	_	_	_	_	Seg=O
31	believe	_	_	_	_	_	_	_	Seg=O
32	that	_	_	_	_	_	_	_	Seg=B-seg
33	it	_	_	_	_	_	_	_	Seg=O
34	is	_	_	_	_	_	_	_	Seg=O
35	an	_	_	_	_	_	_	_	Seg=O
36	important	_	_	_	_	_	_	_	Seg=O
37	step	_	_	_	_	_	_	_	Seg=O
38	in	_	_	_	_	_	_	_	Seg=O
39	pandemic	_	_	_	_	_	_	_	Seg=O
40	control	_	_	_	_	_	_	_	Seg=O
41	.	_	_	_	_	_	_	_	Seg=O
42	We	_	_	_	_	_	_	_	Seg=B-seg
43	discuss	_	_	_	_	_	_	_	Seg=O
44	briefly	_	_	_	_	_	_	_	Seg=O
45	if	_	_	_	_	_	_	_	Seg=B-seg
46	contact	_	_	_	_	_	_	_	Seg=O
47	tracing	_	_	_	_	_	_	_	Seg=O
48	will	_	_	_	_	_	_	_	Seg=O
49	be	_	_	_	_	_	_	_	Seg=O
50	successful	_	_	_	_	_	_	_	Seg=O
51	in	_	_	_	_	_	_	_	Seg=O
52	the	_	_	_	_	_	_	_	Seg=O
53	control	_	_	_	_	_	_	_	Seg=O
54	of	_	_	_	_	_	_	_	Seg=O
55	the	_	_	_	_	_	_	_	Seg=O
56	Corona	_	_	_	_	_	_	_	Seg=O
57	virus	_	_	_	_	_	_	_	Seg=O
58	pandemic	_	_	_	_	_	_	_	Seg=O
59	or	_	_	_	_	_	_	_	Seg=B-seg
60	is	_	_	_	_	_	_	_	Seg=O
61	it	_	_	_	_	_	_	_	Seg=O
62	just	_	_	_	_	_	_	_	Seg=O
63	a	_	_	_	_	_	_	_	Seg=O
64	tool	_	_	_	_	_	_	_	Seg=O
65	governments	_	_	_	_	_	_	_	Seg=B-seg
66	are	_	_	_	_	_	_	_	Seg=O
67	using	_	_	_	_	_	_	_	Seg=O
68	to	_	_	_	_	_	_	_	Seg=B-seg
69	cover	_	_	_	_	_	_	_	Seg=O
70	their	_	_	_	_	_	_	_	Seg=O
71	helplessness	_	_	_	_	_	_	_	Seg=O
72	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 62eb733bffcf9bbbe0eebb0a85133e1b0692525b
1	One	_	_	_	_	_	_	_	Seg=B-seg
2	hundred	_	_	_	_	_	_	_	Seg=O
3	and	_	_	_	_	_	_	_	Seg=O
4	sixty	_	_	_	_	_	_	_	Seg=O
5	-	_	_	_	_	_	_	_	Seg=O
6	eight	_	_	_	_	_	_	_	Seg=O
7	ganglia	_	_	_	_	_	_	_	Seg=O
8	from	_	_	_	_	_	_	_	Seg=O
9	54	_	_	_	_	_	_	_	Seg=O
10	cattle	_	_	_	_	_	_	_	Seg=O
11	aged	_	_	_	_	_	_	_	Seg=B-seg
12	10	_	_	_	_	_	_	_	Seg=O
13	days	_	_	_	_	_	_	_	Seg=O
14	to	_	_	_	_	_	_	_	Seg=O
15	10	_	_	_	_	_	_	_	Seg=O
16	years	_	_	_	_	_	_	_	Seg=O
17	were	_	_	_	_	_	_	_	Seg=B-seg
18	examined	_	_	_	_	_	_	_	Seg=O
19	microscopically	_	_	_	_	_	_	_	Seg=O
20	.	_	_	_	_	_	_	_	Seg=O
21	Samples	_	_	_	_	_	_	_	Seg=B-seg
22	from	_	_	_	_	_	_	_	Seg=O
23	six	_	_	_	_	_	_	_	Seg=O
24	autonomic	_	_	_	_	_	_	_	Seg=O
25	ganglia	_	_	_	_	_	_	_	Seg=O
26	and	_	_	_	_	_	_	_	Seg=O
27	one	_	_	_	_	_	_	_	Seg=O
28	sensory	_	_	_	_	_	_	_	Seg=O
29	ganglion	_	_	_	_	_	_	_	Seg=O
30	were	_	_	_	_	_	_	_	Seg=O
31	represented	_	_	_	_	_	_	_	Seg=O
32	.	_	_	_	_	_	_	_	Seg=O
33	Thirteen	_	_	_	_	_	_	_	Seg=B-seg
34	animals	_	_	_	_	_	_	_	Seg=O
35	were	_	_	_	_	_	_	_	Seg=O
36	clinically	_	_	_	_	_	_	_	Seg=O
37	normal	_	_	_	_	_	_	_	Seg=O
38	and	_	_	_	_	_	_	_	Seg=B-seg
39	41	_	_	_	_	_	_	_	Seg=O
40	were	_	_	_	_	_	_	_	Seg=O
41	submitted	_	_	_	_	_	_	_	Seg=O
42	for	_	_	_	_	_	_	_	Seg=O
43	post	_	_	_	_	_	_	_	Seg=O
44	-	_	_	_	_	_	_	_	Seg=O
45	mortem	_	_	_	_	_	_	_	Seg=O
46	examination	_	_	_	_	_	_	_	Seg=O
47	.	_	_	_	_	_	_	_	Seg=O
48	Neuronal	_	_	_	_	_	_	_	Seg=B-seg
49	vacuolation	_	_	_	_	_	_	_	Seg=O
50	,	_	_	_	_	_	_	_	Seg=O
51	spheroid	_	_	_	_	_	_	_	Seg=O
52	formation	_	_	_	_	_	_	_	Seg=O
53	,	_	_	_	_	_	_	_	Seg=O
54	lipofuscin	_	_	_	_	_	_	_	Seg=O
55	accumulation	_	_	_	_	_	_	_	Seg=O
56	and	_	_	_	_	_	_	_	Seg=O
57	central	_	_	_	_	_	_	_	Seg=O
58	chromatolysis	_	_	_	_	_	_	_	Seg=O
59	were	_	_	_	_	_	_	_	Seg=O
60	observed	_	_	_	_	_	_	_	Seg=O
61	sporadically	_	_	_	_	_	_	_	Seg=O
62	and	_	_	_	_	_	_	_	Seg=B-seg
63	were	_	_	_	_	_	_	_	Seg=O
64	of	_	_	_	_	_	_	_	Seg=O
65	varying	_	_	_	_	_	_	_	Seg=O
66	magnitude	_	_	_	_	_	_	_	Seg=O
67	.	_	_	_	_	_	_	_	Seg=O
68	Neuronal	_	_	_	_	_	_	_	Seg=B-seg
69	vacuolation	_	_	_	_	_	_	_	Seg=O
70	and	_	_	_	_	_	_	_	Seg=O
71	spheroid	_	_	_	_	_	_	_	Seg=O
72	formation	_	_	_	_	_	_	_	Seg=O
73	were	_	_	_	_	_	_	_	Seg=O
74	not	_	_	_	_	_	_	_	Seg=O
75	age	_	_	_	_	_	_	_	Seg=O
76	-	_	_	_	_	_	_	_	Seg=O
77	related	_	_	_	_	_	_	_	Seg=O
78	changes	_	_	_	_	_	_	_	Seg=O
79	,	_	_	_	_	_	_	_	Seg=O
80	while	_	_	_	_	_	_	_	Seg=B-seg
81	lipofuscin	_	_	_	_	_	_	_	Seg=O
82	accumulation	_	_	_	_	_	_	_	Seg=O
83	was	_	_	_	_	_	_	_	Seg=O
84	more	_	_	_	_	_	_	_	Seg=O
85	common	_	_	_	_	_	_	_	Seg=O
86	in	_	_	_	_	_	_	_	Seg=O
87	older	_	_	_	_	_	_	_	Seg=O
88	animals	_	_	_	_	_	_	_	Seg=O
89	and	_	_	_	_	_	_	_	Seg=B-seg
90	central	_	_	_	_	_	_	_	Seg=O
91	chromatolysis	_	_	_	_	_	_	_	Seg=O
92	was	_	_	_	_	_	_	_	Seg=O
93	more	_	_	_	_	_	_	_	Seg=O
94	common	_	_	_	_	_	_	_	Seg=O
95	in	_	_	_	_	_	_	_	Seg=O
96	younger	_	_	_	_	_	_	_	Seg=O
97	cattle	_	_	_	_	_	_	_	Seg=O
98	.	_	_	_	_	_	_	_	Seg=O
99	Nonsuppurative	_	_	_	_	_	_	_	Seg=B-seg
100	inflammation	_	_	_	_	_	_	_	Seg=O
101	and	_	_	_	_	_	_	_	Seg=O
102	neuronophagia	_	_	_	_	_	_	_	Seg=O
103	were	_	_	_	_	_	_	_	Seg=O
104	also	_	_	_	_	_	_	_	Seg=O
105	common	_	_	_	_	_	_	_	Seg=O
106	findings	_	_	_	_	_	_	_	Seg=O
107	(	_	_	_	_	_	_	_	Seg=B-seg
108	23	_	_	_	_	_	_	_	Seg=O
109	out	_	_	_	_	_	_	_	Seg=O
110	of	_	_	_	_	_	_	_	Seg=O
111	54	_	_	_	_	_	_	_	Seg=O
112	animals	_	_	_	_	_	_	_	Seg=O
113	,	_	_	_	_	_	_	_	Seg=O
114	42.6	_	_	_	_	_	_	_	Seg=O
115	%	_	_	_	_	_	_	_	Seg=O
116	)	_	_	_	_	_	_	_	Seg=O
117	in	_	_	_	_	_	_	_	Seg=B-seg
118	autonomic	_	_	_	_	_	_	_	Seg=O
119	ganglia	_	_	_	_	_	_	_	Seg=O
120	that	_	_	_	_	_	_	_	Seg=B-seg
121	did	_	_	_	_	_	_	_	Seg=O
122	not	_	_	_	_	_	_	_	Seg=O
123	contain	_	_	_	_	_	_	_	Seg=O
124	herpesvirus	_	_	_	_	_	_	_	Seg=O
125	DNA	_	_	_	_	_	_	_	Seg=O
126	as	_	_	_	_	_	_	_	Seg=B-seg
127	determined	_	_	_	_	_	_	_	Seg=O
128	by	_	_	_	_	_	_	_	Seg=O
129	polymerase	_	_	_	_	_	_	_	Seg=O
130	chain	_	_	_	_	_	_	_	Seg=O
131	reaction	_	_	_	_	_	_	_	Seg=O
132	.	_	_	_	_	_	_	_	Seg=O
133	Renaut	_	_	_	_	_	_	_	Seg=B-seg
134	bodies	_	_	_	_	_	_	_	Seg=O
135	,	_	_	_	_	_	_	_	Seg=O
136	features	_	_	_	_	_	_	_	Seg=O
137	of	_	_	_	_	_	_	_	Seg=O
138	peripheral	_	_	_	_	_	_	_	Seg=O
139	nerves	_	_	_	_	_	_	_	Seg=O
140	,	_	_	_	_	_	_	_	Seg=O
141	were	_	_	_	_	_	_	_	Seg=O
142	most	_	_	_	_	_	_	_	Seg=O
143	commonly	_	_	_	_	_	_	_	Seg=O
144	noted	_	_	_	_	_	_	_	Seg=O
145	in	_	_	_	_	_	_	_	Seg=O
146	the	_	_	_	_	_	_	_	Seg=O
147	vagus	_	_	_	_	_	_	_	Seg=O
148	.	_	_	_	_	_	_	_	Seg=O
149	None	_	_	_	_	_	_	_	Seg=B-seg
150	of	_	_	_	_	_	_	_	Seg=O
151	the	_	_	_	_	_	_	_	Seg=O
152	histopathological	_	_	_	_	_	_	_	Seg=O
153	findings	_	_	_	_	_	_	_	Seg=O
154	were	_	_	_	_	_	_	_	Seg=O
155	related	_	_	_	_	_	_	_	Seg=O
156	to	_	_	_	_	_	_	_	Seg=O
157	any	_	_	_	_	_	_	_	Seg=O
158	particular	_	_	_	_	_	_	_	Seg=O
159	disease	_	_	_	_	_	_	_	Seg=O
160	in	_	_	_	_	_	_	_	Seg=B-seg
161	which	_	_	_	_	_	_	_	Seg=O
162	loss	_	_	_	_	_	_	_	Seg=O
163	of	_	_	_	_	_	_	_	Seg=O
164	autonomic	_	_	_	_	_	_	_	Seg=O
165	nervous	_	_	_	_	_	_	_	Seg=O
166	system	_	_	_	_	_	_	_	Seg=O
167	function	_	_	_	_	_	_	_	Seg=O
168	might	_	_	_	_	_	_	_	Seg=O
169	be	_	_	_	_	_	_	_	Seg=O
170	expected	_	_	_	_	_	_	_	Seg=O
171	.	_	_	_	_	_	_	_	Seg=O
172	Furthermore	_	_	_	_	_	_	_	Seg=B-seg
173	,	_	_	_	_	_	_	_	Seg=O
174	all	_	_	_	_	_	_	_	Seg=O
175	changes	_	_	_	_	_	_	_	Seg=O
176	were	_	_	_	_	_	_	_	Seg=O
177	as	_	_	_	_	_	_	_	Seg=O
178	common	_	_	_	_	_	_	_	Seg=O
179	in	_	_	_	_	_	_	_	Seg=O
180	clinically	_	_	_	_	_	_	_	Seg=O
181	normal	_	_	_	_	_	_	_	Seg=O
182	animals	_	_	_	_	_	_	_	Seg=O
183	as	_	_	_	_	_	_	_	Seg=O
184	in	_	_	_	_	_	_	_	Seg=O
185	animals	_	_	_	_	_	_	_	Seg=O
186	with	_	_	_	_	_	_	_	Seg=O
187	disease	_	_	_	_	_	_	_	Seg=O
188	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 63751161a879bf0d284633c4364091ae729003ec
1	Globalization	_	_	_	_	_	_	_	Seg=B-seg
2	may	_	_	_	_	_	_	_	Seg=O
3	be	_	_	_	_	_	_	_	Seg=O
4	viewed	_	_	_	_	_	_	_	Seg=O
5	as	_	_	_	_	_	_	_	Seg=O
6	the	_	_	_	_	_	_	_	Seg=O
7	growing	_	_	_	_	_	_	_	Seg=O
8	interdependence	_	_	_	_	_	_	_	Seg=O
9	of	_	_	_	_	_	_	_	Seg=O
10	countries	_	_	_	_	_	_	_	Seg=O
11	worldwide	_	_	_	_	_	_	_	Seg=O
12	through	_	_	_	_	_	_	_	Seg=O
13	the	_	_	_	_	_	_	_	Seg=O
14	increasing	_	_	_	_	_	_	_	Seg=O
15	volume	_	_	_	_	_	_	_	Seg=O
16	and	_	_	_	_	_	_	_	Seg=O
17	variety	_	_	_	_	_	_	_	Seg=O
18	of	_	_	_	_	_	_	_	Seg=O
19	cross	_	_	_	_	_	_	_	Seg=O
20	-	_	_	_	_	_	_	_	Seg=O
21	border	_	_	_	_	_	_	_	Seg=O
22	transactions	_	_	_	_	_	_	_	Seg=O
23	in	_	_	_	_	_	_	_	Seg=O
24	goods	_	_	_	_	_	_	_	Seg=O
25	and	_	_	_	_	_	_	_	Seg=O
26	services	_	_	_	_	_	_	_	Seg=O
27	,	_	_	_	_	_	_	_	Seg=O
28	and	_	_	_	_	_	_	_	Seg=O
29	also	_	_	_	_	_	_	_	Seg=O
30	through	_	_	_	_	_	_	_	Seg=O
31	the	_	_	_	_	_	_	_	Seg=O
32	more	_	_	_	_	_	_	_	Seg=O
33	rapid	_	_	_	_	_	_	_	Seg=O
34	and	_	_	_	_	_	_	_	Seg=O
35	widespread	_	_	_	_	_	_	_	Seg=O
36	diffusion	_	_	_	_	_	_	_	Seg=O
37	of	_	_	_	_	_	_	_	Seg=O
38	technology	_	_	_	_	_	_	_	Seg=O
39	.	_	_	_	_	_	_	_	Seg=O
40	Globalization	_	_	_	_	_	_	_	Seg=B-seg
41	is	_	_	_	_	_	_	_	Seg=O
42	not	_	_	_	_	_	_	_	Seg=O
43	just	_	_	_	_	_	_	_	Seg=O
44	an	_	_	_	_	_	_	_	Seg=O
45	economic	_	_	_	_	_	_	_	Seg=O
46	phenomenon	_	_	_	_	_	_	_	Seg=O
47	,	_	_	_	_	_	_	_	Seg=O
48	although	_	_	_	_	_	_	_	Seg=B-seg
49	it	_	_	_	_	_	_	_	Seg=O
50	is	_	_	_	_	_	_	_	Seg=O
51	frequently	_	_	_	_	_	_	_	Seg=O
52	described	_	_	_	_	_	_	_	Seg=O
53	as	_	_	_	_	_	_	_	Seg=O
54	such	_	_	_	_	_	_	_	Seg=O
55	,	_	_	_	_	_	_	_	Seg=O
56	but	_	_	_	_	_	_	_	Seg=B-seg
57	includes	_	_	_	_	_	_	_	Seg=O
58	commerce	_	_	_	_	_	_	_	Seg=O
59	,	_	_	_	_	_	_	_	Seg=O
60	disease	_	_	_	_	_	_	_	Seg=O
61	and	_	_	_	_	_	_	_	Seg=O
62	travel	_	_	_	_	_	_	_	Seg=O
63	,	_	_	_	_	_	_	_	Seg=O
64	and	_	_	_	_	_	_	_	Seg=O
65	immigration	_	_	_	_	_	_	_	Seg=O
66	,	_	_	_	_	_	_	_	Seg=O
67	and	_	_	_	_	_	_	_	Seg=B-seg
68	as	_	_	_	_	_	_	_	Seg=O
69	such	_	_	_	_	_	_	_	Seg=O
70	it	_	_	_	_	_	_	_	Seg=O
71	affects	_	_	_	_	_	_	_	Seg=O
72	blood	_	_	_	_	_	_	_	Seg=O
73	safety	_	_	_	_	_	_	_	Seg=O
74	and	_	_	_	_	_	_	_	Seg=O
75	supply	_	_	_	_	_	_	_	Seg=O
76	in	_	_	_	_	_	_	_	Seg=O
77	various	_	_	_	_	_	_	_	Seg=O
78	ways	_	_	_	_	_	_	_	Seg=O
79	.	_	_	_	_	_	_	_	Seg=O
80	The	_	_	_	_	_	_	_	Seg=B-seg
81	relatively	_	_	_	_	_	_	_	Seg=O
82	short	_	_	_	_	_	_	_	Seg=O
83	travel	_	_	_	_	_	_	_	Seg=O
84	times	_	_	_	_	_	_	_	Seg=O
85	offered	_	_	_	_	_	_	_	Seg=B-seg
86	by	_	_	_	_	_	_	_	Seg=O
87	modern	_	_	_	_	_	_	_	Seg=O
88	aviation	_	_	_	_	_	_	_	Seg=O
89	can	_	_	_	_	_	_	_	Seg=B-seg
90	result	_	_	_	_	_	_	_	Seg=O
91	in	_	_	_	_	_	_	_	Seg=O
92	the	_	_	_	_	_	_	_	Seg=O
93	rapid	_	_	_	_	_	_	_	Seg=O
94	spread	_	_	_	_	_	_	_	Seg=O
95	of	_	_	_	_	_	_	_	Seg=O
96	blood	_	_	_	_	_	_	_	Seg=O
97	-	_	_	_	_	_	_	_	Seg=O
98	borne	_	_	_	_	_	_	_	Seg=O
99	pathogens	_	_	_	_	_	_	_	Seg=O
100	before	_	_	_	_	_	_	_	Seg=B-seg
101	measures	_	_	_	_	_	_	_	Seg=O
102	to	_	_	_	_	_	_	_	Seg=B-seg
103	counteract	_	_	_	_	_	_	_	Seg=O
104	transmission	_	_	_	_	_	_	_	Seg=O
105	can	_	_	_	_	_	_	_	Seg=B-seg
106	be	_	_	_	_	_	_	_	Seg=O
107	put	_	_	_	_	_	_	_	Seg=O
108	in	_	_	_	_	_	_	_	Seg=O
109	place	_	_	_	_	_	_	_	Seg=O
110	;	_	_	_	_	_	_	_	Seg=O
111	this	_	_	_	_	_	_	_	Seg=B-seg
112	would	_	_	_	_	_	_	_	Seg=O
113	have	_	_	_	_	_	_	_	Seg=O
114	happened	_	_	_	_	_	_	_	Seg=O
115	with	_	_	_	_	_	_	_	Seg=O
116	SARS	_	_	_	_	_	_	_	Seg=O
117	if	_	_	_	_	_	_	_	Seg=B-seg
118	the	_	_	_	_	_	_	_	Seg=O
119	basic	_	_	_	_	_	_	_	Seg=O
120	life	_	_	_	_	_	_	_	Seg=O
121	cycle	_	_	_	_	_	_	_	Seg=O
122	of	_	_	_	_	_	_	_	Seg=O
123	the	_	_	_	_	_	_	_	Seg=O
124	SARS	_	_	_	_	_	_	_	Seg=O
125	virus	_	_	_	_	_	_	_	Seg=O
126	did	_	_	_	_	_	_	_	Seg=O
127	not	_	_	_	_	_	_	_	Seg=O
128	include	_	_	_	_	_	_	_	Seg=O
129	an	_	_	_	_	_	_	_	Seg=O
130	asymptomatic	_	_	_	_	_	_	_	Seg=O
131	viraemia	_	_	_	_	_	_	_	Seg=O
132	.	_	_	_	_	_	_	_	Seg=O
133	This	_	_	_	_	_	_	_	Seg=B-seg
134	risk	_	_	_	_	_	_	_	Seg=O
135	can	_	_	_	_	_	_	_	Seg=O
136	be	_	_	_	_	_	_	_	Seg=O
137	amplified	_	_	_	_	_	_	_	Seg=O
138	by	_	_	_	_	_	_	_	Seg=O
139	ecological	_	_	_	_	_	_	_	Seg=O
140	factors	_	_	_	_	_	_	_	Seg=O
141	which	_	_	_	_	_	_	_	Seg=B-seg
142	effect	_	_	_	_	_	_	_	Seg=O
143	the	_	_	_	_	_	_	_	Seg=O
144	spread	_	_	_	_	_	_	_	Seg=O
145	of	_	_	_	_	_	_	_	Seg=O
146	these	_	_	_	_	_	_	_	Seg=O
147	pathogens	_	_	_	_	_	_	_	Seg=O
148	once	_	_	_	_	_	_	_	Seg=B-seg
149	they	_	_	_	_	_	_	_	Seg=O
150	are	_	_	_	_	_	_	_	Seg=O
151	transferred	_	_	_	_	_	_	_	Seg=O
152	to	_	_	_	_	_	_	_	Seg=O
153	a	_	_	_	_	_	_	_	Seg=O
154	naïve	_	_	_	_	_	_	_	Seg=O
155	ecosystem	_	_	_	_	_	_	_	Seg=O
156	,	_	_	_	_	_	_	_	Seg=O
157	as	_	_	_	_	_	_	_	Seg=B-seg
158	happened	_	_	_	_	_	_	_	Seg=O
159	with	_	_	_	_	_	_	_	Seg=O
160	West	_	_	_	_	_	_	_	Seg=O
161	Nile	_	_	_	_	_	_	_	Seg=O
162	virus	_	_	_	_	_	_	_	Seg=O
163	(	_	_	_	_	_	_	_	Seg=O
164	WNV	_	_	_	_	_	_	_	Seg=O
165	)	_	_	_	_	_	_	_	Seg=O
166	in	_	_	_	_	_	_	_	Seg=O
167	North	_	_	_	_	_	_	_	Seg=O
168	America	_	_	_	_	_	_	_	Seg=O
169	.	_	_	_	_	_	_	_	Seg=O
170	The	_	_	_	_	_	_	_	Seg=B-seg
171	rationalization	_	_	_	_	_	_	_	Seg=O
172	and	_	_	_	_	_	_	_	Seg=O
173	contraction	_	_	_	_	_	_	_	Seg=O
174	of	_	_	_	_	_	_	_	Seg=O
175	the	_	_	_	_	_	_	_	Seg=O
176	plasma	_	_	_	_	_	_	_	Seg=O
177	products	_	_	_	_	_	_	_	Seg=O
178	industry	_	_	_	_	_	_	_	Seg=O
179	may	_	_	_	_	_	_	_	Seg=O
180	be	_	_	_	_	_	_	_	Seg=O
181	viewed	_	_	_	_	_	_	_	Seg=O
182	as	_	_	_	_	_	_	_	Seg=O
183	one	_	_	_	_	_	_	_	Seg=O
184	aspect	_	_	_	_	_	_	_	Seg=O
185	of	_	_	_	_	_	_	_	Seg=O
186	globalization	_	_	_	_	_	_	_	Seg=O
187	imposed	_	_	_	_	_	_	_	Seg=B-seg
188	by	_	_	_	_	_	_	_	Seg=O
189	the	_	_	_	_	_	_	_	Seg=O
190	remorseless	_	_	_	_	_	_	_	Seg=O
191	inevitability	_	_	_	_	_	_	_	Seg=O
192	of	_	_	_	_	_	_	_	Seg=O
193	the	_	_	_	_	_	_	_	Seg=O
194	market	_	_	_	_	_	_	_	Seg=O
195	;	_	_	_	_	_	_	_	Seg=O
196	the	_	_	_	_	_	_	_	Seg=B-seg
197	effect	_	_	_	_	_	_	_	Seg=O
198	of	_	_	_	_	_	_	_	Seg=O
199	this	_	_	_	_	_	_	_	Seg=O
200	development	_	_	_	_	_	_	_	Seg=O
201	on	_	_	_	_	_	_	_	Seg=O
202	the	_	_	_	_	_	_	_	Seg=O
203	safety	_	_	_	_	_	_	_	Seg=O
204	and	_	_	_	_	_	_	_	Seg=O
205	supply	_	_	_	_	_	_	_	Seg=O
206	of	_	_	_	_	_	_	_	Seg=O
207	products	_	_	_	_	_	_	_	Seg=O
208	has	_	_	_	_	_	_	_	Seg=O
209	yet	_	_	_	_	_	_	_	Seg=O
210	to	_	_	_	_	_	_	_	Seg=O
211	be	_	_	_	_	_	_	_	Seg=O
212	seen	_	_	_	_	_	_	_	Seg=O
213	,	_	_	_	_	_	_	_	Seg=O
214	but	_	_	_	_	_	_	_	Seg=B-seg
215	the	_	_	_	_	_	_	_	Seg=O
216	oversight	_	_	_	_	_	_	_	Seg=O
217	and	_	_	_	_	_	_	_	Seg=O
218	assurance	_	_	_	_	_	_	_	Seg=O
219	of	_	_	_	_	_	_	_	Seg=O
220	a	_	_	_	_	_	_	_	Seg=O
221	shrinking	_	_	_	_	_	_	_	Seg=O
222	number	_	_	_	_	_	_	_	Seg=O
223	of	_	_	_	_	_	_	_	Seg=O
224	players	_	_	_	_	_	_	_	Seg=O
225	will	_	_	_	_	_	_	_	Seg=O
226	present	_	_	_	_	_	_	_	Seg=O
227	particular	_	_	_	_	_	_	_	Seg=O
228	challenges	_	_	_	_	_	_	_	Seg=O
229	.	_	_	_	_	_	_	_	Seg=O
230	Similarly	_	_	_	_	_	_	_	Seg=B-seg
231	,	_	_	_	_	_	_	_	Seg=O
232	the	_	_	_	_	_	_	_	Seg=O
233	monopolization	_	_	_	_	_	_	_	Seg=O
234	of	_	_	_	_	_	_	_	Seg=O
235	technology	_	_	_	_	_	_	_	Seg=O
236	,	_	_	_	_	_	_	_	Seg=O
237	through	_	_	_	_	_	_	_	Seg=O
238	patent	_	_	_	_	_	_	_	Seg=O
239	enforcement	_	_	_	_	_	_	_	Seg=O
240	which	_	_	_	_	_	_	_	Seg=B-seg
241	puts	_	_	_	_	_	_	_	Seg=O
242	access	_	_	_	_	_	_	_	Seg=O
243	beyond	_	_	_	_	_	_	_	Seg=O
244	the	_	_	_	_	_	_	_	Seg=O
245	reach	_	_	_	_	_	_	_	Seg=O
246	of	_	_	_	_	_	_	_	Seg=O
247	developing	_	_	_	_	_	_	_	Seg=O
248	countries	_	_	_	_	_	_	_	Seg=O
249	,	_	_	_	_	_	_	_	Seg=O
250	can	_	_	_	_	_	_	_	Seg=B-seg
251	have	_	_	_	_	_	_	_	Seg=O
252	an	_	_	_	_	_	_	_	Seg=O
253	effect	_	_	_	_	_	_	_	Seg=O
254	on	_	_	_	_	_	_	_	Seg=O
255	blood	_	_	_	_	_	_	_	Seg=O
256	safety	_	_	_	_	_	_	_	Seg=O
257	.	_	_	_	_	_	_	_	Seg=O
258	The	_	_	_	_	_	_	_	Seg=B-seg
259	challenges	_	_	_	_	_	_	_	Seg=O
260	presented	_	_	_	_	_	_	_	Seg=B-seg
261	to	_	_	_	_	_	_	_	Seg=O
262	blood	_	_	_	_	_	_	_	Seg=O
263	safety	_	_	_	_	_	_	_	Seg=O
264	by	_	_	_	_	_	_	_	Seg=O
265	globalization	_	_	_	_	_	_	_	Seg=O
266	are	_	_	_	_	_	_	_	Seg=B-seg
267	heightening	_	_	_	_	_	_	_	Seg=O
268	the	_	_	_	_	_	_	_	Seg=O
269	tensions	_	_	_	_	_	_	_	Seg=O
270	between	_	_	_	_	_	_	_	Seg=O
271	the	_	_	_	_	_	_	_	Seg=O
272	traditional	_	_	_	_	_	_	_	Seg=O
273	focus	_	_	_	_	_	_	_	Seg=O
274	on	_	_	_	_	_	_	_	Seg=O
275	the	_	_	_	_	_	_	_	Seg=O
276	product	_	_	_	_	_	_	_	Seg=O
277	safety	_	_	_	_	_	_	_	Seg=O
278	-	_	_	_	_	_	_	_	Seg=O
279	zero	_	_	_	_	_	_	_	Seg=O
280	-	_	_	_	_	_	_	_	Seg=O
281	risk	_	_	_	_	_	_	_	Seg=O
282	paradigm	_	_	_	_	_	_	_	Seg=O
283	and	_	_	_	_	_	_	_	Seg=O
284	the	_	_	_	_	_	_	_	Seg=O
285	need	_	_	_	_	_	_	_	Seg=O
286	to	_	_	_	_	_	_	_	Seg=B-seg
287	view	_	_	_	_	_	_	_	Seg=O
288	the	_	_	_	_	_	_	_	Seg=O
289	delivery	_	_	_	_	_	_	_	Seg=O
290	of	_	_	_	_	_	_	_	Seg=O
291	safe	_	_	_	_	_	_	_	Seg=O
292	blood	_	_	_	_	_	_	_	Seg=O
293	as	_	_	_	_	_	_	_	Seg=O
294	an	_	_	_	_	_	_	_	Seg=O
295	integrated	_	_	_	_	_	_	_	Seg=O
296	process	_	_	_	_	_	_	_	Seg=O
297	.	_	_	_	_	_	_	_	Seg=O
298	As	_	_	_	_	_	_	_	Seg=B-seg
299	an	_	_	_	_	_	_	_	Seg=O
300	illustration	_	_	_	_	_	_	_	Seg=O
301	of	_	_	_	_	_	_	_	Seg=O
302	this	_	_	_	_	_	_	_	Seg=O
303	tension	_	_	_	_	_	_	_	Seg=O
304	,	_	_	_	_	_	_	_	Seg=O
305	donor	_	_	_	_	_	_	_	Seg=O
306	deferral	_	_	_	_	_	_	_	Seg=O
307	measures	_	_	_	_	_	_	_	Seg=O
308	imposed	_	_	_	_	_	_	_	Seg=B-seg
309	by	_	_	_	_	_	_	_	Seg=O
310	globalization	_	_	_	_	_	_	_	Seg=O
311	-	_	_	_	_	_	_	_	Seg=O
312	induced	_	_	_	_	_	_	_	Seg=O
313	risks	_	_	_	_	_	_	_	Seg=O
314	such	_	_	_	_	_	_	_	Seg=B-seg
315	as	_	_	_	_	_	_	_	Seg=O
316	vCJD	_	_	_	_	_	_	_	Seg=O
317	and	_	_	_	_	_	_	_	Seg=O
318	WNV	_	_	_	_	_	_	_	Seg=O
319	have	_	_	_	_	_	_	_	Seg=B-seg
320	resulted	_	_	_	_	_	_	_	Seg=O
321	in	_	_	_	_	_	_	_	Seg=O
322	the	_	_	_	_	_	_	_	Seg=O
323	loss	_	_	_	_	_	_	_	Seg=O
324	of	_	_	_	_	_	_	_	Seg=O
325	the	_	_	_	_	_	_	_	Seg=O
326	safest	_	_	_	_	_	_	_	Seg=O
327	and	_	_	_	_	_	_	_	Seg=O
328	most	_	_	_	_	_	_	_	Seg=O
329	committed	_	_	_	_	_	_	_	Seg=O
330	portion	_	_	_	_	_	_	_	Seg=O
331	of	_	_	_	_	_	_	_	Seg=O
332	the	_	_	_	_	_	_	_	Seg=O
333	blood	_	_	_	_	_	_	_	Seg=O
334	donor	_	_	_	_	_	_	_	Seg=O
335	population	_	_	_	_	_	_	_	Seg=O
336	in	_	_	_	_	_	_	_	Seg=O
337	many	_	_	_	_	_	_	_	Seg=O
338	Western	_	_	_	_	_	_	_	Seg=O
339	countries	_	_	_	_	_	_	_	Seg=O
340	,	_	_	_	_	_	_	_	Seg=O
341	leading	_	_	_	_	_	_	_	Seg=B-seg
342	to	_	_	_	_	_	_	_	Seg=O
343	an	_	_	_	_	_	_	_	Seg=O
344	increased	_	_	_	_	_	_	_	Seg=O
345	risk	_	_	_	_	_	_	_	Seg=O
346	to	_	_	_	_	_	_	_	Seg=O
347	safety	_	_	_	_	_	_	_	Seg=O
348	and	_	_	_	_	_	_	_	Seg=O
349	supply	_	_	_	_	_	_	_	Seg=O
350	.	_	_	_	_	_	_	_	Seg=O
351	It	_	_	_	_	_	_	_	Seg=B-seg
352	is	_	_	_	_	_	_	_	Seg=O
353	only	_	_	_	_	_	_	_	Seg=O
354	through	_	_	_	_	_	_	_	Seg=O
355	an	_	_	_	_	_	_	_	Seg=O
356	appreciation	_	_	_	_	_	_	_	Seg=O
357	of	_	_	_	_	_	_	_	Seg=O
358	the	_	_	_	_	_	_	_	Seg=O
359	basic	_	_	_	_	_	_	_	Seg=O
360	needs	_	_	_	_	_	_	_	Seg=O
361	of	_	_	_	_	_	_	_	Seg=O
362	transfusion	_	_	_	_	_	_	_	Seg=O
363	medicine	_	_	_	_	_	_	_	Seg=O
364	,	_	_	_	_	_	_	_	Seg=O
365	including	_	_	_	_	_	_	_	Seg=B-seg
366	the	_	_	_	_	_	_	_	Seg=O
367	enunciation	_	_	_	_	_	_	_	Seg=O
368	of	_	_	_	_	_	_	_	Seg=O
369	appropriate	_	_	_	_	_	_	_	Seg=O
370	principles	_	_	_	_	_	_	_	Seg=O
371	to	_	_	_	_	_	_	_	Seg=B-seg
372	manage	_	_	_	_	_	_	_	Seg=O
373	,	_	_	_	_	_	_	_	Seg=O
374	rather	_	_	_	_	_	_	_	Seg=O
375	than	_	_	_	_	_	_	_	Seg=O
376	eliminate	_	_	_	_	_	_	_	Seg=O
377	,	_	_	_	_	_	_	_	Seg=O
378	risks	_	_	_	_	_	_	_	Seg=O
379	,	_	_	_	_	_	_	_	Seg=O
380	that	_	_	_	_	_	_	_	Seg=B-seg
381	the	_	_	_	_	_	_	_	Seg=O
382	challenges	_	_	_	_	_	_	_	Seg=O
383	imposed	_	_	_	_	_	_	_	Seg=O
384	by	_	_	_	_	_	_	_	Seg=O
385	globalization	_	_	_	_	_	_	_	Seg=O
386	may	_	_	_	_	_	_	_	Seg=O
387	be	_	_	_	_	_	_	_	Seg=O
388	overcome	_	_	_	_	_	_	_	Seg=O
389	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 652a0d29d11f0cf636c350e3a1a8c82c0340bb09
1	In	_	_	_	_	_	_	_	Seg=B-seg
2	this	_	_	_	_	_	_	_	Seg=O
3	study	_	_	_	_	_	_	_	Seg=O
4	,	_	_	_	_	_	_	_	Seg=O
5	we	_	_	_	_	_	_	_	Seg=O
6	explore	_	_	_	_	_	_	_	Seg=O
7	the	_	_	_	_	_	_	_	Seg=O
8	usage	_	_	_	_	_	_	_	Seg=O
9	of	_	_	_	_	_	_	_	Seg=O
10	e	_	_	_	_	_	_	_	Seg=O
11	-	_	_	_	_	_	_	_	Seg=O
12	scooter	_	_	_	_	_	_	_	Seg=O
13	sharing	_	_	_	_	_	_	_	Seg=O
14	services	_	_	_	_	_	_	_	Seg=O
15	in	_	_	_	_	_	_	_	Seg=O
16	Austin	_	_	_	_	_	_	_	Seg=O
17	,	_	_	_	_	_	_	_	Seg=O
18	Texas	_	_	_	_	_	_	_	Seg=O
19	over	_	_	_	_	_	_	_	Seg=O
20	about	_	_	_	_	_	_	_	Seg=O
21	a	_	_	_	_	_	_	_	Seg=O
22	sixmonth	_	_	_	_	_	_	_	Seg=O
23	period	_	_	_	_	_	_	_	Seg=O
24	.	_	_	_	_	_	_	_	Seg=O
25	The	_	_	_	_	_	_	_	Seg=B-seg
26	study	_	_	_	_	_	_	_	Seg=O
27	is	_	_	_	_	_	_	_	Seg=O
28	based	_	_	_	_	_	_	_	Seg=O
29	on	_	_	_	_	_	_	_	Seg=O
30	trip	_	_	_	_	_	_	_	Seg=O
31	records	_	_	_	_	_	_	_	Seg=O
32	of	_	_	_	_	_	_	_	Seg=O
33	all	_	_	_	_	_	_	_	Seg=O
34	the	_	_	_	_	_	_	_	Seg=O
35	shared	_	_	_	_	_	_	_	Seg=O
36	e	_	_	_	_	_	_	_	Seg=O
37	-	_	_	_	_	_	_	_	Seg=O
38	scooter	_	_	_	_	_	_	_	Seg=O
39	operators	_	_	_	_	_	_	_	Seg=O
40	in	_	_	_	_	_	_	_	Seg=O
41	Austin	_	_	_	_	_	_	_	Seg=O
42	and	_	_	_	_	_	_	_	Seg=B-seg
43	includes	_	_	_	_	_	_	_	Seg=O
44	trip	_	_	_	_	_	_	_	Seg=O
45	start	_	_	_	_	_	_	_	Seg=O
46	and	_	_	_	_	_	_	_	Seg=O
47	end	_	_	_	_	_	_	_	Seg=O
48	locations	_	_	_	_	_	_	_	Seg=O
49	.	_	_	_	_	_	_	_	Seg=O
50	We	_	_	_	_	_	_	_	Seg=B-seg
51	use	_	_	_	_	_	_	_	Seg=O
52	both	_	_	_	_	_	_	_	Seg=O
53	analysis	_	_	_	_	_	_	_	Seg=O
54	of	_	_	_	_	_	_	_	Seg=O
55	trip	_	_	_	_	_	_	_	Seg=O
56	patterns	_	_	_	_	_	_	_	Seg=O
57	and	_	_	_	_	_	_	_	Seg=O
58	spatial	_	_	_	_	_	_	_	Seg=O
59	regression	_	_	_	_	_	_	_	Seg=O
60	techniques	_	_	_	_	_	_	_	Seg=O
61	to	_	_	_	_	_	_	_	Seg=B-seg
62	examine	_	_	_	_	_	_	_	Seg=O
63	how	_	_	_	_	_	_	_	Seg=O
64	the	_	_	_	_	_	_	_	Seg=O
65	built	_	_	_	_	_	_	_	Seg=O
66	environment	_	_	_	_	_	_	_	Seg=O
67	,	_	_	_	_	_	_	_	Seg=O
68	land	_	_	_	_	_	_	_	Seg=O
69	use	_	_	_	_	_	_	_	Seg=O
70	,	_	_	_	_	_	_	_	Seg=O
71	and	_	_	_	_	_	_	_	Seg=O
72	demographics	_	_	_	_	_	_	_	Seg=O
73	affect	_	_	_	_	_	_	_	Seg=O
74	escooter	_	_	_	_	_	_	_	Seg=O
75	trip	_	_	_	_	_	_	_	Seg=O
76	generation	_	_	_	_	_	_	_	Seg=O
77	.	_	_	_	_	_	_	_	Seg=O
78	Our	_	_	_	_	_	_	_	Seg=B-seg
79	findings	_	_	_	_	_	_	_	Seg=O
80	show	_	_	_	_	_	_	_	Seg=O
81	that	_	_	_	_	_	_	_	Seg=B-seg
82	people	_	_	_	_	_	_	_	Seg=O
83	use	_	_	_	_	_	_	_	Seg=O
84	e	_	_	_	_	_	_	_	Seg=O
85	-	_	_	_	_	_	_	_	Seg=O
86	scooters	_	_	_	_	_	_	_	Seg=O
87	almost	_	_	_	_	_	_	_	Seg=O
88	exclusively	_	_	_	_	_	_	_	Seg=O
89	in	_	_	_	_	_	_	_	Seg=O
90	central	_	_	_	_	_	_	_	Seg=O
91	Austin	_	_	_	_	_	_	_	Seg=O
92	.	_	_	_	_	_	_	_	Seg=O
93	Commuting	_	_	_	_	_	_	_	Seg=B-seg
94	does	_	_	_	_	_	_	_	Seg=O
95	not	_	_	_	_	_	_	_	Seg=O
96	seem	_	_	_	_	_	_	_	Seg=O
97	to	_	_	_	_	_	_	_	Seg=O
98	be	_	_	_	_	_	_	_	Seg=O
99	the	_	_	_	_	_	_	_	Seg=O
100	main	_	_	_	_	_	_	_	Seg=O
101	trip	_	_	_	_	_	_	_	Seg=O
102	purpose	_	_	_	_	_	_	_	Seg=O
103	,	_	_	_	_	_	_	_	Seg=O
104	and	_	_	_	_	_	_	_	Seg=B-seg
105	usage	_	_	_	_	_	_	_	Seg=O
106	of	_	_	_	_	_	_	_	Seg=O
107	e	_	_	_	_	_	_	_	Seg=O
108	-	_	_	_	_	_	_	_	Seg=O
109	scooters	_	_	_	_	_	_	_	Seg=O
110	is	_	_	_	_	_	_	_	Seg=O
111	associated	_	_	_	_	_	_	_	Seg=O
112	with	_	_	_	_	_	_	_	Seg=O
113	areas	_	_	_	_	_	_	_	Seg=O
114	with	_	_	_	_	_	_	_	Seg=O
115	high	_	_	_	_	_	_	_	Seg=O
116	employment	_	_	_	_	_	_	_	Seg=O
117	rates	_	_	_	_	_	_	_	Seg=O
118	,	_	_	_	_	_	_	_	Seg=O
119	and	_	_	_	_	_	_	_	Seg=O
120	in	_	_	_	_	_	_	_	Seg=O
121	areas	_	_	_	_	_	_	_	Seg=O
122	with	_	_	_	_	_	_	_	Seg=O
123	bicycle	_	_	_	_	_	_	_	Seg=O
124	infrastructure	_	_	_	_	_	_	_	Seg=O
125	.	_	_	_	_	_	_	_	Seg=O
126	People	_	_	_	_	_	_	_	Seg=B-seg
127	use	_	_	_	_	_	_	_	Seg=O
128	e	_	_	_	_	_	_	_	Seg=O
129	-	_	_	_	_	_	_	_	Seg=O
130	scooter	_	_	_	_	_	_	_	Seg=O
131	sharing	_	_	_	_	_	_	_	Seg=O
132	regardless	_	_	_	_	_	_	_	Seg=B-seg
133	of	_	_	_	_	_	_	_	Seg=O
134	the	_	_	_	_	_	_	_	Seg=O
135	affluence	_	_	_	_	_	_	_	Seg=O
136	of	_	_	_	_	_	_	_	Seg=O
137	the	_	_	_	_	_	_	_	Seg=O
138	neighborhood	_	_	_	_	_	_	_	Seg=O
139	,	_	_	_	_	_	_	_	Seg=O
140	although	_	_	_	_	_	_	_	Seg=B-seg
141	less	_	_	_	_	_	_	_	Seg=O
142	affluent	_	_	_	_	_	_	_	Seg=O
143	areas	_	_	_	_	_	_	_	Seg=O
144	with	_	_	_	_	_	_	_	Seg=O
145	high	_	_	_	_	_	_	_	Seg=O
146	usage	_	_	_	_	_	_	_	Seg=O
147	rates	_	_	_	_	_	_	_	Seg=O
148	have	_	_	_	_	_	_	_	Seg=O
149	large	_	_	_	_	_	_	_	Seg=O
150	student	_	_	_	_	_	_	_	Seg=O
151	populations	_	_	_	_	_	_	_	Seg=O
152	,	_	_	_	_	_	_	_	Seg=O
153	suggesting	_	_	_	_	_	_	_	Seg=B-seg
154	that	_	_	_	_	_	_	_	Seg=B-seg
155	students	_	_	_	_	_	_	_	Seg=O
156	use	_	_	_	_	_	_	_	Seg=O
157	this	_	_	_	_	_	_	_	Seg=O
158	mode	_	_	_	_	_	_	_	Seg=O
159	of	_	_	_	_	_	_	_	Seg=O
160	travel	_	_	_	_	_	_	_	Seg=O
161	.	_	_	_	_	_	_	_	Seg=O
162	Implications	_	_	_	_	_	_	_	Seg=B-seg
163	for	_	_	_	_	_	_	_	Seg=O
164	planners	_	_	_	_	_	_	_	Seg=O
165	suggest	_	_	_	_	_	_	_	Seg=O
166	that	_	_	_	_	_	_	_	Seg=B-seg
167	better	_	_	_	_	_	_	_	Seg=O
168	bicycle	_	_	_	_	_	_	_	Seg=O
169	infrastructure	_	_	_	_	_	_	_	Seg=O
170	will	_	_	_	_	_	_	_	Seg=O
171	facilitate	_	_	_	_	_	_	_	Seg=O
172	e	_	_	_	_	_	_	_	Seg=O
173	-	_	_	_	_	_	_	_	Seg=O
174	scooter	_	_	_	_	_	_	_	Seg=O
175	usage	_	_	_	_	_	_	_	Seg=O
176	,	_	_	_	_	_	_	_	Seg=O
177	college	_	_	_	_	_	_	_	Seg=B-seg
178	towns	_	_	_	_	_	_	_	Seg=O
179	are	_	_	_	_	_	_	_	Seg=O
180	a	_	_	_	_	_	_	_	Seg=O
181	ready	_	_	_	_	_	_	_	Seg=O
182	market	_	_	_	_	_	_	_	Seg=O
183	for	_	_	_	_	_	_	_	Seg=O
184	e	_	_	_	_	_	_	_	Seg=O
185	-	_	_	_	_	_	_	_	Seg=O
186	scooter	_	_	_	_	_	_	_	Seg=O
187	sharing	_	_	_	_	_	_	_	Seg=O
188	services	_	_	_	_	_	_	_	Seg=O
189	,	_	_	_	_	_	_	_	Seg=O
190	and	_	_	_	_	_	_	_	Seg=B-seg
191	e	_	_	_	_	_	_	_	Seg=O
192	-	_	_	_	_	_	_	_	Seg=O
193	scooters	_	_	_	_	_	_	_	Seg=O
194	may	_	_	_	_	_	_	_	Seg=O
195	be	_	_	_	_	_	_	_	Seg=O
196	a	_	_	_	_	_	_	_	Seg=O
197	substitute	_	_	_	_	_	_	_	Seg=O
198	for	_	_	_	_	_	_	_	Seg=O
199	some	_	_	_	_	_	_	_	Seg=O
200	short	_	_	_	_	_	_	_	Seg=O
201	non	_	_	_	_	_	_	_	Seg=O
202	-	_	_	_	_	_	_	_	Seg=O
203	work	_	_	_	_	_	_	_	Seg=O
204	trips	_	_	_	_	_	_	_	Seg=O
205	,	_	_	_	_	_	_	_	Seg=O
206	reducing	_	_	_	_	_	_	_	Seg=B-seg
207	car	_	_	_	_	_	_	_	Seg=O
208	usage	_	_	_	_	_	_	_	Seg=O
209	,	_	_	_	_	_	_	_	Seg=O
210	and	_	_	_	_	_	_	_	Seg=B-seg
211	benefiting	_	_	_	_	_	_	_	Seg=O
212	the	_	_	_	_	_	_	_	Seg=O
213	environment	_	_	_	_	_	_	_	Seg=O
214	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 6726c162b4f4584114ad508ebfb14a3726ff2837
1	Genomics	_	_	_	_	_	_	_	Seg=B-seg
2	-	_	_	_	_	_	_	_	Seg=O
3	based	_	_	_	_	_	_	_	Seg=O
4	neoantigen	_	_	_	_	_	_	_	Seg=O
5	discovery	_	_	_	_	_	_	_	Seg=O
6	can	_	_	_	_	_	_	_	Seg=O
7	be	_	_	_	_	_	_	_	Seg=O
8	enhanced	_	_	_	_	_	_	_	Seg=O
9	by	_	_	_	_	_	_	_	Seg=O
10	proteomic	_	_	_	_	_	_	_	Seg=O
11	evidence	_	_	_	_	_	_	_	Seg=O
12	,	_	_	_	_	_	_	_	Seg=O
13	but	_	_	_	_	_	_	_	Seg=B-seg
14	there	_	_	_	_	_	_	_	Seg=O
15	remains	_	_	_	_	_	_	_	Seg=O
16	a	_	_	_	_	_	_	_	Seg=O
17	lack	_	_	_	_	_	_	_	Seg=O
18	of	_	_	_	_	_	_	_	Seg=O
19	consensus	_	_	_	_	_	_	_	Seg=O
20	on	_	_	_	_	_	_	_	Seg=O
21	the	_	_	_	_	_	_	_	Seg=O
22	performance	_	_	_	_	_	_	_	Seg=O
23	of	_	_	_	_	_	_	_	Seg=O
24	different	_	_	_	_	_	_	_	Seg=O
25	quality	_	_	_	_	_	_	_	Seg=O
26	control	_	_	_	_	_	_	_	Seg=O
27	methods	_	_	_	_	_	_	_	Seg=O
28	for	_	_	_	_	_	_	_	Seg=O
29	variant	_	_	_	_	_	_	_	Seg=O
30	peptide	_	_	_	_	_	_	_	Seg=O
31	identification	_	_	_	_	_	_	_	Seg=O
32	in	_	_	_	_	_	_	_	Seg=O
33	proteogenomics	_	_	_	_	_	_	_	Seg=O
34	.	_	_	_	_	_	_	_	Seg=O
35	We	_	_	_	_	_	_	_	Seg=B-seg
36	propose	_	_	_	_	_	_	_	Seg=O
37	to	_	_	_	_	_	_	_	Seg=O
38	use	_	_	_	_	_	_	_	Seg=O
39	the	_	_	_	_	_	_	_	Seg=O
40	difference	_	_	_	_	_	_	_	Seg=O
41	between	_	_	_	_	_	_	_	Seg=O
42	accurately	_	_	_	_	_	_	_	Seg=O
43	predicted	_	_	_	_	_	_	_	Seg=O
44	and	_	_	_	_	_	_	_	Seg=O
45	observed	_	_	_	_	_	_	_	Seg=O
46	retention	_	_	_	_	_	_	_	Seg=O
47	times	_	_	_	_	_	_	_	Seg=O
48	for	_	_	_	_	_	_	_	Seg=O
49	each	_	_	_	_	_	_	_	Seg=O
50	peptide	_	_	_	_	_	_	_	Seg=O
51	as	_	_	_	_	_	_	_	Seg=O
52	a	_	_	_	_	_	_	_	Seg=O
53	metric	_	_	_	_	_	_	_	Seg=O
54	to	_	_	_	_	_	_	_	Seg=B-seg
55	evaluate	_	_	_	_	_	_	_	Seg=O
56	different	_	_	_	_	_	_	_	Seg=O
57	quality	_	_	_	_	_	_	_	Seg=O
58	control	_	_	_	_	_	_	_	Seg=O
59	methods	_	_	_	_	_	_	_	Seg=O
60	.	_	_	_	_	_	_	_	Seg=O
61	To	_	_	_	_	_	_	_	Seg=B-seg
62	this	_	_	_	_	_	_	_	Seg=O
63	end	_	_	_	_	_	_	_	Seg=O
64	,	_	_	_	_	_	_	_	Seg=O
65	we	_	_	_	_	_	_	_	Seg=O
66	develop	_	_	_	_	_	_	_	Seg=O
67	AutoRT	_	_	_	_	_	_	_	Seg=O
68	,	_	_	_	_	_	_	_	Seg=O
69	a	_	_	_	_	_	_	_	Seg=B-seg
70	deep	_	_	_	_	_	_	_	Seg=O
71	learning	_	_	_	_	_	_	_	Seg=O
72	algorithm	_	_	_	_	_	_	_	Seg=O
73	with	_	_	_	_	_	_	_	Seg=O
74	high	_	_	_	_	_	_	_	Seg=O
75	accuracy	_	_	_	_	_	_	_	Seg=O
76	in	_	_	_	_	_	_	_	Seg=O
77	retention	_	_	_	_	_	_	_	Seg=O
78	time	_	_	_	_	_	_	_	Seg=O
79	prediction	_	_	_	_	_	_	_	Seg=O
80	.	_	_	_	_	_	_	_	Seg=O
81	Analysis	_	_	_	_	_	_	_	Seg=B-seg
82	of	_	_	_	_	_	_	_	Seg=O
83	three	_	_	_	_	_	_	_	Seg=O
84	cancer	_	_	_	_	_	_	_	Seg=O
85	data	_	_	_	_	_	_	_	Seg=O
86	sets	_	_	_	_	_	_	_	Seg=O
87	with	_	_	_	_	_	_	_	Seg=O
88	a	_	_	_	_	_	_	_	Seg=O
89	total	_	_	_	_	_	_	_	Seg=O
90	of	_	_	_	_	_	_	_	Seg=O
91	287	_	_	_	_	_	_	_	Seg=O
92	tumor	_	_	_	_	_	_	_	Seg=O
93	samples	_	_	_	_	_	_	_	Seg=O
94	using	_	_	_	_	_	_	_	Seg=B-seg
95	different	_	_	_	_	_	_	_	Seg=O
96	quality	_	_	_	_	_	_	_	Seg=O
97	control	_	_	_	_	_	_	_	Seg=O
98	strategies	_	_	_	_	_	_	_	Seg=O
99	results	_	_	_	_	_	_	_	Seg=B-seg
100	in	_	_	_	_	_	_	_	Seg=O
101	substantially	_	_	_	_	_	_	_	Seg=O
102	different	_	_	_	_	_	_	_	Seg=O
103	numbers	_	_	_	_	_	_	_	Seg=O
104	of	_	_	_	_	_	_	_	Seg=O
105	identified	_	_	_	_	_	_	_	Seg=O
106	variant	_	_	_	_	_	_	_	Seg=O
107	peptides	_	_	_	_	_	_	_	Seg=O
108	and	_	_	_	_	_	_	_	Seg=O
109	putative	_	_	_	_	_	_	_	Seg=O
110	neoantigens	_	_	_	_	_	_	_	Seg=O
111	.	_	_	_	_	_	_	_	Seg=O
112	Our	_	_	_	_	_	_	_	Seg=B-seg
113	systematic	_	_	_	_	_	_	_	Seg=O
114	evaluation	_	_	_	_	_	_	_	Seg=O
115	,	_	_	_	_	_	_	_	Seg=O
116	using	_	_	_	_	_	_	_	Seg=B-seg
117	the	_	_	_	_	_	_	_	Seg=O
118	proposed	_	_	_	_	_	_	_	Seg=O
119	retention	_	_	_	_	_	_	_	Seg=O
120	time	_	_	_	_	_	_	_	Seg=O
121	metric	_	_	_	_	_	_	_	Seg=O
122	,	_	_	_	_	_	_	_	Seg=O
123	provides	_	_	_	_	_	_	_	Seg=B-seg
124	insights	_	_	_	_	_	_	_	Seg=O
125	and	_	_	_	_	_	_	_	Seg=O
126	practical	_	_	_	_	_	_	_	Seg=O
127	guidance	_	_	_	_	_	_	_	Seg=O
128	on	_	_	_	_	_	_	_	Seg=O
129	the	_	_	_	_	_	_	_	Seg=O
130	selection	_	_	_	_	_	_	_	Seg=O
131	of	_	_	_	_	_	_	_	Seg=O
132	quality	_	_	_	_	_	_	_	Seg=O
133	control	_	_	_	_	_	_	_	Seg=O
134	strategies	_	_	_	_	_	_	_	Seg=O
135	.	_	_	_	_	_	_	_	Seg=O
136	We	_	_	_	_	_	_	_	Seg=B-seg
137	implement	_	_	_	_	_	_	_	Seg=O
138	the	_	_	_	_	_	_	_	Seg=O
139	recommended	_	_	_	_	_	_	_	Seg=O
140	strategy	_	_	_	_	_	_	_	Seg=O
141	in	_	_	_	_	_	_	_	Seg=O
142	a	_	_	_	_	_	_	_	Seg=O
143	computational	_	_	_	_	_	_	_	Seg=O
144	workflow	_	_	_	_	_	_	_	Seg=O
145	named	_	_	_	_	_	_	_	Seg=B-seg
146	NeoFlow	_	_	_	_	_	_	_	Seg=O
147	to	_	_	_	_	_	_	_	Seg=B-seg
148	support	_	_	_	_	_	_	_	Seg=O
149	proteogenomics	_	_	_	_	_	_	_	Seg=O
150	-	_	_	_	_	_	_	_	Seg=O
151	based	_	_	_	_	_	_	_	Seg=O
152	neoantigen	_	_	_	_	_	_	_	Seg=O
153	prioritization	_	_	_	_	_	_	_	Seg=O
154	,	_	_	_	_	_	_	_	Seg=O
155	enabling	_	_	_	_	_	_	_	Seg=B-seg
156	more	_	_	_	_	_	_	_	Seg=O
157	sensitive	_	_	_	_	_	_	_	Seg=O
158	discovery	_	_	_	_	_	_	_	Seg=O
159	of	_	_	_	_	_	_	_	Seg=O
160	putative	_	_	_	_	_	_	_	Seg=O
161	neoantigens	_	_	_	_	_	_	_	Seg=O
162	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 69403975272536434ad77f177871ffa4c828873e
1	The	_	_	_	_	_	_	_	Seg=B-seg
2	availability	_	_	_	_	_	_	_	Seg=O
3	of	_	_	_	_	_	_	_	Seg=O
4	monoclonal	_	_	_	_	_	_	_	Seg=O
5	antibodies	_	_	_	_	_	_	_	Seg=O
6	(	_	_	_	_	_	_	_	Seg=O
7	mAbs	_	_	_	_	_	_	_	Seg=O
8	)	_	_	_	_	_	_	_	Seg=O
9	specific	_	_	_	_	_	_	_	Seg=O
10	for	_	_	_	_	_	_	_	Seg=O
11	the	_	_	_	_	_	_	_	Seg=O
12	SARS	_	_	_	_	_	_	_	Seg=O
13	-	_	_	_	_	_	_	_	Seg=O
14	coronavirus	_	_	_	_	_	_	_	Seg=O
15	(	_	_	_	_	_	_	_	Seg=O
16	SARS	_	_	_	_	_	_	_	Seg=O
17	-	_	_	_	_	_	_	_	Seg=O
18	CoV	_	_	_	_	_	_	_	Seg=O
19	)	_	_	_	_	_	_	_	Seg=O
20	is	_	_	_	_	_	_	_	Seg=O
21	important	_	_	_	_	_	_	_	Seg=O
22	for	_	_	_	_	_	_	_	Seg=O
23	the	_	_	_	_	_	_	_	Seg=O
24	development	_	_	_	_	_	_	_	Seg=O
25	of	_	_	_	_	_	_	_	Seg=O
26	both	_	_	_	_	_	_	_	Seg=O
27	diagnostic	_	_	_	_	_	_	_	Seg=O
28	tools	_	_	_	_	_	_	_	Seg=O
29	and	_	_	_	_	_	_	_	Seg=O
30	treatment	_	_	_	_	_	_	_	Seg=O
31	of	_	_	_	_	_	_	_	Seg=O
32	infection	_	_	_	_	_	_	_	Seg=O
33	.	_	_	_	_	_	_	_	Seg=O
34	A	_	_	_	_	_	_	_	Seg=B-seg
35	molecular	_	_	_	_	_	_	_	Seg=O
36	characterization	_	_	_	_	_	_	_	Seg=O
37	of	_	_	_	_	_	_	_	Seg=O
38	nine	_	_	_	_	_	_	_	Seg=O
39	monoclonal	_	_	_	_	_	_	_	Seg=O
40	antibodies	_	_	_	_	_	_	_	Seg=O
41	raised	_	_	_	_	_	_	_	Seg=B-seg
42	in	_	_	_	_	_	_	_	Seg=O
43	immune	_	_	_	_	_	_	_	Seg=O
44	mice	_	_	_	_	_	_	_	Seg=O
45	,	_	_	_	_	_	_	_	Seg=O
46	using	_	_	_	_	_	_	_	Seg=B-seg
47	highly	_	_	_	_	_	_	_	Seg=O
48	purified	_	_	_	_	_	_	_	Seg=O
49	,	_	_	_	_	_	_	_	Seg=O
50	inactivated	_	_	_	_	_	_	_	Seg=O
51	SARS	_	_	_	_	_	_	_	Seg=O
52	-	_	_	_	_	_	_	_	Seg=O
53	CoV	_	_	_	_	_	_	_	Seg=O
54	as	_	_	_	_	_	_	_	Seg=O
55	the	_	_	_	_	_	_	_	Seg=O
56	inoculating	_	_	_	_	_	_	_	Seg=O
57	antigen	_	_	_	_	_	_	_	Seg=O
58	,	_	_	_	_	_	_	_	Seg=O
59	is	_	_	_	_	_	_	_	Seg=B-seg
60	presented	_	_	_	_	_	_	_	Seg=O
61	in	_	_	_	_	_	_	_	Seg=O
62	this	_	_	_	_	_	_	_	Seg=O
63	report	_	_	_	_	_	_	_	Seg=O
64	.	_	_	_	_	_	_	_	Seg=O
65	These	_	_	_	_	_	_	_	Seg=B-seg
66	antibodies	_	_	_	_	_	_	_	Seg=O
67	are	_	_	_	_	_	_	_	Seg=O
68	specific	_	_	_	_	_	_	_	Seg=O
69	for	_	_	_	_	_	_	_	Seg=O
70	numerous	_	_	_	_	_	_	_	Seg=O
71	viral	_	_	_	_	_	_	_	Seg=O
72	protein	_	_	_	_	_	_	_	Seg=O
73	targets	_	_	_	_	_	_	_	Seg=O
74	,	_	_	_	_	_	_	_	Seg=O
75	and	_	_	_	_	_	_	_	Seg=B-seg
76	six	_	_	_	_	_	_	_	Seg=O
77	of	_	_	_	_	_	_	_	Seg=O
78	them	_	_	_	_	_	_	_	Seg=O
79	are	_	_	_	_	_	_	_	Seg=O
80	able	_	_	_	_	_	_	_	Seg=O
81	to	_	_	_	_	_	_	_	Seg=O
82	effectively	_	_	_	_	_	_	_	Seg=O
83	neutralize	_	_	_	_	_	_	_	Seg=O
84	SARS	_	_	_	_	_	_	_	Seg=O
85	-	_	_	_	_	_	_	_	Seg=O
86	CoV	_	_	_	_	_	_	_	Seg=O
87	in	_	_	_	_	_	_	_	Seg=O
88	vitro	_	_	_	_	_	_	_	Seg=O
89	,	_	_	_	_	_	_	_	Seg=O
90	including	_	_	_	_	_	_	_	Seg=B-seg
91	one	_	_	_	_	_	_	_	Seg=O
92	with	_	_	_	_	_	_	_	Seg=O
93	a	_	_	_	_	_	_	_	Seg=O
94	neutralizing	_	_	_	_	_	_	_	Seg=O
95	titre	_	_	_	_	_	_	_	Seg=O
96	of	_	_	_	_	_	_	_	Seg=O
97	0.075	_	_	_	_	_	_	_	Seg=O
98	nM.	_	_	_	_	_	_	_	Seg=O
99	A	_	_	_	_	_	_	_	Seg=B-seg
100	phylogenetic	_	_	_	_	_	_	_	Seg=O
101	analysis	_	_	_	_	_	_	_	Seg=O
102	of	_	_	_	_	_	_	_	Seg=O
103	the	_	_	_	_	_	_	_	Seg=O
104	heavy	_	_	_	_	_	_	_	Seg=O
105	and	_	_	_	_	_	_	_	Seg=O
106	light	_	_	_	_	_	_	_	Seg=O
107	chain	_	_	_	_	_	_	_	Seg=O
108	sequences	_	_	_	_	_	_	_	Seg=O
109	reveals	_	_	_	_	_	_	_	Seg=O
110	that	_	_	_	_	_	_	_	Seg=B-seg
111	the	_	_	_	_	_	_	_	Seg=O
112	mAbs	_	_	_	_	_	_	_	Seg=O
113	share	_	_	_	_	_	_	_	Seg=O
114	considerable	_	_	_	_	_	_	_	Seg=O
115	homology	_	_	_	_	_	_	_	Seg=O
116	.	_	_	_	_	_	_	_	Seg=O
117	The	_	_	_	_	_	_	_	Seg=B-seg
118	majority	_	_	_	_	_	_	_	Seg=O
119	of	_	_	_	_	_	_	_	Seg=O
120	the	_	_	_	_	_	_	_	Seg=O
121	heavy	_	_	_	_	_	_	_	Seg=O
122	chains	_	_	_	_	_	_	_	Seg=O
123	belong	_	_	_	_	_	_	_	Seg=O
124	to	_	_	_	_	_	_	_	Seg=O
125	a	_	_	_	_	_	_	_	Seg=O
126	single	_	_	_	_	_	_	_	Seg=O
127	Ig	_	_	_	_	_	_	_	Seg=O
128	germline	_	_	_	_	_	_	_	Seg=O
129	V	_	_	_	_	_	_	_	Seg=O
130	-	_	_	_	_	_	_	_	Seg=O
131	gene	_	_	_	_	_	_	_	Seg=O
132	family	_	_	_	_	_	_	_	Seg=O
133	,	_	_	_	_	_	_	_	Seg=O
134	while	_	_	_	_	_	_	_	Seg=B-seg
135	considerably	_	_	_	_	_	_	_	Seg=O
136	more	_	_	_	_	_	_	_	Seg=O
137	sequence	_	_	_	_	_	_	_	Seg=O
138	variation	_	_	_	_	_	_	_	Seg=O
139	is	_	_	_	_	_	_	_	Seg=O
140	evident	_	_	_	_	_	_	_	Seg=O
141	in	_	_	_	_	_	_	_	Seg=O
142	the	_	_	_	_	_	_	_	Seg=O
143	light	_	_	_	_	_	_	_	Seg=O
144	chain	_	_	_	_	_	_	_	Seg=O
145	sequences	_	_	_	_	_	_	_	Seg=O
146	.	_	_	_	_	_	_	_	Seg=O
147	These	_	_	_	_	_	_	_	Seg=B-seg
148	analyses	_	_	_	_	_	_	_	Seg=O
149	demonstrate	_	_	_	_	_	_	_	Seg=O
150	that	_	_	_	_	_	_	_	Seg=B-seg
151	neutralization	_	_	_	_	_	_	_	Seg=O
152	ability	_	_	_	_	_	_	_	Seg=O
153	can	_	_	_	_	_	_	_	Seg=O
154	be	_	_	_	_	_	_	_	Seg=O
155	correlated	_	_	_	_	_	_	_	Seg=O
156	with	_	_	_	_	_	_	_	Seg=O
157	specific	_	_	_	_	_	_	_	Seg=O
158	murine	_	_	_	_	_	_	_	Seg=O
159	V	_	_	_	_	_	_	_	Seg=O
160	H	_	_	_	_	_	_	_	Seg=O
161	-gene	_	_	_	_	_	_	_	Seg=O
162	alleles	_	_	_	_	_	_	_	Seg=O
163	.	_	_	_	_	_	_	_	Seg=O
164	For	_	_	_	_	_	_	_	Seg=B-seg
165	instance	_	_	_	_	_	_	_	Seg=O
166	,	_	_	_	_	_	_	_	Seg=O
167	one	_	_	_	_	_	_	_	Seg=O
168	evident	_	_	_	_	_	_	_	Seg=O
169	trend	_	_	_	_	_	_	_	Seg=O
170	is	_	_	_	_	_	_	_	Seg=O
171	high	_	_	_	_	_	_	_	Seg=O
172	sequence	_	_	_	_	_	_	_	Seg=O
173	conservation	_	_	_	_	_	_	_	Seg=O
174	in	_	_	_	_	_	_	_	Seg=O
175	the	_	_	_	_	_	_	_	Seg=O
176	V	_	_	_	_	_	_	_	Seg=O
177	H	_	_	_	_	_	_	_	Seg=O
178	chains	_	_	_	_	_	_	_	Seg=O
179	of	_	_	_	_	_	_	_	Seg=O
180	the	_	_	_	_	_	_	_	Seg=O
181	neutralizing	_	_	_	_	_	_	_	Seg=O
182	mAbs	_	_	_	_	_	_	_	Seg=O
183	,	_	_	_	_	_	_	_	Seg=O
184	particularly	_	_	_	_	_	_	_	Seg=O
185	in	_	_	_	_	_	_	_	Seg=O
186	CDR-1	_	_	_	_	_	_	_	Seg=O
187	and	_	_	_	_	_	_	_	Seg=O
188	CDR-2	_	_	_	_	_	_	_	Seg=O
189	.	_	_	_	_	_	_	_	Seg=O
190	The	_	_	_	_	_	_	_	Seg=B-seg
191	results	_	_	_	_	_	_	_	Seg=O
192	suggest	_	_	_	_	_	_	_	Seg=O
193	that	_	_	_	_	_	_	_	Seg=B-seg
194	optimization	_	_	_	_	_	_	_	Seg=O
195	of	_	_	_	_	_	_	_	Seg=O
196	murine	_	_	_	_	_	_	_	Seg=O
197	mAbs	_	_	_	_	_	_	_	Seg=O
198	for	_	_	_	_	_	_	_	Seg=O
199	neutralization	_	_	_	_	_	_	_	Seg=O
200	of	_	_	_	_	_	_	_	Seg=O
201	SARS	_	_	_	_	_	_	_	Seg=O
202	-	_	_	_	_	_	_	_	Seg=O
203	CoV	_	_	_	_	_	_	_	Seg=O
204	infection	_	_	_	_	_	_	_	Seg=O
205	will	_	_	_	_	_	_	_	Seg=O
206	likely	_	_	_	_	_	_	_	Seg=O
207	be	_	_	_	_	_	_	_	Seg=O
208	possible	_	_	_	_	_	_	_	Seg=O
209	,	_	_	_	_	_	_	_	Seg=O
210	and	_	_	_	_	_	_	_	Seg=B-seg
211	will	_	_	_	_	_	_	_	Seg=O
212	aid	_	_	_	_	_	_	_	Seg=O
213	in	_	_	_	_	_	_	_	Seg=O
214	the	_	_	_	_	_	_	_	Seg=O
215	development	_	_	_	_	_	_	_	Seg=O
216	of	_	_	_	_	_	_	_	Seg=O
217	diagnostic	_	_	_	_	_	_	_	Seg=O
218	tools	_	_	_	_	_	_	_	Seg=O
219	and	_	_	_	_	_	_	_	Seg=O
220	passive	_	_	_	_	_	_	_	Seg=O
221	treatments	_	_	_	_	_	_	_	Seg=O
222	for	_	_	_	_	_	_	_	Seg=O
223	SARS	_	_	_	_	_	_	_	Seg=O
224	-	_	_	_	_	_	_	_	Seg=O
225	CoV	_	_	_	_	_	_	_	Seg=O
226	infection	_	_	_	_	_	_	_	Seg=O
227	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 698d5442e3e3a15439c7222d5abd9016a14f7fbe
1	With	_	_	_	_	_	_	_	Seg=B-seg
2	growing	_	_	_	_	_	_	_	Seg=O
3	evidence	_	_	_	_	_	_	_	Seg=O
4	of	_	_	_	_	_	_	_	Seg=O
5	inhalation	_	_	_	_	_	_	_	Seg=O
6	of	_	_	_	_	_	_	_	Seg=O
7	small	_	_	_	_	_	_	_	Seg=O
8	infectious	_	_	_	_	_	_	_	Seg=O
9	particles	_	_	_	_	_	_	_	Seg=O
10	as	_	_	_	_	_	_	_	Seg=O
11	an	_	_	_	_	_	_	_	Seg=O
12	important	_	_	_	_	_	_	_	Seg=O
13	mode	_	_	_	_	_	_	_	Seg=O
14	of	_	_	_	_	_	_	_	Seg=O
15	transmission	_	_	_	_	_	_	_	Seg=O
16	for	_	_	_	_	_	_	_	Seg=O
17	SARS	_	_	_	_	_	_	_	Seg=O
18	-	_	_	_	_	_	_	_	Seg=O
19	CoV-2	_	_	_	_	_	_	_	Seg=O
20	,	_	_	_	_	_	_	_	Seg=O
21	workplace	_	_	_	_	_	_	_	Seg=O
22	risk	_	_	_	_	_	_	_	Seg=O
23	assessments	_	_	_	_	_	_	_	Seg=O
24	should	_	_	_	_	_	_	_	Seg=O
25	focus	_	_	_	_	_	_	_	Seg=O
26	on	_	_	_	_	_	_	_	Seg=O
27	eliminating	_	_	_	_	_	_	_	Seg=O
28	or	_	_	_	_	_	_	_	Seg=O
29	minimizing	_	_	_	_	_	_	_	Seg=O
30	such	_	_	_	_	_	_	_	Seg=O
31	exposures	_	_	_	_	_	_	_	Seg=O
32	by	_	_	_	_	_	_	_	Seg=B-seg
33	applying	_	_	_	_	_	_	_	Seg=O
34	the	_	_	_	_	_	_	_	Seg=O
35	hierarchy	_	_	_	_	_	_	_	Seg=O
36	of	_	_	_	_	_	_	_	Seg=O
37	controls	_	_	_	_	_	_	_	Seg=O
38	.	_	_	_	_	_	_	_	Seg=O
39	We	_	_	_	_	_	_	_	Seg=B-seg
40	adapt	_	_	_	_	_	_	_	Seg=O
41	a	_	_	_	_	_	_	_	Seg=O
42	control	_	_	_	_	_	_	_	Seg=O
43	banding	_	_	_	_	_	_	_	Seg=O
44	model	_	_	_	_	_	_	_	Seg=O
45	for	_	_	_	_	_	_	_	Seg=O
46	aerosol	_	_	_	_	_	_	_	Seg=O
47	-	_	_	_	_	_	_	_	Seg=O
48	transmissible	_	_	_	_	_	_	_	Seg=O
49	infectious	_	_	_	_	_	_	_	Seg=O
50	disease	_	_	_	_	_	_	_	Seg=O
51	pandemic	_	_	_	_	_	_	_	Seg=O
52	planning	_	_	_	_	_	_	_	Seg=O
53	to	_	_	_	_	_	_	_	Seg=B-seg
54	encourage	_	_	_	_	_	_	_	Seg=O
55	the	_	_	_	_	_	_	_	Seg=O
56	use	_	_	_	_	_	_	_	Seg=O
57	of	_	_	_	_	_	_	_	Seg=O
58	source	_	_	_	_	_	_	_	Seg=O
59	and	_	_	_	_	_	_	_	Seg=O
60	pathway	_	_	_	_	_	_	_	Seg=O
61	controls	_	_	_	_	_	_	_	Seg=O
62	before	_	_	_	_	_	_	_	Seg=O
63	receptor	_	_	_	_	_	_	_	Seg=O
64	controls	_	_	_	_	_	_	_	Seg=O
65	(	_	_	_	_	_	_	_	Seg=B-seg
66	personal	_	_	_	_	_	_	_	Seg=O
67	protective	_	_	_	_	_	_	_	Seg=O
68	equipment	_	_	_	_	_	_	_	Seg=O
69	)	_	_	_	_	_	_	_	Seg=O
70	.	_	_	_	_	_	_	_	Seg=O
71	Built	_	_	_	_	_	_	_	Seg=B-seg
72	on	_	_	_	_	_	_	_	Seg=O
73	the	_	_	_	_	_	_	_	Seg=O
74	recognition	_	_	_	_	_	_	_	Seg=O
75	that	_	_	_	_	_	_	_	Seg=B-seg
76	aerosol	_	_	_	_	_	_	_	Seg=O
77	-	_	_	_	_	_	_	_	Seg=O
78	transmissible	_	_	_	_	_	_	_	Seg=O
79	organisms	_	_	_	_	_	_	_	Seg=O
80	are	_	_	_	_	_	_	_	Seg=O
81	likely	_	_	_	_	_	_	_	Seg=O
82	to	_	_	_	_	_	_	_	Seg=O
83	exhibit	_	_	_	_	_	_	_	Seg=O
84	a	_	_	_	_	_	_	_	Seg=O
85	dose	_	_	_	_	_	_	_	Seg=O
86	-	_	_	_	_	_	_	_	Seg=O
87	response	_	_	_	_	_	_	_	Seg=O
88	function	_	_	_	_	_	_	_	Seg=O
89	,	_	_	_	_	_	_	_	Seg=O
90	such	_	_	_	_	_	_	_	Seg=B-seg
91	that	_	_	_	_	_	_	_	Seg=O
92	higher	_	_	_	_	_	_	_	Seg=O
93	exposures	_	_	_	_	_	_	_	Seg=O
94	result	_	_	_	_	_	_	_	Seg=O
95	from	_	_	_	_	_	_	_	Seg=O
96	longer	_	_	_	_	_	_	_	Seg=O
97	contact	_	_	_	_	_	_	_	Seg=O
98	times	_	_	_	_	_	_	_	Seg=O
99	or	_	_	_	_	_	_	_	Seg=O
100	higher	_	_	_	_	_	_	_	Seg=O
101	air	_	_	_	_	_	_	_	Seg=O
102	concentrations	_	_	_	_	_	_	_	Seg=O
103	,	_	_	_	_	_	_	_	Seg=O
104	this	_	_	_	_	_	_	_	Seg=B-seg
105	control	_	_	_	_	_	_	_	Seg=O
106	banding	_	_	_	_	_	_	_	Seg=O
107	model	_	_	_	_	_	_	_	Seg=O
108	offers	_	_	_	_	_	_	_	Seg=O
109	a	_	_	_	_	_	_	_	Seg=O
110	systematic	_	_	_	_	_	_	_	Seg=O
111	method	_	_	_	_	_	_	_	Seg=O
112	for	_	_	_	_	_	_	_	Seg=B-seg
113	identifying	_	_	_	_	_	_	_	Seg=O
114	a	_	_	_	_	_	_	_	Seg=O
115	set	_	_	_	_	_	_	_	Seg=O
116	of	_	_	_	_	_	_	_	Seg=O
117	source	_	_	_	_	_	_	_	Seg=O
118	and	_	_	_	_	_	_	_	Seg=O
119	pathway	_	_	_	_	_	_	_	Seg=O
120	controls	_	_	_	_	_	_	_	Seg=O
121	that	_	_	_	_	_	_	_	Seg=B-seg
122	could	_	_	_	_	_	_	_	Seg=O
123	eliminate	_	_	_	_	_	_	_	Seg=O
124	or	_	_	_	_	_	_	_	Seg=O
125	reduce	_	_	_	_	_	_	_	Seg=O
126	the	_	_	_	_	_	_	_	Seg=O
127	need	_	_	_	_	_	_	_	Seg=O
128	for	_	_	_	_	_	_	_	Seg=O
129	receptor	_	_	_	_	_	_	_	Seg=O
130	controls	_	_	_	_	_	_	_	Seg=O
131	.	_	_	_	_	_	_	_	Seg=O
132	We	_	_	_	_	_	_	_	Seg=B-seg
133	describe	_	_	_	_	_	_	_	Seg=O
134	several	_	_	_	_	_	_	_	Seg=O
135	examples	_	_	_	_	_	_	_	Seg=O
136	for	_	_	_	_	_	_	_	Seg=O
137	workers	_	_	_	_	_	_	_	Seg=O
138	at	_	_	_	_	_	_	_	Seg=O
139	high	_	_	_	_	_	_	_	Seg=O
140	risk	_	_	_	_	_	_	_	Seg=O
141	of	_	_	_	_	_	_	_	Seg=O
142	exposure	_	_	_	_	_	_	_	Seg=O
143	in	_	_	_	_	_	_	_	Seg=O
144	essential	_	_	_	_	_	_	_	Seg=O
145	or	_	_	_	_	_	_	_	Seg=O
146	return	_	_	_	_	_	_	_	Seg=O
147	to	_	_	_	_	_	_	_	Seg=O
148	work	_	_	_	_	_	_	_	Seg=O
149	categories	_	_	_	_	_	_	_	Seg=O
150	.	_	_	_	_	_	_	_	Seg=O
151	The	_	_	_	_	_	_	_	Seg=B-seg
152	goal	_	_	_	_	_	_	_	Seg=O
153	of	_	_	_	_	_	_	_	Seg=B-seg
154	using	_	_	_	_	_	_	_	Seg=O
155	control	_	_	_	_	_	_	_	Seg=O
156	banding	_	_	_	_	_	_	_	Seg=O
157	for	_	_	_	_	_	_	_	Seg=O
158	such	_	_	_	_	_	_	_	Seg=O
159	workers	_	_	_	_	_	_	_	Seg=O
160	is	_	_	_	_	_	_	_	Seg=B-seg
161	to	_	_	_	_	_	_	_	Seg=O
162	develop	_	_	_	_	_	_	_	Seg=O
163	effective	_	_	_	_	_	_	_	Seg=O
164	infection	_	_	_	_	_	_	_	Seg=O
165	and	_	_	_	_	_	_	_	Seg=O
166	disease	_	_	_	_	_	_	_	Seg=O
167	prevention	_	_	_	_	_	_	_	Seg=O
168	programs	_	_	_	_	_	_	_	Seg=O
169	and	_	_	_	_	_	_	_	Seg=B-seg
170	conserve	_	_	_	_	_	_	_	Seg=O
171	personal	_	_	_	_	_	_	_	Seg=O
172	protective	_	_	_	_	_	_	_	Seg=O
173	equipment	_	_	_	_	_	_	_	Seg=O
174	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 69bce356ec4ad3fcc2a0d7ba9ecfaf0d90d8e423
1	Most	_	_	_	_	_	_	_	Seg=B-seg
2	biological	_	_	_	_	_	_	_	Seg=O
3	processes	_	_	_	_	_	_	_	Seg=O
4	are	_	_	_	_	_	_	_	Seg=O
5	described	_	_	_	_	_	_	_	Seg=O
6	as	_	_	_	_	_	_	_	Seg=O
7	a	_	_	_	_	_	_	_	Seg=O
8	series	_	_	_	_	_	_	_	Seg=O
9	of	_	_	_	_	_	_	_	Seg=O
10	interactions	_	_	_	_	_	_	_	Seg=O
11	between	_	_	_	_	_	_	_	Seg=O
12	proteins	_	_	_	_	_	_	_	Seg=O
13	and	_	_	_	_	_	_	_	Seg=O
14	other	_	_	_	_	_	_	_	Seg=O
15	molecules	_	_	_	_	_	_	_	Seg=O
16	,	_	_	_	_	_	_	_	Seg=O
17	and	_	_	_	_	_	_	_	Seg=B-seg
18	interactions	_	_	_	_	_	_	_	Seg=O
19	are	_	_	_	_	_	_	_	Seg=O
20	in	_	_	_	_	_	_	_	Seg=O
21	turn	_	_	_	_	_	_	_	Seg=O
22	described	_	_	_	_	_	_	_	Seg=O
23	in	_	_	_	_	_	_	_	Seg=O
24	terms	_	_	_	_	_	_	_	Seg=O
25	of	_	_	_	_	_	_	_	Seg=O
26	atomic	_	_	_	_	_	_	_	Seg=O
27	structures	_	_	_	_	_	_	_	Seg=O
28	.	_	_	_	_	_	_	_	Seg=O
29	To	_	_	_	_	_	_	_	Seg=B-seg
30	annotate	_	_	_	_	_	_	_	Seg=O
31	protein	_	_	_	_	_	_	_	Seg=O
32	functions	_	_	_	_	_	_	_	Seg=O
33	as	_	_	_	_	_	_	_	Seg=O
34	sets	_	_	_	_	_	_	_	Seg=O
35	of	_	_	_	_	_	_	_	Seg=O
36	interaction	_	_	_	_	_	_	_	Seg=O
37	states	_	_	_	_	_	_	_	Seg=O
38	at	_	_	_	_	_	_	_	Seg=O
39	atomic	_	_	_	_	_	_	_	Seg=O
40	resolution	_	_	_	_	_	_	_	Seg=O
41	,	_	_	_	_	_	_	_	Seg=O
42	and	_	_	_	_	_	_	_	Seg=B-seg
43	thereby	_	_	_	_	_	_	_	Seg=O
44	to	_	_	_	_	_	_	_	Seg=O
45	better	_	_	_	_	_	_	_	Seg=O
46	understand	_	_	_	_	_	_	_	Seg=O
47	the	_	_	_	_	_	_	_	Seg=O
48	relation	_	_	_	_	_	_	_	Seg=O
49	between	_	_	_	_	_	_	_	Seg=O
50	protein	_	_	_	_	_	_	_	Seg=O
51	interactions	_	_	_	_	_	_	_	Seg=O
52	and	_	_	_	_	_	_	_	Seg=O
53	biological	_	_	_	_	_	_	_	Seg=O
54	functions	_	_	_	_	_	_	_	Seg=O
55	,	_	_	_	_	_	_	_	Seg=O
56	we	_	_	_	_	_	_	_	Seg=B-seg
57	conducted	_	_	_	_	_	_	_	Seg=O
58	exhaustive	_	_	_	_	_	_	_	Seg=O
59	all	_	_	_	_	_	_	_	Seg=O
60	-	_	_	_	_	_	_	_	Seg=O
61	against	_	_	_	_	_	_	_	Seg=O
62	-	_	_	_	_	_	_	_	Seg=O
63	all	_	_	_	_	_	_	_	Seg=O
64	atomic	_	_	_	_	_	_	_	Seg=O
65	structure	_	_	_	_	_	_	_	Seg=O
66	comparisons	_	_	_	_	_	_	_	Seg=O
67	of	_	_	_	_	_	_	_	Seg=O
68	all	_	_	_	_	_	_	_	Seg=O
69	known	_	_	_	_	_	_	_	Seg=O
70	binding	_	_	_	_	_	_	_	Seg=O
71	sites	_	_	_	_	_	_	_	Seg=O
72	for	_	_	_	_	_	_	_	Seg=O
73	ligands	_	_	_	_	_	_	_	Seg=O
74	including	_	_	_	_	_	_	_	Seg=B-seg
75	small	_	_	_	_	_	_	_	Seg=O
76	molecules	_	_	_	_	_	_	_	Seg=O
77	,	_	_	_	_	_	_	_	Seg=O
78	proteins	_	_	_	_	_	_	_	Seg=O
79	and	_	_	_	_	_	_	_	Seg=O
80	nucleic	_	_	_	_	_	_	_	Seg=O
81	acids	_	_	_	_	_	_	_	Seg=O
82	,	_	_	_	_	_	_	_	Seg=O
83	and	_	_	_	_	_	_	_	Seg=B-seg
84	identified	_	_	_	_	_	_	_	Seg=O
85	recurring	_	_	_	_	_	_	_	Seg=O
86	elementary	_	_	_	_	_	_	_	Seg=O
87	motifs	_	_	_	_	_	_	_	Seg=O
88	.	_	_	_	_	_	_	_	Seg=O
89	By	_	_	_	_	_	_	_	Seg=B-seg
90	integrating	_	_	_	_	_	_	_	Seg=O
91	the	_	_	_	_	_	_	_	Seg=O
92	elementary	_	_	_	_	_	_	_	Seg=O
93	motifs	_	_	_	_	_	_	_	Seg=O
94	associated	_	_	_	_	_	_	_	Seg=B-seg
95	with	_	_	_	_	_	_	_	Seg=O
96	each	_	_	_	_	_	_	_	Seg=O
97	subunit	_	_	_	_	_	_	_	Seg=O
98	,	_	_	_	_	_	_	_	Seg=O
99	we	_	_	_	_	_	_	_	Seg=B-seg
100	defined	_	_	_	_	_	_	_	Seg=O
101	composite	_	_	_	_	_	_	_	Seg=O
102	motifs	_	_	_	_	_	_	_	Seg=O
103	that	_	_	_	_	_	_	_	Seg=B-seg
104	represent	_	_	_	_	_	_	_	Seg=O
105	context	_	_	_	_	_	_	_	Seg=O
106	-	_	_	_	_	_	_	_	Seg=O
107	dependent	_	_	_	_	_	_	_	Seg=O
108	combinations	_	_	_	_	_	_	_	Seg=O
109	of	_	_	_	_	_	_	_	Seg=O
110	elementary	_	_	_	_	_	_	_	Seg=O
111	motifs	_	_	_	_	_	_	_	Seg=O
112	.	_	_	_	_	_	_	_	Seg=O
113	It	_	_	_	_	_	_	_	Seg=B-seg
114	is	_	_	_	_	_	_	_	Seg=O
115	demonstrated	_	_	_	_	_	_	_	Seg=O
116	that	_	_	_	_	_	_	_	Seg=O
117	function	_	_	_	_	_	_	_	Seg=O
118	similarity	_	_	_	_	_	_	_	Seg=O
119	can	_	_	_	_	_	_	_	Seg=O
120	be	_	_	_	_	_	_	_	Seg=O
121	better	_	_	_	_	_	_	_	Seg=O
122	inferred	_	_	_	_	_	_	_	Seg=O
123	from	_	_	_	_	_	_	_	Seg=O
124	composite	_	_	_	_	_	_	_	Seg=O
125	motif	_	_	_	_	_	_	_	Seg=O
126	similarity	_	_	_	_	_	_	_	Seg=O
127	compared	_	_	_	_	_	_	_	Seg=B-seg
128	to	_	_	_	_	_	_	_	Seg=O
129	the	_	_	_	_	_	_	_	Seg=O
130	similarity	_	_	_	_	_	_	_	Seg=O
131	of	_	_	_	_	_	_	_	Seg=O
132	protein	_	_	_	_	_	_	_	Seg=O
133	sequences	_	_	_	_	_	_	_	Seg=O
134	or	_	_	_	_	_	_	_	Seg=O
135	of	_	_	_	_	_	_	_	Seg=O
136	individual	_	_	_	_	_	_	_	Seg=O
137	binding	_	_	_	_	_	_	_	Seg=O
138	sites	_	_	_	_	_	_	_	Seg=O
139	.	_	_	_	_	_	_	_	Seg=O
140	By	_	_	_	_	_	_	_	Seg=B-seg
141	integrating	_	_	_	_	_	_	_	Seg=O
142	the	_	_	_	_	_	_	_	Seg=O
143	composite	_	_	_	_	_	_	_	Seg=O
144	motifs	_	_	_	_	_	_	_	Seg=O
145	associated	_	_	_	_	_	_	_	Seg=B-seg
146	with	_	_	_	_	_	_	_	Seg=O
147	each	_	_	_	_	_	_	_	Seg=O
148	protein	_	_	_	_	_	_	_	Seg=O
149	function	_	_	_	_	_	_	_	Seg=O
150	,	_	_	_	_	_	_	_	Seg=O
151	we	_	_	_	_	_	_	_	Seg=B-seg
152	define	_	_	_	_	_	_	_	Seg=O
153	meta	_	_	_	_	_	_	_	Seg=O
154	-	_	_	_	_	_	_	_	Seg=O
155	composite	_	_	_	_	_	_	_	Seg=O
156	motifs	_	_	_	_	_	_	_	Seg=O
157	each	_	_	_	_	_	_	_	Seg=B-seg
158	of	_	_	_	_	_	_	_	Seg=O
159	which	_	_	_	_	_	_	_	Seg=O
160	is	_	_	_	_	_	_	_	Seg=O
161	regarded	_	_	_	_	_	_	_	Seg=O
162	as	_	_	_	_	_	_	_	Seg=O
163	a	_	_	_	_	_	_	_	Seg=O
164	time	_	_	_	_	_	_	_	Seg=O
165	-	_	_	_	_	_	_	_	Seg=O
166	independent	_	_	_	_	_	_	_	Seg=O
167	diagrammatic	_	_	_	_	_	_	_	Seg=O
168	representation	_	_	_	_	_	_	_	Seg=O
169	of	_	_	_	_	_	_	_	Seg=O
170	a	_	_	_	_	_	_	_	Seg=O
171	biological	_	_	_	_	_	_	_	Seg=O
172	process	_	_	_	_	_	_	_	Seg=O
173	.	_	_	_	_	_	_	_	Seg=O
174	It	_	_	_	_	_	_	_	Seg=B-seg
175	is	_	_	_	_	_	_	_	Seg=O
176	shown	_	_	_	_	_	_	_	Seg=O
177	that	_	_	_	_	_	_	_	Seg=O
178	meta	_	_	_	_	_	_	_	Seg=O
179	-	_	_	_	_	_	_	_	Seg=O
180	composite	_	_	_	_	_	_	_	Seg=O
181	motifs	_	_	_	_	_	_	_	Seg=O
182	provide	_	_	_	_	_	_	_	Seg=O
183	richer	_	_	_	_	_	_	_	Seg=O
184	annotations	_	_	_	_	_	_	_	Seg=O
185	of	_	_	_	_	_	_	_	Seg=O
186	biological	_	_	_	_	_	_	_	Seg=O
187	processes	_	_	_	_	_	_	_	Seg=O
188	than	_	_	_	_	_	_	_	Seg=O
189	sequence	_	_	_	_	_	_	_	Seg=O
190	clusters	_	_	_	_	_	_	_	Seg=O
191	.	_	_	_	_	_	_	_	Seg=O
192	The	_	_	_	_	_	_	_	Seg=B-seg
193	present	_	_	_	_	_	_	_	Seg=O
194	results	_	_	_	_	_	_	_	Seg=O
195	serve	_	_	_	_	_	_	_	Seg=O
196	as	_	_	_	_	_	_	_	Seg=O
197	a	_	_	_	_	_	_	_	Seg=O
198	basis	_	_	_	_	_	_	_	Seg=O
199	for	_	_	_	_	_	_	_	Seg=B-seg
200	bridging	_	_	_	_	_	_	_	Seg=O
201	atomic	_	_	_	_	_	_	_	Seg=O
202	structures	_	_	_	_	_	_	_	Seg=O
203	to	_	_	_	_	_	_	_	Seg=O
204	higher	_	_	_	_	_	_	_	Seg=O
205	-	_	_	_	_	_	_	_	Seg=O
206	order	_	_	_	_	_	_	_	Seg=O
207	biological	_	_	_	_	_	_	_	Seg=O
208	phenomena	_	_	_	_	_	_	_	Seg=O
209	by	_	_	_	_	_	_	_	Seg=O
210	classification	_	_	_	_	_	_	_	Seg=O
211	and	_	_	_	_	_	_	_	Seg=O
212	integration	_	_	_	_	_	_	_	Seg=O
213	of	_	_	_	_	_	_	_	Seg=O
214	binding	_	_	_	_	_	_	_	Seg=O
215	site	_	_	_	_	_	_	_	Seg=O
216	structures	_	_	_	_	_	_	_	Seg=O
217	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 6ad3708c2049874524e4242c18e8fb41c673ccde
1	Interferons	_	_	_	_	_	_	_	Seg=B-seg
2	(	_	_	_	_	_	_	_	Seg=O
3	IFNs	_	_	_	_	_	_	_	Seg=O
4	)	_	_	_	_	_	_	_	Seg=O
5	are	_	_	_	_	_	_	_	Seg=O
6	secreted	_	_	_	_	_	_	_	Seg=O
7	proteins	_	_	_	_	_	_	_	Seg=O
8	of	_	_	_	_	_	_	_	Seg=O
9	the	_	_	_	_	_	_	_	Seg=O
10	cytokine	_	_	_	_	_	_	_	Seg=O
11	family	_	_	_	_	_	_	_	Seg=O
12	that	_	_	_	_	_	_	_	Seg=B-seg
13	regulate	_	_	_	_	_	_	_	Seg=O
14	innate	_	_	_	_	_	_	_	Seg=O
15	and	_	_	_	_	_	_	_	Seg=O
16	adaptive	_	_	_	_	_	_	_	Seg=O
17	immune	_	_	_	_	_	_	_	Seg=O
18	responses	_	_	_	_	_	_	_	Seg=O
19	to	_	_	_	_	_	_	_	Seg=O
20	infection	_	_	_	_	_	_	_	Seg=O
21	.	_	_	_	_	_	_	_	Seg=O
22	Although	_	_	_	_	_	_	_	Seg=B-seg
23	the	_	_	_	_	_	_	_	Seg=O
24	importance	_	_	_	_	_	_	_	Seg=O
25	of	_	_	_	_	_	_	_	Seg=O
26	IFNs	_	_	_	_	_	_	_	Seg=O
27	in	_	_	_	_	_	_	_	Seg=O
28	the	_	_	_	_	_	_	_	Seg=O
29	antiviral	_	_	_	_	_	_	_	Seg=O
30	response	_	_	_	_	_	_	_	Seg=O
31	has	_	_	_	_	_	_	_	Seg=O
32	long	_	_	_	_	_	_	_	Seg=O
33	been	_	_	_	_	_	_	_	Seg=O
34	appreciated	_	_	_	_	_	_	_	Seg=O
35	,	_	_	_	_	_	_	_	Seg=O
36	their	_	_	_	_	_	_	_	Seg=B-seg
37	role	_	_	_	_	_	_	_	Seg=O
38	in	_	_	_	_	_	_	_	Seg=O
39	bacterial	_	_	_	_	_	_	_	Seg=O
40	infections	_	_	_	_	_	_	_	Seg=O
41	is	_	_	_	_	_	_	_	Seg=O
42	more	_	_	_	_	_	_	_	Seg=O
43	complex	_	_	_	_	_	_	_	Seg=O
44	and	_	_	_	_	_	_	_	Seg=B-seg
45	is	_	_	_	_	_	_	_	Seg=O
46	currently	_	_	_	_	_	_	_	Seg=O
47	a	_	_	_	_	_	_	_	Seg=O
48	major	_	_	_	_	_	_	_	Seg=O
49	focus	_	_	_	_	_	_	_	Seg=O
50	of	_	_	_	_	_	_	_	Seg=O
51	investigation	_	_	_	_	_	_	_	Seg=O
52	.	_	_	_	_	_	_	_	Seg=O
53	This	_	_	_	_	_	_	_	Seg=B-seg
54	review	_	_	_	_	_	_	_	Seg=O
55	summarizes	_	_	_	_	_	_	_	Seg=O
56	our	_	_	_	_	_	_	_	Seg=O
57	current	_	_	_	_	_	_	_	Seg=O
58	knowledge	_	_	_	_	_	_	_	Seg=O
59	of	_	_	_	_	_	_	_	Seg=O
60	the	_	_	_	_	_	_	_	Seg=O
61	role	_	_	_	_	_	_	_	Seg=O
62	of	_	_	_	_	_	_	_	Seg=O
63	these	_	_	_	_	_	_	_	Seg=O
64	cytokines	_	_	_	_	_	_	_	Seg=O
65	in	_	_	_	_	_	_	_	Seg=O
66	host	_	_	_	_	_	_	_	Seg=O
67	defense	_	_	_	_	_	_	_	Seg=O
68	against	_	_	_	_	_	_	_	Seg=O
69	the	_	_	_	_	_	_	_	Seg=O
70	bacterial	_	_	_	_	_	_	_	Seg=O
71	pathogen	_	_	_	_	_	_	_	Seg=O
72	Listeria	_	_	_	_	_	_	_	Seg=O
73	monocytogenes	_	_	_	_	_	_	_	Seg=O
74	and	_	_	_	_	_	_	_	Seg=B-seg
75	highlights	_	_	_	_	_	_	_	Seg=O
76	recent	_	_	_	_	_	_	_	Seg=O
77	discoveries	_	_	_	_	_	_	_	Seg=O
78	on	_	_	_	_	_	_	_	Seg=O
79	the	_	_	_	_	_	_	_	Seg=O
80	molecular	_	_	_	_	_	_	_	Seg=O
81	mechanisms	_	_	_	_	_	_	_	Seg=O
82	evolved	_	_	_	_	_	_	_	Seg=B-seg
83	by	_	_	_	_	_	_	_	Seg=O
84	this	_	_	_	_	_	_	_	Seg=O
85	intracellular	_	_	_	_	_	_	_	Seg=O
86	bacterium	_	_	_	_	_	_	_	Seg=O
87	to	_	_	_	_	_	_	_	Seg=B-seg
88	subvert	_	_	_	_	_	_	_	Seg=O
89	IFN	_	_	_	_	_	_	_	Seg=O
90	responses	_	_	_	_	_	_	_	Seg=O
91	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 6c26acf9ba8059cbd9caa58acb1a64538cfb7df9
1	H9N2	_	_	_	_	_	_	_	Seg=B-seg
2	Avian	_	_	_	_	_	_	_	Seg=O
3	influenza	_	_	_	_	_	_	_	Seg=O
4	virus	_	_	_	_	_	_	_	Seg=O
5	has	_	_	_	_	_	_	_	Seg=O
6	repeatedly	_	_	_	_	_	_	_	Seg=O
7	infected	_	_	_	_	_	_	_	Seg=O
8	humans	_	_	_	_	_	_	_	Seg=O
9	and	_	_	_	_	_	_	_	Seg=O
10	other	_	_	_	_	_	_	_	Seg=O
11	mammals	_	_	_	_	_	_	_	Seg=O
12	,	_	_	_	_	_	_	_	Seg=O
13	which	_	_	_	_	_	_	_	Seg=B-seg
14	highlights	_	_	_	_	_	_	_	Seg=O
15	the	_	_	_	_	_	_	_	Seg=O
16	need	_	_	_	_	_	_	_	Seg=O
17	to	_	_	_	_	_	_	_	Seg=B-seg
18	determine	_	_	_	_	_	_	_	Seg=O
19	the	_	_	_	_	_	_	_	Seg=O
20	pathogenicity	_	_	_	_	_	_	_	Seg=O
21	and	_	_	_	_	_	_	_	Seg=O
22	the	_	_	_	_	_	_	_	Seg=O
23	corresponding	_	_	_	_	_	_	_	Seg=O
24	mechanism	_	_	_	_	_	_	_	Seg=O
25	of	_	_	_	_	_	_	_	Seg=O
26	this	_	_	_	_	_	_	_	Seg=O
27	virus	_	_	_	_	_	_	_	Seg=O
28	for	_	_	_	_	_	_	_	Seg=O
29	mammals	_	_	_	_	_	_	_	Seg=O
30	.	_	_	_	_	_	_	_	Seg=O
31	In	_	_	_	_	_	_	_	Seg=B-seg
32	this	_	_	_	_	_	_	_	Seg=O
33	study	_	_	_	_	_	_	_	Seg=O
34	,	_	_	_	_	_	_	_	Seg=O
35	we	_	_	_	_	_	_	_	Seg=O
36	found	_	_	_	_	_	_	_	Seg=O
37	two	_	_	_	_	_	_	_	Seg=O
38	H9N2	_	_	_	_	_	_	_	Seg=O
39	viruses	_	_	_	_	_	_	_	Seg=O
40	with	_	_	_	_	_	_	_	Seg=O
41	similar	_	_	_	_	_	_	_	Seg=O
42	genetic	_	_	_	_	_	_	_	Seg=O
43	background	_	_	_	_	_	_	_	Seg=O
44	but	_	_	_	_	_	_	_	Seg=O
45	with	_	_	_	_	_	_	_	Seg=O
46	different	_	_	_	_	_	_	_	Seg=O
47	pathogenicity	_	_	_	_	_	_	_	Seg=O
48	in	_	_	_	_	_	_	_	Seg=O
49	mice	_	_	_	_	_	_	_	Seg=O
50	.	_	_	_	_	_	_	_	Seg=O
51	The	_	_	_	_	_	_	_	Seg=B-seg
52	A	_	_	_	_	_	_	_	Seg=O
53	/	_	_	_	_	_	_	_	Seg=O
54	duck	_	_	_	_	_	_	_	Seg=O
55	/	_	_	_	_	_	_	_	Seg=O
56	Nanjing/06/2003	_	_	_	_	_	_	_	Seg=O
57	(	_	_	_	_	_	_	_	Seg=O
58	NJ06	_	_	_	_	_	_	_	Seg=O
59	)	_	_	_	_	_	_	_	Seg=O
60	virus	_	_	_	_	_	_	_	Seg=O
61	was	_	_	_	_	_	_	_	Seg=O
62	highly	_	_	_	_	_	_	_	Seg=O
63	pathogenic	_	_	_	_	_	_	_	Seg=O
64	for	_	_	_	_	_	_	_	Seg=O
65	mice	_	_	_	_	_	_	_	Seg=O
66	,	_	_	_	_	_	_	_	Seg=O
67	with	_	_	_	_	_	_	_	Seg=O
68	a	_	_	_	_	_	_	_	Seg=O
69	50	_	_	_	_	_	_	_	Seg=O
70	%	_	_	_	_	_	_	_	Seg=O
71	mouse	_	_	_	_	_	_	_	Seg=O
72	lethal	_	_	_	_	_	_	_	Seg=O
73	dose	_	_	_	_	_	_	_	Seg=O
74	(	_	_	_	_	_	_	_	Seg=O
75	MLD	_	_	_	_	_	_	_	Seg=O
76	50	_	_	_	_	_	_	_	Seg=O
77	)	_	_	_	_	_	_	_	Seg=O
78	of	_	_	_	_	_	_	_	Seg=O
79	10	_	_	_	_	_	_	_	Seg=O
80	2.83	_	_	_	_	_	_	_	Seg=O
81	50	_	_	_	_	_	_	_	Seg=O
82	%	_	_	_	_	_	_	_	Seg=O
83	egg	_	_	_	_	_	_	_	Seg=O
84	infectious	_	_	_	_	_	_	_	Seg=O
85	dose	_	_	_	_	_	_	_	Seg=O
86	(	_	_	_	_	_	_	_	Seg=O
87	EID	_	_	_	_	_	_	_	Seg=O
88	50	_	_	_	_	_	_	_	Seg=O
89	)	_	_	_	_	_	_	_	Seg=O
90	,	_	_	_	_	_	_	_	Seg=O
91	whereas	_	_	_	_	_	_	_	Seg=B-seg
92	the	_	_	_	_	_	_	_	Seg=O
93	A	_	_	_	_	_	_	_	Seg=O
94	/	_	_	_	_	_	_	_	Seg=O
95	duck	_	_	_	_	_	_	_	Seg=O
96	/	_	_	_	_	_	_	_	Seg=O
97	Nanjing/01/1999	_	_	_	_	_	_	_	Seg=O
98	(	_	_	_	_	_	_	_	Seg=O
99	NJ01	_	_	_	_	_	_	_	Seg=O
100	)	_	_	_	_	_	_	_	Seg=O
101	virus	_	_	_	_	_	_	_	Seg=O
102	was	_	_	_	_	_	_	_	Seg=O
103	low	_	_	_	_	_	_	_	Seg=O
104	pathogenic	_	_	_	_	_	_	_	Seg=O
105	for	_	_	_	_	_	_	_	Seg=O
106	mice	_	_	_	_	_	_	_	Seg=O
107	,	_	_	_	_	_	_	_	Seg=O
108	with	_	_	_	_	_	_	_	Seg=O
109	a	_	_	_	_	_	_	_	Seg=O
110	MLD	_	_	_	_	_	_	_	Seg=O
111	6.81	_	_	_	_	_	_	_	Seg=O
112	50	_	_	_	_	_	_	_	Seg=O
113	of	_	_	_	_	_	_	_	Seg=O
114	>	_	_	_	_	_	_	_	Seg=O
115	10	_	_	_	_	_	_	_	Seg=O
116	EID	_	_	_	_	_	_	_	Seg=O
117	50	_	_	_	_	_	_	_	Seg=O
118	.	_	_	_	_	_	_	_	Seg=O
119	Further	_	_	_	_	_	_	_	Seg=B-seg
120	studies	_	_	_	_	_	_	_	Seg=O
121	showed	_	_	_	_	_	_	_	Seg=O
122	that	_	_	_	_	_	_	_	Seg=B-seg
123	the	_	_	_	_	_	_	_	Seg=O
124	NJ06	_	_	_	_	_	_	_	Seg=O
125	virus	_	_	_	_	_	_	_	Seg=O
126	grew	_	_	_	_	_	_	_	Seg=O
127	faster	_	_	_	_	_	_	_	Seg=O
128	and	_	_	_	_	_	_	_	Seg=B-seg
129	reached	_	_	_	_	_	_	_	Seg=O
130	significantly	_	_	_	_	_	_	_	Seg=O
131	higher	_	_	_	_	_	_	_	Seg=O
132	titers	_	_	_	_	_	_	_	Seg=O
133	than	_	_	_	_	_	_	_	Seg=O
134	NJ01	_	_	_	_	_	_	_	Seg=O
135	in	_	_	_	_	_	_	_	Seg=O
136	vivo	_	_	_	_	_	_	_	Seg=O
137	and	_	_	_	_	_	_	_	Seg=O
138	in	_	_	_	_	_	_	_	Seg=O
139	vitro	_	_	_	_	_	_	_	Seg=O
140	.	_	_	_	_	_	_	_	Seg=O
141	Moreover	_	_	_	_	_	_	_	Seg=B-seg
142	,	_	_	_	_	_	_	_	Seg=O
143	the	_	_	_	_	_	_	_	Seg=O
144	NJ06	_	_	_	_	_	_	_	Seg=O
145	virus	_	_	_	_	_	_	_	Seg=O
146	induced	_	_	_	_	_	_	_	Seg=O
147	more	_	_	_	_	_	_	_	Seg=O
148	severe	_	_	_	_	_	_	_	Seg=O
149	lung	_	_	_	_	_	_	_	Seg=O
150	lesions	_	_	_	_	_	_	_	Seg=O
151	,	_	_	_	_	_	_	_	Seg=O
152	and	_	_	_	_	_	_	_	Seg=O
153	higher	_	_	_	_	_	_	_	Seg=O
154	levels	_	_	_	_	_	_	_	Seg=O
155	of	_	_	_	_	_	_	_	Seg=O
156	inflammatory	_	_	_	_	_	_	_	Seg=O
157	cellular	_	_	_	_	_	_	_	Seg=O
158	infiltration	_	_	_	_	_	_	_	Seg=O
159	and	_	_	_	_	_	_	_	Seg=O
160	cytokine	_	_	_	_	_	_	_	Seg=O
161	response	_	_	_	_	_	_	_	Seg=O
162	in	_	_	_	_	_	_	_	Seg=O
163	lungs	_	_	_	_	_	_	_	Seg=O
164	than	_	_	_	_	_	_	_	Seg=O
165	NJ01	_	_	_	_	_	_	_	Seg=O
166	did	_	_	_	_	_	_	_	Seg=O
167	.	_	_	_	_	_	_	_	Seg=O
168	However	_	_	_	_	_	_	_	Seg=B-seg
169	,	_	_	_	_	_	_	_	Seg=O
170	only	_	_	_	_	_	_	_	Seg=O
171	12	_	_	_	_	_	_	_	Seg=O
172	different	_	_	_	_	_	_	_	Seg=O
173	amino	_	_	_	_	_	_	_	Seg=O
174	acid	_	_	_	_	_	_	_	Seg=O
175	residues	_	_	_	_	_	_	_	Seg=O
176	(	_	_	_	_	_	_	_	Seg=B-seg
177	HA	_	_	_	_	_	_	_	Seg=O
178	-	_	_	_	_	_	_	_	Seg=O
179	K157E	_	_	_	_	_	_	_	Seg=O
180	,	_	_	_	_	_	_	_	Seg=O
181	NA	_	_	_	_	_	_	_	Seg=O
182	-	_	_	_	_	_	_	_	Seg=O
183	A9	_	_	_	_	_	_	_	Seg=O
184	T	_	_	_	_	_	_	_	Seg=O
185	,	_	_	_	_	_	_	_	Seg=O
186	NA	_	_	_	_	_	_	_	Seg=O
187	-	_	_	_	_	_	_	_	Seg=O
188	R435	_	_	_	_	_	_	_	Seg=O
189	K	_	_	_	_	_	_	_	Seg=O
190	,	_	_	_	_	_	_	_	Seg=O
191	PB2-T149P	_	_	_	_	_	_	_	Seg=O
192	,	_	_	_	_	_	_	_	Seg=O
193	PB2-K627E	_	_	_	_	_	_	_	Seg=O
194	,	_	_	_	_	_	_	_	Seg=O
195	PB1-R187	_	_	_	_	_	_	_	Seg=O
196	K	_	_	_	_	_	_	_	Seg=O
197	,	_	_	_	_	_	_	_	Seg=O
198	PA	_	_	_	_	_	_	_	Seg=O
199	-	_	_	_	_	_	_	_	Seg=O
200	L548	_	_	_	_	_	_	_	Seg=O
201	M	_	_	_	_	_	_	_	Seg=O
202	,	_	_	_	_	_	_	_	Seg=O
203	PA	_	_	_	_	_	_	_	Seg=O
204	-	_	_	_	_	_	_	_	Seg=O
205	M550L	_	_	_	_	_	_	_	Seg=O
206	,	_	_	_	_	_	_	_	Seg=O
207	NP	_	_	_	_	_	_	_	Seg=O
208	-	_	_	_	_	_	_	_	Seg=O
209	G127E	_	_	_	_	_	_	_	Seg=O
210	,	_	_	_	_	_	_	_	Seg=O
211	NP	_	_	_	_	_	_	_	Seg=O
212	-	_	_	_	_	_	_	_	Seg=O
213	P277H	_	_	_	_	_	_	_	Seg=O
214	,	_	_	_	_	_	_	_	Seg=O
215	NP	_	_	_	_	_	_	_	Seg=O
216	-	_	_	_	_	_	_	_	Seg=O
217	D340N	_	_	_	_	_	_	_	Seg=O
218	,	_	_	_	_	_	_	_	Seg=O
219	NS1-D171N	_	_	_	_	_	_	_	Seg=O
220	)	_	_	_	_	_	_	_	Seg=O
221	were	_	_	_	_	_	_	_	Seg=B-seg
222	found	_	_	_	_	_	_	_	Seg=O
223	between	_	_	_	_	_	_	_	Seg=O
224	the	_	_	_	_	_	_	_	Seg=O
225	two	_	_	_	_	_	_	_	Seg=O
226	viruses	_	_	_	_	_	_	_	Seg=O
227	,	_	_	_	_	_	_	_	Seg=O
228	and	_	_	_	_	_	_	_	Seg=B-seg
229	all	_	_	_	_	_	_	_	Seg=O
230	these	_	_	_	_	_	_	_	Seg=O
231	residues	_	_	_	_	_	_	_	Seg=O
232	except	_	_	_	_	_	_	_	Seg=O
233	for	_	_	_	_	_	_	_	Seg=O
234	NA	_	_	_	_	_	_	_	Seg=O
235	-	_	_	_	_	_	_	_	Seg=O
236	R435	_	_	_	_	_	_	_	Seg=O
237	K	_	_	_	_	_	_	_	Seg=O
238	were	_	_	_	_	_	_	_	Seg=O
239	located	_	_	_	_	_	_	_	Seg=O
240	in	_	_	_	_	_	_	_	Seg=O
241	the	_	_	_	_	_	_	_	Seg=O
242	known	_	_	_	_	_	_	_	Seg=O
243	functional	_	_	_	_	_	_	_	Seg=O
244	regions	_	_	_	_	_	_	_	Seg=O
245	involved	_	_	_	_	_	_	_	Seg=B-seg
246	in	_	_	_	_	_	_	_	Seg=O
247	interaction	_	_	_	_	_	_	_	Seg=O
248	of	_	_	_	_	_	_	_	Seg=O
249	viral	_	_	_	_	_	_	_	Seg=O
250	proteins	_	_	_	_	_	_	_	Seg=O
251	or	_	_	_	_	_	_	_	Seg=O
252	between	_	_	_	_	_	_	_	Seg=O
253	the	_	_	_	_	_	_	_	Seg=O
254	virus	_	_	_	_	_	_	_	Seg=O
255	and	_	_	_	_	_	_	_	Seg=O
256	host	_	_	_	_	_	_	_	Seg=O
257	factors	_	_	_	_	_	_	_	Seg=O
258	.	_	_	_	_	_	_	_	Seg=O
259	Summary	_	_	_	_	_	_	_	Seg=B-seg
260	,	_	_	_	_	_	_	_	Seg=O
261	our	_	_	_	_	_	_	_	Seg=O
262	results	_	_	_	_	_	_	_	Seg=O
263	suggest	_	_	_	_	_	_	_	Seg=O
264	that	_	_	_	_	_	_	_	Seg=B-seg
265	multiple	_	_	_	_	_	_	_	Seg=O
266	amino	_	_	_	_	_	_	_	Seg=O
267	acid	_	_	_	_	_	_	_	Seg=O
268	differences	_	_	_	_	_	_	_	Seg=O
269	may	_	_	_	_	_	_	_	Seg=O
270	be	_	_	_	_	_	_	_	Seg=O
271	responsible	_	_	_	_	_	_	_	Seg=O
272	for	_	_	_	_	_	_	_	Seg=O
273	the	_	_	_	_	_	_	_	Seg=O
274	higher	_	_	_	_	_	_	_	Seg=O
275	pathogenicity	_	_	_	_	_	_	_	Seg=O
276	of	_	_	_	_	_	_	_	Seg=O
277	the	_	_	_	_	_	_	_	Seg=O
278	NJ06	_	_	_	_	_	_	_	Seg=O
279	virus	_	_	_	_	_	_	_	Seg=O
280	for	_	_	_	_	_	_	_	Seg=O
281	mice	_	_	_	_	_	_	_	Seg=O
282	,	_	_	_	_	_	_	_	Seg=O
283	resulting	_	_	_	_	_	_	_	Seg=B-seg
284	in	_	_	_	_	_	_	_	Seg=O
285	lethal	_	_	_	_	_	_	_	Seg=O
286	infection	_	_	_	_	_	_	_	Seg=O
287	,	_	_	_	_	_	_	_	Seg=O
288	enhanced	_	_	_	_	_	_	_	Seg=O
289	viral	_	_	_	_	_	_	_	Seg=O
290	replication	_	_	_	_	_	_	_	Seg=O
291	,	_	_	_	_	_	_	_	Seg=O
292	severe	_	_	_	_	_	_	_	Seg=O
293	lung	_	_	_	_	_	_	_	Seg=O
294	lesions	_	_	_	_	_	_	_	Seg=O
295	,	_	_	_	_	_	_	_	Seg=O
296	and	_	_	_	_	_	_	_	Seg=O
297	excessive	_	_	_	_	_	_	_	Seg=O
298	inflammatory	_	_	_	_	_	_	_	Seg=O
299	cellular	_	_	_	_	_	_	_	Seg=O
300	infiltration	_	_	_	_	_	_	_	Seg=O
301	and	_	_	_	_	_	_	_	Seg=O
302	cytokine	_	_	_	_	_	_	_	Seg=O
303	response	_	_	_	_	_	_	_	Seg=O
304	in	_	_	_	_	_	_	_	Seg=O
305	lungs	_	_	_	_	_	_	_	Seg=O
306	.	_	_	_	_	_	_	_	Seg=O
307	These	_	_	_	_	_	_	_	Seg=B-seg
308	observations	_	_	_	_	_	_	_	Seg=O
309	will	_	_	_	_	_	_	_	Seg=O
310	be	_	_	_	_	_	_	_	Seg=O
311	helpful	_	_	_	_	_	_	_	Seg=O
312	for	_	_	_	_	_	_	_	Seg=O
313	better	_	_	_	_	_	_	_	Seg=O
314	understanding	_	_	_	_	_	_	_	Seg=O
315	the	_	_	_	_	_	_	_	Seg=O
316	pathogenic	_	_	_	_	_	_	_	Seg=O
317	potential	_	_	_	_	_	_	_	Seg=O
318	and	_	_	_	_	_	_	_	Seg=O
319	the	_	_	_	_	_	_	_	Seg=O
320	corresponding	_	_	_	_	_	_	_	Seg=O
321	molecular	_	_	_	_	_	_	_	Seg=O
322	basis	_	_	_	_	_	_	_	Seg=O
323	of	_	_	_	_	_	_	_	Seg=O
324	H9N2	_	_	_	_	_	_	_	Seg=O
325	viruses	_	_	_	_	_	_	_	Seg=O
326	that	_	_	_	_	_	_	_	Seg=B-seg
327	might	_	_	_	_	_	_	_	Seg=O
328	pose	_	_	_	_	_	_	_	Seg=O
329	threats	_	_	_	_	_	_	_	Seg=O
330	to	_	_	_	_	_	_	_	Seg=O
331	human	_	_	_	_	_	_	_	Seg=O
332	health	_	_	_	_	_	_	_	Seg=O
333	in	_	_	_	_	_	_	_	Seg=O
334	the	_	_	_	_	_	_	_	Seg=O
335	future	_	_	_	_	_	_	_	Seg=O
336	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 6c7490b3cf8a1eb555a400f3f2685d332be814e0
1	This	_	_	_	_	_	_	_	Seg=B-seg
2	paper	_	_	_	_	_	_	_	Seg=O
3	revisits	_	_	_	_	_	_	_	Seg=O
4-5	Jessop's	_	_	_	_	_	_	_	_
4	Jessop	_	_	_	_	_	_	_	Seg=O
5	's	_	_	_	_	_	_	_	Seg=O
6	governance	_	_	_	_	_	_	_	Seg=O
7	of	_	_	_	_	_	_	_	Seg=O
8	welfare	_	_	_	_	_	_	_	Seg=O
9	framework	_	_	_	_	_	_	_	Seg=O
10	,	_	_	_	_	_	_	_	Seg=O
11	suggesting	_	_	_	_	_	_	_	Seg=B-seg
12	that	_	_	_	_	_	_	_	Seg=B-seg
13	in	_	_	_	_	_	_	_	Seg=O
14	the	_	_	_	_	_	_	_	Seg=O
15	post	_	_	_	_	_	_	_	Seg=O
16	-	_	_	_	_	_	_	_	Seg=O
17	financial	_	_	_	_	_	_	_	Seg=O
18	crisis	_	_	_	_	_	_	_	Seg=O
19	era	_	_	_	_	_	_	_	Seg=O
20	of	_	_	_	_	_	_	_	Seg=O
21	austerity	_	_	_	_	_	_	_	Seg=O
22	we	_	_	_	_	_	_	_	Seg=O
23	need	_	_	_	_	_	_	_	Seg=O
24	to	_	_	_	_	_	_	_	Seg=O
25	look	_	_	_	_	_	_	_	Seg=O
26	again	_	_	_	_	_	_	_	Seg=O
27	at	_	_	_	_	_	_	_	Seg=O
28	its	_	_	_	_	_	_	_	Seg=O
29	analytical	_	_	_	_	_	_	_	Seg=O
30	dimensions	_	_	_	_	_	_	_	Seg=O
31	.	_	_	_	_	_	_	_	Seg=O
32	The	_	_	_	_	_	_	_	Seg=B-seg
33	paper	_	_	_	_	_	_	_	Seg=O
34	reformulates	_	_	_	_	_	_	_	Seg=O
35-36	Jessop's	_	_	_	_	_	_	_	_
35	Jessop	_	_	_	_	_	_	_	Seg=O
36	's	_	_	_	_	_	_	_	Seg=O
37	Schumpeterian	_	_	_	_	_	_	_	Seg=O
38	Welfare	_	_	_	_	_	_	_	Seg=O
39	Postnational	_	_	_	_	_	_	_	Seg=O
40	Regime	_	_	_	_	_	_	_	Seg=O
41	ideal	_	_	_	_	_	_	_	Seg=O
42	-	_	_	_	_	_	_	_	Seg=O
43	type	_	_	_	_	_	_	_	Seg=O
44	framework	_	_	_	_	_	_	_	Seg=O
45	through	_	_	_	_	_	_	_	Seg=O
46	critique	_	_	_	_	_	_	_	Seg=O
47	,	_	_	_	_	_	_	_	Seg=O
48	and	_	_	_	_	_	_	_	Seg=B-seg
49	then	_	_	_	_	_	_	_	Seg=O
50	applies	_	_	_	_	_	_	_	Seg=O
51	its	_	_	_	_	_	_	_	Seg=O
52	reformulated	_	_	_	_	_	_	_	Seg=O
53	Galbrathian	_	_	_	_	_	_	_	Seg=O
54	,	_	_	_	_	_	_	_	Seg=O
55	Affluent	_	_	_	_	_	_	_	Seg=O
56	Postnational	_	_	_	_	_	_	_	Seg=O
57	Oligarchy	_	_	_	_	_	_	_	Seg=O
58	ideal	_	_	_	_	_	_	_	Seg=O
59	-	_	_	_	_	_	_	_	Seg=O
60	type	_	_	_	_	_	_	_	Seg=O
61	to	_	_	_	_	_	_	_	Seg=O
62	the	_	_	_	_	_	_	_	Seg=O
63	case	_	_	_	_	_	_	_	Seg=O
64	of	_	_	_	_	_	_	_	Seg=O
65	the	_	_	_	_	_	_	_	Seg=O
66	English	_	_	_	_	_	_	_	Seg=O
67	NHS	_	_	_	_	_	_	_	Seg=O
68	to	_	_	_	_	_	_	_	Seg=B-seg
69	present	_	_	_	_	_	_	_	Seg=O
70	a	_	_	_	_	_	_	_	Seg=O
71	new	_	_	_	_	_	_	_	Seg=O
72	political	_	_	_	_	_	_	_	Seg=O
73	economy	_	_	_	_	_	_	_	Seg=O
74	of	_	_	_	_	_	_	_	Seg=O
75	health	_	_	_	_	_	_	_	Seg=O
76	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 6cc9687cc3d778c4599f09cf044627beffb07dca
1	There	_	_	_	_	_	_	_	Seg=B-seg
2	is	_	_	_	_	_	_	_	Seg=O
3	an	_	_	_	_	_	_	_	Seg=O
4	urgent	_	_	_	_	_	_	_	Seg=O
5	need	_	_	_	_	_	_	_	Seg=O
6	for	_	_	_	_	_	_	_	Seg=B-seg
7	new	_	_	_	_	_	_	_	Seg=O
8	therapeutic	_	_	_	_	_	_	_	Seg=O
9	strategies	_	_	_	_	_	_	_	Seg=O
10	to	_	_	_	_	_	_	_	Seg=O
11	contain	_	_	_	_	_	_	_	Seg=O
12	the	_	_	_	_	_	_	_	Seg=O
13	spread	_	_	_	_	_	_	_	Seg=O
14	of	_	_	_	_	_	_	_	Seg=O
15	the	_	_	_	_	_	_	_	Seg=O
16	novel	_	_	_	_	_	_	_	Seg=O
17	coronavirus	_	_	_	_	_	_	_	Seg=O
18	disease	_	_	_	_	_	_	_	Seg=O
19	2019	_	_	_	_	_	_	_	Seg=O
20	and	_	_	_	_	_	_	_	Seg=B-seg
21	to	_	_	_	_	_	_	_	Seg=O
22	curtail	_	_	_	_	_	_	_	Seg=O
23	its	_	_	_	_	_	_	_	Seg=O
24	most	_	_	_	_	_	_	_	Seg=O
25	severe	_	_	_	_	_	_	_	Seg=O
26	complications	_	_	_	_	_	_	_	Seg=O
27	.	_	_	_	_	_	_	_	Seg=O
28	Severely	_	_	_	_	_	_	_	Seg=B-seg
29	ill	_	_	_	_	_	_	_	Seg=O
30	patients	_	_	_	_	_	_	_	Seg=O
31	experience	_	_	_	_	_	_	_	Seg=O
32	pathologic	_	_	_	_	_	_	_	Seg=O
33	manifestations	_	_	_	_	_	_	_	Seg=O
34	of	_	_	_	_	_	_	_	Seg=O
35	acute	_	_	_	_	_	_	_	Seg=O
36	respiratory	_	_	_	_	_	_	_	Seg=O
37	distress	_	_	_	_	_	_	_	Seg=O
38	syndrome	_	_	_	_	_	_	_	Seg=O
39	(	_	_	_	_	_	_	_	Seg=O
40	ARDS	_	_	_	_	_	_	_	Seg=O
41	)	_	_	_	_	_	_	_	Seg=O
42	,	_	_	_	_	_	_	_	Seg=O
43	and	_	_	_	_	_	_	_	Seg=B-seg
44	clinical	_	_	_	_	_	_	_	Seg=O
45	reports	_	_	_	_	_	_	_	Seg=O
46	demonstrate	_	_	_	_	_	_	_	Seg=O
47	striking	_	_	_	_	_	_	_	Seg=O
48	neutrophilia	_	_	_	_	_	_	_	Seg=O
49	,	_	_	_	_	_	_	_	Seg=O
50	elevated	_	_	_	_	_	_	_	Seg=O
51	levels	_	_	_	_	_	_	_	Seg=O
52	of	_	_	_	_	_	_	_	Seg=O
53	multiple	_	_	_	_	_	_	_	Seg=O
54	cytokines	_	_	_	_	_	_	_	Seg=O
55	,	_	_	_	_	_	_	_	Seg=O
56	and	_	_	_	_	_	_	_	Seg=O
57	an	_	_	_	_	_	_	_	Seg=O
58	exaggerated	_	_	_	_	_	_	_	Seg=O
59	inflammatory	_	_	_	_	_	_	_	Seg=O
60	response	_	_	_	_	_	_	_	Seg=O
61	in	_	_	_	_	_	_	_	Seg=O
62	fatal	_	_	_	_	_	_	_	Seg=O
63	COVID-19	_	_	_	_	_	_	_	Seg=O
64	.	_	_	_	_	_	_	_	Seg=O
65	Mechanical	_	_	_	_	_	_	_	Seg=B-seg
66	respirator	_	_	_	_	_	_	_	Seg=O
67	devices	_	_	_	_	_	_	_	Seg=O
68	are	_	_	_	_	_	_	_	Seg=O
69	the	_	_	_	_	_	_	_	Seg=O
70	most	_	_	_	_	_	_	_	Seg=O
71	widely	_	_	_	_	_	_	_	Seg=O
72	applied	_	_	_	_	_	_	_	Seg=O
73	therapy	_	_	_	_	_	_	_	Seg=O
74	for	_	_	_	_	_	_	_	Seg=O
75	ARDS	_	_	_	_	_	_	_	Seg=O
76	in	_	_	_	_	_	_	_	Seg=O
77	COVID-19	_	_	_	_	_	_	_	Seg=O
78	,	_	_	_	_	_	_	_	Seg=O
79	yet	_	_	_	_	_	_	_	Seg=B-seg
80	mechanical	_	_	_	_	_	_	_	Seg=O
81	ventilation	_	_	_	_	_	_	_	Seg=O
82	achieves	_	_	_	_	_	_	_	Seg=O
83	strikingly	_	_	_	_	_	_	_	Seg=O
84	poor	_	_	_	_	_	_	_	Seg=O
85	survival	_	_	_	_	_	_	_	Seg=O
86	.	_	_	_	_	_	_	_	Seg=O
87	Many	_	_	_	_	_	_	_	Seg=B-seg
88	patients	_	_	_	_	_	_	_	Seg=O
89	,	_	_	_	_	_	_	_	Seg=O
90	who	_	_	_	_	_	_	_	Seg=B-seg
91	recover	_	_	_	_	_	_	_	Seg=O
92	,	_	_	_	_	_	_	_	Seg=O
93	experience	_	_	_	_	_	_	_	Seg=B-seg
94	impaired	_	_	_	_	_	_	_	Seg=O
95	cognition	_	_	_	_	_	_	_	Seg=O
96	or	_	_	_	_	_	_	_	Seg=O
97	physical	_	_	_	_	_	_	_	Seg=O
98	disability	_	_	_	_	_	_	_	Seg=O
99	.	_	_	_	_	_	_	_	Seg=O
100	In	_	_	_	_	_	_	_	Seg=B-seg
101	this	_	_	_	_	_	_	_	Seg=O
102	review	_	_	_	_	_	_	_	Seg=O
103	,	_	_	_	_	_	_	_	Seg=O
104	we	_	_	_	_	_	_	_	Seg=O
105	argue	_	_	_	_	_	_	_	Seg=O
106	the	_	_	_	_	_	_	_	Seg=O
107	need	_	_	_	_	_	_	_	Seg=O
108	to	_	_	_	_	_	_	_	Seg=B-seg
109	develop	_	_	_	_	_	_	_	Seg=O
110	therapies	_	_	_	_	_	_	_	Seg=O
111	aimed	_	_	_	_	_	_	_	Seg=B-seg
112	at	_	_	_	_	_	_	_	Seg=O
113	inhibiting	_	_	_	_	_	_	_	Seg=O
114	neutrophil	_	_	_	_	_	_	_	Seg=O
115	recruitment	_	_	_	_	_	_	_	Seg=O
116	,	_	_	_	_	_	_	_	Seg=O
117	activation	_	_	_	_	_	_	_	Seg=O
118	,	_	_	_	_	_	_	_	Seg=O
119	degranulation	_	_	_	_	_	_	_	Seg=O
120	,	_	_	_	_	_	_	_	Seg=O
121	and	_	_	_	_	_	_	_	Seg=O
122	neutrophil	_	_	_	_	_	_	_	Seg=O
123	extracellular	_	_	_	_	_	_	_	Seg=O
124	trap	_	_	_	_	_	_	_	Seg=O
125	(	_	_	_	_	_	_	_	Seg=O
126	NET	_	_	_	_	_	_	_	Seg=O
127	)	_	_	_	_	_	_	_	Seg=O
128	release	_	_	_	_	_	_	_	Seg=O
129	.	_	_	_	_	_	_	_	Seg=O
130	Moreover	_	_	_	_	_	_	_	Seg=B-seg
131	,	_	_	_	_	_	_	_	Seg=O
132	we	_	_	_	_	_	_	_	Seg=O
133	suggest	_	_	_	_	_	_	_	Seg=O
134	that	_	_	_	_	_	_	_	Seg=B-seg
135	currently	_	_	_	_	_	_	_	Seg=O
136	available	_	_	_	_	_	_	_	Seg=O
137	pharmacologic	_	_	_	_	_	_	_	Seg=O
138	approaches	_	_	_	_	_	_	_	Seg=O
139	should	_	_	_	_	_	_	_	Seg=O
140	be	_	_	_	_	_	_	_	Seg=O
141	tested	_	_	_	_	_	_	_	Seg=O
142	as	_	_	_	_	_	_	_	Seg=O
143	treatments	_	_	_	_	_	_	_	Seg=O
144	for	_	_	_	_	_	_	_	Seg=O
145	ARDS	_	_	_	_	_	_	_	Seg=O
146	in	_	_	_	_	_	_	_	Seg=O
147	COVID-19	_	_	_	_	_	_	_	Seg=O
148	.	_	_	_	_	_	_	_	Seg=O
149	In	_	_	_	_	_	_	_	Seg=B-seg
150	our	_	_	_	_	_	_	_	Seg=O
151	view	_	_	_	_	_	_	_	Seg=O
152	,	_	_	_	_	_	_	_	Seg=O
153	targeting	_	_	_	_	_	_	_	Seg=O
154	host	_	_	_	_	_	_	_	Seg=O
155	-	_	_	_	_	_	_	_	Seg=O
156	mediated	_	_	_	_	_	_	_	Seg=O
157	immunopathology	_	_	_	_	_	_	_	Seg=O
158	holds	_	_	_	_	_	_	_	Seg=O
159	promise	_	_	_	_	_	_	_	Seg=O
160	to	_	_	_	_	_	_	_	Seg=B-seg
161	alleviate	_	_	_	_	_	_	_	Seg=O
162	progressive	_	_	_	_	_	_	_	Seg=O
163	pathologic	_	_	_	_	_	_	_	Seg=O
164	complications	_	_	_	_	_	_	_	Seg=O
165	of	_	_	_	_	_	_	_	Seg=O
166	ARDS	_	_	_	_	_	_	_	Seg=O
167	and	_	_	_	_	_	_	_	Seg=B-seg
168	reduce	_	_	_	_	_	_	_	Seg=O
169	morbidities	_	_	_	_	_	_	_	Seg=O
170	and	_	_	_	_	_	_	_	Seg=O
171	mortalities	_	_	_	_	_	_	_	Seg=O
172	in	_	_	_	_	_	_	_	Seg=O
173	severely	_	_	_	_	_	_	_	Seg=O
174	ill	_	_	_	_	_	_	_	Seg=O
175	patients	_	_	_	_	_	_	_	Seg=O
176	with	_	_	_	_	_	_	_	Seg=O
177	COVID-19	_	_	_	_	_	_	_	Seg=O
178	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 6eca16767700a8bd776371e815cf5e85d5195f11
1	The	_	_	_	_	_	_	_	Seg=B-seg
2	coronavirus	_	_	_	_	_	_	_	Seg=O
3	disease	_	_	_	_	_	_	_	Seg=O
4	(	_	_	_	_	_	_	_	Seg=O
5	COVID-19	_	_	_	_	_	_	_	Seg=O
6	)	_	_	_	_	_	_	_	Seg=O
7	pandemic	_	_	_	_	_	_	_	Seg=O
8	has	_	_	_	_	_	_	_	Seg=O
9	posed	_	_	_	_	_	_	_	Seg=O
10	a	_	_	_	_	_	_	_	Seg=O
11	challenge	_	_	_	_	_	_	_	Seg=O
12	for	_	_	_	_	_	_	_	Seg=O
13	healthcare	_	_	_	_	_	_	_	Seg=O
14	systems	_	_	_	_	_	_	_	Seg=O
15	,	_	_	_	_	_	_	_	Seg=O
16	and	_	_	_	_	_	_	_	Seg=B-seg
17	healthcare	_	_	_	_	_	_	_	Seg=O
18	workers	_	_	_	_	_	_	_	Seg=O
19	(	_	_	_	_	_	_	_	Seg=O
20	HCWs	_	_	_	_	_	_	_	Seg=O
21	)	_	_	_	_	_	_	_	Seg=O
22	are	_	_	_	_	_	_	_	Seg=O
23	at	_	_	_	_	_	_	_	Seg=O
24	high	_	_	_	_	_	_	_	Seg=O
25	risk	_	_	_	_	_	_	_	Seg=O
26	of	_	_	_	_	_	_	_	Seg=O
27	exposure	_	_	_	_	_	_	_	Seg=O
28	.	_	_	_	_	_	_	_	Seg=O
29	Protecting	_	_	_	_	_	_	_	Seg=B-seg
30	HCWs	_	_	_	_	_	_	_	Seg=O
31	is	_	_	_	_	_	_	_	Seg=O
32	of	_	_	_	_	_	_	_	Seg=O
33	paramount	_	_	_	_	_	_	_	Seg=O
34	importance	_	_	_	_	_	_	_	Seg=O
35	to	_	_	_	_	_	_	_	Seg=B-seg
36	maintain	_	_	_	_	_	_	_	Seg=O
37	continuous	_	_	_	_	_	_	_	Seg=O
38	patient	_	_	_	_	_	_	_	Seg=O
39	care	_	_	_	_	_	_	_	Seg=O
40	and	_	_	_	_	_	_	_	Seg=B-seg
41	keep	_	_	_	_	_	_	_	Seg=O
42	healthcare	_	_	_	_	_	_	_	Seg=O
43	systems	_	_	_	_	_	_	_	Seg=O
44	functioning	_	_	_	_	_	_	_	Seg=O
45	.	_	_	_	_	_	_	_	Seg=O
46	Used	_	_	_	_	_	_	_	Seg=B-seg
47	alongside	_	_	_	_	_	_	_	Seg=O
48	administrative	_	_	_	_	_	_	_	Seg=O
49	and	_	_	_	_	_	_	_	Seg=O
50	engineering	_	_	_	_	_	_	_	Seg=O
51	control	_	_	_	_	_	_	_	Seg=O
52	measures	_	_	_	_	_	_	_	Seg=O
53	,	_	_	_	_	_	_	_	Seg=O
54	personal	_	_	_	_	_	_	_	Seg=B-seg
55	protective	_	_	_	_	_	_	_	Seg=O
56	equipment	_	_	_	_	_	_	_	Seg=O
57	(	_	_	_	_	_	_	_	Seg=O
58	PPE	_	_	_	_	_	_	_	Seg=O
59	)	_	_	_	_	_	_	_	Seg=O
60	is	_	_	_	_	_	_	_	Seg=O
61	the	_	_	_	_	_	_	_	Seg=O
62	last	_	_	_	_	_	_	_	Seg=O
63	line	_	_	_	_	_	_	_	Seg=O
64	of	_	_	_	_	_	_	_	Seg=O
65	defense	_	_	_	_	_	_	_	Seg=O
66	and	_	_	_	_	_	_	_	Seg=O
67	the	_	_	_	_	_	_	_	Seg=O
68	core	_	_	_	_	_	_	_	Seg=O
69	component	_	_	_	_	_	_	_	Seg=O
70	of	_	_	_	_	_	_	_	Seg=O
71	protection	_	_	_	_	_	_	_	Seg=O
72	.	_	_	_	_	_	_	_	Seg=O
73	Current	_	_	_	_	_	_	_	Seg=B-seg
74	data	_	_	_	_	_	_	_	Seg=O
75	suggest	_	_	_	_	_	_	_	Seg=O
76	that	_	_	_	_	_	_	_	Seg=B-seg
77	severe	_	_	_	_	_	_	_	Seg=O
78	acute	_	_	_	_	_	_	_	Seg=O
79	respiratory	_	_	_	_	_	_	_	Seg=O
80	syndrome	_	_	_	_	_	_	_	Seg=O
81	coronavirus	_	_	_	_	_	_	_	Seg=O
82	2	_	_	_	_	_	_	_	Seg=O
83	(	_	_	_	_	_	_	_	Seg=O
84	SARS	_	_	_	_	_	_	_	Seg=O
85	-	_	_	_	_	_	_	_	Seg=O
86	CoV-2	_	_	_	_	_	_	_	Seg=O
87	)	_	_	_	_	_	_	_	Seg=O
88	is	_	_	_	_	_	_	_	Seg=O
89	mainly	_	_	_	_	_	_	_	Seg=O
90	transmitted	_	_	_	_	_	_	_	Seg=O
91	through	_	_	_	_	_	_	_	Seg=O
92	respiratory	_	_	_	_	_	_	_	Seg=O
93	droplets	_	_	_	_	_	_	_	Seg=O
94	and	_	_	_	_	_	_	_	Seg=O
95	close	_	_	_	_	_	_	_	Seg=O
96	contact	_	_	_	_	_	_	_	Seg=O
97	.	_	_	_	_	_	_	_	Seg=O
98	Airborne	_	_	_	_	_	_	_	Seg=B-seg
99	transmission	_	_	_	_	_	_	_	Seg=O
100	may	_	_	_	_	_	_	_	Seg=O
101	occur	_	_	_	_	_	_	_	Seg=O
102	during	_	_	_	_	_	_	_	Seg=O
103	aerosol	_	_	_	_	_	_	_	Seg=O
104	-	_	_	_	_	_	_	_	Seg=O
105	generating	_	_	_	_	_	_	_	Seg=O
106	procedures	_	_	_	_	_	_	_	Seg=O
107	.	_	_	_	_	_	_	_	Seg=O
108	However	_	_	_	_	_	_	_	Seg=B-seg
109	,	_	_	_	_	_	_	_	Seg=O
110	the	_	_	_	_	_	_	_	Seg=O
111	modes	_	_	_	_	_	_	_	Seg=O
112	of	_	_	_	_	_	_	_	Seg=O
113	transmission	_	_	_	_	_	_	_	Seg=O
114	still	_	_	_	_	_	_	_	Seg=O
115	remain	_	_	_	_	_	_	_	Seg=O
116	uncertain	_	_	_	_	_	_	_	Seg=O
117	,	_	_	_	_	_	_	_	Seg=O
118	especially	_	_	_	_	_	_	_	Seg=B-seg
119	regarding	_	_	_	_	_	_	_	Seg=O
120	the	_	_	_	_	_	_	_	Seg=O
121	possibility	_	_	_	_	_	_	_	Seg=O
122	of	_	_	_	_	_	_	_	Seg=O
123	airborne	_	_	_	_	_	_	_	Seg=O
124	transmission	_	_	_	_	_	_	_	Seg=O
125	when	_	_	_	_	_	_	_	Seg=B-seg
126	aerosolgenerating	_	_	_	_	_	_	_	Seg=O
127	procedures	_	_	_	_	_	_	_	Seg=O
128	are	_	_	_	_	_	_	_	Seg=O
129	not	_	_	_	_	_	_	_	Seg=O
130	performed	_	_	_	_	_	_	_	Seg=O
131	.	_	_	_	_	_	_	_	Seg=O
132	Thus	_	_	_	_	_	_	_	Seg=B-seg
133	,	_	_	_	_	_	_	_	Seg=O
134	there	_	_	_	_	_	_	_	Seg=O
135	are	_	_	_	_	_	_	_	Seg=O
136	some	_	_	_	_	_	_	_	Seg=O
137	inconsistencies	_	_	_	_	_	_	_	Seg=O
138	in	_	_	_	_	_	_	_	Seg=O
139	the	_	_	_	_	_	_	_	Seg=O
140	respiratory	_	_	_	_	_	_	_	Seg=O
141	protective	_	_	_	_	_	_	_	Seg=O
142	equipment	_	_	_	_	_	_	_	Seg=O
143	recommended	_	_	_	_	_	_	_	Seg=B-seg
144	by	_	_	_	_	_	_	_	Seg=O
145	international	_	_	_	_	_	_	_	Seg=O
146	and	_	_	_	_	_	_	_	Seg=O
147	national	_	_	_	_	_	_	_	Seg=O
148	organizations	_	_	_	_	_	_	_	Seg=O
149	.	_	_	_	_	_	_	_	Seg=O
150	In	_	_	_	_	_	_	_	Seg=B-seg
151	Korea	_	_	_	_	_	_	_	Seg=O
152	,	_	_	_	_	_	_	_	Seg=O
153	there	_	_	_	_	_	_	_	Seg=O
154	have	_	_	_	_	_	_	_	Seg=O
155	been	_	_	_	_	_	_	_	Seg=O
156	several	_	_	_	_	_	_	_	Seg=O
157	modifications	_	_	_	_	_	_	_	Seg=O
158	to	_	_	_	_	_	_	_	Seg=O
159	PPE	_	_	_	_	_	_	_	Seg=O
160	recommendations	_	_	_	_	_	_	_	Seg=O
161	offering	_	_	_	_	_	_	_	Seg=B-seg
162	options	_	_	_	_	_	_	_	Seg=O
163	in	_	_	_	_	_	_	_	Seg=B-seg
164	choosing	_	_	_	_	_	_	_	Seg=O
165	PPE	_	_	_	_	_	_	_	Seg=O
166	for	_	_	_	_	_	_	_	Seg=O
167	respiratory	_	_	_	_	_	_	_	Seg=O
168	and	_	_	_	_	_	_	_	Seg=O
169	body	_	_	_	_	_	_	_	Seg=O
170	protection	_	_	_	_	_	_	_	Seg=O
171	,	_	_	_	_	_	_	_	Seg=O
172	which	_	_	_	_	_	_	_	Seg=B-seg
173	confuses	_	_	_	_	_	_	_	Seg=O
174	HCWs	_	_	_	_	_	_	_	Seg=O
175	;	_	_	_	_	_	_	_	Seg=O
176	they	_	_	_	_	_	_	_	Seg=B-seg
177	are	_	_	_	_	_	_	_	Seg=O
178	often	_	_	_	_	_	_	_	Seg=O
179	unsure	_	_	_	_	_	_	_	Seg=O
180	what	_	_	_	_	_	_	_	Seg=O
181	to	_	_	_	_	_	_	_	Seg=O
182	wear	_	_	_	_	_	_	_	Seg=O
183	and	_	_	_	_	_	_	_	Seg=O
184	when	_	_	_	_	_	_	_	Seg=O
185	to	_	_	_	_	_	_	_	Seg=O
186	wear	_	_	_	_	_	_	_	Seg=O
187	it	_	_	_	_	_	_	_	Seg=O
188	.	_	_	_	_	_	_	_	Seg=O
189	The	_	_	_	_	_	_	_	Seg=B-seg
190	choice	_	_	_	_	_	_	_	Seg=O
191	of	_	_	_	_	_	_	_	Seg=O
192	PPE	_	_	_	_	_	_	_	Seg=O
193	is	_	_	_	_	_	_	_	Seg=O
194	based	_	_	_	_	_	_	_	Seg=O
195	on	_	_	_	_	_	_	_	Seg=O
196	the	_	_	_	_	_	_	_	Seg=O
197	risk	_	_	_	_	_	_	_	Seg=O
198	of	_	_	_	_	_	_	_	Seg=O
199	exposure	_	_	_	_	_	_	_	Seg=O
200	and	_	_	_	_	_	_	_	Seg=O
201	possible	_	_	_	_	_	_	_	Seg=O
202	modes	_	_	_	_	_	_	_	Seg=O
203	of	_	_	_	_	_	_	_	Seg=O
204	transmission	_	_	_	_	_	_	_	Seg=O
205	.	_	_	_	_	_	_	_	Seg=O
206	The	_	_	_	_	_	_	_	Seg=B-seg
207	level	_	_	_	_	_	_	_	Seg=O
208	of	_	_	_	_	_	_	_	Seg=O
209	protection	_	_	_	_	_	_	_	Seg=O
210	provided	_	_	_	_	_	_	_	Seg=B-seg
211	by	_	_	_	_	_	_	_	Seg=O
212	PPE	_	_	_	_	_	_	_	Seg=O
213	differs	_	_	_	_	_	_	_	Seg=B-seg
214	based	_	_	_	_	_	_	_	Seg=B-seg
215	on	_	_	_	_	_	_	_	Seg=O
216	standards	_	_	_	_	_	_	_	Seg=O
217	and	_	_	_	_	_	_	_	Seg=O
218	test	_	_	_	_	_	_	_	Seg=O
219	methods	_	_	_	_	_	_	_	Seg=O
220	.	_	_	_	_	_	_	_	Seg=O
221	Thus	_	_	_	_	_	_	_	Seg=B-seg
222	,	_	_	_	_	_	_	_	Seg=O
223	understanding	_	_	_	_	_	_	_	Seg=O
224	them	_	_	_	_	_	_	_	Seg=O
225	is	_	_	_	_	_	_	_	Seg=O
226	the	_	_	_	_	_	_	_	Seg=O
227	key	_	_	_	_	_	_	_	Seg=O
228	in	_	_	_	_	_	_	_	Seg=B-seg
229	selecting	_	_	_	_	_	_	_	Seg=O
230	the	_	_	_	_	_	_	_	Seg=O
231	proper	_	_	_	_	_	_	_	Seg=O
232	PPE	_	_	_	_	_	_	_	Seg=O
233	.	_	_	_	_	_	_	_	Seg=O
234	This	_	_	_	_	_	_	_	Seg=B-seg
235	article	_	_	_	_	_	_	_	Seg=O
236	reviews	_	_	_	_	_	_	_	Seg=O
237	evidence	_	_	_	_	_	_	_	Seg=O
238	on	_	_	_	_	_	_	_	Seg=O
239	the	_	_	_	_	_	_	_	Seg=O
240	mode	_	_	_	_	_	_	_	Seg=O
241	of	_	_	_	_	_	_	_	Seg=O
242	SARS	_	_	_	_	_	_	_	Seg=O
243	-	_	_	_	_	_	_	_	Seg=O
244	CoV-2	_	_	_	_	_	_	_	Seg=O
245	transmission	_	_	_	_	_	_	_	Seg=O
246	,	_	_	_	_	_	_	_	Seg=O
247	compares	_	_	_	_	_	_	_	Seg=B-seg
248	the	_	_	_	_	_	_	_	Seg=O
249	current	_	_	_	_	_	_	_	Seg=O
250	PPE	_	_	_	_	_	_	_	Seg=O
251	recommendations	_	_	_	_	_	_	_	Seg=O
252	of	_	_	_	_	_	_	_	Seg=O
253	the	_	_	_	_	_	_	_	Seg=O
254	World	_	_	_	_	_	_	_	Seg=O
255	Health	_	_	_	_	_	_	_	Seg=O
256	Organization	_	_	_	_	_	_	_	Seg=O
257	with	_	_	_	_	_	_	_	Seg=O
258	those	_	_	_	_	_	_	_	Seg=O
259	in	_	_	_	_	_	_	_	Seg=O
260	Korea	_	_	_	_	_	_	_	Seg=O
261	,	_	_	_	_	_	_	_	Seg=O
262	and	_	_	_	_	_	_	_	Seg=B-seg
263	discusses	_	_	_	_	_	_	_	Seg=O
264	standard	_	_	_	_	_	_	_	Seg=O
265	requirements	_	_	_	_	_	_	_	Seg=O
266	and	_	_	_	_	_	_	_	Seg=O
267	the	_	_	_	_	_	_	_	Seg=O
268	proper	_	_	_	_	_	_	_	Seg=O
269	selection	_	_	_	_	_	_	_	Seg=O
270	of	_	_	_	_	_	_	_	Seg=O
271	PPE	_	_	_	_	_	_	_	Seg=O
272	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 70051fcbe18013e7d3e7476158e7893ed2cc7cc8
1	Knowledge	_	_	_	_	_	_	_	Seg=B-seg
2	about	_	_	_	_	_	_	_	Seg=O
3	the	_	_	_	_	_	_	_	Seg=O
4	molecular	_	_	_	_	_	_	_	Seg=O
5	basis	_	_	_	_	_	_	_	Seg=O
6	of	_	_	_	_	_	_	_	Seg=O
7	SARS	_	_	_	_	_	_	_	Seg=O
8	-	_	_	_	_	_	_	_	Seg=O
9	CoV-2	_	_	_	_	_	_	_	Seg=O
10	infection	_	_	_	_	_	_	_	Seg=O
11	is	_	_	_	_	_	_	_	Seg=O
12	incipient	_	_	_	_	_	_	_	Seg=O
13	.	_	_	_	_	_	_	_	Seg=O
14	However	_	_	_	_	_	_	_	Seg=B-seg
15	,	_	_	_	_	_	_	_	Seg=O
16	recent	_	_	_	_	_	_	_	Seg=O
17	experimental	_	_	_	_	_	_	_	Seg=O
18	results	_	_	_	_	_	_	_	Seg=O
19	about	_	_	_	_	_	_	_	Seg=O
20	the	_	_	_	_	_	_	_	Seg=O
21	virus	_	_	_	_	_	_	_	Seg=O
22	interactome	_	_	_	_	_	_	_	Seg=O
23	have	_	_	_	_	_	_	_	Seg=O
24	shown	_	_	_	_	_	_	_	Seg=O
25	that	_	_	_	_	_	_	_	Seg=B-seg
26	this	_	_	_	_	_	_	_	Seg=O
27	single	_	_	_	_	_	_	_	Seg=O
28	-	_	_	_	_	_	_	_	Seg=O
29	positive	_	_	_	_	_	_	_	Seg=O
30	stranded	_	_	_	_	_	_	_	Seg=O
31	RNA	_	_	_	_	_	_	_	Seg=O
32	virus	_	_	_	_	_	_	_	Seg=O
33	produces	_	_	_	_	_	_	_	Seg=O
34	a	_	_	_	_	_	_	_	Seg=O
35	set	_	_	_	_	_	_	_	Seg=O
36	of	_	_	_	_	_	_	_	Seg=O
37	about	_	_	_	_	_	_	_	Seg=O
38	28	_	_	_	_	_	_	_	Seg=O
39	specific	_	_	_	_	_	_	_	Seg=O
40	proteins	_	_	_	_	_	_	_	Seg=O
41	grouped	_	_	_	_	_	_	_	Seg=B-seg
42	into	_	_	_	_	_	_	_	Seg=O
43	16	_	_	_	_	_	_	_	Seg=O
44	non	_	_	_	_	_	_	_	Seg=O
45	-	_	_	_	_	_	_	_	Seg=O
46	structural	_	_	_	_	_	_	_	Seg=O
47	proteins	_	_	_	_	_	_	_	Seg=O
48	(	_	_	_	_	_	_	_	Seg=B-seg
49	Nsp1	_	_	_	_	_	_	_	Seg=O
50	to	_	_	_	_	_	_	_	Seg=O
51	Nsp16	_	_	_	_	_	_	_	Seg=O
52	)	_	_	_	_	_	_	_	Seg=O
53	,	_	_	_	_	_	_	_	Seg=O
54	four	_	_	_	_	_	_	_	Seg=B-seg
55	structural	_	_	_	_	_	_	_	Seg=O
56	proteins	_	_	_	_	_	_	_	Seg=O
57	(	_	_	_	_	_	_	_	Seg=B-seg
58	E	_	_	_	_	_	_	_	Seg=O
59	,	_	_	_	_	_	_	_	Seg=O
60	M	_	_	_	_	_	_	_	Seg=O
61	,	_	_	_	_	_	_	_	Seg=O
62	N	_	_	_	_	_	_	_	Seg=O
63	,	_	_	_	_	_	_	_	Seg=O
64	and	_	_	_	_	_	_	_	Seg=O
65	S	_	_	_	_	_	_	_	Seg=O
66	)	_	_	_	_	_	_	_	Seg=O
67	,	_	_	_	_	_	_	_	Seg=O
68	and	_	_	_	_	_	_	_	Seg=B-seg
69	eight	_	_	_	_	_	_	_	Seg=O
70	accessory	_	_	_	_	_	_	_	Seg=O
71	proteins	_	_	_	_	_	_	_	Seg=O
72	(	_	_	_	_	_	_	_	Seg=B-seg
73	orf3a	_	_	_	_	_	_	_	Seg=O
74	,	_	_	_	_	_	_	_	Seg=O
75	orf6	_	_	_	_	_	_	_	Seg=O
76	,	_	_	_	_	_	_	_	Seg=O
77	orf7a	_	_	_	_	_	_	_	Seg=O
78	,	_	_	_	_	_	_	_	Seg=O
79	orf7b	_	_	_	_	_	_	_	Seg=O
80	,	_	_	_	_	_	_	_	Seg=O
81	orf8	_	_	_	_	_	_	_	Seg=O
82	,	_	_	_	_	_	_	_	Seg=O
83	orf9b	_	_	_	_	_	_	_	Seg=O
84	,	_	_	_	_	_	_	_	Seg=O
85	orf9c	_	_	_	_	_	_	_	Seg=O
86	,	_	_	_	_	_	_	_	Seg=O
87	and	_	_	_	_	_	_	_	Seg=O
88	orf10	_	_	_	_	_	_	_	Seg=O
89	)	_	_	_	_	_	_	_	Seg=O
90	.	_	_	_	_	_	_	_	Seg=O
91	In	_	_	_	_	_	_	_	Seg=B-seg
92	this	_	_	_	_	_	_	_	Seg=O
93	brief	_	_	_	_	_	_	_	Seg=O
94	communication	_	_	_	_	_	_	_	Seg=O
95	,	_	_	_	_	_	_	_	Seg=O
96	the	_	_	_	_	_	_	_	Seg=O
97	network	_	_	_	_	_	_	_	Seg=O
98	model	_	_	_	_	_	_	_	Seg=O
99	of	_	_	_	_	_	_	_	Seg=O
100	the	_	_	_	_	_	_	_	Seg=O
101	interactome	_	_	_	_	_	_	_	Seg=O
102	of	_	_	_	_	_	_	_	Seg=O
103	these	_	_	_	_	_	_	_	Seg=O
104	viral	_	_	_	_	_	_	_	Seg=O
105	proteins	_	_	_	_	_	_	_	Seg=O
106	with	_	_	_	_	_	_	_	Seg=O
107	the	_	_	_	_	_	_	_	Seg=O
108	host	_	_	_	_	_	_	_	Seg=O
109	proteins	_	_	_	_	_	_	_	Seg=O
110	is	_	_	_	_	_	_	_	Seg=O
111	analyzed	_	_	_	_	_	_	_	Seg=O
112	.	_	_	_	_	_	_	_	Seg=O
113	The	_	_	_	_	_	_	_	Seg=B-seg
114	statistical	_	_	_	_	_	_	_	Seg=O
115	analysis	_	_	_	_	_	_	_	Seg=O
116	of	_	_	_	_	_	_	_	Seg=O
117	this	_	_	_	_	_	_	_	Seg=O
118	network	_	_	_	_	_	_	_	Seg=O
119	shows	_	_	_	_	_	_	_	Seg=O
120	that	_	_	_	_	_	_	_	Seg=B-seg
121	it	_	_	_	_	_	_	_	Seg=O
122	has	_	_	_	_	_	_	_	Seg=O
123	a	_	_	_	_	_	_	_	Seg=O
124	modular	_	_	_	_	_	_	_	Seg=O
125	scale	_	_	_	_	_	_	_	Seg=O
126	-	_	_	_	_	_	_	_	Seg=O
127	free	_	_	_	_	_	_	_	Seg=O
128	topology	_	_	_	_	_	_	_	Seg=O
129	in	_	_	_	_	_	_	_	Seg=B-seg
130	which	_	_	_	_	_	_	_	Seg=O
131	the	_	_	_	_	_	_	_	Seg=O
132	virus	_	_	_	_	_	_	_	Seg=O
133	proteins	_	_	_	_	_	_	_	Seg=O
134	orf8	_	_	_	_	_	_	_	Seg=O
135	,	_	_	_	_	_	_	_	Seg=O
136	M	_	_	_	_	_	_	_	Seg=O
137	,	_	_	_	_	_	_	_	Seg=O
138	and	_	_	_	_	_	_	_	Seg=O
139	Nsp7	_	_	_	_	_	_	_	Seg=O
140	are	_	_	_	_	_	_	_	Seg=O
141	the	_	_	_	_	_	_	_	Seg=O
142	three	_	_	_	_	_	_	_	Seg=O
143	nodes	_	_	_	_	_	_	_	Seg=O
144	with	_	_	_	_	_	_	_	Seg=O
145	the	_	_	_	_	_	_	_	Seg=O
146	most	_	_	_	_	_	_	_	Seg=O
147	connections	_	_	_	_	_	_	_	Seg=O
148	(	_	_	_	_	_	_	_	Seg=O
149	links	_	_	_	_	_	_	_	Seg=O
150	)	_	_	_	_	_	_	_	Seg=O
151	.	_	_	_	_	_	_	_	Seg=O
152	This	_	_	_	_	_	_	_	Seg=B-seg
153	result	_	_	_	_	_	_	_	Seg=O
154	suggests	_	_	_	_	_	_	_	Seg=O
155	the	_	_	_	_	_	_	_	Seg=O
156	possibility	_	_	_	_	_	_	_	Seg=O
157	that	_	_	_	_	_	_	_	Seg=B-seg
158	a	_	_	_	_	_	_	_	Seg=O
159	simultaneous	_	_	_	_	_	_	_	Seg=O
160	pharmacological	_	_	_	_	_	_	_	Seg=O
161	attack	_	_	_	_	_	_	_	Seg=O
162	on	_	_	_	_	_	_	_	Seg=O
163	these	_	_	_	_	_	_	_	Seg=O
164	hubs	_	_	_	_	_	_	_	Seg=O
165	could	_	_	_	_	_	_	_	Seg=O
166	assure	_	_	_	_	_	_	_	Seg=O
167	the	_	_	_	_	_	_	_	Seg=O
168	destruction	_	_	_	_	_	_	_	Seg=O
169	of	_	_	_	_	_	_	_	Seg=O
170	the	_	_	_	_	_	_	_	Seg=O
171	network	_	_	_	_	_	_	_	Seg=O
172	and	_	_	_	_	_	_	_	Seg=O
173	the	_	_	_	_	_	_	_	Seg=O
174	elimination	_	_	_	_	_	_	_	Seg=O
175	of	_	_	_	_	_	_	_	Seg=O
176	the	_	_	_	_	_	_	_	Seg=O
177	virus	_	_	_	_	_	_	_	Seg=O
178	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 715bb1882a9b2b1bb0561bbd02a158f6deae2745
1	Viral	_	_	_	_	_	_	_	Seg=B-seg
2	influenza	_	_	_	_	_	_	_	Seg=O
3	is	_	_	_	_	_	_	_	Seg=O
4	a	_	_	_	_	_	_	_	Seg=O
5	seasonal	_	_	_	_	_	_	_	Seg=O
6	infection	_	_	_	_	_	_	_	Seg=O
7	associated	_	_	_	_	_	_	_	Seg=B-seg
8	with	_	_	_	_	_	_	_	Seg=O
9	significant	_	_	_	_	_	_	_	Seg=O
10	morbidity	_	_	_	_	_	_	_	Seg=O
11	and	_	_	_	_	_	_	_	Seg=O
12	mortality	_	_	_	_	_	_	_	Seg=O
13	.	_	_	_	_	_	_	_	Seg=O
14	In	_	_	_	_	_	_	_	Seg=B-seg
15	the	_	_	_	_	_	_	_	Seg=O
16	United	_	_	_	_	_	_	_	Seg=O
17	States	_	_	_	_	_	_	_	Seg=O
18	more	_	_	_	_	_	_	_	Seg=O
19	than	_	_	_	_	_	_	_	Seg=O
20	35,000	_	_	_	_	_	_	_	Seg=O
21	deaths	_	_	_	_	_	_	_	Seg=O
22	and	_	_	_	_	_	_	_	Seg=O
23	200,000	_	_	_	_	_	_	_	Seg=O
24	hospitalizations	_	_	_	_	_	_	_	Seg=O
25	due	_	_	_	_	_	_	_	Seg=B-seg
26	to	_	_	_	_	_	_	_	Seg=O
27	influenza	_	_	_	_	_	_	_	Seg=O
28	occur	_	_	_	_	_	_	_	Seg=B-seg
29	annually	_	_	_	_	_	_	_	Seg=O
30	,	_	_	_	_	_	_	_	Seg=O
31	and	_	_	_	_	_	_	_	Seg=B-seg
32	the	_	_	_	_	_	_	_	Seg=O
33	number	_	_	_	_	_	_	_	Seg=O
34	is	_	_	_	_	_	_	_	Seg=O
35	increasing	_	_	_	_	_	_	_	Seg=O
36	.	_	_	_	_	_	_	_	Seg=O
37	Children	_	_	_	_	_	_	_	Seg=B-seg
38	aged	_	_	_	_	_	_	_	Seg=B-seg
39	less	_	_	_	_	_	_	_	Seg=O
40	than	_	_	_	_	_	_	_	Seg=O
41	1	_	_	_	_	_	_	_	Seg=O
42	year	_	_	_	_	_	_	_	Seg=O
43	and	_	_	_	_	_	_	_	Seg=B-seg
44	adults	_	_	_	_	_	_	_	Seg=O
45	aged	_	_	_	_	_	_	_	Seg=B-seg
46	more	_	_	_	_	_	_	_	Seg=O
47	than	_	_	_	_	_	_	_	Seg=O
48	65	_	_	_	_	_	_	_	Seg=O
49	years	_	_	_	_	_	_	_	Seg=O
50	,	_	_	_	_	_	_	_	Seg=O
51	pregnant	_	_	_	_	_	_	_	Seg=B-seg
52	woman	_	_	_	_	_	_	_	Seg=O
53	,	_	_	_	_	_	_	_	Seg=O
54	and	_	_	_	_	_	_	_	Seg=O
55	people	_	_	_	_	_	_	_	Seg=O
56	of	_	_	_	_	_	_	_	Seg=O
57	any	_	_	_	_	_	_	_	Seg=O
58	age	_	_	_	_	_	_	_	Seg=O
59	with	_	_	_	_	_	_	_	Seg=O
60	comorbid	_	_	_	_	_	_	_	Seg=O
61	illnesses	_	_	_	_	_	_	_	Seg=O
62	are	_	_	_	_	_	_	_	Seg=O
63	at	_	_	_	_	_	_	_	Seg=O
64	highest	_	_	_	_	_	_	_	Seg=O
65	risk	_	_	_	_	_	_	_	Seg=O
66	.	_	_	_	_	_	_	_	Seg=O
67	Annual	_	_	_	_	_	_	_	Seg=B-seg
68	vaccination	_	_	_	_	_	_	_	Seg=O
69	is	_	_	_	_	_	_	_	Seg=O
70	the	_	_	_	_	_	_	_	Seg=O
71	cornerstone	_	_	_	_	_	_	_	Seg=O
72	of	_	_	_	_	_	_	_	Seg=O
73	prevention	_	_	_	_	_	_	_	Seg=O
74	,	_	_	_	_	_	_	_	Seg=O
75	but	_	_	_	_	_	_	_	Seg=B-seg
76	some	_	_	_	_	_	_	_	Seg=O
77	older	_	_	_	_	_	_	_	Seg=O
78	patients	_	_	_	_	_	_	_	Seg=O
79	may	_	_	_	_	_	_	_	Seg=O
80	derive	_	_	_	_	_	_	_	Seg=O
81	less	_	_	_	_	_	_	_	Seg=O
82	benefit	_	_	_	_	_	_	_	Seg=O
83	from	_	_	_	_	_	_	_	Seg=O
84	immunization	_	_	_	_	_	_	_	Seg=O
85	than	_	_	_	_	_	_	_	Seg=O
86	otherwise	_	_	_	_	_	_	_	Seg=O
87	fit	_	_	_	_	_	_	_	Seg=O
88	individuals	_	_	_	_	_	_	_	Seg=O
89	.	_	_	_	_	_	_	_	Seg=O
90	If	_	_	_	_	_	_	_	Seg=B-seg
91	started	_	_	_	_	_	_	_	Seg=O
92	promptly	_	_	_	_	_	_	_	Seg=O
93	,	_	_	_	_	_	_	_	Seg=O
94	antiviral	_	_	_	_	_	_	_	Seg=B-seg
95	medications	_	_	_	_	_	_	_	Seg=O
96	may	_	_	_	_	_	_	_	Seg=O
97	reduce	_	_	_	_	_	_	_	Seg=O
98	complications	_	_	_	_	_	_	_	Seg=O
99	of	_	_	_	_	_	_	_	Seg=O
100	acute	_	_	_	_	_	_	_	Seg=O
101	influenza	_	_	_	_	_	_	_	Seg=O
102	,	_	_	_	_	_	_	_	Seg=O
103	but	_	_	_	_	_	_	_	Seg=B-seg
104	increasing	_	_	_	_	_	_	_	Seg=O
105	resistance	_	_	_	_	_	_	_	Seg=O
106	to	_	_	_	_	_	_	_	Seg=O
107	amantadine	_	_	_	_	_	_	_	Seg=O
108	and	_	_	_	_	_	_	_	Seg=O
109	perhaps	_	_	_	_	_	_	_	Seg=O
110	neuraminidase	_	_	_	_	_	_	_	Seg=O
111	inhibitors	_	_	_	_	_	_	_	Seg=O
112	underscores	_	_	_	_	_	_	_	Seg=O
113	the	_	_	_	_	_	_	_	Seg=O
114	need	_	_	_	_	_	_	_	Seg=O
115	for	_	_	_	_	_	_	_	Seg=O
116	novel	_	_	_	_	_	_	_	Seg=O
117	prevention	_	_	_	_	_	_	_	Seg=O
118	and	_	_	_	_	_	_	_	Seg=O
119	treatment	_	_	_	_	_	_	_	Seg=O
120	strategies	_	_	_	_	_	_	_	Seg=O
121	.	_	_	_	_	_	_	_	Seg=O
122	Pulmonary	_	_	_	_	_	_	_	Seg=B-seg
123	complications	_	_	_	_	_	_	_	Seg=O
124	of	_	_	_	_	_	_	_	Seg=O
125	influenza	_	_	_	_	_	_	_	Seg=O
126	are	_	_	_	_	_	_	_	Seg=O
127	most	_	_	_	_	_	_	_	Seg=O
128	common	_	_	_	_	_	_	_	Seg=O
129	and	_	_	_	_	_	_	_	Seg=B-seg
130	include	_	_	_	_	_	_	_	Seg=O
131	primary	_	_	_	_	_	_	_	Seg=O
132	influenza	_	_	_	_	_	_	_	Seg=O
133	and	_	_	_	_	_	_	_	Seg=O
134	secondary	_	_	_	_	_	_	_	Seg=O
135	bacterial	_	_	_	_	_	_	_	Seg=O
136	infection	_	_	_	_	_	_	_	Seg=O
137	.	_	_	_	_	_	_	_	Seg=O
138	Either	_	_	_	_	_	_	_	Seg=B-seg
139	may	_	_	_	_	_	_	_	Seg=O
140	cause	_	_	_	_	_	_	_	Seg=O
141	pneumonia	_	_	_	_	_	_	_	Seg=O
142	,	_	_	_	_	_	_	_	Seg=O
143	and	_	_	_	_	_	_	_	Seg=B-seg
144	each	_	_	_	_	_	_	_	Seg=O
145	has	_	_	_	_	_	_	_	Seg=O
146	a	_	_	_	_	_	_	_	Seg=O
147	unique	_	_	_	_	_	_	_	Seg=O
148	clinical	_	_	_	_	_	_	_	Seg=O
149	presentation	_	_	_	_	_	_	_	Seg=O
150	and	_	_	_	_	_	_	_	Seg=O
151	pathologic	_	_	_	_	_	_	_	Seg=O
152	basis	_	_	_	_	_	_	_	Seg=O
153	.	_	_	_	_	_	_	_	Seg=O
154	Staphylococcus	_	_	_	_	_	_	_	Seg=B-seg
155	aureus	_	_	_	_	_	_	_	Seg=O
156	,	_	_	_	_	_	_	_	Seg=O
157	including	_	_	_	_	_	_	_	Seg=B-seg
158	methicillin	_	_	_	_	_	_	_	Seg=O
159	-	_	_	_	_	_	_	_	Seg=O
160	resistant	_	_	_	_	_	_	_	Seg=O
161	strains	_	_	_	_	_	_	_	Seg=O
162	,	_	_	_	_	_	_	_	Seg=O
163	is	_	_	_	_	_	_	_	Seg=B-seg
164	an	_	_	_	_	_	_	_	Seg=O
165	important	_	_	_	_	_	_	_	Seg=O
166	cause	_	_	_	_	_	_	_	Seg=O
167	of	_	_	_	_	_	_	_	Seg=O
168	secondary	_	_	_	_	_	_	_	Seg=O
169	bacterial	_	_	_	_	_	_	_	Seg=O
170	pneumonia	_	_	_	_	_	_	_	Seg=O
171	with	_	_	_	_	_	_	_	Seg=O
172	high	_	_	_	_	_	_	_	Seg=O
173	mortality	_	_	_	_	_	_	_	Seg=O
174	.	_	_	_	_	_	_	_	Seg=O
175	During	_	_	_	_	_	_	_	Seg=B-seg
176	influenza	_	_	_	_	_	_	_	Seg=O
177	season	_	_	_	_	_	_	_	Seg=O
178	,	_	_	_	_	_	_	_	Seg=O
179	treatment	_	_	_	_	_	_	_	Seg=O
180	of	_	_	_	_	_	_	_	Seg=O
181	pneumonia	_	_	_	_	_	_	_	Seg=O
182	should	_	_	_	_	_	_	_	Seg=O
183	include	_	_	_	_	_	_	_	Seg=O
184	empiric	_	_	_	_	_	_	_	Seg=O
185	coverage	_	_	_	_	_	_	_	Seg=O
186	for	_	_	_	_	_	_	_	Seg=O
187	this	_	_	_	_	_	_	_	Seg=O
188	pathogen	_	_	_	_	_	_	_	Seg=O
189	.	_	_	_	_	_	_	_	Seg=O
190	Neuromuscular	_	_	_	_	_	_	_	Seg=B-seg
191	and	_	_	_	_	_	_	_	Seg=O
192	cardiac	_	_	_	_	_	_	_	Seg=O
193	complications	_	_	_	_	_	_	_	Seg=O
194	are	_	_	_	_	_	_	_	Seg=O
195	unusual	_	_	_	_	_	_	_	Seg=O
196	but	_	_	_	_	_	_	_	Seg=B-seg
197	may	_	_	_	_	_	_	_	Seg=O
198	manifest	_	_	_	_	_	_	_	Seg=O
199	in	_	_	_	_	_	_	_	Seg=O
200	persons	_	_	_	_	_	_	_	Seg=O
201	of	_	_	_	_	_	_	_	Seg=O
202	any	_	_	_	_	_	_	_	Seg=O
203	age	_	_	_	_	_	_	_	Seg=O
204	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 73924069b04d70bd1ef34a879ed7001f63c1111c
1	COVID-19	_	_	_	_	_	_	_	Seg=B-seg
2	has	_	_	_	_	_	_	_	Seg=O
3	emerged	_	_	_	_	_	_	_	Seg=O
4	as	_	_	_	_	_	_	_	Seg=O
5	global	_	_	_	_	_	_	_	Seg=O
6	medical	_	_	_	_	_	_	_	Seg=O
7	emergency	_	_	_	_	_	_	_	Seg=O
8	in	_	_	_	_	_	_	_	Seg=O
9	recentdecades	_	_	_	_	_	_	_	Seg=O
10	.	_	_	_	_	_	_	_	Seg=O
11	The	_	_	_	_	_	_	_	Seg=B-seg
12	spread	_	_	_	_	_	_	_	Seg=O
13	scenario	_	_	_	_	_	_	_	Seg=O
14	of	_	_	_	_	_	_	_	Seg=O
15	this	_	_	_	_	_	_	_	Seg=O
16	pandemic	_	_	_	_	_	_	_	Seg=O
17	has	_	_	_	_	_	_	_	Seg=O
18	shown	_	_	_	_	_	_	_	Seg=O
19	many	_	_	_	_	_	_	_	Seg=O
20	variations	_	_	_	_	_	_	_	Seg=O
21	.	_	_	_	_	_	_	_	Seg=O
22	Keeping	_	_	_	_	_	_	_	Seg=B-seg
23	all	_	_	_	_	_	_	_	Seg=O
24	this	_	_	_	_	_	_	_	Seg=O
25	in	_	_	_	_	_	_	_	Seg=O
26	mind	_	_	_	_	_	_	_	Seg=O
27	,	_	_	_	_	_	_	_	Seg=O
28	this	_	_	_	_	_	_	_	Seg=B-seg
29	article	_	_	_	_	_	_	_	Seg=O
30	is	_	_	_	_	_	_	_	Seg=O
31	written	_	_	_	_	_	_	_	Seg=O
32	after	_	_	_	_	_	_	_	Seg=O
33	various	_	_	_	_	_	_	_	Seg=O
34	studies	_	_	_	_	_	_	_	Seg=O
35	and	_	_	_	_	_	_	_	Seg=O
36	analysis	_	_	_	_	_	_	_	Seg=O
37	on	_	_	_	_	_	_	_	Seg=O
38	the	_	_	_	_	_	_	_	Seg=O
39	latest	_	_	_	_	_	_	_	Seg=O
40	data	_	_	_	_	_	_	_	Seg=O
41	on	_	_	_	_	_	_	_	Seg=O
42	COVID-19	_	_	_	_	_	_	_	Seg=O
43	spread	_	_	_	_	_	_	_	Seg=O
44	,	_	_	_	_	_	_	_	Seg=O
45	which	_	_	_	_	_	_	_	Seg=B-seg
46	also	_	_	_	_	_	_	_	Seg=O
47	includes	_	_	_	_	_	_	_	Seg=O
48	the	_	_	_	_	_	_	_	Seg=O
49	demographic	_	_	_	_	_	_	_	Seg=O
50	and	_	_	_	_	_	_	_	Seg=O
51	environmental	_	_	_	_	_	_	_	Seg=O
52	factors	_	_	_	_	_	_	_	Seg=O
53	.	_	_	_	_	_	_	_	Seg=O
54	After	_	_	_	_	_	_	_	Seg=B-seg
55	gathering	_	_	_	_	_	_	_	Seg=O
56	data	_	_	_	_	_	_	_	Seg=O
57	from	_	_	_	_	_	_	_	Seg=O
58	various	_	_	_	_	_	_	_	Seg=O
59	resources	_	_	_	_	_	_	_	Seg=O
60	,	_	_	_	_	_	_	_	Seg=O
61	all	_	_	_	_	_	_	_	Seg=B-seg
62	data	_	_	_	_	_	_	_	Seg=O
63	are	_	_	_	_	_	_	_	Seg=O
64	integrated	_	_	_	_	_	_	_	Seg=O
65	and	_	_	_	_	_	_	_	Seg=O
66	passed	_	_	_	_	_	_	_	Seg=O
67	into	_	_	_	_	_	_	_	Seg=O
68	different	_	_	_	_	_	_	_	Seg=O
69	Machine	_	_	_	_	_	_	_	Seg=O
70	Learning	_	_	_	_	_	_	_	Seg=O
71	Models	_	_	_	_	_	_	_	Seg=O
72	to	_	_	_	_	_	_	_	Seg=B-seg
73	check	_	_	_	_	_	_	_	Seg=O
74	the	_	_	_	_	_	_	_	Seg=O
75	fit	_	_	_	_	_	_	_	Seg=O
76	.	_	_	_	_	_	_	_	Seg=O
77	Ensemble	_	_	_	_	_	_	_	Seg=B-seg
78	Learning	_	_	_	_	_	_	_	Seg=O
79	Technique	_	_	_	_	_	_	_	Seg=O
80	,	_	_	_	_	_	_	_	Seg=O
81	Random	_	_	_	_	_	_	_	Seg=O
82	Forest	_	_	_	_	_	_	_	Seg=O
83	,	_	_	_	_	_	_	_	Seg=O
84	gives	_	_	_	_	_	_	_	Seg=O
85	a	_	_	_	_	_	_	_	Seg=O
86	good	_	_	_	_	_	_	_	Seg=O
87	evaluation	_	_	_	_	_	_	_	Seg=O
88	score	_	_	_	_	_	_	_	Seg=O
89	on	_	_	_	_	_	_	_	Seg=O
90	the	_	_	_	_	_	_	_	Seg=O
91	test	_	_	_	_	_	_	_	Seg=O
92	data	_	_	_	_	_	_	_	Seg=O
93	.	_	_	_	_	_	_	_	Seg=O
94	Through	_	_	_	_	_	_	_	Seg=B-seg
95	this	_	_	_	_	_	_	_	Seg=O
96	technique	_	_	_	_	_	_	_	Seg=O
97	,	_	_	_	_	_	_	_	Seg=O
98	various	_	_	_	_	_	_	_	Seg=O
99	important	_	_	_	_	_	_	_	Seg=O
100	factors	_	_	_	_	_	_	_	Seg=O
101	are	_	_	_	_	_	_	_	Seg=O
102	recognised	_	_	_	_	_	_	_	Seg=O
103	and	_	_	_	_	_	_	_	Seg=B-seg
104	their	_	_	_	_	_	_	_	Seg=O
105	contribution	_	_	_	_	_	_	_	Seg=O
106	to	_	_	_	_	_	_	_	Seg=O
107	the	_	_	_	_	_	_	_	Seg=O
108	spread	_	_	_	_	_	_	_	Seg=O
109	is	_	_	_	_	_	_	_	Seg=O
110	analysed	_	_	_	_	_	_	_	Seg=O
111	.	_	_	_	_	_	_	_	Seg=O
112	Also	_	_	_	_	_	_	_	Seg=B-seg
113	,	_	_	_	_	_	_	_	Seg=O
114	linear	_	_	_	_	_	_	_	Seg=O
115	relationship	_	_	_	_	_	_	_	Seg=O
116	between	_	_	_	_	_	_	_	Seg=O
117	various	_	_	_	_	_	_	_	Seg=O
118	features	_	_	_	_	_	_	_	Seg=O
119	is	_	_	_	_	_	_	_	Seg=O
120	plotted	_	_	_	_	_	_	_	Seg=O
121	through	_	_	_	_	_	_	_	Seg=O
122	heatmap	_	_	_	_	_	_	_	Seg=O
123	of	_	_	_	_	_	_	_	Seg=O
124	Pearson	_	_	_	_	_	_	_	Seg=O
125	Correlation	_	_	_	_	_	_	_	Seg=O
126	matrix	_	_	_	_	_	_	_	Seg=O
127	.	_	_	_	_	_	_	_	Seg=O
128	Finally	_	_	_	_	_	_	_	Seg=B-seg
129	,	_	_	_	_	_	_	_	Seg=O
130	Kalman	_	_	_	_	_	_	_	Seg=O
131	Filter	_	_	_	_	_	_	_	Seg=O
132	is	_	_	_	_	_	_	_	Seg=O
133	used	_	_	_	_	_	_	_	Seg=O
134	to	_	_	_	_	_	_	_	Seg=B-seg
135	estimate	_	_	_	_	_	_	_	Seg=O
136	future	_	_	_	_	_	_	_	Seg=O
137	spread	_	_	_	_	_	_	_	Seg=O
138	of	_	_	_	_	_	_	_	Seg=O
139	COVID19	_	_	_	_	_	_	_	Seg=O
140	,	_	_	_	_	_	_	_	Seg=O
141	which	_	_	_	_	_	_	_	Seg=B-seg
142	shows	_	_	_	_	_	_	_	Seg=O
143	good	_	_	_	_	_	_	_	Seg=O
144	result	_	_	_	_	_	_	_	Seg=O
145	on	_	_	_	_	_	_	_	Seg=O
146	test	_	_	_	_	_	_	_	Seg=O
147	data	_	_	_	_	_	_	_	Seg=O
148	.	_	_	_	_	_	_	_	Seg=O
149	The	_	_	_	_	_	_	_	Seg=B-seg
150	inferences	_	_	_	_	_	_	_	Seg=O
151	from	_	_	_	_	_	_	_	Seg=O
152	Random	_	_	_	_	_	_	_	Seg=O
153	Forest	_	_	_	_	_	_	_	Seg=O
154	feature	_	_	_	_	_	_	_	Seg=O
155	importance	_	_	_	_	_	_	_	Seg=O
156	and	_	_	_	_	_	_	_	Seg=O
157	Pearson	_	_	_	_	_	_	_	Seg=O
158	Correlation	_	_	_	_	_	_	_	Seg=O
159	gives	_	_	_	_	_	_	_	Seg=O
160	many	_	_	_	_	_	_	_	Seg=O
161	similarities	_	_	_	_	_	_	_	Seg=O
162	and	_	_	_	_	_	_	_	Seg=O
163	some	_	_	_	_	_	_	_	Seg=O
164	dissimilarities	_	_	_	_	_	_	_	Seg=O
165	,	_	_	_	_	_	_	_	Seg=O
166	and	_	_	_	_	_	_	_	Seg=B-seg
167	these	_	_	_	_	_	_	_	Seg=O
168	techniques	_	_	_	_	_	_	_	Seg=O
169	successfully	_	_	_	_	_	_	_	Seg=O
170	identify	_	_	_	_	_	_	_	Seg=O
171	the	_	_	_	_	_	_	_	Seg=O
172	different	_	_	_	_	_	_	_	Seg=O
173	contributing	_	_	_	_	_	_	_	Seg=O
174	factors	_	_	_	_	_	_	_	Seg=O
175	.	_	_	_	_	_	_	_	Seg=O
176	The	_	_	_	_	_	_	_	Seg=B-seg
177	Kalman	_	_	_	_	_	_	_	Seg=O
178	Filter	_	_	_	_	_	_	_	Seg=O
179	gives	_	_	_	_	_	_	_	Seg=O
180	a	_	_	_	_	_	_	_	Seg=O
181	satisfying	_	_	_	_	_	_	_	Seg=O
182	result	_	_	_	_	_	_	_	Seg=O
183	for	_	_	_	_	_	_	_	Seg=O
184	short	_	_	_	_	_	_	_	Seg=O
185	term	_	_	_	_	_	_	_	Seg=O
186	estimation	_	_	_	_	_	_	_	Seg=O
187	,	_	_	_	_	_	_	_	Seg=O
188	but	_	_	_	_	_	_	_	Seg=B-seg
189	not	_	_	_	_	_	_	_	Seg=O
190	so	_	_	_	_	_	_	_	Seg=O
191	good	_	_	_	_	_	_	_	Seg=O
192	performance	_	_	_	_	_	_	_	Seg=O
193	for	_	_	_	_	_	_	_	Seg=O
194	long	_	_	_	_	_	_	_	Seg=O
195	term	_	_	_	_	_	_	_	Seg=O
196	forecasting	_	_	_	_	_	_	_	Seg=O
197	.	_	_	_	_	_	_	_	Seg=O
198	Overall	_	_	_	_	_	_	_	Seg=B-seg
199	,	_	_	_	_	_	_	_	Seg=O
200	the	_	_	_	_	_	_	_	Seg=O
201	analysis	_	_	_	_	_	_	_	Seg=O
202	,	_	_	_	_	_	_	_	Seg=O
203	plots	_	_	_	_	_	_	_	Seg=O
204	,	_	_	_	_	_	_	_	Seg=O
205	inferences	_	_	_	_	_	_	_	Seg=O
206	and	_	_	_	_	_	_	_	Seg=O
207	forecast	_	_	_	_	_	_	_	Seg=O
208	are	_	_	_	_	_	_	_	Seg=O
209	satisfying	_	_	_	_	_	_	_	Seg=O
210	and	_	_	_	_	_	_	_	Seg=B-seg
211	can	_	_	_	_	_	_	_	Seg=O
212	help	_	_	_	_	_	_	_	Seg=O
213	a	_	_	_	_	_	_	_	Seg=O
214	lot	_	_	_	_	_	_	_	Seg=O
215	in	_	_	_	_	_	_	_	Seg=B-seg
216	fighting	_	_	_	_	_	_	_	Seg=O
217	the	_	_	_	_	_	_	_	Seg=O
218	spread	_	_	_	_	_	_	_	Seg=O
219	of	_	_	_	_	_	_	_	Seg=O
220	the	_	_	_	_	_	_	_	Seg=O
221	virus	_	_	_	_	_	_	_	Seg=O
222	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 7740faa25788c48ed6796fc578d102bcb13879bf
1	To	_	_	_	_	_	_	_	Seg=B-seg
2	trace	_	_	_	_	_	_	_	Seg=O
3	the	_	_	_	_	_	_	_	Seg=O
4	possible	_	_	_	_	_	_	_	Seg=O
5	route	_	_	_	_	_	_	_	Seg=O
6	of	_	_	_	_	_	_	_	Seg=O
7	introduction	_	_	_	_	_	_	_	Seg=O
8	of	_	_	_	_	_	_	_	Seg=O
9	porcine	_	_	_	_	_	_	_	Seg=O
10	epidemic	_	_	_	_	_	_	_	Seg=O
11	diarrhea	_	_	_	_	_	_	_	Seg=O
12	virus	_	_	_	_	_	_	_	Seg=O
13	(	_	_	_	_	_	_	_	Seg=O
14	PEDV	_	_	_	_	_	_	_	Seg=O
15	)	_	_	_	_	_	_	_	Seg=O
16	,	_	_	_	_	_	_	_	Seg=O
17	the	_	_	_	_	_	_	_	Seg=B-seg
18	phylogenetic	_	_	_	_	_	_	_	Seg=O
19	relationships	_	_	_	_	_	_	_	Seg=O
20	of	_	_	_	_	_	_	_	Seg=O
21	PEDV	_	_	_	_	_	_	_	Seg=O
22	strains	_	_	_	_	_	_	_	Seg=O
23	in	_	_	_	_	_	_	_	Seg=O
24	the	_	_	_	_	_	_	_	Seg=O
25	regions	_	_	_	_	_	_	_	Seg=O
26	of	_	_	_	_	_	_	_	Seg=O
27	epidemicity	_	_	_	_	_	_	_	Seg=O
28	in	_	_	_	_	_	_	_	Seg=O
29	the	_	_	_	_	_	_	_	Seg=O
30	Philippines	_	_	_	_	_	_	_	Seg=O
31	to	_	_	_	_	_	_	_	Seg=O
32	PEDV	_	_	_	_	_	_	_	Seg=O
33	strains	_	_	_	_	_	_	_	Seg=O
34	that	_	_	_	_	_	_	_	Seg=B-seg
35	are	_	_	_	_	_	_	_	Seg=O
36	endemic	_	_	_	_	_	_	_	Seg=O
37	in	_	_	_	_	_	_	_	Seg=O
38	other	_	_	_	_	_	_	_	Seg=O
39	countries	_	_	_	_	_	_	_	Seg=O
40	were	_	_	_	_	_	_	_	Seg=B-seg
41	investigated	_	_	_	_	_	_	_	Seg=O
42	.	_	_	_	_	_	_	_	Seg=O
43	Partial	_	_	_	_	_	_	_	Seg=B-seg
44	nucleotide	_	_	_	_	_	_	_	Seg=O
45	sequences	_	_	_	_	_	_	_	Seg=O
46	of	_	_	_	_	_	_	_	Seg=O
47	the	_	_	_	_	_	_	_	Seg=O
48	S1	_	_	_	_	_	_	_	Seg=O
49	spike	_	_	_	_	_	_	_	Seg=O
50	gene	_	_	_	_	_	_	_	Seg=O
51	was	_	_	_	_	_	_	_	Seg=O
52	determined	_	_	_	_	_	_	_	Seg=O
53	from	_	_	_	_	_	_	_	Seg=O
54	the	_	_	_	_	_	_	_	Seg=O
55	PEDV	_	_	_	_	_	_	_	Seg=O
56	-	_	_	_	_	_	_	_	Seg=O
57	positive	_	_	_	_	_	_	_	Seg=O
58	samples	_	_	_	_	_	_	_	Seg=O
59	and	_	_	_	_	_	_	_	Seg=B-seg
60	compared	_	_	_	_	_	_	_	Seg=O
61	with	_	_	_	_	_	_	_	Seg=O
62	S1	_	_	_	_	_	_	_	Seg=O
63	sequences	_	_	_	_	_	_	_	Seg=O
64	from	_	_	_	_	_	_	_	Seg=O
65	other	_	_	_	_	_	_	_	Seg=O
66	countries	_	_	_	_	_	_	_	Seg=O
67	.	_	_	_	_	_	_	_	Seg=O
68	Phylogenetic	_	_	_	_	_	_	_	Seg=B-seg
69	analysis	_	_	_	_	_	_	_	Seg=O
70	indicated	_	_	_	_	_	_	_	Seg=O
71	that	_	_	_	_	_	_	_	Seg=B-seg
72	PEDV	_	_	_	_	_	_	_	Seg=O
73	strains	_	_	_	_	_	_	_	Seg=O
74	in	_	_	_	_	_	_	_	Seg=O
75	the	_	_	_	_	_	_	_	Seg=O
76	Philippines	_	_	_	_	_	_	_	Seg=O
77	segregate	_	_	_	_	_	_	_	Seg=O
78	into	_	_	_	_	_	_	_	Seg=O
79	two	_	_	_	_	_	_	_	Seg=O
80	groups	_	_	_	_	_	_	_	Seg=O
81	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 791bb7fd75fdeed7781334dfb35f216bcea492df
1	The	_	_	_	_	_	_	_	Seg=B-seg
2	carbamate	_	_	_	_	_	_	_	Seg=O
3	group	_	_	_	_	_	_	_	Seg=O
4	is	_	_	_	_	_	_	_	Seg=O
5	a	_	_	_	_	_	_	_	Seg=O
6	key	_	_	_	_	_	_	_	Seg=O
7	structural	_	_	_	_	_	_	_	Seg=O
8	motif	_	_	_	_	_	_	_	Seg=O
9	in	_	_	_	_	_	_	_	Seg=O
10	many	_	_	_	_	_	_	_	Seg=O
11	approved	_	_	_	_	_	_	_	Seg=O
12	drugs	_	_	_	_	_	_	_	Seg=O
13	and	_	_	_	_	_	_	_	Seg=O
14	prodrugs	_	_	_	_	_	_	_	Seg=O
15	.	_	_	_	_	_	_	_	Seg=O
16	There	_	_	_	_	_	_	_	Seg=B-seg
17	is	_	_	_	_	_	_	_	Seg=O
18	an	_	_	_	_	_	_	_	Seg=O
19	increasing	_	_	_	_	_	_	_	Seg=O
20	use	_	_	_	_	_	_	_	Seg=O
21	of	_	_	_	_	_	_	_	Seg=O
22	carbamates	_	_	_	_	_	_	_	Seg=O
23	in	_	_	_	_	_	_	_	Seg=O
24	medicinal	_	_	_	_	_	_	_	Seg=O
25	chemistry	_	_	_	_	_	_	_	Seg=O
26	and	_	_	_	_	_	_	_	Seg=B-seg
27	many	_	_	_	_	_	_	_	Seg=O
28	derivatives	_	_	_	_	_	_	_	Seg=O
29	are	_	_	_	_	_	_	_	Seg=O
30	specifically	_	_	_	_	_	_	_	Seg=O
31	designed	_	_	_	_	_	_	_	Seg=O
32	to	_	_	_	_	_	_	_	Seg=B-seg
33	make	_	_	_	_	_	_	_	Seg=O
34	drug−target	_	_	_	_	_	_	_	Seg=O
35	interactions	_	_	_	_	_	_	_	Seg=O
36	through	_	_	_	_	_	_	_	Seg=O
37	their	_	_	_	_	_	_	_	Seg=O
38	carbamate	_	_	_	_	_	_	_	Seg=O
39	moiety	_	_	_	_	_	_	_	Seg=O
40	.	_	_	_	_	_	_	_	Seg=O
41	In	_	_	_	_	_	_	_	Seg=B-seg
42	this	_	_	_	_	_	_	_	Seg=O
43	Perspective	_	_	_	_	_	_	_	Seg=O
44	,	_	_	_	_	_	_	_	Seg=O
45	we	_	_	_	_	_	_	_	Seg=O
46	present	_	_	_	_	_	_	_	Seg=O
47	properties	_	_	_	_	_	_	_	Seg=O
48	and	_	_	_	_	_	_	_	Seg=O
49	stabilities	_	_	_	_	_	_	_	Seg=O
50	of	_	_	_	_	_	_	_	Seg=O
51	carbamates	_	_	_	_	_	_	_	Seg=O
52	,	_	_	_	_	_	_	_	Seg=O
53	reagents	_	_	_	_	_	_	_	Seg=O
54	and	_	_	_	_	_	_	_	Seg=O
55	chemical	_	_	_	_	_	_	_	Seg=O
56	methodologies	_	_	_	_	_	_	_	Seg=O
57	for	_	_	_	_	_	_	_	Seg=O
58	the	_	_	_	_	_	_	_	Seg=O
59	synthesis	_	_	_	_	_	_	_	Seg=O
60	of	_	_	_	_	_	_	_	Seg=O
61	carbamates	_	_	_	_	_	_	_	Seg=O
62	,	_	_	_	_	_	_	_	Seg=O
63	and	_	_	_	_	_	_	_	Seg=O
64	recent	_	_	_	_	_	_	_	Seg=O
65	applications	_	_	_	_	_	_	_	Seg=O
66	of	_	_	_	_	_	_	_	Seg=O
67	carbamates	_	_	_	_	_	_	_	Seg=O
68	in	_	_	_	_	_	_	_	Seg=O
69	drug	_	_	_	_	_	_	_	Seg=O
70	design	_	_	_	_	_	_	_	Seg=O
71	and	_	_	_	_	_	_	_	Seg=O
72	medicinal	_	_	_	_	_	_	_	Seg=O
73	chemistry	_	_	_	_	_	_	_	Seg=O
74	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 7a305e42035041d1c17926738a1ae7aeaad71444
1	Boolean	_	_	_	_	_	_	_	Seg=B-seg
2	programs	_	_	_	_	_	_	_	Seg=O
3	with	_	_	_	_	_	_	_	Seg=O
4	multiple	_	_	_	_	_	_	_	Seg=O
5	recursive	_	_	_	_	_	_	_	Seg=O
6	threads	_	_	_	_	_	_	_	Seg=O
7	can	_	_	_	_	_	_	_	Seg=O
8	be	_	_	_	_	_	_	_	Seg=O
9	captured	_	_	_	_	_	_	_	Seg=O
10	as	_	_	_	_	_	_	_	Seg=O
11	pushdown	_	_	_	_	_	_	_	Seg=O
12	automata	_	_	_	_	_	_	_	Seg=O
13	with	_	_	_	_	_	_	_	Seg=O
14	multiple	_	_	_	_	_	_	_	Seg=O
15	stacks	_	_	_	_	_	_	_	Seg=O
16	.	_	_	_	_	_	_	_	Seg=O
17	This	_	_	_	_	_	_	_	Seg=B-seg
18	model	_	_	_	_	_	_	_	Seg=O
19	is	_	_	_	_	_	_	_	Seg=O
20	Turing	_	_	_	_	_	_	_	Seg=O
21	complete	_	_	_	_	_	_	_	Seg=O
22	,	_	_	_	_	_	_	_	Seg=O
23	and	_	_	_	_	_	_	_	Seg=B-seg
24	hence	_	_	_	_	_	_	_	Seg=O
25	,	_	_	_	_	_	_	_	Seg=O
26	one	_	_	_	_	_	_	_	Seg=O
27	is	_	_	_	_	_	_	_	Seg=O
28	often	_	_	_	_	_	_	_	Seg=O
29	interested	_	_	_	_	_	_	_	Seg=O
30	in	_	_	_	_	_	_	_	Seg=O
31	analyzing	_	_	_	_	_	_	_	Seg=O
32	a	_	_	_	_	_	_	_	Seg=O
33	restricted	_	_	_	_	_	_	_	Seg=O
34	class	_	_	_	_	_	_	_	Seg=O
35	that	_	_	_	_	_	_	_	Seg=B-seg
36	still	_	_	_	_	_	_	_	Seg=O
37	captures	_	_	_	_	_	_	_	Seg=O
38	useful	_	_	_	_	_	_	_	Seg=O
39	behaviors	_	_	_	_	_	_	_	Seg=O
40	.	_	_	_	_	_	_	_	Seg=O
41	In	_	_	_	_	_	_	_	Seg=B-seg
42	this	_	_	_	_	_	_	_	Seg=O
43	paper	_	_	_	_	_	_	_	Seg=O
44	,	_	_	_	_	_	_	_	Seg=O
45	we	_	_	_	_	_	_	_	Seg=O
46	propose	_	_	_	_	_	_	_	Seg=O
47	a	_	_	_	_	_	_	_	Seg=O
48	new	_	_	_	_	_	_	_	Seg=O
49	class	_	_	_	_	_	_	_	Seg=O
50	of	_	_	_	_	_	_	_	Seg=O
51	bounded	_	_	_	_	_	_	_	Seg=O
52	underapproximations	_	_	_	_	_	_	_	Seg=O
53	for	_	_	_	_	_	_	_	Seg=O
54	multi	_	_	_	_	_	_	_	Seg=O
55	-	_	_	_	_	_	_	_	Seg=O
56	pushdown	_	_	_	_	_	_	_	Seg=O
57	systems	_	_	_	_	_	_	_	Seg=O
58	,	_	_	_	_	_	_	_	Seg=O
59	which	_	_	_	_	_	_	_	Seg=B-seg
60	subsumes	_	_	_	_	_	_	_	Seg=O
61	most	_	_	_	_	_	_	_	Seg=O
62	existing	_	_	_	_	_	_	_	Seg=O
63	classes	_	_	_	_	_	_	_	Seg=O
64	.	_	_	_	_	_	_	_	Seg=O
65	We	_	_	_	_	_	_	_	Seg=B-seg
66	develop	_	_	_	_	_	_	_	Seg=O
67	an	_	_	_	_	_	_	_	Seg=O
68	efficient	_	_	_	_	_	_	_	Seg=O
69	algorithm	_	_	_	_	_	_	_	Seg=O
70	for	_	_	_	_	_	_	_	Seg=B-seg
71	solving	_	_	_	_	_	_	_	Seg=O
72	the	_	_	_	_	_	_	_	Seg=O
73	under	_	_	_	_	_	_	_	Seg=O
74	-	_	_	_	_	_	_	_	Seg=O
75	approximate	_	_	_	_	_	_	_	Seg=O
76	reachability	_	_	_	_	_	_	_	Seg=O
77	problem	_	_	_	_	_	_	_	Seg=O
78	,	_	_	_	_	_	_	_	Seg=O
79	which	_	_	_	_	_	_	_	Seg=B-seg
80	is	_	_	_	_	_	_	_	Seg=O
81	based	_	_	_	_	_	_	_	Seg=O
82	on	_	_	_	_	_	_	_	Seg=O
83	efficient	_	_	_	_	_	_	_	Seg=O
84	fix	_	_	_	_	_	_	_	Seg=O
85	-	_	_	_	_	_	_	_	Seg=O
86	point	_	_	_	_	_	_	_	Seg=O
87	computations	_	_	_	_	_	_	_	Seg=O
88	.	_	_	_	_	_	_	_	Seg=O
89	We	_	_	_	_	_	_	_	Seg=B-seg
90	implement	_	_	_	_	_	_	_	Seg=O
91	it	_	_	_	_	_	_	_	Seg=O
92	in	_	_	_	_	_	_	_	Seg=O
93	our	_	_	_	_	_	_	_	Seg=O
94	tool	_	_	_	_	_	_	_	Seg=O
95	BHIM	_	_	_	_	_	_	_	Seg=O
96	and	_	_	_	_	_	_	_	Seg=B-seg
97	illustrate	_	_	_	_	_	_	_	Seg=O
98	its	_	_	_	_	_	_	_	Seg=O
99	applicability	_	_	_	_	_	_	_	Seg=O
100	by	_	_	_	_	_	_	_	Seg=B-seg
101	generating	_	_	_	_	_	_	_	Seg=O
102	a	_	_	_	_	_	_	_	Seg=O
103	set	_	_	_	_	_	_	_	Seg=O
104	of	_	_	_	_	_	_	_	Seg=O
105	relevant	_	_	_	_	_	_	_	Seg=O
106	benchmarks	_	_	_	_	_	_	_	Seg=O
107	and	_	_	_	_	_	_	_	Seg=B-seg
108	examining	_	_	_	_	_	_	_	Seg=O
109	its	_	_	_	_	_	_	_	Seg=O
110	performance	_	_	_	_	_	_	_	Seg=O
111	.	_	_	_	_	_	_	_	Seg=O
112	As	_	_	_	_	_	_	_	Seg=B-seg
113	an	_	_	_	_	_	_	_	Seg=O
114	additional	_	_	_	_	_	_	_	Seg=O
115	takeaway	_	_	_	_	_	_	_	Seg=O
116	BHIM	_	_	_	_	_	_	_	Seg=O
117	solves	_	_	_	_	_	_	_	Seg=O
118	the	_	_	_	_	_	_	_	Seg=O
119	binary	_	_	_	_	_	_	_	Seg=O
120	reachability	_	_	_	_	_	_	_	Seg=O
121	problem	_	_	_	_	_	_	_	Seg=O
122	in	_	_	_	_	_	_	_	Seg=O
123	pushdown	_	_	_	_	_	_	_	Seg=O
124	automata	_	_	_	_	_	_	_	Seg=O
125	.	_	_	_	_	_	_	_	Seg=O
126	To	_	_	_	_	_	_	_	Seg=B-seg
127	show	_	_	_	_	_	_	_	Seg=O
128	the	_	_	_	_	_	_	_	Seg=O
129	versatility	_	_	_	_	_	_	_	Seg=O
130	of	_	_	_	_	_	_	_	Seg=O
131	our	_	_	_	_	_	_	_	Seg=O
132	approach	_	_	_	_	_	_	_	Seg=O
133	,	_	_	_	_	_	_	_	Seg=O
134	we	_	_	_	_	_	_	_	Seg=B-seg
135	then	_	_	_	_	_	_	_	Seg=O
136	extend	_	_	_	_	_	_	_	Seg=O
137	our	_	_	_	_	_	_	_	Seg=O
138	algorithm	_	_	_	_	_	_	_	Seg=O
139	to	_	_	_	_	_	_	_	Seg=O
140	the	_	_	_	_	_	_	_	Seg=O
141	timed	_	_	_	_	_	_	_	Seg=O
142	setting	_	_	_	_	_	_	_	Seg=O
143	and	_	_	_	_	_	_	_	Seg=B-seg
144	provide	_	_	_	_	_	_	_	Seg=O
145	the	_	_	_	_	_	_	_	Seg=O
146	first	_	_	_	_	_	_	_	Seg=O
147	implementation	_	_	_	_	_	_	_	Seg=O
148	that	_	_	_	_	_	_	_	Seg=B-seg
149	can	_	_	_	_	_	_	_	Seg=O
150	handle	_	_	_	_	_	_	_	Seg=O
151	timed	_	_	_	_	_	_	_	Seg=O
152	multipushdown	_	_	_	_	_	_	_	Seg=O
153	automata	_	_	_	_	_	_	_	Seg=O
154	with	_	_	_	_	_	_	_	Seg=O
155	closed	_	_	_	_	_	_	_	Seg=O
156	guards	_	_	_	_	_	_	_	Seg=O
157	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 7c5cc45af01353704cf642ff1a7af510c6232521
1	We	_	_	_	_	_	_	_	Seg=B-seg
2	describe	_	_	_	_	_	_	_	Seg=O
3	an	_	_	_	_	_	_	_	Seg=O
4	explicit	_	_	_	_	_	_	_	Seg=O
5	mechanism	_	_	_	_	_	_	_	Seg=O
6	for	_	_	_	_	_	_	_	Seg=O
7	the	_	_	_	_	_	_	_	Seg=O
8	emergence	_	_	_	_	_	_	_	Seg=O
9	of	_	_	_	_	_	_	_	Seg=O
10	a	_	_	_	_	_	_	_	Seg=O
11	dynamical	_	_	_	_	_	_	_	Seg=O
12	holographic	_	_	_	_	_	_	_	Seg=O
13	bulk	_	_	_	_	_	_	_	Seg=O
14	from	_	_	_	_	_	_	_	Seg=O
15	the	_	_	_	_	_	_	_	Seg=O
16	structure	_	_	_	_	_	_	_	Seg=O
17	of	_	_	_	_	_	_	_	Seg=O
18	entanglement	_	_	_	_	_	_	_	Seg=O
19	in	_	_	_	_	_	_	_	Seg=O
20	a	_	_	_	_	_	_	_	Seg=O
21	quantum	_	_	_	_	_	_	_	Seg=O
22	state	_	_	_	_	_	_	_	Seg=O
23	.	_	_	_	_	_	_	_	Seg=O
24	We	_	_	_	_	_	_	_	Seg=B-seg
25	start	_	_	_	_	_	_	_	Seg=O
26	with	_	_	_	_	_	_	_	Seg=O
27	a	_	_	_	_	_	_	_	Seg=O
28	generic	_	_	_	_	_	_	_	Seg=O
29	system	_	_	_	_	_	_	_	Seg=O
30	in	_	_	_	_	_	_	_	Seg=O
31	complete	_	_	_	_	_	_	_	Seg=O
32	isolation	_	_	_	_	_	_	_	Seg=O
33	,	_	_	_	_	_	_	_	Seg=O
34	assuming	_	_	_	_	_	_	_	Seg=B-seg
35	it	_	_	_	_	_	_	_	Seg=B-seg
36	has	_	_	_	_	_	_	_	Seg=O
37	a	_	_	_	_	_	_	_	Seg=O
38	classical	_	_	_	_	_	_	_	Seg=O
39	limit	_	_	_	_	_	_	_	Seg=O
40	involving	_	_	_	_	_	_	_	Seg=B-seg
41	coherent	_	_	_	_	_	_	_	Seg=O
42	states	_	_	_	_	_	_	_	Seg=O
43	.	_	_	_	_	_	_	_	Seg=O
44	Then	_	_	_	_	_	_	_	Seg=B-seg
45	we	_	_	_	_	_	_	_	Seg=O
46	entangle	_	_	_	_	_	_	_	Seg=O
47	it	_	_	_	_	_	_	_	Seg=O
48	with	_	_	_	_	_	_	_	Seg=O
49	another	_	_	_	_	_	_	_	Seg=O
50	system	_	_	_	_	_	_	_	Seg=O
51	of	_	_	_	_	_	_	_	Seg=O
52	that	_	_	_	_	_	_	_	Seg=O
53	kind	_	_	_	_	_	_	_	Seg=O
54	,	_	_	_	_	_	_	_	Seg=O
55	and	_	_	_	_	_	_	_	Seg=B-seg
56	subject	_	_	_	_	_	_	_	Seg=O
57	the	_	_	_	_	_	_	_	Seg=O
58	pair	_	_	_	_	_	_	_	Seg=O
59	to	_	_	_	_	_	_	_	Seg=O
60	a	_	_	_	_	_	_	_	Seg=O
61	decohering	_	_	_	_	_	_	_	Seg=O
62	process	_	_	_	_	_	_	_	Seg=O
63	.	_	_	_	_	_	_	_	Seg=O
64	We	_	_	_	_	_	_	_	Seg=B-seg
65	make	_	_	_	_	_	_	_	Seg=O
66	a	_	_	_	_	_	_	_	Seg=O
67	number	_	_	_	_	_	_	_	Seg=O
68	of	_	_	_	_	_	_	_	Seg=O
69	broadly	_	_	_	_	_	_	_	Seg=O
70	applicable	_	_	_	_	_	_	_	Seg=O
71	and	_	_	_	_	_	_	_	Seg=O
72	physically	_	_	_	_	_	_	_	Seg=O
73	reasonable	_	_	_	_	_	_	_	Seg=O
74	assumptions	_	_	_	_	_	_	_	Seg=O
75	about	_	_	_	_	_	_	_	Seg=O
76	this	_	_	_	_	_	_	_	Seg=O
77	setup	_	_	_	_	_	_	_	Seg=O
78	.	_	_	_	_	_	_	_	Seg=O
79	First	_	_	_	_	_	_	_	Seg=B-seg
80	,	_	_	_	_	_	_	_	Seg=O
81	we	_	_	_	_	_	_	_	Seg=O
82	assume	_	_	_	_	_	_	_	Seg=O
83	that	_	_	_	_	_	_	_	Seg=B-seg
84	the	_	_	_	_	_	_	_	Seg=O
85	states	_	_	_	_	_	_	_	Seg=O
86	selected	_	_	_	_	_	_	_	Seg=O
87	by	_	_	_	_	_	_	_	Seg=O
88	the	_	_	_	_	_	_	_	Seg=O
89	decoherence	_	_	_	_	_	_	_	Seg=O
90	(	_	_	_	_	_	_	_	Seg=B-seg
91	called	_	_	_	_	_	_	_	Seg=O
92	pointer	_	_	_	_	_	_	_	Seg=O
93	states	_	_	_	_	_	_	_	Seg=O
94	)	_	_	_	_	_	_	_	Seg=O
95	have	_	_	_	_	_	_	_	Seg=B-seg
96	the	_	_	_	_	_	_	_	Seg=O
97	same	_	_	_	_	_	_	_	Seg=O
98	local	_	_	_	_	_	_	_	Seg=O
99	symmetries	_	_	_	_	_	_	_	Seg=O
100	as	_	_	_	_	_	_	_	Seg=O
101	the	_	_	_	_	_	_	_	Seg=O
102	isolated	_	_	_	_	_	_	_	Seg=O
103	systems	_	_	_	_	_	_	_	Seg=O
104	,	_	_	_	_	_	_	_	Seg=O
105	in	_	_	_	_	_	_	_	Seg=O
106	a	_	_	_	_	_	_	_	Seg=O
107	sense	_	_	_	_	_	_	_	Seg=O
108	which	_	_	_	_	_	_	_	Seg=B-seg
109	is	_	_	_	_	_	_	_	Seg=O
110	made	_	_	_	_	_	_	_	Seg=O
111	precise	_	_	_	_	_	_	_	Seg=O
112	.	_	_	_	_	_	_	_	Seg=O
113	We	_	_	_	_	_	_	_	Seg=B-seg
114	also	_	_	_	_	_	_	_	Seg=O
115	assume	_	_	_	_	_	_	_	Seg=O
116	that	_	_	_	_	_	_	_	Seg=B-seg
117	the	_	_	_	_	_	_	_	Seg=O
118	modular	_	_	_	_	_	_	_	Seg=O
119	Hamiltonians	_	_	_	_	_	_	_	Seg=O
120	of	_	_	_	_	_	_	_	Seg=O
121	pointer	_	_	_	_	_	_	_	Seg=O
122	states	_	_	_	_	_	_	_	Seg=O
123	scale	_	_	_	_	_	_	_	Seg=O
124	inversely	_	_	_	_	_	_	_	Seg=O
125	with	_	_	_	_	_	_	_	Seg=O
126-127	Planck's	_	_	_	_	_	_	_	_
126	Planck	_	_	_	_	_	_	_	Seg=O
127	's	_	_	_	_	_	_	_	Seg=O
128	constant	_	_	_	_	_	_	_	Seg=O
129	,	_	_	_	_	_	_	_	Seg=O
130	so	_	_	_	_	_	_	_	Seg=B-seg
131	that	_	_	_	_	_	_	_	Seg=O
132	the	_	_	_	_	_	_	_	Seg=O
133	pointer	_	_	_	_	_	_	_	Seg=O
134	states	_	_	_	_	_	_	_	Seg=O
135	are	_	_	_	_	_	_	_	Seg=O
136	highly	_	_	_	_	_	_	_	Seg=O
137	entangled	_	_	_	_	_	_	_	Seg=O
138	in	_	_	_	_	_	_	_	Seg=O
139	the	_	_	_	_	_	_	_	Seg=O
140	classical	_	_	_	_	_	_	_	Seg=O
141	limit	_	_	_	_	_	_	_	Seg=O
142	.	_	_	_	_	_	_	_	Seg=O
143	Finally	_	_	_	_	_	_	_	Seg=B-seg
144	,	_	_	_	_	_	_	_	Seg=O
145	we	_	_	_	_	_	_	_	Seg=O
146	require	_	_	_	_	_	_	_	Seg=O
147	the	_	_	_	_	_	_	_	Seg=O
148	timescale	_	_	_	_	_	_	_	Seg=O
149	of	_	_	_	_	_	_	_	Seg=O
150	decoherence	_	_	_	_	_	_	_	Seg=O
151	to	_	_	_	_	_	_	_	Seg=B-seg
152	scale	_	_	_	_	_	_	_	Seg=O
153	in	_	_	_	_	_	_	_	Seg=O
154	a	_	_	_	_	_	_	_	Seg=O
155	certain	_	_	_	_	_	_	_	Seg=O
156	way	_	_	_	_	_	_	_	Seg=O
157	with	_	_	_	_	_	_	_	Seg=O
158-159	Planck's	_	_	_	_	_	_	_	_
158	Planck	_	_	_	_	_	_	_	Seg=O
159	's	_	_	_	_	_	_	_	Seg=O
160	constant	_	_	_	_	_	_	_	Seg=O
161	,	_	_	_	_	_	_	_	Seg=O
162	so	_	_	_	_	_	_	_	Seg=B-seg
163	that	_	_	_	_	_	_	_	Seg=O
164	decoherence	_	_	_	_	_	_	_	Seg=O
165	happens	_	_	_	_	_	_	_	Seg=O
166	very	_	_	_	_	_	_	_	Seg=O
167	frequently	_	_	_	_	_	_	_	Seg=O
168	in	_	_	_	_	_	_	_	Seg=O
169	the	_	_	_	_	_	_	_	Seg=O
170	classical	_	_	_	_	_	_	_	Seg=O
171	limit	_	_	_	_	_	_	_	Seg=O
172	,	_	_	_	_	_	_	_	Seg=O
173	but	_	_	_	_	_	_	_	Seg=O
174	not	_	_	_	_	_	_	_	Seg=O
175	too	_	_	_	_	_	_	_	Seg=O
176	frequently	_	_	_	_	_	_	_	Seg=O
177	.	_	_	_	_	_	_	_	Seg=O
178	Given	_	_	_	_	_	_	_	Seg=B-seg
179	these	_	_	_	_	_	_	_	Seg=O
180	assumptions	_	_	_	_	_	_	_	Seg=O
181	,	_	_	_	_	_	_	_	Seg=O
182	we	_	_	_	_	_	_	_	Seg=B-seg
183	demonstrate	_	_	_	_	_	_	_	Seg=O
184	that	_	_	_	_	_	_	_	Seg=B-seg
185	the	_	_	_	_	_	_	_	Seg=O
186	semiclassical	_	_	_	_	_	_	_	Seg=O
187	evolution	_	_	_	_	_	_	_	Seg=O
188	of	_	_	_	_	_	_	_	Seg=O
189	the	_	_	_	_	_	_	_	Seg=O
190	system	_	_	_	_	_	_	_	Seg=O
191	is	_	_	_	_	_	_	_	Seg=O
192	dominated	_	_	_	_	_	_	_	Seg=O
193	by	_	_	_	_	_	_	_	Seg=O
194	a	_	_	_	_	_	_	_	Seg=O
195	certain	_	_	_	_	_	_	_	Seg=O
196	dynamical	_	_	_	_	_	_	_	Seg=O
197	generalisation	_	_	_	_	_	_	_	Seg=O
198	of	_	_	_	_	_	_	_	Seg=O
199	Uhlmann	_	_	_	_	_	_	_	Seg=O
200	holonomy	_	_	_	_	_	_	_	Seg=O
201	.	_	_	_	_	_	_	_	Seg=O
202	We	_	_	_	_	_	_	_	Seg=B-seg
203	construct	_	_	_	_	_	_	_	Seg=O
204	a	_	_	_	_	_	_	_	Seg=O
205	coherent	_	_	_	_	_	_	_	Seg=O
206	state	_	_	_	_	_	_	_	Seg=O
207	path	_	_	_	_	_	_	_	Seg=O
208	integral	_	_	_	_	_	_	_	Seg=O
209	for	_	_	_	_	_	_	_	Seg=O
210	this	_	_	_	_	_	_	_	Seg=O
211	evolution	_	_	_	_	_	_	_	Seg=O
212	,	_	_	_	_	_	_	_	Seg=O
213	showing	_	_	_	_	_	_	_	Seg=B-seg
214	that	_	_	_	_	_	_	_	Seg=B-seg
215	the	_	_	_	_	_	_	_	Seg=O
216	semiclassical	_	_	_	_	_	_	_	Seg=O
217	fields	_	_	_	_	_	_	_	Seg=O
218	evolve	_	_	_	_	_	_	_	Seg=O
219	in	_	_	_	_	_	_	_	Seg=O
220	a	_	_	_	_	_	_	_	Seg=O
221	spacetime	_	_	_	_	_	_	_	Seg=O
222	with	_	_	_	_	_	_	_	Seg=O
223	one	_	_	_	_	_	_	_	Seg=O
224	more	_	_	_	_	_	_	_	Seg=O
225	dimension	_	_	_	_	_	_	_	Seg=O
226	than	_	_	_	_	_	_	_	Seg=O
227	the	_	_	_	_	_	_	_	Seg=O
228	isolated	_	_	_	_	_	_	_	Seg=O
229	case	_	_	_	_	_	_	_	Seg=O
230	.	_	_	_	_	_	_	_	Seg=O
231	The	_	_	_	_	_	_	_	Seg=B-seg
232	additional	_	_	_	_	_	_	_	Seg=O
233	dimension	_	_	_	_	_	_	_	Seg=O
234	is	_	_	_	_	_	_	_	Seg=O
235	generated	_	_	_	_	_	_	_	Seg=O
236	by	_	_	_	_	_	_	_	Seg=O
237	modular	_	_	_	_	_	_	_	Seg=O
238	flow	_	_	_	_	_	_	_	Seg=O
239	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 7c8f40872fb6e8d5289fec4b0573cc22e15fa180
1	In	_	_	_	_	_	_	_	Seg=B-seg
2	recent	_	_	_	_	_	_	_	Seg=O
3	years	_	_	_	_	_	_	_	Seg=O
4	,	_	_	_	_	_	_	_	Seg=O
5	the	_	_	_	_	_	_	_	Seg=O
6	incidence	_	_	_	_	_	_	_	Seg=O
7	of	_	_	_	_	_	_	_	Seg=O
8	severe	_	_	_	_	_	_	_	Seg=O
9	infectious	_	_	_	_	_	_	_	Seg=O
10	diseases	_	_	_	_	_	_	_	Seg=O
11	has	_	_	_	_	_	_	_	Seg=O
12	increased	_	_	_	_	_	_	_	Seg=O
13	,	_	_	_	_	_	_	_	Seg=O
14	and	_	_	_	_	_	_	_	Seg=B-seg
15	the	_	_	_	_	_	_	_	Seg=O
16	number	_	_	_	_	_	_	_	Seg=O
17	of	_	_	_	_	_	_	_	Seg=O
18	emerging	_	_	_	_	_	_	_	Seg=O
19	infectious	_	_	_	_	_	_	_	Seg=O
20	diseases	_	_	_	_	_	_	_	Seg=O
21	continues	_	_	_	_	_	_	_	Seg=O
22	to	_	_	_	_	_	_	_	Seg=O
23	increase	_	_	_	_	_	_	_	Seg=O
24	.	_	_	_	_	_	_	_	Seg=O
25	The	_	_	_	_	_	_	_	Seg=B-seg
26	Chinese	_	_	_	_	_	_	_	Seg=O
27	government	_	_	_	_	_	_	_	Seg=O
28	and	_	_	_	_	_	_	_	Seg=O
29	military	_	_	_	_	_	_	_	Seg=O
30	forces	_	_	_	_	_	_	_	Seg=O
31	have	_	_	_	_	_	_	_	Seg=O
32	paid	_	_	_	_	_	_	_	Seg=O
33	a	_	_	_	_	_	_	_	Seg=O
34	great	_	_	_	_	_	_	_	Seg=O
35	deal	_	_	_	_	_	_	_	Seg=O
36	of	_	_	_	_	_	_	_	Seg=O
37	attention	_	_	_	_	_	_	_	Seg=O
38	to	_	_	_	_	_	_	_	Seg=O
39	infectious	_	_	_	_	_	_	_	Seg=O
40	disease	_	_	_	_	_	_	_	Seg=O
41	prevention	_	_	_	_	_	_	_	Seg=O
42	and	_	_	_	_	_	_	_	Seg=O
43	control	_	_	_	_	_	_	_	Seg=O
44	,	_	_	_	_	_	_	_	Seg=O
45	and	_	_	_	_	_	_	_	Seg=B-seg
46	using	_	_	_	_	_	_	_	Seg=O
47	military	_	_	_	_	_	_	_	Seg=O
48	-	_	_	_	_	_	_	_	Seg=O
49	civilian	_	_	_	_	_	_	_	Seg=O
50	cooperation	_	_	_	_	_	_	_	Seg=O
51	,	_	_	_	_	_	_	_	Seg=O
52	they	_	_	_	_	_	_	_	Seg=B-seg
53	have	_	_	_	_	_	_	_	Seg=O
54	successfully	_	_	_	_	_	_	_	Seg=O
55	prevented	_	_	_	_	_	_	_	Seg=O
56	numerous	_	_	_	_	_	_	_	Seg=O
57	severe	_	_	_	_	_	_	_	Seg=O
58	epidemic	_	_	_	_	_	_	_	Seg=O
59	situations	_	_	_	_	_	_	_	Seg=O
60	,	_	_	_	_	_	_	_	Seg=O
61	such	_	_	_	_	_	_	_	Seg=B-seg
62	as	_	_	_	_	_	_	_	Seg=O
63	severe	_	_	_	_	_	_	_	Seg=O
64	acute	_	_	_	_	_	_	_	Seg=O
65	respiratory	_	_	_	_	_	_	_	Seg=O
66	syndrome	_	_	_	_	_	_	_	Seg=O
67	(	_	_	_	_	_	_	_	Seg=O
68	SARS	_	_	_	_	_	_	_	Seg=O
69	)	_	_	_	_	_	_	_	Seg=O
70	,	_	_	_	_	_	_	_	Seg=O
71	influenza	_	_	_	_	_	_	_	Seg=O
72	A	_	_	_	_	_	_	_	Seg=O
73	(	_	_	_	_	_	_	_	Seg=O
74	H1N1	_	_	_	_	_	_	_	Seg=O
75	)	_	_	_	_	_	_	_	Seg=O
76	,	_	_	_	_	_	_	_	Seg=O
77	avian	_	_	_	_	_	_	_	Seg=O
78	influenza	_	_	_	_	_	_	_	Seg=O
79	H5N1	_	_	_	_	_	_	_	Seg=O
80	and	_	_	_	_	_	_	_	Seg=O
81	H7N9	_	_	_	_	_	_	_	Seg=O
82	,	_	_	_	_	_	_	_	Seg=O
83	and	_	_	_	_	_	_	_	Seg=O
84	Ebola	_	_	_	_	_	_	_	Seg=O
85	hemorrhagic	_	_	_	_	_	_	_	Seg=O
86	fever	_	_	_	_	_	_	_	Seg=O
87	,	_	_	_	_	_	_	_	Seg=O
88	while	_	_	_	_	_	_	_	Seg=B-seg
89	actively	_	_	_	_	_	_	_	Seg=O
90	maintained	_	_	_	_	_	_	_	Seg=O
91	public	_	_	_	_	_	_	_	Seg=O
92	health	_	_	_	_	_	_	_	Seg=O
93	,	_	_	_	_	_	_	_	Seg=O
94	economic	_	_	_	_	_	_	_	Seg=O
95	development	_	_	_	_	_	_	_	Seg=O
96	,	_	_	_	_	_	_	_	Seg=O
97	and	_	_	_	_	_	_	_	Seg=O
98	national	_	_	_	_	_	_	_	Seg=O
99	construction	_	_	_	_	_	_	_	Seg=O
100	.	_	_	_	_	_	_	_	Seg=O
101	This	_	_	_	_	_	_	_	Seg=B-seg
102	paper	_	_	_	_	_	_	_	Seg=O
103	focuses	_	_	_	_	_	_	_	Seg=O
104	on	_	_	_	_	_	_	_	Seg=O
105	the	_	_	_	_	_	_	_	Seg=O
106	mechanisms	_	_	_	_	_	_	_	Seg=O
107	of	_	_	_	_	_	_	_	Seg=O
108	the	_	_	_	_	_	_	_	Seg=O
109	military	_	_	_	_	_	_	_	Seg=O
110	-	_	_	_	_	_	_	_	Seg=O
111	cooperative	_	_	_	_	_	_	_	Seg=O
112	emergency	_	_	_	_	_	_	_	Seg=O
113	response	_	_	_	_	_	_	_	Seg=O
114	to	_	_	_	_	_	_	_	Seg=O
115	infectious	_	_	_	_	_	_	_	Seg=O
116	diseases	_	_	_	_	_	_	_	Seg=O
117	-	_	_	_	_	_	_	_	Seg=B-seg
118	the	_	_	_	_	_	_	_	Seg=O
119	joint	_	_	_	_	_	_	_	Seg=O
120	working	_	_	_	_	_	_	_	Seg=O
121	mechanism	_	_	_	_	_	_	_	Seg=O
122	,	_	_	_	_	_	_	_	Seg=O
123	the	_	_	_	_	_	_	_	Seg=O
124	information	_	_	_	_	_	_	_	Seg=O
125	-	_	_	_	_	_	_	_	Seg=O
126	sharing	_	_	_	_	_	_	_	Seg=O
127	mechanism	_	_	_	_	_	_	_	Seg=O
128	,	_	_	_	_	_	_	_	Seg=O
129	the	_	_	_	_	_	_	_	Seg=O
130	research	_	_	_	_	_	_	_	Seg=O
131	collaboration	_	_	_	_	_	_	_	Seg=O
132	mechanism	_	_	_	_	_	_	_	Seg=O
133	,	_	_	_	_	_	_	_	Seg=O
134	and	_	_	_	_	_	_	_	Seg=O
135	the	_	_	_	_	_	_	_	Seg=O
136	joint	_	_	_	_	_	_	_	Seg=O
137	disposal	_	_	_	_	_	_	_	Seg=O
138	mechanism	_	_	_	_	_	_	_	Seg=O
139	-	_	_	_	_	_	_	_	Seg=O
140	and	_	_	_	_	_	_	_	Seg=B-seg
141	presents	_	_	_	_	_	_	_	Seg=O
142	a	_	_	_	_	_	_	_	Seg=O
143	sorted	_	_	_	_	_	_	_	Seg=O
144	summary	_	_	_	_	_	_	_	Seg=O
145	of	_	_	_	_	_	_	_	Seg=O
146	the	_	_	_	_	_	_	_	Seg=O
147	practices	_	_	_	_	_	_	_	Seg=O
148	and	_	_	_	_	_	_	_	Seg=O
149	experiences	_	_	_	_	_	_	_	Seg=O
150	of	_	_	_	_	_	_	_	Seg=O
151	cooperative	_	_	_	_	_	_	_	Seg=O
152	emergency	_	_	_	_	_	_	_	Seg=O
153	responses	_	_	_	_	_	_	_	Seg=O
154	to	_	_	_	_	_	_	_	Seg=O
155	infectious	_	_	_	_	_	_	_	Seg=O
156	diseases	_	_	_	_	_	_	_	Seg=O
157	.	_	_	_	_	_	_	_	Seg=O
158	In	_	_	_	_	_	_	_	Seg=B-seg
159	the	_	_	_	_	_	_	_	Seg=O
160	future	_	_	_	_	_	_	_	Seg=O
161	,	_	_	_	_	_	_	_	Seg=O
162	the	_	_	_	_	_	_	_	Seg=O
163	Chinese	_	_	_	_	_	_	_	Seg=O
164	military	_	_	_	_	_	_	_	Seg=O
165	and	_	_	_	_	_	_	_	Seg=O
166	the	_	_	_	_	_	_	_	Seg=O
167	civilian	_	_	_	_	_	_	_	Seg=O
168	sector	_	_	_	_	_	_	_	Seg=O
169	will	_	_	_	_	_	_	_	Seg=O
170	further	_	_	_	_	_	_	_	Seg=O
171	strengthen	_	_	_	_	_	_	_	Seg=O
172	the	_	_	_	_	_	_	_	Seg=O
173	cooperative	_	_	_	_	_	_	_	Seg=O
174	joint	_	_	_	_	_	_	_	Seg=O
175	command	_	_	_	_	_	_	_	Seg=O
176	system	_	_	_	_	_	_	_	Seg=O
177	and	_	_	_	_	_	_	_	Seg=O
178	emergency	_	_	_	_	_	_	_	Seg=O
179	rescue	_	_	_	_	_	_	_	Seg=O
180	force	_	_	_	_	_	_	_	Seg=O
181	and	_	_	_	_	_	_	_	Seg=B-seg
182	will	_	_	_	_	_	_	_	Seg=O
183	reinforce	_	_	_	_	_	_	_	Seg=O
184	their	_	_	_	_	_	_	_	Seg=O
185	collaborative	_	_	_	_	_	_	_	Seg=O
186	information	_	_	_	_	_	_	_	Seg=O
187	-	_	_	_	_	_	_	_	Seg=O
188	sharing	_	_	_	_	_	_	_	Seg=O
189	platform	_	_	_	_	_	_	_	Seg=O
190	and	_	_	_	_	_	_	_	Seg=O
191	technical	_	_	_	_	_	_	_	Seg=O
192	equipment	_	_	_	_	_	_	_	Seg=O
193	system	_	_	_	_	_	_	_	Seg=O
194	to	_	_	_	_	_	_	_	Seg=B-seg
195	further	_	_	_	_	_	_	_	Seg=O
196	improve	_	_	_	_	_	_	_	Seg=O
197	military	_	_	_	_	_	_	_	Seg=O
198	-	_	_	_	_	_	_	_	Seg=O
199	civilian	_	_	_	_	_	_	_	Seg=O
200	collaborative	_	_	_	_	_	_	_	Seg=O
201	emergency	_	_	_	_	_	_	_	Seg=O
202	infectious	_	_	_	_	_	_	_	Seg=O
203	diseases	_	_	_	_	_	_	_	Seg=O
204	disposal	_	_	_	_	_	_	_	Seg=O
205	,	_	_	_	_	_	_	_	Seg=O
206	advance	_	_	_	_	_	_	_	Seg=B-seg
207	the	_	_	_	_	_	_	_	Seg=O
208	level	_	_	_	_	_	_	_	Seg=O
209	of	_	_	_	_	_	_	_	Seg=O
210	infectious	_	_	_	_	_	_	_	Seg=O
211	disease	_	_	_	_	_	_	_	Seg=O
212	prevention	_	_	_	_	_	_	_	Seg=O
213	and	_	_	_	_	_	_	_	Seg=O
214	control	_	_	_	_	_	_	_	Seg=O
215	,	_	_	_	_	_	_	_	Seg=O
216	and	_	_	_	_	_	_	_	Seg=B-seg
217	maintain	_	_	_	_	_	_	_	Seg=O
218	public	_	_	_	_	_	_	_	Seg=O
219	health	_	_	_	_	_	_	_	Seg=O
220	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 7ff1d5c7e68d082ee1f2e6fdfbb6ae1ff931e0db
1	COVID-19	_	_	_	_	_	_	_	Seg=B-seg
2	can	_	_	_	_	_	_	_	Seg=O
3	affect	_	_	_	_	_	_	_	Seg=O
4	the	_	_	_	_	_	_	_	Seg=O
5	hematopoietic	_	_	_	_	_	_	_	Seg=O
6	system	_	_	_	_	_	_	_	Seg=O
7	.	_	_	_	_	_	_	_	Seg=O
8	Thrombocytopenia	_	_	_	_	_	_	_	Seg=B-seg
9	at	_	_	_	_	_	_	_	Seg=O
10	admission	_	_	_	_	_	_	_	Seg=O
11	was	_	_	_	_	_	_	_	Seg=O
12	prevalent	_	_	_	_	_	_	_	Seg=O
13	,	_	_	_	_	_	_	_	Seg=O
14	while	_	_	_	_	_	_	_	Seg=B-seg
15	late	_	_	_	_	_	_	_	Seg=O
16	-	_	_	_	_	_	_	_	Seg=O
17	phase	_	_	_	_	_	_	_	Seg=O
18	or	_	_	_	_	_	_	_	Seg=O
19	delayed	_	_	_	_	_	_	_	Seg=O
20	-	_	_	_	_	_	_	_	Seg=O
21	phase	_	_	_	_	_	_	_	Seg=O
22	thrombocytopenia	_	_	_	_	_	_	_	Seg=O
23	(	_	_	_	_	_	_	_	Seg=B-seg
24	occurred	_	_	_	_	_	_	_	Seg=O
25	14	_	_	_	_	_	_	_	Seg=O
26	days	_	_	_	_	_	_	_	Seg=O
27	after	_	_	_	_	_	_	_	Seg=O
28	symptom	_	_	_	_	_	_	_	Seg=O
29	onset	_	_	_	_	_	_	_	Seg=O
30	)	_	_	_	_	_	_	_	Seg=O
31	is	_	_	_	_	_	_	_	Seg=B-seg
32	obscure	_	_	_	_	_	_	_	Seg=O
33	.	_	_	_	_	_	_	_	Seg=O
34	This	_	_	_	_	_	_	_	Seg=B-seg
35	retrospective	_	_	_	_	_	_	_	Seg=O
36	single	_	_	_	_	_	_	_	Seg=O
37	-	_	_	_	_	_	_	_	Seg=O
38	center	_	_	_	_	_	_	_	Seg=O
39	study	_	_	_	_	_	_	_	Seg=O
40	screened	_	_	_	_	_	_	_	Seg=O
41	450	_	_	_	_	_	_	_	Seg=O
42	COVID-19	_	_	_	_	_	_	_	Seg=O
43	patients	_	_	_	_	_	_	_	Seg=O
44	and	_	_	_	_	_	_	_	Seg=B-seg
45	enrolled	_	_	_	_	_	_	_	Seg=O
46	271	_	_	_	_	_	_	_	Seg=O
47	patients	_	_	_	_	_	_	_	Seg=O
48	at	_	_	_	_	_	_	_	Seg=O
49	the	_	_	_	_	_	_	_	Seg=O
50	Union	_	_	_	_	_	_	_	Seg=O
51	Hospital	_	_	_	_	_	_	_	Seg=O
52	,	_	_	_	_	_	_	_	Seg=O
53	Wuhan	_	_	_	_	_	_	_	Seg=O
54	,	_	_	_	_	_	_	_	Seg=O
55	China	_	_	_	_	_	_	_	Seg=O
56	,	_	_	_	_	_	_	_	Seg=O
57	from	_	_	_	_	_	_	_	Seg=O
58	January	_	_	_	_	_	_	_	Seg=O
59	25th	_	_	_	_	_	_	_	Seg=O
60	to	_	_	_	_	_	_	_	Seg=O
61	March	_	_	_	_	_	_	_	Seg=O
62	9th	_	_	_	_	_	_	_	Seg=O
63	,	_	_	_	_	_	_	_	Seg=O
64	2020	_	_	_	_	_	_	_	Seg=O
65	.	_	_	_	_	_	_	_	Seg=O
66	COVID-19	_	_	_	_	_	_	_	Seg=B-seg
67	associated	_	_	_	_	_	_	_	Seg=O
68	delayed	_	_	_	_	_	_	_	Seg=O
69	-	_	_	_	_	_	_	_	Seg=O
70	phase	_	_	_	_	_	_	_	Seg=O
71	thrombocytopenia	_	_	_	_	_	_	_	Seg=O
72	occurred	_	_	_	_	_	_	_	Seg=O
73	in	_	_	_	_	_	_	_	Seg=O
74	11.8	_	_	_	_	_	_	_	Seg=O
75	%	_	_	_	_	_	_	_	Seg=O
76	percent	_	_	_	_	_	_	_	Seg=O
77	of	_	_	_	_	_	_	_	Seg=O
78	enrolling	_	_	_	_	_	_	_	Seg=O
79	patients	_	_	_	_	_	_	_	Seg=O
80	.	_	_	_	_	_	_	_	Seg=O
81	The	_	_	_	_	_	_	_	Seg=B-seg
82	delayed	_	_	_	_	_	_	_	Seg=O
83	-	_	_	_	_	_	_	_	Seg=O
84	phase	_	_	_	_	_	_	_	Seg=O
85	thrombocytopenia	_	_	_	_	_	_	_	Seg=O
86	in	_	_	_	_	_	_	_	Seg=O
87	COVID-19	_	_	_	_	_	_	_	Seg=O
88	is	_	_	_	_	_	_	_	Seg=O
89	prone	_	_	_	_	_	_	_	Seg=O
90	to	_	_	_	_	_	_	_	Seg=O
91	develop	_	_	_	_	_	_	_	Seg=O
92	in	_	_	_	_	_	_	_	Seg=O
93	elderly	_	_	_	_	_	_	_	Seg=O
94	patients	_	_	_	_	_	_	_	Seg=O
95	or	_	_	_	_	_	_	_	Seg=O
96	patients	_	_	_	_	_	_	_	Seg=O
97	with	_	_	_	_	_	_	_	Seg=O
98	low	_	_	_	_	_	_	_	Seg=O
99	lymphocyte	_	_	_	_	_	_	_	Seg=O
100	count	_	_	_	_	_	_	_	Seg=O
101	on	_	_	_	_	_	_	_	Seg=O
102	admission	_	_	_	_	_	_	_	Seg=O
103	.	_	_	_	_	_	_	_	Seg=O
104	The	_	_	_	_	_	_	_	Seg=B-seg
105	delayed	_	_	_	_	_	_	_	Seg=O
106	-	_	_	_	_	_	_	_	Seg=O
107	phase	_	_	_	_	_	_	_	Seg=O
108	thrombocytopenia	_	_	_	_	_	_	_	Seg=O
109	is	_	_	_	_	_	_	_	Seg=O
110	significantly	_	_	_	_	_	_	_	Seg=O
111	associated	_	_	_	_	_	_	_	Seg=O
112	with	_	_	_	_	_	_	_	Seg=O
113	increased	_	_	_	_	_	_	_	Seg=O
114	length	_	_	_	_	_	_	_	Seg=O
115	of	_	_	_	_	_	_	_	Seg=O
116	hospital	_	_	_	_	_	_	_	Seg=O
117	stay	_	_	_	_	_	_	_	Seg=O
118	and	_	_	_	_	_	_	_	Seg=O
119	higher	_	_	_	_	_	_	_	Seg=O
120	mortality	_	_	_	_	_	_	_	Seg=O
121	rate	_	_	_	_	_	_	_	Seg=O
122	.	_	_	_	_	_	_	_	Seg=O
123	Delayed	_	_	_	_	_	_	_	Seg=B-seg
124	-	_	_	_	_	_	_	_	Seg=O
125	phase	_	_	_	_	_	_	_	Seg=O
126	nadir	_	_	_	_	_	_	_	Seg=O
127	platelet	_	_	_	_	_	_	_	Seg=O
128	counts	_	_	_	_	_	_	_	Seg=O
129	demonstrated	_	_	_	_	_	_	_	Seg=O
130	a	_	_	_	_	_	_	_	Seg=O
131	significantly	_	_	_	_	_	_	_	Seg=O
132	negative	_	_	_	_	_	_	_	Seg=O
133	correlation	_	_	_	_	_	_	_	Seg=O
134	with	_	_	_	_	_	_	_	Seg=O
135	B	_	_	_	_	_	_	_	Seg=O
136	cell	_	_	_	_	_	_	_	Seg=O
137	percentages	_	_	_	_	_	_	_	Seg=O
138	.	_	_	_	_	_	_	_	Seg=O
139	We	_	_	_	_	_	_	_	Seg=B-seg
140	also	_	_	_	_	_	_	_	Seg=O
141	presented	_	_	_	_	_	_	_	Seg=O
142	bone	_	_	_	_	_	_	_	Seg=O
143	marrow	_	_	_	_	_	_	_	Seg=O
144	aspiration	_	_	_	_	_	_	_	Seg=O
145	pathology	_	_	_	_	_	_	_	Seg=O
146	of	_	_	_	_	_	_	_	Seg=O
147	three	_	_	_	_	_	_	_	Seg=O
148	patients	_	_	_	_	_	_	_	Seg=O
149	with	_	_	_	_	_	_	_	Seg=O
150	delayed	_	_	_	_	_	_	_	Seg=O
151	-	_	_	_	_	_	_	_	Seg=O
152	phase	_	_	_	_	_	_	_	Seg=O
153	thrombocytopenia	_	_	_	_	_	_	_	Seg=O
154	,	_	_	_	_	_	_	_	Seg=O
155	showing	_	_	_	_	_	_	_	Seg=B-seg
156	impaired	_	_	_	_	_	_	_	Seg=O
157	maturation	_	_	_	_	_	_	_	Seg=O
158	of	_	_	_	_	_	_	_	Seg=O
159	megakaryocytes	_	_	_	_	_	_	_	Seg=O
160	.	_	_	_	_	_	_	_	Seg=O
161	We	_	_	_	_	_	_	_	Seg=B-seg
162	speculated	_	_	_	_	_	_	_	Seg=O
163	that	_	_	_	_	_	_	_	Seg=B-seg
164	immune	_	_	_	_	_	_	_	Seg=O
165	mediated	_	_	_	_	_	_	_	Seg=O
166	platelet	_	_	_	_	_	_	_	Seg=O
167	destruction	_	_	_	_	_	_	_	Seg=O
168	might	_	_	_	_	_	_	_	Seg=O
169	account	_	_	_	_	_	_	_	Seg=O
170	for	_	_	_	_	_	_	_	Seg=O
171	the	_	_	_	_	_	_	_	Seg=O
172	delayed	_	_	_	_	_	_	_	Seg=O
173	-	_	_	_	_	_	_	_	Seg=O
174	phase	_	_	_	_	_	_	_	Seg=O
175	thrombocytopenia	_	_	_	_	_	_	_	Seg=O
176	in	_	_	_	_	_	_	_	Seg=O
177	a	_	_	_	_	_	_	_	Seg=O
178	group	_	_	_	_	_	_	_	Seg=O
179	of	_	_	_	_	_	_	_	Seg=O
180	patients	_	_	_	_	_	_	_	Seg=O
181	.	_	_	_	_	_	_	_	Seg=O
182	Besides	_	_	_	_	_	_	_	Seg=B-seg
183	,	_	_	_	_	_	_	_	Seg=O
184	clinicians	_	_	_	_	_	_	_	Seg=O
185	need	_	_	_	_	_	_	_	Seg=O
186	to	_	_	_	_	_	_	_	Seg=O
187	pay	_	_	_	_	_	_	_	Seg=O
188	attention	_	_	_	_	_	_	_	Seg=O
189	to	_	_	_	_	_	_	_	Seg=O
190	the	_	_	_	_	_	_	_	Seg=O
191	delayed	_	_	_	_	_	_	_	Seg=O
192	-	_	_	_	_	_	_	_	Seg=O
193	phase	_	_	_	_	_	_	_	Seg=O
194	thrombocytopenia	_	_	_	_	_	_	_	Seg=O
195	especially	_	_	_	_	_	_	_	Seg=O
196	at	_	_	_	_	_	_	_	Seg=O
197	3	_	_	_	_	_	_	_	Seg=O
198	-	_	_	_	_	_	_	_	Seg=O
199	4	_	_	_	_	_	_	_	Seg=O
200	weeks	_	_	_	_	_	_	_	Seg=O
201	after	_	_	_	_	_	_	_	Seg=O
202	symptom	_	_	_	_	_	_	_	Seg=O
203	onset	_	_	_	_	_	_	_	Seg=O
204	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 8edf35c1ee0ae65d00ecd1d87b98f48bcce861ee
1	Mortality	_	_	_	_	_	_	_	Seg=B-seg
2	from	_	_	_	_	_	_	_	Seg=O
3	coronavirus	_	_	_	_	_	_	_	Seg=O
4	disease	_	_	_	_	_	_	_	Seg=O
5	2019	_	_	_	_	_	_	_	Seg=O
6	is	_	_	_	_	_	_	_	Seg=O
7	strongly	_	_	_	_	_	_	_	Seg=O
8	associated	_	_	_	_	_	_	_	Seg=O
9	with	_	_	_	_	_	_	_	Seg=O
10	cardiovascular	_	_	_	_	_	_	_	Seg=O
11	disease	_	_	_	_	_	_	_	Seg=O
12	,	_	_	_	_	_	_	_	Seg=O
13	diabetes	_	_	_	_	_	_	_	Seg=O
14	,	_	_	_	_	_	_	_	Seg=O
15	and	_	_	_	_	_	_	_	Seg=O
16	hypertension	_	_	_	_	_	_	_	Seg=O
17	.	_	_	_	_	_	_	_	Seg=O
18	These	_	_	_	_	_	_	_	Seg=B-seg
19	disorders	_	_	_	_	_	_	_	Seg=O
20	share	_	_	_	_	_	_	_	Seg=O
21	underlying	_	_	_	_	_	_	_	Seg=O
22	pathophysiology	_	_	_	_	_	_	_	Seg=O
23	related	_	_	_	_	_	_	_	Seg=B-seg
24	to	_	_	_	_	_	_	_	Seg=O
25	the	_	_	_	_	_	_	_	Seg=O
26	renin	_	_	_	_	_	_	_	Seg=O
27	-	_	_	_	_	_	_	_	Seg=O
28	angiotensin	_	_	_	_	_	_	_	Seg=O
29	system	_	_	_	_	_	_	_	Seg=O
30	(	_	_	_	_	_	_	_	Seg=O
31	RAS	_	_	_	_	_	_	_	Seg=O
32	)	_	_	_	_	_	_	_	Seg=O
33	that	_	_	_	_	_	_	_	Seg=B-seg
34	may	_	_	_	_	_	_	_	Seg=O
35	be	_	_	_	_	_	_	_	Seg=O
36	clinically	_	_	_	_	_	_	_	Seg=O
37	insightful	_	_	_	_	_	_	_	Seg=O
38	.	_	_	_	_	_	_	_	Seg=O
39	In	_	_	_	_	_	_	_	Seg=B-seg
40	particular	_	_	_	_	_	_	_	Seg=O
41	,	_	_	_	_	_	_	_	Seg=O
42	activity	_	_	_	_	_	_	_	Seg=O
43	of	_	_	_	_	_	_	_	Seg=O
44	the	_	_	_	_	_	_	_	Seg=O
45	angiotensin	_	_	_	_	_	_	_	Seg=O
46	-	_	_	_	_	_	_	_	Seg=O
47	converting	_	_	_	_	_	_	_	Seg=O
48	enzyme	_	_	_	_	_	_	_	Seg=O
49	2	_	_	_	_	_	_	_	Seg=O
50	(	_	_	_	_	_	_	_	Seg=O
51	ACE2	_	_	_	_	_	_	_	Seg=O
52	)	_	_	_	_	_	_	_	Seg=O
53	is	_	_	_	_	_	_	_	Seg=O
54	dysregulated	_	_	_	_	_	_	_	Seg=O
55	in	_	_	_	_	_	_	_	Seg=O
56	cardiovascular	_	_	_	_	_	_	_	Seg=O
57	disease	_	_	_	_	_	_	_	Seg=O
58	,	_	_	_	_	_	_	_	Seg=O
59	and	_	_	_	_	_	_	_	Seg=B-seg
60	this	_	_	_	_	_	_	_	Seg=O
61	enzyme	_	_	_	_	_	_	_	Seg=O
62	is	_	_	_	_	_	_	_	Seg=O
63	used	_	_	_	_	_	_	_	Seg=O
64	by	_	_	_	_	_	_	_	Seg=O
65	severe	_	_	_	_	_	_	_	Seg=O
66	acute	_	_	_	_	_	_	_	Seg=O
67	respiratory	_	_	_	_	_	_	_	Seg=O
68	syndrome	_	_	_	_	_	_	_	Seg=O
69	coronavirus	_	_	_	_	_	_	_	Seg=O
70	2	_	_	_	_	_	_	_	Seg=O
71	(	_	_	_	_	_	_	_	Seg=O
72	SARS	_	_	_	_	_	_	_	Seg=O
73	-	_	_	_	_	_	_	_	Seg=O
74	CoV-2	_	_	_	_	_	_	_	Seg=O
75	)	_	_	_	_	_	_	_	Seg=O
76	to	_	_	_	_	_	_	_	Seg=B-seg
77	initiate	_	_	_	_	_	_	_	Seg=O
78	the	_	_	_	_	_	_	_	Seg=O
79	infection	_	_	_	_	_	_	_	Seg=O
80	.	_	_	_	_	_	_	_	Seg=O
81	Cardiovascular	_	_	_	_	_	_	_	Seg=B-seg
82	disease	_	_	_	_	_	_	_	Seg=O
83	and	_	_	_	_	_	_	_	Seg=O
84	pharmacologic	_	_	_	_	_	_	_	Seg=O
85	RAS	_	_	_	_	_	_	_	Seg=O
86	inhibition	_	_	_	_	_	_	_	Seg=O
87	both	_	_	_	_	_	_	_	Seg=O
88	increase	_	_	_	_	_	_	_	Seg=O
89	ACE2	_	_	_	_	_	_	_	Seg=O
90	levels	_	_	_	_	_	_	_	Seg=O
91	,	_	_	_	_	_	_	_	Seg=O
92	which	_	_	_	_	_	_	_	Seg=B-seg
93	may	_	_	_	_	_	_	_	Seg=O
94	increase	_	_	_	_	_	_	_	Seg=O
95	the	_	_	_	_	_	_	_	Seg=O
96	virulence	_	_	_	_	_	_	_	Seg=O
97	of	_	_	_	_	_	_	_	Seg=O
98	SARS	_	_	_	_	_	_	_	Seg=O
99	-	_	_	_	_	_	_	_	Seg=O
100	CoV-2	_	_	_	_	_	_	_	Seg=O
101	within	_	_	_	_	_	_	_	Seg=O
102	the	_	_	_	_	_	_	_	Seg=O
103	lung	_	_	_	_	_	_	_	Seg=O
104	and	_	_	_	_	_	_	_	Seg=O
105	heart	_	_	_	_	_	_	_	Seg=O
106	.	_	_	_	_	_	_	_	Seg=O
107	Conversely	_	_	_	_	_	_	_	Seg=B-seg
108	,	_	_	_	_	_	_	_	Seg=O
109	mechanistic	_	_	_	_	_	_	_	Seg=O
110	evidence	_	_	_	_	_	_	_	Seg=O
111	from	_	_	_	_	_	_	_	Seg=O
112	related	_	_	_	_	_	_	_	Seg=O
113	coronaviruses	_	_	_	_	_	_	_	Seg=O
114	suggests	_	_	_	_	_	_	_	Seg=O
115	that	_	_	_	_	_	_	_	Seg=B-seg
116	SARS	_	_	_	_	_	_	_	Seg=O
117	-	_	_	_	_	_	_	_	Seg=O
118	CoV-2	_	_	_	_	_	_	_	Seg=O
119	infection	_	_	_	_	_	_	_	Seg=O
120	may	_	_	_	_	_	_	_	Seg=O
121	downregulate	_	_	_	_	_	_	_	Seg=O
122	ACE2	_	_	_	_	_	_	_	Seg=O
123	,	_	_	_	_	_	_	_	Seg=O
124	leading	_	_	_	_	_	_	_	Seg=B-seg
125	to	_	_	_	_	_	_	_	Seg=O
126	toxic	_	_	_	_	_	_	_	Seg=O
127	overaccumulation	_	_	_	_	_	_	_	Seg=O
128	of	_	_	_	_	_	_	_	Seg=O
129	Angiotensin	_	_	_	_	_	_	_	Seg=O
130	II	_	_	_	_	_	_	_	Seg=O
131	that	_	_	_	_	_	_	_	Seg=B-seg
132	induces	_	_	_	_	_	_	_	Seg=O
133	acute	_	_	_	_	_	_	_	Seg=O
134	respiratory	_	_	_	_	_	_	_	Seg=O
135	distress	_	_	_	_	_	_	_	Seg=O
136	syndrome	_	_	_	_	_	_	_	Seg=O
137	and	_	_	_	_	_	_	_	Seg=O
138	fulminant	_	_	_	_	_	_	_	Seg=O
139	myocarditis	_	_	_	_	_	_	_	Seg=O
140	.	_	_	_	_	_	_	_	Seg=O
141	RAS	_	_	_	_	_	_	_	Seg=B-seg
142	inhibition	_	_	_	_	_	_	_	Seg=O
143	could	_	_	_	_	_	_	_	Seg=O
144	mitigate	_	_	_	_	_	_	_	Seg=O
145	this	_	_	_	_	_	_	_	Seg=O
146	effect	_	_	_	_	_	_	_	Seg=O
147	.	_	_	_	_	_	_	_	Seg=O
148	With	_	_	_	_	_	_	_	Seg=B-seg
149	conflicting	_	_	_	_	_	_	_	Seg=O
150	mechanistic	_	_	_	_	_	_	_	Seg=O
151	evidence	_	_	_	_	_	_	_	Seg=O
152	,	_	_	_	_	_	_	_	Seg=O
153	we	_	_	_	_	_	_	_	Seg=O
154	propose	_	_	_	_	_	_	_	Seg=O
155	key	_	_	_	_	_	_	_	Seg=O
156	clinical	_	_	_	_	_	_	_	Seg=O
157	research	_	_	_	_	_	_	_	Seg=O
158	priorities	_	_	_	_	_	_	_	Seg=O
159	necessary	_	_	_	_	_	_	_	Seg=B-seg
160	to	_	_	_	_	_	_	_	Seg=O
161	clarify	_	_	_	_	_	_	_	Seg=O
162	the	_	_	_	_	_	_	_	Seg=O
163	role	_	_	_	_	_	_	_	Seg=O
164	of	_	_	_	_	_	_	_	Seg=O
165	RAS	_	_	_	_	_	_	_	Seg=O
166	inhibition	_	_	_	_	_	_	_	Seg=O
167	in	_	_	_	_	_	_	_	Seg=O
168	COVID-19	_	_	_	_	_	_	_	Seg=O
169	mortality	_	_	_	_	_	_	_	Seg=O
170	that	_	_	_	_	_	_	_	Seg=B-seg
171	could	_	_	_	_	_	_	_	Seg=O
172	be	_	_	_	_	_	_	_	Seg=O
173	rapidly	_	_	_	_	_	_	_	Seg=O
174	addressed	_	_	_	_	_	_	_	Seg=O
175	by	_	_	_	_	_	_	_	Seg=O
176	the	_	_	_	_	_	_	_	Seg=O
177	international	_	_	_	_	_	_	_	Seg=O
178	research	_	_	_	_	_	_	_	Seg=O
179	community	_	_	_	_	_	_	_	Seg=O
180	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = 986a03b193e684ba1acfbc5f275bd7935b3507ec
1	Motivated	_	_	_	_	_	_	_	Seg=B-seg
2	by	_	_	_	_	_	_	_	Seg=O
3	the	_	_	_	_	_	_	_	Seg=O
4	covid-19	_	_	_	_	_	_	_	Seg=O
5	pandemic	_	_	_	_	_	_	_	Seg=O
6	,	_	_	_	_	_	_	_	Seg=O
7	we	_	_	_	_	_	_	_	Seg=B-seg
8	developed	_	_	_	_	_	_	_	Seg=O
9	a	_	_	_	_	_	_	_	Seg=O
10	novel	_	_	_	_	_	_	_	Seg=O
11	Shewhart	_	_	_	_	_	_	_	Seg=O
12	chart	_	_	_	_	_	_	_	Seg=O
13	to	_	_	_	_	_	_	_	Seg=B-seg
14	visualize	_	_	_	_	_	_	_	Seg=O
15	and	_	_	_	_	_	_	_	Seg=O
16	learn	_	_	_	_	_	_	_	Seg=O
17	from	_	_	_	_	_	_	_	Seg=O
18	variation	_	_	_	_	_	_	_	Seg=O
19	in	_	_	_	_	_	_	_	Seg=O
20	reported	_	_	_	_	_	_	_	Seg=O
21	deaths	_	_	_	_	_	_	_	Seg=O
22	in	_	_	_	_	_	_	_	Seg=O
23	an	_	_	_	_	_	_	_	Seg=O
24	epidemic	_	_	_	_	_	_	_	Seg=O
25	.	_	_	_	_	_	_	_	Seg=O
26	Without	_	_	_	_	_	_	_	Seg=B-seg
27	a	_	_	_	_	_	_	_	Seg=O
28	method	_	_	_	_	_	_	_	Seg=O
29	to	_	_	_	_	_	_	_	Seg=B-seg
30	understand	_	_	_	_	_	_	_	Seg=O
31	if	_	_	_	_	_	_	_	Seg=O
32	day	_	_	_	_	_	_	_	Seg=O
33	-	_	_	_	_	_	_	_	Seg=O
34	to	_	_	_	_	_	_	_	Seg=O
35	-	_	_	_	_	_	_	_	Seg=O
36	day	_	_	_	_	_	_	_	Seg=O
37	variation	_	_	_	_	_	_	_	Seg=O
38	in	_	_	_	_	_	_	_	Seg=O
39	outcomes	_	_	_	_	_	_	_	Seg=O
40	may	_	_	_	_	_	_	_	Seg=O
41	be	_	_	_	_	_	_	_	Seg=O
42	attributed	_	_	_	_	_	_	_	Seg=O
43	to	_	_	_	_	_	_	_	Seg=O
44	meaningful	_	_	_	_	_	_	_	Seg=O
45	signals	_	_	_	_	_	_	_	Seg=O
46	of	_	_	_	_	_	_	_	Seg=O
47	change	_	_	_	_	_	_	_	Seg=O
48	-	_	_	_	_	_	_	_	Seg=B-seg
49	rather	_	_	_	_	_	_	_	Seg=O
50	than	_	_	_	_	_	_	_	Seg=O
51	variability	_	_	_	_	_	_	_	Seg=O
52	we	_	_	_	_	_	_	_	Seg=O
53	would	_	_	_	_	_	_	_	Seg=O
54	expect	_	_	_	_	_	_	_	Seg=O
55	-	_	_	_	_	_	_	_	Seg=O
56	care	_	_	_	_	_	_	_	Seg=B-seg
57	providers	_	_	_	_	_	_	_	Seg=O
58	,	_	_	_	_	_	_	_	Seg=O
59	improvement	_	_	_	_	_	_	_	Seg=O
60	leaders	_	_	_	_	_	_	_	Seg=O
61	,	_	_	_	_	_	_	_	Seg=O
62	policy	_	_	_	_	_	_	_	Seg=O
63	-	_	_	_	_	_	_	_	Seg=O
64	makers	_	_	_	_	_	_	_	Seg=O
65	,	_	_	_	_	_	_	_	Seg=O
66	and	_	_	_	_	_	_	_	Seg=O
67	the	_	_	_	_	_	_	_	Seg=O
68	public	_	_	_	_	_	_	_	Seg=O
69	will	_	_	_	_	_	_	_	Seg=O
70	struggle	_	_	_	_	_	_	_	Seg=O
71	to	_	_	_	_	_	_	_	Seg=O
72	recognize	_	_	_	_	_	_	_	Seg=O
73	if	_	_	_	_	_	_	_	Seg=O
74	epidemic	_	_	_	_	_	_	_	Seg=O
75	conditions	_	_	_	_	_	_	_	Seg=O
76	are	_	_	_	_	_	_	_	Seg=O
77	improving	_	_	_	_	_	_	_	Seg=O
78	.	_	_	_	_	_	_	_	Seg=O
79	We	_	_	_	_	_	_	_	Seg=B-seg
80	developed	_	_	_	_	_	_	_	Seg=O
81	a	_	_	_	_	_	_	_	Seg=O
82	novel	_	_	_	_	_	_	_	Seg=O
83	hybrid	_	_	_	_	_	_	_	Seg=O
84	C	_	_	_	_	_	_	_	Seg=O
85	-	_	_	_	_	_	_	_	Seg=O
86	Chart	_	_	_	_	_	_	_	Seg=O
87	and	_	_	_	_	_	_	_	Seg=O
88	I	_	_	_	_	_	_	_	Seg=O
89	-	_	_	_	_	_	_	_	Seg=O
90	Chart	_	_	_	_	_	_	_	Seg=O
91	to	_	_	_	_	_	_	_	Seg=B-seg
92	detect	_	_	_	_	_	_	_	Seg=O
93	within	_	_	_	_	_	_	_	Seg=O
94	a	_	_	_	_	_	_	_	Seg=O
95	geographic	_	_	_	_	_	_	_	Seg=O
96	area	_	_	_	_	_	_	_	Seg=O
97	the	_	_	_	_	_	_	_	Seg=O
98	start	_	_	_	_	_	_	_	Seg=O
99	and	_	_	_	_	_	_	_	Seg=O
100	end	_	_	_	_	_	_	_	Seg=O
101	of	_	_	_	_	_	_	_	Seg=O
102	exponential	_	_	_	_	_	_	_	Seg=O
103	growth	_	_	_	_	_	_	_	Seg=O
104	in	_	_	_	_	_	_	_	Seg=O
105	reported	_	_	_	_	_	_	_	Seg=O
106	deaths	_	_	_	_	_	_	_	Seg=O
107	.	_	_	_	_	_	_	_	Seg=O
108	Reported	_	_	_	_	_	_	_	Seg=B-seg
109	deaths	_	_	_	_	_	_	_	Seg=O
110	were	_	_	_	_	_	_	_	Seg=O
111	the	_	_	_	_	_	_	_	Seg=O
112	unit	_	_	_	_	_	_	_	Seg=O
113	of	_	_	_	_	_	_	_	Seg=O
114	analysis	_	_	_	_	_	_	_	Seg=O
115	owing	_	_	_	_	_	_	_	Seg=B-seg
116	to	_	_	_	_	_	_	_	Seg=O
117	erratic	_	_	_	_	_	_	_	Seg=O
118	reporting	_	_	_	_	_	_	_	Seg=O
119	of	_	_	_	_	_	_	_	Seg=O
120	cases	_	_	_	_	_	_	_	Seg=O
121	from	_	_	_	_	_	_	_	Seg=O
122	variability	_	_	_	_	_	_	_	Seg=O
123	in	_	_	_	_	_	_	_	Seg=O
124	local	_	_	_	_	_	_	_	Seg=O
125	testing	_	_	_	_	_	_	_	Seg=O
126	strategies	_	_	_	_	_	_	_	Seg=O
127	.	_	_	_	_	_	_	_	Seg=O
128	We	_	_	_	_	_	_	_	Seg=B-seg
129	used	_	_	_	_	_	_	_	Seg=O
130	simulation	_	_	_	_	_	_	_	Seg=O
131	and	_	_	_	_	_	_	_	Seg=O
132	case	_	_	_	_	_	_	_	Seg=O
133	studies	_	_	_	_	_	_	_	Seg=O
134	to	_	_	_	_	_	_	_	Seg=B-seg
135	assess	_	_	_	_	_	_	_	Seg=O
136	chart	_	_	_	_	_	_	_	Seg=O
137	performance	_	_	_	_	_	_	_	Seg=O
138	and	_	_	_	_	_	_	_	Seg=B-seg
139	define	_	_	_	_	_	_	_	Seg=O
140	technical	_	_	_	_	_	_	_	Seg=O
141	parameters	_	_	_	_	_	_	_	Seg=O
142	.	_	_	_	_	_	_	_	Seg=O
143	This	_	_	_	_	_	_	_	Seg=B-seg
144	approach	_	_	_	_	_	_	_	Seg=O
145	also	_	_	_	_	_	_	_	Seg=O
146	applies	_	_	_	_	_	_	_	Seg=O
147	to	_	_	_	_	_	_	_	Seg=O
148	other	_	_	_	_	_	_	_	Seg=O
149	critical	_	_	_	_	_	_	_	Seg=O
150	measures	_	_	_	_	_	_	_	Seg=O
151	related	_	_	_	_	_	_	_	Seg=B-seg
152	to	_	_	_	_	_	_	_	Seg=O
153	a	_	_	_	_	_	_	_	Seg=O
154	pandemic	_	_	_	_	_	_	_	Seg=O
155	when	_	_	_	_	_	_	_	Seg=B-seg
156	high	_	_	_	_	_	_	_	Seg=O
157	-	_	_	_	_	_	_	_	Seg=O
158	quality	_	_	_	_	_	_	_	Seg=O
159	data	_	_	_	_	_	_	_	Seg=O
160	are	_	_	_	_	_	_	_	Seg=O
161	available	_	_	_	_	_	_	_	Seg=O
162	.	_	_	_	_	_	_	_	Seg=O
163	The	_	_	_	_	_	_	_	Seg=B-seg
164	hybrid	_	_	_	_	_	_	_	Seg=O
165	chart	_	_	_	_	_	_	_	Seg=O
166	detected	_	_	_	_	_	_	_	Seg=O
167	the	_	_	_	_	_	_	_	Seg=O
168	start	_	_	_	_	_	_	_	Seg=O
169	of	_	_	_	_	_	_	_	Seg=O
170	exponential	_	_	_	_	_	_	_	Seg=O
171	growth	_	_	_	_	_	_	_	Seg=O
172	and	_	_	_	_	_	_	_	Seg=B-seg
173	identified	_	_	_	_	_	_	_	Seg=O
174	early	_	_	_	_	_	_	_	Seg=O
175	signals	_	_	_	_	_	_	_	Seg=O
176	that	_	_	_	_	_	_	_	Seg=B-seg
177	the	_	_	_	_	_	_	_	Seg=O
178	growth	_	_	_	_	_	_	_	Seg=O
179	phase	_	_	_	_	_	_	_	Seg=O
180	was	_	_	_	_	_	_	_	Seg=O
181	ending	_	_	_	_	_	_	_	Seg=O
182	.	_	_	_	_	_	_	_	Seg=O
183	During	_	_	_	_	_	_	_	Seg=B-seg
184	a	_	_	_	_	_	_	_	Seg=O
185	pandemic	_	_	_	_	_	_	_	Seg=O
186	,	_	_	_	_	_	_	_	Seg=O
187	timely	_	_	_	_	_	_	_	Seg=O
188	reliable	_	_	_	_	_	_	_	Seg=O
189	signals	_	_	_	_	_	_	_	Seg=O
190	that	_	_	_	_	_	_	_	Seg=B-seg
191	an	_	_	_	_	_	_	_	Seg=O
192	epidemic	_	_	_	_	_	_	_	Seg=O
193	is	_	_	_	_	_	_	_	Seg=O
194	waxing	_	_	_	_	_	_	_	Seg=O
195	or	_	_	_	_	_	_	_	Seg=O
196	waning	_	_	_	_	_	_	_	Seg=O
197	may	_	_	_	_	_	_	_	Seg=B-seg
198	have	_	_	_	_	_	_	_	Seg=O
199	mortal	_	_	_	_	_	_	_	Seg=O
200	implications	_	_	_	_	_	_	_	Seg=O
201	.	_	_	_	_	_	_	_	Seg=O
202	This	_	_	_	_	_	_	_	Seg=B-seg
203	novel	_	_	_	_	_	_	_	Seg=O
204	chart	_	_	_	_	_	_	_	Seg=O
205	offers	_	_	_	_	_	_	_	Seg=O
206	a	_	_	_	_	_	_	_	Seg=O
207	practical	_	_	_	_	_	_	_	Seg=O
208	tool	_	_	_	_	_	_	_	Seg=O
209	,	_	_	_	_	_	_	_	Seg=O
210	accessible	_	_	_	_	_	_	_	Seg=B-seg
211	to	_	_	_	_	_	_	_	Seg=O
212	system	_	_	_	_	_	_	_	Seg=O
213	leaders	_	_	_	_	_	_	_	Seg=O
214	and	_	_	_	_	_	_	_	Seg=O
215	front	_	_	_	_	_	_	_	Seg=O
216	-	_	_	_	_	_	_	_	Seg=O
217	line	_	_	_	_	_	_	_	Seg=O
218	teams	_	_	_	_	_	_	_	Seg=O
219	,	_	_	_	_	_	_	_	Seg=O
220	to	_	_	_	_	_	_	_	Seg=B-seg
221	visualize	_	_	_	_	_	_	_	Seg=O
222	and	_	_	_	_	_	_	_	Seg=O
223	learn	_	_	_	_	_	_	_	Seg=O
224	from	_	_	_	_	_	_	_	Seg=O
225	daily	_	_	_	_	_	_	_	Seg=O
226	reported	_	_	_	_	_	_	_	Seg=O
227	deaths	_	_	_	_	_	_	_	Seg=O
228	during	_	_	_	_	_	_	_	Seg=O
229	an	_	_	_	_	_	_	_	Seg=O
230	epidemic	_	_	_	_	_	_	_	Seg=O
231	.	_	_	_	_	_	_	_	Seg=O
232	Without	_	_	_	_	_	_	_	Seg=B-seg
233	Shewhart	_	_	_	_	_	_	_	Seg=O
234	charts	_	_	_	_	_	_	_	Seg=O
235	and	_	_	_	_	_	_	_	Seg=O
236	,	_	_	_	_	_	_	_	Seg=O
237	more	_	_	_	_	_	_	_	Seg=O
238	broadly	_	_	_	_	_	_	_	Seg=O
239	,	_	_	_	_	_	_	_	Seg=O
240	a	_	_	_	_	_	_	_	Seg=O
241	theory	_	_	_	_	_	_	_	Seg=O
242	of	_	_	_	_	_	_	_	Seg=O
243	variation	_	_	_	_	_	_	_	Seg=O
244	in	_	_	_	_	_	_	_	Seg=O
245	our	_	_	_	_	_	_	_	Seg=O
246	epidemiological	_	_	_	_	_	_	_	Seg=O
247	arsenal	_	_	_	_	_	_	_	Seg=O
248	,	_	_	_	_	_	_	_	Seg=O
249	we	_	_	_	_	_	_	_	Seg=B-seg
250	lack	_	_	_	_	_	_	_	Seg=O
251	a	_	_	_	_	_	_	_	Seg=O
252	scientific	_	_	_	_	_	_	_	Seg=O
253	method	_	_	_	_	_	_	_	Seg=O
254	for	_	_	_	_	_	_	_	Seg=O
255	real	_	_	_	_	_	_	_	Seg=O
256	-	_	_	_	_	_	_	_	Seg=O
257	time	_	_	_	_	_	_	_	Seg=O
258	assessment	_	_	_	_	_	_	_	Seg=O
259	of	_	_	_	_	_	_	_	Seg=O
260	local	_	_	_	_	_	_	_	Seg=O
261	conditions	_	_	_	_	_	_	_	Seg=O
262	.	_	_	_	_	_	_	_	Seg=O
263	Shewhart	_	_	_	_	_	_	_	Seg=B-seg
264	charts	_	_	_	_	_	_	_	Seg=O
265	should	_	_	_	_	_	_	_	Seg=O
266	become	_	_	_	_	_	_	_	Seg=O
267	a	_	_	_	_	_	_	_	Seg=O
268	standard	_	_	_	_	_	_	_	Seg=O
269	method	_	_	_	_	_	_	_	Seg=O
270	for	_	_	_	_	_	_	_	Seg=B-seg
271	learning	_	_	_	_	_	_	_	Seg=O
272	from	_	_	_	_	_	_	_	Seg=O
273	data	_	_	_	_	_	_	_	Seg=O
274	in	_	_	_	_	_	_	_	Seg=O
275	the	_	_	_	_	_	_	_	Seg=O
276	context	_	_	_	_	_	_	_	Seg=O
277	of	_	_	_	_	_	_	_	Seg=O
278	a	_	_	_	_	_	_	_	Seg=O
279	pandemic	_	_	_	_	_	_	_	Seg=O
280	or	_	_	_	_	_	_	_	Seg=O
281	epidemic	_	_	_	_	_	_	_	Seg=O
282	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = abf6f66d8e18b652d10944bb21e19debca5dc5e8
1	The	_	_	_	_	_	_	_	Seg=B-seg
2	Scutellaria	_	_	_	_	_	_	_	Seg=O
3	species	_	_	_	_	_	_	_	Seg=O
4	(	_	_	_	_	_	_	_	Seg=O
5	Lamiaceae	_	_	_	_	_	_	_	Seg=O
6	)	_	_	_	_	_	_	_	Seg=O
7	is	_	_	_	_	_	_	_	Seg=O
8	used	_	_	_	_	_	_	_	Seg=O
9	as	_	_	_	_	_	_	_	Seg=O
10	a	_	_	_	_	_	_	_	Seg=O
11	source	_	_	_	_	_	_	_	Seg=O
12	of	_	_	_	_	_	_	_	Seg=O
13	flavonoids	_	_	_	_	_	_	_	Seg=O
14	to	_	_	_	_	_	_	_	Seg=B-seg
15	treat	_	_	_	_	_	_	_	Seg=O
16	a	_	_	_	_	_	_	_	Seg=O
17	variety	_	_	_	_	_	_	_	Seg=O
18	of	_	_	_	_	_	_	_	Seg=O
19	diseases	_	_	_	_	_	_	_	Seg=O
20	in	_	_	_	_	_	_	_	Seg=O
21	traditional	_	_	_	_	_	_	_	Seg=O
22	medicine	_	_	_	_	_	_	_	Seg=O
23	.	_	_	_	_	_	_	_	Seg=O
24	In	_	_	_	_	_	_	_	Seg=B-seg
25	spite	_	_	_	_	_	_	_	Seg=O
26	of	_	_	_	_	_	_	_	Seg=O
27	many	_	_	_	_	_	_	_	Seg=O
28	reports	_	_	_	_	_	_	_	Seg=O
29	about	_	_	_	_	_	_	_	Seg=O
30	the	_	_	_	_	_	_	_	Seg=O
31	cytotoxic	_	_	_	_	_	_	_	Seg=O
32	and	_	_	_	_	_	_	_	Seg=O
33	antitumor	_	_	_	_	_	_	_	Seg=O
34	effects	_	_	_	_	_	_	_	Seg=O
35	of	_	_	_	_	_	_	_	Seg=O
36	some	_	_	_	_	_	_	_	Seg=O
37	species	_	_	_	_	_	_	_	Seg=O
38	of	_	_	_	_	_	_	_	Seg=O
39	this	_	_	_	_	_	_	_	Seg=O
40	genus	_	_	_	_	_	_	_	Seg=O
41	,	_	_	_	_	_	_	_	Seg=O
42	anticancer	_	_	_	_	_	_	_	Seg=B-seg
43	researches	_	_	_	_	_	_	_	Seg=O
44	on	_	_	_	_	_	_	_	Seg=O
45	one	_	_	_	_	_	_	_	Seg=O
46	of	_	_	_	_	_	_	_	Seg=O
47	the	_	_	_	_	_	_	_	Seg=O
48	Iranian	_	_	_	_	_	_	_	Seg=O
49	species	_	_	_	_	_	_	_	Seg=O
50	S.	_	_	_	_	_	_	_	Seg=O
51	litwinowii	_	_	_	_	_	_	_	Seg=O
52	have	_	_	_	_	_	_	_	Seg=O
53	not	_	_	_	_	_	_	_	Seg=O
54	yet	_	_	_	_	_	_	_	Seg=O
55	been	_	_	_	_	_	_	_	Seg=O
56	conducted	_	_	_	_	_	_	_	Seg=O
57	.	_	_	_	_	_	_	_	Seg=O
58	The	_	_	_	_	_	_	_	Seg=B-seg
59	cytotoxic	_	_	_	_	_	_	_	Seg=O
60	properties	_	_	_	_	_	_	_	Seg=O
61	of	_	_	_	_	_	_	_	Seg=O
62	total	_	_	_	_	_	_	_	Seg=O
63	methanol	_	_	_	_	_	_	_	Seg=O
64	extract	_	_	_	_	_	_	_	Seg=O
65	of	_	_	_	_	_	_	_	Seg=O
66	S.	_	_	_	_	_	_	_	Seg=O
67	litwinowii	_	_	_	_	_	_	_	Seg=O
68	and	_	_	_	_	_	_	_	Seg=O
69	its	_	_	_	_	_	_	_	Seg=O
70	fractions	_	_	_	_	_	_	_	Seg=O
71	were	_	_	_	_	_	_	_	Seg=O
72	investigated	_	_	_	_	_	_	_	Seg=O
73	on	_	_	_	_	_	_	_	Seg=O
74	different	_	_	_	_	_	_	_	Seg=O
75	cancer	_	_	_	_	_	_	_	Seg=O
76	cell	_	_	_	_	_	_	_	Seg=O
77	lines	_	_	_	_	_	_	_	Seg=O
78	including	_	_	_	_	_	_	_	Seg=B-seg
79	AGS	_	_	_	_	_	_	_	Seg=O
80	,	_	_	_	_	_	_	_	Seg=O
81	HeLa	_	_	_	_	_	_	_	Seg=O
82	,	_	_	_	_	_	_	_	Seg=O
83	MCF-7	_	_	_	_	_	_	_	Seg=O
84	,	_	_	_	_	_	_	_	Seg=O
85	PC12	_	_	_	_	_	_	_	Seg=O
86	and	_	_	_	_	_	_	_	Seg=O
87	NIH	_	_	_	_	_	_	_	Seg=O
88	3T3	_	_	_	_	_	_	_	Seg=O
89	.	_	_	_	_	_	_	_	Seg=O
90	Meanwhile	_	_	_	_	_	_	_	Seg=B-seg
91	,	_	_	_	_	_	_	_	Seg=O
92	the	_	_	_	_	_	_	_	Seg=O
93	role	_	_	_	_	_	_	_	Seg=O
94	of	_	_	_	_	_	_	_	Seg=O
95	apoptosis	_	_	_	_	_	_	_	Seg=O
96	in	_	_	_	_	_	_	_	Seg=O
97	this	_	_	_	_	_	_	_	Seg=O
98	toxicity	_	_	_	_	_	_	_	Seg=O
99	was	_	_	_	_	_	_	_	Seg=O
100	explored	_	_	_	_	_	_	_	Seg=O
101	.	_	_	_	_	_	_	_	Seg=O
102	The	_	_	_	_	_	_	_	Seg=B-seg
103	cells	_	_	_	_	_	_	_	Seg=O
104	were	_	_	_	_	_	_	_	Seg=O
105	cultured	_	_	_	_	_	_	_	Seg=O
106	in	_	_	_	_	_	_	_	Seg=O
107	DMEM	_	_	_	_	_	_	_	Seg=O
108	medium	_	_	_	_	_	_	_	Seg=O
109	and	_	_	_	_	_	_	_	Seg=B-seg
110	incubated	_	_	_	_	_	_	_	Seg=O
111	with	_	_	_	_	_	_	_	Seg=O
112	different	_	_	_	_	_	_	_	Seg=O
113	concentrations	_	_	_	_	_	_	_	Seg=O
114	of	_	_	_	_	_	_	_	Seg=O
115	herb	_	_	_	_	_	_	_	Seg=O
116	plant	_	_	_	_	_	_	_	Seg=O
117	extracts	_	_	_	_	_	_	_	Seg=O
118	.	_	_	_	_	_	_	_	Seg=O
119	Cell	_	_	_	_	_	_	_	Seg=B-seg
120	viability	_	_	_	_	_	_	_	Seg=O
121	was	_	_	_	_	_	_	_	Seg=O
122	quantitated	_	_	_	_	_	_	_	Seg=O
123	by	_	_	_	_	_	_	_	Seg=O
124	MTT	_	_	_	_	_	_	_	Seg=O
125	assay	_	_	_	_	_	_	_	Seg=O
126	.	_	_	_	_	_	_	_	Seg=O
127	Apoptotic	_	_	_	_	_	_	_	Seg=B-seg
128	cells	_	_	_	_	_	_	_	Seg=O
129	were	_	_	_	_	_	_	_	Seg=O
130	determined	_	_	_	_	_	_	_	Seg=O
131	using	_	_	_	_	_	_	_	Seg=B-seg
132	propidium	_	_	_	_	_	_	_	Seg=O
133	iodide	_	_	_	_	_	_	_	Seg=O
134	staining	_	_	_	_	_	_	_	Seg=O
135	of	_	_	_	_	_	_	_	Seg=O
136	DNA	_	_	_	_	_	_	_	Seg=O
137	fragmentation	_	_	_	_	_	_	_	Seg=O
138	by	_	_	_	_	_	_	_	Seg=O
139	flow	_	_	_	_	_	_	_	Seg=O
140	cytometry	_	_	_	_	_	_	_	Seg=O
141	(	_	_	_	_	_	_	_	Seg=O
142	sub	_	_	_	_	_	_	_	Seg=O
143	-	_	_	_	_	_	_	_	Seg=O
144	G1	_	_	_	_	_	_	_	Seg=O
145	peak	_	_	_	_	_	_	_	Seg=O
146	)	_	_	_	_	_	_	_	Seg=O
147	.	_	_	_	_	_	_	_	Seg=O
148	Scutellaria	_	_	_	_	_	_	_	Seg=B-seg
149	litwinowii	_	_	_	_	_	_	_	Seg=O
150	inhibited	_	_	_	_	_	_	_	Seg=O
151	the	_	_	_	_	_	_	_	Seg=O
152	growth	_	_	_	_	_	_	_	Seg=O
153	of	_	_	_	_	_	_	_	Seg=O
154	malignant	_	_	_	_	_	_	_	Seg=O
155	cells	_	_	_	_	_	_	_	Seg=O
156	in	_	_	_	_	_	_	_	Seg=O
157	a	_	_	_	_	_	_	_	Seg=O
158	dose	_	_	_	_	_	_	_	Seg=O
159	-	_	_	_	_	_	_	_	Seg=O
160	dependent	_	_	_	_	_	_	_	Seg=O
161	manner	_	_	_	_	_	_	_	Seg=O
162	.	_	_	_	_	_	_	_	Seg=O
163	Among	_	_	_	_	_	_	_	Seg=B-seg
164	solvent	_	_	_	_	_	_	_	Seg=O
165	fractions	_	_	_	_	_	_	_	Seg=O
166	of	_	_	_	_	_	_	_	Seg=O
167	S.	_	_	_	_	_	_	_	Seg=O
168	litwinowii	_	_	_	_	_	_	_	Seg=O
169	,	_	_	_	_	_	_	_	Seg=O
170	the	_	_	_	_	_	_	_	Seg=O
171	methylene	_	_	_	_	_	_	_	Seg=O
172	chloride	_	_	_	_	_	_	_	Seg=O
173	fraction	_	_	_	_	_	_	_	Seg=O
174	was	_	_	_	_	_	_	_	Seg=O
175	found	_	_	_	_	_	_	_	Seg=O
176	to	_	_	_	_	_	_	_	Seg=O
177	be	_	_	_	_	_	_	_	Seg=O
178	more	_	_	_	_	_	_	_	Seg=O
179	toxic	_	_	_	_	_	_	_	Seg=O
180	compared	_	_	_	_	_	_	_	Seg=B-seg
181	to	_	_	_	_	_	_	_	Seg=O
182	other	_	_	_	_	_	_	_	Seg=O
183	fractions	_	_	_	_	_	_	_	Seg=O
184	.	_	_	_	_	_	_	_	Seg=O
185	The	_	_	_	_	_	_	_	Seg=B-seg
186	IC	_	_	_	_	_	_	_	Seg=O
187	50	_	_	_	_	_	_	_	Seg=O
188	values	_	_	_	_	_	_	_	Seg=O
189	of	_	_	_	_	_	_	_	Seg=O
190	this	_	_	_	_	_	_	_	Seg=O
191	fraction	_	_	_	_	_	_	_	Seg=O
192	against	_	_	_	_	_	_	_	Seg=O
193	AGS	_	_	_	_	_	_	_	Seg=O
194	,	_	_	_	_	_	_	_	Seg=O
195	HeLa	_	_	_	_	_	_	_	Seg=O
196	,	_	_	_	_	_	_	_	Seg=O
197	MCF-7	_	_	_	_	_	_	_	Seg=O
198	and	_	_	_	_	_	_	_	Seg=O
199	PC12	_	_	_	_	_	_	_	Seg=O
200	cell	_	_	_	_	_	_	_	Seg=O
201	lines	_	_	_	_	_	_	_	Seg=O
202	after	_	_	_	_	_	_	_	Seg=O
203	24	_	_	_	_	_	_	_	Seg=O
204	h	_	_	_	_	_	_	_	Seg=O
205	were	_	_	_	_	_	_	_	Seg=O
206	determined	_	_	_	_	_	_	_	Seg=O
207	,	_	_	_	_	_	_	_	Seg=O
208	121.2	_	_	_	_	_	_	_	Seg=O
209	±	_	_	_	_	_	_	_	Seg=O
210	3.1	_	_	_	_	_	_	_	Seg=O
211	,	_	_	_	_	_	_	_	Seg=O
212	40.9	_	_	_	_	_	_	_	Seg=O
213	±	_	_	_	_	_	_	_	Seg=O
214	2.5	_	_	_	_	_	_	_	Seg=O
215	,	_	_	_	_	_	_	_	Seg=O
216	115.9	_	_	_	_	_	_	_	Seg=O
217	±	_	_	_	_	_	_	_	Seg=O
218	3.5	_	_	_	_	_	_	_	Seg=O
219	and	_	_	_	_	_	_	_	Seg=O
220	64.5	_	_	_	_	_	_	_	Seg=O
221	±	_	_	_	_	_	_	_	Seg=O
222	3.4	_	_	_	_	_	_	_	Seg=O
223	μg	_	_	_	_	_	_	_	Seg=O
224	/	_	_	_	_	_	_	_	Seg=O
225	ml	_	_	_	_	_	_	_	Seg=O
226	,	_	_	_	_	_	_	_	Seg=O
227	respectively	_	_	_	_	_	_	_	Seg=O
228	.	_	_	_	_	_	_	_	Seg=O
229	Scutellaria	_	_	_	_	_	_	_	Seg=B-seg
230	litwinowii	_	_	_	_	_	_	_	Seg=O
231	induced	_	_	_	_	_	_	_	Seg=O
232	a	_	_	_	_	_	_	_	Seg=O
233	sub	_	_	_	_	_	_	_	Seg=O
234	-	_	_	_	_	_	_	_	Seg=O
235	G1	_	_	_	_	_	_	_	Seg=O
236	peak	_	_	_	_	_	_	_	Seg=O
237	in	_	_	_	_	_	_	_	Seg=O
238	the	_	_	_	_	_	_	_	Seg=O
239	flow	_	_	_	_	_	_	_	Seg=O
240	cytometry	_	_	_	_	_	_	_	Seg=O
241	histogram	_	_	_	_	_	_	_	Seg=O
242	of	_	_	_	_	_	_	_	Seg=O
243	treated	_	_	_	_	_	_	_	Seg=O
244	cells	_	_	_	_	_	_	_	Seg=O
245	compared	_	_	_	_	_	_	_	Seg=B-seg
246	to	_	_	_	_	_	_	_	Seg=O
247	control	_	_	_	_	_	_	_	Seg=O
248	cells	_	_	_	_	_	_	_	Seg=O
249	indicating	_	_	_	_	_	_	_	Seg=B-seg
250	that	_	_	_	_	_	_	_	Seg=B-seg
251	apoptotic	_	_	_	_	_	_	_	Seg=O
252	cell	_	_	_	_	_	_	_	Seg=O
253	death	_	_	_	_	_	_	_	Seg=O
254	is	_	_	_	_	_	_	_	Seg=O
255	involved	_	_	_	_	_	_	_	Seg=O
256	in	_	_	_	_	_	_	_	Seg=O
257	S.	_	_	_	_	_	_	_	Seg=O
258	litwinowii	_	_	_	_	_	_	_	Seg=O
259	toxicity	_	_	_	_	_	_	_	Seg=O
260	.	_	_	_	_	_	_	_	Seg=O
261	Scutellaria	_	_	_	_	_	_	_	Seg=B-seg
262	litwinowii	_	_	_	_	_	_	_	Seg=O
263	exerts	_	_	_	_	_	_	_	Seg=O
264	cytotoxic	_	_	_	_	_	_	_	Seg=O
265	and	_	_	_	_	_	_	_	Seg=O
266	proapototic	_	_	_	_	_	_	_	Seg=O
267	effects	_	_	_	_	_	_	_	Seg=O
268	in	_	_	_	_	_	_	_	Seg=O
269	a	_	_	_	_	_	_	_	Seg=O
270	variety	_	_	_	_	_	_	_	Seg=O
271	of	_	_	_	_	_	_	_	Seg=O
272	malignant	_	_	_	_	_	_	_	Seg=O
273	cell	_	_	_	_	_	_	_	Seg=O
274	lines	_	_	_	_	_	_	_	Seg=O
275	and	_	_	_	_	_	_	_	Seg=B-seg
276	could	_	_	_	_	_	_	_	Seg=O
277	be	_	_	_	_	_	_	_	Seg=O
278	considered	_	_	_	_	_	_	_	Seg=O
279	as	_	_	_	_	_	_	_	Seg=O
280	a	_	_	_	_	_	_	_	Seg=O
281	potential	_	_	_	_	_	_	_	Seg=O
282	chemotherapeutic	_	_	_	_	_	_	_	Seg=O
283	agent	_	_	_	_	_	_	_	Seg=O
284	in	_	_	_	_	_	_	_	Seg=O
285	cancer	_	_	_	_	_	_	_	Seg=O
286	treatment	_	_	_	_	_	_	_	Seg=O
287	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = ad71472308fc72f2b3fe0044ac4bc2f08c4481b6
1	Feline	_	_	_	_	_	_	_	Seg=B-seg
2	infectious	_	_	_	_	_	_	_	Seg=O
3	peritonitis	_	_	_	_	_	_	_	Seg=O
4	is	_	_	_	_	_	_	_	Seg=O
5	a	_	_	_	_	_	_	_	Seg=O
6	devastating	_	_	_	_	_	_	_	Seg=O
7	,	_	_	_	_	_	_	_	Seg=O
8	fatal	_	_	_	_	_	_	_	Seg=O
9	disease	_	_	_	_	_	_	_	Seg=O
10	of	_	_	_	_	_	_	_	Seg=O
11	domestic	_	_	_	_	_	_	_	Seg=O
12	cats	_	_	_	_	_	_	_	Seg=O
13	caused	_	_	_	_	_	_	_	Seg=B-seg
14	by	_	_	_	_	_	_	_	Seg=O
15	a	_	_	_	_	_	_	_	Seg=O
16	pathogenic	_	_	_	_	_	_	_	Seg=O
17	mutant	_	_	_	_	_	_	_	Seg=O
18	virus	_	_	_	_	_	_	_	Seg=O
19	derived	_	_	_	_	_	_	_	Seg=B-seg
20	from	_	_	_	_	_	_	_	Seg=O
21	the	_	_	_	_	_	_	_	Seg=O
22	ubiquitous	_	_	_	_	_	_	_	Seg=O
23	feline	_	_	_	_	_	_	_	Seg=O
24	enteric	_	_	_	_	_	_	_	Seg=O
25	coronavirus	_	_	_	_	_	_	_	Seg=O
26	(	_	_	_	_	_	_	_	Seg=O
27	FECV	_	_	_	_	_	_	_	Seg=O
28	)	_	_	_	_	_	_	_	Seg=O
29	.	_	_	_	_	_	_	_	Seg=O
30	Infection	_	_	_	_	_	_	_	Seg=B-seg
31	by	_	_	_	_	_	_	_	Seg=O
32	FECV	_	_	_	_	_	_	_	Seg=O
33	is	_	_	_	_	_	_	_	Seg=O
34	generally	_	_	_	_	_	_	_	Seg=O
35	subclinical	_	_	_	_	_	_	_	Seg=O
36	,	_	_	_	_	_	_	_	Seg=O
37	and	_	_	_	_	_	_	_	Seg=B-seg
38	little	_	_	_	_	_	_	_	Seg=O
39	is	_	_	_	_	_	_	_	Seg=O
40	known	_	_	_	_	_	_	_	Seg=O
41	about	_	_	_	_	_	_	_	Seg=O
42	the	_	_	_	_	_	_	_	Seg=O
43	mucosal	_	_	_	_	_	_	_	Seg=O
44	immune	_	_	_	_	_	_	_	Seg=O
45	response	_	_	_	_	_	_	_	Seg=O
46	that	_	_	_	_	_	_	_	Seg=B-seg
47	controls	_	_	_	_	_	_	_	Seg=O
48	and	_	_	_	_	_	_	_	Seg=O
49	eliminates	_	_	_	_	_	_	_	Seg=O
50	the	_	_	_	_	_	_	_	Seg=O
51	virus	_	_	_	_	_	_	_	Seg=O
52	.	_	_	_	_	_	_	_	Seg=O
53	We	_	_	_	_	_	_	_	Seg=B-seg
54	investigated	_	_	_	_	_	_	_	Seg=O
55	the	_	_	_	_	_	_	_	Seg=O
56	mucosal	_	_	_	_	_	_	_	Seg=O
57	immune	_	_	_	_	_	_	_	Seg=O
58	response	_	_	_	_	_	_	_	Seg=O
59	against	_	_	_	_	_	_	_	Seg=O
60	FECV	_	_	_	_	_	_	_	Seg=O
61	in	_	_	_	_	_	_	_	Seg=O
62	an	_	_	_	_	_	_	_	Seg=O
63	endemically	_	_	_	_	_	_	_	Seg=O
64	infected	_	_	_	_	_	_	_	Seg=O
65	breeding	_	_	_	_	_	_	_	Seg=O
66	colony	_	_	_	_	_	_	_	Seg=O
67	over	_	_	_	_	_	_	_	Seg=O
68	a	_	_	_	_	_	_	_	Seg=O
69	seven	_	_	_	_	_	_	_	Seg=O
70	-	_	_	_	_	_	_	_	Seg=O
71	month	_	_	_	_	_	_	_	Seg=O
72	period	_	_	_	_	_	_	_	Seg=O
73	.	_	_	_	_	_	_	_	Seg=O
74	Thirty	_	_	_	_	_	_	_	Seg=B-seg
75	-	_	_	_	_	_	_	_	Seg=O
76	three	_	_	_	_	_	_	_	Seg=O
77	cats	_	_	_	_	_	_	_	Seg=O
78	were	_	_	_	_	_	_	_	Seg=O
79	grouped	_	_	_	_	_	_	_	Seg=O
80	according	_	_	_	_	_	_	_	Seg=O
81	to	_	_	_	_	_	_	_	Seg=O
82	FECV	_	_	_	_	_	_	_	Seg=O
83	seropositivity	_	_	_	_	_	_	_	Seg=O
84	and	_	_	_	_	_	_	_	Seg=O
85	fecal	_	_	_	_	_	_	_	Seg=O
86	virus	_	_	_	_	_	_	_	Seg=O
87	shedding	_	_	_	_	_	_	_	Seg=O
88	into	_	_	_	_	_	_	_	Seg=O
89	naïve	_	_	_	_	_	_	_	Seg=O
90	/	_	_	_	_	_	_	_	Seg=O
91	immunologically	_	_	_	_	_	_	_	Seg=O
92	quiescent	_	_	_	_	_	_	_	Seg=O
93	,	_	_	_	_	_	_	_	Seg=O
94	convalescent	_	_	_	_	_	_	_	Seg=O
95	and	_	_	_	_	_	_	_	Seg=O
96	actively	_	_	_	_	_	_	_	Seg=O
97	infected	_	_	_	_	_	_	_	Seg=O
98	groups	_	_	_	_	_	_	_	Seg=O
99	.	_	_	_	_	_	_	_	Seg=O
100	Blood	_	_	_	_	_	_	_	Seg=B-seg
101	,	_	_	_	_	_	_	_	Seg=O
102	fecal	_	_	_	_	_	_	_	Seg=O
103	samples	_	_	_	_	_	_	_	Seg=O
104	and	_	_	_	_	_	_	_	Seg=O
105	colon	_	_	_	_	_	_	_	Seg=O
106	biopsies	_	_	_	_	_	_	_	Seg=O
107	were	_	_	_	_	_	_	_	Seg=O
108	collected	_	_	_	_	_	_	_	Seg=O
109	to	_	_	_	_	_	_	_	Seg=B-seg
110	assess	_	_	_	_	_	_	_	Seg=O
111	the	_	_	_	_	_	_	_	Seg=O
112	mucosal	_	_	_	_	_	_	_	Seg=O
113	and	_	_	_	_	_	_	_	Seg=O
114	systemic	_	_	_	_	_	_	_	Seg=O
115	immunologic	_	_	_	_	_	_	_	Seg=O
116	and	_	_	_	_	_	_	_	Seg=O
117	virologic	_	_	_	_	_	_	_	Seg=O
118	profile	_	_	_	_	_	_	_	Seg=O
119	.	_	_	_	_	_	_	_	Seg=O
120	Results	_	_	_	_	_	_	_	Seg=B-seg
121	showed	_	_	_	_	_	_	_	Seg=O
122	that	_	_	_	_	_	_	_	Seg=B-seg
123	cats	_	_	_	_	_	_	_	Seg=O
124	with	_	_	_	_	_	_	_	Seg=O
125	active	_	_	_	_	_	_	_	Seg=O
126	FECV	_	_	_	_	_	_	_	Seg=O
127	infections	_	_	_	_	_	_	_	Seg=O
128	have	_	_	_	_	_	_	_	Seg=O
129	strong	_	_	_	_	_	_	_	Seg=O
130	systemic	_	_	_	_	_	_	_	Seg=O
131	IgG	_	_	_	_	_	_	_	Seg=O
132	and	_	_	_	_	_	_	_	Seg=O
133	mucosal	_	_	_	_	_	_	_	Seg=O
134	IgA	_	_	_	_	_	_	_	Seg=O
135	responses	_	_	_	_	_	_	_	Seg=O
136	that	_	_	_	_	_	_	_	Seg=B-seg
137	wane	_	_	_	_	_	_	_	Seg=O
138	after	_	_	_	_	_	_	_	Seg=O
139	virus	_	_	_	_	_	_	_	Seg=O
140	clearance	_	_	_	_	_	_	_	Seg=O
141	.	_	_	_	_	_	_	_	Seg=O
142	Significant	_	_	_	_	_	_	_	Seg=B-seg
143	FECV	_	_	_	_	_	_	_	Seg=O
144	-	_	_	_	_	_	_	_	Seg=O
145	specific	_	_	_	_	_	_	_	Seg=O
146	mucosal	_	_	_	_	_	_	_	Seg=O
147	T	_	_	_	_	_	_	_	Seg=O
148	cell	_	_	_	_	_	_	_	Seg=O
149	IFNγ	_	_	_	_	_	_	_	Seg=O
150	responses	_	_	_	_	_	_	_	Seg=O
151	were	_	_	_	_	_	_	_	Seg=O
152	not	_	_	_	_	_	_	_	Seg=O
153	detected	_	_	_	_	_	_	_	Seg=O
154	in	_	_	_	_	_	_	_	Seg=O
155	any	_	_	_	_	_	_	_	Seg=O
156	of	_	_	_	_	_	_	_	Seg=O
157	the	_	_	_	_	_	_	_	Seg=O
158	three	_	_	_	_	_	_	_	Seg=O
159	groups	_	_	_	_	_	_	_	Seg=O
160	.	_	_	_	_	_	_	_	Seg=O
161	A	_	_	_	_	_	_	_	Seg=B-seg
162	shift	_	_	_	_	_	_	_	Seg=O
163	toward	_	_	_	_	_	_	_	Seg=O
164	an	_	_	_	_	_	_	_	Seg=O
165	inflammatory	_	_	_	_	_	_	_	Seg=O
166	state	_	_	_	_	_	_	_	Seg=O
167	in	_	_	_	_	_	_	_	Seg=O
168	the	_	_	_	_	_	_	_	Seg=O
169	mucosa	_	_	_	_	_	_	_	Seg=O
170	was	_	_	_	_	_	_	_	Seg=O
171	suggested	_	_	_	_	_	_	_	Seg=O
172	by	_	_	_	_	_	_	_	Seg=O
173	increased	_	_	_	_	_	_	_	Seg=O
174	IL17	_	_	_	_	_	_	_	Seg=O
175	:	_	_	_	_	_	_	_	Seg=O
176	FoxP3	_	_	_	_	_	_	_	Seg=O
177	expression	_	_	_	_	_	_	_	Seg=O
178	.	_	_	_	_	_	_	_	Seg=O
179	However	_	_	_	_	_	_	_	Seg=B-seg
180	,	_	_	_	_	_	_	_	Seg=O
181	no	_	_	_	_	_	_	_	Seg=O
182	histologic	_	_	_	_	_	_	_	Seg=O
183	abnormalities	_	_	_	_	_	_	_	Seg=O
184	were	_	_	_	_	_	_	_	Seg=O
185	observed	_	_	_	_	_	_	_	Seg=O
186	,	_	_	_	_	_	_	_	Seg=O
187	and	_	_	_	_	_	_	_	Seg=B-seg
188	no	_	_	_	_	_	_	_	Seg=O
189	shifts	_	_	_	_	_	_	_	Seg=O
190	in	_	_	_	_	_	_	_	Seg=O
191	lymphocyte	_	_	_	_	_	_	_	Seg=O
192	subpopulation	_	_	_	_	_	_	_	Seg=O
193	phenotype	_	_	_	_	_	_	_	Seg=O
194	or	_	_	_	_	_	_	_	Seg=O
195	proliferation	_	_	_	_	_	_	_	Seg=O
196	were	_	_	_	_	_	_	_	Seg=O
197	noted	_	_	_	_	_	_	_	Seg=O
198	.	_	_	_	_	_	_	_	Seg=O
199	Together	_	_	_	_	_	_	_	Seg=B-seg
200	,	_	_	_	_	_	_	_	Seg=O
201	the	_	_	_	_	_	_	_	Seg=O
202	results	_	_	_	_	_	_	_	Seg=O
203	suggest	_	_	_	_	_	_	_	Seg=O
204	that	_	_	_	_	_	_	_	Seg=B-seg
205	control	_	_	_	_	_	_	_	Seg=O
206	of	_	_	_	_	_	_	_	Seg=O
207	FECV	_	_	_	_	_	_	_	Seg=O
208	is	_	_	_	_	_	_	_	Seg=O
209	mediated	_	_	_	_	_	_	_	Seg=O
210	by	_	_	_	_	_	_	_	Seg=O
211	humoral	_	_	_	_	_	_	_	Seg=O
212	mucosal	_	_	_	_	_	_	_	Seg=O
213	and	_	_	_	_	_	_	_	Seg=O
214	systemic	_	_	_	_	_	_	_	Seg=O
215	responses	_	_	_	_	_	_	_	Seg=O
216	and	_	_	_	_	_	_	_	Seg=B-seg
217	that	_	_	_	_	_	_	_	Seg=O
218	perturbations	_	_	_	_	_	_	_	Seg=O
219	in	_	_	_	_	_	_	_	Seg=O
220	the	_	_	_	_	_	_	_	Seg=O
221	primary	_	_	_	_	_	_	_	Seg=O
222	reservoir	_	_	_	_	_	_	_	Seg=O
223	organ	_	_	_	_	_	_	_	Seg=O
224	(	_	_	_	_	_	_	_	Seg=O
225	colon	_	_	_	_	_	_	_	Seg=O
226	)	_	_	_	_	_	_	_	Seg=O
227	are	_	_	_	_	_	_	_	Seg=O
228	minimal	_	_	_	_	_	_	_	Seg=O
229	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = ae382b26740aa78bdfb76f6e470dcf71a3263db9
1	Previous	_	_	_	_	_	_	_	Seg=B-seg
2	analysis	_	_	_	_	_	_	_	Seg=O
3	of	_	_	_	_	_	_	_	Seg=O
4	porcine	_	_	_	_	_	_	_	Seg=O
5	respiratory	_	_	_	_	_	_	_	Seg=O
6	coronavirus	_	_	_	_	_	_	_	Seg=O
7	(	_	_	_	_	_	_	_	Seg=O
8	PRCV	_	_	_	_	_	_	_	Seg=O
9	)	_	_	_	_	_	_	_	Seg=O
10	mRNA	_	_	_	_	_	_	_	Seg=O
11	species	_	_	_	_	_	_	_	Seg=O
12	showed	_	_	_	_	_	_	_	Seg=O
13	that	_	_	_	_	_	_	_	Seg=B-seg
14	mRNAs	_	_	_	_	_	_	_	Seg=O
15	2	_	_	_	_	_	_	_	Seg=O
16	and	_	_	_	_	_	_	_	Seg=O
17	3	_	_	_	_	_	_	_	Seg=O
18	were	_	_	_	_	_	_	_	Seg=O
19	smaller	_	_	_	_	_	_	_	Seg=O
20	than	_	_	_	_	_	_	_	Seg=O
21	the	_	_	_	_	_	_	_	Seg=O
22	corresponding	_	_	_	_	_	_	_	Seg=O
23	transmissible	_	_	_	_	_	_	_	Seg=O
24	gastroenteritis	_	_	_	_	_	_	_	Seg=O
25	virus	_	_	_	_	_	_	_	Seg=O
26	(	_	_	_	_	_	_	_	Seg=O
27	TGEV	_	_	_	_	_	_	_	Seg=O
28	)	_	_	_	_	_	_	_	Seg=O
29	mRNA	_	_	_	_	_	_	_	Seg=O
30	species	_	_	_	_	_	_	_	Seg=O
31	(	_	_	_	_	_	_	_	Seg=O
32	Page	_	_	_	_	_	_	_	Seg=O
33	et	_	_	_	_	_	_	_	Seg=O
34	al	_	_	_	_	_	_	_	Seg=O
35	.	_	_	_	_	_	_	_	Seg=O
36	(	_	_	_	_	_	_	_	Seg=O
37	1991	_	_	_	_	_	_	_	Seg=O
38	)	_	_	_	_	_	_	_	Seg=O
39	J.	_	_	_	_	_	_	_	Seg=O
40	Gen.	_	_	_	_	_	_	_	Seg=O
41	Virol	_	_	_	_	_	_	_	Seg=O
42	.	_	_	_	_	_	_	_	Seg=O
43	72	_	_	_	_	_	_	_	Seg=O
44	,	_	_	_	_	_	_	_	Seg=O
45	579	_	_	_	_	_	_	_	Seg=O
46	-	_	_	_	_	_	_	_	Seg=O
47	587	_	_	_	_	_	_	_	Seg=O
48	)	_	_	_	_	_	_	_	Seg=O
49	.	_	_	_	_	_	_	_	Seg=O
50	Sequence	_	_	_	_	_	_	_	Seg=B-seg
51	analysis	_	_	_	_	_	_	_	Seg=O
52	showed	_	_	_	_	_	_	_	Seg=O
53	that	_	_	_	_	_	_	_	Seg=B-seg
54	mRNA	_	_	_	_	_	_	_	Seg=O
55	3	_	_	_	_	_	_	_	Seg=O
56	was	_	_	_	_	_	_	_	Seg=O
57	smaller	_	_	_	_	_	_	_	Seg=O
58	due	_	_	_	_	_	_	_	Seg=B-seg
59	to	_	_	_	_	_	_	_	Seg=O
60	the	_	_	_	_	_	_	_	Seg=O
61	presence	_	_	_	_	_	_	_	Seg=O
62	of	_	_	_	_	_	_	_	Seg=O
63	a	_	_	_	_	_	_	_	Seg=O
64	new	_	_	_	_	_	_	_	Seg=O
65	putative	_	_	_	_	_	_	_	Seg=O
66	RNA	_	_	_	_	_	_	_	Seg=O
67	-	_	_	_	_	_	_	_	Seg=O
68	leader	_	_	_	_	_	_	_	Seg=O
69	binding	_	_	_	_	_	_	_	Seg=O
70	site	_	_	_	_	_	_	_	Seg=O
71	upstream	_	_	_	_	_	_	_	Seg=O
72	of	_	_	_	_	_	_	_	Seg=O
73	the	_	_	_	_	_	_	_	Seg=O
74	PRCV	_	_	_	_	_	_	_	Seg=O
75	ORF-3	_	_	_	_	_	_	_	Seg=O
76	gene	_	_	_	_	_	_	_	Seg=O
77	.	_	_	_	_	_	_	_	Seg=O
78	However	_	_	_	_	_	_	_	Seg=B-seg
79	,	_	_	_	_	_	_	_	Seg=O
80	this	_	_	_	_	_	_	_	Seg=O
81	observation	_	_	_	_	_	_	_	Seg=O
82	did	_	_	_	_	_	_	_	Seg=O
83	not	_	_	_	_	_	_	_	Seg=O
84	explain	_	_	_	_	_	_	_	Seg=O
85	the	_	_	_	_	_	_	_	Seg=O
86	deletion	_	_	_	_	_	_	_	Seg=O
87	observed	_	_	_	_	_	_	_	Seg=B-seg
88	in	_	_	_	_	_	_	_	Seg=O
89	PRCV	_	_	_	_	_	_	_	Seg=O
90	mRNA	_	_	_	_	_	_	_	Seg=O
91	2	_	_	_	_	_	_	_	Seg=O
92	.	_	_	_	_	_	_	_	Seg=O
93	Polymerase	_	_	_	_	_	_	_	Seg=B-seg
94	chain	_	_	_	_	_	_	_	Seg=O
95	reaction	_	_	_	_	_	_	_	Seg=O
96	(	_	_	_	_	_	_	_	Seg=O
97	PCR	_	_	_	_	_	_	_	Seg=O
98	)	_	_	_	_	_	_	_	Seg=O
99	was	_	_	_	_	_	_	_	Seg=O
100	used	_	_	_	_	_	_	_	Seg=O
101	to	_	_	_	_	_	_	_	Seg=B-seg
102	generate	_	_	_	_	_	_	_	Seg=O
103	cDNA	_	_	_	_	_	_	_	Seg=O
104	from	_	_	_	_	_	_	_	Seg=O
105	the	_	_	_	_	_	_	_	Seg=O
106	3	_	_	_	_	_	_	_	Seg=O
107	'	_	_	_	_	_	_	_	Seg=O
108	coding	_	_	_	_	_	_	_	Seg=O
109	region	_	_	_	_	_	_	_	Seg=O
110	of	_	_	_	_	_	_	_	Seg=O
111	the	_	_	_	_	_	_	_	Seg=O
112	putative	_	_	_	_	_	_	_	Seg=O
113	polymerase	_	_	_	_	_	_	_	Seg=O
114	gene	_	_	_	_	_	_	_	Seg=O
115	to	_	_	_	_	_	_	_	Seg=O
116	the	_	_	_	_	_	_	_	Seg=O
117	poly	_	_	_	_	_	_	_	Seg=O
118	(	_	_	_	_	_	_	_	Seg=O
119	A	_	_	_	_	_	_	_	Seg=O
120	)	_	_	_	_	_	_	_	Seg=O
121	tail	_	_	_	_	_	_	_	Seg=O
122	of	_	_	_	_	_	_	_	Seg=O
123	PRCV	_	_	_	_	_	_	_	Seg=O
124	for	_	_	_	_	_	_	_	Seg=O
125	comparison	_	_	_	_	_	_	_	Seg=O
126	to	_	_	_	_	_	_	_	Seg=O
127	the	_	_	_	_	_	_	_	Seg=O
128	equivalent	_	_	_	_	_	_	_	Seg=O
129	region	_	_	_	_	_	_	_	Seg=O
130	from	_	_	_	_	_	_	_	Seg=O
131	TGEV	_	_	_	_	_	_	_	Seg=O
132	.	_	_	_	_	_	_	_	Seg=O
133	The	_	_	_	_	_	_	_	Seg=B-seg
134	PRCV	_	_	_	_	_	_	_	Seg=O
135	S	_	_	_	_	_	_	_	Seg=O
136	protein	_	_	_	_	_	_	_	Seg=O
137	was	_	_	_	_	_	_	_	Seg=O
138	found	_	_	_	_	_	_	_	Seg=O
139	to	_	_	_	_	_	_	_	Seg=O
140	consist	_	_	_	_	_	_	_	Seg=O
141	of	_	_	_	_	_	_	_	Seg=O
142	1225	_	_	_	_	_	_	_	Seg=O
143	amino	_	_	_	_	_	_	_	Seg=O
144	acids	_	_	_	_	_	_	_	Seg=O
145	,	_	_	_	_	_	_	_	Seg=O
146	which	_	_	_	_	_	_	_	Seg=B-seg
147	had	_	_	_	_	_	_	_	Seg=O
148	98	_	_	_	_	_	_	_	Seg=O
149	%	_	_	_	_	_	_	_	Seg=O
150	similarity	_	_	_	_	_	_	_	Seg=O
151	to	_	_	_	_	_	_	_	Seg=O
152	the	_	_	_	_	_	_	_	Seg=O
153	TGEV	_	_	_	_	_	_	_	Seg=O
154	S	_	_	_	_	_	_	_	Seg=O
155	protein	_	_	_	_	_	_	_	Seg=O
156	.	_	_	_	_	_	_	_	Seg=O
157	However	_	_	_	_	_	_	_	Seg=B-seg
158	,	_	_	_	_	_	_	_	Seg=O
159	the	_	_	_	_	_	_	_	Seg=O
160	PRCV	_	_	_	_	_	_	_	Seg=O
161	S	_	_	_	_	_	_	_	Seg=O
162	gene	_	_	_	_	_	_	_	Seg=O
163	contained	_	_	_	_	_	_	_	Seg=O
164	a	_	_	_	_	_	_	_	Seg=O
165	672	_	_	_	_	_	_	_	Seg=O
166	nucleotide	_	_	_	_	_	_	_	Seg=O
167	deletion	_	_	_	_	_	_	_	Seg=O
168	,	_	_	_	_	_	_	_	Seg=O
169	corresponding	_	_	_	_	_	_	_	Seg=B-seg
170	to	_	_	_	_	_	_	_	Seg=O
171	224	_	_	_	_	_	_	_	Seg=O
172	amino	_	_	_	_	_	_	_	Seg=O
173	acids	_	_	_	_	_	_	_	Seg=O
174	(	_	_	_	_	_	_	_	Seg=B-seg
175	residues	_	_	_	_	_	_	_	Seg=O
176	21	_	_	_	_	_	_	_	Seg=O
177	to	_	_	_	_	_	_	_	Seg=O
178	245	_	_	_	_	_	_	_	Seg=O
179	in	_	_	_	_	_	_	_	Seg=O
180	TGEV	_	_	_	_	_	_	_	Seg=O
181	S	_	_	_	_	_	_	_	Seg=O
182	protein	_	_	_	_	_	_	_	Seg=O
183	)	_	_	_	_	_	_	_	Seg=O
184	,	_	_	_	_	_	_	_	Seg=O
185	59	_	_	_	_	_	_	_	Seg=B-seg
186	nucleotides	_	_	_	_	_	_	_	Seg=O
187	downstream	_	_	_	_	_	_	_	Seg=O
188	of	_	_	_	_	_	_	_	Seg=O
189	the	_	_	_	_	_	_	_	Seg=O
190	S	_	_	_	_	_	_	_	Seg=O
191	gene	_	_	_	_	_	_	_	Seg=O
192	initiation	_	_	_	_	_	_	_	Seg=O
193	codon	_	_	_	_	_	_	_	Seg=O
194	.	_	_	_	_	_	_	_	Seg=O
195	The	_	_	_	_	_	_	_	Seg=B-seg
196	PRCV	_	_	_	_	_	_	_	Seg=O
197	genome	_	_	_	_	_	_	_	Seg=O
198	from	_	_	_	_	_	_	_	Seg=O
199	the	_	_	_	_	_	_	_	Seg=O
200	ORF-3	_	_	_	_	_	_	_	Seg=O
201	gene	_	_	_	_	_	_	_	Seg=O
202	to	_	_	_	_	_	_	_	Seg=O
203	the	_	_	_	_	_	_	_	Seg=O
204	poly	_	_	_	_	_	_	_	Seg=O
205	(	_	_	_	_	_	_	_	Seg=O
206	A	_	_	_	_	_	_	_	Seg=O
207	)	_	_	_	_	_	_	_	Seg=O
208	tail	_	_	_	_	_	_	_	Seg=O
209	was	_	_	_	_	_	_	_	Seg=O
210	sequenced	_	_	_	_	_	_	_	Seg=O
211	for	_	_	_	_	_	_	_	Seg=O
212	comparison	_	_	_	_	_	_	_	Seg=O
213	to	_	_	_	_	_	_	_	Seg=O
214	TGEV	_	_	_	_	_	_	_	Seg=O
215	in	_	_	_	_	_	_	_	Seg=B-seg
216	order	_	_	_	_	_	_	_	Seg=O
217	to	_	_	_	_	_	_	_	Seg=O
218	identify	_	_	_	_	_	_	_	Seg=O
219	other	_	_	_	_	_	_	_	Seg=O
220	potential	_	_	_	_	_	_	_	Seg=O
221	differences	_	_	_	_	_	_	_	Seg=O
222	between	_	_	_	_	_	_	_	Seg=O
223	the	_	_	_	_	_	_	_	Seg=O
224	two	_	_	_	_	_	_	_	Seg=O
225	viruses	_	_	_	_	_	_	_	Seg=O
226	.	_	_	_	_	_	_	_	Seg=O
227	Four	_	_	_	_	_	_	_	Seg=B-seg
228	ORFs	_	_	_	_	_	_	_	Seg=O
229	were	_	_	_	_	_	_	_	Seg=O
230	identified	_	_	_	_	_	_	_	Seg=O
231	that	_	_	_	_	_	_	_	Seg=B-seg
232	showed	_	_	_	_	_	_	_	Seg=O
233	98	_	_	_	_	_	_	_	Seg=O
234	%	_	_	_	_	_	_	_	Seg=O
235	similarity	_	_	_	_	_	_	_	Seg=O
236	to	_	_	_	_	_	_	_	Seg=O
237	the	_	_	_	_	_	_	_	Seg=O
238	TGEV	_	_	_	_	_	_	_	Seg=O
239	ORF-4	_	_	_	_	_	_	_	Seg=O
240	,	_	_	_	_	_	_	_	Seg=O
241	M	_	_	_	_	_	_	_	Seg=O
242	,	_	_	_	_	_	_	_	Seg=O
243	N	_	_	_	_	_	_	_	Seg=O
244	and	_	_	_	_	_	_	_	Seg=O
245	ORF-7	_	_	_	_	_	_	_	Seg=O
246	genes	_	_	_	_	_	_	_	Seg=O
247	.	_	_	_	_	_	_	_	Seg=O
248	No	_	_	_	_	_	_	_	Seg=B-seg
249	other	_	_	_	_	_	_	_	Seg=O
250	deletions	_	_	_	_	_	_	_	Seg=O
251	or	_	_	_	_	_	_	_	Seg=O
252	any	_	_	_	_	_	_	_	Seg=O
253	PRCV	_	_	_	_	_	_	_	Seg=O
254	specific	_	_	_	_	_	_	_	Seg=O
255	sequences	_	_	_	_	_	_	_	Seg=O
256	were	_	_	_	_	_	_	_	Seg=O
257	identified	_	_	_	_	_	_	_	Seg=O
258	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = afac086b9492b66969c0f1af5c95e804d111cb3c
1	It	_	_	_	_	_	_	_	Seg=B-seg
2	is	_	_	_	_	_	_	_	Seg=O
3	increasingly	_	_	_	_	_	_	_	Seg=O
4	evident	_	_	_	_	_	_	_	Seg=O
5	that	_	_	_	_	_	_	_	Seg=O
6	China	_	_	_	_	_	_	_	Seg=O
7	has	_	_	_	_	_	_	_	Seg=O
8	attached	_	_	_	_	_	_	_	Seg=O
9	more	_	_	_	_	_	_	_	Seg=O
10	attention	_	_	_	_	_	_	_	Seg=O
11	to	_	_	_	_	_	_	_	Seg=O
12	discursive	_	_	_	_	_	_	_	Seg=O
13	power	_	_	_	_	_	_	_	Seg=O
14	in	_	_	_	_	_	_	_	Seg=O
15	foreign	_	_	_	_	_	_	_	Seg=O
16	policy	_	_	_	_	_	_	_	Seg=O
17	since	_	_	_	_	_	_	_	Seg=O
18	the	_	_	_	_	_	_	_	Seg=O
19	early	_	_	_	_	_	_	_	Seg=O
20	21st	_	_	_	_	_	_	_	Seg=O
21	century	_	_	_	_	_	_	_	Seg=O
22	.	_	_	_	_	_	_	_	Seg=O
23	Both	_	_	_	_	_	_	_	Seg=B-seg
24	top	_	_	_	_	_	_	_	Seg=O
25	leaders	_	_	_	_	_	_	_	Seg=O
26	and	_	_	_	_	_	_	_	Seg=O
27	government	_	_	_	_	_	_	_	Seg=O
28	agencies	_	_	_	_	_	_	_	Seg=O
29	have	_	_	_	_	_	_	_	Seg=O
30	been	_	_	_	_	_	_	_	Seg=O
31	active	_	_	_	_	_	_	_	Seg=O
32	in	_	_	_	_	_	_	_	Seg=B-seg
33	advocating	_	_	_	_	_	_	_	Seg=O
34	for	_	_	_	_	_	_	_	Seg=O
35	a	_	_	_	_	_	_	_	Seg=O
36	new	_	_	_	_	_	_	_	Seg=O
37	discourse	_	_	_	_	_	_	_	Seg=O
38	on	_	_	_	_	_	_	_	Seg=O
39	various	_	_	_	_	_	_	_	Seg=O
40	international	_	_	_	_	_	_	_	Seg=O
41	occasions	_	_	_	_	_	_	_	Seg=O
42	.	_	_	_	_	_	_	_	Seg=O
43	Previously	_	_	_	_	_	_	_	Seg=B-seg
44	,	_	_	_	_	_	_	_	Seg=O
45	China	_	_	_	_	_	_	_	Seg=O
46	has	_	_	_	_	_	_	_	Seg=O
47	been	_	_	_	_	_	_	_	Seg=O
48	reluctant	_	_	_	_	_	_	_	Seg=O
49	to	_	_	_	_	_	_	_	Seg=O
50	join	_	_	_	_	_	_	_	Seg=O
51	the	_	_	_	_	_	_	_	Seg=O
52	debate	_	_	_	_	_	_	_	Seg=O
53	in	_	_	_	_	_	_	_	Seg=O
54	international	_	_	_	_	_	_	_	Seg=O
55	affairs	_	_	_	_	_	_	_	Seg=O
56	,	_	_	_	_	_	_	_	Seg=O
57	and	_	_	_	_	_	_	_	Seg=B-seg
58	been	_	_	_	_	_	_	_	Seg=O
59	instead	_	_	_	_	_	_	_	Seg=O
60	preoccupied	_	_	_	_	_	_	_	Seg=O
61	with	_	_	_	_	_	_	_	Seg=O
62	domestic	_	_	_	_	_	_	_	Seg=O
63	affairs	_	_	_	_	_	_	_	Seg=O
64	since	_	_	_	_	_	_	_	Seg=O
65	the	_	_	_	_	_	_	_	Seg=O
66	late	_	_	_	_	_	_	_	Seg=O
67	1970s	_	_	_	_	_	_	_	Seg=O
68	.	_	_	_	_	_	_	_	Seg=O
69	The	_	_	_	_	_	_	_	Seg=B-seg
70	situation	_	_	_	_	_	_	_	Seg=O
71	has	_	_	_	_	_	_	_	Seg=O
72	changed	_	_	_	_	_	_	_	Seg=O
73	since	_	_	_	_	_	_	_	Seg=O
74	2009	_	_	_	_	_	_	_	Seg=O
75	because	_	_	_	_	_	_	_	Seg=B-seg
76	of	_	_	_	_	_	_	_	Seg=O
77-78	China's	_	_	_	_	_	_	_	_
77	China	_	_	_	_	_	_	_	Seg=O
78	's	_	_	_	_	_	_	_	Seg=O
79	rapid	_	_	_	_	_	_	_	Seg=O
80	rise	_	_	_	_	_	_	_	Seg=O
81	to	_	_	_	_	_	_	_	Seg=B-seg
82	become	_	_	_	_	_	_	_	Seg=O
83	the	_	_	_	_	_	_	_	Seg=O
84-85	world's	_	_	_	_	_	_	_	_
84	world	_	_	_	_	_	_	_	Seg=O
85	's	_	_	_	_	_	_	_	Seg=O
86	second	_	_	_	_	_	_	_	Seg=O
87	largest	_	_	_	_	_	_	_	Seg=O
88	economy	_	_	_	_	_	_	_	Seg=O
89	.	_	_	_	_	_	_	_	Seg=O
90	With	_	_	_	_	_	_	_	Seg=B-seg
91	regard	_	_	_	_	_	_	_	Seg=O
92	to	_	_	_	_	_	_	_	Seg=O
93	the	_	_	_	_	_	_	_	Seg=O
94	motivations	_	_	_	_	_	_	_	Seg=O
95	behind	_	_	_	_	_	_	_	Seg=O
96	the	_	_	_	_	_	_	_	Seg=O
97	Chinese	_	_	_	_	_	_	_	Seg=O
98-99	government's	_	_	_	_	_	_	_	_
98	government	_	_	_	_	_	_	_	Seg=O
99	's	_	_	_	_	_	_	_	Seg=O
100	support	_	_	_	_	_	_	_	Seg=O
101	for	_	_	_	_	_	_	_	Seg=O
102	discursive	_	_	_	_	_	_	_	Seg=O
103	power	_	_	_	_	_	_	_	Seg=O
104	,	_	_	_	_	_	_	_	Seg=O
105	the	_	_	_	_	_	_	_	Seg=B-seg
106	dominant	_	_	_	_	_	_	_	Seg=O
107	explanation	_	_	_	_	_	_	_	Seg=O
108	is	_	_	_	_	_	_	_	Seg=O
109	based	_	_	_	_	_	_	_	Seg=O
110	on	_	_	_	_	_	_	_	Seg=O
111	the	_	_	_	_	_	_	_	Seg=O
112	'	_	_	_	_	_	_	_	Seg=O
113	'	_	_	_	_	_	_	_	Seg=O
114	rise	_	_	_	_	_	_	_	Seg=O
115	of	_	_	_	_	_	_	_	Seg=O
116	China	_	_	_	_	_	_	_	Seg=O
117	'	_	_	_	_	_	_	_	Seg=O
118	'	_	_	_	_	_	_	_	Seg=O
119	argument	_	_	_	_	_	_	_	Seg=O
120	.	_	_	_	_	_	_	_	Seg=O
121	However	_	_	_	_	_	_	_	Seg=B-seg
122	,	_	_	_	_	_	_	_	Seg=O
123	this	_	_	_	_	_	_	_	Seg=O
124	argument	_	_	_	_	_	_	_	Seg=O
125	does	_	_	_	_	_	_	_	Seg=O
126	not	_	_	_	_	_	_	_	Seg=O
127	explain	_	_	_	_	_	_	_	Seg=O
128	the	_	_	_	_	_	_	_	Seg=O
129	causal	_	_	_	_	_	_	_	Seg=O
130	relationship	_	_	_	_	_	_	_	Seg=O
131	between	_	_	_	_	_	_	_	Seg=O
132-133	China's	_	_	_	_	_	_	_	_
132	China	_	_	_	_	_	_	_	Seg=O
133	's	_	_	_	_	_	_	_	Seg=O
134	rise	_	_	_	_	_	_	_	Seg=O
135	and	_	_	_	_	_	_	_	Seg=O
136	its	_	_	_	_	_	_	_	Seg=O
137	discursive	_	_	_	_	_	_	_	Seg=O
138	power	_	_	_	_	_	_	_	Seg=O
139	strategy	_	_	_	_	_	_	_	Seg=O
140	.	_	_	_	_	_	_	_	Seg=O
141	So	_	_	_	_	_	_	_	Seg=B-seg
142	,	_	_	_	_	_	_	_	Seg=O
143	this	_	_	_	_	_	_	_	Seg=O
144	paper	_	_	_	_	_	_	_	Seg=O
145	aims	_	_	_	_	_	_	_	Seg=O
146	to	_	_	_	_	_	_	_	Seg=O
147	clarify	_	_	_	_	_	_	_	Seg=O
148	the	_	_	_	_	_	_	_	Seg=O
149	motivation	_	_	_	_	_	_	_	Seg=O
150	behind	_	_	_	_	_	_	_	Seg=O
151-152	China's	_	_	_	_	_	_	_	_
151	China	_	_	_	_	_	_	_	Seg=O
152	's	_	_	_	_	_	_	_	Seg=O
153	discursive	_	_	_	_	_	_	_	Seg=O
154	power	_	_	_	_	_	_	_	Seg=O
155	strategy	_	_	_	_	_	_	_	Seg=O
156	through	_	_	_	_	_	_	_	Seg=O
157	document	_	_	_	_	_	_	_	Seg=O
158	reviews	_	_	_	_	_	_	_	Seg=O
159	and	_	_	_	_	_	_	_	Seg=O
160	interviews	_	_	_	_	_	_	_	Seg=O
161	with	_	_	_	_	_	_	_	Seg=O
162	mainstream	_	_	_	_	_	_	_	Seg=O
163	scholars	_	_	_	_	_	_	_	Seg=O
164	.	_	_	_	_	_	_	_	Seg=O
165	It	_	_	_	_	_	_	_	Seg=B-seg
166	concludes	_	_	_	_	_	_	_	Seg=O
167	that	_	_	_	_	_	_	_	Seg=B-seg
168	a	_	_	_	_	_	_	_	Seg=O
169	discursive	_	_	_	_	_	_	_	Seg=O
170	power	_	_	_	_	_	_	_	Seg=O
171	strategy	_	_	_	_	_	_	_	Seg=O
172	has	_	_	_	_	_	_	_	Seg=O
173	been	_	_	_	_	_	_	_	Seg=O
174	the	_	_	_	_	_	_	_	Seg=O
175	fundamental	_	_	_	_	_	_	_	Seg=O
176	principle	_	_	_	_	_	_	_	Seg=O
177	of	_	_	_	_	_	_	_	Seg=O
178	the	_	_	_	_	_	_	_	Seg=O
179	Communist	_	_	_	_	_	_	_	Seg=O
180	Party	_	_	_	_	_	_	_	Seg=O
181	of	_	_	_	_	_	_	_	Seg=O
182	China	_	_	_	_	_	_	_	Seg=O
183	since	_	_	_	_	_	_	_	Seg=O
184	its	_	_	_	_	_	_	_	Seg=O
185	establishment	_	_	_	_	_	_	_	Seg=O
186	in	_	_	_	_	_	_	_	Seg=O
187	1921	_	_	_	_	_	_	_	Seg=O
188	.	_	_	_	_	_	_	_	Seg=O
189	Since	_	_	_	_	_	_	_	Seg=B-seg
190-191	China's	_	_	_	_	_	_	_	_
190	China	_	_	_	_	_	_	_	Seg=O
191	's	_	_	_	_	_	_	_	Seg=O
192	adoption	_	_	_	_	_	_	_	Seg=O
193	of	_	_	_	_	_	_	_	Seg=O
194	an	_	_	_	_	_	_	_	Seg=O
195	opening	_	_	_	_	_	_	_	Seg=O
196	-	_	_	_	_	_	_	_	Seg=O
197	up	_	_	_	_	_	_	_	Seg=O
198	policy	_	_	_	_	_	_	_	Seg=O
199	in	_	_	_	_	_	_	_	Seg=O
200	1978	_	_	_	_	_	_	_	Seg=O
201	,	_	_	_	_	_	_	_	Seg=O
202	this	_	_	_	_	_	_	_	Seg=O
203	tradition	_	_	_	_	_	_	_	Seg=O
204	has	_	_	_	_	_	_	_	Seg=O
205	been	_	_	_	_	_	_	_	Seg=O
206	suppressed	_	_	_	_	_	_	_	Seg=O
207	but	_	_	_	_	_	_	_	Seg=B-seg
208	not	_	_	_	_	_	_	_	Seg=O
209	eliminated	_	_	_	_	_	_	_	Seg=O
210	entirely	_	_	_	_	_	_	_	Seg=O
211	by	_	_	_	_	_	_	_	Seg=O
212	top	_	_	_	_	_	_	_	Seg=O
213	leaders	_	_	_	_	_	_	_	Seg=O
214	.	_	_	_	_	_	_	_	Seg=O
215	As	_	_	_	_	_	_	_	Seg=B-seg
216	China	_	_	_	_	_	_	_	Seg=O
217	continues	_	_	_	_	_	_	_	Seg=O
218	to	_	_	_	_	_	_	_	Seg=O
219	rise	_	_	_	_	_	_	_	Seg=O
220	on	_	_	_	_	_	_	_	Seg=O
221	the	_	_	_	_	_	_	_	Seg=O
222	world	_	_	_	_	_	_	_	Seg=O
223	stage	_	_	_	_	_	_	_	Seg=O
224	,	_	_	_	_	_	_	_	Seg=O
225	the	_	_	_	_	_	_	_	Seg=B-seg
226	principle	_	_	_	_	_	_	_	Seg=O
227	will	_	_	_	_	_	_	_	Seg=O
228	drive	_	_	_	_	_	_	_	Seg=O
229	China	_	_	_	_	_	_	_	Seg=O
230	to	_	_	_	_	_	_	_	Seg=O
231	create	_	_	_	_	_	_	_	Seg=O
232	a	_	_	_	_	_	_	_	Seg=O
233	new	_	_	_	_	_	_	_	Seg=O
234	political	_	_	_	_	_	_	_	Seg=O
235	model	_	_	_	_	_	_	_	Seg=O
236	rather	_	_	_	_	_	_	_	Seg=B-seg
237	than	_	_	_	_	_	_	_	Seg=O
238	be	_	_	_	_	_	_	_	Seg=O
239	a	_	_	_	_	_	_	_	Seg=O
240	mere	_	_	_	_	_	_	_	Seg=O
241	follower	_	_	_	_	_	_	_	Seg=O
242	of	_	_	_	_	_	_	_	Seg=O
243	the	_	_	_	_	_	_	_	Seg=O
244	established	_	_	_	_	_	_	_	Seg=O
245	political	_	_	_	_	_	_	_	Seg=O
246	order	_	_	_	_	_	_	_	Seg=O
247	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = c0aab944289f83044c72b64bf0726624f1b244ce
1	Recently	_	_	_	_	_	_	_	Seg=B-seg
2	developed	_	_	_	_	_	_	_	Seg=O
3	vaccines	_	_	_	_	_	_	_	Seg=O
4	provide	_	_	_	_	_	_	_	Seg=O
5	a	_	_	_	_	_	_	_	Seg=O
6	new	_	_	_	_	_	_	_	Seg=O
7	way	_	_	_	_	_	_	_	Seg=O
8	of	_	_	_	_	_	_	_	Seg=B-seg
9	controlling	_	_	_	_	_	_	_	Seg=O
10	rotavirus	_	_	_	_	_	_	_	Seg=O
11	in	_	_	_	_	_	_	_	Seg=O
12	sub	_	_	_	_	_	_	_	Seg=O
13	-	_	_	_	_	_	_	_	Seg=O
14	Saharan	_	_	_	_	_	_	_	Seg=O
15	Africa	_	_	_	_	_	_	_	Seg=O
16	.	_	_	_	_	_	_	_	Seg=O
17	Models	_	_	_	_	_	_	_	Seg=B-seg
18	for	_	_	_	_	_	_	_	Seg=O
19	the	_	_	_	_	_	_	_	Seg=O
20	transmission	_	_	_	_	_	_	_	Seg=O
21	dynamics	_	_	_	_	_	_	_	Seg=O
22	of	_	_	_	_	_	_	_	Seg=O
23	rotavirus	_	_	_	_	_	_	_	Seg=O
24	are	_	_	_	_	_	_	_	Seg=O
25	critical	_	_	_	_	_	_	_	Seg=O
26	both	_	_	_	_	_	_	_	Seg=B-seg
27	for	_	_	_	_	_	_	_	Seg=O
28	estimating	_	_	_	_	_	_	_	Seg=O
29	current	_	_	_	_	_	_	_	Seg=O
30	burden	_	_	_	_	_	_	_	Seg=O
31	from	_	_	_	_	_	_	_	Seg=O
32	imperfect	_	_	_	_	_	_	_	Seg=O
33	surveillance	_	_	_	_	_	_	_	Seg=O
34	and	_	_	_	_	_	_	_	Seg=B-seg
35	for	_	_	_	_	_	_	_	Seg=O
36	assessing	_	_	_	_	_	_	_	Seg=O
37	potential	_	_	_	_	_	_	_	Seg=O
38	effects	_	_	_	_	_	_	_	Seg=O
39	of	_	_	_	_	_	_	_	Seg=O
40	vaccine	_	_	_	_	_	_	_	Seg=O
41	intervention	_	_	_	_	_	_	_	Seg=O
42	strategies	_	_	_	_	_	_	_	Seg=O
43	.	_	_	_	_	_	_	_	Seg=O
44	We	_	_	_	_	_	_	_	Seg=B-seg
45	examine	_	_	_	_	_	_	_	Seg=O
46	rotavirus	_	_	_	_	_	_	_	Seg=O
47	infection	_	_	_	_	_	_	_	Seg=O
48	in	_	_	_	_	_	_	_	Seg=O
49	the	_	_	_	_	_	_	_	Seg=O
50	Maradi	_	_	_	_	_	_	_	Seg=O
51	area	_	_	_	_	_	_	_	Seg=O
52	in	_	_	_	_	_	_	_	Seg=O
53	southern	_	_	_	_	_	_	_	Seg=O
54	Niger	_	_	_	_	_	_	_	Seg=O
55	using	_	_	_	_	_	_	_	Seg=B-seg
56	hospital	_	_	_	_	_	_	_	Seg=O
57	surveillance	_	_	_	_	_	_	_	Seg=O
58	data	_	_	_	_	_	_	_	Seg=O
59	provided	_	_	_	_	_	_	_	Seg=B-seg
60	by	_	_	_	_	_	_	_	Seg=O
61	Epicentre	_	_	_	_	_	_	_	Seg=O
62	collected	_	_	_	_	_	_	_	Seg=B-seg
63	over	_	_	_	_	_	_	_	Seg=O
64	two	_	_	_	_	_	_	_	Seg=O
65	years	_	_	_	_	_	_	_	Seg=O
66	.	_	_	_	_	_	_	_	Seg=O
67	Additionally	_	_	_	_	_	_	_	Seg=B-seg
68	,	_	_	_	_	_	_	_	Seg=O
69	a	_	_	_	_	_	_	_	Seg=O
70	cluster	_	_	_	_	_	_	_	Seg=O
71	survey	_	_	_	_	_	_	_	Seg=O
72	of	_	_	_	_	_	_	_	Seg=O
73	households	_	_	_	_	_	_	_	Seg=O
74	in	_	_	_	_	_	_	_	Seg=O
75	the	_	_	_	_	_	_	_	Seg=O
76	region	_	_	_	_	_	_	_	Seg=O
77	allows	_	_	_	_	_	_	_	Seg=O
78	us	_	_	_	_	_	_	_	Seg=O
79	to	_	_	_	_	_	_	_	Seg=O
80	estimate	_	_	_	_	_	_	_	Seg=O
81	the	_	_	_	_	_	_	_	Seg=O
82	proportion	_	_	_	_	_	_	_	Seg=O
83	of	_	_	_	_	_	_	_	Seg=O
84	children	_	_	_	_	_	_	_	Seg=O
85	with	_	_	_	_	_	_	_	Seg=O
86	diarrhea	_	_	_	_	_	_	_	Seg=O
87	who	_	_	_	_	_	_	_	Seg=B-seg
88	consulted	_	_	_	_	_	_	_	Seg=O
89	at	_	_	_	_	_	_	_	Seg=O
90	a	_	_	_	_	_	_	_	Seg=O
91	health	_	_	_	_	_	_	_	Seg=O
92	structure	_	_	_	_	_	_	_	Seg=O
93	.	_	_	_	_	_	_	_	Seg=O
94	Model	_	_	_	_	_	_	_	Seg=B-seg
95	fit	_	_	_	_	_	_	_	Seg=O
96	and	_	_	_	_	_	_	_	Seg=O
97	future	_	_	_	_	_	_	_	Seg=O
98	projections	_	_	_	_	_	_	_	Seg=O
99	are	_	_	_	_	_	_	_	Seg=O
100	necessarily	_	_	_	_	_	_	_	Seg=O
101	particular	_	_	_	_	_	_	_	Seg=O
102	to	_	_	_	_	_	_	_	Seg=O
103	a	_	_	_	_	_	_	_	Seg=O
104	given	_	_	_	_	_	_	_	Seg=O
105	model	_	_	_	_	_	_	_	Seg=O
106	;	_	_	_	_	_	_	_	Seg=O
107	thus	_	_	_	_	_	_	_	Seg=B-seg
108	,	_	_	_	_	_	_	_	Seg=O
109	where	_	_	_	_	_	_	_	Seg=O
110	there	_	_	_	_	_	_	_	Seg=O
111	are	_	_	_	_	_	_	_	Seg=O
112	competing	_	_	_	_	_	_	_	Seg=O
113	models	_	_	_	_	_	_	_	Seg=O
114	for	_	_	_	_	_	_	_	Seg=O
115	the	_	_	_	_	_	_	_	Seg=O
116	underlying	_	_	_	_	_	_	_	Seg=O
117	epidemiology	_	_	_	_	_	_	_	Seg=O
118	an	_	_	_	_	_	_	_	Seg=B-seg
119	ensemble	_	_	_	_	_	_	_	Seg=O
120	approach	_	_	_	_	_	_	_	Seg=O
121	can	_	_	_	_	_	_	_	Seg=O
122	account	_	_	_	_	_	_	_	Seg=O
123	for	_	_	_	_	_	_	_	Seg=O
124	that	_	_	_	_	_	_	_	Seg=O
125	uncertainty	_	_	_	_	_	_	_	Seg=O
126	.	_	_	_	_	_	_	_	Seg=O
127	We	_	_	_	_	_	_	_	Seg=B-seg
128	compare	_	_	_	_	_	_	_	Seg=O
129	our	_	_	_	_	_	_	_	Seg=O
130	results	_	_	_	_	_	_	_	Seg=O
131	across	_	_	_	_	_	_	_	Seg=O
132	several	_	_	_	_	_	_	_	Seg=O
133	variants	_	_	_	_	_	_	_	Seg=O
134	of	_	_	_	_	_	_	_	Seg=O
135	Susceptible	_	_	_	_	_	_	_	Seg=O
136	-	_	_	_	_	_	_	_	Seg=O
137	Infectious	_	_	_	_	_	_	_	Seg=O
138	-	_	_	_	_	_	_	_	Seg=O
139	Recovered	_	_	_	_	_	_	_	Seg=O
140	(	_	_	_	_	_	_	_	Seg=O
141	SIR	_	_	_	_	_	_	_	Seg=O
142	)	_	_	_	_	_	_	_	Seg=O
143	compartmental	_	_	_	_	_	_	_	Seg=O
144	models	_	_	_	_	_	_	_	Seg=O
145	to	_	_	_	_	_	_	_	Seg=B-seg
146	quantify	_	_	_	_	_	_	_	Seg=O
147	the	_	_	_	_	_	_	_	Seg=O
148	impact	_	_	_	_	_	_	_	Seg=O
149	of	_	_	_	_	_	_	_	Seg=O
150	modeling	_	_	_	_	_	_	_	Seg=O
151	assumptions	_	_	_	_	_	_	_	Seg=O
152	on	_	_	_	_	_	_	_	Seg=O
153	our	_	_	_	_	_	_	_	Seg=O
154	estimates	_	_	_	_	_	_	_	Seg=O
155	.	_	_	_	_	_	_	_	Seg=O
156	Model	_	_	_	_	_	_	_	Seg=B-seg
157	-	_	_	_	_	_	_	_	Seg=O
158	specific	_	_	_	_	_	_	_	Seg=O
159	parameters	_	_	_	_	_	_	_	Seg=O
160	are	_	_	_	_	_	_	_	Seg=O
161	estimated	_	_	_	_	_	_	_	Seg=O
162	by	_	_	_	_	_	_	_	Seg=O
163	Bayesian	_	_	_	_	_	_	_	Seg=O
164	inference	_	_	_	_	_	_	_	Seg=O
165	using	_	_	_	_	_	_	_	Seg=B-seg
166	Markov	_	_	_	_	_	_	_	Seg=O
167	chain	_	_	_	_	_	_	_	Seg=O
168	Monte	_	_	_	_	_	_	_	Seg=O
169	Carlo	_	_	_	_	_	_	_	Seg=O
170	.	_	_	_	_	_	_	_	Seg=O
171	We	_	_	_	_	_	_	_	Seg=B-seg
172	then	_	_	_	_	_	_	_	Seg=O
173	use	_	_	_	_	_	_	_	Seg=O
174	Bayesian	_	_	_	_	_	_	_	Seg=O
175	model	_	_	_	_	_	_	_	Seg=O
176	averaging	_	_	_	_	_	_	_	Seg=O
177	to	_	_	_	_	_	_	_	Seg=B-seg
178	generate	_	_	_	_	_	_	_	Seg=O
179	ensemble	_	_	_	_	_	_	_	Seg=O
180	estimates	_	_	_	_	_	_	_	Seg=O
181	of	_	_	_	_	_	_	_	Seg=O
182	the	_	_	_	_	_	_	_	Seg=O
183	current	_	_	_	_	_	_	_	Seg=O
184	dynamics	_	_	_	_	_	_	_	Seg=O
185	,	_	_	_	_	_	_	_	Seg=O
186	including	_	_	_	_	_	_	_	Seg=B-seg
187	estimates	_	_	_	_	_	_	_	Seg=O
188	of	_	_	_	_	_	_	_	Seg=O
189	R	_	_	_	_	_	_	_	Seg=O
190	0	_	_	_	_	_	_	_	Seg=O
191	,	_	_	_	_	_	_	_	Seg=O
192	the	_	_	_	_	_	_	_	Seg=O
193	burden	_	_	_	_	_	_	_	Seg=O
194	of	_	_	_	_	_	_	_	Seg=O
195	infection	_	_	_	_	_	_	_	Seg=O
196	in	_	_	_	_	_	_	_	Seg=O
197	the	_	_	_	_	_	_	_	Seg=O
198	region	_	_	_	_	_	_	_	Seg=O
199	,	_	_	_	_	_	_	_	Seg=O
200	as	_	_	_	_	_	_	_	Seg=O
201	well	_	_	_	_	_	_	_	Seg=O
202	as	_	_	_	_	_	_	_	Seg=O
203	the	_	_	_	_	_	_	_	Seg=O
204	impact	_	_	_	_	_	_	_	Seg=O
205	of	_	_	_	_	_	_	_	Seg=O
206	vaccination	_	_	_	_	_	_	_	Seg=O
207	on	_	_	_	_	_	_	_	Seg=O
208	both	_	_	_	_	_	_	_	Seg=O
209	the	_	_	_	_	_	_	_	Seg=O
210	short	_	_	_	_	_	_	_	Seg=O
211	-	_	_	_	_	_	_	_	Seg=O
212	term	_	_	_	_	_	_	_	Seg=O
213	dynamics	_	_	_	_	_	_	_	Seg=O
214	and	_	_	_	_	_	_	_	Seg=O
215	the	_	_	_	_	_	_	_	Seg=O
216	long	_	_	_	_	_	_	_	Seg=O
217	-	_	_	_	_	_	_	_	Seg=O
218	term	_	_	_	_	_	_	_	Seg=O
219	reduction	_	_	_	_	_	_	_	Seg=O
220	of	_	_	_	_	_	_	_	Seg=O
221	rotavirus	_	_	_	_	_	_	_	Seg=O
222	incidence	_	_	_	_	_	_	_	Seg=O
223	under	_	_	_	_	_	_	_	Seg=O
224	varying	_	_	_	_	_	_	_	Seg=O
225	levels	_	_	_	_	_	_	_	Seg=O
226	of	_	_	_	_	_	_	_	Seg=O
227	coverage	_	_	_	_	_	_	_	Seg=O
228	.	_	_	_	_	_	_	_	Seg=O
229	The	_	_	_	_	_	_	_	Seg=B-seg
230	ensemble	_	_	_	_	_	_	_	Seg=O
231	of	_	_	_	_	_	_	_	Seg=O
232	models	_	_	_	_	_	_	_	Seg=O
233	predicts	_	_	_	_	_	_	_	Seg=O
234	that	_	_	_	_	_	_	_	Seg=B-seg
235	the	_	_	_	_	_	_	_	Seg=O
236	current	_	_	_	_	_	_	_	Seg=O
237	burden	_	_	_	_	_	_	_	Seg=O
238	of	_	_	_	_	_	_	_	Seg=O
239	severe	_	_	_	_	_	_	_	Seg=O
240	rotavirus	_	_	_	_	_	_	_	Seg=O
241	disease	_	_	_	_	_	_	_	Seg=O
242	is	_	_	_	_	_	_	_	Seg=O
243	2.6	_	_	_	_	_	_	_	Seg=O
244	-	_	_	_	_	_	_	_	Seg=O
245	3.7	_	_	_	_	_	_	_	Seg=O
246	%	_	_	_	_	_	_	_	Seg=O
247	of	_	_	_	_	_	_	_	Seg=O
248	the	_	_	_	_	_	_	_	Seg=O
249	population	_	_	_	_	_	_	_	Seg=O
250	each	_	_	_	_	_	_	_	Seg=O
251	year	_	_	_	_	_	_	_	Seg=O
252	and	_	_	_	_	_	_	_	Seg=B-seg
253	that	_	_	_	_	_	_	_	Seg=O
254	a	_	_	_	_	_	_	_	Seg=O
255	2-dose	_	_	_	_	_	_	_	Seg=O
256	vaccine	_	_	_	_	_	_	_	Seg=O
257	schedule	_	_	_	_	_	_	_	Seg=O
258	achieving	_	_	_	_	_	_	_	Seg=O
259	70	_	_	_	_	_	_	_	Seg=O
260	%	_	_	_	_	_	_	_	Seg=O
261	coverage	_	_	_	_	_	_	_	Seg=O
262	could	_	_	_	_	_	_	_	Seg=O
263	reduce	_	_	_	_	_	_	_	Seg=O
264	burden	_	_	_	_	_	_	_	Seg=O
265	by	_	_	_	_	_	_	_	Seg=O
266	39	_	_	_	_	_	_	_	Seg=O
267	-	_	_	_	_	_	_	_	Seg=O
268	42	_	_	_	_	_	_	_	Seg=O
269	%	_	_	_	_	_	_	_	Seg=O
270	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = c74ce5464f754301499d7537e87810f46e69c454
1	The	_	_	_	_	_	_	_	Seg=B-seg
2	mechanisms	_	_	_	_	_	_	_	Seg=O
3	of	_	_	_	_	_	_	_	Seg=O
4	inflammation	_	_	_	_	_	_	_	Seg=O
5	and	_	_	_	_	_	_	_	Seg=O
6	cancer	_	_	_	_	_	_	_	Seg=O
7	are	_	_	_	_	_	_	_	Seg=O
8	intertwined	_	_	_	_	_	_	_	Seg=O
9	by	_	_	_	_	_	_	_	Seg=O
10	complex	_	_	_	_	_	_	_	Seg=O
11	networks	_	_	_	_	_	_	_	Seg=O
12	of	_	_	_	_	_	_	_	Seg=O
13	signaling	_	_	_	_	_	_	_	Seg=O
14	pathways	_	_	_	_	_	_	_	Seg=O
15	.	_	_	_	_	_	_	_	Seg=O
16	Dysregulations	_	_	_	_	_	_	_	Seg=B-seg
17	in	_	_	_	_	_	_	_	Seg=O
18	the	_	_	_	_	_	_	_	Seg=O
19	Janus	_	_	_	_	_	_	_	Seg=O
20	kinase	_	_	_	_	_	_	_	Seg=O
21	/	_	_	_	_	_	_	_	Seg=O
22	signal	_	_	_	_	_	_	_	Seg=O
23	transducer	_	_	_	_	_	_	_	Seg=O
24	and	_	_	_	_	_	_	_	Seg=O
25	activator	_	_	_	_	_	_	_	Seg=O
26	of	_	_	_	_	_	_	_	Seg=O
27	transcription	_	_	_	_	_	_	_	Seg=O
28	(	_	_	_	_	_	_	_	Seg=O
29	JAK	_	_	_	_	_	_	_	Seg=O
30	/	_	_	_	_	_	_	_	Seg=O
31	STAT	_	_	_	_	_	_	_	Seg=O
32	)	_	_	_	_	_	_	_	Seg=O
33	pathway	_	_	_	_	_	_	_	Seg=O
34	underlie	_	_	_	_	_	_	_	Seg=O
35	several	_	_	_	_	_	_	_	Seg=O
36	pathogenic	_	_	_	_	_	_	_	Seg=O
37	conditions	_	_	_	_	_	_	_	Seg=O
38	related	_	_	_	_	_	_	_	Seg=B-seg
39	to	_	_	_	_	_	_	_	Seg=O
40	chronic	_	_	_	_	_	_	_	Seg=O
41	inflammatory	_	_	_	_	_	_	_	Seg=O
42	states	_	_	_	_	_	_	_	Seg=O
43	,	_	_	_	_	_	_	_	Seg=O
44	autoimmune	_	_	_	_	_	_	_	Seg=O
45	diseases	_	_	_	_	_	_	_	Seg=O
46	and	_	_	_	_	_	_	_	Seg=O
47	cancer	_	_	_	_	_	_	_	Seg=O
48	.	_	_	_	_	_	_	_	Seg=O
49	Historically	_	_	_	_	_	_	_	Seg=B-seg
50	,	_	_	_	_	_	_	_	Seg=O
51	the	_	_	_	_	_	_	_	Seg=O
52	potential	_	_	_	_	_	_	_	Seg=O
53	application	_	_	_	_	_	_	_	Seg=O
54	of	_	_	_	_	_	_	_	Seg=O
55	JAK	_	_	_	_	_	_	_	Seg=O
56	inhibition	_	_	_	_	_	_	_	Seg=O
57	has	_	_	_	_	_	_	_	Seg=O
58	been	_	_	_	_	_	_	_	Seg=O
59	thoroughly	_	_	_	_	_	_	_	Seg=O
60	explored	_	_	_	_	_	_	_	Seg=O
61	,	_	_	_	_	_	_	_	Seg=O
62	thus	_	_	_	_	_	_	_	Seg=B-seg
63	triggering	_	_	_	_	_	_	_	Seg=O
64	an	_	_	_	_	_	_	_	Seg=O
65	escalation	_	_	_	_	_	_	_	Seg=O
66	of	_	_	_	_	_	_	_	Seg=O
67	favorable	_	_	_	_	_	_	_	Seg=O
68	results	_	_	_	_	_	_	_	Seg=O
69	in	_	_	_	_	_	_	_	Seg=O
70	this	_	_	_	_	_	_	_	Seg=O
71	field	_	_	_	_	_	_	_	Seg=O
72	.	_	_	_	_	_	_	_	Seg=O
73	So	_	_	_	_	_	_	_	Seg=B-seg
74	far	_	_	_	_	_	_	_	Seg=O
75	,	_	_	_	_	_	_	_	Seg=O
76	five	_	_	_	_	_	_	_	Seg=O
77	JAK	_	_	_	_	_	_	_	Seg=O
78	inhibitors	_	_	_	_	_	_	_	Seg=O
79	have	_	_	_	_	_	_	_	Seg=O
80	been	_	_	_	_	_	_	_	Seg=O
81	approved	_	_	_	_	_	_	_	Seg=O
82	by	_	_	_	_	_	_	_	Seg=O
83	the	_	_	_	_	_	_	_	Seg=O
84	Food	_	_	_	_	_	_	_	Seg=O
85	and	_	_	_	_	_	_	_	Seg=O
86	Drug	_	_	_	_	_	_	_	Seg=O
87	Administration	_	_	_	_	_	_	_	Seg=O
88	(	_	_	_	_	_	_	_	Seg=O
89	FDA	_	_	_	_	_	_	_	Seg=O
90	)	_	_	_	_	_	_	_	Seg=O
91	for	_	_	_	_	_	_	_	Seg=O
92	the	_	_	_	_	_	_	_	Seg=O
93	treatment	_	_	_	_	_	_	_	Seg=O
94	of	_	_	_	_	_	_	_	Seg=O
95	different	_	_	_	_	_	_	_	Seg=O
96	diseases	_	_	_	_	_	_	_	Seg=O
97	.	_	_	_	_	_	_	_	Seg=O
98	Considering	_	_	_	_	_	_	_	Seg=B-seg
99	the	_	_	_	_	_	_	_	Seg=O
100	complexity	_	_	_	_	_	_	_	Seg=O
101	of	_	_	_	_	_	_	_	Seg=O
102	JAK	_	_	_	_	_	_	_	Seg=O
103	-	_	_	_	_	_	_	_	Seg=O
104	depending	_	_	_	_	_	_	_	Seg=O
105	processes	_	_	_	_	_	_	_	Seg=O
106	and	_	_	_	_	_	_	_	Seg=O
107	their	_	_	_	_	_	_	_	Seg=O
108	involvement	_	_	_	_	_	_	_	Seg=O
109	in	_	_	_	_	_	_	_	Seg=O
110	multiple	_	_	_	_	_	_	_	Seg=O
111	disorders	_	_	_	_	_	_	_	Seg=O
112	,	_	_	_	_	_	_	_	Seg=O
113	JAK	_	_	_	_	_	_	_	Seg=B-seg
114	inhibitors	_	_	_	_	_	_	_	Seg=O
115	are	_	_	_	_	_	_	_	Seg=O
116	the	_	_	_	_	_	_	_	Seg=O
117	perfect	_	_	_	_	_	_	_	Seg=O
118	candidates	_	_	_	_	_	_	_	Seg=O
119	for	_	_	_	_	_	_	_	Seg=O
120	drug	_	_	_	_	_	_	_	Seg=O
121	repurposing	_	_	_	_	_	_	_	Seg=O
122	and	_	_	_	_	_	_	_	Seg=O
123	for	_	_	_	_	_	_	_	Seg=O
124	the	_	_	_	_	_	_	_	Seg=O
125	assessment	_	_	_	_	_	_	_	Seg=O
126	of	_	_	_	_	_	_	_	Seg=O
127	multitarget	_	_	_	_	_	_	_	Seg=O
128	strategies	_	_	_	_	_	_	_	Seg=O
129	.	_	_	_	_	_	_	_	Seg=O
130	Herein	_	_	_	_	_	_	_	Seg=B-seg
131	we	_	_	_	_	_	_	_	Seg=O
132	reviewed	_	_	_	_	_	_	_	Seg=O
133	the	_	_	_	_	_	_	_	Seg=O
134	recent	_	_	_	_	_	_	_	Seg=O
135	progress	_	_	_	_	_	_	_	Seg=O
136	concerning	_	_	_	_	_	_	_	Seg=B-seg
137	JAK	_	_	_	_	_	_	_	Seg=O
138	inhibition	_	_	_	_	_	_	_	Seg=O
139	,	_	_	_	_	_	_	_	Seg=O
140	including	_	_	_	_	_	_	_	Seg=B-seg
141	the	_	_	_	_	_	_	_	Seg=O
142	innovations	_	_	_	_	_	_	_	Seg=O
143	provided	_	_	_	_	_	_	_	Seg=B-seg
144	by	_	_	_	_	_	_	_	Seg=O
145	the	_	_	_	_	_	_	_	Seg=O
146	release	_	_	_	_	_	_	_	Seg=O
147	of	_	_	_	_	_	_	_	Seg=O
148	JAKs	_	_	_	_	_	_	_	Seg=O
149	crystal	_	_	_	_	_	_	_	Seg=O
150	structures	_	_	_	_	_	_	_	Seg=O
151	and	_	_	_	_	_	_	_	Seg=B-seg
152	the	_	_	_	_	_	_	_	Seg=O
153	improvement	_	_	_	_	_	_	_	Seg=O
154	of	_	_	_	_	_	_	_	Seg=O
155	synthetic	_	_	_	_	_	_	_	Seg=O
156	strategies	_	_	_	_	_	_	_	Seg=O
157	aimed	_	_	_	_	_	_	_	Seg=B-seg
158	to	_	_	_	_	_	_	_	Seg=O
159	simplify	_	_	_	_	_	_	_	Seg=O
160	of	_	_	_	_	_	_	_	Seg=O
161	the	_	_	_	_	_	_	_	Seg=O
162	industrial	_	_	_	_	_	_	_	Seg=O
163	scale	_	_	_	_	_	_	_	Seg=O
164	-	_	_	_	_	_	_	_	Seg=O
165	up	_	_	_	_	_	_	_	Seg=O
166	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = cbf2a8ce743bc19fbf8b89bccaec836b25897cfe
1	Compelling	_	_	_	_	_	_	_	Seg=B-seg
2	evidence	_	_	_	_	_	_	_	Seg=O
3	supports	_	_	_	_	_	_	_	Seg=O
4	the	_	_	_	_	_	_	_	Seg=O
5	role	_	_	_	_	_	_	_	Seg=O
6	of	_	_	_	_	_	_	_	Seg=O
7	oxidative	_	_	_	_	_	_	_	Seg=O
8	stress	_	_	_	_	_	_	_	Seg=O
9	in	_	_	_	_	_	_	_	Seg=O
10-11	Alzheimer's	_	_	_	_	_	_	_	_
10	Alzheimer	_	_	_	_	_	_	_	Seg=O
11	's	_	_	_	_	_	_	_	Seg=O
12	disease	_	_	_	_	_	_	_	Seg=O
13	(	_	_	_	_	_	_	_	Seg=O
14	AD	_	_	_	_	_	_	_	Seg=O
15	)	_	_	_	_	_	_	_	Seg=O
16	pathophysiology	_	_	_	_	_	_	_	Seg=O
17	.	_	_	_	_	_	_	_	Seg=O
18	Interestingly	_	_	_	_	_	_	_	Seg=B-seg
19	,	_	_	_	_	_	_	_	Seg=O
20	Herpes	_	_	_	_	_	_	_	Seg=O
21	simplex	_	_	_	_	_	_	_	Seg=O
22	virus-1	_	_	_	_	_	_	_	Seg=O
23	(	_	_	_	_	_	_	_	Seg=O
24	HSV-1	_	_	_	_	_	_	_	Seg=O
25	)	_	_	_	_	_	_	_	Seg=O
26	,	_	_	_	_	_	_	_	Seg=O
27	a	_	_	_	_	_	_	_	Seg=O
28	neurotropic	_	_	_	_	_	_	_	Seg=O
29	virus	_	_	_	_	_	_	_	Seg=O
30	that	_	_	_	_	_	_	_	Seg=B-seg
31	establishes	_	_	_	_	_	_	_	Seg=O
32	a	_	_	_	_	_	_	_	Seg=O
33	lifelong	_	_	_	_	_	_	_	Seg=O
34	latent	_	_	_	_	_	_	_	Seg=O
35	infection	_	_	_	_	_	_	_	Seg=O
36	in	_	_	_	_	_	_	_	Seg=O
37	the	_	_	_	_	_	_	_	Seg=O
38	trigeminal	_	_	_	_	_	_	_	Seg=O
39	ganglion	_	_	_	_	_	_	_	Seg=O
40	followed	_	_	_	_	_	_	_	Seg=B-seg
41	by	_	_	_	_	_	_	_	Seg=O
42	periodic	_	_	_	_	_	_	_	Seg=O
43	reactivations	_	_	_	_	_	_	_	Seg=O
44	,	_	_	_	_	_	_	_	Seg=O
45	has	_	_	_	_	_	_	_	Seg=B-seg
46	been	_	_	_	_	_	_	_	Seg=O
47	reportedly	_	_	_	_	_	_	_	Seg=O
48	linked	_	_	_	_	_	_	_	Seg=O
49	both	_	_	_	_	_	_	_	Seg=O
50	to	_	_	_	_	_	_	_	Seg=O
51	AD	_	_	_	_	_	_	_	Seg=O
52	and	_	_	_	_	_	_	_	Seg=O
53	to	_	_	_	_	_	_	_	Seg=O
54	oxidative	_	_	_	_	_	_	_	Seg=O
55	stress	_	_	_	_	_	_	_	Seg=O
56	conditions	_	_	_	_	_	_	_	Seg=O
57	.	_	_	_	_	_	_	_	Seg=O
58	Herein	_	_	_	_	_	_	_	Seg=B-seg
59	,	_	_	_	_	_	_	_	Seg=O
60	we	_	_	_	_	_	_	_	Seg=O
61	analyzed	_	_	_	_	_	_	_	Seg=O
62	,	_	_	_	_	_	_	_	Seg=O
63	through	_	_	_	_	_	_	_	Seg=O
64	biochemical	_	_	_	_	_	_	_	Seg=O
65	and	_	_	_	_	_	_	_	Seg=O
66	redox	_	_	_	_	_	_	_	Seg=O
67	proteomic	_	_	_	_	_	_	_	Seg=O
68	approaches	_	_	_	_	_	_	_	Seg=O
69	,	_	_	_	_	_	_	_	Seg=O
70	the	_	_	_	_	_	_	_	Seg=O
71	mouse	_	_	_	_	_	_	_	Seg=O
72	model	_	_	_	_	_	_	_	Seg=O
73	of	_	_	_	_	_	_	_	Seg=O
74	recurrent	_	_	_	_	_	_	_	Seg=O
75	HSV-1	_	_	_	_	_	_	_	Seg=O
76	infection	_	_	_	_	_	_	_	Seg=O
77	we	_	_	_	_	_	_	_	Seg=B-seg
78	previously	_	_	_	_	_	_	_	Seg=O
79	set	_	_	_	_	_	_	_	Seg=O
80	up	_	_	_	_	_	_	_	Seg=O
81	,	_	_	_	_	_	_	_	Seg=O
82	to	_	_	_	_	_	_	_	Seg=B-seg
83	investigate	_	_	_	_	_	_	_	Seg=O
84	whether	_	_	_	_	_	_	_	Seg=O
85	multiple	_	_	_	_	_	_	_	Seg=O
86	virus	_	_	_	_	_	_	_	Seg=O
87	reactivations	_	_	_	_	_	_	_	Seg=O
88	induced	_	_	_	_	_	_	_	Seg=O
89	oxidative	_	_	_	_	_	_	_	Seg=O
90	stress	_	_	_	_	_	_	_	Seg=O
91	in	_	_	_	_	_	_	_	Seg=O
92	the	_	_	_	_	_	_	_	Seg=O
93	mouse	_	_	_	_	_	_	_	Seg=O
94	brain	_	_	_	_	_	_	_	Seg=O
95	and	_	_	_	_	_	_	_	Seg=O
96	affected	_	_	_	_	_	_	_	Seg=O
97	protein	_	_	_	_	_	_	_	Seg=O
98	function	_	_	_	_	_	_	_	Seg=O
99	and	_	_	_	_	_	_	_	Seg=O
100	related	_	_	_	_	_	_	_	Seg=O
101	intracellular	_	_	_	_	_	_	_	Seg=O
102	pathways	_	_	_	_	_	_	_	Seg=O
103	.	_	_	_	_	_	_	_	Seg=O
104	Following	_	_	_	_	_	_	_	Seg=B-seg
105	multiple	_	_	_	_	_	_	_	Seg=O
106	HSV-1	_	_	_	_	_	_	_	Seg=O
107	reactivations	_	_	_	_	_	_	_	Seg=O
108	,	_	_	_	_	_	_	_	Seg=O
109	we	_	_	_	_	_	_	_	Seg=B-seg
110	found	_	_	_	_	_	_	_	Seg=O
111	in	_	_	_	_	_	_	_	Seg=O
112	mouse	_	_	_	_	_	_	_	Seg=O
113	brains	_	_	_	_	_	_	_	Seg=O
114	increased	_	_	_	_	_	_	_	Seg=O
115	levels	_	_	_	_	_	_	_	Seg=O
116	of	_	_	_	_	_	_	_	Seg=O
117	oxidative	_	_	_	_	_	_	_	Seg=O
118	stress	_	_	_	_	_	_	_	Seg=O
119	hallmarks	_	_	_	_	_	_	_	Seg=O
120	,	_	_	_	_	_	_	_	Seg=O
121	including	_	_	_	_	_	_	_	Seg=B-seg
122	4-hydroxynonenal	_	_	_	_	_	_	_	Seg=O
123	(	_	_	_	_	_	_	_	Seg=O
124	HNE	_	_	_	_	_	_	_	Seg=O
125	)	_	_	_	_	_	_	_	Seg=O
126	,	_	_	_	_	_	_	_	Seg=O
127	and	_	_	_	_	_	_	_	Seg=O
128	13	_	_	_	_	_	_	_	Seg=O
129	HNE	_	_	_	_	_	_	_	Seg=O
130	-	_	_	_	_	_	_	_	Seg=O
131	modified	_	_	_	_	_	_	_	Seg=O
132	proteins	_	_	_	_	_	_	_	Seg=O
133	whose	_	_	_	_	_	_	_	Seg=B-seg
134	levels	_	_	_	_	_	_	_	Seg=O
135	were	_	_	_	_	_	_	_	Seg=O
136	found	_	_	_	_	_	_	_	Seg=O
137	significantly	_	_	_	_	_	_	_	Seg=O
138	altered	_	_	_	_	_	_	_	Seg=O
139	in	_	_	_	_	_	_	_	Seg=O
140	the	_	_	_	_	_	_	_	Seg=O
141	cortex	_	_	_	_	_	_	_	Seg=O
142	of	_	_	_	_	_	_	_	Seg=O
143	HSV-1-infected	_	_	_	_	_	_	_	Seg=O
144	mice	_	_	_	_	_	_	_	Seg=O
145	compared	_	_	_	_	_	_	_	Seg=B-seg
146	to	_	_	_	_	_	_	_	Seg=O
147	controls	_	_	_	_	_	_	_	Seg=O
148	.	_	_	_	_	_	_	_	Seg=O
149	We	_	_	_	_	_	_	_	Seg=B-seg
150	focused	_	_	_	_	_	_	_	Seg=O
151	on	_	_	_	_	_	_	_	Seg=O
152	two	_	_	_	_	_	_	_	Seg=O
153	proteins	_	_	_	_	_	_	_	Seg=O
154	previously	_	_	_	_	_	_	_	Seg=B-seg
155	linked	_	_	_	_	_	_	_	Seg=O
156	to	_	_	_	_	_	_	_	Seg=O
157	AD	_	_	_	_	_	_	_	Seg=O
158	pathogenesis	_	_	_	_	_	_	_	Seg=O
159	,	_	_	_	_	_	_	_	Seg=O
160	i.e.	_	_	_	_	_	_	_	Seg=B-seg
161	,	_	_	_	_	_	_	_	Seg=O
162	glucose	_	_	_	_	_	_	_	Seg=O
163	-	_	_	_	_	_	_	_	Seg=O
164	regulated	_	_	_	_	_	_	_	Seg=O
165	protein	_	_	_	_	_	_	_	Seg=O
166	78	_	_	_	_	_	_	_	Seg=O
167	(	_	_	_	_	_	_	_	Seg=O
168	GRP78	_	_	_	_	_	_	_	Seg=O
169	)	_	_	_	_	_	_	_	Seg=O
170	and	_	_	_	_	_	_	_	Seg=O
171	collapsin	_	_	_	_	_	_	_	Seg=O
172	response	_	_	_	_	_	_	_	Seg=O
173	-	_	_	_	_	_	_	_	Seg=O
174	mediated	_	_	_	_	_	_	_	Seg=O
175	protein	_	_	_	_	_	_	_	Seg=O
176	2	_	_	_	_	_	_	_	Seg=O
177	(	_	_	_	_	_	_	_	Seg=O
178	CRMP2	_	_	_	_	_	_	_	Seg=O
179	)	_	_	_	_	_	_	_	Seg=O
180	,	_	_	_	_	_	_	_	Seg=O
181	which	_	_	_	_	_	_	_	Seg=B-seg
182	are	_	_	_	_	_	_	_	Seg=O
183	involved	_	_	_	_	_	_	_	Seg=O
184	in	_	_	_	_	_	_	_	Seg=O
185	the	_	_	_	_	_	_	_	Seg=O
186	unfolded	_	_	_	_	_	_	_	Seg=O
187	protein	_	_	_	_	_	_	_	Seg=O
188	response	_	_	_	_	_	_	_	Seg=O
189	(	_	_	_	_	_	_	_	Seg=O
190	UPR	_	_	_	_	_	_	_	Seg=O
191	)	_	_	_	_	_	_	_	Seg=O
192	and	_	_	_	_	_	_	_	Seg=O
193	in	_	_	_	_	_	_	_	Seg=O
194	microtubule	_	_	_	_	_	_	_	Seg=O
195	stabilization	_	_	_	_	_	_	_	Seg=O
196	,	_	_	_	_	_	_	_	Seg=O
197	respectively	_	_	_	_	_	_	_	Seg=O
198	.	_	_	_	_	_	_	_	Seg=O
199	We	_	_	_	_	_	_	_	Seg=B-seg
200	found	_	_	_	_	_	_	_	Seg=O
201	that	_	_	_	_	_	_	_	Seg=B-seg
202	recurrent	_	_	_	_	_	_	_	Seg=O
203	HSV-1	_	_	_	_	_	_	_	Seg=O
204	infection	_	_	_	_	_	_	_	Seg=O
205	disables	_	_	_	_	_	_	_	Seg=O
206	GRP78	_	_	_	_	_	_	_	Seg=O
207	function	_	_	_	_	_	_	_	Seg=O
208	and	_	_	_	_	_	_	_	Seg=B-seg
209	activates	_	_	_	_	_	_	_	Seg=O
210	the	_	_	_	_	_	_	_	Seg=O
211	UPR	_	_	_	_	_	_	_	Seg=O
212	,	_	_	_	_	_	_	_	Seg=O
213	whereas	_	_	_	_	_	_	_	Seg=B-seg
214	it	_	_	_	_	_	_	_	Seg=O
215	prevents	_	_	_	_	_	_	_	Seg=O
216	CRMP2	_	_	_	_	_	_	_	Seg=O
217	function	_	_	_	_	_	_	_	Seg=O
218	in	_	_	_	_	_	_	_	Seg=O
219	mouse	_	_	_	_	_	_	_	Seg=O
220	brains	_	_	_	_	_	_	_	Seg=O
221	.	_	_	_	_	_	_	_	Seg=O
222	Overall	_	_	_	_	_	_	_	Seg=B-seg
223	,	_	_	_	_	_	_	_	Seg=O
224	these	_	_	_	_	_	_	_	Seg=O
225	data	_	_	_	_	_	_	_	Seg=O
226	suggest	_	_	_	_	_	_	_	Seg=O
227	that	_	_	_	_	_	_	_	Seg=B-seg
228	repeated	_	_	_	_	_	_	_	Seg=O
229	HSV-1	_	_	_	_	_	_	_	Seg=O
230	reactivation	_	_	_	_	_	_	_	Seg=O
231	into	_	_	_	_	_	_	_	Seg=O
232	the	_	_	_	_	_	_	_	Seg=O
233	brain	_	_	_	_	_	_	_	Seg=O
234	may	_	_	_	_	_	_	_	Seg=O
235	contribute	_	_	_	_	_	_	_	Seg=O
236	to	_	_	_	_	_	_	_	Seg=O
237	neurodegeneration	_	_	_	_	_	_	_	Seg=O
238	also	_	_	_	_	_	_	_	Seg=O
239	through	_	_	_	_	_	_	_	Seg=O
240	oxidative	_	_	_	_	_	_	_	Seg=O
241	damage	_	_	_	_	_	_	_	Seg=O
242	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = cc0c8d1b722d78c17b7023fd6058fd11efbd0567
1	OBJECTIVE	_	_	_	_	_	_	_	Seg=B-seg
2	:	_	_	_	_	_	_	_	Seg=O
3	Recent	_	_	_	_	_	_	_	Seg=B-seg
4	experiences	_	_	_	_	_	_	_	Seg=O
5	in	_	_	_	_	_	_	_	Seg=O
6	the	_	_	_	_	_	_	_	Seg=O
7	United	_	_	_	_	_	_	_	Seg=O
8	States	_	_	_	_	_	_	_	Seg=O
9	with	_	_	_	_	_	_	_	Seg=O
10	unprecedented	_	_	_	_	_	_	_	Seg=O
11	terrorist	_	_	_	_	_	_	_	Seg=O
12	attacks	_	_	_	_	_	_	_	Seg=O
13	(	_	_	_	_	_	_	_	Seg=O
14	9/11	_	_	_	_	_	_	_	Seg=O
15	)	_	_	_	_	_	_	_	Seg=O
16	and	_	_	_	_	_	_	_	Seg=O
17	a	_	_	_	_	_	_	_	Seg=O
18	devastating	_	_	_	_	_	_	_	Seg=O
19	natural	_	_	_	_	_	_	_	Seg=O
20	disaster	_	_	_	_	_	_	_	Seg=O
21	(	_	_	_	_	_	_	_	Seg=O
22	Hurricane	_	_	_	_	_	_	_	Seg=O
23	Katrina	_	_	_	_	_	_	_	Seg=O
24	)	_	_	_	_	_	_	_	Seg=O
25	have	_	_	_	_	_	_	_	Seg=O
26	demonstrated	_	_	_	_	_	_	_	Seg=O
27	that	_	_	_	_	_	_	_	Seg=B-seg
28	the	_	_	_	_	_	_	_	Seg=O
29	medical	_	_	_	_	_	_	_	Seg=O
30	care	_	_	_	_	_	_	_	Seg=O
31	of	_	_	_	_	_	_	_	Seg=O
32	mass	_	_	_	_	_	_	_	Seg=O
33	casualties	_	_	_	_	_	_	_	Seg=O
34	during	_	_	_	_	_	_	_	Seg=O
35	such	_	_	_	_	_	_	_	Seg=O
36	disasters	_	_	_	_	_	_	_	Seg=O
37	poses	_	_	_	_	_	_	_	Seg=O
38	ethical	_	_	_	_	_	_	_	Seg=O
39	problems	_	_	_	_	_	_	_	Seg=O
40	not	_	_	_	_	_	_	_	Seg=B-seg
41	normally	_	_	_	_	_	_	_	Seg=O
42	experienced	_	_	_	_	_	_	_	Seg=O
43	in	_	_	_	_	_	_	_	Seg=O
44	civilian	_	_	_	_	_	_	_	Seg=O
45	health	_	_	_	_	_	_	_	Seg=O
46	care	_	_	_	_	_	_	_	Seg=O
47	.	_	_	_	_	_	_	_	Seg=O
48	It	_	_	_	_	_	_	_	Seg=B-seg
49	is	_	_	_	_	_	_	_	Seg=O
50	important	_	_	_	_	_	_	_	Seg=O
51	to	_	_	_	_	_	_	_	Seg=O
52	1	_	_	_	_	_	_	_	Seg=O
53	)	_	_	_	_	_	_	_	Seg=O
54	identify	_	_	_	_	_	_	_	Seg=O
55	the	_	_	_	_	_	_	_	Seg=O
56	unique	_	_	_	_	_	_	_	Seg=O
57	ethical	_	_	_	_	_	_	_	Seg=O
58	challenges	_	_	_	_	_	_	_	Seg=O
59	facing	_	_	_	_	_	_	_	Seg=B-seg
60	physicians	_	_	_	_	_	_	_	Seg=O
61	who	_	_	_	_	_	_	_	Seg=B-seg
62	feel	_	_	_	_	_	_	_	Seg=O
63	an	_	_	_	_	_	_	_	Seg=O
64	obligation	_	_	_	_	_	_	_	Seg=O
65	to	_	_	_	_	_	_	_	Seg=B-seg
66	care	_	_	_	_	_	_	_	Seg=O
67	for	_	_	_	_	_	_	_	Seg=O
68	victims	_	_	_	_	_	_	_	Seg=O
69	of	_	_	_	_	_	_	_	Seg=O
70	such	_	_	_	_	_	_	_	Seg=O
71	disasters	_	_	_	_	_	_	_	Seg=O
72	and	_	_	_	_	_	_	_	Seg=B-seg
73	2	_	_	_	_	_	_	_	Seg=O
74	)	_	_	_	_	_	_	_	Seg=O
75	develop	_	_	_	_	_	_	_	Seg=O
76	a	_	_	_	_	_	_	_	Seg=O
77	national	_	_	_	_	_	_	_	Seg=O
78	consensus	_	_	_	_	_	_	_	Seg=O
79	on	_	_	_	_	_	_	_	Seg=O
80	ethical	_	_	_	_	_	_	_	Seg=O
81	guidelines	_	_	_	_	_	_	_	Seg=O
82	as	_	_	_	_	_	_	_	Seg=O
83	a	_	_	_	_	_	_	_	Seg=O
84	resource	_	_	_	_	_	_	_	Seg=O
85	for	_	_	_	_	_	_	_	Seg=O
86	ethical	_	_	_	_	_	_	_	Seg=O
87	decision	_	_	_	_	_	_	_	Seg=O
88	making	_	_	_	_	_	_	_	Seg=O
89	in	_	_	_	_	_	_	_	Seg=O
90	medical	_	_	_	_	_	_	_	Seg=O
91	disaster	_	_	_	_	_	_	_	Seg=O
92	relief	_	_	_	_	_	_	_	Seg=O
93	.	_	_	_	_	_	_	_	Seg=O
94	STUDY	_	_	_	_	_	_	_	Seg=B-seg
95	DESIGN	_	_	_	_	_	_	_	Seg=O
96	:	_	_	_	_	_	_	_	Seg=O
97	A	_	_	_	_	_	_	_	Seg=B-seg
98	survey	_	_	_	_	_	_	_	Seg=O
99	of	_	_	_	_	_	_	_	Seg=O
100	pertinent	_	_	_	_	_	_	_	Seg=O
101	literature	_	_	_	_	_	_	_	Seg=O
102	was	_	_	_	_	_	_	_	Seg=O
103	performed	_	_	_	_	_	_	_	Seg=O
104	to	_	_	_	_	_	_	_	Seg=B-seg
105	assess	_	_	_	_	_	_	_	Seg=O
106	experience	_	_	_	_	_	_	_	Seg=O
107	and	_	_	_	_	_	_	_	Seg=O
108	opinions	_	_	_	_	_	_	_	Seg=O
109	on	_	_	_	_	_	_	_	Seg=O
110	the	_	_	_	_	_	_	_	Seg=O
111	condition	_	_	_	_	_	_	_	Seg=O
112	of	_	_	_	_	_	_	_	Seg=O
113	medical	_	_	_	_	_	_	_	Seg=O
114	care	_	_	_	_	_	_	_	Seg=O
115	in	_	_	_	_	_	_	_	Seg=O
116	terrorist	_	_	_	_	_	_	_	Seg=O
117	attacks	_	_	_	_	_	_	_	Seg=O
118	and	_	_	_	_	_	_	_	Seg=O
119	natural	_	_	_	_	_	_	_	Seg=O
120	disasters	_	_	_	_	_	_	_	Seg=O
121	,	_	_	_	_	_	_	_	Seg=O
122	the	_	_	_	_	_	_	_	Seg=O
123	ethical	_	_	_	_	_	_	_	Seg=O
124	challenges	_	_	_	_	_	_	_	Seg=O
125	of	_	_	_	_	_	_	_	Seg=O
126	disaster	_	_	_	_	_	_	_	Seg=O
127	medical	_	_	_	_	_	_	_	Seg=O
128	care	_	_	_	_	_	_	_	Seg=O
129	,	_	_	_	_	_	_	_	Seg=O
130	and	_	_	_	_	_	_	_	Seg=O
131	the	_	_	_	_	_	_	_	Seg=O
132	professional	_	_	_	_	_	_	_	Seg=O
133	responsibilities	_	_	_	_	_	_	_	Seg=O
134	and	_	_	_	_	_	_	_	Seg=O
135	responsiveness	_	_	_	_	_	_	_	Seg=O
136	in	_	_	_	_	_	_	_	Seg=O
137	disasters	_	_	_	_	_	_	_	Seg=O
138	.	_	_	_	_	_	_	_	Seg=O
139	CONCLUSIONS	_	_	_	_	_	_	_	Seg=B-seg
140	:	_	_	_	_	_	_	_	Seg=O
141	It	_	_	_	_	_	_	_	Seg=B-seg
142	is	_	_	_	_	_	_	_	Seg=O
143	necessary	_	_	_	_	_	_	_	Seg=O
144	to	_	_	_	_	_	_	_	Seg=O
145	develop	_	_	_	_	_	_	_	Seg=O
146	a	_	_	_	_	_	_	_	Seg=O
147	national	_	_	_	_	_	_	_	Seg=O
148	consensus	_	_	_	_	_	_	_	Seg=O
149	on	_	_	_	_	_	_	_	Seg=O
150	the	_	_	_	_	_	_	_	Seg=O
151	ethical	_	_	_	_	_	_	_	Seg=O
152	guidelines	_	_	_	_	_	_	_	Seg=O
153	for	_	_	_	_	_	_	_	Seg=O
154	physicians	_	_	_	_	_	_	_	Seg=O
155	who	_	_	_	_	_	_	_	Seg=B-seg
156	care	_	_	_	_	_	_	_	Seg=O
157	for	_	_	_	_	_	_	_	Seg=O
158	patients	_	_	_	_	_	_	_	Seg=O
159	,	_	_	_	_	_	_	_	Seg=O
160	victims	_	_	_	_	_	_	_	Seg=O
161	,	_	_	_	_	_	_	_	Seg=O
162	and	_	_	_	_	_	_	_	Seg=O
163	casualties	_	_	_	_	_	_	_	Seg=O
164	of	_	_	_	_	_	_	_	Seg=O
165	disasters	_	_	_	_	_	_	_	Seg=O
166	,	_	_	_	_	_	_	_	Seg=O
167	and	_	_	_	_	_	_	_	Seg=B-seg
168	to	_	_	_	_	_	_	_	Seg=O
169	formulate	_	_	_	_	_	_	_	Seg=O
170	a	_	_	_	_	_	_	_	Seg=O
171	virtuebased	_	_	_	_	_	_	_	Seg=O
172	,	_	_	_	_	_	_	_	Seg=O
173	yet	_	_	_	_	_	_	_	Seg=O
174	practical	_	_	_	_	_	_	_	Seg=O
175	,	_	_	_	_	_	_	_	Seg=O
176	ethical	_	_	_	_	_	_	_	Seg=O
177	approach	_	_	_	_	_	_	_	Seg=O
178	to	_	_	_	_	_	_	_	Seg=O
179	medical	_	_	_	_	_	_	_	Seg=O
180	care	_	_	_	_	_	_	_	Seg=O
181	under	_	_	_	_	_	_	_	Seg=O
182	such	_	_	_	_	_	_	_	Seg=O
183	extreme	_	_	_	_	_	_	_	Seg=O
184	conditions	_	_	_	_	_	_	_	Seg=O
185	.	_	_	_	_	_	_	_	Seg=O
186	An	_	_	_	_	_	_	_	Seg=B-seg
187	educational	_	_	_	_	_	_	_	Seg=O
188	curriculum	_	_	_	_	_	_	_	Seg=O
189	for	_	_	_	_	_	_	_	Seg=O
190	medical	_	_	_	_	_	_	_	Seg=O
191	students	_	_	_	_	_	_	_	Seg=O
192	,	_	_	_	_	_	_	_	Seg=O
193	residents	_	_	_	_	_	_	_	Seg=O
194	,	_	_	_	_	_	_	_	Seg=O
195	and	_	_	_	_	_	_	_	Seg=O
196	practicing	_	_	_	_	_	_	_	Seg=O
197	physicians	_	_	_	_	_	_	_	Seg=O
198	is	_	_	_	_	_	_	_	Seg=O
199	required	_	_	_	_	_	_	_	Seg=O
200	to	_	_	_	_	_	_	_	Seg=B-seg
201	best	_	_	_	_	_	_	_	Seg=O
202	prepare	_	_	_	_	_	_	_	Seg=O
203	all	_	_	_	_	_	_	_	Seg=O
204	physicians	_	_	_	_	_	_	_	Seg=O
205	who	_	_	_	_	_	_	_	Seg=B-seg
206	might	_	_	_	_	_	_	_	Seg=O
207	be	_	_	_	_	_	_	_	Seg=O
208	called	_	_	_	_	_	_	_	Seg=O
209	upon	_	_	_	_	_	_	_	Seg=O
210	,	_	_	_	_	_	_	_	Seg=O
211	in	_	_	_	_	_	_	_	Seg=O
212	the	_	_	_	_	_	_	_	Seg=O
213	future	_	_	_	_	_	_	_	Seg=O
214	,	_	_	_	_	_	_	_	Seg=O
215	to	_	_	_	_	_	_	_	Seg=B-seg
216	triage	_	_	_	_	_	_	_	Seg=O
217	patients	_	_	_	_	_	_	_	Seg=O
218	,	_	_	_	_	_	_	_	Seg=O
219	allocate	_	_	_	_	_	_	_	Seg=O
220	resources	_	_	_	_	_	_	_	Seg=O
221	,	_	_	_	_	_	_	_	Seg=O
222	and	_	_	_	_	_	_	_	Seg=O
223	make	_	_	_	_	_	_	_	Seg=O
224	difficult	_	_	_	_	_	_	_	Seg=O
225	decisions	_	_	_	_	_	_	_	Seg=O
226	about	_	_	_	_	_	_	_	Seg=O
227	treatment	_	_	_	_	_	_	_	Seg=O
228	priorities	_	_	_	_	_	_	_	Seg=O
229	and	_	_	_	_	_	_	_	Seg=O
230	comfort	_	_	_	_	_	_	_	Seg=O
231	care	_	_	_	_	_	_	_	Seg=O
232	.	_	_	_	_	_	_	_	Seg=O
233	It	_	_	_	_	_	_	_	Seg=B-seg
234	is	_	_	_	_	_	_	_	Seg=O
235	not	_	_	_	_	_	_	_	Seg=O
236	appropriate	_	_	_	_	_	_	_	Seg=O
237	to	_	_	_	_	_	_	_	Seg=O
238	address	_	_	_	_	_	_	_	Seg=O
239	these	_	_	_	_	_	_	_	Seg=O
240	questions	_	_	_	_	_	_	_	Seg=O
241	at	_	_	_	_	_	_	_	Seg=O
242	the	_	_	_	_	_	_	_	Seg=O
243	time	_	_	_	_	_	_	_	Seg=O
244	of	_	_	_	_	_	_	_	Seg=O
245	the	_	_	_	_	_	_	_	Seg=O
246	disaster	_	_	_	_	_	_	_	Seg=O
247	,	_	_	_	_	_	_	_	Seg=O
248	but	_	_	_	_	_	_	_	Seg=B-seg
249	rather	_	_	_	_	_	_	_	Seg=O
250	in	_	_	_	_	_	_	_	Seg=O
251	advance	_	_	_	_	_	_	_	Seg=O
252	,	_	_	_	_	_	_	_	Seg=O
253	as	_	_	_	_	_	_	_	Seg=O
254	part	_	_	_	_	_	_	_	Seg=O
255	of	_	_	_	_	_	_	_	Seg=O
256	the	_	_	_	_	_	_	_	Seg=O
257	ethics	_	_	_	_	_	_	_	Seg=O
258	education	_	_	_	_	_	_	_	Seg=O
259	of	_	_	_	_	_	_	_	Seg=O
260	the	_	_	_	_	_	_	_	Seg=O
261	medical	_	_	_	_	_	_	_	Seg=O
262	profession	_	_	_	_	_	_	_	Seg=O
263	.	_	_	_	_	_	_	_	Seg=O
264	Important	_	_	_	_	_	_	_	Seg=B-seg
265	issues	_	_	_	_	_	_	_	Seg=O
266	for	_	_	_	_	_	_	_	Seg=O
267	resolution	_	_	_	_	_	_	_	Seg=O
268	include	_	_	_	_	_	_	_	Seg=O
269	inpatient	_	_	_	_	_	_	_	Seg=O
270	and	_	_	_	_	_	_	_	Seg=O
271	casualty	_	_	_	_	_	_	_	Seg=O
272	triage	_	_	_	_	_	_	_	Seg=O
273	and	_	_	_	_	_	_	_	Seg=O
274	prioritization	_	_	_	_	_	_	_	Seg=O
275	,	_	_	_	_	_	_	_	Seg=O
276	medical	_	_	_	_	_	_	_	Seg=O
277	liability	_	_	_	_	_	_	_	Seg=O
278	,	_	_	_	_	_	_	_	Seg=O
279	altered	_	_	_	_	_	_	_	Seg=O
280	standards	_	_	_	_	_	_	_	Seg=O
281	of	_	_	_	_	_	_	_	Seg=O
282	care	_	_	_	_	_	_	_	Seg=O
283	,	_	_	_	_	_	_	_	Seg=O
284	justice	_	_	_	_	_	_	_	Seg=O
285	and	_	_	_	_	_	_	_	Seg=O
286	equity	_	_	_	_	_	_	_	Seg=O
287	,	_	_	_	_	_	_	_	Seg=O
288	informed	_	_	_	_	_	_	_	Seg=O
289	consent	_	_	_	_	_	_	_	Seg=O
290	and	_	_	_	_	_	_	_	Seg=O
291	patient	_	_	_	_	_	_	_	Seg=O
292	autonomy	_	_	_	_	_	_	_	Seg=O
293	,	_	_	_	_	_	_	_	Seg=O
294	expanding	_	_	_	_	_	_	_	Seg=O
295	scope	_	_	_	_	_	_	_	Seg=O
296	of	_	_	_	_	_	_	_	Seg=O
297	practice	_	_	_	_	_	_	_	Seg=O
298	in	_	_	_	_	_	_	_	Seg=O
299	disaster	_	_	_	_	_	_	_	Seg=O
300	medicine	_	_	_	_	_	_	_	Seg=O
301	,	_	_	_	_	_	_	_	Seg=O
302	and	_	_	_	_	_	_	_	Seg=O
303	the	_	_	_	_	_	_	_	Seg=O
304	moral	_	_	_	_	_	_	_	Seg=O
305	and	_	_	_	_	_	_	_	Seg=O
306	ethical	_	_	_	_	_	_	_	Seg=O
307	responsibilities	_	_	_	_	_	_	_	Seg=O
308	of	_	_	_	_	_	_	_	Seg=O
309	physicians	_	_	_	_	_	_	_	Seg=O
310	to	_	_	_	_	_	_	_	Seg=O
311	care	_	_	_	_	_	_	_	Seg=O
312	for	_	_	_	_	_	_	_	Seg=O
313	disaster	_	_	_	_	_	_	_	Seg=O
314	victims	_	_	_	_	_	_	_	Seg=O
315	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = d25529180f950874e0b4f62a976959d683a2ceaf
1	The	_	_	_	_	_	_	_	Seg=B-seg
2	N	_	_	_	_	_	_	_	Seg=O
3	-	_	_	_	_	_	_	_	Seg=O
4	terminal	_	_	_	_	_	_	_	Seg=O
5	domain	_	_	_	_	_	_	_	Seg=O
6	of	_	_	_	_	_	_	_	Seg=O
7	the	_	_	_	_	_	_	_	Seg=O
8	coronavirus	_	_	_	_	_	_	_	Seg=O
9	nucleocapsid	_	_	_	_	_	_	_	Seg=O
10	(	_	_	_	_	_	_	_	Seg=O
11	N	_	_	_	_	_	_	_	Seg=O
12	)	_	_	_	_	_	_	_	Seg=O
13	protein	_	_	_	_	_	_	_	Seg=O
14	adopts	_	_	_	_	_	_	_	Seg=O
15	a	_	_	_	_	_	_	_	Seg=O
16	fold	_	_	_	_	_	_	_	Seg=O
17	resembling	_	_	_	_	_	_	_	Seg=B-seg
18	a	_	_	_	_	_	_	_	Seg=O
19	right	_	_	_	_	_	_	_	Seg=O
20	hand	_	_	_	_	_	_	_	Seg=O
21	with	_	_	_	_	_	_	_	Seg=O
22	a	_	_	_	_	_	_	_	Seg=O
23	flexible	_	_	_	_	_	_	_	Seg=O
24	,	_	_	_	_	_	_	_	Seg=O
25	positively	_	_	_	_	_	_	_	Seg=O
26	charged	_	_	_	_	_	_	_	Seg=O
27	b	_	_	_	_	_	_	_	Seg=O
28	-	_	_	_	_	_	_	_	Seg=O
29	hairpin	_	_	_	_	_	_	_	Seg=O
30	and	_	_	_	_	_	_	_	Seg=O
31	a	_	_	_	_	_	_	_	Seg=O
32	hydrophobic	_	_	_	_	_	_	_	Seg=O
33	palm	_	_	_	_	_	_	_	Seg=O
34	.	_	_	_	_	_	_	_	Seg=O
35	This	_	_	_	_	_	_	_	Seg=B-seg
36	domain	_	_	_	_	_	_	_	Seg=O
37	was	_	_	_	_	_	_	_	Seg=O
38	shown	_	_	_	_	_	_	_	Seg=O
39	to	_	_	_	_	_	_	_	Seg=O
40	interact	_	_	_	_	_	_	_	Seg=O
41	with	_	_	_	_	_	_	_	Seg=O
42	the	_	_	_	_	_	_	_	Seg=O
43	genomic	_	_	_	_	_	_	_	Seg=O
44	RNA	_	_	_	_	_	_	_	Seg=O
45	for	_	_	_	_	_	_	_	Seg=O
46	coronavirus	_	_	_	_	_	_	_	Seg=O
47	infectious	_	_	_	_	_	_	_	Seg=O
48	bronchitis	_	_	_	_	_	_	_	Seg=O
49	virus	_	_	_	_	_	_	_	Seg=O
50	(	_	_	_	_	_	_	_	Seg=O
51	IBV	_	_	_	_	_	_	_	Seg=O
52	)	_	_	_	_	_	_	_	Seg=O
53	and	_	_	_	_	_	_	_	Seg=O
54	severe	_	_	_	_	_	_	_	Seg=O
55	acute	_	_	_	_	_	_	_	Seg=O
56	respiratory	_	_	_	_	_	_	_	Seg=O
57	syndrome	_	_	_	_	_	_	_	Seg=O
58	coronavirus	_	_	_	_	_	_	_	Seg=O
59	(	_	_	_	_	_	_	_	Seg=O
60	SARS	_	_	_	_	_	_	_	Seg=O
61	-	_	_	_	_	_	_	_	Seg=O
62	CoV	_	_	_	_	_	_	_	Seg=O
63	)	_	_	_	_	_	_	_	Seg=O
64	.	_	_	_	_	_	_	_	Seg=O
65	Based	_	_	_	_	_	_	_	Seg=B-seg
66	on	_	_	_	_	_	_	_	Seg=O
67	its	_	_	_	_	_	_	_	Seg=O
68	3D	_	_	_	_	_	_	_	Seg=O
69	structure	_	_	_	_	_	_	_	Seg=O
70	,	_	_	_	_	_	_	_	Seg=O
71	we	_	_	_	_	_	_	_	Seg=B-seg
72	used	_	_	_	_	_	_	_	Seg=O
73	site	_	_	_	_	_	_	_	Seg=O
74	-	_	_	_	_	_	_	_	Seg=O
75	directed	_	_	_	_	_	_	_	Seg=O
76	mutagenesis	_	_	_	_	_	_	_	Seg=O
77	to	_	_	_	_	_	_	_	Seg=B-seg
78	identify	_	_	_	_	_	_	_	Seg=O
79	residues	_	_	_	_	_	_	_	Seg=O
80	essential	_	_	_	_	_	_	_	Seg=B-seg
81	for	_	_	_	_	_	_	_	Seg=O
82	the	_	_	_	_	_	_	_	Seg=O
83	RNA	_	_	_	_	_	_	_	Seg=O
84	-	_	_	_	_	_	_	_	Seg=O
85	binding	_	_	_	_	_	_	_	Seg=O
86	activity	_	_	_	_	_	_	_	Seg=O
87	of	_	_	_	_	_	_	_	Seg=O
88	the	_	_	_	_	_	_	_	Seg=O
89	IBV	_	_	_	_	_	_	_	Seg=O
90	N	_	_	_	_	_	_	_	Seg=O
91	protein	_	_	_	_	_	_	_	Seg=O
92	and	_	_	_	_	_	_	_	Seg=O
93	viral	_	_	_	_	_	_	_	Seg=O
94	infectivity	_	_	_	_	_	_	_	Seg=O
95	.	_	_	_	_	_	_	_	Seg=O
96	Alanine	_	_	_	_	_	_	_	Seg=B-seg
97	substitution	_	_	_	_	_	_	_	Seg=O
98	of	_	_	_	_	_	_	_	Seg=O
99	either	_	_	_	_	_	_	_	Seg=O
100	Arg-76	_	_	_	_	_	_	_	Seg=O
101	or	_	_	_	_	_	_	_	Seg=O
102	Tyr-94	_	_	_	_	_	_	_	Seg=O
103	in	_	_	_	_	_	_	_	Seg=O
104	the	_	_	_	_	_	_	_	Seg=O
105	N	_	_	_	_	_	_	_	Seg=O
106	-	_	_	_	_	_	_	_	Seg=O
107	terminal	_	_	_	_	_	_	_	Seg=O
108	domain	_	_	_	_	_	_	_	Seg=O
109	of	_	_	_	_	_	_	_	Seg=O
110	IBV	_	_	_	_	_	_	_	Seg=O
111	N	_	_	_	_	_	_	_	Seg=O
112	protein	_	_	_	_	_	_	_	Seg=O
113	led	_	_	_	_	_	_	_	Seg=O
114	to	_	_	_	_	_	_	_	Seg=O
115	a	_	_	_	_	_	_	_	Seg=O
116	significant	_	_	_	_	_	_	_	Seg=O
117	decrease	_	_	_	_	_	_	_	Seg=O
118	in	_	_	_	_	_	_	_	Seg=O
119	its	_	_	_	_	_	_	_	Seg=O
120	RNA	_	_	_	_	_	_	_	Seg=O
121	-	_	_	_	_	_	_	_	Seg=O
122	binding	_	_	_	_	_	_	_	Seg=O
123	activity	_	_	_	_	_	_	_	Seg=O
124	and	_	_	_	_	_	_	_	Seg=O
125	a	_	_	_	_	_	_	_	Seg=O
126	total	_	_	_	_	_	_	_	Seg=O
127	loss	_	_	_	_	_	_	_	Seg=O
128	of	_	_	_	_	_	_	_	Seg=O
129	the	_	_	_	_	_	_	_	Seg=O
130	infectivity	_	_	_	_	_	_	_	Seg=O
131	of	_	_	_	_	_	_	_	Seg=O
132	the	_	_	_	_	_	_	_	Seg=O
133	viral	_	_	_	_	_	_	_	Seg=O
134	RNA	_	_	_	_	_	_	_	Seg=O
135	to	_	_	_	_	_	_	_	Seg=O
136	Vero	_	_	_	_	_	_	_	Seg=O
137	cells	_	_	_	_	_	_	_	Seg=O
138	.	_	_	_	_	_	_	_	Seg=O
139	In	_	_	_	_	_	_	_	Seg=B-seg
140	contrast	_	_	_	_	_	_	_	Seg=O
141	,	_	_	_	_	_	_	_	Seg=O
142	mutation	_	_	_	_	_	_	_	Seg=O
143	of	_	_	_	_	_	_	_	Seg=O
144	amino	_	_	_	_	_	_	_	Seg=O
145	acid	_	_	_	_	_	_	_	Seg=O
146	Gln-74	_	_	_	_	_	_	_	Seg=O
147	to	_	_	_	_	_	_	_	Seg=O
148	an	_	_	_	_	_	_	_	Seg=O
149	alanine	_	_	_	_	_	_	_	Seg=O
150	,	_	_	_	_	_	_	_	Seg=O
151	which	_	_	_	_	_	_	_	Seg=B-seg
152	does	_	_	_	_	_	_	_	Seg=O
153	not	_	_	_	_	_	_	_	Seg=O
154	affect	_	_	_	_	_	_	_	Seg=O
155	the	_	_	_	_	_	_	_	Seg=O
156	binding	_	_	_	_	_	_	_	Seg=O
157	activity	_	_	_	_	_	_	_	Seg=O
158	of	_	_	_	_	_	_	_	Seg=O
159	the	_	_	_	_	_	_	_	Seg=O
160	N	_	_	_	_	_	_	_	Seg=O
161	-	_	_	_	_	_	_	_	Seg=O
162	terminal	_	_	_	_	_	_	_	Seg=O
163	domain	_	_	_	_	_	_	_	Seg=O
164	,	_	_	_	_	_	_	_	Seg=O
165	showed	_	_	_	_	_	_	_	Seg=B-seg
166	minimal	_	_	_	_	_	_	_	Seg=O
167	,	_	_	_	_	_	_	_	Seg=O
168	if	_	_	_	_	_	_	_	Seg=O
169	any	_	_	_	_	_	_	_	Seg=O
170	,	_	_	_	_	_	_	_	Seg=O
171	detrimental	_	_	_	_	_	_	_	Seg=O
172	effect	_	_	_	_	_	_	_	Seg=O
173	on	_	_	_	_	_	_	_	Seg=O
174	the	_	_	_	_	_	_	_	Seg=O
175	infectivity	_	_	_	_	_	_	_	Seg=O
176	of	_	_	_	_	_	_	_	Seg=O
177	IBV	_	_	_	_	_	_	_	Seg=O
178	.	_	_	_	_	_	_	_	Seg=O
179	This	_	_	_	_	_	_	_	Seg=B-seg
180	study	_	_	_	_	_	_	_	Seg=O
181	thus	_	_	_	_	_	_	_	Seg=O
182	identifies	_	_	_	_	_	_	_	Seg=O
183	residues	_	_	_	_	_	_	_	Seg=O
184	critical	_	_	_	_	_	_	_	Seg=B-seg
185	for	_	_	_	_	_	_	_	Seg=O
186	RNA	_	_	_	_	_	_	_	Seg=O
187	binding	_	_	_	_	_	_	_	Seg=O
188	on	_	_	_	_	_	_	_	Seg=O
189	the	_	_	_	_	_	_	_	Seg=O
190	nucleocapsid	_	_	_	_	_	_	_	Seg=O
191	surface	_	_	_	_	_	_	_	Seg=O
192	,	_	_	_	_	_	_	_	Seg=O
193	and	_	_	_	_	_	_	_	Seg=B-seg
194	presents	_	_	_	_	_	_	_	Seg=O
195	biochemical	_	_	_	_	_	_	_	Seg=O
196	and	_	_	_	_	_	_	_	Seg=O
197	genetic	_	_	_	_	_	_	_	Seg=O
198	evidence	_	_	_	_	_	_	_	Seg=O
199	that	_	_	_	_	_	_	_	Seg=B-seg
200	directly	_	_	_	_	_	_	_	Seg=O
201	links	_	_	_	_	_	_	_	Seg=O
202	the	_	_	_	_	_	_	_	Seg=O
203	RNA	_	_	_	_	_	_	_	Seg=O
204	binding	_	_	_	_	_	_	_	Seg=O
205	capacity	_	_	_	_	_	_	_	Seg=O
206	of	_	_	_	_	_	_	_	Seg=O
207	the	_	_	_	_	_	_	_	Seg=O
208	coronavirus	_	_	_	_	_	_	_	Seg=O
209	N	_	_	_	_	_	_	_	Seg=O
210	protein	_	_	_	_	_	_	_	Seg=O
211	to	_	_	_	_	_	_	_	Seg=O
212	the	_	_	_	_	_	_	_	Seg=O
213	viral	_	_	_	_	_	_	_	Seg=O
214	infectivity	_	_	_	_	_	_	_	Seg=O
215	in	_	_	_	_	_	_	_	Seg=O
216	cultured	_	_	_	_	_	_	_	Seg=O
217	cells	_	_	_	_	_	_	_	Seg=O
218	.	_	_	_	_	_	_	_	Seg=O
219	This	_	_	_	_	_	_	_	Seg=B-seg
220	information	_	_	_	_	_	_	_	Seg=O
221	would	_	_	_	_	_	_	_	Seg=O
222	be	_	_	_	_	_	_	_	Seg=O
223	useful	_	_	_	_	_	_	_	Seg=O
224	in	_	_	_	_	_	_	_	Seg=O
225	development	_	_	_	_	_	_	_	Seg=O
226	of	_	_	_	_	_	_	_	Seg=O
227	preventive	_	_	_	_	_	_	_	Seg=O
228	and	_	_	_	_	_	_	_	Seg=O
229	treatment	_	_	_	_	_	_	_	Seg=O
230	approaches	_	_	_	_	_	_	_	Seg=O
231	against	_	_	_	_	_	_	_	Seg=O
232	coronavirus	_	_	_	_	_	_	_	Seg=O
233	infection	_	_	_	_	_	_	_	Seg=O
234	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = e28346ba72cc0451ddb4afe2179ae0f070b54aed
1	Acquired	_	_	_	_	_	_	_	Seg=B-seg
2	myasthenia	_	_	_	_	_	_	_	Seg=O
3	gravis	_	_	_	_	_	_	_	Seg=O
4	was	_	_	_	_	_	_	_	Seg=O
5	diagnosed	_	_	_	_	_	_	_	Seg=O
6	in	_	_	_	_	_	_	_	Seg=O
7	a	_	_	_	_	_	_	_	Seg=O
8	five	_	_	_	_	_	_	_	Seg=O
9	-	_	_	_	_	_	_	_	Seg=O
10	year	_	_	_	_	_	_	_	Seg=O
11	-	_	_	_	_	_	_	_	Seg=O
12	old	_	_	_	_	_	_	_	Seg=O
13	domestic	_	_	_	_	_	_	_	Seg=O
14	shorthair	_	_	_	_	_	_	_	Seg=O
15	,	_	_	_	_	_	_	_	Seg=O
16	neutered	_	_	_	_	_	_	_	Seg=O
17	,	_	_	_	_	_	_	_	Seg=O
18	female	_	_	_	_	_	_	_	Seg=O
19	cat	_	_	_	_	_	_	_	Seg=O
20	with	_	_	_	_	_	_	_	Seg=O
21	generalised	_	_	_	_	_	_	_	Seg=O
22	muscle	_	_	_	_	_	_	_	Seg=O
23	weakness	_	_	_	_	_	_	_	Seg=O
24	,	_	_	_	_	_	_	_	Seg=O
25	tremors	_	_	_	_	_	_	_	Seg=O
26	,	_	_	_	_	_	_	_	Seg=O
27	dysphagia	_	_	_	_	_	_	_	Seg=O
28	and	_	_	_	_	_	_	_	Seg=O
29	alterations	_	_	_	_	_	_	_	Seg=O
30	in	_	_	_	_	_	_	_	Seg=O
31	voice	_	_	_	_	_	_	_	Seg=O
32	.	_	_	_	_	_	_	_	Seg=O
33	Radiographs	_	_	_	_	_	_	_	Seg=B-seg
34	indicated	_	_	_	_	_	_	_	Seg=O
35	the	_	_	_	_	_	_	_	Seg=O
36	presence	_	_	_	_	_	_	_	Seg=O
37	of	_	_	_	_	_	_	_	Seg=O
38	a	_	_	_	_	_	_	_	Seg=O
39	mass	_	_	_	_	_	_	_	Seg=O
40	in	_	_	_	_	_	_	_	Seg=O
41	the	_	_	_	_	_	_	_	Seg=O
42	anterior	_	_	_	_	_	_	_	Seg=O
43	thorax	_	_	_	_	_	_	_	Seg=O
44	.	_	_	_	_	_	_	_	Seg=O
45	A	_	_	_	_	_	_	_	Seg=B-seg
46	response	_	_	_	_	_	_	_	Seg=O
47	to	_	_	_	_	_	_	_	Seg=O
48	edrophonium	_	_	_	_	_	_	_	Seg=O
49	chloride	_	_	_	_	_	_	_	Seg=O
50	,	_	_	_	_	_	_	_	Seg=O
51	and	_	_	_	_	_	_	_	Seg=O
52	raised	_	_	_	_	_	_	_	Seg=O
53	levels	_	_	_	_	_	_	_	Seg=O
54	of	_	_	_	_	_	_	_	Seg=O
55	anti	_	_	_	_	_	_	_	Seg=O
56	-	_	_	_	_	_	_	_	Seg=O
57	acetylcholine	_	_	_	_	_	_	_	Seg=O
58	receptor	_	_	_	_	_	_	_	Seg=O
59	antibodies	_	_	_	_	_	_	_	Seg=O
60	in	_	_	_	_	_	_	_	Seg=O
61	the	_	_	_	_	_	_	_	Seg=O
62	serum	_	_	_	_	_	_	_	Seg=O
63	,	_	_	_	_	_	_	_	Seg=O
64	confirmed	_	_	_	_	_	_	_	Seg=O
65	the	_	_	_	_	_	_	_	Seg=O
66	diagnosis	_	_	_	_	_	_	_	Seg=O
67	and	_	_	_	_	_	_	_	Seg=B-seg
68	indicated	_	_	_	_	_	_	_	Seg=O
69	an	_	_	_	_	_	_	_	Seg=O
70	immune	_	_	_	_	_	_	_	Seg=O
71	-	_	_	_	_	_	_	_	Seg=O
72	mediated	_	_	_	_	_	_	_	Seg=O
73	aetiology	_	_	_	_	_	_	_	Seg=O
74	.	_	_	_	_	_	_	_	Seg=O
75	Clinical	_	_	_	_	_	_	_	Seg=B-seg
76	remission	_	_	_	_	_	_	_	Seg=O
77	occurred	_	_	_	_	_	_	_	Seg=O
78	following	_	_	_	_	_	_	_	Seg=B-seg
79	thymectomy	_	_	_	_	_	_	_	Seg=O
80	and	_	_	_	_	_	_	_	Seg=O
81	the	_	_	_	_	_	_	_	Seg=O
82	use	_	_	_	_	_	_	_	Seg=O
83	of	_	_	_	_	_	_	_	Seg=O
84	immunosuppressive	_	_	_	_	_	_	_	Seg=O
85	corticosteroids	_	_	_	_	_	_	_	Seg=O
86	.	_	_	_	_	_	_	_	Seg=O
87	This	_	_	_	_	_	_	_	Seg=B-seg
88	is	_	_	_	_	_	_	_	Seg=O
89	the	_	_	_	_	_	_	_	Seg=O
90	first	_	_	_	_	_	_	_	Seg=O
91	fully	_	_	_	_	_	_	_	Seg=O
92	-	_	_	_	_	_	_	_	Seg=O
93	documented	_	_	_	_	_	_	_	Seg=O
94	case	_	_	_	_	_	_	_	Seg=O
95	of	_	_	_	_	_	_	_	Seg=O
96	acquired	_	_	_	_	_	_	_	Seg=O
97	feline	_	_	_	_	_	_	_	Seg=O
98	myasthenia	_	_	_	_	_	_	_	Seg=O
99	gravis	_	_	_	_	_	_	_	Seg=O
100	associated	_	_	_	_	_	_	_	Seg=B-seg
101	with	_	_	_	_	_	_	_	Seg=O
102	the	_	_	_	_	_	_	_	Seg=O
103	presence	_	_	_	_	_	_	_	Seg=O
104	of	_	_	_	_	_	_	_	Seg=O
105	a	_	_	_	_	_	_	_	Seg=O
106	thymic	_	_	_	_	_	_	_	Seg=O
107	abnormality	_	_	_	_	_	_	_	Seg=O
108	in	_	_	_	_	_	_	_	Seg=B-seg
109	the	_	_	_	_	_	_	_	Seg=O
110	United	_	_	_	_	_	_	_	Seg=O
111	Kingdom	_	_	_	_	_	_	_	Seg=O
112	.	_	_	_	_	_	_	_	Seg=O
113	The	_	_	_	_	_	_	_	Seg=B-seg
114	clinical	_	_	_	_	_	_	_	Seg=O
115	features	_	_	_	_	_	_	_	Seg=O
116	,	_	_	_	_	_	_	_	Seg=O
117	laboratory	_	_	_	_	_	_	_	Seg=O
118	findings	_	_	_	_	_	_	_	Seg=O
119	and	_	_	_	_	_	_	_	Seg=O
120	response	_	_	_	_	_	_	_	Seg=O
121	to	_	_	_	_	_	_	_	Seg=O
122	treatment	_	_	_	_	_	_	_	Seg=O
123	are	_	_	_	_	_	_	_	Seg=O
124	compared	_	_	_	_	_	_	_	Seg=O
125	with	_	_	_	_	_	_	_	Seg=O
126	those	_	_	_	_	_	_	_	Seg=O
127	reported	_	_	_	_	_	_	_	Seg=B-seg
128	previously	_	_	_	_	_	_	_	Seg=O
129	in	_	_	_	_	_	_	_	Seg=O
130	cats	_	_	_	_	_	_	_	Seg=O
131	and	_	_	_	_	_	_	_	Seg=O
132	other	_	_	_	_	_	_	_	Seg=O
133	species	_	_	_	_	_	_	_	Seg=O
134	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = e4c385d140cb5798b6fe90aabe8fefcc0dabfd99
1	Surface	_	_	_	_	_	_	_	Seg=B-seg
2	modified	_	_	_	_	_	_	_	Seg=O
3	bioactive	_	_	_	_	_	_	_	Seg=O
4	virus	_	_	_	_	_	_	_	Seg=O
5	-	_	_	_	_	_	_	_	Seg=O
6	mimicking	_	_	_	_	_	_	_	Seg=O
7	organic	_	_	_	_	_	_	_	Seg=O
8	nanovesicles	_	_	_	_	_	_	_	Seg=O
9	represent	_	_	_	_	_	_	_	Seg=O
10	themselves	_	_	_	_	_	_	_	Seg=O
11	as	_	_	_	_	_	_	_	Seg=O
12	complex	_	_	_	_	_	_	_	Seg=O
13	biomimetic	_	_	_	_	_	_	_	Seg=O
14	structures	_	_	_	_	_	_	_	Seg=O
15	that	_	_	_	_	_	_	_	Seg=B-seg
16	have	_	_	_	_	_	_	_	Seg=O
17	abilities	_	_	_	_	_	_	_	Seg=O
18	to	_	_	_	_	_	_	_	Seg=B-seg
19	dissect	_	_	_	_	_	_	_	Seg=O
20	the	_	_	_	_	_	_	_	Seg=O
21	functions	_	_	_	_	_	_	_	Seg=O
22	of	_	_	_	_	_	_	_	Seg=O
23	individual	_	_	_	_	_	_	_	Seg=O
24	entities	_	_	_	_	_	_	_	Seg=O
25	in	_	_	_	_	_	_	_	Seg=O
26	a	_	_	_	_	_	_	_	Seg=O
27	complex	_	_	_	_	_	_	_	Seg=O
28	biochemical	_	_	_	_	_	_	_	Seg=O
29	system	_	_	_	_	_	_	_	Seg=O
30	.	_	_	_	_	_	_	_	Seg=O
31	The	_	_	_	_	_	_	_	Seg=B-seg
32	customized	_	_	_	_	_	_	_	Seg=O
33	surface	_	_	_	_	_	_	_	Seg=O
34	of	_	_	_	_	_	_	_	Seg=O
35	nanovesicles	_	_	_	_	_	_	_	Seg=O
36	from	_	_	_	_	_	_	_	Seg=O
37	(	_	_	_	_	_	_	_	Seg=O
38	glyco)dendrimersomes	_	_	_	_	_	_	_	Seg=O
39	has	_	_	_	_	_	_	_	Seg=O
40	structural	_	_	_	_	_	_	_	Seg=O
41	modifications	_	_	_	_	_	_	_	Seg=O
42	that	_	_	_	_	_	_	_	Seg=B-seg
43	contribute	_	_	_	_	_	_	_	Seg=O
44	to	_	_	_	_	_	_	_	Seg=O
45	manifest	_	_	_	_	_	_	_	Seg=O
46	the	_	_	_	_	_	_	_	Seg=O
47	SARS	_	_	_	_	_	_	_	Seg=O
48	-	_	_	_	_	_	_	_	Seg=O
49	CoV-2	_	_	_	_	_	_	_	Seg=O
50	and	_	_	_	_	_	_	_	Seg=O
51	host	_	_	_	_	_	_	_	Seg=O
52	pathogenic	_	_	_	_	_	_	_	Seg=O
53	molecular	_	_	_	_	_	_	_	Seg=O
54	interactions	_	_	_	_	_	_	_	Seg=O
55	that	_	_	_	_	_	_	_	Seg=B-seg
56	help	_	_	_	_	_	_	_	Seg=O
57	the	_	_	_	_	_	_	_	Seg=O
58	virus	_	_	_	_	_	_	_	Seg=O
59	to	_	_	_	_	_	_	_	Seg=O
60	evade	_	_	_	_	_	_	_	Seg=O
61	the	_	_	_	_	_	_	_	Seg=O
62	human	_	_	_	_	_	_	_	Seg=O
63	immune	_	_	_	_	_	_	_	Seg=O
64	system	_	_	_	_	_	_	_	Seg=O
65	.	_	_	_	_	_	_	_	Seg=O
66	Nanovesicles	_	_	_	_	_	_	_	Seg=B-seg
67	also	_	_	_	_	_	_	_	Seg=O
68	have	_	_	_	_	_	_	_	Seg=O
69	a	_	_	_	_	_	_	_	Seg=O
70	potential	_	_	_	_	_	_	_	Seg=O
71	role	_	_	_	_	_	_	_	Seg=O
72	in	_	_	_	_	_	_	_	Seg=O
73	dynamic	_	_	_	_	_	_	_	Seg=O
74	biomedical	_	_	_	_	_	_	_	Seg=O
75	applications	_	_	_	_	_	_	_	Seg=O
76	such	_	_	_	_	_	_	_	Seg=B-seg
77	as	_	_	_	_	_	_	_	Seg=O
78	designing	_	_	_	_	_	_	_	Seg=O
79	galectin	_	_	_	_	_	_	_	Seg=O
80	targeting	_	_	_	_	_	_	_	Seg=O
81	drugs	_	_	_	_	_	_	_	Seg=O
82	,	_	_	_	_	_	_	_	Seg=O
83	evaluation	_	_	_	_	_	_	_	Seg=O
84	of	_	_	_	_	_	_	_	Seg=O
85	antibodies	_	_	_	_	_	_	_	Seg=O
86	to	_	_	_	_	_	_	_	Seg=B-seg
87	design	_	_	_	_	_	_	_	Seg=O
88	antiviral	_	_	_	_	_	_	_	Seg=O
89	therapeutics	_	_	_	_	_	_	_	Seg=O
90	or	_	_	_	_	_	_	_	Seg=O
91	vaccines	_	_	_	_	_	_	_	Seg=O
92	and	_	_	_	_	_	_	_	Seg=B-seg
93	targeted	_	_	_	_	_	_	_	Seg=O
94	delivery	_	_	_	_	_	_	_	Seg=O
95	of	_	_	_	_	_	_	_	Seg=O
96	drugs	_	_	_	_	_	_	_	Seg=O
97	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = e9dda9694a2e4c405b84595621b777223793d69a
1	Functional	_	_	_	_	_	_	_	Seg=B-seg
2	protein	_	_	_	_	_	_	_	Seg=O
3	microarrays	_	_	_	_	_	_	_	Seg=O
4	are	_	_	_	_	_	_	_	Seg=O
5	emerging	_	_	_	_	_	_	_	Seg=O
6	as	_	_	_	_	_	_	_	Seg=O
7	a	_	_	_	_	_	_	_	Seg=O
8	promising	_	_	_	_	_	_	_	Seg=O
9	new	_	_	_	_	_	_	_	Seg=O
10	tool	_	_	_	_	_	_	_	Seg=O
11	for	_	_	_	_	_	_	_	Seg=O
12	large	_	_	_	_	_	_	_	Seg=O
13	-	_	_	_	_	_	_	_	Seg=O
14	scale	_	_	_	_	_	_	_	Seg=O
15	and	_	_	_	_	_	_	_	Seg=O
16	highthroughput	_	_	_	_	_	_	_	Seg=O
17	studies	_	_	_	_	_	_	_	Seg=O
18	.	_	_	_	_	_	_	_	Seg=O
19	In	_	_	_	_	_	_	_	Seg=B-seg
20	this	_	_	_	_	_	_	_	Seg=O
21	article	_	_	_	_	_	_	_	Seg=O
22	,	_	_	_	_	_	_	_	Seg=O
23	we	_	_	_	_	_	_	_	Seg=O
24	will	_	_	_	_	_	_	_	Seg=O
25	review	_	_	_	_	_	_	_	Seg=O
26	their	_	_	_	_	_	_	_	Seg=O
27	applications	_	_	_	_	_	_	_	Seg=O
28	in	_	_	_	_	_	_	_	Seg=O
29	basic	_	_	_	_	_	_	_	Seg=O
30	proteomics	_	_	_	_	_	_	_	Seg=O
31	research	_	_	_	_	_	_	_	Seg=O
32	,	_	_	_	_	_	_	_	Seg=O
33	where	_	_	_	_	_	_	_	Seg=B-seg
34	various	_	_	_	_	_	_	_	Seg=O
35	types	_	_	_	_	_	_	_	Seg=O
36	of	_	_	_	_	_	_	_	Seg=O
37	assays	_	_	_	_	_	_	_	Seg=O
38	have	_	_	_	_	_	_	_	Seg=O
39	been	_	_	_	_	_	_	_	Seg=O
40	developed	_	_	_	_	_	_	_	Seg=O
41	to	_	_	_	_	_	_	_	Seg=B-seg
42	probe	_	_	_	_	_	_	_	Seg=O
43	binding	_	_	_	_	_	_	_	Seg=O
44	activities	_	_	_	_	_	_	_	Seg=O
45	to	_	_	_	_	_	_	_	Seg=O
46	other	_	_	_	_	_	_	_	Seg=O
47	biomolecules	_	_	_	_	_	_	_	Seg=O
48	,	_	_	_	_	_	_	_	Seg=O
49	such	_	_	_	_	_	_	_	Seg=B-seg
50	as	_	_	_	_	_	_	_	Seg=O
51	proteins	_	_	_	_	_	_	_	Seg=O
52	,	_	_	_	_	_	_	_	Seg=O
53	DNA	_	_	_	_	_	_	_	Seg=O
54	,	_	_	_	_	_	_	_	Seg=O
55	RNA	_	_	_	_	_	_	_	Seg=O
56	,	_	_	_	_	_	_	_	Seg=O
57	small	_	_	_	_	_	_	_	Seg=O
58	molecules	_	_	_	_	_	_	_	Seg=O
59	,	_	_	_	_	_	_	_	Seg=O
60	and	_	_	_	_	_	_	_	Seg=O
61	glycans	_	_	_	_	_	_	_	Seg=O
62	.	_	_	_	_	_	_	_	Seg=O
63	We	_	_	_	_	_	_	_	Seg=B-seg
64	will	_	_	_	_	_	_	_	Seg=O
65	also	_	_	_	_	_	_	_	Seg=O
66	report	_	_	_	_	_	_	_	Seg=O
67	recent	_	_	_	_	_	_	_	Seg=O
68	progress	_	_	_	_	_	_	_	Seg=O
69	of	_	_	_	_	_	_	_	Seg=B-seg
70	using	_	_	_	_	_	_	_	Seg=O
71	functional	_	_	_	_	_	_	_	Seg=O
72	protein	_	_	_	_	_	_	_	Seg=O
73	microarrays	_	_	_	_	_	_	_	Seg=O
74	in	_	_	_	_	_	_	_	Seg=B-seg
75	profiling	_	_	_	_	_	_	_	Seg=O
76	protein	_	_	_	_	_	_	_	Seg=O
77	posttranslational	_	_	_	_	_	_	_	Seg=O
78	modifications	_	_	_	_	_	_	_	Seg=O
79	,	_	_	_	_	_	_	_	Seg=O
80	including	_	_	_	_	_	_	_	Seg=B-seg
81	phosphorylation	_	_	_	_	_	_	_	Seg=O
82	,	_	_	_	_	_	_	_	Seg=O
83	ubiquitylation	_	_	_	_	_	_	_	Seg=O
84	,	_	_	_	_	_	_	_	Seg=O
85	acetylation	_	_	_	_	_	_	_	Seg=O
86	,	_	_	_	_	_	_	_	Seg=O
87	and	_	_	_	_	_	_	_	Seg=O
88	nitrosylation	_	_	_	_	_	_	_	Seg=O
89	.	_	_	_	_	_	_	_	Seg=O
90	Finally	_	_	_	_	_	_	_	Seg=B-seg
91	,	_	_	_	_	_	_	_	Seg=O
92	we	_	_	_	_	_	_	_	Seg=O
93	will	_	_	_	_	_	_	_	Seg=O
94	discuss	_	_	_	_	_	_	_	Seg=O
95	potential	_	_	_	_	_	_	_	Seg=O
96	of	_	_	_	_	_	_	_	Seg=O
97	functional	_	_	_	_	_	_	_	Seg=O
98	protein	_	_	_	_	_	_	_	Seg=O
99	microarrays	_	_	_	_	_	_	_	Seg=O
100	in	_	_	_	_	_	_	_	Seg=O
101	biomarker	_	_	_	_	_	_	_	Seg=O
102	identification	_	_	_	_	_	_	_	Seg=O
103	and	_	_	_	_	_	_	_	Seg=O
104	clinical	_	_	_	_	_	_	_	Seg=O
105	diagnostics	_	_	_	_	_	_	_	Seg=O
106	.	_	_	_	_	_	_	_	Seg=O
107	We	_	_	_	_	_	_	_	Seg=B-seg
108	strongly	_	_	_	_	_	_	_	Seg=O
109	believe	_	_	_	_	_	_	_	Seg=O
110	that	_	_	_	_	_	_	_	Seg=B-seg
111	functional	_	_	_	_	_	_	_	Seg=O
112	protein	_	_	_	_	_	_	_	Seg=O
113	microarrays	_	_	_	_	_	_	_	Seg=O
114	will	_	_	_	_	_	_	_	Seg=O
115	soon	_	_	_	_	_	_	_	Seg=O
116	become	_	_	_	_	_	_	_	Seg=O
117	an	_	_	_	_	_	_	_	Seg=O
118	indispensible	_	_	_	_	_	_	_	Seg=O
119	and	_	_	_	_	_	_	_	Seg=O
120	invaluable	_	_	_	_	_	_	_	Seg=O
121	tool	_	_	_	_	_	_	_	Seg=O
122	in	_	_	_	_	_	_	_	Seg=O
123	proteomics	_	_	_	_	_	_	_	Seg=O
124	research	_	_	_	_	_	_	_	Seg=O
125	and	_	_	_	_	_	_	_	Seg=O
126	systems	_	_	_	_	_	_	_	Seg=O
127	biology	_	_	_	_	_	_	_	Seg=O
128	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = eaccbbd4d93f295b6c22ae217f159c288b29deb6
1	Porcine	_	_	_	_	_	_	_	Seg=B-seg
2	reproductive	_	_	_	_	_	_	_	Seg=O
3	and	_	_	_	_	_	_	_	Seg=O
4	respiratory	_	_	_	_	_	_	_	Seg=O
5	syndrome	_	_	_	_	_	_	_	Seg=O
6	(	_	_	_	_	_	_	_	Seg=O
7	PRRS	_	_	_	_	_	_	_	Seg=O
8	)	_	_	_	_	_	_	_	Seg=O
9	has	_	_	_	_	_	_	_	Seg=O
10	been	_	_	_	_	_	_	_	Seg=O
11	one	_	_	_	_	_	_	_	Seg=O
12	of	_	_	_	_	_	_	_	Seg=O
13	the	_	_	_	_	_	_	_	Seg=O
14	most	_	_	_	_	_	_	_	Seg=O
15	economically	_	_	_	_	_	_	_	Seg=O
16	important	_	_	_	_	_	_	_	Seg=O
17	diseases	_	_	_	_	_	_	_	Seg=O
18	affecting	_	_	_	_	_	_	_	Seg=B-seg
19	swine	_	_	_	_	_	_	_	Seg=O
20	industry	_	_	_	_	_	_	_	Seg=O
21	worldwide	_	_	_	_	_	_	_	Seg=O
22	and	_	_	_	_	_	_	_	Seg=B-seg
23	causes	_	_	_	_	_	_	_	Seg=O
24	great	_	_	_	_	_	_	_	Seg=O
25	economic	_	_	_	_	_	_	_	Seg=O
26	losses	_	_	_	_	_	_	_	Seg=O
27	each	_	_	_	_	_	_	_	Seg=O
28	year	_	_	_	_	_	_	_	Seg=O
29	.	_	_	_	_	_	_	_	Seg=O
30	PRRS	_	_	_	_	_	_	_	Seg=B-seg
31	virus	_	_	_	_	_	_	_	Seg=O
32	(	_	_	_	_	_	_	_	Seg=O
33	PRRSV	_	_	_	_	_	_	_	Seg=O
34	)	_	_	_	_	_	_	_	Seg=O
35	replicates	_	_	_	_	_	_	_	Seg=O
36	mainly	_	_	_	_	_	_	_	Seg=O
37	in	_	_	_	_	_	_	_	Seg=O
38	porcine	_	_	_	_	_	_	_	Seg=O
39	alveolar	_	_	_	_	_	_	_	Seg=O
40	macrophages	_	_	_	_	_	_	_	Seg=O
41	(	_	_	_	_	_	_	_	Seg=O
42	PAMs	_	_	_	_	_	_	_	Seg=O
43	)	_	_	_	_	_	_	_	Seg=O
44	and	_	_	_	_	_	_	_	Seg=O
45	dendritic	_	_	_	_	_	_	_	Seg=O
46	cells	_	_	_	_	_	_	_	Seg=O
47	(	_	_	_	_	_	_	_	Seg=O
48	DCs	_	_	_	_	_	_	_	Seg=O
49	)	_	_	_	_	_	_	_	Seg=O
50	and	_	_	_	_	_	_	_	Seg=B-seg
51	develops	_	_	_	_	_	_	_	Seg=O
52	persistent	_	_	_	_	_	_	_	Seg=O
53	infections	_	_	_	_	_	_	_	Seg=O
54	,	_	_	_	_	_	_	_	Seg=O
55	antibody	_	_	_	_	_	_	_	Seg=O
56	-	_	_	_	_	_	_	_	Seg=O
57	dependent	_	_	_	_	_	_	_	Seg=O
58	enhancement	_	_	_	_	_	_	_	Seg=O
59	(	_	_	_	_	_	_	_	Seg=O
60	ADE	_	_	_	_	_	_	_	Seg=O
61	)	_	_	_	_	_	_	_	Seg=O
62	,	_	_	_	_	_	_	_	Seg=O
63	interstitial	_	_	_	_	_	_	_	Seg=O
64	pneumonia	_	_	_	_	_	_	_	Seg=O
65	and	_	_	_	_	_	_	_	Seg=O
66	immunosuppression	_	_	_	_	_	_	_	Seg=O
67	.	_	_	_	_	_	_	_	Seg=O
68	But	_	_	_	_	_	_	_	Seg=B-seg
69	the	_	_	_	_	_	_	_	Seg=O
70	molecular	_	_	_	_	_	_	_	Seg=O
71	mechanisms	_	_	_	_	_	_	_	Seg=O
72	of	_	_	_	_	_	_	_	Seg=O
73	PRRSV	_	_	_	_	_	_	_	Seg=O
74	infection	_	_	_	_	_	_	_	Seg=O
75	still	_	_	_	_	_	_	_	Seg=O
76	are	_	_	_	_	_	_	_	Seg=O
77	poorly	_	_	_	_	_	_	_	Seg=O
78	understood	_	_	_	_	_	_	_	Seg=O
79	.	_	_	_	_	_	_	_	Seg=O
80	Here	_	_	_	_	_	_	_	Seg=B-seg
81	we	_	_	_	_	_	_	_	Seg=O
82	report	_	_	_	_	_	_	_	Seg=O
83	on	_	_	_	_	_	_	_	Seg=O
84	the	_	_	_	_	_	_	_	Seg=O
85	first	_	_	_	_	_	_	_	Seg=O
86	genome	_	_	_	_	_	_	_	Seg=O
87	-	_	_	_	_	_	_	_	Seg=O
88	wide	_	_	_	_	_	_	_	Seg=O
89	host	_	_	_	_	_	_	_	Seg=O
90	transcriptional	_	_	_	_	_	_	_	Seg=O
91	responses	_	_	_	_	_	_	_	Seg=O
92	to	_	_	_	_	_	_	_	Seg=O
93	classical	_	_	_	_	_	_	_	Seg=O
94	North	_	_	_	_	_	_	_	Seg=O
95	American	_	_	_	_	_	_	_	Seg=O
96	type	_	_	_	_	_	_	_	Seg=O
97	PRRSV	_	_	_	_	_	_	_	Seg=O
98	(	_	_	_	_	_	_	_	Seg=O
99	N	_	_	_	_	_	_	_	Seg=O
100	-	_	_	_	_	_	_	_	Seg=O
101	PRRSV	_	_	_	_	_	_	_	Seg=O
102	)	_	_	_	_	_	_	_	Seg=O
103	strain	_	_	_	_	_	_	_	Seg=O
104	CH	_	_	_	_	_	_	_	Seg=O
105	1a	_	_	_	_	_	_	_	Seg=O
106	infection	_	_	_	_	_	_	_	Seg=O
107	using	_	_	_	_	_	_	_	Seg=B-seg
108	Solexa	_	_	_	_	_	_	_	Seg=O
109	/	_	_	_	_	_	_	_	Seg=O
110-111	Illumina's	_	_	_	_	_	_	_	_
110	Illumina	_	_	_	_	_	_	_	Seg=O
111	's	_	_	_	_	_	_	_	Seg=O
112	digital	_	_	_	_	_	_	_	Seg=O
113	gene	_	_	_	_	_	_	_	Seg=O
114	expression	_	_	_	_	_	_	_	Seg=O
115	(	_	_	_	_	_	_	_	Seg=O
116	DGE	_	_	_	_	_	_	_	Seg=O
117	)	_	_	_	_	_	_	_	Seg=O
118	system	_	_	_	_	_	_	_	Seg=O
119	,	_	_	_	_	_	_	_	Seg=O
120	a	_	_	_	_	_	_	_	Seg=O
121	tagbased	_	_	_	_	_	_	_	Seg=O
122	high	_	_	_	_	_	_	_	Seg=O
123	-	_	_	_	_	_	_	_	Seg=O
124	throughput	_	_	_	_	_	_	_	Seg=O
125	transcriptome	_	_	_	_	_	_	_	Seg=O
126	sequencing	_	_	_	_	_	_	_	Seg=O
127	method	_	_	_	_	_	_	_	Seg=O
128	,	_	_	_	_	_	_	_	Seg=O
129	and	_	_	_	_	_	_	_	Seg=B-seg
130	analyse	_	_	_	_	_	_	_	Seg=O
131	systematically	_	_	_	_	_	_	_	Seg=O
132	the	_	_	_	_	_	_	_	Seg=O
133	relationship	_	_	_	_	_	_	_	Seg=O
134	between	_	_	_	_	_	_	_	Seg=O
135	pulmonary	_	_	_	_	_	_	_	Seg=O
136	gene	_	_	_	_	_	_	_	Seg=O
137	expression	_	_	_	_	_	_	_	Seg=O
138	profiles	_	_	_	_	_	_	_	Seg=O
139	after	_	_	_	_	_	_	_	Seg=O
140	N	_	_	_	_	_	_	_	Seg=O
141	-	_	_	_	_	_	_	_	Seg=O
142	PRRSV	_	_	_	_	_	_	_	Seg=O
143	infection	_	_	_	_	_	_	_	Seg=O
144	and	_	_	_	_	_	_	_	Seg=O
145	infection	_	_	_	_	_	_	_	Seg=O
146	pathology	_	_	_	_	_	_	_	Seg=O
147	.	_	_	_	_	_	_	_	Seg=O
148	Our	_	_	_	_	_	_	_	Seg=B-seg
149	results	_	_	_	_	_	_	_	Seg=O
150	suggest	_	_	_	_	_	_	_	Seg=O
151	that	_	_	_	_	_	_	_	Seg=B-seg
152	N	_	_	_	_	_	_	_	Seg=O
153	-	_	_	_	_	_	_	_	Seg=O
154	PRRSV	_	_	_	_	_	_	_	Seg=O
155	appeared	_	_	_	_	_	_	_	Seg=O
156	to	_	_	_	_	_	_	_	Seg=O
157	utilize	_	_	_	_	_	_	_	Seg=O
158	multiple	_	_	_	_	_	_	_	Seg=O
159	strategies	_	_	_	_	_	_	_	Seg=O
160	for	_	_	_	_	_	_	_	Seg=O
161	its	_	_	_	_	_	_	_	Seg=O
162	replication	_	_	_	_	_	_	_	Seg=O
163	and	_	_	_	_	_	_	_	Seg=O
164	spread	_	_	_	_	_	_	_	Seg=O
165	in	_	_	_	_	_	_	_	Seg=O
166	infected	_	_	_	_	_	_	_	Seg=O
167	pigs	_	_	_	_	_	_	_	Seg=O
168	,	_	_	_	_	_	_	_	Seg=O
169	including	_	_	_	_	_	_	_	Seg=B-seg
170	subverting	_	_	_	_	_	_	_	Seg=O
171	host	_	_	_	_	_	_	_	Seg=O
172	innate	_	_	_	_	_	_	_	Seg=O
173	immune	_	_	_	_	_	_	_	Seg=O
174	response	_	_	_	_	_	_	_	Seg=O
175	,	_	_	_	_	_	_	_	Seg=O
176	inducing	_	_	_	_	_	_	_	Seg=B-seg
177	an	_	_	_	_	_	_	_	Seg=O
178	anti	_	_	_	_	_	_	_	Seg=O
179	-	_	_	_	_	_	_	_	Seg=O
180	apoptotic	_	_	_	_	_	_	_	Seg=O
181	and	_	_	_	_	_	_	_	Seg=O
182	anti	_	_	_	_	_	_	_	Seg=O
183	-	_	_	_	_	_	_	_	Seg=O
184	inflammatory	_	_	_	_	_	_	_	Seg=O
185	state	_	_	_	_	_	_	_	Seg=O
186	as	_	_	_	_	_	_	_	Seg=B-seg
187	well	_	_	_	_	_	_	_	Seg=O
188	as	_	_	_	_	_	_	_	Seg=O
189	developing	_	_	_	_	_	_	_	Seg=O
190	ADE	_	_	_	_	_	_	_	Seg=O
191	.	_	_	_	_	_	_	_	Seg=O
192	Upregulation	_	_	_	_	_	_	_	Seg=B-seg
193	expression	_	_	_	_	_	_	_	Seg=O
194	of	_	_	_	_	_	_	_	Seg=O
195	virus	_	_	_	_	_	_	_	Seg=O
196	-	_	_	_	_	_	_	_	Seg=O
197	induced	_	_	_	_	_	_	_	Seg=O
198	pro	_	_	_	_	_	_	_	Seg=O
199	-	_	_	_	_	_	_	_	Seg=O
200	inflammatory	_	_	_	_	_	_	_	Seg=O
201	cytokines	_	_	_	_	_	_	_	Seg=O
202	,	_	_	_	_	_	_	_	Seg=O
203	chemokines	_	_	_	_	_	_	_	Seg=O
204	,	_	_	_	_	_	_	_	Seg=O
205	adhesion	_	_	_	_	_	_	_	Seg=O
206	molecules	_	_	_	_	_	_	_	Seg=O
207	and	_	_	_	_	_	_	_	Seg=O
208	inflammatory	_	_	_	_	_	_	_	Seg=O
209	enzymes	_	_	_	_	_	_	_	Seg=O
210	and	_	_	_	_	_	_	_	Seg=O
211	inflammatory	_	_	_	_	_	_	_	Seg=O
212	cells	_	_	_	_	_	_	_	Seg=O
213	,	_	_	_	_	_	_	_	Seg=O
214	antibodies	_	_	_	_	_	_	_	Seg=O
215	,	_	_	_	_	_	_	_	Seg=O
216	complement	_	_	_	_	_	_	_	Seg=O
217	activation	_	_	_	_	_	_	_	Seg=O
218	were	_	_	_	_	_	_	_	Seg=O
219	likely	_	_	_	_	_	_	_	Seg=O
220	to	_	_	_	_	_	_	_	Seg=O
221	result	_	_	_	_	_	_	_	Seg=O
222	in	_	_	_	_	_	_	_	Seg=O
223	the	_	_	_	_	_	_	_	Seg=O
224	development	_	_	_	_	_	_	_	Seg=O
225	of	_	_	_	_	_	_	_	Seg=O
226	inflammatory	_	_	_	_	_	_	_	Seg=O
227	responses	_	_	_	_	_	_	_	Seg=O
228	during	_	_	_	_	_	_	_	Seg=O
229	N	_	_	_	_	_	_	_	Seg=O
230	-	_	_	_	_	_	_	_	Seg=O
231	PRRSV	_	_	_	_	_	_	_	Seg=O
232	infection	_	_	_	_	_	_	_	Seg=O
233	processes	_	_	_	_	_	_	_	Seg=O
234	.	_	_	_	_	_	_	_	Seg=O
235	N	_	_	_	_	_	_	_	Seg=B-seg
236	-	_	_	_	_	_	_	_	Seg=O
237	PRRSV	_	_	_	_	_	_	_	Seg=O
238	-	_	_	_	_	_	_	_	Seg=O
239	induced	_	_	_	_	_	_	_	Seg=O
240	immunosuppression	_	_	_	_	_	_	_	Seg=O
241	might	_	_	_	_	_	_	_	Seg=O
242	be	_	_	_	_	_	_	_	Seg=O
243	mediated	_	_	_	_	_	_	_	Seg=O
244	by	_	_	_	_	_	_	_	Seg=O
245	apoptosis	_	_	_	_	_	_	_	Seg=O
246	of	_	_	_	_	_	_	_	Seg=O
247	infected	_	_	_	_	_	_	_	Seg=O
248	cells	_	_	_	_	_	_	_	Seg=O
249	,	_	_	_	_	_	_	_	Seg=O
250	which	_	_	_	_	_	_	_	Seg=B-seg
251	caused	_	_	_	_	_	_	_	Seg=O
252	depletion	_	_	_	_	_	_	_	Seg=O
253	of	_	_	_	_	_	_	_	Seg=O
254	immune	_	_	_	_	_	_	_	Seg=O
255	cells	_	_	_	_	_	_	_	Seg=O
256	and	_	_	_	_	_	_	_	Seg=B-seg
257	induced	_	_	_	_	_	_	_	Seg=O
258	an	_	_	_	_	_	_	_	Seg=O
259	anti	_	_	_	_	_	_	_	Seg=O
260	-	_	_	_	_	_	_	_	Seg=O
261	inflammatory	_	_	_	_	_	_	_	Seg=O
262	cytokine	_	_	_	_	_	_	_	Seg=O
263	response	_	_	_	_	_	_	_	Seg=O
264	in	_	_	_	_	_	_	_	Seg=B-seg
265	which	_	_	_	_	_	_	_	Seg=O
266	they	_	_	_	_	_	_	_	Seg=O
267	were	_	_	_	_	_	_	_	Seg=O
268	unable	_	_	_	_	_	_	_	Seg=O
269	to	_	_	_	_	_	_	_	Seg=O
270	eradicate	_	_	_	_	_	_	_	Seg=O
271	the	_	_	_	_	_	_	_	Seg=O
272	primary	_	_	_	_	_	_	_	Seg=O
273	infection	_	_	_	_	_	_	_	Seg=O
274	.	_	_	_	_	_	_	_	Seg=O
275	Our	_	_	_	_	_	_	_	Seg=B-seg
276	systems	_	_	_	_	_	_	_	Seg=O
277	analysis	_	_	_	_	_	_	_	Seg=O
278	will	_	_	_	_	_	_	_	Seg=O
279	benefit	_	_	_	_	_	_	_	Seg=O
280	for	_	_	_	_	_	_	_	Seg=O
281	better	_	_	_	_	_	_	_	Seg=O
282	understanding	_	_	_	_	_	_	_	Seg=O
283	the	_	_	_	_	_	_	_	Seg=O
284	molecular	_	_	_	_	_	_	_	Seg=O
285	pathogenesis	_	_	_	_	_	_	_	Seg=O
286	of	_	_	_	_	_	_	_	Seg=O
287	N	_	_	_	_	_	_	_	Seg=O
288	-	_	_	_	_	_	_	_	Seg=O
289	PRRSV	_	_	_	_	_	_	_	Seg=O
290	infection	_	_	_	_	_	_	_	Seg=O
291	,	_	_	_	_	_	_	_	Seg=O
292	developing	_	_	_	_	_	_	_	Seg=O
293	novel	_	_	_	_	_	_	_	Seg=O
294	antiviral	_	_	_	_	_	_	_	Seg=O
295	therapies	_	_	_	_	_	_	_	Seg=O
296	and	_	_	_	_	_	_	_	Seg=O
297	identifying	_	_	_	_	_	_	_	Seg=O
298	genetic	_	_	_	_	_	_	_	Seg=O
299	components	_	_	_	_	_	_	_	Seg=O
300	for	_	_	_	_	_	_	_	Seg=O
301	swine	_	_	_	_	_	_	_	Seg=O
302	resistance	_	_	_	_	_	_	_	Seg=O
303	/	_	_	_	_	_	_	_	Seg=O
304	susceptibility	_	_	_	_	_	_	_	Seg=O
305	to	_	_	_	_	_	_	_	Seg=O
306	PRRS	_	_	_	_	_	_	_	Seg=O
307	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = ec79ce88059cfd9ffc56a62863ab0b2de34c4d1d
1	Background	_	_	_	_	_	_	_	Seg=B-seg
2	:	_	_	_	_	_	_	_	Seg=O
3	Public	_	_	_	_	_	_	_	Seg=B-seg
4	health	_	_	_	_	_	_	_	Seg=O
5	and	_	_	_	_	_	_	_	Seg=O
6	health	_	_	_	_	_	_	_	Seg=O
7	promotion	_	_	_	_	_	_	_	Seg=O
8	rely	_	_	_	_	_	_	_	Seg=O
9	on	_	_	_	_	_	_	_	Seg=O
10	many	_	_	_	_	_	_	_	Seg=O
11	different	_	_	_	_	_	_	_	Seg=O
12	interventions	_	_	_	_	_	_	_	Seg=O
13	,	_	_	_	_	_	_	_	Seg=O
14	which	_	_	_	_	_	_	_	Seg=B-seg
15	range	_	_	_	_	_	_	_	Seg=O
16	from	_	_	_	_	_	_	_	Seg=O
17	health	_	_	_	_	_	_	_	Seg=O
18	education	_	_	_	_	_	_	_	Seg=O
19	and	_	_	_	_	_	_	_	Seg=O
20	communication	_	_	_	_	_	_	_	Seg=O
21	,	_	_	_	_	_	_	_	Seg=O
22	through	_	_	_	_	_	_	_	Seg=O
23	community	_	_	_	_	_	_	_	Seg=O
24	mobilisation	_	_	_	_	_	_	_	Seg=O
25	and	_	_	_	_	_	_	_	Seg=O
26	changes	_	_	_	_	_	_	_	Seg=O
27	to	_	_	_	_	_	_	_	Seg=O
28	environmental	_	_	_	_	_	_	_	Seg=O
29	conditions	_	_	_	_	_	_	_	Seg=O
30	,	_	_	_	_	_	_	_	Seg=O
31	to	_	_	_	_	_	_	_	Seg=O
32	legal	_	_	_	_	_	_	_	Seg=O
33	and	_	_	_	_	_	_	_	Seg=O
34	fiscal	_	_	_	_	_	_	_	Seg=O
35	actions	_	_	_	_	_	_	_	Seg=O
36	.	_	_	_	_	_	_	_	Seg=O
37	The	_	_	_	_	_	_	_	Seg=B-seg
38	introduction	_	_	_	_	_	_	_	Seg=O
39	of	_	_	_	_	_	_	_	Seg=O
40	the	_	_	_	_	_	_	_	Seg=O
41	increased	_	_	_	_	_	_	_	Seg=O
42	tax	_	_	_	_	_	_	_	Seg=O
43	on	_	_	_	_	_	_	_	Seg=O
44	sugar	_	_	_	_	_	_	_	Seg=O
45	-	_	_	_	_	_	_	_	Seg=O
46	sweetened	_	_	_	_	_	_	_	Seg=O
47	beverages	_	_	_	_	_	_	_	Seg=O
48	(	_	_	_	_	_	_	_	Seg=O
49	SSB	_	_	_	_	_	_	_	Seg=O
50	)	_	_	_	_	_	_	_	Seg=O
51	,	_	_	_	_	_	_	_	Seg=O
52	popularly	_	_	_	_	_	_	_	Seg=B-seg
53	called	_	_	_	_	_	_	_	Seg=O
54	sugar	_	_	_	_	_	_	_	Seg=O
55	tax	_	_	_	_	_	_	_	Seg=O
56	(	_	_	_	_	_	_	_	Seg=O
57	ST	_	_	_	_	_	_	_	Seg=O
58	)	_	_	_	_	_	_	_	Seg=O
59	,	_	_	_	_	_	_	_	Seg=O
60	and	_	_	_	_	_	_	_	Seg=B-seg
61	a	_	_	_	_	_	_	_	Seg=O
62	mandatory	_	_	_	_	_	_	_	Seg=O
63	programme	_	_	_	_	_	_	_	Seg=O
64	of	_	_	_	_	_	_	_	Seg=O
65	vaccinations	_	_	_	_	_	_	_	Seg=O
66	are	_	_	_	_	_	_	_	Seg=O
67	the	_	_	_	_	_	_	_	Seg=O
68	strategies	_	_	_	_	_	_	_	Seg=O
69	inciting	_	_	_	_	_	_	_	Seg=B-seg
70	the	_	_	_	_	_	_	_	Seg=O
71	most	_	_	_	_	_	_	_	Seg=O
72	vivid	_	_	_	_	_	_	_	Seg=O
73	discussions	_	_	_	_	_	_	_	Seg=O
74	in	_	_	_	_	_	_	_	Seg=O
75	Polish	_	_	_	_	_	_	_	Seg=O
76	society	_	_	_	_	_	_	_	Seg=O
77	.	_	_	_	_	_	_	_	Seg=O
78	The	_	_	_	_	_	_	_	Seg=B-seg
79	study	_	_	_	_	_	_	_	Seg=O
80	was	_	_	_	_	_	_	_	Seg=O
81	intended	_	_	_	_	_	_	_	Seg=O
82	to	_	_	_	_	_	_	_	Seg=O
83	assess	_	_	_	_	_	_	_	Seg=O
84	the	_	_	_	_	_	_	_	Seg=O
85	determinants	_	_	_	_	_	_	_	Seg=O
86	of	_	_	_	_	_	_	_	Seg=O
87	the	_	_	_	_	_	_	_	Seg=O
88	attitudes	_	_	_	_	_	_	_	Seg=O
89	of	_	_	_	_	_	_	_	Seg=O
90	Polish	_	_	_	_	_	_	_	Seg=O
91	society	_	_	_	_	_	_	_	Seg=O
92	regarding	_	_	_	_	_	_	_	Seg=B-seg
93	the	_	_	_	_	_	_	_	Seg=O
94	ST	_	_	_	_	_	_	_	Seg=O
95	and	_	_	_	_	_	_	_	Seg=O
96	to	_	_	_	_	_	_	_	Seg=O
97	vaccinations	_	_	_	_	_	_	_	Seg=O
98	.	_	_	_	_	_	_	_	Seg=O
99	Methods	_	_	_	_	_	_	_	Seg=B-seg
100	:	_	_	_	_	_	_	_	Seg=O
101	For	_	_	_	_	_	_	_	Seg=B-seg
102	the	_	_	_	_	_	_	_	Seg=O
103	analysis	_	_	_	_	_	_	_	Seg=O
104	,	_	_	_	_	_	_	_	Seg=O
105	the	_	_	_	_	_	_	_	Seg=O
106	data	_	_	_	_	_	_	_	Seg=O
107	originating	_	_	_	_	_	_	_	Seg=B-seg
108	from	_	_	_	_	_	_	_	Seg=O
109	the	_	_	_	_	_	_	_	Seg=O
110	survey	_	_	_	_	_	_	_	Seg=O
111	of	_	_	_	_	_	_	_	Seg=O
112	a	_	_	_	_	_	_	_	Seg=O
113	representative	_	_	_	_	_	_	_	Seg=O
114	adult	_	_	_	_	_	_	_	Seg=O
115	sample	_	_	_	_	_	_	_	Seg=O
116	of	_	_	_	_	_	_	_	Seg=O
117	Polish	_	_	_	_	_	_	_	Seg=O
118	society	_	_	_	_	_	_	_	Seg=O
119	(	_	_	_	_	_	_	_	Seg=B-seg
120	n	_	_	_	_	_	_	_	Seg=O
121	=	_	_	_	_	_	_	_	Seg=O
122	1000	_	_	_	_	_	_	_	Seg=O
123	)	_	_	_	_	_	_	_	Seg=O
124	was	_	_	_	_	_	_	_	Seg=B-seg
125	used	_	_	_	_	_	_	_	Seg=O
126	.	_	_	_	_	_	_	_	Seg=O
127	The	_	_	_	_	_	_	_	Seg=B-seg
128	survey	_	_	_	_	_	_	_	Seg=O
129	was	_	_	_	_	_	_	_	Seg=O
130	based	_	_	_	_	_	_	_	Seg=O
131	on	_	_	_	_	_	_	_	Seg=O
132	computer	_	_	_	_	_	_	_	Seg=O
133	-	_	_	_	_	_	_	_	Seg=O
134	assisted	_	_	_	_	_	_	_	Seg=O
135	telephone	_	_	_	_	_	_	_	Seg=O
136	interviewing	_	_	_	_	_	_	_	Seg=O
137	(	_	_	_	_	_	_	_	Seg=O
138	CATI	_	_	_	_	_	_	_	Seg=O
139	)	_	_	_	_	_	_	_	Seg=O
140	.	_	_	_	_	_	_	_	Seg=O
141	The	_	_	_	_	_	_	_	Seg=B-seg
142	assessment	_	_	_	_	_	_	_	Seg=O
143	of	_	_	_	_	_	_	_	Seg=O
144	the	_	_	_	_	_	_	_	Seg=O
145	relationships	_	_	_	_	_	_	_	Seg=O
146	between	_	_	_	_	_	_	_	Seg=O
147	the	_	_	_	_	_	_	_	Seg=O
148	selected	_	_	_	_	_	_	_	Seg=O
149	variables	_	_	_	_	_	_	_	Seg=O
150	and	_	_	_	_	_	_	_	Seg=O
151	the	_	_	_	_	_	_	_	Seg=O
152	opinions	_	_	_	_	_	_	_	Seg=O
153	about	_	_	_	_	_	_	_	Seg=O
154	the	_	_	_	_	_	_	_	Seg=O
155	introduction	_	_	_	_	_	_	_	Seg=O
156	of	_	_	_	_	_	_	_	Seg=O
157	the	_	_	_	_	_	_	_	Seg=O
158	ST	_	_	_	_	_	_	_	Seg=O
159	and	_	_	_	_	_	_	_	Seg=O
160	the	_	_	_	_	_	_	_	Seg=O
161	safety	_	_	_	_	_	_	_	Seg=O
162	and	_	_	_	_	_	_	_	Seg=O
163	effectiveness	_	_	_	_	_	_	_	Seg=O
164	of	_	_	_	_	_	_	_	Seg=O
165	vaccinations	_	_	_	_	_	_	_	Seg=O
166	were	_	_	_	_	_	_	_	Seg=O
167	carried	_	_	_	_	_	_	_	Seg=O
168	out	_	_	_	_	_	_	_	Seg=O
169	using	_	_	_	_	_	_	_	Seg=B-seg
170	the	_	_	_	_	_	_	_	Seg=O
171	chi	_	_	_	_	_	_	_	Seg=O
172	2	_	_	_	_	_	_	_	Seg=O
173	test	_	_	_	_	_	_	_	Seg=O
174	and	_	_	_	_	_	_	_	Seg=O
175	univariate	_	_	_	_	_	_	_	Seg=O
176	logistic	_	_	_	_	_	_	_	Seg=O
177	regression	_	_	_	_	_	_	_	Seg=O
178	models	_	_	_	_	_	_	_	Seg=O
179	.	_	_	_	_	_	_	_	Seg=O
180	Results	_	_	_	_	_	_	_	Seg=B-seg
181	:	_	_	_	_	_	_	_	Seg=O
182	The	_	_	_	_	_	_	_	Seg=B-seg
183	acceptance	_	_	_	_	_	_	_	Seg=O
184	of	_	_	_	_	_	_	_	Seg=O
185	the	_	_	_	_	_	_	_	Seg=O
186	ST	_	_	_	_	_	_	_	Seg=O
187	and	_	_	_	_	_	_	_	Seg=O
188	vaccination	_	_	_	_	_	_	_	Seg=O
189	showed	_	_	_	_	_	_	_	Seg=O
190	a	_	_	_	_	_	_	_	Seg=O
191	significant	_	_	_	_	_	_	_	Seg=O
192	relationship	_	_	_	_	_	_	_	Seg=O
193	to	_	_	_	_	_	_	_	Seg=O
194	the	_	_	_	_	_	_	_	Seg=O
195	level	_	_	_	_	_	_	_	Seg=O
196	of	_	_	_	_	_	_	_	Seg=O
197	health	_	_	_	_	_	_	_	Seg=O
198	literacy	_	_	_	_	_	_	_	Seg=O
199	(	_	_	_	_	_	_	_	Seg=O
200	HL	_	_	_	_	_	_	_	Seg=O
201	)	_	_	_	_	_	_	_	Seg=O
202	but	_	_	_	_	_	_	_	Seg=O
203	not	_	_	_	_	_	_	_	Seg=O
204	to	_	_	_	_	_	_	_	Seg=O
205	eHealth	_	_	_	_	_	_	_	Seg=O
206	literacy	_	_	_	_	_	_	_	Seg=O
207	(	_	_	_	_	_	_	_	Seg=O
208	eHL	_	_	_	_	_	_	_	Seg=O
209	)	_	_	_	_	_	_	_	Seg=O
210	.	_	_	_	_	_	_	_	Seg=O
211	Respondents	_	_	_	_	_	_	_	Seg=B-seg
212	having	_	_	_	_	_	_	_	Seg=B-seg
213	a	_	_	_	_	_	_	_	Seg=O
214	higher	_	_	_	_	_	_	_	Seg=O
215	rather	_	_	_	_	_	_	_	Seg=O
216	than	_	_	_	_	_	_	_	Seg=O
217	lower	_	_	_	_	_	_	_	Seg=O
218	HL	_	_	_	_	_	_	_	Seg=O
219	;	_	_	_	_	_	_	_	Seg=O
220	older	_	_	_	_	_	_	_	Seg=O
221	rather	_	_	_	_	_	_	_	Seg=O
222	than	_	_	_	_	_	_	_	Seg=O
223	younger	_	_	_	_	_	_	_	Seg=O
224	;	_	_	_	_	_	_	_	Seg=O
225	married	_	_	_	_	_	_	_	Seg=O
226	rather	_	_	_	_	_	_	_	Seg=O
227	than	_	_	_	_	_	_	_	Seg=O
228	singles	_	_	_	_	_	_	_	Seg=O
229	;	_	_	_	_	_	_	_	Seg=O
230	retired	_	_	_	_	_	_	_	Seg=O
231	,	_	_	_	_	_	_	_	Seg=O
232	or	_	_	_	_	_	_	_	Seg=O
233	on	_	_	_	_	_	_	_	Seg=O
234	a	_	_	_	_	_	_	_	Seg=O
235	disability	_	_	_	_	_	_	_	Seg=O
236	pension	_	_	_	_	_	_	_	Seg=O
237	,	_	_	_	_	_	_	_	Seg=O
238	rather	_	_	_	_	_	_	_	Seg=O
239	than	_	_	_	_	_	_	_	Seg=O
240	vocationally	_	_	_	_	_	_	_	Seg=O
241	active	_	_	_	_	_	_	_	Seg=O
242	and	_	_	_	_	_	_	_	Seg=O
243	nonusers	_	_	_	_	_	_	_	Seg=O
244	of	_	_	_	_	_	_	_	Seg=O
245	the	_	_	_	_	_	_	_	Seg=O
246	Internet	_	_	_	_	_	_	_	Seg=O
247	rather	_	_	_	_	_	_	_	Seg=O
248	than	_	_	_	_	_	_	_	Seg=O
249	users	_	_	_	_	_	_	_	Seg=O
250	were	_	_	_	_	_	_	_	Seg=B-seg
251	more	_	_	_	_	_	_	_	Seg=O
252	likely	_	_	_	_	_	_	_	Seg=O
253	to	_	_	_	_	_	_	_	Seg=O
254	show	_	_	_	_	_	_	_	Seg=O
255	an	_	_	_	_	_	_	_	Seg=O
256	acceptance	_	_	_	_	_	_	_	Seg=O
257	for	_	_	_	_	_	_	_	Seg=O
258	both	_	_	_	_	_	_	_	Seg=O
259	interventions	_	_	_	_	_	_	_	Seg=O
260	.	_	_	_	_	_	_	_	Seg=O
261	Those	_	_	_	_	_	_	_	Seg=B-seg
262	more	_	_	_	_	_	_	_	Seg=B-seg
263	frequently	_	_	_	_	_	_	_	Seg=O
264	using	_	_	_	_	_	_	_	Seg=O
265	health	_	_	_	_	_	_	_	Seg=O
266	care	_	_	_	_	_	_	_	Seg=O
267	services	_	_	_	_	_	_	_	Seg=O
268	and	_	_	_	_	_	_	_	Seg=B-seg
269	those	_	_	_	_	_	_	_	Seg=O
270	with	_	_	_	_	_	_	_	Seg=O
271	chronic	_	_	_	_	_	_	_	Seg=O
272	diseases	_	_	_	_	_	_	_	Seg=O
273	showed	_	_	_	_	_	_	_	Seg=O
274	a	_	_	_	_	_	_	_	Seg=O
275	greater	_	_	_	_	_	_	_	Seg=O
276	belief	_	_	_	_	_	_	_	Seg=O
277	in	_	_	_	_	_	_	_	Seg=O
278	the	_	_	_	_	_	_	_	Seg=O
279	safety	_	_	_	_	_	_	_	Seg=O
280	and	_	_	_	_	_	_	_	Seg=O
281	effectiveness	_	_	_	_	_	_	_	Seg=O
282	of	_	_	_	_	_	_	_	Seg=O
283	vaccinations	_	_	_	_	_	_	_	Seg=O
284	.	_	_	_	_	_	_	_	Seg=O
285	Conclusions	_	_	_	_	_	_	_	Seg=B-seg
286	:	_	_	_	_	_	_	_	Seg=O
287	The	_	_	_	_	_	_	_	Seg=B-seg
288	relationship	_	_	_	_	_	_	_	Seg=O
289	between	_	_	_	_	_	_	_	Seg=O
290	the	_	_	_	_	_	_	_	Seg=O
291	opinions	_	_	_	_	_	_	_	Seg=O
292	of	_	_	_	_	_	_	_	Seg=O
293	the	_	_	_	_	_	_	_	Seg=O
294	two	_	_	_	_	_	_	_	Seg=O
295	public	_	_	_	_	_	_	_	Seg=O
296	health	_	_	_	_	_	_	_	Seg=O
297	interventions	_	_	_	_	_	_	_	Seg=O
298	analysed	_	_	_	_	_	_	_	Seg=O
299	and	_	_	_	_	_	_	_	Seg=O
300	the	_	_	_	_	_	_	_	Seg=O
301	sociodemographic	_	_	_	_	_	_	_	Seg=O
302	variables	_	_	_	_	_	_	_	Seg=O
303	demonstrated	_	_	_	_	_	_	_	Seg=O
304	similar	_	_	_	_	_	_	_	Seg=O
305	patterns	_	_	_	_	_	_	_	Seg=O
306	.	_	_	_	_	_	_	_	Seg=O
307	Interestingly	_	_	_	_	_	_	_	Seg=B-seg
308	,	_	_	_	_	_	_	_	Seg=O
309	the	_	_	_	_	_	_	_	Seg=O
310	opinions	_	_	_	_	_	_	_	Seg=O
311	were	_	_	_	_	_	_	_	Seg=O
312	associated	_	_	_	_	_	_	_	Seg=O
313	only	_	_	_	_	_	_	_	Seg=O
314	with	_	_	_	_	_	_	_	Seg=O
315	HL	_	_	_	_	_	_	_	Seg=O
316	and	_	_	_	_	_	_	_	Seg=O
317	not	_	_	_	_	_	_	_	Seg=O
318	with	_	_	_	_	_	_	_	Seg=O
319	eHL	_	_	_	_	_	_	_	Seg=O
320	and	_	_	_	_	_	_	_	Seg=B-seg
321	users	_	_	_	_	_	_	_	Seg=O
322	of	_	_	_	_	_	_	_	Seg=O
323	the	_	_	_	_	_	_	_	Seg=O
324	Internet	_	_	_	_	_	_	_	Seg=O
325	were	_	_	_	_	_	_	_	Seg=O
326	more	_	_	_	_	_	_	_	Seg=O
327	sceptical	_	_	_	_	_	_	_	Seg=O
328	about	_	_	_	_	_	_	_	Seg=O
329	the	_	_	_	_	_	_	_	Seg=O
330	interventions	_	_	_	_	_	_	_	Seg=O
331	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = ece140f2d510d370f594707b718066f7173a39e1
1	Since	_	_	_	_	_	_	_	Seg=B-seg
2	it	_	_	_	_	_	_	_	Seg=O
3	emerged	_	_	_	_	_	_	_	Seg=O
4	in	_	_	_	_	_	_	_	Seg=O
5	Brazil	_	_	_	_	_	_	_	Seg=O
6	in	_	_	_	_	_	_	_	Seg=O
7	May	_	_	_	_	_	_	_	Seg=O
8	2015	_	_	_	_	_	_	_	Seg=O
9	,	_	_	_	_	_	_	_	Seg=O
10	the	_	_	_	_	_	_	_	Seg=B-seg
11	mosquito	_	_	_	_	_	_	_	Seg=O
12	-	_	_	_	_	_	_	_	Seg=O
13	borne	_	_	_	_	_	_	_	Seg=O
14	Zika	_	_	_	_	_	_	_	Seg=O
15	virus	_	_	_	_	_	_	_	Seg=O
16	(	_	_	_	_	_	_	_	Seg=O
17	ZIKV	_	_	_	_	_	_	_	Seg=O
18	)	_	_	_	_	_	_	_	Seg=O
19	has	_	_	_	_	_	_	_	Seg=O
20	raised	_	_	_	_	_	_	_	Seg=O
21	global	_	_	_	_	_	_	_	Seg=O
22	concern	_	_	_	_	_	_	_	Seg=O
23	due	_	_	_	_	_	_	_	Seg=B-seg
24	to	_	_	_	_	_	_	_	Seg=O
25	its	_	_	_	_	_	_	_	Seg=O
26	association	_	_	_	_	_	_	_	Seg=O
27	with	_	_	_	_	_	_	_	Seg=O
28	a	_	_	_	_	_	_	_	Seg=O
29	significant	_	_	_	_	_	_	_	Seg=O
30	rise	_	_	_	_	_	_	_	Seg=O
31	in	_	_	_	_	_	_	_	Seg=O
32	the	_	_	_	_	_	_	_	Seg=O
33	number	_	_	_	_	_	_	_	Seg=O
34	of	_	_	_	_	_	_	_	Seg=O
35	infants	_	_	_	_	_	_	_	Seg=O
36	born	_	_	_	_	_	_	_	Seg=B-seg
37	with	_	_	_	_	_	_	_	Seg=O
38	microcephaly	_	_	_	_	_	_	_	Seg=O
39	and	_	_	_	_	_	_	_	Seg=O
40	neurological	_	_	_	_	_	_	_	Seg=O
41	disorders	_	_	_	_	_	_	_	Seg=O
42	such	_	_	_	_	_	_	_	Seg=B-seg
43	as	_	_	_	_	_	_	_	Seg=O
44	Guillain	_	_	_	_	_	_	_	Seg=O
45	-	_	_	_	_	_	_	_	Seg=O
46	Barré	_	_	_	_	_	_	_	Seg=O
47	syndrome	_	_	_	_	_	_	_	Seg=O
48	We	_	_	_	_	_	_	_	Seg=B-seg
49	developed	_	_	_	_	_	_	_	Seg=O
50	prototype	_	_	_	_	_	_	_	Seg=O
51	subunit	_	_	_	_	_	_	_	Seg=O
52	and	_	_	_	_	_	_	_	Seg=O
53	adenoviral	_	_	_	_	_	_	_	Seg=O
54	-	_	_	_	_	_	_	_	Seg=O
55	based	_	_	_	_	_	_	_	Seg=O
56	Zika	_	_	_	_	_	_	_	Seg=O
57	vaccines	_	_	_	_	_	_	_	Seg=O
58	encoding	_	_	_	_	_	_	_	Seg=B-seg
59	the	_	_	_	_	_	_	_	Seg=O
60	extracellular	_	_	_	_	_	_	_	Seg=O
61	portion	_	_	_	_	_	_	_	Seg=O
62	of	_	_	_	_	_	_	_	Seg=O
63	the	_	_	_	_	_	_	_	Seg=O
64	ZIKV	_	_	_	_	_	_	_	Seg=O
65	envelope	_	_	_	_	_	_	_	Seg=O
66	gene	_	_	_	_	_	_	_	Seg=O
67	(	_	_	_	_	_	_	_	Seg=O
68	E	_	_	_	_	_	_	_	Seg=O
69	)	_	_	_	_	_	_	_	Seg=O
70	fused	_	_	_	_	_	_	_	Seg=B-seg
71	to	_	_	_	_	_	_	_	Seg=O
72	the	_	_	_	_	_	_	_	Seg=O
73	T4	_	_	_	_	_	_	_	Seg=O
74	fibritin	_	_	_	_	_	_	_	Seg=O
75	foldon	_	_	_	_	_	_	_	Seg=O
76	trimerization	_	_	_	_	_	_	_	Seg=O
77	domain	_	_	_	_	_	_	_	Seg=O
78	(	_	_	_	_	_	_	_	Seg=O
79	Efl	_	_	_	_	_	_	_	Seg=O
80	)	_	_	_	_	_	_	_	Seg=O
81	.	_	_	_	_	_	_	_	Seg=O
82	The	_	_	_	_	_	_	_	Seg=B-seg
83	subunit	_	_	_	_	_	_	_	Seg=O
84	vaccine	_	_	_	_	_	_	_	Seg=O
85	was	_	_	_	_	_	_	_	Seg=O
86	delivered	_	_	_	_	_	_	_	Seg=O
87	intradermally	_	_	_	_	_	_	_	Seg=O
88	through	_	_	_	_	_	_	_	Seg=O
89	carboxymethyl	_	_	_	_	_	_	_	Seg=O
90	cellulose	_	_	_	_	_	_	_	Seg=O
91	microneedle	_	_	_	_	_	_	_	Seg=O
92	array	_	_	_	_	_	_	_	Seg=O
93	(	_	_	_	_	_	_	_	Seg=O
94	MNA	_	_	_	_	_	_	_	Seg=O
95	)	_	_	_	_	_	_	_	Seg=O
96	.	_	_	_	_	_	_	_	Seg=O
97	The	_	_	_	_	_	_	_	Seg=B-seg
98	immunogenicity	_	_	_	_	_	_	_	Seg=O
99	of	_	_	_	_	_	_	_	Seg=O
100	these	_	_	_	_	_	_	_	Seg=O
101	two	_	_	_	_	_	_	_	Seg=O
102	vaccines	_	_	_	_	_	_	_	Seg=O
103	,	_	_	_	_	_	_	_	Seg=O
104	named	_	_	_	_	_	_	_	Seg=B-seg
105	Ad5	_	_	_	_	_	_	_	Seg=O
106	.	_	_	_	_	_	_	_	Seg=O
107	ZIKV	_	_	_	_	_	_	_	Seg=O
108	-	_	_	_	_	_	_	_	Seg=O
109	Efl	_	_	_	_	_	_	_	Seg=O
110	and	_	_	_	_	_	_	_	Seg=O
111	ZIKV	_	_	_	_	_	_	_	Seg=O
112	-	_	_	_	_	_	_	_	Seg=O
113	rEfl	_	_	_	_	_	_	_	Seg=O
114	,	_	_	_	_	_	_	_	Seg=O
115	was	_	_	_	_	_	_	_	Seg=B-seg
116	tested	_	_	_	_	_	_	_	Seg=O
117	in	_	_	_	_	_	_	_	Seg=O
118	C57BL/6	_	_	_	_	_	_	_	Seg=O
119	mice	_	_	_	_	_	_	_	Seg=O
120	.	_	_	_	_	_	_	_	Seg=O
121	Prime	_	_	_	_	_	_	_	Seg=B-seg
122	/	_	_	_	_	_	_	_	Seg=O
123	boost	_	_	_	_	_	_	_	Seg=O
124	immunization	_	_	_	_	_	_	_	Seg=O
125	regimen	_	_	_	_	_	_	_	Seg=O
126	was	_	_	_	_	_	_	_	Seg=O
127	associated	_	_	_	_	_	_	_	Seg=O
128	with	_	_	_	_	_	_	_	Seg=O
129	induction	_	_	_	_	_	_	_	Seg=O
130	of	_	_	_	_	_	_	_	Seg=O
131	a	_	_	_	_	_	_	_	Seg=O
132	ZIKV	_	_	_	_	_	_	_	Seg=O
133	-	_	_	_	_	_	_	_	Seg=O
134	specific	_	_	_	_	_	_	_	Seg=O
135	antibody	_	_	_	_	_	_	_	Seg=O
136	response	_	_	_	_	_	_	_	Seg=O
137	,	_	_	_	_	_	_	_	Seg=O
138	which	_	_	_	_	_	_	_	Seg=B-seg
139	provided	_	_	_	_	_	_	_	Seg=O
140	neutralizing	_	_	_	_	_	_	_	Seg=O
141	immunity	_	_	_	_	_	_	_	Seg=O
142	.	_	_	_	_	_	_	_	Seg=O
143	Moreover	_	_	_	_	_	_	_	Seg=B-seg
144	,	_	_	_	_	_	_	_	Seg=O
145	protection	_	_	_	_	_	_	_	Seg=O
146	was	_	_	_	_	_	_	_	Seg=O
147	evaluated	_	_	_	_	_	_	_	Seg=O
148	in	_	_	_	_	_	_	_	Seg=O
149	seven	_	_	_	_	_	_	_	Seg=O
150	-	_	_	_	_	_	_	_	Seg=O
151	day	_	_	_	_	_	_	_	Seg=O
152	-	_	_	_	_	_	_	_	Seg=O
153	old	_	_	_	_	_	_	_	Seg=O
154	pups	_	_	_	_	_	_	_	Seg=O
155	after	_	_	_	_	_	_	_	Seg=O
156	virulent	_	_	_	_	_	_	_	Seg=O
157	ZIKV	_	_	_	_	_	_	_	Seg=O
158	intraperitoneal	_	_	_	_	_	_	_	Seg=O
159	challenge	_	_	_	_	_	_	_	Seg=O
160	.	_	_	_	_	_	_	_	Seg=O
161	Pups	_	_	_	_	_	_	_	Seg=B-seg
162	born	_	_	_	_	_	_	_	Seg=B-seg
163	to	_	_	_	_	_	_	_	Seg=O
164	mice	_	_	_	_	_	_	_	Seg=O
165	immunized	_	_	_	_	_	_	_	Seg=B-seg
166	with	_	_	_	_	_	_	_	Seg=O
167	Ad5	_	_	_	_	_	_	_	Seg=O
168	.	_	_	_	_	_	_	_	Seg=O
169	ZIKV	_	_	_	_	_	_	_	Seg=O
170	-	_	_	_	_	_	_	_	Seg=O
171	Efl	_	_	_	_	_	_	_	Seg=O
172	were	_	_	_	_	_	_	_	Seg=B-seg
173	all	_	_	_	_	_	_	_	Seg=O
174	protected	_	_	_	_	_	_	_	Seg=O
175	against	_	_	_	_	_	_	_	Seg=O
176	lethal	_	_	_	_	_	_	_	Seg=O
177	challenge	_	_	_	_	_	_	_	Seg=O
178	infection	_	_	_	_	_	_	_	Seg=O
179	without	_	_	_	_	_	_	_	Seg=B-seg
180	weight	_	_	_	_	_	_	_	Seg=O
181	loss	_	_	_	_	_	_	_	Seg=O
182	or	_	_	_	_	_	_	_	Seg=O
183	neurological	_	_	_	_	_	_	_	Seg=O
184	signs	_	_	_	_	_	_	_	Seg=O
185	,	_	_	_	_	_	_	_	Seg=O
186	while	_	_	_	_	_	_	_	Seg=B-seg
187	pups	_	_	_	_	_	_	_	Seg=O
188	born	_	_	_	_	_	_	_	Seg=B-seg
189	to	_	_	_	_	_	_	_	Seg=O
190	dams	_	_	_	_	_	_	_	Seg=O
191	immunized	_	_	_	_	_	_	_	Seg=B-seg
192	with	_	_	_	_	_	_	_	Seg=O
193	MNA	_	_	_	_	_	_	_	Seg=O
194	-	_	_	_	_	_	_	_	Seg=O
195	ZIKV	_	_	_	_	_	_	_	Seg=O
196	-	_	_	_	_	_	_	_	Seg=O
197	rEfl	_	_	_	_	_	_	_	Seg=O
198	were	_	_	_	_	_	_	_	Seg=B-seg
199	partially	_	_	_	_	_	_	_	Seg=O
200	protected	_	_	_	_	_	_	_	Seg=O
201	(	_	_	_	_	_	_	_	Seg=B-seg
202	50	_	_	_	_	_	_	_	Seg=O
203	%	_	_	_	_	_	_	_	Seg=O
204	)	_	_	_	_	_	_	_	Seg=O
205	.	_	_	_	_	_	_	_	Seg=O
206	No	_	_	_	_	_	_	_	Seg=B-seg
207	protection	_	_	_	_	_	_	_	Seg=O
208	was	_	_	_	_	_	_	_	Seg=O
209	seen	_	_	_	_	_	_	_	Seg=O
210	in	_	_	_	_	_	_	_	Seg=O
211	pups	_	_	_	_	_	_	_	Seg=O
212	born	_	_	_	_	_	_	_	Seg=B-seg
213	to	_	_	_	_	_	_	_	Seg=O
214	phosphate	_	_	_	_	_	_	_	Seg=O
215	buffered	_	_	_	_	_	_	_	Seg=O
216	saline	_	_	_	_	_	_	_	Seg=O
217	-	_	_	_	_	_	_	_	Seg=O
218	immunized	_	_	_	_	_	_	_	Seg=O
219	mice	_	_	_	_	_	_	_	Seg=O
220	.	_	_	_	_	_	_	_	Seg=O
221	This	_	_	_	_	_	_	_	Seg=B-seg
222	study	_	_	_	_	_	_	_	Seg=O
223	illustrates	_	_	_	_	_	_	_	Seg=O
224	the	_	_	_	_	_	_	_	Seg=O
225	preliminary	_	_	_	_	_	_	_	Seg=O
226	efficacy	_	_	_	_	_	_	_	Seg=O
227	of	_	_	_	_	_	_	_	Seg=O
228	the	_	_	_	_	_	_	_	Seg=O
229	E	_	_	_	_	_	_	_	Seg=O
230	ZIKV	_	_	_	_	_	_	_	Seg=O
231	antigen	_	_	_	_	_	_	_	Seg=O
232	vaccination	_	_	_	_	_	_	_	Seg=O
233	in	_	_	_	_	_	_	_	Seg=B-seg
234	controlling	_	_	_	_	_	_	_	Seg=O
235	ZIKV	_	_	_	_	_	_	_	Seg=O
236	infectivity	_	_	_	_	_	_	_	Seg=O
237	,	_	_	_	_	_	_	_	Seg=O
238	providing	_	_	_	_	_	_	_	Seg=B-seg
239	a	_	_	_	_	_	_	_	Seg=O
240	promising	_	_	_	_	_	_	_	Seg=O
241	candidate	_	_	_	_	_	_	_	Seg=O
242	vaccine	_	_	_	_	_	_	_	Seg=O
243	and	_	_	_	_	_	_	_	Seg=O
244	antigen	_	_	_	_	_	_	_	Seg=O
245	format	_	_	_	_	_	_	_	Seg=O
246	for	_	_	_	_	_	_	_	Seg=O
247	the	_	_	_	_	_	_	_	Seg=O
248	prevention	_	_	_	_	_	_	_	Seg=O
249	of	_	_	_	_	_	_	_	Seg=O
250	Zika	_	_	_	_	_	_	_	Seg=O
251	virus	_	_	_	_	_	_	_	Seg=O
252	disease	_	_	_	_	_	_	_	Seg=O
253	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = edfc9c542b75092b7000be09fd4496c4122c28d7
1	By	_	_	_	_	_	_	_	Seg=B-seg
2	equipping	_	_	_	_	_	_	_	Seg=O
3	a	_	_	_	_	_	_	_	Seg=O
4	previously	_	_	_	_	_	_	_	Seg=O
5	reported	_	_	_	_	_	_	_	Seg=O
6	dynamic	_	_	_	_	_	_	_	Seg=O
7	causal	_	_	_	_	_	_	_	Seg=O
8	model	_	_	_	_	_	_	_	Seg=O
9	of	_	_	_	_	_	_	_	Seg=O
10	COVID-19	_	_	_	_	_	_	_	Seg=O
11	with	_	_	_	_	_	_	_	Seg=O
12	an	_	_	_	_	_	_	_	Seg=O
13	isolation	_	_	_	_	_	_	_	Seg=O
14	state	_	_	_	_	_	_	_	Seg=O
15	,	_	_	_	_	_	_	_	Seg=O
16	we	_	_	_	_	_	_	_	Seg=B-seg
17	modelled	_	_	_	_	_	_	_	Seg=O
18	the	_	_	_	_	_	_	_	Seg=O
19	effects	_	_	_	_	_	_	_	Seg=O
20	of	_	_	_	_	_	_	_	Seg=O
21	self	_	_	_	_	_	_	_	Seg=O
22	-	_	_	_	_	_	_	_	Seg=O
23	isolation	_	_	_	_	_	_	_	Seg=O
24	consequent	_	_	_	_	_	_	_	Seg=O
25	on	_	_	_	_	_	_	_	Seg=O
26	tracking	_	_	_	_	_	_	_	Seg=O
27	and	_	_	_	_	_	_	_	Seg=O
28	tracing	_	_	_	_	_	_	_	Seg=O
29	.	_	_	_	_	_	_	_	Seg=O
30	Specifically	_	_	_	_	_	_	_	Seg=B-seg
31	,	_	_	_	_	_	_	_	Seg=O
32	we	_	_	_	_	_	_	_	Seg=O
33	included	_	_	_	_	_	_	_	Seg=O
34	a	_	_	_	_	_	_	_	Seg=O
35	quarantine	_	_	_	_	_	_	_	Seg=O
36	or	_	_	_	_	_	_	_	Seg=O
37	isolation	_	_	_	_	_	_	_	Seg=O
38	state	_	_	_	_	_	_	_	Seg=O
39	occupied	_	_	_	_	_	_	_	Seg=B-seg
40	by	_	_	_	_	_	_	_	Seg=O
41	people	_	_	_	_	_	_	_	Seg=O
42	who	_	_	_	_	_	_	_	Seg=B-seg
43	believe	_	_	_	_	_	_	_	Seg=O
44	they	_	_	_	_	_	_	_	Seg=B-seg
45	might	_	_	_	_	_	_	_	Seg=O
46	be	_	_	_	_	_	_	_	Seg=O
47	infected	_	_	_	_	_	_	_	Seg=O
48	but	_	_	_	_	_	_	_	Seg=B-seg
49	are	_	_	_	_	_	_	_	Seg=O
50	asymptomatic	_	_	_	_	_	_	_	Seg=O
51	-	_	_	_	_	_	_	_	Seg=B-seg
52	and	_	_	_	_	_	_	_	Seg=O
53	only	_	_	_	_	_	_	_	Seg=O
54	leave	_	_	_	_	_	_	_	Seg=O
55	if	_	_	_	_	_	_	_	Seg=B-seg
56	they	_	_	_	_	_	_	_	Seg=O
57	test	_	_	_	_	_	_	_	Seg=O
58	negative	_	_	_	_	_	_	_	Seg=O
59	.	_	_	_	_	_	_	_	Seg=O
60	We	_	_	_	_	_	_	_	Seg=B-seg
61	recovered	_	_	_	_	_	_	_	Seg=O
62	maximum	_	_	_	_	_	_	_	Seg=O
63	posteriori	_	_	_	_	_	_	_	Seg=O
64	estimates	_	_	_	_	_	_	_	Seg=O
65	of	_	_	_	_	_	_	_	Seg=O
66	the	_	_	_	_	_	_	_	Seg=O
67	model	_	_	_	_	_	_	_	Seg=O
68	parameters	_	_	_	_	_	_	_	Seg=O
69	using	_	_	_	_	_	_	_	Seg=B-seg
70	time	_	_	_	_	_	_	_	Seg=O
71	series	_	_	_	_	_	_	_	Seg=O
72	of	_	_	_	_	_	_	_	Seg=O
73	new	_	_	_	_	_	_	_	Seg=O
74	cases	_	_	_	_	_	_	_	Seg=O
75	,	_	_	_	_	_	_	_	Seg=O
76	daily	_	_	_	_	_	_	_	Seg=O
77	deaths	_	_	_	_	_	_	_	Seg=O
78	,	_	_	_	_	_	_	_	Seg=O
79	and	_	_	_	_	_	_	_	Seg=O
80	tests	_	_	_	_	_	_	_	Seg=O
81	for	_	_	_	_	_	_	_	Seg=O
82	the	_	_	_	_	_	_	_	Seg=O
83	UK	_	_	_	_	_	_	_	Seg=O
84	.	_	_	_	_	_	_	_	Seg=O
85	These	_	_	_	_	_	_	_	Seg=B-seg
86	parameters	_	_	_	_	_	_	_	Seg=O
87	were	_	_	_	_	_	_	_	Seg=O
88	used	_	_	_	_	_	_	_	Seg=O
89	to	_	_	_	_	_	_	_	Seg=B-seg
90	simulate	_	_	_	_	_	_	_	Seg=O
91	the	_	_	_	_	_	_	_	Seg=O
92	trajectory	_	_	_	_	_	_	_	Seg=O
93	of	_	_	_	_	_	_	_	Seg=O
94	the	_	_	_	_	_	_	_	Seg=O
95	outbreak	_	_	_	_	_	_	_	Seg=O
96	in	_	_	_	_	_	_	_	Seg=O
97	the	_	_	_	_	_	_	_	Seg=O
98	UK	_	_	_	_	_	_	_	Seg=O
99	over	_	_	_	_	_	_	_	Seg=O
100	an	_	_	_	_	_	_	_	Seg=O
101	18month	_	_	_	_	_	_	_	Seg=O
102	period	_	_	_	_	_	_	_	Seg=O
103	.	_	_	_	_	_	_	_	Seg=O
104	Several	_	_	_	_	_	_	_	Seg=B-seg
105	clear	_	_	_	_	_	_	_	Seg=O
106	-	_	_	_	_	_	_	_	Seg=O
107	cut	_	_	_	_	_	_	_	Seg=O
108	conclusions	_	_	_	_	_	_	_	Seg=O
109	emerged	_	_	_	_	_	_	_	Seg=O
110	from	_	_	_	_	_	_	_	Seg=O
111	these	_	_	_	_	_	_	_	Seg=O
112	simulations	_	_	_	_	_	_	_	Seg=O
113	.	_	_	_	_	_	_	_	Seg=O
114	For	_	_	_	_	_	_	_	Seg=B-seg
115	example	_	_	_	_	_	_	_	Seg=O
116	,	_	_	_	_	_	_	_	Seg=O
117	under	_	_	_	_	_	_	_	Seg=O
118	plausible	_	_	_	_	_	_	_	Seg=O
119	(	_	_	_	_	_	_	_	Seg=O
120	graded	_	_	_	_	_	_	_	Seg=O
121	)	_	_	_	_	_	_	_	Seg=O
122	relaxations	_	_	_	_	_	_	_	Seg=O
123	of	_	_	_	_	_	_	_	Seg=O
124	social	_	_	_	_	_	_	_	Seg=O
125	distancing	_	_	_	_	_	_	_	Seg=O
126	,	_	_	_	_	_	_	_	Seg=O
127	a	_	_	_	_	_	_	_	Seg=O
128	rebound	_	_	_	_	_	_	_	Seg=O
129	of	_	_	_	_	_	_	_	Seg=O
130	infections	_	_	_	_	_	_	_	Seg=O
131	within	_	_	_	_	_	_	_	Seg=O
132	weeks	_	_	_	_	_	_	_	Seg=O
133	is	_	_	_	_	_	_	_	Seg=O
134	unlikely	_	_	_	_	_	_	_	Seg=O
135	.	_	_	_	_	_	_	_	Seg=O
136	The	_	_	_	_	_	_	_	Seg=B-seg
137	emergence	_	_	_	_	_	_	_	Seg=O
138	of	_	_	_	_	_	_	_	Seg=O
139	a	_	_	_	_	_	_	_	Seg=O
140	later	_	_	_	_	_	_	_	Seg=O
141	second	_	_	_	_	_	_	_	Seg=O
142	wave	_	_	_	_	_	_	_	Seg=O
143	depends	_	_	_	_	_	_	_	Seg=O
144	almost	_	_	_	_	_	_	_	Seg=O
145	exclusively	_	_	_	_	_	_	_	Seg=O
146	on	_	_	_	_	_	_	_	Seg=O
147	the	_	_	_	_	_	_	_	Seg=O
148	rate	_	_	_	_	_	_	_	Seg=O
149	at	_	_	_	_	_	_	_	Seg=B-seg
150	which	_	_	_	_	_	_	_	Seg=O
151	we	_	_	_	_	_	_	_	Seg=O
152	lose	_	_	_	_	_	_	_	Seg=O
153	immunity	_	_	_	_	_	_	_	Seg=O
154	,	_	_	_	_	_	_	_	Seg=O
155	inherited	_	_	_	_	_	_	_	Seg=B-seg
156	from	_	_	_	_	_	_	_	Seg=O
157	the	_	_	_	_	_	_	_	Seg=O
158	first	_	_	_	_	_	_	_	Seg=O
159	wave	_	_	_	_	_	_	_	Seg=O
160	.	_	_	_	_	_	_	_	Seg=O
161	There	_	_	_	_	_	_	_	Seg=B-seg
162	exists	_	_	_	_	_	_	_	Seg=O
163	no	_	_	_	_	_	_	_	Seg=O
164	testing	_	_	_	_	_	_	_	Seg=O
165	strategy	_	_	_	_	_	_	_	Seg=O
166	that	_	_	_	_	_	_	_	Seg=B-seg
167	can	_	_	_	_	_	_	_	Seg=O
168	attenuate	_	_	_	_	_	_	_	Seg=O
169	mortality	_	_	_	_	_	_	_	Seg=O
170	rates	_	_	_	_	_	_	_	Seg=O
171	,	_	_	_	_	_	_	_	Seg=O
172	other	_	_	_	_	_	_	_	Seg=B-seg
173	than	_	_	_	_	_	_	_	Seg=O
174	by	_	_	_	_	_	_	_	Seg=O
175	deferring	_	_	_	_	_	_	_	Seg=O
176	or	_	_	_	_	_	_	_	Seg=O
177	delaying	_	_	_	_	_	_	_	Seg=O
178	a	_	_	_	_	_	_	_	Seg=O
179	second	_	_	_	_	_	_	_	Seg=O
180	wave	_	_	_	_	_	_	_	Seg=O
181	.	_	_	_	_	_	_	_	Seg=O
182	A	_	_	_	_	_	_	_	Seg=B-seg
183	sufficiently	_	_	_	_	_	_	_	Seg=O
184	powerful	_	_	_	_	_	_	_	Seg=O
185	tracking	_	_	_	_	_	_	_	Seg=O
186	and	_	_	_	_	_	_	_	Seg=O
187	tracing	_	_	_	_	_	_	_	Seg=O
188	policy	_	_	_	_	_	_	_	Seg=O
189	-	_	_	_	_	_	_	_	Seg=B-seg
190	implemented	_	_	_	_	_	_	_	Seg=O
191	at	_	_	_	_	_	_	_	Seg=O
192	the	_	_	_	_	_	_	_	Seg=O
193	time	_	_	_	_	_	_	_	Seg=O
194	of	_	_	_	_	_	_	_	Seg=O
195	writing	_	_	_	_	_	_	_	Seg=O
196	(	_	_	_	_	_	_	_	Seg=O
197	10th	_	_	_	_	_	_	_	Seg=O
198	May	_	_	_	_	_	_	_	Seg=O
199	2020)	_	_	_	_	_	_	_	Seg=O
200	-	_	_	_	_	_	_	_	Seg=O
201	will	_	_	_	_	_	_	_	Seg=B-seg
202	defer	_	_	_	_	_	_	_	Seg=O
203	any	_	_	_	_	_	_	_	Seg=O
204	second	_	_	_	_	_	_	_	Seg=O
205	wave	_	_	_	_	_	_	_	Seg=O
206	beyond	_	_	_	_	_	_	_	Seg=O
207	a	_	_	_	_	_	_	_	Seg=O
208	time	_	_	_	_	_	_	_	Seg=O
209	horizon	_	_	_	_	_	_	_	Seg=O
210	of	_	_	_	_	_	_	_	Seg=O
211	18	_	_	_	_	_	_	_	Seg=O
212	months	_	_	_	_	_	_	_	Seg=O
213	.	_	_	_	_	_	_	_	Seg=O
214	Crucially	_	_	_	_	_	_	_	Seg=B-seg
215	,	_	_	_	_	_	_	_	Seg=O
216	this	_	_	_	_	_	_	_	Seg=O
217	deferment	_	_	_	_	_	_	_	Seg=O
218	is	_	_	_	_	_	_	_	Seg=O
219	within	_	_	_	_	_	_	_	Seg=O
220	current	_	_	_	_	_	_	_	Seg=O
221	testing	_	_	_	_	_	_	_	Seg=O
222	capabilities	_	_	_	_	_	_	_	Seg=O
223	(	_	_	_	_	_	_	_	Seg=B-seg
224	requiring	_	_	_	_	_	_	_	Seg=O
225	an	_	_	_	_	_	_	_	Seg=O
226	efficacy	_	_	_	_	_	_	_	Seg=O
227	of	_	_	_	_	_	_	_	Seg=O
228	tracing	_	_	_	_	_	_	_	Seg=O
229	and	_	_	_	_	_	_	_	Seg=O
230	tracking	_	_	_	_	_	_	_	Seg=O
231	of	_	_	_	_	_	_	_	Seg=O
232	about	_	_	_	_	_	_	_	Seg=O
233	20	_	_	_	_	_	_	_	Seg=O
234	%	_	_	_	_	_	_	_	Seg=O
235	of	_	_	_	_	_	_	_	Seg=O
236	asymptomatic	_	_	_	_	_	_	_	Seg=O
237	infected	_	_	_	_	_	_	_	Seg=O
238	cases	_	_	_	_	_	_	_	Seg=O
239	,	_	_	_	_	_	_	_	Seg=O
240	with	_	_	_	_	_	_	_	Seg=O
241	less	_	_	_	_	_	_	_	Seg=O
242	than	_	_	_	_	_	_	_	Seg=O
243	50,000	_	_	_	_	_	_	_	Seg=O
244	tests	_	_	_	_	_	_	_	Seg=O
245	per	_	_	_	_	_	_	_	Seg=O
246	day	_	_	_	_	_	_	_	Seg=O
247	)	_	_	_	_	_	_	_	Seg=O
248	.	_	_	_	_	_	_	_	Seg=O
249	These	_	_	_	_	_	_	_	Seg=B-seg
250	conclusions	_	_	_	_	_	_	_	Seg=O
251	are	_	_	_	_	_	_	_	Seg=O
252	based	_	_	_	_	_	_	_	Seg=O
253	upon	_	_	_	_	_	_	_	Seg=O
254	a	_	_	_	_	_	_	_	Seg=O
255	dynamic	_	_	_	_	_	_	_	Seg=O
256	causal	_	_	_	_	_	_	_	Seg=O
257	model	_	_	_	_	_	_	_	Seg=O
258	for	_	_	_	_	_	_	_	Seg=B-seg
259	which	_	_	_	_	_	_	_	Seg=O
260	we	_	_	_	_	_	_	_	Seg=O
261	provide	_	_	_	_	_	_	_	Seg=O
262	some	_	_	_	_	_	_	_	Seg=O
263	construct	_	_	_	_	_	_	_	Seg=O
264	and	_	_	_	_	_	_	_	Seg=O
265	face	_	_	_	_	_	_	_	Seg=O
266	validation	_	_	_	_	_	_	_	Seg=O
267	using	_	_	_	_	_	_	_	Seg=B-seg
268	a	_	_	_	_	_	_	_	Seg=O
269	comparative	_	_	_	_	_	_	_	Seg=O
270	analysis	_	_	_	_	_	_	_	Seg=O
271	of	_	_	_	_	_	_	_	Seg=O
272	the	_	_	_	_	_	_	_	Seg=O
273	United	_	_	_	_	_	_	_	Seg=O
274	Kingdom	_	_	_	_	_	_	_	Seg=O
275	and	_	_	_	_	_	_	_	Seg=O
276	Germany	_	_	_	_	_	_	_	Seg=O
277	,	_	_	_	_	_	_	_	Seg=O
278	supplemented	_	_	_	_	_	_	_	Seg=B-seg
279	with	_	_	_	_	_	_	_	Seg=O
280	recent	_	_	_	_	_	_	_	Seg=O
281	serological	_	_	_	_	_	_	_	Seg=O
282	studies	_	_	_	_	_	_	_	Seg=O
283	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = ef5ed79925e5ef75119e387b2de2680fea9b3e1f
1	Streptobacillus	_	_	_	_	_	_	_	Seg=B-seg
2	felis	_	_	_	_	_	_	_	Seg=O
3	is	_	_	_	_	_	_	_	Seg=O
4	a	_	_	_	_	_	_	_	Seg=O
5	fastidious	_	_	_	_	_	_	_	Seg=O
6	microorganism	_	_	_	_	_	_	_	Seg=O
7	and	_	_	_	_	_	_	_	Seg=O
8	a	_	_	_	_	_	_	_	Seg=O
9	novel	_	_	_	_	_	_	_	Seg=O
10	member	_	_	_	_	_	_	_	Seg=O
11	of	_	_	_	_	_	_	_	Seg=O
12	the	_	_	_	_	_	_	_	Seg=O
13	potentially	_	_	_	_	_	_	_	Seg=O
14	zoonotic	_	_	_	_	_	_	_	Seg=O
15	bacteria	_	_	_	_	_	_	_	Seg=O
16	causing	_	_	_	_	_	_	_	Seg=B-seg
17	rat	_	_	_	_	_	_	_	Seg=O
18	bite	_	_	_	_	_	_	_	Seg=O
19	fever	_	_	_	_	_	_	_	Seg=O
20	.	_	_	_	_	_	_	_	Seg=O
21	Since	_	_	_	_	_	_	_	Seg=B-seg
22	its	_	_	_	_	_	_	_	Seg=O
23	description	_	_	_	_	_	_	_	Seg=O
24	,	_	_	_	_	_	_	_	Seg=O
25	this	_	_	_	_	_	_	_	Seg=O
26	is	_	_	_	_	_	_	_	Seg=O
27	the	_	_	_	_	_	_	_	Seg=O
28	second	_	_	_	_	_	_	_	Seg=O
29	isolation	_	_	_	_	_	_	_	Seg=O
30	of	_	_	_	_	_	_	_	Seg=O
31	S.	_	_	_	_	_	_	_	Seg=O
32	felis	_	_	_	_	_	_	_	Seg=O
33	in	_	_	_	_	_	_	_	Seg=O
34	a	_	_	_	_	_	_	_	Seg=O
35	diseased	_	_	_	_	_	_	_	Seg=O
36	member	_	_	_	_	_	_	_	Seg=O
37	of	_	_	_	_	_	_	_	Seg=O
38	the	_	_	_	_	_	_	_	Seg=O
39	Felidae	_	_	_	_	_	_	_	Seg=O
40	.	_	_	_	_	_	_	_	Seg=O
41	Interestingly	_	_	_	_	_	_	_	Seg=B-seg
42	,	_	_	_	_	_	_	_	Seg=O
43	the	_	_	_	_	_	_	_	Seg=O
44	strain	_	_	_	_	_	_	_	Seg=O
45	from	_	_	_	_	_	_	_	Seg=O
46	this	_	_	_	_	_	_	_	Seg=O
47	study	_	_	_	_	_	_	_	Seg=O
48	was	_	_	_	_	_	_	_	Seg=O
49	isolated	_	_	_	_	_	_	_	Seg=O
50	from	_	_	_	_	_	_	_	Seg=O
51	a	_	_	_	_	_	_	_	Seg=O
52	zoo	_	_	_	_	_	_	_	Seg=O
53	held	_	_	_	_	_	_	_	Seg=O
54	,	_	_	_	_	_	_	_	Seg=O
55	rusty	_	_	_	_	_	_	_	Seg=O
56	-	_	_	_	_	_	_	_	Seg=O
57	spotted	_	_	_	_	_	_	_	Seg=O
58	cat	_	_	_	_	_	_	_	Seg=O
59	(	_	_	_	_	_	_	_	Seg=B-seg
60	Prionailurus	_	_	_	_	_	_	_	Seg=O
61	rubiginosus	_	_	_	_	_	_	_	Seg=O
62	)	_	_	_	_	_	_	_	Seg=O
63	,	_	_	_	_	_	_	_	Seg=O
64	with	_	_	_	_	_	_	_	Seg=B-seg
65	pneumonia	_	_	_	_	_	_	_	Seg=O
66	,	_	_	_	_	_	_	_	Seg=O
67	thereby	_	_	_	_	_	_	_	Seg=B-seg
68	indicating	_	_	_	_	_	_	_	Seg=O
69	a	_	_	_	_	_	_	_	Seg=O
70	possible	_	_	_	_	_	_	_	Seg=O
71	broader	_	_	_	_	_	_	_	Seg=O
72	host	_	_	_	_	_	_	_	Seg=O
73	range	_	_	_	_	_	_	_	Seg=O
74	in	_	_	_	_	_	_	_	Seg=O
75	feline	_	_	_	_	_	_	_	Seg=O
76	species	_	_	_	_	_	_	_	Seg=O
77	.	_	_	_	_	_	_	_	Seg=O
78	A	_	_	_	_	_	_	_	Seg=B-seg
79	recent	_	_	_	_	_	_	_	Seg=O
80	preliminary	_	_	_	_	_	_	_	Seg=O
81	sampling	_	_	_	_	_	_	_	Seg=O
82	of	_	_	_	_	_	_	_	Seg=O
83	domestic	_	_	_	_	_	_	_	Seg=O
84	cats	_	_	_	_	_	_	_	Seg=O
85	(	_	_	_	_	_	_	_	Seg=B-seg
86	Felis	_	_	_	_	_	_	_	Seg=O
87	silvestris	_	_	_	_	_	_	_	Seg=O
88	forma	_	_	_	_	_	_	_	Seg=O
89	catus	_	_	_	_	_	_	_	Seg=O
90	)	_	_	_	_	_	_	_	Seg=O
91	revealed	_	_	_	_	_	_	_	Seg=B-seg
92	that	_	_	_	_	_	_	_	Seg=B-seg
93	this	_	_	_	_	_	_	_	Seg=O
94	microorganism	_	_	_	_	_	_	_	Seg=O
95	is	_	_	_	_	_	_	_	Seg=O
96	common	_	_	_	_	_	_	_	Seg=O
97	in	_	_	_	_	_	_	_	Seg=O
98	the	_	_	_	_	_	_	_	Seg=O
99	oropharynx	_	_	_	_	_	_	_	Seg=O
100	,	_	_	_	_	_	_	_	Seg=O
101	suggesting	_	_	_	_	_	_	_	Seg=B-seg
102	that	_	_	_	_	_	_	_	Seg=B-seg
103	S.	_	_	_	_	_	_	_	Seg=O
104	felis	_	_	_	_	_	_	_	Seg=O
105	is	_	_	_	_	_	_	_	Seg=O
106	a	_	_	_	_	_	_	_	Seg=O
107	member	_	_	_	_	_	_	_	Seg=O
108	of	_	_	_	_	_	_	_	Seg=O
109	their	_	_	_	_	_	_	_	Seg=O
110	normal	_	_	_	_	_	_	_	Seg=O
111	microbiota	_	_	_	_	_	_	_	Seg=O
112	.	_	_	_	_	_	_	_	Seg=O
113	Due	_	_	_	_	_	_	_	Seg=B-seg
114	to	_	_	_	_	_	_	_	Seg=O
115	unawareness	_	_	_	_	_	_	_	Seg=O
116	,	_	_	_	_	_	_	_	Seg=O
117	fastidiousness	_	_	_	_	_	_	_	Seg=O
118	,	_	_	_	_	_	_	_	Seg=O
119	antibiotic	_	_	_	_	_	_	_	Seg=O
120	sensitivity	_	_	_	_	_	_	_	Seg=O
121	and	_	_	_	_	_	_	_	Seg=O
122	lack	_	_	_	_	_	_	_	Seg=O
123	of	_	_	_	_	_	_	_	Seg=O
124	diagnostics	_	_	_	_	_	_	_	Seg=O
125	the	_	_	_	_	_	_	_	Seg=B-seg
126	role	_	_	_	_	_	_	_	Seg=O
127	of	_	_	_	_	_	_	_	Seg=O
128	S.	_	_	_	_	_	_	_	Seg=O
129	felis	_	_	_	_	_	_	_	Seg=O
130	as	_	_	_	_	_	_	_	Seg=O
131	a	_	_	_	_	_	_	_	Seg=O
132	cat	_	_	_	_	_	_	_	Seg=O
133	and	_	_	_	_	_	_	_	Seg=O
134	human	_	_	_	_	_	_	_	Seg=O
135	pathogen	_	_	_	_	_	_	_	Seg=O
136	might	_	_	_	_	_	_	_	Seg=O
137	be	_	_	_	_	_	_	_	Seg=O
138	underreported	_	_	_	_	_	_	_	Seg=O
139	as	_	_	_	_	_	_	_	Seg=O
140	with	_	_	_	_	_	_	_	Seg=O
141	other	_	_	_	_	_	_	_	Seg=O
142	Streptobacillus	_	_	_	_	_	_	_	Seg=O
143	infections	_	_	_	_	_	_	_	Seg=O
144	.	_	_	_	_	_	_	_	Seg=O
145	More	_	_	_	_	_	_	_	Seg=B-seg
146	studies	_	_	_	_	_	_	_	Seg=O
147	are	_	_	_	_	_	_	_	Seg=O
148	necessary	_	_	_	_	_	_	_	Seg=O
149	to	_	_	_	_	_	_	_	Seg=B-seg
150	elucidate	_	_	_	_	_	_	_	Seg=O
151	the	_	_	_	_	_	_	_	Seg=O
152	role	_	_	_	_	_	_	_	Seg=O
153	of	_	_	_	_	_	_	_	Seg=O
154	S.	_	_	_	_	_	_	_	Seg=O
155	felis	_	_	_	_	_	_	_	Seg=O
156	in	_	_	_	_	_	_	_	Seg=O
157	domestic	_	_	_	_	_	_	_	Seg=O
158	cats	_	_	_	_	_	_	_	Seg=O
159	and	_	_	_	_	_	_	_	Seg=O
160	other	_	_	_	_	_	_	_	Seg=O
161	Felidae	_	_	_	_	_	_	_	Seg=O
162	in	_	_	_	_	_	_	_	Seg=B-seg
163	order	_	_	_	_	_	_	_	Seg=O
164	to	_	_	_	_	_	_	_	Seg=O
165	better	_	_	_	_	_	_	_	Seg=O
166	estimate	_	_	_	_	_	_	_	Seg=O
167	its	_	_	_	_	_	_	_	Seg=O
168	zoonotic	_	_	_	_	_	_	_	Seg=O
169	potential	_	_	_	_	_	_	_	Seg=O
170	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = f54b1d2032db8537d80fc36e29bc6fcdfb878435
1	H1N1	_	_	_	_	_	_	_	Seg=B-seg
2	swine	_	_	_	_	_	_	_	Seg=O
3	influenza	_	_	_	_	_	_	_	Seg=O
4	viruses	_	_	_	_	_	_	_	Seg=O
5	(	_	_	_	_	_	_	_	Seg=O
6	SIV	_	_	_	_	_	_	_	Seg=O
7	)	_	_	_	_	_	_	_	Seg=O
8	are	_	_	_	_	_	_	_	Seg=O
9	prevalent	_	_	_	_	_	_	_	Seg=O
10	in	_	_	_	_	_	_	_	Seg=O
11	pigs	_	_	_	_	_	_	_	Seg=O
12	globally	_	_	_	_	_	_	_	Seg=O
13	,	_	_	_	_	_	_	_	Seg=O
14	and	_	_	_	_	_	_	_	Seg=B-seg
15	occasionally	_	_	_	_	_	_	_	Seg=O
16	emerge	_	_	_	_	_	_	_	Seg=O
17	in	_	_	_	_	_	_	_	Seg=O
18	humans	_	_	_	_	_	_	_	Seg=O
19	,	_	_	_	_	_	_	_	Seg=O
20	which	_	_	_	_	_	_	_	Seg=B-seg
21	raises	_	_	_	_	_	_	_	Seg=O
22	concern	_	_	_	_	_	_	_	Seg=O
23	about	_	_	_	_	_	_	_	Seg=O
24	their	_	_	_	_	_	_	_	Seg=O
25	pandemic	_	_	_	_	_	_	_	Seg=O
26	threats	_	_	_	_	_	_	_	Seg=O
27	.	_	_	_	_	_	_	_	Seg=O
28	To	_	_	_	_	_	_	_	Seg=B-seg
29	stimulate	_	_	_	_	_	_	_	Seg=O
30	hemagglutination	_	_	_	_	_	_	_	Seg=O
31	(	_	_	_	_	_	_	_	Seg=O
32	HA	_	_	_	_	_	_	_	Seg=O
33	)	_	_	_	_	_	_	_	Seg=O
34	of	_	_	_	_	_	_	_	Seg=O
35	A	_	_	_	_	_	_	_	Seg=O
36	/	_	_	_	_	_	_	_	Seg=O
37	Swine	_	_	_	_	_	_	_	Seg=O
38	/	_	_	_	_	_	_	_	Seg=O
39	Guangdong	_	_	_	_	_	_	_	Seg=O
40	/	_	_	_	_	_	_	_	Seg=O
41	LM/2004	_	_	_	_	_	_	_	Seg=O
42	(	_	_	_	_	_	_	_	Seg=O
43	H1N1	_	_	_	_	_	_	_	Seg=O
44	)	_	_	_	_	_	_	_	Seg=O
45	(	_	_	_	_	_	_	_	Seg=O
46	SW	_	_	_	_	_	_	_	Seg=O
47	/	_	_	_	_	_	_	_	Seg=O
48	GD/04	_	_	_	_	_	_	_	Seg=O
49	)	_	_	_	_	_	_	_	Seg=O
50	antibody	_	_	_	_	_	_	_	Seg=O
51	response	_	_	_	_	_	_	_	Seg=O
52	,	_	_	_	_	_	_	_	Seg=O
53	eukaryotic	_	_	_	_	_	_	_	Seg=B-seg
54	expression	_	_	_	_	_	_	_	Seg=O
55	plasmid	_	_	_	_	_	_	_	Seg=O
56	pCI	_	_	_	_	_	_	_	Seg=O
57	-	_	_	_	_	_	_	_	Seg=O
58	neo	_	_	_	_	_	_	_	Seg=O
59	-	_	_	_	_	_	_	_	Seg=O
60	HA	_	_	_	_	_	_	_	Seg=O
61	was	_	_	_	_	_	_	_	Seg=O
62	constructed	_	_	_	_	_	_	_	Seg=O
63	and	_	_	_	_	_	_	_	Seg=B-seg
64	used	_	_	_	_	_	_	_	Seg=O
65	as	_	_	_	_	_	_	_	Seg=O
66	an	_	_	_	_	_	_	_	Seg=O
67	immunogen	_	_	_	_	_	_	_	Seg=O
68	to	_	_	_	_	_	_	_	Seg=B-seg
69	prepare	_	_	_	_	_	_	_	Seg=O
70	monoclonal	_	_	_	_	_	_	_	Seg=O
71	antibodies	_	_	_	_	_	_	_	Seg=O
72	(	_	_	_	_	_	_	_	Seg=O
73	mAbs	_	_	_	_	_	_	_	Seg=O
74	)	_	_	_	_	_	_	_	Seg=O
75	.	_	_	_	_	_	_	_	Seg=O
76	Five	_	_	_	_	_	_	_	Seg=B-seg
77	mAbs	_	_	_	_	_	_	_	Seg=O
78	(	_	_	_	_	_	_	_	Seg=B-seg
79	designed	_	_	_	_	_	_	_	Seg=O
80	8C4	_	_	_	_	_	_	_	Seg=O
81	,	_	_	_	_	_	_	_	Seg=O
82	8C6	_	_	_	_	_	_	_	Seg=O
83	,	_	_	_	_	_	_	_	Seg=O
84	9D6	_	_	_	_	_	_	_	Seg=O
85	,	_	_	_	_	_	_	_	Seg=O
86	8A4	_	_	_	_	_	_	_	Seg=O
87	,	_	_	_	_	_	_	_	Seg=O
88	and	_	_	_	_	_	_	_	Seg=O
89	8B1	_	_	_	_	_	_	_	Seg=O
90	)	_	_	_	_	_	_	_	Seg=O
91	against	_	_	_	_	_	_	_	Seg=B-seg
92	HA	_	_	_	_	_	_	_	Seg=O
93	protein	_	_	_	_	_	_	_	Seg=O
94	were	_	_	_	_	_	_	_	Seg=O
95	obtained	_	_	_	_	_	_	_	Seg=O
96	and	_	_	_	_	_	_	_	Seg=B-seg
97	characterized	_	_	_	_	_	_	_	Seg=O
98	.	_	_	_	_	_	_	_	Seg=O
99	Western	_	_	_	_	_	_	_	Seg=B-seg
100	blot	_	_	_	_	_	_	_	Seg=O
101	showed	_	_	_	_	_	_	_	Seg=O
102	that	_	_	_	_	_	_	_	Seg=B-seg
103	the	_	_	_	_	_	_	_	Seg=O
104	70	_	_	_	_	_	_	_	Seg=O
105	kDa	_	_	_	_	_	_	_	Seg=O
106	HA	_	_	_	_	_	_	_	Seg=O
107	protein	_	_	_	_	_	_	_	Seg=O
108	could	_	_	_	_	_	_	_	Seg=O
109	be	_	_	_	_	_	_	_	Seg=O
110	detected	_	_	_	_	_	_	_	Seg=O
111	by	_	_	_	_	_	_	_	Seg=O
112	all	_	_	_	_	_	_	_	Seg=O
113	mAbs	_	_	_	_	_	_	_	Seg=O
114	in	_	_	_	_	_	_	_	Seg=O
115	MDCK	_	_	_	_	_	_	_	Seg=O
116	cells	_	_	_	_	_	_	_	Seg=O
117	infected	_	_	_	_	_	_	_	Seg=B-seg
118	with	_	_	_	_	_	_	_	Seg=O
119	SW	_	_	_	_	_	_	_	Seg=O
120	/	_	_	_	_	_	_	_	Seg=O
121	GD/04	_	_	_	_	_	_	_	Seg=O
122	.	_	_	_	_	_	_	_	Seg=O
123	Three	_	_	_	_	_	_	_	Seg=B-seg
124	mAbs-8C4	_	_	_	_	_	_	_	Seg=O
125	,	_	_	_	_	_	_	_	Seg=O
126	8C6	_	_	_	_	_	_	_	Seg=O
127	,	_	_	_	_	_	_	_	Seg=O
128	and	_	_	_	_	_	_	_	Seg=O
129	9D6-have	_	_	_	_	_	_	_	Seg=O
130	hemagglutination	_	_	_	_	_	_	_	Seg=O
131	inhibition	_	_	_	_	_	_	_	Seg=O
132	(	_	_	_	_	_	_	_	Seg=O
133	HI	_	_	_	_	_	_	_	Seg=O
134	)	_	_	_	_	_	_	_	Seg=O
135	and	_	_	_	_	_	_	_	Seg=O
136	neutralization	_	_	_	_	_	_	_	Seg=O
137	test	_	_	_	_	_	_	_	Seg=O
138	(	_	_	_	_	_	_	_	Seg=O
139	NT	_	_	_	_	_	_	_	Seg=O
140	)	_	_	_	_	_	_	_	Seg=O
141	activities	_	_	_	_	_	_	_	Seg=O
142	,	_	_	_	_	_	_	_	Seg=O
143	and	_	_	_	_	_	_	_	Seg=O
144	8C6	_	_	_	_	_	_	_	Seg=O
145	induces	_	_	_	_	_	_	_	Seg=O
146	the	_	_	_	_	_	_	_	Seg=O
147	highest	_	_	_	_	_	_	_	Seg=O
148	HI	_	_	_	_	_	_	_	Seg=O
149	and	_	_	_	_	_	_	_	Seg=O
150	NT	_	_	_	_	_	_	_	Seg=O
151	titers	_	_	_	_	_	_	_	Seg=O
152	.	_	_	_	_	_	_	_	Seg=O
153	The	_	_	_	_	_	_	_	Seg=B-seg
154	protection	_	_	_	_	_	_	_	Seg=O
155	efficacy	_	_	_	_	_	_	_	Seg=O
156	of	_	_	_	_	_	_	_	Seg=O
157	8C6	_	_	_	_	_	_	_	Seg=O
158	was	_	_	_	_	_	_	_	Seg=O
159	investigated	_	_	_	_	_	_	_	Seg=O
160	in	_	_	_	_	_	_	_	Seg=O
161	BALB	_	_	_	_	_	_	_	Seg=O
162	/	_	_	_	_	_	_	_	Seg=O
163	c	_	_	_	_	_	_	_	Seg=O
164	mice	_	_	_	_	_	_	_	Seg=O
165	challenged	_	_	_	_	_	_	_	Seg=B-seg
166	with	_	_	_	_	_	_	_	Seg=O
167	homologous	_	_	_	_	_	_	_	Seg=O
168	or	_	_	_	_	_	_	_	Seg=O
169	heterologous	_	_	_	_	_	_	_	Seg=O
170	strains	_	_	_	_	_	_	_	Seg=O
171	of	_	_	_	_	_	_	_	Seg=O
172	the	_	_	_	_	_	_	_	Seg=O
173	H1	_	_	_	_	_	_	_	Seg=O
174	subtype	_	_	_	_	_	_	_	Seg=O
175	SIV	_	_	_	_	_	_	_	Seg=O
176	.	_	_	_	_	_	_	_	Seg=O
177	The	_	_	_	_	_	_	_	Seg=B-seg
178	results	_	_	_	_	_	_	_	Seg=O
179	indicate	_	_	_	_	_	_	_	Seg=O
180	that	_	_	_	_	_	_	_	Seg=B-seg
181	mAb	_	_	_	_	_	_	_	Seg=O
182	8C6	_	_	_	_	_	_	_	Seg=O
183	protected	_	_	_	_	_	_	_	Seg=O
184	the	_	_	_	_	_	_	_	Seg=O
185	mice	_	_	_	_	_	_	_	Seg=O
186	from	_	_	_	_	_	_	_	Seg=O
187	viral	_	_	_	_	_	_	_	Seg=O
188	infections	_	_	_	_	_	_	_	Seg=O
189	,	_	_	_	_	_	_	_	Seg=O
190	especially	_	_	_	_	_	_	_	Seg=O
191	the	_	_	_	_	_	_	_	Seg=O
192	homologous	_	_	_	_	_	_	_	Seg=O
193	strain	_	_	_	_	_	_	_	Seg=O
194	,	_	_	_	_	_	_	_	Seg=O
195	which	_	_	_	_	_	_	_	Seg=B-seg
196	was	_	_	_	_	_	_	_	Seg=O
197	clearly	_	_	_	_	_	_	_	Seg=O
198	demonstrated	_	_	_	_	_	_	_	Seg=O
199	by	_	_	_	_	_	_	_	Seg=O
200	the	_	_	_	_	_	_	_	Seg=O
201	body	_	_	_	_	_	_	_	Seg=O
202	weight	_	_	_	_	_	_	_	Seg=O
203	changes	_	_	_	_	_	_	_	Seg=O
204	and	_	_	_	_	_	_	_	Seg=O
205	reduction	_	_	_	_	_	_	_	Seg=O
206	of	_	_	_	_	_	_	_	Seg=O
207	viral	_	_	_	_	_	_	_	Seg=O
208	load	_	_	_	_	_	_	_	Seg=O
209	.	_	_	_	_	_	_	_	Seg=O
210	Thus	_	_	_	_	_	_	_	Seg=B-seg
211	,	_	_	_	_	_	_	_	Seg=O
212	our	_	_	_	_	_	_	_	Seg=O
213	findings	_	_	_	_	_	_	_	Seg=O
214	document	_	_	_	_	_	_	_	Seg=O
215	for	_	_	_	_	_	_	_	Seg=O
216	the	_	_	_	_	_	_	_	Seg=O
217	first	_	_	_	_	_	_	_	Seg=O
218	time	_	_	_	_	_	_	_	Seg=O
219	that	_	_	_	_	_	_	_	Seg=B-seg
220	mAb	_	_	_	_	_	_	_	Seg=O
221	8C6	_	_	_	_	_	_	_	Seg=O
222	might	_	_	_	_	_	_	_	Seg=O
223	be	_	_	_	_	_	_	_	Seg=O
224	of	_	_	_	_	_	_	_	Seg=O
225	potential	_	_	_	_	_	_	_	Seg=O
226	therapeutic	_	_	_	_	_	_	_	Seg=O
227	value	_	_	_	_	_	_	_	Seg=O
228	for	_	_	_	_	_	_	_	Seg=O
229	H1	_	_	_	_	_	_	_	Seg=O
230	subtype	_	_	_	_	_	_	_	Seg=O
231	SIV	_	_	_	_	_	_	_	Seg=O
232	infection	_	_	_	_	_	_	_	Seg=O
233	.	_	_	_	_	_	_	_	Seg=O

# newdoc_id = f950928cf284b3633029222291dc8d26dca43124
1	Amid	_	_	_	_	_	_	_	Seg=B-seg
2	the	_	_	_	_	_	_	_	Seg=O
3	global	_	_	_	_	_	_	_	Seg=O
4	pandemic	_	_	_	_	_	_	_	Seg=O
5	of	_	_	_	_	_	_	_	Seg=O
6	a	_	_	_	_	_	_	_	Seg=O
7	novel	_	_	_	_	_	_	_	Seg=O
8	Coronavirus	_	_	_	_	_	_	_	Seg=O
9	Disease	_	_	_	_	_	_	_	Seg=O
10	2019	_	_	_	_	_	_	_	Seg=O
11	(	_	_	_	_	_	_	_	Seg=O
12	COVID-19	_	_	_	_	_	_	_	Seg=O
13	)	_	_	_	_	_	_	_	Seg=O
14	,	_	_	_	_	_	_	_	Seg=O
15	healthcare	_	_	_	_	_	_	_	Seg=O
16	delivery	_	_	_	_	_	_	_	Seg=O
17	system	_	_	_	_	_	_	_	Seg=O
18	is	_	_	_	_	_	_	_	Seg=O
19	being	_	_	_	_	_	_	_	Seg=O
20	stretched	_	_	_	_	_	_	_	Seg=O
21	.	_	_	_	_	_	_	_	Seg=O
22	In	_	_	_	_	_	_	_	Seg=B-seg
23	Japan	_	_	_	_	_	_	_	Seg=O
24	,	_	_	_	_	_	_	_	Seg=O
25	rapid	_	_	_	_	_	_	_	Seg=O
26	spread	_	_	_	_	_	_	_	Seg=O
27	of	_	_	_	_	_	_	_	Seg=O
28	the	_	_	_	_	_	_	_	Seg=O
29	epidemic	_	_	_	_	_	_	_	Seg=O
30	brings	_	_	_	_	_	_	_	Seg=O
31	hospitals	_	_	_	_	_	_	_	Seg=O
32	to	_	_	_	_	_	_	_	Seg=O
33	the	_	_	_	_	_	_	_	Seg=O
34	brink	_	_	_	_	_	_	_	Seg=O
35	of	_	_	_	_	_	_	_	Seg=O
36	exhaustion	_	_	_	_	_	_	_	Seg=O
37	.	_	_	_	_	_	_	_	Seg=O
38	This	_	_	_	_	_	_	_	Seg=B-seg
39	commentary	_	_	_	_	_	_	_	Seg=O
40	aims	_	_	_	_	_	_	_	Seg=O
41	to	_	_	_	_	_	_	_	Seg=O
42	briefly	_	_	_	_	_	_	_	Seg=O
43	review	_	_	_	_	_	_	_	Seg=O
44	related	_	_	_	_	_	_	_	Seg=O
45	policies	_	_	_	_	_	_	_	Seg=O
46	of	_	_	_	_	_	_	_	Seg=O
47	Japan	_	_	_	_	_	_	_	Seg=O
48	in	_	_	_	_	_	_	_	Seg=B-seg
49	managing	_	_	_	_	_	_	_	Seg=O
50	healthcare	_	_	_	_	_	_	_	Seg=O
51	delivery	_	_	_	_	_	_	_	Seg=O
52	system	_	_	_	_	_	_	_	Seg=O
53	.	_	_	_	_	_	_	_	Seg=O
54	Among	_	_	_	_	_	_	_	Seg=B-seg
55	the	_	_	_	_	_	_	_	Seg=O
56	relevant	_	_	_	_	_	_	_	Seg=O
57	actions	_	_	_	_	_	_	_	Seg=O
58	,	_	_	_	_	_	_	_	Seg=O
59	strengthening	_	_	_	_	_	_	_	Seg=O
60	the	_	_	_	_	_	_	_	Seg=O
61	hospitalized	_	_	_	_	_	_	_	Seg=O
62	care	_	_	_	_	_	_	_	Seg=O
63	is	_	_	_	_	_	_	_	Seg=O
64	emphasized	_	_	_	_	_	_	_	Seg=O
65	to	_	_	_	_	_	_	_	Seg=B-seg
66	save	_	_	_	_	_	_	_	Seg=O
67	lives	_	_	_	_	_	_	_	Seg=O
68	.	_	_	_	_	_	_	_	Seg=O
69	Despite	_	_	_	_	_	_	_	Seg=B-seg
70	of	_	_	_	_	_	_	_	Seg=O
71	limitations	_	_	_	_	_	_	_	Seg=O
72	,	_	_	_	_	_	_	_	Seg=O
73	the	_	_	_	_	_	_	_	Seg=B-seg
74	policies	_	_	_	_	_	_	_	Seg=O
75	show	_	_	_	_	_	_	_	Seg=O
76	a	_	_	_	_	_	_	_	Seg=O
77	success	_	_	_	_	_	_	_	Seg=O
78	in	_	_	_	_	_	_	_	Seg=B-seg
79	preventing	_	_	_	_	_	_	_	Seg=O
80	a	_	_	_	_	_	_	_	Seg=O
81	collapse	_	_	_	_	_	_	_	Seg=O
82	of	_	_	_	_	_	_	_	Seg=O
83	healthcare	_	_	_	_	_	_	_	Seg=O
84	delivery	_	_	_	_	_	_	_	Seg=O
85	system	_	_	_	_	_	_	_	Seg=O
86	and	_	_	_	_	_	_	_	Seg=B-seg
87	skyrocketing	_	_	_	_	_	_	_	Seg=O
88	mortality	_	_	_	_	_	_	_	Seg=O
89	from	_	_	_	_	_	_	_	Seg=O
90	happening	_	_	_	_	_	_	_	Seg=O
91	so	_	_	_	_	_	_	_	Seg=O
92	far	_	_	_	_	_	_	_	Seg=O
93	.	_	_	_	_	_	_	_	Seg=O
94	On	_	_	_	_	_	_	_	Seg=B-seg
95	the	_	_	_	_	_	_	_	Seg=O
96	other	_	_	_	_	_	_	_	Seg=O
97	hand	_	_	_	_	_	_	_	Seg=O
98	,	_	_	_	_	_	_	_	Seg=O
99	huge	_	_	_	_	_	_	_	Seg=O
100	concerns	_	_	_	_	_	_	_	Seg=O
101	remain	_	_	_	_	_	_	_	Seg=O
102	if	_	_	_	_	_	_	_	Seg=B-seg
103	the	_	_	_	_	_	_	_	Seg=O
104	infections	_	_	_	_	_	_	_	Seg=O
105	continue	_	_	_	_	_	_	_	Seg=O
106	to	_	_	_	_	_	_	_	Seg=O
107	rapidly	_	_	_	_	_	_	_	Seg=O
108	increase	_	_	_	_	_	_	_	Seg=O
109	.	_	_	_	_	_	_	_	Seg=O
110	The	_	_	_	_	_	_	_	Seg=B-seg
111	experience	_	_	_	_	_	_	_	Seg=O
112	in	_	_	_	_	_	_	_	Seg=O
113	Japan	_	_	_	_	_	_	_	Seg=O
114	indicates	_	_	_	_	_	_	_	Seg=O
115	the	_	_	_	_	_	_	_	Seg=O
116	urgency	_	_	_	_	_	_	_	Seg=O
117	of	_	_	_	_	_	_	_	Seg=B-seg
118	planning	_	_	_	_	_	_	_	Seg=O
119	of	_	_	_	_	_	_	_	Seg=O
120	healthcare	_	_	_	_	_	_	_	Seg=O
121	delivery	_	_	_	_	_	_	_	Seg=O
122	system	_	_	_	_	_	_	_	Seg=O
123	,	_	_	_	_	_	_	_	Seg=O
124	mobilizing	_	_	_	_	_	_	_	Seg=B-seg
125	all	_	_	_	_	_	_	_	Seg=O
126	relevant	_	_	_	_	_	_	_	Seg=O
127	social	_	_	_	_	_	_	_	Seg=O
128	sectors	_	_	_	_	_	_	_	Seg=O
129	by	_	_	_	_	_	_	_	Seg=O
130	consensus	_	_	_	_	_	_	_	Seg=O
131	,	_	_	_	_	_	_	_	Seg=O
132	and	_	_	_	_	_	_	_	Seg=B-seg
133	guiding	_	_	_	_	_	_	_	Seg=O
134	people	_	_	_	_	_	_	_	Seg=O
135	with	_	_	_	_	_	_	_	Seg=O
136	calm	_	_	_	_	_	_	_	Seg=O
137	manner	_	_	_	_	_	_	_	Seg=O
138	based	_	_	_	_	_	_	_	Seg=B-seg
139	on	_	_	_	_	_	_	_	Seg=O
140	the	_	_	_	_	_	_	_	Seg=O
141	best	_	_	_	_	_	_	_	Seg=O
142	shared	_	_	_	_	_	_	_	Seg=O
143	knowledge	_	_	_	_	_	_	_	Seg=O
144	and	_	_	_	_	_	_	_	Seg=O
145	evidences	_	_	_	_	_	_	_	Seg=O
146	.	_	_	_	_	_	_	_	Seg=O
